PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20971733-0	2010	Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis.	Bleomycin	107-116	coagulation factor II (thrombin) receptor-like 1	Mus musculus	0-29
20971733-5	2010	Using a bleomycin model of pulmonary fibrosis, we show that bleomycin induces PAR-2 expression, as well as both myofibroblast differentiation and collagen synthesis.	Bleomycin	8-17	pulmonary adenoma resistance 2	Mus musculus	78-83
20971733-5	2010	Using a bleomycin model of pulmonary fibrosis, we show that bleomycin induces PAR-2 expression, as well as both myofibroblast differentiation and collagen synthesis.	Bleomycin	60-69	pulmonary adenoma resistance 2	Mus musculus	78-83
20971733-7	2010	Moreover, fibrin deposition in the lungs of fibrotic PAR-2-/- mice is reduced compared with wild-type mice due to differential tissue factor expression in response to bleomycin.	Bleomycin	167-176	pulmonary adenoma resistance 2	Mus musculus	53-58
20833777-2	2010	Here we report that mice lacking TNC are protected from interstitial fibrosis in the bleomycin model of ALI.	Bleomycin	85-94	tenascin C	Mus musculus	33-36
20833777-3	2010	Three weeks after exposure to bleomycin, TNC-null mice had accumulated 85% less lung collagen than wild-type mice.	Bleomycin	30-39	tenascin C	Mus musculus	41-44
20846163-0	2010	The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	41-50	calpastatin	Mus musculus	4-21
20846163-7	2010	In this study, we examined the preventive effect of Calpeptin, a calpain inhibitor, on bleomycin-induced pulmonary fibrosis.	Bleomycin	87-96	calpastatin	Mus musculus	65-82
20846163-8	2010	We performed histological examinations and quantitative measurements of IL-6, TGF-beta1, collagen type Ialpha1 and angiopoietin-1 in bleomycin-treated mouse lung tissues with or without the administration of Calpeptin.	Bleomycin	133-142	angiopoietin 1	Mus musculus	115-129
20705543-6	2010	RESULTS: XRCC1 knockdown sensitized cells to the clastogenic and cytotoxic effects of oxidants [hydrogen peroxide (H2O2), bleomycin] but not to the nonoxidant paclitaxel.	Bleomycin	122-131	X-ray repair cross complementing 1	Homo sapiens	9-14
21234123-4	2010	It is therefore presumed that TSP-1 deficient mice would fare better to bleomycin-induced pulmonary fibrosis because TGFbeta would not be efficiently converted to the active form.	Bleomycin	72-81	thrombospondin 1	Mus musculus	30-35
21177177-0	2010	[Gefitinib inhibits alpha-smooth muscle actin expression in mice with bleomycin-induced lung fibrosis].	Bleomycin	70-79	actin alpha 2, smooth muscle, aorta	Mus musculus	20-45
21177177-1	2010	OBJECTIVE: To evaluate the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, on the expression of alpha-smooth muscle actin (alpha-SMA) in mice with lung fibrosis induced by bleomycin.	Bleomycin	205-214	actin alpha 2, smooth muscle, aorta	Mus musculus	129-154
21177177-1	2010	OBJECTIVE: To evaluate the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, on the expression of alpha-smooth muscle actin (alpha-SMA) in mice with lung fibrosis induced by bleomycin.	Bleomycin	205-214	actin alpha 2, smooth muscle, aorta	Mus musculus	156-165
21177177-7	2010	The phosphorylation of EGFR in the pulmonary mesenchymal cells and epithelial cells and the expression levels of alpha-SMA mRNA and protein were inhibited by gefitinib treatment in mice with intratracheal administration of bleomycin (P<0.05).	Bleomycin	223-232	epidermal growth factor receptor	Mus musculus	23-27
21177177-7	2010	The phosphorylation of EGFR in the pulmonary mesenchymal cells and epithelial cells and the expression levels of alpha-SMA mRNA and protein were inhibited by gefitinib treatment in mice with intratracheal administration of bleomycin (P<0.05).	Bleomycin	223-232	actin alpha 2, smooth muscle, aorta	Mus musculus	113-122
21177177-8	2010	CONCLUSION: Gefitinib offers protection against lung fibrosis induced by bleomycin in mice probably by inhibiting the downstream signals of EGFR and by downregulating the expression of alpha-SMA.	Bleomycin	73-82	epidermal growth factor receptor	Mus musculus	140-144
20185425-2	2010	We have previously reported that angiopoietin (Ang)-1 was correlated with bleomycin-induced pulmonary fibrosis.	Bleomycin	74-83	angiopoietin 1	Homo sapiens	33-53
20617520-7	2010	RESULTS: CB1(-/-) mice were protected from bleomycin-induced dermal fibrosis, with reduced dermal thickening, hydroxyproline content, and myofibroblast counts.	Bleomycin	43-52	cannabinoid receptor 1 (brain)	Mus musculus	9-12
20617520-9	2010	In contrast, activation of CB1 with ACEA increased leukocyte infiltration and enhanced the fibrotic response to bleomycin.	Bleomycin	112-121	cannabinoid receptor 1 (brain)	Mus musculus	27-30
20939757-6	2010	Furthermore, concentrations of serum SP-D were measured in normal control and bleomycin-treated rats.	Bleomycin	78-87	surfactant protein D	Rattus norvegicus	37-41
20725963-1	2010	The formation of hypertrophic scars (HSF) is a frequent medical outcome of wound repair and often requires further therapy with treatments such as silicone gel sheets (SGS) or apoptosis-inducing agents, including bleomycin.	Bleomycin	213-222	interleukin 6	Homo sapiens	37-40
20889544-3	2010	HIMF expression in the lung was reported to be regulated by Th2 cytokines (IL-4 and IL-13) via the transcription factor STAT6 pathway in a bleomycin-induced pulmonary fibrosis model.	Bleomycin	139-148	resistin like alpha	Mus musculus	0-4
20889544-3	2010	HIMF expression in the lung was reported to be regulated by Th2 cytokines (IL-4 and IL-13) via the transcription factor STAT6 pathway in a bleomycin-induced pulmonary fibrosis model.	Bleomycin	139-148	signal transducer and activator of transcription 6	Mus musculus	120-125
20857141-8	2010	In vivo, the bleomycin model was used in order to examine ILK"s expression and localization in the fibrotic lung.	Bleomycin	13-22	integrin linked kinase	Mus musculus	58-61
20949050-0	2010	Resistance to bleomycin-induced lung fibrosis in MMP-8 deficient mice is mediated by interleukin-10.	Bleomycin	14-23	matrix metallopeptidase 8	Mus musculus	49-54
20949050-0	2010	Resistance to bleomycin-induced lung fibrosis in MMP-8 deficient mice is mediated by interleukin-10.	Bleomycin	14-23	interleukin 10	Mus musculus	85-99
20939757-9	2010	Serum SP-D levels of bleomycin-treated rats were significantly higher than those of normal rats.	Bleomycin	21-30	surfactant protein D	Rattus norvegicus	6-10
20651228-0	2010	Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury.	Bleomycin	65-74	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	0-29
21244753-5	2010	Therefore, the aim of this study is to investigate the effects of GW0742, a synthetic high affinity PPAR beta/delta agonist, and its possible role in preventing the advance of inflammatory and apoptotic processes induced by bleomycin, that long-term leads to the appearance of pulmonary fibrosis.	Bleomycin	224-233	peroxisome proliferator activator receptor delta	Mus musculus	100-109
20513440-0	2010	Heat shock protein 70 protects against bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	39-48	heat shock protein 1B	Mus musculus	0-21
20513440-4	2010	In this study, we examined the effect of expression of HSP70 on bleomycin-induced pulmonary fibrosis in mice, a tentative animal model of IPF.	Bleomycin	64-73	heat shock protein 1B	Mus musculus	55-60
20513440-5	2010	Bleomycin-induced pulmonary injury and inflammatory response were ameliorated in transgenic mice overexpressing HSP70 compared to wild-type mice, even though bleomycin-induced pulmonary fibrosis and dysfunction were also suppressed in the transgenic mice.	Bleomycin	0-9	heat shock protein 1B	Mus musculus	112-117
20513440-6	2010	The production of TGF-beta1 and expression of pro-inflammatory cytokines was lower in cells from the transgenic mice than wild-type mice after the administration of bleomycin.	Bleomycin	165-174	transforming growth factor, beta 1	Mus musculus	18-27
20513440-9	2010	These results suggest that HSP70 plays a protective role against bleomycin-induced pulmonary injury, inflammation, fibrosis and dysfunction through cytoprotective effects and by inhibiting the production of TGF-beta1, TGF-beta1-dependent EMT of epithelial cells and expression of pro-inflammatory cytokines.	Bleomycin	65-74	heat shock protein 1B	Mus musculus	27-32
20513440-9	2010	These results suggest that HSP70 plays a protective role against bleomycin-induced pulmonary injury, inflammation, fibrosis and dysfunction through cytoprotective effects and by inhibiting the production of TGF-beta1, TGF-beta1-dependent EMT of epithelial cells and expression of pro-inflammatory cytokines.	Bleomycin	65-74	transforming growth factor, beta 1	Mus musculus	218-227
20815874-0	2010	T regulatory cells and attenuated bleomycin-induced fibrosis in lungs of CCR7-/- mice.	Bleomycin	34-43	chemokine (C-C motif) receptor 7	Mus musculus	73-77
20815874-3	2010	The objective of this study was to investigate whether the absence of CCR7 protects against bleomycin (BLM)-induced PF.	Bleomycin	92-101	chemokine (C-C motif) receptor 7	Mus musculus	70-74
20463180-8	2010	In bleomycin-treated mice, Apo A-I protein in BALF was lower than that in sham-treated control animals.	Bleomycin	3-12	apolipoprotein A-I	Mus musculus	27-34
20463180-10	2010	Intranasal treatment with Apo A-I protein reduced the bleomycin-induced increases in number of inflammatory cells and collagen deposition in sham-treated mice in a dose-dependent manner.	Bleomycin	54-63	apolipoprotein A-I	Mus musculus	26-33
20818495-0	2010	Changes in factor VII-activating protease in a bleomycin-induced lung injury rat model and its influence on human pulmonary fibroblasts in vitro.	Bleomycin	47-56	hyaluronan binding protein 2	Rattus norvegicus	11-41
20818495-3	2010	This study was designed to determine the dynamic expression changes in FSAP in a bleomycin-induced pulmonary fibrosis rat model and the influence of FSAP on human pulmonary fibroblasts (HPF).	Bleomycin	81-90	hyaluronan binding protein 2	Rattus norvegicus	71-75
20818495-4	2010	The expression of FSAP was examined in a rat model of bleomycin-induced pulmonary fibrosis by immunohistochemical staining, quantitative real-time RT-PCR and Western blot analysis.	Bleomycin	54-63	hyaluronan binding protein 2	Rattus norvegicus	18-22
20818495-7	2010	FSAP was observed prominently in alveolar epithelial cells as well as microvascular endothelial cells of the lung parenchyma and was markedly increased at the early phase of bleomycin-induced pulmonary fibrosis, but decreased at the late stage, particularly during the pulmonary fibrosis.	Bleomycin	174-183	hyaluronan binding protein 2	Rattus norvegicus	0-4
20939987-0	2010	Effects of Chinese herbal medicine Shenlong Decoction on mRNA expressions of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in lung tissue of rats with pulmonary fibrosis induced by bleomycin.	Bleomycin	206-215	matrix metallopeptidase 2	Rattus norvegicus	77-103
20939987-0	2010	Effects of Chinese herbal medicine Shenlong Decoction on mRNA expressions of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in lung tissue of rats with pulmonary fibrosis induced by bleomycin.	Bleomycin	206-215	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	108-147
20939987-1	2010	OBJECTIVE: To observe the expressions of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in rats with pulmonary fibrosis (PF) induced by bleomycin, and to explore the mechanisms of Shenlong Decoction in preventing and treating PF.	Bleomycin	177-186	matrix metallopeptidase 2	Rattus norvegicus	41-67
20939987-1	2010	OBJECTIVE: To observe the expressions of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in rats with pulmonary fibrosis (PF) induced by bleomycin, and to explore the mechanisms of Shenlong Decoction in preventing and treating PF.	Bleomycin	177-186	matrix metallopeptidase 2	Rattus norvegicus	69-74
20939987-1	2010	OBJECTIVE: To observe the expressions of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in rats with pulmonary fibrosis (PF) induced by bleomycin, and to explore the mechanisms of Shenlong Decoction in preventing and treating PF.	Bleomycin	177-186	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	80-119
20939987-1	2010	OBJECTIVE: To observe the expressions of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in rats with pulmonary fibrosis (PF) induced by bleomycin, and to explore the mechanisms of Shenlong Decoction in preventing and treating PF.	Bleomycin	177-186	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	121-127
20651228-9	2010	This study shows that the inactivation of the N-terminal catalytic site of ACE significantly reduced bleomycin-induced lung fibrosis and implicates AcSDKP in the mechanism of protection.	Bleomycin	101-110	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	75-78
20643828-3	2010	In this study, we found up-regulation of miR-21 in the lungs of mice with bleomycin-induced fibrosis and also in the lungs of patients with IPF.	Bleomycin	74-83	microRNA 21a	Mus musculus	41-47
20668224-8	2010	However, free-living phenotypes of ML7400DK paralleled those of known bacA mutants, i.e. ML7400DK showed decreased sensitivity to the antibiotics bleomycin and gentamicin as well as increased sensitivity to membrane-disturbing reagents such as SDS.	Bleomycin	146-155	putative udecaprenol kinase BacA	Escherichia coli	70-74
20600766-7	2010	Expression of miR-338* and its candidate gene LPA1 related to IPF of tectorigenin-treated pulmonary fibroblasts in bleomycin-treated rats were further investigated.	Bleomycin	115-124	microRNA 338	Rattus norvegicus	14-21
20600766-7	2010	Expression of miR-338* and its candidate gene LPA1 related to IPF of tectorigenin-treated pulmonary fibroblasts in bleomycin-treated rats were further investigated.	Bleomycin	115-124	lysophosphatidic acid receptor 1	Rattus norvegicus	46-50
20624949-0	2010	Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model.	Bleomycin	85-94	negative elongation factor complex member C/D, Th1l	Mus musculus	54-57
20624949-0	2010	Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model.	Bleomycin	85-94	heart and neural crest derivatives expressed 2	Mus musculus	58-61
20812903-5	2010	We also discuss how the mammalian transporter hCT2 (SLC22A16) could be used to predict the outcome of tumor responses towards bleomycin therapy, and highlight the importance of further exploring this permease with respect to its regulation and pharmacological substrates for treating a wide range of cancers.	Bleomycin	126-135	solute carrier family 22 member 16	Homo sapiens	46-50
20812903-5	2010	We also discuss how the mammalian transporter hCT2 (SLC22A16) could be used to predict the outcome of tumor responses towards bleomycin therapy, and highlight the importance of further exploring this permease with respect to its regulation and pharmacological substrates for treating a wide range of cancers.	Bleomycin	126-135	solute carrier family 22 member 16	Homo sapiens	52-60
20703090-5	2010	Strains containing mutations in Eco1 are sensitive to DNA damaging agents that cause double-strand breaks, such as X-rays and bleomycin.	Bleomycin	126-135	Eco1p	Saccharomyces cerevisiae S288C	32-36
20649573-0	2010	A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.	Bleomycin	86-95	lysophosphatidic acid receptor 1	Mus musculus	23-29
19767450-3	2010	To evaluate whether endothelial cells could represent an additional source for fibroblasts, bleomycin-induced lung fibrosis was established in Tie2-Cre/CAG-CAT-LacZ double-transgenic mice, in which LacZ was stably expressed in pan-endothelial cells.	Bleomycin	92-101	TEK receptor tyrosine kinase	Mus musculus	143-147
20336479-0	2010	Deficiency in the divalent metal transporter 1 increases bleomycin-induced lung injury.	Bleomycin	57-66	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	Mus musculus	18-46
20336479-4	2010	We tested the postulate that metal import by DMT1 would participate in preventing lung injury after exposure to bleomycin.	Bleomycin	112-121	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	Mus musculus	45-49
20336479-10	2010	We conclude that DMT1 participates in the inflammatory lung injury after bleomycin with mk/mk mice having increased inflammation and damage following exposure.	Bleomycin	73-82	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	Mus musculus	17-21
20705596-0	2010	Protective effects of a bacterially expressed NIF-KGF fusion protein against bleomycin-induced acute lung injury in mice.	Bleomycin	77-86	fibroblast growth factor 7	Mus musculus	50-53
20819676-10	2010	CONCLUSIONS: These results reveal that gefitinib reduces pulmonary fibrosis induced by bleomycin in mice and suggest that administration of small molecule EGFR tyrosine kinase inhibitors has the potential to prevent pulmonary fibrosis by inhibiting the proliferation of mesenchymal cells, and that targeting tyrosine kinase receptors might be useful for the treatment of pulmonary fibrosis in humans.	Bleomycin	87-96	epidermal growth factor receptor	Mus musculus	155-159
20550546-0	2010	Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis.	Bleomycin	52-61	folate receptor 2 (fetal)	Mus musculus	28-48
20550546-4	2010	Immunostaining with anti-human or -mouse FRbeta monoclonal antibody (mAb) revealed that FRbeta-expressing macrophages were present predominantly in fibrotic areas of the lungs of patients with UIP and mice with bleomycin-induced PF.	Bleomycin	211-220	folate receptor beta	Homo sapiens	88-94
20550546-5	2010	Intranasal administration of a recombinant immunotoxin, consisting of immunoglobulin heavy and light chain Fv portions of an anti-mouse FRbeta mAb and truncated Pseudomonas exotoxin A, increased survival significantly and reduced levels of total hydroxyproline and fibrosis in bleomycin-induced PF.	Bleomycin	277-286	folate receptor 2 (fetal)	Mus musculus	136-142
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Bleomycin	89-98	regulator of G protein signaling 6	Homo sapiens	170-175
20396861-8	2010	Nox4 expression was also increased during bleomycin-induced fibroblast differentiation, and downregulation of Nox4 reduced alpha-SMA levels and extracellular matrix (ECM) accumulation.	Bleomycin	42-51	NADPH oxidase 4	Homo sapiens	0-4
20226872-1	2010	The PDE4 inhibitor roflumilast mitigates bleomycin-induced lung fibrotic remodeling in rodents.	Bleomycin	41-50	phosphodiesterase 4A	Homo sapiens	4-8
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Bleomycin	89-98	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-239
20510675-5	2010	AS605240 also inhibited augmented expression of TNF-alpha and IL-1beta induced by bleomycin instillation.	Bleomycin	82-91	tumor necrosis factor	Rattus norvegicus	48-57
20493858-0	2010	Extracellular superoxide dismutase attenuates release of pulmonary hyaluronan from the extracellular matrix following bleomycin exposure.	Bleomycin	118-127	superoxide dismutase 3, extracellular	Mus musculus	0-34
20493858-2	2010	It has been previously shown that EC-SOD knock-out mice are more susceptible to bleomycin-induced lung injury, however, the molecular mechanism(s) remains unclear.	Bleomycin	80-89	superoxide dismutase 3, extracellular	Mus musculus	34-40
20493858-3	2010	We report here that bleomycin-induced lung damage, in EC-SOD KO mice, is associated with increased hyaluronan release into alveolar fluid.	Bleomycin	20-29	superoxide dismutase 3, extracellular	Mus musculus	54-60
20493858-5	2010	Our results indicate that EC-SOD attenuates bleomycin-induced pulmonary injury, at least in part, by preventing superoxide-mediated release of hyaluronan into alveolar space.	Bleomycin	44-53	superoxide dismutase 3, extracellular	Mus musculus	26-32
22338413-11	2010	Using the Univariate regression analysis there was significant relationship between BPT and age, cumulative bleomycin dose and initial GFR at the beginning of treatment.	Bleomycin	108-117	Rap guanine nucleotide exchange factor 5	Homo sapiens	135-138
20417706-6	2010	Real-time PCR results confirmed that miR-146a was particularly strongly induced and its overexpression in cells led to slower proliferation as well as higher sensitivity to the DNA damaging agent, bleomycin.	Bleomycin	197-206	microRNA 146a	Homo sapiens	37-45
20498529-0	2010	Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis.	Bleomycin	68-77	chemokine (C-X-C motif) receptor 4	Mus musculus	21-45
21348427-0	2010	Toll like receptor 2 mediates bleomycin-induced acute lung injury, inflammation and fibrosis in mice.	Bleomycin	30-39	toll-like receptor 2	Mus musculus	0-20
20135637-0	2010	Influence of p53 expression on sensitivity of cancer cells to bleomycin.	Bleomycin	62-71	tumor protein p53	Homo sapiens	13-16
20135637-1	2010	In this study, we determined whether p53 expression affected the sensitivity of non-small cell lung cancer (NSCLC) and colon cancer cells to bleomycin (BLM).	Bleomycin	141-150	tumor protein p53	Homo sapiens	37-40
20135637-1	2010	In this study, we determined whether p53 expression affected the sensitivity of non-small cell lung cancer (NSCLC) and colon cancer cells to bleomycin (BLM).	Bleomycin	152-155	tumor protein p53	Homo sapiens	37-40
20510675-5	2010	AS605240 also inhibited augmented expression of TNF-alpha and IL-1beta induced by bleomycin instillation.	Bleomycin	82-91	interleukin 1 beta	Rattus norvegicus	62-70
20191584-0	2010	Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway.	Bleomycin	40-49	inducible T cell co-stimulator	Mus musculus	0-22
20348281-0	2010	Fibroblast-specific expression of AC6 enhances beta-adrenergic and prostacyclin signaling and blunts bleomycin-induced pulmonary fibrosis.	Bleomycin	101-110	adenylate cyclase 6	Mus musculus	34-37
20410070-1	2010	OBJECTIVES: Reduced caveolin-1 levels in lung fibroblasts from patients with scleroderma and the lungs of bleomycin-treated mice promote collagen overexpression and lung fibrosis.	Bleomycin	106-115	caveolin 1	Homo sapiens	20-30
20410070-2	2010	This study was undertaken to determine whether caveolin-1 is deficient in leucocytes from bleomycin-treated mice and patients with scleroderma and to examine the consequences of this deficiency and its reversal.	Bleomycin	90-99	caveolin 1, caveolae protein	Mus musculus	47-57
20410070-8	2010	In bleomycin-treated mice, caveolin-1 expression was diminished in monocytes and CSD peptide inhibited leucocyte recruitment into the lungs.	Bleomycin	3-12	caveolin 1, caveolae protein	Mus musculus	27-37
20484822-4	2010	We found that bleomycin treatment increased syndecan-4 expression.	Bleomycin	14-23	syndecan 4	Mus musculus	44-54
20484822-5	2010	Moreover, we observed a marked decrease in neutrophil recruitment and an increase in both myofibroblast recruitment and interstitial fibrosis in bleomycin-treated syndecan-4-null (Sdc4-/-) mice.	Bleomycin	145-154	syndecan 4	Mus musculus	163-173
20484822-5	2010	Moreover, we observed a marked decrease in neutrophil recruitment and an increase in both myofibroblast recruitment and interstitial fibrosis in bleomycin-treated syndecan-4-null (Sdc4-/-) mice.	Bleomycin	145-154	syndecan 4	Mus musculus	180-184
20501949-2	2010	We found that mice lacking plasminogen activation inhibitor-1 (PAI-1), which are protected from bleomycin-induced pulmonary fibrosis, exhibit lung overproduction of the antifibrotic lipid mediator prostaglandin E2 (PGE2).	Bleomycin	96-105	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	27-61
20501949-2	2010	We found that mice lacking plasminogen activation inhibitor-1 (PAI-1), which are protected from bleomycin-induced pulmonary fibrosis, exhibit lung overproduction of the antifibrotic lipid mediator prostaglandin E2 (PGE2).	Bleomycin	96-105	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	63-68
24278517-10	2010	Interestingly, the expression of triggering receptor expressed on myeloid cells 2 (Trem2) , secreted phosphoprotein 1 (Spp1) , and several proteases such as Tpsab1, Mcpt1, and Cma1 was considerably induced in the lung after bleomycin treatment, despite little evidence that they are involved in pulmonary fibrogenesis.	Bleomycin	224-233	triggering receptor expressed on myeloid cells 2	Rattus norvegicus	33-81
24278517-10	2010	Interestingly, the expression of triggering receptor expressed on myeloid cells 2 (Trem2) , secreted phosphoprotein 1 (Spp1) , and several proteases such as Tpsab1, Mcpt1, and Cma1 was considerably induced in the lung after bleomycin treatment, despite little evidence that they are involved in pulmonary fibrogenesis.	Bleomycin	224-233	triggering receptor expressed on myeloid cells 2	Rattus norvegicus	83-88
24278517-10	2010	Interestingly, the expression of triggering receptor expressed on myeloid cells 2 (Trem2) , secreted phosphoprotein 1 (Spp1) , and several proteases such as Tpsab1, Mcpt1, and Cma1 was considerably induced in the lung after bleomycin treatment, despite little evidence that they are involved in pulmonary fibrogenesis.	Bleomycin	224-233	secreted phosphoprotein 1	Rattus norvegicus	92-117
24278517-10	2010	Interestingly, the expression of triggering receptor expressed on myeloid cells 2 (Trem2) , secreted phosphoprotein 1 (Spp1) , and several proteases such as Tpsab1, Mcpt1, and Cma1 was considerably induced in the lung after bleomycin treatment, despite little evidence that they are involved in pulmonary fibrogenesis.	Bleomycin	224-233	secreted phosphoprotein 1	Rattus norvegicus	119-123
24278517-10	2010	Interestingly, the expression of triggering receptor expressed on myeloid cells 2 (Trem2) , secreted phosphoprotein 1 (Spp1) , and several proteases such as Tpsab1, Mcpt1, and Cma1 was considerably induced in the lung after bleomycin treatment, despite little evidence that they are involved in pulmonary fibrogenesis.	Bleomycin	224-233	tryptase alpha/beta 1	Rattus norvegicus	157-163
24278517-10	2010	Interestingly, the expression of triggering receptor expressed on myeloid cells 2 (Trem2) , secreted phosphoprotein 1 (Spp1) , and several proteases such as Tpsab1, Mcpt1, and Cma1 was considerably induced in the lung after bleomycin treatment, despite little evidence that they are involved in pulmonary fibrogenesis.	Bleomycin	224-233	mast cell protease 1	Rattus norvegicus	165-170
24278517-10	2010	Interestingly, the expression of triggering receptor expressed on myeloid cells 2 (Trem2) , secreted phosphoprotein 1 (Spp1) , and several proteases such as Tpsab1, Mcpt1, and Cma1 was considerably induced in the lung after bleomycin treatment, despite little evidence that they are involved in pulmonary fibrogenesis.	Bleomycin	224-233	chymase 1	Rattus norvegicus	176-180
20154224-8	2010	Real-time quantitative RT-PCR results demonstrated that, at 4-8 h, bleomycin induced expression of TNF and TNF receptor family genes known to induce the extrinsic apoptotic pathway.	Bleomycin	67-76	tumor necrosis factor	Homo sapiens	107-110
20576117-7	2010	Analysis of allergic airway inflammation and bleomycin-induced inflammation in CAT2-deficient mice revealed that while inflammation was independent of CAT2 expression, bleomycin-induced fibrosis was dependent upon CAT2.	Bleomycin	45-54	dominant cataract 2	Mus musculus	79-83
20167853-0	2010	The role of surfactant protein A in bleomycin-induced acute lung injury.	Bleomycin	36-45	surfactant associated protein A1	Mus musculus	12-32
20167853-3	2010	OBJECTIVES: Investigate the role of SP-A in the murine model of noninfectious lung injury induced by bleomycin treatment.	Bleomycin	101-110	surfactant associated protein A1	Mus musculus	36-40
20167853-5	2010	MEASUREMENTS AND MAIN RESULTS: On challenge with bleomycin, SP-A(-/-) mice had a decreased survival rate as compared with WT mice.	Bleomycin	49-58	surfactant associated protein A1	Mus musculus	60-64
20167853-8	2010	Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling and active caspase-3 staining suggested the increased apoptosis in the lung sections from SP-A(-/-) mice challenged with bleomycin.	Bleomycin	198-207	caspase 3	Mus musculus	88-97
20167853-8	2010	Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling and active caspase-3 staining suggested the increased apoptosis in the lung sections from SP-A(-/-) mice challenged with bleomycin.	Bleomycin	198-207	surfactant associated protein A1	Mus musculus	167-171
20167853-9	2010	SP-A also specifically reduced bleomycin-induced apoptosis in mouse lung epithelial 12 cells in vitro.	Bleomycin	31-40	surfactant associated protein A1	Mus musculus	0-4
20498020-3	2010	We demonstrate that after administration of a high dose of bleomycin that induces acute tissue damage and airway inflammation and is lethal to wild-type (WT) mice, Th17 cell-derived IL-22 and IL-17A are expressed in the lung.	Bleomycin	59-68	interleukin 22	Mus musculus	182-187
20498020-3	2010	We demonstrate that after administration of a high dose of bleomycin that induces acute tissue damage and airway inflammation and is lethal to wild-type (WT) mice, Th17 cell-derived IL-22 and IL-17A are expressed in the lung.	Bleomycin	59-68	interleukin 17A	Mus musculus	192-198
20498020-4	2010	Bleomycin-induced disease was ameliorated in Il22-/- mice or after anti-IL-22 monoclonal antibody (mAb) treatment of WT mice, indicating a proinflammatory/pathological role for IL-22 in airway inflammation.	Bleomycin	0-9	interleukin 22	Mus musculus	72-77
20498020-4	2010	Bleomycin-induced disease was ameliorated in Il22-/- mice or after anti-IL-22 monoclonal antibody (mAb) treatment of WT mice, indicating a proinflammatory/pathological role for IL-22 in airway inflammation.	Bleomycin	0-9	interleukin 22	Mus musculus	177-182
20498020-5	2010	However, despite increased bleomycin-induced IL-22 production, Il17a-/- mice were protected from airway inflammation, suggesting that IL-17A may regulate the expression and/or proinflammatory properties of IL-22.	Bleomycin	27-36	interleukin 22	Mus musculus	45-50
20498020-5	2010	However, despite increased bleomycin-induced IL-22 production, Il17a-/- mice were protected from airway inflammation, suggesting that IL-17A may regulate the expression and/or proinflammatory properties of IL-22.	Bleomycin	27-36	interleukin 17A	Mus musculus	134-140
20498020-7	2010	Anti-IL-22 mAb was delivered to Il17a-/- mice and was found to exacerbate bleomycin-induced airway inflammation, indicating that IL-22 is tissue protective in the absence of IL-17A.	Bleomycin	74-83	interleukin 22	Mus musculus	5-10
20498020-7	2010	Anti-IL-22 mAb was delivered to Il17a-/- mice and was found to exacerbate bleomycin-induced airway inflammation, indicating that IL-22 is tissue protective in the absence of IL-17A.	Bleomycin	74-83	interleukin 22	Mus musculus	129-134
20498020-8	2010	Finally, in an in vitro culture system, IL-22 administration protected airway epithelial cells from bleomycin-induced apoptosis, and this protection was reversed after coadministration of IL-17A.	Bleomycin	100-109	interleukin 22	Mus musculus	40-45
20498020-8	2010	Finally, in an in vitro culture system, IL-22 administration protected airway epithelial cells from bleomycin-induced apoptosis, and this protection was reversed after coadministration of IL-17A.	Bleomycin	100-109	interleukin 17A	Mus musculus	188-194
20418892-0	2010	Bleomycin induces upregulation of lysyl oxidase in cultured human fetal lung fibroblasts.	Bleomycin	0-9	lysyl oxidase	Homo sapiens	34-47
20418892-10	2010	CONCLUSION: Bleomycin induces upregulation of LO in cultured human fetal lung fibroblasts, which may be the mechanism of bleomycin-induced pulmonary fibrosis.	Bleomycin	12-21	lysyl oxidase	Homo sapiens	46-48
20418892-10	2010	CONCLUSION: Bleomycin induces upregulation of LO in cultured human fetal lung fibroblasts, which may be the mechanism of bleomycin-induced pulmonary fibrosis.	Bleomycin	121-130	lysyl oxidase	Homo sapiens	46-48
20154224-5	2010	Time course experiments revealed that bleomycin induced apoptosis within 4 h. Caspase-8, the initiator caspase for the extrinsic pathway, was activated within 2 h and preceded activation of the effector caspases-3 and -6 (4 h).	Bleomycin	38-47	caspase 8	Homo sapiens	78-87
20154224-5	2010	Time course experiments revealed that bleomycin induced apoptosis within 4 h. Caspase-8, the initiator caspase for the extrinsic pathway, was activated within 2 h and preceded activation of the effector caspases-3 and -6 (4 h).	Bleomycin	38-47	caspase 3	Homo sapiens	203-220
20154224-7	2010	Bleomycin induced the expression of Bcl-2 and Bcl-x(L), Bcl-2 family member proteins that protect cells from the mitochondria-dependent intrinsic apoptosis.	Bleomycin	0-9	BCL2 apoptosis regulator	Homo sapiens	36-41
20154224-7	2010	Bleomycin induced the expression of Bcl-2 and Bcl-x(L), Bcl-2 family member proteins that protect cells from the mitochondria-dependent intrinsic apoptosis.	Bleomycin	0-9	BCL2 like 1	Homo sapiens	46-54
20154224-7	2010	Bleomycin induced the expression of Bcl-2 and Bcl-x(L), Bcl-2 family member proteins that protect cells from the mitochondria-dependent intrinsic apoptosis.	Bleomycin	0-9	BCL2 apoptosis regulator	Homo sapiens	56-61
20154224-8	2010	Real-time quantitative RT-PCR results demonstrated that, at 4-8 h, bleomycin induced expression of TNF and TNF receptor family genes known to induce the extrinsic apoptotic pathway.	Bleomycin	67-76	tumor necrosis factor	Homo sapiens	99-102
20191584-10	2010	CONCLUSION: Our results indicate that ICOSL expression on antigen-presenting cells plays a previously unknown regulatory role during the development of bleomycin-induced tissue fibrosis that is independent of the ICOS/ICOSL pathway.	Bleomycin	152-161	icos ligand	Mus musculus	38-43
19711344-11	2010	Bleomycin-induced upregulation of BCL-XL/BCLXL1 and MDM2 suggests that it is the ratio of proapoptotic and antiapoptotic proteins that regulates the apoptosis response of HCC cells toward chemotherapy, thereby playing a decisive role between treatment sensitivity vs. drug resistance.	Bleomycin	0-9	MDM2 proto-oncogene	Homo sapiens	52-56
19711344-11	2010	Bleomycin-induced upregulation of BCL-XL/BCLXL1 and MDM2 suggests that it is the ratio of proapoptotic and antiapoptotic proteins that regulates the apoptosis response of HCC cells toward chemotherapy, thereby playing a decisive role between treatment sensitivity vs. drug resistance.	Bleomycin	0-9	BCL2 like 1	Homo sapiens	34-40
20191584-10	2010	CONCLUSION: Our results indicate that ICOSL expression on antigen-presenting cells plays a previously unknown regulatory role during the development of bleomycin-induced tissue fibrosis that is independent of the ICOS/ICOSL pathway.	Bleomycin	152-161	inducible T cell co-stimulator	Mus musculus	38-42
20201077-12	2010	Similar to human SSc, the expression of miR-29a was reduced in the bleomycin model of skin fibrosis.	Bleomycin	67-76	microRNA 29a	Homo sapiens	40-47
20201077-13	2010	Inhibition of PDGF-B and TGFbeta pathways by treatment with imatinib restored the levels of miR-29a in vitro and in the bleomycin model in vivo.	Bleomycin	120-129	platelet derived growth factor subunit B	Homo sapiens	14-20
20201077-13	2010	Inhibition of PDGF-B and TGFbeta pathways by treatment with imatinib restored the levels of miR-29a in vitro and in the bleomycin model in vivo.	Bleomycin	120-129	transforming growth factor beta 1	Homo sapiens	25-32
20101203-0	2010	Activation of PARP-1 in response to bleomycin depends on the Ku antigen and protein phosphatase 5.	Bleomycin	36-45	poly(ADP-ribose) polymerase 1	Homo sapiens	14-20
20684286-1	2010	OBJECTIVE: To study the effect of anti-basic jibroblast grouth factor (bFGF) on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism.	Bleomycin	80-89	fibroblast growth factor 2	Rattus norvegicus	71-75
20684286-10	2010	CONCLUSION: Anti-bFGF alleviates bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	33-42	fibroblast growth factor 2	Rattus norvegicus	17-21
20220086-8	2010	The adoptive transfer of NKT cells preincubated with anti-TIM1 mAbs into Jalpha18(-/-) mice aggravated bleomycin-induced pulmonary fibrosis by suppressing IFN-gamma production.	Bleomycin	103-112	thymoma insertional mutation	Mus musculus	58-62
20101203-0	2010	Activation of PARP-1 in response to bleomycin depends on the Ku antigen and protein phosphatase 5.	Bleomycin	36-45	protein phosphatase 5 catalytic subunit	Homo sapiens	76-97
20101203-3	2010	Here we used bleomycin, a radiomimetic that generates DSBs with high specificity to focus on the response of PARP-1 to DSBs.	Bleomycin	13-22	poly(ADP-ribose) polymerase 1	Homo sapiens	109-115
20101203-4	2010	We report that the induction of PARP-1 activity by bleomycin depends on the Ku antigen, a nonhomologous-DNA-End-Joining factor and protein phosphatase 5 (PP5).	Bleomycin	51-60	poly(ADP-ribose) polymerase 1	Homo sapiens	32-38
20101203-4	2010	We report that the induction of PARP-1 activity by bleomycin depends on the Ku antigen, a nonhomologous-DNA-End-Joining factor and protein phosphatase 5 (PP5).	Bleomycin	51-60	protein phosphatase 5 catalytic subunit	Homo sapiens	131-152
20101203-4	2010	We report that the induction of PARP-1 activity by bleomycin depends on the Ku antigen, a nonhomologous-DNA-End-Joining factor and protein phosphatase 5 (PP5).	Bleomycin	51-60	protein phosphatase 5 catalytic subunit	Homo sapiens	154-157
20101203-5	2010	PARP-1 activation in response to bleomycin was reduced over 10-fold in Ku-deficient cells, whereas its activation in response to U.V.	Bleomycin	33-42	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
20101203-8	2010	Similarly, PARP-1 activation subsequent to bleomycin was reduced 2-fold on ablation of PP5 and was increased 5-fold when PP5 was overexpressed.	Bleomycin	43-52	poly(ADP-ribose) polymerase 1	Homo sapiens	11-17
20101203-8	2010	Similarly, PARP-1 activation subsequent to bleomycin was reduced 2-fold on ablation of PP5 and was increased 5-fold when PP5 was overexpressed.	Bleomycin	43-52	protein phosphatase 5 catalytic subunit	Homo sapiens	87-90
20101203-8	2010	Similarly, PARP-1 activation subsequent to bleomycin was reduced 2-fold on ablation of PP5 and was increased 5-fold when PP5 was overexpressed.	Bleomycin	43-52	protein phosphatase 5 catalytic subunit	Homo sapiens	121-124
19520917-5	2010	Inhibition of this phosphorylation by PI3K inhibitors or by dominant-negative Akt (T308A/S473A) expression abrogated the effects of bleomycin on fibroblast proliferation and collagen production, suggesting the role of PI3K/Akt in the fibrogenic process.	Bleomycin	132-141	AKT serine/threonine kinase 1	Homo sapiens	78-81
19520917-0	2010	Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production.	Bleomycin	44-53	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	0-29
19520917-0	2010	Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production.	Bleomycin	44-53	AKT serine/threonine kinase 1	Homo sapiens	30-33
19520917-5	2010	Inhibition of this phosphorylation by PI3K inhibitors or by dominant-negative Akt (T308A/S473A) expression abrogated the effects of bleomycin on fibroblast proliferation and collagen production, suggesting the role of PI3K/Akt in the fibrogenic process.	Bleomycin	132-141	AKT serine/threonine kinase 1	Homo sapiens	223-226
19520917-6	2010	Activation of PI3K/Akt by bleomycin also led to transcriptional activation and protein expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor, which contributed to the fibroproliferative and collagen-inducing effects of bleomycin.	Bleomycin	26-35	AKT serine/threonine kinase 1	Homo sapiens	19-22
19520917-6	2010	Activation of PI3K/Akt by bleomycin also led to transcriptional activation and protein expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor, which contributed to the fibroproliferative and collagen-inducing effects of bleomycin.	Bleomycin	26-35	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-132
19520917-6	2010	Activation of PI3K/Akt by bleomycin also led to transcriptional activation and protein expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor, which contributed to the fibroproliferative and collagen-inducing effects of bleomycin.	Bleomycin	26-35	hypoxia inducible factor 1 subunit alpha	Homo sapiens	134-144
19520917-3	2010	Exposure of lung fibroblasts to bleomycin, a known inducer of fibrosis, resulted in rapid activation of PI3K/Akt and a parallel increase in fibroblast proliferation and collagen production, characteristics of lung fibrosis.	Bleomycin	32-41	AKT serine/threonine kinase 1	Homo sapiens	109-112
19520917-6	2010	Activation of PI3K/Akt by bleomycin also led to transcriptional activation and protein expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor, which contributed to the fibroproliferative and collagen-inducing effects of bleomycin.	Bleomycin	26-35	vascular endothelial growth factor A	Homo sapiens	150-184
19520917-6	2010	Activation of PI3K/Akt by bleomycin also led to transcriptional activation and protein expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor, which contributed to the fibroproliferative and collagen-inducing effects of bleomycin.	Bleomycin	263-272	AKT serine/threonine kinase 1	Homo sapiens	19-22
19520917-6	2010	Activation of PI3K/Akt by bleomycin also led to transcriptional activation and protein expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor, which contributed to the fibroproliferative and collagen-inducing effects of bleomycin.	Bleomycin	263-272	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-132
19520917-6	2010	Activation of PI3K/Akt by bleomycin also led to transcriptional activation and protein expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor, which contributed to the fibroproliferative and collagen-inducing effects of bleomycin.	Bleomycin	263-272	hypoxia inducible factor 1 subunit alpha	Homo sapiens	134-144
19520917-8	2010	Inhibition of ROS generation by antioxidant enzymes, catalase and superoxide dismutase mimetic MnTBAP, abrogated the fibrogenic effects of bleomycin as well as its induction of PI3K/Akt and HIF-1alpha activation.	Bleomycin	139-148	catalase	Homo sapiens	53-61
19520917-8	2010	Inhibition of ROS generation by antioxidant enzymes, catalase and superoxide dismutase mimetic MnTBAP, abrogated the fibrogenic effects of bleomycin as well as its induction of PI3K/Akt and HIF-1alpha activation.	Bleomycin	139-148	AKT serine/threonine kinase 1	Homo sapiens	182-185
19520917-8	2010	Inhibition of ROS generation by antioxidant enzymes, catalase and superoxide dismutase mimetic MnTBAP, abrogated the fibrogenic effects of bleomycin as well as its induction of PI3K/Akt and HIF-1alpha activation.	Bleomycin	139-148	hypoxia inducible factor 1 subunit alpha	Homo sapiens	190-200
20176803-0	2010	Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent.	Bleomycin	0-9	interleukin 17A	Mus musculus	54-60
20157051-8	2010	C21 also reduced monocyte chemoattractant protein 1 and tumor necrosis factor-alpha in vitro and in bleomycin-induced toxic cutaneous inflammation in vivo.	Bleomycin	100-109	TBL1X/Y related 1	Homo sapiens	0-3
19646463-6	2010	In the lung, lack of Nrf2 exacerbated toxicity caused by multiple oxidative insults including supplemental respiratory therapy (e.g., hyperoxia, mechanical ventilation), cigarette smoke, allergen, virus, bacterial endotoxin and other inflammatory agents (e.g., carrageenin), environmental pollution (e.g., particles), and a fibrotic agent bleomycin.	Bleomycin	339-348	NFE2 like bZIP transcription factor 2	Homo sapiens	21-25
19913099-1	2010	We previously reported that the endogenous cystathionine gamma-lyase (CSE)/hydrogen sulfide (H(2)S) pathway is implicated in the pathogenesis of bleomycin-induced pulmonary fibrosis in rats, but the exact cellular mechanisms are not well characterized.	Bleomycin	145-154	cystathionine gamma-lyase	Rattus norvegicus	43-68
19913099-1	2010	We previously reported that the endogenous cystathionine gamma-lyase (CSE)/hydrogen sulfide (H(2)S) pathway is implicated in the pathogenesis of bleomycin-induced pulmonary fibrosis in rats, but the exact cellular mechanisms are not well characterized.	Bleomycin	145-154	cystathionine gamma-lyase	Rattus norvegicus	70-73
20388759-2	2010	In fact, PAI-1 knockout mice are protected from bleomycin-induced pulmonary fibrosis.	Bleomycin	48-57	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	9-14
20388759-3	2010	This study was conducted to determine whether the intrapulmonary administration of small interfering RNA (siRNA) targeting PAI-1 (PAI-1-siRNA) limits the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	169-178	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	123-128
20388759-3	2010	This study was conducted to determine whether the intrapulmonary administration of small interfering RNA (siRNA) targeting PAI-1 (PAI-1-siRNA) limits the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	169-178	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	130-135
20388759-9	2010	The repeated administration of PAI-1-siRNA initiated during either the inflammatory or the fibrotic phase into bleomycin-injured mice reduced the PAI-1 level in BAL fluid and limited the accumulation of collagen in the lungs.	Bleomycin	111-120	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	31-36
20388759-9	2010	The repeated administration of PAI-1-siRNA initiated during either the inflammatory or the fibrotic phase into bleomycin-injured mice reduced the PAI-1 level in BAL fluid and limited the accumulation of collagen in the lungs.	Bleomycin	111-120	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	146-151
20302663-12	2010	CONCLUSIONS: Iloprost prevents bleomycin-induced pulmonary fibrosis, possibly by upregulating antifibrotic mediators (IFNgamma and CXCL10) and downregulating pro-inflammatory and pro-fibrotic cytokines (TNFalpha, IL-6, and TGFbeta1).	Bleomycin	31-40	interferon gamma	Mus musculus	118-126
20302663-12	2010	CONCLUSIONS: Iloprost prevents bleomycin-induced pulmonary fibrosis, possibly by upregulating antifibrotic mediators (IFNgamma and CXCL10) and downregulating pro-inflammatory and pro-fibrotic cytokines (TNFalpha, IL-6, and TGFbeta1).	Bleomycin	31-40	chemokine (C-X-C motif) ligand 10	Mus musculus	131-137
20302663-12	2010	CONCLUSIONS: Iloprost prevents bleomycin-induced pulmonary fibrosis, possibly by upregulating antifibrotic mediators (IFNgamma and CXCL10) and downregulating pro-inflammatory and pro-fibrotic cytokines (TNFalpha, IL-6, and TGFbeta1).	Bleomycin	31-40	tumor necrosis factor	Mus musculus	203-211
20302663-12	2010	CONCLUSIONS: Iloprost prevents bleomycin-induced pulmonary fibrosis, possibly by upregulating antifibrotic mediators (IFNgamma and CXCL10) and downregulating pro-inflammatory and pro-fibrotic cytokines (TNFalpha, IL-6, and TGFbeta1).	Bleomycin	31-40	interleukin 6	Mus musculus	213-217
20302663-12	2010	CONCLUSIONS: Iloprost prevents bleomycin-induced pulmonary fibrosis, possibly by upregulating antifibrotic mediators (IFNgamma and CXCL10) and downregulating pro-inflammatory and pro-fibrotic cytokines (TNFalpha, IL-6, and TGFbeta1).	Bleomycin	31-40	transforming growth factor, beta 1	Mus musculus	223-231
20333255-1	2010	BACKGROUND: The role of the receptor for advanced glycation end-products (RAGE) has been shown to differ in two different mouse models of asbestos and bleomycin induced pulmonary fibrosis.	Bleomycin	151-160	advanced glycosylation end product-specific receptor	Mus musculus	74-78
20300636-0	2010	Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages.	Bleomycin	50-59	amyloid P component, serum	Homo sapiens	0-15
20300636-4	2010	SAP therapeutically inhibits established bleomycin-induced pulmonary fibrosis, when administered systemically or locally to the lungs.	Bleomycin	41-50	amyloid P component, serum	Homo sapiens	0-3
20000738-8	2010	Treatment with the DSB-inducing agent bleomycin enhanced binding of these proteins to H2AX, suggesting an active role of H2AX in coordinating the functional pathways of each protein in DNA damage recognition and repair.	Bleomycin	38-47	H2A.X variant histone	Homo sapiens	86-90
19940127-3	2010	We report here the surprising and unexpected observation that cells expressing Delta105-125 PrP and related mutants are hypersensitive to the toxic effects of two classes of antibiotics (aminoglycosides and bleomycin analogues) that are commonly used for selection of stably transfected cell lines.	Bleomycin	207-216	prion protein	Mus musculus	92-95
20000738-8	2010	Treatment with the DSB-inducing agent bleomycin enhanced binding of these proteins to H2AX, suggesting an active role of H2AX in coordinating the functional pathways of each protein in DNA damage recognition and repair.	Bleomycin	38-47	H2A.X variant histone	Homo sapiens	121-125
19916059-0	2010	Connective tissue growth factor is induced in bleomycin-induced skin scleroderma.	Bleomycin	46-55	cellular communication network factor 2	Mus musculus	0-31
20034962-5	2010	In this study, we examined the effect of PC-SOD on bleomycin-induced pulmonary fibrosis.	Bleomycin	51-60	superoxide dismutase 1	Homo sapiens	41-47
20034962-7	2010	Intravenous administration of PC-SOD suppressed the bleomycin-induced increase in the number of leukocytes in bronchoalveolar lavage fluid.	Bleomycin	52-61	superoxide dismutase 1	Homo sapiens	30-36
20034962-8	2010	Bleomycin-induced collagen deposition and increased hydroxyproline levels in the lung were also suppressed in animals treated with PC-SOD, suggesting that PC-SOD suppresses bleomycin-induced pulmonary fibrosis.	Bleomycin	0-9	superoxide dismutase 1	Homo sapiens	131-137
20034962-8	2010	Bleomycin-induced collagen deposition and increased hydroxyproline levels in the lung were also suppressed in animals treated with PC-SOD, suggesting that PC-SOD suppresses bleomycin-induced pulmonary fibrosis.	Bleomycin	0-9	superoxide dismutase 1	Homo sapiens	155-161
20034962-8	2010	Bleomycin-induced collagen deposition and increased hydroxyproline levels in the lung were also suppressed in animals treated with PC-SOD, suggesting that PC-SOD suppresses bleomycin-induced pulmonary fibrosis.	Bleomycin	173-182	superoxide dismutase 1	Homo sapiens	131-137
20034962-8	2010	Bleomycin-induced collagen deposition and increased hydroxyproline levels in the lung were also suppressed in animals treated with PC-SOD, suggesting that PC-SOD suppresses bleomycin-induced pulmonary fibrosis.	Bleomycin	173-182	superoxide dismutase 1	Homo sapiens	155-161
20034962-10	2010	Intratracheal administration or inhalation of PC-SOD also attenuated the bleomycin-induced inflammatory response and fibrosis.	Bleomycin	73-82	superoxide dismutase 1	Homo sapiens	46-52
19914848-1	2010	We examined the effect of the anthracyclines aclarubicin, bleomycin, daunorubicin, doxorubicin and idarubicin on human gamma- and beta-globin promoter activity in an in vitro luciferase assay, ex vivo in erythroid cultures and in vivo in transgenic mice carrying the human gamma-globin gene.	Bleomycin	58-67	hemoglobin subunit gamma 1	Homo sapiens	119-141
19959748-2	2010	Because bleomycin (BLM) causes lung injury, which is characterized by an inflammatory response followed by a fibrotic degeneration, we postulated that blocking GSK-3 activity with a specific inhibitor could affect the inflammatory and profibrotic cytokine network generated in the BLM-induced process of pulmonary inflammation and fibrosis.	Bleomycin	8-17	glycogen synthase kinase 3 beta	Mus musculus	160-165
19959748-2	2010	Because bleomycin (BLM) causes lung injury, which is characterized by an inflammatory response followed by a fibrotic degeneration, we postulated that blocking GSK-3 activity with a specific inhibitor could affect the inflammatory and profibrotic cytokine network generated in the BLM-induced process of pulmonary inflammation and fibrosis.	Bleomycin	19-22	glycogen synthase kinase 3 beta	Mus musculus	160-165
19448157-0	2010	Imbalance in the pro-hepatocyte growth factor activation system in bleomycin-induced lung fibrosis in mice.	Bleomycin	67-76	hepatocyte growth factor	Mus musculus	21-45
19448157-14	2010	By demonstrating an imbalance between HGFA and HAI-1 expression in BAL fluid, our results highlight a defective thrombin-dependent proHGF activation system at the fibrotic phase of bleomycin-induced pulmonary fibrosis.	Bleomycin	181-190	coagulation factor II	Mus musculus	112-120
19916059-4	2010	In this report, we use an antibody recognizing CCN2 to assess the cell types in mouse dermis which express CCN2 in the bleomycin model of skin scleroderma.	Bleomycin	119-128	cellular communication network factor 2	Mus musculus	107-111
19916059-7	2010	However, upon exposure to bleomycin, CCN2 was observed in the dermis.	Bleomycin	26-35	cellular communication network factor 2	Mus musculus	37-41
19916059-11	2010	Moreover, CCN2-expressing pericytes significantly contribute to the appearance of myofibroblasts in bleomycin-induced skin scleroderma.	Bleomycin	100-109	cellular communication network factor 2	Mus musculus	10-14
20094730-0	2010	Localization of HSP47 mRNA in murine bleomycin-induced pulmonary fibrosis.	Bleomycin	37-46	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	16-21
19513812-6	2010	These results suggest that Lv-shCD36 can inhibit activation of L-TGF-beta1 secreted in bleomycin-treated NR8383 cells by decreasing the expression of CD36 on the cell membrane, thereby reducing binding of CD36 to TSP-1.	Bleomycin	87-96	transforming growth factor, beta 1	Rattus norvegicus	65-74
20094730-3	2010	The aim of the present study was to investigate the localization of HSP47 messenger ribonucleic acid (mRNA) in normal lung and in the lungs of mice in bleomycin-induced pulmonary fibrosis, using in situ hybridization.	Bleomycin	151-160	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	68-73
20094730-5	2010	The lung cells expressing HSP47 mRNA were identified in control (saline alone) and bleomycin-treated mice by in situ hybridization.	Bleomycin	83-92	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	26-31
20094730-6	2010	The signal for HSP47 mRNA was markedly increased in bleomycin-treated lungs compared with that of controls.	Bleomycin	52-61	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	15-20
20094730-8	2010	These results suggest that these cells may synthesize procollagen in the fibrotic process of bleomycin-treated lungs through upregulation of HSP47 mRNA and play an important role in fibrogenesis.	Bleomycin	93-102	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	141-146
20107320-4	2010	In particular CAPNS1 depletion affects gamma-H2AX appearance or persistence in U2OS osteosarcoma cells 24 hours after MMC addition or UV light exposure; in HT1080 upon camptothecin treatment for 4 hours and 48 hours after addition of MMC; in MDA-MB-231, 24 hours after UV light exposure and 2 hours after bleomycin addition.	Bleomycin	305-314	calpain small subunit 1	Homo sapiens	14-20
19395679-11	2010	In vivo, lung Nkx2.5 expression was significantly diminished in bleomycin-induced pulmonary fibrosis.	Bleomycin	64-73	NK2 homeobox 5	Homo sapiens	14-20
19909737-4	2010	Biochemical measurements revealed that bleomycin caused a significant decrease in lung superoxidae dismutase (SOD) activity, which was accompanied with a significant increase in malondialdehyde (MDA) levels and myeloperoxidase (MPO) activity on the 7th and 14th days.	Bleomycin	39-48	myeloperoxidase	Mus musculus	211-226
19909737-4	2010	Biochemical measurements revealed that bleomycin caused a significant decrease in lung superoxidae dismutase (SOD) activity, which was accompanied with a significant increase in malondialdehyde (MDA) levels and myeloperoxidase (MPO) activity on the 7th and 14th days.	Bleomycin	39-48	myeloperoxidase	Mus musculus	228-231
19909737-6	2010	Enzyme-linked immunosorbent assay and radio-immunity assay showed that treatment with neferine alleviated bleomycin-induced increase of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and endothelin-1 in plasma or in tissue.	Bleomycin	106-115	tumor necrosis factor	Mus musculus	171-204
19909737-6	2010	Enzyme-linked immunosorbent assay and radio-immunity assay showed that treatment with neferine alleviated bleomycin-induced increase of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and endothelin-1 in plasma or in tissue.	Bleomycin	106-115	interleukin 6	Mus musculus	206-224
19909737-6	2010	Enzyme-linked immunosorbent assay and radio-immunity assay showed that treatment with neferine alleviated bleomycin-induced increase of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and endothelin-1 in plasma or in tissue.	Bleomycin	106-115	endothelin 1	Mus musculus	229-241
19909737-7	2010	Additionally, neferine blocked bleomycin-induced increases of NF-kappaB in nuclear extracts and TGF-beta(1) in total protein extracts of murine RAW264.7 macrophages.	Bleomycin	31-40	transforming growth factor, beta 1	Mus musculus	96-107
20039704-3	2010	Biological replicate analyses of bleomycin-treated HeLa cells expressing either WT-PP5 or mutant inactive PP5 lead to the identification of six potential target proteins of PP5 action.	Bleomycin	33-42	protein phosphatase 5 catalytic subunit	Homo sapiens	83-86
20039704-3	2010	Biological replicate analyses of bleomycin-treated HeLa cells expressing either WT-PP5 or mutant inactive PP5 lead to the identification of six potential target proteins of PP5 action.	Bleomycin	33-42	protein phosphatase 5 catalytic subunit	Homo sapiens	106-109
20039704-3	2010	Biological replicate analyses of bleomycin-treated HeLa cells expressing either WT-PP5 or mutant inactive PP5 lead to the identification of six potential target proteins of PP5 action.	Bleomycin	33-42	protein phosphatase 5 catalytic subunit	Homo sapiens	106-109
20178555-6	2010	Combination chemotherapy with cisplatin, etoposide, and bleomycin or carboplatin was administered to the first patient, and shortly thereafter, the tumor size decreased by more than half; serum alpha-fetoprotein was normalized after four chemotherapy cycles.	Bleomycin	56-65	alpha fetoprotein	Homo sapiens	194-211
19915156-0	2010	Amphiregulin attenuates bleomycin-induced pneumopathy in mice.	Bleomycin	24-33	amphiregulin	Mus musculus	0-12
19915156-4	2010	The purpose of the present study was to investigate the role of amphiregulin in an experimental model of bleomycin-induced pneumopathy in mice.	Bleomycin	105-114	amphiregulin	Mus musculus	64-76
19915156-9	2010	Expression of intrinsic amphiregulin was increased in murine lung tissues after bleomycin instillation.	Bleomycin	80-89	amphiregulin	Mus musculus	24-36
19915156-12	2010	Amphiregulin may play a protective role in bleomycin-induced pneumopathy in mice, probably through the activation of survival signals.	Bleomycin	43-52	amphiregulin	Mus musculus	0-12
20090941-1	2010	BACKGROUND: We have previously explored a therapeutic strategy for specifically targeting the profibrotic activity of IL-13 during experimental pulmonary fibrosis using a fusion protein comprised of human IL-13 and a mutated form of Pseudomonas aeruginosa exotoxin A (IL13-PE) and observed that the intranasal delivery of IL13-PE reduced bleomycin-induced pulmonary fibrosis through its elimination of IL-13-responsive cells in the lung.	Bleomycin	338-347	interleukin 13	Homo sapiens	118-123
20008146-4	2010	We observed significantly higher levels of alpha2AP expression in the skin of bleomycin-injected systemic sclerosis model mice in comparison with the levels seen in control mice.	Bleomycin	78-87	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	43-51
20090941-8	2010	Surprisingly, histological analysis showed that a prior P. aeruginosa infection attenuated the development of bleomycin-induced pulmonary fibrosis, which was modestly further attenuated by the intranasal administration of IL13-PE.	Bleomycin	110-119	interleukin 13	Mus musculus	222-226
20356498-8	2010	5-FU (10 mg/L, 48 h) and bleomycin (100 mg/L, 48 h) also induced BIC RNA up-regulation (5.2 +/- 1.1 vs 1.7 +/- 0.7, 11.5 +/- 0.7 vs 1.7 +/- 0.7, both P < 0.05).	Bleomycin	25-34	MIR155 host gene	Homo sapiens	65-68
20008146-7	2010	Interestingly, alpha2AP also induced transforming growth factor-beta expression through the same pathways, and the inhibition of ERK1/2 and JNK slowed the progression of bleomycin-induced fibrosis.	Bleomycin	170-179	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	15-23
20008146-7	2010	Interestingly, alpha2AP also induced transforming growth factor-beta expression through the same pathways, and the inhibition of ERK1/2 and JNK slowed the progression of bleomycin-induced fibrosis.	Bleomycin	170-179	mitogen-activated protein kinase 3	Mus musculus	129-135
20008146-7	2010	Interestingly, alpha2AP also induced transforming growth factor-beta expression through the same pathways, and the inhibition of ERK1/2 and JNK slowed the progression of bleomycin-induced fibrosis.	Bleomycin	170-179	mitogen-activated protein kinase 8	Mus musculus	140-143
20008147-3	2010	After bleomycin-induced injury, inflammation, as indicated by the influx of neutrophils in bronchoalveolar lavage (BAL), peaked at 7 days post-injury in the wild-type mice and began to wane thereafter; however, in Timp3(-/-) mice, inflammation persisted up to 28 days.	Bleomycin	6-15	tissue inhibitor of metalloproteinase 3	Mus musculus	214-219
19956889-10	2010	Both bleomycin and cisplatin induced up-regulation of ICAM-1, tPA and PAI-1.	Bleomycin	5-14	intercellular adhesion molecule 1	Homo sapiens	54-60
20359365-2	2010	The purpose of this study was to examine whether inhibition of SPARC can regulate collagen expression in vitro and in vivo, and subsequently attenuate fibrotic stimulation by bleomycin in mouse skin and lungs.	Bleomycin	175-184	secreted acidic cysteine rich glycoprotein	Mus musculus	63-68
20359365-9	2010	Skin and lung fibrosis induced by bleomycin was markedly reduced by treatment with SPARC siRNA.	Bleomycin	34-43	secreted acidic cysteine rich glycoprotein	Mus musculus	83-88
21063112-5	2010	RESULTS: The development of bleomycin-induced inflammation and fibrosis in wildtype mice correlated with the rapid activation of ASM, and was markedly attenuated in the absence of ASM activity.	Bleomycin	28-37	sphingomyelin phosphodiesterase 1, acid lysosomal	Mus musculus	129-132
21063112-6	2010	Along with the elevated ASM activity, there also was an elevation of acid ceramidase (AC) activity, which was sustained for up to 14 days post-bleomycin treatment.	Bleomycin	143-152	sphingomyelin phosphodiesterase 1, acid lysosomal	Mus musculus	24-27
21063112-6	2010	Along with the elevated ASM activity, there also was an elevation of acid ceramidase (AC) activity, which was sustained for up to 14 days post-bleomycin treatment.	Bleomycin	143-152	N-acylsphingosine amidohydrolase 1	Mus musculus	69-84
21063112-6	2010	Along with the elevated ASM activity, there also was an elevation of acid ceramidase (AC) activity, which was sustained for up to 14 days post-bleomycin treatment.	Bleomycin	143-152	N-acylsphingosine amidohydrolase 1	Mus musculus	86-88
21063112-9	2010	CONCLUSIONS: These data demonstrate that the sphingomyelin/ceramide signaling pathway is involved in the pathogenesis of bleomycin-induced pulmonary fibrosis, and suggest that inhibition of ASM may potentially slow the fibrotic process in the lung.	Bleomycin	121-130	sphingomyelin phosphodiesterase 1, acid lysosomal	Mus musculus	190-193
19758314-0	2010	Tumor necrosis factor-alpha processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma.	Bleomycin	79-88	tumor necrosis factor	Mus musculus	0-27
19758314-0	2010	Tumor necrosis factor-alpha processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma.	Bleomycin	79-88	protein phosphatase 1, regulatory inhibitor subunit 1A	Mus musculus	39-50
21499441-6	2010	Both, NPM and NCL interact with p53 and hinder its phosphorylation at Serine 15 in response to bleomycin.	Bleomycin	95-104	nucleolin	Homo sapiens	14-17
21499441-6	2010	Both, NPM and NCL interact with p53 and hinder its phosphorylation at Serine 15 in response to bleomycin.	Bleomycin	95-104	tumor protein p53	Homo sapiens	32-35
21499441-8	2010	In addition, our data indicate that down regulation of NCL and to a lesser extent NPM increase the number of AT cells arrested in G2/M in response to bleomycin.	Bleomycin	150-159	nucleolin	Homo sapiens	55-58
19757088-0	2010	Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice.	Bleomycin	91-100	transforming growth factor, beta 1	Mus musculus	55-63
19757088-0	2010	Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice.	Bleomycin	91-100	mitogen-activated protein kinase 3	Mus musculus	72-78
21499441-9	2010	Together this data indicate that the lack of PP1 activation in AT cells result in increased NPM and NCL protein levels which prevents p53 phosphorylation in response to bleomycin and contributes to a defective G2/M checkpoint.	Bleomycin	169-178	inorganic pyrophosphatase 1	Homo sapiens	45-48
21499441-9	2010	Together this data indicate that the lack of PP1 activation in AT cells result in increased NPM and NCL protein levels which prevents p53 phosphorylation in response to bleomycin and contributes to a defective G2/M checkpoint.	Bleomycin	169-178	nucleolin	Homo sapiens	100-103
21499441-9	2010	Together this data indicate that the lack of PP1 activation in AT cells result in increased NPM and NCL protein levels which prevents p53 phosphorylation in response to bleomycin and contributes to a defective G2/M checkpoint.	Bleomycin	169-178	tumor protein p53	Homo sapiens	134-137
19956889-10	2010	Both bleomycin and cisplatin induced up-regulation of ICAM-1, tPA and PAI-1.	Bleomycin	5-14	plasminogen activator, tissue type	Homo sapiens	62-65
19956889-10	2010	Both bleomycin and cisplatin induced up-regulation of ICAM-1, tPA and PAI-1.	Bleomycin	5-14	serpin family E member 1	Homo sapiens	70-75
19893044-6	2009	Bleomycin-treated CD103(-/-) mice had persistent neutrophilic inflammation, increased fibrosis, and increased mortality compared with wild-type mice, a phenotype that was partially recapitulated in bleomycin/nFMLP-treated Mmp7(-/-) mice.	Bleomycin	0-9	integrin alpha E, epithelial-associated	Mus musculus	18-23
19894211-5	2010	An RRM-deficient mdt1-RRM0 allele shares the severe bleomycin hypersensitivity, inefficient recombinational telomere maintenance and slt2 synthetic sickness phenotypes, but not the cell wall toxin hypersensitivity with mdt1Delta.	Bleomycin	52-61	Pin4p	Saccharomyces cerevisiae S288C	17-21
19893044-6	2009	Bleomycin-treated CD103(-/-) mice had persistent neutrophilic inflammation, increased fibrosis, and increased mortality compared with wild-type mice, a phenotype that was partially recapitulated in bleomycin/nFMLP-treated Mmp7(-/-) mice.	Bleomycin	0-9	matrix metallopeptidase 7	Mus musculus	222-226
19265174-0	2009	Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice.	Bleomycin	56-65	interleukin 18	Homo sapiens	34-39
19893044-6	2009	Bleomycin-treated CD103(-/-) mice had persistent neutrophilic inflammation, increased fibrosis, and increased mortality compared with wild-type mice, a phenotype that was partially recapitulated in bleomycin/nFMLP-treated Mmp7(-/-) mice.	Bleomycin	198-207	integrin alpha E, epithelial-associated	Mus musculus	18-23
19265174-0	2009	Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice.	Bleomycin	56-65	interleukin 1 beta	Homo sapiens	44-52
19995276-3	2009	The authors hypothesized that synthetic neutrophil elastase inhibitor, sivelestat (ONO-5046), can inhibit the bleomycin-induced pulmonary fibrosis in rats by blocking the apoptotic pathways in epithelial cells.	Bleomycin	110-119	elastase, neutrophil expressed	Rattus norvegicus	40-59
19265174-3	2009	In the present study, we examined the role of the proinflammatory cytokines IL-18 and IL-1beta in the mechanism of bleomycin-induced lung injury.	Bleomycin	115-124	interleukin 18	Mus musculus	76-81
19265174-3	2009	In the present study, we examined the role of the proinflammatory cytokines IL-18 and IL-1beta in the mechanism of bleomycin-induced lung injury.	Bleomycin	115-124	interleukin 1 beta	Mus musculus	86-94
19265174-4	2009	We performed immunohistochemical analysis of IL-18 and IL-18 receptor (R) alpha chain expression in the lungs of five patients with bleomycin-induced lethal lung injury.	Bleomycin	132-141	interleukin 18	Mus musculus	55-60
19265174-5	2009	Enhanced expression of both IL-18 and IL-18Ralpha was observed in the lungs of all five patients with bleomycin-induced lung injury.	Bleomycin	102-111	interleukin 18	Homo sapiens	28-33
19265174-5	2009	Enhanced expression of both IL-18 and IL-18Ralpha was observed in the lungs of all five patients with bleomycin-induced lung injury.	Bleomycin	102-111	interleukin 18 receptor 1	Homo sapiens	38-49
19265174-7	2009	Intravenous administration of bleomycin induced the expression of IL-1beta and IL-18 in the serum and lungs of wild-type C57BL/6 mice.	Bleomycin	30-39	interleukin 1 beta	Mus musculus	66-74
19265174-7	2009	Intravenous administration of bleomycin induced the expression of IL-1beta and IL-18 in the serum and lungs of wild-type C57BL/6 mice.	Bleomycin	30-39	interleukin 18	Mus musculus	79-84
19265174-9	2009	Moreover, bleomycin-induced lung injury was significantly attenuated in caspase-1(-/-), IL-18(-/-), and IL-18Ralpha(-/-) mice in comparison with control mice.	Bleomycin	10-19	caspase 1	Mus musculus	72-81
19265174-9	2009	Moreover, bleomycin-induced lung injury was significantly attenuated in caspase-1(-/-), IL-18(-/-), and IL-18Ralpha(-/-) mice in comparison with control mice.	Bleomycin	10-19	interleukin 18	Mus musculus	88-93
19265174-9	2009	Moreover, bleomycin-induced lung injury was significantly attenuated in caspase-1(-/-), IL-18(-/-), and IL-18Ralpha(-/-) mice in comparison with control mice.	Bleomycin	10-19	interleukin 18 receptor 1	Mus musculus	104-115
19460787-7	2009	The results of this study indicated that the BLTR antagonist inhibited the development of bleomycin-induced pulmonary fibrosis in mice by decreasing inflammation and altering TGF-beta, IL-6, IL-13 and IFN-gamma.	Bleomycin	90-99	leukotriene B4 receptor 1	Mus musculus	45-49
19884654-4	2009	Initial analysis revealed that Mfge8-/- mice exhibited enhanced pulmonary fibrosis after bleomycin-induced lung injury.	Bleomycin	89-98	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	31-36
19995276-7	2009	In rats, sivelestat decreased neutrophil counts and the cytokine-induced neutrophil chemoattractant (CINC)-1 in the bronchoalveolar lavage (BAL) fluid of bleomycin-treated rats.	Bleomycin	154-163	C-X-C motif chemokine ligand 1	Rattus norvegicus	56-108
19995276-8	2009	Sivelestat also decreased the bleomycin-induced lung inflammatory cell apoptosis by decreasing caspase-3 and -9 activities.	Bleomycin	30-39	caspase 3	Rattus norvegicus	95-111
19995276-12	2009	In conclusion, bleomycin caused the lung inflammatory cell apoptosis through the caspase-9 and -3 pathways in rats.	Bleomycin	15-24	caspase 9	Rattus norvegicus	81-97
19556518-8	2009	In vivo, using cell fate reporter mice, approximately one-third of S100A4-positive fibroblasts were derived from lung epithelium 2 weeks after bleomycin administration.	Bleomycin	143-152	S100 calcium binding protein A4	Mus musculus	67-73
19966781-0	2009	Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta.	Bleomycin	55-64	prostaglandin F receptor	Mus musculus	0-32
19966781-4	2009	Given that the loss of cytosolic phospholipase A(2) (cPLA(2)) suppresses bleomycin-induced pulmonary fibrosis, we examined the roles of prostaglandins using mice lacking each prostoaglandin receptor.	Bleomycin	73-82	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	23-60
20193348-0	2009	[The effect of autologous bone marrow-derived cells mobilized by granulocyte colony stimulating factor on bleomycin-induced lung injury in mice.].	Bleomycin	106-115	colony stimulating factor 3 (granulocyte)	Mus musculus	65-102
20193348-13	2009	CONCLUSION: Mobilization of BMDC by G-CSF showed a protective effect on lung injury induced by bleomycin in mice, but did not have significant influence on survival time.	Bleomycin	95-104	colony stimulating factor 3 (granulocyte)	Mus musculus	36-41
19956603-0	2009	Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis.	Bleomycin	106-115	fibroblast growth factor 7	Homo sapiens	34-60
19679120-8	2009	Mutant plants were hypersensitive to DNA-damaging reagents including hydroxyurea, methylmethane sulfonate, and bleocin, demonstrating a role for ARP5 in DNA repair.	Bleomycin	111-118	actin-related protein 5	Arabidopsis thaliana	145-149
19202007-2	2009	Gelsolin (GSN), an actin-binding protein and a substrate of caspase-3, was recently shown to play a major role in bleomycin- or lipopolysaccharide-induced lung injury.	Bleomycin	114-123	gelsolin	Homo sapiens	0-8
19202007-2	2009	Gelsolin (GSN), an actin-binding protein and a substrate of caspase-3, was recently shown to play a major role in bleomycin- or lipopolysaccharide-induced lung injury.	Bleomycin	114-123	gelsolin	Homo sapiens	10-13
19633559-4	2009	In particular, nalp3 mediated inflammasome activation of caspase-1 and conversion of pro-IL-1 to IL-1 play a key role in silica-mediated and bleomycin-mediated pulmonary fibrosis.	Bleomycin	141-150	NLR family pyrin domain containing 3	Homo sapiens	15-20
19633559-4	2009	In particular, nalp3 mediated inflammasome activation of caspase-1 and conversion of pro-IL-1 to IL-1 play a key role in silica-mediated and bleomycin-mediated pulmonary fibrosis.	Bleomycin	141-150	caspase 1	Homo sapiens	57-66
19633559-4	2009	In particular, nalp3 mediated inflammasome activation of caspase-1 and conversion of pro-IL-1 to IL-1 play a key role in silica-mediated and bleomycin-mediated pulmonary fibrosis.	Bleomycin	141-150	interleukin 1 alpha	Homo sapiens	97-101
19883310-3	2009	The aim of this study was to confirm the prognostic impact of HGAL protein expression in an independent, well-characterized cohort of 232 patients with classic HL treated uniformly with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD).	Bleomycin	199-208	germinal center associated signaling and motility	Homo sapiens	62-66
19812063-6	2009	Inactivation of AtRPA70a by T-DNA insertion did not affect growth under normal conditions, but resulted in increased sensitivity to genotoxic agents such as methylmethane sulfonate, bleomycin and hydroxyurea.	Bleomycin	182-191	replication protein A 1A	Arabidopsis thaliana	16-24
19556518-11	2009	CONCLUSIONS: Both EMT and bone marrow progenitors contribute to S100A4-positive fibroblasts in bleomycin-induced lung fibrosis.	Bleomycin	95-104	S100 calcium binding protein A4	Mus musculus	64-70
19679873-6	2009	Using the model of bleomycin-induced scleroderma, we found that the early influx of inflammatory cells into the skin and lungs, and the subsequent development of fibrosis in these organs, were markedly attenuated in Egr-1 null mice.	Bleomycin	19-28	early growth response 1	Mus musculus	216-221
19527713-0	2009	Bleomycin-induced over-replication involves sustained inhibition of mitotic entry through the ATM/ATR pathway.	Bleomycin	0-9	ATM serine/threonine kinase	Homo sapiens	94-97
19527713-0	2009	Bleomycin-induced over-replication involves sustained inhibition of mitotic entry through the ATM/ATR pathway.	Bleomycin	0-9	ATR serine/threonine kinase	Homo sapiens	98-101
19527713-4	2009	During bleomycin-induced over-replication, mitotic entry is inhibited through tyrosine phosphorylation of CDK1 along the ATM/ATR pathway in the early phase of treatment.	Bleomycin	7-16	cyclin dependent kinase 1	Homo sapiens	106-110
19527713-4	2009	During bleomycin-induced over-replication, mitotic entry is inhibited through tyrosine phosphorylation of CDK1 along the ATM/ATR pathway in the early phase of treatment.	Bleomycin	7-16	ATM serine/threonine kinase	Homo sapiens	121-124
19527713-4	2009	During bleomycin-induced over-replication, mitotic entry is inhibited through tyrosine phosphorylation of CDK1 along the ATM/ATR pathway in the early phase of treatment.	Bleomycin	7-16	ATR serine/threonine kinase	Homo sapiens	125-128
19527713-5	2009	Bleomycin-induced over-replication is inhibited by the inhibitors of the ATM/ATR pathway through abrogation of bleomycin-induced G2 arrest, and the ATM/ATR inhibitors promote cell death instead of over-replication.	Bleomycin	0-9	ATM serine/threonine kinase	Homo sapiens	73-76
19527713-5	2009	Bleomycin-induced over-replication is inhibited by the inhibitors of the ATM/ATR pathway through abrogation of bleomycin-induced G2 arrest, and the ATM/ATR inhibitors promote cell death instead of over-replication.	Bleomycin	0-9	ATR serine/threonine kinase	Homo sapiens	77-80
19527713-5	2009	Bleomycin-induced over-replication is inhibited by the inhibitors of the ATM/ATR pathway through abrogation of bleomycin-induced G2 arrest, and the ATM/ATR inhibitors promote cell death instead of over-replication.	Bleomycin	0-9	ATM serine/threonine kinase	Homo sapiens	148-151
19527713-5	2009	Bleomycin-induced over-replication is inhibited by the inhibitors of the ATM/ATR pathway through abrogation of bleomycin-induced G2 arrest, and the ATM/ATR inhibitors promote cell death instead of over-replication.	Bleomycin	0-9	ATR serine/threonine kinase	Homo sapiens	152-155
19527713-5	2009	Bleomycin-induced over-replication is inhibited by the inhibitors of the ATM/ATR pathway through abrogation of bleomycin-induced G2 arrest, and the ATM/ATR inhibitors promote cell death instead of over-replication.	Bleomycin	111-120	ATM serine/threonine kinase	Homo sapiens	73-76
19527713-5	2009	Bleomycin-induced over-replication is inhibited by the inhibitors of the ATM/ATR pathway through abrogation of bleomycin-induced G2 arrest, and the ATM/ATR inhibitors promote cell death instead of over-replication.	Bleomycin	111-120	ATR serine/threonine kinase	Homo sapiens	77-80
19527713-7	2009	Time-lapse imaging of clone cells that express a live cell marker of endogenous cyclin B1 revealed that cyclin B1 is degraded in G2-arrested cells upon bleomycin treatment.	Bleomycin	152-161	cyclin B1	Homo sapiens	80-89
19527713-7	2009	Time-lapse imaging of clone cells that express a live cell marker of endogenous cyclin B1 revealed that cyclin B1 is degraded in G2-arrested cells upon bleomycin treatment.	Bleomycin	152-161	cyclin B1	Homo sapiens	104-113
19498056-0	2009	Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	102-111	fibroblast growth factor 10	Mus musculus	18-45
19498056-2	2009	OBJECTIVES: To test for the protective and regenerative effect of Fgf10 overexpression in a bleomycin-induced mouse model of pulmonary inflammation and fibrosis.	Bleomycin	92-101	fibroblast growth factor 10	Mus musculus	66-71
19498056-4	2009	Exogenous Fgf10 expression in the alveolar epithelium was induced for 7 days with doxycycline during the first, second, and third weeks after bleomycin pump implantation, and lungs were examined at 28 days.	Bleomycin	142-151	fibroblast growth factor 10	Mus musculus	10-15
20079242-0	2009	[Effect of aerosolized STAT1 antisense oligonucleotides on the expressions of cytokines and collagens in lung tissue of pulmonary fibrosis rats induced by bleomycin].	Bleomycin	155-164	signal transducer and activator of transcription 1	Rattus norvegicus	23-28
20079242-1	2009	OBJECTIVE: To investigate the effects of aerosolized signal transducer and activator of transcription 1 (STAT1) antisense oligonucleotides (ASON) on the expressions of TGF-beta(1), PAI-1, collagen Type I and III and hydroxyproline in lung tissue of pulmonary fibrosis induced by bleomycin (BLM) in rats.	Bleomycin	279-288	signal transducer and activator of transcription 1	Rattus norvegicus	105-110
19498056-3	2009	METHODS: In SP-C-rtTA; tet(O)Fgf10 double-transgenic mice, lung fibrosis was induced in 2-month-old transgenic mice by subcutaneous delivery of bleomycin (BLM), using an osmotic minipump for 1 week.	Bleomycin	144-153	fibroblast growth factor 10	Mus musculus	29-34
19652365-6	2009	Moreover, we demonstrated a causal link between FXa and fibrosis development by showing that a direct FXa inhibitor attenuated bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	127-136	coagulation factor X	Homo sapiens	48-51
19714649-0	2009	Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis.	Bleomycin	117-126	peroxisome proliferator activated receptor gamma	Mus musculus	8-56
19714649-8	2009	Deletion of PPARgamma resulted in enhanced susceptibility to bleomycin-induced skin fibrosis, as indicated by increases in all measures of skin fibrosis and enhanced sensitivity of fibroblasts to TGFbeta1 in PPAR-deficient mice.	Bleomycin	61-70	peroxisome proliferator activated receptor gamma	Mus musculus	12-21
19714649-8	2009	Deletion of PPARgamma resulted in enhanced susceptibility to bleomycin-induced skin fibrosis, as indicated by increases in all measures of skin fibrosis and enhanced sensitivity of fibroblasts to TGFbeta1 in PPAR-deficient mice.	Bleomycin	61-70	transforming growth factor, beta 1	Mus musculus	196-204
19714649-8	2009	Deletion of PPARgamma resulted in enhanced susceptibility to bleomycin-induced skin fibrosis, as indicated by increases in all measures of skin fibrosis and enhanced sensitivity of fibroblasts to TGFbeta1 in PPAR-deficient mice.	Bleomycin	61-70	peroxisome proliferator activated receptor alpha	Mus musculus	12-16
19498056-9	2009	CONCLUSIONS: In the bleomycin model of lung inflammation and fibrosis, Fgf10 overexpression during both the inflammatory and fibrotic phases results in a greatly reduced extent of lung fibrosis, suggesting that FGF10 may be useful as a novel approach to the treatment of pulmonary fibrosis.	Bleomycin	20-29	fibroblast growth factor 10	Mus musculus	71-76
19498056-9	2009	CONCLUSIONS: In the bleomycin model of lung inflammation and fibrosis, Fgf10 overexpression during both the inflammatory and fibrotic phases results in a greatly reduced extent of lung fibrosis, suggesting that FGF10 may be useful as a novel approach to the treatment of pulmonary fibrosis.	Bleomycin	20-29	fibroblast growth factor 10	Mus musculus	211-216
19652365-6	2009	Moreover, we demonstrated a causal link between FXa and fibrosis development by showing that a direct FXa inhibitor attenuated bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	127-136	coagulation factor X	Homo sapiens	102-105
19767828-3	2009	We identified OPT2 from a high-throughput screen that when deleted results in mutants that displayed sensitivity to the anticancer agent bleomycin.	Bleomycin	137-146	Opt2p	Saccharomyces cerevisiae S288C	14-18
19433312-7	2009	Finally, in the mouse model of bleomycin-induced pulmonary fibrosis, treatment with the mTOR inhibitor rapamycin resulted in reduced numbers of CXCR4-expressing fibrocytes in the peripheral blood and lung as well as reduced lung collagen deposition.	Bleomycin	31-40	mechanistic target of rapamycin kinase	Mus musculus	88-92
19689301-4	2009	Thus, in initial studies, IL-13 signaling via IL-13Ralpha2 was shown to play an important role in the fibrosis developing in both oxazolone colitis and bleomycin-induced pulmonary fibrosis; later, it was also shown to be critical to the development of fibrosis in a model of chronic colitis induced by trinitrobenzene sulphonic acid (TNBS).	Bleomycin	152-161	interleukin 13	Homo sapiens	26-31
19689301-4	2009	Thus, in initial studies, IL-13 signaling via IL-13Ralpha2 was shown to play an important role in the fibrosis developing in both oxazolone colitis and bleomycin-induced pulmonary fibrosis; later, it was also shown to be critical to the development of fibrosis in a model of chronic colitis induced by trinitrobenzene sulphonic acid (TNBS).	Bleomycin	152-161	interleukin 13 receptor subunit alpha 2	Homo sapiens	46-58
19433312-7	2009	Finally, in the mouse model of bleomycin-induced pulmonary fibrosis, treatment with the mTOR inhibitor rapamycin resulted in reduced numbers of CXCR4-expressing fibrocytes in the peripheral blood and lung as well as reduced lung collagen deposition.	Bleomycin	31-40	chemokine (C-X-C motif) receptor 4	Mus musculus	144-149
19630521-8	2009	Polq(-/-) cells were moderately more sensitive to bleomycin than Polq(+/+) cells and were not hypersensitive to paraquat or hydrogen peroxide.	Bleomycin	50-59	polymerase (DNA directed), theta	Mus musculus	0-4
19549112-3	2009	Administration of a low dose of bleomycin (BLM) by sonoporation with the anti-EGFR antibody produced a marked growth inhibition of Ca9-22 cells in vitro.	Bleomycin	32-41	epidermal growth factor receptor	Homo sapiens	78-82
19549112-3	2009	Administration of a low dose of bleomycin (BLM) by sonoporation with the anti-EGFR antibody produced a marked growth inhibition of Ca9-22 cells in vitro.	Bleomycin	43-46	epidermal growth factor receptor	Homo sapiens	78-82
19630521-12	2009	The sensitivity of POLQ-defective bone marrow stromal cells to ionizing radiation and bleomycin and the increase in micronuclei in red blood cells support a role for this DNA polymerase in cellular tolerance of DNA damage that can lead to double-strand DNA breaks.	Bleomycin	86-95	polymerase (DNA directed), theta	Mus musculus	19-23
19565505-3	2009	This study was undertaken to investigate the role of CTGF in enhanced expression of type I collagen in bleomycin-induced lung fibrosis, and to delineate the mechanisms of action underlying the effects of CTGF on Col1a2 (collagen gene type I alpha2) in this mouse model and in human pulmonary fibroblasts.	Bleomycin	103-112	cellular communication network factor 2	Mus musculus	53-57
19565505-6	2009	RESULTS: In the mouse lung tissue, CTGF expression and promoter activity peaked 1 week after bleomycin challenge, whereas type I collagen expression and Col1a2 promoter activity peaked 2 weeks postchallenge.	Bleomycin	93-102	cellular communication network factor 2	Mus musculus	35-39
19218193-3	2009	OBJECTIVES: To determine if lung injury depends on the NALP3 inflammasome and if bleomycin (BLM)-induced lung injury triggers local production of uric acid, thereby activating the NALP3 inflammasome in the lung.	Bleomycin	92-95	NLR family, pyrin domain containing 3	Mus musculus	180-185
19565505-7	2009	Fibroblasts isolated from the mouse lungs 14 days after bleomycin treatment retained a profibrotic expression pattern, characterized by greatly elevated levels of type I collagen and CTGF protein and increased promoter activity.	Bleomycin	56-65	cellular communication network factor 2	Mus musculus	183-187
19565505-9	2009	Moreover, in vivo, anti-CTGF antibodies applied after bleomycin challenge significantly reduced the Col1a2 promoter activity by approximately 25%.	Bleomycin	54-63	cellular communication network factor 2	Mus musculus	24-28
19565505-9	2009	Moreover, in vivo, anti-CTGF antibodies applied after bleomycin challenge significantly reduced the Col1a2 promoter activity by approximately 25%.	Bleomycin	54-63	collagen, type I, alpha 2	Mus musculus	100-106
19565505-10	2009	The enhanced Col1a2 promoter activity in fibroblasts from bleomycin-treated lungs was partly dependent on Smad signaling, whereas CTGF acted on the Col1a2 promoter by a mechanism that was independent of the Smad binding site, but was, instead, dependent on the ERK-1/2 and JNK MAPK pathways.	Bleomycin	58-67	collagen, type I, alpha 2	Mus musculus	13-19
19429264-0	2009	Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta.	Bleomycin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	119-149
18988920-3	2009	Hepatocyte growth factor (HGF) inhibits progression of bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	55-64	hepatocyte growth factor	Mus musculus	0-24
18988920-3	2009	Hepatocyte growth factor (HGF) inhibits progression of bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	55-64	hepatocyte growth factor	Mus musculus	26-29
19196821-0	2009	Interleukin-1 receptor-related protein ST2 suppresses the initial stage of bleomycin-induced lung injury.	Bleomycin	75-84	interleukin 1 receptor-like 1	Mus musculus	39-42
19196821-6	2009	In bleomycin-treated ST2-overexpressing mice, the increase of neutrophils in the bronchoalveolar lavage fluid (BALF) was markedly suppressed.	Bleomycin	3-12	interleukin 1 receptor-like 1	Mus musculus	21-24
19138753-0	2009	Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling.	Bleomycin	92-101	NFE2 like bZIP transcription factor 2	Rattus norvegicus	150-154
19138753-0	2009	Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling.	Bleomycin	92-101	Kelch-like ECH-associated protein 1	Rattus norvegicus	155-160
19138753-2	2009	The levels of reactive-oxygen species (ROS), lipid peroxidation (LPO), hydroxyproline and the activity of myeloperoxidase (MPO) were increased due to bleomycin challenge and were brought back to near normal status on EGCG supplementation.	Bleomycin	150-159	myeloperoxidase	Rattus norvegicus	106-121
19138753-2	2009	The levels of reactive-oxygen species (ROS), lipid peroxidation (LPO), hydroxyproline and the activity of myeloperoxidase (MPO) were increased due to bleomycin challenge and were brought back to near normal status on EGCG supplementation.	Bleomycin	150-159	myeloperoxidase	Rattus norvegicus	123-126
19138753-7	2009	The declined activities of Phase II enzymes such as glutathione-S-transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1) in bleomycin-injured rats were restored upon EGCG treatment.	Bleomycin	131-140	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	88-120
19138753-7	2009	The declined activities of Phase II enzymes such as glutathione-S-transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1) in bleomycin-injured rats were restored upon EGCG treatment.	Bleomycin	131-140	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	122-126
19138753-11	2009	This study demonstrates the involvement of Nrf2-Keap1 signaling through which EGCG enhances antioxidant activities and Phase II enzymes with subsequent restraint inflammation during bleomycin-induced pulmonary fibrosis.	Bleomycin	182-191	NFE2 like bZIP transcription factor 2	Rattus norvegicus	43-47
19138753-11	2009	This study demonstrates the involvement of Nrf2-Keap1 signaling through which EGCG enhances antioxidant activities and Phase II enzymes with subsequent restraint inflammation during bleomycin-induced pulmonary fibrosis.	Bleomycin	182-191	Kelch-like ECH-associated protein 1	Rattus norvegicus	48-53
19767876-3	2009	The results on day 7 showed that plasma H2S concentration and pulmonary CSE activity (H2S production rate) were significantly lower in rats treated with bleomycin and saline (fibrosis-alone) than in controls, whereas on day 28 plasma H2S concentration was higher and pulmonary CSE activity was the same as that of controls.	Bleomycin	153-162	cystathionine gamma-lyase	Rattus norvegicus	72-75
19767876-3	2009	The results on day 7 showed that plasma H2S concentration and pulmonary CSE activity (H2S production rate) were significantly lower in rats treated with bleomycin and saline (fibrosis-alone) than in controls, whereas on day 28 plasma H2S concentration was higher and pulmonary CSE activity was the same as that of controls.	Bleomycin	153-162	cystathionine gamma-lyase	Rattus norvegicus	277-280
19767876-4	2009	The relative CSE mRNA level in the lungs of rats treated with bleomycin was significantly higher than control values on days 7 and 28.	Bleomycin	62-71	cystathionine gamma-lyase	Rattus norvegicus	13-16
19359440-6	2009	Bleomycin-induced fibrosis was significantly higher in SAMP mice compared with SAMR controls.	Bleomycin	0-9	X-prolyl aminopeptidase (aminopeptidase P) 1, soluble	Mus musculus	55-59
19406902-1	2009	Strain D7 of Saccharomyces cerevisiae was used to measure the induction by bleomycin (BLM) of mitotic recombination at the trp5 locus and point mutations at ilv1 in the presence and absence of acridine compounds.	Bleomycin	75-84	tryptophan synthase TRP5	Saccharomyces cerevisiae S288C	123-127
19118846-8	2009	The BAL fluid concentrations of interleukin-1beta, interleukin-6, RANTES, and high mobility group box 1 were significantly increased by pneumonectomy and enhanced by the additional administration of bleomycin.	Bleomycin	199-208	interleukin 1 beta	Mus musculus	32-49
19118846-8	2009	The BAL fluid concentrations of interleukin-1beta, interleukin-6, RANTES, and high mobility group box 1 were significantly increased by pneumonectomy and enhanced by the additional administration of bleomycin.	Bleomycin	199-208	interleukin 6	Mus musculus	51-64
19118846-8	2009	The BAL fluid concentrations of interleukin-1beta, interleukin-6, RANTES, and high mobility group box 1 were significantly increased by pneumonectomy and enhanced by the additional administration of bleomycin.	Bleomycin	199-208	chemokine (C-C motif) ligand 5	Mus musculus	66-72
19118846-8	2009	The BAL fluid concentrations of interleukin-1beta, interleukin-6, RANTES, and high mobility group box 1 were significantly increased by pneumonectomy and enhanced by the additional administration of bleomycin.	Bleomycin	199-208	high mobility group box 1	Mus musculus	78-103
19213772-4	2009	The results were validated in the bleomycin-induced animal model of pulmonary inflammation and fibrosis using genetically-modified mice lacking gelsolin expression.	Bleomycin	34-43	gelsolin	Mus musculus	144-152
19218193-3	2009	OBJECTIVES: To determine if lung injury depends on the NALP3 inflammasome and if bleomycin (BLM)-induced lung injury triggers local production of uric acid, thereby activating the NALP3 inflammasome in the lung.	Bleomycin	81-90	NLR family, pyrin domain containing 3	Mus musculus	180-185
19454822-8	2009	With respect to the concentrations of the insulin receptor, GLUT2, PKC and PKA in the pancreatic islets of the bleomycin group, there was an increase in GLUT2 (48.4%) and PKC (70.8%) and a reduction in PKA (38.5%).	Bleomycin	111-120	insulin receptor	Rattus norvegicus	42-58
19234103-0	2009	Prominin-1/CD133+ lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis.	Bleomycin	59-68	prominin 1	Mus musculus	0-10
19454822-8	2009	With respect to the concentrations of the insulin receptor, GLUT2, PKC and PKA in the pancreatic islets of the bleomycin group, there was an increase in GLUT2 (48.4%) and PKC (70.8%) and a reduction in PKA (38.5%).	Bleomycin	111-120	solute carrier family 2 member 2	Rattus norvegicus	60-65
19454822-8	2009	With respect to the concentrations of the insulin receptor, GLUT2, PKC and PKA in the pancreatic islets of the bleomycin group, there was an increase in GLUT2 (48.4%) and PKC (70.8%) and a reduction in PKA (38.5%).	Bleomycin	111-120	protein kinase C, gamma	Rattus norvegicus	67-70
19454822-8	2009	With respect to the concentrations of the insulin receptor, GLUT2, PKC and PKA in the pancreatic islets of the bleomycin group, there was an increase in GLUT2 (48.4%) and PKC (70.8%) and a reduction in PKA (38.5%).	Bleomycin	111-120	solute carrier family 2 member 2	Rattus norvegicus	153-158
19454822-8	2009	With respect to the concentrations of the insulin receptor, GLUT2, PKC and PKA in the pancreatic islets of the bleomycin group, there was an increase in GLUT2 (48.4%) and PKC (70.8%) and a reduction in PKA (38.5%).	Bleomycin	111-120	protein kinase C, gamma	Rattus norvegicus	171-174
19234103-0	2009	Prominin-1/CD133+ lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis.	Bleomycin	59-68	prominin 1	Mus musculus	11-16
19204734-0	2009	Injection of bleomycin in newborn mice induces autoimmune sialitis that is transferred by CD4 T cells.	Bleomycin	13-22	CD4 antigen	Mus musculus	90-93
19068238-11	2009	The tissue specific expression of CHK2 and its ability to respond to bleomycin treatment suggests that some checkpoint proteins may serve as suitable biomarkers for DNA damage in rainbow trout and other fish species.	Bleomycin	69-78	serine/threonine-protein kinase Chk2	Oncorhynchus mykiss	34-38
19428379-0	2009	Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells.	Bleomycin	135-144	RAD51 recombinase	Homo sapiens	79-84
19442053-0	2009	Bleomycin and its role in inducing apoptosis and senescence in lung cells - modulating effects of caveolin-1.	Bleomycin	0-9	caveolin 1	Homo sapiens	98-108
19442053-7	2009	We summarize recent data about the effects of bleomycin in terms of lung cell biology and emphasize that bleomycin-induced injury of lung cells is accompanied by altered expression levels of caveolin-1.	Bleomycin	46-55	caveolin 1	Homo sapiens	191-201
19442053-7	2009	We summarize recent data about the effects of bleomycin in terms of lung cell biology and emphasize that bleomycin-induced injury of lung cells is accompanied by altered expression levels of caveolin-1.	Bleomycin	105-114	caveolin 1	Homo sapiens	191-201
19442053-8	2009	Caveolin-1 is involved in bleomycin-induced apoptosis and senescence of normal and lung cancer cells.	Bleomycin	26-35	caveolin 1	Homo sapiens	0-10
19101991-5	2009	Agents such as bleomycin, As(2)O(3) and H(2)O(2), which produce reactive oxygen species (ROS), also induced CatS expression; however, other agents that damage DNA such as taxol and cisplatin did not.	Bleomycin	15-24	cathepsin S	Felis catus	108-112
19426591-1	2009	AIM: To investigate the effect of aerosolized signal transducer and activator of transcription 1 (STAT1) antisense oligodeoxynucleotides (ASON) on the expression of inflammatory mediators in bronchoalveolar lavage fluid (BALF) and typeI and typeIII collagen mRNA of the bleomycin-induced rat pulmonary fibrosis.	Bleomycin	270-279	signal transducer and activator of transcription 1	Rattus norvegicus	98-103
19147812-6	2009	Finally, we show that the expression levels of both the LPA2 receptor and alphavbeta6 integrin are up-regulated and are spatially and temporally associated following bleomycin-induced lung injury.	Bleomycin	166-175	lysophosphatidic acid receptor 2	Homo sapiens	56-60
18836136-8	2009	Finally, we demonstrated that mice lacking JNK1 were protected against TGF-beta1 and bleomycin-induced pro-fibrotic gene expression and pulmonary fibrosis.	Bleomycin	85-94	mitogen-activated protein kinase 8	Mus musculus	43-47
19333940-7	2009	RESULTS: CB2(-/-) mice were more sensitive to bleomycin-induced dermal fibrosis than were CB2(+/+) mice, and showed increased dermal thickness.	Bleomycin	46-55	cannabinoid receptor 2 (macrophage)	Mus musculus	9-12
19333940-11	2009	The phenotype of CB2(-/-) mice was mimicked by transplantation of CB2(-/-) bone marrow into CB2(+/+) mice, whereas CB2(-/-) mice transplanted with bone marrow from CB2(+/+) mice did not display an increased sensitivity to bleomycin-induced fibrosis, indicating that leukocyte expression of CB2 critically influences experimental fibrosis.	Bleomycin	222-231	cannabinoid receptor 2 (macrophage)	Mus musculus	17-20
19232499-6	2009	Our current study demonstrates that IL-16, and its activator caspase 3, are highly expressed at the mRNA level in the lungs of mice prior to the deposition of collagen following intratracheal bleomycin administration.	Bleomycin	192-201	interleukin 16	Mus musculus	36-41
19232499-6	2009	Our current study demonstrates that IL-16, and its activator caspase 3, are highly expressed at the mRNA level in the lungs of mice prior to the deposition of collagen following intratracheal bleomycin administration.	Bleomycin	192-201	caspase 3	Mus musculus	61-70
18836137-0	2009	Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis.	Bleomycin	40-49	C-X-C motif chemokine receptor 2	Homo sapiens	31-36
18836137-3	2009	We hypothesized that CXCR2-mediated neutrophil recruitment is essential for the cascade of events leading to bleomycin-induced pulmonary fibrosis.	Bleomycin	109-118	C-X-C motif chemokine receptor 2	Homo sapiens	21-26
18836137-4	2009	CXCL1/KC was detected as early as 6 hours after bleomycin instillation and returned to basal levels after Day 8.	Bleomycin	48-57	C-X-C motif chemokine ligand 1	Homo sapiens	0-5
18836137-10	2009	DF2162 treatment reduced bleomycin-induced expression of von Willebrand Factor, a marker of angiogenesis, in the lung.	Bleomycin	25-34	von Willebrand factor	Homo sapiens	57-78
18836137-12	2009	In conclusion, we show that CXCR2 plays an important role in mediating fibrosis after bleomycin instillation.	Bleomycin	86-95	C-X-C motif chemokine receptor 2	Homo sapiens	28-33
19151753-7	2009	Lesional skin fibroblasts in mice with bleomycin-induced fibrosis of skin displayed evidence of c-Abl activation in situ, and elevated phospho-c-Abl correlated with increased local expression of Egr-1.	Bleomycin	39-48	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	96-101
19397440-6	2009	Rad51 foci appeared in bleomycin-treated cells after prolonged exposure to the drug when the cells were arrested in the G2 phase of the cell cycle.	Bleomycin	23-32	RAD51 recombinase	Homo sapiens	0-5
19595124-0	2009	[Therapeutic effects of aerosolized signal transducer and activator of transcription 1 antisense oligonucleotide administered at different time points on bleomycin-induced pulmonary fibrosis: experiment with rats].	Bleomycin	154-163	signal transducer and activator of transcription 1	Rattus norvegicus	36-86
19222034-2	2009	By probing an array of 2000 natural products, containing 50 bleomycin (BLM) derivatives, with cell lysates that overexpress RFP-fused Shble protein, we successfully observed interactions between Shble protein and BLMs on the array.	Bleomycin	60-69	tripartite motif containing 27	Homo sapiens	124-127
19151753-7	2009	Lesional skin fibroblasts in mice with bleomycin-induced fibrosis of skin displayed evidence of c-Abl activation in situ, and elevated phospho-c-Abl correlated with increased local expression of Egr-1.	Bleomycin	39-48	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	143-148
19151753-7	2009	Lesional skin fibroblasts in mice with bleomycin-induced fibrosis of skin displayed evidence of c-Abl activation in situ, and elevated phospho-c-Abl correlated with increased local expression of Egr-1.	Bleomycin	39-48	early growth response 1	Mus musculus	195-200
19074376-2	2009	In their free-living state, S. meliloti and B. abortus mutants lacking BacA have reductions in their outer membrane lipid A very-long-chain fatty acid (VLCFA) contents and exhibit low-level resistance to the glycopeptide bleomycin in comparison to their respective parent strains.	Bleomycin	221-230	putative udecaprenol kinase BacA	Escherichia coli	71-75
19060230-2	2009	PAR(1) knockout mice are protected from bleomycin-induced lung inflammation and fibrosis and this protection is associated with marked attenuation in CCL2 induction.	Bleomycin	40-49	coagulation factor II (thrombin) receptor	Mus musculus	0-6
19060230-4	2009	METHODS: Using immunohistochemistry and dual immunofluorescence, we examined PAR(1) and CCL2 expression in the bleomycin model and human IPF lung.	Bleomycin	111-120	coagulation factor II thrombin receptor	Homo sapiens	77-83
18703794-8	2009	In addition, A2aR-null mice are more susceptible to bleomycin-induced lung injury, consistent with a role for endogenous adenosine in inhibiting the inflammation that may lead to fibrosis.	Bleomycin	52-61	adenosine A2a receptor	Mus musculus	13-17
18703794-9	2009	Indeed, the bleomycin treated A2aR-null mice demonstrate increased lung inflammation, HA accumulation, and histologic damage.	Bleomycin	12-21	adenosine A2a receptor	Mus musculus	30-34
19179605-0	2009	Aortic carboxypeptidase-like protein is expressed in fibrotic human lung and its absence protects against bleomycin-induced lung fibrosis.	Bleomycin	106-115	AE binding protein 1	Homo sapiens	0-36
19179605-4	2009	In this study, we demonstrate that aortic carboxypeptidase-like protein (ACLP), a collagen-associated protein with a discoidin-like domain, is expressed at high levels in human fibrotic lung tissue and human fibroblasts, and that its expression increases markedly in the lungs of bleomycin-injured mice.	Bleomycin	280-289	AE binding protein 1	Homo sapiens	35-71
19179605-4	2009	In this study, we demonstrate that aortic carboxypeptidase-like protein (ACLP), a collagen-associated protein with a discoidin-like domain, is expressed at high levels in human fibrotic lung tissue and human fibroblasts, and that its expression increases markedly in the lungs of bleomycin-injured mice.	Bleomycin	280-289	AE binding protein 1	Homo sapiens	73-77
19179605-5	2009	Importantly, ACLP-deficient mice accumulated significantly fewer myofibroblasts and less collagen in the lung after bleomycin injury, as compared with wild-type controls, despite equivalent levels of bleomycin-induced inflammation.	Bleomycin	116-125	AE binding protein 1	Mus musculus	13-17
19179605-5	2009	Importantly, ACLP-deficient mice accumulated significantly fewer myofibroblasts and less collagen in the lung after bleomycin injury, as compared with wild-type controls, despite equivalent levels of bleomycin-induced inflammation.	Bleomycin	200-209	AE binding protein 1	Mus musculus	13-17
19250543-3	2009	The aim of our study was to investigate the role of ING4 in the pathogenesis of pulmonary fibrosis both in the bleomycin (BLM)-model and in two different types of human pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and cryptogenic organizing pneumonia (COP).	Bleomycin	111-120	inhibitor of growth family member 4	Homo sapiens	52-56
19576016-1	2009	OBJECTIVE: To investigate the role of COX-2 inhibitor celecoxib in enhancing the lethal effects of bleomycin in Tca8113 cell line.	Bleomycin	99-108	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	38-43
19259351-0	2009	Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis.	Bleomycin	45-54	matrix metallopeptidase 2	Rattus norvegicus	26-31
19259351-0	2009	Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis.	Bleomycin	45-54	matrix metallopeptidase 9	Rattus norvegicus	36-41
19259351-3	2009	MATERIALS AND METHODS: The level of MMPs in BAL fluid of 54 bleomycin-treated rats was assessed by zymography from 1 to 28 days after intratracheal bleomycin instillation.	Bleomycin	60-69	matrix metallopeptidase 2	Rattus norvegicus	36-40
19259351-3	2009	MATERIALS AND METHODS: The level of MMPs in BAL fluid of 54 bleomycin-treated rats was assessed by zymography from 1 to 28 days after intratracheal bleomycin instillation.	Bleomycin	148-157	matrix metallopeptidase 2	Rattus norvegicus	36-40
19259351-5	2009	RESULTS: MMP-2 and MMP-9 were markedly increased in both the BAL fluid and in the lung parenchyma of the bleomycin-treated rats, especially in the early phase with the peak on the 4th day.	Bleomycin	105-114	matrix metallopeptidase 2	Rattus norvegicus	9-14
19259351-5	2009	RESULTS: MMP-2 and MMP-9 were markedly increased in both the BAL fluid and in the lung parenchyma of the bleomycin-treated rats, especially in the early phase with the peak on the 4th day.	Bleomycin	105-114	matrix metallopeptidase 9	Rattus norvegicus	19-24
19259351-9	2009	CONCLUSION: In bleomycin-induced pulmonary fibrosis, MMP-2 and MMP-9 may play important roles, especially in the early phase.	Bleomycin	15-24	matrix metallopeptidase 2	Rattus norvegicus	53-58
19259351-9	2009	CONCLUSION: In bleomycin-induced pulmonary fibrosis, MMP-2 and MMP-9 may play important roles, especially in the early phase.	Bleomycin	15-24	matrix metallopeptidase 9	Rattus norvegicus	63-68
19250543-3	2009	The aim of our study was to investigate the role of ING4 in the pathogenesis of pulmonary fibrosis both in the bleomycin (BLM)-model and in two different types of human pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and cryptogenic organizing pneumonia (COP).	Bleomycin	122-125	inhibitor of growth family member 4	Homo sapiens	52-56
19073610-13	2009	Syndecan-1 is also significantly elevated in the lavage fluid of EC-SOD-null mice after asbestos and bleomycin exposure.	Bleomycin	101-110	syndecan 1	Mus musculus	0-10
19073610-13	2009	Syndecan-1 is also significantly elevated in the lavage fluid of EC-SOD-null mice after asbestos and bleomycin exposure.	Bleomycin	101-110	superoxide dismutase 3, extracellular	Mus musculus	65-71
19180474-0	2009	alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma?	Bleomycin	48-57	pro-opiomelanocortin-alpha	Mus musculus	0-36
18676775-1	2009	We have previously demonstrated that myofibroblasts from lungs with bleomycin-induced fibrosis overexpress FasL molecules.	Bleomycin	68-77	Fas ligand	Homo sapiens	107-111
19180474-10	2009	In addition, alpha-MSH suppressed BLM-induced oxidative stress and enhanced the expression of superoxide dismutase 2 (SOD2) and heme oxygenase 1 (HO-1).	Bleomycin	34-37	pro-opiomelanocortin-alpha	Mus musculus	13-22
19254480-1	2009	Previous study showed that aerosolized signal transducer and activator of transcription-1 (STAT1) antisense oligodeoxynucleotide (ASON) inhibited the expression of STAT1 and ICAM-1 mRNA and protein in alveolar macrophages (AMs) and decreased the concentrations of TGF-beta, PDGF and TNF-alpha in bronchioalveolar lavage fluid (BALF) in bleomycin (BLM)-induced rat pulmonary fibrosis.	Bleomycin	336-345	signal transducer and activator of transcription 1	Rattus norvegicus	39-89
19154443-11	2009	The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts.	Bleomycin	30-39	tumor necrosis factor	Rattus norvegicus	88-96
19154443-11	2009	The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts.	Bleomycin	30-39	transforming growth factor, beta 1	Rattus norvegicus	127-134
19154443-11	2009	The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts.	Bleomycin	30-39	endothelin 1	Rattus norvegicus	189-201
19154443-11	2009	The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts.	Bleomycin	30-39	solute carrier family 13 member 2	Rattus norvegicus	210-215
19154443-11	2009	The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts.	Bleomycin	30-39	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	217-223
19154443-11	2009	The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts.	Bleomycin	30-39	tumor necrosis factor	Rattus norvegicus	285-293
19154443-11	2009	The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts.	Bleomycin	30-39	interleukin 13	Rattus norvegicus	295-309
19154443-11	2009	The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts.	Bleomycin	30-39	transforming growth factor, beta 1	Rattus norvegicus	311-318
19154443-11	2009	The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts.	Bleomycin	30-39	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	320-326
19254480-1	2009	Previous study showed that aerosolized signal transducer and activator of transcription-1 (STAT1) antisense oligodeoxynucleotide (ASON) inhibited the expression of STAT1 and ICAM-1 mRNA and protein in alveolar macrophages (AMs) and decreased the concentrations of TGF-beta, PDGF and TNF-alpha in bronchioalveolar lavage fluid (BALF) in bleomycin (BLM)-induced rat pulmonary fibrosis.	Bleomycin	336-345	signal transducer and activator of transcription 1	Rattus norvegicus	91-96
18785980-12	2009	Bleomycin challenge provoked severe pulmonary fibrosis, with marked increases in fibrosis fraction, hydroxyproline content and myeloperoxidase activity in lung tissue.	Bleomycin	0-9	myeloperoxidase	Mus musculus	127-142
19254480-1	2009	Previous study showed that aerosolized signal transducer and activator of transcription-1 (STAT1) antisense oligodeoxynucleotide (ASON) inhibited the expression of STAT1 and ICAM-1 mRNA and protein in alveolar macrophages (AMs) and decreased the concentrations of TGF-beta, PDGF and TNF-alpha in bronchioalveolar lavage fluid (BALF) in bleomycin (BLM)-induced rat pulmonary fibrosis.	Bleomycin	336-345	signal transducer and activator of transcription 1	Rattus norvegicus	164-169
19254480-1	2009	Previous study showed that aerosolized signal transducer and activator of transcription-1 (STAT1) antisense oligodeoxynucleotide (ASON) inhibited the expression of STAT1 and ICAM-1 mRNA and protein in alveolar macrophages (AMs) and decreased the concentrations of TGF-beta, PDGF and TNF-alpha in bronchioalveolar lavage fluid (BALF) in bleomycin (BLM)-induced rat pulmonary fibrosis.	Bleomycin	336-345	intercellular adhesion molecule 1	Rattus norvegicus	174-180
18579356-0	2009	A TSP-1 synthetic peptide inhibits bleomycin-induced lung fibrosis in mice.	Bleomycin	35-44	tumor suppressor region 1	Mus musculus	2-7
19225928-9	2009	The patient was treated postoperatively with three cycles of chemotherapy consisting of bleomycin, etoposide, and cisplatin; with this regimen, serum AFP decreased to 16 ng/ml from 12 600 ng/ml just before the initiation of chemotherapy.	Bleomycin	88-97	alpha fetoprotein	Homo sapiens	150-153
18722097-0	2009	A TSP-1 functional fragment inhibits activation of latent transforming growth factor-beta1 derived from rat alveolar macrophage after bleomycin treatment.	Bleomycin	134-143	thrombospondin 1	Rattus norvegicus	2-7
18722097-0	2009	A TSP-1 functional fragment inhibits activation of latent transforming growth factor-beta1 derived from rat alveolar macrophage after bleomycin treatment.	Bleomycin	134-143	transforming growth factor, beta 1	Rattus norvegicus	58-90
18722097-2	2009	Active transforming growth factor-beta1 (TGF-beta1) plays a key role in lung fibrosis induced by bleomycin, TSP-1 (thrombospondin-1) being critical to the activation of L (latent)-TGF-beta1 by virtue of an association of the TSP-1/L-TGF-beta1 complex with CD36, involving the sequence CSVTCG of the TSP-1 functional fragment.	Bleomycin	97-106	transforming growth factor, beta 1	Rattus norvegicus	7-39
19056849-0	2009	Latent transforming growth factor-beta-binding protein-4 regulates transforming growth factor-beta1 bioavailability for activation by fibrogenic lung fibroblasts in response to bleomycin.	Bleomycin	177-186	latent transforming growth factor beta binding protein 4	Mus musculus	0-56
19056849-0	2009	Latent transforming growth factor-beta-binding protein-4 regulates transforming growth factor-beta1 bioavailability for activation by fibrogenic lung fibroblasts in response to bleomycin.	Bleomycin	177-186	transforming growth factor, beta 1	Mus musculus	67-99
19056849-2	2009	We have previously shown that a subset of rat lung fibroblasts with fibrogenic characteristics [Thy-1 (-) fibroblasts] responds to stimuli (bleomycin, interleukin-4, etc) with increased latent transforming growth factor (TGF)-beta activation, whereas non-fibrogenic Thy-1-expressing [Thy-1 (+)] fibroblasts do not.	Bleomycin	140-149	Thy-1 cell surface antigen	Rattus norvegicus	96-101
19056849-5	2009	Treatment of fibroblasts with bleomycin up-regulated LTBP-4 mRNA, protein, and soluble LTBP-4-bound large latent TGF-beta1 complexes in Thy-1 (-) fibroblasts to significantly higher levels than in Thy-1 (+) fibroblasts.	Bleomycin	30-39	latent transforming growth factor beta binding protein 4	Mus musculus	53-59
19056849-5	2009	Treatment of fibroblasts with bleomycin up-regulated LTBP-4 mRNA, protein, and soluble LTBP-4-bound large latent TGF-beta1 complexes in Thy-1 (-) fibroblasts to significantly higher levels than in Thy-1 (+) fibroblasts.	Bleomycin	30-39	latent transforming growth factor beta binding protein 4	Mus musculus	87-93
19056849-5	2009	Treatment of fibroblasts with bleomycin up-regulated LTBP-4 mRNA, protein, and soluble LTBP-4-bound large latent TGF-beta1 complexes in Thy-1 (-) fibroblasts to significantly higher levels than in Thy-1 (+) fibroblasts.	Bleomycin	30-39	transforming growth factor, beta 1	Mus musculus	113-122
19056849-5	2009	Treatment of fibroblasts with bleomycin up-regulated LTBP-4 mRNA, protein, and soluble LTBP-4-bound large latent TGF-beta1 complexes in Thy-1 (-) fibroblasts to significantly higher levels than in Thy-1 (+) fibroblasts.	Bleomycin	30-39	thymus cell antigen 1, theta	Mus musculus	136-141
19056849-5	2009	Treatment of fibroblasts with bleomycin up-regulated LTBP-4 mRNA, protein, and soluble LTBP-4-bound large latent TGF-beta1 complexes in Thy-1 (-) fibroblasts to significantly higher levels than in Thy-1 (+) fibroblasts.	Bleomycin	30-39	thymus cell antigen 1, theta	Mus musculus	197-202
19056849-6	2009	Bleomycin-induced TGF-beta1 activation required LTBP-4, since lung fibroblasts deficient in LTBP-4 did not activate TGF-beta1.	Bleomycin	0-9	transforming growth factor, beta 1	Mus musculus	18-27
19056849-6	2009	Bleomycin-induced TGF-beta1 activation required LTBP-4, since lung fibroblasts deficient in LTBP-4 did not activate TGF-beta1.	Bleomycin	0-9	latent transforming growth factor beta binding protein 4	Mus musculus	48-54
19056849-6	2009	Bleomycin-induced TGF-beta1 activation required LTBP-4, since lung fibroblasts deficient in LTBP-4 did not activate TGF-beta1.	Bleomycin	0-9	latent transforming growth factor beta binding protein 4	Mus musculus	92-98
19056849-7	2009	Expression of LTBP-4 restored TGF-beta1 activation in response to bleomycin, but expression either of LTBP-4 lacking the TGF-beta-binding site or only the TGF-beta-binding domain did not.	Bleomycin	66-75	latent transforming growth factor beta binding protein 4	Mus musculus	14-20
19056849-7	2009	Expression of LTBP-4 restored TGF-beta1 activation in response to bleomycin, but expression either of LTBP-4 lacking the TGF-beta-binding site or only the TGF-beta-binding domain did not.	Bleomycin	66-75	transforming growth factor, beta 1	Mus musculus	30-39
19056849-8	2009	Bleomycin treatment of mice increased LTBP-4 expression in the lung.	Bleomycin	0-9	latent transforming growth factor beta binding protein 4	Mus musculus	38-44
19056849-10	2009	Together, these data identify a critical role for LTBP-4 in the regulation of latent TGF-beta1 activation in bleomycin-induced lung fibrosis.	Bleomycin	109-118	latent transforming growth factor beta binding protein 4	Mus musculus	50-56
19056849-10	2009	Together, these data identify a critical role for LTBP-4 in the regulation of latent TGF-beta1 activation in bleomycin-induced lung fibrosis.	Bleomycin	109-118	transforming growth factor, beta 1	Mus musculus	85-94
18722097-2	2009	Active transforming growth factor-beta1 (TGF-beta1) plays a key role in lung fibrosis induced by bleomycin, TSP-1 (thrombospondin-1) being critical to the activation of L (latent)-TGF-beta1 by virtue of an association of the TSP-1/L-TGF-beta1 complex with CD36, involving the sequence CSVTCG of the TSP-1 functional fragment.	Bleomycin	97-106	thrombospondin 1	Rattus norvegicus	108-113
18579356-2	2009	Activated alveolar macrophages released increased amounts of transforming growth factor-beta1(TGF-beta1) in response to bleomycin-induced lung injury.	Bleomycin	120-129	transforming growth factor, beta 1	Mus musculus	94-103
18579356-8	2009	TSP-1 synthetic peptide reduced the tissue fibrotic pathologies and collagen accumulation in the model, resulting in the decreased severity of bleomycin-induced lung injury.	Bleomycin	143-152	tumor suppressor region 1	Mus musculus	0-5
18976720-0	2009	VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	37-46	kinase insert domain protein receptor	Mus musculus	0-7
18976720-7	2009	Early administration of SU5416 inhibited pulmonary collagen deposition, histopathologic fibroplasias and the activation of TGF-beta1/Smad3 signaling pathway in bleomycin-stimulated lung.	Bleomycin	160-169	transforming growth factor, beta 1	Mus musculus	123-132
18976720-3	2009	The aim of the present study was to assess whether disruption of VEGF pathway would attenuate bleomycin-induced pulmonary fibrosis.	Bleomycin	94-103	vascular endothelial growth factor A	Mus musculus	65-69
18976720-7	2009	Early administration of SU5416 inhibited pulmonary collagen deposition, histopathologic fibroplasias and the activation of TGF-beta1/Smad3 signaling pathway in bleomycin-stimulated lung.	Bleomycin	160-169	SMAD family member 3	Mus musculus	133-138
18976720-4	2009	METHODS: Bleomycin-induced pulmonary fibrosis mice were treated intraperitoneally with VEGF receptor tyrosine kinase inhibitor SU5416 at different phases after bleomycin infusion.	Bleomycin	9-18	vascular endothelial growth factor A	Mus musculus	87-91
19817697-10	2009	CONCLUSION: The Wnt/beta-catenin pathway is activated in bleomycin-induced lung fibrosis, and downstream genes were localized in AM, alveolar epithelium, and interstitium.	Bleomycin	57-66	catenin (cadherin associated protein), beta 1	Mus musculus	20-32
19104148-6	2009	Signaling through beta-catenin has been implicated in EMT; we found that in primary AECs, alpha3 integrin was required for beta-catenin phosphorylation at tyrosine residue 654 (Y654), formation of the pY654-beta-catenin/pSmad2 complex, and initiation of EMT, both in vitro and in vivo during the fibrotic phase following bleomycin injury.	Bleomycin	321-330	catenin (cadherin associated protein), beta 1	Mus musculus	18-30
18580965-0	2008	Increased severity of bleomycin-induced skin fibrosis in mice with leukocyte-specific protein 1 deficiency.	Bleomycin	22-31	lymphocyte specific 1	Mus musculus	67-95
19109203-4	2009	In this study, we report that bleomycin (BLM), a well-known fibrogenic agent functioning as a TLR2 agonist, induced the maturation of dendritic cells and release of cytokines.	Bleomycin	30-39	toll like receptor 2	Homo sapiens	94-98
19109203-4	2009	In this study, we report that bleomycin (BLM), a well-known fibrogenic agent functioning as a TLR2 agonist, induced the maturation of dendritic cells and release of cytokines.	Bleomycin	41-44	toll like receptor 2	Homo sapiens	94-98
18580965-7	2008	The skin in Lsp1(-/-) mice injected with bleomycin had higher densities of neutrophils, macrophages, and fibrocytes.	Bleomycin	41-50	lymphocyte specific 1	Mus musculus	12-16
18776186-5	2008	Interestingly, GAPDH-small interfering RNA knockdown sensitized the cells to methyl methane sulfonate and bleomycin, which generate lesions that are repaired by APE1, but showed normal sensitivity to 254-nm UV.	Bleomycin	106-115	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	15-20
19630211-0	2008	The role of strain variation in BAX and BCL-2 expression in murine bleomycin-induced pulmonary fibrosis.	Bleomycin	67-76	B cell leukemia/lymphoma 2	Mus musculus	40-45
19630211-1	2008	This study hypothesized that the expression of apoptosis-regulatory genes, such as BCL-2 and BAX may be affected by genetic variation in bleomycin-induced pulmonary fibrosis in C57BL/6 and NMRI mice.	Bleomycin	137-146	B cell leukemia/lymphoma 2	Mus musculus	83-88
19630211-1	2008	This study hypothesized that the expression of apoptosis-regulatory genes, such as BCL-2 and BAX may be affected by genetic variation in bleomycin-induced pulmonary fibrosis in C57BL/6 and NMRI mice.	Bleomycin	137-146	BCL2-associated X protein	Mus musculus	93-96
19630211-7	2008	The expression of BAX protein was significantly (p<0.05) upregulated in alveolar epithelial cells of both strains and downregulated in myofibroblasts and lymphocytes of the lung tissues of C57BL/6 mice and also in lymphocytes of NMRI mice at 2 weeks after bleomycin instillation.	Bleomycin	259-268	BCL2-associated X protein	Mus musculus	18-21
18809378-3	2008	In a mouse model of lung injury induced by bleomycin or lipopolysaccharide, Rad9 expression is increased in type II alveolar epithelial cells from the early stage of lung injury.	Bleomycin	43-52	RAD9 checkpoint clamp component A	Mus musculus	76-80
18809378-4	2008	A549 cells and mouse primary alveolar epithelial cells also upregulated Rad9 expression after exposure to bleomycin.	Bleomycin	106-115	RAD9 checkpoint clamp component A	Mus musculus	72-76
18809378-5	2008	Gene silencing of Rad9 using siRNA decreased the G2/M arrest in A549 cells induced by bleomycin and also decreased the survival of A549 cells following exposure to bleomycin and hydrogen peroxide.	Bleomycin	86-95	RAD9 checkpoint clamp component A	Mus musculus	18-22
18809378-5	2008	Gene silencing of Rad9 using siRNA decreased the G2/M arrest in A549 cells induced by bleomycin and also decreased the survival of A549 cells following exposure to bleomycin and hydrogen peroxide.	Bleomycin	164-173	RAD9 checkpoint clamp component A	Mus musculus	18-22
18776186-5	2008	Interestingly, GAPDH-small interfering RNA knockdown sensitized the cells to methyl methane sulfonate and bleomycin, which generate lesions that are repaired by APE1, but showed normal sensitivity to 254-nm UV.	Bleomycin	106-115	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	161-165
18946333-4	2008	In bleomycin-induced fibrosis, B cells produce fibrogenic cytokines upon interaction of an endogenous ligand (hyaluronan) with toll-like receptor-4.	Bleomycin	3-12	toll like receptor 4	Homo sapiens	127-147
18975310-6	2008	In the skin from bleomycin-treated mice, dermal fibroblasts expressed CD40, and mast cells and CD4+ T cells expressed CD154.	Bleomycin	17-26	CD40 antigen	Mus musculus	70-74
18975310-6	2008	In the skin from bleomycin-treated mice, dermal fibroblasts expressed CD40, and mast cells and CD4+ T cells expressed CD154.	Bleomycin	17-26	CD40 ligand	Mus musculus	118-123
18975310-9	2008	Finally, the anti-CD154 antibody inhibited the bleomycin-induced skin sclerosis by suppressing fibroblast proliferation and down-regulating MCP-1 expression.	Bleomycin	47-56	CD40 ligand	Mus musculus	18-23
18975310-9	2008	Finally, the anti-CD154 antibody inhibited the bleomycin-induced skin sclerosis by suppressing fibroblast proliferation and down-regulating MCP-1 expression.	Bleomycin	47-56	chemokine (C-C motif) ligand 2	Mus musculus	140-145
18975313-0	2008	CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model.	Bleomycin	34-43	CD19 antigen	Mus musculus	0-4
18975313-6	2008	Bleomycin was also administered into selectin-deficient or intercellular adhesion molecule 1-deficient mouse strains.	Bleomycin	0-9	intercellular adhesion molecule 1	Mus musculus	59-92
18975313-8	2008	RESULTS: CD19 deficiency significantly reduced susceptibility to intratracheal bleomycin challenge on day 16, while CD19 overexpression augmented fibrosis even on day 10.	Bleomycin	79-88	CD19 antigen	Mus musculus	9-13
18949888-6	2008	Increasing caveolin-1 expression markedly improved bleomycin-induced pulmonary fibrosis.	Bleomycin	51-60	caveolin 1	Homo sapiens	11-21
18949888-8	2008	Systemic administration of penetratin-caveolin-1 peptide to mice with bleomycin-induced lung fibrosis reduced fibrosis.	Bleomycin	70-79	caveolin 1, caveolae protein	Mus musculus	38-48
18640828-2	2008	TSP-1 is expressed in the lung tissue of animal models of bleomycin-induced pulmonary fibrosis and in patients with some interstitial lung diseases.	Bleomycin	58-67	thrombospondin 1	Homo sapiens	0-5
18941258-0	2008	Letter of retraction: Dual effect of AMD3100, a CXCR4 antagonist, on bleomycin-indiced lung inflammation.	Bleomycin	69-78	C-X-C motif chemokine receptor 4	Homo sapiens	48-53
19099094-0	2008	Influence of a DNA-hsp65 vaccine on bleomycin-induced lung injury.	Bleomycin	36-45	heat shock protein 1 (chaperonin)	Mus musculus	19-24
19099094-9	2008	CONCLUSIONS: Immunization with the DNA-hsp65 vaccine reduced the deposition of noncollagen matrix in a model of bleomycin-induced lung lesion.	Bleomycin	112-121	heat shock protein 1 (chaperonin)	Mus musculus	39-44
18441281-9	2008	In bleomycin-induced pulmonary fibrosis in mice, HMGB1 protein was predominantly up-regulated in bronchiolar epithelial cells at early phase and in alveolar epithelial and inflammatory cells in fibrotic lesions at later phase.	Bleomycin	3-12	high mobility group box 1	Mus musculus	49-54
18811877-0	2008	Effects of Th2 pulmonary inflammation in mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	51-60	heart and neural crest derivatives expressed 2	Mus musculus	11-14
18811877-5	2008	METHODS: Bleomycin was administered to ovalbumin (OVA)-sensitized Bcl6 transgenic and wild-type mice by intratracheal instillation during sequential OVA antigen challenge.	Bleomycin	9-18	B cell leukemia/lymphoma 6	Mus musculus	66-70
18811877-8	2008	RESULTS: Although OVA-sensitized, bleomycin-treated Bcl6 transgenic mice had markedly lower numbers of eosinophils in both BAL and lung tissue compared with OVA-sensitized, bleomycin-treated wild-type mice, the development of pulmonary fibrosis in response to bleomycin was similar in Bcl6 transgenic mice and wild-type mice.	Bleomycin	34-43	B cell leukemia/lymphoma 6	Mus musculus	52-56
18811877-8	2008	RESULTS: Although OVA-sensitized, bleomycin-treated Bcl6 transgenic mice had markedly lower numbers of eosinophils in both BAL and lung tissue compared with OVA-sensitized, bleomycin-treated wild-type mice, the development of pulmonary fibrosis in response to bleomycin was similar in Bcl6 transgenic mice and wild-type mice.	Bleomycin	34-43	B cell leukemia/lymphoma 6	Mus musculus	285-289
18536743-1	2008	A burgeoning body of evidence suggests that RhoA/Rho kinase (ROCK) signalling plays an important role in the pathogenesis of various experimental models of pulmonary hypertension (PH), including chronic hypoxia-, monocrotaline-, bleomycin-, shunt- and vascular endothelial growth factor receptor inhibition plus chronic hypoxia-induced PH.	Bleomycin	229-238	ras homolog family member A	Homo sapiens	44-48
18536743-4	2008	Also, phosphorylation of RhoA and prevention of its translocation to the plasma membrane are involved in the protective effect of the type 5-PDE inhibitor, sildenafil, against hypoxia- and bleomycin-induced PH.	Bleomycin	189-198	ras homolog family member A	Homo sapiens	25-29
18931716-1	2008	OBJECTIVE: To explore the expression levels of MHC II molecules and its regulator genes CIITA on bleomycin-induced pulmonary fibrosis in rats, and to investigate the underlying immunologic mechanisms of pulmonary fibrosis.	Bleomycin	97-106	class II, major histocompatibility complex, transactivator	Rattus norvegicus	88-93
18772333-8	2008	Bleomycin-induced scleroderma in the mouse was accompanied by increased Egr-1 accumulation in lesional fibroblasts.	Bleomycin	0-9	early growth response 1	Mus musculus	72-77
18658275-0	2008	Dysregulation of lung injury and repair in moesin-deficient mice treated with intratracheal bleomycin.	Bleomycin	92-101	moesin	Mus musculus	43-49
18658275-5	2008	Compared with Msn(+/Y) mice, Msn(-/Y) mice displayed abnormalities of alveolar architecture and, when treated with bleomycin, developed more prominent lung injury and fibrosis and lower body weight and survival rate.	Bleomycin	115-124	moesin	Mus musculus	29-32
18709547-0	2008	Adenosine A2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis.	Bleomycin	124-133	adenosine A2a receptor	Mus musculus	0-22
18709547-2	2008	Previous studies in our lab demonstrated that A(2A) receptor-deficient and A(2A) antagonist-treated mice were protected from developing bleomycin-induced dermal fibrosis, thus the aim of this study was to determine whether the adenosine A(2A) receptor regulates recruitment of fibrocytes to the dermis in this bleomycin-induced model of dermal fibrosis.	Bleomycin	310-319	adenosine A2a receptor	Mus musculus	227-251
18713087-7	2008	Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation.	Bleomycin	241-250	thymoma viral proto-oncogene 1	Mus musculus	29-32
19138287-0	2008	Anti-Ma2 paraneoplastic encephalitis associated with testicular germ cell tumor treated by carboplatin, etoposide and bleomycin.	Bleomycin	118-127	PNMA family member 2	Homo sapiens	5-8
19138287-4	2008	To our knowledge, this is the first case in which orchiectomy followed by carboplatin, etoposide and bleomycin for a testicular tumor with anti-Ma2 encephalitis was performed.	Bleomycin	101-110	PNMA family member 2	Homo sapiens	144-147
19697510-4	2008	In this article, we describe recent advances concerning immunological aspects in the pathogenesis of bleomycin-induced murine scleroderma, laying stress on the involvement of interleukin-13 (IL-13) and plasminogen activator inhibitor-1 (PAI-1).	Bleomycin	101-110	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	237-242
18827617-2	2008	Beta-human chorionic gonadotropin and alpha-fetoprotein were elevated at presentation and responded to four cycles of bleomycin, etoposide, and cisplatin although the tumor did not regress.	Bleomycin	118-127	alpha fetoprotein	Homo sapiens	38-55
19080365-6	2008	Moreover, simvastatin down-regulated the increased expression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) induced by bleomycin at both gene and protein levels.	Bleomycin	164-173	transforming growth factor, beta 1	Mus musculus	65-97
19080365-6	2008	Moreover, simvastatin down-regulated the increased expression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) induced by bleomycin at both gene and protein levels.	Bleomycin	164-173	transforming growth factor, beta 1	Mus musculus	99-108
19080365-6	2008	Moreover, simvastatin down-regulated the increased expression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) induced by bleomycin at both gene and protein levels.	Bleomycin	164-173	cellular communication network factor 2	Mus musculus	114-145
19080365-6	2008	Moreover, simvastatin down-regulated the increased expression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) induced by bleomycin at both gene and protein levels.	Bleomycin	164-173	cellular communication network factor 2	Mus musculus	147-151
19080365-7	2008	Simultaneously, the accumulation of neutrophils and lymphocytes and the increased production of tumor necrosis factor-alpha (TNF-alpha) in bronchial alveolar lavage fluid were inhibited by simvastatin in early inflammatory phase after bleomycin infusion.	Bleomycin	235-244	tumor necrosis factor	Mus musculus	96-123
19080365-7	2008	Simultaneously, the accumulation of neutrophils and lymphocytes and the increased production of tumor necrosis factor-alpha (TNF-alpha) in bronchial alveolar lavage fluid were inhibited by simvastatin in early inflammatory phase after bleomycin infusion.	Bleomycin	235-244	tumor necrosis factor	Mus musculus	125-134
18723675-2	2008	We find that this modification stimulates RPA2 to become hyperphosphorylated in response to mitotic DNA damage caused by bleomycin treatment.	Bleomycin	121-130	replication protein A2	Homo sapiens	42-46
18723675-3	2008	Cells in which endogenous RPA2 was replaced by a mutant subunit lacking both Cdc2 sites had a significant defect in mitotic release into a 2N G(1) phase after exposure to bleomycin.	Bleomycin	171-180	replication protein A2	Homo sapiens	26-30
18723675-3	2008	Cells in which endogenous RPA2 was replaced by a mutant subunit lacking both Cdc2 sites had a significant defect in mitotic release into a 2N G(1) phase after exposure to bleomycin.	Bleomycin	171-180	cyclin dependent kinase 1	Homo sapiens	77-81
18421017-4	2008	Significant down-regulation of RAGE was observed in lung homogenate and alveolar epithelial type II cells from patients with idiopathic pulmonary fibrosis, as well as in bleomycin-treated mice, demonstrated by RT-PCR, Western blotting, and immunohistochemistry.	Bleomycin	170-179	advanced glycosylation end-product specific receptor	Homo sapiens	31-35
18684219-6	2008	In addition, bleomycin injection resulted in a marked increase of myeloperoxidase activity and malondialdehyde level that was attenuated by oxymatrine.	Bleomycin	13-22	myeloperoxidase	Mus musculus	66-81
18713087-0	2008	Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice.	Bleomycin	82-91	erythropoietin	Homo sapiens	18-32
18713087-2	2008	The purpose of this study was to determine whether human recombinant EPO reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice.	Bleomycin	122-131	erythropoietin	Homo sapiens	69-72
18713087-7	2008	Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation.	Bleomycin	241-250	mitogen-activated protein kinase 1	Mus musculus	37-40
18713087-7	2008	Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation.	Bleomycin	241-250	erythropoietin	Mus musculus	114-117
18713087-7	2008	Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation.	Bleomycin	241-250	erythropoietin	Mus musculus	181-184
18598692-7	2008	Both pirfenidone and prednisolone suppressed the increase in lung interleukin (IL)-1beta, IL-6, IL-12p40 and monocyte chemoattractant protein (MCP)-1 levels induced by bleomycin.	Bleomycin	168-177	interleukin 1 beta	Mus musculus	66-88
18690397-1	2008	To ascertain whether connective tissue growth factor (CTGF) participates in the remodeling of pulmonary artery at the early-stage of bleomycin (BLM)-induced pulmonary fibrosis, mean pulmonary arterial pressure, the expression of type I and type III collagens, and the expression and location of CTGF in pulmonary artery and arteriole were investigated in the present study.	Bleomycin	133-142	cellular communication network factor 2	Rattus norvegicus	21-52
18690397-1	2008	To ascertain whether connective tissue growth factor (CTGF) participates in the remodeling of pulmonary artery at the early-stage of bleomycin (BLM)-induced pulmonary fibrosis, mean pulmonary arterial pressure, the expression of type I and type III collagens, and the expression and location of CTGF in pulmonary artery and arteriole were investigated in the present study.	Bleomycin	133-142	cellular communication network factor 2	Rattus norvegicus	54-58
18598692-7	2008	Both pirfenidone and prednisolone suppressed the increase in lung interleukin (IL)-1beta, IL-6, IL-12p40 and monocyte chemoattractant protein (MCP)-1 levels induced by bleomycin.	Bleomycin	168-177	interleukin 6	Mus musculus	90-94
18598692-7	2008	Both pirfenidone and prednisolone suppressed the increase in lung interleukin (IL)-1beta, IL-6, IL-12p40 and monocyte chemoattractant protein (MCP)-1 levels induced by bleomycin.	Bleomycin	168-177	interleukin 12b	Mus musculus	96-104
18598692-7	2008	Both pirfenidone and prednisolone suppressed the increase in lung interleukin (IL)-1beta, IL-6, IL-12p40 and monocyte chemoattractant protein (MCP)-1 levels induced by bleomycin.	Bleomycin	168-177	chemokine (C-C motif) ligand 2	Mus musculus	109-149
18598692-8	2008	On the other hand, pirfenidone prevented the bleomycin-induced decrease in lung interferon (IFN)-gamma levels, while prednisolone had no such effect.	Bleomycin	45-54	interferon gamma	Mus musculus	80-102
18463164-5	2008	Treatment with bleomycin, which induces DSBs, revealed an increase in the degree of colocalization between S100A11 and Rad54B.	Bleomycin	15-24	S100 calcium binding protein A11	Homo sapiens	107-114
18583319-3	2008	Mice lacking the gene for Id1 had increased susceptibility to bleomycin-induced lung fibrosis, and fibroblasts lacking Id1 exhibited enhanced responses to TGF-beta(1).	Bleomycin	62-71	inhibitor of DNA binding 1, HLH protein	Mus musculus	26-29
18321937-5	2008	The expression of serotonin receptors 5-HT2A and 5-HT2B increased in the lung after bleomycin treatment, as assessed by PCR, specific binding and immunohistochemistry.	Bleomycin	84-93	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	38-55
18321937-6	2008	Blockage of 5-HT2A receptors by ketanserin and 5-HT2B receptors by SB215505 reduced bleomycin-induced lung fibrosis, as demonstrated by reduced lung collagen content and reduced procollagen 1 and procollagen 3 mRNA expression.	Bleomycin	84-93	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	12-18
18638383-0	2008	Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis.	Bleomycin	103-112	cathepsin K	Mus musculus	18-29
18638383-2	2008	Due to its potent collagenolytic activity, cathepsin K, a lysosomal cysteine protease is an interesting target molecule with therapeutic potential to attenuate bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	160-169	cathepsin K	Mus musculus	43-54
18638383-2	2008	Due to its potent collagenolytic activity, cathepsin K, a lysosomal cysteine protease is an interesting target molecule with therapeutic potential to attenuate bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	160-169	cathepsin R	Mus musculus	58-85
18638383-3	2008	We here tested the hypothesis that over-expression of cathepsin K in the lungs of mice is protective in bleomycin-induced pulmonary fibrosis.	Bleomycin	104-113	cathepsin K	Mus musculus	54-65
18638383-6	2008	RESULTS: Cathepsin K protein levels were strongly increased in alveolar macrophages and lung parenchymal tissue of mock-treated cathepsin K transgenic (cath K tg) mice relative to wild-type mice and further increased particularly in cath K tg but also wild-type mice in response to bleomycin.	Bleomycin	282-291	cathepsin K	Mus musculus	9-20
18638383-9	2008	CONCLUSION: Over-expression of cathepsin K reduced lung collagen deposition and improved lung function parameters in the lungs of transgenic mice, thereby providing at least partial protection against bleomycin-induced lung fibrosis.	Bleomycin	201-210	cathepsin K	Mus musculus	31-42
18576327-3	2008	The aim of the present study was to examine the role of Rac1 in bleomycin-induced scleroderma, using mice with a fibroblast-specific deletion of Rac1.	Bleomycin	64-73	Rac family small GTPase 1	Mus musculus	56-60
18576327-10	2008	Conversely, deletion of Rac1 resulted in resistance to bleomycin-induced fibrosis and inflammation.	Bleomycin	55-64	Rac family small GTPase 1	Mus musculus	24-28
19061577-1	2008	A 1(1/2)-year-old boy developed hyperpigmentation of the palms and feet along with flagellate pigmentation over the trunk following intralesional injection of bleomycin for cystic hygroma.	Bleomycin	159-168	DXS435E	Homo sapiens	0-7
18441099-5	2008	ACE-2 mRNA and activity were also decreased similarly in the lungs of bleomycin-treated rats and C57-BL6 mice.	Bleomycin	70-79	angiotensin I converting enzyme 2	Rattus norvegicus	0-5
18441099-6	2008	In mice exposed to low doses of bleomycin, lung collagen accumulation was enhanced by intratracheal administration of either ACE-2-specific small interfering RNAs (siRNAs) or the peptide DX(600), a competitive inhibitor of ACE-2 (P<0.05).	Bleomycin	32-41	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	125-130
18441099-6	2008	In mice exposed to low doses of bleomycin, lung collagen accumulation was enhanced by intratracheal administration of either ACE-2-specific small interfering RNAs (siRNAs) or the peptide DX(600), a competitive inhibitor of ACE-2 (P<0.05).	Bleomycin	32-41	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	223-228
18441099-7	2008	Administration of either ACE-2 siRNA or DX(600) significantly increased the ANG II content of mouse lung tissue above the level induced by bleomycin alone.	Bleomycin	139-148	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	25-30
18441099-7	2008	Administration of either ACE-2 siRNA or DX(600) significantly increased the ANG II content of mouse lung tissue above the level induced by bleomycin alone.	Bleomycin	139-148	angiotensinogen	Homo sapiens	76-82
18441099-9	2008	Moreover, purified recombinant human ACE-2, delivered to mice systemically by osmotic minipump, attenuated bleomycin-induced lung collagen accumulation.	Bleomycin	107-116	angiotensin converting enzyme 2	Homo sapiens	37-42
18591765-4	2008	Intratracheal administration of bleomycin (6.5 U/kg body weight) to rats resulted in significant reduction of body weight, enzymic antioxidants (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) and non-enzymic antioxidants (reduced glutathione, vitamin C, vitamin E and vitamin A).	Bleomycin	32-41	catalase	Rattus norvegicus	167-175
18591765-4	2008	Intratracheal administration of bleomycin (6.5 U/kg body weight) to rats resulted in significant reduction of body weight, enzymic antioxidants (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) and non-enzymic antioxidants (reduced glutathione, vitamin C, vitamin E and vitamin A).	Bleomycin	32-41	glutathione-disulfide reductase	Rattus norvegicus	204-225
18463164-5	2008	Treatment with bleomycin, which induces DSBs, revealed an increase in the degree of colocalization between S100A11 and Rad54B.	Bleomycin	15-24	RAD54 homolog B	Homo sapiens	119-125
18350568-10	2008	Alveolar mononuclear phagocytic hyperplasia was reduced by as much as 100% in animals treated with bleomycin and EPO compared to animals treated with bleomycin alone (p &lt; 0.03).	Bleomycin	150-159	erythropoietin	Mus musculus	113-116
18350568-8	2008	A 6-fold decrease in the number of prominent endothelial cells--suspected to be indicative of cellular activation and inflammatory response--was observed in lung sections derived from mice treated with bleomycin and EPO compared to animals injected with bleomycin alone (p &lt; 0.008).	Bleomycin	254-263	erythropoietin	Mus musculus	216-219
18350568-9	2008	Additionally, there was twice the number of ICAM1-positive endothelial cells in animals treated with bleomycin alone compared with the number in the bleomycin and EPO-treated group (p &lt; 0.05).	Bleomycin	101-110	intercellular adhesion molecule 1	Mus musculus	44-49
18462759-4	2008	Bleomycin administration significantly (P&lt;0.05) reduced the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) in the lung tissues.	Bleomycin	0-9	catalase	Rattus norvegicus	105-113
18462759-4	2008	Bleomycin administration significantly (P&lt;0.05) reduced the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) in the lung tissues.	Bleomycin	0-9	catalase	Rattus norvegicus	115-118
18462759-9	2008	Immunohistochemical studies revealed that DAS reduced the bleomycin-induced activation of inducible nitric oxide synthase (iNOS) and nuclear factor kappa-B (NF-kappaB) and decreased the augmented levels of the early inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), in the lung tissues.	Bleomycin	58-67	nitric oxide synthase 2	Rattus norvegicus	90-121
18462759-9	2008	Immunohistochemical studies revealed that DAS reduced the bleomycin-induced activation of inducible nitric oxide synthase (iNOS) and nuclear factor kappa-B (NF-kappaB) and decreased the augmented levels of the early inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), in the lung tissues.	Bleomycin	58-67	nitric oxide synthase 2	Rattus norvegicus	123-127
18462759-5	2008	Bleomycin caused a significant decrease in the level of reduced glutathione (GSH), which was accompanied with significant increase in lipid peroxidation (LPO) level, and myeloperoxidase (MPO) activity, in the lung tissues.	Bleomycin	0-9	myeloperoxidase	Rattus norvegicus	170-185
18462759-9	2008	Immunohistochemical studies revealed that DAS reduced the bleomycin-induced activation of inducible nitric oxide synthase (iNOS) and nuclear factor kappa-B (NF-kappaB) and decreased the augmented levels of the early inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), in the lung tissues.	Bleomycin	58-67	tumor necrosis factor	Rattus norvegicus	270-279
18462759-5	2008	Bleomycin caused a significant decrease in the level of reduced glutathione (GSH), which was accompanied with significant increase in lipid peroxidation (LPO) level, and myeloperoxidase (MPO) activity, in the lung tissues.	Bleomycin	0-9	myeloperoxidase	Rattus norvegicus	187-190
18462759-9	2008	Immunohistochemical studies revealed that DAS reduced the bleomycin-induced activation of inducible nitric oxide synthase (iNOS) and nuclear factor kappa-B (NF-kappaB) and decreased the augmented levels of the early inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), in the lung tissues.	Bleomycin	58-67	interleukin 1 beta	Rattus norvegicus	285-302
18245174-7	2008	In vivo, tagln expression was significantly increased in ATII cells of mice during bleomycin-induced lung fibrosis, as well as in lung specimen obtained from IPF patients, as assessed by RT-PCR and immunohistochemistry.	Bleomycin	83-92	transgelin	Mus musculus	9-14
18462759-9	2008	Immunohistochemical studies revealed that DAS reduced the bleomycin-induced activation of inducible nitric oxide synthase (iNOS) and nuclear factor kappa-B (NF-kappaB) and decreased the augmented levels of the early inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), in the lung tissues.	Bleomycin	58-67	interleukin 1 beta	Rattus norvegicus	304-312
18467694-0	2008	CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma.	Bleomycin	85-94	CD19 antigen	Mus musculus	0-4
18467694-4	2008	Bleomycin-treated wild-type mice exhibited dermal and lung fibrosis, hyper-gamma-globulinemia, autoantibody production, and enhanced serum and skin expression of various cytokines, including fibrogenic interleukin-4, interleukin-6, and transforming growth factor-beta1, all of which were inhibited by CD19 deficiency.	Bleomycin	0-9	interleukin 4	Mus musculus	202-215
18467694-4	2008	Bleomycin-treated wild-type mice exhibited dermal and lung fibrosis, hyper-gamma-globulinemia, autoantibody production, and enhanced serum and skin expression of various cytokines, including fibrogenic interleukin-4, interleukin-6, and transforming growth factor-beta1, all of which were inhibited by CD19 deficiency.	Bleomycin	0-9	interleukin 6	Mus musculus	217-230
18467694-4	2008	Bleomycin-treated wild-type mice exhibited dermal and lung fibrosis, hyper-gamma-globulinemia, autoantibody production, and enhanced serum and skin expression of various cytokines, including fibrogenic interleukin-4, interleukin-6, and transforming growth factor-beta1, all of which were inhibited by CD19 deficiency.	Bleomycin	0-9	transforming growth factor, beta 1	Mus musculus	236-268
18467694-7	2008	These results suggest that bleomycin induces fibrosis by enhancing hyaluronan production, which activates B cells to produce fibrogenic cytokines mainly via TLR4 and induce autoantibody production, and that CD19 deficiency suppresses fibrosis and autoantibody production by inhibiting TLR4 signals.	Bleomycin	27-36	toll-like receptor 4	Mus musculus	157-161
18467694-7	2008	These results suggest that bleomycin induces fibrosis by enhancing hyaluronan production, which activates B cells to produce fibrogenic cytokines mainly via TLR4 and induce autoantibody production, and that CD19 deficiency suppresses fibrosis and autoantibody production by inhibiting TLR4 signals.	Bleomycin	27-36	toll-like receptor 4	Mus musculus	285-289
18582404-0	2008	Aerosolized STAT1 antisense oligodeoxynucleotides decrease the concentrations of inflammatory mediators in bronchoalveolar lavage fluid in bleomycin-induced rat pulmonary fibrosis.	Bleomycin	139-148	signal transducer and activator of transcription 1	Rattus norvegicus	12-17
18338242-0	2008	IL-17 producing gammadelta T cells are required for a controlled inflammatory response after bleomycin-induced lung injury.	Bleomycin	93-102	interleukin 17A	Mus musculus	0-5
18589176-12	2008	Furthermore, the increased mRNA levels of TGF-beta1, PDGF-A, PDGF-B, and IGF-I following bleomycin injection were also significantly decreased by MSC treatment.	Bleomycin	89-98	transforming growth factor, beta 1	Rattus norvegicus	42-51
18378696-3	2008	Nip1/Ctp1 was phosphorylated in asynchronous, exponentially growing cells and further phosphorylated in response to bleomycin treatment.	Bleomycin	116-125	translation initiation factor eIF3 core subunit c	Saccharomyces cerevisiae S288C	0-4
18378696-3	2008	Nip1/Ctp1 was phosphorylated in asynchronous, exponentially growing cells and further phosphorylated in response to bleomycin treatment.	Bleomycin	116-125	Ctp1p	Saccharomyces cerevisiae S288C	5-9
18589176-12	2008	Furthermore, the increased mRNA levels of TGF-beta1, PDGF-A, PDGF-B, and IGF-I following bleomycin injection were also significantly decreased by MSC treatment.	Bleomycin	89-98	platelet derived growth factor subunit A	Rattus norvegicus	53-59
18589176-12	2008	Furthermore, the increased mRNA levels of TGF-beta1, PDGF-A, PDGF-B, and IGF-I following bleomycin injection were also significantly decreased by MSC treatment.	Bleomycin	89-98	platelet derived growth factor subunit B	Rattus norvegicus	61-67
18589176-12	2008	Furthermore, the increased mRNA levels of TGF-beta1, PDGF-A, PDGF-B, and IGF-I following bleomycin injection were also significantly decreased by MSC treatment.	Bleomycin	89-98	insulin-like growth factor 1	Rattus norvegicus	73-78
18500976-0	2008	Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	50-59	angiotensin II receptor, type 2	Mus musculus	0-30
18162602-0	2008	PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.	Bleomycin	81-90	peroxisome proliferator activated receptor gamma	Homo sapiens	0-10
18403600-0	2008	A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis.	Bleomycin	73-82	chemokine (C-C motif) receptor 4	Mus musculus	22-26
18403600-3	2008	Intrapulmonary administration of bleomycin sulfate provoked lethal inflammatory and fibrotic responses in WT (CCR4(+/+)) mice, but such responses were absent in CCR4(-/-) mice.	Bleomycin	33-50	chemokine (C-C motif) receptor 4	Mus musculus	110-114
18096870-0	2008	Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice.	Bleomycin	25-34	interleukin 6	Mus musculus	8-21
18096870-1	2008	Interleukin-6 (IL-6) is known to be involved in the pathogenesis of various inflammatory diseases, but its role in bleomycin (BLM)-induced lung injury and subsequent fibrotic changes remains to be determined.	Bleomycin	115-124	interleukin 6	Mus musculus	0-13
18203815-10	2008	Finally, we demonstrated that systemic administration of CSD peptide to bleomycin-treated mice blocks epithelial cell apoptosis, inflammatory cell infiltration, and changes in tissue morphology as well as signaling molecule activation and collagen, tenascin-C, and ASMA expression associated with lung fibrosis.	Bleomycin	72-81	tenascin C	Mus musculus	249-259
18096870-6	2008	On Day 2, BLM administration induced significant increases in the numbers of total cells, macrophages, and neutrophils in BAL fluid, which were attenuated in IL-6(-/-) mice (P &lt; 0.05).	Bleomycin	10-13	interleukin 6	Mus musculus	158-162
18203815-10	2008	Finally, we demonstrated that systemic administration of CSD peptide to bleomycin-treated mice blocks epithelial cell apoptosis, inflammatory cell infiltration, and changes in tissue morphology as well as signaling molecule activation and collagen, tenascin-C, and ASMA expression associated with lung fibrosis.	Bleomycin	72-81	actin alpha 2, smooth muscle, aorta	Mus musculus	265-269
18234257-0	2008	Suppression of a DNA base excision repair gene, hOGG1, increases bleomycin sensitivity of human lung cancer cell line.	Bleomycin	65-74	8-oxoguanine DNA glycosylase	Homo sapiens	48-53
18355908-4	2008	METHODS: SOCS1-haplodeficient mice treated with bleomycin (BLM) were evaluated for pulmonary inflammation and fibrosis compared with wild-type mice.	Bleomycin	48-57	suppressor of cytokine signaling 1	Mus musculus	9-14
18234257-3	2008	In this study, we have investigated if down-regulation of human 8-oxoguanine DNA glycosylase (hOGG1), an important BER enzyme, could alter cellular sensitivity to bleomycin, thereby reducing chemotherapeutic resistance in human tumor cell.	Bleomycin	163-172	8-oxoguanine DNA glycosylase	Homo sapiens	64-92
18234257-3	2008	In this study, we have investigated if down-regulation of human 8-oxoguanine DNA glycosylase (hOGG1), an important BER enzyme, could alter cellular sensitivity to bleomycin, thereby reducing chemotherapeutic resistance in human tumor cell.	Bleomycin	163-172	8-oxoguanine DNA glycosylase	Homo sapiens	94-99
18234257-6	2008	We demonstrated that hOGG1 gene knockdown enhanced bleomycin cytotoxicity and reduced the ability of colony formation of the lung cancer cell lines.	Bleomycin	51-60	8-oxoguanine DNA glycosylase	Homo sapiens	21-26
18234257-9	2008	Our results indicated that hOGG1 deficiency allowed the accumulation of bleomycin-induced DNA damage and chromosomal breaks by compromising DNA damage repair capacity, thereby increasing cellular sensitivity to bleomycin.	Bleomycin	72-81	8-oxoguanine DNA glycosylase	Homo sapiens	27-32
18234257-9	2008	Our results indicated that hOGG1 deficiency allowed the accumulation of bleomycin-induced DNA damage and chromosomal breaks by compromising DNA damage repair capacity, thereby increasing cellular sensitivity to bleomycin.	Bleomycin	211-220	8-oxoguanine DNA glycosylase	Homo sapiens	27-32
18398146-2	2008	A plausible candidate is the gene for bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, an essential component of chemotherapy regimens for disseminated testicular germ-cell cancer (TC).	Bleomycin	38-47	bleomycin hydrolase	Homo sapiens	59-63
18727865-12	2008	The TGF-beta(1) mRNA expression in the curcumin treated group was 0.61 +/- 0.09 and 0.48 +/- 0.16 respectively on the 21(st) and 28(th) day after bleomycin administration (P &lt; 0.05).	Bleomycin	146-155	transforming growth factor, beta 1	Rattus norvegicus	4-15
18727865-14	2008	CONCLUSION: Curcumin could suppress BLM-induced pulmonary fibrosis in rats at the fibrosing stage, with the possible mechanism of inhibiting the synthesis and deposition of type I collagen protein and depressing the overexpression of TGF-beta(1) mRNA.	Bleomycin	36-39	transforming growth factor, beta 1	Rattus norvegicus	234-245
18398146-10	2008	CONCLUSION: The homozygous variant G/G of BLMH gene SNP A1450G is associated with reduced survival and higher prevalence of early relapses in TC patients treated with bleomycin-containing chemotherapy.	Bleomycin	167-176	bleomycin hydrolase	Homo sapiens	42-46
18243046-5	2008	Furthermore, the status of the fragile histidine triad gene (FHIT) in chromosome band 3p14.2 was studied by fluorescence in situ hybridization (FISH) in epithelial cells that had been cultured after removal of bleomycin.	Bleomycin	210-219	fragile histidine triad diadenosine triphosphatase	Homo sapiens	61-65
17879944-0	2008	Histone H1.2 is translocated to mitochondria and associates with Bak in bleomycin-induced apoptotic cells.	Bleomycin	72-81	H1.2 linker histone, cluster member	Homo sapiens	0-12
17879944-0	2008	Histone H1.2 is translocated to mitochondria and associates with Bak in bleomycin-induced apoptotic cells.	Bleomycin	72-81	BCL2 antagonist/killer 1	Homo sapiens	65-68
17879944-3	2008	Here, we investigated the localization of histone H1.2 in the bleomycin-treated human squamous carcinoma SCCTF cells.	Bleomycin	62-71	H1.2 linker histone, cluster member	Homo sapiens	42-54
17879944-4	2008	The presence of DNA double-strand breaks in the bleomycin-treated cells was examined by Western analysis using antibody against phosphorylated histone H2AX (gamma-H2AX).	Bleomycin	48-57	H2A.X variant histone	Homo sapiens	143-155
17879944-5	2008	Incubation of SCCTF cells for 48 h with 10 microM bleomycin induced apoptosis, as determined by cleavage of lamin B1 to 28 kDa fragment and DNA ladder formation.	Bleomycin	50-59	lamin B1	Homo sapiens	108-116
17879944-7	2008	Histone H1.2 was translocated from the nucleus to the mitochondria after treatment with bleomycin and co-localized with Bak in mitochondria.	Bleomycin	88-97	H1.2 linker histone, cluster member	Homo sapiens	0-12
17879944-8	2008	Our present results suggest that histone H1.2 plays an important role in transmitting apoptotic signals from the nucleus to the mitochondria following double-stranded breaks of DNA by bleomycin.	Bleomycin	184-193	H1.2 linker histone, cluster member	Homo sapiens	33-45
18179361-6	2008	Endogenous or exogenous TRX1 or both protect the lungs against ischemia-reperfusion injury, influenza infection, bleomycin-induced injury, or lethal pulmonary inflammation caused by interleukin-2 and interleukin-18.	Bleomycin	113-122	thioredoxin	Homo sapiens	24-28
18262831-4	2008	There was a significant increase in the amount of DNA damage in CD4+ T-cells, CD8+ T-cells, NK cells and B-cells when treated with H2O2 and bleomycin, whereas monocytes had the lowest sensitivity to H2O2 compared with the other cell fractions, but no lower sensitivity to bleomycin.	Bleomycin	140-149	CD4 molecule	Homo sapiens	64-67
18262831-4	2008	There was a significant increase in the amount of DNA damage in CD4+ T-cells, CD8+ T-cells, NK cells and B-cells when treated with H2O2 and bleomycin, whereas monocytes had the lowest sensitivity to H2O2 compared with the other cell fractions, but no lower sensitivity to bleomycin.	Bleomycin	140-149	CD8a molecule	Homo sapiens	78-81
18262831-4	2008	There was a significant increase in the amount of DNA damage in CD4+ T-cells, CD8+ T-cells, NK cells and B-cells when treated with H2O2 and bleomycin, whereas monocytes had the lowest sensitivity to H2O2 compared with the other cell fractions, but no lower sensitivity to bleomycin.	Bleomycin	272-281	CD4 molecule	Homo sapiens	64-67
18096707-9	2008	EDA-null mice failed to develop significant fibrosis 21 days after bleomycin challenge, whereas wild-type controls developed the expected increase in total lung collagen.	Bleomycin	67-76	ectodysplasin-A	Mus musculus	0-3
18096707-10	2008	Histologic analysis of EDA-null lungs after bleomycin showed less collagen and fewer alpha-SMA-expressing myofibroblasts compared with that observed in wild-type mice.	Bleomycin	44-53	ectodysplasin-A	Mus musculus	23-26
18165226-3	2008	Previous studies indicate that EC-SOD protects the lung in both bleomycin- and asbestos-induced models of pulmonary fibrosis.	Bleomycin	64-73	superoxide dismutase 3, extracellular	Mus musculus	31-37
18178676-6	2008	SP-C-TIMP-1 mice reduced MMP expression in response to bleomycin.	Bleomycin	55-64	tissue inhibitor of metalloproteinase 1	Mus musculus	5-11
18201696-5	2008	METHODS: The regulation of CCN2 expression was examined in vivo in a model of fibrosis induced by bleomycin.	Bleomycin	98-107	cellular communication network factor 2	Mus musculus	27-31
18201696-7	2008	RESULTS: Bleomycin-induced skin fibrosis in the mouse was associated with substantial CCN2 up-regulation in lesional fibroblasts.	Bleomycin	9-18	cellular communication network factor 2	Mus musculus	86-90
17965319-0	2008	PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.	Bleomycin	28-37	phosphodiesterase 5A, cGMP-specific	Mus musculus	0-5
17950632-0	2008	Role of carbohydrate moiety of bleomycin-A2 in caspase-3 activation and internucleosomal chromatin fragmentation in apoptosis of laryngeal carcinoma cells.	Bleomycin	31-40	caspase 3	Homo sapiens	47-56
17953974-0	2008	Inherited susceptibility to bleomycin-induced micronuclei: correlating polymorphisms in GSTT1, GSTM1 and DNA repair genes with mutagen sensitivity.	Bleomycin	28-37	glutathione S-transferase theta 1	Homo sapiens	88-93
17953974-0	2008	Inherited susceptibility to bleomycin-induced micronuclei: correlating polymorphisms in GSTT1, GSTM1 and DNA repair genes with mutagen sensitivity.	Bleomycin	28-37	glutathione S-transferase mu 1	Homo sapiens	95-100
17934065-6	2008	Arginase-1 and -2 mRNA and protein expression was increased in primary fibroblasts isolated from bleomycin-treated mice, compared with controls, and assessed by qRT-PCR and Western blot analysis.	Bleomycin	97-106	arginase, liver	Mus musculus	0-17
18082847-1	2008	Mutagen sensitivity assay, by measuring chromosome damage induced by an in vitro treatment of peripheral lymphocytes with bleomycin, has been proposed as a biomarker for assessing cancer susceptibility.	Bleomycin	122-131	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	3-4
18082847-2	2008	Recently, a single nucleotide polymorphism (SNP A1450G) of the gene for bleomycin hydrolase (BLHX), a specific neutral cysteine protease able to metabolise bleomycin, was proposed as a plausible candidate to variation in mutagen sensitivity.	Bleomycin	72-81	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	10-11
18082847-2	2008	Recently, a single nucleotide polymorphism (SNP A1450G) of the gene for bleomycin hydrolase (BLHX), a specific neutral cysteine protease able to metabolise bleomycin, was proposed as a plausible candidate to variation in mutagen sensitivity.	Bleomycin	72-81	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	88-89
18082847-2	2008	Recently, a single nucleotide polymorphism (SNP A1450G) of the gene for bleomycin hydrolase (BLHX), a specific neutral cysteine protease able to metabolise bleomycin, was proposed as a plausible candidate to variation in mutagen sensitivity.	Bleomycin	72-81	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	88-89
18082847-7	2008	A substantial effect of BLHX polymorphism in predetermining individual mutagen sensitivity status was observed: subjects with the BLHX A/A genotype displayed significantly lower mean levels of bleomycin-induced MN frequency than the carriers of A/G or G/G variant alleles combined (12.00+/-3.76 MN/1000 BN vs. 16.37+/-8.86 MN/1000 BN, respectively; P=0.029).	Bleomycin	193-202	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	0-1
18082847-7	2008	A substantial effect of BLHX polymorphism in predetermining individual mutagen sensitivity status was observed: subjects with the BLHX A/A genotype displayed significantly lower mean levels of bleomycin-induced MN frequency than the carriers of A/G or G/G variant alleles combined (12.00+/-3.76 MN/1000 BN vs. 16.37+/-8.86 MN/1000 BN, respectively; P=0.029).	Bleomycin	193-202	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	135-136
18082847-7	2008	A substantial effect of BLHX polymorphism in predetermining individual mutagen sensitivity status was observed: subjects with the BLHX A/A genotype displayed significantly lower mean levels of bleomycin-induced MN frequency than the carriers of A/G or G/G variant alleles combined (12.00+/-3.76 MN/1000 BN vs. 16.37+/-8.86 MN/1000 BN, respectively; P=0.029).	Bleomycin	193-202	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	135-136
18082847-7	2008	A substantial effect of BLHX polymorphism in predetermining individual mutagen sensitivity status was observed: subjects with the BLHX A/A genotype displayed significantly lower mean levels of bleomycin-induced MN frequency than the carriers of A/G or G/G variant alleles combined (12.00+/-3.76 MN/1000 BN vs. 16.37+/-8.86 MN/1000 BN, respectively; P=0.029).	Bleomycin	193-202	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	135-136
18082847-8	2008	The multiple regression analysis, including BLHX genotype and age, confirmed the significant effect of BLHX variant alleles (A/G, G/G) on the chromosome damage induced by bleomycin (P=0.01), whereas age correlated only with the spontaneous MN frequency.	Bleomycin	171-180	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	125-133
18032699-4	2008	Activity of the RhoA/ROCK pathway and ROCK expression were increased in hypoxia- and bleomycin-induced PHT.	Bleomycin	85-94	ras homolog family member A	Rattus norvegicus	16-20
17916809-3	2008	OBJECTIVES: To analyze the expression of alpha(v)beta6 in human pulmonary fibrosis, and to functionally test the efficacy of therapeutic inhibition of alpha(v)beta6-mediated TGF-beta activation in murine bleomycin-induced pulmonary fibrosis.	Bleomycin	204-213	transforming growth factor beta 1	Homo sapiens	174-182
17965319-0	2008	PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.	Bleomycin	28-37	ras homolog family member A	Mus musculus	133-137
17965319-11	2008	These data demonstrate that PDE5 inhibition ameliorates RV hypertrophy and pulmonary fibrosis associated with intratracheal bleomycin in a manner that is associated with improved NOS coupling and a reduction in reactive oxygen species signaling.	Bleomycin	124-133	phosphodiesterase 5A, cGMP-specific	Mus musculus	28-32
18395486-7	2008	Furthermore, in vivo, neutralization of both JE and MCP5, the two functional orthologs of CCL2, during bleomycin-induced pulmonary fibrosis significantly reduced collagen deposition as well as JE and CCR2 expression.	Bleomycin	103-112	C-C motif chemokine ligand 2	Homo sapiens	90-94
18260360-5	2008	Since the serum alpha-fetoprotein (AFP) level was present at a high level at 1,297 ng/ml, he was given combination chemotherapy consisting of 3 cycles of PEB, cisplatin, etoposide and bleomycin and one cycle of PE, cisplatin and etoposide.	Bleomycin	184-193	alpha fetoprotein	Homo sapiens	16-33
18260360-5	2008	Since the serum alpha-fetoprotein (AFP) level was present at a high level at 1,297 ng/ml, he was given combination chemotherapy consisting of 3 cycles of PEB, cisplatin, etoposide and bleomycin and one cycle of PE, cisplatin and etoposide.	Bleomycin	184-193	alpha fetoprotein	Homo sapiens	35-38
18395486-7	2008	Furthermore, in vivo, neutralization of both JE and MCP5, the two functional orthologs of CCL2, during bleomycin-induced pulmonary fibrosis significantly reduced collagen deposition as well as JE and CCR2 expression.	Bleomycin	103-112	C-C motif chemokine receptor 2	Homo sapiens	200-204
18395486-8	2008	Also in the bleomycin model, CTGF, which is highly induced following TGFbeta stimulation, was attenuated with anti-JE/anti-MCP5 treatment.	Bleomycin	12-21	cellular communication network factor 2	Homo sapiens	29-33
18395486-8	2008	Also in the bleomycin model, CTGF, which is highly induced following TGFbeta stimulation, was attenuated with anti-JE/anti-MCP5 treatment.	Bleomycin	12-21	transforming growth factor beta 1	Homo sapiens	69-76
17951314-3	2007	The aim of this study was to examine the contribution of RAGE during the acute inflammation and chronic fibrotic phases of lung injury induced by intratracheal instillation of bleomycin in mice.	Bleomycin	176-185	advanced glycosylation end product-specific receptor	Mus musculus	57-61
17951314-4	2007	Bleomycin-induced lung fibrosis was evaluated in wild-type and RAGE-deficient (RAGE-/-) mice.	Bleomycin	0-9	advanced glycosylation end product-specific receptor	Mus musculus	79-87
17951314-8	2007	In addition, bleomycin administration induced high mobility group box 1 (HMGB-1) production, one of the ligands of RAGE, from inflammatory cells that accumulated within the air space.	Bleomycin	13-22	high mobility group box 1	Mus musculus	46-71
17951314-8	2007	In addition, bleomycin administration induced high mobility group box 1 (HMGB-1) production, one of the ligands of RAGE, from inflammatory cells that accumulated within the air space.	Bleomycin	13-22	high mobility group box 1	Mus musculus	73-79
17951314-8	2007	In addition, bleomycin administration induced high mobility group box 1 (HMGB-1) production, one of the ligands of RAGE, from inflammatory cells that accumulated within the air space.	Bleomycin	13-22	advanced glycosylation end product-specific receptor	Mus musculus	115-119
17673693-8	2007	In functional studies performed in the bleomycin-induced lung fibrosis model, the level of expression of these two genes was closely correlated with specific early events associated with lung fibrosis, namely activation of polymorphonuclear neutrophil-derived serine proteases and tumor necrosis factor-alpha-dependent inflammatory syndrome.	Bleomycin	39-48	tumor necrosis factor	Mus musculus	281-308
17951314-12	2007	Our results suggested that RAGE contributes to bleomycin-induced lung fibrosis through EMT and profibrotic cytokine production.	Bleomycin	47-56	advanced glycosylation end product-specific receptor	Mus musculus	27-31
17630322-4	2007	In the present study, we demonstrated increased expression of AGTR1 und AGTR2 in human and rodent lung tissues from patients with IPF and mice subjected to bleomycin-induced fibrosis, respectively.	Bleomycin	156-165	angiotensin II receptor type 1	Homo sapiens	62-67
17916677-0	2007	Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2.	Bleomycin	0-9	erb-b2 receptor tyrosine kinase 2	Mus musculus	86-90
17630322-4	2007	In the present study, we demonstrated increased expression of AGTR1 und AGTR2 in human and rodent lung tissues from patients with IPF and mice subjected to bleomycin-induced fibrosis, respectively.	Bleomycin	156-165	angiotensin II receptor type 2	Homo sapiens	72-77
17916677-2	2007	Transgenic mice unable to signal through HER2/HER3 had significantly less bleomycin-induced pulmonary fibrosis and showed a survival benefit.	Bleomycin	74-83	erb-b2 receptor tyrosine kinase 2	Mus musculus	41-45
17916677-2	2007	Transgenic mice unable to signal through HER2/HER3 had significantly less bleomycin-induced pulmonary fibrosis and showed a survival benefit.	Bleomycin	74-83	erb-b2 receptor tyrosine kinase 3	Mus musculus	46-50
17916677-4	2007	We tested this hypothesis in a bleomycin lung injury model using 2C4, a monoclonal antibody directed against HER2 that blocks HER2/HER3 signaling.	Bleomycin	31-40	erb-b2 receptor tyrosine kinase 2	Mus musculus	109-113
18008008-3	2007	TERT-deficient mice showed significantly reduced lung fibrosis following bleomycin (BLM) insult.	Bleomycin	73-82	telomerase reverse transcriptase	Mus musculus	0-4
17992263-6	2007	Exogenous rIL-1beta recapitulated a high degree of bleomycin-induced lung pathology, and specific blockade of IL-1R1 by IL-1 receptor antagonist dramatically reduced bleomycin-induced inflammation.	Bleomycin	51-60	interleukin 1 complex	Mus musculus	11-15
17992263-5	2007	Further, in bone marrow chimera experiments, bleomycin-induced inflammation required primarily MyD88 signaling from radioresistant resident cells.	Bleomycin	45-54	myeloid differentiation primary response gene 88	Mus musculus	95-100
17992263-6	2007	Exogenous rIL-1beta recapitulated a high degree of bleomycin-induced lung pathology, and specific blockade of IL-1R1 by IL-1 receptor antagonist dramatically reduced bleomycin-induced inflammation.	Bleomycin	51-60	interleukin 1 beta	Rattus norvegicus	10-19
17948061-5	2007	However, compared to wild-type mice, Tdp1-/- mice are hypersensitive to CPT and bleomycin but not to etoposide.	Bleomycin	80-89	tyrosyl-DNA phosphodiesterase 1	Mus musculus	37-41
18595259-15	2007	CONCLUSION: Early AT II apoptosis may be induced by bleomycin, which may be explained by the increase of intracellular free calcium concentration, depression of MMP, increased expressions of Fas and Bax, and increase of Caspase-3, Caspase-8, and Caspase-9 activities.	Bleomycin	52-61	BCL2 associated X, apoptosis regulator	Rattus norvegicus	199-202
18595259-15	2007	CONCLUSION: Early AT II apoptosis may be induced by bleomycin, which may be explained by the increase of intracellular free calcium concentration, depression of MMP, increased expressions of Fas and Bax, and increase of Caspase-3, Caspase-8, and Caspase-9 activities.	Bleomycin	52-61	caspase 3	Rattus norvegicus	220-229
18595259-15	2007	CONCLUSION: Early AT II apoptosis may be induced by bleomycin, which may be explained by the increase of intracellular free calcium concentration, depression of MMP, increased expressions of Fas and Bax, and increase of Caspase-3, Caspase-8, and Caspase-9 activities.	Bleomycin	52-61	caspase 8	Rattus norvegicus	231-240
18595259-15	2007	CONCLUSION: Early AT II apoptosis may be induced by bleomycin, which may be explained by the increase of intracellular free calcium concentration, depression of MMP, increased expressions of Fas and Bax, and increase of Caspase-3, Caspase-8, and Caspase-9 activities.	Bleomycin	52-61	caspase 9	Rattus norvegicus	246-255
17992263-6	2007	Exogenous rIL-1beta recapitulated a high degree of bleomycin-induced lung pathology, and specific blockade of IL-1R1 by IL-1 receptor antagonist dramatically reduced bleomycin-induced inflammation.	Bleomycin	166-175	interleukin 1 receptor, type I	Mus musculus	110-116
17992263-7	2007	Finally, we found that lung IL-1beta production and inflammation in response to bleomycin required ASC, an inflammasome adaptor molecule.	Bleomycin	80-89	interleukin 1 beta	Mus musculus	28-36
17992263-8	2007	In conclusion, bleomycin-induced lung pathology required the inflammasome and IL-1R1/MyD88 signaling, and IL-1 represented a critical effector of pathology and therapeutic target of chronic lung inflammation and fibrosis.	Bleomycin	15-24	interleukin 1 receptor, type I	Mus musculus	78-84
17992263-8	2007	In conclusion, bleomycin-induced lung pathology required the inflammasome and IL-1R1/MyD88 signaling, and IL-1 represented a critical effector of pathology and therapeutic target of chronic lung inflammation and fibrosis.	Bleomycin	15-24	myeloid differentiation primary response gene 88	Mus musculus	85-90
17992263-8	2007	In conclusion, bleomycin-induced lung pathology required the inflammasome and IL-1R1/MyD88 signaling, and IL-1 represented a critical effector of pathology and therapeutic target of chronic lung inflammation and fibrosis.	Bleomycin	15-24	interleukin 1 complex	Mus musculus	78-82
17923702-5	2007	Antibodies specific for acetyl-lysine 3016 demonstrate rapid (within 5 min) in vivo acetylation of ATM following exposure to bleomycin.	Bleomycin	125-134	ATM serine/threonine kinase	Homo sapiens	99-102
17958745-6	2007	We found that the lack of alpha2AP attenuated bleomycin-induced TGF-beta(1) synthesis and fibrosis.	Bleomycin	46-55	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	26-34
17600313-7	2007	When mice lacking MK2 (MK2-/-) were exposed to bleomycin, more collagen accumulated and more fibroblasts populated fibrotic regions in their lungs than in similarly treated wild-type mice.	Bleomycin	47-56	MAP kinase-activated protein kinase 2	Mus musculus	18-21
17600313-7	2007	When mice lacking MK2 (MK2-/-) were exposed to bleomycin, more collagen accumulated and more fibroblasts populated fibrotic regions in their lungs than in similarly treated wild-type mice.	Bleomycin	47-56	MAP kinase-activated protein kinase 2	Mus musculus	23-26
17600313-8	2007	While there were many vimentin-positive cells in the bleomycin-treated MK2-/- mouse lungs, few alpha-SMA-positive cells were observed in these lungs compared with wild-type mouse lungs.	Bleomycin	53-62	MAP kinase-activated protein kinase 2	Mus musculus	71-74
17958745-6	2007	We found that the lack of alpha2AP attenuated bleomycin-induced TGF-beta(1) synthesis and fibrosis.	Bleomycin	46-55	transforming growth factor, beta 1	Mus musculus	64-75
17717145-0	2007	Inhibitor of differentiation 1 promotes endothelial survival in a bleomycin model of lung injury in mice.	Bleomycin	66-75	inhibitor of DNA binding 1, HLH protein	Mus musculus	0-30
17641298-3	2007	We found, in a mouse model of bleomycin lung fibrosis, that SPHK1 and alpha-SMA were colocalized within lung fibrotic foci and that these expressions were significantly increased in primary cultured fibroblasts.	Bleomycin	30-39	sphingosine kinase 1	Mus musculus	60-65
17641298-3	2007	We found, in a mouse model of bleomycin lung fibrosis, that SPHK1 and alpha-SMA were colocalized within lung fibrotic foci and that these expressions were significantly increased in primary cultured fibroblasts.	Bleomycin	30-39	actin alpha 2, smooth muscle, aorta	Mus musculus	70-79
17717145-4	2007	In this study we found that, on bleomycin challenge, Id1 expression was significantly up-regulated in the lungs, predominantly in endothelial cells, as revealed by double immunolabeling and quantitative flow cytometric analysis.	Bleomycin	32-41	inhibitor of DNA binding 1, HLH protein	Mus musculus	53-56
17717145-5	2007	Mice with Id1 loss-of-function (Id1(-/-)) displayed increased vascular permeability and endothelial apoptosis in the lungs after bleomycin-induced injury.	Bleomycin	129-138	inhibitor of DNA binding 1, HLH protein	Mus musculus	10-13
17717145-5	2007	Mice with Id1 loss-of-function (Id1(-/-)) displayed increased vascular permeability and endothelial apoptosis in the lungs after bleomycin-induced injury.	Bleomycin	129-138	inhibitor of DNA binding 1, HLH protein	Mus musculus	32-35
17717145-6	2007	Cultured Id1(-/-) lung microvascular endothelial cells also showed decreased survival when exposed to bleomycin.	Bleomycin	102-111	inhibitor of DNA binding 1, HLH protein	Mus musculus	9-12
17717145-9	2007	In addition, bleomycin-exposed Id1(-/-) mice showed increased lung collagen accumulation and fibrogenesis, suggesting that Id1 up-regulation in the lung may play a critical role in lung homeostasis.	Bleomycin	13-22	inhibitor of DNA binding 1, HLH protein	Mus musculus	31-34
17717145-9	2007	In addition, bleomycin-exposed Id1(-/-) mice showed increased lung collagen accumulation and fibrogenesis, suggesting that Id1 up-regulation in the lung may play a critical role in lung homeostasis.	Bleomycin	13-22	inhibitor of DNA binding 1, HLH protein	Mus musculus	123-126
17991999-5	2007	These results suggest that H-NS plays an important role in both homologous recombination and repair of bleomycin-induced damage, while StpA can substitute the H-NS function.	Bleomycin	103-112	H-NS	Escherichia coli	27-31
17685459-0	2007	Polymorphism in nucleotide excision repair gene XPC correlates with bleomycin-induced chromosomal aberrations.	Bleomycin	68-77	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	48-51
17886030-0	2007	Recombinant human thioredoxin-1 becomes oxidized in circulation and suppresses bleomycin-induced neutrophil recruitment in the rat airway.	Bleomycin	79-88	thioredoxin 1	Rattus norvegicus	18-31
17886030-2	2007	This study investigated the optimal delivery method and the mechanisms of recombinant human TRX (rhTRX) to suppress neutrophil recruitment in a rat bleomycin (BLM)-induced sustained acute lung injury model.	Bleomycin	148-157	thioredoxin	Homo sapiens	92-95
17478448-3	2007	The present study evaluates the expression of caveolin-1, especially in bronchiolization, in C57BL/6J mice with bleomycin-induced lung fibrosis and in various types of re-epithelialization in human interstitial pneumonias (IPs).	Bleomycin	112-121	caveolin 1, caveolae protein	Mus musculus	46-56
17886030-2	2007	This study investigated the optimal delivery method and the mechanisms of recombinant human TRX (rhTRX) to suppress neutrophil recruitment in a rat bleomycin (BLM)-induced sustained acute lung injury model.	Bleomycin	159-162	thioredoxin	Homo sapiens	92-95
17883878-2	2007	We attempted to eradicate tumors derived from mouse colon cancer cells, CT26, by combining bleomycin (BLM)-incorporated HVJ-E (HVJ-E/BLM) with cisplatin (CDDP) administration.	Bleomycin	91-100	Bloom syndrome, RecQ like helicase	Mus musculus	102-105
17883878-2	2007	We attempted to eradicate tumors derived from mouse colon cancer cells, CT26, by combining bleomycin (BLM)-incorporated HVJ-E (HVJ-E/BLM) with cisplatin (CDDP) administration.	Bleomycin	91-100	Bloom syndrome, RecQ like helicase	Mus musculus	127-136
17496151-0	2007	Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis.	Bleomycin	40-49	prostaglandin-endoperoxide synthase 2	Mus musculus	0-16
17496151-5	2007	However, bleomycin-induced alterations in respiratory mechanics were more severe in COX-2 knockout mice than in wild-type mice, as illustrated by a greater decrease in static compliance compared with genotype-matched, saline-treated control mice (26 +/- 3% versus 11 +/- 4% decreases for COX-2 knockout and wild-type mice, respectively; P &lt; 0.05).	Bleomycin	9-18	cytochrome c oxidase II, mitochondrial	Mus musculus	84-89
17496151-5	2007	However, bleomycin-induced alterations in respiratory mechanics were more severe in COX-2 knockout mice than in wild-type mice, as illustrated by a greater decrease in static compliance compared with genotype-matched, saline-treated control mice (26 +/- 3% versus 11 +/- 4% decreases for COX-2 knockout and wild-type mice, respectively; P &lt; 0.05).	Bleomycin	9-18	cytochrome c oxidase II, mitochondrial	Mus musculus	288-293
17496151-7	2007	Whereas the fibrotic effects of bleomycin were not altered in wild-type or COX-2 knockout mice overexpressing COX-1, the exaggerated lung function decrement in bleomycin-treated COX-2 knockout mice was prevented by COX-1 overexpression and coincided with decreased airway cysteinyl leukotriene levels.	Bleomycin	160-169	cytochrome c oxidase II, mitochondrial	Mus musculus	178-183
17496151-7	2007	Whereas the fibrotic effects of bleomycin were not altered in wild-type or COX-2 knockout mice overexpressing COX-1, the exaggerated lung function decrement in bleomycin-treated COX-2 knockout mice was prevented by COX-1 overexpression and coincided with decreased airway cysteinyl leukotriene levels.	Bleomycin	160-169	cytochrome c oxidase I, mitochondrial	Mus musculus	215-220
17921313-4	2007	Moreover, loss of RAD51 caused marked hypersensitivity to the double-strand break-inducing agent bleomycin in P. patens but not in Arabidopsis.	Bleomycin	97-106	RAS associated with diabetes protein 51	Arabidopsis thaliana	18-23
17883846-0	2007	Host predisposition by endogenous Transforming Growth Factor-beta1 overexpression promotes pulmonary fibrosis following bleomycin injury.	Bleomycin	120-129	transforming growth factor, beta 1	Mus musculus	34-66
17785842-4	2007	We find that injections of rat SAP in rats reduce all of the above bleomycin-induced changes, suggesting that the SAP injections reduced the bleomycin-induced pulmonary fibrosis.	Bleomycin	67-76	amyloid P component, serum	Rattus norvegicus	31-34
17785842-4	2007	We find that injections of rat SAP in rats reduce all of the above bleomycin-induced changes, suggesting that the SAP injections reduced the bleomycin-induced pulmonary fibrosis.	Bleomycin	67-76	amyloid P component, serum	Rattus norvegicus	114-117
17785842-4	2007	We find that injections of rat SAP in rats reduce all of the above bleomycin-induced changes, suggesting that the SAP injections reduced the bleomycin-induced pulmonary fibrosis.	Bleomycin	141-150	amyloid P component, serum	Rattus norvegicus	31-34
17785842-4	2007	We find that injections of rat SAP in rats reduce all of the above bleomycin-induced changes, suggesting that the SAP injections reduced the bleomycin-induced pulmonary fibrosis.	Bleomycin	141-150	amyloid P component, serum	Rattus norvegicus	114-117
17785842-5	2007	We repeated these studies in mice, and find that injections of murine SAP decrease bleomycin-induced pulmonary fibrosis.	Bleomycin	83-92	amyloid P component, serum	Rattus norvegicus	70-73
17785842-7	2007	Delayed SAP injections also reduce the bleomycin-induced decrease in peripheral blood hemoglobin oxygen saturation, and an increase in lung collagen, leukocyte infiltration, and fibrosis.	Bleomycin	39-48	amyloid P component, serum	Rattus norvegicus	8-11
17463394-3	2007	After intratracheal instillation of bleomycin, SDF-1 levels in serum and bronchial alveolar lavage fluid increased.	Bleomycin	36-45	chemokine (C-X-C motif) ligand 12	Mus musculus	47-52
17463394-5	2007	Both SDF-1 and lung lysates from bleomycin-treated mice induced migration of bone marrow-derived stem cells in vitro that was blocked by a CXCR4 antagonist, TN14003.	Bleomycin	33-42	chemokine (C-X-C motif) ligand 12	Mus musculus	5-10
17463394-5	2007	Both SDF-1 and lung lysates from bleomycin-treated mice induced migration of bone marrow-derived stem cells in vitro that was blocked by a CXCR4 antagonist, TN14003.	Bleomycin	33-42	chemokine (C-X-C motif) receptor 4	Mus musculus	139-144
17463394-8	2007	Our data suggest that the SDF-1/CXCR4 axis is important in the complex sequence of events triggered by bleomycin exposure that eventuates in lung repair.	Bleomycin	103-112	chemokine (C-X-C motif) ligand 12	Mus musculus	26-31
17463394-8	2007	Our data suggest that the SDF-1/CXCR4 axis is important in the complex sequence of events triggered by bleomycin exposure that eventuates in lung repair.	Bleomycin	103-112	chemokine (C-X-C motif) receptor 4	Mus musculus	32-37
17478448-4	2007	Immunohistochemically, levels of caveolin-1 decreased in the bronchiolar epithelium of mice treated with bleomycin.	Bleomycin	105-114	caveolin 1, caveolae protein	Mus musculus	33-43
17636027-2	2007	Here we show that absence of the SQ/TQ cluster domain-containing protein Mdt1 (Ybl051c) renders Saccharomyces cerevisiae particularly hypersensitive to bleomycin, a drug that causes 3"-phospho-glycolate-blocked DNA double-strand breaks (DSBs).	Bleomycin	152-161	Pin4p	Saccharomyces cerevisiae S288C	73-77
17636027-5	2007	Epistasis analyses indicate that MDT1 acts in the repair of bleomycin-induced DSBs by regulating the efficiency of the homologous recombination pathway as well as telomere-related functions of the KU complex.	Bleomycin	60-69	Pin4p	Saccharomyces cerevisiae S288C	33-37
17569779-3	2007	We hypothesized that in combination with bleomycin injury, overexpression of CCL18 will worsen the severity of lung inflammation and fibrosis.	Bleomycin	41-50	C-C motif chemokine ligand 18	Homo sapiens	77-82
17825173-0	2007	Effect of intramuscular injection of hepatocyte growth factor plasmid DNA with electroporation on bleomycin-induced lung fibrosis in rats.	Bleomycin	98-107	hepatocyte growth factor	Rattus norvegicus	37-61
17825173-2	2007	The objective of this study was to determine whether intramuscular injection of the hepatocyte growth factor (HGF) plasmid DNA by in vivo electroporation could prevent bleomycin-induced pulmonary fibrosis in rats, and to investigate the possible mechanisms.	Bleomycin	168-177	hepatocyte growth factor	Rattus norvegicus	84-108
17825173-2	2007	The objective of this study was to determine whether intramuscular injection of the hepatocyte growth factor (HGF) plasmid DNA by in vivo electroporation could prevent bleomycin-induced pulmonary fibrosis in rats, and to investigate the possible mechanisms.	Bleomycin	168-177	hepatocyte growth factor	Rattus norvegicus	110-113
17825173-15	2007	CONCLUSIONS: Injection of the plasmid pcDNA3.1-hHGF into skeletal muscle with electroporation has a potential role in the treatment of bleomycin-induced lung fibrosis.	Bleomycin	135-144	hepatocyte growth factor	Homo sapiens	47-51
18070551-12	2007	The sry gene (322 bp) was detected in lungs of female rats receiving MSC on the first day of bleomycin induced lung injury.	Bleomycin	93-102	sex determining region Y	Rattus norvegicus	4-7
17569779-5	2007	Additive effects of CCL18 overexpression and bleomycin injury were observed on pulmonary inflammation, particularly on T-cell infiltration, and increased levels of tumor necrosis factor-alpha, interferon-gamma, matrix metalloproteinase (MMP)-2, and MMP-9.	Bleomycin	45-54	tumor necrosis factor	Mus musculus	164-191
17446530-5	2007	Fumagillin, an irreversible inhibitor of the enzymatic activity of MetAP2, attenuated collagen deposition in the bleomycin model of acute lung injury in mice.	Bleomycin	113-122	methionine aminopeptidase 2	Mus musculus	67-73
17569779-5	2007	Additive effects of CCL18 overexpression and bleomycin injury were observed on pulmonary inflammation, particularly on T-cell infiltration, and increased levels of tumor necrosis factor-alpha, interferon-gamma, matrix metalloproteinase (MMP)-2, and MMP-9.	Bleomycin	45-54	matrix metallopeptidase 2	Mus musculus	211-243
17569779-5	2007	Additive effects of CCL18 overexpression and bleomycin injury were observed on pulmonary inflammation, particularly on T-cell infiltration, and increased levels of tumor necrosis factor-alpha, interferon-gamma, matrix metalloproteinase (MMP)-2, and MMP-9.	Bleomycin	45-54	matrix metallopeptidase 9	Mus musculus	249-254
17569779-6	2007	Despite the additive effect on inflammation, CCL18 overexpression unexpectedly attenuated the bleomycin-induced collagen accumulation.	Bleomycin	94-103	C-C motif chemokine ligand 18	Homo sapiens	45-50
17655495-0	2007	Effect of bleomycin and cisplatin on the expression profile of SRA1, a novel member of pre-mRNA splicing factors, in HL-60 human promyelocytic leukemia cells.	Bleomycin	10-19	steroid receptor RNA activator 1	Homo sapiens	63-67
17655495-2	2007	In the present study, we investigated the significance of alterations at the mRNA expression levels of the SRA1 gene after treatment of HL-60 human promyelocytic leukemia cells with the anticancer drugs cisplatin and bleomycin.	Bleomycin	217-226	steroid receptor RNA activator 1	Homo sapiens	107-111
17655495-6	2007	The results showed that mRNA levels of SRA1 were up-regulated upon treatment with the antibiotic bleomycin, whereas they were down-regulated by treatment of HL-60 human promyelocytic leukemia cells with cisplatin.	Bleomycin	97-106	steroid receptor RNA activator 1	Homo sapiens	39-43
17579094-4	2007	We have recently reported that IL-6 and TGF-beta(1) plays an important role in proliferation and differentiation of lung fibroblasts, and all-trans-retinoic acid (ATRA) prevented bleomycin-induced lung fibrosis through the inhibition of these cytokines.	Bleomycin	179-188	interleukin 6	Mus musculus	31-35
17363777-5	2007	Seven days after intratracheal bleomycin (0.025 units), HPS1 and HPS2 mice exhibited increased mortality and diffuse pulmonary fibrosis compared to strain-matched C57BL/6J wild-type (WT) mice.	Bleomycin	31-40	HPS1, biogenesis of lysosomal organelles complex 3 subunit 1	Mus musculus	56-60
17363777-7	2007	The early airway and parenchymal cellular inflammatory responses to bleomycin were similar in HPS2 and WT mice.	Bleomycin	68-77	adaptor-related protein complex 3, beta 1 subunit	Mus musculus	94-98
17363777-8	2007	Greater elevations in levels of TGF-beta and IL-12p40 were produced in the lungs and AMs from bleomycin-challenged HPS mice than in WT mice.	Bleomycin	94-103	interleukin 12b	Mus musculus	45-53
17880775-0	2007	Glycogen synthase kinase-3beta inhibition attenuates the development of bleomycin-induced lung injury.	Bleomycin	72-81	glycogen synthase kinase 3 beta	Mus musculus	0-30
17880775-2	2007	The aim of this study is to investigate the effects of TDZD-8, a potent and selective GSK-3beta inhibitor, on the development of lung injury caused by administration of bleomycin (BLM).	Bleomycin	169-178	glycogen synthase kinase 3 beta	Mus musculus	86-95
17880775-2	2007	The aim of this study is to investigate the effects of TDZD-8, a potent and selective GSK-3beta inhibitor, on the development of lung injury caused by administration of bleomycin (BLM).	Bleomycin	180-183	glycogen synthase kinase 3 beta	Mus musculus	86-95
17880775-4	2007	An increase in immunoreactivity to nitrotyrosine, iNOS, TNF-alpha and IL-1beta was also observed in the lungs of BLM-treated mice.	Bleomycin	113-116	nitric oxide synthase 2, inducible	Mus musculus	50-54
17880775-4	2007	An increase in immunoreactivity to nitrotyrosine, iNOS, TNF-alpha and IL-1beta was also observed in the lungs of BLM-treated mice.	Bleomycin	113-116	tumor necrosis factor	Mus musculus	56-65
17880775-4	2007	An increase in immunoreactivity to nitrotyrosine, iNOS, TNF-alpha and IL-1beta was also observed in the lungs of BLM-treated mice.	Bleomycin	113-116	interleukin 1 beta	Mus musculus	70-78
17880775-5	2007	In contrast, administration of BLM-treated mice with TDZD-8 (1 mg/kg daily) significantly reduced (I) the degree of lung injury, (II) the increase in staining (immunohistochemistry) for myeloperoxidase (MPO), nitrotyrosine, iNOS, TNF-alpha and IL-1beta and (III) the degree of apoptosis, as evaluated by Bax and Bcl-2 immunoreactivity and TUNEL staining.	Bleomycin	31-34	myeloperoxidase	Mus musculus	186-201
17880775-5	2007	In contrast, administration of BLM-treated mice with TDZD-8 (1 mg/kg daily) significantly reduced (I) the degree of lung injury, (II) the increase in staining (immunohistochemistry) for myeloperoxidase (MPO), nitrotyrosine, iNOS, TNF-alpha and IL-1beta and (III) the degree of apoptosis, as evaluated by Bax and Bcl-2 immunoreactivity and TUNEL staining.	Bleomycin	31-34	myeloperoxidase	Mus musculus	203-206
17880775-5	2007	In contrast, administration of BLM-treated mice with TDZD-8 (1 mg/kg daily) significantly reduced (I) the degree of lung injury, (II) the increase in staining (immunohistochemistry) for myeloperoxidase (MPO), nitrotyrosine, iNOS, TNF-alpha and IL-1beta and (III) the degree of apoptosis, as evaluated by Bax and Bcl-2 immunoreactivity and TUNEL staining.	Bleomycin	31-34	nitric oxide synthase 2, inducible	Mus musculus	224-228
17880775-5	2007	In contrast, administration of BLM-treated mice with TDZD-8 (1 mg/kg daily) significantly reduced (I) the degree of lung injury, (II) the increase in staining (immunohistochemistry) for myeloperoxidase (MPO), nitrotyrosine, iNOS, TNF-alpha and IL-1beta and (III) the degree of apoptosis, as evaluated by Bax and Bcl-2 immunoreactivity and TUNEL staining.	Bleomycin	31-34	tumor necrosis factor	Mus musculus	230-239
17880775-5	2007	In contrast, administration of BLM-treated mice with TDZD-8 (1 mg/kg daily) significantly reduced (I) the degree of lung injury, (II) the increase in staining (immunohistochemistry) for myeloperoxidase (MPO), nitrotyrosine, iNOS, TNF-alpha and IL-1beta and (III) the degree of apoptosis, as evaluated by Bax and Bcl-2 immunoreactivity and TUNEL staining.	Bleomycin	31-34	interleukin 1 beta	Mus musculus	244-252
17880775-5	2007	In contrast, administration of BLM-treated mice with TDZD-8 (1 mg/kg daily) significantly reduced (I) the degree of lung injury, (II) the increase in staining (immunohistochemistry) for myeloperoxidase (MPO), nitrotyrosine, iNOS, TNF-alpha and IL-1beta and (III) the degree of apoptosis, as evaluated by Bax and Bcl-2 immunoreactivity and TUNEL staining.	Bleomycin	31-34	BCL2-associated X protein	Mus musculus	304-307
17880775-5	2007	In contrast, administration of BLM-treated mice with TDZD-8 (1 mg/kg daily) significantly reduced (I) the degree of lung injury, (II) the increase in staining (immunohistochemistry) for myeloperoxidase (MPO), nitrotyrosine, iNOS, TNF-alpha and IL-1beta and (III) the degree of apoptosis, as evaluated by Bax and Bcl-2 immunoreactivity and TUNEL staining.	Bleomycin	31-34	B cell leukemia/lymphoma 2	Mus musculus	312-317
17274978-0	2007	Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.	Bleomycin	56-65	transforming growth factor beta receptor 1	Homo sapiens	14-44
17431224-9	2007	MEASUREMENTS AND MAIN RESULTS: M-CSF-/- and CCL2-/- mice had less lung fibrosis, mononuclear phagocyte recruitment, collagen deposition, and connective tissue growth factor (CTGF) expression after bleomycin administration than wild-type littermates.	Bleomycin	197-206	colony stimulating factor 1 (macrophage)	Mus musculus	31-36
17431224-9	2007	MEASUREMENTS AND MAIN RESULTS: M-CSF-/- and CCL2-/- mice had less lung fibrosis, mononuclear phagocyte recruitment, collagen deposition, and connective tissue growth factor (CTGF) expression after bleomycin administration than wild-type littermates.	Bleomycin	197-206	chemokine (C-C motif) ligand 2	Mus musculus	44-48
17499192-0	2007	Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis.	Bleomycin	66-75	matrix metallopeptidase 2	Mus musculus	43-47
17499192-0	2007	Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis.	Bleomycin	66-75	tissue inhibitor of metalloproteinase 1	Mus musculus	48-54
17499192-7	2007	At day one, bleomycin elicited a raise in pro-MMP-9 level in BAL that was significantly attenuated in anti-PMN depleted mice, whereas TIMP-1 and MMP-2 release were similar in both groups at day(1) and day(14).	Bleomycin	12-21	matrix metallopeptidase 9	Mus musculus	42-51
17499192-7	2007	At day one, bleomycin elicited a raise in pro-MMP-9 level in BAL that was significantly attenuated in anti-PMN depleted mice, whereas TIMP-1 and MMP-2 release were similar in both groups at day(1) and day(14).	Bleomycin	12-21	tubulin-specific chaperone E	Mus musculus	107-110
17499192-9	2007	At day(14), bleomycin elicited a raise of TIMP-1 protein and RNA levels regardless of anti-PMN treatment, whereas MMP-9 returned to basal level.	Bleomycin	12-21	tissue inhibitor of metalloproteinase 1	Mus musculus	42-48
17499192-9	2007	At day(14), bleomycin elicited a raise of TIMP-1 protein and RNA levels regardless of anti-PMN treatment, whereas MMP-9 returned to basal level.	Bleomycin	12-21	tubulin-specific chaperone E	Mus musculus	91-94
17499192-10	2007	Bleomycin enhanced MMP-8 level in BAL at day(14) only for the control group.	Bleomycin	0-9	matrix metallopeptidase 8	Mus musculus	19-24
17442269-5	2007	Moreover, the telomere-specific KU mutation yku80-135i also dramatically increases rad52Delta bleomycin hypersensitivity, almost to the level of rad52Deltayku80Delta.	Bleomycin	94-103	ATP-dependent DNA helicase YKU80	Saccharomyces cerevisiae S288C	44-49
17569781-7	2007	Therefore, MSCs protect lung tissue from BLM-induced injury by blocking TNF-alpha and IL-1, two fundamental proinflammatory cytokines in lung.	Bleomycin	41-44	tumor necrosis factor	Mus musculus	72-81
17569781-7	2007	Therefore, MSCs protect lung tissue from BLM-induced injury by blocking TNF-alpha and IL-1, two fundamental proinflammatory cytokines in lung.	Bleomycin	41-44	interleukin 1 complex	Mus musculus	86-90
17331968-5	2007	Following bleomycin challenge, the strongest induction of tissue factor and plasminogen activator inhibitor (PAI)-1 mRNA expression was observed in alveolar macrophages (approximately 250- and 60-fold induction, respectively).	Bleomycin	10-19	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	109-112
17545612-4	2007	As evidenced by increased Ser(139)-phosphorylated histone H2AX (gammaH2AX), impaired Ku70 function diminished cellular capability to repair DNA DSBs induced by bleomycin, doxorubicin, and etoposide, thereby enhancing their cell-killing effect.	Bleomycin	160-169	H2A.X variant histone	Homo sapiens	50-62
17545612-4	2007	As evidenced by increased Ser(139)-phosphorylated histone H2AX (gammaH2AX), impaired Ku70 function diminished cellular capability to repair DNA DSBs induced by bleomycin, doxorubicin, and etoposide, thereby enhancing their cell-killing effect.	Bleomycin	160-169	X-ray repair cross complementing 6	Homo sapiens	85-89
17507800-6	2007	The chemosensitivity of C666-1 cells to bleomycin and cisplatin was enhanced by siRNA targeting LMP1.	Bleomycin	40-49	PDZ and LIM domain 7	Homo sapiens	96-100
17507800-8	2007	Also, cotransfection of constitutive active AKT plasmid with LMP-1 siRNA plasmid abrogates sensitivity of C666-1 to bleomycin and cisplatin.	Bleomycin	116-125	AKT serine/threonine kinase 1	Homo sapiens	44-47
17507800-8	2007	Also, cotransfection of constitutive active AKT plasmid with LMP-1 siRNA plasmid abrogates sensitivity of C666-1 to bleomycin and cisplatin.	Bleomycin	116-125	PDZ and LIM domain 7	Homo sapiens	61-66
17485510-6	2007	SEMA 7A also played an important role in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	61-70	sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin) 7A	Mus musculus	0-7
17387717-0	2007	Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression.	Bleomycin	14-23	transforming growth factor beta 1	Homo sapiens	68-77
17387717-4	2007	Bleomycin (BM), a potent antineoplastic antibiotic increases TGF-beta1 transcription, TGF-beta1 gene expression, and TGF-beta protein.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	61-70
17387717-4	2007	Bleomycin (BM), a potent antineoplastic antibiotic increases TGF-beta1 transcription, TGF-beta1 gene expression, and TGF-beta protein.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	86-95
17387717-4	2007	Bleomycin (BM), a potent antineoplastic antibiotic increases TGF-beta1 transcription, TGF-beta1 gene expression, and TGF-beta protein.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	61-69
17387717-4	2007	Bleomycin (BM), a potent antineoplastic antibiotic increases TGF-beta1 transcription, TGF-beta1 gene expression, and TGF-beta protein.	Bleomycin	11-13	transforming growth factor beta 1	Homo sapiens	61-70
17387717-4	2007	Bleomycin (BM), a potent antineoplastic antibiotic increases TGF-beta1 transcription, TGF-beta1 gene expression, and TGF-beta protein.	Bleomycin	11-13	transforming growth factor beta 1	Homo sapiens	86-95
17387717-4	2007	Bleomycin (BM), a potent antineoplastic antibiotic increases TGF-beta1 transcription, TGF-beta1 gene expression, and TGF-beta protein.	Bleomycin	11-13	transforming growth factor beta 1	Homo sapiens	61-69
17485510-7	2007	TGF-beta(1) and bleomycin also activated phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB)/AKT via SEMA 7A-dependent mechanisms, and PKB/AKT inhibition diminished TGF-beta(1)-induced fibrosis.	Bleomycin	16-25	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	41-70
17485510-7	2007	TGF-beta(1) and bleomycin also activated phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB)/AKT via SEMA 7A-dependent mechanisms, and PKB/AKT inhibition diminished TGF-beta(1)-induced fibrosis.	Bleomycin	16-25	thymoma viral proto-oncogene 1	Mus musculus	100-103
17485510-7	2007	TGF-beta(1) and bleomycin also activated phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB)/AKT via SEMA 7A-dependent mechanisms, and PKB/AKT inhibition diminished TGF-beta(1)-induced fibrosis.	Bleomycin	16-25	thymoma viral proto-oncogene 1	Mus musculus	105-108
17485510-7	2007	TGF-beta(1) and bleomycin also activated phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB)/AKT via SEMA 7A-dependent mechanisms, and PKB/AKT inhibition diminished TGF-beta(1)-induced fibrosis.	Bleomycin	16-25	sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin) 7A	Mus musculus	113-120
17485510-7	2007	TGF-beta(1) and bleomycin also activated phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB)/AKT via SEMA 7A-dependent mechanisms, and PKB/AKT inhibition diminished TGF-beta(1)-induced fibrosis.	Bleomycin	16-25	thymoma viral proto-oncogene 1	Mus musculus	147-150
17485510-7	2007	TGF-beta(1) and bleomycin also activated phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB)/AKT via SEMA 7A-dependent mechanisms, and PKB/AKT inhibition diminished TGF-beta(1)-induced fibrosis.	Bleomycin	16-25	thymoma viral proto-oncogene 1	Mus musculus	151-154
17485510-7	2007	TGF-beta(1) and bleomycin also activated phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB)/AKT via SEMA 7A-dependent mechanisms, and PKB/AKT inhibition diminished TGF-beta(1)-induced fibrosis.	Bleomycin	16-25	transforming growth factor, beta 1	Mus musculus	177-188
17593629-0	2007	Bleomycin induces caveolin-1 and -2 expression in epithelial lung cancer A549 cells.	Bleomycin	0-9	caveolin 1	Homo sapiens	18-35
17593629-2	2007	The expression of caveolin-1 and -2 in lung epithelial-derived A549 cells was analysed in terms of apoptosis after exposure to bleomycin.	Bleomycin	127-136	caveolin 1	Homo sapiens	18-35
17593629-6	2007	RESULTS: Caveolin-1 and -2 were up-regulated 1 h after exposure to bleomycin and preceding the occurrence of caspase-8, and of caspase-3 and caspase-9 cleavage products.	Bleomycin	67-76	caveolin 1	Homo sapiens	9-26
17593629-6	2007	RESULTS: Caveolin-1 and -2 were up-regulated 1 h after exposure to bleomycin and preceding the occurrence of caspase-8, and of caspase-3 and caspase-9 cleavage products.	Bleomycin	67-76	caspase 8	Homo sapiens	109-118
17593629-7	2007	Sucrose density gradient centrifugation revealed that bleomycin exposure led to a partial translocation of caveolin-1 from caveolin-rich membrane fractions to non-raft fractions.	Bleomycin	54-63	caveolin 1	Homo sapiens	107-117
17593629-9	2007	CONCLUSION: The early up-regulation of caveolin-1 and -2 following bleomycin exposure is a rather apoptosis-independent event related to other unknown mechanisms of bleomycin-mediated cell injury.	Bleomycin	67-76	caveolin 1	Homo sapiens	39-56
17593629-9	2007	CONCLUSION: The early up-regulation of caveolin-1 and -2 following bleomycin exposure is a rather apoptosis-independent event related to other unknown mechanisms of bleomycin-mediated cell injury.	Bleomycin	165-174	caveolin 1	Homo sapiens	39-56
17440075-5	2007	Mesothelial cells exposed to asbestos or bleomycin for 96 h acquired senescent-like morphology and displayed elevated senescence-associated beta-galactosidase activity, reduced bromodeoxyuridine (BrdUrd) incorporation, and reduced colony formation.	Bleomycin	41-50	galactosidase, beta 1	Mus musculus	140-158
17442973-0	2007	Dual effect of AMD3100, a CXCR4 antagonist, on bleomycin-induced lung inflammation.	Bleomycin	47-56	chemokine (C-X-C motif) receptor 4	Mus musculus	26-31
17147981-0	2007	SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice.	Bleomycin	62-71	mast cell protease 1	Mus musculus	31-36
17147981-0	2007	SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice.	Bleomycin	62-71	chemokine (C-C motif) ligand 4	Mus musculus	41-51
17147981-5	2007	In the early stages of bleomycin-induced skin lesions, immunohistochemical analysis showed the expression of both MCP-1 and MIP-1 beta in dermal inflammatory cells.	Bleomycin	23-32	mast cell protease 1	Mus musculus	114-119
17147981-5	2007	In the early stages of bleomycin-induced skin lesions, immunohistochemical analysis showed the expression of both MCP-1 and MIP-1 beta in dermal inflammatory cells.	Bleomycin	23-32	chemokine (C-C motif) ligand 4	Mus musculus	124-134
17322370-1	2007	We investigated the pathogenic roles of CC chemokine ligand (CCL)3 and its receptors, CC chemokine receptor (CCR)1 and CCR5, in bleomycin (BLM)-induced pulmonary fibrosis (PF).	Bleomycin	128-137	chemokine (C-C motif) ligand 3	Mus musculus	40-66
16990614-1	2007	The Fas/Fas ligand (FasL) apoptotic pathway has been shown to be involved in bleomycin-induced lung fibrosis.	Bleomycin	77-86	Fas ligand (TNF superfamily, member 6)	Mus musculus	20-24
16990614-4	2007	In addition, we show that FasL surface molecules are overexpressed on alpha-SMA-positive cells in mice with bleomycin-induced fibrosis, and in humans with idiopathic pulmonary fibrosis.	Bleomycin	108-117	Fas ligand (TNF superfamily, member 6)	Mus musculus	26-30
17526177-9	2007	CONCLUSION: Early stage application of HXD can alleviate bleomycin-induced alveolitis and pulmonary fibrosis in mice to certain degree, suggesting that Chinese herbs with supplementing qi and activating blood circulation effect could play a definite preventive action on pulmonary fibrosis, and the inhibition on expressions of TGF-beta1 in lung tissues may be one of the mechanisms.	Bleomycin	57-66	transforming growth factor, beta 1	Mus musculus	328-337
17706116-5	2007	After treatment with bleomycin, the expression of CD147 and MMP2 and 9 in both MCF7 and MCF7/AdrR cells remained unchanged (P &gt; 0.05).	Bleomycin	21-30	basigin (Ok blood group)	Homo sapiens	50-55
17706116-5	2007	After treatment with bleomycin, the expression of CD147 and MMP2 and 9 in both MCF7 and MCF7/AdrR cells remained unchanged (P &gt; 0.05).	Bleomycin	21-30	matrix metallopeptidase 2	Homo sapiens	60-64
17209037-9	2007	Finally, they demonstrate that Bax, Bid, and MMP-12 play similar roles in bleomycin-induced fibrosis, thereby highlighting the importance of this Bid-activated, Bax-mediated pathway and downstream MMP-12 in a variety of fibrogenic settings.	Bleomycin	74-83	BCL2-associated X protein	Mus musculus	31-34
17209037-9	2007	Finally, they demonstrate that Bax, Bid, and MMP-12 play similar roles in bleomycin-induced fibrosis, thereby highlighting the importance of this Bid-activated, Bax-mediated pathway and downstream MMP-12 in a variety of fibrogenic settings.	Bleomycin	74-83	BH3 interacting domain death agonist	Mus musculus	36-39
17209037-9	2007	Finally, they demonstrate that Bax, Bid, and MMP-12 play similar roles in bleomycin-induced fibrosis, thereby highlighting the importance of this Bid-activated, Bax-mediated pathway and downstream MMP-12 in a variety of fibrogenic settings.	Bleomycin	74-83	matrix metallopeptidase 12	Mus musculus	45-51
17209037-9	2007	Finally, they demonstrate that Bax, Bid, and MMP-12 play similar roles in bleomycin-induced fibrosis, thereby highlighting the importance of this Bid-activated, Bax-mediated pathway and downstream MMP-12 in a variety of fibrogenic settings.	Bleomycin	74-83	BH3 interacting domain death agonist	Mus musculus	146-149
17209037-9	2007	Finally, they demonstrate that Bax, Bid, and MMP-12 play similar roles in bleomycin-induced fibrosis, thereby highlighting the importance of this Bid-activated, Bax-mediated pathway and downstream MMP-12 in a variety of fibrogenic settings.	Bleomycin	74-83	BCL2-associated X protein	Mus musculus	161-164
17209037-9	2007	Finally, they demonstrate that Bax, Bid, and MMP-12 play similar roles in bleomycin-induced fibrosis, thereby highlighting the importance of this Bid-activated, Bax-mediated pathway and downstream MMP-12 in a variety of fibrogenic settings.	Bleomycin	74-83	matrix metallopeptidase 12	Mus musculus	197-203
17303001-6	2007	We induced Smad3 knockout mice lung fibrosis by bleomycin.	Bleomycin	48-57	SMAD family member 3	Mus musculus	11-16
17303001-11	2007	Compared to wild-type mice, Smad3 knockout mice showed attenuated lung fibrosis after bleomycin treatment, manifested by lower collagen production and myofibroblast differentiation.	Bleomycin	86-95	SMAD family member 3	Mus musculus	28-33
17322370-1	2007	We investigated the pathogenic roles of CC chemokine ligand (CCL)3 and its receptors, CC chemokine receptor (CCR)1 and CCR5, in bleomycin (BLM)-induced pulmonary fibrosis (PF).	Bleomycin	128-137	chemokine (C-C motif) receptor 1	Mus musculus	86-114
17307869-7	2007	Despite the well-established role of T-bet in adaptive immunity, we also show that RAG2(-/-) mice, which lack T and B cells, are vulnerable to bleomycin-induced scleroderma and that RAG2/T-bet double-deficient mice maintain the increased sensitivity to bleomycin observed in T-bet(-/-) mice.	Bleomycin	253-262	recombination activating gene 2	Mus musculus	182-186
17454104-1	2007	The authors have investigated gene expression of ST2 in the lung tissue of a bleomycin (BLM)-induced lung fibrosis model in vivo and in a human lung fibroblast cell line, WI38, and a human type II alveolar epithelial cell line, A549, reacting to proinflammatory and type 2 helper T cell (Th2)-type cytokine stimuli in vitro.	Bleomycin	77-86	ST2	Homo sapiens	49-52
17454104-1	2007	The authors have investigated gene expression of ST2 in the lung tissue of a bleomycin (BLM)-induced lung fibrosis model in vivo and in a human lung fibroblast cell line, WI38, and a human type II alveolar epithelial cell line, A549, reacting to proinflammatory and type 2 helper T cell (Th2)-type cytokine stimuli in vitro.	Bleomycin	88-91	ST2	Homo sapiens	49-52
16751304-8	2007	RESULTS: The bleomycin treatment led to considerable pulmonary fibrotic changes accompanied by marked increase in TGF-beta1 expression in infiltrating macrophages.	Bleomycin	13-22	transforming growth factor, beta 1	Mus musculus	114-123
17177178-0	2007	An essential role for CCAAT/enhancer binding protein beta in bleomycin-induced pulmonary fibrosis.	Bleomycin	61-70	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	22-57
17177178-5	2007	Our findings indicated that, compared to wild-type mice, animals deficient in C/EBPbeta showed significantly reduced fibrotic lesions and collagen deposition in the lung upon endotracheal injection of bleomycin.	Bleomycin	201-210	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	78-87
17177178-6	2007	Further studies on the mechanisms by which C/EBPbeta regulates fibrosis indicated that knockout of C/EBPbeta attenuates inflammatory cytokine expression in bleomycin-treated mice.	Bleomycin	156-165	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	43-52
17177178-6	2007	Further studies on the mechanisms by which C/EBPbeta regulates fibrosis indicated that knockout of C/EBPbeta attenuates inflammatory cytokine expression in bleomycin-treated mice.	Bleomycin	156-165	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	99-108
17572999-14	2007	(5) The expression of TGF-beta(1) mRNA in lung tissues in the curcumin group and the bleomycin group were 0.51 +/- 0.11, 0.59 +/- 0.13 at day 21, and 0.50 +/- 0.07, 0.64 +/- 0.11 at day 28, all being not statistically different between the two groups (q = 1.55, 3.13, all P &gt; 0.05).	Bleomycin	85-94	transforming growth factor, beta 1	Rattus norvegicus	22-33
17572999-15	2007	(6) The concentrations of IFN-gamma in BALF in the curcumin group and the bleomycin group were 0.49 +/- 0.17, 0.50 +/- 0.08 at day 21, and 0.52 +/- 0.15, 0.52 +/- 0.11 at day 28, all being not statistically different between the two groups (q = 1.85, 2.03, all P &gt; 0.05).	Bleomycin	74-83	interferon gamma	Rattus norvegicus	26-35
17572999-16	2007	(7) The expression of IFN-gamma mRNA in the curcumin group and the bleomycin group were (28 +/- 5) ng/L, (35 +/- 13) ng/L at day 21, and (30 +/- 11) ng/L, (39 +/- 13) ng/L at day 28, no significant difference between the two groups (q = 0.17, 0.00, all P &gt; 0.05).	Bleomycin	67-76	interferon gamma	Rattus norvegicus	22-31
17156798-4	2007	Contrary to this expectation, we observed that ade2 recombinants induced by bleomycin, beta-propiolactone, and ultraviolet radiation occur more frequently among trp5 convertants than among total colonies.	Bleomycin	76-85	phosphoribosylaminoimidazole carboxylase ADE2	Saccharomyces cerevisiae S288C	47-51
17156798-4	2007	Contrary to this expectation, we observed that ade2 recombinants induced by bleomycin, beta-propiolactone, and ultraviolet radiation occur more frequently among trp5 convertants than among total colonies.	Bleomycin	76-85	tryptophan synthase TRP5	Saccharomyces cerevisiae S288C	161-165
17304115-2	2007	The present research was designed to determine production and effects of alpha-MSH in acute bleomycin-induced lung injury in rats.	Bleomycin	92-101	proopiomelanocortin	Rattus norvegicus	73-82
17304115-3	2007	Intratracheal bleomycin instillation induced alpha-MSH expression in lung infiltrating cells and a marked peptide increase in the circulation.	Bleomycin	14-23	proopiomelanocortin	Rattus norvegicus	45-54
17304115-7	2007	Several stress-related genes, which were either upregulated or reduced by bleomycin, were only marginally altered during NDP-alpha-MSH treatment.	Bleomycin	74-83	proopiomelanocortin	Rattus norvegicus	125-134
17304115-8	2007	NDP-alpha-MSH prevented bleomycin-related transcriptional alterations in genes involved in lung fluid homeostasis, including upregulation of Na/K-transporting ATPase and epithelial sodium channels and downregulation of cystic fibrosis transmembrane conductance regulator.	Bleomycin	24-33	proopiomelanocortin	Rattus norvegicus	4-13
17304115-8	2007	NDP-alpha-MSH prevented bleomycin-related transcriptional alterations in genes involved in lung fluid homeostasis, including upregulation of Na/K-transporting ATPase and epithelial sodium channels and downregulation of cystic fibrosis transmembrane conductance regulator.	Bleomycin	24-33	CF transmembrane conductance regulator	Rattus norvegicus	219-270
17304115-9	2007	Bleomycin-induced expression of proinflammatory and profibrotic factors (interleukin 6, tumor necrosis factor-alpha, transforming growth factor-beta1, and inducible nitric oxide synthase) and chemokines (chemokine [C-C motif] ligand 2 and chemokine [C-C motif] ligand 5) was likewise significantly reduced by NDP-alpha-MSH.	Bleomycin	0-9	interleukin 6	Rattus norvegicus	73-149
17304115-9	2007	Bleomycin-induced expression of proinflammatory and profibrotic factors (interleukin 6, tumor necrosis factor-alpha, transforming growth factor-beta1, and inducible nitric oxide synthase) and chemokines (chemokine [C-C motif] ligand 2 and chemokine [C-C motif] ligand 5) was likewise significantly reduced by NDP-alpha-MSH.	Bleomycin	0-9	nitric oxide synthase 2	Rattus norvegicus	155-186
17304115-9	2007	Bleomycin-induced expression of proinflammatory and profibrotic factors (interleukin 6, tumor necrosis factor-alpha, transforming growth factor-beta1, and inducible nitric oxide synthase) and chemokines (chemokine [C-C motif] ligand 2 and chemokine [C-C motif] ligand 5) was likewise significantly reduced by NDP-alpha-MSH.	Bleomycin	0-9	C-C motif chemokine ligand 2	Rattus norvegicus	204-269
17304115-9	2007	Bleomycin-induced expression of proinflammatory and profibrotic factors (interleukin 6, tumor necrosis factor-alpha, transforming growth factor-beta1, and inducible nitric oxide synthase) and chemokines (chemokine [C-C motif] ligand 2 and chemokine [C-C motif] ligand 5) was likewise significantly reduced by NDP-alpha-MSH.	Bleomycin	0-9	proopiomelanocortin	Rattus norvegicus	313-322
17304115-10	2007	In conclusion, treatment with the alpha-MSH analogue NDP-alpha-MSH greatly improved the clinical and molecular picture of bleomycin-induced lung injury.	Bleomycin	122-131	proopiomelanocortin	Rattus norvegicus	34-43
17304115-10	2007	In conclusion, treatment with the alpha-MSH analogue NDP-alpha-MSH greatly improved the clinical and molecular picture of bleomycin-induced lung injury.	Bleomycin	122-131	proopiomelanocortin	Rattus norvegicus	57-66
17307869-6	2007	In this study, we show that mice deficient in the transcription factor T-box expressed in T cells (T-bet), a master regulator of type 1 immunity, display increased sensitivity to bleomycin-induced dermal sclerosis.	Bleomycin	179-188	T-box 21	Mus musculus	99-104
17307869-7	2007	Despite the well-established role of T-bet in adaptive immunity, we also show that RAG2(-/-) mice, which lack T and B cells, are vulnerable to bleomycin-induced scleroderma and that RAG2/T-bet double-deficient mice maintain the increased sensitivity to bleomycin observed in T-bet(-/-) mice.	Bleomycin	143-152	recombination activating gene 2	Mus musculus	83-87
17307869-7	2007	Despite the well-established role of T-bet in adaptive immunity, we also show that RAG2(-/-) mice, which lack T and B cells, are vulnerable to bleomycin-induced scleroderma and that RAG2/T-bet double-deficient mice maintain the increased sensitivity to bleomycin observed in T-bet(-/-) mice.	Bleomycin	253-262	T-box 21	Mus musculus	187-192
17307869-7	2007	Despite the well-established role of T-bet in adaptive immunity, we also show that RAG2(-/-) mice, which lack T and B cells, are vulnerable to bleomycin-induced scleroderma and that RAG2/T-bet double-deficient mice maintain the increased sensitivity to bleomycin observed in T-bet(-/-) mice.	Bleomycin	253-262	T-box 21	Mus musculus	187-192
17200183-0	2007	Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis.	Bleomycin	50-59	elastase, neutrophil expressed	Mus musculus	13-32
17241526-7	2007	After bleomycin was injected intratracheally, increases in the lung AT1 receptor and ACE activity were observed by d 1, 3 and 7.	Bleomycin	6-15	angiotensin I converting enzyme	Rattus norvegicus	85-88
17056705-0	2007	Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis.	Bleomycin	69-78	hepatocyte growth factor	Homo sapiens	17-41
17056705-5	2007	Electroporation-mediated, nonviral gene transfer of HGF in vivo was performed 7 days after bleomycin-induced lung injury in the rat.	Bleomycin	91-100	hepatocyte growth factor	Rattus norvegicus	52-55
17056705-7	2007	Electroporation-mediated in vivo HGF gene transfer using pCikhHGF 7 days after intratracheal bleomycin reduced pulmonary fibrosis as assessed by histology and hydroxyproline determination 14 days after bleomycin compared with controls treated with the same vector not containing the HGF sequence (pCik).	Bleomycin	93-102	hepatocyte growth factor	Homo sapiens	33-36
17056705-7	2007	Electroporation-mediated in vivo HGF gene transfer using pCikhHGF 7 days after intratracheal bleomycin reduced pulmonary fibrosis as assessed by histology and hydroxyproline determination 14 days after bleomycin compared with controls treated with the same vector not containing the HGF sequence (pCik).	Bleomycin	93-102	hepatocyte growth factor	Homo sapiens	62-65
17056705-7	2007	Electroporation-mediated in vivo HGF gene transfer using pCikhHGF 7 days after intratracheal bleomycin reduced pulmonary fibrosis as assessed by histology and hydroxyproline determination 14 days after bleomycin compared with controls treated with the same vector not containing the HGF sequence (pCik).	Bleomycin	202-211	hepatocyte growth factor	Homo sapiens	33-36
17056705-7	2007	Electroporation-mediated in vivo HGF gene transfer using pCikhHGF 7 days after intratracheal bleomycin reduced pulmonary fibrosis as assessed by histology and hydroxyproline determination 14 days after bleomycin compared with controls treated with the same vector not containing the HGF sequence (pCik).	Bleomycin	202-211	hepatocyte growth factor	Homo sapiens	62-65
17056705-10	2007	In conclusion, electroporation-mediated gene transfer of hHGF decreases bleomycin-induced pulmonary fibrosis, possibly by increasing alveolar epithelial cell proliferation and reducing apoptosis, resulting in improved alveolar wound repair.	Bleomycin	72-81	hepatocyte growth factor	Homo sapiens	57-61
17189489-1	2007	The QDR2 gene of Saccharomyces cerevisiae encodes a putative plasma membrane drug:H(+) antiporter that confers resistance against quinidine, barban, bleomycin, and cisplatin.	Bleomycin	149-158	cation transporter	Saccharomyces cerevisiae S288C	4-8
16931807-13	2007	We conclude there is sustained activation of Smad signaling in lung fibroblasts isolated from bleomycin-exposed rats, with an imbalance between the levels of p-Smad3 and Smad7.	Bleomycin	94-103	SMAD family member 7	Rattus norvegicus	45-49
16931807-13	2007	We conclude there is sustained activation of Smad signaling in lung fibroblasts isolated from bleomycin-exposed rats, with an imbalance between the levels of p-Smad3 and Smad7.	Bleomycin	94-103	SMAD family member 3	Rattus norvegicus	160-165
16931807-13	2007	We conclude there is sustained activation of Smad signaling in lung fibroblasts isolated from bleomycin-exposed rats, with an imbalance between the levels of p-Smad3 and Smad7.	Bleomycin	94-103	SMAD family member 7	Rattus norvegicus	170-175
17102953-6	2007	Our findings that lpr and gld mice were resistant to the induction of dermal sclerosis by bleomycin further suggest that Fas/FasL pathway is an important contributor involved in the pathophysiology of bleomycin-induced dermal sclerosis.	Bleomycin	90-99	Fas ligand (TNF superfamily, member 6)	Mus musculus	125-129
17102953-6	2007	Our findings that lpr and gld mice were resistant to the induction of dermal sclerosis by bleomycin further suggest that Fas/FasL pathway is an important contributor involved in the pathophysiology of bleomycin-induced dermal sclerosis.	Bleomycin	201-210	Fas ligand (TNF superfamily, member 6)	Mus musculus	125-129
17283121-7	2007	Treatment with bleomycin, a DNA-damaging alkylating agent, induced polyADP-ribosylation of PARP-1 protein and inhibited its interaction with TCF-4.	Bleomycin	15-24	poly(ADP-ribose) polymerase 1	Homo sapiens	91-97
17283121-7	2007	Treatment with bleomycin, a DNA-damaging alkylating agent, induced polyADP-ribosylation of PARP-1 protein and inhibited its interaction with TCF-4.	Bleomycin	15-24	transcription factor 7 like 2	Homo sapiens	141-146
17283121-8	2007	Bleomycin conversely increased the amounts of Ku70 coimmunoprecipitated with TCF-4 and removed beta-catenin from TCF-4.	Bleomycin	0-9	X-ray repair cross complementing 6	Homo sapiens	46-50
17283121-8	2007	Bleomycin conversely increased the amounts of Ku70 coimmunoprecipitated with TCF-4 and removed beta-catenin from TCF-4.	Bleomycin	0-9	transcription factor 7 like 2	Homo sapiens	77-82
17283121-8	2007	Bleomycin conversely increased the amounts of Ku70 coimmunoprecipitated with TCF-4 and removed beta-catenin from TCF-4.	Bleomycin	0-9	catenin beta 1	Homo sapiens	95-107
17283121-8	2007	Bleomycin conversely increased the amounts of Ku70 coimmunoprecipitated with TCF-4 and removed beta-catenin from TCF-4.	Bleomycin	0-9	transcription factor 7 like 2	Homo sapiens	113-118
17007609-1	2007	Bleomycin hydrolase (BH) is a hexameric papain family cysteine protease which is involved in preparing peptides for antigen presentation and has been implicated in tumour cell resistance to bleomycin chemotherapy.	Bleomycin	190-199	bleomycin hydrolase	Saccharomyces cerevisiae S288C	0-19
16998095-8	2007	The role of the chemokine CXCL12 in disease pathogenesis was confirmed in the murine bleomycin model of lung injury, with C57BL/6(CXCR4+/-) mice demonstrating significantly less collagen deposition than C57BL/6(CXCR4+/+) mice.	Bleomycin	85-94	chemokine (C-X-C motif) ligand 12	Mus musculus	26-32
17200183-4	2007	In neutrophil elastase-null mice, biochemical and morphological characteristics of pulmonary fibrosis were attenuated for at least 60 days after bleomycin administration despite a typical response to bleomycin as evidenced by assessment of indices of DNA and cell damage.	Bleomycin	145-154	elastase, neutrophil expressed	Mus musculus	3-22
17200183-4	2007	In neutrophil elastase-null mice, biochemical and morphological characteristics of pulmonary fibrosis were attenuated for at least 60 days after bleomycin administration despite a typical response to bleomycin as evidenced by assessment of indices of DNA and cell damage.	Bleomycin	200-209	elastase, neutrophil expressed	Mus musculus	3-22
17200183-5	2007	Neutrophil burden of bleomycin-treated wild-type and neutrophil elastase-null mice was comparable, and marked neutrophilic alveolitis was manifest in bleomycin-treated neutrophil elastase-null mice.	Bleomycin	21-30	elastase, neutrophil expressed	Mus musculus	53-72
17200183-5	2007	Neutrophil burden of bleomycin-treated wild-type and neutrophil elastase-null mice was comparable, and marked neutrophilic alveolitis was manifest in bleomycin-treated neutrophil elastase-null mice.	Bleomycin	150-159	elastase, neutrophil expressed	Mus musculus	168-187
17200183-6	2007	An absence of immunostaining for active transforming growth factor (TGF)-beta in lung tissue from bleomycin-treated neutrophil elastase-null mice suggested a defect in TGF-beta activation, which was confirmed by biochemical assessment of TGF-beta levels in bronchoalveolar lavage fluid and lung tissue.	Bleomycin	98-107	elastase, neutrophil expressed	Mus musculus	116-135
17200183-6	2007	An absence of immunostaining for active transforming growth factor (TGF)-beta in lung tissue from bleomycin-treated neutrophil elastase-null mice suggested a defect in TGF-beta activation, which was confirmed by biochemical assessment of TGF-beta levels in bronchoalveolar lavage fluid and lung tissue.	Bleomycin	98-107	transforming growth factor, beta 1	Mus musculus	168-176
17200183-6	2007	An absence of immunostaining for active transforming growth factor (TGF)-beta in lung tissue from bleomycin-treated neutrophil elastase-null mice suggested a defect in TGF-beta activation, which was confirmed by biochemical assessment of TGF-beta levels in bronchoalveolar lavage fluid and lung tissue.	Bleomycin	98-107	transforming growth factor, beta 1	Mus musculus	238-246
17135359-5	2007	When compared with bleomycin-treated GITR+/+ mice, bleomycin-treated GITR-/- mice exhibited a reduced degree of i) lung infiltration with polymorphonuclear neutrophils (MPO activity); ii) edema formation; iii) histological evidence of lung injury; iv) TNF-alpha and interleukin (IL)-1beta production; v) nitrotyrosine formation; and vi) NF-kappaB activation.	Bleomycin	51-60	tumor necrosis factor receptor superfamily, member 18	Mus musculus	69-73
17504234-0	2007	Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA.	Bleomycin	15-24	angiotensinogen	Rattus norvegicus	122-137
17504234-2	2007	Previous studies showed that apoptosis of alveolar epithelial cells in response to BLEO could be abrogated by antisense oligonucleotides against angiotensinogen (AGT) mRNA and requires angiotensin II (ANG II) synthesis de novo [17].	Bleomycin	83-87	angiotensinogen	Rattus norvegicus	145-160
17504234-2	2007	Previous studies showed that apoptosis of alveolar epithelial cells in response to BLEO could be abrogated by antisense oligonucleotides against angiotensinogen (AGT) mRNA and requires angiotensin II (ANG II) synthesis de novo [17].	Bleomycin	83-87	angiotensinogen	Rattus norvegicus	162-165
17504234-2	2007	Previous studies showed that apoptosis of alveolar epithelial cells in response to BLEO could be abrogated by antisense oligonucleotides against angiotensinogen (AGT) mRNA and requires angiotensin II (ANG II) synthesis de novo [17].	Bleomycin	83-87	angiotensinogen	Rattus norvegicus	185-199
17504234-2	2007	Previous studies showed that apoptosis of alveolar epithelial cells in response to BLEO could be abrogated by antisense oligonucleotides against angiotensinogen (AGT) mRNA and requires angiotensin II (ANG II) synthesis de novo [17].	Bleomycin	83-87	angiotensinogen	Rattus norvegicus	201-207
17504234-4	2007	administration of antisense oligonucleotides against AGT mRNA might attenuate BLEO-induced apoptosis of AECs and prevent pulmonary fibrosis.	Bleomycin	78-82	angiotensinogen	Rattus norvegicus	53-56
17504234-5	2007	In a BLEO-induced rat model of lung fibrosis, endogenous lung AGT was upregulated in vivo as early as 3 hours after BLEO instillation, as detected by RT-PCR, in situ hybridization and immunohistochemistry.	Bleomycin	5-9	angiotensinogen	Rattus norvegicus	62-65
17504234-5	2007	In a BLEO-induced rat model of lung fibrosis, endogenous lung AGT was upregulated in vivo as early as 3 hours after BLEO instillation, as detected by RT-PCR, in situ hybridization and immunohistochemistry.	Bleomycin	116-120	angiotensinogen	Rattus norvegicus	62-65
17504234-9	2007	The intratracheal AGT antisense reduced BLEO-induced pulmonary fibrosis measured by lung hydroxyproline assay, decreased lung AGT and active caspase-3 proteins, and reduced the number of apoptotic epithelial cells but had no effect on the serum ANG II concentration.	Bleomycin	40-44	angiotensinogen	Rattus norvegicus	18-21
17504234-10	2007	These data are consistent with the hypothesis that lung-derived AGT and local pulmonary ANG II are required for BLEO-induced pulmonary fibrosis, and suggest the possibility of antisense-based manipulation of the local angiotensin system as a potential treatment of fibrotic lung diseases.	Bleomycin	112-116	angiotensinogen	Rattus norvegicus	64-67
17504234-10	2007	These data are consistent with the hypothesis that lung-derived AGT and local pulmonary ANG II are required for BLEO-induced pulmonary fibrosis, and suggest the possibility of antisense-based manipulation of the local angiotensin system as a potential treatment of fibrotic lung diseases.	Bleomycin	112-116	angiotensinogen	Rattus norvegicus	88-94
17135359-0	2007	Genetic and pharmacological inhibition of GITR-GITRL interaction reduces chronic lung injury induced by bleomycin instillation.	Bleomycin	104-113	tumor necrosis factor receptor superfamily, member 18	Mus musculus	42-46
17135359-0	2007	Genetic and pharmacological inhibition of GITR-GITRL interaction reduces chronic lung injury induced by bleomycin instillation.	Bleomycin	104-113	tumor necrosis factor (ligand) superfamily, member 18	Mus musculus	47-52
17135359-5	2007	When compared with bleomycin-treated GITR+/+ mice, bleomycin-treated GITR-/- mice exhibited a reduced degree of i) lung infiltration with polymorphonuclear neutrophils (MPO activity); ii) edema formation; iii) histological evidence of lung injury; iv) TNF-alpha and interleukin (IL)-1beta production; v) nitrotyrosine formation; and vi) NF-kappaB activation.	Bleomycin	51-60	myeloperoxidase	Mus musculus	169-172
17135359-5	2007	When compared with bleomycin-treated GITR+/+ mice, bleomycin-treated GITR-/- mice exhibited a reduced degree of i) lung infiltration with polymorphonuclear neutrophils (MPO activity); ii) edema formation; iii) histological evidence of lung injury; iv) TNF-alpha and interleukin (IL)-1beta production; v) nitrotyrosine formation; and vi) NF-kappaB activation.	Bleomycin	19-28	tumor necrosis factor receptor superfamily, member 18	Mus musculus	37-41
17135359-5	2007	When compared with bleomycin-treated GITR+/+ mice, bleomycin-treated GITR-/- mice exhibited a reduced degree of i) lung infiltration with polymorphonuclear neutrophils (MPO activity); ii) edema formation; iii) histological evidence of lung injury; iv) TNF-alpha and interleukin (IL)-1beta production; v) nitrotyrosine formation; and vi) NF-kappaB activation.	Bleomycin	51-60	tumor necrosis factor	Mus musculus	252-261
17135359-5	2007	When compared with bleomycin-treated GITR+/+ mice, bleomycin-treated GITR-/- mice exhibited a reduced degree of i) lung infiltration with polymorphonuclear neutrophils (MPO activity); ii) edema formation; iii) histological evidence of lung injury; iv) TNF-alpha and interleukin (IL)-1beta production; v) nitrotyrosine formation; and vi) NF-kappaB activation.	Bleomycin	51-60	interleukin 1 beta	Mus musculus	266-288
17135359-7	2007	Our results clearly demonstrate that GITR-GITRL interaction plays an important role in the chronic lung injury induced by bleomycin in the mice.	Bleomycin	122-131	tumor necrosis factor receptor superfamily, member 18	Mus musculus	37-41
17135359-7	2007	Our results clearly demonstrate that GITR-GITRL interaction plays an important role in the chronic lung injury induced by bleomycin in the mice.	Bleomycin	122-131	tumor necrosis factor (ligand) superfamily, member 18	Mus musculus	42-47
17702637-0	2007	Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin.	Bleomycin	79-88	matrix metallopeptidase 9	Mus musculus	18-22
17662641-0	2007	Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells.	Bleomycin	37-46	caveolin 1	Homo sapiens	18-28
17702637-7	2007	Using IGFBP-3 substrate zymography we found that BAL from TG mice at 1 week after bleomycin cleaved IGFBP-3.	Bleomycin	82-91	insulin-like growth factor binding protein 3	Mus musculus	100-107
17702637-3	2007	We studied the effect of MMP9 overexpression in bleomycin-driven lung fibrosis using transgenic mice expressing human MMP9 in alveolar macrophages (hMMP9-TG).	Bleomycin	48-57	matrix metallopeptidase 9	Mus musculus	25-29
17662641-1	2007	Bleomycin is an anti-cancer drug that induces both apoptosis and senescence, two processes thought to involve caveolin-1.	Bleomycin	0-9	caveolin 1	Homo sapiens	110-120
17662641-2	2007	Here we investigate the role of caveolin-1 in bleomycin-induced senescence.	Bleomycin	46-55	caveolin 1	Homo sapiens	32-42
17702637-5	2007	The decreased fibrosis in hMMP9-TG mice was preceded by a significant reduction of neutrophils and lymphocytes in bronchoalveolar lavage (BAL) at 1 and 4 weeks post-bleomycin, respectively, as well as by significantly less TIMP-1 than the WT mice.	Bleomycin	165-174	matrix metallopeptidase 9	Homo sapiens	26-31
17662641-3	2007	We show that bleomycin-treated A549 cells exhibit: senescence-like cell morphology; a senescence-associated increase in SA-beta-galactosidase activity; cell cycle arrest; and upregulation of p53 and p21.	Bleomycin	13-22	galactosidase beta 1	Homo sapiens	123-141
17179647-9	2007	Cells treated with the combination of HFEMF at SARs from 50 to 200 W/kg and bleomycin exhibited increased HPRT mutations.	Bleomycin	76-85	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	106-110
17662641-3	2007	We show that bleomycin-treated A549 cells exhibit: senescence-like cell morphology; a senescence-associated increase in SA-beta-galactosidase activity; cell cycle arrest; and upregulation of p53 and p21.	Bleomycin	13-22	tumor protein p53	Homo sapiens	191-194
17662641-3	2007	We show that bleomycin-treated A549 cells exhibit: senescence-like cell morphology; a senescence-associated increase in SA-beta-galactosidase activity; cell cycle arrest; and upregulation of p53 and p21.	Bleomycin	13-22	H3 histone pseudogene 16	Homo sapiens	199-202
17662641-4	2007	As predicted, we find that caveolin-1 amount increases in response to bleomycin-treatment and that modulation of caveolin-1 affects p21 and p53 levels, cell cycling, and senescence (SA-beta-galactosidase activity).	Bleomycin	70-79	caveolin 1	Homo sapiens	27-37
17662641-4	2007	As predicted, we find that caveolin-1 amount increases in response to bleomycin-treatment and that modulation of caveolin-1 affects p21 and p53 levels, cell cycling, and senescence (SA-beta-galactosidase activity).	Bleomycin	70-79	galactosidase beta 1	Homo sapiens	185-203
17662641-5	2007	Interestingly, senescence-associated cell cycle arrest via p53 and p21 and SA-beta-galactosidase activity is reduced in young A549 cells when short hairpin RNA specific for caveolin-1 was applied before bleomycin-treatment.	Bleomycin	203-212	galactosidase beta 1	Homo sapiens	78-96
17662641-5	2007	Interestingly, senescence-associated cell cycle arrest via p53 and p21 and SA-beta-galactosidase activity is reduced in young A549 cells when short hairpin RNA specific for caveolin-1 was applied before bleomycin-treatment.	Bleomycin	203-212	caveolin 1	Homo sapiens	173-183
17662641-6	2007	Our results support the hypothesis that downregulation of caveolin-1 expression affects bleomycin-induced cell cycle arrest and subsequent cellular senescence that is driven by p53 and p21.	Bleomycin	88-97	caveolin 1	Homo sapiens	58-68
17662641-6	2007	Our results support the hypothesis that downregulation of caveolin-1 expression affects bleomycin-induced cell cycle arrest and subsequent cellular senescence that is driven by p53 and p21.	Bleomycin	88-97	tumor protein p53	Homo sapiens	177-180
17662641-6	2007	Our results support the hypothesis that downregulation of caveolin-1 expression affects bleomycin-induced cell cycle arrest and subsequent cellular senescence that is driven by p53 and p21.	Bleomycin	88-97	H3 histone pseudogene 16	Homo sapiens	185-188
17035056-6	2007	Bleomycin caused a significant decrease in lung GSH, which was accompanied with significant increases in MDA level, MPO activity, and collagen contents of the lung tissue concomitant with increased levels of the pro-inflammatory mediators and cell count in BALF.	Bleomycin	0-9	myeloperoxidase	Rattus norvegicus	116-119
17710235-8	2007	In the mouse model of lung fibrosis induced by bleomycin, a PPARalpha agonist significantly inhibited the fibrotic response, while PPARalpha knockout mice developed more serious fibrosis.	Bleomycin	47-56	peroxisome proliferator activated receptor alpha	Mus musculus	60-69
16840775-5	2006	A recent study using bleomycin-exposed mice showed that manipulations of the plasminogen activation system influenced the amount of free HGF within bronchoalveolar lavage fluid without affecting total lung HGF mRNA or protein.	Bleomycin	21-30	plasminogen	Mus musculus	77-88
17178917-4	2006	We also demonstrated that cav-1 markedly ameliorated bleomycin (BLM)-induced pulmonary fibrosis, as indicated by histological analysis, hydroxyproline content, and immunoblot analysis.	Bleomycin	53-62	caveolin 1	Homo sapiens	26-31
17178917-4	2006	We also demonstrated that cav-1 markedly ameliorated bleomycin (BLM)-induced pulmonary fibrosis, as indicated by histological analysis, hydroxyproline content, and immunoblot analysis.	Bleomycin	64-67	caveolin 1	Homo sapiens	26-31
16840775-5	2006	A recent study using bleomycin-exposed mice showed that manipulations of the plasminogen activation system influenced the amount of free HGF within bronchoalveolar lavage fluid without affecting total lung HGF mRNA or protein.	Bleomycin	21-30	hepatocyte growth factor	Mus musculus	137-140
17031387-7	2006	The antitumour/proapoptotic effects of doxorubicin and bleomycin were assessed by cell proliferation and caspase-3 activity assay.	Bleomycin	55-64	caspase 3	Homo sapiens	105-114
17078097-4	2006	We reisolated the SPT10 gene in a functional genome-wide screen designed to identify haploid yeast mutants that are hypersensitive to the antitumor drug bleomycin, which acts by damaging DNA.	Bleomycin	153-162	Spt10p	Saccharomyces cerevisiae S288C	18-23
17065376-7	2006	Surprisingly, although Smad3 null mice, deficient in TGF-beta signal transmission, are resistant to bleomycin- and TGF-beta-mediated fibrosis, they develop spontaneous age-related airspace enlargement, consistent with emphysema, with a lack of ability to repair tissue damage appropriately.	Bleomycin	100-109	SMAD family member 3	Mus musculus	23-28
16788144-6	2006	Activation of ATM and the MRN complex by hypertonicity and bleomycin was additive as was activation of their downstream targets including gammaH2AX and Chk2 indicating that the cellular response to DSB was intact in hypertonic conditions.	Bleomycin	59-68	ATM serine/threonine kinase	Homo sapiens	14-17
16879607-1	2006	OBJECTIVES: To evaluate the prognostic role of pretreatment serum levels of soluble CD30 (sCD30) in patients with advanced stage classical Hodgkin"s lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine or equivalent regimens.	Bleomycin	189-198	TNF receptor superfamily member 8	Homo sapiens	84-88
16733664-1	2006	Immunohistochemical and in vitro studies indicate that caveolin-1, which occurs abundantly in alveolar epithelial type I cells and microvascular endothelial cells of the lung, is selectively downregulated in the alveolar epithelium following exposure to bleomycin.	Bleomycin	254-263	caveolin 1	Rattus norvegicus	55-65
16733664-2	2006	Bleomycin is also known to enhance the expression levels of metalloproteinases and of the metalloproteinase inducer CD147/EMMPRIN in lung cells.	Bleomycin	0-9	basigin (Ok blood group)	Rattus norvegicus	122-129
16733664-6	2006	Here we report that treatment with bleomycin downregulates caveolin-1 and increases CD147 and MMP-2 and -9 expression/activity in R3/1 cells using RT-PCR, Western blot analysis, MMP-2 activity assay and immunocytochemistry.	Bleomycin	35-44	caveolin 1	Rattus norvegicus	59-69
16733664-6	2006	Here we report that treatment with bleomycin downregulates caveolin-1 and increases CD147 and MMP-2 and -9 expression/activity in R3/1 cells using RT-PCR, Western blot analysis, MMP-2 activity assay and immunocytochemistry.	Bleomycin	35-44	matrix metallopeptidase 2	Rattus norvegicus	94-106
16733664-6	2006	Here we report that treatment with bleomycin downregulates caveolin-1 and increases CD147 and MMP-2 and -9 expression/activity in R3/1 cells using RT-PCR, Western blot analysis, MMP-2 activity assay and immunocytochemistry.	Bleomycin	35-44	matrix metallopeptidase 2	Rattus norvegicus	94-99
17086735-0	2006	CXC chemokine receptor 3 modulates bleomycin-induced pulmonary injury via involving inflammatory process.	Bleomycin	35-44	chemokine (C-X-C motif) receptor 3	Mus musculus	0-24
16997324-3	2006	Both the blm3-1 and blm10-Delta mutations were reported to cause sensitivity to bleomycin and other forms of DNA damage, suggesting a role for Blm10/PA200-proteasome complexes in DNA repair.	Bleomycin	80-89	mRNA-binding ubiquitin-specific protease UBP3	Saccharomyces cerevisiae S288C	9-13
16997324-3	2006	Both the blm3-1 and blm10-Delta mutations were reported to cause sensitivity to bleomycin and other forms of DNA damage, suggesting a role for Blm10/PA200-proteasome complexes in DNA repair.	Bleomycin	80-89	Blm10p	Saccharomyces cerevisiae S288C	20-25
16997324-3	2006	Both the blm3-1 and blm10-Delta mutations were reported to cause sensitivity to bleomycin and other forms of DNA damage, suggesting a role for Blm10/PA200-proteasome complexes in DNA repair.	Bleomycin	80-89	Blm10p	Saccharomyces cerevisiae S288C	143-148
16997324-3	2006	Both the blm3-1 and blm10-Delta mutations were reported to cause sensitivity to bleomycin and other forms of DNA damage, suggesting a role for Blm10/PA200-proteasome complexes in DNA repair.	Bleomycin	80-89	proteasome activator subunit 4	Homo sapiens	149-154
16997324-9	2006	These results remove key components of the previously reported connection between Blm10/PA200-proteasome complexes and DNA repair, and they suggest a novel way to interpret sensitivity to bleomycin as resulting from defects in transcription elongation.	Bleomycin	188-197	Blm10p	Saccharomyces cerevisiae S288C	82-87
17035402-7	2006	Among patients with detectable LOH at the TP53 locus (on chromosome 17p), increasing bleomycin sensitivity was associated with increased risk of developing cancer (P(trend) &lt; 0.001) and aneuploidy (P(trend) = 0.005).	Bleomycin	85-94	tumor protein p53	Homo sapiens	42-46
16799078-3	2006	OBJECTIVES, METHODS, AND RESULTS: We show in mice that the loss of function of the neurokinin-1 receptor (NK-1R)-due to either a pharmacologic or genetic manipulation-results in a sequence of morphologic changes in response to bleomycin treatment that precede the development of AC.	Bleomycin	227-236	tachykinin receptor 1	Mus musculus	83-104
16799078-3	2006	OBJECTIVES, METHODS, AND RESULTS: We show in mice that the loss of function of the neurokinin-1 receptor (NK-1R)-due to either a pharmacologic or genetic manipulation-results in a sequence of morphologic changes in response to bleomycin treatment that precede the development of AC.	Bleomycin	227-236	tachykinin receptor 1	Mus musculus	106-111
16799078-5	2006	The loss of function of the NK-1R results in changes of the apoptotic rate and in a delay of DNA break recovery of alveolar epithelial cells following bleomycin treatment.	Bleomycin	151-160	tachykinin receptor 1	Mus musculus	28-33
16648243-0	2006	Increased bleomycin-induced lung injury in mice deficient in the transcription factor T-bet.	Bleomycin	10-19	T-box 21	Mus musculus	86-91
17213041-1	2006	To investigate simultaneously localization and relative activity of MMPs during extracellular matrix (ECM) remodeling in bleomycin-induced pulmonary fibrosis in rat, we analyzed the time course of the expression, activity and/or concentration of gelatinases MMP-2 and MMP-9, collagenase MMP-1, matrylisin MMP-7, TIMP-1 and TIMP-2, both in alveolar space (cellular and extracellular compartments) and in lung tissue.	Bleomycin	121-130	matrix metallopeptidase 1	Rattus norvegicus	68-72
16809410-0	2006	In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung.	Bleomycin	39-48	interleukin 10	Mus musculus	8-13
16809410-0	2006	In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung.	Bleomycin	39-48	transforming growth factor, beta 1	Mus musculus	123-131
16809410-12	2006	Alveolar macrophages from bleomycin injected mice produced TGF-beta1 spontaneously ex vivo, which was significantly suppressed by treatment of the mice in vivo or by treatment of the explanted macrophages ex vivo with IL-10.	Bleomycin	26-35	transforming growth factor, beta 1	Mus musculus	59-68
16809410-12	2006	Alveolar macrophages from bleomycin injected mice produced TGF-beta1 spontaneously ex vivo, which was significantly suppressed by treatment of the mice in vivo or by treatment of the explanted macrophages ex vivo with IL-10.	Bleomycin	26-35	interleukin 10	Mus musculus	218-223
16741154-5	2006	METHODS: We looked at the effects of the EGFR-TKIs gefitinib (20, 90, 200 mg/kg) and AG1478 (12 mg/kg) on a bleomycin-induced lung fibrosis model in mice.	Bleomycin	108-117	epidermal growth factor receptor	Mus musculus	41-45
16741154-8	2006	Immunohistochemistry revealed that phosphorylation of EGFR in lung mesenchymal cells induced by bleomycin was inhibited by gefitinib.	Bleomycin	96-105	epidermal growth factor receptor	Mus musculus	54-58
16741154-11	2006	CONCLUSIONS: These findings suggest that, in the preclinical setting, EGFR-TKIs may have a protective effect on lung fibrosis induced by bleomycin.	Bleomycin	137-146	epidermal growth factor receptor	Mus musculus	70-74
17086735-1	2006	OBJECTIVE: To investigate the role of CXC chemokine receptor 3 (CXCR3) in bleomycin-induced lung injury by using CXCR3 gene deficient mice.	Bleomycin	74-83	chemokine (C-X-C motif) receptor 3	Mus musculus	38-62
17086735-1	2006	OBJECTIVE: To investigate the role of CXC chemokine receptor 3 (CXCR3) in bleomycin-induced lung injury by using CXCR3 gene deficient mice.	Bleomycin	74-83	chemokine (C-X-C motif) receptor 3	Mus musculus	64-69
17086735-8	2006	RESULTS: On day 7 after bleomycin injection via trachea, CXCR3 knockout mice were protected from bleomycin-induced lung injury as evidenced by fewer accumulation of inflammatory cells in the airway and lung interstitium compared with their wild type littermates (P &lt; 0.05).	Bleomycin	24-33	chemokine (C-X-C motif) receptor 3	Mus musculus	57-62
17086735-8	2006	RESULTS: On day 7 after bleomycin injection via trachea, CXCR3 knockout mice were protected from bleomycin-induced lung injury as evidenced by fewer accumulation of inflammatory cells in the airway and lung interstitium compared with their wild type littermates (P &lt; 0.05).	Bleomycin	97-106	chemokine (C-X-C motif) receptor 3	Mus musculus	57-62
17086735-11	2006	CONCLUSION: CXCR3 signaling promotes inflammatory cells recruiting and initiates inflammatory cytokines cascade following endotracheal bleomycin administration, indicating that CXCR3 might be a therapeutic target for pulmonary injury.	Bleomycin	135-144	chemokine (C-X-C motif) receptor 3	Mus musculus	12-17
17086735-11	2006	CONCLUSION: CXCR3 signaling promotes inflammatory cells recruiting and initiates inflammatory cytokines cascade following endotracheal bleomycin administration, indicating that CXCR3 might be a therapeutic target for pulmonary injury.	Bleomycin	135-144	chemokine (C-X-C motif) receptor 3	Mus musculus	177-182
16690978-0	2006	Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis.	Bleomycin	60-69	discoidin domain receptor family, member 1	Mus musculus	0-27
16916326-5	2006	Administration of N(omega)-nitro-L-arginine methyl ester, a potent inhibitor of NO synthase, worsened the fibrotic response in bleomycin-treated eNOS-TG mice.	Bleomycin	127-136	nitric oxide synthase 3, endothelial cell	Mus musculus	145-149
16916326-6	2006	Gelatinolytic activity in lung homogenates, corresponding to metalloproteinase-9 (MMP-9), was significantly increased in bleomycin-injured WT mice on day 14.	Bleomycin	121-130	matrix metallopeptidase 9	Mus musculus	82-87
16916326-7	2006	In contrast, the level of tissue inhibitor of metalloproteinases-1 (TIMP-1), an endogenous MMP-9 inhibitor, was increased in the bleomycin-treated eNOS-TG mice compared with WT.	Bleomycin	129-138	tissue inhibitor of metalloproteinase 1	Mus musculus	26-66
16916326-7	2006	In contrast, the level of tissue inhibitor of metalloproteinases-1 (TIMP-1), an endogenous MMP-9 inhibitor, was increased in the bleomycin-treated eNOS-TG mice compared with WT.	Bleomycin	129-138	tissue inhibitor of metalloproteinase 1	Mus musculus	68-74
16916326-7	2006	In contrast, the level of tissue inhibitor of metalloproteinases-1 (TIMP-1), an endogenous MMP-9 inhibitor, was increased in the bleomycin-treated eNOS-TG mice compared with WT.	Bleomycin	129-138	matrix metallopeptidase 9	Mus musculus	91-96
16916326-7	2006	In contrast, the level of tissue inhibitor of metalloproteinases-1 (TIMP-1), an endogenous MMP-9 inhibitor, was increased in the bleomycin-treated eNOS-TG mice compared with WT.	Bleomycin	129-138	nitric oxide synthase 3, endothelial cell	Mus musculus	147-151
16916326-9	2006	CONCLUSION: These data suggested that eNOS overexpression attenuates bleomycin-induced lung injury by ameliorating the MMP-9/TIMP-1 balance.	Bleomycin	69-78	nitric oxide synthase 3, endothelial cell	Mus musculus	38-42
16916326-9	2006	CONCLUSION: These data suggested that eNOS overexpression attenuates bleomycin-induced lung injury by ameliorating the MMP-9/TIMP-1 balance.	Bleomycin	69-78	matrix metallopeptidase 9	Mus musculus	119-124
16916326-9	2006	CONCLUSION: These data suggested that eNOS overexpression attenuates bleomycin-induced lung injury by ameliorating the MMP-9/TIMP-1 balance.	Bleomycin	69-78	tissue inhibitor of metalloproteinase 1	Mus musculus	125-131
16690978-3	2006	OBJECTIVES: To investigate the inflammatory and fibrotic responses of DDR1 knockout and wild-type mice to bleomycin-induced lung injury.	Bleomycin	106-115	discoidin domain receptor family, member 1	Mus musculus	70-74
16690978-6	2006	MEASUREMENTS AND MAIN RESULTS: Compared with wild-type animals, DDR1-null mice were largely protected against bleomycin-induced injury.	Bleomycin	110-119	discoidin domain receptor family, member 1	Mus musculus	64-68
16690978-7	2006	Bleomycin-induced increases in collagen protein levels and tenascin-C mRNA levels were abrogated in knockout animals.	Bleomycin	0-9	tenascin C	Mus musculus	59-69
16643955-2	2006	We previously reported that the intraperitoneal administration of recombinant human thioredoxin (rhTRX) attenuates inflammatory cytokine- or bleomycin-induced lung injury in mice.	Bleomycin	141-150	thioredoxin	Homo sapiens	84-95
16816364-5	2006	The survival rate after bleomycin was significantly decreased in GATA-3-tg mice compared with wild-type mice.	Bleomycin	24-33	GATA binding protein 3	Mus musculus	65-71
16872605-4	2006	We further demonstrate that UG prevents PF suppressing bleomycin-induced production of pro-inflammatory T-helper 2 cytokines and TGF-beta, which are also pro-fibrotic.	Bleomycin	55-64	transforming growth factor, beta 1	Mus musculus	129-137
16473862-0	2006	COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis.	Bleomycin	44-53	cytochrome c oxidase II, mitochondrial	Mus musculus	0-5
16473862-6	2006	These findings suggest that prostacyclin analogs will protect against bleomycin-induced pulmonary fibrosis in COX-2(-/-) mice.	Bleomycin	70-79	cytochrome c oxidase II, mitochondrial	Mus musculus	110-115
16871530-9	2006	Adenosine A2A receptor-deficient and A2A receptor antagonist-treated mice were protected from developing bleomycin-induced dermal fibrosis.	Bleomycin	105-114	adenosine A2a receptor	Mus musculus	0-22
16691201-4	2006	Dermal fibrosis was induced by subcutaneous injection of bleomycin into the dorsal skin of MCP-1-/- and wild-type C57BL/6 mice.	Bleomycin	57-66	chemokine (C-C motif) ligand 2	Mus musculus	91-96
16691201-8	2006	In comparison, the dermis of bleomycin-injected MCP-1-/- mice displayed a uniform pattern of fibril diameters that was similar to normal skin (average diameter 76.7 nm).	Bleomycin	29-38	chemokine (C-C motif) ligand 2	Mus musculus	48-53
16691201-9	2006	The findings implicate MCP-1 as a key determinant in the development of skin fibrosis induced by bleomycin, and suggest that MCP-1 may influence collagen fiber formation in vivo.	Bleomycin	97-106	chemokine (C-C motif) ligand 2	Mus musculus	23-28
16887060-0	2006	[Effect of interferon-gamma on bleomycin induced pulmonary fibrosis in rats].	Bleomycin	31-40	interferon gamma	Rattus norvegicus	11-27
16887060-1	2006	OBJECTIVE: To observe the effects of interferon-gamma (IFN-gamma) on lung injury induced by bleomycin and its mechanism.	Bleomycin	92-101	interferon gamma	Rattus norvegicus	37-53
16887060-1	2006	OBJECTIVE: To observe the effects of interferon-gamma (IFN-gamma) on lung injury induced by bleomycin and its mechanism.	Bleomycin	92-101	interferon gamma	Rattus norvegicus	55-64
16887060-7	2006	CONCLUSION: IFN-gamma might aggravate lung injury induced by bleomycin, and it might attribute to an increase in TNF-alpha.	Bleomycin	61-70	interferon gamma	Rattus norvegicus	12-21
16816364-6	2006	The degree of pulmonary fibrosis was much greater in GATA-3-tg mice than in wild-type mice 28 days after bleomycin treatment.	Bleomycin	105-114	GATA binding protein 3	Mus musculus	53-59
16816364-7	2006	Lung interferon-gamma concentration was significantly decreased in GATA-3-tg mice compared with wild-type mice by 7 days after either saline or bleomycin treatment.	Bleomycin	144-153	interferon gamma	Mus musculus	5-21
16816364-7	2006	Lung interferon-gamma concentration was significantly decreased in GATA-3-tg mice compared with wild-type mice by 7 days after either saline or bleomycin treatment.	Bleomycin	144-153	GATA binding protein 3	Mus musculus	67-73
16879498-9	2006	5 Circulating plasma levels of TNF-alpha/IL-1beta were augmented in bleomycin-exposed rats compared with controls.	Bleomycin	68-77	tumor necrosis factor	Rattus norvegicus	31-40
16879498-9	2006	5 Circulating plasma levels of TNF-alpha/IL-1beta were augmented in bleomycin-exposed rats compared with controls.	Bleomycin	68-77	interleukin 1 beta	Rattus norvegicus	41-49
16710477-8	2006	We also demonstrate that pulmonary edema and TGF-beta activity are similarly reduced in Par1-/- mice following bleomycin-induced lung injury.	Bleomycin	111-120	coagulation factor II (thrombin) receptor	Mus musculus	88-92
17026855-0	2006	TIMP-1 is a key factor of fibrogenic response to bleomycin in mouse lung.	Bleomycin	49-58	tissue inhibitor of metalloproteinase 1	Mus musculus	0-6
17026855-3	2006	We investigated MMP-9, MMP-2, TIMP-1, TIMP-2 and TIMP-3 in the fibrotic response to bleomycin of fibrosis prone C57BL/6J and fibrosis resistant BALB/c mice.	Bleomycin	84-93	matrix metallopeptidase 9	Mus musculus	16-21
17026855-3	2006	We investigated MMP-9, MMP-2, TIMP-1, TIMP-2 and TIMP-3 in the fibrotic response to bleomycin of fibrosis prone C57BL/6J and fibrosis resistant BALB/c mice.	Bleomycin	84-93	tissue inhibitor of metalloproteinase 3	Mus musculus	49-55
17026855-10	2006	At day 1, bleomycin enhanced TIMP-1, MMP-2 and MMP-9 protein levels in BALF, and induced corresponding genes in lung tissue of both strains.	Bleomycin	10-19	tissue inhibitor of metalloproteinase 1	Mus musculus	29-35
17026855-10	2006	At day 1, bleomycin enhanced TIMP-1, MMP-2 and MMP-9 protein levels in BALF, and induced corresponding genes in lung tissue of both strains.	Bleomycin	10-19	matrix metallopeptidase 2	Mus musculus	37-42
17026855-10	2006	At day 1, bleomycin enhanced TIMP-1, MMP-2 and MMP-9 protein levels in BALF, and induced corresponding genes in lung tissue of both strains.	Bleomycin	10-19	matrix metallopeptidase 9	Mus musculus	47-52
17026855-15	2006	The present study shows that early altered regulation of TIMP-1 following bleomycin administration may be involved in bleomycin-induced pulmonary fibrosis.	Bleomycin	74-83	tissue inhibitor of metalloproteinase 1	Mus musculus	57-63
17026855-15	2006	The present study shows that early altered regulation of TIMP-1 following bleomycin administration may be involved in bleomycin-induced pulmonary fibrosis.	Bleomycin	118-127	tissue inhibitor of metalloproteinase 1	Mus musculus	57-63
16518603-13	2006	The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma.	Bleomycin	30-39	DNA damage inducible transcript 3	Homo sapiens	82-86
16601095-5	2006	RESULTS: Losartan reduced the inflammation induced by bleomycin, as indicated by lower myeloperoxidase activity and protein content in the bronchoalveolar lavage fluid.	Bleomycin	54-63	myeloperoxidase	Rattus norvegicus	87-102
16601095-9	2006	A reduction in COX-2 expression by bleomycin was seen at 3 days which was relieved by losartan.	Bleomycin	35-44	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	15-20
16439138-2	2006	to peptide-based DNA binding intercalators and metal complexes was examined through the study of actinomycin and Co(III).bleomycin-B2.	Bleomycin	121-133	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	113-120
16439138-4	2006	In addition, for Co(III).bleomycin-B2 the established cleavage site-selectivity for 5"-GT and 5"-GC sites was correlated to drug-DNA association in this binding-only assay; our results also suggest a tetranucleotide site-selectivity for metallobleomycin involving cross-strand, "back-to-back" 5"-GT and 5"-GC sites such as 5"-ACGT and 5"-ACGC.	Bleomycin	25-34	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	17-24
16515894-6	2006	Therefore, cell survival, mutagenesis and DSB induction and repair in the rad52, yku70 and rad52 yku70 mutants after hydrogen peroxide (H(2)O(2)), menadione (MD) or bleomycin (BLM) exposure were compared to those obtained for the corresponding wild type.	Bleomycin	165-174	recombinase RAD52	Saccharomyces cerevisiae S288C	91-96
16306138-7	2006	These results demonstrate that the initial bleomycin-induced oxidative stress causes a direct apoptotic effect in lung epithelial cells involving a regulatory role of caspase-8 on caspase-9.	Bleomycin	43-52	caspase 8	Mus musculus	167-176
16456147-0	2006	A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	50-59	inhibitor of kappaB kinase beta	Mus musculus	8-27
16565485-0	2006	Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.	Bleomycin	66-75	carboxypeptidase B2 (plasma)	Mus musculus	0-43
16306138-7	2006	These results demonstrate that the initial bleomycin-induced oxidative stress causes a direct apoptotic effect in lung epithelial cells involving a regulatory role of caspase-8 on caspase-9.	Bleomycin	43-52	caspase 9	Mus musculus	180-189
16388800-6	2006	When SNEV overexpressing cells were treated with bleomycin or bleomycin combined with BSO, inducing DNA damage as well as reactive oxygen species, a significantly lower fraction of apoptotic cells was found in comparison to vector control cells.	Bleomycin	49-58	pre-mRNA processing factor 19	Homo sapiens	5-9
16388800-6	2006	When SNEV overexpressing cells were treated with bleomycin or bleomycin combined with BSO, inducing DNA damage as well as reactive oxygen species, a significantly lower fraction of apoptotic cells was found in comparison to vector control cells.	Bleomycin	62-71	pre-mRNA processing factor 19	Homo sapiens	5-9
16187293-0	2006	Evidence for TGF-beta1 and bleomycin intracellular signaling through autocrine regulation of Smad 3 binding to the proximal promoter of the Smad 7 gene.	Bleomycin	27-36	SMAD family member 3	Homo sapiens	93-99
16734880-4	2006	Four courses of chemotherapy, including cisplatin, etoposide, and bleomycin, normalized the level of DU-PAN-2, and the metastatic lesions disappeared.	Bleomycin	66-75	poly(A) specific ribonuclease subunit PAN2	Homo sapiens	104-109
16547283-0	2006	Ecto-5"-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury.	Bleomycin	93-102	5' nucleotidase, ecto	Mus musculus	0-20
16547283-0	2006	Ecto-5"-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury.	Bleomycin	93-102	5' nucleotidase, ecto	Mus musculus	22-26
16547283-6	2006	Results demonstrated that CD73(-/-) mice challenged with bleomycin no longer accumulated adenosine in their lungs, suggesting that the primary means of adenosine production following bleomycin injury resulted from the release and subsequent dephosphorylation of adenine nucleotides.	Bleomycin	57-66	5' nucleotidase, ecto	Mus musculus	26-30
16547283-6	2006	Results demonstrated that CD73(-/-) mice challenged with bleomycin no longer accumulated adenosine in their lungs, suggesting that the primary means of adenosine production following bleomycin injury resulted from the release and subsequent dephosphorylation of adenine nucleotides.	Bleomycin	183-192	5' nucleotidase, ecto	Mus musculus	26-30
16547283-7	2006	CD73(-/-) mice challenged with bleomycin exhibited enhanced pulmonary inflammation and fibrosis as well as exaggerated expression of proinflammatory and profibrotic mediators in the lung.	Bleomycin	31-40	5' nucleotidase, ecto	Mus musculus	0-4
16547283-8	2006	Intranasal instillations of exogenous nucleotidase restored the ability of lungs of CD73(-/-) mice to accumulate adenosine following bleomycin challenge.	Bleomycin	133-142	5' nucleotidase, ecto	Mus musculus	84-88
16547283-10	2006	CD73(+/+) animals challenged with bleomycin and supplemented with exogenous nucleotidase also exhibited reduced inflammation.	Bleomycin	34-43	5' nucleotidase, ecto	Mus musculus	0-4
16547283-11	2006	Together, these findings suggest that CD73-dependent adenosine production contributes to anti-inflammatory pathways in bleomycin-induced lung injury.	Bleomycin	119-128	5' nucleotidase, ecto	Mus musculus	38-42
16690523-2	2006	Mitoxantrone, vinblastine and CCNU (lomustine) (MVC) combines the most effective chemotherapeutic agents of previous regimens for poor prognosis HD, and eliminates marginally active agents with unnecessary toxicities, such as bleomycin and dacarbazine.	Bleomycin	226-235	cyclin O	Homo sapiens	30-34
16187293-0	2006	Evidence for TGF-beta1 and bleomycin intracellular signaling through autocrine regulation of Smad 3 binding to the proximal promoter of the Smad 7 gene.	Bleomycin	27-36	SMAD family member 7	Homo sapiens	140-146
16187293-1	2006	Both Bleomycin and TGF-beta1 increase the transcription of the COL1A1 gene.	Bleomycin	5-14	collagen type I alpha 1 chain	Homo sapiens	63-69
16187293-2	2006	Bleomycin acts through TGF-beta1.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	23-32
16187293-3	2006	Bleomycin stimulates the COL1A1 promoter through the distal TGF-beta response element by intracellular and extracellular signaling.	Bleomycin	0-9	collagen type I alpha 1 chain	Homo sapiens	25-31
16187293-3	2006	Bleomycin stimulates the COL1A1 promoter through the distal TGF-beta response element by intracellular and extracellular signaling.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	60-68
16187293-4	2006	As demonstrated in this manuscript, Bleomycin"s intracellular signaling can be explained by a decrease of Smad 3 transcription factor binding to the SBE located in the proximal promoter of the inhibitory Smad 7 gene.	Bleomycin	36-45	SMAD family member 3	Homo sapiens	106-112
16187293-4	2006	As demonstrated in this manuscript, Bleomycin"s intracellular signaling can be explained by a decrease of Smad 3 transcription factor binding to the SBE located in the proximal promoter of the inhibitory Smad 7 gene.	Bleomycin	36-45	SMAD family member 7	Homo sapiens	204-210
16187293-6	2006	Bleomycin"s extracellular signaling results from the secretion of more latent TGF-beta produced by lung fibroblasts and cleaved to active TGF-beta extracellularly.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	78-86
16187293-6	2006	Bleomycin"s extracellular signaling results from the secretion of more latent TGF-beta produced by lung fibroblasts and cleaved to active TGF-beta extracellularly.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	138-146
16187293-7	2006	Since the TGF-beta genes are auto-induced in human embryonic IMR-90 lung fibroblasts, this study indicates an autocrine mechanism to maintain homeostasis in vivo for fibroblasts and other cell types, which produce TGF-beta1 to limit the fibrogenic response to TGF-beta1 and Bleomycin.	Bleomycin	274-283	transforming growth factor beta 1	Homo sapiens	10-18
16187293-7	2006	Since the TGF-beta genes are auto-induced in human embryonic IMR-90 lung fibroblasts, this study indicates an autocrine mechanism to maintain homeostasis in vivo for fibroblasts and other cell types, which produce TGF-beta1 to limit the fibrogenic response to TGF-beta1 and Bleomycin.	Bleomycin	274-283	transforming growth factor beta 1	Homo sapiens	214-223
16139849-0	2006	Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.	Bleomycin	93-102	tumor protein p53	Homo sapiens	39-42
16361083-8	2006	RNAi Inhibition of DDH expression in A431 cells led to increased sensitivity to UVB-induced apoptosis and cytotoxicity of bleomycin treatment.	Bleomycin	122-131	dihydrodiol dehydrogenase	Homo sapiens	19-22
16537427-3	2006	Here, we report that the proapoptotic Bcl-2 family member Bid is required for the development of pulmonary fibrosis after the intratracheal instillation of bleomycin.	Bleomycin	156-165	B cell leukemia/lymphoma 2	Mus musculus	38-43
16537427-3	2006	Here, we report that the proapoptotic Bcl-2 family member Bid is required for the development of pulmonary fibrosis after the intratracheal instillation of bleomycin.	Bleomycin	156-165	BH3 interacting domain death agonist	Mus musculus	58-61
16537427-4	2006	Mice lacking Bid exhibited significantly less pulmonary fibrosis in response to bleomycin compared with WT mice.	Bleomycin	80-89	BH3 interacting domain death agonist	Mus musculus	13-16
16537427-6	2006	Bleomycin induced similar levels cell death in vitro in alveolar epithelial cells isolated from WT and bid(-/-) mice.	Bleomycin	0-9	BH3 interacting domain death agonist	Mus musculus	103-106
16356754-5	2006	We find that phosphorylation by Pim-1 enhances the phosphatase activity of Cdc25C and in transfected cells that are arrested in G2/M by bleomycin, Pim-1 can enhance progression into G1.	Bleomycin	136-145	cell division cycle 25C	Homo sapiens	75-81
16356754-5	2006	We find that phosphorylation by Pim-1 enhances the phosphatase activity of Cdc25C and in transfected cells that are arrested in G2/M by bleomycin, Pim-1 can enhance progression into G1.	Bleomycin	136-145	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	147-152
16479003-3	2006	The expression of CAF-1 and PCNA is dramatically induced in quiescent cells upon the generation of DSBs by the radiomimetic drug bleocin (a bleomycin compound) or by ionizing radiation.	Bleomycin	140-149	chromatin assembly factor 1 subunit A	Homo sapiens	18-23
16479003-3	2006	The expression of CAF-1 and PCNA is dramatically induced in quiescent cells upon the generation of DSBs by the radiomimetic drug bleocin (a bleomycin compound) or by ionizing radiation.	Bleomycin	140-149	proliferating cell nuclear antigen	Homo sapiens	28-32
16139849-2	2006	Aim of this study was to examine the effects of either MMR-deficiency or p53 inactivation, or both, on cellular responses to bleomycin.	Bleomycin	125-134	tumor protein p53	Homo sapiens	73-76
16139849-11	2006	In conclusion, our data show that loss of MMR and p53 function exerts opposite and independent effects on apoptosis and chromosomal damage induced by bleomycin.	Bleomycin	150-159	tumor protein p53	Homo sapiens	50-53
16504062-5	2006	Here we investigated fibrotic response to bleomycin in MMP-12 deficient mice.	Bleomycin	42-51	matrix metallopeptidase 12	Mus musculus	55-61
16504062-13	2006	Bleomycin elicited macrophage accumulation in BAL of MMP-12 -/- and wild type (WT) mice, and MMP-12 deficiency had no significant effect on BAL cells composition.	Bleomycin	0-9	matrix metallopeptidase 12	Mus musculus	53-59
16424224-5	2006	In this study, using a bleomycin-induced pulmonary fibrosis mouse model, we administered siRNA against DDR1 transnasally and evaluated histological changes, cytokine expression, and signaling molecule activation in the lungs.	Bleomycin	23-32	discoidin domain receptor family, member 1	Mus musculus	103-107
16504062-15	2006	Bleomycin elicit a raise of TGF-beta protein, MMP-2 and TIMP-1 protein and mRNA in BAL fluids and lung respectively, and no significant difference was observed between MMP-12 -/- and WT mice considering those parameters.	Bleomycin	0-9	matrix metallopeptidase 2	Mus musculus	46-51
16504062-15	2006	Bleomycin elicit a raise of TGF-beta protein, MMP-2 and TIMP-1 protein and mRNA in BAL fluids and lung respectively, and no significant difference was observed between MMP-12 -/- and WT mice considering those parameters.	Bleomycin	0-9	tissue inhibitor of metalloproteinase 1	Mus musculus	56-62
16239626-1	2006	RATIONALE: The chemokine receptors CXCR3 and CCR4 have recently been described as playing a pivotal role in the mouse model of bleomycin-induced fibrosis.	Bleomycin	127-136	chemokine (C-X-C motif) receptor 3	Mus musculus	35-40
16239626-1	2006	RATIONALE: The chemokine receptors CXCR3 and CCR4 have recently been described as playing a pivotal role in the mouse model of bleomycin-induced fibrosis.	Bleomycin	127-136	chemokine (C-C motif) receptor 4	Mus musculus	45-49
16424224-9	2006	Furthermore, siRNA against DDR1 significantly inhibited bleomycin-induced P38 MAPK activation in the lungs.	Bleomycin	56-65	mitogen-activated protein kinase 14	Homo sapiens	74-77
16424224-10	2006	Considered together, we propose that DDR1 contributes to the development of bleomycin-induced pulmonary inflammation and fibrosis.	Bleomycin	76-85	discoidin domain receptor tyrosine kinase 1	Homo sapiens	37-41
16224105-8	2006	To test this hypothesis, transgenic mice with lung-specific expression of human EC-SOD were treated with asbestos or bleomycin to initiate an interstitial lung injury.	Bleomycin	117-126	superoxide dismutase 3	Homo sapiens	80-86
16224105-10	2006	We also demonstrate that EC-SOD knockout mice possess greater lung inflammation in response to bleomycin and bacteria when compared with wild types.	Bleomycin	95-104	superoxide dismutase 3, extracellular	Mus musculus	25-31
16424224-6	2006	Histologically, siRNA against DDR1 successfully reduced in vivo DDR1 expression and attenuated bleomycin-induced infiltration of inflammatory cells.	Bleomycin	95-104	discoidin domain receptor tyrosine kinase 1	Homo sapiens	30-34
16424224-9	2006	Furthermore, siRNA against DDR1 significantly inhibited bleomycin-induced P38 MAPK activation in the lungs.	Bleomycin	56-65	discoidin domain receptor tyrosine kinase 1	Homo sapiens	27-31
16155090-0	2006	Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	89-98	thromboxane A synthase 1, platelet	Mus musculus	26-46
15964043-0	2006	Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines.	Bleomycin	41-50	toll like receptor 2	Homo sapiens	15-35
15964043-2	2006	In this study, we demonstrate that cell activation is initiated upon the recognition of bleomycin as a pathogen-associated molecular pattern by toll-like receptor (TLR) 2.	Bleomycin	88-97	toll like receptor 2	Homo sapiens	164-167
15964043-3	2006	The THP1 human monocytic cell line, which constitutively expresses high levels of TLR2, secretes interleukin (IL)-1beta, IL-8, and tumor necrosis factor (TNF)-alpha during bleomycin exposure.	Bleomycin	172-181	GLI family zinc finger 2	Homo sapiens	4-8
15964043-3	2006	The THP1 human monocytic cell line, which constitutively expresses high levels of TLR2, secretes interleukin (IL)-1beta, IL-8, and tumor necrosis factor (TNF)-alpha during bleomycin exposure.	Bleomycin	172-181	tumor necrosis factor	Homo sapiens	131-164
15964043-5	2006	Collectively, these observations identify TLR2 activation as a critical event that triggers NF-kappaB activation and secretion of cytokines and chemokines during bleomycin exposure.	Bleomycin	162-171	toll like receptor 2	Homo sapiens	42-46
15964043-5	2006	Collectively, these observations identify TLR2 activation as a critical event that triggers NF-kappaB activation and secretion of cytokines and chemokines during bleomycin exposure.	Bleomycin	162-171	nuclear factor kappa B subunit 1	Homo sapiens	92-101
15964043-7	2006	Whether bleomycin engages with other cellular receptors that results in activation of alternate signaling pathways and whether the TLR2-agonist activity of bleomycin contribute to its anti-neoplastic property deserve further study.	Bleomycin	156-165	toll like receptor 2	Homo sapiens	131-135
16438734-13	2006	The expression of Smad3 and Smad4 mRNA was clearly attenuated by bleomycin, but was recovered by EM703.	Bleomycin	65-74	SMAD family member 3	Mus musculus	18-23
16438734-13	2006	The expression of Smad3 and Smad4 mRNA was clearly attenuated by bleomycin, but was recovered by EM703.	Bleomycin	65-74	SMAD family member 4	Mus musculus	28-33
16600115-0	2006	[Changes of tight junction and Cx43 expression in microvessel endothelial cells of mouse lung induced by bleomycin].	Bleomycin	105-114	gap junction protein, alpha 3	Mus musculus	31-35
16600115-1	2006	OBJECTIVE: To investigate the changes of expression of connexin-43 (Cx43) and the tight junction of microvessel endothelial cells (EC) to approach the effects in bleomycin (BLM) induced pulmonary fibrosis (PF).	Bleomycin	162-171	gap junction protein, alpha 1	Rattus norvegicus	55-66
16338226-3	2006	Significant lung fibrotic changes as assessed by histologic findings and hydroxyproline content, and increased procoagulant activity and thrombin generation in bronchoalveolar lavage fluid were detected in rats after intratracheal injection of bleomycin.	Bleomycin	244-253	coagulation factor II	Rattus norvegicus	137-145
16338226-4	2006	Intratracheal administration of an adenovirus vector expressing TFPI significantly decreased bleomycin-induced procoagulant and thrombin generation resulting in a strong inhibition of pulmonary fibrosis.	Bleomycin	93-102	tissue factor pathway inhibitor	Rattus norvegicus	64-68
16338226-4	2006	Intratracheal administration of an adenovirus vector expressing TFPI significantly decreased bleomycin-induced procoagulant and thrombin generation resulting in a strong inhibition of pulmonary fibrosis.	Bleomycin	93-102	coagulation factor II	Rattus norvegicus	128-136
16338226-6	2006	This is the first report showing that direct inhibition of TF-mediated coagulation activation abrogates bleomycin-induced pulmonary fibrosis.	Bleomycin	104-113	coagulation factor III, tissue factor	Rattus norvegicus	59-61
16179636-7	2006	Furthermore, inhibition of PTEN in mice worsened bleomycin-induced fibrosis.	Bleomycin	49-58	phosphatase and tensin homolog	Mus musculus	27-31
16313495-9	2006	Bleomycin administration significantly reduced the activities of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in lung tissue.	Bleomycin	0-9	catalase	Rattus norvegicus	65-73
16313495-9	2006	Bleomycin administration significantly reduced the activities of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in lung tissue.	Bleomycin	0-9	catalase	Rattus norvegicus	75-78
17314493-0	2006	Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet.	Bleomycin	10-19	negative elongation factor complex member C/D, Th1l	Mus musculus	62-65
17314493-0	2006	Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet.	Bleomycin	10-19	T-box 21	Mus musculus	96-101
17314493-7	2006	Bleomycin-induced early mast cells and eosinophil accumulation, and eosinophil degranulation, in the lesional tissue were greater in T-bet(-/-) mice than in wild-type control mice.	Bleomycin	0-9	T-box 21	Mus musculus	133-138
17314493-11	2006	These results demonstrate that in mice lacking T-bet bleomycin induced exaggerated skin fibrosis, suggesting that T-bet has an important physiologic role in regulation of tissue repair by promoting Th1 immune responses that prevent excessive ECM accumulation.	Bleomycin	53-62	T-box 21	Mus musculus	47-52
17314493-11	2006	These results demonstrate that in mice lacking T-bet bleomycin induced exaggerated skin fibrosis, suggesting that T-bet has an important physiologic role in regulation of tissue repair by promoting Th1 immune responses that prevent excessive ECM accumulation.	Bleomycin	53-62	T-box 21	Mus musculus	114-119
17314493-11	2006	These results demonstrate that in mice lacking T-bet bleomycin induced exaggerated skin fibrosis, suggesting that T-bet has an important physiologic role in regulation of tissue repair by promoting Th1 immune responses that prevent excessive ECM accumulation.	Bleomycin	53-62	negative elongation factor complex member C/D, Th1l	Mus musculus	198-201
16423267-5	2006	The authors found that keratinocyte growth factor (KGF) is a strong growth factor for alveolar type II cells, and that KGF instillation prevents bleomycin-induced lung injury.	Bleomycin	145-154	fibroblast growth factor 7	Rattus norvegicus	119-122
16330873-2	2006	OBJECTIVE: To study the effect of losartan, an angiotensin II antagonist, on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism.	Bleomycin	77-86	angiotensinogen	Rattus norvegicus	47-61
16317386-0	2005	ROLE OF ENDOGENOUS AND EXOGENOUS LIGANDS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha IN THE DEVELOPMENT OF BLEOMYCIN-INDUCED LUNG INJURY.	Bleomycin	120-129	peroxisome proliferator activated receptor alpha	Mus musculus	49-97
16314464-0	2005	Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.	Bleomycin	64-73	chemokine (C-C motif) ligand 11	Mus musculus	19-24
16314464-0	2005	Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.	Bleomycin	64-73	chemokine (C-C motif) receptor 3	Mus musculus	30-53
16314464-0	2005	Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.	Bleomycin	64-73	chemokine (C-C motif) receptor 3	Mus musculus	55-59
16314464-2	2005	The present study examined the pulmonary expression of CCL11 and CCR3 during bleomycin (blm)-induced lung injury and determined their importance in the recruitment of inflammatory cells and the development of lung fibrosis.	Bleomycin	77-86	chemokine (C-C motif) ligand 11	Mus musculus	55-60
16314464-2	2005	The present study examined the pulmonary expression of CCL11 and CCR3 during bleomycin (blm)-induced lung injury and determined their importance in the recruitment of inflammatory cells and the development of lung fibrosis.	Bleomycin	77-86	chemokine (C-C motif) receptor 3	Mus musculus	65-69
16314464-2	2005	The present study examined the pulmonary expression of CCL11 and CCR3 during bleomycin (blm)-induced lung injury and determined their importance in the recruitment of inflammatory cells and the development of lung fibrosis.	Bleomycin	88-91	chemokine (C-C motif) ligand 11	Mus musculus	55-60
16445573-0	2005	Feitai, a Chinese herbal medicine, reduces transforming growth factor-beta1 and monocyte chemoattractant protein-1 expression in bleomycin-induced lung fibrosis in mice.	Bleomycin	129-138	chemokine (C-C motif) ligand 2	Mus musculus	80-114
17027527-5	2006	We have also demonstrated that IL-13Ralpha2 expression is greatly increased in lung cells when mice were challenged intranasally with bleomycin or Aspergillus fumigatus.	Bleomycin	134-143	interleukin 13 receptor, alpha 2	Mus musculus	31-43
16317386-2	2005	The aim of the present study was to examine the effects of endogenous and exogenous the PPAR-alpha ligand on the development of lung injury caused by bleomycin administration.	Bleomycin	150-159	peroxisome proliferator activated receptor alpha	Mus musculus	88-98
16317386-3	2005	Lung injury was induced in PPAR-alpha wild-type (WT) mice and PPAR-alpha knockout (KO) mice by intratracheal administration of bleomycin.	Bleomycin	127-136	peroxisome proliferator activated receptor alpha	Mus musculus	62-72
16317386-4	2005	An increase of immunoreactivity to poly-ADP-ribose, TNF-alpha, and IL-1 beta, as well as a significant loss of body weight and mortality was observed in the lung of bleomycin-treated PPAR-alpha WT mice.	Bleomycin	165-174	tumor necrosis factor	Mus musculus	52-61
16317386-4	2005	An increase of immunoreactivity to poly-ADP-ribose, TNF-alpha, and IL-1 beta, as well as a significant loss of body weight and mortality was observed in the lung of bleomycin-treated PPAR-alpha WT mice.	Bleomycin	165-174	interleukin 1 beta	Mus musculus	67-76
16317386-4	2005	An increase of immunoreactivity to poly-ADP-ribose, TNF-alpha, and IL-1 beta, as well as a significant loss of body weight and mortality was observed in the lung of bleomycin-treated PPAR-alpha WT mice.	Bleomycin	165-174	peroxisome proliferator activated receptor alpha	Mus musculus	183-193
16317386-6	2005	On the contrary, the treatment of PPAR-alpha WT with WY-14643 (1 mg/kg daily) significantly reduced the degree of lung injury, the rise in myeloperoxidase activity, and the increase in staining (immunohistochemistry) for poly-ADP-ribose, TNF-alpha, and IL-1 beta caused by bleomycin administration.	Bleomycin	273-282	peroxisome proliferator activated receptor alpha	Mus musculus	34-44
16317386-7	2005	Thus, endogenous and exogenous PPAR-alpha ligands reduce the degree of lung injury induced by bleomycin in the mice.	Bleomycin	94-103	peroxisome proliferator activated receptor alpha	Mus musculus	31-41
16251407-9	2005	Our findings indicate that Stat1-/- mice are more susceptible to bleomycin-induced lung fibrosis than wild-type mice due to 1) enhanced fibroblast proliferation in response to growth factors (EGF and PDGF), 2) stimulation of fibroblast growth by a Stat1-independent IFN-gamma signaling pathway, and 3) increased activation of Stat3.	Bleomycin	65-74	signal transducer and activator of transcription 1	Mus musculus	27-32
16037485-0	2005	Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury.	Bleomycin	75-84	hyaluronan-mediated motility receptor	Rattus norvegicus	47-52
16037485-3	2005	Using a function blocking anti-RHAMM antibody (R36), we investigated the expression and role of RHAMM in the inflammatory response to intratracheal bleomycin in rats.	Bleomycin	148-157	hyaluronan-mediated motility receptor	Rattus norvegicus	96-101
16296884-4	2005	This study demonstrates that low doses of gamma radiation and bleomycin induce RAD52-dependent recombination repair pathway in the wild-type strain D-261.	Bleomycin	62-71	recombinase RAD52	Saccharomyces cerevisiae S288C	79-84
16251408-0	2005	Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma.	Bleomycin	39-48	interferon gamma	Mus musculus	89-105
16251408-5	2005	The transforming growth factor (TGF)-beta1 levels were higher in the lung after injecting bleomycin, and blockade of TGF-beta1 by neutralizing monoclonal antibody attenuated the pulmonary fibrosis in CD1d-/- mice.	Bleomycin	90-99	transforming growth factor, beta 1	Mus musculus	4-42
16251411-2	2005	In this study, we evaluated bleomycin-induced lung fibrosis in mice with genetic deletion of SFTPC.	Bleomycin	28-37	surfactant associated protein C	Mus musculus	93-98
16251411-3	2005	Compared with wild-type (SFTPC+/+) controls, mice lacking surfactant protein C (SFTPC-/-) had greater lung neutrophil influx at 1 week after intratracheal bleomycin, greater weight loss during the first 2 weeks, and increased mortality.	Bleomycin	155-164	surfactant associated protein C	Mus musculus	80-89
16251411-4	2005	At 3 and 6 weeks after bleomycin, lungs from SFTPC-/- mice had increased fibroblast numbers, augmented collagen accumulation, and greater parenchymal distortion.	Bleomycin	23-32	surfactant associated protein C	Mus musculus	45-50
16251411-7	2005	By terminal dUTP nick-end labeling staining, widespread cell injury was observed in SFTPC-/- and SFTPC+/+ mice 1 week after bleomycin; however, ongoing apoptosis of epithelial and interstitial cells occurred in lungs of SFTPC-/- mice, but not SFTPC+/+ mice, 6 weeks after bleomycin.	Bleomycin	124-133	surfactant associated protein C	Mus musculus	97-102
16251411-7	2005	By terminal dUTP nick-end labeling staining, widespread cell injury was observed in SFTPC-/- and SFTPC+/+ mice 1 week after bleomycin; however, ongoing apoptosis of epithelial and interstitial cells occurred in lungs of SFTPC-/- mice, but not SFTPC+/+ mice, 6 weeks after bleomycin.	Bleomycin	124-133	surfactant associated protein C	Mus musculus	97-102
16251411-7	2005	By terminal dUTP nick-end labeling staining, widespread cell injury was observed in SFTPC-/- and SFTPC+/+ mice 1 week after bleomycin; however, ongoing apoptosis of epithelial and interstitial cells occurred in lungs of SFTPC-/- mice, but not SFTPC+/+ mice, 6 weeks after bleomycin.	Bleomycin	124-133	surfactant associated protein C	Mus musculus	97-102
16251411-8	2005	Thus, SP-C functions to limit lung inflammation, inhibit collagen accumulation, and restore normal lung structure after bleomycin.	Bleomycin	120-129	sparse coat	Mus musculus	6-10
16154539-1	2005	Serum thymic factor (FTS), a thymic peptide hormone, has been reported to attenuate the bleomycin-induced pulmonary injury and also experimental pancreatitis and diabetes.	Bleomycin	88-97	AKT interacting protein	Rattus norvegicus	21-24
16281866-2	2005	After 4 courses of chemotherapy with cisplatin (CDDP), etoposide (VP-16) and bleomycin hydrochloride (BLM), the mediastinal mass reduced in size significantly and the serum AFP level reached within normal range.	Bleomycin	102-105	alpha fetoprotein	Homo sapiens	173-176
16170329-4	2005	Jasmonic acid and methyl jasmonate (0.25-3 mM) were each equally cytotoxic to both clones, whereas mutant p53-expressing cells were resistant to treatment with the radiomimetic agent neocarzinostatin and the chemotherapeutic agent bleomycin.	Bleomycin	231-240	tumor protein p53	Homo sapiens	106-109
16170329-5	2005	Neocarzinostatin and bleomycin induced an elevation in the p53 levels in wt p53-expressing cells, whereas methyl jasmonate did not.	Bleomycin	21-30	tumor protein p53	Homo sapiens	59-62
16170329-5	2005	Neocarzinostatin and bleomycin induced an elevation in the p53 levels in wt p53-expressing cells, whereas methyl jasmonate did not.	Bleomycin	21-30	tumor protein p53	Homo sapiens	76-79
16170329-7	2005	In contrast, neocarzinostatin and bleomycin induced death only in wt p53-expressing cells, in an apoptotic mode.	Bleomycin	34-43	tumor protein p53	Homo sapiens	69-72
16324271-1	2005	OBJECTIVE: To observe the protective role of recombinant Chinese interferon-gamma (INF-gamma) in pulmonary injury (PI) induced by bleomycin (BLM) in C57 mice.	Bleomycin	130-139	interferon gamma	Mus musculus	65-81
16324271-1	2005	OBJECTIVE: To observe the protective role of recombinant Chinese interferon-gamma (INF-gamma) in pulmonary injury (PI) induced by bleomycin (BLM) in C57 mice.	Bleomycin	130-139	interferon gamma	Mus musculus	83-92
16324271-1	2005	OBJECTIVE: To observe the protective role of recombinant Chinese interferon-gamma (INF-gamma) in pulmonary injury (PI) induced by bleomycin (BLM) in C57 mice.	Bleomycin	141-144	interferon gamma	Mus musculus	65-81
16324271-1	2005	OBJECTIVE: To observe the protective role of recombinant Chinese interferon-gamma (INF-gamma) in pulmonary injury (PI) induced by bleomycin (BLM) in C57 mice.	Bleomycin	141-144	interferon gamma	Mus musculus	83-92
16331820-0	2005	[Effect of VEGF gene transfer on the bleomycin-induced pulmonary hypertension in immature rabbits].	Bleomycin	37-46	vascular endothelial growth factor A	Oryctolagus cuniculus	11-15
16335208-0	2005	[Effects of moxibustion at Feishu (BL 13) and Gaohuang (BL 43) on expression of TGF-beta1 in the bleomycin -induced pulmonary fibrosis].	Bleomycin	97-106	transforming growth factor, beta 1	Rattus norvegicus	80-89
16335208-7	2005	CONCLUSION: Both moxibustion at Feishu (BL 13) and Gaohuang (BL 43), and prednisone treatment can significantly suppress the expression of TGF-beta1mRNA in the pulmonary tissue in the rat of bleomycin-induced pulmonary fibrosis.	Bleomycin	191-200	transforming growth factor, beta 1	Rattus norvegicus	139-148
16148050-0	2005	Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death pathway.	Bleomycin	0-9	mitogen-activated protein kinase 8	Mus musculus	57-60
16331820-1	2005	OBJECTIVE: To investigate the effect of vascular endothelial growth factor (VEGF) gene transfer on the bleomycin(BLM)-induced pulmonary hypertension in immature rabbits.	Bleomycin	103-112	vascular endothelial growth factor A	Oryctolagus cuniculus	40-74
16331820-1	2005	OBJECTIVE: To investigate the effect of vascular endothelial growth factor (VEGF) gene transfer on the bleomycin(BLM)-induced pulmonary hypertension in immature rabbits.	Bleomycin	103-112	vascular endothelial growth factor A	Oryctolagus cuniculus	76-80
16331820-1	2005	OBJECTIVE: To investigate the effect of vascular endothelial growth factor (VEGF) gene transfer on the bleomycin(BLM)-induced pulmonary hypertension in immature rabbits.	Bleomycin	113-116	vascular endothelial growth factor A	Oryctolagus cuniculus	40-74
16331820-1	2005	OBJECTIVE: To investigate the effect of vascular endothelial growth factor (VEGF) gene transfer on the bleomycin(BLM)-induced pulmonary hypertension in immature rabbits.	Bleomycin	113-116	vascular endothelial growth factor A	Oryctolagus cuniculus	76-80
16331820-11	2005	CONCLUSION: VEGF gene transfer in immature rabbits with BLM-induced pulmonary hypertension could attenuate the increasing of PAP and wall thickness in middle and small pulmonary arteries, and increase the level of VEGFmRNA and eNOSmRNA expression in pulmonary arterial endothelial cells.	Bleomycin	56-59	vascular endothelial growth factor A	Oryctolagus cuniculus	12-16
15994463-8	2005	As proof of principle, SP-D OE mice were highly resistant to bleomycin-induced morbidity and mortality at doses up to 3 U/kg.	Bleomycin	61-70	surfactant associated protein D	Mus musculus	23-27
16148050-8	2005	Furthermore, fibroblast cells deficient in Bax and Bak, but not Bid, were resistant to bleomycin-induced cell death.	Bleomycin	87-96	BCL2-associated X protein	Mus musculus	43-46
16148050-8	2005	Furthermore, fibroblast cells deficient in Bax and Bak, but not Bid, were resistant to bleomycin-induced cell death.	Bleomycin	87-96	BCL2-antagonist/killer 1	Mus musculus	51-54
16148050-10	2005	Bleomycin-induced Bax activation was prevented by the expression of a dominant negative JNK in MLE-12 cells.	Bleomycin	0-9	BCL2-associated X protein	Mus musculus	18-21
16148050-10	2005	Bleomycin-induced Bax activation was prevented by the expression of a dominant negative JNK in MLE-12 cells.	Bleomycin	0-9	mitogen-activated protein kinase 8	Mus musculus	88-91
16007157-5	2005	Here, we report that high expression levels of HMGA1 proteins in MCF-7 or mouse embryonic stem cells results in diminished BRCA1 expression and enhanced sensitivity to Cisplatin and Bleomycin.	Bleomycin	182-191	high mobility group AT-hook 1	Homo sapiens	47-52
16148050-11	2005	Dominant negative JNK prevented cell death in MLE-12 cells and in primary rat alveolar type II cells exposed to bleomycin.	Bleomycin	112-121	mitogen-activated protein kinase 8	Mus musculus	18-21
16148050-12	2005	These data indicate that bleomycin induces cell death through a JNK-dependent mitochondrial death pathway in alveolar epithelial cells.	Bleomycin	25-34	mitogen-activated protein kinase 8	Mus musculus	64-67
15947421-1	2005	Bleomycin-induced lung injury triggers a profound and durable increase in tissue inhibitor of metalloproteinase (TIMP)-1 expression, suggesting a potential role for this antiproteinase in the regulation of lung inflammation and fibrosis.	Bleomycin	0-9	tissue inhibitor of metalloproteinase 1	Mus musculus	74-120
16172745-7	2005	Indeed, the correlation of the differences in hydroxyproline levels in the lungs of bleomycin-treated mice strongly suggests that a reduced molar pro-MMP-9/TIMP-1 ratio in bronchoalveolar lavage fluid is associated with collagen deposition, beginning as early as the inflammatory events at day 1 after bleomycin administration.	Bleomycin	84-93	matrix metallopeptidase 9	Mus musculus	146-155
16172745-7	2005	Indeed, the correlation of the differences in hydroxyproline levels in the lungs of bleomycin-treated mice strongly suggests that a reduced molar pro-MMP-9/TIMP-1 ratio in bronchoalveolar lavage fluid is associated with collagen deposition, beginning as early as the inflammatory events at day 1 after bleomycin administration.	Bleomycin	84-93	tissue inhibitor of metalloproteinase 1	Mus musculus	156-162
16172745-7	2005	Indeed, the correlation of the differences in hydroxyproline levels in the lungs of bleomycin-treated mice strongly suggests that a reduced molar pro-MMP-9/TIMP-1 ratio in bronchoalveolar lavage fluid is associated with collagen deposition, beginning as early as the inflammatory events at day 1 after bleomycin administration.	Bleomycin	302-311	matrix metallopeptidase 9	Mus musculus	146-155
16191100-0	2005	Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury.	Bleomycin	81-90	interleukin 2	Mus musculus	10-14
16191100-0	2005	Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury.	Bleomycin	81-90	BCL2-associated X protein	Mus musculus	15-18
16191100-5	2005	We investigated the effects of IL-2-Bax, a novel apoptosis-inducing IL-2R-targeted chimeric protein, on bleomycin-induced lung injury in mice.	Bleomycin	104-113	interleukin 2	Mus musculus	31-35
16191100-8	2005	Bleomycin induced a BAL lymphocytosis that was significantly attenuated by IL-2-Bax and IL-2-PE66(4Glu).	Bleomycin	0-9	interleukin 2	Mus musculus	75-79
16191100-8	2005	Bleomycin induced a BAL lymphocytosis that was significantly attenuated by IL-2-Bax and IL-2-PE66(4Glu).	Bleomycin	0-9	BCL2-associated X protein	Mus musculus	80-83
16191100-8	2005	Bleomycin induced a BAL lymphocytosis that was significantly attenuated by IL-2-Bax and IL-2-PE66(4Glu).	Bleomycin	0-9	interleukin 2	Mus musculus	88-92
16191100-10	2005	These results show that IL-2-Bax reduces the lymphocytic infiltration of the lungs in response to bleomycin, but this effect is not accompanied by a decrease in lung fibrosis.	Bleomycin	98-107	interleukin 2	Mus musculus	24-28
16191100-10	2005	These results show that IL-2-Bax reduces the lymphocytic infiltration of the lungs in response to bleomycin, but this effect is not accompanied by a decrease in lung fibrosis.	Bleomycin	98-107	BCL2-associated X protein	Mus musculus	29-32
15947421-3	2005	Using TIMP-1 null mutation mice, we demonstrate that TIMP-1 deficiency amplifies acute lung injury as determined by exaggerated pulmonary neutrophilia, hemorrhage, and vascular permeability compared with wild-type littermates after bleomycin exposure.	Bleomycin	232-241	tissue inhibitor of metalloproteinase 1	Mus musculus	53-59
15792964-0	2005	Protection against bleomycin-induced lung injury by IL-18 in mice.	Bleomycin	19-28	interleukin 18	Mus musculus	52-57
15946810-9	2005	In vitro data revealed that the LD50 of bleomycin encapsulated in Bleosome was approximately three-fold higher than free bleomycin solution for SCC cells, and nearly 30 times higher for NEB-1 cells.	Bleomycin	40-49	serpin family B member 3	Homo sapiens	144-147
15946810-9	2005	In vitro data revealed that the LD50 of bleomycin encapsulated in Bleosome was approximately three-fold higher than free bleomycin solution for SCC cells, and nearly 30 times higher for NEB-1 cells.	Bleomycin	40-49	cleavage and polyadenylation specific factor 4	Homo sapiens	186-191
15946810-10	2005	However, Bleosome containing 30 microg/ml of active bleomycin killed more than twice as many SCC cells than NEB-1 cells.	Bleomycin	52-61	serpin family B member 3	Homo sapiens	93-96
15844216-0	2005	Apoptosis and release of CD44s in bleomycin-treated L132 cells.	Bleomycin	34-43	CD44 molecule (Indian blood group)	Homo sapiens	25-29
16203623-9	2005	If antigen-specific T-cell engagement is required for the development of lung fibrosis, bleomycin-induced fibrosis should be reduced in the TCRbeta transgenic mice.	Bleomycin	88-97	T cell receptor beta chain	Mus musculus	140-147
16120623-2	2005	METHODS: Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia.	Bleomycin	102-111	colony stimulating factor 3	Homo sapiens	261-266
15946810-11	2005	At that concentration, the potency of liposomal bleomycin on causing cell death of SCC cells was found to be similar to that of free bleomycin solution.	Bleomycin	48-57	serpin family B member 3	Homo sapiens	83-86
15946810-13	2005	It seems that SCC cells were particularly susceptible to Bleosome containing high levels of bleomycin.	Bleomycin	92-101	serpin family B member 3	Homo sapiens	14-17
15805137-9	2005	Nuclear accumulation of LTA4 hydrolase was also conspicuous in epithelial cells during alveolar repair following bleomycin-induced acute lung injury in mice, as well as in hyperplastic type II cells associated with fibrotic lung tissues from patients with idiopathic pulmonary fibrosis.	Bleomycin	113-122	leukotriene A4 hydrolase	Mus musculus	24-38
16049324-4	2005	The majority of cells demonstrating TGF-beta activation and myofibroblast differentiation in bleomycin-induced lesions were Thy-1-negative.	Bleomycin	93-102	transforming growth factor beta 1	Homo sapiens	36-44
16049324-4	2005	The majority of cells demonstrating TGF-beta activation and myofibroblast differentiation in bleomycin-induced lesions were Thy-1-negative.	Bleomycin	93-102	Thy-1 cell surface antigen	Homo sapiens	124-129
15792964-1	2005	The role of interleukin (IL)-18 in the protection from interstitial pneumonia and pulmonary fibrosis induced by bleomycin (BLM) was investigated by comparing the severity of BLM-induced lung injuries between wild-type and C57BL/6 mice with a targeted knockout mutation of the IL-18 gene (IL-18-/- mice).	Bleomycin	112-121	interleukin 18	Mus musculus	12-31
16034133-0	2005	Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	71-80	hemolytic complement	Mus musculus	29-48
16034133-5	2005	C5-deficient mice had an exaggerated inflammatory phenotype compared with C5-sufficient mice during acute bleomycin-induced lung injury.	Bleomycin	106-115	hemolytic complement	Mus musculus	0-2
16034133-7	2005	In contrast, C5 had a detrimental effect during chronic stages of bleomycin-induced injury, indicating a profibrotic role for C5.	Bleomycin	66-75	hemolytic complement	Mus musculus	13-15
16002726-5	2005	Transfection of the sflt-1 gene at 3 days before or 7 days after the intratracheal instillation of bleomycin decreased the number of inflammatory cells, the protein concentration in the bronchoalveolar lavage fluid and with von Willebrand factor expression at 14 days.	Bleomycin	99-108	FMS-like tyrosine kinase 1	Mus musculus	20-26
16000067-10	2005	Cells lacking hTERT showed a significantly increased sensitivity, compared with control cells, to ionizing radiation or chemotherapeutic agents that induce DNA double- strand breaks, such as topoisomerase inhibitors or bleomycin.	Bleomycin	219-228	telomerase reverse transcriptase	Homo sapiens	14-19
15963921-1	2005	We examined therapeutic gene transfer of human hepatocyte growth factor (hHGF) to alveolar septa in mouse bleomycin-induced lung fibrosis using macroaggregated albumin-polyethylenimine complex (MAA-PEI).	Bleomycin	106-115	hepatocyte growth factor	Homo sapiens	47-71
15963921-1	2005	We examined therapeutic gene transfer of human hepatocyte growth factor (hHGF) to alveolar septa in mouse bleomycin-induced lung fibrosis using macroaggregated albumin-polyethylenimine complex (MAA-PEI).	Bleomycin	106-115	hepatocyte growth factor	Homo sapiens	73-77
15948962-8	2005	There is no delay of the S-phase when germlings of both sldI (RAD50) and mreA(MRE11) inactivation strains were exposed to the DNA damage caused by bleomycin.	Bleomycin	147-156	MRE11 homolog, double strand break repair nuclease	Homo sapiens	78-83
15963921-3	2005	The exogenous source of hHGF gene expression increased the endogenous mouse HGF in the lungs and significantly decreased TNF-alpha, IL-6, and collagen synthesis after bleomycin injury.	Bleomycin	167-176	hepatocyte growth factor	Homo sapiens	24-28
15963921-3	2005	The exogenous source of hHGF gene expression increased the endogenous mouse HGF in the lungs and significantly decreased TNF-alpha, IL-6, and collagen synthesis after bleomycin injury.	Bleomycin	167-176	hepatocyte growth factor	Mus musculus	25-28
15928672-0	2005	Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).	Bleomycin	9-18	BOP	Homo sapiens	47-50
15955252-2	2005	When compared to bleomycin-treated iNOSWT mice, iNOSKO mice, which had received bleomycin, exhibited a reduced degree of the (i) lost of body weight, (ii) mortality rate, (iii) infiltration of the lung with polymorphonuclear neutrophils (MPO activity), (iv) edema formation, (v) histological evidence of lung injury, (vi) lung collagen deposition and (vii) lung Transforming Growth Factor beta1 (TGF-beta1) expression.	Bleomycin	80-89	myeloperoxidase	Mus musculus	238-241
15955252-2	2005	When compared to bleomycin-treated iNOSWT mice, iNOSKO mice, which had received bleomycin, exhibited a reduced degree of the (i) lost of body weight, (ii) mortality rate, (iii) infiltration of the lung with polymorphonuclear neutrophils (MPO activity), (iv) edema formation, (v) histological evidence of lung injury, (vi) lung collagen deposition and (vii) lung Transforming Growth Factor beta1 (TGF-beta1) expression.	Bleomycin	80-89	transforming growth factor, beta 1	Mus musculus	362-394
15955252-2	2005	When compared to bleomycin-treated iNOSWT mice, iNOSKO mice, which had received bleomycin, exhibited a reduced degree of the (i) lost of body weight, (ii) mortality rate, (iii) infiltration of the lung with polymorphonuclear neutrophils (MPO activity), (iv) edema formation, (v) histological evidence of lung injury, (vi) lung collagen deposition and (vii) lung Transforming Growth Factor beta1 (TGF-beta1) expression.	Bleomycin	80-89	transforming growth factor, beta 1	Mus musculus	396-405
15955252-8	2005	CONCLUSION: Taken together, our results clearly demonstrate that iNOS plays an important role in the lung injury induced by bleomycin in the mice.	Bleomycin	124-133	nitric oxide synthase 2, inducible	Mus musculus	65-69
15920145-7	2005	Furthermore, fibroblasts from bleomycin-treated rats exhibited increased responsiveness to estradiol treatment, causing dose-dependent increases in procollagen 1 and transforming growth factor-beta1 mRNA expression relative to untreated controls.	Bleomycin	30-39	transforming growth factor, beta 1	Rattus norvegicus	148-198
16212889-0	2005	STAT1 antisense oligonucleotides attenuate the proinflammatory cytokine release of alveolar macrophages in bleomycin-induced fibrosis.	Bleomycin	107-116	signal transducer and activator of transcription 1	Rattus norvegicus	0-5
15988138-4	2005	Cells transfected with the c-myc, v-mos, or v-fgr gene increased their sensitivity to bleomycin, while those transfected with the H-ras gene developed resistance.	Bleomycin	86-95	myc proto-oncogene protein	Mesocricetus auratus	27-32
16021985-2	2005	The purpose of this study was to evaluate the effects of an angiotensin II type 1 receptor blocker, valsartan, on systemic, cellular, and fibrotic consequences of pulmonary injury induced by the anti-neoplastic antibiotic, bleomycin.	Bleomycin	223-232	angiotensin II receptor, type 1b	Rattus norvegicus	60-90
15937080-2	2005	In a prior study, susceptibility to bleomycin induced pulmonary fibrosis was mapped to loci Blmpf1 and Blmpf2 on chromosomes 17 and 11, respectively, in a C57BL/6J (B6, susceptible) and C3Hf/KAM (C3H, resistant) mouse cross.	Bleomycin	36-45	bleomycin-induced pulmonary fibrosis 1	Mus musculus	92-98
15937080-2	2005	In a prior study, susceptibility to bleomycin induced pulmonary fibrosis was mapped to loci Blmpf1 and Blmpf2 on chromosomes 17 and 11, respectively, in a C57BL/6J (B6, susceptible) and C3Hf/KAM (C3H, resistant) mouse cross.	Bleomycin	36-45	bleomycin-induced pulmonary fibrosis 2	Mus musculus	103-109
15937080-4	2005	RESULTS: In this study, gene expression analysis with microarrays revealed 1892 genes or ESTs (expressed sequence tags) to be differentially expressed between bleomycin treated B6 and C3H mice and 67 of these genetic elements map to Blmpf1 or Blmpf2.	Bleomycin	159-168	bleomycin-induced pulmonary fibrosis 1	Mus musculus	233-239
15937080-4	2005	RESULTS: In this study, gene expression analysis with microarrays revealed 1892 genes or ESTs (expressed sequence tags) to be differentially expressed between bleomycin treated B6 and C3H mice and 67 of these genetic elements map to Blmpf1 or Blmpf2.	Bleomycin	159-168	bleomycin-induced pulmonary fibrosis 2	Mus musculus	243-249
15910444-0	2005	Gene transfer of vascular endothelial growth factor reduces bleomycin-induced pulmonary hypertension in immature rabbits.	Bleomycin	60-69	vascular endothelial growth factor A	Oryctolagus cuniculus	17-51
15910444-1	2005	BACKGROUND: The purpose of the present paper was to investigate the effect of gene transfer of vascular endothelial growth factor (VEGF) on bleomycin (BLM)-induced pulmonary hypertension in immature rabbits.	Bleomycin	140-149	vascular endothelial growth factor A	Oryctolagus cuniculus	95-129
15900213-2	2005	Bleomycin is mainly excreted by the kidneys, but can also be inactivated by bleomycin hydrolase (BMH).	Bleomycin	0-9	bleomycin hydrolase	Homo sapiens	76-95
15900213-2	2005	Bleomycin is mainly excreted by the kidneys, but can also be inactivated by bleomycin hydrolase (BMH).	Bleomycin	0-9	bleomycin hydrolase	Homo sapiens	97-100
15900213-5	2005	We investigated the relation between the BMH genotype and the risk of bleomycin-induced pneumonitis (BIP).	Bleomycin	70-79	bleomycin hydrolase	Homo sapiens	41-44
15910444-1	2005	BACKGROUND: The purpose of the present paper was to investigate the effect of gene transfer of vascular endothelial growth factor (VEGF) on bleomycin (BLM)-induced pulmonary hypertension in immature rabbits.	Bleomycin	140-149	vascular endothelial growth factor A	Oryctolagus cuniculus	131-135
15843564-3	2005	However, following challenge with the fibrogenic agent, bleomycin, fibroblasts showed loss of EP2 expression.	Bleomycin	56-65	prostaglandin E receptor 2 (subtype EP2)	Mus musculus	94-97
15855637-0	2005	Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis.	Bleomycin	77-86	coagulation factor II (thrombin) receptor	Mus musculus	11-42
15855637-2	2005	The aim of this study was to examine the contribution of the major thrombin receptor, proteinase-activated receptor-1 (PAR-1), during the acute inflammatory and chronic fibrotic phases of lung injury induced by intratracheal instillation of bleomycin in mice.	Bleomycin	241-250	coagulation factor II (thrombin) receptor	Mus musculus	86-117
15855637-2	2005	The aim of this study was to examine the contribution of the major thrombin receptor, proteinase-activated receptor-1 (PAR-1), during the acute inflammatory and chronic fibrotic phases of lung injury induced by intratracheal instillation of bleomycin in mice.	Bleomycin	241-250	coagulation factor II (thrombin) receptor	Mus musculus	119-124
15855637-4	2005	PAR-1-/- mice were also protected from bleomycin-induced pulmonary fibrosis with total lung collagen accumulation reduced by 59 +/- 5% (P &lt; 0.05).	Bleomycin	39-48	coagulation factor II (thrombin) receptor	Mus musculus	0-5
15894690-4	2005	To test for increased mutagenicity of cells from BRCA1 carriers, the frequency of chromosome breaks was measured in cultured blood lymphocytes following in vitro exposure to bleomycin in female BRCA1 carriers and was compared with noncarrier relatives.	Bleomycin	174-183	BRCA1 DNA repair associated	Homo sapiens	194-199
15803328-0	2005	Increased expression of p53 and p21 (Waf1/Cip1) in the lesional skin of bleomycin-induced scleroderma.	Bleomycin	72-81	transformation related protein 53, pseudogene	Mus musculus	24-27
15803328-0	2005	Increased expression of p53 and p21 (Waf1/Cip1) in the lesional skin of bleomycin-induced scleroderma.	Bleomycin	72-81	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	32-35
15803328-0	2005	Increased expression of p53 and p21 (Waf1/Cip1) in the lesional skin of bleomycin-induced scleroderma.	Bleomycin	72-81	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	37-41
15803328-0	2005	Increased expression of p53 and p21 (Waf1/Cip1) in the lesional skin of bleomycin-induced scleroderma.	Bleomycin	72-81	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	42-46
15803328-3	2005	In this study, we examined the induction of apoptosis and the expression of p53, p21 (Waf1/Cip1), and proliferating cell nuclear antigen (PCNA) in the lesional skin following bleomycin exposure in this model.	Bleomycin	175-184	transformation related protein 53, pseudogene	Mus musculus	76-79
15803328-3	2005	In this study, we examined the induction of apoptosis and the expression of p53, p21 (Waf1/Cip1), and proliferating cell nuclear antigen (PCNA) in the lesional skin following bleomycin exposure in this model.	Bleomycin	175-184	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	81-84
15803328-3	2005	In this study, we examined the induction of apoptosis and the expression of p53, p21 (Waf1/Cip1), and proliferating cell nuclear antigen (PCNA) in the lesional skin following bleomycin exposure in this model.	Bleomycin	175-184	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	86-90
15803328-3	2005	In this study, we examined the induction of apoptosis and the expression of p53, p21 (Waf1/Cip1), and proliferating cell nuclear antigen (PCNA) in the lesional skin following bleomycin exposure in this model.	Bleomycin	175-184	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	91-95
15803328-3	2005	In this study, we examined the induction of apoptosis and the expression of p53, p21 (Waf1/Cip1), and proliferating cell nuclear antigen (PCNA) in the lesional skin following bleomycin exposure in this model.	Bleomycin	175-184	proliferating cell nuclear antigen	Mus musculus	102-136
15803328-3	2005	In this study, we examined the induction of apoptosis and the expression of p53, p21 (Waf1/Cip1), and proliferating cell nuclear antigen (PCNA) in the lesional skin following bleomycin exposure in this model.	Bleomycin	175-184	proliferating cell nuclear antigen	Mus musculus	138-142
15803328-6	2005	Immunohistochemical examination showed increased expression of p53 and p21 mainly in the infiltrating mononuclear cells at 2 weeks after bleomycin treatment.	Bleomycin	137-146	transformation related protein 53, pseudogene	Mus musculus	63-66
15803328-6	2005	Immunohistochemical examination showed increased expression of p53 and p21 mainly in the infiltrating mononuclear cells at 2 weeks after bleomycin treatment.	Bleomycin	137-146	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	71-74
15803328-7	2005	Bleomycin treatment markedly enhanced PCNA expression at 1-2 weeks, mainly in mesenchyme, as compared with control phosphate buffered saline treatment.	Bleomycin	0-9	proliferating cell nuclear antigen	Mus musculus	38-42
15803328-8	2005	Reverse transcriptase-polymerase chain reaction analysis showed that the expression of p53 and p21 mRNA was concurrently upregulated at 1-2 weeks after bleomycin treatment.	Bleomycin	152-161	transformation related protein 53, pseudogene	Mus musculus	87-90
15803328-8	2005	Reverse transcriptase-polymerase chain reaction analysis showed that the expression of p53 and p21 mRNA was concurrently upregulated at 1-2 weeks after bleomycin treatment.	Bleomycin	152-161	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	95-98
15803328-10	2005	Our findings suggest that apoptotic processes are involved in the pathophysiology of bleomycin-induced scleroderma, which may be mediated, in part, by the upregulation of p53 and p21.	Bleomycin	85-94	transformation related protein 53, pseudogene	Mus musculus	171-174
15803328-10	2005	Our findings suggest that apoptotic processes are involved in the pathophysiology of bleomycin-induced scleroderma, which may be mediated, in part, by the upregulation of p53 and p21.	Bleomycin	85-94	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	179-182
15843564-6	2005	EP2(-/-), but not EP1(-/-) or EP3(-/-) mice, showed exaggerated fibrotic responses to bleomycin administration in vivo as compared with wild-type controls.	Bleomycin	86-95	prostaglandin E receptor 2 (subtype EP2)	Mus musculus	0-3
15862142-0	2005	[A preliminary study of CTGF in bleomycin-induced mouse pulmonary fibrosis].	Bleomycin	32-41	cellular communication network factor 2	Mus musculus	24-28
15618458-3	2005	Protein and mRNA expression of FSP1 was minimal in untreated lungs, but increased by 1 week after bleomycin administration and remained increased at 2 and 3 weeks after treatment.	Bleomycin	98-107	S100 calcium binding protein A4	Homo sapiens	31-35
15618458-4	2005	By immunohistochemistry, the number of FSP1(+) cells increased in a dose-dependent manner in the lungs after bleomycin treatment.	Bleomycin	109-118	S100 calcium binding protein A4	Homo sapiens	39-43
15618458-5	2005	Colocalization of alpha1 procollagen and FSP1 in interstitial cells demonstrated that FSP1(+) fibroblasts contribute to the deposition of collagen after bleomycin administration.	Bleomycin	153-162	S100 calcium binding protein A4	Homo sapiens	86-90
15644425-0	2005	Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and the development of bleomycin-induced lung injury.	Bleomycin	103-112	poly (ADP-ribose) polymerase family, member 1	Mus musculus	14-41
15644425-2	2005	The aim of our study was to evaluate the therapeutic efficacy of in vivo inhibition of PARP in an experimental model of lung injury caused by bleomycin administration.	Bleomycin	142-151	poly (ADP-ribose) polymerase family, member 1	Mus musculus	87-91
15644425-3	2005	Mice subjected to intratracheal administration of bleomycin developed significant lung injury and apoptosis (measured by Annexin V coloration).	Bleomycin	50-59	annexin A5	Mus musculus	121-130
15644425-4	2005	An increase of immunoreactivity to nitrotyrosine and PARP, as well as a significant loss of body weight and mortality, was observed in the lung of bleomycin-treated mice.	Bleomycin	147-156	poly (ADP-ribose) polymerase family, member 1	Mus musculus	53-57
15644425-7	2005	These results demonstrate that treatment with PARP inhibitors reduces the development of inflammation and tissue injury events induced by bleomycin administration in the mice.	Bleomycin	138-147	poly (ADP-ribose) polymerase family, member 1	Mus musculus	46-50
15862142-1	2005	AIM: To investigate CTGF"s role in bleomycin-induced pulmonary fibrosis.	Bleomycin	35-44	cellular communication network factor 2	Mus musculus	20-24
15665032-8	2005	Furthermore, administration of recombinant HGF to bleomycin-treated mice increased lung MMP activities and enhanced myofibroblast apoptosis, while in vivo MMI270 injections together with HGF inhibited such MMP activation, leading to suppressed myofibroblast apoptosis.	Bleomycin	50-59	hepatocyte growth factor	Mus musculus	187-190
15909493-6	2005	Comparing pretreatment and post-treatment scintigraphies the mean T1/2 99mTc-DTPA values decreased as the bleomycin dose increased.	Bleomycin	106-115	interleukin 1 receptor like 1	Homo sapiens	66-76
15665032-7	2005	In bleomycin-treated mice, c-Met expression was found on interstitial myofibroblasts and HGF increased apoptosis in culture of myofibroblasts isolated from bleomycin-treated murine lungs.	Bleomycin	3-12	met proto-oncogene	Mus musculus	27-32
15665032-7	2005	In bleomycin-treated mice, c-Met expression was found on interstitial myofibroblasts and HGF increased apoptosis in culture of myofibroblasts isolated from bleomycin-treated murine lungs.	Bleomycin	3-12	hepatocyte growth factor	Mus musculus	89-92
15788228-1	2005	Flavonoids were examined for synergistic effects with ascorbate on enhancement of DNA degradation induced by a bleomycin(BLM)-Fe complex.	Bleomycin	111-120	BLM RecQ like helicase	Homo sapiens	121-124
15665032-7	2005	In bleomycin-treated mice, c-Met expression was found on interstitial myofibroblasts and HGF increased apoptosis in culture of myofibroblasts isolated from bleomycin-treated murine lungs.	Bleomycin	156-165	hepatocyte growth factor	Mus musculus	89-92
15665032-8	2005	Furthermore, administration of recombinant HGF to bleomycin-treated mice increased lung MMP activities and enhanced myofibroblast apoptosis, while in vivo MMI270 injections together with HGF inhibited such MMP activation, leading to suppressed myofibroblast apoptosis.	Bleomycin	50-59	hepatocyte growth factor	Mus musculus	43-46
15665032-8	2005	Furthermore, administration of recombinant HGF to bleomycin-treated mice increased lung MMP activities and enhanced myofibroblast apoptosis, while in vivo MMI270 injections together with HGF inhibited such MMP activation, leading to suppressed myofibroblast apoptosis.	Bleomycin	50-59	matrix metallopeptidase 2	Mus musculus	88-91
15802347-3	2005	However, the role of angiotensin II in the pathobiology of pulmonary fibrosis in vivo remains unclear and the therapeutic potential for targeting angiotensin II in a bleomycin-induced pulmonary fibrosis model is not well known.	Bleomycin	166-175	angiotensinogen	Homo sapiens	146-160
15802347-4	2005	Therefore, the aim of this study was to test whether the angiotensin II antagonist, losartan, attenuated the development of bleomycin-induced pulmonary fibrosis in two distinct murine strains, C57/BL6 and Sv129.	Bleomycin	124-133	angiotensinogen	Homo sapiens	57-71
15730388-0	2005	Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma.	Bleomycin	88-97	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	0-33
15730388-2	2005	In this study, we investigated the role of PAI-1 in bleomycin-induced murine scleroderma.	Bleomycin	52-61	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	43-48
15730388-6	2005	The production of active PAI-1 protein in the lesional skin was significantly increased 3 and 4 weeks after bleomycin treatment.	Bleomycin	108-117	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	25-30
15730388-8	2005	10 microg of bleomycin was subcutaneously injected to PAI-1-/- and wild type (WT) mice 5 days per week for 4 weeks.	Bleomycin	13-22	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	54-59
15730388-10	2005	Dermal thickness and collagen contents in the skin were significantly increased by bleomycin injection in both PAI-1-/- and WT mice, and the rate of increase was similar.	Bleomycin	83-92	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	111-116
15856276-8	2005	A further interesting outcome of our study is the shift of caveolin-1 from the lipid raft/caveolae fractions to the non-caveolar fractions after bleomycin treatment indicating an intracellular retention of caveolin-1.	Bleomycin	145-154	caveolin 1	Rattus norvegicus	59-69
15856276-8	2005	A further interesting outcome of our study is the shift of caveolin-1 from the lipid raft/caveolae fractions to the non-caveolar fractions after bleomycin treatment indicating an intracellular retention of caveolin-1.	Bleomycin	145-154	caveolin 1	Rattus norvegicus	206-216
15767545-0	2005	Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells.	Bleomycin	102-111	RAD21 cohesin complex component	Homo sapiens	15-20
15767545-7	2005	Moreover, MCF-7 cell sensitivity to two DNA-damaging chemotherapeutic agents, etoposide and bleomycin, was increased after inhibition of RAD21 expression with a dose reduction factor 50 (DRF50) of 1.42 and 3.71, respectively.	Bleomycin	92-101	RAD21 cohesin complex component	Homo sapiens	137-142
15767545-8	2005	At the highest concentrations of etoposide and bleomycin administered, cells transfected with a single siRNA duplex targeted against RAD21 showed 57% and 60% survival as compared with control cells, respectively.	Bleomycin	47-56	RAD21 cohesin complex component	Homo sapiens	133-138
15854415-3	2005	TUNEL, immunohistochemistry and in situ hybridization were used to detect the change of cell apoptosis, Fas/FasL mRNA and protein in mice with pulmonary fibrosis caused by bleomycin.	Bleomycin	172-181	Fas ligand (TNF superfamily, member 6)	Mus musculus	108-112
15557019-9	2005	Bleomycin-induced increase in TGF-beta1 in epithelial cells and extracellular matrix was attenuated by IFN-beta.	Bleomycin	0-9	interferon beta 1, fibroblast	Mus musculus	103-111
15649438-0	2005	The yeast multidrug transporter Qdr3 (Ybr043c): localization and role as a determinant of resistance to quinidine, barban, cisplatin, and bleomycin.	Bleomycin	138-147	Qdr3p	Saccharomyces cerevisiae S288C	32-36
15649438-3	2005	The increased expression of QDR3, or QDR2, also leads to increased resistance to the anticancer agents cisplatin and bleomycin.	Bleomycin	117-126	Qdr3p	Saccharomyces cerevisiae S288C	28-32
15649438-3	2005	The increased expression of QDR3, or QDR2, also leads to increased resistance to the anticancer agents cisplatin and bleomycin.	Bleomycin	117-126	cation transporter	Saccharomyces cerevisiae S288C	37-41
15502109-0	2005	CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.	Bleomycin	18-27	chemokine (C-X-C motif) ligand 11	Mus musculus	0-6
15502109-4	2005	We hypothesized that net aberrant vascular remodeling seen during the pathogenesis of fibroplasia and deposition of extracellular matrix during bleomycin-induced pulmonary fibrosis can be attenuated by treatment with the angiostatic ELR(-) CXC chemokine, CXCL11.	Bleomycin	144-153	chemokine (C-X-C motif) ligand 11	Mus musculus	255-261
15713430-8	2005	Bleomycin-induced pulmonary injury and lung fibrosis was indicated by increased lung hydroxyproline content, and elevated nitric oxide synthase, myeoloperoxidase, platelet activating factor, and tumor necrosis factor-alpha in lung tissues.	Bleomycin	0-9	tumor necrosis factor	Rattus norvegicus	145-222
15713430-11	2005	Co-administration of bleomycin and mesna reduced bleomycin-induced weight loss and attenuated lung injury as evaluated by the significant reduction in hydroxyproline content, nitric oxide synthase activity, and concentrations of myeoloperoxidase, platelet activating factor, and tumor necrosis factor-alpha in lung tissues.	Bleomycin	21-30	tumor necrosis factor	Rattus norvegicus	229-306
15713430-11	2005	Co-administration of bleomycin and mesna reduced bleomycin-induced weight loss and attenuated lung injury as evaluated by the significant reduction in hydroxyproline content, nitric oxide synthase activity, and concentrations of myeoloperoxidase, platelet activating factor, and tumor necrosis factor-alpha in lung tissues.	Bleomycin	49-58	tumor necrosis factor	Rattus norvegicus	229-306
15681821-4	2005	In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily intraperitoneal injections of AG1879 (bleomycin-AG1879) versus a chemically inactive analog (bleomycin-control).	Bleomycin	35-44	thymoma viral proto-oncogene 1	Mus musculus	134-141
15681821-4	2005	In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily intraperitoneal injections of AG1879 (bleomycin-AG1879) versus a chemically inactive analog (bleomycin-control).	Bleomycin	35-44	PTK2 protein tyrosine kinase 2	Mus musculus	146-149
15681821-4	2005	In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily intraperitoneal injections of AG1879 (bleomycin-AG1879) versus a chemically inactive analog (bleomycin-control).	Bleomycin	265-274	thymoma viral proto-oncogene 1	Mus musculus	134-141
15681821-4	2005	In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily intraperitoneal injections of AG1879 (bleomycin-AG1879) versus a chemically inactive analog (bleomycin-control).	Bleomycin	265-274	thymoma viral proto-oncogene 1	Mus musculus	134-141
15681821-5	2005	PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice.	Bleomycin	83-92	thymoma viral proto-oncogene 1	Mus musculus	0-7
15681821-5	2005	PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice.	Bleomycin	83-92	PTK2 protein tyrosine kinase 2	Mus musculus	12-15
15681821-5	2005	PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice.	Bleomycin	137-146	thymoma viral proto-oncogene 1	Mus musculus	0-7
15681821-5	2005	PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice.	Bleomycin	137-146	PTK2 protein tyrosine kinase 2	Mus musculus	12-15
15557019-0	2005	Interferon-{beta} inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-{beta} and thrombospondin.	Bleomycin	27-36	interferon beta 1, fibroblast	Mus musculus	0-16
15557019-4	2005	We therefore attempted to determine effects of IFN-beta and investigated the mechanism of action of IFN-beta in bleomycin-induced pulmonary fibrosis.	Bleomycin	112-121	interferon beta 1, fibroblast	Mus musculus	100-108
15557019-9	2005	Bleomycin-induced increase in TGF-beta1 in epithelial cells and extracellular matrix was attenuated by IFN-beta.	Bleomycin	0-9	transforming growth factor, beta 1	Mus musculus	30-39
15557019-10	2005	TSP-1/2 was limited in platelets of control mice, but was present in foamy cells in fibrotic regions induced by bleomycin.	Bleomycin	112-121	tumor suppressor region 1	Mus musculus	0-7
15502109-5	2005	In a preclinical model, systemic administration of CXCL11 reduced pulmonary collagen deposition, procollagen gene expression, and histopathologic fibroplasia and extracellular matrix deposition in the lung of bleomycin-treated mice.	Bleomycin	209-218	chemokine (C-X-C motif) ligand 11	Mus musculus	51-57
15502109-6	2005	CXCL11 treatment significantly reduced bleomycin-induced pulmonary fibrosis without altering specific lung leukocyte populations.	Bleomycin	39-48	chemokine (C-X-C motif) ligand 11	Mus musculus	0-6
15663794-2	2005	We investigated these factors in the fibrotic response to bleomycin of p47phox -/- (KO) mice, deficient for ROS production through the NADPH-oxidase pathway.	Bleomycin	58-67	neutrophil cytosolic factor 1	Mus musculus	71-78
15502109-8	2005	The angiogenic activity in the lung was significantly decreased, however, and CXCL11 treatment reduced the total number of endothelial cells in the lung following bleomycin exposure.	Bleomycin	163-172	chemokine (C-X-C motif) ligand 11	Mus musculus	78-84
15684285-4	2005	An increase in immunoreactivity to nitrotyrosine, poly(ADP ribose) polymerase (PARP) and inducible nitric oxide synthase as well as a significant loss of body weight and mortality was observed in the lung of bleomycin-treated mice.	Bleomycin	208-217	poly (ADP-ribose) polymerase family, member 1	Mus musculus	50-77
15684285-4	2005	An increase in immunoreactivity to nitrotyrosine, poly(ADP ribose) polymerase (PARP) and inducible nitric oxide synthase as well as a significant loss of body weight and mortality was observed in the lung of bleomycin-treated mice.	Bleomycin	208-217	poly (ADP-ribose) polymerase family, member 1	Mus musculus	79-83
15684285-11	2005	These results demonstrate that the two peroxisome proliferator-activated receptor-gamma agonists, rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, significantly reduce lung injury induced by bleomycin in mice.	Bleomycin	198-207	peroxisome proliferator activated receptor gamma	Mus musculus	39-87
15663794-6	2005	At day 1, the bleomycin-induced acute inflammatory response (increased neutrophil count and MMP-9 activity in the BAL fluid) was strikingly greater in KO than wild-type (WT) mice, while IL-6 levels increased significantly more in the latter.	Bleomycin	14-23	matrix metallopeptidase 9	Mus musculus	92-97
15671058-1	2005	In an attempt to determine the possible role of Ku-dependent end joining in mutagenesis resulting from DNA double-strand breaks, mutations induced by bleomycin at the hprt locus in plateau phase normal CHO-K1 and Ku-deficient xrs-6 cells were examined.	Bleomycin	150-159	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	167-171
15651999-2	2005	We previously suggested that epimorphin contributes to repair of bleomycin-induced pulmonary fibrosis in mice via epithelium-mesenchyme interactions.	Bleomycin	65-74	syntaxin 2	Mus musculus	29-39
15632004-0	2005	IL-9 protects against bleomycin-induced lung injury: involvement of prostaglandins.	Bleomycin	22-31	interleukin 9	Mus musculus	0-4
15650396-6	2005	In addition to its beneficial effects in other organs, the protective effect of TRX in the lungs has been shown against ischemia/ reperfusion injury, influenza infection, bleomycin-induced injury, or lethal inflammation caused by interleukin- 2 and interleukin-18.	Bleomycin	171-180	thioredoxin	Homo sapiens	80-83
16333983-4	2005	To test the hypothesis that FKBP65 is upregulated at times when extracellular matrix proteins are being actively synthesized and assembled, adult mice were treated with bleomycin to cause reinitiation of matrix protein production during the ensuing development of pulmonary fibrosis.	Bleomycin	169-178	FK506 binding protein 10	Mus musculus	28-34
16333983-5	2005	After bleomycin instillation, FKBP65 expression was reactivated in the lung with a pattern similar to that observed for tropoelastin and type I collagen.	Bleomycin	6-15	FKBP prolyl isomerase 10	Homo sapiens	30-36
15671058-0	2005	Extreme cytotoxicity and susceptibility to hprt mutagenesis in Ku-deficient xrs-6 cells treated with bleomycin in plateau phase.	Bleomycin	101-110	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	43-47
15605356-0	2005	RAD6 gene is involved in heat shock induction of bleomycin resistance in Saccharomyces cerevisiae.	Bleomycin	49-58	E2 ubiquitin-conjugating protein RAD6	Saccharomyces cerevisiae S288C	0-4
15671058-6	2005	For both cell lines bleomycin treatment resulted in a marked increase in the incidence of complete hprt deletions, while point mutations in hprt cDNA were rare.	Bleomycin	20-29	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	99-103
15774188-13	2005	CONCLUSIONS: These data imply that CXCR3 signaling promotes CD(4)(+) T-cell recruiting and initiates fibrogenic cytokine cascade following intratracheal bleomycin administration and indicate that CXCR3 might be a therapeutic target for pulmonary fibrosis treatment.	Bleomycin	153-162	chemokine (C-X-C motif) receptor 3	Mus musculus	35-40
15672859-1	2005	Osteopontin (OPN) produced by alveolar macrophages functions as a fibrogenic cytokine in the development of bleomycin (BLM)-induced murine pulmonary fibrosis, and OPN mRNA is expressed on lung tissues from patients with idiopathic pulmonary fibrosis (IPF).	Bleomycin	108-117	secreted phosphoprotein 1	Mus musculus	0-11
15672859-1	2005	Osteopontin (OPN) produced by alveolar macrophages functions as a fibrogenic cytokine in the development of bleomycin (BLM)-induced murine pulmonary fibrosis, and OPN mRNA is expressed on lung tissues from patients with idiopathic pulmonary fibrosis (IPF).	Bleomycin	108-117	secreted phosphoprotein 1	Mus musculus	13-16
15774188-13	2005	CONCLUSIONS: These data imply that CXCR3 signaling promotes CD(4)(+) T-cell recruiting and initiates fibrogenic cytokine cascade following intratracheal bleomycin administration and indicate that CXCR3 might be a therapeutic target for pulmonary fibrosis treatment.	Bleomycin	153-162	chemokine (C-X-C motif) receptor 3	Mus musculus	196-201
15774188-0	2005	[The pivotal role of CXCR3 in the pathogenesis of bleomycin-induced pulmonary fibrosis].	Bleomycin	50-59	chemokine (C-X-C motif) receptor 3	Mus musculus	21-26
15774188-1	2005	OBJECTIVE: To investigate the contribution of chemokine receptor-CXCR3 to the fibrotic disease process induced by bleomycin in CXCR3 gene deficient mice.	Bleomycin	114-123	chemokine (C-X-C motif) receptor 3	Mus musculus	65-70
15321784-10	2004	In addition to TNF-alpha, bleomycin administration also resulted in the upregulated expression of TGF-beta in the lungs of both strains at 8 h and in an enhanced expression of TGF-beta receptors I and II in C57Bl/6J mice only.	Bleomycin	26-35	transforming growth factor, beta 1	Mus musculus	98-106
15774188-1	2005	OBJECTIVE: To investigate the contribution of chemokine receptor-CXCR3 to the fibrotic disease process induced by bleomycin in CXCR3 gene deficient mice.	Bleomycin	114-123	chemokine (C-X-C motif) receptor 3	Mus musculus	127-132
15774188-10	2005	RESULTS: On day 14 after bleomycin injection, CXCR3 knockout mice were protected from BLM-induced lung injury and fibrosis as evidenced by less inflammatory cells in the lung interstitium and hydroxyproline content in the lung tissue compared to the wild type littermates [3.92 +/- 0.37 vs 5.33 +/- 0.34, P &lt; 0.05; (67.0 +/- 24.2) microg/left lung vs (211.5 +/- 24.2) microg/left lung, P &lt; 0.01].	Bleomycin	25-34	chemokine (C-X-C motif) receptor 3	Mus musculus	46-51
15285999-0	2004	C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	38-47	natriuretic peptide type C	Mus musculus	0-26
15285999-8	2004	CNP infusion significantly attenuated BLM-induced pulmonary fibrosis, as indicated by significant decreases in Ashcroft score and lung hydroxyproline content.	Bleomycin	38-41	natriuretic peptide type C	Mus musculus	0-3
15321784-10	2004	In addition to TNF-alpha, bleomycin administration also resulted in the upregulated expression of TGF-beta in the lungs of both strains at 8 h and in an enhanced expression of TGF-beta receptors I and II in C57Bl/6J mice only.	Bleomycin	26-35	transforming growth factor, beta receptor II	Mus musculus	176-203
15321784-11	2004	The upregulation of TGF-beta receptor expression was preceded in this strain by an increased expression of IL-4, IL-13, and IL-13 receptor-alpha (at 8 h after bleomycin) and followed by an upregulation of gp130 and IL-6.	Bleomycin	159-168	transforming growth factor, beta 1	Mus musculus	20-28
15507241-0	2004	Increase in p21 expression independent of the p53 pathway in bleomycin-induced lung fibrosis.	Bleomycin	61-70	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	12-15
15507241-4	2004	Although no difference in nuclear p21 expression was observed, the level of cytoplasmic p21 expression was found to be higher in fibrotic lungs at day 14 after bleomycin injection.	Bleomycin	160-169	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	88-91
15507241-5	2004	p21 expression was found to increase independent of p53 in fibrotic lungs at 14 days after bleomycin induction.	Bleomycin	91-100	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	0-3
15507241-2	2004	We have studied the variation in the expression of p21, p53, p27 and PCNA in bleomycin-induced lung fibrosis using animal mouse models using immuno-histochemistry and gene-expression analysis.	Bleomycin	77-86	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	51-54
15507241-2	2004	We have studied the variation in the expression of p21, p53, p27 and PCNA in bleomycin-induced lung fibrosis using animal mouse models using immuno-histochemistry and gene-expression analysis.	Bleomycin	77-86	transformation related protein 53, pseudogene	Mus musculus	56-59
15507241-2	2004	We have studied the variation in the expression of p21, p53, p27 and PCNA in bleomycin-induced lung fibrosis using animal mouse models using immuno-histochemistry and gene-expression analysis.	Bleomycin	77-86	dynactin 6	Mus musculus	61-64
15507241-2	2004	We have studied the variation in the expression of p21, p53, p27 and PCNA in bleomycin-induced lung fibrosis using animal mouse models using immuno-histochemistry and gene-expression analysis.	Bleomycin	77-86	proliferating cell nuclear antigen	Mus musculus	69-73
15564778-0	2004	Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma.	Bleomycin	69-78	interleukin 13	Mus musculus	16-30
15564778-6	2004	RESULTS: RT-PCR showed that both IL-4 and IL-13 mRNA levels in skin lesions were increased and peaked after 4 weeks of bleomycin treatment.	Bleomycin	119-128	interleukin 4	Mus musculus	33-37
15564778-6	2004	RESULTS: RT-PCR showed that both IL-4 and IL-13 mRNA levels in skin lesions were increased and peaked after 4 weeks of bleomycin treatment.	Bleomycin	119-128	interleukin 13	Mus musculus	42-47
15564778-10	2004	In skin lesions, IL-13 receptor (IL-13R) alpha2 expression was augmented mainly in the infiltrating mononuclear cells after 4 weeks of bleomycin exposure.	Bleomycin	135-144	interleukin 13	Mus musculus	17-22
15564778-10	2004	In skin lesions, IL-13 receptor (IL-13R) alpha2 expression was augmented mainly in the infiltrating mononuclear cells after 4 weeks of bleomycin exposure.	Bleomycin	135-144	interleukin 13 receptor, alpha 2	Mus musculus	33-47
15564778-12	2004	On the contrary, mRNA expression of IL-13Ralpha1 and IL- 13Ralpha2 was significantly altered in the cultured fibroblasts derived from bleomycin-treated skin.	Bleomycin	134-143	interleukin 13 receptor, alpha 1	Mus musculus	36-48
15564778-12	2004	On the contrary, mRNA expression of IL-13Ralpha1 and IL- 13Ralpha2 was significantly altered in the cultured fibroblasts derived from bleomycin-treated skin.	Bleomycin	134-143	interleukin 13 receptor, alpha 2	Mus musculus	53-66
15564778-13	2004	CONCLUSION: These data demonstrate that in skin lesions levels of IL-13 as well as its receptor increase in parallel with DSc progression, suggesting that IL-13 promotes the progression of cutaneous fibrosis/sclerosis in the murine model of bleomycin-induced scleroderma.	Bleomycin	241-250	interleukin 13	Mus musculus	66-71
15564778-13	2004	CONCLUSION: These data demonstrate that in skin lesions levels of IL-13 as well as its receptor increase in parallel with DSc progression, suggesting that IL-13 promotes the progression of cutaneous fibrosis/sclerosis in the murine model of bleomycin-induced scleroderma.	Bleomycin	241-250	interleukin 13	Mus musculus	155-160
15541506-8	2004	This effect was associated with significant inhibition of bleomycin-induced tumor necrosis factor alpha and transforming growth factor beta expression in lung homogenates.	Bleomycin	58-67	tumor necrosis factor	Mus musculus	76-103
15563670-4	2004	Perforin and granzyme B expression were upregulated predominantly in infiltrating mononuclear cells after bleomycin instillation in wild-type mice.	Bleomycin	106-115	granzyme B	Mus musculus	13-23
16116501-8	2004	RESULTS: Treatment of rats with BLM (15 mg/kg) resulted in a significant 3.4 and 2.9 folds increase in malondialdehyde (MDA) and nitric oxide (NO) production in lung tissue, respectively and a significant 39%, 35%, 54% and 44% decrease in reduced glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GSHPx) and adenosine triphosphate (ATP), respectively as compared to the control group.	Bleomycin	32-35	glutathione peroxidase 1	Rattus norvegicus	318-323
15256388-4	2004	We investigated if Balb/c mice, known to be fibrosis resistant partly due to lack of CTGF induction upon stimulation with bleomycin, can be transformed into fibrosis-sensitive individuals by generation of a CTGF-rich environment using transient overexpression of CTGF by adenoviral gene transfer (AdCTGF).	Bleomycin	122-131	cellular communication network factor 2	Mus musculus	85-89
15538737-0	2004	C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases.	Bleomycin	52-61	chemokine (C-C motif) receptor 2	Mus musculus	0-24
15538737-0	2004	C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases.	Bleomycin	52-61	chemokine (C-C motif) receptor 2	Mus musculus	26-30
15538737-5	2004	Pulmonary fibrosis was induced in CCR2-/- and wild-type (CCR2+/+) mice by intratracheal instillation of bleomycin.	Bleomycin	104-113	chemokine (C-C motif) receptor 2	Mus musculus	34-38
15538737-12	2004	These results suggest that the CCL2/CCR2 functional pathway is involved in the pathogenesis of bleomycin-induced pulmonary fibrosis and that CCR2 deficiency may improve the outcome of this disease by regulating macrophage infiltration and macrophage-derived MMP-2 and MMP-9 production.	Bleomycin	95-104	chemokine (C-C motif) ligand 2	Mus musculus	31-35
15538737-12	2004	These results suggest that the CCL2/CCR2 functional pathway is involved in the pathogenesis of bleomycin-induced pulmonary fibrosis and that CCR2 deficiency may improve the outcome of this disease by regulating macrophage infiltration and macrophage-derived MMP-2 and MMP-9 production.	Bleomycin	95-104	chemokine (C-C motif) receptor 2	Mus musculus	36-40
15572670-6	2004	N-Methyl-N"-nitro-N-nitrosoguanidine, etoposide, and bleomycin also induced C/EBPalpha.	Bleomycin	53-62	CCAAT enhancer binding protein alpha	Homo sapiens	76-86
15256388-7	2004	However, concomitant administration of AdCTGF and bleomycin leads to a persistent upregulation of tissue inhibitor of metalloproteinase-1 gene and a significant fibrotic response in Balb/c similar to that in C57BL/6 mice.	Bleomycin	50-59	tissue inhibitor of metalloproteinase 1	Mus musculus	98-137
15480737-2	2004	Increased levels of ET-1 from tissues and bronchoalveolar lavage have been reported in patients with pulmonary fibrosis and in animal models after intratracheal bleomycin.	Bleomycin	161-170	endothelin 1	Homo sapiens	20-24
15509536-3	2004	We demonstrate in wild-type mice that bleomycin-induced lung PGE(2) production is predominantly COX-2 mediated.	Bleomycin	38-47	prostaglandin-endoperoxide synthase 2	Mus musculus	96-101
15509536-4	2004	Furthermore, COX-2(+/-) mice show limited induction of PGE(2) and an enhanced fibrotic response with increased lung collagen content compared with wild-type mice after bleomycin injury (P &lt; 0.001).	Bleomycin	168-177	prostaglandin-endoperoxide synthase 2	Mus musculus	13-18
15509536-6	2004	COX-2(-/-) mice show an enhanced and persistent inflammatory response to bleomycin, however the fibrotic response to injury was unaltered compared with wild-type animals.	Bleomycin	73-82	prostaglandin-endoperoxide synthase 2	Mus musculus	0-5
15480737-6	2004	Isolated fibroblasts expressed both ET(A) and ET(B) receptor mRNA, and ET(A) receptor mRNA was upregulated by bleomycin.	Bleomycin	110-119	endothelin receptor type A	Rattus norvegicus	71-76
15466168-4	2004	In this study, we used expression profiling and genetic analysis in mouse models of bleomycin-induced pulmonary fibrosis and identified MHC class II antigen Ealpha (H2-Ea) as a risk factor for this disease.	Bleomycin	84-93	histocompatibility 2, class II antigen E alpha	Mus musculus	136-163
15298984-3	2004	Extracellular superoxide dismutase (EC-SOD) is an antioxidant enzyme that protects the lung in a bleomycin-induced pulmonary fibrosis model, but its role has not been studied in asbestos-mediated disease.	Bleomycin	97-106	superoxide dismutase 3, extracellular	Mus musculus	0-34
15298984-3	2004	Extracellular superoxide dismutase (EC-SOD) is an antioxidant enzyme that protects the lung in a bleomycin-induced pulmonary fibrosis model, but its role has not been studied in asbestos-mediated disease.	Bleomycin	97-106	superoxide dismutase 3, extracellular	Mus musculus	36-42
15555446-1	2004	AIM: To evaluate the balance between matrix metalloprotease-9 (MMP-9) and its inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1) in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	142-151	matrix metallopeptidase 9	Mus musculus	37-61
15555446-1	2004	AIM: To evaluate the balance between matrix metalloprotease-9 (MMP-9) and its inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1) in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	142-151	tissue inhibitor of metalloproteinase 1	Mus musculus	89-129
15555446-1	2004	AIM: To evaluate the balance between matrix metalloprotease-9 (MMP-9) and its inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1) in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	142-151	tissue inhibitor of metalloproteinase 1	Mus musculus	131-137
15555446-11	2004	CONCLUSION: There was an imbalance between macrophage-derived MMP-9 and TIMP-1 in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	82-91	matrix metallopeptidase 9	Mus musculus	62-67
15555446-11	2004	CONCLUSION: There was an imbalance between macrophage-derived MMP-9 and TIMP-1 in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	82-91	tissue inhibitor of metalloproteinase 1	Mus musculus	72-78
15205180-3	2004	We found that IP-10 is highly expressed in a mouse model of pulmonary fibrosis induced by bleomycin.	Bleomycin	90-99	chemokine (C-X-C motif) ligand 10	Mus musculus	14-19
15205180-4	2004	IP-10-deficient mice exhibited increased pulmonary fibrosis after administration of bleomycin, suggesting that IP-10 limits the development of fibrosis in this model.	Bleomycin	84-93	chemokine (C-X-C motif) ligand 10	Mus musculus	0-5
15205180-4	2004	IP-10-deficient mice exhibited increased pulmonary fibrosis after administration of bleomycin, suggesting that IP-10 limits the development of fibrosis in this model.	Bleomycin	84-93	chemokine (C-X-C motif) ligand 10	Mus musculus	111-116
15205180-6	2004	IP-10 significantly inhibited fibroblast responses to the chemotactic, but not the proliferative activity generated, suggesting that IP-10 may attenuate fibroblast accumulation in bleomycin-induced pulmonary fibrosis by limiting fibroblast migration.	Bleomycin	180-189	chemokine (C-X-C motif) ligand 10	Mus musculus	0-5
15205180-6	2004	IP-10 significantly inhibited fibroblast responses to the chemotactic, but not the proliferative activity generated, suggesting that IP-10 may attenuate fibroblast accumulation in bleomycin-induced pulmonary fibrosis by limiting fibroblast migration.	Bleomycin	180-189	chemokine (C-X-C motif) ligand 10	Mus musculus	133-138
15205180-7	2004	Consistent with this inhibitory activity of IP-10 on fibroblast migration, fibroblast accumulation in the lung after bleomycin exposure was dramatically increased in IP-10-deficient mice compared with wild-type mice.	Bleomycin	117-126	chemokine (C-X-C motif) ligand 10	Mus musculus	44-49
15205180-7	2004	Consistent with this inhibitory activity of IP-10 on fibroblast migration, fibroblast accumulation in the lung after bleomycin exposure was dramatically increased in IP-10-deficient mice compared with wild-type mice.	Bleomycin	117-126	chemokine (C-X-C motif) ligand 10	Mus musculus	166-171
15205180-8	2004	Conversely, transgenic mice overexpressing IP-10 were protected from mortality after bleomycin exposure, and demonstrated decreased fibroblast accumulation in the lung after challenge compared with wild-type mice.	Bleomycin	85-94	chemokine (C-X-C motif) ligand 10	Mus musculus	43-48
15448639-3	2004	Arabidopsis plants defective for the expression of AtSNM1 did not show hypersensitivity to the ICL-forming agents but to the chemotherapeutic agent bleomycin and to H(2)O(2).	Bleomycin	148-157	DNA repair metallo-beta-lactamase family protein	Arabidopsis thaliana	51-57
15466168-4	2004	In this study, we used expression profiling and genetic analysis in mouse models of bleomycin-induced pulmonary fibrosis and identified MHC class II antigen Ealpha (H2-Ea) as a risk factor for this disease.	Bleomycin	84-93	histocompatibility 2, class II antigen E alpha	Mus musculus	165-170
15466168-7	2004	These results show that H2-Ea expression protects mice from bleomycin-induced pulmonary fibrosis, which implicates H2-Ea as a candidate susceptibility gene for pulmonary fibrosis.	Bleomycin	60-69	histocompatibility 2, class II antigen E alpha	Mus musculus	24-29
15482567-0	2004	Decreased expression of aquaporin-5 in bleomycin-induced lung fibrosis in the mouse.	Bleomycin	39-48	aquaporin 5	Mus musculus	24-35
15383605-3	2004	We measured CCL17 and CCL22 during the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	55-64	chemokine (C-C motif) ligand 17	Mus musculus	12-17
15383605-3	2004	We measured CCL17 and CCL22 during the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	55-64	chemokine (C-C motif) ligand 22	Mus musculus	22-27
15383605-6	2004	CCR4 is the receptor for CCL17 and CCL22 therefore, to further characterize the role of CCL17 and CCL22, we measured CCR4 mRNA in lung tissue of bleomycin-treated mice by real-time quantitative PCR.	Bleomycin	145-154	chemokine (C-C motif) receptor 4	Mus musculus	0-4
15383605-6	2004	CCR4 is the receptor for CCL17 and CCL22 therefore, to further characterize the role of CCL17 and CCL22, we measured CCR4 mRNA in lung tissue of bleomycin-treated mice by real-time quantitative PCR.	Bleomycin	145-154	chemokine (C-C motif) receptor 4	Mus musculus	117-121
15383605-7	2004	CCR4 was significantly elevated in bleomycin-treated mice as compared with control mice.	Bleomycin	35-44	chemokine (C-C motif) receptor 4	Mus musculus	0-4
15383605-10	2004	Immunolocalization of bleomycin-treated lung tissue and human idiopathic pulmonary fibrosis tissue specimens showed that epithelial cells expressed CCL17.	Bleomycin	22-31	C-C motif chemokine ligand 17	Homo sapiens	148-153
15208274-3	2004	We hypothesized that NRF2 protects lungs from injury and fibrosis induced by bleomycin, an anti-neoplastic agent that causes pulmonary fibrosis in susceptible patients.	Bleomycin	77-86	NFE2 like bZIP transcription factor 2	Homo sapiens	21-25
15555311-7	2004	While in bleomycin treated groups, the expression of VEGF increased markedly.	Bleomycin	9-18	vascular endothelial growth factor A	Rattus norvegicus	53-57
15555311-10	2004	CONCLUSION: The high expression of VEGF is related to vascular endothelial cells injury which may be one of important factors in the formation of bleomycin-induced pulmonary fibrosis.	Bleomycin	146-155	vascular endothelial growth factor A	Rattus norvegicus	35-39
15371238-1	2004	Tumor necrosis factor-alpha (TNF-a) is produced by alveolar macrophages (AM) in response to bleomycin (BLM) exposure.	Bleomycin	92-101	tumor necrosis factor	Rattus norvegicus	0-27
15371238-1	2004	Tumor necrosis factor-alpha (TNF-a) is produced by alveolar macrophages (AM) in response to bleomycin (BLM) exposure.	Bleomycin	92-101	tumor necrosis factor	Rattus norvegicus	29-34
15337842-3	2004	Indeed, we have good evidence, not yet published, that tetrathiomolybdate inhibits pulmonary levels of transforming growth factor-beta and tumor necrosis factor-alpha expression in these bleomycin experiments.	Bleomycin	187-196	tumor necrosis factor	Mus musculus	139-166
15322207-0	2004	Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6.	Bleomycin	57-66	signal transducer and activator of transcription 6	Mus musculus	127-133
15322207-2	2004	FIZZ1 is induced in alveolar type II epithelial cells (AECs) in bleomycin (BLM)-induced lung fibrosis, and found to induce myofibroblast differentiation in vitro.	Bleomycin	64-73	resistin like alpha	Mus musculus	0-5
15322207-2	2004	FIZZ1 is induced in alveolar type II epithelial cells (AECs) in bleomycin (BLM)-induced lung fibrosis, and found to induce myofibroblast differentiation in vitro.	Bleomycin	75-78	resistin like alpha	Mus musculus	0-5
15208274-5	2004	Bleomycin-induced increases in lung weight, epithelial cell death, and inflammation were significantly greater in Nrf2-/- mice than in Nrf2+/+ mice.	Bleomycin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	114-118
15255863-4	2004	Furthermore, using chromosomal tandem-repeat recombination substrates, we show that AtErcc1p is required for bleomycin induction of mitotic recombination in the chromosomal context.	Bleomycin	109-118	nucleotide repair protein	Arabidopsis thaliana	84-92
15208274-5	2004	Bleomycin-induced increases in lung weight, epithelial cell death, and inflammation were significantly greater in Nrf2-/- mice than in Nrf2+/+ mice.	Bleomycin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	135-139
15208274-6	2004	Indices of lung fibrosis (hydroxyproline content, collagen accumulation, fibrotic score, cell proliferation) were significantly greater in bleomycin-treated Nrf2-/- mice, compared with Nrf2+/+ mice.	Bleomycin	139-148	nuclear factor, erythroid derived 2, like 2	Mus musculus	157-161
15208274-7	2004	NRF2 expression and activity were elevated in Nrf2+/+ mice by bleomycin.	Bleomycin	62-71	nuclear factor, erythroid derived 2, like 2	Mus musculus	0-4
15208274-7	2004	NRF2 expression and activity were elevated in Nrf2+/+ mice by bleomycin.	Bleomycin	62-71	nuclear factor, erythroid derived 2, like 2	Mus musculus	46-50
15208274-8	2004	Bleomycin caused greater up-regulation of several NRF2-inducible antioxidant enzyme genes and protein products in Nrf2+/+ mice compared with Nrf2-/- mice.	Bleomycin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	50-54
15208274-8	2004	Bleomycin caused greater up-regulation of several NRF2-inducible antioxidant enzyme genes and protein products in Nrf2+/+ mice compared with Nrf2-/- mice.	Bleomycin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	114-118
15208274-9	2004	Further, bleomycin-induced transcripts and protein levels of lung injury and fibrosis markers were significantly attenuated in Nrf2+/+ mice compared with Nrf2-/- mice.	Bleomycin	9-18	nuclear factor, erythroid derived 2, like 2	Mus musculus	127-131
15208274-9	2004	Further, bleomycin-induced transcripts and protein levels of lung injury and fibrosis markers were significantly attenuated in Nrf2+/+ mice compared with Nrf2-/- mice.	Bleomycin	9-18	nuclear factor, erythroid derived 2, like 2	Mus musculus	154-158
15286810-4	2004	Here we show that a population of human CD45(+)Col I(+)CXCR4(+) circulating fibrocytes migrates in response to CXCL12 and traffics to the lungs in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	165-174	protein tyrosine phosphatase receptor type C	Homo sapiens	40-44
15286810-4	2004	Here we show that a population of human CD45(+)Col I(+)CXCR4(+) circulating fibrocytes migrates in response to CXCL12 and traffics to the lungs in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	165-174	C-X-C motif chemokine receptor 4	Homo sapiens	55-60
15286810-4	2004	Here we show that a population of human CD45(+)Col I(+)CXCR4(+) circulating fibrocytes migrates in response to CXCL12 and traffics to the lungs in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	165-174	C-X-C motif chemokine ligand 12	Homo sapiens	111-117
15286810-5	2004	Next, we demonstrated that murine CD45(+)Col I(+)CXCR4(+) fibrocytes also traffic to the lungs in response to a bleomycin challenge.	Bleomycin	112-121	protein tyrosine phosphatase, receptor type, C	Mus musculus	34-38
15286810-5	2004	Next, we demonstrated that murine CD45(+)Col I(+)CXCR4(+) fibrocytes also traffic to the lungs in response to a bleomycin challenge.	Bleomycin	112-121	chemokine (C-X-C motif) receptor 4	Mus musculus	49-54
15286810-7	2004	Treatment of bleomycin-exposed animals with specific neutralizing anti-CXCL12 Ab"s inhibited intrapulmonary recruitment of CD45(+)Col I(+)CXCR4(+) circulating fibrocytes and attenuated lung fibrosis.	Bleomycin	13-22	chemokine (C-X-C motif) ligand 12	Mus musculus	71-77
15286810-7	2004	Treatment of bleomycin-exposed animals with specific neutralizing anti-CXCL12 Ab"s inhibited intrapulmonary recruitment of CD45(+)Col I(+)CXCR4(+) circulating fibrocytes and attenuated lung fibrosis.	Bleomycin	13-22	protein tyrosine phosphatase, receptor type, C	Mus musculus	123-127
15286810-7	2004	Treatment of bleomycin-exposed animals with specific neutralizing anti-CXCL12 Ab"s inhibited intrapulmonary recruitment of CD45(+)Col I(+)CXCR4(+) circulating fibrocytes and attenuated lung fibrosis.	Bleomycin	13-22	chemokine (C-X-C motif) receptor 4	Mus musculus	138-143
15215176-7	2004	Electron microscopy revealed an absence of small diameter collagen fibrils in the dermis from bleomycin-treated Smad3(-/-) mice.	Bleomycin	94-103	SMAD family member 3	Mus musculus	112-117
15215176-9	2004	Together, these results indicate that ablation of Smad3 is associated with markedly altered fibroblast regulation in vivo and in vitro, and confers partial protection from bleomycin-induced scleroderma in mice.	Bleomycin	172-181	SMAD family member 3	Mus musculus	50-55
15197407-0	2004	Skeletal muscle targeting in vivo electroporation-mediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	79-88	hepatocyte growth factor	Mus musculus	59-62
14977632-0	2004	Essential role for cathepsin D in bleomycin-induced apoptosis of alveolar epithelial cells.	Bleomycin	34-43	cathepsin D	Rattus norvegicus	19-30
14977632-1	2004	Our earlier studies showed that bleomycin-induced apoptosis of type II alveolar epithelial cells (AECs) requires the autocrine synthesis and proteolytic processing of angiotensinogen into ANG II and that inhibitors of ANG-converting enzyme (ACEis) block bleomycin-induced apoptosis (Li X, Zhang H, Soledad-Conrad V, Zhuang J, and Uhal BD.	Bleomycin	32-41	angiotensinogen	Rattus norvegicus	167-182
14977632-1	2004	Our earlier studies showed that bleomycin-induced apoptosis of type II alveolar epithelial cells (AECs) requires the autocrine synthesis and proteolytic processing of angiotensinogen into ANG II and that inhibitors of ANG-converting enzyme (ACEis) block bleomycin-induced apoptosis (Li X, Zhang H, Soledad-Conrad V, Zhuang J, and Uhal BD.	Bleomycin	32-41	angiotensinogen	Rattus norvegicus	188-194
14977632-1	2004	Our earlier studies showed that bleomycin-induced apoptosis of type II alveolar epithelial cells (AECs) requires the autocrine synthesis and proteolytic processing of angiotensinogen into ANG II and that inhibitors of ANG-converting enzyme (ACEis) block bleomycin-induced apoptosis (Li X, Zhang H, Soledad-Conrad V, Zhuang J, and Uhal BD.	Bleomycin	254-263	angiotensinogen	Rattus norvegicus	167-182
15293605-0	2004	Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis.	Bleomycin	53-62	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	37-42
14977632-4	2004	Primary cultures of rat type II AECs challenged with bleomycin in vitro showed upregulation and secretion of CatD enzymatic activity and immunoreactive protein but no increases in CatD mRNA.	Bleomycin	53-62	cathepsin D	Rattus norvegicus	109-113
14977632-5	2004	The aspartyl protease inhibitor pepstatin A, which completely blocked CatD enzymatic activity, inhibited bleomycin-induced nuclear fragmentation by 76% and reduced bleomycin-induced caspase-3 activation by 47%.	Bleomycin	105-114	cathepsin D	Rattus norvegicus	70-74
14977632-5	2004	The aspartyl protease inhibitor pepstatin A, which completely blocked CatD enzymatic activity, inhibited bleomycin-induced nuclear fragmentation by 76% and reduced bleomycin-induced caspase-3 activation by 47%.	Bleomycin	164-173	caspase 3	Rattus norvegicus	182-191
14977632-6	2004	Antisense oligonucleotides against CatD mRNA reduced CatD-immunoreactive protein and inhibited bleomycin-induced nuclear fragmentation by 48%.	Bleomycin	95-104	cathepsin D	Rattus norvegicus	35-39
14977632-9	2004	These data indicate a critical role for CatD in bleomycin-induced apoptosis of cultured AEC and suggest that the role(s) of CatD in AEC apoptosis include the conversion of newly synthesized angiotensinogen to ANG II.	Bleomycin	48-57	cathepsin D	Rattus norvegicus	40-44
14977632-9	2004	These data indicate a critical role for CatD in bleomycin-induced apoptosis of cultured AEC and suggest that the role(s) of CatD in AEC apoptosis include the conversion of newly synthesized angiotensinogen to ANG II.	Bleomycin	48-57	angiotensinogen	Rattus norvegicus	190-205
14977632-9	2004	These data indicate a critical role for CatD in bleomycin-induced apoptosis of cultured AEC and suggest that the role(s) of CatD in AEC apoptosis include the conversion of newly synthesized angiotensinogen to ANG II.	Bleomycin	48-57	angiotensinogen	Rattus norvegicus	209-215
15293605-2	2004	The present study was undertaken to investigate whether treatment with the antifibrotic drug pirfenidone attenuates the bleomycin (BL)-induced overexpression of HSP47 in the lungs.	Bleomycin	120-129	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	161-166
15293605-2	2004	The present study was undertaken to investigate whether treatment with the antifibrotic drug pirfenidone attenuates the bleomycin (BL)-induced overexpression of HSP47 in the lungs.	Bleomycin	131-133	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	161-166
15384255-0	2004	Bleomycin induces IL-8 and ICAM-1 expression in microvascular pulmonary endothelial cells.	Bleomycin	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
15384255-0	2004	Bleomycin induces IL-8 and ICAM-1 expression in microvascular pulmonary endothelial cells.	Bleomycin	0-9	intercellular adhesion molecule 1	Homo sapiens	27-33
15197407-3	2004	The aim of this study is to establish nonviral HGF gene therapy of bleomycin-induced lung fibrosis avoiding the viral vector-related side effects.	Bleomycin	67-76	hepatocyte growth factor	Mus musculus	47-50
15197407-10	2004	Our data indicate that HGF gene therapy with a single skeletal muscle-targeting electroporation has a therapeutic potential for bleomycin-induced lung fibrosis and this strategy can be applied as a practical gene therapy protocol for various organs.	Bleomycin	128-137	hepatocyte growth factor	Mus musculus	23-26
15212977-7	2004	Myeloperoxidase activities and MDA levels, which were significantly higher in the bleomycin group, were then significantly attenuated by erdosteine.	Bleomycin	82-91	myeloperoxidase	Rattus norvegicus	0-15
15135727-3	2004	The phenotypes of yeast strains that express this mutant show that the contribution of TDP1 to the repair of two kinds of damaged termini-induced, respectively, by camptothecin (CPT) and by bleomycin-strongly depends on enzyme activity.	Bleomycin	190-199	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	87-91
15149862-2	2004	We investigated the hypothesis that WRN and TP53 are involved in cellular responses to DNA replication-blocking lesions by exposing WRN deficient and TP53 mutant lymphoblastoid cell lines (LCLs) to 1-beta-d-arabinofuranosylcytosine (AraC) and bleomycin.	Bleomycin	243-252	WRN RecQ like helicase	Homo sapiens	36-39
15149862-3	2004	Loss of WRN or TP53 function resulted in induction of apoptosis and lesser proliferative survival in response to AraC and bleomycin.	Bleomycin	122-131	WRN RecQ like helicase	Homo sapiens	8-11
15149862-3	2004	Loss of WRN or TP53 function resulted in induction of apoptosis and lesser proliferative survival in response to AraC and bleomycin.	Bleomycin	122-131	tumor protein p53	Homo sapiens	15-19
15189779-0	2004	A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters.	Bleomycin	49-58	chymase 1	Homo sapiens	11-18
15189779-1	2004	We evaluated whether a chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[(3,4-dioxo-1-phenyl-7-(2-pyridyloxy))-2-heptyl]acetamide (NK3201), suppressed bleomycin-induced pulmonary fibrosis.	Bleomycin	183-192	chymase 1	Homo sapiens	23-30
15189779-3	2004	Four weeks after the instillation of bleomycin, pulmonary chymase activity in placebo-treated hamsters was significantly higher than in control hamsters, whereas the activity in NK3201-treated hamsters was significantly lower than in placebo-treated hamsters.	Bleomycin	37-46	chymase 1	Homo sapiens	58-65
15149862-0	2004	Distinct functions for WRN and TP53 in a shared pathway of cellular response to 1-beta-D-arabinofuranosylcytosine and bleomycin.	Bleomycin	118-127	WRN RecQ like helicase	Homo sapiens	23-26
15149862-0	2004	Distinct functions for WRN and TP53 in a shared pathway of cellular response to 1-beta-D-arabinofuranosylcytosine and bleomycin.	Bleomycin	118-127	tumor protein p53	Homo sapiens	31-35
14977630-0	2004	Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice.	Bleomycin	8-17	secreted phosphoprotein 1	Mus musculus	43-54
14977630-6	2004	In this study, we demonstrate immunoreactivity for osteopontin in lung epithelial and inflammatory cells in human usual interstitial pneumonitis and murine bleomycin-induced lung fibrosis.	Bleomycin	156-165	secreted phosphoprotein 1	Homo sapiens	51-62
14977630-7	2004	After treatment with bleomycin, osteopontin-null mice develop lung fibrosis characterized by dilated distal air spaces and reduced type I collagen expression compared with wild-type controls.	Bleomycin	21-30	secreted phosphoprotein 1	Mus musculus	32-43
15126102-2	2004	The production of IL-10 by pulmonary macrophages is increased in the inflammation that accompanies bleomycin lung injury.	Bleomycin	99-108	interleukin 10	Mus musculus	18-23
15126102-3	2004	In the present study, IL-10 deficient and wildtype mice received 0.075 units of bleomycin intratracheally at day 0 and were sacrificed at day 7 or day 14.	Bleomycin	80-89	interleukin 10	Mus musculus	22-27
15165187-4	2004	AtRAD17 mutants show increased sensitivity to the DNA-damaging chemicals bleomycin and mitomycin C (MMC), which can be reversed by complementation, suggesting that the loss of function of Rad17 disturbs DNA repair in plant cells.	Bleomycin	73-82	RADIATION SENSITIVE 17	Arabidopsis thaliana	0-7
15221420-9	2004	As shown by real-time RT-PCR and immunoblotting, bleomycin-treatment of R3/1 cells resulted in a decrease in mRNA and protein for both caveolin-1 and caveolin-2 in comparison with controls.	Bleomycin	49-58	caveolin 1	Rattus norvegicus	135-145
15221420-9	2004	As shown by real-time RT-PCR and immunoblotting, bleomycin-treatment of R3/1 cells resulted in a decrease in mRNA and protein for both caveolin-1 and caveolin-2 in comparison with controls.	Bleomycin	49-58	caveolin 2	Rattus norvegicus	150-160
15165187-4	2004	AtRAD17 mutants show increased sensitivity to the DNA-damaging chemicals bleomycin and mitomycin C (MMC), which can be reversed by complementation, suggesting that the loss of function of Rad17 disturbs DNA repair in plant cells.	Bleomycin	73-82	RADIATION SENSITIVE 17	Arabidopsis thaliana	188-193
15100325-7	2004	The initial pulmonary inflammation caused by bleomycin was also attenuated by alpha-GalCer with the reduction of the macrophage inflammatory protein-2 level.	Bleomycin	45-54	chemokine (C-X-C motif) ligand 2	Mus musculus	117-150
15064241-2	2004	We examined a new therapeutic strategy that comprises the transfection of the mutant MCP-1 gene into skeletal muscles as a biofactory for anti-MCP-1 therapy against bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	165-174	chemokine (C-C motif) ligand 2	Mus musculus	143-148
15064241-3	2004	Overexpression of the mutant MCP-1 gene at 10-14 days after intratracheal instillation of bleomycin resulted in decreased DNA damage, apoptosis, and pulmonary fibrosis at 14 days.	Bleomycin	90-99	chemokine (C-C motif) ligand 2	Mus musculus	29-34
15064241-4	2004	However, overexpression of the mutant MCP-1 at 0-4 days after bleomycin instillation did not result in decreased pathological grade, DNA damage, or apoptosis at 7 and 14 days.	Bleomycin	62-71	chemokine (C-C motif) ligand 2	Mus musculus	38-43
15195196-7	2004	Drug-induced pulmonary fibrosis may involve release of free oxygen radicals and various cytokines for example IL-Ibeta and TNF-alpha via activation of nuclear transcription factor NF-beta as in the case of bleomycin and mitomycin or via release of TGF-beta as in case of tamoxifen or via inhibition of macrophages" and lymphocytes" phospholipases as in the case of amiodarone with the resultant accumulation of phospholipids and reduction of the immune system.	Bleomycin	206-215	tumor necrosis factor	Homo sapiens	123-132
15064241-2	2004	We examined a new therapeutic strategy that comprises the transfection of the mutant MCP-1 gene into skeletal muscles as a biofactory for anti-MCP-1 therapy against bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	165-174	chemokine (C-C motif) ligand 2	Mus musculus	85-90
15007625-4	2004	We exploited the power of yeast genetics to isolate for the first time several bleomycin-resistant mutants derived from a strain deleted for the IMP2 gene encoding a transcriptional co-activator.	Bleomycin	79-88	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	145-149
15181831-0	2004	[Regulative effect of STAT1 on inflammation of lung tissue in bleomycin-induced rat interstitial pulmonary fibrosis].	Bleomycin	62-71	signal transducer and activator of transcription 1	Rattus norvegicus	22-27
15181831-1	2004	OBJECTIVE: To investigate the role of signal transducer and activator of transcription 1 (STAT1) in alveolar macrophage (AM) in bleomycin-induced rat pulmonary fibrosis.	Bleomycin	128-137	signal transducer and activator of transcription 1	Rattus norvegicus	38-88
15181831-1	2004	OBJECTIVE: To investigate the role of signal transducer and activator of transcription 1 (STAT1) in alveolar macrophage (AM) in bleomycin-induced rat pulmonary fibrosis.	Bleomycin	128-137	signal transducer and activator of transcription 1	Rattus norvegicus	90-95
15181831-6	2004	After bleomycin treatment, the STAT1 activation of AM significantly increased on day 1, reached the peak value on day 7, and then gradually decreased, yet it remained significantly above the value of the NS group on day 28 (P &lt; 0.05).	Bleomycin	6-15	signal transducer and activator of transcription 1	Rattus norvegicus	31-36
15181831-8	2004	After intratracheal instillation of bleomycin, the number of positive staining cells for ICAM-1 expression significantly increased on day 1, reached the peak value on day 7, gradually decreased from then on, but still it was higher than that of the NS group on day 28 (P &lt; 0.05).	Bleomycin	36-45	intercellular adhesion molecule 1	Rattus norvegicus	89-95
15181831-10	2004	CONCLUSION: STAT1 was found abnormally activated in AM in bleomycin-induced rat interstitial pulmonary fibrosis (IPF).	Bleomycin	58-67	signal transducer and activator of transcription 1	Rattus norvegicus	12-17
15003936-3	2004	Because the cyclin-dependent kinase inhibitor p21 induces G1 arrest and DNA repair and because it also prevents apoptosis in some cells, we hypothesized that p21 gene transfer may attenuate bleomycin-induced pulmonary fibrosis in mice, the pathogenesis of which likely involves epithelial cell apoptosis.	Bleomycin	190-199	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	158-161
12972397-5	2004	We also confirmed the expression of HDGF protein and mRNA in the lungs of bleomycin-instilled mice, mainly in the bronchial and alveolar epithelial cells, by immunohistochemical analysis and in situ hybridization.	Bleomycin	74-83	heparin binding growth factor	Mus musculus	36-40
15003936-6	2004	Adenoviral transfer of the human p21 gene at 7 days after intratracheal instillation of bleomycin led to a decrease in the number of apoptotic cells, lung inflammation, and fibrosis at 14 days.	Bleomycin	88-97	cyclin dependent kinase inhibitor 1A	Homo sapiens	33-36
15154911-6	2004	Smad3 null mice are resistant to radiation-induced cutaneous fibrosis, bleomycin-induced pulmonary fibrosis, carbon tetrachloride-induced hepatic fibrosis as well as glomerular fibrosis induced by induction of type 1 diabetes with streptozotocin.	Bleomycin	71-80	SMAD family member 3	Mus musculus	0-5
14716302-5	2004	The expression of wild-type LMP1 enhanced both spontaneous and bleomycin-induced MN formation.	Bleomycin	63-72	PDZ and LIM domain 7	Homo sapiens	28-32
14716302-10	2004	In this study, H1299 cells harboring LMP1 were shown to be more sensitive to UV and bleomycin than those with a vector control.	Bleomycin	84-93	PDZ and LIM domain 7	Homo sapiens	37-41
14982862-1	2004	Mice deficient in the plasminogen activator inhibitor-1 gene (PAI-1-/- mice) are relatively protected from developing pulmonary fibrosis from bleomycin administration.	Bleomycin	142-151	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	22-55
15013706-5	2004	DNA damage-associated frequencies of translocations after exposure to hydrogen peroxide (H(2)O(2)), bleomycin, phleomycin, cisplatin, and camptothecin are higher in the rad9 diploid than in wild type.	Bleomycin	100-109	chromatin-binding protein RAD9	Saccharomyces cerevisiae S288C	169-173
14617519-5	2004	We found 1) cytokine levels induced by SP-A2 (1A, 1A(0)) were significantly higher than those by SP-A1 (6A(2), 6A(4)) in the presence of bleomycin.	Bleomycin	137-146	surfactant protein A2	Homo sapiens	39-44
14617519-5	2004	We found 1) cytokine levels induced by SP-A2 (1A, 1A(0)) were significantly higher than those by SP-A1 (6A(2), 6A(4)) in the presence of bleomycin.	Bleomycin	137-146	surfactant protein A1	Homo sapiens	97-102
14617519-6	2004	2) In the presence of bleomycin, ozone-induced oxidation significantly decreased the ability of 1A and 1A/6A(4), but not of 6A(4), to stimulate TNF-alpha production.	Bleomycin	22-31	tumor necrosis factor	Homo sapiens	144-153
14617519-7	2004	3) The synergistic effect of bleomycin/SP-A, either before or after oxidation, can be inhibited to the level of bleomycin alone by surfactant lipids.	Bleomycin	112-121	surfactant protein A1	Homo sapiens	39-43
14617519-9	2004	The results indicate that differences among SP-A variants may partly explain the individual variability of pulmonary complications observed during bleomycin chemotherapy and/or in an environment that may promote protein oxidation.	Bleomycin	147-156	surfactant protein A1	Homo sapiens	44-48
14982862-1	2004	Mice deficient in the plasminogen activator inhibitor-1 gene (PAI-1-/- mice) are relatively protected from developing pulmonary fibrosis from bleomycin administration.	Bleomycin	142-151	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	62-67
14982862-4	2004	Following bleomycin administration, we found that HGF protein levels were higher in bronchoalveolar lavage fluid from PAI-1-/- mice compared to wild-type (PAI-1+/+) mice.	Bleomycin	10-19	hepatocyte growth factor	Mus musculus	50-53
14982862-6	2004	Conversely, intratracheal instillation of urokinase into bleomycin-injured PAI-1+/+ mice to activate plasminogen caused a significant increase in HGF within bronchoalveolar lavage and caused less collagen accumulation in the lungs.	Bleomycin	57-66	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	75-80
14982862-6	2004	Conversely, intratracheal instillation of urokinase into bleomycin-injured PAI-1+/+ mice to activate plasminogen caused a significant increase in HGF within bronchoalveolar lavage and caused less collagen accumulation in the lungs.	Bleomycin	57-66	hepatocyte growth factor	Mus musculus	146-149
14982862-7	2004	Administration of an anti-HGF neutralizing antibody markedly increased collagen accumulation in the lungs of bleomycin-injured PAI-1-/- mice.	Bleomycin	109-118	hepatocyte growth factor	Mus musculus	26-29
14982862-7	2004	Administration of an anti-HGF neutralizing antibody markedly increased collagen accumulation in the lungs of bleomycin-injured PAI-1-/- mice.	Bleomycin	109-118	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	127-132
14719107-0	2004	Induction of apoptosis by bleomycin in p53-null HL-60 leukemia cells.	Bleomycin	26-35	tumor protein p53	Homo sapiens	39-42
14972770-0	2004	Heart angiotensin-converting enzyme activity increased after intraperitoneal bleomycin administration in rat.	Bleomycin	77-86	angiotensin I converting enzyme	Rattus norvegicus	6-35
14972770-3	2004	In order to evaluate serum and tissue ACE activity in bleomycin-associated lung damage, the authors studied morphological and enzymatic alterations as well as blood pressure in male Sprague-Dawley rats.	Bleomycin	54-63	angiotensin I converting enzyme	Rattus norvegicus	38-41
14972770-6	2004	Bleomycin also had significantly lowered lung and aorta N-acetyl-beta-D-glucosaminidase (NAG) activity, whereas heart and serum NAG activity increased significantly.	Bleomycin	0-9	O-GlcNAcase	Rattus norvegicus	56-87
14972770-6	2004	Bleomycin also had significantly lowered lung and aorta N-acetyl-beta-D-glucosaminidase (NAG) activity, whereas heart and serum NAG activity increased significantly.	Bleomycin	0-9	O-GlcNAcase	Rattus norvegicus	89-92
14767587-10	2004	Immunoblotting studies demonstrated increased levels of eNOS in the rat lung at 4, 7 and 14 days and iNOS at 7 and 14 days after bleomycin inhalation.	Bleomycin	129-138	nitric oxide synthase 2	Rattus norvegicus	101-105
15137460-2	2004	In this study, we investigated the level of transforming growth factor-beta1 (TGF-beta1) in various mice strains, in order to determine whether the expression of TGF-beta1 correlates with the susceptibility to bleomycin-induced scleroderma.	Bleomycin	210-219	transforming growth factor, beta 1	Mus musculus	162-171
15137460-6	2004	TGF-beta1 concentrations in culture supernatants of skin fibroblasts and spleen macrophages were significantly increased by bleomycin stimulation in B10.A and C3H/HeJ strains, and TGF-beta1 gene expression in fibroblasts derived from B10.A and C3H/HeJ strains was significantly increased by bleomycin stimulation.	Bleomycin	124-133	transforming growth factor, beta 1	Mus musculus	0-9
15137460-6	2004	TGF-beta1 concentrations in culture supernatants of skin fibroblasts and spleen macrophages were significantly increased by bleomycin stimulation in B10.A and C3H/HeJ strains, and TGF-beta1 gene expression in fibroblasts derived from B10.A and C3H/HeJ strains was significantly increased by bleomycin stimulation.	Bleomycin	291-300	transforming growth factor, beta 1	Mus musculus	0-9
15137460-7	2004	Thus we conclude that C3H/HeJ and B10.A mice are susceptible to bleomycin-induced scleroderma, which may be, in part, due to increased TGF-beta1 gene expression and protein production.	Bleomycin	64-73	transforming growth factor, beta 1	Mus musculus	135-144
14985557-7	2004	RESULTS: Bleomycin treatment induced pulmonary cytotoxicity, increased levels of active transforming growth factor beta (TGF-beta), enhanced lung collagen accumulation, and decreased glutathione content.	Bleomycin	9-18	transforming growth factor, beta 1	Mus musculus	121-129
14719107-8	2004	These results indicate that BLM-induced apoptosis in HL-60 cells results from the activation of a mitochondria-dependent caspase cascade which includes also the activation of the initiator caspase-8.	Bleomycin	28-31	caspase 8	Homo sapiens	189-198
14694243-0	2004	Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist.	Bleomycin	13-22	angiotensin II receptor, type 1b	Rattus norvegicus	74-104
12754187-5	2004	After bleomycin-induced lung injury, an increase in lung ANG II concentration was observed by day 3 that preceded increases in lung collagen and was maintained until death at day 21.	Bleomycin	6-15	angiotensinogen	Homo sapiens	57-63
14712301-3	2004	(In this study, working with a bleomycin(BLM)-induced scleroderma model mice, we performed two transfections of human hepatocyte growth factor (HGF) cDNA into the skeletal muscle and showed that this treatment not only helped to prevent the dermal sclerosis simultaneously injected BLM but also improved the symptoms of dermal sclerosis induced by BLM 4 weeks previously.)	Bleomycin	31-40	hepatocyte growth factor	Homo sapiens	118-142
14712301-3	2004	(In this study, working with a bleomycin(BLM)-induced scleroderma model mice, we performed two transfections of human hepatocyte growth factor (HGF) cDNA into the skeletal muscle and showed that this treatment not only helped to prevent the dermal sclerosis simultaneously injected BLM but also improved the symptoms of dermal sclerosis induced by BLM 4 weeks previously.)	Bleomycin	31-40	hepatocyte growth factor	Homo sapiens	144-147
14712301-3	2004	(In this study, working with a bleomycin(BLM)-induced scleroderma model mice, we performed two transfections of human hepatocyte growth factor (HGF) cDNA into the skeletal muscle and showed that this treatment not only helped to prevent the dermal sclerosis simultaneously injected BLM but also improved the symptoms of dermal sclerosis induced by BLM 4 weeks previously.)	Bleomycin	41-44	hepatocyte growth factor	Homo sapiens	118-142
14712301-3	2004	(In this study, working with a bleomycin(BLM)-induced scleroderma model mice, we performed two transfections of human hepatocyte growth factor (HGF) cDNA into the skeletal muscle and showed that this treatment not only helped to prevent the dermal sclerosis simultaneously injected BLM but also improved the symptoms of dermal sclerosis induced by BLM 4 weeks previously.)	Bleomycin	41-44	hepatocyte growth factor	Homo sapiens	144-147
12972405-0	2004	Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis.	Bleomycin	50-59	platelet-derived growth factor, C polypeptide	Mus musculus	14-20
12972405-0	2004	Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis.	Bleomycin	50-59	platelet-derived growth factor, D polypeptide	Mus musculus	25-31
12972405-4	2004	Our findings demonstrate that administration of bleomycin to murine lungs leads to a significant increase in PDGF-C mRNA expression and a significant decrease in PDGF-D mRNA expression.	Bleomycin	48-57	platelet-derived growth factor, C polypeptide	Mus musculus	109-115
12972405-4	2004	Our findings demonstrate that administration of bleomycin to murine lungs leads to a significant increase in PDGF-C mRNA expression and a significant decrease in PDGF-D mRNA expression.	Bleomycin	48-57	platelet-derived growth factor, D polypeptide	Mus musculus	162-168
12972405-6	2004	Moreover, there is in vivo phosphorylation of the PDGF-receptor that binds PDGF-C in response to bleomycin administration.	Bleomycin	97-106	platelet-derived growth factor, C polypeptide	Mus musculus	75-81
12972405-7	2004	These observations strongly suggest a role for PDGF-C in bleomycin-induced pulmonary fibrosis.	Bleomycin	57-66	platelet-derived growth factor, C polypeptide	Mus musculus	47-53
15515172-7	2004	In contrast to L5178Y cells, the response of TK6 cells to MMS and bleomycin was characterized by the induction of p53-dependent genes that are involved in DNA repair, cell cycle regulation, and apoptosis.	Bleomycin	66-75	tumor protein p53	Homo sapiens	114-117
14962088-12	2004	These findings suggest that excessive apoptosis, which is mediated by Fas/Fas ligand pathway and caspase-3 activation, is involved in the pathogenesis of bleomycin-induced scleroderma, possibly by playing an inflammatory role.	Bleomycin	154-163	caspase 3	Mus musculus	97-106
12816730-0	2003	Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta.	Bleomycin	87-96	tumor necrosis factor	Mus musculus	18-45
14609568-8	2003	These findings suggest that CCR2 signaling plays a key role in bleomycin-induced pulmonary fibrosis by regulating fibrogenic cytokine expression and fibroblast responsiveness to TGF-beta.	Bleomycin	63-72	chemokine (C-C motif) receptor 2	Mus musculus	28-32
14609568-8	2003	These findings suggest that CCR2 signaling plays a key role in bleomycin-induced pulmonary fibrosis by regulating fibrogenic cytokine expression and fibroblast responsiveness to TGF-beta.	Bleomycin	63-72	transforming growth factor, beta 1	Mus musculus	178-186
12816730-4	2003	In this study we evaluated whether TNF-alpha overexpression altered the development of pulmonary fibrosis due to bleomycin or transforming growth factor-beta (TGF-beta).	Bleomycin	113-122	tumor necrosis factor	Mus musculus	35-44
12816730-8	2003	TNF-alpha transgenic mice tolerated bleomycin or AdTGF-beta, whereas the transgene-negative littermates demonstrated severe pulmonary fibrosis after either agent.	Bleomycin	36-45	tumor necrosis factor	Mus musculus	0-9
12816730-10	2003	In addition, recombinant human TNF-alpha attenuated bleomycin-induced pulmonary fibrosis.	Bleomycin	52-61	tumor necrosis factor	Homo sapiens	31-40
12857673-0	2003	Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis.	Bleomycin	52-61	interferon gamma	Mus musculus	8-24
12857673-1	2003	IFN-gamma production is upregulated in lung cells (LC) of bleomycin-treated C57BL/6 mice.	Bleomycin	58-67	interferon gamma	Mus musculus	0-9
12857673-2	2003	The present study characterizes the time course, cellular source, and regulation of IFN-gamma expression in bleomycin-induced lung injury.	Bleomycin	108-117	interferon gamma	Mus musculus	84-93
12857673-11	2003	Our data show that enhanced IFN-gamma production in the lungs of bleomycin-treated mice is at least partly IL-12 and IL-18 dependent.	Bleomycin	65-74	interferon gamma	Mus musculus	28-37
12857673-11	2003	Our data show that enhanced IFN-gamma production in the lungs of bleomycin-treated mice is at least partly IL-12 and IL-18 dependent.	Bleomycin	65-74	interleukin 18	Mus musculus	117-122
12857673-13	2003	Endogenous IFN-gamma may play a proinflammatory or profibrotic role in bleomycin-induced lung fibrosis.	Bleomycin	71-80	interferon gamma	Mus musculus	11-20
14613307-7	2003	The mRNA for lysyl oxidase (LOX), an enzyme for cross-linking of collagens, had a delayed increase in the lung after bleomycin administration.	Bleomycin	117-126	lysyl oxidase	Mus musculus	13-26
12857673-3	2003	IFN-gamma mRNA in LC from bleomycin-treated mice peaked 3 days after intratracheal instillation.	Bleomycin	26-35	interferon gamma	Mus musculus	0-9
14633624-0	2003	Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice.	Bleomycin	49-58	angiotensin II receptor, type 1a	Mus musculus	41-45
14633624-2	2003	Recent studies demonstrated a role for the synthesis and binding of angiotensin II to receptor AT1 in the induction of AEC apoptosis by bleomycin (BLEO) and other proapoptotic stimuli.	Bleomycin	136-145	angiotensin II receptor, type 1a	Mus musculus	95-98
14633624-2	2003	Recent studies demonstrated a role for the synthesis and binding of angiotensin II to receptor AT1 in the induction of AEC apoptosis by bleomycin (BLEO) and other proapoptotic stimuli.	Bleomycin	147-151	angiotensin II receptor, type 1a	Mus musculus	95-98
14633624-3	2003	On this basis we hypothesized that BLEO-induced apoptosis and lung fibrosis in mice would be inhibited by the AT1 antagonist losartan (LOS) or by targeted deletion of the AT1 gene.	Bleomycin	35-39	angiotensin II receptor, type 1a	Mus musculus	110-113
14613307-7	2003	The mRNA for lysyl oxidase (LOX), an enzyme for cross-linking of collagens, had a delayed increase in the lung after bleomycin administration.	Bleomycin	117-126	lysyl oxidase	Mus musculus	28-31
14633624-3	2003	On this basis we hypothesized that BLEO-induced apoptosis and lung fibrosis in mice would be inhibited by the AT1 antagonist losartan (LOS) or by targeted deletion of the AT1 gene.	Bleomycin	35-39	angiotensin II receptor, type 1a	Mus musculus	171-174
14668599-2	2003	He was treated with platinum/etoposide/bleomycin chemotherapy with a decrease in serum alpha-fetoprotein and in the size of the primary tumor.	Bleomycin	39-48	alpha fetoprotein	Homo sapiens	87-104
14633624-5	2003	Co-administration of LOS abrogated BLEO-induced increases in total lung caspase 3 activity detected 6 hours after in vivo administration and reduced by 57% BLEO-induced caspase 3 activity in blood-depleted lung explants exposed to BLEO ex vivo (both P &lt; 0.05).	Bleomycin	35-39	caspase 3	Mus musculus	72-81
14633624-5	2003	Co-administration of LOS abrogated BLEO-induced increases in total lung caspase 3 activity detected 6 hours after in vivo administration and reduced by 57% BLEO-induced caspase 3 activity in blood-depleted lung explants exposed to BLEO ex vivo (both P &lt; 0.05).	Bleomycin	156-160	caspase 3	Mus musculus	169-178
14633624-5	2003	Co-administration of LOS abrogated BLEO-induced increases in total lung caspase 3 activity detected 6 hours after in vivo administration and reduced by 57% BLEO-induced caspase 3 activity in blood-depleted lung explants exposed to BLEO ex vivo (both P &lt; 0.05).	Bleomycin	156-160	caspase 3	Mus musculus	169-178
14607953-2	2003	We found that overexpression of IL-5 in transgenic mice (IL-5(TG)) or by adenoviral gene transfer increased bleomycin (blm)-induced lung injury, fibrosis, and eosinophilia.	Bleomycin	108-117	interleukin 5	Mus musculus	32-36
14680076-6	2003	The bleomycin-induced increases in lung tumour necrosis factor-alpha and myeloperoxidase activity were reduced by NAC treatment.	Bleomycin	4-13	myeloperoxidase	Rattus norvegicus	73-88
14680076-7	2003	The numbers of mucus secretory cells in airway epithelium, and the Muc5ac messenger ribonucleic acid and protein expression, were markedly augmented in rats exposed to bleomycin.	Bleomycin	168-177	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	67-73
14607953-2	2003	We found that overexpression of IL-5 in transgenic mice (IL-5(TG)) or by adenoviral gene transfer increased bleomycin (blm)-induced lung injury, fibrosis, and eosinophilia.	Bleomycin	108-117	interleukin 5	Mus musculus	57-61
14607953-2	2003	We found that overexpression of IL-5 in transgenic mice (IL-5(TG)) or by adenoviral gene transfer increased bleomycin (blm)-induced lung injury, fibrosis, and eosinophilia.	Bleomycin	119-122	interleukin 5	Mus musculus	32-36
14607953-2	2003	We found that overexpression of IL-5 in transgenic mice (IL-5(TG)) or by adenoviral gene transfer increased bleomycin (blm)-induced lung injury, fibrosis, and eosinophilia.	Bleomycin	119-122	interleukin 5	Mus musculus	57-61
12816738-0	2003	Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury.	Bleomycin	71-80	thioredoxin 1	Mus musculus	21-32
12930837-2	2003	We have previously reported that transforming growth factor-beta1 (TGF-beta1) is a critical mediator of ALI after intratracheal administration of bleomycin or Escherichia coli endotoxin, at least in part due to effects on lung endothelial and alveolar epithelial permeability.	Bleomycin	146-155	transforming growth factor, beta 1	Rattus norvegicus	33-65
12930837-2	2003	We have previously reported that transforming growth factor-beta1 (TGF-beta1) is a critical mediator of ALI after intratracheal administration of bleomycin or Escherichia coli endotoxin, at least in part due to effects on lung endothelial and alveolar epithelial permeability.	Bleomycin	146-155	transforming growth factor, beta 1	Rattus norvegicus	67-76
12816738-9	2003	Wild-type mice given recombinant TRX treatment and TRX-transgenic mice demonstrated a decrease in bleomycin-induced cellular infiltrates and fibrotic changes in the lung tissue.	Bleomycin	98-107	thioredoxin 1	Mus musculus	33-36
12816738-9	2003	Wild-type mice given recombinant TRX treatment and TRX-transgenic mice demonstrated a decrease in bleomycin-induced cellular infiltrates and fibrotic changes in the lung tissue.	Bleomycin	98-107	thioredoxin 1	Mus musculus	51-54
12777247-0	2003	Involvement of serum response factor isoforms in myofibroblast differentiation during bleomycin-induced lung injury.	Bleomycin	86-95	serum response factor	Mus musculus	15-36
14585735-0	2003	Effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity.	Bleomycin	60-69	colony stimulating factor 3	Rattus norvegicus	50-55
12777247-3	2003	We studied the expression and the localization of SRF in bleomycin-induced pulmonary fibrosis, where myofibroblasts are abundant.	Bleomycin	57-66	serum response factor	Mus musculus	50-53
12777247-4	2003	We found that SRF levels were upregulated in bleomycin-exposed mouse lungs mainly due to de novo synthesis of SRFDelta5, a less myogenic SRF isoform.	Bleomycin	45-54	serum response factor	Mus musculus	14-17
12777247-4	2003	We found that SRF levels were upregulated in bleomycin-exposed mouse lungs mainly due to de novo synthesis of SRFDelta5, a less myogenic SRF isoform.	Bleomycin	45-54	serum response factor	Mus musculus	110-113
12777247-10	2003	Treatment of lung fibroblasts with tumor necrosis factor-alpha, which is produced early in the bleomycin model, induced SRFDelta5 expression and SRF/SRFDelta5 cytoplasmic accumulation, whereas addition of transforming growth factor-beta1 caused SRF/SRFDelta5 nuclear translocation followed by SM alpha-actin synthesis.	Bleomycin	95-104	tumor necrosis factor	Mus musculus	35-62
14585735-1	2003	We evaluated the effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin (BLM)-induced lung injury that developed diffuse alveolar damage and subsequent pulmonary fibrosis (PF) of varying severity.	Bleomycin	77-86	colony stimulating factor 3	Rattus norvegicus	28-65
14585735-1	2003	We evaluated the effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin (BLM)-induced lung injury that developed diffuse alveolar damage and subsequent pulmonary fibrosis (PF) of varying severity.	Bleomycin	77-86	colony stimulating factor 3	Rattus norvegicus	67-72
14585735-1	2003	We evaluated the effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin (BLM)-induced lung injury that developed diffuse alveolar damage and subsequent pulmonary fibrosis (PF) of varying severity.	Bleomycin	88-91	colony stimulating factor 3	Rattus norvegicus	28-65
14585735-1	2003	We evaluated the effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin (BLM)-induced lung injury that developed diffuse alveolar damage and subsequent pulmonary fibrosis (PF) of varying severity.	Bleomycin	88-91	colony stimulating factor 3	Rattus norvegicus	67-72
14575803-0	2003	Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	36-45	chymase 1, mast cell	Mus musculus	25-32
14557415-7	2003	Furthermore, intranasal TGF-beta1 plasmid administration ameliorates bleomycin-induced fibrosis in wild-type but not IL-10-deficient mice, strongly suggesting that the amelioration is IL-10 dependent and that IL-10 protects mice from TGF-beta1-mediated fibrosis.	Bleomycin	69-78	transforming growth factor, beta 1	Mus musculus	24-33
14557415-7	2003	Furthermore, intranasal TGF-beta1 plasmid administration ameliorates bleomycin-induced fibrosis in wild-type but not IL-10-deficient mice, strongly suggesting that the amelioration is IL-10 dependent and that IL-10 protects mice from TGF-beta1-mediated fibrosis.	Bleomycin	69-78	interleukin 10	Mus musculus	184-189
14557415-7	2003	Furthermore, intranasal TGF-beta1 plasmid administration ameliorates bleomycin-induced fibrosis in wild-type but not IL-10-deficient mice, strongly suggesting that the amelioration is IL-10 dependent and that IL-10 protects mice from TGF-beta1-mediated fibrosis.	Bleomycin	69-78	interleukin 10	Mus musculus	184-189
14558142-7	2003	Moreover, the interaction between IMP2 and GAL6/BLH1, a recently isolated gene involved in the regulation of GAL genes that shares with Imp2 the ability to protect cells from the glycopeptide bleomycin, was also analysed.	Bleomycin	192-201	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	34-38
14558142-7	2003	Moreover, the interaction between IMP2 and GAL6/BLH1, a recently isolated gene involved in the regulation of GAL genes that shares with Imp2 the ability to protect cells from the glycopeptide bleomycin, was also analysed.	Bleomycin	192-201	bleomycin hydrolase	Saccharomyces cerevisiae S288C	43-47
14558142-7	2003	Moreover, the interaction between IMP2 and GAL6/BLH1, a recently isolated gene involved in the regulation of GAL genes that shares with Imp2 the ability to protect cells from the glycopeptide bleomycin, was also analysed.	Bleomycin	192-201	bleomycin hydrolase	Saccharomyces cerevisiae S288C	48-52
14558142-7	2003	Moreover, the interaction between IMP2 and GAL6/BLH1, a recently isolated gene involved in the regulation of GAL genes that shares with Imp2 the ability to protect cells from the glycopeptide bleomycin, was also analysed.	Bleomycin	192-201	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	136-140
14575803-2	2003	Intratracheal injection of bleomycin to mice significantly increased not only hydroxyproline content but also chymase activity in the lung.	Bleomycin	27-36	chymase 1, mast cell	Mus musculus	110-117
14575803-3	2003	Administration of a chymase inhibitor SUN C8077 (7-chloro-3-(3-amynophenyl) quinazoline-2, 4-dione methanesulfonate) dose-dependently reversed the bleomycin-induced increase in hydroxyproline content as well as chymase activity in the lung.	Bleomycin	147-156	chymase 1	Homo sapiens	20-27
14575803-3	2003	Administration of a chymase inhibitor SUN C8077 (7-chloro-3-(3-amynophenyl) quinazoline-2, 4-dione methanesulfonate) dose-dependently reversed the bleomycin-induced increase in hydroxyproline content as well as chymase activity in the lung.	Bleomycin	147-156	chymase 1	Homo sapiens	211-218
12842808-0	2003	Increased expression of collagen-binding heat shock protein 47 in murine bleomycin-induced pneumopathy.	Bleomycin	73-82	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	41-62
12842808-3	2003	The aim of the present study was to investigate the association between HSP47 expression and collagen accumulation in bleomycin (BLM)-induced murine fibrosis.	Bleomycin	118-127	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	72-77
14559807-5	2003	Most notably we demonstrate that BRCA1 induces a 10-1000-fold increase in resistance to a range of DNA-damaging agents, in particular those that give rise to double-strand breaks such as etoposide or bleomycin.	Bleomycin	200-209	BRCA1 DNA repair associated	Homo sapiens	33-38
12925209-0	2003	Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma.	Bleomycin	90-99	chemokine (C-C motif) ligand 2	Mus musculus	8-42
14583340-0	2003	Enhanced bleomycin-induced pulmonary damage in mice lacking extracellular superoxide dismutase.	Bleomycin	9-18	superoxide dismutase 3, extracellular	Mus musculus	60-94
14583340-4	2003	Mice null for ec-sod display a marked increase in lung inflammation at 14 d post-bleomycin treatment as compared to their wild-type counterparts.	Bleomycin	81-90	superoxide dismutase 3, extracellular	Mus musculus	14-20
14583340-7	2003	2-Pyrrolidone levels in the lung hydrolysates from ec-sod null mice were increased at both 7 and 14 d post-bleomycin treatment as compared to wild-type mice, indicating EC-SOD can inhibit oxidative fragmentation of proteins in this specific model of oxidative stress.	Bleomycin	107-116	superoxide dismutase 3, extracellular	Mus musculus	51-57
14583340-7	2003	2-Pyrrolidone levels in the lung hydrolysates from ec-sod null mice were increased at both 7 and 14 d post-bleomycin treatment as compared to wild-type mice, indicating EC-SOD can inhibit oxidative fragmentation of proteins in this specific model of oxidative stress.	Bleomycin	107-116	superoxide dismutase 3, extracellular	Mus musculus	169-175
14533198-6	2003	CONCLUSIONS: Our results suggest that a combination of MBD2-antisense electrotransfer gene therapy and chemotherapy with bleomycin is a candidate new approach to anticancer therapy.	Bleomycin	121-130	methyl-CpG binding domain protein 2	Homo sapiens	55-59
14516132-7	2003	The intratracheal injection of bleomycin in mice induced an increase in senescence-associated beta-galactosidase activity in type II epithelial cells, reaching a maximum at day 7.	Bleomycin	31-40	galactosidase, beta 1	Mus musculus	94-112
12928422-3	2003	This led us to investigate whether the specific targeting of resident lung cells responsive to IL-4 and IL-13 exerted a therapeutic effect in an experimental model of IIP, namely the bleomycin-induced model of pulmonary fibrosis.	Bleomycin	183-192	interleukin 4	Mus musculus	95-99
12928422-4	2003	IL-4, IL-13, and their corresponding receptor subunits, IL-4Ralpha, IL-13Ralpha1, and IL-13Ralpha2, were maximally expressed at the mRNA and protein levels in whole lung samples on day 21 or 28 after an intratracheal bleomycin challenge.	Bleomycin	217-226	interleukin 4	Mus musculus	0-4
12928422-4	2003	IL-4, IL-13, and their corresponding receptor subunits, IL-4Ralpha, IL-13Ralpha1, and IL-13Ralpha2, were maximally expressed at the mRNA and protein levels in whole lung samples on day 21 or 28 after an intratracheal bleomycin challenge.	Bleomycin	217-226	interleukin 13	Mus musculus	6-11
12928422-4	2003	IL-4, IL-13, and their corresponding receptor subunits, IL-4Ralpha, IL-13Ralpha1, and IL-13Ralpha2, were maximally expressed at the mRNA and protein levels in whole lung samples on day 21 or 28 after an intratracheal bleomycin challenge.	Bleomycin	217-226	interleukin 4 receptor, alpha	Mus musculus	56-66
14669454-0	2003	[Manifestation of glutathione S-transferase GSTM1 and GSTT1 in female patients with bleomycin-positive chromosome instability].	Bleomycin	84-93	glutathione S-transferase kappa 1	Homo sapiens	18-43
14669454-0	2003	[Manifestation of glutathione S-transferase GSTM1 and GSTT1 in female patients with bleomycin-positive chromosome instability].	Bleomycin	84-93	glutathione S-transferase mu 1	Homo sapiens	44-49
14669454-0	2003	[Manifestation of glutathione S-transferase GSTM1 and GSTT1 in female patients with bleomycin-positive chromosome instability].	Bleomycin	84-93	glutathione S-transferase theta 1	Homo sapiens	54-59
12928422-4	2003	IL-4, IL-13, and their corresponding receptor subunits, IL-4Ralpha, IL-13Ralpha1, and IL-13Ralpha2, were maximally expressed at the mRNA and protein levels in whole lung samples on day 21 or 28 after an intratracheal bleomycin challenge.	Bleomycin	217-226	interleukin 13 receptor, alpha 2	Mus musculus	86-98
12928422-5	2003	The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group.	Bleomycin	148-157	interleukin 13	Mus musculus	36-41
12928422-5	2003	The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group.	Bleomycin	148-157	interleukin 13	Mus musculus	73-77
12928422-5	2003	The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group.	Bleomycin	251-260	interleukin 13	Mus musculus	36-41
12928422-5	2003	The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group.	Bleomycin	251-260	interleukin 13	Mus musculus	73-77
12928422-6	2003	The intranasal IL13-PE therapy significantly reduced the numbers of IL-4 and IL-13 receptor-positive mononuclear cells and macrophages and the levels of profibrotic cytokine and chemokine in the lungs of bleomycin-challenged mice on day 28.	Bleomycin	204-213	interleukin 13	Mus musculus	15-19
12928422-7	2003	Thus, this study demonstrates that IL-4- and/or IL-13-binding cells are required for the maintenance of pulmonary fibrosis induced by bleomycin and highlights the importance of further investigation of antifibrotic therapeutics that target these cells during pulmonary fibrosis.	Bleomycin	134-143	interleukin 4	Mus musculus	35-39
12928422-7	2003	Thus, this study demonstrates that IL-4- and/or IL-13-binding cells are required for the maintenance of pulmonary fibrosis induced by bleomycin and highlights the importance of further investigation of antifibrotic therapeutics that target these cells during pulmonary fibrosis.	Bleomycin	134-143	interleukin 13	Mus musculus	48-53
12925209-0	2003	Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma.	Bleomycin	90-99	chemokine (C-C motif) receptor 2	Mus musculus	60-65
12925209-5	2003	Immunohistochemical analysis showed that expression of monocyte chemoattractant protein-1 in the infiltrating mononuclear cells was enhanced at 2 to 3 wk following bleomycin treatment, whereas expression of monocyte chemoattractant protein-1 in fibroblasts was detected at later stages in the sclerotic skin.	Bleomycin	164-173	chemokine (C-C motif) ligand 2	Mus musculus	55-89
12925209-6	2003	Reverse transcriptase-polymerase chain reaction analysis showed that monocyte chemoattractant protein-1 mRNA expression in the lesional skin peaked at 2 to 3 wk following bleomycin treatment.	Bleomycin	171-180	chemokine (C-C motif) ligand 2	Mus musculus	69-103
12925209-7	2003	Expression of CCR-2, a major receptor for monocyte chemo-attractant protein-1, was also upregulated in the lesional skin at both protein and mRNA levels following bleomycin treatment.	Bleomycin	163-172	chemokine (C-C motif) receptor 2	Mus musculus	14-77
12925209-10	2003	These data suggest that monocyte chemoattractant protein-1 and CCR-2 signaling plays an important part in the pathogenesis of bleomycin-induced scleroderma.	Bleomycin	126-135	chemokine (C-C motif) ligand 2	Mus musculus	24-58
12925209-10	2003	These data suggest that monocyte chemoattractant protein-1 and CCR-2 signaling plays an important part in the pathogenesis of bleomycin-induced scleroderma.	Bleomycin	126-135	chemokine (C-C motif) receptor 2	Mus musculus	63-68
12944467-4	2003	After bleomycin treatment in culture, WRN and c-Abl are dissociated and followed by an Abl kinase-dependent WRN relocalization to the nucleoplasm.	Bleomycin	6-15	WRN RecQ like helicase	Homo sapiens	38-41
12944467-4	2003	After bleomycin treatment in culture, WRN and c-Abl are dissociated and followed by an Abl kinase-dependent WRN relocalization to the nucleoplasm.	Bleomycin	6-15	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	46-51
12944467-4	2003	After bleomycin treatment in culture, WRN and c-Abl are dissociated and followed by an Abl kinase-dependent WRN relocalization to the nucleoplasm.	Bleomycin	6-15	WRN RecQ like helicase	Homo sapiens	108-111
12944467-6	2003	WRN is tyrosine phosphorylated either transiently by treatment of HeLa cells with bleomycin or constitutively in cells from chronic myeloid leukemia (CML) patients, and these phosphorylations are prevented by treatment with the Abl kinase inhibitor STI-571.	Bleomycin	82-91	WRN RecQ like helicase	Homo sapiens	0-3
12679322-0	2003	Induction of arginase I and II in bleomycin-induced fibrosis of mouse lung.	Bleomycin	34-43	arginase, liver	Mus musculus	13-30
12941834-9	2003	An immunohistochemistry analysis showed that phosphorylated EGFR and proliferation cell nuclear antigen were highly expressed by the regenerated epithelial cells in the mice treated with bleomycin and the vehicle.	Bleomycin	187-196	epidermal growth factor receptor	Mus musculus	60-64
12941834-12	2003	These results suggest that the inhibition of EGFR phosphorylation augments bleomycin-induced pulmonary fibrosis by reducing regenerative epithelial proliferation.	Bleomycin	75-84	epidermal growth factor receptor	Mus musculus	45-49
12783868-3	2003	The phenotypes of nat3-Delta and mdm20-Delta mutants are identical or nearly the same and include the following: diminished growth at elevated temperatures and on hyperosmotic and nonfermentable media; diminished mating; defective actin cables formation; abnormal mitochondrial and vacuolar inheritance; inhibition of growth by DNA-damaging agents such as methyl methanesulfonate, bleomycin, camptothecin, and hydroxyurea; and inhibition of growth by the antimitotic drugs benomyl and thiabendazole.	Bleomycin	381-390	peptide alpha-N-acetyltransferase complex B subunit NAT3	Saccharomyces cerevisiae S288C	18-22
12679322-6	2003	Arginase I mRNA was undetectable before bleomycin treatment but was induced 5-10 days after this treatment.	Bleomycin	40-49	arginase, liver	Mus musculus	0-10
12940625-0	2003	Effects of granulocyte colony-stimulating factor on the kinetics of inflammatory cells in the peripheral blood and pulmonary lesions during the development of bleomycin-induced lung injury in rats.	Bleomycin	159-168	colony stimulating factor 3	Rattus norvegicus	11-48
12875966-1	2003	Mice with homozygous deletion of the plasminogen activator inhibitor-1 gene (PAI-1(-/-)) are relatively protected from bleomycin-induced pulmonary fibrosis.	Bleomycin	119-128	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	37-70
12875966-1	2003	Mice with homozygous deletion of the plasminogen activator inhibitor-1 gene (PAI-1(-/-)) are relatively protected from bleomycin-induced pulmonary fibrosis.	Bleomycin	119-128	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	77-82
12940625-1	2003	We evaluated the effects of granulocyte colony-stimulating factor (G-CSF) on the kinetics of inflammatory cells during the development of inflammation in bleomycin (BLM)-induced lung injury.	Bleomycin	154-163	colony stimulating factor 3	Rattus norvegicus	67-72
12839562-6	2003	Importantly, in bleomycin-injected skin, fibroblasts showed predominantly nuclear localization of Smad3 and intense staining for phospho-Smad2/3.	Bleomycin	16-25	SMAD family member 3	Mus musculus	98-103
12839562-6	2003	Importantly, in bleomycin-injected skin, fibroblasts showed predominantly nuclear localization of Smad3 and intense staining for phospho-Smad2/3.	Bleomycin	16-25	SMAD family member 2	Mus musculus	137-142
12839562-8	2003	Expression of Smad7, the endogenous inhibitor of transforming growth factor-beta/Smad signaling, was strongly induced in dermal cells by transforming growth factor-beta, but not by bleomycin injections.	Bleomycin	181-190	SMAD family member 7	Mus musculus	14-19
12839562-9	2003	Collectively, these results indicate that bleomycin-induced murine scleroderma is associated with rapid and sustained induction of transforming growth factor-beta/Smad signaling in resident dermal fibroblasts.	Bleomycin	42-51	SMAD family member 7	Mus musculus	163-167
12796376-8	2003	For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74% compared with 81% for those with LMP-1-negative tumors (P = 0.23, by log-rank test).	Bleomycin	47-56	PDZ and LIM domain 7	Homo sapiens	165-170
12598228-2	2003	We previously reported that bleomycin-induced pulmonary fibrosis was exaggerated in granulocyte-macrophage colony-stimulating factor knockout (GM-CSF(-/-)) mice compared with wild-type (GM-CSF(+/+)) mice and that increased fibrosis was associated with decreased PGE(2) levels in lung homogenates and alveolar macrophage cultures.	Bleomycin	28-37	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	143-149
12598228-2	2003	We previously reported that bleomycin-induced pulmonary fibrosis was exaggerated in granulocyte-macrophage colony-stimulating factor knockout (GM-CSF(-/-)) mice compared with wild-type (GM-CSF(+/+)) mice and that increased fibrosis was associated with decreased PGE(2) levels in lung homogenates and alveolar macrophage cultures.	Bleomycin	28-37	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	186-192
12767239-0	2003	Identification of the internal axial ligand of HO2-cobalt(III)-bleomycin: 1H[15N] HSQC NMR investigation of bleomycin, deglycobleomycin, and their hydroperoxide-cobalt(III) complexes.	Bleomycin	63-72	heme oxygenase 2	Homo sapiens	47-50
12759241-6	2003	E-cadherin ectodomain was shed into the bronchoalveolar lavage fluid of bleomycin-injured wild-type mice, but was not shed in matrilysin-null mice.	Bleomycin	72-81	cadherin 1	Mus musculus	0-10
12761881-0	2003	TGF-beta1-induced Smad 3 binding to the Smad 7 gene: knockout of Smad 7 gene transcription by sense phosphorothioate oligos, autoregulation, and effect on TGF-beta1 secretion: bleomycin acts through TGF-beta1.	Bleomycin	176-185	transforming growth factor beta 1	Homo sapiens	0-9
12761881-0	2003	TGF-beta1-induced Smad 3 binding to the Smad 7 gene: knockout of Smad 7 gene transcription by sense phosphorothioate oligos, autoregulation, and effect on TGF-beta1 secretion: bleomycin acts through TGF-beta1.	Bleomycin	176-185	SMAD family member 7	Homo sapiens	40-46
12761881-1	2003	Bleomycin produces its fibrogenic effect, at least in part, by TGF-beta1 secretion.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	63-72
12761881-2	2003	Treatment of IMR-90 human embryonic lung fibroblasts with bleomycin at 0.5 microg/ml results in a 1.6-fold increase of TGF-beta1 as determined by a specific ELISA assay for TGF-beta1 after acidification of the conditioned media.	Bleomycin	58-67	transforming growth factor beta 1	Homo sapiens	119-128
12761881-2	2003	Treatment of IMR-90 human embryonic lung fibroblasts with bleomycin at 0.5 microg/ml results in a 1.6-fold increase of TGF-beta1 as determined by a specific ELISA assay for TGF-beta1 after acidification of the conditioned media.	Bleomycin	58-67	transforming growth factor beta 1	Homo sapiens	173-182
12707016-0	2003	Increased basigin in bleomycin-induced lung injury.	Bleomycin	21-30	basigin	Mus musculus	10-17
12707016-3	2003	To investigate whether basigin might be expressed in fibro-inflammatory lung processes, we generated bleomycin-induced lung injury in mice.	Bleomycin	101-110	basigin	Mus musculus	23-30
12707014-0	2003	Retrovirally introduced prostaglandin D2 synthase suppresses lung injury induced by bleomycin.	Bleomycin	84-93	prostaglandin D2 synthase (brain)	Mus musculus	24-49
12707016-5	2003	Western blots of radioimmunoprecipitation assay RIPA-insoluble fractions of bleomycin-treated lungs showed increased basigin compared with RIPA-insoluble fractions of lung from untreated mice.	Bleomycin	76-85	basigin	Mus musculus	117-124
12707014-4	2003	Intravenous injection of PGDS cDNA-expressing fibroblasts significantly reduced lung edema, leukocyte infiltration in bronchoalveolar lavage (BAL) fluid, and pulmonary collagen content at 4 wk after instillation of bleomycin.	Bleomycin	215-224	prostaglandin D2 synthase (brain)	Mus musculus	25-29
12707016-6	2003	By quantitative reverse transcriptase-polymerase chain reaction, lung basigin mRNA was significantly increased 14 d after bleomycin, and by in situ hybridization, basigin mRNA was prominent in bronchiolar epithelium.	Bleomycin	122-131	basigin	Mus musculus	70-77
12707016-7	2003	Western blots of bronchoalveolar lavage fluid (BALF) showed various forms of basigin after bleomycin that were not present in BALF from untreated lung.	Bleomycin	91-100	basigin	Mus musculus	77-84
12707016-8	2003	These results demonstrate that bleomycin-induced lung injury is associated with increased basigin expression in bronchiolar epithelium, deposition of basigin in fibrotic sites, and increased basigin in BALF.	Bleomycin	31-40	basigin	Mus musculus	90-97
12707016-8	2003	These results demonstrate that bleomycin-induced lung injury is associated with increased basigin expression in bronchiolar epithelium, deposition of basigin in fibrotic sites, and increased basigin in BALF.	Bleomycin	31-40	basigin	Mus musculus	150-157
12707016-8	2003	These results demonstrate that bleomycin-induced lung injury is associated with increased basigin expression in bronchiolar epithelium, deposition of basigin in fibrotic sites, and increased basigin in BALF.	Bleomycin	31-40	basigin	Mus musculus	150-157
12771616-0	2003	Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis.	Bleomycin	51-60	colony stimulating factor 3	Rattus norvegicus	10-47
12771616-9	2003	Lung static compliance on day 15 was severely decreased with bleomycin alone and showed a further significant decrease when granulocyte colony-stimulating factor was added (controls, 3.85 +/- 0.14 mL/kPa; bleomycin, 1.44 +/- 0.06 mL/kPa; and bleomycin + granulocyte colony-stimulating factor, 0.65 +/- 0.09 mL/kPa; control vs. bleomycin, p &lt;.0001; and bleomycin vs. bleomycin + granulocyte colony-stimulating factor, p =.0003).	Bleomycin	205-214	colony stimulating factor 3	Rattus norvegicus	124-161
12771616-9	2003	Lung static compliance on day 15 was severely decreased with bleomycin alone and showed a further significant decrease when granulocyte colony-stimulating factor was added (controls, 3.85 +/- 0.14 mL/kPa; bleomycin, 1.44 +/- 0.06 mL/kPa; and bleomycin + granulocyte colony-stimulating factor, 0.65 +/- 0.09 mL/kPa; control vs. bleomycin, p &lt;.0001; and bleomycin vs. bleomycin + granulocyte colony-stimulating factor, p =.0003).	Bleomycin	205-214	colony stimulating factor 3	Rattus norvegicus	124-161
12771616-9	2003	Lung static compliance on day 15 was severely decreased with bleomycin alone and showed a further significant decrease when granulocyte colony-stimulating factor was added (controls, 3.85 +/- 0.14 mL/kPa; bleomycin, 1.44 +/- 0.06 mL/kPa; and bleomycin + granulocyte colony-stimulating factor, 0.65 +/- 0.09 mL/kPa; control vs. bleomycin, p &lt;.0001; and bleomycin vs. bleomycin + granulocyte colony-stimulating factor, p =.0003).	Bleomycin	205-214	colony stimulating factor 3	Rattus norvegicus	124-161
12771616-9	2003	Lung static compliance on day 15 was severely decreased with bleomycin alone and showed a further significant decrease when granulocyte colony-stimulating factor was added (controls, 3.85 +/- 0.14 mL/kPa; bleomycin, 1.44 +/- 0.06 mL/kPa; and bleomycin + granulocyte colony-stimulating factor, 0.65 +/- 0.09 mL/kPa; control vs. bleomycin, p &lt;.0001; and bleomycin vs. bleomycin + granulocyte colony-stimulating factor, p =.0003).	Bleomycin	205-214	colony stimulating factor 3	Rattus norvegicus	124-161
12771616-2	2003	Increased use of granulocyte colony-stimulating factor in patients receiving chemotherapy has been paralleled by an increased incidence of bleomycin-induced pulmonary toxicity.	Bleomycin	139-148	colony stimulating factor 3	Homo sapiens	17-54
12771616-9	2003	Lung static compliance on day 15 was severely decreased with bleomycin alone and showed a further significant decrease when granulocyte colony-stimulating factor was added (controls, 3.85 +/- 0.14 mL/kPa; bleomycin, 1.44 +/- 0.06 mL/kPa; and bleomycin + granulocyte colony-stimulating factor, 0.65 +/- 0.09 mL/kPa; control vs. bleomycin, p &lt;.0001; and bleomycin vs. bleomycin + granulocyte colony-stimulating factor, p =.0003).	Bleomycin	205-214	colony stimulating factor 3	Rattus norvegicus	124-161
12771616-10	2003	Lung morphology with bleomycin + granulocyte colony-stimulating factor showed, in addition to the changes observed with bleomycin alone, four patterns indicating more severe disease: honeycomb foci, pleural thickening with hyaline fibrosis, interstitial granuloma with increased number of macrophages but not neutrophils, and established interstitial fibrosis.	Bleomycin	120-129	colony stimulating factor 3	Rattus norvegicus	33-70
12771616-3	2003	We investigated whether granulocyte colony-stimulating factor (25 microg x kg(-1) x day(-1), 4 days) enhanced endotracheal bleomycin-induced (5 mg/kg) acute lung injury and fibrosis in rats.	Bleomycin	123-132	colony stimulating factor 3	Rattus norvegicus	24-61
12771616-12	2003	CONCLUSIONS: Granulocyte colony-stimulating factor enhances bleomycin-induced lung toxicity by a mechanism that probably involves neutrophils.	Bleomycin	60-69	colony stimulating factor 3	Rattus norvegicus	13-50
12771616-6	2003	INTERVENTIONS: We compared the effects of alveolar instillation of bleomycin in rats treated with either granulocyte colony-stimulating factor or saline.	Bleomycin	67-76	colony stimulating factor 3	Rattus norvegicus	105-142
12750320-7	2003	Decreases in silencing and viability are observed in most hta1tpe alleles after treatment with low and high concentrations, respectively, of bleomycin, which forms double-strand breaks (DSBs).	Bleomycin	141-150	histone H2A	Saccharomyces cerevisiae S288C	58-62
12750320-8	2003	In the absence of the DSB and telomere-binding protein yKu70, the bleomycin sensitivity of hta1tpe alleles is further enhanced.	Bleomycin	66-75	ATP-dependent DNA helicase YKU70	Saccharomyces cerevisiae S288C	55-60
12750320-8	2003	In the absence of the DSB and telomere-binding protein yKu70, the bleomycin sensitivity of hta1tpe alleles is further enhanced.	Bleomycin	66-75	histone H2A	Saccharomyces cerevisiae S288C	91-95
12637229-1	2003	Bleomycin-induced lung injury in mice was used to illustrate the plausibility of quantitating changes in elastin or protein concentration in histologically defined regions of mouse lungs.	Bleomycin	0-9	elastin	Mus musculus	105-112
12682445-5	2003	Bleomycin-induced acute lung injury is an example of thrombin signaling-dependent pathology.	Bleomycin	0-9	coagulation factor II, thrombin	Homo sapiens	53-61
12682450-8	2003	Pharmacologic inhibition of TGF-beta also protected wild-type mice from pulmonary edema induced by bleomycin or Escherichia coli endotoxin.	Bleomycin	99-108	transforming growth factor, beta 1	Mus musculus	28-36
12892616-0	2003	[The effect of murine interferon-gamma transgene expression on bleomycin-induced pulmonary fibrosis in mice].	Bleomycin	63-72	interferon gamma	Mus musculus	22-38
12892616-1	2003	OBJECTIVE: To investigate the effect of murine interferon-gamma (IFN-gamma) transgene expression on bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	100-109	interferon gamma	Mus musculus	47-63
12892616-1	2003	OBJECTIVE: To investigate the effect of murine interferon-gamma (IFN-gamma) transgene expression on bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	100-109	interferon gamma	Mus musculus	65-74
12892616-14	2003	(2) Early mIFN-gamma transgene expression via adenoviral vector in this bleomycin model aggravated alveolitis and fibrosis to some degree.	Bleomycin	72-81	interferon gamma	Mus musculus	10-20
12687556-6	2003	RESULTS: TNFRp55(-/-) mice began to develop severe sclerotic changes of the dermis on day 3 of the subcutaneous injections of bleomycin, while wild-type mice did not.	Bleomycin	126-135	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	9-16
12687556-8	2003	Induction of MMP-1 expression was significantly inhibited in the skin from bleomycin-treated TNFRp55(-/-) mice, and this phenomenon was also observed in vitro.	Bleomycin	75-84	matrix metallopeptidase 13	Mus musculus	13-18
12687556-8	2003	Induction of MMP-1 expression was significantly inhibited in the skin from bleomycin-treated TNFRp55(-/-) mice, and this phenomenon was also observed in vitro.	Bleomycin	75-84	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	93-100
12468440-0	2003	Bleomycin-induced pulmonary fibrosis is attenuated in gamma-glutamyl transpeptidase-deficient mice.	Bleomycin	0-9	gamma-glutamyltransferase 1	Mus musculus	54-83
12715156-0	2003	Disruption of the Saccharomyces cerevisiae cell-wall pathway gene SLG1 causes hypersensitivity to the antitumor drug bleomycin.	Bleomycin	117-126	Slg1p	Saccharomyces cerevisiae S288C	66-70
12715156-4	2003	Deletion of the SLG1 gene in parental strains caused hypersensitivity to bleomycin, and this correlated with an accumulation of damaged DNA.	Bleomycin	73-82	Slg1p	Saccharomyces cerevisiae S288C	16-20
12715156-5	2003	A plasmid that expresses the native SLG1 gene or that increases PKC1 gene dosage restored bleomycin resistance to the slg1Delta mutant.	Bleomycin	90-99	Slg1p	Saccharomyces cerevisiae S288C	36-40
12715156-5	2003	A plasmid that expresses the native SLG1 gene or that increases PKC1 gene dosage restored bleomycin resistance to the slg1Delta mutant.	Bleomycin	90-99	protein kinase C	Saccharomyces cerevisiae S288C	64-68
12715156-6	2003	Two-dimensional gel electrophoresis revealed that exposure to bleomycin triggered the expression of certain proteins, presumably to maintain cell wall function, in a Slg1-dependent manner.	Bleomycin	62-71	Slg1p	Saccharomyces cerevisiae S288C	166-170
12844025-2	2003	CASE REPORT: This case report describes acute respiratory distress syndrome, due to diffuse pneumonitis, in a patient with malignant non-Hodgkin"s lymphoma being treated with combination chemotherapy which included doxorubicin, cyclophosphamide, bleomycin, vindesin and intrathecal methotrexate with G-CSF (filgrastine- Neupogen).	Bleomycin	246-255	colony stimulating factor 3	Homo sapiens	300-305
12468440-9	2003	These findings suggest that increased neutrophils and matrix metalloproteinase-9 during the early inflammatory response and adequate thiol reserves are key elements in the fibrotic response after bleomycin-induced pulmonary injury.	Bleomycin	196-205	matrix metallopeptidase 9	Mus musculus	54-80
12468440-4	2003	At 1 month, lungs from bleomycin-treated GGT-/- mice exhibited minimal areas of fibrosis compared with wild-type mice(light microscopy fibrosis index: 510 +/- 756 versus 1975 +/- 817, p &lt; 0.01).	Bleomycin	23-32	gamma-glutamyltransferase 1	Mus musculus	41-44
12468440-5	2003	Lung collagen content revealed a significant increase in bleomycin-treated wild-type (15.1 +/- 3.8 versus 8.5 +/- 0.7 microg hydroxy(OH)-proline/mg dry weight, p &lt; 0.01) but not in GGT-/- (10.4 +/- 1.7 versus 8.8 +/- 0.8).	Bleomycin	57-66	gamma-glutamyltransferase 1	Mus musculus	184-190
12468440-7	2003	These values decreased after 72 hours of bleomycin in both GGT-/- and wild-type but reached their respective control values after 1 month.	Bleomycin	41-50	gamma-glutamyltransferase 1	Mus musculus	59-65
12573988-1	2003	Primary cultures of rat type II alveolar epithelial cells (AECs) or human AEC-derived A549 cells, when exposed to bleomycin (Bleo), exhibited concentration-dependent apoptosis detected by altered nuclear morphology, fragmentation of DNA, activation of caspase-3, and net cell loss over time.	Bleomycin	114-123	caspase 3	Homo sapiens	252-261
12573988-1	2003	Primary cultures of rat type II alveolar epithelial cells (AECs) or human AEC-derived A549 cells, when exposed to bleomycin (Bleo), exhibited concentration-dependent apoptosis detected by altered nuclear morphology, fragmentation of DNA, activation of caspase-3, and net cell loss over time.	Bleomycin	125-129	caspase 3	Homo sapiens	252-261
12573988-4	2003	Apoptosis of rat AECs or A549 cells in response to Bleo was inhibited 91% by the ANG-converting enzyme inhibitor captopril or 82%, respectively, by neutralizing antibodies specific for ANG II (both P &lt; 0.01).	Bleomycin	51-55	angiotensinogen	Rattus norvegicus	185-191
12573988-2	2003	In both cell culture models, exposure to Bleo caused time-dependent increases in angiotensinogen (ANGEN) mRNA.	Bleomycin	41-45	angiotensinogen	Rattus norvegicus	81-96
12573988-5	2003	Antagonists of ANG receptor AT(1) (losartan, L-158809, or saralasin), but not an AT(2)-selective blocker (PD-123319), inhibited Bleo-induced apoptosis of either rat AECs (79%, P &lt; 0.01) or A549 cells (83%, P &lt; 0.01) and also reduced the activity of caspase-3 by 52% (P &lt; 0.05).	Bleomycin	128-132	angiogenin	Rattus norvegicus	15-18
12573988-2	2003	In both cell culture models, exposure to Bleo caused time-dependent increases in angiotensinogen (ANGEN) mRNA.	Bleomycin	41-45	angiotensinogen	Rattus norvegicus	98-103
12573988-5	2003	Antagonists of ANG receptor AT(1) (losartan, L-158809, or saralasin), but not an AT(2)-selective blocker (PD-123319), inhibited Bleo-induced apoptosis of either rat AECs (79%, P &lt; 0.01) or A549 cells (83%, P &lt; 0.01) and also reduced the activity of caspase-3 by 52% (P &lt; 0.05).	Bleomycin	128-132	angiotensin II receptor, type 1a	Rattus norvegicus	28-33
12573988-3	2003	Antisense oligonucleotides against ANGEN mRNA inhibited Bleo-induced apoptosis of rat AEC or A549 cells by 83 and 84%, respectively (P &lt; 0.01 and P &lt; 0.05), and prevented Bleo-induced net cell loss.	Bleomycin	56-60	angiotensinogen	Rattus norvegicus	35-40
12573988-3	2003	Antisense oligonucleotides against ANGEN mRNA inhibited Bleo-induced apoptosis of rat AEC or A549 cells by 83 and 84%, respectively (P &lt; 0.01 and P &lt; 0.05), and prevented Bleo-induced net cell loss.	Bleomycin	177-181	angiotensinogen	Rattus norvegicus	35-40
12573988-5	2003	Antagonists of ANG receptor AT(1) (losartan, L-158809, or saralasin), but not an AT(2)-selective blocker (PD-123319), inhibited Bleo-induced apoptosis of either rat AECs (79%, P &lt; 0.01) or A549 cells (83%, P &lt; 0.01) and also reduced the activity of caspase-3 by 52% (P &lt; 0.05).	Bleomycin	128-132	caspase 3	Rattus norvegicus	255-264
12573988-4	2003	Apoptosis of rat AECs or A549 cells in response to Bleo was inhibited 91% by the ANG-converting enzyme inhibitor captopril or 82%, respectively, by neutralizing antibodies specific for ANG II (both P &lt; 0.01).	Bleomycin	51-55	angiogenin	Rattus norvegicus	81-84
12573990-0	2003	Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin.	Bleomycin	88-97	decorin	Mus musculus	31-38
12403781-4	2003	Here we report that the expression of human securin is suppressed in cells treated with the DNA-damaging drugs doxorubicin and bleomycin.	Bleomycin	127-136	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	44-51
12574379-3	2003	Lethal pulmonary injury after bleomycin treatment was higher in IL-4(-/-) vs IL-4(+/+) mice.	Bleomycin	30-39	interleukin 4	Mus musculus	77-81
12574379-3	2003	Lethal pulmonary injury after bleomycin treatment was higher in IL-4(-/-) vs IL-4(+/+) mice.	Bleomycin	30-39	interleukin 4	Mus musculus	64-68
12376355-1	2002	Plasminogen activator inhibitor-1 (PAI-1)-deficient transgenic mice have improved survival and less fibrosis after intratracheal bleomycin instillation.	Bleomycin	129-138	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	0-33
12496444-0	2003	Repression of bleomycin-induced pneumopathy by TNF.	Bleomycin	14-23	tumor necrosis factor	Mus musculus	47-50
12496444-2	2003	As a potent proinflammatory cytokine, TNF has been suggested to play critical roles in the pathogenesis of the human disease and its animal model, bleomycin-induced pneumopathy.	Bleomycin	147-156	tumor necrosis factor	Homo sapiens	38-41
12496444-7	2003	Contrary to previous reports that showed that TNF was a central mediator of pulmonary inflammation, we have demonstrated that TNF is essential for repressing pulmonary inflammation in bleomycin-induced pneumopathy.	Bleomycin	184-193	tumor necrosis factor	Mus musculus	126-129
12616606-0	2003	Codon 64 of K-ras gene mutation pattern in hepatocellular carcinomas induced by bleomycin and 1-nitropyrene in A/J mice.	Bleomycin	80-89	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	12-17
12616606-9	2003	Codon 64 of the K-ras gene mutation may thus play an important role in the induction of hepatocellular carcinomas by bleomycin in the existence of 1-nitropyrene.	Bleomycin	117-126	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	16-21
15132891-1	2003	AIM: To investigate the role of signal transducer and activator of transcription 1(STAT(1)) in alveolar macrophages (AMs) from rats with bleomycin-induced pulmonary fibrosis.	Bleomycin	137-146	signal transducer and activator of transcription 1	Rattus norvegicus	32-82
15132891-1	2003	AIM: To investigate the role of signal transducer and activator of transcription 1(STAT(1)) in alveolar macrophages (AMs) from rats with bleomycin-induced pulmonary fibrosis.	Bleomycin	137-146	signal transducer and activator of transcription 1	Rattus norvegicus	83-90
15132891-5	2003	After bleomycin treatment, the STAT(1) activation of AMs was significantly increased on day 1, climaxed on day 7, and then gradually decreased, but remaining significantly higher than that of NS group on day 28 (P&lt;0.05).	Bleomycin	6-15	signal transducer and activator of transcription 1	Rattus norvegicus	31-38
15132891-10	2003	CONCLUSION: STAT(1) was abnormally activated in AMs of rats with bleomycin-induced interstitial pulmonary fibrosis (IPF).	Bleomycin	65-74	signal transducer and activator of transcription 1	Rattus norvegicus	12-19
12475858-0	2002	Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice.	Bleomycin	172-181	vascular cell adhesion molecule 1	Mus musculus	42-75
12475858-16	2002	14-MRMLs clearly attenuated the expression of VCAM-1 mRNA during the early phase of bleomycin-induced lung injury, and this might be one mechanism of inhibition of neutrophil and macrophage migration into the airspace by 14-MRMLs.	Bleomycin	84-93	vascular cell adhesion molecule 1	Mus musculus	46-52
12460192-5	2002	Thus, we tested whether the treatment with other DNA-damaging agents, such as doxorubicin, bleomycin, and gamma-irradiation, could induce 4-1BB expression.	Bleomycin	91-100	TNF receptor superfamily member 9	Homo sapiens	138-143
12460192-9	2002	Interestingly, at subcytotoxic concentrations, doxorubicin and bleomycin considerably enhanced 4-1BB expression induced by CD3 ligation in CEM cells.	Bleomycin	63-72	TNF receptor superfamily member 9	Homo sapiens	95-100
14586153-8	2003	However, for individual patients with concern for bleomycin-induced pulmonary fibrosis, VIP remains an attractive first-line regimen.	Bleomycin	50-59	vasoactive intestinal peptide	Homo sapiens	88-91
12376365-0	2002	Bleomycin-induced lung fibrosis in IL-4-overexpressing and knockout mice.	Bleomycin	0-9	interleukin 4	Mus musculus	35-39
12376365-5	2002	Comparing Bleo- to Sal-treated controls within each group of mice showed increases in all lung fibrosis parameters in IL-4 KO and WT, but not in any of the parameters in IL-4 TG mice.	Bleomycin	10-14	interleukin 4	Mus musculus	118-122
12376365-6	2002	The severity of Bleo-induced fibrotic response was decreased in overexpressed IL-4 TG compared with IL-4 KO mice.	Bleomycin	16-20	interleukin 4	Mus musculus	78-82
12376365-6	2002	The severity of Bleo-induced fibrotic response was decreased in overexpressed IL-4 TG compared with IL-4 KO mice.	Bleomycin	16-20	interleukin 4	Mus musculus	100-104
12408953-0	2002	Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-kappaB/Rel.	Bleomycin	0-9	selectin E	Homo sapiens	18-28
12445185-8	2002	In addition, bleomycin (100 ng per ml) and cisplatin (1 mM) also induced myofibroblast apoptosis by activating caspase-3, suggesting that these agents have a potential therapeutic value for abnormal scar formation.	Bleomycin	13-22	caspase 3	Rattus norvegicus	111-120
12414509-0	2002	Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis.	Bleomycin	58-67	intercellular adhesion molecule 1	Mus musculus	0-33
12414509-0	2002	Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis.	Bleomycin	58-67	selectin, lymphocyte	Mus musculus	38-48
12414509-4	2002	After 16 days of intratracheal bleomycin challenge, collagen deposition was inhibited in both L-selectin(-/-) and ICAM-1(-/-) mice when compared with wild-type littermates.	Bleomycin	31-40	selectin, lymphocyte	Mus musculus	94-104
12414509-4	2002	After 16 days of intratracheal bleomycin challenge, collagen deposition was inhibited in both L-selectin(-/-) and ICAM-1(-/-) mice when compared with wild-type littermates.	Bleomycin	31-40	intercellular adhesion molecule 1	Mus musculus	114-120
12449100-0	2002	Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lung prevents bleomycin-induced pulmonary fibrosis via a Fas-Fas ligand-independent pathway.	Bleomycin	90-99	heme oxygenase 1	Mus musculus	51-67
12449100-0	2002	Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lung prevents bleomycin-induced pulmonary fibrosis via a Fas-Fas ligand-independent pathway.	Bleomycin	90-99	Fas ligand (TNF superfamily, member 6)	Mus musculus	133-147
12449100-2	2002	Because enhanced expression of HO-1 confers protection against many types of cell and tissue damage by modulating apoptotic cell death or cytokine expression profiles, we hypothesized that adenovirus-mediated transfer of HO-1 cDNA and subsequent overexpression of the protein in lung would provide therapeutic benefit in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	339-348	heme oxygenase 1	Mus musculus	31-35
12449100-2	2002	Because enhanced expression of HO-1 confers protection against many types of cell and tissue damage by modulating apoptotic cell death or cytokine expression profiles, we hypothesized that adenovirus-mediated transfer of HO-1 cDNA and subsequent overexpression of the protein in lung would provide therapeutic benefit in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	339-348	heme oxygenase 1	Mus musculus	221-225
12449100-5	2002	Consistent with the concept that HO-1 overexpression prevents fibrosis via a pathway independent of Fas-FasL interaction, Ad.HO-1 administration prevented bleomycin-induced pulmonary fibrosis in gld/gld mice, which express nonfunctional FasL.	Bleomycin	155-164	heme oxygenase 1	Mus musculus	125-129
12384553-0	2002	An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents.	Bleomycin	129-138	X-ray repair cross complementing 5	Homo sapiens	47-51
12384553-5	2002	Moreover, transfection of M059K cells with Ku86 antisense ASOs markedly increased cell death after treatment with ionizing radiation, bleomycin, and etoposide.	Bleomycin	134-143	X-ray repair cross complementing 5	Homo sapiens	43-47
12408953-0	2002	Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-kappaB/Rel.	Bleomycin	0-9	nuclear factor kappa B subunit 1	Homo sapiens	137-146
12356575-0	2002	Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	52-61	interleukin 13	Homo sapiens	15-20
12356575-0	2002	Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	52-61	homeobox C10	Homo sapiens	25-28
12225958-5	2002	Bleomycin-exposed lung fibroblasts (BLF) exhibited increased production of versican (VS), heparan sulfate proteoglycan (HSPG), and biglycan (BG) compared with normal lung fibroblasts (NLF).	Bleomycin	0-9	versican	Rattus norvegicus	75-83
12356575-4	2002	In this study we demonstrate that IL-13 and C10 are elevated in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	84-93	interleukin 13	Homo sapiens	34-39
12225958-5	2002	Bleomycin-exposed lung fibroblasts (BLF) exhibited increased production of versican (VS), heparan sulfate proteoglycan (HSPG), and biglycan (BG) compared with normal lung fibroblasts (NLF).	Bleomycin	0-9	versican	Rattus norvegicus	85-87
12356575-4	2002	In this study we demonstrate that IL-13 and C10 are elevated in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	84-93	homeobox C10	Homo sapiens	44-47
12356575-5	2002	Neutralization of IL-13, but not IL-4, attenuated bleomycin-induced pulmonary fibrosis and levels of C10, suggesting that IL-13 has an important role in the development of pulmonary fibrosis.	Bleomycin	50-59	interleukin 13	Homo sapiens	18-23
12225958-5	2002	Bleomycin-exposed lung fibroblasts (BLF) exhibited increased production of versican (VS), heparan sulfate proteoglycan (HSPG), and biglycan (BG) compared with normal lung fibroblasts (NLF).	Bleomycin	0-9	syndecan 2	Rattus norvegicus	90-118
12356575-5	2002	Neutralization of IL-13, but not IL-4, attenuated bleomycin-induced pulmonary fibrosis and levels of C10, suggesting that IL-13 has an important role in the development of pulmonary fibrosis.	Bleomycin	50-59	interleukin 13	Homo sapiens	122-127
12225958-5	2002	Bleomycin-exposed lung fibroblasts (BLF) exhibited increased production of versican (VS), heparan sulfate proteoglycan (HSPG), and biglycan (BG) compared with normal lung fibroblasts (NLF).	Bleomycin	0-9	syndecan 2	Rattus norvegicus	120-124
12225958-5	2002	Bleomycin-exposed lung fibroblasts (BLF) exhibited increased production of versican (VS), heparan sulfate proteoglycan (HSPG), and biglycan (BG) compared with normal lung fibroblasts (NLF).	Bleomycin	0-9	biglycan	Rattus norvegicus	131-139
12356575-6	2002	IL-13 is a potent inducer of C10 in vivo, and neutralization of C10 attenuated bleomycin-induced pulmonary fibrosis and intrapulmonary macrophage numbers.	Bleomycin	79-88	homeobox C10	Homo sapiens	64-67
12370117-9	2002	RESULTS: Growth hormone protects CHO-4 cells from bleomycin- and radiation-induced cell death.	Bleomycin	50-59	gonadotropin releasing hormone receptor	Rattus norvegicus	9-23
12370117-15	2002	The increased survival in response to radiation and bleomycin treatment induced by growth hormone correlates with an enhanced ability of the cells to repair damaged DNA.	Bleomycin	52-61	gonadotropin releasing hormone receptor	Rattus norvegicus	83-97
12416544-12	2002	We conclude that continuously infused IT bleomycin is well tolerated; the MTD (and recommended dose for a phase II efficacy trial) of IT bleomycin is 16 U/wk.	Bleomycin	137-146	metallothionein 1E	Homo sapiens	74-77
12167044-1	2002	Metabolic inactivation of the antitumor antibiotic bleomycin is believed to be mediated exclusively via the action of bleomycin hydrolase, a cysteine proteinase that is widely distributed in nature.	Bleomycin	51-60	bleomycin hydrolase	Homo sapiens	118-137
12231503-0	2002	Bleomycin sensitivity of mice expressing dominant-negative p53 in the lung epithelium.	Bleomycin	0-9	transformation related protein 53, pseudogene	Mus musculus	59-62
12231503-3	2002	We show here that a transgene with a dominant-negative mutant form of human p53 expressed from the surfactant protein C promoter sensitizes mice to bleomycin-induced lung injury.	Bleomycin	148-157	tumor protein p53	Homo sapiens	76-79
12192538-1	2002	We have previously reported that transforming growth factor beta (TGF-beta) produced by rat hepatoma cell line KDH-8 cells suppressed the interleukin-2 (IL-2) production of T cells and the tumoricidal activity of macrophages in KDH-8 tumor-bearing rats and that the inhibition of TGF-beta production by low-dose bleomycin restored these activities significantly.	Bleomycin	312-321	transforming growth factor, beta 1	Rattus norvegicus	66-74
12217216-3	2002	In the present study we examined potential causes of this phenotypic variation and tested whether constitutive PDGF-B expression exacerbated fibrosis induced by bleomycin and silica.	Bleomycin	161-170	platelet derived growth factor, B polypeptide	Mus musculus	111-117
12231503-5	2002	These observations suggest that compromising p53 function in the alveolar epithelium impairs recovery of the lung from bleomycin-induced injury.	Bleomycin	119-128	transformation related protein 53, pseudogene	Mus musculus	45-48
12665304-3	2002	In the present study the levels of Hsp47 after exposure to two chemotherapeutic agents (bleomycin and mitomycin).	Bleomycin	88-97	serine (or cysteine) peptidase inhibitor, clade H, member 1	Mus musculus	35-40
12175310-2	2002	In an attempt to assess the possible role of TP53 in suppressing such repair errors, bleomycin-induced mutagenesis at the HPRT locus was examined in immortalized 184B5 human mammary epithelial cells (TP53(+)), and in a TP53-defective derivative, 184B5-E6tfxc6.	Bleomycin	85-94	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	122-126
12167044-2	2002	While the spectrum of antitumor activity exhibited by the bleomycins is believed to reflect the anatomical distribution of bleomycin hydrolase within the host, little has been done to characterize the product of the putative inactivation at a chemical or biochemical level.	Bleomycin	58-68	bleomycin hydrolase	Homo sapiens	123-142
12154054-0	2002	Bleomycin resistance in mammalian cells expressing a genetic suppressor element derived from the SRPK1 gene.	Bleomycin	0-9	SRSF protein kinase 1	Homo sapiens	97-102
12154054-3	2002	One of these GSEs, GSE(BLM), conferring an approximately 2-fold bleomycin resistance in DC-3F cells, displayed 98% identity with an amino acid sequence located in the functional domain of human SRPK1.	Bleomycin	64-73	SRSF protein kinase 1	Homo sapiens	194-199
12060565-0	2002	Combined SP-A-bleomycin effect on cytokines by THP-1 cells: impact of surfactant lipids on this effect.	Bleomycin	14-23	GLI family zinc finger 2	Homo sapiens	47-52
12140739-7	2002	We determined the effect of cytoplasmic NFkappaB decoys on bleomycin-induced inflammation.	Bleomycin	59-68	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	40-48
12140188-8	2002	Functional studies of bleomycin hydrolase activity indicate that this enzyme modulates bleomycin-induced pulmonary fibrosis, suggesting that it may be a candidate gene for Blmpf2.	Bleomycin	22-31	bleomycin-induced pulmonary fibrosis 2	Mus musculus	172-178
12140188-9	2002	The data suggest sex-specific models of susceptibility to bleomycin-induced lung fibrosis, with an interaction between Blmpf2 and Blmpf1 for the more susceptible males and Blmpf1 as the major locus in females.	Bleomycin	58-67	bleomycin-induced pulmonary fibrosis 2	Mus musculus	119-125
12140188-9	2002	The data suggest sex-specific models of susceptibility to bleomycin-induced lung fibrosis, with an interaction between Blmpf2 and Blmpf1 for the more susceptible males and Blmpf1 as the major locus in females.	Bleomycin	58-67	bleomycin-induced pulmonary fibrosis 1	Mus musculus	130-136
12140188-9	2002	The data suggest sex-specific models of susceptibility to bleomycin-induced lung fibrosis, with an interaction between Blmpf2 and Blmpf1 for the more susceptible males and Blmpf1 as the major locus in females.	Bleomycin	58-67	bleomycin-induced pulmonary fibrosis 1	Mus musculus	172-178
12182708-5	2002	An atku80 knockout mutant shows hypersensitivity to the DNA-damaging agents menadione and bleomycin, consistent with a role for AtKu80 in the repair of DSBs in vivo in Arabidopsis.	Bleomycin	90-99	Ku80 family protein	Arabidopsis thaliana	3-9
12121784-0	2002	Structures of HO(2)-Co(III)bleomycin A(2) bound to d(GAGCTC)(2) and d(GGAAGCTTCC)(2): structure-reactivity relationships of Co and Fe bleomycins.	Bleomycin	134-144	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	23-26
12121784-2	2002	In order to enlarge the understanding of its structure and reactivity, three-dimensional structures of HO(2)-Co(III)bleomycin bound to two DNA oligomers, d(GAGCTC)(2) (I) and d(GGAAGCTTCC)(2) (II), that have 5"-GC-3" binding sites, have been determined by nuclear magnetic resonance (NMR) methods.	Bleomycin	116-125	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	112-115
12060565-3	2002	We studied the effects of human SP-A on bleomycin-induced cytokine production and mRNA expression in THP-1 macrophage-like cells and obtained the following results.	Bleomycin	40-49	surfactant protein A1	Homo sapiens	32-36
12060565-3	2002	We studied the effects of human SP-A on bleomycin-induced cytokine production and mRNA expression in THP-1 macrophage-like cells and obtained the following results.	Bleomycin	40-49	GLI family zinc finger 2	Homo sapiens	101-106
12060565-4	2002	1) Bleomycin-treated THP-1 cells increased tumor necrosis factor (TNF)-alpha, interleukin (IL)-8, and IL-1beta production in dose- and time-dependent patterns, as we have observed with SP-A.	Bleomycin	3-12	GLI family zinc finger 2	Homo sapiens	21-26
12060565-2	2002	In the present study, we investigated the hypothesis that SP-A is involved in bleomycin-induced pulmonary fibrosis.	Bleomycin	78-87	surfactant protein A1	Homo sapiens	58-62
12060565-4	2002	1) Bleomycin-treated THP-1 cells increased tumor necrosis factor (TNF)-alpha, interleukin (IL)-8, and IL-1beta production in dose- and time-dependent patterns, as we have observed with SP-A.	Bleomycin	3-12	tumor necrosis factor	Homo sapiens	43-76
12060565-4	2002	1) Bleomycin-treated THP-1 cells increased tumor necrosis factor (TNF)-alpha, interleukin (IL)-8, and IL-1beta production in dose- and time-dependent patterns, as we have observed with SP-A.	Bleomycin	3-12	C-X-C motif chemokine ligand 8	Homo sapiens	78-96
12060565-4	2002	1) Bleomycin-treated THP-1 cells increased tumor necrosis factor (TNF)-alpha, interleukin (IL)-8, and IL-1beta production in dose- and time-dependent patterns, as we have observed with SP-A.	Bleomycin	3-12	interleukin 1 beta	Homo sapiens	102-110
12060565-4	2002	1) Bleomycin-treated THP-1 cells increased tumor necrosis factor (TNF)-alpha, interleukin (IL)-8, and IL-1beta production in dose- and time-dependent patterns, as we have observed with SP-A.	Bleomycin	3-12	surfactant protein A1	Homo sapiens	185-189
12060565-7	2002	3) Although the bleomycin effect on cytokine production was not significantly affected by the presence of surfactant lipid, the additive and synergistic effect of SP-A-bleomycin on cytokine production was significantly reduced.	Bleomycin	168-177	surfactant protein A1	Homo sapiens	163-167
12060565-8	2002	We speculate that the elevated cytokine levels resulting from the bleomycin-SP-A synergism are responsible for bleomycin-induced pulmonary fibrosis and that surfactant lipids can help ameliorate pulmonary complications observed during bleomycin chemotherapy.	Bleomycin	66-75	surfactant protein A1	Homo sapiens	76-80
12060565-8	2002	We speculate that the elevated cytokine levels resulting from the bleomycin-SP-A synergism are responsible for bleomycin-induced pulmonary fibrosis and that surfactant lipids can help ameliorate pulmonary complications observed during bleomycin chemotherapy.	Bleomycin	111-120	surfactant protein A1	Homo sapiens	76-80
12051713-0	2002	Regulation of Smad3 expression in bleomycin-induced pulmonary fibrosis: a negative feedback loop of TGF-beta signaling.	Bleomycin	34-43	SMAD family member 3	Homo sapiens	14-19
12060566-0	2002	A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis.	Bleomycin	52-61	mitogen-activated protein kinase 14	Mus musculus	2-5
12060566-1	2002	To elucidate the pathophysiology of pulmonary fibrosis, we investigated the involvement of p38 mitogen-activated protein kinase (MAPK), which is one of the major signal transduction pathways of proinflammatory cytokines, in a murine model of bleomycin-induced lung fibrosis.	Bleomycin	242-251	mitogen-activated protein kinase 14	Mus musculus	91-94
12060566-2	2002	p38 MAPK and its substrate, activating transcription factor (ATF)-2, in bronchoalveolar lavage fluid cells were phosphorylated by intratracheal exposure of bleomycin, and the phosphorylation of ATF-2 was inhibited by subcutaneous administration of a specific inhibitor of p38 MAPK, FR-167653.	Bleomycin	156-165	mitogen-activated protein kinase 14	Mus musculus	0-3
12060566-2	2002	p38 MAPK and its substrate, activating transcription factor (ATF)-2, in bronchoalveolar lavage fluid cells were phosphorylated by intratracheal exposure of bleomycin, and the phosphorylation of ATF-2 was inhibited by subcutaneous administration of a specific inhibitor of p38 MAPK, FR-167653.	Bleomycin	156-165	activating transcription factor 2	Mus musculus	28-67
12060566-2	2002	p38 MAPK and its substrate, activating transcription factor (ATF)-2, in bronchoalveolar lavage fluid cells were phosphorylated by intratracheal exposure of bleomycin, and the phosphorylation of ATF-2 was inhibited by subcutaneous administration of a specific inhibitor of p38 MAPK, FR-167653.	Bleomycin	156-165	activating transcription factor 2	Mus musculus	194-199
12060566-2	2002	p38 MAPK and its substrate, activating transcription factor (ATF)-2, in bronchoalveolar lavage fluid cells were phosphorylated by intratracheal exposure of bleomycin, and the phosphorylation of ATF-2 was inhibited by subcutaneous administration of a specific inhibitor of p38 MAPK, FR-167653.	Bleomycin	156-165	mitogen-activated protein kinase 14	Mus musculus	0-8
12060566-3	2002	FR-167653 also inhibited augmented expression of tumor necrosis factor -alpha, connective tissue growth factor, and apoptosis of lung cells induced by bleomycin administration.	Bleomycin	151-160	cellular communication network factor 2	Mus musculus	79-110
12060566-5	2002	These findings demonstrated that p38 MAPK is involved in bleomycin-induced pulmonary fibrosis, and its inhibitor, FR-167653, may be a feasible therapeutic agent.	Bleomycin	57-66	mitogen-activated protein kinase 14	Mus musculus	33-41
12060572-0	2002	Role of macrophage migration inhibitory factor in bleomycin-induced lung injury and fibrosis in mice.	Bleomycin	50-59	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	8-46
12060572-3	2002	In this study, we examined the role of MIF in bleomycin (BLM)-induced lung injury and fibrosis.	Bleomycin	46-55	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	39-42
12060572-3	2002	In this study, we examined the role of MIF in bleomycin (BLM)-induced lung injury and fibrosis.	Bleomycin	57-60	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	39-42
12093752-5	2002	Others have shown that mutation of yeast PA200 results in hypersensitivity to bleomycin, and exposure of yeast to DNA damaging agents induces the PA200 message.	Bleomycin	78-87	proteasome activator subunit 4	Homo sapiens	41-46
12096208-0	2002	P-selectin upregulation in bleomycin induced lung injury in rats: effect of N-acetyl-L-cysteine.	Bleomycin	27-36	selectin P	Rattus norvegicus	0-10
12096208-7	2002	RESULTS: Bleomycin administration resulted in an upregulation of P-selectin at 1 hour, returning to baseline at 3 hours.	Bleomycin	9-18	selectin P	Rattus norvegicus	65-75
12096208-8	2002	Myeloperoxidase activity showed a significant increase at 6 hours after bleomycin administration that lasted for 3 days.	Bleomycin	72-81	myeloperoxidase	Rattus norvegicus	0-15
12096208-10	2002	CONCLUSION: Upregulation of P-selectin in the lung is associated with neutrophil recruitment in response to bleomycin.	Bleomycin	108-117	selectin P	Rattus norvegicus	28-38
12051713-0	2002	Regulation of Smad3 expression in bleomycin-induced pulmonary fibrosis: a negative feedback loop of TGF-beta signaling.	Bleomycin	34-43	transforming growth factor beta 1	Homo sapiens	100-108
12051713-4	2002	In this study, we investigated the expression of Smad2 and Smad3 in an in vivo animal model of lung fibrosis induced by bleomycin.	Bleomycin	120-129	SMAD family member 2	Homo sapiens	49-54
12051713-4	2002	In this study, we investigated the expression of Smad2 and Smad3 in an in vivo animal model of lung fibrosis induced by bleomycin.	Bleomycin	120-129	SMAD family member 3	Homo sapiens	59-64
12051713-5	2002	We found that the expression of Smad3 was regulated in lungs during bleomycin-induced pulmonary fibrosis.	Bleomycin	68-77	SMAD family member 3	Homo sapiens	32-37
12051713-6	2002	The decline of Smad3 mRNA was evident at day three of post-bleomycin instillation and the expression of Smad3 continually decreased during the reparative phase of lung injury (days 8 and 12), whereas the expression of Smad2 showed little change after bleomycin administration.	Bleomycin	59-68	SMAD family member 3	Homo sapiens	15-20
12051713-6	2002	The decline of Smad3 mRNA was evident at day three of post-bleomycin instillation and the expression of Smad3 continually decreased during the reparative phase of lung injury (days 8 and 12), whereas the expression of Smad2 showed little change after bleomycin administration.	Bleomycin	251-260	SMAD family member 3	Homo sapiens	104-109
12051713-9	2002	These studies provide direct evidence for a differential regulation of Smad3 expression that is distinct from that of Smad2 during bleomycin-induced pulmonary fibrosis and suggest a ligand-induced negative feedback loop that modulates cellular TGF-beta signaling.	Bleomycin	131-140	transforming growth factor beta 1	Homo sapiens	244-252
12003792-0	2002	Bleomycin upregulates expression of gamma-glutamylcysteine synthetase in pulmonary artery endothelial cells.	Bleomycin	0-9	glutamate-cysteine ligase catalytic subunit	Homo sapiens	36-69
12003792-4	2002	gamma-Glutamylcysteine synthetase (gamma-GCS) controls the key regulatory step in GSH synthesis, and Northern blots indicate that the gamma-GCS catalytic subunit [gamma-GCS heavy chain (gamma-GCS(h))] is upregulated by bleomycin within 3 h. The promoter for human gamma-GCS(h) contains consensus sites for nuclear factor-kappaB (NF-kappaB) and the antioxidant response element (ARE), both of which are activated in response to oxidative stress.	Bleomycin	219-228	glutamate-cysteine ligase catalytic subunit	Homo sapiens	0-33
12003792-5	2002	Electrophoretic mobility shift assays show that bleomycin activates the transcription factor NF-kappaB as well as the ARE-binding factors Nrf-1 and -2.	Bleomycin	48-57	nuclear factor kappa B subunit 1	Homo sapiens	93-102
12003792-5	2002	Electrophoretic mobility shift assays show that bleomycin activates the transcription factor NF-kappaB as well as the ARE-binding factors Nrf-1 and -2.	Bleomycin	48-57	nuclear respiratory factor 1	Homo sapiens	138-150
12003776-8	2002	These results suggest that ACE inhibitor treatment decreases lung injury and the development of pulmonary hypertension in bleomycin-treated mice.	Bleomycin	122-131	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	27-30
12003776-1	2002	The present study was undertaken to investigate the effects of treatment with the angiotensin-converting enzyme (ACE) inhibitor enalapril in a mouse model of pulmonary hypertension induced by bleomycin.	Bleomycin	192-201	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	82-111
12003776-1	2002	The present study was undertaken to investigate the effects of treatment with the angiotensin-converting enzyme (ACE) inhibitor enalapril in a mouse model of pulmonary hypertension induced by bleomycin.	Bleomycin	192-201	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	113-116
12003792-6	2002	Nrf-1 and -2 activation by bleomycin is inhibited by the ROS quenching agent N-acetylcysteine (NAC), but not by U-0126, a MEK1/2 inhibitor that blocks bleomycin-induced MAPK activation.	Bleomycin	27-36	nuclear respiratory factor 1	Homo sapiens	0-12
12003776-2	2002	Bleomycin-induced lung injury in mice is mediated by enhanced tumor necrosis factor-alpha (TNF) expression in the lung, which determines the murine strain sensitivity to bleomycin, and murine strains are sensitive (C57BL/6) or resistant (BALB/c).	Bleomycin	0-9	tumor necrosis factor	Mus musculus	62-89
12003776-2	2002	Bleomycin-induced lung injury in mice is mediated by enhanced tumor necrosis factor-alpha (TNF) expression in the lung, which determines the murine strain sensitivity to bleomycin, and murine strains are sensitive (C57BL/6) or resistant (BALB/c).	Bleomycin	0-9	tumor necrosis factor	Mus musculus	91-94
12003792-6	2002	Nrf-1 and -2 activation by bleomycin is inhibited by the ROS quenching agent N-acetylcysteine (NAC), but not by U-0126, a MEK1/2 inhibitor that blocks bleomycin-induced MAPK activation.	Bleomycin	151-160	nuclear respiratory factor 1	Homo sapiens	0-12
12003776-2	2002	Bleomycin-induced lung injury in mice is mediated by enhanced tumor necrosis factor-alpha (TNF) expression in the lung, which determines the murine strain sensitivity to bleomycin, and murine strains are sensitive (C57BL/6) or resistant (BALB/c).	Bleomycin	170-179	tumor necrosis factor	Mus musculus	91-94
12003792-7	2002	In contrast, NF-kappaB activation by bleomycin is inhibited by U-0126, but not by NAC.	Bleomycin	37-46	nuclear factor kappa B subunit 1	Homo sapiens	13-22
12003776-4	2002	Bleomycin treatment induced activation of nuclear factor (NF)-kappaB and activator protein (AP)-1 and enhanced collagen and TNF mRNA expression in the lung of C57BL/6 but not in BALB/c mice.	Bleomycin	0-9	tumor necrosis factor	Mus musculus	124-127
12082022-10	2002	XRCC1 codon 280 polymorphism had a significant effect (P = 0.012) in predetermining whether the individual was classified as non-sensitive, sensitive or hypersensitive to bleomycin.	Bleomycin	171-180	X-ray repair cross complementing 1	Homo sapiens	0-5
12082022-11	2002	Although based on relatively few individuals, our results suggest that bleomycin sensitivity is partially explained by genetic polymorphisms affecting DNA repair (XRCC1) and in vitro metabolism of bleomycin (BLHX).	Bleomycin	71-80	X-ray repair cross complementing 1	Homo sapiens	163-168
12173380-2	2002	METHODS: All patients were treated with radical surgery followed by six cycles of combined chemotherapy: CHOP-Bleo (cyclophosphamide, doxorubicine, vincristine, prednisone, and bleomycin) or variants (epirubicin instead of doxorubicin).	Bleomycin	110-114	DNA damage inducible transcript 3	Homo sapiens	105-109
12042032-0	2002	Increase in the beta chain of hepatocyte growth factor (HGF beta) precedes c-met expression after bleomycin-induced lung injury in the rat.	Bleomycin	98-107	hepatocyte growth factor	Rattus norvegicus	30-54
12042032-0	2002	Increase in the beta chain of hepatocyte growth factor (HGF beta) precedes c-met expression after bleomycin-induced lung injury in the rat.	Bleomycin	98-107	hepatocyte growth factor	Rattus norvegicus	56-59
12042032-3	2002	In this study it was demonstrated that there was an increase in the beta chain of HGF 4 days after bleomycin administration, coinciding with the time of maximal type II AEC proliferation.	Bleomycin	99-108	hepatocyte growth factor	Rattus norvegicus	82-85
12042032-6	2002	However, 4 days after bleomycin injury, using Western blot analysis, an increase in c-met was detected in AEC protein extracts.	Bleomycin	22-31	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	84-89
12042032-8	2002	These findings suggest that HGF may regulate its own receptor on AECs and is an important mitogen for AECs 4 days after bleomycin administration.	Bleomycin	120-129	hepatocyte growth factor	Rattus norvegicus	28-31
12023853-7	2002	To examine this hypothesis, we assessed the effect of a direct thrombin inhibitor in bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	85-94	coagulation factor II	Rattus norvegicus	63-71
12024033-7	2002	The Dna2p is also distributed throughout the nucleus in cells growing in the presence of double-strand-break-inducing agents such as bleomycin.	Bleomycin	133-142	DNA replication helicase/nuclease 2	Homo sapiens	4-9
11983918-7	2002	Furthermore, matrilysin knockout mice were dramatically protected from pulmonary fibrosis in response to intratracheal bleomycin.	Bleomycin	119-128	matrix metallopeptidase 7	Mus musculus	13-23
11880297-0	2002	Role of extracellular superoxide dismutase in bleomycin-induced pulmonary fibrosis.	Bleomycin	46-55	superoxide dismutase 3, extracellular	Mus musculus	8-42
11880297-4	2002	We hypothesized that EC-SOD plays an important role in attenuating bleomycin-induced lung injury.	Bleomycin	67-76	superoxide dismutase 3, extracellular	Mus musculus	21-27
11880297-7	2002	Using mice that overexpress EC-SOD specifically in the lung, we found a 53 +/- 14% reduction in bleomycin-induced lung injury assessed histologically and a 17 +/- 6% reduction in lung collagen content 2 wk after bleomycin administration.	Bleomycin	96-105	superoxide dismutase 3, extracellular	Mus musculus	28-34
11880297-7	2002	Using mice that overexpress EC-SOD specifically in the lung, we found a 53 +/- 14% reduction in bleomycin-induced lung injury assessed histologically and a 17 +/- 6% reduction in lung collagen content 2 wk after bleomycin administration.	Bleomycin	212-221	superoxide dismutase 3, extracellular	Mus musculus	28-34
11880297-8	2002	We conclude that EC-SOD plays an important role in reducing the magnitude of lung injury from extracellular free radicals after bleomycin administration.	Bleomycin	128-137	superoxide dismutase 3, extracellular	Mus musculus	17-23
11880309-5	2002	In rats treated with 1 unit of bleomycin, serum SP-D was elevated on days 3, 7, 14, and 28 after instillation, and SP-D mRNA was increased in focal areas as detected by in situ hybridization.	Bleomycin	31-40	surfactant protein D	Rattus norvegicus	48-52
11880309-5	2002	In rats treated with 1 unit of bleomycin, serum SP-D was elevated on days 3, 7, 14, and 28 after instillation, and SP-D mRNA was increased in focal areas as detected by in situ hybridization.	Bleomycin	31-40	surfactant protein D	Rattus norvegicus	115-119
11880309-7	2002	After instillation of 2 units of bleomycin, the serum levels of SP-D were higher, and SP-D was also increased in BALF and lung homogenates.	Bleomycin	33-42	surfactant protein D	Rattus norvegicus	64-68
11880309-7	2002	After instillation of 2 units of bleomycin, the serum levels of SP-D were higher, and SP-D was also increased in BALF and lung homogenates.	Bleomycin	33-42	surfactant protein D	Rattus norvegicus	86-90
11984592-0	2002	A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis.	Bleomycin	50-59	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	18-46
11984592-5	2002	Disruption of the gene encoding cPLA(2) (Pla2g4a) attenuated IPF and inflammation induced by bleomycin administration.	Bleomycin	93-102	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	32-39
11984592-5	2002	Disruption of the gene encoding cPLA(2) (Pla2g4a) attenuated IPF and inflammation induced by bleomycin administration.	Bleomycin	93-102	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	41-48
11984592-6	2002	Bleomycin-induced overproduction of thromboxanes and leukotrienes in lung was significantly reduced in cPLA(2)-null mice.	Bleomycin	0-9	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	103-109
12509248-7	2002	The antisense Ku70 increased the chemosensitivity of the cells to some DNA-damaging agents such as bleomycin and methyl methanesulfonate, but not to cisplatin, mitomycin C, and paclitaxel.	Bleomycin	99-108	X-ray repair cross complementing 6	Homo sapiens	14-18
12023853-8	2002	Immunohistochemical studies showed that expression of thrombin and PAR-1 in lung tissue increased dramatically after intratracheal instillation of bleomycin, compared with saline-treated animals.	Bleomycin	147-156	coagulation factor II, thrombin	Homo sapiens	54-62
12023853-8	2002	Immunohistochemical studies showed that expression of thrombin and PAR-1 in lung tissue increased dramatically after intratracheal instillation of bleomycin, compared with saline-treated animals.	Bleomycin	147-156	coagulation factor II thrombin receptor	Homo sapiens	67-72
12023853-9	2002	After bleomycin instillation, there was a doubling in the amount of lung collagen after 14 days, which was preceded by elevations in alpha(1)(I) procollagen and connective tissue growth factor (CTGF) mRNA levels.	Bleomycin	6-15	cellular communication network factor 2	Homo sapiens	161-192
12023853-9	2002	After bleomycin instillation, there was a doubling in the amount of lung collagen after 14 days, which was preceded by elevations in alpha(1)(I) procollagen and connective tissue growth factor (CTGF) mRNA levels.	Bleomycin	6-15	cellular communication network factor 2	Homo sapiens	194-198
12023853-10	2002	However, when bleomycin-treated animals concurrently received a continuous infusion of a direct thrombin inhibitor at an anticoagulant dose, lung collagen accumulation in response to bleomycin was attenuated by up to 40%.	Bleomycin	14-23	coagulation factor II, thrombin	Homo sapiens	96-104
12023853-10	2002	However, when bleomycin-treated animals concurrently received a continuous infusion of a direct thrombin inhibitor at an anticoagulant dose, lung collagen accumulation in response to bleomycin was attenuated by up to 40%.	Bleomycin	183-192	coagulation factor II, thrombin	Homo sapiens	96-104
11927620-6	2002	Consistent with these in vitro findings, recombinant IL-7 decreased bleomycin-induced pulmonary fibrosis in vivo, independent of IFN-gamma.	Bleomycin	68-77	interleukin 7	Homo sapiens	53-57
11936776-5	2002	Using immunohistochemistry and in situ hybridization, 4 and 7 days after bleomycin administration the expression of TbetaR-I on AECs was reduced whereas that of TbetaR-II was unaltered.	Bleomycin	73-82	transforming growth factor, beta receptor 1	Rattus norvegicus	116-124
11936776-5	2002	Using immunohistochemistry and in situ hybridization, 4 and 7 days after bleomycin administration the expression of TbetaR-I on AECs was reduced whereas that of TbetaR-II was unaltered.	Bleomycin	73-82	transforming growth factor, beta receptor 2	Rattus norvegicus	161-170
11936776-6	2002	However, 14 and 28 days after bleomycin injury, when there is decreased proliferation and induction of differentiation of type II AECs, there was a return of TbetaR-I expression on AECs.	Bleomycin	30-39	transforming growth factor, beta receptor 1	Rattus norvegicus	158-166
11936776-7	2002	In contrast, TbetaR-I and TbetaR-II were observed on interstitial fibroblasts at all time intervals after bleomycin administration.	Bleomycin	106-115	transforming growth factor, beta receptor 1	Rattus norvegicus	13-21
11936776-7	2002	In contrast, TbetaR-I and TbetaR-II were observed on interstitial fibroblasts at all time intervals after bleomycin administration.	Bleomycin	106-115	transforming growth factor, beta receptor 2	Rattus norvegicus	26-35
11936776-8	2002	Because both TbetaR-I and TbetaR-II are required for signal transduction, the reduction of TbetaR-I levels on the alveolar epithelium may alter the sensitivity of AECs to the antiproliferative effects of TGF-beta1 present in increased quantities following bleomycin injury.	Bleomycin	256-265	transforming growth factor, beta 1	Rattus norvegicus	204-213
11936776-10	2002	Ourfindings suggest that during bleomycin-induced pulmonary fibrosis, the effects of TGF-beta1 on cells may be regulated by the expression of TbetaRs.	Bleomycin	32-41	transforming growth factor, beta 1	Rattus norvegicus	85-94
11935354-6	2002	The results of this investigation on Fe(II)- and Co(II)-bleomycin are most consistent with a six-coordinate structure with five endogenous N-donors and a solvent molecule or the carbamoyl group as the sixth ligand.	Bleomycin	56-65	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	49-55
11839532-7	2002	Treatment of adult mice with intratracheal bleomycin caused similar time-dependent decreases in lung SP-B mRNA and CAT activity.	Bleomycin	43-52	surfactant associated protein B	Mus musculus	101-105
11839532-8	2002	These findings indicate that the human SP-B promoter fragment directs tissue- and lung cell-specific transgene expression and contains cis-acting elements involved in regulated expression during development, fetal lung explant culture, and responsiveness to TGF-beta and bleomycin-induced lung injury.	Bleomycin	271-280	surfactant protein B	Homo sapiens	39-43
11839555-0	2002	Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	28-37	SMAD family member 3	Mus musculus	0-5
11839555-4	2002	Mice deficient in Smad3 demonstrated suppressed type I procollagen mRNA expression and reduced hydroxyproline content in the lungs compared with wild-type mice treated with bleomycin.	Bleomycin	173-182	SMAD family member 3	Mus musculus	18-23
11839555-5	2002	Furthermore, loss of Smad3 greatly attenuated morphological fibrotic responses to bleomycin in the mouse lungs, suggesting that Smad3 is implicated in the pathogenesis of pulmonary fibrosis.	Bleomycin	82-91	SMAD family member 3	Mus musculus	21-26
11839555-5	2002	Furthermore, loss of Smad3 greatly attenuated morphological fibrotic responses to bleomycin in the mouse lungs, suggesting that Smad3 is implicated in the pathogenesis of pulmonary fibrosis.	Bleomycin	82-91	SMAD family member 3	Mus musculus	128-133
11839555-6	2002	These results show that Smad3 contributes to bleomycin-induced lung injury and that Smad3 may serve as a novel target for potential therapeutic treatment of lung fibrosis.	Bleomycin	45-54	SMAD family member 3	Mus musculus	24-29
11926293-0	2002	Granulocyte colony-stimulating factor exacerbates the acute lung injury and pulmonary fibrosis induced by intratracheal administration of bleomycin in rats.	Bleomycin	138-147	colony stimulating factor 3	Rattus norvegicus	0-37
11784117-0	2002	IL-12p40(-/-) mice treated with intratracheal bleomycin exhibit decreased pulmonary inflammation and increased fibrosis.	Bleomycin	46-55	interleukin 12b	Mus musculus	0-8
11805012-0	2002	Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologic malignancies.	Bleomycin	0-9	transferrin	Homo sapiens	40-51
11805012-14	2002	When hemolyzed samples were excluded, bleomycin-detectable iron was found only when the transferrin saturation was &gt;80%, suggesting high specificity.	Bleomycin	38-47	transferrin	Homo sapiens	88-99
11926293-1	2002	We investigated the effects of granulocyte colony-stimulating factor (G-CSF) on lung injury induced by intratracheal administration of bleomycin (BLM, 2 mg/200 micro1) in rats.	Bleomycin	135-144	colony stimulating factor 3	Rattus norvegicus	70-75
11926293-2	2002	In experiment 1, G-CSF (10, 30 and 100 microg/kg/day, s.c.) was administered to rats treated with BLM or saline for 7 days starting immediately after BLM administration.	Bleomycin	98-101	colony stimulating factor 3	Rattus norvegicus	17-22
11926293-6	2002	In experiment 2, 100 microg/kg/day of G-CSF was administered to rats treated with BLM or saline for up to 28 days starting immediately after BLM administration.	Bleomycin	82-85	colony stimulating factor 3	Rattus norvegicus	38-43
11926293-8	2002	These findings suggest that G-CSF administration to BLM-treated rats influenced and exacerbated the BLM-induced acute lung injury, and also exacerbated pulmonary fibrosis in a dose-dependent fashion.	Bleomycin	52-55	colony stimulating factor 3	Rattus norvegicus	28-33
11926293-8	2002	These findings suggest that G-CSF administration to BLM-treated rats influenced and exacerbated the BLM-induced acute lung injury, and also exacerbated pulmonary fibrosis in a dose-dependent fashion.	Bleomycin	100-103	colony stimulating factor 3	Rattus norvegicus	28-33
12415616-0	2002	Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53.	Bleomycin	48-57	transformation related protein 53, pseudogene	Mus musculus	105-108
12555812-3	2002	It has been postulated that bleomycin hydrolase, a protease encoded by the BLH1 gene in humans, may account for tumor resistance to bleomycin.	Bleomycin	28-37	bleomycin hydrolase	Saccharomyces cerevisiae S288C	75-79
12555812-4	2002	In support of such a notion, earlier studies showed that exogenous expression of yeast Blh1 in human cells can enhance resistance to bleomycin.	Bleomycin	133-142	bleomycin hydrolase	Saccharomyces cerevisiae S288C	87-91
12555812-5	2002	Here we show that (i) yeast blh1delta mutants are not sensitive to bleomycin, (ii) bleomycin-hypersensitive yeast mutants were no more sensitive to this agent upon deletion of the BLH1/LAP3/GAL6 gene, and (iii) overproduction of Blhl in either the parent or bleomycin-hypersensitive mutants did not confer additional resistance to these strains.	Bleomycin	83-92	bleomycin hydrolase	Saccharomyces cerevisiae S288C	180-184
12555812-5	2002	Here we show that (i) yeast blh1delta mutants are not sensitive to bleomycin, (ii) bleomycin-hypersensitive yeast mutants were no more sensitive to this agent upon deletion of the BLH1/LAP3/GAL6 gene, and (iii) overproduction of Blhl in either the parent or bleomycin-hypersensitive mutants did not confer additional resistance to these strains.	Bleomycin	83-92	bleomycin hydrolase	Saccharomyces cerevisiae S288C	185-189
12555812-5	2002	Here we show that (i) yeast blh1delta mutants are not sensitive to bleomycin, (ii) bleomycin-hypersensitive yeast mutants were no more sensitive to this agent upon deletion of the BLH1/LAP3/GAL6 gene, and (iii) overproduction of Blhl in either the parent or bleomycin-hypersensitive mutants did not confer additional resistance to these strains.	Bleomycin	83-92	bleomycin hydrolase	Saccharomyces cerevisiae S288C	190-194
12555812-5	2002	Here we show that (i) yeast blh1delta mutants are not sensitive to bleomycin, (ii) bleomycin-hypersensitive yeast mutants were no more sensitive to this agent upon deletion of the BLH1/LAP3/GAL6 gene, and (iii) overproduction of Blhl in either the parent or bleomycin-hypersensitive mutants did not confer additional resistance to these strains.	Bleomycin	83-92	bleomycin hydrolase	Saccharomyces cerevisiae S288C	180-184
12555812-5	2002	Here we show that (i) yeast blh1delta mutants are not sensitive to bleomycin, (ii) bleomycin-hypersensitive yeast mutants were no more sensitive to this agent upon deletion of the BLH1/LAP3/GAL6 gene, and (iii) overproduction of Blhl in either the parent or bleomycin-hypersensitive mutants did not confer additional resistance to these strains.	Bleomycin	83-92	bleomycin hydrolase	Saccharomyces cerevisiae S288C	185-189
12555812-5	2002	Here we show that (i) yeast blh1delta mutants are not sensitive to bleomycin, (ii) bleomycin-hypersensitive yeast mutants were no more sensitive to this agent upon deletion of the BLH1/LAP3/GAL6 gene, and (iii) overproduction of Blhl in either the parent or bleomycin-hypersensitive mutants did not confer additional resistance to these strains.	Bleomycin	83-92	bleomycin hydrolase	Saccharomyces cerevisiae S288C	190-194
11781070-1	2002	V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma.	Bleomycin	78-87	actin alpha 2, smooth muscle, aorta	Mus musculus	27-52
11781070-7	2002	Immunohistochemical examination showed that alpha-SMA-reactive cells were detectable on fibroblastic cells in bleomycin-injected skin at 1 week.	Bleomycin	110-119	actin alpha 2, smooth muscle, aorta	Mus musculus	44-53
11781070-9	2002	After 3 weeks" treatment with bleomycin, the number of alpha-SMA-reactive fibroblasts showed an 11-fold increase compared with that in control PBS-treated mice.	Bleomycin	30-39	actin alpha 2, smooth muscle, aorta	Mus musculus	55-64
11781070-10	2002	alpha-SMA-positive cells were also detected in lung parenchyma after bleomycin treatment.	Bleomycin	69-78	actin alpha 2, smooth muscle, aorta	Mus musculus	0-9
11781070-11	2002	Following concomitant treatment with anti-transforming growth factor-beta (TGF-beta) antibody with bleomycin, the number of alpha-SMA-positive fibroblastic cells was significantly reduced up to 50%, along with the reduction of dermal sclerosis.	Bleomycin	99-108	transforming growth factor, beta 1	Mus musculus	75-83
11781070-11	2002	Following concomitant treatment with anti-transforming growth factor-beta (TGF-beta) antibody with bleomycin, the number of alpha-SMA-positive fibroblastic cells was significantly reduced up to 50%, along with the reduction of dermal sclerosis.	Bleomycin	99-108	actin alpha 2, smooth muscle, aorta	Mus musculus	124-133
11781070-13	2002	Results showed an increase of alpha-SMA expression in lesional skin at 3 weeks of bleomycin treatment, which was reduced following anti-TGF-beta antibody treatment.	Bleomycin	82-91	actin alpha 2, smooth muscle, aorta	Mus musculus	30-39
11781070-14	2002	These data suggest that fibroblastic cells are phenotypically altered into myofibroblasts during the fibrotic process in the experimental model of bleomycin-induced scleroderma, which was considered mediated, for the most part, by TGF-beta.	Bleomycin	147-156	transforming growth factor, beta 1	Mus musculus	231-239
11726394-0	2001	Expression of yeast apurinic/apyrimidinic endonuclease (APN1) protects lung epithelial cells from bleomycin toxicity.	Bleomycin	98-107	DNA-(apurinic or apyrimidinic site) lyase APN1	Saccharomyces cerevisiae S288C	56-60
11841596-6	2002	Findings show that BLM-induced pulmonary injury resulted in increases in bronchoalveolar lavage fluid (BALF) biomarkers including total protein, lactate dehydrogenase (LDH), glutathione-peroxidase (GSH-Px), superoxide dismutase (SOD), and catalase (CAT).	Bleomycin	19-22	glutathione peroxidase 1	Rattus norvegicus	198-204
11841596-6	2002	Findings show that BLM-induced pulmonary injury resulted in increases in bronchoalveolar lavage fluid (BALF) biomarkers including total protein, lactate dehydrogenase (LDH), glutathione-peroxidase (GSH-Px), superoxide dismutase (SOD), and catalase (CAT).	Bleomycin	19-22	catalase	Rattus norvegicus	239-247
11841596-6	2002	Findings show that BLM-induced pulmonary injury resulted in increases in bronchoalveolar lavage fluid (BALF) biomarkers including total protein, lactate dehydrogenase (LDH), glutathione-peroxidase (GSH-Px), superoxide dismutase (SOD), and catalase (CAT).	Bleomycin	19-22	catalase	Rattus norvegicus	249-252
11726394-3	2001	In this study, we used a DNA repair protein, yeast apurinic/apyrimidinic endonuclease (APN1) to reduce the toxicity of bleomycin on lung cells.	Bleomycin	119-128	DNA-(apurinic or apyrimidinic site) lyase APN1	Saccharomyces cerevisiae S288C	87-91
11726394-8	2001	The protective effect of APN1 against bleomycin was determined by single cell gel electrophoresis/Comet assay and by clonogenic survival assay following bleomycin treatment.	Bleomycin	38-47	DNA-(apurinic or apyrimidinic site) lyase APN1	Saccharomyces cerevisiae S288C	25-29
11726394-8	2001	The protective effect of APN1 against bleomycin was determined by single cell gel electrophoresis/Comet assay and by clonogenic survival assay following bleomycin treatment.	Bleomycin	153-162	DNA-(apurinic or apyrimidinic site) lyase APN1	Saccharomyces cerevisiae S288C	25-29
11726394-9	2001	The A549 population expressing APN1 showed a significant reduction of DNA damage in the presence of 20, 50, and 100 microg/ml bleomycin; similarly, the APN1-expressing A549 population also demonstrated increased survival in the presence of bleomycin compared with the vector-transduced A549 population.	Bleomycin	126-135	DNA-(apurinic or apyrimidinic site) lyase APN1	Saccharomyces cerevisiae S288C	31-35
11726394-9	2001	The A549 population expressing APN1 showed a significant reduction of DNA damage in the presence of 20, 50, and 100 microg/ml bleomycin; similarly, the APN1-expressing A549 population also demonstrated increased survival in the presence of bleomycin compared with the vector-transduced A549 population.	Bleomycin	240-249	DNA-(apurinic or apyrimidinic site) lyase APN1	Saccharomyces cerevisiae S288C	31-35
11726394-9	2001	The A549 population expressing APN1 showed a significant reduction of DNA damage in the presence of 20, 50, and 100 microg/ml bleomycin; similarly, the APN1-expressing A549 population also demonstrated increased survival in the presence of bleomycin compared with the vector-transduced A549 population.	Bleomycin	240-249	DNA-(apurinic or apyrimidinic site) lyase APN1	Saccharomyces cerevisiae S288C	152-156
11726394-11	2001	The current study suggests that the yeast DNA repair protein, APN1, can reduce bleomycin toxicity to target lung cells.	Bleomycin	79-88	DNA-(apurinic or apyrimidinic site) lyase APN1	Saccharomyces cerevisiae S288C	62-66
11705698-0	2001	Altered expression of extracellular superoxide dismutase in mouse lung after bleomycin treatment.	Bleomycin	77-86	superoxide dismutase 3, extracellular	Mus musculus	22-56
11866990-2	2001	METHODS: (1) Dynamic changes of MMP(2) expression were observed in bleomycin-induced rat pulmonary fibrosis by use of immunohistochemical technique.	Bleomycin	67-76	matrix metallopeptidase 2	Rattus norvegicus	32-38
11866990-5	2001	RESULTS: (1) On day 1-7th after receiving bleomycin, the infiltrated pulmonary macrophages and septa mesenchymal cells showed positive reaction with anti-MMP(2) and an increase in number.	Bleomycin	42-51	matrix metallopeptidase 2	Rattus norvegicus	154-160
11866990-7	2001	(2) The gene expression of MMP(2) mRNA of PFbs were enhanced after bleomycin treatment from the Day 1 and decreased by Day 28.	Bleomycin	67-76	matrix metallopeptidase 2	Rattus norvegicus	27-33
11713104-0	2001	Bleomycin upregulates gene expression of angiotensin-converting enzyme via mitogen-activated protein kinase and early growth response 1 transcription factor.	Bleomycin	0-9	angiotensin I converting enzyme	Homo sapiens	41-70
11713104-4	2001	In the present study, we demonstrate that bleomycin, a chemotherapeutic agent which induces pulmonary fibrosis in animals and humans, increases gene expression of ACE.	Bleomycin	42-51	angiotensin I converting enzyme	Homo sapiens	163-166
11713104-5	2001	Treatment of primary bovine pulmonary artery endothelial cells with 0.1 to 1.0 microg/ml bleomycin increased ACE enzymatic activity and ACE mRNA, as monitored by hippuryl-L-histidyl-L-leucine assay and competitive quantitative reverse transcriptase polymerase chain reaction (RT-PCR), respectively.	Bleomycin	89-98	angiotensin I converting enzyme	Bos taurus	109-112
11713104-5	2001	Treatment of primary bovine pulmonary artery endothelial cells with 0.1 to 1.0 microg/ml bleomycin increased ACE enzymatic activity and ACE mRNA, as monitored by hippuryl-L-histidyl-L-leucine assay and competitive quantitative reverse transcriptase polymerase chain reaction (RT-PCR), respectively.	Bleomycin	89-98	angiotensin I converting enzyme	Bos taurus	136-139
11713104-6	2001	Luciferase reporter constructs showed that upregulation of ACE transcription by bleomycin is mediated through element(s) in the 97-bp ACE promoter.	Bleomycin	80-89	angiotensin I converting enzyme	Homo sapiens	59-62
11713104-6	2001	Luciferase reporter constructs showed that upregulation of ACE transcription by bleomycin is mediated through element(s) in the 97-bp ACE promoter.	Bleomycin	80-89	angiotensin I converting enzyme	Homo sapiens	134-137
11713104-7	2001	Bleomycin activated p42/p44 mitogen-activated protein kinase (MAPK) and induced nuclear translocation and activation of the early growth response (Egr)-1 transcription factor, a factor previously shown to positively regulate ACE expression.	Bleomycin	0-9	cyclin dependent kinase 20	Homo sapiens	20-23
11713104-7	2001	Bleomycin activated p42/p44 mitogen-activated protein kinase (MAPK) and induced nuclear translocation and activation of the early growth response (Egr)-1 transcription factor, a factor previously shown to positively regulate ACE expression.	Bleomycin	0-9	angiotensin I converting enzyme	Homo sapiens	225-228
11713104-8	2001	The MAPK kinase1/2 (MEK1/2) inhibitor U0126 blocked MAPK and Egr-1 activation by bleomycin, suggesting that Egr-1 activation is MAPK dependent.	Bleomycin	81-90	mitogen-activated protein kinase kinase 1	Homo sapiens	20-26
11713104-8	2001	The MAPK kinase1/2 (MEK1/2) inhibitor U0126 blocked MAPK and Egr-1 activation by bleomycin, suggesting that Egr-1 activation is MAPK dependent.	Bleomycin	81-90	early growth response 1	Homo sapiens	61-66
11713104-8	2001	The MAPK kinase1/2 (MEK1/2) inhibitor U0126 blocked MAPK and Egr-1 activation by bleomycin, suggesting that Egr-1 activation is MAPK dependent.	Bleomycin	81-90	early growth response 1	Homo sapiens	108-113
11713104-9	2001	These data provide the first evidence that bleomycin activates ACE gene expression through the MAPK pathway and Egr-1.	Bleomycin	43-52	angiotensin I converting enzyme	Homo sapiens	63-66
11713104-9	2001	These data provide the first evidence that bleomycin activates ACE gene expression through the MAPK pathway and Egr-1.	Bleomycin	43-52	early growth response 1	Homo sapiens	112-117
11705698-7	2001	Notably, at 7 d post-treatment, the truncated form of EC-SOD was found in the bronchoalveolar lavage fluid of bleomycin-treated mice, suggesting that EC-SOD is being removed from the extracellular matrix through proteolysis.	Bleomycin	110-119	superoxide dismutase 3, extracellular	Mus musculus	54-60
11705698-7	2001	Notably, at 7 d post-treatment, the truncated form of EC-SOD was found in the bronchoalveolar lavage fluid of bleomycin-treated mice, suggesting that EC-SOD is being removed from the extracellular matrix through proteolysis.	Bleomycin	110-119	superoxide dismutase 3, extracellular	Mus musculus	150-156
11585902-4	2001	Deletion of TPP1 in an apn1 apn2 mutant background dramatically increased the sensitivity of the double mutant to DNA damage caused by H2O2 and bleomycin but not to damage caused by methyl methanesulfonate.	Bleomycin	144-153	polynucleotide 3'-phosphatase	Saccharomyces cerevisiae S288C	12-16
11842813-1	2001	Mutational alteration of the BLM3 gene in Saccharomyces cerevisiae confers hypersensitivities to lethal effects of ionizing radiation, anticancer bleomycins and structurally-related phleomycins.	Bleomycin	146-156	mRNA-binding ubiquitin-specific protease UBP3	Saccharomyces cerevisiae S288C	29-33
11585902-4	2001	Deletion of TPP1 in an apn1 apn2 mutant background dramatically increased the sensitivity of the double mutant to DNA damage caused by H2O2 and bleomycin but not to damage caused by methyl methanesulfonate.	Bleomycin	144-153	DNA-(apurinic or apyrimidinic site) lyase APN1	Saccharomyces cerevisiae S288C	23-27
11604067-3	2001	We report for the first time that ionizing radiation and bleomycin, a radiomimetic drug, which produce single- and double-strand breaks, increased expression of KIN in human cells established from tumors, including MeWo melanoma, MCF7 breast adenocarcinoma, and ATM+ GM3657 lymphoblast cells.	Bleomycin	57-66	Kin17 DNA and RNA binding protein	Homo sapiens	161-164
11604067-3	2001	We report for the first time that ionizing radiation and bleomycin, a radiomimetic drug, which produce single- and double-strand breaks, increased expression of KIN in human cells established from tumors, including MeWo melanoma, MCF7 breast adenocarcinoma, and ATM+ GM3657 lymphoblast cells.	Bleomycin	57-66	ATM serine/threonine kinase	Homo sapiens	262-265
11583966-0	2001	Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis.	Bleomycin	115-124	coagulation factor II	Rattus norvegicus	7-15
11591761-5	2001	We demonstrate that CCR2(-/-) mice are protected from fibrosis in both the FITC and bleomycin pulmonary fibrosis models.	Bleomycin	84-93	chemokine (C-C motif) receptor 2	Mus musculus	20-24
11593023-3	2001	The LIG4(-/-) cells showed a marked sensitivity to X-rays, bleomycin, and VP-16 and were more x-ray-sensitive in G(1) than late S or G(2)/M, suggesting a critical role of Lig4 in DSB repair by NHEJ.	Bleomycin	59-68	ligase IV, DNA, ATP-dependent	Mus musculus	4-8
11583966-0	2001	Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis.	Bleomycin	115-124	cellular communication network factor 2	Rattus norvegicus	68-99
11583966-5	2001	Thrombin levels in bronchoalveolar lavage fluid and expression of thrombin and protease-activated receptor-1 in lung tissue were increased after intratracheal instillation of bleomycin.	Bleomycin	175-184	coagulation factor II	Rattus norvegicus	0-8
11583966-5	2001	Thrombin levels in bronchoalveolar lavage fluid and expression of thrombin and protease-activated receptor-1 in lung tissue were increased after intratracheal instillation of bleomycin.	Bleomycin	175-184	coagulation factor II	Rattus norvegicus	66-74
11583966-5	2001	Thrombin levels in bronchoalveolar lavage fluid and expression of thrombin and protease-activated receptor-1 in lung tissue were increased after intratracheal instillation of bleomycin.	Bleomycin	175-184	coagulation factor II (thrombin) receptor	Rattus norvegicus	79-108
11583966-6	2001	The characteristic doubling in lung collagen in bleomycin-treated animals (38.4 +/- 2.0 mg versus 17.1 +/- 1.4 mg, P &lt; 0.01) was preceded by significant elevations in alpha1(I) procollagen and CTGF mRNA levels (3.0 +/- 0.4-fold and 6.3 +/- 0.4-fold respectively, (P &lt; 0.01), and total inflammatory cell number.	Bleomycin	48-57	cellular communication network factor 2	Rattus norvegicus	196-200
11583966-8	2001	This is the first report showing that direct thrombin inhibition abrogates lung collagen accumulation in bleomycin-induced pulmonary fibrosis.	Bleomycin	105-114	coagulation factor II	Rattus norvegicus	45-53
11555678-0	2001	Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits.	Bleomycin	55-64	72 kDa type IV collagenase	Oryctolagus cuniculus	8-13
11554846-8	2001	After treatment with bleomycin, non-S-phase cells also displayed heterogeneous nuclear foci containing tightly bound proliferating cell nuclear antigen (PCNA), suggesting an ongoing process of unscheduled DNA synthesis.	Bleomycin	21-30	proliferating cell nuclear antigen	Homo sapiens	117-151
11554846-8	2001	After treatment with bleomycin, non-S-phase cells also displayed heterogeneous nuclear foci containing tightly bound proliferating cell nuclear antigen (PCNA), suggesting an ongoing process of unscheduled DNA synthesis.	Bleomycin	21-30	proliferating cell nuclear antigen	Homo sapiens	153-157
11770421-0	2001	[The research of pancadherin and beta-catenin expression in pulmonary tissue of mice with bleomycin-induced pulmonary fibrosis].	Bleomycin	90-99	catenin (cadherin associated protein), beta 1	Mus musculus	33-45
11770421-1	2001	OBJECTIVE: To investigate the changes of pancadherin(Pan-cd) and beta-catenin(beta-cat) expression in pulmonary tissue of mice with bleomycin (BLM)-induced pulmonary injury and explore the relation between the Pan-cd/beta-cat expression and pulmonary fibrosis.	Bleomycin	132-141	catenin (cadherin associated protein), beta 1	Mus musculus	65-77
11770421-1	2001	OBJECTIVE: To investigate the changes of pancadherin(Pan-cd) and beta-catenin(beta-cat) expression in pulmonary tissue of mice with bleomycin (BLM)-induced pulmonary injury and explore the relation between the Pan-cd/beta-cat expression and pulmonary fibrosis.	Bleomycin	143-146	catenin (cadherin associated protein), beta 1	Mus musculus	65-77
11454863-5	2001	The effect of S100B is reflected in vivo by a reduced accumulation of p53, p21, and MDM2 protein levels in co-transfection assays and in response to bleomycin.	Bleomycin	149-158	S100 calcium binding protein B	Homo sapiens	14-19
11504697-0	2001	Respiratory distress after intratracheal bleomycin: selective deficiency of surfactant proteins B and C.	Bleomycin	41-50	surfactant protein B	Rattus norvegicus	76-103
11504697-9	2001	We conclude that respiratory distress after bleomycin in rats results from surfactant dysfunction in part secondary to selective downregulation of SP-B and SP-C.	Bleomycin	44-53	surfactant protein B	Rattus norvegicus	147-151
11504697-9	2001	We conclude that respiratory distress after bleomycin in rats results from surfactant dysfunction in part secondary to selective downregulation of SP-B and SP-C.	Bleomycin	44-53	surfactant protein C	Rattus norvegicus	156-160
11595717-7	2001	In clonogenic assays using Rif-1 cells, MGd enhanced the activity of Bleo approximately 1000-fold.	Bleomycin	69-73	replication timing regulatory factor 1	Mus musculus	27-32
11555678-6	2001	The total MMP-2 level estimated by gelatin zymography increased significantly at 3, 7, and 14 days after bleomycin administration, compared with controls.	Bleomycin	105-114	72 kDa type IV collagenase	Oryctolagus cuniculus	10-15
11555678-11	2001	The ratio of activated MMP-2 to total MMP-2 estimated by gelatin zymography increased significantly at 3, 7, 14, and 28 days after bleomycin treatment.	Bleomycin	131-140	72 kDa type IV collagenase	Oryctolagus cuniculus	23-28
11555678-11	2001	The ratio of activated MMP-2 to total MMP-2 estimated by gelatin zymography increased significantly at 3, 7, 14, and 28 days after bleomycin treatment.	Bleomycin	131-140	72 kDa type IV collagenase	Oryctolagus cuniculus	38-43
11555678-13	2001	An increased expression of MT1-MMP protein was observed by Western blot following administration of bleomycin.	Bleomycin	100-109	matrix metalloproteinase-14	Oryctolagus cuniculus	27-34
11555678-15	2001	These results suggest that type II alveolar epithelial cells express MT1-MMP and activate MMP-2 on their cell surfaces, which may lead to the elongation and migration of alveolar epithelial cells in the repair process of bleomycin-induced pulmonary fibrosis.	Bleomycin	221-230	matrix metalloproteinase-14	Oryctolagus cuniculus	69-76
11555678-15	2001	These results suggest that type II alveolar epithelial cells express MT1-MMP and activate MMP-2 on their cell surfaces, which may lead to the elongation and migration of alveolar epithelial cells in the repair process of bleomycin-induced pulmonary fibrosis.	Bleomycin	221-230	72 kDa type IV collagenase	Oryctolagus cuniculus	90-95
11758165-6	2001	RESULTS: (1) The MMP-2 gene expression of fibroblasts increased 2.05 times(t = 10.667, P &lt; 0.01) higher than that of control in 24 hours after bleomycin instillation and remained at the high level until the 28th day after exposure.	Bleomycin	146-155	matrix metallopeptidase 2	Rattus norvegicus	17-22
11489978-0	2001	Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice.	Bleomycin	14-23	CD28 antigen	Mus musculus	49-53
11526498-4	2001	Here, we demonstrate that reintroduction of ATM into AT cells restores the activation of p53 by the radio-mimetic agent bleomycin.	Bleomycin	120-129	ATM serine/threonine kinase	Homo sapiens	44-47
11526498-4	2001	Here, we demonstrate that reintroduction of ATM into AT cells restores the activation of p53 by the radio-mimetic agent bleomycin.	Bleomycin	120-129	tumor protein p53	Homo sapiens	89-92
11489978-4	2001	In this study, we determined whether costimulation via CD28 on T cells was crucial for the development of lung fibrosis by intratracheally administering bleomycin into CD28-deficient mice.	Bleomycin	153-162	CD28 antigen	Mus musculus	55-59
11489978-5	2001	Compared with wild-type mice, the CD28-deficient mice showed markedly impaired lung fibrosis after injection with low doses of bleomycin, as judged by histological changes and hydroxyproline content in the lungs.	Bleomycin	127-136	CD28 antigen	Mus musculus	34-38
11489978-6	2001	In addition, bleomycin-induced T cell infiltration into the airways and production of several cytokines and chemokines including IL-5 were also impaired in the CD28-deficient mice.	Bleomycin	13-22	interleukin 5	Mus musculus	129-133
11489978-6	2001	In addition, bleomycin-induced T cell infiltration into the airways and production of several cytokines and chemokines including IL-5 were also impaired in the CD28-deficient mice.	Bleomycin	13-22	CD28 antigen	Mus musculus	160-164
11489978-7	2001	Furthermore, adoptive transfer of CD28-positive T cells from wild-type mice recovered the impaired bleomycin-induced lung fibrosis in CD28-deficient mice.	Bleomycin	99-108	CD28 antigen	Mus musculus	34-38
11489978-7	2001	Furthermore, adoptive transfer of CD28-positive T cells from wild-type mice recovered the impaired bleomycin-induced lung fibrosis in CD28-deficient mice.	Bleomycin	99-108	CD28 antigen	Mus musculus	134-138
11451896-0	2001	Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule-1 messenger RNA induction preventing neutrophil-induced lung injury and fibrosis in bleomycin-challenged mice.	Bleomycin	158-167	vascular cell adhesion molecule 1	Mus musculus	42-75
11554783-0	2001	Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	56-65	interleukin 4	Mus musculus	5-18
11554783-2	2001	To investigate the potential role of this cytokine, lung IL-4 expression was examined in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	107-116	interleukin 4	Mus musculus	57-61
11554783-6	2001	Both in-situ hybridization and immunohistochemistry showed low or undetectable IL-4 expression in control lungs and in injured lungs before day 3 after bleomycin injection.	Bleomycin	152-161	interleukin 4	Mus musculus	79-83
11404251-7	2001	These findings support the notion that IL-12 attenuates bleomycin-induced pulmonary fibrosis via modulation of IFN-gamma production.	Bleomycin	56-65	interferon gamma	Mus musculus	111-120
11451903-0	2001	Epimorphin in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	14-23	syntaxin 2	Mus musculus	0-10
11451907-0	2001	Evidence that neutrophil elastase-deficient mice are resistant to bleomycin-induced fibrosis.	Bleomycin	66-75	elastase, neutrophil expressed	Mus musculus	14-33
11438635-1	2001	UNLABELLED: Previous study of the bleomycin-induced lung injury model suggested that (111)In-labeled antirat intercellular adhesion molecule-1 (aICAM-1) might be a useful acute respiratory distress syndrome (ARDS) diagnostic agent.	Bleomycin	34-43	intercellular adhesion molecule 1	Rattus norvegicus	109-142
11406125-3	2001	The protein level of phospho-JNK increased in p53 wild-type mouse cerebellar granule neurons after exposure to bleomycin.	Bleomycin	111-120	mitogen-activated protein kinase 8	Mus musculus	29-32
11406125-3	2001	The protein level of phospho-JNK increased in p53 wild-type mouse cerebellar granule neurons after exposure to bleomycin.	Bleomycin	111-120	transformation related protein 53, pseudogene	Mus musculus	46-49
11406125-5	2001	Caspase-3-like protease was activated and poly(ADP-ribose) polymerase (PARP) was cleaved in the bleomycin-induced apoptosis.	Bleomycin	96-105	poly (ADP-ribose) polymerase family, member 1	Mus musculus	42-69
11406125-5	2001	Caspase-3-like protease was activated and poly(ADP-ribose) polymerase (PARP) was cleaved in the bleomycin-induced apoptosis.	Bleomycin	96-105	poly (ADP-ribose) polymerase family, member 1	Mus musculus	71-75
11350787-3	2001	In response to bleomycin-induced lung injury, Cx46 was upregulated by alveolar epithelial cells, whereas Cx32 and Cx43 expression were largely unchanged.	Bleomycin	15-24	gap junction protein alpha 3	Homo sapiens	46-50
11350791-1	2001	We previously demonstrated essential roles of the Fas-Fas ligand (FasL) pathway in bleomycin-induced pneumopathy in mice.	Bleomycin	83-92	Fas ligand (TNF superfamily, member 6)	Mus musculus	50-64
11350791-1	2001	We previously demonstrated essential roles of the Fas-Fas ligand (FasL) pathway in bleomycin-induced pneumopathy in mice.	Bleomycin	83-92	Fas ligand (TNF superfamily, member 6)	Mus musculus	66-70
11350791-5	2001	The results of RT-PCR showed that IL-12p40, IL-12 receptor (R) beta2, interferon-gamma, tumor necrosis factor-alpha and FasL mRNAs were upregulated after bleomycin instillation.	Bleomycin	154-163	interleukin 12b	Mus musculus	34-42
11350791-5	2001	The results of RT-PCR showed that IL-12p40, IL-12 receptor (R) beta2, interferon-gamma, tumor necrosis factor-alpha and FasL mRNAs were upregulated after bleomycin instillation.	Bleomycin	154-163	interferon gamma	Mus musculus	70-115
11350791-5	2001	The results of RT-PCR showed that IL-12p40, IL-12 receptor (R) beta2, interferon-gamma, tumor necrosis factor-alpha and FasL mRNAs were upregulated after bleomycin instillation.	Bleomycin	154-163	Fas ligand (TNF superfamily, member 6)	Mus musculus	120-124
11350791-7	2001	The results of enzyme-linked immunosorbent assay showed that the levels of IL-12p40, but not of IL-12p70, were increased in lung tissue after bleomycin instillation.	Bleomycin	142-151	interleukin 12b	Mus musculus	75-83
11465510-3	2001	In order to determine if the genotype of the p53 donor or the genotype of the sp donor determined the binding efficiency, p53 expression was induced by retinoic acid and sp synthesis by bleomycin.	Bleomycin	186-195	tumor protein p53	Homo sapiens	45-48
11401891-0	2001	Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse.	Bleomycin	61-70	protein C	Mus musculus	42-51
11401891-1	2001	It is well recognized that activation of the coagulation system plays an important role in bleomycin (BLM)-induced lung injury and fibrosis.	Bleomycin	91-100	Bloom syndrome, RecQ like helicase	Mus musculus	102-105
11465510-3	2001	In order to determine if the genotype of the p53 donor or the genotype of the sp donor determined the binding efficiency, p53 expression was induced by retinoic acid and sp synthesis by bleomycin.	Bleomycin	186-195	tumor protein p53	Homo sapiens	122-125
11413161-3	2001	Pharmacologic inhibition of TGF-beta also protected wild-type mice from pulmonary edema induced by bleomycin or Escherichia coli endotoxin.	Bleomycin	99-108	transforming growth factor, beta 1	Mus musculus	28-36
11491168-2	2001	Previous studies have shown that both CTGF messenger ribonuclear acid (mRNA) and protein are expressed in renal fibrosis and bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	125-134	cellular communication network factor 2	Mus musculus	38-42
11484935-2	2001	We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53.	Bleomycin	62-71	BCL2 apoptosis regulator	Homo sapiens	242-247
11484935-2	2001	We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53.	Bleomycin	62-71	tumor protein p53	Homo sapiens	287-290
11352724-0	2001	Solution structure of Co(III)-bleomycin-OOH bound to a phosphoglycolate lesion containing oligonucleotide: implications for bleomycin-induced double-strand DNA cleavage.	Bleomycin	30-39	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	22-29
11353797-4	2001	We demonstrate that HepG2 cells uniformly induce both tTG mRNA and enzyme activity upon treatment with cisplatin, doxorubicin, and bleomycin, chemotherapeutic agents with different modes of action.	Bleomycin	131-140	transglutaminase 2	Homo sapiens	54-57
11352724-0	2001	Solution structure of Co(III)-bleomycin-OOH bound to a phosphoglycolate lesion containing oligonucleotide: implications for bleomycin-induced double-strand DNA cleavage.	Bleomycin	124-133	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	22-29
11328587-0	2001	Use of bleomycin- and heat shock-induced calreticulin promoter for construction of a mammalian expression vector.	Bleomycin	7-16	calreticulin	Homo sapiens	41-53
11350823-0	2001	Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin.	Bleomycin	101-110	interferon gamma	Mus musculus	49-65
11350823-1	2001	Because mouse strains susceptible to bleomycin, such as C57BL/ 6J, tend to produce T helper type 1 (Th1) cytokines in response to immune activation, we hypothesized that the inflammatory response to bleomycin is mediated, in part, by local production of the Th1 cytokine interferon-gamma (IFN-gamma).	Bleomycin	199-208	interferon gamma	Mus musculus	271-287
11350823-1	2001	Because mouse strains susceptible to bleomycin, such as C57BL/ 6J, tend to produce T helper type 1 (Th1) cytokines in response to immune activation, we hypothesized that the inflammatory response to bleomycin is mediated, in part, by local production of the Th1 cytokine interferon-gamma (IFN-gamma).	Bleomycin	199-208	interferon gamma	Mus musculus	289-298
11350823-2	2001	Consistent with this hypothesis, fibrosis-prone C57BL/6J and A/J mice demonstrated significantly elevated expression of IFN-gamma protein (by enzyme-linked immunosorbent assay) in bronchoalveolar lavage fluid at 24 h, and subsequently increased lung inflammation, weight loss, and mortality 10 d after intratracheal bleomycin administration compared with fibrosis-resistant BALB/c mice or saline control mice.	Bleomycin	316-325	interferon gamma	Mus musculus	120-129
11350823-4	2001	IFN-gamma(-/-) mice demonstrated significantly lower parenchymal inflammation, weight loss, and mortality 10 d after 5 U/kg intratracheal bleomycin administration compared with control mice.	Bleomycin	138-147	interferon gamma	Mus musculus	0-9
11350823-5	2001	At 3 wk after 1.5 U/kg bleomycin exposure, single lung collagen determined by hydroxyproline assay was significantly lower in IFN-gamma(-/-) mice compared with wild-type C57BL/6J mice.	Bleomycin	23-32	interferon gamma	Mus musculus	126-135
11350823-6	2001	Together, these results suggest that IFN-gamma mediates, in part, bleomycin-induced pulmonary inflammation and fibrosis.	Bleomycin	66-75	interferon gamma	Mus musculus	37-46
11350830-0	2001	Selective induction of tissue inhibitor of metalloproteinase-1 in bleomycin-induced pulmonary fibrosis.	Bleomycin	66-75	tissue inhibitor of metalloproteinase 1	Mus musculus	23-62
11350830-2	2001	We demonstrate that TIMP-1 messenger RNA (mRNA) and protein expression are selectively and markedly increased in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	131-140	tissue inhibitor of metalloproteinase 1	Mus musculus	20-26
11350830-3	2001	Northern analysis showed that lung steady-state TIMP-1 mRNA levels increased 14-fold after bleomycin administration compared with control mice.	Bleomycin	91-100	tissue inhibitor of metalloproteinase 1	Mus musculus	48-54
11350830-6	2001	Metalloproteinase inhibitory activity of relative molecular mass of ~ 21 to 28 kD, corresponding to the molecular weights for TIMP-1 and TIMP-2, was identified in lung extracts of bleomycin-injured mice by reverse zymography.	Bleomycin	180-189	tissue inhibitor of metalloproteinase 1	Mus musculus	126-132
11350830-6	2001	Metalloproteinase inhibitory activity of relative molecular mass of ~ 21 to 28 kD, corresponding to the molecular weights for TIMP-1 and TIMP-2, was identified in lung extracts of bleomycin-injured mice by reverse zymography.	Bleomycin	180-189	tissue inhibitor of metalloproteinase 2	Mus musculus	137-143
11350830-7	2001	Western analysis demonstrated that TIMP-1 protein levels in bronchoalveolar lavage fluid (BALF) of bleomycin-treated mice increased 220- and 151-fold at Days 4 and 28, respectively, compared with control mice.	Bleomycin	99-108	tissue inhibitor of metalloproteinase 1	Mus musculus	35-41
11350830-9	2001	These results demonstrate that TIMP-1 gene expression is selectively increased, and that the expression of TIMP-1 and TIMP-2 is differentially regulated in bleomycin-induced pulmonary fibrosis.	Bleomycin	156-165	tissue inhibitor of metalloproteinase 1	Mus musculus	107-113
11350830-9	2001	These results demonstrate that TIMP-1 gene expression is selectively increased, and that the expression of TIMP-1 and TIMP-2 is differentially regulated in bleomycin-induced pulmonary fibrosis.	Bleomycin	156-165	tissue inhibitor of metalloproteinase 2	Mus musculus	118-124
11350830-10	2001	The profound and durable increase in TIMP-1 and TIMP-2 proteins suggests an important regulatory role for these antiproteases in the inflammatory and fibrotic responses to bleomycin-induced lung injury.	Bleomycin	172-181	tissue inhibitor of metalloproteinase 1	Mus musculus	37-43
11350830-10	2001	The profound and durable increase in TIMP-1 and TIMP-2 proteins suggests an important regulatory role for these antiproteases in the inflammatory and fibrotic responses to bleomycin-induced lung injury.	Bleomycin	172-181	tissue inhibitor of metalloproteinase 2	Mus musculus	48-54
11380620-5	2001	RESULTS: Using immunocytochemistry, we found that WRNp forms distinct nuclear foci in response to DNA damaging agents, including camptothecin (CPT), etoposide, 4-nitroquinolin-N-oxide and bleomycin.	Bleomycin	188-197	WRN RecQ like helicase	Homo sapiens	50-54
11378548-1	2001	UNLABELLED: The purpose of this study was to determine the effect of granulocyte colony-stimulating factor (filgrastim, G-CSF) for maintenance of chemotherapy dose-intensity in patients with stage I or II Hodgkin"s lymphoma treated with six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).	Bleomycin	264-273	colony stimulating factor 3	Homo sapiens	69-106
11345135-4	2001	Flow cytometric analysis demonstrated that all pancreatic cancer cell lines studied responded with cell surface CD95R and CD95L upregulation to bleomycin treatment, and PANC1 (mt p53) cells demonstrated a dose-dependent response to interferon gamma and bleomycin treatment with CD95R and CD95L up-regulation.	Bleomycin	144-153	Fas ligand	Homo sapiens	122-127
11345135-4	2001	Flow cytometric analysis demonstrated that all pancreatic cancer cell lines studied responded with cell surface CD95R and CD95L upregulation to bleomycin treatment, and PANC1 (mt p53) cells demonstrated a dose-dependent response to interferon gamma and bleomycin treatment with CD95R and CD95L up-regulation.	Bleomycin	144-153	tumor protein p53	Homo sapiens	179-182
11345135-4	2001	Flow cytometric analysis demonstrated that all pancreatic cancer cell lines studied responded with cell surface CD95R and CD95L upregulation to bleomycin treatment, and PANC1 (mt p53) cells demonstrated a dose-dependent response to interferon gamma and bleomycin treatment with CD95R and CD95L up-regulation.	Bleomycin	144-153	Fas ligand	Homo sapiens	288-293
11345135-5	2001	However, only bleomycin sensitized PANC1 cells to CD95-mediated apoptosis.	Bleomycin	14-23	Fas cell surface death receptor	Homo sapiens	50-54
11290559-0	2001	Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	164-173	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
11290559-9	2001	Furthermore, mice deficient in COX-2 exhibit an enhanced response to bleomycin.	Bleomycin	69-78	cytochrome c oxidase II, mitochondrial	Mus musculus	31-36
11133995-8	2001	Revertant clones (Rev1-3) derived from SX10 showed a restored x-ray resistance; Rev1 reverted to the original nucleotide G at position 1413, whereas Rev2 and Rev3 to C. Transfection of a mouse DNA ligase IV cDNA vector into SX10 restored the resistance to both x-rays and bleomycin.	Bleomycin	272-281	REV1, DNA directed polymerase	Mus musculus	18-24
11133995-8	2001	Revertant clones (Rev1-3) derived from SX10 showed a restored x-ray resistance; Rev1 reverted to the original nucleotide G at position 1413, whereas Rev2 and Rev3 to C. Transfection of a mouse DNA ligase IV cDNA vector into SX10 restored the resistance to both x-rays and bleomycin.	Bleomycin	272-281	REV1, DNA directed polymerase	Mus musculus	18-22
11133995-8	2001	Revertant clones (Rev1-3) derived from SX10 showed a restored x-ray resistance; Rev1 reverted to the original nucleotide G at position 1413, whereas Rev2 and Rev3 to C. Transfection of a mouse DNA ligase IV cDNA vector into SX10 restored the resistance to both x-rays and bleomycin.	Bleomycin	272-281	ligase IV, DNA, ATP-dependent	Mus musculus	193-206
11239001-7	2001	We also analyzed the PCNA complex induced by a radiomimetic agent, Bleomycin (BLM), which produces predominantly single- and double-strand DNA breaks.	Bleomycin	67-76	proliferating cell nuclear antigen	Homo sapiens	21-25
11276015-1	2001	Bleomycin-induced pulmonary fibrosis is known to be associated with the increased activity of two gelatinases, matrix metalloproteinase (MMP)-2 and MMP-9, in bronchoalveolar lavage (BAL).	Bleomycin	0-9	matrix metallopeptidase 2	Mus musculus	111-143
11276015-1	2001	Bleomycin-induced pulmonary fibrosis is known to be associated with the increased activity of two gelatinases, matrix metalloproteinase (MMP)-2 and MMP-9, in bronchoalveolar lavage (BAL).	Bleomycin	0-9	matrix metallopeptidase 9	Mus musculus	148-153
11239001-7	2001	We also analyzed the PCNA complex induced by a radiomimetic agent, Bleomycin (BLM), which produces predominantly single- and double-strand DNA breaks.	Bleomycin	78-81	proliferating cell nuclear antigen	Homo sapiens	21-25
11292065-0	2001	Expression of thioredoxin in bleomycin-injured airway epithelium: possible role of protection against bleomycin induced epithelial injury.	Bleomycin	29-38	thioredoxin 1	Mus musculus	14-25
11292065-0	2001	Expression of thioredoxin in bleomycin-injured airway epithelium: possible role of protection against bleomycin induced epithelial injury.	Bleomycin	102-111	thioredoxin 1	Mus musculus	14-25
11292065-7	2001	In the lungs of BLM-treated mice, the expression of TRX was strongly induced in bronchial epithelial cells.	Bleomycin	16-19	thioredoxin 1	Mus musculus	52-55
11313858-5	2001	In addition to characteristics of BLM(-/-) cells reported previously by the other group, they are hypersensitive to genotoxic agents such as etoposide, bleomycin and 4-nitroquinoline-1-oxide and irradiation with the short wave length of UV (UVC) light, whereas they exhibit normal sensitivity to X-ray irradiation and hydroxyurea.	Bleomycin	152-161	BLM RecQ like helicase	Homo sapiens	34-37
11254537-0	2001	Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin.	Bleomycin	87-96	decorin	Mus musculus	34-41
11238047-6	2001	Additionally, triptolide blocked bleomycin-induced increase in TGF-beta mRNA in cultured normal human lung fibroblasts.	Bleomycin	33-42	transforming growth factor beta 1	Homo sapiens	63-71
11254537-6	2001	The ability of vector-derived decorin to inhibit TGF-beta was examined in a bioassay and its effect on bleomycin-induced pulmonary fibrosis was determined by histomorphology and lung hydroxyproline.	Bleomycin	103-112	decorin	Mus musculus	30-37
11254537-9	2001	These results suggest that a single administration of AdDec was able to generate a local pulmonary environment that effectively blocked the fibrogenic response to bleomycin by inhibition of TGF-beta.	Bleomycin	163-172	transforming growth factor, beta 1	Mus musculus	190-198
11245625-0	2001	Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	43-52	secreted phosphoprotein 1	Mus musculus	8-19
11280790-10	2001	NT2/D1 cells transduced with Ape1/ref-1 exhibited 2-fold higher AP endonuclease activity in the oligonucleotide cleavage assay, and this was reflected in a 2-3-fold increase in protection against bleomycin.	Bleomycin	196-205	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	29-33
11280790-0	2001	Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation.	Bleomycin	107-116	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	22-26
11280790-10	2001	NT2/D1 cells transduced with Ape1/ref-1 exhibited 2-fold higher AP endonuclease activity in the oligonucleotide cleavage assay, and this was reflected in a 2-3-fold increase in protection against bleomycin.	Bleomycin	196-205	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	34-39
11280790-12	2001	We conclude that: (a) Ape1/ref-1 is expressed at relatively high levels in some GCTs; (b) elevated expression of Ape1/ref-1 in testicular cancer cell lines results in resistance to certain therapeutic agents; and (c) Ape1/ref-1 expression in GCT cell lines determined by immunohistochemistry and repair activity assays parallels the level of protection from bleomycin.	Bleomycin	358-367	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	22-26
11280790-12	2001	We conclude that: (a) Ape1/ref-1 is expressed at relatively high levels in some GCTs; (b) elevated expression of Ape1/ref-1 in testicular cancer cell lines results in resistance to certain therapeutic agents; and (c) Ape1/ref-1 expression in GCT cell lines determined by immunohistochemistry and repair activity assays parallels the level of protection from bleomycin.	Bleomycin	358-367	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	27-32
11280790-12	2001	We conclude that: (a) Ape1/ref-1 is expressed at relatively high levels in some GCTs; (b) elevated expression of Ape1/ref-1 in testicular cancer cell lines results in resistance to certain therapeutic agents; and (c) Ape1/ref-1 expression in GCT cell lines determined by immunohistochemistry and repair activity assays parallels the level of protection from bleomycin.	Bleomycin	358-367	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	113-117
11280790-12	2001	We conclude that: (a) Ape1/ref-1 is expressed at relatively high levels in some GCTs; (b) elevated expression of Ape1/ref-1 in testicular cancer cell lines results in resistance to certain therapeutic agents; and (c) Ape1/ref-1 expression in GCT cell lines determined by immunohistochemistry and repair activity assays parallels the level of protection from bleomycin.	Bleomycin	358-367	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	118-123
11280790-12	2001	We conclude that: (a) Ape1/ref-1 is expressed at relatively high levels in some GCTs; (b) elevated expression of Ape1/ref-1 in testicular cancer cell lines results in resistance to certain therapeutic agents; and (c) Ape1/ref-1 expression in GCT cell lines determined by immunohistochemistry and repair activity assays parallels the level of protection from bleomycin.	Bleomycin	358-367	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	113-117
11280790-12	2001	We conclude that: (a) Ape1/ref-1 is expressed at relatively high levels in some GCTs; (b) elevated expression of Ape1/ref-1 in testicular cancer cell lines results in resistance to certain therapeutic agents; and (c) Ape1/ref-1 expression in GCT cell lines determined by immunohistochemistry and repair activity assays parallels the level of protection from bleomycin.	Bleomycin	358-367	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	118-123
11125026-0	2001	Regulation of bleomycin-induced DNA breakage and chromatin structure in lung endothelial cells by integrins and poly(ADP-ribose) polymerase.	Bleomycin	14-23	poly (ADP-ribose) polymerase family, member 1	Mus musculus	112-139
11266464-4	2001	In wild-type cells, RPA was localized primarily to the nucleus but, in a KAP142 deletion strain, RPA was mislocalized to the cytoplasm and the strain was highly sensitive to bleomycin (BLM).	Bleomycin	174-183	karyopherin MSN5	Saccharomyces cerevisiae S288C	73-79
11159011-0	2001	Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor.	Bleomycin	15-24	caspase 1	Mus musculus	58-65
11172740-1	2001	We investigated the amplification of bleomycin-induced DNA cleavage by synthetic triamides containing N-methylpyrrole (Py) and/or N-methylimidazole (Im), PyPyPy, PyPyIm, PyImPy, and PyImIm, using 32P-labeled DNA fragments obtained from the human c-Ha-ras-1 and p53 genes.	Bleomycin	37-46	HRas proto-oncogene, GTPase	Homo sapiens	246-256
11172740-1	2001	We investigated the amplification of bleomycin-induced DNA cleavage by synthetic triamides containing N-methylpyrrole (Py) and/or N-methylimidazole (Im), PyPyPy, PyPyIm, PyImPy, and PyImIm, using 32P-labeled DNA fragments obtained from the human c-Ha-ras-1 and p53 genes.	Bleomycin	37-46	tumor protein p53	Homo sapiens	261-264
21413361-3	2001	When DNA damage is induced by bleomycin, MMS, or a single double-strand cleavage (DSB), yKu80p and components of repressed subtelomeric chromatin (Sir proteins) are displaced from telomere clusters.	Bleomycin	30-39	ATP-dependent DNA helicase YKU80	Saccharomyces cerevisiae S288C	88-94
11125026-3	2001	We determined the role of PARP in suppression of bleomycin genotoxicity by integrins using wild-type and PARP knockout mouse lung endothelial cells (MLEC), and the PARP inhibitor, 3-aminobenzamide (3AB).	Bleomycin	49-58	poly (ADP-ribose) polymerase family, member 1	Mus musculus	26-30
11125026-11	2001	Bleomycin caused large increases in PARP activity in wild-type but not knockout MLEC, and integrin clustering inhibited the activation of PARP.	Bleomycin	0-9	poly (ADP-ribose) polymerase family, member 1	Mus musculus	36-40
11802938-2	2001	METHODS: The dynamic change of FN was observed in bleomycin-induced rat pulmonary fibrosis using immunohistochemical technique.	Bleomycin	50-59	fibronectin 1	Rattus norvegicus	31-33
11287832-4	2001	OBJECTIVE: To investigate the effect of two preparations of recombinant IFN-alpha (IFN-alphaA/D and IFN-alpha2a) on Bleo-induced lung injury in C57BL/6 mice.	Bleomycin	116-120	interferon alpha	Mus musculus	72-81
11287832-12	2001	CONCLUSION: IFN-alpha may enhance Bleo-induced lung injury but this effect varies with different IFN preparations.	Bleomycin	34-38	interferon alpha	Mus musculus	12-21
11802938-4	2001	RESULTS: (1) The pulmonary tissue of rats which received bleomycin showed continuously strong positive reaction with anti-FN.	Bleomycin	57-66	fibronectin 1	Rattus norvegicus	122-124
11112155-4	2000	We found that HGF significantly attenuated collagen accumulation induced by bleomycin as determined by quantitation of hydroxyproline content and by scoring of the extent of fibrosis.	Bleomycin	76-85	hepatocyte growth factor	Mus musculus	14-17
11108812-0	2000	Effect of antibody against integrin alpha4 on bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	46-55	integrin alpha 4	Mus musculus	27-42
11108812-4	2000	In this study, we tested the hypothesis that neutralizing antibody for integrin alpha4 (PS2) may reduce bleomycin (BL)-induced lung fibrosis in vivo.	Bleomycin	104-113	integrin alpha 4	Mus musculus	71-86
11108812-4	2000	In this study, we tested the hypothesis that neutralizing antibody for integrin alpha4 (PS2) may reduce bleomycin (BL)-induced lung fibrosis in vivo.	Bleomycin	104-113	trefoil factor 1	Mus musculus	88-91
11108812-4	2000	In this study, we tested the hypothesis that neutralizing antibody for integrin alpha4 (PS2) may reduce bleomycin (BL)-induced lung fibrosis in vivo.	Bleomycin	115-117	integrin alpha 4	Mus musculus	71-86
11108812-4	2000	In this study, we tested the hypothesis that neutralizing antibody for integrin alpha4 (PS2) may reduce bleomycin (BL)-induced lung fibrosis in vivo.	Bleomycin	115-117	trefoil factor 1	Mus musculus	88-91
11072242-0	2000	Induction of apoptosis in head-and-neck squamous carcinoma cells by gamma-irradiation and bleomycin is p53-independent.	Bleomycin	90-99	tumor protein p53	Homo sapiens	103-106
11104787-0	2000	Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.	Bleomycin	0-9	fibrinogen alpha chain	Mus musculus	40-50
11104787-1	2000	Mice deleted for the plasminogen activator inhibitor-1 (PAI-1) gene are relatively protected from developing pulmonary fibrosis induced by bleomycin.	Bleomycin	139-148	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	21-54
11104787-1	2000	Mice deleted for the plasminogen activator inhibitor-1 (PAI-1) gene are relatively protected from developing pulmonary fibrosis induced by bleomycin.	Bleomycin	139-148	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	56-61
11086072-7	2000	Furthermore, MM cells with Ku86v have increased sensitivity to irradiation, mitomycin C, and bleomycin compared with patient MM cells or normal bone marrow donor cells with Ku86.	Bleomycin	93-102	X-ray repair cross complementing 5	Homo sapiens	27-32
11086072-7	2000	Furthermore, MM cells with Ku86v have increased sensitivity to irradiation, mitomycin C, and bleomycin compared with patient MM cells or normal bone marrow donor cells with Ku86.	Bleomycin	93-102	X-ray repair cross complementing 5	Homo sapiens	27-31
11192539-0	2000	N-acetyl-L-cysteine inhibits bleomycin-induced interleukin-8 secretion by bronchial epithelial cells.	Bleomycin	29-38	C-X-C motif chemokine ligand 8	Homo sapiens	47-60
11192539-6	2000	In the present study, we showed that BLM induced the expression of IL-8 protein and mRNA in BEAS-2B cells, and N-acetyl-L-cysteine (NAC) inhibited IL-8 expression.	Bleomycin	37-40	C-X-C motif chemokine ligand 8	Homo sapiens	67-71
11192539-6	2000	In the present study, we showed that BLM induced the expression of IL-8 protein and mRNA in BEAS-2B cells, and N-acetyl-L-cysteine (NAC) inhibited IL-8 expression.	Bleomycin	37-40	C-X-C motif chemokine ligand 8	Homo sapiens	147-151
11001857-4	2000	We found that the expression of both TbetaRI and TbetaRII was altered in rat lungs during pulmonary fibrosis induced by bleomycin.	Bleomycin	120-129	transforming growth factor, beta receptor 1	Rattus norvegicus	37-44
11194894-0	2000	Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts.	Bleomycin	0-9	fibronectin 1	Homo sapiens	60-71
11194894-0	2000	Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts.	Bleomycin	0-9	decorin	Homo sapiens	76-83
11194894-3	2000	Northern blot analysis showed that bleomycin upregulated alpha(I) collagen, fibronectin and decorin gene expression dose-dependently between 1 nM and 1 microM.	Bleomycin	35-44	fibronectin 1	Homo sapiens	76-87
11194894-3	2000	Northern blot analysis showed that bleomycin upregulated alpha(I) collagen, fibronectin and decorin gene expression dose-dependently between 1 nM and 1 microM.	Bleomycin	35-44	decorin	Homo sapiens	92-99
11194894-4	2000	Bleomycin at 100 nM upregulated alpha1(I) collagen, fibronectin and decorin mRNA expression with a peak at 6 h following stimulation in normal skin fibroblast monolayers.	Bleomycin	0-9	fibronectin 1	Homo sapiens	52-63
11194894-4	2000	Bleomycin at 100 nM upregulated alpha1(I) collagen, fibronectin and decorin mRNA expression with a peak at 6 h following stimulation in normal skin fibroblast monolayers.	Bleomycin	0-9	decorin	Homo sapiens	68-75
11194894-7	2000	Bleomycin also mildly upregulated mRNA expression of transforming growth factor-beta (TGF-beta) and connective tissue growth factor (CTGF) coordinately in normal skin fibroblasts.	Bleomycin	0-9	cellular communication network factor 2	Homo sapiens	100-131
11194894-7	2000	Bleomycin also mildly upregulated mRNA expression of transforming growth factor-beta (TGF-beta) and connective tissue growth factor (CTGF) coordinately in normal skin fibroblasts.	Bleomycin	0-9	cellular communication network factor 2	Homo sapiens	133-137
11194894-8	2000	Our results indicate that bleomycin modulates gene expression of extracellular matrix proteins in dermal fibroblasts, and this effect may be mediated by TGF-beta and CTGF.	Bleomycin	26-35	cellular communication network factor 2	Homo sapiens	166-170
11106002-5	2000	instillation of Bleo (Bleo-Sur); (2) i.t.	Bleomycin	16-20	ATP-binding cassette, sub-family C (CFTR/MRP), member 8	Mus musculus	27-30
11004683-9	2000	Short-term exposure (16 hr) to subtoxic daunomycin (DM)-, and bleomycin (BM)-concentrations significantly (up to 4-fold) enhanced LRP expression in 2/4 cell lines tested.	Bleomycin	62-71	major vault protein	Homo sapiens	130-133
11004683-9	2000	Short-term exposure (16 hr) to subtoxic daunomycin (DM)-, and bleomycin (BM)-concentrations significantly (up to 4-fold) enhanced LRP expression in 2/4 cell lines tested.	Bleomycin	73-75	major vault protein	Homo sapiens	130-133
11000131-5	2000	Similarly, hyaluronan fragments augment PAI-1 and diminish uPA mRNA levels in freshly isolated inflammatory alveolar macrophages from bleomycin-treated rats.	Bleomycin	134-143	plasminogen activator, urokinase	Rattus norvegicus	59-62
11000135-0	2000	Bleomycin-induced pulmonary injury in mice deficient in SPARC.	Bleomycin	0-9	secreted acidic cysteine rich glycoprotein	Mus musculus	56-61
11000135-4	2000	Bleomycin (0.15 U/mouse) given intratracheally induced significantly more pulmonary fibrosis in mice deficient in SPARC compared with that in wild-type control mice, with the mutant mice demonstrating greater neutrophil accumulation in the lung.	Bleomycin	0-9	secreted acidic cysteine rich glycoprotein	Mus musculus	114-119
11029377-0	2000	Antisense oligonucleotides to NF-kappaB improve survival in bleomycin-induced pneumopathy of the mouse.	Bleomycin	60-69	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	30-39
11029377-1	2000	We examined the effect of antisense oligonucleotides to the p65 subunit of NF-kappaB on the survival of bleomycin (BLM)-induced pneumonitis in C57BL/6 mice (female, 8 wk of age, 17 to 20 g body weight).	Bleomycin	104-113	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	75-84
11076310-3	2000	In bleomycin-treated C57B1/6 mice, IFN-gamma production was increased up to 20-fold at 3 and 6 days in LIL, and at 3 days in PBLT lymphocytes.	Bleomycin	3-12	interferon gamma	Mus musculus	35-44
11076310-8	2000	The increase in IFN-gamma may play a role in the pathogenesis of bleomycin-induced lung injury.	Bleomycin	65-74	interferon gamma	Mus musculus	16-25
11153598-3	2000	It was hypothesized that a human lung fibroblast (HFL-1) and a human lung epithelial cell line (BEAS-2B) might release eosinophil chemotactic activity (ECA) in response to bleomycin, a chemotherapeutic agent associated with pulmonary fibrosis.	Bleomycin	172-181	complement factor H related 1	Homo sapiens	50-55
11153598-5	2000	HFL-1 and BEAS-2B cells released ECA in a dose- and time-dependent manner in response to bleomycin, and partial characterization revealed that the ECA was heterogeneous.	Bleomycin	89-98	complement factor H related 1	Homo sapiens	0-5
11153598-8	2000	In both cases, the release of GM-CSF was significantly increased in response to bleomycin.	Bleomycin	80-89	colony stimulating factor 2	Homo sapiens	30-36
11079315-5	2000	After three courses of chemotherapy with CDDP, Bleomycin and VP-16, the mass reduced in size and the serum AFP level decreased to the normal range.	Bleomycin	47-56	alpha fetoprotein	Homo sapiens	107-110
11034414-0	2000	GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism.	Bleomycin	17-26	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	0-6
11034414-6	2000	Analysis of whole lung homogenates from saline- or bleomycin-treated mice revealed that GM-CSF-/- animals had reduced levels of PGE2.	Bleomycin	51-60	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	88-94
11001857-4	2000	We found that the expression of both TbetaRI and TbetaRII was altered in rat lungs during pulmonary fibrosis induced by bleomycin.	Bleomycin	120-129	transforming growth factor, beta receptor 2	Rattus norvegicus	49-57
11001857-5	2000	The increase in TbetaRI mRNA level was evident after 3 days of bleomycin administration, and TbetaRI mRNA continually increased for over 12 days after bleomycin instillation, whereas TbetaRII mRNA declined at day 3 post bleomycin instillation and then increased during the reparative phase of lung injury (days 8 and 12).	Bleomycin	63-72	transforming growth factor, beta receptor 1	Rattus norvegicus	16-23
11001857-7	2000	In bleomycin-induced pulmonary fibrosis, an extensive immunostaining for TbetaRI and TbetaRII was present in the cells at the sites of injury and active fibrosis.	Bleomycin	3-12	transforming growth factor, beta receptor 1	Rattus norvegicus	73-80
11001857-7	2000	In bleomycin-induced pulmonary fibrosis, an extensive immunostaining for TbetaRI and TbetaRII was present in the cells at the sites of injury and active fibrosis.	Bleomycin	3-12	transforming growth factor, beta receptor 2	Rattus norvegicus	85-93
11072666-2	2000	Models of experimental organ fibrosis such as bleomycin- or irradiation-induced lung fibrosis indicate that the continuous overexpression of major growth factors such as transforming growth factor beta 1 plays a major role in the tissue reorganization process and the modulation of the accompanying immune response.	Bleomycin	46-55	transforming growth factor beta 1	Homo sapiens	170-203
10993916-0	2000	Nitric oxide-dependent activation of p53 suppresses bleomycin-induced apoptosis in the lung.	Bleomycin	52-61	transformation related protein 53, pseudogene	Mus musculus	37-40
10993916-4	2000	The effects of bleomycin were associated with translocation of p53 from the cytosol to the nucleus only in alveolar macrophages that had been exposed to the drug in vivo, suggesting that the lung microenvironment regulated p53 activation.	Bleomycin	15-24	transformation related protein 53, pseudogene	Mus musculus	63-66
11006407-6	2000	Wortmannin significantly increased the BLM-induced aberration frequencies in all but the ATM-/- cells, elevating the sensitivity of p53-/- cells to ATM-/- levels and that of wild-type cells to intermediate levels.	Bleomycin	39-42	tumor protein p53	Homo sapiens	132-135
10993916-4	2000	The effects of bleomycin were associated with translocation of p53 from the cytosol to the nucleus only in alveolar macrophages that had been exposed to the drug in vivo, suggesting that the lung microenvironment regulated p53 activation.	Bleomycin	15-24	transformation related protein 53, pseudogene	Mus musculus	223-226
10993916-7	2000	Strikingly, rates of bleomycin-induced apoptosis were at least twofold higher in p53(-/)- C57BL/6 mice compared with heterozygous or wild-type littermates.	Bleomycin	21-30	transformation related protein 53, pseudogene	Mus musculus	81-84
10993916-9	2000	Consistent with a role for apoptosis in chronic lung injury, levels of bleomycin-induced inflammation were substantially higher in iNOS(-/)- and p53(-/)- mice compared with wild-type controls.	Bleomycin	71-80	nitric oxide synthase 2, inducible	Mus musculus	131-135
10993916-9	2000	Consistent with a role for apoptosis in chronic lung injury, levels of bleomycin-induced inflammation were substantially higher in iNOS(-/)- and p53(-/)- mice compared with wild-type controls.	Bleomycin	71-80	transformation related protein 53, pseudogene	Mus musculus	145-148
11006407-6	2000	Wortmannin significantly increased the BLM-induced aberration frequencies in all but the ATM-/- cells, elevating the sensitivity of p53-/- cells to ATM-/- levels and that of wild-type cells to intermediate levels.	Bleomycin	39-42	ATM serine/threonine kinase	Homo sapiens	148-151
10934155-0	2000	Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin.	Bleomycin	75-84	matrix metallopeptidase 9	Mus musculus	0-12
11062748-2	2000	Here, we evaluated the ability of the PARP inhibitor, 6(5H)-phenanthridinone, to modulate the antiproliferative activity of bleomycin, carmustin and doxorubicin in a murine (RDM4) and a human (U937) lymphoma cell lines.	Bleomycin	124-133	poly (ADP-ribose) polymerase family, member 1	Mus musculus	38-42
10991907-7	2000	Furthermore, curcumin remarkably suppressed the BLM-induced alveolar macrophage production of TNF-alpha, superoxide and nitric oxide.	Bleomycin	48-51	tumor necrosis factor	Rattus norvegicus	94-103
10946246-5	2000	296 (1992) 205-217] had suggested that Bleomycin sulfate (Blenoxane), BLM, might be a female-specific mutagen.	Bleomycin	39-56	Bloom syndrome, RecQ like helicase	Mus musculus	70-73
10946246-5	2000	296 (1992) 205-217] had suggested that Bleomycin sulfate (Blenoxane), BLM, might be a female-specific mutagen.	Bleomycin	58-67	Bloom syndrome, RecQ like helicase	Mus musculus	70-73
10956623-0	2000	Role of diminished epithelial GM-CSF in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	60-69	colony stimulating factor 2	Rattus norvegicus	30-36
10956623-5	2000	In contrast, there is a consistent reduction in expression of GM-CSF mRNA in the lung during the first week after bleomycin injury.	Bleomycin	114-123	colony stimulating factor 2	Rattus norvegicus	62-68
10956623-6	2000	Bleomycin-treated rats given neutralizing rabbit anti-rat GM-CSF IgG develop increased fibrosis.	Bleomycin	0-9	colony stimulating factor 2	Rattus norvegicus	58-64
10956623-7	2000	Type II AECs isolated from rats after bleomycin injury demonstrate diminished expression of GM-CSF mRNA immediately after isolation and in response to stimulation in vitro with endotoxin compared with that in normal type II cells.	Bleomycin	38-47	colony stimulating factor 2	Rattus norvegicus	92-98
10956623-8	2000	These data demonstrate a defect in the ability of type II epithelial cells from bleomycin-treated rats to express GM-CSF mRNA and a protective role for GM-CSF in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	80-89	colony stimulating factor 2	Rattus norvegicus	114-120
10956623-8	2000	These data demonstrate a defect in the ability of type II epithelial cells from bleomycin-treated rats to express GM-CSF mRNA and a protective role for GM-CSF in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	80-89	colony stimulating factor 2	Rattus norvegicus	152-158
10956623-8	2000	These data demonstrate a defect in the ability of type II epithelial cells from bleomycin-treated rats to express GM-CSF mRNA and a protective role for GM-CSF in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	182-191	colony stimulating factor 2	Rattus norvegicus	152-158
10940316-9	2000	NFkappaB activation in response to tumor necrosis factor and bleomycin, the latter causing topoisomerase II-independent DNA damage, was intact in both cell lines.	Bleomycin	61-70	nuclear factor kappa B subunit 1	Homo sapiens	0-8
10934155-6	2000	Gelatinase B was identified immunohistochemically in terminal bronchiolar cells and bronchiolized cells 7 and 14 days after bleomycin in gelatinase B+/+ mice, and whole lung gelatinase B mRNA was increased at the same times.	Bleomycin	124-133	matrix metallopeptidase 9	Mus musculus	0-12
10918614-3	2000	In contrast, the cytotoxicity of the DNA damaging agents X-irradiation, cisplatin or bleomycin was p53-independent.	Bleomycin	85-94	transformation related protein 53, pseudogene	Mus musculus	99-102
10919982-0	2000	Increased expression of epimorphin in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	38-47	syntaxin 2	Mus musculus	24-34
10919982-4	2000	However, from Day 7 until Day 28 after bleomycin treatment, increasing levels of epimorphin immunoreactivity were detected in the mesenchymal cells and in the extracellular matrix within intra-alveolar fibrotic lesions.	Bleomycin	39-48	syntaxin 2	Mus musculus	81-91
10919982-6	2000	Re-epithelialization of epimorphin-rich intra-alveolar fibrosis was complete by Day 28 after bleomycin, and by Day 56, epimorphin immunoreactivity had declined.	Bleomycin	93-102	syntaxin 2	Mus musculus	24-34
10806175-0	2000	Roles of ICAM-1 for abnormal leukocyte recruitment in the microcirculation of bleomycin-induced fibrotic lung injury.	Bleomycin	78-87	intercellular adhesion molecule 1	Rattus norvegicus	9-15
10966061-0	2000	Effect of interferon-gamma on experimental scleroderma induced by bleomycin.	Bleomycin	66-75	interferon gamma	Homo sapiens	10-26
10839301-7	2000	Additionally, augmentation of CD95 receptor expression was found in three RCC cell lines, including one p53-mutated cell line, whereas another p53-mutated cell line showed no or only a weak CD95 receptor upregulation after exposure to topotecan or bleomycin, respectively.	Bleomycin	248-257	Fas cell surface death receptor	Homo sapiens	30-34
10839301-9	2000	Thus, although a functionally intact CD95 signalling cascade is present in most RCC cell lines, the anticancer drugs topotecan and bleomycin that induce upregulation of CD95 receptor and ligand fail to effectively activate CD95-mediated apoptosis.	Bleomycin	131-140	Fas cell surface death receptor	Homo sapiens	169-173
10839301-9	2000	Thus, although a functionally intact CD95 signalling cascade is present in most RCC cell lines, the anticancer drugs topotecan and bleomycin that induce upregulation of CD95 receptor and ligand fail to effectively activate CD95-mediated apoptosis.	Bleomycin	131-140	Fas cell surface death receptor	Homo sapiens	169-173
10854324-3	2000	This NO-mediated increase in enzymatically active DNA-PK not only protects cells from the toxic effects of NO, but also provides crossprotection against clinically important DNA-damaging agents, such as X-ray radiation, adriamycin, bleomycin and cisplatin.	Bleomycin	232-241	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	50-56
10797547-4	2000	Exposure to bleomycin significantly increased the numbers of TUNEL-, p53-, and c-Jun-positive neurons in the wild-type mouse cerebellar internal granular layer (IGL) and Purkinje cell layer (PL).	Bleomycin	12-21	transformation related protein 53, pseudogene	Mus musculus	69-72
10797547-4	2000	Exposure to bleomycin significantly increased the numbers of TUNEL-, p53-, and c-Jun-positive neurons in the wild-type mouse cerebellar internal granular layer (IGL) and Purkinje cell layer (PL).	Bleomycin	12-21	jun proto-oncogene	Mus musculus	79-84
10797547-6	2000	These results are consistent with our previous observations in dissociated neuronal culture showing that the amount of c-Jun protein increases significantly after addition of bleomycin in p53 wild-type cerebellar granule cells.	Bleomycin	175-184	jun proto-oncogene	Mus musculus	119-124
10797547-6	2000	These results are consistent with our previous observations in dissociated neuronal culture showing that the amount of c-Jun protein increases significantly after addition of bleomycin in p53 wild-type cerebellar granule cells.	Bleomycin	175-184	transformation related protein 53, pseudogene	Mus musculus	188-191
10781421-0	2000	Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo.	Bleomycin	60-69	interleukin 10	Mus musculus	20-34
10783125-0	2000	Bleomycin-mediated pulmonary toxicity: evidence for a p53-mediated response.	Bleomycin	0-9	transformation related protein 53, pseudogene	Mus musculus	54-57
10783125-4	2000	p53-positive cells first appeared at 5 d after treatment and peaked at 7 d; PCNA-positive cells appeared at 1 d after treatment and peaked at 7 d; and p21-positive cells appeared at 5 d and peaked at 9 d. Western blot analysis confirmed that bleomycin upregulated the DNA damage-inducible proteins in a similar fashion.	Bleomycin	242-251	transformation related protein 53, pseudogene	Mus musculus	0-3
10783125-4	2000	p53-positive cells first appeared at 5 d after treatment and peaked at 7 d; PCNA-positive cells appeared at 1 d after treatment and peaked at 7 d; and p21-positive cells appeared at 5 d and peaked at 9 d. Western blot analysis confirmed that bleomycin upregulated the DNA damage-inducible proteins in a similar fashion.	Bleomycin	242-251	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	151-154
10783125-5	2000	This is the first evidence that bleomycin causes a p53-dependent response associated with acute injury in the lung.	Bleomycin	32-41	transformation related protein 53, pseudogene	Mus musculus	51-54
10757755-8	2000	Chromosomal reconstruction in rad52/rad52 strains was dose dependent after gamma irradiation, but greater after high, rather than low, bleomycin doses with or without LH.	Bleomycin	135-144	recombinase RAD52	Saccharomyces cerevisiae S288C	30-35
10781820-2	2000	We found that ATM(-/-) DT40 cells were more susceptible than wild-type cells to apoptosis induced not only by ionizing radiation and bleomycin but also by non-DNA-damaging apoptotic stimuli such as C(2)-ceramide.	Bleomycin	133-142	ATM serine/threonine kinase	Homo sapiens	14-17
10739677-2	2000	The multidrug-resistant FM3A/M cells overexpressing Pgp were resistant to apoptotic cell death induced either by Pgp-related drugs including vincristine and vinblastine, which are pumped out by Pgp, or by the Pgp-unrelated drugs including 5"-fluorouracil (5-FU) and bleomycin, which are not targets for Pgp, compared with the parental FM3A cells.	Bleomycin	266-275	phosphoglycolate phosphatase	Mus musculus	52-55
10747776-8	2000	The analysis of the structures previously derived for HOO-Co(III)-bleomycin and HOO-Co(III)-pepleomycin led us to propose the six-coordinate structure with only endogenous ligands, as the one held in solution by the Co(II) derivative of bleomycin.	Bleomycin	66-75	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	216-222
10747776-8	2000	The analysis of the structures previously derived for HOO-Co(III)-bleomycin and HOO-Co(III)-pepleomycin led us to propose the six-coordinate structure with only endogenous ligands, as the one held in solution by the Co(II) derivative of bleomycin.	Bleomycin	237-246	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	216-222
10934788-1	2000	Bleomycin, an antitumour antibiotic was used to study the possible relationship between DNA single strand breaks repair capacity, antioxidant enzymes level and cytotoxic activity of the drug in mouse cells: AKR and BALB/c and in human cells: CRL 2088 and CRL 1307 (xeroderma pigmentosum).	Bleomycin	0-9	interleukin 31 receptor A	Homo sapiens	242-245
10934788-1	2000	Bleomycin, an antitumour antibiotic was used to study the possible relationship between DNA single strand breaks repair capacity, antioxidant enzymes level and cytotoxic activity of the drug in mouse cells: AKR and BALB/c and in human cells: CRL 2088 and CRL 1307 (xeroderma pigmentosum).	Bleomycin	0-9	interleukin 31 receptor A	Homo sapiens	255-258
10757755-8	2000	Chromosomal reconstruction in rad52/rad52 strains was dose dependent after gamma irradiation, but greater after high, rather than low, bleomycin doses with or without LH.	Bleomycin	135-144	recombinase RAD52	Saccharomyces cerevisiae S288C	36-41
10679116-0	2000	Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice.	Bleomycin	44-53	chemokine (C-C motif) receptor 1	Mus musculus	16-20
10679116-1	2000	We have investigated the involvement of chemokine receptor CCR1-positive cells in bleomycin-induced lung injury, a model of pulmonary fibrosis.	Bleomycin	82-91	chemokine (C-C motif) receptor 1	Mus musculus	59-63
10679116-5	2000	These results suggest that CCR1-positive cells play significant roles in the pathogenesis of pulmonary fibrosis subsequent to bleomycin-induced lung injury, and that CCR1 could be a novel molecular target for intervention therapy against pulmonary fibrosis.	Bleomycin	126-135	chemokine (C-C motif) receptor 1	Mus musculus	27-31
10679116-5	2000	These results suggest that CCR1-positive cells play significant roles in the pathogenesis of pulmonary fibrosis subsequent to bleomycin-induced lung injury, and that CCR1 could be a novel molecular target for intervention therapy against pulmonary fibrosis.	Bleomycin	126-135	chemokine (C-C motif) receptor 1	Mus musculus	166-170
10679116-2	2000	After bleomycin challenge in C57BL/6J mice, the expression of CCR1 mRNA increased and peaked at day 7, which paralleled to the expression of its ligands, macrophage-inflammatory protein-1 alpha and RANTES.	Bleomycin	6-15	chemokine (C-C motif) receptor 1	Mus musculus	62-66
10679116-2	2000	After bleomycin challenge in C57BL/6J mice, the expression of CCR1 mRNA increased and peaked at day 7, which paralleled to the expression of its ligands, macrophage-inflammatory protein-1 alpha and RANTES.	Bleomycin	6-15	chemokine (C-C motif) ligand 3	Mus musculus	154-193
10679116-2	2000	After bleomycin challenge in C57BL/6J mice, the expression of CCR1 mRNA increased and peaked at day 7, which paralleled to the expression of its ligands, macrophage-inflammatory protein-1 alpha and RANTES.	Bleomycin	6-15	chemokine (C-C motif) ligand 5	Mus musculus	198-204
10751606-0	2000	A comparison of the roles of p53 mutation and AraC inhibition in the enhancement of bleomycin-induced chromatid aberrations in mouse and human cells.	Bleomycin	84-93	transformation related protein 53, pseudogene	Mus musculus	29-32
10751606-1	2000	Previous studies have shown that p53 is involved in the repair of bleomycin-induced DNA damage, and that the frequency of bleomycin-induced chromatid aberrations is elevated in G(2)-treated p53 null transgenic mouse embryo fibroblasts (MEF) as compared to isogenic controls.	Bleomycin	66-75	transformation related protein 53, pseudogene	Mus musculus	33-36
10751606-5	2000	AraC treatment significantly increased the frequency of bleomycin-induced chromatid aberrations in p53+/+ MEF to the levels in p53-/- (no AraC) but had no effect in p53-/- MEF.	Bleomycin	56-65	tumor protein p53	Homo sapiens	127-130
10751606-1	2000	Previous studies have shown that p53 is involved in the repair of bleomycin-induced DNA damage, and that the frequency of bleomycin-induced chromatid aberrations is elevated in G(2)-treated p53 null transgenic mouse embryo fibroblasts (MEF) as compared to isogenic controls.	Bleomycin	66-75	transformation related protein 53, pseudogene	Mus musculus	190-193
10751606-5	2000	AraC treatment significantly increased the frequency of bleomycin-induced chromatid aberrations in p53+/+ MEF to the levels in p53-/- (no AraC) but had no effect in p53-/- MEF.	Bleomycin	56-65	tumor protein p53	Homo sapiens	127-130
10751606-7	2000	Similar results were observed in p53-mutant WTK1 and wild-type TK6 human lymphoblast cells exposed to 0 to 3 microg/ml bleomycin in G(2).	Bleomycin	119-128	tumor protein p53	Homo sapiens	33-36
10751606-1	2000	Previous studies have shown that p53 is involved in the repair of bleomycin-induced DNA damage, and that the frequency of bleomycin-induced chromatid aberrations is elevated in G(2)-treated p53 null transgenic mouse embryo fibroblasts (MEF) as compared to isogenic controls.	Bleomycin	122-131	transformation related protein 53, pseudogene	Mus musculus	33-36
10751606-1	2000	Previous studies have shown that p53 is involved in the repair of bleomycin-induced DNA damage, and that the frequency of bleomycin-induced chromatid aberrations is elevated in G(2)-treated p53 null transgenic mouse embryo fibroblasts (MEF) as compared to isogenic controls.	Bleomycin	122-131	transformation related protein 53, pseudogene	Mus musculus	190-193
10751606-4	2000	The frequency of bleomycin-induced chromatid aberrations was significantly higher in p53-/- cells than wild-type cells in the absence of AraC.	Bleomycin	17-26	tumor protein p53	Homo sapiens	85-88
10751606-5	2000	AraC treatment significantly increased the frequency of bleomycin-induced chromatid aberrations in p53+/+ MEF to the levels in p53-/- (no AraC) but had no effect in p53-/- MEF.	Bleomycin	56-65	tumor protein p53	Homo sapiens	99-102
10631140-6	2000	Extending telomerically from the SRO, two additional genes-BLMH, encoding a hydrolase involved in bleomycin resistance, and ACCN1, encoding an amiloride-sensitive cation channel expressed in the CNS-were located in the deleted intervals of seven and three patients, respectively.	Bleomycin	98-107	bleomycin hydrolase	Homo sapiens	59-63
10657022-4	2000	The expression of p53 and p21 mRNA was concurrently up-regulated in the alveolar epithelial cells at 1 h to 7 days after intratracheal instillation of bleomycin.	Bleomycin	151-160	transformation related protein 53, pseudogene	Mus musculus	18-21
10657022-4	2000	The expression of p53 and p21 mRNA was concurrently up-regulated in the alveolar epithelial cells at 1 h to 7 days after intratracheal instillation of bleomycin.	Bleomycin	151-160	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	26-29
10639534-0	2000	Role of E-selectin in bleomycin induced lung fibrosis in mice.	Bleomycin	22-31	selectin, endothelial cell	Mus musculus	8-18
10639534-4	2000	METHODS: BLM (100 mg/kg) was injected into the tail veins of ICR mice to evaluate the induction of E-selectin, an adhesion molecule known to induce neutrophil attachment on endothelial cells.	Bleomycin	9-12	selectin, endothelial cell	Mus musculus	99-109
10669330-6	2000	In contrast, clinically relevant bleomycin concentrations reduced p24 levels by approximately 50% without affecting proliferation.	Bleomycin	33-42	transmembrane p24 trafficking protein 2	Homo sapiens	66-69
10631140-6	2000	Extending telomerically from the SRO, two additional genes-BLMH, encoding a hydrolase involved in bleomycin resistance, and ACCN1, encoding an amiloride-sensitive cation channel expressed in the CNS-were located in the deleted intervals of seven and three patients, respectively.	Bleomycin	98-107	acid sensing ion channel subunit 2	Homo sapiens	124-129
10539931-0	1999	Fatal pulmonary fibrosis after a low cumulated dose of bleomycin: role of alpha1-antitrypsin deficiency?	Bleomycin	55-64	serpin family A member 1	Homo sapiens	74-92
10600896-1	1999	Bleomycin (BLM) induces lung injury and fibrosis in the murine lung and enhances tumor necrosis factor (TNF)-alpha and collagen mRNA expression in the murine lung.	Bleomycin	0-9	tumor necrosis factor	Mus musculus	81-114
10600896-1	1999	Bleomycin (BLM) induces lung injury and fibrosis in the murine lung and enhances tumor necrosis factor (TNF)-alpha and collagen mRNA expression in the murine lung.	Bleomycin	11-14	tumor necrosis factor	Mus musculus	81-114
10592326-0	1999	Attenuation of bleomycin-induced Hprt mutant frequency in female and male rats by calorie restriction.	Bleomycin	15-24	hypoxanthine phosphoribosyltransferase 1	Rattus norvegicus	33-37
10553099-0	1999	IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.	Bleomycin	42-51	chemokine (C-X-C motif) ligand 10	Mus musculus	0-30
10553099-4	1999	To test this hypothesis, we measured IP-10 by specific ELISA in whole lung homogenates in either bleomycin-treated or control mice and correlated these levels with lung hydroxyproline.	Bleomycin	97-106	chemokine (C-X-C motif) ligand 10	Mus musculus	37-42
10553099-5	1999	We found that lung tissue from mice treated with bleomycin, compared with that from saline-treated controls, demonstrated a decrease in the presence of IP-10 that was correlated to a greater angiogenic response and total lung hydroxyproline content.	Bleomycin	49-58	chemokine (C-X-C motif) ligand 10	Mus musculus	152-157
10612569-0	1999	Expression of transforming growth factor-beta1 and tumour necrosis factor-alpha in bronchoalveolar lavage cells in murine pulmonary fibrosis after intraperitoneal administration of bleomycin.	Bleomycin	181-190	transforming growth factor, beta 1	Mus musculus	14-46
10612569-1	1999	OBJECTIVE: We previously observed increased expression of interleukin-1beta, platelet-derived growth factor-A, and insulin-like growth factor-I in bronchoalveolar lavage (BAL) cells during the development of pulmonary fibrosis after an intraperitoneal administration of bleomycin in mice.	Bleomycin	270-279	interleukin 1 beta	Mus musculus	58-75
10612569-1	1999	OBJECTIVE: We previously observed increased expression of interleukin-1beta, platelet-derived growth factor-A, and insulin-like growth factor-I in bronchoalveolar lavage (BAL) cells during the development of pulmonary fibrosis after an intraperitoneal administration of bleomycin in mice.	Bleomycin	270-279	insulin-like growth factor 1	Mus musculus	94-143
10612569-3	1999	METHODOLOGY: We investigated the mRNA expression levels of TNF-alpha and TGF-beta1 in BAL cells of Institute for Cancer Research mice after 10 days of the intraperitoneal administration of bleomycin with or without treatment with a specific neutrophil elastase inhibitor, ONO-5046 x Na.	Bleomycin	189-198	transforming growth factor, beta 1	Mus musculus	73-82
10612569-4	1999	RESULTS: On day 1 but not on days 15 and 29, the relative amount of TGF-beta1 mRNA in the bleomycin-treated mice was significantly decreased compared with control mice.	Bleomycin	90-99	transforming growth factor, beta 1	Mus musculus	68-77
10612569-5	1999	In the mice treated with both bleomycin and ONO-5046 x Na intermediate values for TGF-beta1 were obtained.	Bleomycin	30-39	transforming growth factor, beta 1	Mus musculus	82-91
10612569-7	1999	CONCLUSIONS: These results suggest that a reduced expression of TGF-beta1 in BAL cells in the early phase may be important during the development of murine pulmonary fibrosis induced by an intraperitoneal administration of bleomycin.	Bleomycin	223-232	transforming growth factor, beta 1	Mus musculus	64-73
10515451-9	1999	Importantly, the human uPA adenovirus significantly reduced (p&lt;0.05) lung hydroxyproline (281.2+/-22.8 microg/lung), thus attenuating by 38% the bleomycin-induced increase in lung collagen.	Bleomycin	148-157	plasminogen activator, urokinase	Homo sapiens	23-26
10556151-17	1999	We conclude that changes in the collagen-elastin matrix contribute to changes in the viscoelastic properties of bleomycin-treated rat lungs.	Bleomycin	112-121	elastin	Rattus norvegicus	41-48
15328905-4	1999	AA8-Ape1 cells did exhibit increased resistance to bleomycin following a chronic 3-day exposure, but not to more acute challenges of 1 h. Most notably, the AA8-Ape1 line displayed approximately 1.7-fold elevated resistance to the replication-blocking nucleoside analog dioxolane cytidine (L-OddC); this improved resistance was abrogated by the addition of Tc to the medium.	Bleomycin	51-60	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	4-8
15328905-5	1999	These studies demonstrate that Ape1 is not rate-limiting in the repair of MMS- or H2O2-induced DNA damage, that Ape1 may dictate the sensitivity of bleomycin, depending on dosing scheme, and for the first time, that Ape1 can influence cellular resistance to the anticancer/antiviral antimetabolite L-OddC.	Bleomycin	148-157	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	112-116
15328905-5	1999	These studies demonstrate that Ape1 is not rate-limiting in the repair of MMS- or H2O2-induced DNA damage, that Ape1 may dictate the sensitivity of bleomycin, depending on dosing scheme, and for the first time, that Ape1 can influence cellular resistance to the anticancer/antiviral antimetabolite L-OddC.	Bleomycin	148-157	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	112-116
10514416-0	1999	The role of p53 in bleomycin-induced DNA damage in the lung.	Bleomycin	19-28	transformation related protein 53, pseudogene	Mus musculus	12-15
10514416-4	1999	Bleomycin induced p21 expression in a p53-dependent manner in p53+/+ mice but neither p53 nor p21 expression in p53-/- mice.	Bleomycin	0-9	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	18-21
10514416-4	1999	Bleomycin induced p21 expression in a p53-dependent manner in p53+/+ mice but neither p53 nor p21 expression in p53-/- mice.	Bleomycin	0-9	transformation related protein 53, pseudogene	Mus musculus	38-41
10514416-4	1999	Bleomycin induced p21 expression in a p53-dependent manner in p53+/+ mice but neither p53 nor p21 expression in p53-/- mice.	Bleomycin	0-9	transformation related protein 53, pseudogene	Mus musculus	62-65
10514416-4	1999	Bleomycin induced p21 expression in a p53-dependent manner in p53+/+ mice but neither p53 nor p21 expression in p53-/- mice.	Bleomycin	0-9	transformation related protein 53, pseudogene	Mus musculus	62-65
10514416-4	1999	Bleomycin induced p21 expression in a p53-dependent manner in p53+/+ mice but neither p53 nor p21 expression in p53-/- mice.	Bleomycin	0-9	transformation related protein 53, pseudogene	Mus musculus	62-65
10514416-11	1999	Our results suggest that the lung cells and small intestinal cells respond to the bleomycin treatment in different ways in terms of the induction of apoptosis and that p53 carries out an essential role in the early response to and repair of DNA damage by a non-apoptotic mechanism which appears to be crucial in the noncycling lung cells and enterocytes.	Bleomycin	82-91	transformation related protein 53, pseudogene	Mus musculus	168-171
10515451-0	1999	Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes.	Bleomycin	13-22	plasminogen activator, urokinase	Mus musculus	65-101
10515451-2	1999	Transgenic mice having increased fibrinolytic activity due to genetic deficiency of PAI-1 develop less fibrosis after bleomycin-induced lung inflammation.	Bleomycin	118-127	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	84-89
10502292-6	1999	Single-stranded PTs inhibited both collagen synthesis and noncollagen protein synthesis induced by TGF-beta1, the mediator of the bleomycin fibrogenic effect.	Bleomycin	130-139	transforming growth factor, beta 1	Rattus norvegicus	99-108
10515451-10	1999	The improvement in bleomycin-induced lung fibrosis resulting from treatment with the human uPA adenovirus further supports the importance of the fibrinolytic system during inflammatory lung injury and repair.	Bleomycin	19-28	plasminogen activator, urokinase	Homo sapiens	91-94
10484471-0	1999	Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	59-68	secreted acidic cysteine rich glycoprotein	Mus musculus	38-43
10484471-6	1999	Protein from bleomycin-treated WT lung contained significantly more hydroxyproline (191.9 microg/lung) than protein from either bleomycin-treated SPARC-null lungs or saline-treated WT and SPARC-null lungs (147.4 microg/lung, 125.4 microg/lung, and 113.	Bleomycin	128-137	secreted acidic cysteine rich glycoprotein	Mus musculus	146-151
10484471-5	1999	Relative levels of SPARC mRNA were increased 2.7-fold (P &lt; 0.001) in bleomycin-treated WT lungs in comparison with saline-treated lungs.	Bleomycin	72-81	secreted acidic cysteine rich glycoprotein	Mus musculus	19-24
10446979-9	1999	UV irradiation, bleomycin, and doxorubicin increased wild-type p53 expression and decreased MAP4 expression.	Bleomycin	16-25	tumor protein p53	Homo sapiens	63-66
10487979-2	1999	Activated alveolar macrophages obtained from rat lungs after bleomycin-induced pulmonary injury released increased amounts of active TGF-beta1 as well as plasmin, a protease, and thrombospondin-1 (TSP-1), a trimeric glycoprotein.	Bleomycin	61-70	transforming growth factor, beta 1	Rattus norvegicus	133-142
10487979-2	1999	Activated alveolar macrophages obtained from rat lungs after bleomycin-induced pulmonary injury released increased amounts of active TGF-beta1 as well as plasmin, a protease, and thrombospondin-1 (TSP-1), a trimeric glycoprotein.	Bleomycin	61-70	thrombospondin 1	Rattus norvegicus	179-195
10487979-2	1999	Activated alveolar macrophages obtained from rat lungs after bleomycin-induced pulmonary injury released increased amounts of active TGF-beta1 as well as plasmin, a protease, and thrombospondin-1 (TSP-1), a trimeric glycoprotein.	Bleomycin	61-70	thrombospondin 1	Rattus norvegicus	197-202
10487852-0	1999	Relationship of keratinocyte growth factor and hepatocyte growth factor levels in rat lung lavage fluid to epithelial cell regeneration after bleomycin.	Bleomycin	142-151	fibroblast growth factor 7	Rattus norvegicus	16-42
10487852-0	1999	Relationship of keratinocyte growth factor and hepatocyte growth factor levels in rat lung lavage fluid to epithelial cell regeneration after bleomycin.	Bleomycin	142-151	hepatocyte growth factor	Rattus norvegicus	47-71
10487852-10	1999	The results demonstrate that both HGF and KGF are present in the lung in greatly increased amounts soon after bleomycin-induced epithelial cell necrosis.	Bleomycin	110-119	hepatocyte growth factor	Rattus norvegicus	34-37
10487852-10	1999	The results demonstrate that both HGF and KGF are present in the lung in greatly increased amounts soon after bleomycin-induced epithelial cell necrosis.	Bleomycin	110-119	fibroblast growth factor 7	Rattus norvegicus	42-45
10463600-5	1999	The Ku-protein level and Ku DNA binding activity were decreased after treatment with bleomycin, adriamycin, or vincristine, and the decreases were blocked by the treatment of z-DEVD-fmk, a specific inhibitor of caspase-3, suggesting that loss of Ku DNA binding is, in part, due to a caspase-mediated decrease in Ku protein levels.	Bleomycin	85-94	caspase 3	Homo sapiens	211-220
10446979-9	1999	UV irradiation, bleomycin, and doxorubicin increased wild-type p53 expression and decreased MAP4 expression.	Bleomycin	16-25	microtubule associated protein 4	Homo sapiens	92-96
10413648-2	1999	Administration of anti-TGF-beta antibody is shown to be effective for inhibiting lung fibrosis induced by bleomycin in an experimental animal model.	Bleomycin	106-115	transforming growth factor, beta 1	Mus musculus	23-31
10424609-0	1999	T-cell chemokines interferon-inducible protein-10 and monokine induced by interferon-gamma are upregulated in bleomycin-induced lung injury.	Bleomycin	110-119	C-X-C motif chemokine ligand 9	Homo sapiens	54-90
10413648-10	1999	Our results suggest that administration of an antibody against TGF-beta is useful in preventing experimental dermal sclerosis induced by bleomycin and raises a possibility of the therapeutic approach of anti-TGF-beta antibody in scleroderma.	Bleomycin	137-146	transforming growth factor, beta 1	Mus musculus	63-71
10393693-0	1999	Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice.	Bleomycin	57-66	SMAD family member 7	Mus musculus	42-47
10393693-7	1999	These data indicated that gene transfer of Smad7 (but not Smad6) prevented bleomycin-induced lung fibrosis, suggesting that Smad7 may have applicability in the treatment of pulmonary fibrosis.	Bleomycin	75-84	SMAD family member 7	Mus musculus	43-48
10393693-3	1999	To investigate whether this novel molecule can be exploited for therapy of lung fibrosis, we determined the effect of exogenous Smad7, introduced by a recombinant human type 5 adenovirus vector, on bleomycin-induced lung fibrosis in mice.	Bleomycin	198-207	SMAD family member 7	Homo sapiens	128-133
10393693-7	1999	These data indicated that gene transfer of Smad7 (but not Smad6) prevented bleomycin-induced lung fibrosis, suggesting that Smad7 may have applicability in the treatment of pulmonary fibrosis.	Bleomycin	75-84	SMAD family member 7	Mus musculus	124-129
10393693-6	1999	In addition, we found that expression of Smad7 transgene blocked Smad2 phosphorylation induced by bleomycin in mouse lungs.	Bleomycin	98-107	SMAD family member 7	Mus musculus	41-46
10393693-6	1999	In addition, we found that expression of Smad7 transgene blocked Smad2 phosphorylation induced by bleomycin in mouse lungs.	Bleomycin	98-107	SMAD family member 2	Mus musculus	65-70
10431842-0	1999	Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis.	Bleomycin	126-135	vascular endothelial growth factor A	Rattus norvegicus	64-98
10431842-0	1999	Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis.	Bleomycin	126-135	kinase insert domain receptor	Rattus norvegicus	109-113
10431842-7	1999	Bleomycin-induced fibrogenesis was characterised by a decrease in Flk1 immunoreactivity of Clara cells, and an increase in VEGF-immunoreactive myofibroblasts and type 2 pneumocytes by day 5 p.t., followed by a progressive accumulation of Flk1-immunoreactive mast cells by day 24 p.t.	Bleomycin	0-9	kinase insert domain receptor	Rattus norvegicus	66-70
10431842-7	1999	Bleomycin-induced fibrogenesis was characterised by a decrease in Flk1 immunoreactivity of Clara cells, and an increase in VEGF-immunoreactive myofibroblasts and type 2 pneumocytes by day 5 p.t., followed by a progressive accumulation of Flk1-immunoreactive mast cells by day 24 p.t.	Bleomycin	0-9	vascular endothelial growth factor A	Rattus norvegicus	123-127
10431842-7	1999	Bleomycin-induced fibrogenesis was characterised by a decrease in Flk1 immunoreactivity of Clara cells, and an increase in VEGF-immunoreactive myofibroblasts and type 2 pneumocytes by day 5 p.t., followed by a progressive accumulation of Flk1-immunoreactive mast cells by day 24 p.t.	Bleomycin	0-9	kinase insert domain receptor	Rattus norvegicus	238-242
10431842-0	1999	Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis.	Bleomycin	126-135	Fms related receptor tyrosine kinase 1	Rattus norvegicus	118-122
10431842-10	1999	Since mast cells are known to be chemotactically attracted by VEGF, we suggest that VEGF/Flk1 represents the molecular link between proliferation of myofibroblasts, accumulation of mast cells, and the burst of fibrosis at sites of initial lesions in bleomycin-induced fibrosis.	Bleomycin	250-259	vascular endothelial growth factor A	Rattus norvegicus	84-88
10431842-10	1999	Since mast cells are known to be chemotactically attracted by VEGF, we suggest that VEGF/Flk1 represents the molecular link between proliferation of myofibroblasts, accumulation of mast cells, and the burst of fibrosis at sites of initial lesions in bleomycin-induced fibrosis.	Bleomycin	250-259	kinase insert domain receptor	Rattus norvegicus	89-93
10226062-11	1999	These results show that TGF-alpha contributes significantly to the pathogenesis of pulmonary fibrosis after bleomycin-induced injury, and that compensatory increases in other EGF family members do not occur in TGF-alpha-deficient mice.	Bleomycin	108-117	transforming growth factor alpha	Mus musculus	24-33
10404591-2	1999	Although its conserved cellular function is as yet unknown, human bleomycin hydrolase (hBH) has clinical significance in that it is thought to be the major cause of tumor cell resistance to bleomycin chemotherapy.	Bleomycin	66-75	bleomycin hydrolase	Homo sapiens	87-90
10354508-0	1999	The relationship of p53 and stress proteins in response to bleomycin and retinoic acid in the p53 heterozygous mouse.	Bleomycin	59-68	transformation related protein 53, pseudogene	Mus musculus	20-23
10354508-0	1999	The relationship of p53 and stress proteins in response to bleomycin and retinoic acid in the p53 heterozygous mouse.	Bleomycin	59-68	transformation related protein 53, pseudogene	Mus musculus	94-97
10354508-2	1999	dose of bleomycin was administered simultaneously with [35S]methionine to 4-month-old p53 wild type (+/+) and p53 heterozygous (+/-) C57BL/6 mice.	Bleomycin	8-17	transformation related protein 53, pseudogene	Mus musculus	86-89
10354508-2	1999	dose of bleomycin was administered simultaneously with [35S]methionine to 4-month-old p53 wild type (+/+) and p53 heterozygous (+/-) C57BL/6 mice.	Bleomycin	8-17	transformation related protein 53, pseudogene	Mus musculus	110-113
10353821-1	1999	Bleomycin hydrolase (BH) is a cysteine proteinase that inactivates the anticancer drug bleomycin.	Bleomycin	87-96	bleomycin hydrolase	Homo sapiens	0-19
10353821-1	1999	Bleomycin hydrolase (BH) is a cysteine proteinase that inactivates the anticancer drug bleomycin.	Bleomycin	87-96	bleomycin hydrolase	Homo sapiens	21-23
10229865-1	1999	We determined whether human lung fibroblasts might release chemotactic activity for neutrophils (NCA) and monocytes (MCA) in response to bleomycin.	Bleomycin	137-146	CEA cell adhesion molecule 4	Homo sapiens	97-100
10229865-3	1999	Human lung fibroblasts released NCA and MCA in a dose- and time-dependent manner in response to bleomycin.	Bleomycin	96-105	CEA cell adhesion molecule 4	Homo sapiens	32-35
10229865-13	1999	The concentrations of IL-8, G-CSF, monocyte chemoattractant protein-1, GM-CSF, and TGF-beta in the supernatant fluids significantly increased in response to bleomycin.	Bleomycin	157-166	C-X-C motif chemokine ligand 8	Homo sapiens	22-26
10229865-13	1999	The concentrations of IL-8, G-CSF, monocyte chemoattractant protein-1, GM-CSF, and TGF-beta in the supernatant fluids significantly increased in response to bleomycin.	Bleomycin	157-166	colony stimulating factor 3	Homo sapiens	28-33
10229865-13	1999	The concentrations of IL-8, G-CSF, monocyte chemoattractant protein-1, GM-CSF, and TGF-beta in the supernatant fluids significantly increased in response to bleomycin.	Bleomycin	157-166	C-C motif chemokine ligand 2	Homo sapiens	35-69
10229865-13	1999	The concentrations of IL-8, G-CSF, monocyte chemoattractant protein-1, GM-CSF, and TGF-beta in the supernatant fluids significantly increased in response to bleomycin.	Bleomycin	157-166	colony stimulating factor 2	Homo sapiens	71-77
10229865-13	1999	The concentrations of IL-8, G-CSF, monocyte chemoattractant protein-1, GM-CSF, and TGF-beta in the supernatant fluids significantly increased in response to bleomycin.	Bleomycin	157-166	transforming growth factor beta 1	Homo sapiens	83-91
10229865-14	1999	These data suggest that lung fibroblasts may modulate inflammatory cell recruitment into the lung by releasing NCA and MCA in response to bleomycin.	Bleomycin	138-147	CEA cell adhesion molecule 4	Homo sapiens	111-114
10226062-2	1999	To determine whether the development of pulmonary fibrosis depends on TGF-alpha, we induced lung injury with bleomycin in TGF-alpha null-mutation transgenic mice and wild-type mice.	Bleomycin	109-118	transforming growth factor alpha	Mus musculus	122-131
10226062-4	1999	At Days 7 and 10 after bleomycin treatment, lung total RNA content was 1.5 times greater in wild-genotype mice than in TGF-alpha-deficient animals.	Bleomycin	23-32	transforming growth factor alpha	Mus musculus	119-128
10226062-6	1999	Wild-genotype mice had significantly higher lung fibrosis scores at Days 7 and 14 after bleomycin treatment than did TGF-alpha-deficient animals.	Bleomycin	88-97	transforming growth factor alpha	Mus musculus	117-126
10226062-8	1999	To determine whether expression of other members of the epidermal growth factor (EGF) family is increased after bleomycin-induced injury, we measured lung EGF and heparin-binding- epidermal growth factor (HB-EGF) mRNA levels.	Bleomycin	112-121	epidermal growth factor	Mus musculus	56-79
10226062-8	1999	To determine whether expression of other members of the epidermal growth factor (EGF) family is increased after bleomycin-induced injury, we measured lung EGF and heparin-binding- epidermal growth factor (HB-EGF) mRNA levels.	Bleomycin	112-121	epidermal growth factor	Mus musculus	81-84
10226062-9	1999	Steady-state HB-EGF mRNA levels were 321% and 478% of control values in bleomycin-treated lungs at Days 7 and 10, respectively, but were not significantly different in TGF-alpha-deficient and in wild-genotype mice.	Bleomycin	72-81	heparin-binding EGF-like growth factor	Mus musculus	13-19
10381895-10	1999	These data suggest that transfer of the eNOS gene in vivo can selectively reduce pulmonary vascular resistance and pulmonary pressor responses to ET-1, angiotensin II, and hypoxia; enhance pulmonary depressor responses; and attenuate pulmonary hypertension induced by bleomycin.	Bleomycin	268-277	nitric oxide synthase 3, endothelial cell	Mus musculus	40-44
10362718-2	1999	We postulated that bleomycin might stimulate A549 cells, a type II pneumocyte cell line, to release neutrophil and monocyte chemotactic activities (NCA and MCA, respectively).	Bleomycin	19-28	CEA cell adhesion molecule 4	Homo sapiens	148-151
10362718-4	1999	A549 cell supernatant fluids showed NCA and MCA in response to bleomycin in a dose- and time-dependent manner (P &lt; 0.05).	Bleomycin	63-72	CEA cell adhesion molecule 4	Homo sapiens	36-39
10362718-11	1999	Immunoreactive leukotriene B4 receptor, interleukin-8, granulocyte colony-stimulating factor, and monocyte chemoattractant protein-1 significantly increased in supernatant fluids in response to bleomycin.	Bleomycin	194-203	C-X-C motif chemokine ligand 8	Homo sapiens	40-53
10362718-11	1999	Immunoreactive leukotriene B4 receptor, interleukin-8, granulocyte colony-stimulating factor, and monocyte chemoattractant protein-1 significantly increased in supernatant fluids in response to bleomycin.	Bleomycin	194-203	colony stimulating factor 3	Homo sapiens	55-132
10429947-0	1999	Mice with a targeted intronic deletion in the Col1a1 gene respond to bleomycin-induced pulmonary fibrosis with increased expression of the mutant allele.	Bleomycin	69-78	collagen, type I, alpha 1	Mus musculus	46-52
10410269-13	1999	CONCLUSION: These results suggest that bleomycin, as well as IL-1 beta and TNF-alpha, induce NO release from mononuclear cells, and that these cytokines furthermore stimulate fibroblasts to produce NO, which raises the possibility of the involvement of NO in the development of tissue fibrosis induced by bleomycin.	Bleomycin	305-314	tumor necrosis factor	Mus musculus	75-84
10408853-8	1999	The mean in vitro bleomycin-induced breaks per cell (a marker of cancer susceptibility) was significantly higher (0.92) for patients who overexpressed p53 in lung tumour tissue than that for patients with no detectable p53 expression in lung tumour tissue (0.65).	Bleomycin	18-27	tumor protein p53	Homo sapiens	151-154
10408853-8	1999	The mean in vitro bleomycin-induced breaks per cell (a marker of cancer susceptibility) was significantly higher (0.92) for patients who overexpressed p53 in lung tumour tissue than that for patients with no detectable p53 expression in lung tumour tissue (0.65).	Bleomycin	18-27	tumor protein p53	Homo sapiens	219-222
10090171-8	1999	The cellular release of IL-1beta, TNF-alpha, and IL-6 was elevated in response to bleomycin exposure in both controls and patients with SSc.	Bleomycin	82-91	interleukin 1 beta	Homo sapiens	24-32
10228032-0	1999	Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis.	Bleomycin	83-92	chemokine (C-X-C motif) ligand 2	Mus musculus	37-70
10228032-3	1999	We hypothesized that net angiogenesis during the pathogenesis of fibroplasia and deposition of extracellular matrix during bleomycin-induced pulmonary fibrosis are dependent in part upon an overexpression of the angiogenic CXC chemokine, macrophage inflammatory protein-2 (MIP-2).	Bleomycin	123-132	chemokine (C-X-C motif) ligand 2	Mus musculus	238-271
10228032-3	1999	We hypothesized that net angiogenesis during the pathogenesis of fibroplasia and deposition of extracellular matrix during bleomycin-induced pulmonary fibrosis are dependent in part upon an overexpression of the angiogenic CXC chemokine, macrophage inflammatory protein-2 (MIP-2).	Bleomycin	123-132	chemokine (C-X-C motif) ligand 2	Mus musculus	273-278
10228032-4	1999	To test this hypothesis, we measured MIP-2 by specific ELISA in whole lung homogenates in either bleomycin-treated or control CBA/J mice and correlated these levels with lung hydroxyproline.	Bleomycin	97-106	chemokine (C-X-C motif) ligand 2	Mus musculus	37-42
10228032-5	1999	We found that lung tissue from mice treated with bleomycin, compared with that from saline-treated controls, demonstrated a significant increase in the presence of MIP-2 that was correlated to a greater angiogenic response and total lung hydroxyproline content.	Bleomycin	49-58	chemokine (C-X-C motif) ligand 2	Mus musculus	164-169
10228032-6	1999	Neutralizing anti-MIP-2 Abs inhibited the angiogenic activity of day 16 bleomycin-treated lung specimens using an in vivo angiogenesis bioassay.	Bleomycin	72-81	chemokine (C-X-C motif) ligand 2	Mus musculus	18-23
10228032-7	1999	Furthermore, when MIP-2 was depleted in vivo by passive immunization, bleomycin-induced pulmonary fibrosis was significantly reduced without a change in the presence of pulmonary neutrophils, fibroblast proliferation, or collagen gene expression.	Bleomycin	70-79	chemokine (C-X-C motif) ligand 2	Mus musculus	18-23
10417748-0	1999	Perspective article: transforming growth factor-beta: crossroad of glucocorticoid and bleomycin regulation of collagen synthesis in lung fibroblasts.	Bleomycin	86-95	transforming growth factor beta 1	Homo sapiens	21-52
10417748-3	1999	Both glucocorticoids and bleomycin have recently been shown to affect collagen synthesis in opposite directions, by utilizing a common pathway of involving transforming growth factor-beta activator protein binding to the transforming growth factor-beta element.	Bleomycin	25-34	transforming growth factor beta 1	Homo sapiens	156-187
10417748-3	1999	Both glucocorticoids and bleomycin have recently been shown to affect collagen synthesis in opposite directions, by utilizing a common pathway of involving transforming growth factor-beta activator protein binding to the transforming growth factor-beta element.	Bleomycin	25-34	transforming growth factor beta 1	Homo sapiens	221-252
10417748-4	1999	This article presents a mechanistic overview of collagen synthesis regulation by glucocorticoids and bleomycin through the transforming growth factor-beta pathway.	Bleomycin	101-110	transforming growth factor beta 1	Homo sapiens	123-154
10101016-0	1999	Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice.	Bleomycin	81-90	tumor necrosis factor receptor superfamily, member 1b	Mus musculus	20-23
10101016-10	1999	Even though silica and bleomycin induced increases in TNF in the TNFR Ko mice, the mice were protected from the fibrogenic effects of these agents.	Bleomycin	23-32	tumor necrosis factor	Mus musculus	54-57
10101016-10	1999	Even though silica and bleomycin induced increases in TNF in the TNFR Ko mice, the mice were protected from the fibrogenic effects of these agents.	Bleomycin	23-32	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	65-69
10201943-11	1999	Furthermore, baseline and HA fragment-induced MME gene expression in alveolar Mphi from bleomycin-treated rats was inhibited by IFN-gamma.	Bleomycin	88-97	interferon gamma	Rattus norvegicus	128-137
10200322-2	1999	Bleomycin (BLM), a clinically used glycopeptide anticancer agent, is deaminated in vitro by Blmh.	Bleomycin	0-9	bleomycin hydrolase	Mus musculus	92-96
10200322-2	1999	Bleomycin (BLM), a clinically used glycopeptide anticancer agent, is deaminated in vitro by Blmh.	Bleomycin	11-14	bleomycin hydrolase	Mus musculus	92-96
10090171-8	1999	The cellular release of IL-1beta, TNF-alpha, and IL-6 was elevated in response to bleomycin exposure in both controls and patients with SSc.	Bleomycin	82-91	tumor necrosis factor	Homo sapiens	34-43
10090171-8	1999	The cellular release of IL-1beta, TNF-alpha, and IL-6 was elevated in response to bleomycin exposure in both controls and patients with SSc.	Bleomycin	82-91	interleukin 6	Homo sapiens	49-53
20654463-2	1999	We have studied the effects of these compounds on the induction of gene conversion at the trp5 locus in Saccharomyces cerevisiae strain D7 by two chemical mutagens: bleomycin (BLM) and beta-propiolactone (beta-PL).	Bleomycin	165-174	tryptophan synthase TRP5	Saccharomyces cerevisiae S288C	90-94
10088601-8	1999	Analysis of selected cytokines 1 day after initiation of BLM-induced pulmonary fibrosis indicated that the levels of TNF-alpha and IFN-gamma appeared to segregate with fibrosis in both the SCID and wild-type mice.	Bleomycin	57-60	tumor necrosis factor	Mus musculus	117-126
10088601-8	1999	Analysis of selected cytokines 1 day after initiation of BLM-induced pulmonary fibrosis indicated that the levels of TNF-alpha and IFN-gamma appeared to segregate with fibrosis in both the SCID and wild-type mice.	Bleomycin	57-60	interferon gamma	Mus musculus	131-140
11820951-8	1999	The mRNA of MMP-1, MMP-2 were expressed at lower levels in the normal lung tissue and there was an increase in first week, and fourth week group of bleomycin rats with a peak in one week group.	Bleomycin	148-157	matrix metallopeptidase 1	Rattus norvegicus	12-17
11820951-8	1999	The mRNA of MMP-1, MMP-2 were expressed at lower levels in the normal lung tissue and there was an increase in first week, and fourth week group of bleomycin rats with a peak in one week group.	Bleomycin	148-157	matrix metallopeptidase 2	Rattus norvegicus	19-24
11820952-1	1999	OBJECTIVE: Using anti-transforming growth factor-beta(1) antibody binding to transforming growth factor-beta(1) (TGF-beta(1)) in conditioned supernatant obtained from alveolar macrophages (AM) in broncho-alveolar lavage fluid (BALF) in bleomycin-induced rats, we investigated the effect of binding of TGF beta(1) to anti-TGF beta(1) antibody on proliferation and synthesis of collagen by fibroblast in pulmonary fibrosis.	Bleomycin	236-245	transforming growth factor, beta 1	Rattus norvegicus	22-56
11820952-1	1999	OBJECTIVE: Using anti-transforming growth factor-beta(1) antibody binding to transforming growth factor-beta(1) (TGF-beta(1)) in conditioned supernatant obtained from alveolar macrophages (AM) in broncho-alveolar lavage fluid (BALF) in bleomycin-induced rats, we investigated the effect of binding of TGF beta(1) to anti-TGF beta(1) antibody on proliferation and synthesis of collagen by fibroblast in pulmonary fibrosis.	Bleomycin	236-245	transforming growth factor, beta 1	Rattus norvegicus	77-111
11820952-1	1999	OBJECTIVE: Using anti-transforming growth factor-beta(1) antibody binding to transforming growth factor-beta(1) (TGF-beta(1)) in conditioned supernatant obtained from alveolar macrophages (AM) in broncho-alveolar lavage fluid (BALF) in bleomycin-induced rats, we investigated the effect of binding of TGF beta(1) to anti-TGF beta(1) antibody on proliferation and synthesis of collagen by fibroblast in pulmonary fibrosis.	Bleomycin	236-245	transforming growth factor, beta 1	Rattus norvegicus	113-124
10668470-8	1999	Bleomycin treatment produced a moderate increase of ssb at lower concentrations and a striking increase of dsb at higher concentrations that coincided with the presence of apoptosis and DNA ladders.	Bleomycin	0-9	small RNA binding exonuclease protection factor La	Homo sapiens	52-55
9923599-1	1999	The transposon Tn5 carries a gene, ble, which confers resistance to bleomycin (Bm) and gives a survival advantage to its host cell.	Bleomycin	68-77	bleomycin resistance protein	Escherichia coli	35-38
9923599-1	1999	The transposon Tn5 carries a gene, ble, which confers resistance to bleomycin (Bm) and gives a survival advantage to its host cell.	Bleomycin	79-81	bleomycin resistance protein	Escherichia coli	35-38
9892418-8	1999	Fibrotic lesions in bleomycin-treated rat lungs were rich in VEGF-positive cells presenting with a heterogeneous phenotype (mainly SP-D-positive type II pneumocytes, alpha-SM actin-positive myofibroblasts).	Bleomycin	20-29	vascular endothelial growth factor A	Rattus norvegicus	61-65
9892418-8	1999	Fibrotic lesions in bleomycin-treated rat lungs were rich in VEGF-positive cells presenting with a heterogeneous phenotype (mainly SP-D-positive type II pneumocytes, alpha-SM actin-positive myofibroblasts).	Bleomycin	20-29	surfactant protein D	Rattus norvegicus	131-135
9843859-0	1998	Alveolar macrophage apoptosis and TNF-alpha, but not p53, expression correlate with murine response to bleomycin.	Bleomycin	103-112	tumor necrosis factor	Mus musculus	34-43
10546901-0	1999	An allele of the yeast RPB7 gene, encoding an essential subunit of RNA polymerase II, reduces cellular resistance to the antitumor drug bleomycin.	Bleomycin	136-145	DNA-directed RNA polymerase II subunit RPB7	Saccharomyces cerevisiae S288C	23-27
10546901-3	1999	In the yeast Saccharomyces cerevisiae, the transcriptional activator Imp2 is required to fend off the toxic effects of bleomycin.	Bleomycin	119-128	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	69-73
10546901-4	1999	However, it remains unclear whether Imp2 controls the expression of a protein that either repairs bleomycin-induced DNA lesions, or detoxifies the drug, and or both.	Bleomycin	98-107	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	36-40
10546901-10	1999	Two dimensional gel analysis revealed that the expression of several proteins were diminished or absent in the rpb7::mini-Tn3 mutant when challenged with bleomycin.	Bleomycin	154-163	DNA-directed RNA polymerase II subunit RPB7	Saccharomyces cerevisiae S288C	111-115
10836326-0	1999	ICAM-1 mediates lung leukocyte recruitment but not pulmonary fibrosis in a murine model of bleomycin-induced lung injury.	Bleomycin	91-100	intercellular adhesion molecule 1	Mus musculus	0-6
10836326-3	1999	The purpose of this report was to investigate the role of the ICAM-1/LFA-1alpha pathway in a murine model of bleomycin-induced lung injury.	Bleomycin	109-118	intercellular adhesion molecule 1	Mus musculus	62-68
10836326-3	1999	The purpose of this report was to investigate the role of the ICAM-1/LFA-1alpha pathway in a murine model of bleomycin-induced lung injury.	Bleomycin	109-118	integrin alpha L	Mus musculus	69-79
10836326-10	1999	This study suggests that the intercellular adhesion molecule-1/lymphocyte function-associated antigen-1alpha pathway mediates the accumulation of inflammatory cells in the injured lung caused by bleomycin; however, other mechanisms are important for the subsequent development of pulmonary fibrosis.	Bleomycin	195-204	intercellular adhesion molecule 1	Mus musculus	29-62
9841917-5	1998	Cisplatin, mitomycin, methotrexate, mitoxantrone, doxorubicin, and bleomycin at concentrations present in the sera of patients during therapy led to an upregulation of both CD95 receptor and CD95 ligand.	Bleomycin	67-76	Fas cell surface death receptor	Homo sapiens	173-177
9841917-5	1998	Cisplatin, mitomycin, methotrexate, mitoxantrone, doxorubicin, and bleomycin at concentrations present in the sera of patients during therapy led to an upregulation of both CD95 receptor and CD95 ligand.	Bleomycin	67-76	Fas cell surface death receptor	Homo sapiens	191-195
9843859-11	1998	However, p53-deficient mice developed BLM-induced lung injury, exhibited similar lung cell proliferation (measured as proliferating cell nuclear antigen immunostaining), and accumulated similar amounts of lung hydroxyproline (65 +/- 6.9 microgram/lung) as did C57BL/6 (62 +/- 6.5 microgram/lung) mice.	Bleomycin	38-41	transformation related protein 53, pseudogene	Mus musculus	9-12
9823965-9	1998	Collectively, these data suggest that the most suitable cytotoxic agents for use in combination with PARP inhibitors are methylating agents, bleomycin and ionizing radiation, but not anti-metabolites.	Bleomycin	141-150	poly (ADP-ribose) polymerase family, member 1	Mus musculus	101-105
9877498-0	1998	Loss of immunoreactivity for RTI40, a type I cell-specific protein in the alveolar epithelium of rat lungs with bleomycin-induced fibrosis.	Bleomycin	112-121	podoplanin	Rattus norvegicus	29-34
9877498-5	1998	Western blot analysis revealed elevated levels of RTI40 in the bronchoalveolar fluid of bleomycin-treated rats with a maximum at day 7 after treatment.	Bleomycin	88-97	podoplanin	Rattus norvegicus	50-55
9877498-6	1998	Twenty-eight days after bleomycin application, the bronchoalveolar fluid contained three times the amount of RTI40 x mg protein(-1) of control lungs, as determined by semiquantitative dot blot.	Bleomycin	24-33	podoplanin	Rattus norvegicus	109-114
9881949-6	1998	GM-CSF mRNA was already increased in the total lung at 6 hours and maximal at 12 hours after bleomycin instillation and returned to basal levels at 24 hours.	Bleomycin	93-102	colony stimulating factor 2	Rattus norvegicus	0-6
9881949-9	1998	Our results show for the first time that GM-CSF is expressed, very early and temporarily, by inflammatory cells accumulating in the alveolus after bleomycin administration and before the appearance of TGF-beta1.	Bleomycin	147-156	colony stimulating factor 2	Rattus norvegicus	41-47
9855622-1	1998	Bleomycin hydrolase (BH) is a highly conserved cysteine proteinase that deamidates and inactivates the anticancer drug bleomycin.	Bleomycin	119-128	bleomycin hydrolase	Homo sapiens	0-19
9855622-1	1998	Bleomycin hydrolase (BH) is a highly conserved cysteine proteinase that deamidates and inactivates the anticancer drug bleomycin.	Bleomycin	119-128	bleomycin hydrolase	Homo sapiens	21-23
11480082-1	1998	OBJECTIVE: mRNA for tumour necrosis factor-alpha(TNF-alpha) and procollagen I [pro alpha 1(I)] and III (pro alpha 1(III) was measured in bleomycin treated mice to evaluate their roles in pulmonary fibrosis.	Bleomycin	137-146	tumor necrosis factor	Mus musculus	49-58
11480082-6	1998	RESULT: The levels of TNF-alpha mRNA in lungs of bleomycin groups on days 3,7 were significantly higher than those of control group (t = 10.33 and 12.54 respectively; P &lt; 0.01).	Bleomycin	49-58	tumor necrosis factor	Rattus norvegicus	22-31
11480082-10	1998	The increased expression of TNF-alpha gene may play an important role in the early events of bleomycin-induced pulmonary fibrosis.	Bleomycin	93-102	tumor necrosis factor	Rattus norvegicus	28-37
9881949-0	1998	Early granulocyte-macrophage colony-stimulating factor expression by alveolar inflammatory cells during bleomycin-induced rat lung fibrosis.	Bleomycin	104-113	colony stimulating factor 2	Rattus norvegicus	6-54
9881949-5	1998	Herein we have studied, using RT-competitive PCR, the expression of GM-CSF mRNA during the early steps of pulmonary fibrosis development after intra-alveolar instillation of bleomycin, a well-established experimental model of this lesion.	Bleomycin	174-183	colony stimulating factor 2	Rattus norvegicus	68-74
9839161-0	1998	Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice.	Bleomycin	56-65	tumor necrosis factor	Mus musculus	39-42
9839161-16	1998	Furthermore, in addition to the release of the TNF ligand, it appears that the presence of TNF receptors is necessary for the development of BLM-induced lung injury, and signaling through these receptors may contribute to the regulation of the TGF-beta 1 mRNA expression observed in response to bleomycin.	Bleomycin	295-304	tumor necrosis factor	Mus musculus	91-94
9839161-16	1998	Furthermore, in addition to the release of the TNF ligand, it appears that the presence of TNF receptors is necessary for the development of BLM-induced lung injury, and signaling through these receptors may contribute to the regulation of the TGF-beta 1 mRNA expression observed in response to bleomycin.	Bleomycin	295-304	transforming growth factor, beta 1	Mus musculus	244-254
9848274-1	1998	Molecular analysis of a bleomycin-induced rearrangement of the aprt gene in CHO cells revealed that it consisted of a nearly perfect three-way exchange among non-homologous sequences, consistent with a mechanism involving cyclically permuted misjoining of the six ends of three double-strand breaks.	Bleomycin	24-33	adenine phosphoribosyltransferase	Cricetulus griseus	63-67
9823772-0	1998	The role of IL-5 in bleomycin-induced pulmonary fibrosis.	Bleomycin	20-29	interleukin 5	Mus musculus	12-16
9748474-1	1998	Mammalian bleomycin hydrolases (BH) are enzymes with proven exopeptidase activity responsible for deamidation of the beta-aminoalanine moiety in bleomycin and are thought to limit the therapeutic efficacy of the drug.	Bleomycin	10-19	hemoglobin subunit alpha 1	Homo sapiens	32-34
9786884-2	1998	The antitumor drug bleomycin produces exclusively OAS in the form of C-4-keto-C-1-aldehydes in unbroken DNA strands and 3"-phosphoglycolate esters terminating strand breaks.	Bleomycin	19-28	complement C4A (Rodgers blood group)	Homo sapiens	69-72
9786884-2	1998	The antitumor drug bleomycin produces exclusively OAS in the form of C-4-keto-C-1-aldehydes in unbroken DNA strands and 3"-phosphoglycolate esters terminating strand breaks.	Bleomycin	19-28	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	78-81
9748474-2	1998	We have recently determined that the highly conserved BH-like domain in the C-terminus of human bleomycin hydrolase (hBH) is critical both for in vitro aminopeptidase and bleomycin metabolizing activities.	Bleomycin	96-105	hemoglobin subunit alpha 1	Homo sapiens	54-56
9748474-2	1998	We have recently determined that the highly conserved BH-like domain in the C-terminus of human bleomycin hydrolase (hBH) is critical both for in vitro aminopeptidase and bleomycin metabolizing activities.	Bleomycin	96-105	hemoglobin subunit alpha 1	Homo sapiens	117-120
9748474-4	1998	CHO cells expressing hBH had 50% less chromatid breaks after bleomycin treatment compared with mock transfected cells.	Bleomycin	61-70	hemoglobin subunit alpha 1	Homo sapiens	21-24
9748474-6	1998	These results demonstrate that intracellular hBH levels can influence the clastogenic action of bleomycin and that the C-terminus has a functional role in the biological activity of hBH.	Bleomycin	96-105	hemoglobin subunit alpha 1	Homo sapiens	45-48
10190124-15	1998	When exposure of gamma-ray or bleomycin to neurons died in p53 dependent manner.	Bleomycin	30-39	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	59-62
9766634-0	1998	TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury.	Bleomycin	46-55	tumor necrosis factor	Mus musculus	0-3
9766634-0	1998	TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury.	Bleomycin	46-55	interleukin 6	Mus musculus	8-12
9766634-0	1998	TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury.	Bleomycin	46-55	chemokine (C-C motif) ligand 3	Mus musculus	21-31
9766634-1	1998	Previously, macrophage inflammatory protein-1alpha (MIP-1alpha), a member of the C-C chemokine family, has been implicated in bleomycin-induced pulmonary fibrosis, a model of the human disease idiopathic pulmonary fibrosis.	Bleomycin	126-135	C-C motif chemokine ligand 3	Homo sapiens	12-50
9766634-1	1998	Previously, macrophage inflammatory protein-1alpha (MIP-1alpha), a member of the C-C chemokine family, has been implicated in bleomycin-induced pulmonary fibrosis, a model of the human disease idiopathic pulmonary fibrosis.	Bleomycin	126-135	C-C motif chemokine ligand 3	Homo sapiens	52-62
9766634-2	1998	Neutralization of MIP-1alpha protein with anti-MIP-1alpha antibodies significantly attenuated both mononuclear phagocyte recruitment and pulmonary fibrosis in bleomycin-challenged CBA/J mice.	Bleomycin	159-168	chemokine (C-C motif) ligand 3	Mus musculus	18-28
9766634-2	1998	Neutralization of MIP-1alpha protein with anti-MIP-1alpha antibodies significantly attenuated both mononuclear phagocyte recruitment and pulmonary fibrosis in bleomycin-challenged CBA/J mice.	Bleomycin	159-168	chemokine (C-C motif) ligand 3	Mus musculus	47-57
9766634-3	1998	However, the specific stimuli for MIP-1alpha expression in the bleomycin-induced lesion have not been characterized.	Bleomycin	63-72	chemokine (C-C motif) ligand 3	Mus musculus	34-44
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	62-71	tumor necrosis factor	Mus musculus	73-94
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	62-71	tumor necrosis factor	Mus musculus	96-99
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	62-71	chemokine (C-C motif) ligand 3	Mus musculus	166-176
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	194-203	tumor necrosis factor	Mus musculus	73-94
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	194-203	tumor necrosis factor	Mus musculus	96-99
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	194-203	interleukin 6	Mus musculus	105-118
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	194-203	interleukin 6	Mus musculus	120-124
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	194-203	chemokine (C-C motif) ligand 3	Mus musculus	166-176
9766634-5	1998	Elevated levels of bioactive TNF and IL-6 were detected in bronchoalveolar lavage (BAL) fluid and lung homogenates from bleomycin-treated CBA/J mice at time points post-bleomycin challenge, which precede MIP-1alpha protein expression.	Bleomycin	120-129	tumor necrosis factor	Mus musculus	29-32
9766634-5	1998	Elevated levels of bioactive TNF and IL-6 were detected in bronchoalveolar lavage (BAL) fluid and lung homogenates from bleomycin-treated CBA/J mice at time points post-bleomycin challenge, which precede MIP-1alpha protein expression.	Bleomycin	120-129	interleukin 6	Mus musculus	37-41
9766634-5	1998	Elevated levels of bioactive TNF and IL-6 were detected in bronchoalveolar lavage (BAL) fluid and lung homogenates from bleomycin-treated CBA/J mice at time points post-bleomycin challenge, which precede MIP-1alpha protein expression.	Bleomycin	120-129	chemokine (C-C motif) ligand 3	Mus musculus	204-214
9766634-5	1998	Elevated levels of bioactive TNF and IL-6 were detected in bronchoalveolar lavage (BAL) fluid and lung homogenates from bleomycin-treated CBA/J mice at time points post-bleomycin challenge, which precede MIP-1alpha protein expression.	Bleomycin	169-178	tumor necrosis factor	Mus musculus	29-32
9766634-5	1998	Elevated levels of bioactive TNF and IL-6 were detected in bronchoalveolar lavage (BAL) fluid and lung homogenates from bleomycin-treated CBA/J mice at time points post-bleomycin challenge, which precede MIP-1alpha protein expression.	Bleomycin	169-178	interleukin 6	Mus musculus	37-41
9766634-6	1998	Treatment of bleomycin-challenged mice with soluble TNF receptor (sTNFr) or anti-IL-6 antibodies significantly decreased MIP-1alpha protein expression in the lungs.	Bleomycin	13-22	tumor necrosis factor	Mus musculus	52-55
9766634-6	1998	Treatment of bleomycin-challenged mice with soluble TNF receptor (sTNFr) or anti-IL-6 antibodies significantly decreased MIP-1alpha protein expression in the lungs.	Bleomycin	13-22	interleukin 6	Mus musculus	81-85
9766634-6	1998	Treatment of bleomycin-challenged mice with soluble TNF receptor (sTNFr) or anti-IL-6 antibodies significantly decreased MIP-1alpha protein expression in the lungs.	Bleomycin	13-22	chemokine (C-C motif) ligand 3	Mus musculus	121-131
9766634-7	1998	Furthermore, normal alveolar macrophages secreted elevated levels of MIP-1alpha protein in response to treatment with TNF plus IL-6 or bleomycin plus IL-6, but not TNF, bleomycin, or IL-6 alone.	Bleomycin	135-144	chemokine (C-C motif) ligand 3	Mus musculus	69-79
9766634-7	1998	Furthermore, normal alveolar macrophages secreted elevated levels of MIP-1alpha protein in response to treatment with TNF plus IL-6 or bleomycin plus IL-6, but not TNF, bleomycin, or IL-6 alone.	Bleomycin	169-178	chemokine (C-C motif) ligand 3	Mus musculus	69-79
9766634-8	1998	Finally, leukocytes recovered from the BAL fluid of bleomycin-challenged mice secreted higher levels of MIP-1alpha protein, compared to controls, when treated with TNF alone.	Bleomycin	52-61	chemokine (C-C motif) ligand 3	Mus musculus	104-114
10397478-9	1998	L-CAV-treated cells were also significantly more sensitive to cisplatin, 5-fluorouracil, mitoxantrone and bleomycin than were untreated controls.	Bleomycin	106-115	caveolin 2	Homo sapiens	2-5
9766634-8	1998	Finally, leukocytes recovered from the BAL fluid of bleomycin-challenged mice secreted higher levels of MIP-1alpha protein, compared to controls, when treated with TNF alone.	Bleomycin	52-61	tumor necrosis factor	Mus musculus	164-167
9766634-9	1998	Based on the data presented here, we propose that TNF and IL-6 are part of a cytokine network that modulates MIP-1alpha protein expression in the profibrotic inflammatory lesion during the response to intratracheal bleomycin challenge.	Bleomycin	215-224	tumor necrosis factor	Mus musculus	50-53
9766634-9	1998	Based on the data presented here, we propose that TNF and IL-6 are part of a cytokine network that modulates MIP-1alpha protein expression in the profibrotic inflammatory lesion during the response to intratracheal bleomycin challenge.	Bleomycin	215-224	interleukin 6	Mus musculus	58-62
9766634-9	1998	Based on the data presented here, we propose that TNF and IL-6 are part of a cytokine network that modulates MIP-1alpha protein expression in the profibrotic inflammatory lesion during the response to intratracheal bleomycin challenge.	Bleomycin	215-224	chemokine (C-C motif) ligand 3	Mus musculus	109-119
9713990-6	1998	Under conditions of cellular stress (ultraviolet irradiation or exposure to bleomycin or cisplatin), expression of TP53TG1 was induced in a wild-type TP53-dependent manner, indicating that this gene is likely to play an important role in the signaling pathway of TP53 and may function in response to cellular damage.	Bleomycin	76-85	TP53 target 1	Homo sapiens	115-122
9751125-3	1998	Bleomycin-induced apoptosis was accompanied by decreases in bcl-2 and bcl-xl and increases in p53, bak, and bax protein levels.	Bleomycin	0-9	B cell leukemia/lymphoma 2	Mus musculus	60-65
9751125-3	1998	Bleomycin-induced apoptosis was accompanied by decreases in bcl-2 and bcl-xl and increases in p53, bak, and bax protein levels.	Bleomycin	0-9	BCL2-like 1	Mus musculus	70-76
9751125-3	1998	Bleomycin-induced apoptosis was accompanied by decreases in bcl-2 and bcl-xl and increases in p53, bak, and bax protein levels.	Bleomycin	0-9	transformation related protein 53, pseudogene	Mus musculus	94-97
9751125-3	1998	Bleomycin-induced apoptosis was accompanied by decreases in bcl-2 and bcl-xl and increases in p53, bak, and bax protein levels.	Bleomycin	0-9	BCL2-associated X protein	Mus musculus	108-111
9751125-5	1998	Bleomycin-induced apoptosis was partially dependent on p53, whereas TGF-beta-induced apoptosis was independent of p53.	Bleomycin	0-9	transformation related protein 53, pseudogene	Mus musculus	55-58
9713990-6	1998	Under conditions of cellular stress (ultraviolet irradiation or exposure to bleomycin or cisplatin), expression of TP53TG1 was induced in a wild-type TP53-dependent manner, indicating that this gene is likely to play an important role in the signaling pathway of TP53 and may function in response to cellular damage.	Bleomycin	76-85	tumor protein p53	Homo sapiens	115-119
9713990-6	1998	Under conditions of cellular stress (ultraviolet irradiation or exposure to bleomycin or cisplatin), expression of TP53TG1 was induced in a wild-type TP53-dependent manner, indicating that this gene is likely to play an important role in the signaling pathway of TP53 and may function in response to cellular damage.	Bleomycin	76-85	tumor protein p53	Homo sapiens	150-154
9700098-0	1998	Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis.	Bleomycin	66-75	cellular communication network factor 2	Mus musculus	0-31
9875145-0	1998	Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats.	Bleomycin	73-82	fibroblast growth factor 7	Rattus norvegicus	37-63
9875145-3	1998	The present study examined whether KGF would prevent bleomycin-induced lung fibrosis.	Bleomycin	53-62	fibroblast growth factor 7	Rattus norvegicus	35-38
9875145-6	1998	Double instillation of KGF prevented the loss of body weight and reduction in total lung capacity (TLC) due to Bleo, and markedly attenuated the protein accumulation and mRNA expression of collagen types I and III and the decreased expression of surfactant protein mRNAs in the fibrotic lesions of Bleo-treated rats.	Bleomycin	111-115	fibroblast growth factor 7	Rattus norvegicus	23-26
9700098-7	1998	CTGF mRNA expression was upregulated in the sensitive, but not in the resistant, mouse strain after administration of bleomycin.	Bleomycin	118-127	cellular communication network factor 2	Mus musculus	0-4
11326882-0	1998	[Expression of surfactant protein SP-A, SP-B, and SP-C mRNA in lungs of rats with bleomycin-induced pulmonary fibrosis].	Bleomycin	82-91	surfactant protein C	Rattus norvegicus	50-54
9819620-8	1998	Bleomycin was responsible for all nodular lesions, cytosine-arabinoside and interleukin-2 for pulmonary edema.	Bleomycin	0-9	interleukin 2	Homo sapiens	76-89
9693281-0	1998	Expression of B7-1, B7-2, and interleukin 12 in bleomycin-induced pneumopathy in mice.	Bleomycin	48-57	CD80 antigen	Mus musculus	14-24
9693281-5	1998	METHODS: In this study, we investigated the expression of B7-1, B7-2, and IL-12 in bleomycin-induced pneumopathy in mice using reverse transcription polymerase chain reaction (RT-PCR), RT in situ PCR, and immunohistochemistry.	Bleomycin	83-92	CD80 antigen	Mus musculus	58-62
9693281-6	1998	RESULTS: We observed concurrent upregulation of B7-1, B7-2, and IL-12p40 mRNA in the lung tissues at 1 h to 7 days after bleomycin instillation into the trachea.	Bleomycin	121-130	CD80 antigen	Mus musculus	48-52
9693281-6	1998	RESULTS: We observed concurrent upregulation of B7-1, B7-2, and IL-12p40 mRNA in the lung tissues at 1 h to 7 days after bleomycin instillation into the trachea.	Bleomycin	121-130	interleukin 12b	Mus musculus	64-72
9771487-7	1998	Zymograms demonstrated the highest level of gelatinase A (MMP-2) activity in BAL fluid in the first 2 weeks after bleomycin.	Bleomycin	114-123	matrix metallopeptidase 2	Rattus norvegicus	44-56
9771487-7	1998	Zymograms demonstrated the highest level of gelatinase A (MMP-2) activity in BAL fluid in the first 2 weeks after bleomycin.	Bleomycin	114-123	matrix metallopeptidase 2	Rattus norvegicus	58-63
11326882-8	1998	CONCLUSION: The results show that the changes of expressions of SP-A, SP-B and SP-CmRNA occur during the development of bleomycin-induced pulmonary fibrosis in rats and they may play a role in the pathogenesis of lung fibrosis.	Bleomycin	120-129	surfactant protein A1	Rattus norvegicus	64-68
11326882-8	1998	CONCLUSION: The results show that the changes of expressions of SP-A, SP-B and SP-CmRNA occur during the development of bleomycin-induced pulmonary fibrosis in rats and they may play a role in the pathogenesis of lung fibrosis.	Bleomycin	120-129	surfactant protein B	Rattus norvegicus	70-74
9569231-0	1998	Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	70-79	endothelin 1	Rattus norvegicus	10-22
9609745-0	1998	Induction of tenascin in rat lungs undergoing bleomycin-induced pulmonary fibrosis.	Bleomycin	46-55	tenascin C	Rattus norvegicus	13-21
9609745-2	1998	In the present study, we investigated the expression of extracellular matrix glycoprotein tenascin (TN) during pulmonary injury induced by bleomycin.	Bleomycin	139-148	tenascin C	Rattus norvegicus	90-98
9609745-2	1998	In the present study, we investigated the expression of extracellular matrix glycoprotein tenascin (TN) during pulmonary injury induced by bleomycin.	Bleomycin	139-148	tenascin C	Rattus norvegicus	100-102
9609745-6	1998	The induction and localization of TN mRNA during bleomycin-induced pulmonary injury were also examined by in situ hybridization.	Bleomycin	49-58	tenascin C	Rattus norvegicus	34-36
9609745-7	1998	TN mRNA was focally induced in rat lungs 3 days after bleomycin administration.	Bleomycin	54-63	tenascin C	Rattus norvegicus	0-2
9609745-13	1998	This study demonstrated that TN is a unique early-response extracellular matrix component to bleomycin-induced pulmonary injury and is induced at the sites of the inflammation, suggesting a potential role of TN as a modulator of pulmonary inflammation and repair.	Bleomycin	93-102	tenascin C	Rattus norvegicus	29-31
9622642-0	1998	Changes in c-Jun but not Bcl-2 family proteins in p53-dependent apoptosis of mouse cerebellar granule neurons induced by DNA damaging agent bleomycin.	Bleomycin	140-149	jun proto-oncogene	Mus musculus	11-16
9622642-0	1998	Changes in c-Jun but not Bcl-2 family proteins in p53-dependent apoptosis of mouse cerebellar granule neurons induced by DNA damaging agent bleomycin.	Bleomycin	140-149	transformation related protein 53, pseudogene	Mus musculus	50-53
9622642-4	1998	In contrast, cells from p53-deficient mice were resistant to bleomycin-induced neuronal death.	Bleomycin	61-70	transformation related protein 53, pseudogene	Mus musculus	24-27
9622642-6	1998	These results show that p53 is required for the bleomycin-induced cerebellar granule cell death.	Bleomycin	48-57	transformation related protein 53, pseudogene	Mus musculus	24-27
9604718-4	1998	Total protein in bronchoalveolar lavage (BAL) fluids after bleomycin injury from KGF-pretreated rats was significantly lower than the levels in saline-pretreated rats.	Bleomycin	59-68	fibroblast growth factor 7	Rattus norvegicus	81-84
9604718-9	1998	Numbers of type II pneumocytes and Clara cells in KGF-pretreated lungs after a high dose of bleomycin were close to the normal in intact lungs.	Bleomycin	92-101	fibroblast growth factor 7	Rattus norvegicus	50-53
9604718-11	1998	In conclusion, KGF prevents bleomycin-induced end-stage pulmonary injury and mortality probably at least partly by decreasing protein-rich pulmonary edema, protein expression of fibrogenic cytokines TGF beta and PDGF-BB, and type II cell loss during the course of lung injury.	Bleomycin	28-37	fibroblast growth factor 7	Rattus norvegicus	15-18
9622642-9	1998	In contrast, the levels of c-Jun protein significantly increased 6 h after treatment with bleomycin in wild type but not in p53-deficient cerebellar granule cells.	Bleomycin	90-99	jun proto-oncogene	Mus musculus	27-32
9622642-10	1998	These results raise the possibility that c-Jun is required for p53-dependent neuronal apoptosis induced by bleomycin.	Bleomycin	107-116	jun proto-oncogene	Mus musculus	41-46
9622642-10	1998	These results raise the possibility that c-Jun is required for p53-dependent neuronal apoptosis induced by bleomycin.	Bleomycin	107-116	transformation related protein 53, pseudogene	Mus musculus	63-66
9604718-0	1998	Keratinocyte growth factor decreases pulmonary edema, transforming growth factor-beta and platelet-derived growth factor-BB expression, and alveolar type II cell loss in bleomycin-induced lung injury.	Bleomycin	170-179	fibroblast growth factor 7	Rattus norvegicus	0-26
9604718-1	1998	Keratinocyte growth factor (KGF), a potent growth factor for type II pneumocytes and Clara cells, has been shown to prevent the end-stage pulmonary fibrosis and mortality in a rat model of bleomycin-induced lung injury.	Bleomycin	189-198	fibroblast growth factor 7	Rattus norvegicus	0-26
9604718-1	1998	Keratinocyte growth factor (KGF), a potent growth factor for type II pneumocytes and Clara cells, has been shown to prevent the end-stage pulmonary fibrosis and mortality in a rat model of bleomycin-induced lung injury.	Bleomycin	189-198	fibroblast growth factor 7	Rattus norvegicus	28-31
9584198-1	1998	Yeast bleomycin hydrolase, Gal6p, is a cysteine peptidase that detoxifies the anticancer drug bleomycin.	Bleomycin	6-15	bleomycin hydrolase	Saccharomyces cerevisiae S288C	27-32
9584198-6	1998	Variant Gal6 proteins that fail to bind nucleic acid also exhibit reduced ability to protect cells from bleomycin toxicity, suggesting that the nucleic acid binding activity of Gal6p is important in bleomycin detoxification and may be involved in its normal biological functions.	Bleomycin	104-113	bleomycin hydrolase	Saccharomyces cerevisiae S288C	8-12
9584198-6	1998	Variant Gal6 proteins that fail to bind nucleic acid also exhibit reduced ability to protect cells from bleomycin toxicity, suggesting that the nucleic acid binding activity of Gal6p is important in bleomycin detoxification and may be involved in its normal biological functions.	Bleomycin	104-113	bleomycin hydrolase	Saccharomyces cerevisiae S288C	177-182
9584198-6	1998	Variant Gal6 proteins that fail to bind nucleic acid also exhibit reduced ability to protect cells from bleomycin toxicity, suggesting that the nucleic acid binding activity of Gal6p is important in bleomycin detoxification and may be involved in its normal biological functions.	Bleomycin	199-208	bleomycin hydrolase	Saccharomyces cerevisiae S288C	8-12
9584198-6	1998	Variant Gal6 proteins that fail to bind nucleic acid also exhibit reduced ability to protect cells from bleomycin toxicity, suggesting that the nucleic acid binding activity of Gal6p is important in bleomycin detoxification and may be involved in its normal biological functions.	Bleomycin	199-208	bleomycin hydrolase	Saccharomyces cerevisiae S288C	177-182
9569231-3	1998	Lung Et-1 content doubled by 3 d following the intratracheal instillation of bleomycin, and continued to increase up to 7 d when values were about threefold greater than controls.	Bleomycin	77-86	endothelin 1	Homo sapiens	5-9
9528853-5	1998	By 8 days after a brief exposure to DNA strand breaking agents, bleomycin or actinomycin D, p53 protein is at baseline levels, while the p53 transactivation level is only slightly above its baseline.	Bleomycin	64-73	tumor protein p53	Homo sapiens	92-95
9544689-0	1998	Early detection of bleomycin-induced lung injury in rat using indium-111-labeled antibody directed against intercellular adhesion molecule-1.	Bleomycin	19-28	intercellular adhesion molecule 1	Rattus norvegicus	107-140
9544689-1	1998	UNLABELLED: We have investigated whether an (111)In-labeled mouse monoclonal antibody to rat intercellular adhesion molecule-1 ((111)In*aICAM-1) could detect lung injury early in rats treated with bleomycin.	Bleomycin	197-206	intercellular adhesion molecule 1	Rattus norvegicus	93-126
9544689-10	1998	Lung ICAM-1 immunofluorescence intensity increased in the bleomycin-treated samples compared to uninjured lungs.	Bleomycin	58-67	intercellular adhesion molecule 1	Rattus norvegicus	5-11
9645446-11	1998	In addition, increased numbers of phenotypically altered myofibroblasts (alpha-smooth muscle actin immunopositive) and fibroblast (vimentin immunopositive) were seen in bleomycin-treated lungs and found to express HSP47.	Bleomycin	169-178	actin gamma 2, smooth muscle	Rattus norvegicus	73-98
9545552-6	1998	Parallel measurements, in a variety of clinical conditions in which there was a complete saturation of the plasma transferrin, showed that the bleomycin assay and the aconitase assay can give similar results for LMrFe.	Bleomycin	143-152	transferrin	Homo sapiens	114-125
9546047-3	1998	In this work we investigated the hydrolytic activity of PepC towards various substrates: bleomycin A2, aminoacyl-p-nitroanilides (pNA) and peptides.	Bleomycin	89-101	peptidase C	Homo sapiens	56-60
9659353-4	1998	METHODS: Bleomycin-induced lung injury was assessed by light microscopic examination, measurement of neutrophil elastase activity and of the interleukin 8 (IL-8) content in bronchoalveolar lavage (BAL) fluid.	Bleomycin	9-18	elastase, neutrophil expressed	Rattus norvegicus	101-120
9502424-4	1998	The effect of bleomycin on the expression of the enzymes responsible for extracellular matrix degradation, the matrix metalloproteinases (MMPs), and their inhibitors (TIMPs), was selective and showed temporal differences during the development of fibrosis.	Bleomycin	14-23	matrix metallopeptidase 13	Mus musculus	138-142
9502424-5	1998	Of the MMPs tested, bleomycin treatment resulted in the up-regulation of gelatinase A and macrophage metalloelastase gene expression in whole-lung homogenates, whereas gelatinase B, stromelysin-1, and interstitial collagenase gene expression was not significantly changed.	Bleomycin	20-29	matrix metallopeptidase 13	Mus musculus	7-11
9502424-5	1998	Of the MMPs tested, bleomycin treatment resulted in the up-regulation of gelatinase A and macrophage metalloelastase gene expression in whole-lung homogenates, whereas gelatinase B, stromelysin-1, and interstitial collagenase gene expression was not significantly changed.	Bleomycin	20-29	matrix metallopeptidase 2	Mus musculus	73-85
9502424-5	1998	Of the MMPs tested, bleomycin treatment resulted in the up-regulation of gelatinase A and macrophage metalloelastase gene expression in whole-lung homogenates, whereas gelatinase B, stromelysin-1, and interstitial collagenase gene expression was not significantly changed.	Bleomycin	20-29	matrix metallopeptidase 12	Mus musculus	90-116
9502424-5	1998	Of the MMPs tested, bleomycin treatment resulted in the up-regulation of gelatinase A and macrophage metalloelastase gene expression in whole-lung homogenates, whereas gelatinase B, stromelysin-1, and interstitial collagenase gene expression was not significantly changed.	Bleomycin	20-29	matrix metallopeptidase 13	Mus musculus	201-225
9502424-7	1998	The strong correlation between enhanced extracellular matrix gene expression, differential MMP and TIMP gene expression, and histopathological evidence of fibrosis suggest that dysregulated matrix remodeling is likely to contribute to the pathology of bleomycin-induced pulmonary fibrosis.	Bleomycin	252-261	tissue inhibitor of metalloproteinase 1	Mus musculus	99-103
9486589-0	1998	Induction of tumor necrosis factor-alpha as a cause of bleomycin-related toxicity.	Bleomycin	55-64	tumor necrosis factor	Homo sapiens	13-40
9486589-5	1998	RESULTS: Compared with the pretreatment value, TNF-alpha was significantly increased 3, 4.5, and 24 hours after bleomycin infusion.	Bleomycin	112-121	tumor necrosis factor	Homo sapiens	47-56
9486589-7	1998	CONCLUSIONS: The increase in TNF-alpha after administration of bleomycin suggests a role for this cytokine in the development of the acute side effects and probably also in the occurrence of bleomycin-induced pulmonary toxicity.	Bleomycin	63-72	tumor necrosis factor	Homo sapiens	29-38
9486589-7	1998	CONCLUSIONS: The increase in TNF-alpha after administration of bleomycin suggests a role for this cytokine in the development of the acute side effects and probably also in the occurrence of bleomycin-induced pulmonary toxicity.	Bleomycin	191-200	tumor necrosis factor	Homo sapiens	29-38
9534208-0	1998	Immunodetection of the murine chemotactic protein CP-10 in bleomycin-induced pulmonary injury.	Bleomycin	59-68	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	50-55
9485374-1	1998	Bleomycin hydrolase (BH) is unusual among cysteine proteinases because it appears to form multihomomeric structures, inactivates the antitumor glycopeptide bleomycin, and contains a unique C-terminal amino acid sequence.	Bleomycin	156-165	bleomycin hydrolase	Homo sapiens	0-19
9485374-1	1998	Bleomycin hydrolase (BH) is unusual among cysteine proteinases because it appears to form multihomomeric structures, inactivates the antitumor glycopeptide bleomycin, and contains a unique C-terminal amino acid sequence.	Bleomycin	156-165	bleomycin hydrolase	Homo sapiens	21-23
9534208-7	1998	In contrast, nanomolar levels of CP-10 were detected in unconcentrated BAL fluids from C57BL/6 mice after bleomycin-induced injury, and the presence of monomeric CP-10 was demonstrable by Western blotting.	Bleomycin	106-115	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	33-38
9534208-9	1998	We conclude that CP-10 may contribute to the recruitment of inflammatory cells in bleomycin-induced lung damage.	Bleomycin	82-91	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	17-22
9446803-6	1998	Furthermore, when PC3 cells were treated with a panel of apoptosis-inducing agents, it was found that camptothecin, bleomycin, VP16 and TNF-alpha induced varying amounts of cytosolic accumulation of cytochrome c either prior to or concurrent with PARP cleavage while vinblastine and BHPP did not.	Bleomycin	116-125	cytochrome c, somatic	Homo sapiens	199-211
9446803-6	1998	Furthermore, when PC3 cells were treated with a panel of apoptosis-inducing agents, it was found that camptothecin, bleomycin, VP16 and TNF-alpha induced varying amounts of cytosolic accumulation of cytochrome c either prior to or concurrent with PARP cleavage while vinblastine and BHPP did not.	Bleomycin	116-125	collagen type XI alpha 2 chain	Homo sapiens	247-251
9516963-6	1998	Data demonstrated p53-dependent sensitization (&gt; or = 4-fold) to bleomycin, actinomycin D, and 5-fluorouracil and considerably less p53-dependence (&lt; or = 2-fold) for doxorubicin, topotecan, etoposide, and cisplatin in Cl.#27 compared to an equivalent clone containing the pGRE5-EBV vector alone (VC#3).	Bleomycin	68-77	tumor protein p53	Homo sapiens	18-21
9814439-0	1998	PCR-directed DNA sequencing of "nondeletion" HPRT-mutants induced by bleomycin in CHO K1-BH4 cells.	Bleomycin	69-78	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	45-49
9814439-2	1998	Earlier, we have shown that bleomycin induces a high proportion of large deletions involving one or more exons in the hypoxanthine-guanine phosphoribosyltransferase (hprt) locus in a Chinese hamster ovary (CHO) cell line CHO K1-BH4, in which no spontaneously occurring large deletions were detected by a polymerase chain reaction (PCR)-based deletion screening assay.	Bleomycin	28-37	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	118-164
9707099-0	1998	Effects of poly(ADP-ribose) polymerase inhibition on cell death and chromosome damage induced by VP16 and bleomycin.	Bleomycin	106-115	poly(ADP-ribose) polymerase 1	Homo sapiens	11-38
9814439-2	1998	Earlier, we have shown that bleomycin induces a high proportion of large deletions involving one or more exons in the hypoxanthine-guanine phosphoribosyltransferase (hprt) locus in a Chinese hamster ovary (CHO) cell line CHO K1-BH4, in which no spontaneously occurring large deletions were detected by a polymerase chain reaction (PCR)-based deletion screening assay.	Bleomycin	28-37	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	166-170
9814439-6	1998	We therefore also investigated the hprt mutation spectra induced by bleomycin with pretreatment by TRIEN (triethylenetetramine), a superoxide dismutase (SOD) inhibitor, and TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), a SOD mimic.	Bleomycin	68-77	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	35-39
9814439-9	1998	Due to the small sample size, we are unable to draw a definitive conclusion about the effects of TRIEN and TEMPOL on bleomycin-induced spectrum of "nondeletion" type hprt mutations.	Bleomycin	117-126	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	166-170
9412578-0	1997	Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin.	Bleomycin	139-148	hepatocyte growth factor	Mus musculus	42-66
9331073-1	1997	Bleomycin hydrolase (BH) is the only known eukaryotic enzyme that inactivates the widely used antineoplastic agent bleomycin (BLM) and is a primary candidate gene for protection against lethal BLM-induced pulmonary fibrosis and for BLM resistance in tumors.	Bleomycin	115-124	bleomycin hydrolase	Homo sapiens	0-19
9416971-1	1997	We reported previously that treatment with antibody to transforming growth factor-beta (TGF-beta) caused a marked attenuation of bleomycin (BL)-induced lung fibrosis (LF) in mice.	Bleomycin	129-138	transforming growth factor, beta 1	Mus musculus	88-96
10374444-0	1997	[The therapeutic effect of TGF-beta monoclonal antibody to bleomycin-induced pulmonary fibrosis in rats].	Bleomycin	59-68	transforming growth factor, beta 1	Rattus norvegicus	27-35
10374444-3	1997	The purpose of this study was to evaluate the effects of TGF-beta monoclonal antibody on bleomycin-induced interstitial pulmonary fibrosis.	Bleomycin	89-98	transforming growth factor, beta 1	Rattus norvegicus	57-65
10374444-4	1997	METHOD: The effect of TGF-beta monoclonal antibody to bleomycin-induced pulmonary fibrosis in rat was studied either in vivo or in vitro.	Bleomycin	54-63	transforming growth factor, beta 1	Rattus norvegicus	22-30
9353266-8	1997	Induction of CD95 ligand mRNA by bleomycin was further reduced by combined treatment with N-acetylcysteine and deferoxamine.	Bleomycin	33-42	Fas cell surface death receptor	Homo sapiens	13-17
9374524-1	1997	Bleomycin hydrolase is a cysteine peptidase discovered through its ability to detoxify the anti-cancer glycopeptide, bleomycin.	Bleomycin	117-126	bleomycin hydrolase	Saccharomyces cerevisiae S288C	0-19
9604692-0	1997	The in vitro study on genotoxic activity of adriamycin and bleomycin in cells of mice with different catalase and superoxide dismutase activity.	Bleomycin	59-68	catalase	Mus musculus	101-109
9452752-11	1997	Release of endothelial factors (vWF.ag endothelin-1) and perturbed hemostasis related to the HIV infection (protein-S deficiency, anti-cardiolipin antibodies) could be an expression of and aggravate the vascular toxicity of bleomycin.	Bleomycin	224-233	endothelin 1	Homo sapiens	39-51
9342355-2	1997	To dissect such misrepair events at a molecular level, large-scale, bleomycin-induced rearrangements in the aprt gene of Chinese hamster ovary D422 cells were mapped, the breakpoints were sequenced, and the original non-aprt parental sequences involved in each rearrangement were recovered from nonmutant cells.	Bleomycin	68-77	adenine phosphoribosyltransferase	Cricetulus griseus	108-112
9342355-2	1997	To dissect such misrepair events at a molecular level, large-scale, bleomycin-induced rearrangements in the aprt gene of Chinese hamster ovary D422 cells were mapped, the breakpoints were sequenced, and the original non-aprt parental sequences involved in each rearrangement were recovered from nonmutant cells.	Bleomycin	68-77	adenine phosphoribosyltransferase	Cricetulus griseus	220-224
9390197-3	1997	On the other hand, low-dose bleomycin restored the macrophage cytotoxic activities, NO production, IFN gamma mRNA expression and TNF alpha production in the KDH-8-bearing rats.	Bleomycin	28-37	interferon gamma	Rattus norvegicus	99-108
9390197-3	1997	On the other hand, low-dose bleomycin restored the macrophage cytotoxic activities, NO production, IFN gamma mRNA expression and TNF alpha production in the KDH-8-bearing rats.	Bleomycin	28-37	tumor necrosis factor	Rattus norvegicus	129-138
9390197-5	1997	These results suggest that low-dose bleomycin restored the cytokine production and macrophage tumoricidal activities in the KDH-8-bearing rats by decreasing KDH-8-derived TGF beta.	Bleomycin	36-45	transforming growth factor, beta 1	Rattus norvegicus	171-179
9331073-1	1997	Bleomycin hydrolase (BH) is the only known eukaryotic enzyme that inactivates the widely used antineoplastic agent bleomycin (BLM) and is a primary candidate gene for protection against lethal BLM-induced pulmonary fibrosis and for BLM resistance in tumors.	Bleomycin	115-124	bleomycin hydrolase	Homo sapiens	21-23
9374029-1	1997	In 0.05 M H2SO4 solution, two reductive peaks, P1 and P2, of bleomycin were obtained.	Bleomycin	61-70	crystallin gamma F, pseudogene	Homo sapiens	47-56
9334814-9	1997	Moreover, a significant correlation between MRP expression and chemoresistance against daunomycin (DM), doxorubicin (DOX), etoposide (VP-16) and vinblastine (VBL), but not cisplatin (CDDP) and bleomycin (Bleo) (MTT-based survival assay), was detected.	Bleomycin	193-202	ATP binding cassette subfamily C member 3	Homo sapiens	44-47
9334814-9	1997	Moreover, a significant correlation between MRP expression and chemoresistance against daunomycin (DM), doxorubicin (DOX), etoposide (VP-16) and vinblastine (VBL), but not cisplatin (CDDP) and bleomycin (Bleo) (MTT-based survival assay), was detected.	Bleomycin	193-202	host cell factor C1	Homo sapiens	134-139
9334814-9	1997	Moreover, a significant correlation between MRP expression and chemoresistance against daunomycin (DM), doxorubicin (DOX), etoposide (VP-16) and vinblastine (VBL), but not cisplatin (CDDP) and bleomycin (Bleo) (MTT-based survival assay), was detected.	Bleomycin	204-208	ATP binding cassette subfamily C member 3	Homo sapiens	44-47
9334814-9	1997	Moreover, a significant correlation between MRP expression and chemoresistance against daunomycin (DM), doxorubicin (DOX), etoposide (VP-16) and vinblastine (VBL), but not cisplatin (CDDP) and bleomycin (Bleo) (MTT-based survival assay), was detected.	Bleomycin	204-208	host cell factor C1	Homo sapiens	134-139
9308925-5	1997	Analysis of the expression of CD44, a receptor for hyaluronan, by Western blotting revealed a 30% increase of CD44 molecules expressed on AM from bleomycin-treated rats at day 5 compared with control rats.	Bleomycin	146-155	CD44 molecule (Indian blood group)	Rattus norvegicus	30-34
9308925-5	1997	Analysis of the expression of CD44, a receptor for hyaluronan, by Western blotting revealed a 30% increase of CD44 molecules expressed on AM from bleomycin-treated rats at day 5 compared with control rats.	Bleomycin	146-155	CD44 molecule (Indian blood group)	Rattus norvegicus	110-114
9254594-1	1997	Pepleomycin (PEP)1 is a metalloglycopeptide antitumor antibiotic that has improved pharmacological properties than does bleomycin (BLM).	Bleomycin	120-129	prolyl endopeptidase	Homo sapiens	13-16
9254594-1	1997	Pepleomycin (PEP)1 is a metalloglycopeptide antitumor antibiotic that has improved pharmacological properties than does bleomycin (BLM).	Bleomycin	131-134	prolyl endopeptidase	Homo sapiens	13-16
9230758-0	1997	Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	44-53	elastase, neutrophil expressed	Mus musculus	11-30
9395719-0	1997	Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis.	Bleomycin	108-117	coagulation factor II	Rattus norvegicus	0-8
9395719-5	1997	The supernatants of AM stimulated with thrombin also increased the growth of fibroblasts from the lungs of rats with bleomycin-induced lung injury.	Bleomycin	117-126	coagulation factor II	Rattus norvegicus	39-47
9279246-0	1997	Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist.	Bleomycin	26-35	endothelin 1	Homo sapiens	10-22
9154642-7	1997	Pretreatment with KGF at 48 hr protected against bleomycin-induced alterations in pulmonary physiology and increased surfactant protein C-positive (SP-C)-positive cells and SP-A, SP-B, SP-C, and SP-D mRNA levels after bleomycin instillation when compared to saline pretreated rats on day 1 or day 7.	Bleomycin	49-58	fibroblast growth factor 7	Rattus norvegicus	18-21
9341282-6	1997	Levels of promotor cytokines, such as TNF alpha, TGF beta, INF gamma, and IL-2, were significantly higher in lung tissue from the bleomycin group.	Bleomycin	130-139	tumor necrosis factor	Mus musculus	38-47
9341282-6	1997	Levels of promotor cytokines, such as TNF alpha, TGF beta, INF gamma, and IL-2, were significantly higher in lung tissue from the bleomycin group.	Bleomycin	130-139	transforming growth factor, beta 1	Mus musculus	49-57
9341282-6	1997	Levels of promotor cytokines, such as TNF alpha, TGF beta, INF gamma, and IL-2, were significantly higher in lung tissue from the bleomycin group.	Bleomycin	130-139	interleukin 2	Mus musculus	74-78
9341282-8	1997	Expression of IL-4 was high in the bleomycin group, and was not inhibited in the glucocorticoid group.	Bleomycin	35-44	interleukin 4	Mus musculus	14-18
9341282-9	1997	Expression of the down-regulator cytokine IL-10 was also high in the bleomycin group and very low in the glucocorticoid group.	Bleomycin	69-78	interleukin 10	Mus musculus	42-47
9218781-8	1997	Comparison of glyoxalase I with other known structures shows the enzyme to belong to a new structural family which includes the Fe2+-dependent dihydroxybiphenyl dioxygenase and the bleomycin resistance protein.	Bleomycin	181-190	glyoxalase I	Homo sapiens	14-26
9255642-13	1997	CONCLUSIONS: Patients with septic shock rarely have iron saturated transferrin in their plasma leading to the presence of bleomycin-detectable iron.	Bleomycin	122-131	transferrin	Homo sapiens	67-78
9441129-10	1997	In conclusion, EM can ameliorate bleomycin-induced pulmonary fibrosis possibly through suppression of TNF-alpha and PDGF as well as the inhibition on accumulation of inflammatory cells in the lung.	Bleomycin	33-42	tumor necrosis factor	Rattus norvegicus	102-111
9195876-0	1997	A model of the structure of HOO-Co.bleomycin bound to d(CCAGTACTGG): recognition at the d(GpT) site and implications for double-stranded DNA cleavage.	Bleomycin	35-44	glutamic--pyruvic transaminase	Homo sapiens	90-93
9154642-5	1997	Conversely, intratracheal KGF pretreatment at 48 or 72 hr before bleomycin resulted in minimal to no visible lung injury.	Bleomycin	65-74	fibroblast growth factor 7	Rattus norvegicus	26-29
9177462-0	1997	Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice.	Bleomycin	53-62	tumor necrosis factor	Mus musculus	79-88
9177462-0	1997	Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice.	Bleomycin	53-62	stromal antigen 1	Mus musculus	92-96
9177462-2	1997	Increased anti-tumor effectiveness on SA-1 tumors was observed after combining TNF-alpha, injected either intratumorally or peritumorally, with electrochemotherapy using suboptimal dose of bleomycin (BLM).	Bleomycin	189-198	stromal antigen 1	Mus musculus	38-42
9177462-2	1997	Increased anti-tumor effectiveness on SA-1 tumors was observed after combining TNF-alpha, injected either intratumorally or peritumorally, with electrochemotherapy using suboptimal dose of bleomycin (BLM).	Bleomycin	200-203	stromal antigen 1	Mus musculus	38-42
9154642-7	1997	Pretreatment with KGF at 48 hr protected against bleomycin-induced alterations in pulmonary physiology and increased surfactant protein C-positive (SP-C)-positive cells and SP-A, SP-B, SP-C, and SP-D mRNA levels after bleomycin instillation when compared to saline pretreated rats on day 1 or day 7.	Bleomycin	49-58	surfactant protein C	Rattus norvegicus	117-146
9154642-7	1997	Pretreatment with KGF at 48 hr protected against bleomycin-induced alterations in pulmonary physiology and increased surfactant protein C-positive (SP-C)-positive cells and SP-A, SP-B, SP-C, and SP-D mRNA levels after bleomycin instillation when compared to saline pretreated rats on day 1 or day 7.	Bleomycin	218-227	fibroblast growth factor 7	Rattus norvegicus	18-21
9154642-9	1997	We conclude that KGF pretreatment attenuates bleomycin lung injury and increases type II cell proliferation and surfactant protein gene expression after bleomycin instillation in the rat.	Bleomycin	45-54	fibroblast growth factor 7	Rattus norvegicus	17-20
9154642-9	1997	We conclude that KGF pretreatment attenuates bleomycin lung injury and increases type II cell proliferation and surfactant protein gene expression after bleomycin instillation in the rat.	Bleomycin	153-162	fibroblast growth factor 7	Rattus norvegicus	17-20
9099426-4	1997	Results of this study showed that lungs of animals treated with bleomycin were seriously damaged, as evidenced by significant histological changes and increases in lung weight, lipid peroxidation, myeloperoxidase activity and hydroxyproline content as well as decreases in lung angiotensin converting enzyme (ACE) and alkaline phosphatase (AKP) activities.	Bleomycin	64-73	myeloperoxidase	Rattus norvegicus	197-212
9106360-6	1997	Actinomycin sharply decreases the extent of cleavage at GpC sites by both bleomycin and deglycobleomycin whereas cleavage at GpT sites is much less affected, while novel cleavage sites are generated at GpA, ApT and, to a lesser extent, TpT steps.	Bleomycin	74-83	glycophorin C (Gerbich blood group)	Homo sapiens	56-59
9115755-0	1997	Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis.	Bleomycin	40-49	interleukin 5	Mus musculus	5-18
9115755-2	1997	To investigate the potential role of this cytokine, lung IL-5 expression was examined in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	107-116	interleukin 5	Mus musculus	57-61
9221384-11	1997	Tumor necrosis factor alpha (TNF-alpha) has been shown to be a key cytokine in bleomycin-induced fibrosing alveolitis as well as in IPF; it also exerts catabolizing effects.	Bleomycin	79-88	tumor necrosis factor	Rattus norvegicus	0-27
9221384-11	1997	Tumor necrosis factor alpha (TNF-alpha) has been shown to be a key cytokine in bleomycin-induced fibrosing alveolitis as well as in IPF; it also exerts catabolizing effects.	Bleomycin	79-88	tumor necrosis factor	Rattus norvegicus	29-38
9060836-0	1997	Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis.	Bleomycin	150-159	transforming growth factor, beta 1	Mus musculus	0-56
9060836-7	1997	After bleomycin, TGF-beta 1 gene expression was maximally enhanced at 10 days, with the signal being predominant in macrophages.	Bleomycin	6-15	transforming growth factor, beta 1	Mus musculus	17-27
9099426-4	1997	Results of this study showed that lungs of animals treated with bleomycin were seriously damaged, as evidenced by significant histological changes and increases in lung weight, lipid peroxidation, myeloperoxidase activity and hydroxyproline content as well as decreases in lung angiotensin converting enzyme (ACE) and alkaline phosphatase (AKP) activities.	Bleomycin	64-73	angiotensin I converting enzyme	Rattus norvegicus	278-307
9099426-4	1997	Results of this study showed that lungs of animals treated with bleomycin were seriously damaged, as evidenced by significant histological changes and increases in lung weight, lipid peroxidation, myeloperoxidase activity and hydroxyproline content as well as decreases in lung angiotensin converting enzyme (ACE) and alkaline phosphatase (AKP) activities.	Bleomycin	64-73	angiotensin I converting enzyme	Rattus norvegicus	309-312
9099426-6	1997	In contrast, pretreatment of rats with alpha-tocopherol liposomes 30 min prior to bleomycin administration resulted in little or no histological changes and conferred a significant protection against bleomycin-induced changes in edema, lipid peroxidation, hydroxyproline content, and ACE, AKP and myeloperoxidase activities.	Bleomycin	200-209	angiotensin I converting enzyme	Rattus norvegicus	284-287
9099426-6	1997	In contrast, pretreatment of rats with alpha-tocopherol liposomes 30 min prior to bleomycin administration resulted in little or no histological changes and conferred a significant protection against bleomycin-induced changes in edema, lipid peroxidation, hydroxyproline content, and ACE, AKP and myeloperoxidase activities.	Bleomycin	200-209	myeloperoxidase	Rattus norvegicus	297-312
9166104-7	1997	Bleomycin injections increased collagen deposition, as evaluated by the lung hydroxyproline content, more markedly in wild type, than in delta TNF/LT alpha, mice.	Bleomycin	0-9	tumor necrosis factor	Mus musculus	143-146
9118704-1	1997	STUDY OBJECTIVES: The purpose of this study is to determine whether co-administration of granulocyte colony stimulating factor (G-CSF) and bleomycin results in enhanced pulmonary toxicity compared with bleomycin alone.	Bleomycin	202-211	colony stimulating factor 3	Homo sapiens	89-126
9118704-8	1997	RESULTS: Of the 29 patients who received concurrent chemotherapy and G-CSF, ten (34%; 95% confidence interval [CI], 17.9 to 54.3%) were believed to have clinically significant bleomycin toxicity.	Bleomycin	176-185	colony stimulating factor 3	Homo sapiens	69-74
9166104-7	1997	Bleomycin injections increased collagen deposition, as evaluated by the lung hydroxyproline content, more markedly in wild type, than in delta TNF/LT alpha, mice.	Bleomycin	0-9	lymphotoxin A	Mus musculus	147-155
9070353-8	1997	Bleomycin treatment also resulted in a strain-dependent loss of CC10 mRNA-expressing cells.	Bleomycin	0-9	secretoglobin, family 1A, member 1 (uteroglobin)	Mus musculus	64-68
9022073-8	1997	Furthermore, bleomycin treatment of HepG2 cells increased CD95 ligand (CD95L) mRNA expression.	Bleomycin	13-22	Fas ligand	Homo sapiens	58-69
9022073-8	1997	Furthermore, bleomycin treatment of HepG2 cells increased CD95 ligand (CD95L) mRNA expression.	Bleomycin	13-22	Fas ligand	Homo sapiens	71-76
9022073-9	1997	Most notably, bleomycin-induced apoptosis in HepG2 cells was almost completely inhibited by antibodies which interfere with CD95 receptor/ligand interaction.	Bleomycin	14-23	Fas cell surface death receptor	Homo sapiens	124-128
9022073-10	1997	These data suggest that apoptosis induced by bleomycin is mediated, at least in part, by p53-dependent stimulation of the CD95 receptor/ligand system.	Bleomycin	45-54	tumor protein p53	Homo sapiens	89-92
9022073-10	1997	These data suggest that apoptosis induced by bleomycin is mediated, at least in part, by p53-dependent stimulation of the CD95 receptor/ligand system.	Bleomycin	45-54	Fas cell surface death receptor	Homo sapiens	122-126
9022073-3	1997	At concentrations present in the sera of patients during therapy, bleomycin induced transient accumulation of nuclear wild-type (wt) p53 and upregulated expression of cell surface CD95 (APO-1/Fas) receptor in hepatoma cells carrying wt p53 (HepG2).	Bleomycin	66-75	tumor protein p53	Homo sapiens	133-136
9022073-3	1997	At concentrations present in the sera of patients during therapy, bleomycin induced transient accumulation of nuclear wild-type (wt) p53 and upregulated expression of cell surface CD95 (APO-1/Fas) receptor in hepatoma cells carrying wt p53 (HepG2).	Bleomycin	66-75	Fas cell surface death receptor	Homo sapiens	180-184
9022073-3	1997	At concentrations present in the sera of patients during therapy, bleomycin induced transient accumulation of nuclear wild-type (wt) p53 and upregulated expression of cell surface CD95 (APO-1/Fas) receptor in hepatoma cells carrying wt p53 (HepG2).	Bleomycin	66-75	Fas cell surface death receptor	Homo sapiens	186-205
9022073-3	1997	At concentrations present in the sera of patients during therapy, bleomycin induced transient accumulation of nuclear wild-type (wt) p53 and upregulated expression of cell surface CD95 (APO-1/Fas) receptor in hepatoma cells carrying wt p53 (HepG2).	Bleomycin	66-75	tumor protein p53	Homo sapiens	236-239
9070353-12	1997	The strain-dependent changes in CC10 and SPC gene expression after bleomycin treatment are suggestive of a role for the epithelium in pulmonary fibrosis versus repair.	Bleomycin	67-76	secretoglobin, family 1A, member 1 (uteroglobin)	Mus musculus	32-36
9086326-0	1997	Altered immunohistochemical localization of basic fibroblast growth factor after bleomycin-induced lung injury.	Bleomycin	81-90	fibroblast growth factor 2	Rattus norvegicus	44-74
8998084-1	1997	The incidence of apoptosis and the expression of Fas antigen (Fas)/Fas ligand (FasL) mRNA in bleomycin-induced pulmonary fibrosis in mice were examined.	Bleomycin	93-102	Fas (TNF receptor superfamily member 6)	Mus musculus	49-60
8998084-1	1997	The incidence of apoptosis and the expression of Fas antigen (Fas)/Fas ligand (FasL) mRNA in bleomycin-induced pulmonary fibrosis in mice were examined.	Bleomycin	93-102	Fas ligand (TNF superfamily, member 6)	Mus musculus	79-83
8998084-12	1997	FasL mRNA was also upregulated in infiltrating lymphocytes after bleomycin treatment, but not in the control mice.	Bleomycin	65-74	Fas ligand (TNF superfamily, member 6)	Mus musculus	0-4
9086326-3	1997	We investigated the distribution of bFGF after bleomycin-induced lung injury in the rat in hope of learning how bFGF might participate in the process of lung injury, repair and fibrosis.	Bleomycin	47-56	fibroblast growth factor 2	Rattus norvegicus	36-40
9086326-4	1997	Increased immunoreactive bFGF was found in the extracellular matrix after bleomycin and co-localized to a marker of active cell proliferation.	Bleomycin	74-83	fibroblast growth factor 2	Rattus norvegicus	25-29
9086326-6	1997	In addition, a marked increase in the number of mast cells with strong reactivity for bFGF was found at days 14 and 21 after bleomycin.	Bleomycin	125-134	fibroblast growth factor 2	Rattus norvegicus	86-90
8982000-2	1997	An Escherichia coli homolog of BacA, SbmA, is implicated in the uptake of microcin B17, microcin J25 (formerly microcin 25), and bleomycin.	Bleomycin	129-138	putative udecaprenol kinase BacA	Escherichia coli	31-35
8982000-3	1997	When expressed in E. coli with the lacZ promoter, the R. meliloti bacA gene was found to suppress all the known defects of E. coli sbmA mutants, namely, increased resistance to microcin B17, microcin J25, and bleomycin, demonstrating the functional similarity between the two proteins.	Bleomycin	209-218	putative udecaprenol kinase BacA	Escherichia coli	66-70
8982000-4	1997	The R. meliloti bacA386::Tn(pho)A mutant, as well as a newly constructed bacA deletion mutant, was found to show increased resistance to bleomycin.	Bleomycin	137-146	putative udecaprenol kinase BacA	Escherichia coli	16-20
11173634-5	1997	Interestingly, the DNA damage (gamma radiation, bleomycin, ETO) or okadaic acic (30 nM) reduced the [PMA+STA] induced apoptosis.	Bleomycin	48-57	GCY	Homo sapiens	105-108
9199490-2	1997	injection of human recombinant interferon-2alpha (IFN-alpha) on Bleomycin-induced pulmonary injury in hamsters.	Bleomycin	64-73	interferon alpha 1	Homo sapiens	50-59
9199490-23	1997	These results suggest that IFN-alpha augments Bleo-induced lung injury but that this effect is complex and does not follow a simple-dose-response pattern.	Bleomycin	46-50	interferon alpha 1	Homo sapiens	27-36
9292710-4	1997	Smears that were P-gp-negative by the 7th day were associated with a good 30-day response to bleomycin in the majority of cases, while P-gp-positive smears were associated with a significant reaccumulation of fluid at 30 days.	Bleomycin	93-102	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
9292710-5	1997	P-gp status is a valuable prognostic indicator of response to intracavitary bleomycin treatment in effusions from breast or ovarian cancer.	Bleomycin	76-85	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
9100454-5	1996	Expression of IL-1 alpha mRNA in AM from bleomycin-treated rats was significantly higher than that in AM of control, but there was no significant difference in the mRNA levels of IL-1 beta in AM of these two groups.	Bleomycin	41-50	interleukin 1 alpha	Rattus norvegicus	14-24
8952531-0	1996	Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality.	Bleomycin	54-63	fibroblast growth factor 7	Rattus norvegicus	0-26
8952531-5	1996	Intratracheal pretreatment with KGF in rats receiving intratracheal bleomycin (2.5 U) improved survival at 3 weeks to 100% (20/20 rats) from 40% (8/20 rats) in controls.	Bleomycin	68-77	fibroblast growth factor 7	Rattus norvegicus	32-35
8952531-6	1996	All KGF-pretreated rats receiving bleomycin were well at 3 weeks and without histological evidence of pulmonary fibrosis whereas the 8 surviving control rats exhibited severe respiratory distress.	Bleomycin	34-43	fibroblast growth factor 7	Rattus norvegicus	4-7
8952531-9	1996	In conclusion, radiation- and bleomycin-induced pulmonary injury and respiratory death are ameliorated by KGF pretreatment, suggesting a protective role for KGF-induced type II pneumocyte proliferation in lung injury.	Bleomycin	30-39	fibroblast growth factor 7	Rattus norvegicus	106-109
8952531-9	1996	In conclusion, radiation- and bleomycin-induced pulmonary injury and respiratory death are ameliorated by KGF pretreatment, suggesting a protective role for KGF-induced type II pneumocyte proliferation in lung injury.	Bleomycin	30-39	fibroblast growth factor 7	Rattus norvegicus	157-160
8959330-0	1996	Bleomycin-induced differentiation of bcl-2-transfected U937 leukemia cells.	Bleomycin	0-9	BCL2 apoptosis regulator	Homo sapiens	37-42
8959330-2	1996	Sublethal concentrations of bleomycin (1 microgram/ml) induced a decrease in cell growth in both vector-only and bcl-2-transfected U937 cells.	Bleomycin	28-37	BCL2 apoptosis regulator	Homo sapiens	113-118
8959330-5	1996	In contrast, bcl-2-transfected U937 cells maintained viable cell numbers and colony forming cells for up to 2 weeks in the presence of bleomycin.	Bleomycin	135-144	BCL2 apoptosis regulator	Homo sapiens	13-18
8959330-8	1996	In contrast, differentiated bcl-2-transfected U937 cells remained viable for 2 weeks following bleomycin treatment.	Bleomycin	95-104	BCL2 apoptosis regulator	Homo sapiens	28-33
9100454-8	1996	These results suggest that cell-associated IL-1 (IL-1 alpha) is produced continuously in AM from rats with bleomycin-induced pulmonary fibrosis and may be important in regulation of this disorder by inhibiting fibroblast growth.	Bleomycin	107-116	interleukin 1 alpha	Rattus norvegicus	49-59
8910371-9	1996	hdf2(-) strains are sensitive to bleomycin and methyl methanesulfonate, but this sensitivity is reduced in comparison with hdf1(-) strains.	Bleomycin	33-42	ATP-dependent DNA helicase YKU80	Saccharomyces cerevisiae S288C	0-4
8943756-4	1996	A bleomycin based assay was used to detect non-transferrin bound iron.	Bleomycin	2-11	transferrin	Homo sapiens	47-58
8823477-1	1996	PURPOSE: A Phase II study to evaluate the effect of a five-drug regimen, VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin (VIP/VB) on complete response rate, continuous disease-free survival, and toxicity in patients with advanced germ-cell tumor.	Bleomycin	120-129	vasoactive intestinal peptide	Homo sapiens	131-137
8718865-1	1996	The bleomycin-inactivating enzyme, bleomycin hydrolase, is believed to be involved in tumor resistance to the anticancer drug bleomycin.	Bleomycin	4-13	bleomycin hydrolase	Saccharomyces cerevisiae S288C	35-54
8913076-6	1996	After three courses of chemotherapy, consisting of cisplatin, etoposide and bleomycin, the tumor became smaller and the serum AFP level became normal.	Bleomycin	76-85	alpha fetoprotein	Homo sapiens	126-129
8949991-0	1996	Electrochemotherapy with bleomycin in SA-1 tumor-bearing mice--natural resistance and immune responsiveness.	Bleomycin	25-34	stromal antigen 1	Mus musculus	38-42
8921272-3	1996	When cerebellar neurons from 15- to 16-day postnatal wild-type mice were treated with ionizing radiation or DNA-damaging agents, massive neuron death occurred after 24-72 h. In contrast, neurons from p53-/- mice evidently resisted gamma-irradiation and some DNA-damaging agents, such as etoposide and bleomycin.	Bleomycin	301-310	transformation related protein 53, pseudogene	Mus musculus	200-203
8718865-7	1996	However, the ability of bleomycin hydrolase to hydrolyze and inactivate bleomycin was totally abolished in all three mutants, suggesting that the cysteine thiol and histidine imidazole are critical for hydrolyzing bleomycin.	Bleomycin	72-81	bleomycin hydrolase	Saccharomyces cerevisiae S288C	24-43
8703482-0	1996	Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury.	Bleomycin	121-130	transforming growth factor, beta 1	Rattus norvegicus	59-69
8703482-4	1996	In a model of pulmonary inflammation and fibrosis induced by the antineoplastic antibiotic, bleomycin, we have demonstrated that explanted alveolar macrophages secrete progressively increasing quantities of a biologically active form of TGF-beta 1, the secretion of which was maximal 7 days after bleomycin administration.	Bleomycin	92-101	transforming growth factor, beta 1	Rattus norvegicus	237-247
8703482-4	1996	In a model of pulmonary inflammation and fibrosis induced by the antineoplastic antibiotic, bleomycin, we have demonstrated that explanted alveolar macrophages secrete progressively increasing quantities of a biologically active form of TGF-beta 1, the secretion of which was maximal 7 days after bleomycin administration.	Bleomycin	297-306	transforming growth factor, beta 1	Rattus norvegicus	237-247
8703482-11	1996	Because the diminution of active TGF-beta 1 coincides with the resolution of inflammation, this suggests that the availability of plasmin regulates the biologically active form of TGF-beta 1, and thus, the inflammation seen after bleomycin-induced lung injury.	Bleomycin	230-239	transforming growth factor, beta 1	Rattus norvegicus	180-190
8679639-7	1996	Bleomycin activity was greatly reduced in cells at a tandem NF-E2/AP1 DNA sequence element.	Bleomycin	0-9	nuclear factor, erythroid 2	Homo sapiens	60-65
9596825-0	1996	[Consecutive study on alveolar macrophage release of tumor necrosis factor-alpha and platelet-derived growth factor in bleomycin-induced pulmonary fibrosis in rats].	Bleomycin	119-128	tumor necrosis factor	Rattus norvegicus	53-80
9596825-1	1996	OBJECTIVE: Observe consecutively alveolar macrophage (AM) release of tumor necrosis factor-alpha (TNF-alpha) and platelet-derived growth factor (PDGF in bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	153-162	tumor necrosis factor	Rattus norvegicus	69-96
9596825-1	1996	OBJECTIVE: Observe consecutively alveolar macrophage (AM) release of tumor necrosis factor-alpha (TNF-alpha) and platelet-derived growth factor (PDGF in bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	153-162	tumor necrosis factor	Rattus norvegicus	98-107
8679639-7	1996	Bleomycin activity was greatly reduced in cells at a tandem NF-E2/AP1 DNA sequence element.	Bleomycin	0-9	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-69
9206100-8	1996	CONCLUSIONS: AMs are the main sources of TGF-beta 1 and PDGF in the lung tissues with fibrosis induced by Bleomycin-A5 AMs are activated in the first weekend and secrete TGF-beta 1 and PDGF to promote fibroblasts proliferation and fibrosis.	Bleomycin	106-115	transforming growth factor, beta 1	Rattus norvegicus	41-51
8891198-7	1996	Further, we have shown that passive immunotherapy with either anti-MCP-1 or anti-MIP-1 alpha antibodies significantly reduced mononuclear phagocyte accumulation in bleomycin-challenged mice.	Bleomycin	164-173	chemokine (C-C motif) ligand 2	Mus musculus	67-72
8891198-7	1996	Further, we have shown that passive immunotherapy with either anti-MCP-1 or anti-MIP-1 alpha antibodies significantly reduced mononuclear phagocyte accumulation in bleomycin-challenged mice.	Bleomycin	164-173	chemokine (C-C motif) ligand 3	Mus musculus	81-92
8891198-8	1996	These experiments strongly support the hypothesis that MIP-1 alpha and MCP-1 contribute to the recruitment of leukocytes during the pulmonary inflammatory response to bleomycin challenge.	Bleomycin	167-176	C-C motif chemokine ligand 3	Homo sapiens	55-66
8891198-8	1996	These experiments strongly support the hypothesis that MIP-1 alpha and MCP-1 contribute to the recruitment of leukocytes during the pulmonary inflammatory response to bleomycin challenge.	Bleomycin	167-176	C-C motif chemokine ligand 2	Homo sapiens	71-76
8680680-0	1996	The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury.	Bleomycin	49-58	CD3 antigen, epsilon polypeptide	Mus musculus	22-25
8774378-1	1996	We have investigated whether enhanced secretion of transforming growth factor-beta (TGF-beta) by distal respiratory epithelial cells was associated with the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	172-181	transforming growth factor, beta 1	Mus musculus	84-92
8774378-4	1996	Exposure to bleomycin and other potentially fibrogenic stimuli in vitro did not stimulate production of TGF-beta by the epithelial cells but release was enhanced by treatment of the cells with interferon-gamma.	Bleomycin	12-21	interferon gamma	Mus musculus	193-209
8774378-6	1996	However, the concentration of TGF-beta in bronchoalveolar lavage (BAL) fluids was significantly elevated compared to controls at 1 and 2 weeks after bleomycin-induced injury in these mice.	Bleomycin	149-158	transforming growth factor, beta 1	Mus musculus	30-38
8613443-10	1996	Dose survival studies with use of a tetrazolium colorimetric assay showed that the MOS/ADR1 cells were cross-resistant to vincristine, vinblastine, etoposide, bleomycin, mitomycin C, and actinomycin D but not to dacarbazine, cisplatin, carboplatin, cytosine arabinoside, carmustine, cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil.	Bleomycin	159-168	Moloney sarcoma oncogene	Mus musculus	83-86
8628275-0	1996	The Saccharomyces cerevisiae IMP2 gene encodes a transcriptional activator that mediates protection against DNA damage caused by bleomycin and other oxidants.	Bleomycin	129-138	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	29-33
8628275-4	1996	A DNA clone containing the IMP2 gene that complemented the most sensitive bleomycin mutant was identified.	Bleomycin	74-83	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	27-31
8628275-5	1996	A role for IMP2 in defense against the toxic effects of bleomycin has not been previously reported.	Bleomycin	56-65	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	11-15
8628275-6	1996	imp2 null mutants were constructed and were found to be 15-fold more sensitive to bleomycin than wild-type strains.	Bleomycin	82-91	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	0-4
8626469-4	1996	Here we show that hdf1-disrupted S. cerevisiae strains are strongly sensitive toward the radiomimetic antibiotic bleomycin.	Bleomycin	113-122	ATP-dependent DNA helicase YKU70	Saccharomyces cerevisiae S288C	18-22
8726930-0	1996	Integrin alpha E beta 7 expression on BAL CD4+, CD8+, and gamma delta T-cells in bleomycin-induced lung fibrosis in mouse.	Bleomycin	81-90	CD4 antigen	Mus musculus	42-45
8649799-4	1996	Induction of DNA strand breaks in normal control fibroblasts by exposure to bleomycin led as expected to G(1)/S cell cycle arrest, induction of p2l(WAF1) and a rapid reduction in the rate of DNA synthesis in cells already in S phase.	Bleomycin	76-85	cyclin dependent kinase inhibitor 1A	Homo sapiens	148-152
8617091-0	1996	Increased expression of platelet-derived growth factor A and insulin-like growth factor-I in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	129-138	insulin-like growth factor 1	Mus musculus	61-89
8639621-1	1996	We have cloned the cDNA of human bleomycin hydrolase (hBH), a protease which is thought to be involved in the metabolic inactivation of the antineoplastic drug bleomycin.	Bleomycin	33-42	hemoglobin subunit alpha 1	Homo sapiens	54-57
8639621-9	1996	The human enzyme effectively degrades both forms of bleomycin (A2 and B2) in vitro and could indeed be responsible for the resistance of various tumors to this widely used anticancer drug.	Bleomycin	52-61	ATPase H+ transporting V0 subunit a2	Homo sapiens	63-72
8611700-2	1996	In an animal model of bleomycin-induced lung fibrosis, increased expression of type 1 plasminogen activator inhibitor (PAI-1) is associated with accumulation of fibrin in fibroproliferative lesions.	Bleomycin	22-31	serpin family E member 1	Rattus norvegicus	119-124
8640929-0	1996	The relationship between p53 status, DNA repair and chromatid aberration induction in G2 mouse embryo fibroblast cells treated with bleomycin.	Bleomycin	132-141	transformation related protein 53, pseudogene	Mus musculus	25-28
8640929-1	1996	The involvement of p53 in the formation of chromosome aberrations was assessed by analyzing bleomycin-induced, chromatid-type aberrations in G2 phase fibroblasts derived from embryos from wild-type and p53 knock-out mice.	Bleomycin	92-101	transformation related protein 53, pseudogene	Mus musculus	19-22
8640929-1	1996	The involvement of p53 in the formation of chromosome aberrations was assessed by analyzing bleomycin-induced, chromatid-type aberrations in G2 phase fibroblasts derived from embryos from wild-type and p53 knock-out mice.	Bleomycin	92-101	transformation related protein 53, pseudogene	Mus musculus	202-205
8640929-3	1996	The p53-deficient cells also showed an overdispersed distribution of bleomycin-induced chromatid aberrations, a greater amount of overall genomic instability and a possible loss of a cell death pathway.	Bleomycin	69-78	transformation related protein 53, pseudogene	Mus musculus	4-7
8612529-7	1996	Neutralizing antibody to TGF-beta (TGF-beta-Ab) attenuated the inhibition of proliferation by TGF-beta and bleomycin in a concentration-dependent manner.	Bleomycin	107-116	transforming growth factor, beta 1	Rattus norvegicus	25-33
8612529-7	1996	Neutralizing antibody to TGF-beta (TGF-beta-Ab) attenuated the inhibition of proliferation by TGF-beta and bleomycin in a concentration-dependent manner.	Bleomycin	107-116	transforming growth factor, beta 1	Rattus norvegicus	35-43
8612529-7	1996	Neutralizing antibody to TGF-beta (TGF-beta-Ab) attenuated the inhibition of proliferation by TGF-beta and bleomycin in a concentration-dependent manner.	Bleomycin	107-116	transforming growth factor, beta 1	Rattus norvegicus	35-43
8612529-12	1996	The cytotoxic effect of bleomycin is mediated by TGF-beta and inhibition of TGF-beta and bleomycin with TGF-beta-Ab attenuates the additive effects of those compounds on isolated rat hepatocytes.	Bleomycin	24-33	transforming growth factor, beta 1	Rattus norvegicus	49-57
8612529-12	1996	The cytotoxic effect of bleomycin is mediated by TGF-beta and inhibition of TGF-beta and bleomycin with TGF-beta-Ab attenuates the additive effects of those compounds on isolated rat hepatocytes.	Bleomycin	24-33	transforming growth factor, beta 1	Rattus norvegicus	76-84
8612529-12	1996	The cytotoxic effect of bleomycin is mediated by TGF-beta and inhibition of TGF-beta and bleomycin with TGF-beta-Ab attenuates the additive effects of those compounds on isolated rat hepatocytes.	Bleomycin	24-33	transforming growth factor, beta 1	Rattus norvegicus	76-84
11666481-0	1996	Photoinduced DNA Cleavage Reactions by Designed Analogues of Co(III)-Bleomycin: The Metalated Core Is the Primary Determinant of Sequence Specificity.	Bleomycin	69-78	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	64-67
11666481-1	1996	A 2,4"-bithiazole group has been covalently attached to the Co(III) complex of a designed ligand PMAH that mimics the metal-binding locus of the antitumor drug bleomycin (BLM).	Bleomycin	160-169	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	60-67
8681040-0	1996	Expression of CD44 isoforms during bleomycin-or radiation-induced pulmonary fibrosis in rats and mini-pigs.	Bleomycin	35-44	CD44 molecule (Indian blood group)	Rattus norvegicus	14-18
8643678-6	1996	A large decrease in mosaic clone frequency is observed when Rrp1 overexpression precedes treatment with gamma-rays, bleomycin, or paraquat.	Bleomycin	116-125	Recombination repair protein 1	Drosophila melanogaster	60-64
8720458-2	1996	The binding of a mouse monoclonal antibody (MEP-1) reacting specifically with type I pneumocytes was assessed on paraffin sections of normal specimens as well as those with pulmonary fibrosis induced by bleomycin or radiation treatment.	Bleomycin	203-212	meprin A subunit alpha	Rattus norvegicus	44-49
8579115-0	1996	Lung fibroblast alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis.	Bleomycin	82-91	actin gamma 2, smooth muscle	Rattus norvegicus	16-41
8579115-9	1996	TGF-beta 1 gene expression was greater in cells from bleomycin-treated animals than those from control lungs.	Bleomycin	53-62	transforming growth factor, beta 1	Rattus norvegicus	0-10
8814878-5	1996	Importantly, the effective substitution of the oxazole O-1 for the histidine N-1 further illustrates that this group does not require deprotonation upon metal complexation, oxygen activation, or the ensuing oxidation reactions, that the functional bleomycin A2 tautomer is the imidazole N"-H tautomer, and that the imidazole N"-H functionality is not contributing to the polynucleotide recognition through H-bonding to the phosphate backbone or nucleotide bases.	Bleomycin	248-257	immunoglobulin kappa variable 2D-40	Homo sapiens	55-58
8747891-2	1996	Inositol 1,4,5-trisphosphate and diacyl glycerol levels in formyl-methionyl-leucyl-phenylalanine (FMLP)-stimulated PMN were decreased by cis-diammine-dichloroplatinum (CDDP), 5-fluorouracil (5-FU), 137Cs, and peplomycin (PLM, a bleomycin analog) in this order.	Bleomycin	228-237	formyl peptide receptor 1	Homo sapiens	98-102
7590166-0	1995	Bleomycin-induced beta-lactamase overexpression in Escherichia coli carrying a bleomycin-resistance gene from Streptomyces verticillus and its application to screen bleomycin analogues.	Bleomycin	0-9	beta-lactamase	Escherichia coli	18-32
8635193-0	1995	Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin.	Bleomycin	143-152	interleukin 2	Rattus norvegicus	15-28
8635193-0	1995	Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin.	Bleomycin	143-152	distal membrane arm assembly component 2 like	Rattus norvegicus	113-124
8635193-7	1995	In vitro experiments also showed that TGF beta activity, mRNA expression, and protein synthesis in KDH-8 tumor cells were reduced by bleomycin treatment, and that bleomycin-treated-KDH-8-tumor-cell-conditioned medium did not inhibit IL-2 production from normal rat splenocytes.	Bleomycin	133-142	transforming growth factor, beta 1	Rattus norvegicus	38-46
8635193-7	1995	In vitro experiments also showed that TGF beta activity, mRNA expression, and protein synthesis in KDH-8 tumor cells were reduced by bleomycin treatment, and that bleomycin-treated-KDH-8-tumor-cell-conditioned medium did not inhibit IL-2 production from normal rat splenocytes.	Bleomycin	133-142	interleukin 2	Rattus norvegicus	233-237
8635193-7	1995	In vitro experiments also showed that TGF beta activity, mRNA expression, and protein synthesis in KDH-8 tumor cells were reduced by bleomycin treatment, and that bleomycin-treated-KDH-8-tumor-cell-conditioned medium did not inhibit IL-2 production from normal rat splenocytes.	Bleomycin	163-172	transforming growth factor, beta 1	Rattus norvegicus	38-46
8635193-7	1995	In vitro experiments also showed that TGF beta activity, mRNA expression, and protein synthesis in KDH-8 tumor cells were reduced by bleomycin treatment, and that bleomycin-treated-KDH-8-tumor-cell-conditioned medium did not inhibit IL-2 production from normal rat splenocytes.	Bleomycin	163-172	interleukin 2	Rattus norvegicus	233-237
8635193-8	1995	These results suggest that bleomycin treatment restored IL-2 production in tumor-bearing rats through reducing the tumor-derived TGF beta.	Bleomycin	27-36	interleukin 2	Rattus norvegicus	56-60
8635193-8	1995	These results suggest that bleomycin treatment restored IL-2 production in tumor-bearing rats through reducing the tumor-derived TGF beta.	Bleomycin	27-36	transforming growth factor, beta 1	Rattus norvegicus	129-137
7503773-3	1995	Various drugs that cause DNA damage effectively induced RNR3 expression; alkylating agents (cisplatin, mitomycin C and N-methyl-N"-nitro-N-nitrosoguanidine), a radical producer (bleomycin), and an intercalator (actinomycin D) induced RNR3.	Bleomycin	178-187	ribonucleotide-diphosphate reductase subunit RNR3	Saccharomyces cerevisiae S288C	234-238
8574890-8	1995	Immunoelectron microscopy with preembedded rat lungs (bleomycin-exposed cases) confirmed the altered ICAM-1 distribution at the alveolar epithelial surface.	Bleomycin	54-63	intercellular adhesion molecule 1	Rattus norvegicus	101-107
7547247-6	1995	Control cells containing a non-temperature-sensitive mutant p53 (phe132) were sensitive to both etoposide and bleomycin after 24 h at 32 degrees C and 37 degrees C, indicating that the results are not simply due to temperature effects on pharmacokinetics or DNA damage.	Bleomycin	110-119	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	60-63
8550840-0	1996	Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.	Bleomycin	0-9	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	99-132
8550840-4	1996	2 wk after 0.075 U of bleomycin, the lungs of transgenic mice overexpressing PAI-1 contained significantly more hydroxyproline (118 +/- 8 micrograms) than littermate controls (70.5 +/- 8 micrograms, P &lt; 0.005).	Bleomycin	22-31	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	77-82
8550840-5	1996	3 wk after administration of a higher dose of bleomycin (0.15 U), the lung hydroxyproline content of mice completely deficient in PAI-1 (49 +/- 8 micrograms) was not significantly different (P = 0.63) than that of control animals receiving saline (37 +/- 1 micrograms), while hydroxyproline content was significantly increased in heterozygote (77 +/- 12 micrograms, P = 0.06) and wild-type (124 +/- 19 micrograms, P &lt; 0.001) littermates.	Bleomycin	46-55	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	130-135
8569173-0	1996	Differential expression of elastin and alpha 1(I) collagen mRNA in mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	77-86	elastin	Mus musculus	27-34
8569173-6	1996	An increase in elastin mRNA expression in muscular arteries was observed 3 days after bleomycin instillation.	Bleomycin	86-95	elastin	Mus musculus	15-22
8569173-11	1996	Obvious in areas of fibrosis, elastin mRNA expression was occasionally increased in the pleura and airway wall 7 days after bleomycin treatment; alpha 1(I) collagen mRNA expression was generally stronger than elastin mRNA expression in areas of fibrosis and was frequently intense in the adventitia of airways and associated blood vessels.	Bleomycin	124-133	elastin	Mus musculus	30-37
8569173-12	1996	The fibrotic areas showed increased elastin mRNA expression 14 and 30 days after bleomycin treatment.	Bleomycin	81-90	elastin	Mus musculus	36-43
8569173-15	1996	In conclusion, lung elastin biosynthesis is markedly altered by bleomycin treatment.	Bleomycin	64-73	elastin	Mus musculus	20-27
7590166-0	1995	Bleomycin-induced beta-lactamase overexpression in Escherichia coli carrying a bleomycin-resistance gene from Streptomyces verticillus and its application to screen bleomycin analogues.	Bleomycin	79-88	beta-lactamase	Escherichia coli	18-32
7590166-0	1995	Bleomycin-induced beta-lactamase overexpression in Escherichia coli carrying a bleomycin-resistance gene from Streptomyces verticillus and its application to screen bleomycin analogues.	Bleomycin	165-174	beta-lactamase	Escherichia coli	18-32
7500978-2	1995	As bleomycin has been shown to activate poly(ADP-ribose) synthesis in several cell systems, the response to bleomycin with regard to PARP assay was first investigated.	Bleomycin	3-12	poly (ADP-ribose) polymerase 1	Rattus norvegicus	133-137
7476893-0	1995	Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells.	Bleomycin	58-67	bleomycin hydrolase	Saccharomyces cerevisiae S288C	31-35
7476893-1	1995	Tumor resistance to the glycopeptide anticancer drug bleomycin (BLM) has been suggested to involve metabolic inactivation by BLM hydrolase.	Bleomycin	53-62	bleomycin hydrolase	Homo sapiens	125-138
7500978-2	1995	As bleomycin has been shown to activate poly(ADP-ribose) synthesis in several cell systems, the response to bleomycin with regard to PARP assay was first investigated.	Bleomycin	108-117	poly (ADP-ribose) polymerase 1	Rattus norvegicus	133-137
7544811-8	1995	Taken together, these observations suggest that the induction of PAI-1 and TF gene expression plays and important role in the formation and persistence of extracellular fibrin in bleomycin injured murine lungs.	Bleomycin	179-188	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	65-70
7655019-4	1995	Bcl-XL expression dramatically reduces the cytotoxicity of bleomycin, cisplatin, etoposide, vincristine, hygromycin B, and mycophenolic acid for up to 4 days in culture.	Bleomycin	59-68	BCL2 like 1	Homo sapiens	0-6
8556994-0	1995	Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression.	Bleomycin	67-76	interferon gamma	Mus musculus	47-63
8556994-0	1995	Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression.	Bleomycin	67-76	transforming growth factor, beta 1	Mus musculus	125-133
8556994-1	1995	The present study was undertaken to elucidate the mechanism for the antifibrotic effect of interferon gamma (IFN-gamma) in the bleomycin (BL)-mouse model of lung fibrosis.	Bleomycin	127-136	interferon gamma	Mus musculus	91-118
7638617-1	1995	Bleomycin hydrolase is a cysteine protease that hydrolyzes the anticancer drug bleomycin.	Bleomycin	79-88	bleomycin hydrolase	Saccharomyces cerevisiae S288C	0-19
8576540-2	1995	FK 565 and Bleomycin produced an increase in GM-CSF release indicating that these agents are capable of stimulating peritoneal macrophage populations.	Bleomycin	11-20	colony stimulating factor 2	Homo sapiens	45-51
7543734-1	1995	Bleomycin-induced pulmonary fibrosis is associated with increased lung transforming growth factor-beta (TGF-beta) gene expression, but cellular localization of the source of this expression has not been unequivocally established.	Bleomycin	0-9	transforming growth factor, beta 1	Rattus norvegicus	104-112
7543734-4	1995	Before day 3 after bleomycin treatment, scattered bronchiolar epithelial cells, mononuclear cells, and eosinophils expressed elevated levels of TGF-beta 1.	Bleomycin	19-28	transforming growth factor, beta 1	Rattus norvegicus	144-154
8576540-0	1995	Bleomycin and FK 565 enhance the release of GM-CSF from LPS-stimulated BALB/c peritoneal macrophages.	Bleomycin	0-9	colony stimulating factor 2	Homo sapiens	44-50
7541221-0	1995	Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis.	Bleomycin	93-102	transforming growth factor beta 1	Homo sapiens	24-55
7541221-0	1995	Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis.	Bleomycin	93-102	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	66-88
7541221-6	1995	During the "inflammatory" phase (days 1 and 3) of bleomycin-induced injury there was an increase in the mRNA and protein expression of all three TGF-beta isoforms in the injured areas, most prominently in parenchymal cells and alveolar macrophages.	Bleomycin	50-59	transforming growth factor beta 1	Homo sapiens	145-153
7541278-5	1995	CC-16 content was decreased in alveolar fluids from idiopathic pulmonary fibrosis (IPF: 1.3 +/- 0.1 mg/L) and bleomycin lung (1.1 +/- 0.2 versus 2.1 +/- 0.2 mg/L in controls, p &lt; 0.05), whereas there was a three- to ninefold increase in secretory PLA2 activity (p &lt; 0.05 versus controls).	Bleomycin	110-119	secretoglobin family 1A member 1	Homo sapiens	0-5
7530823-0	1994	[CHOP-Bleo therapy in high-malignancy non-Hodgkin lymphoma].	Bleomycin	6-10	DNA damage inducible transcript 3	Homo sapiens	1-5
7537861-5	1995	Cross-sensitivity to other DNA-damaging agents including bleomycin, mitomycin C and methyl methanesulfonate indicated that sxi-2, sxi-3 and sxi-4 appear to be specifically hypersensitive to genotoxic agents that cause DNA DSBs, whereas sxi-1 appeared to be hypersensitive to multiple types of DNA lesions.	Bleomycin	57-66	SXI2	Homo sapiens	123-128
8826931-9	1995	CONCLUSION: If bleomycin is with held when diffusing capacity is diminished to 50% predicted, clinical compromise of pulmonary function appears to be minimal in pediatric patients receiving alternating cycles of COP/ ABVD in combination with low-dose mantle radiotherapy.	Bleomycin	15-24	caspase recruitment domain family member 16	Homo sapiens	212-215
7537554-0	1995	Interaction of lactoferrin with ascorbate and the relationship with bleomycin-dependent DNA damage.	Bleomycin	68-77	lactotransferrin	Bos taurus	15-26
7538902-3	1995	Following DNA strand break damage induced by bleomycin, both SDI1 induction and G1-S cell cycle arrest are p53 dependent, consistent with SDI1 being the key mediator.	Bleomycin	45-54	cyclin dependent kinase inhibitor 1A	Homo sapiens	61-65
7538902-3	1995	Following DNA strand break damage induced by bleomycin, both SDI1 induction and G1-S cell cycle arrest are p53 dependent, consistent with SDI1 being the key mediator.	Bleomycin	45-54	tumor protein p53	Homo sapiens	107-110
7538902-3	1995	Following DNA strand break damage induced by bleomycin, both SDI1 induction and G1-S cell cycle arrest are p53 dependent, consistent with SDI1 being the key mediator.	Bleomycin	45-54	cyclin dependent kinase inhibitor 1A	Homo sapiens	138-142
7539030-9	1995	Both MCP-1 and MIP-1 alpha are expressed in a time-dependent manner after bleomycin challenge, and passive immunization of these animals with either anti-MIP-1 alpha or anti-MCP-1 antibodies attenuated leukocyte accumulation.	Bleomycin	74-83	C-C motif chemokine ligand 2	Homo sapiens	5-10
7539030-9	1995	Both MCP-1 and MIP-1 alpha are expressed in a time-dependent manner after bleomycin challenge, and passive immunization of these animals with either anti-MIP-1 alpha or anti-MCP-1 antibodies attenuated leukocyte accumulation.	Bleomycin	74-83	C-C motif chemokine ligand 3	Homo sapiens	15-26
7539030-13	1995	Our work has clearly established that the C-C chemokines MCP-1 and MIP-1 alpha are expressed and contribute to the initiation and maintenance of the bleomycin-induced pulmonary lesion.	Bleomycin	149-158	C-C motif chemokine ligand 2	Homo sapiens	57-62
7539030-13	1995	Our work has clearly established that the C-C chemokines MCP-1 and MIP-1 alpha are expressed and contribute to the initiation and maintenance of the bleomycin-induced pulmonary lesion.	Bleomycin	149-158	C-C motif chemokine ligand 3	Homo sapiens	67-78
7539741-0	1995	Amelioration of bleomycin-induced lung fibrosis by treatment with the platelet activating factor receptor antagonist WEB 2086 in hamsters.	Bleomycin	16-25	platelet activating factor receptor	Homo sapiens	70-105
7539741-2	1995	This study tested the effectiveness of a platelet activating factor (PAF) receptor antagonist, WEB 2086, against bleomycin (BLEO)-induced lung fibrosis in hamsters.	Bleomycin	113-122	platelet activating factor receptor	Homo sapiens	41-82
7539741-2	1995	This study tested the effectiveness of a platelet activating factor (PAF) receptor antagonist, WEB 2086, against bleomycin (BLEO)-induced lung fibrosis in hamsters.	Bleomycin	124-128	platelet activating factor receptor	Homo sapiens	41-82
7531396-6	1995	This non-transferrin-bound iron is capable of catalyzing bleomycin degradation of DNA, suggesting that this labile form of iron is able to catalyze free radical formation and cause tubule cell injury.	Bleomycin	57-66	transferrin	Homo sapiens	9-20
7530224-1	1994	Extracts of a bleomycin (Bm)-producing Streptomyces verticillus ATCC15003 were found to possess an acetyltransferase activity which inactivates Bm in the presence of acetyl coenzyme A. DNA fragments of S. verticillus were introduced into S. lividans by cloning and transformants selected for resistance to Bm.	Bleomycin	14-23	acetyltransferase	Escherichia coli	99-116
7530224-1	1994	Extracts of a bleomycin (Bm)-producing Streptomyces verticillus ATCC15003 were found to possess an acetyltransferase activity which inactivates Bm in the presence of acetyl coenzyme A. DNA fragments of S. verticillus were introduced into S. lividans by cloning and transformants selected for resistance to Bm.	Bleomycin	25-27	acetyltransferase	Escherichia coli	99-116
7536165-6	1994	We also found that bleomycin-induced fibrosis increases the percentage of Ia expression in Thy1 (-), but not Thy1 (+) fibroblasts.	Bleomycin	19-28	Thy-1 cell surface antigen	Rattus norvegicus	91-95
7526703-3	1994	Using immunohistochemistry, we demonstrate that TGF-beta 2 and TGF-beta 3 were localized to alveolar macrophages as well as epithelial and smooth muscle cells of both normal rat lungs and rat lungs obtained at all time intervals after bleomycin administration.	Bleomycin	235-244	transforming growth factor, beta 3	Rattus norvegicus	63-73
7527830-0	1994	Kinetics of macrophage subpopulations and expression of monocyte chemoattractant protein-1 (MCP-1) in bleomycin-induced lung injury of rats studied by a novel monoclonal antibody against rat MCP-1.	Bleomycin	102-111	C-C motif chemokine ligand 2	Rattus norvegicus	92-97
7527830-1	1994	We investigated the kinetics of macrophage subpopulations and the expression of monocyte chemoattractant protein 1 (MCP-1) in a rat model of bleomycin-induced lung injury.	Bleomycin	141-150	C-C motif chemokine ligand 2	Rattus norvegicus	116-121
7527830-5	1994	Shortly after intratracheal instillation of bleomycin, the number of exudate macrophages recognized by mAb TRPM-3 increased in the injured lungs, peaked 3 days later, and decreased thereafter, whereas tissue macrophages identified by mAb ED2 increased slowly and peaked 2 weeks after instillation.	Bleomycin	44-53	transient receptor potential cation channel, subfamily M, member 3	Rattus norvegicus	107-113
7525712-0	1994	Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury.	Bleomycin	77-86	chemokine (C-C motif) ligand 3	Mus musculus	34-73
7525712-1	1994	We investigated the role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in bleomycin-induced lung injury, a model of interstitial lung disease.	Bleomycin	85-94	chemokine (C-C motif) ligand 3	Mus musculus	69-80
7525712-3	1994	Intratracheal challenge of CBA/J mice with bleomycin resulted in a significant time-dependent increase in MIP-1 alpha protein levels both in whole-lung homogenates and bronchoalveolar lavage fluid.	Bleomycin	43-52	chemokine (C-C motif) ligand 3	Mus musculus	106-117
7525712-7	1994	Interestingly, passive immunization of bleomycin-challenged mice with anti-MIP-1 alpha Abs significantly reduced pulmonary mononuclear phagocyte accumulation and fibrosis.	Bleomycin	39-48	chemokine (C-C motif) ligand 3	Mus musculus	75-86
7525712-8	1994	These experiments establish that MIP-1 alpha protein is expressed in the lungs of bleomycin-treated mice and provide evidence that MIP-1 alpha promotes leukocyte accumulation and activation.	Bleomycin	82-91	chemokine (C-C motif) ligand 3	Mus musculus	33-44
7525714-0	1994	Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis.	Bleomycin	59-68	C-C motif chemokine ligand 2	Rattus norvegicus	5-39
7525714-3	1994	In this study, MCP-1 expression in lungs of rats with bleomycin (BLM)-induced pulmonary fibrosis is examined to evaluate its cellular origin and potential role in pathogenesis.	Bleomycin	54-63	C-C motif chemokine ligand 2	Rattus norvegicus	15-20
7524566-0	1994	Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats.	Bleomycin	107-116	transforming growth factor alpha	Rattus norvegicus	14-46
7524566-0	1994	Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats.	Bleomycin	107-116	epidermal growth factor receptor	Rattus norvegicus	51-83
7527830-0	1994	Kinetics of macrophage subpopulations and expression of monocyte chemoattractant protein-1 (MCP-1) in bleomycin-induced lung injury of rats studied by a novel monoclonal antibody against rat MCP-1.	Bleomycin	102-111	C-C motif chemokine ligand 2	Rattus norvegicus	56-90
7524566-2	1994	At 2 and 4 days after a single intratracheal injection of bleomycin, TGF-alpha mRNA levels increased to 159% and 184% of control values, respectively.	Bleomycin	58-67	transforming growth factor alpha	Rattus norvegicus	69-78
7524566-3	1994	EGF-R mRNA levels increased to 163%, 314%, and 170% of control values at 1, 7, and 14 days after bleomycin instillation.	Bleomycin	97-106	epidermal growth factor receptor	Rattus norvegicus	0-5
7524566-4	1994	TGF-alpha protein levels in whole lung extracts increased to 230% of control values at 4 days after bleomycin administration.	Bleomycin	100-109	transforming growth factor alpha	Rattus norvegicus	0-9
7524566-5	1994	TGF-alpha and EGF-R immunoreactivity was detected in macrophages, alveolar septal cells, and airway epithelium of control and bleomycin-injured animals with an apparent increase in the intensity and number of specifically immunostained cells following lung injury.	Bleomycin	126-135	transforming growth factor alpha	Rattus norvegicus	0-9
7524566-5	1994	TGF-alpha and EGF-R immunoreactivity was detected in macrophages, alveolar septal cells, and airway epithelium of control and bleomycin-injured animals with an apparent increase in the intensity and number of specifically immunostained cells following lung injury.	Bleomycin	126-135	epidermal growth factor receptor	Rattus norvegicus	14-19
7526703-8	1994	Our findings suggest that altered secretion of TGF-beta 1-3 activity by type II alveolar epithelial cells during bleomycin-induced lung injury may regulate pulmonary alveolar epithelial cell proliferation during injury and repair phases.	Bleomycin	113-122	transforming growth factor, beta 1	Rattus norvegicus	47-57
7524566-7	1994	We conclude that TGF-alpha and the EGF-R are present in normal and bleomycin-injured rat lung and that the expression of this growth factor and its receptor are up-regulated following lung injury.	Bleomycin	67-76	transforming growth factor alpha	Rattus norvegicus	17-26
7524566-7	1994	We conclude that TGF-alpha and the EGF-R are present in normal and bleomycin-injured rat lung and that the expression of this growth factor and its receptor are up-regulated following lung injury.	Bleomycin	67-76	epidermal growth factor receptor	Rattus norvegicus	35-40
7523683-0	1994	Single base-pair deletions induced by bleomycin at potential double-strand cleavage sites in the aprt gene of stationary phase Chinese hamster ovary D422 cells.	Bleomycin	38-47	adenine phosphoribosyltransferase	Cricetulus griseus	97-101
7526703-0	1994	Regulation of type II alveolar epithelial cell proliferation by TGF-beta during bleomycin-induced lung injury in rats.	Bleomycin	80-89	transforming growth factor, beta 1	Rattus norvegicus	64-72
7526703-3	1994	Using immunohistochemistry, we demonstrate that TGF-beta 2 and TGF-beta 3 were localized to alveolar macrophages as well as epithelial and smooth muscle cells of both normal rat lungs and rat lungs obtained at all time intervals after bleomycin administration.	Bleomycin	235-244	transforming growth factor, beta 2	Rattus norvegicus	48-58
7524599-4	1994	Granulocyte colony-stimulating factor, by augmenting white cell production, pulmonary sequestration and margination and production of toxic oxygen species, may exacerbate underlying subclinical bleomycin pulmonary toxicity.	Bleomycin	194-203	colony stimulating factor 3	Homo sapiens	0-37
7942004-5	1994	Skull irradiation and chemotherapy (cisplatinum, vinblastine and bleomycin) had only a transient effect on reducing tumor size and normalizing the serum level of HCG.	Bleomycin	65-74	chorionic gonadotropin subunit beta 5	Homo sapiens	162-165
7528044-6	1994	In addition, several treatments known to decrease bleomycin induced collagen deposition and synthesis, namely administration of antibodies against CD11a, CD11b, TNF-alpha and IL-1ra, also decreased platelet trapping.	Bleomycin	50-59	integrin alpha L	Mus musculus	147-152
7528044-6	1994	In addition, several treatments known to decrease bleomycin induced collagen deposition and synthesis, namely administration of antibodies against CD11a, CD11b, TNF-alpha and IL-1ra, also decreased platelet trapping.	Bleomycin	50-59	integrin alpha M	Mus musculus	154-159
7528044-6	1994	In addition, several treatments known to decrease bleomycin induced collagen deposition and synthesis, namely administration of antibodies against CD11a, CD11b, TNF-alpha and IL-1ra, also decreased platelet trapping.	Bleomycin	50-59	tumor necrosis factor	Mus musculus	161-170
7528044-6	1994	In addition, several treatments known to decrease bleomycin induced collagen deposition and synthesis, namely administration of antibodies against CD11a, CD11b, TNF-alpha and IL-1ra, also decreased platelet trapping.	Bleomycin	50-59	interleukin 1 receptor antagonist	Mus musculus	175-181
7531409-0	1994	Effect of anti-calmodulin drugs on the growth and sensitivity of C6 rat glioma cells to bleomycin.	Bleomycin	88-97	calmodulin 1	Rattus norvegicus	15-25
7520998-7	1994	In contrast, exposure to hydrogen peroxide or bleomycin induced DNA damage, but no HSP synthesis, suggesting that oxidation-induced DNA damage and HSP synthesis proceed independently in U937 cells.	Bleomycin	46-55	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	147-150
7923116-4	1994	Induction of p53 is also abnormal in AT cells following treatment with methylmethanesulfonate and bleomycin but appears relatively normal following treatment with UV-C irradiation or the topoisomerase inhibitors, etoposide and camptothecin.	Bleomycin	98-107	tumor protein p53	Homo sapiens	13-16
7531413-3	1994	By contrast, both rad51 and rad52 mutants deficient in double-strand breaks repair were hypersensitive to adriamycin and bleomycin, but the rad1 and rad10 mutants deficient in nucleotide excision repair were not.	Bleomycin	121-130	recombinase RAD51	Saccharomyces cerevisiae S288C	18-23
7531413-3	1994	By contrast, both rad51 and rad52 mutants deficient in double-strand breaks repair were hypersensitive to adriamycin and bleomycin, but the rad1 and rad10 mutants deficient in nucleotide excision repair were not.	Bleomycin	121-130	recombinase RAD52	Saccharomyces cerevisiae S288C	28-33
7513778-0	1994	Possible toxicity with the association of G-CSF and bleomycin.	Bleomycin	52-61	colony stimulating factor 3	Homo sapiens	42-47
8041736-9	1994	Analogously, the increase in catalytic iron (bleomycin-detectable iron) that accompanies hypoxia/reoxygenation did not occur in the presence of cytochrome P-450 inhibitors.	Bleomycin	45-54	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	144-160
7518191-6	1994	The results show an increase in the number of cells resembling fibroblasts and strongly positive for alpha-smooth muscle actin, desmin and procollagen mRNA expression in lungs of animals treated with bleomycin, with the increase being maximal between days 7 and 14 after bleomycin treatment.	Bleomycin	200-209	actin gamma 2, smooth muscle	Rattus norvegicus	101-126
7518191-6	1994	The results show an increase in the number of cells resembling fibroblasts and strongly positive for alpha-smooth muscle actin, desmin and procollagen mRNA expression in lungs of animals treated with bleomycin, with the increase being maximal between days 7 and 14 after bleomycin treatment.	Bleomycin	200-209	desmin	Rattus norvegicus	128-134
8119156-5	1994	In BBM and BLM, half-maximal inhibition of binding was obtained with 0.4-0.9 nM chPTHrP-(1-36) and 0.2-0.6 nM rat PTH-(1-34).	Bleomycin	11-14	parathyroid hormone	Rattus norvegicus	82-85
7513993-0	1994	Semi-artificial hydroxylating enzymes created by flavins binding to cytochrome P450 2B4 and by bleomycin binding to NADPH-cytochrome P450 reductase.	Bleomycin	95-104	cytochrome p450 oxidoreductase	Homo sapiens	116-147
7513993-1	1994	To create a semi-artificial monomolecular oxygenase system, FAD or FMN were covalently bound to cytochrome P450 2B4 as electron donor centers and bleomycin to NADPH-cytochrome P450 reductase as a generator of active oxygen species.	Bleomycin	146-155	cytochrome p450 oxidoreductase	Homo sapiens	159-190
7513699-0	1994	Bleomycin stimulates pro-alpha 1 (I) collagen promoter through transforming growth factor beta response element by intracellular and extracellular signaling.	Bleomycin	0-9	distal membrane arm assembly component 2 like	Rattus norvegicus	83-94
7513699-1	1994	The role of transforming growth factor beta as a mediator of the fibrogenic effect of bleomycin in lung has been investigated at the transcriptional level.	Bleomycin	86-95	distal membrane arm assembly component 2 like	Rattus norvegicus	32-43
7513699-6	1994	Mutation of the transforming growth factor beta response element greatly reduced the bleomycin effect, which also infers intracellular signaling.	Bleomycin	85-94	distal membrane arm assembly component 2 like	Rattus norvegicus	36-47
7513699-7	1994	In addition, plasmin added to the media greatly enhanced bleomycin stimulation of promoter activity demonstrating that transforming growth factor beta mediates the bleomycin effect through extracellular signaling.	Bleomycin	57-66	distal membrane arm assembly component 2 like	Rattus norvegicus	139-150
7513699-7	1994	In addition, plasmin added to the media greatly enhanced bleomycin stimulation of promoter activity demonstrating that transforming growth factor beta mediates the bleomycin effect through extracellular signaling.	Bleomycin	164-173	distal membrane arm assembly component 2 like	Rattus norvegicus	139-150
7516893-0	1994	Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice.	Bleomycin	85-94	tumor necrosis factor	Homo sapiens	39-42
7521798-0	1994	[The effect of IL-1 receptor antagonist on bleomycin-induced pulmonary fibrosis].	Bleomycin	43-52	interleukin 1 receptor antagonist	Homo sapiens	15-39
7516893-3	1994	Infusion of a 55 kD human recombinant soluble TNF receptor rsTNFR-beta, at a rate of 20 micrograms.day-1, prevented the bleomycin/silica induced increase of lung hydroxyproline content, as measured 15 days after instillation.	Bleomycin	120-129	tumor necrosis factor	Homo sapiens	46-49
8114714-4	1994	We exposed human cell lines containing wild-type p53 alleles to several different DNA-damaging agents and found that agents which rapidly induce DNA strand breaks, such as ionizing radiation, bleomycin, and DNA topoisomerase-targeted drugs, rapidly triggered p53 protein elevations.	Bleomycin	192-201	tumor protein p53	Homo sapiens	49-52
8114714-4	1994	We exposed human cell lines containing wild-type p53 alleles to several different DNA-damaging agents and found that agents which rapidly induce DNA strand breaks, such as ionizing radiation, bleomycin, and DNA topoisomerase-targeted drugs, rapidly triggered p53 protein elevations.	Bleomycin	192-201	tumor protein p53	Homo sapiens	259-262
7506365-6	1994	In comparison to G12 cells, the gpt locus in G10 cells is up to 13 times more sensitive to bleomycin mutagenesis and 5 times more responsive to X-ray mutagenesis.	Bleomycin	91-100	glutamic--pyruvic transaminase	Homo sapiens	32-35
7504890-0	1993	Rat alveolar myofibroblasts acquire alpha-smooth muscle actin expression during bleomycin-induced pulmonary fibrosis.	Bleomycin	80-89	actin gamma 2, smooth muscle	Rattus norvegicus	36-61
7508709-9	1994	However, bleomycin (0.6 microgram/ml) significantly decreased the 4.2-kb LO mRNA in contrast to the levels of the alpha 1(I) collagen mRNAs, which were unchanged.	Bleomycin	9-18	lysyl oxidase	Homo sapiens	73-75
27315707-0	1994	Suppressive Effects of Lactoferrin on Bleomycin-dependent DNA Damage by the Iron Ion and Ascorbate.	Bleomycin	38-47	lactotransferrin	Bos taurus	23-34
7893118-15	1994	Advanced cancers with unresectable lymph nodes (inguinal and iliac) and/or metastases (pulmonary) require combination chemotherapy with MTX-cisplatin-bleomycin.	Bleomycin	150-159	metaxin 1	Homo sapiens	136-139
7504660-0	1993	The in vitro action of FK 565, bleomycin and cyclosporin A on different cell populations, with respect to the release of GM-CSF in the mouse.	Bleomycin	31-40	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	121-127
7504928-0	1993	Regulation of rat pulmonary endothelial cell interleukin-6 production by bleomycin: effects of cellular fatty acid composition.	Bleomycin	73-82	interleukin 6	Rattus norvegicus	45-58
7504928-1	1993	Previous studies have shown upregulation of lung cell interleukin-6 (IL-6) production in bleomycin-induced pulmonary fibrosis.	Bleomycin	89-98	interleukin 6	Rattus norvegicus	54-67
7504928-1	1993	Previous studies have shown upregulation of lung cell interleukin-6 (IL-6) production in bleomycin-induced pulmonary fibrosis.	Bleomycin	89-98	interleukin 6	Rattus norvegicus	69-73
7504928-2	1993	To further elucidate the regulatory mechanisms governing this disease, the effects of bleomycin on the production of the pleiotropic cytokine, IL-6, were investigated in lung endothelial cells.	Bleomycin	86-95	interleukin 6	Rattus norvegicus	143-147
7506494-0	1993	Alveolar macrophage secretion of a 92-kDa gelatinase in response to bleomycin.	Bleomycin	68-77	matrix metallopeptidase 9	Rattus norvegicus	35-52
7506494-3	1993	Macrophages stimulated with 0.01-1.0 microgram/ml of bleomycin secreted significantly more of a 92-kDa gelatinase than did unstimulated controls.	Bleomycin	53-62	matrix metallopeptidase 9	Rattus norvegicus	96-113
8306363-2	1993	A 12-year-old patient with a pineal immature teratoma and increase of alpha-fetoprotein serum levels was treated with total excision and cisplatin, vinblastine, and bleomycin (PVB) in combination given twice.	Bleomycin	165-174	alpha fetoprotein	Homo sapiens	70-87
7504660-3	1993	Bleomycin increased GM-CSF release in the BALB/c and the "Scid" mouse.	Bleomycin	0-9	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	20-26
7691887-1	1993	In a model of pulmonary inflammation and fibrosis induced by the antineoplastic antibiotic, bleomycin, we previously demonstrated that TGF-beta was markedly elevated within 7 d of bleomycin administration.	Bleomycin	92-101	transforming growth factor, beta 1	Rattus norvegicus	135-143
7691887-1	1993	In a model of pulmonary inflammation and fibrosis induced by the antineoplastic antibiotic, bleomycin, we previously demonstrated that TGF-beta was markedly elevated within 7 d of bleomycin administration.	Bleomycin	180-189	transforming growth factor, beta 1	Rattus norvegicus	135-143
7691887-3	1993	In this study, we have demonstrated that alveolar macrophages stimulated by bleomycin-induced injury secrete large quantities of biologically active TGF-beta 1 when explanted into tissue culture.	Bleomycin	76-85	transforming growth factor, beta 1	Rattus norvegicus	149-159
7691887-6	1993	High doses of the corticosteroid methylprednisolone given intramuscularly before and concomitantly with bleomycin administration prevented the influx of alveolar macrophages into the lungs, diminishing both the number of macrophages present in the alveoli and the total lung content of TGF-beta.	Bleomycin	104-113	transforming growth factor, beta 1	Rattus norvegicus	286-294
7691887-9	1993	The findings in this study demonstrate that during bleomycin-induced injury, alveolar macrophages not only secrete large quantities of active TGF-beta 1, but are a predominant source of the enhanced TGF-beta response seen in this model.	Bleomycin	51-60	transforming growth factor, beta 1	Rattus norvegicus	142-152
7691887-9	1993	The findings in this study demonstrate that during bleomycin-induced injury, alveolar macrophages not only secrete large quantities of active TGF-beta 1, but are a predominant source of the enhanced TGF-beta response seen in this model.	Bleomycin	51-60	transforming growth factor, beta 1	Rattus norvegicus	142-150
7693990-0	1993	Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.	Bleomycin	143-152	neural proliferation, differentiation and control 1	Homo sapiens	158-161
7689565-0	1993	Cells enriched for catalase are sensitized to the toxicities of bleomycin, adriamycin, and paraquat.	Bleomycin	64-73	catalase	Homo sapiens	19-27
7690890-3	1993	We found that the proportion of the deletion mutants induced by bleomycin at the hypoxanthine-guanine phosphoribosyltransferase (hprt) locus in K1-BH4 cells was 45.5% (25/55).	Bleomycin	64-73	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	81-127
7504843-1	1993	BACKGROUND: Increased production of transforming growth factor beta (TGF-beta) seems to have an important role in the pathophysiology of bleomycin induced lung fibrosis.	Bleomycin	137-146	transforming growth factor, beta 1	Mus musculus	69-77
7504843-3	1993	METHODS: The study was designed to evaluate the antifibrotic potential of TGF-beta antibody in mice treated with bleomycin, which is a model of lung fibrosis.	Bleomycin	113-122	transforming growth factor, beta 1	Mus musculus	74-82
7504843-7	1993	RESULTS: Administration of 250 micrograms of TGF-beta 2 antibody after instillation of bleomycin followed by 100 micrograms on day 5 and 100 micrograms on day 9 significantly reduced the bleomycin induced increases in the accumulation of lung collagen from 445.8 (42.3) micrograms/lung to 336.7 (56.6) micrograms/lung at 14 days.	Bleomycin	87-96	transforming growth factor, beta 2	Mus musculus	45-55
7504843-7	1993	RESULTS: Administration of 250 micrograms of TGF-beta 2 antibody after instillation of bleomycin followed by 100 micrograms on day 5 and 100 micrograms on day 9 significantly reduced the bleomycin induced increases in the accumulation of lung collagen from 445.8 (42.3) micrograms/lung to 336.7 (56.6) micrograms/lung at 14 days.	Bleomycin	187-196	transforming growth factor, beta 2	Mus musculus	45-55
7504843-8	1993	Similarly, the combined treatment with 250 micrograms TGF-beta 2 antibody and 250 micrograms TGF-beta 1 antibody after bleomycin instillation followed by 100 micrograms of each antibody on day 5 also caused a significant reduction in bleomycin induced increases in lung collagen accumulation and myeloperoxidase activity at 14 days.	Bleomycin	119-128	transforming growth factor, beta 2	Mus musculus	54-64
7504843-8	1993	Similarly, the combined treatment with 250 micrograms TGF-beta 2 antibody and 250 micrograms TGF-beta 1 antibody after bleomycin instillation followed by 100 micrograms of each antibody on day 5 also caused a significant reduction in bleomycin induced increases in lung collagen accumulation and myeloperoxidase activity at 14 days.	Bleomycin	119-128	transforming growth factor, beta 1	Mus musculus	93-103
7504843-8	1993	Similarly, the combined treatment with 250 micrograms TGF-beta 2 antibody and 250 micrograms TGF-beta 1 antibody after bleomycin instillation followed by 100 micrograms of each antibody on day 5 also caused a significant reduction in bleomycin induced increases in lung collagen accumulation and myeloperoxidase activity at 14 days.	Bleomycin	234-243	transforming growth factor, beta 2	Mus musculus	54-64
7504843-8	1993	Similarly, the combined treatment with 250 micrograms TGF-beta 2 antibody and 250 micrograms TGF-beta 1 antibody after bleomycin instillation followed by 100 micrograms of each antibody on day 5 also caused a significant reduction in bleomycin induced increases in lung collagen accumulation and myeloperoxidase activity at 14 days.	Bleomycin	234-243	transforming growth factor, beta 1	Mus musculus	93-103
7504843-8	1993	Similarly, the combined treatment with 250 micrograms TGF-beta 2 antibody and 250 micrograms TGF-beta 1 antibody after bleomycin instillation followed by 100 micrograms of each antibody on day 5 also caused a significant reduction in bleomycin induced increases in lung collagen accumulation and myeloperoxidase activity at 14 days.	Bleomycin	234-243	myeloperoxidase	Mus musculus	296-311
7504843-9	1993	CONCLUSIONS: These results suggest that TGF-beta has an important role in the aetiology of bleomycin induced lung fibrosis; the neutralisation of TGF-beta by systemic treatment with its antibodies offers a new mode of pharmacological intervention which may be useful in treating lung fibrosis.	Bleomycin	91-100	transforming growth factor, beta 1	Mus musculus	40-48
7504843-9	1993	CONCLUSIONS: These results suggest that TGF-beta has an important role in the aetiology of bleomycin induced lung fibrosis; the neutralisation of TGF-beta by systemic treatment with its antibodies offers a new mode of pharmacological intervention which may be useful in treating lung fibrosis.	Bleomycin	91-100	transforming growth factor, beta 1	Mus musculus	146-154
7689565-4	1993	Desferrioxamine afforded the cells enriched for catalase modest protection from the toxicities of bleomycin, paraquat, or adriamycin, suggesting that enrichment for iron as a consequence of the increased cellular content of catalase accounted for some of the increased sensitivities.	Bleomycin	98-107	catalase	Homo sapiens	48-56
7689565-5	1993	The increased sensitivity of the LFN7C/B3 cells to bleomycin and paraquat was also attributed to the ability of catalase in cells to prevent the drug-induced consumption of O2; by capturing H2O2 before it can escape the cell and converting it to O2, catalase can maintain the concentration of O2 either for repeated rounds of chemical reduction or for direct interaction with the toxin.	Bleomycin	51-60	catalase	Homo sapiens	112-120
7689565-5	1993	The increased sensitivity of the LFN7C/B3 cells to bleomycin and paraquat was also attributed to the ability of catalase in cells to prevent the drug-induced consumption of O2; by capturing H2O2 before it can escape the cell and converting it to O2, catalase can maintain the concentration of O2 either for repeated rounds of chemical reduction or for direct interaction with the toxin.	Bleomycin	51-60	catalase	Homo sapiens	250-258
8317554-5	1993	Both manganese SOD and copper, zinc SOD activities were significantly induced by paraquat, interleukin-1, tumor necrosis factor, adriamycin, and bleomycin in lymphocytes and neutrophils from asymptomatic non-aged adults, whereas neither activity was induced in aged individuals.	Bleomycin	145-154	superoxide dismutase 2	Homo sapiens	15-18
7504622-0	1993	Role of granulocyte-macrophage colony-stimulating factor in pulmonary fibrosis induced in mice by bleomycin.	Bleomycin	98-107	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	8-56
7504622-1	1993	The role of granulocyte-macrophage colony-stimulating factor (GM-CSF) in pulmonary fibrosis elicited in mice by the intratracheal instillation of bleomycin was investigated by (1) evaluation of GM-CSF mRNA levels, (2) administration of GM-CSF, and (3) administration of anti-GM-CSF antibody.	Bleomycin	146-155	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	12-60
7504622-1	1993	The role of granulocyte-macrophage colony-stimulating factor (GM-CSF) in pulmonary fibrosis elicited in mice by the intratracheal instillation of bleomycin was investigated by (1) evaluation of GM-CSF mRNA levels, (2) administration of GM-CSF, and (3) administration of anti-GM-CSF antibody.	Bleomycin	146-155	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	62-68
7504622-2	1993	A significant increase of the GM-CSF mRNA level was evident in the lung RNA on day 5 after bleomycin instillation, but not on day 15.	Bleomycin	91-100	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	30-36
7504622-3	1993	Abdominal infusion of GM-CSF (0.5 micrograms/h during days 7-15) did prevent the collagen deposition induced by bleomycin, as measured by the lung hydroxyproline content on day 15.	Bleomycin	112-121	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	22-28
8142610-2	1993	Pro-inflammatory cytokines, particularly IL-1 and TNF, have been implicated in some ROI-mediated pathologies, including bleomycin toxicity and ischaemia/reperfusion injury.	Bleomycin	120-129	interleukin 1 alpha	Homo sapiens	41-53
7688761-0	1993	Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	105-114	transforming growth factor, beta 1	Rattus norvegicus	57-90
7688761-5	1993	After the increase of TGF-beta 1 mRNA the messages for biglycan and collagen III steadily increased to reach a maximum 10 d after bleomycin instillation.	Bleomycin	130-139	transforming growth factor, beta 1	Rattus norvegicus	22-32
7688761-5	1993	After the increase of TGF-beta 1 mRNA the messages for biglycan and collagen III steadily increased to reach a maximum 10 d after bleomycin instillation.	Bleomycin	130-139	biglycan	Rattus norvegicus	55-63
8317554-7	1993	Enzyme induction with paraquat, adriamycin, or bleomycin was inhibitable by neutralizing antibody to interleukin-1 and tumor necrosis factor, suggesting that the inductions observed with these three drugs are due to the distal mediators, interleukin-1 or tumor necrosis factor released from the cells.	Bleomycin	47-56	tumor necrosis factor	Homo sapiens	119-140
8317554-7	1993	Enzyme induction with paraquat, adriamycin, or bleomycin was inhibitable by neutralizing antibody to interleukin-1 and tumor necrosis factor, suggesting that the inductions observed with these three drugs are due to the distal mediators, interleukin-1 or tumor necrosis factor released from the cells.	Bleomycin	47-56	interleukin 1 alpha	Homo sapiens	238-276
7694632-3	1993	Transforming growth factor-beta 1 (TGF-beta 1) mRNA was found to increase sevenfold by 5 days after bleomycin treatment of C57BL/6J (sensitive) mice.	Bleomycin	100-109	transforming growth factor, beta 1	Mus musculus	0-33
7689686-1	1993	The transposon Tn5 expresses a gene, ble, whose product increases the viability of Escherichia coli and also confers resistance to the DNA-cleaving antibiotic bleomycin and the DNA-alkylating agent ethylmethanesulphonate.	Bleomycin	159-168	bleomycin resistance protein	Escherichia coli	37-40
7689686-2	1993	We find that the Ble protein induces expression of an alkylation inducible gene, aidC, and that both the AidC gene product and DNA polymerase I are required for Ble to confer bleomycin resistance.	Bleomycin	175-184	bleomycin resistance protein	Escherichia coli	17-20
7689686-2	1993	We find that the Ble protein induces expression of an alkylation inducible gene, aidC, and that both the AidC gene product and DNA polymerase I are required for Ble to confer bleomycin resistance.	Bleomycin	175-184	bleomycin resistance protein	Escherichia coli	161-164
7694632-3	1993	Transforming growth factor-beta 1 (TGF-beta 1) mRNA was found to increase sevenfold by 5 days after bleomycin treatment of C57BL/6J (sensitive) mice.	Bleomycin	100-109	transforming growth factor, beta 1	Mus musculus	35-45
7694632-4	1993	BALB/cBy (resistant) animals demonstrated a lower level of TGF-beta 1 mRNA induction, approximately threefold, after bleomycin administration.	Bleomycin	117-126	transforming growth factor, beta 1	Mus musculus	59-69
7694632-7	1993	Analysis of (C57BL/6JxBALB/cBy)F1 hybrids, which are shown in this report to be sensitive to bleomycin-induced fibrosis, revealed a high IL-1 beta mRNA level, similar to that in the resistant parent.	Bleomycin	93-102	interleukin 1 beta	Mus musculus	137-146
7694632-10	1993	This result indicates a possible association between sensitivity to bleomycin-induced fibrosis and inducibility of IL-6 mRNA upon drug treatment.	Bleomycin	68-77	interleukin 6	Mus musculus	115-119
8463237-12	1993	However, blh1 mutants show hypersensitivity to bleomycin, indicating that bleomycin hydrolase is able to inactivate bleomycin in vivo and to protect cells from bleomycin-induced toxicity.	Bleomycin	47-56	bleomycin hydrolase	Saccharomyces cerevisiae S288C	9-13
8463237-12	1993	However, blh1 mutants show hypersensitivity to bleomycin, indicating that bleomycin hydrolase is able to inactivate bleomycin in vivo and to protect cells from bleomycin-induced toxicity.	Bleomycin	47-56	bleomycin hydrolase	Saccharomyces cerevisiae S288C	74-93
8463237-12	1993	However, blh1 mutants show hypersensitivity to bleomycin, indicating that bleomycin hydrolase is able to inactivate bleomycin in vivo and to protect cells from bleomycin-induced toxicity.	Bleomycin	74-83	bleomycin hydrolase	Saccharomyces cerevisiae S288C	9-13
8463237-12	1993	However, blh1 mutants show hypersensitivity to bleomycin, indicating that bleomycin hydrolase is able to inactivate bleomycin in vivo and to protect cells from bleomycin-induced toxicity.	Bleomycin	74-83	bleomycin hydrolase	Saccharomyces cerevisiae S288C	9-13
7681521-7	1993	The U1 snRNA promoter was also capable of expressing bleomycin resistance in the context of a self-inactivating retrovirus vector, whereby it was discovered that the mouse 3T3 cells used in this experiment were 10 times more sensitive to bleomycin than human or hamster cell lines.	Bleomycin	53-62	RNA, U1 small nuclear 1	Homo sapiens	4-12
7683934-5	1993	Administration of BLM, 5 mg/kg, on day 8, restored IL-2 and IL-6 production and significantly increased TNF production by day 14 of tumor burden as compared with the amounts of cytokine produced by the mitogen-stimulated untreated tumor-bearing rat spleen cells.	Bleomycin	18-21	interleukin 2	Rattus norvegicus	51-55
7683934-5	1993	Administration of BLM, 5 mg/kg, on day 8, restored IL-2 and IL-6 production and significantly increased TNF production by day 14 of tumor burden as compared with the amounts of cytokine produced by the mitogen-stimulated untreated tumor-bearing rat spleen cells.	Bleomycin	18-21	interleukin 6	Rattus norvegicus	60-64
7683934-5	1993	Administration of BLM, 5 mg/kg, on day 8, restored IL-2 and IL-6 production and significantly increased TNF production by day 14 of tumor burden as compared with the amounts of cytokine produced by the mitogen-stimulated untreated tumor-bearing rat spleen cells.	Bleomycin	18-21	tumor necrosis factor-like	Rattus norvegicus	104-107
7682247-2	1993	The binding of heat shock factor (HSF) in response to heat and varying concentrations of bleomycin in the four cell lines was examined using a gel shift assay and a synthetic heat shock element (HSE).	Bleomycin	89-98	interleukin 6	Homo sapiens	15-32
7682247-2	1993	The binding of heat shock factor (HSF) in response to heat and varying concentrations of bleomycin in the four cell lines was examined using a gel shift assay and a synthetic heat shock element (HSE).	Bleomycin	89-98	interleukin 6	Homo sapiens	34-37
7682247-3	1993	Heat (45 degrees C, 10 min) and exposure to 1 micrograms/ml bleomycin for 1 h at 37 degrees C induced similar levels of HSF binding in all four cell lines.	Bleomycin	60-69	interleukin 6	Homo sapiens	120-123
7682247-4	1993	We also examined if bleomycin dose and the length of recovery from bleomycin treatment affected the induction of HSF binding.	Bleomycin	20-29	interleukin 6	Homo sapiens	113-116
7682247-4	1993	We also examined if bleomycin dose and the length of recovery from bleomycin treatment affected the induction of HSF binding.	Bleomycin	67-76	interleukin 6	Homo sapiens	113-116
7682247-5	1993	The level of activated HSF binding to HSE was higher in cells treated with low doses (1 ng/ml) of bleomycin than in cells treated with 1 or 25 micrograms/ml bleomycin.	Bleomycin	98-107	interleukin 6	Homo sapiens	23-26
7682247-6	1993	The amount of activated HSF was directly proportional to the time elapsed since bleomycin treatment.	Bleomycin	80-89	interleukin 6	Homo sapiens	24-27
7682247-7	1993	Our results therefore indicate no difference between CHO and its bleomycin-sensitive derivatives in the ability to initiate the heat shock response as determined by the production of activated HSF in response to either heat or bleomycin.	Bleomycin	227-236	interleukin 6	Homo sapiens	193-196
7679265-0	1993	Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies.	Bleomycin	66-75	CD1d1 antigen	Mus musculus	96-101
7679265-4	1993	Histologic studies indicated that anti CD-11 mAbs attenuated the fibrosing alveolitis induced by silica or bleomycin and in addition markedly decreased the lymphoid infiltration and platelet microthrombi associated with both types of alveolitis.	Bleomycin	107-116	CD1d1 antigen	Mus musculus	39-44
8426200-8	1993	CONCLUSION: Pelvic XRT and cumulative cyclophosphamide dosages greater than 9.5 g/m2 are associated with a high risk of permanent sterility in lymphoma patients treated with the CHOP-Bleo regimen.	Bleomycin	183-187	DNA damage inducible transcript 3	Homo sapiens	178-182
7682247-5	1993	The level of activated HSF binding to HSE was higher in cells treated with low doses (1 ng/ml) of bleomycin than in cells treated with 1 or 25 micrograms/ml bleomycin.	Bleomycin	157-166	interleukin 6	Homo sapiens	23-26
7681521-7	1993	The U1 snRNA promoter was also capable of expressing bleomycin resistance in the context of a self-inactivating retrovirus vector, whereby it was discovered that the mouse 3T3 cells used in this experiment were 10 times more sensitive to bleomycin than human or hamster cell lines.	Bleomycin	238-247	RNA, U1 small nuclear 1	Homo sapiens	4-12
7683505-0	1993	Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica.	Bleomycin	100-109	interleukin 1 receptor antagonist	Mus musculus	0-33
7679254-5	1993	The present experiments revealed that bleomycin also induced AM phi to secrete a second chemotactic factor, transforming growth factor-beta (TGF-beta).	Bleomycin	38-47	transforming growth factor, beta 1	Rattus norvegicus	141-149
7679254-9	1993	Bleomycin-stimulated AM phi s secreted significantly more TGF-beta than did unstimulated controls.	Bleomycin	0-9	transforming growth factor, beta 1	Rattus norvegicus	58-66
7679254-10	1993	Further, in vitro exposure of AM phi to bleomycin induced TGF-beta mRNA expression in a time- and concentration-dependent manner, with maximal mRNA being detected following a 16-h incubation with 1 microgram/ml bleomycin.	Bleomycin	40-49	transforming growth factor, beta 1	Rattus norvegicus	58-66
7679254-10	1993	Further, in vitro exposure of AM phi to bleomycin induced TGF-beta mRNA expression in a time- and concentration-dependent manner, with maximal mRNA being detected following a 16-h incubation with 1 microgram/ml bleomycin.	Bleomycin	211-220	transforming growth factor, beta 1	Rattus norvegicus	58-66
8424954-6	1993	However, in the presence of 3.5 mg bleomycin/ml medium wild-type cells have a slight growth advantage compared to blh1 mutant cells.	Bleomycin	35-44	bleomycin hydrolase	Saccharomyces cerevisiae S288C	114-118
7683505-0	1993	Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica.	Bleomycin	100-109	interleukin 1 receptor antagonist	Mus musculus	35-41
7683505-5	1993	IL-1ra was also effective in reducing the lung hydroxyproline content when given on day 25 after instillation of bleomycin or silica, indicating that it may reverse established PF.	Bleomycin	113-122	interleukin 1 receptor antagonist	Mus musculus	0-6
7688869-4	1993	Cells from old healthy subjects and from subjects with MEN 1 showed increased sensitivity to clastogenic effects of bleomycin.	Bleomycin	116-125	menin 1	Homo sapiens	55-60
8386655-5	1993	The standard drug treatment worldwide for testicular cancer is PEB (cisplatin, etoposide, bleomycin) x3 for good risk and x4 for high risk patients, but there is cumulating evidence that VIP (cisplatin, ifosfamide, etoposide) is more effective for poor risk patients.	Bleomycin	90-99	vasoactive intestinal peptide	Homo sapiens	187-190
1279258-0	1992	[Adjuvant chemotherapy with MVP-CAB (methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin and bleomycin) for epithelial tumors of the upper urinary tract].	Bleomycin	110-119	neural proliferation, differentiation and control 1	Homo sapiens	32-35
1283520-0	1992	Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi"s sarcoma.	Bleomycin	12-21	colony stimulating factor 2	Homo sapiens	68-116
1462359-3	1992	X-irradiation, bleomycin and H2O2 activated PARP.	Bleomycin	15-24	poly(ADP-ribose) polymerase 1	Gallus gallus	44-48
1280451-0	1992	Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin.	Bleomycin	132-141	poly (ADP-ribose) polymerase family, member 1	Mus musculus	65-92
1384968-1	1992	The sensitivity of the human glucocorticoid receptor (hGR) gene to mutagenesis by the cancer chemotherapeutic drugs adriamycin, bleomycin, and chlorambucil was evaluated using glucocorticoid-sensitive (dexs) subclones of the human leukemic cell line CEM-C7.	Bleomycin	128-137	nuclear receptor subfamily 3 group C member 1	Homo sapiens	29-52
1374309-0	1992	[Enhancement of bleomycin or hyperthermia induced tumor cell damage by ADPRT inhibitor].	Bleomycin	16-25	poly(ADP-ribose) polymerase 1	Homo sapiens	71-76
1384342-6	1992	In agreement with past work, the chemotactic activity in bleomycin-CM was due to fibronectin, as evidenced by the almost complete inhibition of activity by anti-fibronectin antibodies.	Bleomycin	57-66	fibronectin 1	Rattus norvegicus	81-92
1384342-6	1992	In agreement with past work, the chemotactic activity in bleomycin-CM was due to fibronectin, as evidenced by the almost complete inhibition of activity by anti-fibronectin antibodies.	Bleomycin	57-66	fibronectin 1	Rattus norvegicus	161-172
1384080-0	1992	Transfection of the Escherichia coli nth gene into radiosensitive Chinese hamster cells: effects on sensitivity to radiation, hydrogen peroxide, and bleomycin sulfate.	Bleomycin	149-166	endonuclease III	Escherichia coli	37-40
1384080-10	1992	The increased sensitivity of x7nth1 and x7nth6 to bleomycin sulfate toxicity may indicate that, when thymine damage and single-strand breaks are in close proximity on opposite strands of the DNA, endonuclease III, which incises DNA at the site of damaged residues, can increase the number of double-strand breaks and hence decrease the level of cell survival.	Bleomycin	50-67	endonuclease III	Escherichia coli	196-212
1376744-11	1992	Synergism with IL-1 beta was also noted with the fibrogenic agent bleomycin.	Bleomycin	66-75	interleukin 1 beta	Rattus norvegicus	15-24
1384296-5	1992	After chemotherapy and operation of right-posterior lobectomy, PVB (cisplatinum, vinblastine, bleomycin) chemotherapy produced a complete remission and the elevated serum AFP was normalized.	Bleomycin	94-103	alpha fetoprotein	Homo sapiens	171-174
1434213-5	1992	Using an experimental rat model of alveolitis induced by bleomycin, the expression of TNF-alpha mRNA in alveolar macrophages recovered by BAL was evaluated by Northern analysis.	Bleomycin	57-66	tumor necrosis factor	Rattus norvegicus	86-95
1434213-6	1992	Alveolar macrophages from bleomycin-treated rats expressed a significant level of TNF-alpha mRNA.	Bleomycin	26-35	tumor necrosis factor	Rattus norvegicus	82-91
1434294-9	1992	Chemotherapy (CHOP-Bleo, or PPA) in both cases and additional radiotherapy in case 2 markedly reduced the tumor size.	Bleomycin	19-23	DNA damage inducible transcript 3	Homo sapiens	14-18
1627644-9	1992	The N-terminal regions of the constructed protein and APEX nuclease were cleaved frequently during the extraction and purification processes of protein to produce the 31, 33 and 35 kDa C-terminal fragments showing priming activities for DNA polymerase on acid-depurinated DNA and bleomycin-damaged DNA.	Bleomycin	280-289	apurinic/apyrimidinic endonuclease 1	Mus musculus	54-67
1374375-6	1992	Interaction between RAD6 and RAD52 genes was epistatic for low bleomycin concentrations.	Bleomycin	63-72	E2 ubiquitin-conjugating protein RAD6	Saccharomyces cerevisiae S288C	20-24
1378925-1	1992	Bleomycin hydrolase (BH) is a cysteine proteinase that terminates the pharmacological action of bleomycin (BLM).	Bleomycin	96-105	bleomycin hydrolase	Oryctolagus cuniculus	0-19
1378925-1	1992	Bleomycin hydrolase (BH) is a cysteine proteinase that terminates the pharmacological action of bleomycin (BLM).	Bleomycin	96-105	bleomycin hydrolase	Oryctolagus cuniculus	21-23
1378925-1	1992	Bleomycin hydrolase (BH) is a cysteine proteinase that terminates the pharmacological action of bleomycin (BLM).	Bleomycin	107-110	bleomycin hydrolase	Oryctolagus cuniculus	0-19
1378925-1	1992	Bleomycin hydrolase (BH) is a cysteine proteinase that terminates the pharmacological action of bleomycin (BLM).	Bleomycin	107-110	bleomycin hydrolase	Oryctolagus cuniculus	21-23
1414690-1	1992	Interleukin 1 (IL-1) and tumor necrosis factor (TNF) have been implicated in the pathogenesis of bleomycin- and silica-induced lung damage.	Bleomycin	97-106	interleukin 1 alpha	Homo sapiens	15-19
1414690-1	1992	Interleukin 1 (IL-1) and tumor necrosis factor (TNF) have been implicated in the pathogenesis of bleomycin- and silica-induced lung damage.	Bleomycin	97-106	tumor necrosis factor	Homo sapiens	25-46
1414690-1	1992	Interleukin 1 (IL-1) and tumor necrosis factor (TNF) have been implicated in the pathogenesis of bleomycin- and silica-induced lung damage.	Bleomycin	97-106	tumor necrosis factor	Homo sapiens	48-51
1376697-1	1992	The bleomycin assay measures non-transferrin-bound iron, able to catalyze free radical reactions, in human plasma.	Bleomycin	4-13	transferrin	Homo sapiens	33-44
1374375-6	1992	Interaction between RAD6 and RAD52 genes was epistatic for low bleomycin concentrations.	Bleomycin	63-72	recombinase RAD52	Saccharomyces cerevisiae S288C	29-34
1374375-7	1992	RAD3 and RAD52 genes act independently in processing DNA damage induced by high concentrations of bleomycin.	Bleomycin	98-107	TFIIH/NER complex ATP-dependent 5'-3' DNA helicase subunit RAD3	Saccharomyces cerevisiae S288C	0-4
1374375-7	1992	RAD3 and RAD52 genes act independently in processing DNA damage induced by high concentrations of bleomycin.	Bleomycin	98-107	recombinase RAD52	Saccharomyces cerevisiae S288C	9-14
1374377-4	1992	All of the physiological defects of ssb-113, including temperature-sensitive growth, temperature-sensitive DNA synthesis, sensitivity to UV irradiation, methyl methanesulfonate, and bleomycin, and reduced recombinational capacity, are restored to wild-type levels.	Bleomycin	182-191	single-stranded DNA-binding protein	Escherichia coli	36-39
1373389-0	1992	Alveolar accumulation of fibronectin and hyaluronan precedes bleomycin-induced pulmonary fibrosis in the rat.	Bleomycin	61-70	fibronectin 1	Rattus norvegicus	25-36
1373569-5	1992	A 24-h treatment with BLM (0.5-100 mU/ml) was found to result in 1) a concentration-dependent decrease in the ability of the macrophage to produce superoxide anion in response to phorbol 12,13-dibutyrate, 2) an increase in secreted interleukin-1 beta (IL-1 beta), and 3) a decrease in intracellular levels of adenosine 3",5"-cyclic monophosphate.	Bleomycin	22-25	interleukin 1 beta	Homo sapiens	232-250
1373569-5	1992	A 24-h treatment with BLM (0.5-100 mU/ml) was found to result in 1) a concentration-dependent decrease in the ability of the macrophage to produce superoxide anion in response to phorbol 12,13-dibutyrate, 2) an increase in secreted interleukin-1 beta (IL-1 beta), and 3) a decrease in intracellular levels of adenosine 3",5"-cyclic monophosphate.	Bleomycin	22-25	interleukin 1 beta	Homo sapiens	252-261
1373569-6	1992	Kinetic studies revealed a time-dependent appearance of BLM-induced cytokines; tumor necrosis factor-alpha could be detected as early as 4 h after stimulation, followed by IL-1 beta at 8 h. The secretion of these cytokines was found to precede the release of prostaglandin E2, which became significant only at 24 h. Taken together, the present results imply that the human alveolar macrophage does not contribute to BLM-induced oxidant injury of the lung but that it may contribute to the development of BLM-induced pulmonary fibrosis.	Bleomycin	56-59	interleukin 1 beta	Homo sapiens	172-181
1373389-10	1992	These data demonstrate that fibronectin accumulates in the alveolar tissue during the early inflammatory phase of the bleomycin-induced lung injury, parallelling hyaluronan accumulation and preceding the development of pulmonary fibrosis.	Bleomycin	118-127	fibronectin 1	Rattus norvegicus	28-39
1374023-3	1992	Significant increases in tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) mRNA were found in lungs of bleomycin-treated responder CBA mice but not in nonresponder BALB/c mice.	Bleomycin	140-149	tumor necrosis factor	Mus musculus	25-52
1371688-9	1992	These results suggest bleomycin regulation of TGF-beta at both the mRNA and protein levels.	Bleomycin	22-31	transforming growth factor, beta 1	Rattus norvegicus	46-54
1371688-12	1992	Following bleomycin treatment, TGF-beta mRNA was shown to be located more prominently in those fibroblasts that contain primarily collagen type I mRNAs.	Bleomycin	10-19	transforming growth factor, beta 1	Rattus norvegicus	31-39
1375871-4	1992	This study shows that bleomycin and its analogues activate rat peritoneal macrophages and increase interleukin-6 release, O2- production, cell spreading, phagocytosis and random migration of macrophages, but only bleomycin enhances peritoneal macrophage invasion into a monolayer of rat lung endothelial cells in vitro.	Bleomycin	22-31	interleukin 6	Rattus norvegicus	99-112
1384148-2	1992	In a phase II study using ifosfamide in combination with cisplatin/bleomycin (BIP) in advanced and recurrent cervical cancer, we demonstrated a response rate of 69%.	Bleomycin	67-76	heat shock protein family A (Hsp70) member 5	Homo sapiens	78-81
1371205-0	1992	Changes in distribution, morphology, and tumor necrosis factor-alpha secretion of alveolar macrophage subpopulations during the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	143-152	tumor necrosis factor	Rattus norvegicus	41-68
1371205-7	1992	Tumor necrosis factor-alpha secretion increased with time in 14- and 28-day samples of bleomycin-treated rats, particularly in subpopulations of densities 1.075 to 1.097 g/ml.	Bleomycin	87-96	tumor necrosis factor	Rattus norvegicus	0-27
1371205-9	1992	When coupled with previous studies suggesting that TNF-alpha plays a role in the fibrotic process in this disease model, these data indicate that AM of densities 1.075 to 1.097 g/ml are responsible for the production of TNF-alpha associated with bleomycin-induced pulmonary fibrosis.	Bleomycin	246-255	tumor necrosis factor	Rattus norvegicus	220-229
1371688-3	1992	Bleomycin treatment of rat lung fibroblast cultures resulted in an increase of total cellular transforming growth factor-beta (TGF-beta) mRNA and increased secretion of TGF-beta protein into the conditioned media.	Bleomycin	0-9	transforming growth factor, beta 1	Rattus norvegicus	127-135
1371688-3	1992	Bleomycin treatment of rat lung fibroblast cultures resulted in an increase of total cellular transforming growth factor-beta (TGF-beta) mRNA and increased secretion of TGF-beta protein into the conditioned media.	Bleomycin	0-9	transforming growth factor, beta 1	Rattus norvegicus	169-177
1371688-5	1992	The bleomycin-induced increase of TGF-beta mRNA was decreased by cells cultured in the presence of either cycloheximide, an inhibitor of protein synthesis, or 2-mercapto-1-(beta-4-pyridethyl) benzimidazole, an inhibitor of RNA synthesis.	Bleomycin	4-13	transforming growth factor, beta 1	Rattus norvegicus	34-42
1371688-7	1992	Transcription of TGF-beta mRNA was increased 12 h after bleomycin treatment, whereas the transcription of type I procollagen, type III procollagen, and beta-actin mRNAs were increased after 48 h of bleomycin treatment.	Bleomycin	56-65	transforming growth factor, beta 1	Rattus norvegicus	17-25
1371688-7	1992	Transcription of TGF-beta mRNA was increased 12 h after bleomycin treatment, whereas the transcription of type I procollagen, type III procollagen, and beta-actin mRNAs were increased after 48 h of bleomycin treatment.	Bleomycin	198-207	actin, beta	Rattus norvegicus	152-162
1374023-3	1992	Significant increases in tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) mRNA were found in lungs of bleomycin-treated responder CBA mice but not in nonresponder BALB/c mice.	Bleomycin	140-149	tumor necrosis factor	Mus musculus	54-63
1374023-3	1992	Significant increases in tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) mRNA were found in lungs of bleomycin-treated responder CBA mice but not in nonresponder BALB/c mice.	Bleomycin	140-149	transforming growth factor, beta 1	Mus musculus	102-110
1722831-1	1991	We studied the effects of recombinant human interleukin-1 beta (rhIL-1 beta) pretreatment on bleomycin (BLM)-induced pneumonitis in mice.	Bleomycin	93-102	interleukin 1 beta	Homo sapiens	44-62
1382047-1	1992	The proportion of hypoxic cells in the RIF-1 tumor was observed for 24 hr after treatments with bleomycin, cisplatin, cyclophosphamide, and mitomycin C.	Bleomycin	96-105	replication timing regulatory factor 1	Homo sapiens	39-44
1382047-3	1992	It was observed that at 1/2 hr after bleomycin, hypoxic fraction was elevated but returned to baseline levels by 2 hr.	Bleomycin	37-46	angiotensin II receptor type 1	Homo sapiens	21-27
1370702-6	1992	Myeloperoxidase levels were measured in plasma and BAL and found to be elevated only in plasma at 7 days after bleomycin.	Bleomycin	111-120	myeloperoxidase	Rattus norvegicus	0-15
1724791-0	1991	Mutation screening of bleomycin-induced V79 Chinese hamster hprt mutants using multiplex polymerase chain reaction.	Bleomycin	22-31	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	60-64
1724791-1	1991	We have shown by the filter hybridization technique that bleomycin (BLM) induces different types of mutations at the hprt gene locus of V79 Chinese hamster cells.	Bleomycin	57-66	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	117-121
1724791-1	1991	We have shown by the filter hybridization technique that bleomycin (BLM) induces different types of mutations at the hprt gene locus of V79 Chinese hamster cells.	Bleomycin	68-71	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	117-121
1715176-0	1991	Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis.	Bleomycin	51-60	coagulation factor II	Rattus norvegicus	0-8
1656994-8	1991	Compounds that increased Fe3+/bleomycin-dependent DNA damage up to a maintained plateau were non-selective inhibitors of both 5-lipoxygenase and cyclo-oxygenase.	Bleomycin	30-39	arachidonate 5-lipoxygenase	Homo sapiens	126-140
1715176-4	1991	In bleomycin-treated rats, thrombin activity in the BAL fluid was significantly elevated on day 2 and maximal on day 6.	Bleomycin	3-12	coagulation factor II	Rattus norvegicus	27-35
1715176-5	1991	The FGA of the BAL fluid from bleomycin-treated rats on day 6 was significantly decreased by its treatment with various thrombin inhibitors, such as alpha 1-protease inhibitor, antithrombin III, hirudin, and MD-805.	Bleomycin	30-39	coagulation factor II	Rattus norvegicus	120-128
1715176-5	1991	The FGA of the BAL fluid from bleomycin-treated rats on day 6 was significantly decreased by its treatment with various thrombin inhibitors, such as alpha 1-protease inhibitor, antithrombin III, hirudin, and MD-805.	Bleomycin	30-39	serpin family A member 1	Rattus norvegicus	149-175
1715176-5	1991	The FGA of the BAL fluid from bleomycin-treated rats on day 6 was significantly decreased by its treatment with various thrombin inhibitors, such as alpha 1-protease inhibitor, antithrombin III, hirudin, and MD-805.	Bleomycin	30-39	serpin family C member 1	Rattus norvegicus	177-193
1715176-8	1991	These results suggest that the FGA of the BAL fluid from bleomycin-treated rats was at least partly due to thrombin is responsible, at least in part, for fibroblast growth and pulmonary fibrosis in bleomycin-induced interstitial lung disease.	Bleomycin	57-66	coagulation factor II	Rattus norvegicus	107-115
1715176-8	1991	These results suggest that the FGA of the BAL fluid from bleomycin-treated rats was at least partly due to thrombin is responsible, at least in part, for fibroblast growth and pulmonary fibrosis in bleomycin-induced interstitial lung disease.	Bleomycin	198-207	coagulation factor II	Rattus norvegicus	107-115
1712423-0	1991	Molecular characterization of mutations at the hprt locus in V79 Chinese hamster cells induced by bleomycin in the presence of inhibitors of DNA repair.	Bleomycin	98-107	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	47-51
1712423-2	1991	43% of the BLM-induced thioguanine-resistant mutants suffer from large alterations of hprt DNA sequences.	Bleomycin	11-14	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	86-90
1705203-0	1991	Insulin-like growth factor-1 (IGF-1) mRNA expression in bone marrow derived macrophages is stimulated by chrysotile asbestos and bleomycin.	Bleomycin	129-138	insulin like growth factor 1	Homo sapiens	0-28
1715415-0	1991	[Combination chemotherapy with methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin, and bleomycin (MVP-CAB) for metastatic urothelial cancer].	Bleomycin	105-114	neural proliferation, differentiation and control 1	Homo sapiens	120-123
2014946-6	1991	INTERVENTION: Treatment was given according to Ann Arbor stage: Patients in stage IV were treated with CHOP-bleomycin and maintained on interferon therapy; those in stage III received CHOP-bleomycin and radiotherapy; and those in stages I and II received COP-bleomycin and radiotherapy.	Bleomycin	108-117	DNA damage inducible transcript 3	Homo sapiens	103-107
2014946-6	1991	INTERVENTION: Treatment was given according to Ann Arbor stage: Patients in stage IV were treated with CHOP-bleomycin and maintained on interferon therapy; those in stage III received CHOP-bleomycin and radiotherapy; and those in stages I and II received COP-bleomycin and radiotherapy.	Bleomycin	189-198	DNA damage inducible transcript 3	Homo sapiens	184-188
2014946-6	1991	INTERVENTION: Treatment was given according to Ann Arbor stage: Patients in stage IV were treated with CHOP-bleomycin and maintained on interferon therapy; those in stage III received CHOP-bleomycin and radiotherapy; and those in stages I and II received COP-bleomycin and radiotherapy.	Bleomycin	189-198	DNA damage inducible transcript 3	Homo sapiens	184-188
1705203-0	1991	Insulin-like growth factor-1 (IGF-1) mRNA expression in bone marrow derived macrophages is stimulated by chrysotile asbestos and bleomycin.	Bleomycin	129-138	insulin like growth factor 1	Homo sapiens	30-35
1703735-10	1991	The specific activity of lysosomal hyaluronidase was the same in bleomycin-treated lungs and control lungs.	Bleomycin	65-74	hyaluronidase 2	Homo sapiens	25-48
1707417-0	1991	Cells containing factor XIIIa and pulmonary fibrosis induced by bleomycin.	Bleomycin	64-73	coagulation factor XIII A chain	Homo sapiens	17-29
1709710-0	1991	[The role of thrombin on lung fibroblast growth and fibrosis in bleomycin-induced lung disorder].	Bleomycin	64-73	coagulation factor II	Rattus norvegicus	13-21
1725569-0	1991	Protective effect of liposome-entrapped superoxide dismutase and catalase on bleomycin-induced lung injury in rats.	Bleomycin	77-86	catalase	Rattus norvegicus	65-73
1723008-5	1991	Haemolytic activity is also exhibited by bleomycin-Fe(III) reduced in the NADPH-cytochrome P450 reductase reaction.	Bleomycin	41-50	cytochrome p450 oxidoreductase	Homo sapiens	74-105
1723845-0	1991	Protective effect of liposome-entrapped superoxide dismutase and catalase on bleomycin-induced lung injury in rats.	Bleomycin	77-86	catalase	Rattus norvegicus	65-73
1723845-3	1991	Liposome-entrapped catalase and/or superoxide dismutase increase antioxidant enzyme activities in the lung tissue of bleomycin-treated rats.	Bleomycin	117-126	catalase	Rattus norvegicus	19-27
1723845-4	1991	The level of lipid peroxidation products (malondialdehyde, conjugated dienes, lipid hydroperoxides) was significantly lower in liposome-entrapped catalase and/or superoxide dismutase supplemented rats with bleomycin-injured lungs.	Bleomycin	206-215	catalase	Rattus norvegicus	146-154
1715270-0	1991	Analysis of bleomycin-induced mutagenic functions related to the PSO4 (= xs9) gene of Saccharomyces cerevisiae.	Bleomycin	12-21	E3 ubiquitin-protein ligase PRP19	Saccharomyces cerevisiae S288C	65-69
1715270-8	1991	These facts suggest that the mutagenicity of bleomycin depends on at least one inducible error-prone repair pathway and that the PSO4 gene product could act as a mutation triggering factor.	Bleomycin	45-54	E3 ubiquitin-protein ligase PRP19	Saccharomyces cerevisiae S288C	129-133
1702754-4	1990	Recombinant interferon-gamma increased the expression of Ia on type II cells in vitro by 35% to the level obtained on type II cells in bleomycin-induced lung disease.	Bleomycin	135-144	interferon gamma	Rattus norvegicus	12-28
1725166-0	1991	Protective effects of human recombinant MnSOD in adjuvant arthritis and bleomycin-induced lung fibrosis.	Bleomycin	72-81	superoxide dismutase 2	Homo sapiens	40-45
1725166-9	1991	MnSOD (50 mg/kg, s.c.), administered 2 h before and then 2 and 4 days after bleomycin, markedly inhibited lung fibrosis, as evident from lung weight and collagen content measured by the 3rd week.	Bleomycin	76-85	superoxide dismutase 2	Homo sapiens	0-5
1702097-9	1991	Northern blotting revealed significant increases in TGF-beta mRNA in bleomycin-stimulated endothelial cells.	Bleomycin	69-78	transforming growth factor, beta 1	Rattus norvegicus	52-60
1702097-10	1991	Thus in vitro stimulation of endothelial cells by bleomycin upregulates TGF-beta production, presumably by increased transcription.	Bleomycin	50-59	transforming growth factor, beta 1	Rattus norvegicus	72-80
1702097-11	1991	In view of the chemotactic and matrix synthesis stimulatory properties of this cytokine, such an increase in TGF-beta production may play an important role in bleomycin-induced pulmonary fibrosis.	Bleomycin	159-168	transforming growth factor, beta 1	Rattus norvegicus	109-117
2258640-7	1990	In vivo studies in mice have demonstrated that IFN-gamma inhibits the collagen synthesis associated with the fibrotic response to an implanted foreign body, bleomycin-induced pulmonary fibrosis, and the healing response to cutaneous thermal burns.	Bleomycin	157-166	interferon gamma	Mus musculus	47-56
1704443-8	1990	The results suggested the G-CSF producing tumor to be heterologous and the cells with different functional properties, including G-CSF production, sensitivity to bleomycin, and keratinization, to pre-exist in the parental cell population.	Bleomycin	162-171	colony stimulating factor 3 (granulocyte)	Mus musculus	26-31
1707456-3	1990	Concentrations of immunoreactive bleomycin of between 11 and 19 ng L-1 were found in the effluents but a lower concentration range less than 5-17 ng L-1 was found in river and potable water samples.	Bleomycin	33-42	immunoglobulin kappa variable 1-16	Homo sapiens	67-70
1704933-1	1990	We assessed the response of various tumors, following each of three consecutive courses of CHOP or CHOP-Bleo therapy in 32 untreated patients with intermediate or high-grade non-Hodgkin"s lymphoma (NHL), and also retrospectively compared these results to those for a group in whom complete remission (CR) had been obtained within five courses and a non-CR group.	Bleomycin	104-108	DNA damage inducible transcript 3	Homo sapiens	99-103
1698540-0	1990	The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas.	Bleomycin	41-50	calmodulin 1	Homo sapiens	14-24
1716490-1	1990	A major role of TNF in pulmonary fibrosis is supported by the following evidences obtained from pulmonary fibrosis induced in mice by bleomycin or silica particles; 1) these diseases are associated with a marked and lasting increase of the TNF mRNA within the lung, 2) they can be prevented by a treatment with anti TNF antibody or aggravated by a perfusion of mouse recombinant TNF, 3) an infusion of TNF-alpha can reproduce the alterations observed during pulmonary fibrosis such as growth of fibroblasts, collagen deposition, cell necrosis.	Bleomycin	134-143	tumor necrosis factor	Mus musculus	16-19
1708910-0	1990	[CHOP-bleo versus m-BACOD in the treatment of intermediate and high-grade malignant lymphomas].	Bleomycin	6-10	DNA damage inducible transcript 3	Homo sapiens	1-5
1696433-5	1990	In the relatively resistant BALB/cN mice, bleomycin did not alter alpha 1IV procollagen mRNA/poly (A+)RNA and only transiently increased laminin A, B1, B2, and alpha 2IV procollagen mRNA/poly (A+)RNA.	Bleomycin	42-51	laminin B1	Mus musculus	137-154
1701859-6	1990	Following cisplatin-vinblastine-bleomycin (PVB) therapy and whole-brain irradiation (50 Gy), the tumor disappeared on CT, although the AFP level did not return to normal.	Bleomycin	32-41	alpha fetoprotein	Homo sapiens	135-138
1703327-10	1990	It was concluded that the alternate chemotherapy regimen CHOP-Bleo/CMED shows similar effects than the classical CHOP-Bleo treatment, and provides a lesser amount of adriamycin, which makes it feasible to use this or other anthracycline drugs in case of relapse; the use of this regimen must be borne in mind when the patient is carrying a myocardiopathy.	Bleomycin	62-66	DNA damage inducible transcript 3	Homo sapiens	57-61
1701928-0	1990	Significance of thrombin in bleomycin-induced pulmonary fibrosis.	Bleomycin	28-37	coagulation factor II	Rattus norvegicus	16-24
1696099-1	1990	In order to investigate the effect of an antisquamous cell carcinoma drug, peplomycin, the new analogue of bleomycin, on the production of a squamous cell carcinoma-associated tumor marker termed "SCC" (or TA-4), we carried out in vitro and in vivo experiments using the uterine cervical epidermoid cancer cell line SKG-IIIa, together with the investigation of the effect of sodium butyrate which was reported to be one of the representative gene modulators.	Bleomycin	107-116	serpin family B member 3	Homo sapiens	197-200
1693490-3	1990	BLM-CH44 was injected around tumor and total dose of BLM was 120 mg, that of MTX was 180 mg, and that of CDDP was 225 mg. After therapy, the sign of extra-esophageal spread disappeared and a radical operation was performed.	Bleomycin	0-3	metaxin 1	Homo sapiens	77-80
1701928-4	1990	In bleomycin-treated rats, thrombin activity in the BALF was significantly elevated on Day 2, and maximal on Day 6.	Bleomycin	3-12	coagulation factor II	Rattus norvegicus	27-35
1701928-5	1990	The FGA of the BALF from bleomycin-treated rats on Day 6 was significantly decreased by its treatment with various thrombin inhibitors, such as alpha 1-antitrypsin, antithrombin III, hirudin and MD-805.	Bleomycin	25-34	coagulation factor II	Rattus norvegicus	115-123
1701928-5	1990	The FGA of the BALF from bleomycin-treated rats on Day 6 was significantly decreased by its treatment with various thrombin inhibitors, such as alpha 1-antitrypsin, antithrombin III, hirudin and MD-805.	Bleomycin	25-34	serpin family C member 1	Rattus norvegicus	165-181
1701928-7	1990	These results suggest that the FGA of the BALF from bleomycin-treated rats was at least partly due to thrombin, and that thrombin is responsible, at least in part, for fibroblast growth and pulmonary fibrosis in bleomycin-induced interstitial lung disease.	Bleomycin	52-61	coagulation factor II	Rattus norvegicus	102-110
1701928-7	1990	These results suggest that the FGA of the BALF from bleomycin-treated rats was at least partly due to thrombin, and that thrombin is responsible, at least in part, for fibroblast growth and pulmonary fibrosis in bleomycin-induced interstitial lung disease.	Bleomycin	212-221	coagulation factor II	Rattus norvegicus	121-129
1692949-2	1990	The interaction between hyperthermia and 111In-BLMC against human SCLC (N417) cells was studied for bleomycin (BLM) (15 micrograms/ml) or 111In-BLMC (40-50 microCi carried by 15 micrograms BLM/ml) for 5 min or 1.5, 2, or 4 hr at 37 degrees C or 43 degrees C exposures.	Bleomycin	47-50	SCLC1	Homo sapiens	66-70
2161816-3	1990	Among the antitumor agents tested, the activities of bleomycin-group antibiotics were more strongly enhanced by SDB-ethylenediamine and the potentiation was higher in the parental cells than in V79/ADM cells.	Bleomycin	53-62	ADM	Cricetulus griseus	194-201
1696541-0	1990	Bleomycin-induced lung injury in the rat: effects of the platelet-activating factor (PAF) receptor antagonist BN 52021 and platelet depletion.	Bleomycin	0-9	platelet-activating factor receptor	Rattus norvegicus	57-98
1696541-9	1990	PAF may partially contribute to the acute inflammatory reaction seen after intratracheal bleomycin in rats.	Bleomycin	89-98	PCNA clamp associated factor	Rattus norvegicus	0-3
1690597-0	1990	Damage and repair induced by bleomycin in the domain of human amplified MYC oncogenes.	Bleomycin	29-38	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	72-75
1691603-9	1990	The ratio of SP-A to total phospholipid decreased 14 to 28 days after instillation of bleomycin.	Bleomycin	86-95	surfactant protein A1	Rattus norvegicus	13-17
1690968-1	1990	Intraoperative local chemotherapy was performed on patients with esophageal cancer, using oil bleomycin (oil BLM).	Bleomycin	94-103	BLM RecQ like helicase	Homo sapiens	109-112
1691254-0	1990	[Combination chemotherapy with methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, and bleomycin: MVP-CAB for disseminated urological cancer].	Bleomycin	106-115	neural proliferation, differentiation and control 1	Homo sapiens	121-124
33761308-6	2021	Finally, using a bleomycin mouse model of pulmonary fibrosis, we show that ablation of kindlin-2 effectively reduced the levels of PYCR1, proline and collagen matrix and alleviate the progression of pulmonary fibrosis in vivo.	Bleomycin	17-26	fermitin family member 2	Mus musculus	87-96
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Bleomycin	167-176	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Bleomycin	178-181	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34
1693314-1	1990	A series of phase II studies using ifosfamide (IFX) as a single agent and in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer have been coordinated at the West Midlands CRC Clinical Trials Unit (Birmingham, UK).	Bleomycin	108-117	heat shock protein family A (Hsp70) member 5	Homo sapiens	119-122
1693316-2	1990	In a phase II study, coordinated at the West Midlands CRC Clinical Trials Unit, Birmingham, using ifosfamide (IFX) in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer, we demonstrated a response rate of 69%.	Bleomycin	149-158	heat shock protein family A (Hsp70) member 5	Homo sapiens	160-163
1710590-1	1990	Calf thymus DNA was incubated with bleomycin and FeCl3 in the presence of isolated rat liver microsomal NADH-cytochrome b5 reductase, cytochrome b5 and NADH which catalyze redox cycling of the bleomycin-Fe-complex.	Bleomycin	35-44	cytochrome b5 type A	Rattus norvegicus	109-122
1710590-1	1990	Calf thymus DNA was incubated with bleomycin and FeCl3 in the presence of isolated rat liver microsomal NADH-cytochrome b5 reductase, cytochrome b5 and NADH which catalyze redox cycling of the bleomycin-Fe-complex.	Bleomycin	35-44	cytochrome b5 type A	Rattus norvegicus	134-147
1710590-1	1990	Calf thymus DNA was incubated with bleomycin and FeCl3 in the presence of isolated rat liver microsomal NADH-cytochrome b5 reductase, cytochrome b5 and NADH which catalyze redox cycling of the bleomycin-Fe-complex.	Bleomycin	193-202	cytochrome b5 type A	Rattus norvegicus	134-147
1714572-1	1990	The self-complementary d(GGGGAGCTCCCC) dodecanucleotide cleavage by bleomycin occurs at G(4)pA(5) site rather than G(6)pC(7) site which is known as the preferential sequence.	Bleomycin	68-77	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	115-121
33817984-7	2021	The bleomycin-exposed rats displayed a robust increase in both the number of Iba1-positive macrophages and protein expression of Interferon regulatory factor 8 in the SG starting as early at 1-week post exposure and lasted for at least 4 weeks, which was largely attenuated by minocycline.	Bleomycin	4-13	allograft inflammatory factor 1	Rattus norvegicus	77-81
33817984-7	2021	The bleomycin-exposed rats displayed a robust increase in both the number of Iba1-positive macrophages and protein expression of Interferon regulatory factor 8 in the SG starting as early at 1-week post exposure and lasted for at least 4 weeks, which was largely attenuated by minocycline.	Bleomycin	4-13	interferon regulatory factor 8	Rattus norvegicus	129-159
33809068-4	2021	Bleomycin-treated CHO-DUK cells, which are one of the host cell lines deficient in dihydrofolate reductase (Dhfr) activity, exhibited a substantial number of cells containing radial formations or non-radial formations with chromosomal rearrangements, suggesting that DSBs may be associated with chromosomal rearrangements.	Bleomycin	0-9	dihydrofolate reductase	Cricetulus griseus	83-106
33805743-4	2021	In this study, the role of Mmp14 was explored in experimental lung fibrosis induced with bleomycin in a conditional mouse model of lung epithelial MMP14-specific genetic deletion.	Bleomycin	89-98	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	27-32
33805152-9	2021	HIF1alpha targets were evaluated by immunohistochemistry in bleomycin-treated rats with/without nintedanib and in patient samples with IPF.	Bleomycin	60-69	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	0-9
33805152-13	2021	Nintedanib completely reduced HIF1alpha upregulation in the IPF-CM and rat-bleomycin models.	Bleomycin	75-84	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	30-39
33815402-0	2021	The Protective Effects of IL-31RA Deficiency During Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	52-61	interleukin 31 receptor A	Homo sapiens	26-33
33815402-6	2021	Notably, the loss of IL-31 signaling attenuated collagen deposition and lung function decline during bleomycin-induced pulmonary fibrosis.	Bleomycin	101-110	interleukin 31	Mus musculus	21-26
33815402-10	2021	Our findings suggest a pathogenic role for IL-31/IL-31RA signaling during bleomycin-induced pulmonary fibrosis.	Bleomycin	74-83	interleukin 31	Homo sapiens	43-48
33815402-10	2021	Our findings suggest a pathogenic role for IL-31/IL-31RA signaling during bleomycin-induced pulmonary fibrosis.	Bleomycin	74-83	interleukin 31 receptor A	Homo sapiens	49-56
33778007-12	2021	Enhancing adenosine levels with ENT1/ENT2 inhibitor dipyridamole at a time when bleomycin-induced ALI was present, reduced further injury.	Bleomycin	80-89	solute carrier family 29 (nucleoside transporters), member 1	Mus musculus	32-36
33809068-4	2021	Bleomycin-treated CHO-DUK cells, which are one of the host cell lines deficient in dihydrofolate reductase (Dhfr) activity, exhibited a substantial number of cells containing radial formations or non-radial formations with chromosomal rearrangements, suggesting that DSBs may be associated with chromosomal rearrangements.	Bleomycin	0-9	dihydrofolate reductase	Cricetulus griseus	108-112
33778007-12	2021	Enhancing adenosine levels with ENT1/ENT2 inhibitor dipyridamole at a time when bleomycin-induced ALI was present, reduced further injury.	Bleomycin	80-89	solute carrier family 29 (nucleoside transporters), member 2	Mus musculus	37-41
30366943-5	2019	When introduced into dermis or bleomycin-injured lungs of mice, collectins MBL and SP-D were endocytosed and routed for lysosomal degradation by uPARAP-positive fibroblasts.	Bleomycin	31-40	mannose-binding lectin (protein C) 2	Mus musculus	75-78
30366943-5	2019	When introduced into dermis or bleomycin-injured lungs of mice, collectins MBL and SP-D were endocytosed and routed for lysosomal degradation by uPARAP-positive fibroblasts.	Bleomycin	31-40	surfactant associated protein D	Mus musculus	83-87
30366943-5	2019	When introduced into dermis or bleomycin-injured lungs of mice, collectins MBL and SP-D were endocytosed and routed for lysosomal degradation by uPARAP-positive fibroblasts.	Bleomycin	31-40	mannose receptor, C type 2	Mus musculus	145-151
34954323-6	2022	Bleomycin and tunicamycin combination models in vivo and in vitro showed that CHOP downregulation rescued alveolar epithelial cell senescence, reduced fibroblast activation mediated by the senescence-associated secretory phenotype, and improved pulmonary fibrosis pathology.	Bleomycin	0-9	DNA damage inducible transcript 3	Homo sapiens	78-82
34414534-3	2022	Although the potent protective role of Tbeta4 in bleomycin-induced pulmonary fibrosis has been validated, the underlying mechanism is not clear; moreover, the influence of Tbeta4 on lipopolysaccharide (LPS)-induced lung injury/fibrosis has not been reported.	Bleomycin	49-58	transforming growth factor alpha regulated gene 3	Mus musculus	39-45
26629034-4	2015	Hodroxyproline content, myeloperoxidase (MPO) activity, tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) levels increased in the rat lung tissues after bleomycin administration, while superoxide dismutase (SOD) activity decreased in the rat lung tissues.	Bleomycin	190-199	tumor necrosis factor	Rattus norvegicus	56-83
26629034-7	2015	It partly reversed the bleomycin-induced increase of hydroxyproline content, MPO activity, TNF-alpha and TGF-beta levels in the lung tissues, significantly inhibited the bleomycin-induced decrease of SOD activity, Excessive collagen deposition was also inhibited by magnolol administration.	Bleomycin	23-32	myeloperoxidase	Rattus norvegicus	77-80
26629034-7	2015	It partly reversed the bleomycin-induced increase of hydroxyproline content, MPO activity, TNF-alpha and TGF-beta levels in the lung tissues, significantly inhibited the bleomycin-induced decrease of SOD activity, Excessive collagen deposition was also inhibited by magnolol administration.	Bleomycin	23-32	tumor necrosis factor	Rattus norvegicus	91-100
26629034-7	2015	It partly reversed the bleomycin-induced increase of hydroxyproline content, MPO activity, TNF-alpha and TGF-beta levels in the lung tissues, significantly inhibited the bleomycin-induced decrease of SOD activity, Excessive collagen deposition was also inhibited by magnolol administration.	Bleomycin	23-32	transforming growth factor, beta 1	Rattus norvegicus	105-113
26629034-7	2015	It partly reversed the bleomycin-induced increase of hydroxyproline content, MPO activity, TNF-alpha and TGF-beta levels in the lung tissues, significantly inhibited the bleomycin-induced decrease of SOD activity, Excessive collagen deposition was also inhibited by magnolol administration.	Bleomycin	170-179	myeloperoxidase	Rattus norvegicus	77-80
26629034-7	2015	It partly reversed the bleomycin-induced increase of hydroxyproline content, MPO activity, TNF-alpha and TGF-beta levels in the lung tissues, significantly inhibited the bleomycin-induced decrease of SOD activity, Excessive collagen deposition was also inhibited by magnolol administration.	Bleomycin	170-179	transforming growth factor, beta 1	Rattus norvegicus	105-113
34852209-6	2022	Post-treatment with GRK2 inhibitor reduced ECM accumulation in lungs in bleomycin-challenged mice, suggesting that GRK2 activation contributes to the progressive phase of pulmonary fibrosis.	Bleomycin	72-81	G protein-coupled receptor kinase 2	Mus musculus	20-24
34606948-10	2022	XFBD can reduce bleomycin-induced pulmonary fibrosis by inhibiting IL-6/STAT3 activation and related macrophage infiltration.	Bleomycin	16-25	interleukin 6	Mus musculus	67-71
34606948-10	2022	XFBD can reduce bleomycin-induced pulmonary fibrosis by inhibiting IL-6/STAT3 activation and related macrophage infiltration.	Bleomycin	16-25	signal transducer and activator of transcription 3	Mus musculus	72-77
34852209-6	2022	Post-treatment with GRK2 inhibitor reduced ECM accumulation in lungs in bleomycin-challenged mice, suggesting that GRK2 activation contributes to the progressive phase of pulmonary fibrosis.	Bleomycin	72-81	G protein-coupled receptor kinase 2	Mus musculus	115-119
34935642-6	2021	In vivo, E4 reversed bleomycin induction of PAI-1 and increased uPA activity.	Bleomycin	21-30	serpin family E member 1	Homo sapiens	44-49
34453744-0	2022	Inhibition of the Arp2/3 complex represses human lung myofibroblast differentiation and attenuates bleomycin-induced pulmonary fibrosis.	Bleomycin	99-108	actin related protein 2	Homo sapiens	18-24
34453744-2	2022	EXPERIMENTAL APPROACH: Expression of Arp2/3 components was assessed in human lung fibroblasts and in the bleomycin-induced pulmonary fibrosis model in mice.	Bleomycin	105-114	actin related protein 2	Homo sapiens	37-43
34453744-5	2022	KEY RESULTS: Expression of Arp2/3 complex subunits mRNAs was increased in fibroblasts treated with TGF-beta1 and in the lungs of bleomycin-treated mice compared to controls.	Bleomycin	129-138	ARP2 actin-related protein 2	Mus musculus	27-33
34478832-9	2022	Additionally, LDLR (1.0 Gy) significantly reduced bleomycin-induced increases in interstitial macrophages, CD103+ dendritic cells and neutrophil-DC hybrids.	Bleomycin	50-59	integrin alpha E, epithelial-associated	Mus musculus	107-112
34478832-10	2022	Overall, bleomycin-treated mice exhibited significantly higher percentages of non-aerated lung in left than right lungs and LDLR (1.0 Gy) limited further reductions in aerated lung volume in right but not left lungs.	Bleomycin	9-18	low density lipoprotein receptor	Mus musculus	124-128
34478832-13	2022	Mechanistically, LDLR at 1.0 Gy significantly suppressed bleomycin-induced accumulation of pulmonary interstitial macrophages, CD103+ dendritic cells and neutrophil-DC hybrids.	Bleomycin	57-66	low density lipoprotein receptor	Mus musculus	17-21
34478832-13	2022	Mechanistically, LDLR at 1.0 Gy significantly suppressed bleomycin-induced accumulation of pulmonary interstitial macrophages, CD103+ dendritic cells and neutrophil-DC hybrids.	Bleomycin	57-66	integrin alpha E, epithelial-associated	Mus musculus	127-132
34931319-0	2022	Needle-free jet injection-induced small-droplet aerosol formation during intralesional bleomycin therapy.	Bleomycin	87-96	F-box and leucine rich repeat protein 15	Homo sapiens	12-15
34931319-3	2022	Here, we aim to explore jet injector-induced small-droplet aerosol formation of bleomycin in relation to air ventilation and to provide safety measures for clinical practice.	Bleomycin	80-89	F-box and leucine rich repeat protein 15	Homo sapiens	24-27
34762934-8	2021	GSK3335103 was shown to engage with the alphavbeta6 integrin and inhibit the activation of TGFbeta in both ex vivo IPF tissue and in a murine model of bleomycin-induced lung fibrosis, as measured by alphavbeta6 engagement, TGFbeta signalling and collagen deposition, with a prolonged duration of action observed in vivo.	Bleomycin	151-160	transforming growth factor alpha	Mus musculus	91-98
34977153-13	2021	Moreover, clock gene expression is correlated with the sensitivity of anticancer drugs such as bleomycin and methotrexate in pan-RCC.	Bleomycin	95-104	clock circadian regulator	Homo sapiens	10-15
34728227-10	2021	Also, lung glutathione content, catalase, glutathione peroxidase and superoxide dismutase activities significantly increased in the carnosol/bleomycin-treated group than the bleomycin group.	Bleomycin	174-183	catalase	Rattus norvegicus	32-40
34656852-12	2021	In addition, after bleomycin induction, the expressions of proinflammatory factors and collagen-related factors in CARMA3-KO mice were much lower than those in WT mice.	Bleomycin	19-28	caspase recruitment domain family, member 10	Mus musculus	115-121
34728227-9	2021	KEY FINDINGS: Carnosol treatment significantly reduced malondialdehyde, nitric oxide, protein carbonyl, tumor necrosis factor- alpha, interleukin-6 levels and myeloperoxidase activity in the lungs of rats exposed to bleomycin.	Bleomycin	216-225	tumor necrosis factor	Rattus norvegicus	104-132
34728227-9	2021	KEY FINDINGS: Carnosol treatment significantly reduced malondialdehyde, nitric oxide, protein carbonyl, tumor necrosis factor- alpha, interleukin-6 levels and myeloperoxidase activity in the lungs of rats exposed to bleomycin.	Bleomycin	216-225	interleukin 6	Rattus norvegicus	134-147
34728227-9	2021	KEY FINDINGS: Carnosol treatment significantly reduced malondialdehyde, nitric oxide, protein carbonyl, tumor necrosis factor- alpha, interleukin-6 levels and myeloperoxidase activity in the lungs of rats exposed to bleomycin.	Bleomycin	216-225	myeloperoxidase	Rattus norvegicus	159-174
34728227-10	2021	Also, lung glutathione content, catalase, glutathione peroxidase and superoxide dismutase activities significantly increased in the carnosol/bleomycin-treated group than the bleomycin group.	Bleomycin	141-150	catalase	Rattus norvegicus	32-40
34656852-14	2021	CONCLUSION: Our Results shows that CARMA3 plays an important role in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	89-98	caspase recruitment domain family, member 10	Mus musculus	35-41
34634687-0	2021	Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: Restoring autophagy in alveolar epithelial cells.	Bleomycin	41-50	vasoactive intestinal polypeptide	Mus musculus	0-29
34912332-9	2021	Also progesterone treatment decreased the gene expression of Col1a2 (P <0.05), Ctgf (P <01), End1 (0.001) in bleomycin- injured lung tissues.	Bleomycin	109-118	collagen, type I, alpha 2	Mus musculus	61-67
34758440-7	2021	Furthermore, HAL significantly reduced the levels of HA, LN, PC-III and IV-C in serum, TNF-alpha and IL-6 in BALF, and TGF-beta1, HYP and Col I in lung tissues of bleomycin (BLM)-treated rats.	Bleomycin	163-172	transforming growth factor, beta 1	Rattus norvegicus	119-128
34783198-0	2021	MicroRNA-411-3p inhibits bleomycin-induced skin fibrosis by regulating transforming growth factor-beta/Smad ubiquitin regulatory factor-2 signalling.	Bleomycin	25-34	tumor necrosis factor	Homo sapiens	71-102
34844843-0	2021	A role for FcgammaRIIB in the development of murine bleomycin-induced fibrosis.	Bleomycin	52-61	Fc receptor, IgG, low affinity IIb	Mus musculus	11-22
34844843-4	2021	OBJECTIVE: The aim of the present study was to investigate the role of FcgammaRIIB in the development of a murine bleomycin-induced scleroderma model.	Bleomycin	114-123	Fc receptor, IgG, low affinity IIb	Mus musculus	71-82
34844843-5	2021	METHODS: The experimental fibrosis model was generated by the subcutaneous injection of bleomycin into wild-type (WT) and FcgammaRIIB-deficient (FcgammaRIIB-/-) mice.	Bleomycin	88-97	Fc receptor, IgG, low affinity IIb	Mus musculus	122-133
34844843-9	2021	In the skin of bleomycin-treated mice, the numbers of CD8+ T cells, F4/80+ macrophages, MPO+ neutrophils, NK1.1+NK cells, and B220+ B cells were significantly higher in FcgammaRIIB-/- mice than in WT mice.	Bleomycin	15-24	adhesion G protein-coupled receptor E1	Mus musculus	68-73
34844843-9	2021	In the skin of bleomycin-treated mice, the numbers of CD8+ T cells, F4/80+ macrophages, MPO+ neutrophils, NK1.1+NK cells, and B220+ B cells were significantly higher in FcgammaRIIB-/- mice than in WT mice.	Bleomycin	15-24	myeloperoxidase	Mus musculus	88-91
34844843-9	2021	In the skin of bleomycin-treated mice, the numbers of CD8+ T cells, F4/80+ macrophages, MPO+ neutrophils, NK1.1+NK cells, and B220+ B cells were significantly higher in FcgammaRIIB-/- mice than in WT mice.	Bleomycin	15-24	Fc gamma receptor IIb	Homo sapiens	169-180
34912332-9	2021	Also progesterone treatment decreased the gene expression of Col1a2 (P <0.05), Ctgf (P <01), End1 (0.001) in bleomycin- injured lung tissues.	Bleomycin	109-118	cellular communication network factor 2	Mus musculus	79-83
34912332-9	2021	Also progesterone treatment decreased the gene expression of Col1a2 (P <0.05), Ctgf (P <01), End1 (0.001) in bleomycin- injured lung tissues.	Bleomycin	109-118	SRY (sex determining region Y)-box 11	Mus musculus	93-97
34859108-13	2021	MiR-101 mimics effectively suppressed collagen deposition in the bleomycin-induced fibrosis mouse model.	Bleomycin	65-74	microRNA 101a	Mus musculus	0-7
34868320-6	2021	The expression levels of HIF-1alpha (hypoxia-inducible factor-1alpha), alpha-SMA (alpha-smooth muscle actin), gammaH2AFX (gammaH2A histone family, member X), ZO-1 (zonula occludens-1), ROS (reactive oxygen species) content, and proliferation ability of A549 cells were detected after treatment with bleomycin and HUCMSCs conditioned medium (HUCMSCs-CM), respectively, or together in vitro.	Bleomycin	299-308	hypoxia inducible factor 1 subunit alpha	Homo sapiens	25-35
34838790-5	2022	Similar expression profiles of LIGHT and HVEM were reproduced in bleomycin-treated mice.	Bleomycin	65-74	tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)	Mus musculus	41-45
34868320-6	2021	The expression levels of HIF-1alpha (hypoxia-inducible factor-1alpha), alpha-SMA (alpha-smooth muscle actin), gammaH2AFX (gammaH2A histone family, member X), ZO-1 (zonula occludens-1), ROS (reactive oxygen species) content, and proliferation ability of A549 cells were detected after treatment with bleomycin and HUCMSCs conditioned medium (HUCMSCs-CM), respectively, or together in vitro.	Bleomycin	299-308	hypoxia inducible factor 1 subunit alpha	Homo sapiens	37-68
34868320-6	2021	The expression levels of HIF-1alpha (hypoxia-inducible factor-1alpha), alpha-SMA (alpha-smooth muscle actin), gammaH2AFX (gammaH2A histone family, member X), ZO-1 (zonula occludens-1), ROS (reactive oxygen species) content, and proliferation ability of A549 cells were detected after treatment with bleomycin and HUCMSCs conditioned medium (HUCMSCs-CM), respectively, or together in vitro.	Bleomycin	299-308	tight junction protein 1	Homo sapiens	164-182
34831433-8	2021	In addition, we found that neutralizing IL-9 in both preventive and therapeutic settings ameliorates bleomycin-induced pulmonary fibrosis.	Bleomycin	101-110	interleukin 9	Homo sapiens	40-44
34806652-7	2021	Mice with endothelial-specific transgenic overexpression of SREBP2 (EC-SREBP2(N)-Tg mice) that were administered bleomycin to induce PF demonstrated exacerbated vascular remodeling and increased mesenchymal transition in the lung.	Bleomycin	113-122	sterol regulatory element binding factor 2	Mus musculus	60-66
34806652-7	2021	Mice with endothelial-specific transgenic overexpression of SREBP2 (EC-SREBP2(N)-Tg mice) that were administered bleomycin to induce PF demonstrated exacerbated vascular remodeling and increased mesenchymal transition in the lung.	Bleomycin	113-122	sterol regulatory element binding transcription factor 2	Homo sapiens	71-77
34807516-9	2022	Mice with fibroblast-specific knockout of TFAM are prone to fibrotic tissue remodeling with fibrotic responses even to NaCl instillation and enhanced sensitivity to bleomycin injection and TbetaRIact-overexpression.	Bleomycin	165-174	transcription factor A, mitochondrial	Mus musculus	42-46
34774095-9	2021	Importantly, vascular permeability, a representative SSc-like vascular feature of bleomycin-treated mice, was attenuated by Ccr6 siRNA treatment, and CCR6 siRNA suppressed the angiogenic activity of human dermal microvascular endothelial cells assayed by in vitro tube formation.	Bleomycin	82-91	chemokine (C-C motif) receptor 6	Mus musculus	124-128
34830288-0	2021	Scleroderma-like Impairment in the Network of Telocytes/CD34+ Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis.	Bleomycin	111-120	CD34 antigen	Mus musculus	56-60
34830288-5	2021	CD34 immunofluorescence revealed a severe impairment in the dermal network of TCs/CD34+ stromal cells in bleomycin-treated mice.	Bleomycin	105-114	CD34 molecule	Homo sapiens	0-4
34830288-5	2021	CD34 immunofluorescence revealed a severe impairment in the dermal network of TCs/CD34+ stromal cells in bleomycin-treated mice.	Bleomycin	105-114	CD34 molecule	Homo sapiens	82-86
34830288-6	2021	CD31/CD34 double immunofluorescence confirmed that CD31-/CD34+ TC counts were greatly reduced in the skin of bleomycin-treated mice compared with control mice.	Bleomycin	109-118	platelet/endothelial cell adhesion molecule 1	Mus musculus	0-4
34830288-6	2021	CD31/CD34 double immunofluorescence confirmed that CD31-/CD34+ TC counts were greatly reduced in the skin of bleomycin-treated mice compared with control mice.	Bleomycin	109-118	CD34 antigen	Mus musculus	5-9
34830288-6	2021	CD31/CD34 double immunofluorescence confirmed that CD31-/CD34+ TC counts were greatly reduced in the skin of bleomycin-treated mice compared with control mice.	Bleomycin	109-118	platelet/endothelial cell adhesion molecule 1	Mus musculus	51-55
34830288-6	2021	CD31/CD34 double immunofluorescence confirmed that CD31-/CD34+ TC counts were greatly reduced in the skin of bleomycin-treated mice compared with control mice.	Bleomycin	109-118	CD34 antigen	Mus musculus	57-61
34830288-8	2021	The analyses of skin samples from mice treated with bleomycin for different times by either TEM or double immunostaining and immunoblotting for the CD34/alpha-SMA antigens collectively suggested that, although a few TCs may transition to alpha-SMA+ myofibroblasts in the early disease stage, most of these cells rather undergo degeneration, and then are lost.	Bleomycin	52-61	CD34 antigen	Mus musculus	148-152
34830288-8	2021	The analyses of skin samples from mice treated with bleomycin for different times by either TEM or double immunostaining and immunoblotting for the CD34/alpha-SMA antigens collectively suggested that, although a few TCs may transition to alpha-SMA+ myofibroblasts in the early disease stage, most of these cells rather undergo degeneration, and then are lost.	Bleomycin	52-61	actin alpha 2, smooth muscle, aorta	Mus musculus	153-162
34830288-8	2021	The analyses of skin samples from mice treated with bleomycin for different times by either TEM or double immunostaining and immunoblotting for the CD34/alpha-SMA antigens collectively suggested that, although a few TCs may transition to alpha-SMA+ myofibroblasts in the early disease stage, most of these cells rather undergo degeneration, and then are lost.	Bleomycin	52-61	actin alpha 2, smooth muscle, aorta	Mus musculus	238-247
34774095-9	2021	Importantly, vascular permeability, a representative SSc-like vascular feature of bleomycin-treated mice, was attenuated by Ccr6 siRNA treatment, and CCR6 siRNA suppressed the angiogenic activity of human dermal microvascular endothelial cells assayed by in vitro tube formation.	Bleomycin	82-91	chemokine (C-C motif) receptor 6	Mus musculus	150-154
34829903-0	2021	Gas6 Ameliorates Inflammatory Response and Apoptosis in Bleomycin-Induced Acute Lung Injury.	Bleomycin	56-65	growth arrest specific 6	Mus musculus	0-4
34237151-4	2021	EXPERIMENTAL APPROACH: ALI/ARDS and pulmonary fibrosis were induced experimentally in wild-type and cortistatin-deficient mice by pulmonary infusion of the bacterial endotoxin LPS or the chemotherapeutic drug bleomycin, and the histopathological signs, pulmonary leukocyte infiltration and cytokines and fibrotic markers were evaluated.	Bleomycin	209-218	cortistatin	Mus musculus	100-111
34803671-9	2021	In conclusion, AZM effectively attenuated BLM-induced PF in mice, which may play a role by partially inhibiting the JNK/c-Jun and TGF-beta1/Smad signaling pathways and reducing production of LOX and LOXL2.	Bleomycin	42-45	mitogen-activated protein kinase 8	Mus musculus	116-119
34803671-9	2021	In conclusion, AZM effectively attenuated BLM-induced PF in mice, which may play a role by partially inhibiting the JNK/c-Jun and TGF-beta1/Smad signaling pathways and reducing production of LOX and LOXL2.	Bleomycin	42-45	jun proto-oncogene	Mus musculus	120-125
34803671-9	2021	In conclusion, AZM effectively attenuated BLM-induced PF in mice, which may play a role by partially inhibiting the JNK/c-Jun and TGF-beta1/Smad signaling pathways and reducing production of LOX and LOXL2.	Bleomycin	42-45	transforming growth factor, beta 1	Mus musculus	130-139
34803671-9	2021	In conclusion, AZM effectively attenuated BLM-induced PF in mice, which may play a role by partially inhibiting the JNK/c-Jun and TGF-beta1/Smad signaling pathways and reducing production of LOX and LOXL2.	Bleomycin	42-45	lysyl oxidase	Mus musculus	191-194
34803671-9	2021	In conclusion, AZM effectively attenuated BLM-induced PF in mice, which may play a role by partially inhibiting the JNK/c-Jun and TGF-beta1/Smad signaling pathways and reducing production of LOX and LOXL2.	Bleomycin	42-45	lysyl oxidase-like 2	Mus musculus	199-204
34795157-8	2021	In this study, we showed that ET-2 is expressed in the lung epithelium, and ET-2 deletion in epithelial cells of mice results in the exacerbation of bleomycin-induced pulmonary fibrosis.	Bleomycin	149-158	endothelin 2	Mus musculus	30-34
34795157-8	2021	In this study, we showed that ET-2 is expressed in the lung epithelium, and ET-2 deletion in epithelial cells of mice results in the exacerbation of bleomycin-induced pulmonary fibrosis.	Bleomycin	149-158	endothelin 2	Mus musculus	76-80
34107237-4	2021	This study showed significantly higher levels of Wnt11 expression in cells from both IPF patients and bleomycin-treated mice, as well as in TGFbeta treated mouse lung fibroblasts.	Bleomycin	102-111	Wnt family member 11	Homo sapiens	49-54
34107237-7	2021	The potential importance of this signaling pathway was supported by in vivo evidence showing significantly increased levels of Wnt11 and activated JNK in lungs of mice with bleomycin induced pulmonary fibrosis.	Bleomycin	173-182	wingless-type MMTV integration site family, member 11	Mus musculus	127-132
34107237-7	2021	The potential importance of this signaling pathway was supported by in vivo evidence showing significantly increased levels of Wnt11 and activated JNK in lungs of mice with bleomycin induced pulmonary fibrosis.	Bleomycin	173-182	mitogen-activated protein kinase 8	Mus musculus	147-150
34803671-0	2021	Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis Partly by Inhibiting the Expression of LOX and LOXL-2.	Bleomycin	24-33	lysyl oxidase	Mus musculus	100-103
34803671-0	2021	Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis Partly by Inhibiting the Expression of LOX and LOXL-2.	Bleomycin	24-33	lysyl oxidase-like 2	Mus musculus	108-114
34237151-5	2021	KEY RESULTS: Partially-deficient mice in cortistatin showed exacerbated pulmonary damage, pulmonary inflammation, alveolar oedema and fibrosis, and subsequent increased respiratory failure and mortality when challenged to LPS or bleomycin, even at low doses.	Bleomycin	229-238	cortistatin	Mus musculus	41-52
34450310-5	2021	Here, the progression of lung fibroblast proliferation and the expression levels of AMPK and FOXM1 were observed by intratracheally instilled of bleomycin (BLM) and intraperitoneal injection of metformin in C57BL/6J mice.	Bleomycin	145-154	forkhead box M1	Mus musculus	93-98
34450310-5	2021	Here, the progression of lung fibroblast proliferation and the expression levels of AMPK and FOXM1 were observed by intratracheally instilled of bleomycin (BLM) and intraperitoneal injection of metformin in C57BL/6J mice.	Bleomycin	145-154	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	84-88
34666752-4	2021	Precision-cut lung slices generated from lung explants from patients with idiopathic pulmonary fibrosis or bleomycin-challenged mouse lungs were treated with integrin inhibitors or standard-of-care drugs (nintedanib or pirfenidone) and analyzed for changes in fibrotic gene expression or TGF-beta signaling.	Bleomycin	107-116	transforming growth factor alpha	Mus musculus	288-296
34520400-7	2021	Using a mouse model of bleomycin-induced pulmonary fibrosis, we show that myofibroblast-specific Sox9 overexpression augments fibroblast activation and pulmonary fibrosis.	Bleomycin	23-32	SRY (sex determining region Y)-box 9	Mus musculus	97-101
34719405-8	2021	When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group.	Bleomycin	78-87	interleukin 6	Mus musculus	104-122
34719405-8	2021	When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group.	Bleomycin	78-87	interleukin 4	Mus musculus	124-128
34719405-8	2021	When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group.	Bleomycin	78-87	interleukin 13	Mus musculus	133-138
34702278-16	2021	Finally, FBXO17 was related with drug sensitivity of bleomycin, gemcitabine, and lenvatinib.	Bleomycin	53-62	F-box protein 17	Homo sapiens	9-15
34666752-5	2021	Bleomycin-challenged mice treated with dual alphavbeta6/alphavbeta1 integrin inhibitor, PLN-74809, were assessed for changes in pulmonary collagen deposition and Smad3 phosphorylation.	Bleomycin	0-9	SMAD family member 3	Mus musculus	162-167
34681813-7	2021	Utilization of an in vivo lung injury model by treating bleomycin on mice followed by ATL treatment to demonstrate the therapeutic effectiveness, such as, less collagen deposition and lower E-cadherin expression.	Bleomycin	56-65	cadherin 1	Mus musculus	190-200
34645797-3	2021	Through iTRAQ (isobaric tagging for relative and absolute quantification) quantitative proteomics, TSSK4 was identified to be upregulated in bleomycin-induced fibrotic mice model, which was further confirmed in clinical IPF patients" tissue specimens.	Bleomycin	141-150	testis-specific serine kinase 4	Mus musculus	99-104
34649259-5	2021	METHODS: Dermal fibrosis was induced by repetitive intradermal injections of bleomycin in wild-type and cortistatin-deficient mice.	Bleomycin	77-86	cortistatin	Mus musculus	104-115
34649259-8	2021	Bleomycin-challenged skin lesions of mice that are partially- and totally-deficient in cortistatin showed exacerbated histopathological signs of scleroderma, characterized by thicker and more fibrotic dermal layer, enlarged epidermis and increased inflammatory infiltration in comparison to those of wild-type mice.	Bleomycin	0-9	cortistatin	Mus musculus	87-98
34649259-9	2021	Cortistatin-deficiency enhanced dermal collagen deposits, connective tissue growth factor expression and loss of microvessels, and predisposed to suffer severe complications that co-occur with dermal exposition to bleomycin, including pulmonary fibrotic disease and increased mortality.	Bleomycin	214-223	cortistatin	Mus musculus	0-11
34649259-13	2021	Cortistatin-based therapies emerge as attractive candidates to treat severe forms of systemic sclerosis, and to manage fibrosis-related side effects of bleomycin-chemotherapy in oncologic patients.	Bleomycin	152-161	cortistatin	Homo sapiens	0-11
34722630-2	2021	PIEZO1, a mechanosensitive calcium channel, is expressed in myeloid cell and has been found to play an important role in bleomycin-induced pulmonary fibrosis.	Bleomycin	121-130	piezo-type mechanosensitive ion channel component 1	Rattus norvegicus	0-6
34625478-2	2022	Whether Nestin plays a critical role in the pathogenesis of IPF needs to be clarified.Nestin expression in lung tissues from bleomycin-treated mice and IPF patients was determined.	Bleomycin	125-134	nestin	Mus musculus	86-92
34692765-0	2021	Therapeutic Effects of the Bcl-2 Inhibitor on Bleomycin-induced Pulmonary Fibrosis in Mice.	Bleomycin	46-55	B cell leukemia/lymphoma 2	Mus musculus	27-32
34692765-4	2021	In this study, we aimed to investigate the therapeutic effect of a Bcl-2 homology domain 3 mimetic inhibitor, ABT-199, on bleomycin (BLM)-induced pulmonary fibrosis in mice, and explore possible underlying mechanism.	Bleomycin	122-131	B cell leukemia/lymphoma 2	Mus musculus	67-72
34692765-4	2021	In this study, we aimed to investigate the therapeutic effect of a Bcl-2 homology domain 3 mimetic inhibitor, ABT-199, on bleomycin (BLM)-induced pulmonary fibrosis in mice, and explore possible underlying mechanism.	Bleomycin	133-136	B cell leukemia/lymphoma 2	Mus musculus	67-72
34375009-0	2021	Bergenin attenuates bleomycin-induced pulmonary fibrosis in mice via inhibiting TGF-beta1 signaling pathway.	Bleomycin	20-29	transforming growth factor, beta 1	Mus musculus	80-89
34600594-11	2021	In the lung tissues of 1 mg/kg BLM-induced mice, RAGE expression was gradually decreased in 1- and 2 weeks in immunohistochemistry and western blot analysis, and 3 mg/kg of BLM-induced mice exhibited decreased RAGE levels while alpha-SMA expression was increased.	Bleomycin	31-34	advanced glycosylation end product-specific receptor	Mus musculus	49-53
34600594-11	2021	In the lung tissues of 1 mg/kg BLM-induced mice, RAGE expression was gradually decreased in 1- and 2 weeks in immunohistochemistry and western blot analysis, and 3 mg/kg of BLM-induced mice exhibited decreased RAGE levels while alpha-SMA expression was increased.	Bleomycin	31-34	advanced glycosylation end product-specific receptor	Mus musculus	210-214
34600594-11	2021	In the lung tissues of 1 mg/kg BLM-induced mice, RAGE expression was gradually decreased in 1- and 2 weeks in immunohistochemistry and western blot analysis, and 3 mg/kg of BLM-induced mice exhibited decreased RAGE levels while alpha-SMA expression was increased.	Bleomycin	31-34	actin alpha 2, smooth muscle, aorta	Mus musculus	228-237
34600594-11	2021	In the lung tissues of 1 mg/kg BLM-induced mice, RAGE expression was gradually decreased in 1- and 2 weeks in immunohistochemistry and western blot analysis, and 3 mg/kg of BLM-induced mice exhibited decreased RAGE levels while alpha-SMA expression was increased.	Bleomycin	173-176	advanced glycosylation end product-specific receptor	Mus musculus	49-53
34600594-11	2021	In the lung tissues of 1 mg/kg BLM-induced mice, RAGE expression was gradually decreased in 1- and 2 weeks in immunohistochemistry and western blot analysis, and 3 mg/kg of BLM-induced mice exhibited decreased RAGE levels while alpha-SMA expression was increased.	Bleomycin	173-176	advanced glycosylation end product-specific receptor	Mus musculus	210-214
34600594-11	2021	In the lung tissues of 1 mg/kg BLM-induced mice, RAGE expression was gradually decreased in 1- and 2 weeks in immunohistochemistry and western blot analysis, and 3 mg/kg of BLM-induced mice exhibited decreased RAGE levels while alpha-SMA expression was increased.	Bleomycin	173-176	actin alpha 2, smooth muscle, aorta	Mus musculus	228-237
34475978-11	2021	Expression of mEGFP was mainly observed in the fibrotic region in bleomycin-induced pulmonary fibrosis; 1.94+-0.08% of alpha-SMA-positive cells were mEGFP-positive and 9.68+-2.06% of S100A4-positive cells were mEGFP-positive in bleomycin-induced pulmonary fibrosis.	Bleomycin	66-75	actin alpha 2, smooth muscle, aorta	Mus musculus	119-128
34284287-4	2021	We found IGU decreased pulmonary inflammation and fibrosis and expression of fibrosis-related genes such as Collagen I, alpha-smooth muscle actin (alpha-SMA) and matrix metalloproteinase-2 (MMP-2) induced by bleomycin.	Bleomycin	208-217	actin alpha 2, smooth muscle, aorta	Mus musculus	147-156
34284287-4	2021	We found IGU decreased pulmonary inflammation and fibrosis and expression of fibrosis-related genes such as Collagen I, alpha-smooth muscle actin (alpha-SMA) and matrix metalloproteinase-2 (MMP-2) induced by bleomycin.	Bleomycin	208-217	matrix metallopeptidase 2	Mus musculus	162-188
34284287-4	2021	We found IGU decreased pulmonary inflammation and fibrosis and expression of fibrosis-related genes such as Collagen I, alpha-smooth muscle actin (alpha-SMA) and matrix metalloproteinase-2 (MMP-2) induced by bleomycin.	Bleomycin	208-217	matrix metallopeptidase 2	Mus musculus	190-195
34533865-7	2021	Moreover, Ifnb-/- mice displayed enhanced pro-fibrotic indices upon exposure to bleomycin.	Bleomycin	80-89	interferon beta 1, fibroblast	Mus musculus	10-14
34603325-0	2021	Increased Monocyte-Derived CD11b+ Macrophage Subpopulations Following Cigarette Smoke Exposure Are Associated With Impaired Bleomycin-Induced Tissue Remodelling.	Bleomycin	124-133	integrin alpha M	Mus musculus	27-32
34425215-4	2021	Fibroblasts expressing BRD4, a member of the BET protein family, were enriched in the tissue regions corresponding to bleomycin-induced fibrotic lesions.	Bleomycin	118-127	bromodomain containing 4	Mus musculus	23-27
34425215-5	2021	Additionally, pulmonary fibroblasts isolated from bleomycin-instilled mice showed a significantly increased association of BRD4 with the promoters of two pro-fibrotic genes linked to the entry into the TGF-beta1 autocrine/paracrine loop, thrombospondin 1 (Thbs1) and integrin beta3 (Itgb3), as well as with the promoter of a myofibroblast marker gene, actin alpha 2 (Acta2).	Bleomycin	50-59	bromodomain containing 4	Mus musculus	123-127
34425215-5	2021	Additionally, pulmonary fibroblasts isolated from bleomycin-instilled mice showed a significantly increased association of BRD4 with the promoters of two pro-fibrotic genes linked to the entry into the TGF-beta1 autocrine/paracrine loop, thrombospondin 1 (Thbs1) and integrin beta3 (Itgb3), as well as with the promoter of a myofibroblast marker gene, actin alpha 2 (Acta2).	Bleomycin	50-59	transforming growth factor, beta 1	Mus musculus	202-211
34425215-5	2021	Additionally, pulmonary fibroblasts isolated from bleomycin-instilled mice showed a significantly increased association of BRD4 with the promoters of two pro-fibrotic genes linked to the entry into the TGF-beta1 autocrine/paracrine loop, thrombospondin 1 (Thbs1) and integrin beta3 (Itgb3), as well as with the promoter of a myofibroblast marker gene, actin alpha 2 (Acta2).	Bleomycin	50-59	thrombospondin 1	Mus musculus	238-254
34425215-5	2021	Additionally, pulmonary fibroblasts isolated from bleomycin-instilled mice showed a significantly increased association of BRD4 with the promoters of two pro-fibrotic genes linked to the entry into the TGF-beta1 autocrine/paracrine loop, thrombospondin 1 (Thbs1) and integrin beta3 (Itgb3), as well as with the promoter of a myofibroblast marker gene, actin alpha 2 (Acta2).	Bleomycin	50-59	thrombospondin 1	Mus musculus	256-261
34425215-5	2021	Additionally, pulmonary fibroblasts isolated from bleomycin-instilled mice showed a significantly increased association of BRD4 with the promoters of two pro-fibrotic genes linked to the entry into the TGF-beta1 autocrine/paracrine loop, thrombospondin 1 (Thbs1) and integrin beta3 (Itgb3), as well as with the promoter of a myofibroblast marker gene, actin alpha 2 (Acta2).	Bleomycin	50-59	integrin beta 3	Mus musculus	267-281
34425215-5	2021	Additionally, pulmonary fibroblasts isolated from bleomycin-instilled mice showed a significantly increased association of BRD4 with the promoters of two pro-fibrotic genes linked to the entry into the TGF-beta1 autocrine/paracrine loop, thrombospondin 1 (Thbs1) and integrin beta3 (Itgb3), as well as with the promoter of a myofibroblast marker gene, actin alpha 2 (Acta2).	Bleomycin	50-59	integrin beta 3	Mus musculus	283-288
34425215-5	2021	Additionally, pulmonary fibroblasts isolated from bleomycin-instilled mice showed a significantly increased association of BRD4 with the promoters of two pro-fibrotic genes linked to the entry into the TGF-beta1 autocrine/paracrine loop, thrombospondin 1 (Thbs1) and integrin beta3 (Itgb3), as well as with the promoter of a myofibroblast marker gene, actin alpha 2 (Acta2).	Bleomycin	50-59	actin alpha 2, smooth muscle, aorta	Mus musculus	367-372
34343908-0	2021	Pharmaceutical targeting of succinate dehydrogenase in fibroblasts controls bleomycin-induced lung fibrosis.	Bleomycin	76-85	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	28-51
34650521-0	2021	Peripheral Hybrid CB1R and iNOS Antagonist MRI-1867 Displays Anti-Fibrotic Efficacy in Bleomycin-Induced Skin Fibrosis.	Bleomycin	87-96	nitric oxide synthase 2, inducible	Mus musculus	27-31
34650521-5	2021	Skin fibrosis was induced in C57BL/6J (B6) and Mdr1a/b-Bcrp triple knock-out (KO) mice by daily subcutaneous injections of bleomycin (2 IU/100 microL) for 28 days.	Bleomycin	123-132	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	47-54
34650521-5	2021	Skin fibrosis was induced in C57BL/6J (B6) and Mdr1a/b-Bcrp triple knock-out (KO) mice by daily subcutaneous injections of bleomycin (2 IU/100 microL) for 28 days.	Bleomycin	123-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-59
34650521-11	2021	However, the skin level of MRI-1867, an MDR1 substrate, was dramatically lower in B6 mice (0.023 microM) than in Mdr1a/b-Bcrp KO mice (8.8 microM) due to a bleomycin-induced increase in efflux activity of MDR1 in fibrotic skin.	Bleomycin	156-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-44
34650521-11	2021	However, the skin level of MRI-1867, an MDR1 substrate, was dramatically lower in B6 mice (0.023 microM) than in Mdr1a/b-Bcrp KO mice (8.8 microM) due to a bleomycin-induced increase in efflux activity of MDR1 in fibrotic skin.	Bleomycin	156-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	113-120
34650521-11	2021	However, the skin level of MRI-1867, an MDR1 substrate, was dramatically lower in B6 mice (0.023 microM) than in Mdr1a/b-Bcrp KO mice (8.8 microM) due to a bleomycin-induced increase in efflux activity of MDR1 in fibrotic skin.	Bleomycin	156-165	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
34650521-11	2021	However, the skin level of MRI-1867, an MDR1 substrate, was dramatically lower in B6 mice (0.023 microM) than in Mdr1a/b-Bcrp KO mice (8.8 microM) due to a bleomycin-induced increase in efflux activity of MDR1 in fibrotic skin.	Bleomycin	156-165	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	205-209
34650521-13	2021	MRI-1867 treatment attenuated bleomycin-induced established skin fibrosis and the associated increase in endocannabinoids in Mdr1a/b-Bcrp KO mice but not in B6 mice.	Bleomycin	30-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	125-132
34650521-13	2021	MRI-1867 treatment attenuated bleomycin-induced established skin fibrosis and the associated increase in endocannabinoids in Mdr1a/b-Bcrp KO mice but not in B6 mice.	Bleomycin	30-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	133-137
34506963-9	2022	Besides, TGF-beta/Smad3/miR-21 feedback loop signaling was upregulated in bleomycin-treated HUVEC and VM specimens, which was accompanied by increased collagen deposition.	Bleomycin	74-83	transforming growth factor alpha	Homo sapiens	9-17
34506963-9	2022	Besides, TGF-beta/Smad3/miR-21 feedback loop signaling was upregulated in bleomycin-treated HUVEC and VM specimens, which was accompanied by increased collagen deposition.	Bleomycin	74-83	SMAD family member 3	Homo sapiens	18-23
34506963-9	2022	Besides, TGF-beta/Smad3/miR-21 feedback loop signaling was upregulated in bleomycin-treated HUVEC and VM specimens, which was accompanied by increased collagen deposition.	Bleomycin	74-83	microRNA 21	Homo sapiens	24-30
34481508-14	2021	AM receptor was co-expressed with the endothelial cell protein CD31 in alveolar capillaries, and markedly reduced after bleomycin.	Bleomycin	120-129	G protein-coupled receptor 182	Homo sapiens	0-11
34530920-11	2021	SF-MSCs inhibited the reduction in serum transforming growth factor-beta1 and the increase of interleukin-6 in both the serum and the bronchoalveolar lavage fluid during bleomycin-induced pulmonary fibrosis.	Bleomycin	170-179	interleukin 6	Mus musculus	94-107
34481508-14	2021	AM receptor was co-expressed with the endothelial cell protein CD31 in alveolar capillaries, and markedly reduced after bleomycin.	Bleomycin	120-129	platelet and endothelial cell adhesion molecule 1	Rattus norvegicus	63-67
34483252-0	2021	Macrophage exosomes transfer angiotensin II type 1 receptor to lung fibroblasts mediating bleomycin-induced pulmonary fibrosis.	Bleomycin	90-99	angiotensin II, type I receptor-associated protein	Mus musculus	29-59
34484791-1	2021	The article description and significance to dermatologists: bleomycin flagellate dermatitis is a rare cutaneous manifestation, believed to be due to the lack of bleomycin hydrolase enzyme in the skin, which inactivates bleomycin, resulting in its accumulation.	Bleomycin	60-69	bleomycin hydrolase	Homo sapiens	161-180
34446559-3	2021	Herein, we showed that LRRK2 expression was clearly reduced in mammalian fibrotic lungs, and LRRK2-deficient mice exhibited aggravated bleomycin-induced pulmonary fibrosis.	Bleomycin	135-144	leucine rich repeat kinase 2	Homo sapiens	23-28
34446559-3	2021	Herein, we showed that LRRK2 expression was clearly reduced in mammalian fibrotic lungs, and LRRK2-deficient mice exhibited aggravated bleomycin-induced pulmonary fibrosis.	Bleomycin	135-144	leucine rich repeat kinase 2	Homo sapiens	93-98
34446559-4	2021	Furthermore, we demonstrated that in bleomycin-treated mice, LRRK2 expression was dramatically decreased in alveolar type II epithelial (AT2) cells, and its deficiency resulted in profound dysfunction of AT2 cells, characterized by impaired autophagy and accelerated cellular senescence.	Bleomycin	37-46	leucine-rich repeat kinase 2	Mus musculus	61-66
34733976-2	2021	Apolipoprotein A-1 (ApoA-1) has been reported to ameliorate the bleomycin (BLM)-induced IPF model.	Bleomycin	64-73	apolipoprotein A-I	Mus musculus	0-18
34733976-2	2021	Apolipoprotein A-1 (ApoA-1) has been reported to ameliorate the bleomycin (BLM)-induced IPF model.	Bleomycin	64-73	apolipoprotein A-I	Mus musculus	20-26
34733976-2	2021	Apolipoprotein A-1 (ApoA-1) has been reported to ameliorate the bleomycin (BLM)-induced IPF model.	Bleomycin	75-78	apolipoprotein A-I	Mus musculus	0-18
34733976-2	2021	Apolipoprotein A-1 (ApoA-1) has been reported to ameliorate the bleomycin (BLM)-induced IPF model.	Bleomycin	75-78	apolipoprotein A-I	Mus musculus	20-26
34484791-1	2021	The article description and significance to dermatologists: bleomycin flagellate dermatitis is a rare cutaneous manifestation, believed to be due to the lack of bleomycin hydrolase enzyme in the skin, which inactivates bleomycin, resulting in its accumulation.	Bleomycin	219-228	bleomycin hydrolase	Homo sapiens	161-180
34378880-1	2021	OBJECTIVE: Promotion of the proliferative expansion of CD4+Foxp3+ regulatory T cells (Tregs) is one of the side effects that limits the use of bleomycin (BLM) in the treatment of tumors.	Bleomycin	143-152	CD4 antigen	Mus musculus	55-58
34526900-2	2021	Previous work has shown that global deletion of galectin-3 reduces collagen deposition in a bleomycin-induced pulmonary fibrosis model (MacKinnon et al., Am.	Bleomycin	92-101	lectin, galactose binding, soluble 3	Mus musculus	48-58
34502263-0	2021	RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury.	Bleomycin	72-81	regulator of G-protein signaling 5	Mus musculus	0-4
34502263-6	2021	In line with this, RGS5 was markedly increased in murine lungs following bleomycin injury.	Bleomycin	73-82	regulator of G-protein signaling 5	Mus musculus	19-23
34502263-11	2021	As a conclusion, loss of RGS5 preserves lung function and attenuates hyperinflammation in the acute phase of bleomycin-induced pulmonary fibrosis and LPS-induced lung injury.	Bleomycin	109-118	regulator of G-protein signaling 5	Mus musculus	25-29
34425896-9	2021	The CD45-/ALDHbr cell population, and especially its CD45-/ALDHbr/PDGFRalpha+ subpopulation, was significantly reduced in the lung during bleomycin-induced pulmonary fibrosis.	Bleomycin	138-147	protein tyrosine phosphatase, receptor type, C	Mus musculus	4-8
34425896-9	2021	The CD45-/ALDHbr cell population, and especially its CD45-/ALDHbr/PDGFRalpha+ subpopulation, was significantly reduced in the lung during bleomycin-induced pulmonary fibrosis.	Bleomycin	138-147	protein tyrosine phosphatase, receptor type, C	Mus musculus	53-57
34425896-9	2021	The CD45-/ALDHbr cell population, and especially its CD45-/ALDHbr/PDGFRalpha+ subpopulation, was significantly reduced in the lung during bleomycin-induced pulmonary fibrosis.	Bleomycin	138-147	platelet derived growth factor receptor, alpha polypeptide	Mus musculus	66-76
34425896-11	2021	When transferred in vivo into bleomycin-pretreated mice, CD45-/ALDHbr cells reached the site of injury, ameliorated pulmonary fibrosis, recovered the reduced expression of ALDH mRNA, and prolonged survival, which was associated with the upregulation of the retinol-metabolizing pathway and the suppression of profibrotic cytokines.	Bleomycin	30-39	protein tyrosine phosphatase, receptor type, C	Mus musculus	57-61
34425896-11	2021	When transferred in vivo into bleomycin-pretreated mice, CD45-/ALDHbr cells reached the site of injury, ameliorated pulmonary fibrosis, recovered the reduced expression of ALDH mRNA, and prolonged survival, which was associated with the upregulation of the retinol-metabolizing pathway and the suppression of profibrotic cytokines.	Bleomycin	30-39	aldehyde dehydrogenase family 3, subfamily A1	Mus musculus	172-176
34400514-7	2021	The bleomycin (BLM) model of lung fibrosis showed increases in PDIA3 in SCGB1A1 cells in the lung parenchyma.	Bleomycin	4-13	protein disulfide isomerase family A member 3	Homo sapiens	63-68
34400514-7	2021	The bleomycin (BLM) model of lung fibrosis showed increases in PDIA3 in SCGB1A1 cells in the lung parenchyma.	Bleomycin	4-13	secretoglobin family 1A member 1	Homo sapiens	72-79
34400514-7	2021	The bleomycin (BLM) model of lung fibrosis showed increases in PDIA3 in SCGB1A1 cells in the lung parenchyma.	Bleomycin	15-18	protein disulfide isomerase family A member 3	Homo sapiens	63-68
34400514-7	2021	The bleomycin (BLM) model of lung fibrosis showed increases in PDIA3 in SCGB1A1 cells in the lung parenchyma.	Bleomycin	15-18	secretoglobin family 1A member 1	Homo sapiens	72-79
34378791-3	2022	EXPERIMENTAL APPROACH: Expressions of PPARgamma and bioactive DNA methyltranferases, and PPARgamma promoter methylation status were examined from fibrotic lungs of idiopathic pulmonary fibrosis (IPF) patients and bleomycin (Blm)-treated mice.	Bleomycin	213-222	peroxisome proliferator activated receptor gamma	Homo sapiens	38-47
34378880-1	2021	OBJECTIVE: Promotion of the proliferative expansion of CD4+Foxp3+ regulatory T cells (Tregs) is one of the side effects that limits the use of bleomycin (BLM) in the treatment of tumors.	Bleomycin	143-152	forkhead box P3	Mus musculus	59-64
34440175-2	2021	The present study aimed to investigate whether curative potential of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is predicted by the metabolic response of normal tissues in patients with Hodgkin lymphoma (HL).	Bleomycin	82-91	lipase C, hepatic type	Homo sapiens	221-223
34400742-6	2021	Interestingly, bleomycin treatment activated the local renin-angiotensin system (RAS) in the lung, manifested by the induction of renin, angiotensinogen, angiotensin II and angiotensin receptor type 1 (AT1R).	Bleomycin	15-24	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	137-152
34400742-6	2021	Interestingly, bleomycin treatment activated the local renin-angiotensin system (RAS) in the lung, manifested by the induction of renin, angiotensinogen, angiotensin II and angiotensin receptor type 1 (AT1R).	Bleomycin	15-24	angiotensin II, type I receptor-associated protein	Mus musculus	202-206
34400742-8	2021	We also showed that treatment of bleomycin-induced vitamin D-deficient mice with AT1R antagonist losartan relieved weight loss, substantially ameliorated lung fibrosis and markedly blocked TGF-beta induction in the lung.	Bleomycin	33-42	angiotensin II, type I receptor-associated protein	Mus musculus	81-85
34400742-8	2021	We also showed that treatment of bleomycin-induced vitamin D-deficient mice with AT1R antagonist losartan relieved weight loss, substantially ameliorated lung fibrosis and markedly blocked TGF-beta induction in the lung.	Bleomycin	33-42	transforming growth factor alpha	Mus musculus	189-197
34090209-9	2021	In mice with bleomycin-induced pulmonary fibrosis, the relative expression of CFL-1 was increased, and the percentage of fibrocytes was higher than that in the saline group (P < 0.05).	Bleomycin	13-22	cofilin 1, non-muscle	Mus musculus	78-83
34090209-10	2021	In bleomycin-induced mice, interference with Lv-CFL-1 decreased the expression of CFL-1, the percentage of fibrocytes was lower, and the lung tissue showed less fibrosis (P < 0.05).	Bleomycin	3-12	cofilin 1, non-muscle	Mus musculus	48-53
34090209-10	2021	In bleomycin-induced mice, interference with Lv-CFL-1 decreased the expression of CFL-1, the percentage of fibrocytes was lower, and the lung tissue showed less fibrosis (P < 0.05).	Bleomycin	3-12	cofilin 1, non-muscle	Mus musculus	82-87
34132118-8	2021	Older ABCA3E292V mice exhibit increased vulnerability to exogenous lung injury by bleomycin.	Bleomycin	82-91	ATP-binding cassette, sub-family A (ABC1), member 3	Mus musculus	6-11
34142927-4	2021	METHODS: We established a bleomycin-induced pulmonary toxicity model to detect the relevance between HMGB1 and pathological changes in the early inflammatory and late fibrotic stages.	Bleomycin	26-35	high mobility group box 1	Mus musculus	101-106
34142927-5	2021	RESULTS: We found that bleomycin-induced increase in inflammatory cytokines interleukin (IL)-beta1, tumor necrosis factor (TNF)-alpha, monocyte chemotactic protein (MCP)-1, and inflammatory lesions in lung tissue in the early stage of the model.	Bleomycin	23-32	tumor necrosis factor	Mus musculus	100-133
34142927-5	2021	RESULTS: We found that bleomycin-induced increase in inflammatory cytokines interleukin (IL)-beta1, tumor necrosis factor (TNF)-alpha, monocyte chemotactic protein (MCP)-1, and inflammatory lesions in lung tissue in the early stage of the model.	Bleomycin	23-32	chemokine (C-C motif) ligand 2	Mus musculus	135-171
34142927-6	2021	However, markers of fibrosis such as transforming growth factor (TGF)-beta1 and alpha-smooth muscle actin (alpha-SMA) were significantly elevated on day 7 after bleomycin instillation.	Bleomycin	161-170	transforming growth factor, beta 1	Mus musculus	37-75
34142927-6	2021	However, markers of fibrosis such as transforming growth factor (TGF)-beta1 and alpha-smooth muscle actin (alpha-SMA) were significantly elevated on day 7 after bleomycin instillation.	Bleomycin	161-170	actin alpha 2, smooth muscle, aorta	Mus musculus	107-116
34142927-8	2021	However, early (from day 0 to 14 after bleomycin instillation) or late (from day 14 to 28) intervention with HMGB1 neutralizing antibody or glycyrrhizic acid alleviated inflammation and fibrosis through down-regulating the inflammatory signaling mitogen-activated protein kinase (MAPK) and fibrotic signaling Smad3 pathway.	Bleomycin	39-48	SMAD family member 3	Mus musculus	309-314
34148362-3	2021	HDAC3 is preferentially upregulated with concomitant Nrf2 suppression in fibrotic lungs of both idiopathic pulmonary fibrosis patients and bleomycin-treated mice.	Bleomycin	139-148	histone deacetylase 3	Homo sapiens	0-5
34148362-3	2021	HDAC3 is preferentially upregulated with concomitant Nrf2 suppression in fibrotic lungs of both idiopathic pulmonary fibrosis patients and bleomycin-treated mice.	Bleomycin	139-148	NFE2 like bZIP transcription factor 2	Homo sapiens	53-57
34148362-7	2021	HDAC3 and FOXM1 inducibly bound to Nrf2 promoter locus containing the motif in lung tissues of bleomycin mice, accompanied by reduced local histone3 acetylation, which were relieved by RGFP966.	Bleomycin	95-104	histone deacetylase 3	Mus musculus	0-5
34148362-7	2021	HDAC3 and FOXM1 inducibly bound to Nrf2 promoter locus containing the motif in lung tissues of bleomycin mice, accompanied by reduced local histone3 acetylation, which were relieved by RGFP966.	Bleomycin	95-104	forkhead box M1	Mus musculus	10-15
34148362-7	2021	HDAC3 and FOXM1 inducibly bound to Nrf2 promoter locus containing the motif in lung tissues of bleomycin mice, accompanied by reduced local histone3 acetylation, which were relieved by RGFP966.	Bleomycin	95-104	nuclear factor, erythroid derived 2, like 2	Mus musculus	35-39
34142927-0	2021	Glycyrrhizic acid, as an inhibitor of HMGB1, alleviates bleomycin-induced pulmonary toxicity in mice through the MAPK and Smad3 pathways.	Bleomycin	56-65	high mobility group box 1	Mus musculus	38-43
34142927-0	2021	Glycyrrhizic acid, as an inhibitor of HMGB1, alleviates bleomycin-induced pulmonary toxicity in mice through the MAPK and Smad3 pathways.	Bleomycin	56-65	SMAD family member 3	Mus musculus	122-127
34377373-9	2021	Mouse models utilizing intratracheal administration of EVs demonstrate efficient attenuation of bleomycin-induced lung fibrosis development accompanied by reduced expression of both beta-catenin and markers of cellular senescence.	Bleomycin	96-105	catenin (cadherin associated protein), beta 1	Mus musculus	182-194
34329195-4	2021	Our previous study demonstrated that core fucosylation (CF) modification, catalyzed by a specific core fucosyltransferase (FUT8) can regulate the activation of multiple signaling pathways, and inhibiting CF can alleviate pulmonary fibrosis in mice induced by bleomycin.	Bleomycin	259-268	fucosyltransferase 8	Mus musculus	123-127
34266726-10	2021	Moreover, Akt/mTOR/p70S6K phosphorylation was involved in EndoMT and BMP-7 suppressed TGF-beta- or bleomycin-induced theses phosphorylation in HUVECs or SSc mouse model.	Bleomycin	99-108	thymoma viral proto-oncogene 1	Mus musculus	10-13
34266726-10	2021	Moreover, Akt/mTOR/p70S6K phosphorylation was involved in EndoMT and BMP-7 suppressed TGF-beta- or bleomycin-induced theses phosphorylation in HUVECs or SSc mouse model.	Bleomycin	99-108	mechanistic target of rapamycin kinase	Mus musculus	14-18
34266726-10	2021	Moreover, Akt/mTOR/p70S6K phosphorylation was involved in EndoMT and BMP-7 suppressed TGF-beta- or bleomycin-induced theses phosphorylation in HUVECs or SSc mouse model.	Bleomycin	99-108	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	19-25
34266726-10	2021	Moreover, Akt/mTOR/p70S6K phosphorylation was involved in EndoMT and BMP-7 suppressed TGF-beta- or bleomycin-induced theses phosphorylation in HUVECs or SSc mouse model.	Bleomycin	99-108	bone morphogenetic protein 7	Mus musculus	69-74
34260993-9	2021	CAE suppressed the bleomycin or TM-induced increases in ER-stress biomarker, BiP, and PERK pathway proteins, resulting in a decrease in ER stress in mouse lung tissues and A549 cells, respectively.	Bleomycin	19-28	heat shock protein 5	Mus musculus	77-80
34260993-9	2021	CAE suppressed the bleomycin or TM-induced increases in ER-stress biomarker, BiP, and PERK pathway proteins, resulting in a decrease in ER stress in mouse lung tissues and A549 cells, respectively.	Bleomycin	19-28	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	86-90
34260993-10	2021	Additionally, CAE treatment suppressed the bleomycin or TM-induced increase in the ER-stress downstream proteins, activating ATF3 and increased the levels of PINK1 in AEC IIs, both in vivo and in vitro.	Bleomycin	43-52	activating transcription factor 3	Mus musculus	125-129
34260993-10	2021	Additionally, CAE treatment suppressed the bleomycin or TM-induced increase in the ER-stress downstream proteins, activating ATF3 and increased the levels of PINK1 in AEC IIs, both in vivo and in vitro.	Bleomycin	43-52	PTEN induced putative kinase 1	Mus musculus	158-163
34349830-0	2021	Danggui Buxue Tang Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Suppressing the TLR4/NLRP3 Signaling Pathway in Rats.	Bleomycin	31-40	toll-like receptor 4	Rattus norvegicus	87-91
34349830-0	2021	Danggui Buxue Tang Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Suppressing the TLR4/NLRP3 Signaling Pathway in Rats.	Bleomycin	31-40	NLR family, pyrin domain containing 3	Rattus norvegicus	92-97
34367191-7	2021	We found that at day 14, which corresponds to the inflammatory-to-fibrotic transition phase after bleomycin injection, TLR4, MD2, and Myd88 were induced, and the transcriptome was differentially enriched for genes in those pathways.	Bleomycin	98-107	toll-like receptor 4	Mus musculus	119-123
34349830-13	2021	Conclusion: DBT exhibited a potent effect on BLM-induced PF rats by inhibiting the TLR4/NLRP3 signaling pathway.	Bleomycin	45-48	toll-like receptor 4	Rattus norvegicus	83-87
34367191-7	2021	We found that at day 14, which corresponds to the inflammatory-to-fibrotic transition phase after bleomycin injection, TLR4, MD2, and Myd88 were induced, and the transcriptome was differentially enriched for genes in those pathways.	Bleomycin	98-107	lymphocyte antigen 96	Mus musculus	125-128
34367191-7	2021	We found that at day 14, which corresponds to the inflammatory-to-fibrotic transition phase after bleomycin injection, TLR4, MD2, and Myd88 were induced, and the transcriptome was differentially enriched for genes in those pathways.	Bleomycin	98-107	myeloid differentiation primary response gene 88	Mus musculus	134-139
34349830-13	2021	Conclusion: DBT exhibited a potent effect on BLM-induced PF rats by inhibiting the TLR4/NLRP3 signaling pathway.	Bleomycin	45-48	NLR family, pyrin domain containing 3	Rattus norvegicus	88-93
34278915-5	2022	Our results showed a significant decrease of catalase and superoxide dismutase activities and an increase in lipid peroxidation compared to control group after BLM injection.	Bleomycin	160-163	catalase	Rattus norvegicus	45-53
34182522-7	2021	Graded talc and bleomycin induced the same levels of changes in serum CRP levels and serum leukocyte counts.	Bleomycin	16-25	C-reactive protein	Homo sapiens	70-73
34239012-5	2021	Following bleomycin-induced lung injury, Il11-/- mice are protected from pulmonary fibrosis and exhibit lesser ERK, STAT3 and NF-kB activation, reduced Il1b, Timp1, Ccl2 and diminished IL6 expression, both at baseline and after injury: placing Il11 activity upstream of IL6 in this model.	Bleomycin	10-19	interleukin 11	Mus musculus	244-248
34243624-0	2021	Osteopontin silencing attenuates bleomycin-induced murine pulmonary fibrosis by regulating epithelial-mesenchymal transition.	Bleomycin	33-42	secreted phosphoprotein 1	Mus musculus	0-11
34323400-6	2021	Moreover, MRI-1867 treatment abrogated bleomycin-induced increases in lung levels of the profibrotic interleukin-11 via iNOS inhibition and reversed mitochondrial dysfunction via CB1 R inhibition.	Bleomycin	39-48	interleukin 11	Homo sapiens	101-115
34323400-6	2021	Moreover, MRI-1867 treatment abrogated bleomycin-induced increases in lung levels of the profibrotic interleukin-11 via iNOS inhibition and reversed mitochondrial dysfunction via CB1 R inhibition.	Bleomycin	39-48	nitric oxide synthase 2, inducible	Mus musculus	120-124
34323400-6	2021	Moreover, MRI-1867 treatment abrogated bleomycin-induced increases in lung levels of the profibrotic interleukin-11 via iNOS inhibition and reversed mitochondrial dysfunction via CB1 R inhibition.	Bleomycin	39-48	cannabinoid receptor 1 (brain)	Mus musculus	179-184
34289031-0	2022	Transcriptome analysis reveals key genes modulated by ALK5 inhibition in a bleomycin model of systemic sclerosis.	Bleomycin	75-84	transforming growth factor, beta receptor I	Mus musculus	54-58
34121240-4	2021	We employed the bleomycin (BLM)-induced lung fibrosis animal models and used TGF-beta1 to induce the epithelial-mesenchymal transition (EMT) of A549 cells in vitro.	Bleomycin	16-25	transforming growth factor, beta 1	Mus musculus	77-86
34121240-4	2021	We employed the bleomycin (BLM)-induced lung fibrosis animal models and used TGF-beta1 to induce the epithelial-mesenchymal transition (EMT) of A549 cells in vitro.	Bleomycin	27-30	transforming growth factor, beta 1	Mus musculus	77-86
34276664-6	2021	recently demonstrated a protective role of PTX3 using the bleomycin (BLM)-induced experimental model of lung fibrosis, in line with the reported role of PTX3 in tissue repair.	Bleomycin	58-67	pentraxin 3	Homo sapiens	43-47
34422900-6	2021	Bleomycin-induced lung fibrosis model exhibited high expression of Gremlin2 in the bronchoalveolar lavage fluid (BALF) and lung tissue.	Bleomycin	0-9	gremlin 2, DAN family BMP antagonist	Homo sapiens	67-75
34422900-7	2021	Isolation of primary cells from bleomycin-induced fibrosis lung showed a good correlation of Gremlin2 and Acta2 (alpha-SMA) expressions.	Bleomycin	32-41	gremlin 2, DAN family BMP antagonist	Homo sapiens	93-101
34422900-7	2021	Isolation of primary cells from bleomycin-induced fibrosis lung showed a good correlation of Gremlin2 and Acta2 (alpha-SMA) expressions.	Bleomycin	32-41	actin alpha 2, smooth muscle	Homo sapiens	106-111
34422900-7	2021	Isolation of primary cells from bleomycin-induced fibrosis lung showed a good correlation of Gremlin2 and Acta2 (alpha-SMA) expressions.	Bleomycin	32-41	actin alpha 1, skeletal muscle	Homo sapiens	113-122
34202229-2	2021	We showed that sirtuin 3 (SIRT3), a mitochondrial protein regulating cell fate and aging, is deficient in the AECs of idiopathic pulmonary fibrosis (IPF) patients and that asbestos- and bleomycin-induced lung fibrosis is augmented in Sirt3 knockout (Sirt3-/-) mice associated with AEC mtDNA damage and intrinsic apoptosis.	Bleomycin	186-195	sirtuin 3	Homo sapiens	26-31
34220507-8	2021	Significantly, our results showed that Myricetin has potent effect on bleomycin-induced pulmonary inflammation by inhibiting the infiltration of inflammatory cells and the secretion of inflammatory cytokines IL-6, IL-1alpha, TNF-alpha and IFN-gamma.	Bleomycin	70-79	interleukin 6	Homo sapiens	208-212
34220507-8	2021	Significantly, our results showed that Myricetin has potent effect on bleomycin-induced pulmonary inflammation by inhibiting the infiltration of inflammatory cells and the secretion of inflammatory cytokines IL-6, IL-1alpha, TNF-alpha and IFN-gamma.	Bleomycin	70-79	interleukin 1 alpha	Homo sapiens	214-223
34220507-8	2021	Significantly, our results showed that Myricetin has potent effect on bleomycin-induced pulmonary inflammation by inhibiting the infiltration of inflammatory cells and the secretion of inflammatory cytokines IL-6, IL-1alpha, TNF-alpha and IFN-gamma.	Bleomycin	70-79	tumor necrosis factor	Homo sapiens	225-234
34235177-5	2021	We found that GSK-3 inhibition down-modulates gene expression and protein levels of MMP-9, MMP-2, and their inhibitors TIMP-1 and TIMP-2 in inflammatory cells harvested from bronchoalveolar lavage fluid (BALF) of mice treated with bleomycin as well as in interstitial alveolar macrophages and cuboidalized epithelial alveolar cells.	Bleomycin	231-240	glycogen synthase kinase 3 beta	Mus musculus	14-19
34220507-8	2021	Significantly, our results showed that Myricetin has potent effect on bleomycin-induced pulmonary inflammation by inhibiting the infiltration of inflammatory cells and the secretion of inflammatory cytokines IL-6, IL-1alpha, TNF-alpha and IFN-gamma.	Bleomycin	70-79	interferon gamma	Homo sapiens	239-248
34235177-5	2021	We found that GSK-3 inhibition down-modulates gene expression and protein levels of MMP-9, MMP-2, and their inhibitors TIMP-1 and TIMP-2 in inflammatory cells harvested from bronchoalveolar lavage fluid (BALF) of mice treated with bleomycin as well as in interstitial alveolar macrophages and cuboidalized epithelial alveolar cells.	Bleomycin	231-240	matrix metallopeptidase 9	Mus musculus	84-89
34086758-9	2021	We also demonstrated a significant positive correlation between lung hydroxyproline expression levels and interleukin-18 binding protein levels in bronchoalveolar lavage fluid from bleomycin-treated mice (Spearman r = 0.509, p = 0.004).	Bleomycin	181-190	interleukin 18 binding protein	Mus musculus	106-136
34235177-5	2021	We found that GSK-3 inhibition down-modulates gene expression and protein levels of MMP-9, MMP-2, and their inhibitors TIMP-1 and TIMP-2 in inflammatory cells harvested from bronchoalveolar lavage fluid (BALF) of mice treated with bleomycin as well as in interstitial alveolar macrophages and cuboidalized epithelial alveolar cells.	Bleomycin	231-240	matrix metallopeptidase 2	Mus musculus	91-96
34235177-5	2021	We found that GSK-3 inhibition down-modulates gene expression and protein levels of MMP-9, MMP-2, and their inhibitors TIMP-1 and TIMP-2 in inflammatory cells harvested from bronchoalveolar lavage fluid (BALF) of mice treated with bleomycin as well as in interstitial alveolar macrophages and cuboidalized epithelial alveolar cells.	Bleomycin	231-240	tissue inhibitor of metalloproteinase 1	Mus musculus	119-125
34235177-5	2021	We found that GSK-3 inhibition down-modulates gene expression and protein levels of MMP-9, MMP-2, and their inhibitors TIMP-1 and TIMP-2 in inflammatory cells harvested from bronchoalveolar lavage fluid (BALF) of mice treated with bleomycin as well as in interstitial alveolar macrophages and cuboidalized epithelial alveolar cells.	Bleomycin	231-240	tissue inhibitor of metalloproteinase 2	Mus musculus	130-136
34070506-6	2021	In a model of bleomycin-induced pulmonary fibrosis, pHD decreased the level of tissue IL-1beta and TGF-beta, prevented the infiltration of the lung parenchyma by CD16+ cells, and reduced perivascular and peribronchial inflammation.	Bleomycin	14-23	interleukin 1 alpha	Homo sapiens	86-94
34204949-6	2021	We recently reported that the stepwise elevation of intrinsic p38 signaling in the lungs is correlated with a worsening severity of bleomycin-induced fibrosis, indicating an importance of this pathway in the progression of pulmonary fibrosis.	Bleomycin	132-141	mitogen-activated protein kinase 14	Homo sapiens	62-65
34124033-0	2021	Depletion of Numb and Numblike in Murine Lung Epithelial Cells Ameliorates Bleomycin-Induced Lung Fibrosis by Inhibiting the beta-Catenin Signaling Pathway.	Bleomycin	75-84	numb-like	Mus musculus	22-30
34124033-5	2021	Here, we demonstrate that the membrane-associated protein NUMB is required for pathological activation of beta-catenin signaling in lung epithelial cells following bleomycin-induced injury.	Bleomycin	164-173	NUMB endocytic adaptor protein	Mus musculus	58-62
34124033-5	2021	Here, we demonstrate that the membrane-associated protein NUMB is required for pathological activation of beta-catenin signaling in lung epithelial cells following bleomycin-induced injury.	Bleomycin	164-173	catenin (cadherin associated protein), beta 1	Mus musculus	106-118
34124033-6	2021	Importantly, depletion of Numb and Numblike reduces accumulation of fibrotic lesions, preserves lung functions, and increases survival rates after bleomycin treatment of mice.	Bleomycin	147-156	NUMB endocytic adaptor protein	Mus musculus	26-30
34124033-6	2021	Importantly, depletion of Numb and Numblike reduces accumulation of fibrotic lesions, preserves lung functions, and increases survival rates after bleomycin treatment of mice.	Bleomycin	147-156	numb-like	Mus musculus	35-43
34200311-0	2021	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin.	Bleomycin	88-97	heat shock protein 90 alpha family class A member 1	Homo sapiens	14-19
34200311-3	2021	In the next step of the preclinical analysis, herein, we aimed to evaluate the efficacy of an Hsp90 inhibitor, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), in the treatment of established experimental dermal fibrosis induced by bleomycin.	Bleomycin	246-255	heat shock protein 90 alpha family class A member 1	Homo sapiens	94-99
34070506-6	2021	In a model of bleomycin-induced pulmonary fibrosis, pHD decreased the level of tissue IL-1beta and TGF-beta, prevented the infiltration of the lung parenchyma by CD16+ cells, and reduced perivascular and peribronchial inflammation.	Bleomycin	14-23	transforming growth factor alpha	Homo sapiens	99-107
34068694-0	2021	Deglycosylated Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-beta1 Signaling Pathway.	Bleomycin	39-48	transforming growth factor beta 1	Homo sapiens	84-93
34268377-0	2021	Andrographolide alleviates bleomycin-induced NLRP3 inflammasome activation and epithelial-mesenchymal transition in lung epithelial cells by suppressing AKT/mTOR signaling pathway.	Bleomycin	27-36	NLR family, pyrin domain containing 3	Rattus norvegicus	45-50
34268377-0	2021	Andrographolide alleviates bleomycin-induced NLRP3 inflammasome activation and epithelial-mesenchymal transition in lung epithelial cells by suppressing AKT/mTOR signaling pathway.	Bleomycin	27-36	AKT serine/threonine kinase 1	Rattus norvegicus	153-156
34268414-0	2021	Collagen triple helix repeat containing-1 exerts antifibrotic effects on human skin fibroblast and bleomycin-induced dermal fibrosis models.	Bleomycin	99-108	collagen triple helix repeat containing 1	Homo sapiens	0-41
34268377-0	2021	Andrographolide alleviates bleomycin-induced NLRP3 inflammasome activation and epithelial-mesenchymal transition in lung epithelial cells by suppressing AKT/mTOR signaling pathway.	Bleomycin	27-36	mechanistic target of rapamycin kinase	Rattus norvegicus	157-161
34268377-2	2021	This study investigated whether and how Andro alleviates bleomycin (BLM)-induced NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and epithelial-mesenchymal transition (EMT) in the lung epithelial cells.	Bleomycin	57-66	NLR family, pyrin domain containing 3	Rattus norvegicus	133-138
34853246-5	2021	Here, we show that the DDRs observed as the phosphorylation of H2AX (gammaH2AX) and caspase-3-dependent apoptosis-induction are under critical control in the intestine of C57BL mice that were injected intraperitoneally with bleomycin, a natural glycopeptide used clinically as an antitumor agent.	Bleomycin	224-233	H2A.X variant histone	Mus musculus	63-67
34087992-4	2021	CRISPR/Cas9 genome editing technology was employed to knock-in 2A-tdTomato and EF1 alpha promoter-driven Bleomycin resistance gene to the translational ISL1 C-terminal region.	Bleomycin	105-114	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	79-88
34087992-4	2021	CRISPR/Cas9 genome editing technology was employed to knock-in 2A-tdTomato and EF1 alpha promoter-driven Bleomycin resistance gene to the translational ISL1 C-terminal region.	Bleomycin	105-114	ISL LIM homeobox 1	Homo sapiens	152-156
34374245-1	2021	Objective: To investigate the effects of interleukin 11 (IL-11) antagonist on bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	78-87	interleukin 11	Mus musculus	41-55
34374245-1	2021	Objective: To investigate the effects of interleukin 11 (IL-11) antagonist on bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	78-87	interleukin 11	Mus musculus	57-62
34374245-1	2021	Objective: To investigate the effects of interleukin 11 (IL-11) antagonist on bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	89-92	interleukin 11	Mus musculus	41-55
34374245-1	2021	Objective: To investigate the effects of interleukin 11 (IL-11) antagonist on bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	89-92	interleukin 11	Mus musculus	57-62
34374245-13	2021	Conclusion: The IL-11 antagonist alleviates BLM-induced pulmonary fibrosis in mice, which provides a new idea for the clinical treatment of pulmonary fibrosis.	Bleomycin	44-47	interleukin 11	Mus musculus	16-21
34343038-0	2022	Endothelial-Specific Loss of Sphingosine-1-Phosphate Receptor 1 Increases Vascular Permeability and Exacerbates Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	112-121	sphingosine-1-phosphate receptor 1	Mus musculus	29-63
34343038-8	2022	Following a low dose intratracheal bleomycin challenge, EC-S1pr1-/- mice had increased and persistent vascular permeability compared to wild-type mice, which was strongly correlated with the amount and localization of resulting pulmonary fibrosis.	Bleomycin	35-44	sphingosine-1-phosphate receptor 1	Mus musculus	59-64
34853246-5	2021	Here, we show that the DDRs observed as the phosphorylation of H2AX (gammaH2AX) and caspase-3-dependent apoptosis-induction are under critical control in the intestine of C57BL mice that were injected intraperitoneally with bleomycin, a natural glycopeptide used clinically as an antitumor agent.	Bleomycin	224-233	H2A.X variant histone	Mus musculus	69-78
34853246-5	2021	Here, we show that the DDRs observed as the phosphorylation of H2AX (gammaH2AX) and caspase-3-dependent apoptosis-induction are under critical control in the intestine of C57BL mice that were injected intraperitoneally with bleomycin, a natural glycopeptide used clinically as an antitumor agent.	Bleomycin	224-233	caspase 3	Mus musculus	84-93
35508454-6	2022	Here, we found that P16, P21 and fibrosis markers (alphaSMA and Collagen-I) were prominently increased in lung tissues of IPF patients and bleomycin-induced mouse models, while the expression of KLF4 and TERT were decreased in AECs.	Bleomycin	139-148	telomerase reverse transcriptase	Mus musculus	204-208
34195593-4	2021	Specifically, we hypothesized that alphavbeta3 integrin engagement on fibronectin induces pericyte transition into myofibroblastic phenotypes in the murine bleomycin lung injury model.	Bleomycin	156-165	fibronectin 1	Mus musculus	70-81
34195593-8	2021	After intratracheal bleomycin treatment of mice, Myh11 lineage-positive cells showed significantly increased contractile and secretory markers, as well as alphav integrin expression.	Bleomycin	20-29	myosin, heavy polypeptide 11, smooth muscle	Mus musculus	49-54
34195593-9	2021	According to RNASeq measurements, many disease and tissue-remodeling genesets were upregulated in Myh11 lineage-positive cells in response to bleomycin-induced lung injury.	Bleomycin	142-151	myosin, heavy polypeptide 11, smooth muscle	Mus musculus	98-103
35510614-0	2022	FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway.	Bleomycin	48-57	forkhead box O4	Mus musculus	0-5
35510614-7	2022	Furthermore, FOXO4-DRI could increase the percentage of type 2 alveolar epithelial cells (AEC2) and fibroblasts, and decrease the myofibroblasts in bleomycin (BLM)-induced PF mouse model.	Bleomycin	148-157	forkhead box O4	Mus musculus	13-18
35510614-7	2022	Furthermore, FOXO4-DRI could increase the percentage of type 2 alveolar epithelial cells (AEC2) and fibroblasts, and decrease the myofibroblasts in bleomycin (BLM)-induced PF mouse model.	Bleomycin	159-162	forkhead box O4	Mus musculus	13-18
35420997-4	2022	Six1 was also upregulated in bleomycin (BLM)-treated mice and in a model of spontaneous lung fibrosis driven by deletion of Telomeric Repeat Binding Factor 1 (Trf1) in AT2 cells.	Bleomycin	29-38	sine oculis-related homeobox 1	Mus musculus	0-4
35584329-9	2022	In addition, DOCK2 was also dramatically induced in the lungs of patients with IPF and in bleomycin and TGF-beta induced pulmonary fibrosis in C57BL/6 mice.	Bleomycin	90-99	dedicator of cytokinesis 2	Homo sapiens	13-18
35584329-10	2022	Further, increased lung DOCK2 expression co-localized with the FMT marker alpha-SMA in the bleomycin-induced pulmonary fibrosis model, implicating DOCK2 in the regulation of lung fibroblast phenotypic changes.	Bleomycin	91-100	dedicator of cyto-kinesis 2	Mus musculus	24-29
35584329-10	2022	Further, increased lung DOCK2 expression co-localized with the FMT marker alpha-SMA in the bleomycin-induced pulmonary fibrosis model, implicating DOCK2 in the regulation of lung fibroblast phenotypic changes.	Bleomycin	91-100	dedicator of cyto-kinesis 2	Mus musculus	147-152
35584329-11	2022	Importantly, DOCK2 deficiency also attenuated bleomycin-induced pulmonary fibrosis and alpha-SMA expression.	Bleomycin	46-55	dedicator of cyto-kinesis 2	Mus musculus	13-18
35584329-11	2022	Importantly, DOCK2 deficiency also attenuated bleomycin-induced pulmonary fibrosis and alpha-SMA expression.	Bleomycin	46-55	survival of motor neuron 1, telomeric	Homo sapiens	93-96
35634278-6	2022	Fibroblast-specific deletion of P2rx4 in mice decreased lung fibrosis and collagen expression in lung fibroblasts in the bleomycin model.	Bleomycin	121-130	purinergic receptor P2X, ligand-gated ion channel 4	Mus musculus	32-37
35628193-0	2022	Dichotomous Roles of Men1 in Macrophages and Fibroblasts in Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	60-69	multiple endocrine neoplasia 1	Mus musculus	21-25
35628193-3	2022	The results showed that Men1, which encodes menin protein, was significantly downregulated in bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	94-103	multiple endocrine neoplasia 1	Mus musculus	24-28
35628193-3	2022	The results showed that Men1, which encodes menin protein, was significantly downregulated in bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	94-103	multiple endocrine neoplasia 1	Mus musculus	44-49
35628193-3	2022	The results showed that Men1, which encodes menin protein, was significantly downregulated in bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	105-108	multiple endocrine neoplasia 1	Mus musculus	24-28
35628193-3	2022	The results showed that Men1, which encodes menin protein, was significantly downregulated in bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	105-108	multiple endocrine neoplasia 1	Mus musculus	44-49
35472619-2	2022	Herein, we recognized that lncRNA mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG) was abnormally upregulated within human idiopathic pulmonary fibrosis (IPF) lung tissue, bleomycin (BLM)-caused pulmonary fibrotic model mice and TGF-beta1-stimulated mice type II alveolar epithelial cells.	Bleomycin	180-189	mir-100-let-7a-2-mir-125b-1 cluster host gene	Homo sapiens	81-89
35472619-2	2022	Herein, we recognized that lncRNA mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG) was abnormally upregulated within human idiopathic pulmonary fibrosis (IPF) lung tissue, bleomycin (BLM)-caused pulmonary fibrotic model mice and TGF-beta1-stimulated mice type II alveolar epithelial cells.	Bleomycin	180-189	transforming growth factor, beta 1	Mus musculus	237-246
35522243-7	2022	This regulatory role of JAK2 in the pathogenesis of pulmonary fibrosis was further demonstrated by the attenuation of bleomycin-induced murine pulmonary fibrosis using a JAK2-selective pharmacological inhibitor CEP33779.	Bleomycin	118-127	Janus kinase 2	Mus musculus	24-28
35522243-7	2022	This regulatory role of JAK2 in the pathogenesis of pulmonary fibrosis was further demonstrated by the attenuation of bleomycin-induced murine pulmonary fibrosis using a JAK2-selective pharmacological inhibitor CEP33779.	Bleomycin	118-127	Janus kinase 2	Mus musculus	170-174
35389887-7	2022	Deletion of Zip8 in AEC2s in mice impaired AEC2 renewal, increased susceptibility of the mice to bleomycin injury, and the mice developed spontaneous lung fibrosis.	Bleomycin	97-106	solute carrier family 39 (metal ion transporter), member 8	Mus musculus	12-16
35625905-10	2022	Additionally, meleagrin inhibited bleomycin-induced apoptosis by abating the activities of pro-apoptotic proteins Bax and caspase-3 while elevating Bcl2.	Bleomycin	34-43	BCL2-associated X protein	Mus musculus	114-117
35625905-10	2022	Additionally, meleagrin inhibited bleomycin-induced apoptosis by abating the activities of pro-apoptotic proteins Bax and caspase-3 while elevating Bcl2.	Bleomycin	34-43	caspase 3	Mus musculus	122-131
35625905-10	2022	Additionally, meleagrin inhibited bleomycin-induced apoptosis by abating the activities of pro-apoptotic proteins Bax and caspase-3 while elevating Bcl2.	Bleomycin	34-43	B cell leukemia/lymphoma 2	Mus musculus	148-152
35549947-5	2022	Fe3+-based metal-phenolic networks (MPNs) with bovine serum albumin (BSA) modification served as drug delivery carriers to encapsulate bleomycin (BLM), forming BFE@BSA NPs.	Bleomycin	135-144	albumin	Homo sapiens	54-67
35508454-8	2022	Over-expression of KLF4 in AECs could protect TERT expression and suppress the development of pulmonary fibrosis in bleomycin-induced mouse models.	Bleomycin	116-125	Kruppel-like factor 4 (gut)	Mus musculus	19-23
35508454-9	2022	In the mechanism exploration of TERT regulation, KLF4 and TERT were both down-regulated in bleomycin-induced senescent MLE-12 and BEAS-2B cells.	Bleomycin	91-100	telomerase reverse transcriptase	Mus musculus	32-36
35508454-9	2022	In the mechanism exploration of TERT regulation, KLF4 and TERT were both down-regulated in bleomycin-induced senescent MLE-12 and BEAS-2B cells.	Bleomycin	91-100	Kruppel-like factor 4 (gut)	Mus musculus	49-53
35508454-9	2022	In the mechanism exploration of TERT regulation, KLF4 and TERT were both down-regulated in bleomycin-induced senescent MLE-12 and BEAS-2B cells.	Bleomycin	91-100	telomerase reverse transcriptase	Mus musculus	58-62
35509004-2	2022	Hps1ep/ep (pale ear) is a naturally occurring HPS-1 mouse model that exhibits high sensitivity to bleomycin-induced pulmonary fibrosis (PF).	Bleomycin	98-107	HPS1, biogenesis of lysosomal organelles complex 3 subunit 1	Mus musculus	46-51
35148253-3	2022	Here we show that bleomycin-induced PF is reduced in Ask1 knockout mice (Ask1-/-) compared with wild-type (WT) mice, with improved survival and histological and functional parameters restored to basal levels.	Bleomycin	18-27	mitogen-activated protein kinase kinase kinase 5	Mus musculus	73-77
35148253-0	2022	ASK1 Regulates Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	15-24	mitogen-activated protein kinase kinase kinase 5	Mus musculus	0-4
35148253-4	2022	In WT mice, bleomycin caused activation of ASK1, p38, and ERK1/2 in lung tissue, as well as changes in redox indicators (thioredoxin and heme-oxygenase-1), collagen content, and epithelial mesenchymal transition markers (EMT).	Bleomycin	12-21	mitogen-activated protein kinase kinase kinase 5	Mus musculus	43-47
35148253-3	2022	Here we show that bleomycin-induced PF is reduced in Ask1 knockout mice (Ask1-/-) compared with wild-type (WT) mice, with improved survival and histological and functional parameters restored to basal levels.	Bleomycin	18-27	mitogen-activated protein kinase kinase kinase 5	Mus musculus	53-57
35148253-4	2022	In WT mice, bleomycin caused activation of ASK1, p38, and ERK1/2 in lung tissue, as well as changes in redox indicators (thioredoxin and heme-oxygenase-1), collagen content, and epithelial mesenchymal transition markers (EMT).	Bleomycin	12-21	mitogen-activated protein kinase 14	Mus musculus	49-52
35148253-4	2022	In WT mice, bleomycin caused activation of ASK1, p38, and ERK1/2 in lung tissue, as well as changes in redox indicators (thioredoxin and heme-oxygenase-1), collagen content, and epithelial mesenchymal transition markers (EMT).	Bleomycin	12-21	mitogen-activated protein kinase 3	Mus musculus	58-64
35148253-4	2022	In WT mice, bleomycin caused activation of ASK1, p38, and ERK1/2 in lung tissue, as well as changes in redox indicators (thioredoxin and heme-oxygenase-1), collagen content, and epithelial mesenchymal transition markers (EMT).	Bleomycin	12-21	thioredoxin 1	Mus musculus	121-132
35148253-4	2022	In WT mice, bleomycin caused activation of ASK1, p38, and ERK1/2 in lung tissue, as well as changes in redox indicators (thioredoxin and heme-oxygenase-1), collagen content, and epithelial mesenchymal transition markers (EMT).	Bleomycin	12-21	heme oxygenase 1	Mus musculus	137-153
35148253-5	2022	These changes were largely restored toward untreated WT control levels in bleomycin-treated Ask1-/- mice.	Bleomycin	74-83	mitogen-activated protein kinase kinase kinase 5	Mus musculus	92-96
35148253-8	2022	Our results suggest that ASK1 plays a central role in the development of bleomycin-induced PF in mice via p38 and ERK1/2 signaling.	Bleomycin	73-82	mitogen-activated protein kinase kinase kinase 5	Mus musculus	25-29
35487030-3	2022	Our previous study demonstrated that Wnt/beta-catenin signaling is aberrantly activated in the lungs of bleomycin-treated mice and induces myofibroblast differentiation of LR-MSCs.	Bleomycin	104-113	wingless-type MMTV integration site family, member 8B	Mus musculus	37-40
35487030-3	2022	Our previous study demonstrated that Wnt/beta-catenin signaling is aberrantly activated in the lungs of bleomycin-treated mice and induces myofibroblast differentiation of LR-MSCs.	Bleomycin	104-113	catenin (cadherin associated protein), beta 1	Mus musculus	41-53
35488265-14	2022	LG283 treatment remarkably inhibited the enhanced expression of alpha-SMA and phosphorylated Smad3, as well as those of Snail 1 and 2, in the bleomycin-injected skin.	Bleomycin	142-151	snail family transcriptional repressor 1	Homo sapiens	120-133
35112775-3	2022	In a previous study, we compared the effects of CS in a rat model of bleomycin (BLM) and lipopolysaccharide (LPS) induced lung disease.	Bleomycin	69-78	citrate synthase	Rattus norvegicus	48-50
35112775-3	2022	In a previous study, we compared the effects of CS in a rat model of bleomycin (BLM) and lipopolysaccharide (LPS) induced lung disease.	Bleomycin	80-83	citrate synthase	Rattus norvegicus	48-50
35459189-0	2022	PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model.	Bleomycin	80-89	serpin family F member 1	Rattus norvegicus	0-4
35467071-1	2022	Human bleomycin hydrolase (hBH) catalyzes deamidation of the anticancer drug, bleomycins (BLM).	Bleomycin	78-88	bleomycin hydrolase	Homo sapiens	6-25
35467071-1	2022	Human bleomycin hydrolase (hBH) catalyzes deamidation of the anticancer drug, bleomycins (BLM).	Bleomycin	78-88	bleomycin hydrolase	Homo sapiens	27-30
35467071-1	2022	Human bleomycin hydrolase (hBH) catalyzes deamidation of the anticancer drug, bleomycins (BLM).	Bleomycin	90-93	bleomycin hydrolase	Homo sapiens	6-25
35467071-1	2022	Human bleomycin hydrolase (hBH) catalyzes deamidation of the anticancer drug, bleomycins (BLM).	Bleomycin	90-93	bleomycin hydrolase	Homo sapiens	27-30
35459189-4	2022	The purpose of this experiment is to observe the effect of PEDF on bleomycin (BLM)-induced pulmonary fibrosis in rats.	Bleomycin	67-76	serpin family F member 1	Rattus norvegicus	59-63
35459189-4	2022	The purpose of this experiment is to observe the effect of PEDF on bleomycin (BLM)-induced pulmonary fibrosis in rats.	Bleomycin	78-81	serpin family F member 1	Rattus norvegicus	59-63
35396386-0	2022	Pyroptosis executor gasdermin D plays a key role in scleroderma and bleomycin-induced skin fibrosis.	Bleomycin	68-77	gasdermin D	Homo sapiens	20-31
35548340-0	2022	An Herbal Product Alleviates Bleomycin-Induced Pulmonary Fibrosis in Mice via Regulating NF-kappaB/TNF-alpha Signaling in Macrophages.	Bleomycin	29-38	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	89-98
35548340-0	2022	An Herbal Product Alleviates Bleomycin-Induced Pulmonary Fibrosis in Mice via Regulating NF-kappaB/TNF-alpha Signaling in Macrophages.	Bleomycin	29-38	tumor necrosis factor	Mus musculus	99-108
35548340-15	2022	Conclusion: Fuzheng Huayu formula has a good effect against pulmonary fibrosis induced by bleomycin in mice, whose action mechanism was associated with down-regulation of NF-kappaB/TNF-alpha signaling pathway in pro-inflammatory macrophages.	Bleomycin	90-99	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	171-180
35548340-15	2022	Conclusion: Fuzheng Huayu formula has a good effect against pulmonary fibrosis induced by bleomycin in mice, whose action mechanism was associated with down-regulation of NF-kappaB/TNF-alpha signaling pathway in pro-inflammatory macrophages.	Bleomycin	90-99	tumor necrosis factor	Mus musculus	181-190
35396386-3	2022	Here, we found that GSDMD was significantly up-regulated and activated in the skin of scleroderma patients and bleomycin-induced mouse model.	Bleomycin	111-120	gasdermin D	Homo sapiens	20-25
35396386-4	2022	What"s more, the ablation of GSDMD ameliorates bleomycin-induced skin fibrosis according to HE staining, Masson staining and the detection of hydroxyproline contents.	Bleomycin	47-56	gasdermin D	Mus musculus	29-34
35397395-6	2022	RESULTS: Bleomycin instillation induced body weight loss, declined lung function, pulmonary fibrosis, and extensive collagen deposition in the mice, accompanied with decreased pulmonary expression of PPARalpha, all of which were partially improved by pemafibrate at a dose of 2 mg/kg.	Bleomycin	9-18	peroxisome proliferator activated receptor alpha	Mus musculus	200-209
35073245-10	2022	Collectively, these results highlight that ALCAM contributes to bleomycin-induced pulmonary fibrosis associated with apoptosis through PI3K and ERK signaling pathways in response to TGF-beta.	Bleomycin	64-73	activated leukocyte cell adhesion molecule	Mus musculus	43-48
35146813-6	2022	Notably, repeated inhalation of the nanoformulations accelerates the clearance of locoregional collagen by boosting the intralesional expression of MMP13 and alveolar re-epithelialization mediated by KGFs, which synergistically ameliorates the lung function of a bleomycin-induced murine model.	Bleomycin	263-272	matrix metallopeptidase 13	Mus musculus	148-153
35073245-10	2022	Collectively, these results highlight that ALCAM contributes to bleomycin-induced pulmonary fibrosis associated with apoptosis through PI3K and ERK signaling pathways in response to TGF-beta.	Bleomycin	64-73	mitogen-activated protein kinase 1	Mus musculus	144-147
35073245-4	2022	Thus, a bleomycin-induced pulmonary fibrosis model was established with wild type and ALCAM-/- mice.	Bleomycin	8-17	activated leukocyte cell adhesion molecule	Mus musculus	86-91
35073245-9	2022	Further investigation for identification of the signaling pathway revealed that PI3K and ERK signaling pathways are involved in bleomycin-induced fibrosis.	Bleomycin	128-137	mitogen-activated protein kinase 1	Mus musculus	89-92
35073245-10	2022	Collectively, these results highlight that ALCAM contributes to bleomycin-induced pulmonary fibrosis associated with apoptosis through PI3K and ERK signaling pathways in response to TGF-beta.	Bleomycin	64-73	transforming growth factor alpha	Mus musculus	182-190
35170357-5	2022	Administration of a nanomolar-potent, mono-selective kinase inhibitor of IRE1alpha (KIRA8)-or conditional epithelial IRE1alpha gene knockout-both reduce DATP cell number and fibrosis in the bleomycin model, indicating that IRE1alpha cell-autonomously promotes transition into the DATP state.	Bleomycin	190-199	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	73-82
35170357-5	2022	Administration of a nanomolar-potent, mono-selective kinase inhibitor of IRE1alpha (KIRA8)-or conditional epithelial IRE1alpha gene knockout-both reduce DATP cell number and fibrosis in the bleomycin model, indicating that IRE1alpha cell-autonomously promotes transition into the DATP state.	Bleomycin	190-199	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	117-126
35530937-0	2022	Erratum to collagen triple helix repeat containing-1 exerts antifibrotic effects on human skin fibroblast and bleomycin-induced dermal fibrosis models.	Bleomycin	110-119	collagen triple helix repeat containing 1	Homo sapiens	11-52
35170357-5	2022	Administration of a nanomolar-potent, mono-selective kinase inhibitor of IRE1alpha (KIRA8)-or conditional epithelial IRE1alpha gene knockout-both reduce DATP cell number and fibrosis in the bleomycin model, indicating that IRE1alpha cell-autonomously promotes transition into the DATP state.	Bleomycin	190-199	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	223-232
35170357-8	2022	Finally, KIRA8 treatment increases the differentiation of Krt19CreERT2-lineage-traced DATPs into type 1 alveolar epithelial cells after bleomycin injury, indicating that relief from IRE1alpha signaling enables DATPs to exit the transitional state.	Bleomycin	136-145	keratin 19	Homo sapiens	58-63
35196901-1	2022	We previously showed that pericyte-like cells derived from the FoxD1-lineage contribute to myofibroblasts following bleomycin-induced lung injury.	Bleomycin	116-125	forkhead box D1	Mus musculus	63-68
35220029-0	2022	Nifuroxazide-loaded cubosomes exhibit an advancement in pulmonary delivery and attenuate bleomycin-induced lung fibrosis by regulating the STAT3 and NF-kappaB signaling: A new challenge for unmet therapeutic needs.	Bleomycin	89-98	signal transducer and activator of transcription 3	Rattus norvegicus	139-144
35202914-0	2022	Coomassie brilliant blue G-250 dye attenuates bleomycin-induced lung fibrosis by regulating the NF-kappaB and NLRP3 crosstalk: A novel approach for filling an unmet medical need.	Bleomycin	46-55	NLR family, pyrin domain containing 3	Rattus norvegicus	110-115
35048404-4	2022	In this study, we determined the role of Runt-related transcription factor 1 (RUNX1), an evolutionarily conserved transcription factor, in the differentiation of human lung fibroblasts (HLFs) in vitro and in an animal model of bleomycin (BLM)-induced lung fibrosis.	Bleomycin	227-236	RUNX family transcription factor 1	Homo sapiens	41-76
35048404-4	2022	In this study, we determined the role of Runt-related transcription factor 1 (RUNX1), an evolutionarily conserved transcription factor, in the differentiation of human lung fibroblasts (HLFs) in vitro and in an animal model of bleomycin (BLM)-induced lung fibrosis.	Bleomycin	227-236	RUNX family transcription factor 1	Homo sapiens	78-83
35341735-4	2022	Wild-type (WT) mice that received subcutaneous bleomycin (BLM) injections developed skin fibrosis accompanied by elevated interleukin (IL)-33 expression in the dermis.	Bleomycin	47-56	interleukin 33	Mus musculus	122-141
35361882-5	2022	Here, we observed the increased expression of BMP1 in both human IPF lungs and mouse fibrotic lungs induced by bleomycin.	Bleomycin	111-120	bone morphogenetic protein 1	Homo sapiens	46-50
35341735-4	2022	Wild-type (WT) mice that received subcutaneous bleomycin (BLM) injections developed skin fibrosis accompanied by elevated interleukin (IL)-33 expression in the dermis.	Bleomycin	58-61	interleukin 33	Mus musculus	122-141
35021035-8	2022	MEASUREMENTS AND MAIN RESULTS: Bleomycin or ABT-510 increased lung TGF-beta1 activity and macrophage influx, caused pulmonary hypertension and led to alveolar and microvascular hypoplasia.	Bleomycin	31-40	transforming growth factor beta 1	Homo sapiens	67-76
35332068-7	2022	In contrast, eosinophil, IL-4 and VE-cadherin levels were unchanged in bleomycin-treated mice and not influenced by pirfenidone.	Bleomycin	71-80	cadherin 5	Mus musculus	34-45
35122869-8	2022	Genetic inactivation of Chit1 attenuated bleomycin-induced fibrosis (decreasing the Ashcroft scoring by 28%) and decreased expression of profibrotic factors in lung tissues.	Bleomycin	41-50	chitinase 1 (chitotriosidase)	Mus musculus	24-29
35104243-4	2022	Short-term treatment of mice with a novel nanoparticle composed of a carboxylated FDA-approved biodegradable polymer, poly(lactic-co-glycolic) acid (PLG), which modulates activation and trafficking of MARCO+ inflammatory monocytes, markedly attenuated bleomycin-induced skin and lung inflammation and fibrosis.	Bleomycin	252-261	macrophage receptor with collagenous structure	Mus musculus	201-206
35268069-0	2022	Potential "Therapeutic" Effects of Tocotrienol-Rich Fraction (TRF) and Carotene "Against" Bleomycin-Induced Pulmonary Fibrosis in Rats via TGF-beta/Smad, PI3K/Akt/mTOR and NF-kappaB Signaling Pathways.	Bleomycin	90-99	transforming growth factor alpha	Rattus norvegicus	139-147
35238669-3	2022	USP38 deficiency aggravates IL-33-induced lung inflammatory response and bleomycin-induced pulmonary fibrosis.	Bleomycin	73-82	ubiquitin specific peptidase 38	Homo sapiens	0-5
35281428-10	2022	Furthermore, we found that IL-19 aggravated lung fibrosis in murine bleomycin-induced lung fibrosis.	Bleomycin	68-77	interleukin 19	Mus musculus	27-32
35213624-1	2022	The caveolin-1 scaffolding domain (CSD, amino acids 82-101 of caveolin-1) has been shown to suppress bleomycin-induced lung and skin fibrosis and angiotensin II (AngII)-induced myocardial fibrosis.	Bleomycin	101-110	caveolin 1, caveolae protein	Mus musculus	4-14
35107021-3	2022	Deletion of Pdgfa with Cx3cr1-CreERT2 decreased bleomycin-induced lung fibrosis.	Bleomycin	48-57	platelet derived growth factor, alpha	Mus musculus	12-17
35220710-0	2022	Blocking Toll-like receptor 9 attenuates bleomycin-induced pulmonary injury.	Bleomycin	41-50	toll-like receptor 9	Mus musculus	9-29
35213624-1	2022	The caveolin-1 scaffolding domain (CSD, amino acids 82-101 of caveolin-1) has been shown to suppress bleomycin-induced lung and skin fibrosis and angiotensin II (AngII)-induced myocardial fibrosis.	Bleomycin	101-110	caveolin 1, caveolae protein	Mus musculus	62-72
35213624-5	2022	In addition, while bone marrow monocytes isolated from bleomycin-treated mice showed greatly enhanced migration in vitro toward CXCL12, treatment in vivo with CSD and its subregions almost completely suppressed this enhanced migration.	Bleomycin	55-64	chemokine (C-X-C motif) ligand 12	Mus musculus	128-134
35211116-4	2022	We show using immunophenotypic analyses that Cdh11-/- mice have fewer recruited monocyte-derived macrophages and Ly6Chi monocytes in the lungs compared to wild-type mice in the intraperitoneal bleomycin-induced pulmonary fibrosis model.	Bleomycin	193-202	cadherin 11	Mus musculus	45-50
35197539-3	2022	We found significantly increased PD-L1 in the lungs of idiopathic pulmonary fibrosis patients and mice with pulmonary fibrosis induced by bleomycin and TGF-beta.	Bleomycin	138-147	CD274 molecule	Homo sapiens	33-38
35178456-6	2022	Histopathological changes, inflammatory factors (IL-6, IL-1beta, and TNF-alpha), and the proteins of the TLR4/MyD88/NF-kappaB pathway in bleomycin- (BLM-) induced mice model were examined by hematoxylin-eosin (H&E), Masson or immunohistochemistry staining, Western blot, and enzyme-linked immunosorbent assay analysis.	Bleomycin	137-146	toll-like receptor 4	Mus musculus	105-109
35178456-6	2022	Histopathological changes, inflammatory factors (IL-6, IL-1beta, and TNF-alpha), and the proteins of the TLR4/MyD88/NF-kappaB pathway in bleomycin- (BLM-) induced mice model were examined by hematoxylin-eosin (H&E), Masson or immunohistochemistry staining, Western blot, and enzyme-linked immunosorbent assay analysis.	Bleomycin	137-146	myeloid differentiation primary response gene 88	Mus musculus	110-115
35178456-6	2022	Histopathological changes, inflammatory factors (IL-6, IL-1beta, and TNF-alpha), and the proteins of the TLR4/MyD88/NF-kappaB pathway in bleomycin- (BLM-) induced mice model were examined by hematoxylin-eosin (H&E), Masson or immunohistochemistry staining, Western blot, and enzyme-linked immunosorbent assay analysis.	Bleomycin	137-146	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125
35181688-6	2022	Furthermore, SDC2-transgenic mice exposed to bleomycin-induced lung injury in an inflammatory arthritis model expressed lower levels of PAD2 and were protected from the development of pulmonary fibrosis.	Bleomycin	45-54	syndecan 2	Mus musculus	13-17
35136032-1	2022	Recent studies reported that Methyl-CpG-binding domain protein 2 (MBD2) promoted M2 macrophages accumulation to increase bleomycin-induced pulmonary fibrosis.	Bleomycin	121-130	methyl-CpG binding domain protein 2	Mus musculus	29-64
35136032-1	2022	Recent studies reported that Methyl-CpG-binding domain protein 2 (MBD2) promoted M2 macrophages accumulation to increase bleomycin-induced pulmonary fibrosis.	Bleomycin	121-130	methyl-CpG binding domain protein 2	Mus musculus	66-70
35120332-8	2022	Thus, DHA exerts therapeutic effects against bleomycin-induced pulmonary inflammation and PF by inhibiting JAK2-STAT3 activation.	Bleomycin	45-54	Janus kinase 2	Rattus norvegicus	107-111
35120332-8	2022	Thus, DHA exerts therapeutic effects against bleomycin-induced pulmonary inflammation and PF by inhibiting JAK2-STAT3 activation.	Bleomycin	45-54	signal transducer and activator of transcription 3	Rattus norvegicus	112-117
35126110-0	2021	Wenfei Buqi Tongluo Formula Against Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-beta/Smad3 Pathway.	Bleomycin	36-45	transforming growth factor alpha	Mus musculus	87-95
34710342-4	2022	Likewise, data from three different pleural fibrosis models (TGF-beta, carbon black/bleomycin, and streptococcal empyema) consistently demonstrated DOCK2 upregulation and its colocalization with alpha-SMA in the pleura.	Bleomycin	84-93	dedicator of cytokinesis 2	Homo sapiens	148-153
35086828-2	2022	Herein, we demonstrated that lungs originated from IPF patients and mice after bleomycin (BLM)-induced pulmonary fibrosis are characterized by the altered DNA methylation along with overexpression of methyl-CpG-binding domain 2 (MBD2) in myofibroblasts, a reader responsible for interpreting DNA methylome-encoded information.	Bleomycin	79-88	methyl-CpG binding domain protein 2	Mus musculus	200-227
35086828-2	2022	Herein, we demonstrated that lungs originated from IPF patients and mice after bleomycin (BLM)-induced pulmonary fibrosis are characterized by the altered DNA methylation along with overexpression of methyl-CpG-binding domain 2 (MBD2) in myofibroblasts, a reader responsible for interpreting DNA methylome-encoded information.	Bleomycin	79-88	methyl-CpG binding domain protein 2	Mus musculus	229-233
35086828-2	2022	Herein, we demonstrated that lungs originated from IPF patients and mice after bleomycin (BLM)-induced pulmonary fibrosis are characterized by the altered DNA methylation along with overexpression of methyl-CpG-binding domain 2 (MBD2) in myofibroblasts, a reader responsible for interpreting DNA methylome-encoded information.	Bleomycin	90-93	methyl-CpG binding domain protein 2	Mus musculus	200-227
35086828-2	2022	Herein, we demonstrated that lungs originated from IPF patients and mice after bleomycin (BLM)-induced pulmonary fibrosis are characterized by the altered DNA methylation along with overexpression of methyl-CpG-binding domain 2 (MBD2) in myofibroblasts, a reader responsible for interpreting DNA methylome-encoded information.	Bleomycin	90-93	methyl-CpG binding domain protein 2	Mus musculus	229-233
35256943-3	2022	In this study, we report that P21 expression was increased in alveolar epithelial type 2 cells (AEC2s) in a time-dependent manner following multiple bleomycin-induced PF.	Bleomycin	149-158	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	30-33
34985777-9	2022	ADAR2 expression increased significantly in a bleomycin mouse model, implicating a role of ADAR2 in lung fibrosis.	Bleomycin	46-55	adenosine deaminase, RNA-specific, B1	Mus musculus	0-5
34985777-9	2022	ADAR2 expression increased significantly in a bleomycin mouse model, implicating a role of ADAR2 in lung fibrosis.	Bleomycin	46-55	adenosine deaminase, RNA-specific, B1	Mus musculus	91-96
35086525-5	2022	Administration of GSE4-nanoparticles attenuated bleomycin-induced skin fibrosis as measured by Masson"s staining of collagen and reduced Acta2 and Ctgf mRNA expression, whereas transduction of dermal fibroblasts with a lentiviral GSE4 expression vector reduced COL1A1, ACTA2 and CTGF gene expression after stimulation with bleomycin or TGF-beta, in parallel to a reduction of the phospho-histone H2A.X marker of DNA damage.	Bleomycin	48-57	actin alpha 2, smooth muscle	Homo sapiens	137-142
35086525-5	2022	Administration of GSE4-nanoparticles attenuated bleomycin-induced skin fibrosis as measured by Masson"s staining of collagen and reduced Acta2 and Ctgf mRNA expression, whereas transduction of dermal fibroblasts with a lentiviral GSE4 expression vector reduced COL1A1, ACTA2 and CTGF gene expression after stimulation with bleomycin or TGF-beta, in parallel to a reduction of the phospho-histone H2A.X marker of DNA damage.	Bleomycin	48-57	cellular communication network factor 2	Homo sapiens	147-151
35126110-0	2021	Wenfei Buqi Tongluo Formula Against Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-beta/Smad3 Pathway.	Bleomycin	36-45	SMAD family member 3	Mus musculus	96-101
35013220-4	2022	Here, we demonstrate that the levels of ACP5 are increased in IPF patient samples and mice with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	96-105	acid phosphatase 5, tartrate resistant	Homo sapiens	40-44
35039472-5	2022	Lentivirus-mediated DOT1L knockdown or DOT1L-specific inhibitor EPZ5676 alleviated the pathogenesis of bleomycin-induced mouse pulmonary fibrosis.	Bleomycin	103-112	DOT1-like, histone H3 methyltransferase (S. cerevisiae)	Mus musculus	39-44
35039607-7	2022	Finally, mir-7b and its target gene Gria1 and mir-486b and its target gene Shc4 were further validated in a bleomycin-induced ALI mouse model.	Bleomycin	108-117	microRNA 3107	Mus musculus	46-54
35039607-7	2022	Finally, mir-7b and its target gene Gria1 and mir-486b and its target gene Shc4 were further validated in a bleomycin-induced ALI mouse model.	Bleomycin	108-117	SHC (Src homology 2 domain containing) family, member 4	Mus musculus	75-79
35069531-4	2021	Fbxw7 is identified to be a crucial suppressing factor for pulmonary fibrosis development and progression in a mouse model induced by intratracheal bleomycin treatment.	Bleomycin	148-157	F-box and WD-40 domain protein 7	Mus musculus	0-5
35069531-5	2021	Myeloid cell-specific Fbxw7 deletion increases pulmonary monocyte-macrophages accumulation in lung tissue, and eventually promotes bleomycin-induced collagen deposition and progressive pulmonary fibrosis.	Bleomycin	131-140	F-box and WD-40 domain protein 7	Mus musculus	22-27
35069531-6	2021	Notably, the expression of TGF-beta in profibrotic macrophages was significantly upregulated in myeloid cell-specific Fbxw7 deletion mice after bleomycin treatment.	Bleomycin	144-153	transforming growth factor alpha	Mus musculus	27-35
35069531-6	2021	Notably, the expression of TGF-beta in profibrotic macrophages was significantly upregulated in myeloid cell-specific Fbxw7 deletion mice after bleomycin treatment.	Bleomycin	144-153	F-box and WD-40 domain protein 7	Mus musculus	118-123
35013220-4	2022	Here, we demonstrate that the levels of ACP5 are increased in IPF patient samples and mice with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	107-110	acid phosphatase 5, tartrate resistant	Homo sapiens	40-44
34931663-5	2022	Although commitment of the alveolar epithelium is unaffected, alpha-SMA+ mesenchymal cells persist in the alveoli accompanied by increased collagen deposition and mutants exhibit exacerbated fibrosis following bleomycin challenge.	Bleomycin	210-219	actin alpha 1, skeletal muscle	Homo sapiens	62-71
35083881-5	2022	Upon bleomycin (BLM) treatment, Ldlr-deficient (Ldlr-/-) mice exhibited remarkably higher LDL levels, abundant apoptosis, increased fibroblast-like endothelial and ATII cells and significantly earlier and more severe fibrotic response compared to wild-type mice.	Bleomycin	5-14	low density lipoprotein receptor	Mus musculus	32-36
35083881-5	2022	Upon bleomycin (BLM) treatment, Ldlr-deficient (Ldlr-/-) mice exhibited remarkably higher LDL levels, abundant apoptosis, increased fibroblast-like endothelial and ATII cells and significantly earlier and more severe fibrotic response compared to wild-type mice.	Bleomycin	5-14	low density lipoprotein receptor	Mus musculus	48-52
35083881-5	2022	Upon bleomycin (BLM) treatment, Ldlr-deficient (Ldlr-/-) mice exhibited remarkably higher LDL levels, abundant apoptosis, increased fibroblast-like endothelial and ATII cells and significantly earlier and more severe fibrotic response compared to wild-type mice.	Bleomycin	16-19	low density lipoprotein receptor	Mus musculus	32-36
35083881-5	2022	Upon bleomycin (BLM) treatment, Ldlr-deficient (Ldlr-/-) mice exhibited remarkably higher LDL levels, abundant apoptosis, increased fibroblast-like endothelial and ATII cells and significantly earlier and more severe fibrotic response compared to wild-type mice.	Bleomycin	16-19	low density lipoprotein receptor	Mus musculus	48-52
34986347-5	2022	Overexpressing human CXCL4 in mice aggravates, whereas blocking CXCL4 reduces, bleomycin-induced fibrosis.	Bleomycin	79-88	platelet factor 4	Homo sapiens	21-26
34986347-5	2022	Overexpressing human CXCL4 in mice aggravates, whereas blocking CXCL4 reduces, bleomycin-induced fibrosis.	Bleomycin	79-88	platelet factor 4	Mus musculus	64-69
2480245-1	1989	Cis-platinum, 5-fluorouracil and bleomycin are active agents in head and neck SCC.	Bleomycin	33-42	serpin family B member 3	Homo sapiens	78-81
35187969-0	2022	Protective effects of alpha-lipoic acid on bleomycin-induced skin fibrosis through the repression of NADPH Oxidase 4 and TGF-beta1/Smad3 signaling pathways.	Bleomycin	43-52	NADPH oxidase 4	Mus musculus	101-116
35187969-0	2022	Protective effects of alpha-lipoic acid on bleomycin-induced skin fibrosis through the repression of NADPH Oxidase 4 and TGF-beta1/Smad3 signaling pathways.	Bleomycin	43-52	transforming growth factor, beta 1	Mus musculus	121-130
35187969-0	2022	Protective effects of alpha-lipoic acid on bleomycin-induced skin fibrosis through the repression of NADPH Oxidase 4 and TGF-beta1/Smad3 signaling pathways.	Bleomycin	43-52	SMAD family member 3	Mus musculus	131-136
35355726-0	2022	ACPA Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-beta-Smad2/3 Signaling-Mediated Lung Fibroblast Activation.	Bleomycin	16-25	transforming growth factor alpha	Mus musculus	67-75
35355726-0	2022	ACPA Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-beta-Smad2/3 Signaling-Mediated Lung Fibroblast Activation.	Bleomycin	16-25	SMAD family member 2	Mus musculus	76-83
2482074-1	1989	Treatment of permeable human fibroblasts with bleomycin elicits DNA repair synthesis that is only partially sensitive to aphidicolin, an inhibitor of mammalian DNA polymerases alpha and delta.	Bleomycin	46-55	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	160-181
2482074-5	1989	On the basis of these data and the relative sensitivity of bleomycin-induced repair synthesis to N2-(p-n-butylphenyl)-2"-deoxyguanosine 5"-triphosphate (BuPdGTP), 2",3"-dideoxythymidine 5"-triphosphate (ddTTP), and N-ethylmaleimide (NEM), long-patch repair is attributed to DNA polymerase delta and short-patch repair to DNA polymerase beta.	Bleomycin	59-68	DNA polymerase delta 1, catalytic subunit	Homo sapiens	274-294
2482074-5	1989	On the basis of these data and the relative sensitivity of bleomycin-induced repair synthesis to N2-(p-n-butylphenyl)-2"-deoxyguanosine 5"-triphosphate (BuPdGTP), 2",3"-dideoxythymidine 5"-triphosphate (ddTTP), and N-ethylmaleimide (NEM), long-patch repair is attributed to DNA polymerase delta and short-patch repair to DNA polymerase beta.	Bleomycin	59-68	DNA polymerase beta	Homo sapiens	321-340
2480115-1	1989	Bleomycin-induced DNA repair synthesis in the permeabilized HeLa cells was sensitive to aphidicolin, an inhibitor of DNA polymerase alpha and delta, and to dideoxythymidine triphosphate (ddTTP), a specific inhibitor of DNA polymerase beta.	Bleomycin	0-9	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	117-137
2480115-1	1989	Bleomycin-induced DNA repair synthesis in the permeabilized HeLa cells was sensitive to aphidicolin, an inhibitor of DNA polymerase alpha and delta, and to dideoxythymidine triphosphate (ddTTP), a specific inhibitor of DNA polymerase beta.	Bleomycin	0-9	DNA polymerase beta	Homo sapiens	219-238
2482841-1	1989	Our previous studies have demonstrated that 3-aminobenzamide (3AB), an inhibitor of adenosine diphosphate-ribosyl transferase (ADPRT) could enhance the cytotoxicity (in vitro) and antitumor activity (in vivo) of bleomycin (BLM) A5 and peplomycin (PEP) against S-180, hepatoma and Ehrlich ascites carcinoma (EAC).	Bleomycin	212-221	ADP-ribosyltransferase 1	Mus musculus	84-125
2481974-7	1989	CHOP therapy with bleomycin and methotrexate was performed.	Bleomycin	18-27	DNA damage inducible transcript 3	Homo sapiens	0-4
2482841-1	1989	Our previous studies have demonstrated that 3-aminobenzamide (3AB), an inhibitor of adenosine diphosphate-ribosyl transferase (ADPRT) could enhance the cytotoxicity (in vitro) and antitumor activity (in vivo) of bleomycin (BLM) A5 and peplomycin (PEP) against S-180, hepatoma and Ehrlich ascites carcinoma (EAC).	Bleomycin	212-221	ADP-ribosyltransferase 1	Mus musculus	127-132
2474861-0	1989	Ethyl methane sulfonate- and bleomycin-generated deletion mutations at HPRT locus in xeroderma pigmentosum complementation group D fibroblasts.	Bleomycin	29-38	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	71-75
2475571-0	1989	Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.	Bleomycin	52-61	tumor necrosis factor	Mus musculus	0-21
2475571-0	1989	Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.	Bleomycin	52-61	tumor necrosis factor	Mus musculus	22-31
2475571-1	1989	The role of TNF-alpha/cachectin in the pneumopathy elicited by bleomycin has been investigated.	Bleomycin	63-72	tumor necrosis factor	Mus musculus	12-21
2475571-1	1989	The role of TNF-alpha/cachectin in the pneumopathy elicited by bleomycin has been investigated.	Bleomycin	63-72	tumor necrosis factor	Mus musculus	22-31
2475571-2	1989	After a single intratracheal bleomycin instillation, an increase of the lung TNF-alpha mRNA level was evident, from days 5 to 15, as shown by Northern gel analysis of whole lung RNA.	Bleomycin	29-38	tumor necrosis factor	Mus musculus	77-86
2475571-4	1989	In mice passively immunized with rabbit anti-mouse TNF-alpha IgG, the bleomycin-induced collagen deposition, evaluated by the total lung hydroxyproline assay on day 15, was prevented.	Bleomycin	70-79	tumor necrosis factor	Mus musculus	51-60
2475571-5	1989	Depletion of the CD4 and CD8 T lymphocytes by an in vivo treatment with mAb prevented the bleomycin-induced increase of TNF mRNA level and fibrosis.	Bleomycin	90-99	CD4 antigen	Mus musculus	17-20
2475571-5	1989	Depletion of the CD4 and CD8 T lymphocytes by an in vivo treatment with mAb prevented the bleomycin-induced increase of TNF mRNA level and fibrosis.	Bleomycin	90-99	tumor necrosis factor	Mus musculus	120-123
2475571-6	1989	After an administration of bleomycin in continuous intraperitoneal perfusion, the diffuse alveolar damage observed by light and electron microscopy was almost completely prevented by anti-TNF antibody.	Bleomycin	27-36	tumor necrosis factor	Mus musculus	188-191
2475571-7	1989	These results indicate that in response to bleomycin, the T lymphocytes induce, by an undefined mechanism, an increase of the pulmonary TNF production, which leads to alveolar damage, growth of fibroblast, and collagen deposition.	Bleomycin	43-52	tumor necrosis factor	Mus musculus	136-139
2475572-2	1989	Total lung TGF-beta was elevated within 2 h of intratracheal bleomycin administration and peaked 7 d later at levels 30-fold higher than controls.	Bleomycin	61-70	transforming growth factor, beta 1	Rattus norvegicus	11-19
2475572-4	1989	The peak TGF-beta levels preceded the maximum collagen and noncollagen protein synthesis measured by [3H]proline incorporation into lung fibroblast explants of bleomycin-treated rats.	Bleomycin	160-169	transforming growth factor, beta 1	Rattus norvegicus	9-17
2476934-10	1989	Within 3 days after bleomycin-induced lung injury, lavage procoagulant activity was increased and fibrinolytic activity was depressed due to increased antiplasmin and PAI activities.	Bleomycin	20-29	serpin family E member 1	Rattus norvegicus	167-170
2482780-0	1989	Bleomycin induces the hsp 70 heat shock promoter in cultured cells.	Bleomycin	0-9	heat shock protein family A (Hsp70) member 4	Homo sapiens	22-28
2482780-5	1989	Doses of bleomycin, which have previously been shown to augment lung fibroblast proliferation, induce the hsp 70 heat shock promoter in the transfected cells.	Bleomycin	9-18	heat shock protein family A (Hsp70) member 4	Homo sapiens	106-112
2482780-7	1989	These observations suggest that bleomycin exposure may cause significant alterations in important DNA promoter regions such as the hsp 70 promoter and point to new ways to assess bleomycin-induced changes in cells.	Bleomycin	32-41	heat shock protein family A (Hsp70) member 4	Homo sapiens	131-137
2506856-1	1989	Bleomycin hydrolase, which hydrolyzes the carboxamide bond in the pyrimidoblamic acid moiety of the bleomycin molecule, also cleaved several p-nitroanilide substrates with a neutral or basic amino acid residue and dipeptide substrates such as L-leucyl-glycine.	Bleomycin	100-109	bleomycin hydrolase	Homo sapiens	0-19
2568172-3	1989	In addition, the MX2 cells display slight collateral sensitivity to bleomycin.	Bleomycin	68-77	MX dynamin like GTPase 2	Homo sapiens	17-20
2471391-4	1989	A system for repair of this bleomycin-damaged DNA was constructed with a priming factor, DNA polymerase (DNA polymerase beta or Klenow fragment of DNA polymerase I), ATP, T4 DNA ligase and four deoxynucleoside triphosphates.	Bleomycin	28-37	DNA polymerase beta	Homo sapiens	105-124
2720910-9	1989	These observations indicate repair of bleomycin-induced DNA damage in trout cells occurs through a mechanism similar to that in mammalian cells, utilizing DNA polymerase beta.	Bleomycin	38-47	DNA polymerase beta	Homo sapiens	155-174
2476991-3	1989	The mononucleosomes released from the bleomycin-treated nuclei contained the core histones H2A, H2B, H3, and H4; while HMG1 and HMG2 proteins, in addition to the core histones, were detected in the mononucleosomes obtained by micrococcal nuclease digestion of nuclei.	Bleomycin	38-47	high mobility group box 1 pseudogene 5	Homo sapiens	119-123
2476991-3	1989	The mononucleosomes released from the bleomycin-treated nuclei contained the core histones H2A, H2B, H3, and H4; while HMG1 and HMG2 proteins, in addition to the core histones, were detected in the mononucleosomes obtained by micrococcal nuclease digestion of nuclei.	Bleomycin	38-47	high mobility group box 2	Homo sapiens	128-132
2476991-5	1989	HMG1 and HMG2 were exclusively dissociated from chromatin with 1 mM bleomycin under the solvent condition where the DNA strand-breaking activity of the drug is repressed.	Bleomycin	68-77	high mobility group box 1 pseudogene 5	Homo sapiens	0-4
2476991-5	1989	HMG1 and HMG2 were exclusively dissociated from chromatin with 1 mM bleomycin under the solvent condition where the DNA strand-breaking activity of the drug is repressed.	Bleomycin	68-77	high mobility group box 2	Homo sapiens	9-13
2469858-10	1989	We hypothesize that the substantial increase in alpha-smooth muscle actin containing cells in fibrotic regions of involved parenchyma after bleomycin injury is responsible for the altered morphologic, biochemical, and mechanical properties that we have observed.	Bleomycin	140-149	actin gamma 2, smooth muscle	Rattus norvegicus	48-73
2473971-0	1989	High induction of poly(ADP-ribose) polymerase activity in bleomycin-resistant HeLa cells.	Bleomycin	58-67	poly(ADP-ribose) polymerase 1	Homo sapiens	18-45
2473971-1	1989	Poly(ADP-ribose) polymerase activity was measured in bleomycin (BLM)-resistant HeLa (HeLa-BLMr) and the parental HeLa cells after BLM treatment.	Bleomycin	53-62	poly(ADP-ribose) polymerase 1	Homo sapiens	0-27
2469858-0	1989	Alpha-smooth muscle actin in parenchymal cells of bleomycin-injured rat lung.	Bleomycin	50-59	actin gamma 2, smooth muscle	Rattus norvegicus	0-25
2473848-0	1989	Effects of photo-activated bleomycin on deoxyribonuclease I, exonuclease III and deoxyribonucleic acid polymerase I reactions.	Bleomycin	27-36	deoxyribonuclease 1	Homo sapiens	40-59
2466835-7	1989	The presence of such complexes would account for the ability of non-transferrin-bound iron to be measurable by the bleomycin assay and for its rapid clearance from the circulation by the liver.	Bleomycin	115-124	transferrin	Homo sapiens	68-79
2473848-2	1989	Photo-activated bleomycin stimulated the action of deoxyribonuclease I (DNase I) to degrade DNA and the DNA synthesis by DNA polymerase I with DNase I.	Bleomycin	16-25	deoxyribonuclease 1	Homo sapiens	51-70
2473848-2	1989	Photo-activated bleomycin stimulated the action of deoxyribonuclease I (DNase I) to degrade DNA and the DNA synthesis by DNA polymerase I with DNase I.	Bleomycin	16-25	deoxyribonuclease 1	Homo sapiens	72-79
2473848-2	1989	Photo-activated bleomycin stimulated the action of deoxyribonuclease I (DNase I) to degrade DNA and the DNA synthesis by DNA polymerase I with DNase I.	Bleomycin	16-25	deoxyribonuclease 1	Homo sapiens	143-150
2473848-3	1989	On the other hand, although UV-irradiated bleomycin scarcely broke the DNA strand in the presence of 1,2-benzenediol (catechol), it stimulated the action of DNase I to degrade DNA in the presence of catechol.	Bleomycin	42-51	deoxyribonuclease 1	Homo sapiens	157-164
2473848-5	1989	These findings suggest that the ability of bleomycin to bind to double-helical DNA forming regions sensitive to DNase I was increased by an appropriate dose of UV irradiation and that catechol inhibited the activity of the UV-irradiated bleomycin to break the DNA strand rather than to bind to DNA.	Bleomycin	43-52	deoxyribonuclease 1	Homo sapiens	112-119
2473848-5	1989	These findings suggest that the ability of bleomycin to bind to double-helical DNA forming regions sensitive to DNase I was increased by an appropriate dose of UV irradiation and that catechol inhibited the activity of the UV-irradiated bleomycin to break the DNA strand rather than to bind to DNA.	Bleomycin	237-246	deoxyribonuclease 1	Homo sapiens	112-119
2467879-2	1989	In normal and athymic nude (rnu/rnu) rats, a single intratracheal administration of bleomycin (5 U/kg) leads to pulmonary fibrosis accompanied by parenchymal hyperplasia of mast cells that are histochemically like PMC rather than IMMC.	Bleomycin	84-93	forkhead box N1	Rattus norvegicus	28-31
2472050-5	1989	Serum human chorionic gonadotropin (hCG) and hCG-beta levels were very high preoperatively (4,8000 mIU/ml, 57 ng/ml, respectively) and they decreased to normal after vinblastine-bleomycin cisplatin combination chemotherapy three times postoperatively.	Bleomycin	178-187	chorionic gonadotropin subunit beta 5	Homo sapiens	36-39
2914273-9	1989	Differential sensitivities among the five cell lines to 5-fluorouracil, cisplatinum, and bleomycin appear to be mediated through other mechanism beside the mdr-1 gene.	Bleomycin	89-98	ATP binding cassette subfamily B member 1	Homo sapiens	156-161
2467879-2	1989	In normal and athymic nude (rnu/rnu) rats, a single intratracheal administration of bleomycin (5 U/kg) leads to pulmonary fibrosis accompanied by parenchymal hyperplasia of mast cells that are histochemically like PMC rather than IMMC.	Bleomycin	84-93	forkhead box N1	Rattus norvegicus	32-35
2464942-1	1989	Previous work in this laboratory has demonstrated increased secretion of fibroblast growth factor (MDGF) activity by alveolar macrophages obtained from mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	162-171	pro-platelet basic protein	Mus musculus	99-103
2464942-2	1989	The mechanism by which bleomycin promotes this increase in MDGF secretion is not clear, however.	Bleomycin	23-32	pro-platelet basic protein	Mus musculus	59-63
2464942-5	1989	Alveolar macrophages incubated with 0.01 microgram to 1 microgram/ml bleomycin for 18 hours secreted significantly more MDGF than macrophages incubated without bleomycin.	Bleomycin	69-78	pro-platelet basic protein	Mus musculus	120-124
2464942-7	1989	Maximal MDGF production was seen with bleomycin doses of greater than or equal to 0.1 microgram/ml.	Bleomycin	38-47	pro-platelet basic protein	Mus musculus	8-12
2464942-8	1989	When alveolar macrophages were incubated with 0.1 microgram/ml bleomycin for 0.5-18 hours, MDGF activity was detected as early as 1 hour, with peak responses found at 4-8 hours.	Bleomycin	63-72	pro-platelet basic protein	Mus musculus	91-95
2464942-9	1989	Macrophages stimulated with bleomycin continued to produce significant amounts of MDGF even after bleomycin was removed and replaced with fresh (bleomycin-free) media.	Bleomycin	28-37	pro-platelet basic protein	Mus musculus	82-86
2464942-9	1989	Macrophages stimulated with bleomycin continued to produce significant amounts of MDGF even after bleomycin was removed and replaced with fresh (bleomycin-free) media.	Bleomycin	98-107	pro-platelet basic protein	Mus musculus	82-86
2464942-9	1989	Macrophages stimulated with bleomycin continued to produce significant amounts of MDGF even after bleomycin was removed and replaced with fresh (bleomycin-free) media.	Bleomycin	98-107	pro-platelet basic protein	Mus musculus	82-86
2464942-10	1989	MDGF secretion by bleomycin-stimulated alveolar macrophages was inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguairetic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity(ABSTRACT TRUNCATED AT 250 WORDS)	Bleomycin	18-27	pro-platelet basic protein	Mus musculus	0-4
2464942-10	1989	MDGF secretion by bleomycin-stimulated alveolar macrophages was inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguairetic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity(ABSTRACT TRUNCATED AT 250 WORDS)	Bleomycin	18-27	arachidonate 5-lipoxygenase	Rattus norvegicus	100-114
2464942-10	1989	MDGF secretion by bleomycin-stimulated alveolar macrophages was inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguairetic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity(ABSTRACT TRUNCATED AT 250 WORDS)	Bleomycin	18-27	arachidonate 5-lipoxygenase	Rattus norvegicus	258-272
2468183-1	1989	A series of phase II studies using ifosfamide as a single agent and in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer were coordinated at the West Midlands Cancer Research Campaign Clinical Trials Unit, Birmingham, UK.	Bleomycin	102-111	heat shock protein family A (Hsp70) member 5	Homo sapiens	113-116
2469583-3	1989	A precipitous decrease in growth occurred at a temperature of approximately 42.5 degrees C. Concomitant application of hyperthermia, bleomycin and irradiation (hyperthermochemoradiotherapy, HCR) had a maximal effect on cell growth, compared to findings in cells treated with only one or two of these modalities.	Bleomycin	133-142	coiled-coil alpha-helical rod protein 1	Homo sapiens	190-193
2523211-8	1989	of 4 months duration with CHOP-Bleomycin.	Bleomycin	31-40	DNA damage inducible transcript 3	Homo sapiens	26-30
2468427-0	1989	Occurrence of an anti-peplomycin IgE antibody cross-reacting with bleomycin in a patient with cervical uterine cancer.	Bleomycin	66-75	immunoglobulin heavy constant epsilon	Homo sapiens	33-36
2469543-1	1989	Calmodulin antagonists, such as trifluoperazine, can enhance the cytotoxic effects of bleomycin both in tissue culture and in vivo.	Bleomycin	86-95	calmodulin 1	Homo sapiens	0-10
2469583-6	1989	Fractionated HCR (hyperthermia: 42 degrees C, 60 min; chemotherapy: 2 micrograms/ml of bleomycin, 60 min; radiotherapy: 2 Gy) at a time interval of under 21 h was less effective than a single HCR (hyperthermia: 42 degrees C, 120 min; chemotherapy: 2 micrograms/ml of bleomycin, 120 min; radiotherapy: 4 Gy).	Bleomycin	267-276	coiled-coil alpha-helical rod protein 1	Homo sapiens	13-16
2461264-1	1988	A protein factor having exonucleolytic activity on bleomycin-damaged DNA and providing priming sites for DNA polymerases existed in a DNA polymerase beta fraction partially purified by ion exchange chromatography from an extract of permeable mouse ascites sarcoma (SR-C3H/He) cells.	Bleomycin	51-60	polymerase (DNA directed), beta	Mus musculus	134-153
2472533-6	1989	After 24 h of incubation with interleukin-2 (IL-2), BAL lymphocytes from bleomycin-treated rabbits had nearly a 4-fold greater proliferative response than lymphocytes from untreated rabbits.	Bleomycin	73-82	interleukin-2	Oryctolagus cuniculus	30-43
2472533-6	1989	After 24 h of incubation with interleukin-2 (IL-2), BAL lymphocytes from bleomycin-treated rabbits had nearly a 4-fold greater proliferative response than lymphocytes from untreated rabbits.	Bleomycin	73-82	interleukin-2	Oryctolagus cuniculus	45-49
2472533-9	1989	After 24 h of incubation with IL-2, significant CDCMC activity was detected in lung lymphocytes from bleomycin-treated animals, but not in lung lymphocytes from control animals.	Bleomycin	101-110	interleukin-2	Oryctolagus cuniculus	30-34
2454690-3	1988	Patients not meeting these criteria were switched to a combination of Etoposide, Ifosfamide, Methotrexate, and Bleomycin (VIM-Bleo).	Bleomycin	111-120	vimentin	Homo sapiens	122-125
2461873-9	1988	In patients undergoing Bleo treatment, varying levels of APR can be expected, and this could explain the rapid development of fibrosis in individual cases.	Bleomycin	23-27	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	57-60
2459112-1	1988	In contrast to ligase-deficient (cdc9) Saccharomyces cerevisiae, which did not rejoin bleomycin-induced DNA breaks, ligase-proficient (CDC9) yeast cells eliminated approximately 90% of DNA breaks within 90 to 120 min after treatment.	Bleomycin	86-95	DNA ligase (ATP) CDC9	Saccharomyces cerevisiae S288C	135-139
2459594-1	1988	Isolated and purified microsomal NADH-cytochrome b5 reductase (EC 1.6.2.2) was incubated with bleomycin (BLM) and FeCl3 in the presence of NADH.	Bleomycin	94-103	cytochrome b5 type A	Homo sapiens	38-51
2459594-1	1988	Isolated and purified microsomal NADH-cytochrome b5 reductase (EC 1.6.2.2) was incubated with bleomycin (BLM) and FeCl3 in the presence of NADH.	Bleomycin	105-108	cytochrome b5 type A	Homo sapiens	38-51
2457084-2	1988	Within 4 weeks after bleomycin treatment, the pulmonary content of mRNAs encoding fibronectin, alpha 2I procollagen and alpha 1III procollagen was increased.	Bleomycin	21-30	fibronectin 1	Mus musculus	82-93
2481844-0	1988	[Modified CHOP-Bleo protocol in the treatment of malignant non-Hodgkin"s lymphoma of low cell differentiation].	Bleomycin	15-19	DNA damage inducible transcript 3	Homo sapiens	10-14
2450783-3	1988	The bleomycin resistance of cells harboring a ble gene could be accounted for by a sequestering effect of the bleomycin-binding protein.	Bleomycin	110-119	bleomycin resistance protein	Escherichia coli	4-7
2457562-0	1988	Angiotensin converting enzyme in bleomycin-treated patients.	Bleomycin	33-42	angiotensin I converting enzyme	Homo sapiens	0-29
2451429-1	1988	Cathepsin B activity was quantitated in alveolar macrophages obtained from hamsters 10, 21, and 105 days after the intratracheal instillation of porcine pancreatic elastase, bleomycin, or normal saline.	Bleomycin	174-183	cathepsin B	Homo sapiens	0-11
2454980-1	1988	A 1 U/ml solution of bleomycin sulfate in physiologic saline solution was injected intralesionally in 38 patients, and was compared with physiologic saline solution injection into paired warts in the same patient.	Bleomycin	21-38	ubiquilin 4	Homo sapiens	0-5
2451030-1	1988	Phenothiazines and structurally related calmodulin antagonists acted synergistically with bleomycin in killing malignant cells in culture.	Bleomycin	90-99	calmodulin 2	Mus musculus	40-50
2451525-3	1988	Protection of lung tissue from bleomycin-induced toxicity may occur through both specific metabolic inactivation of bleomycin by the enzyme bleomycin hydrolase, as well as by such non-specific antioxidants as catalase and the glutathione system.	Bleomycin	31-40	bleomycin hydrolase	Mus musculus	140-159
2451525-3	1988	Protection of lung tissue from bleomycin-induced toxicity may occur through both specific metabolic inactivation of bleomycin by the enzyme bleomycin hydrolase, as well as by such non-specific antioxidants as catalase and the glutathione system.	Bleomycin	31-40	catalase	Mus musculus	209-217
2451525-3	1988	Protection of lung tissue from bleomycin-induced toxicity may occur through both specific metabolic inactivation of bleomycin by the enzyme bleomycin hydrolase, as well as by such non-specific antioxidants as catalase and the glutathione system.	Bleomycin	116-125	bleomycin hydrolase	Mus musculus	140-159
2462439-1	1988	We report the results of phase II studies using a combination of ifosfamide, cis-platinum and bleomycin (BIP) in advanced and recurrent cervical cancer.	Bleomycin	94-103	heat shock protein family A (Hsp70) member 5	Homo sapiens	105-108
2449832-5	1988	High dose intratracheal bleomycin instillation (500 micrograms) induced an increase in ACE activity relative to total protein.	Bleomycin	24-33	angiotensin I converting enzyme	Rattus norvegicus	87-90
2449832-6	1988	When a lower dose of bleomycin (50 micrograms) or when a 30-h exposure to 100% oxygen were used, both ACE and protein increased but enzyme specific activity did not change.	Bleomycin	21-30	angiotensin I converting enzyme	Rattus norvegicus	102-105
2465144-0	1988	Effect of murine gamma interferon on the cellular responses to bleomycin in mice.	Bleomycin	63-72	interferon gamma	Mus musculus	17-33
2465144-1	1988	Because in vitro studies have shown inhibition of fibroblast proliferation and collagen synthesis by interferon, we tested the hypothesis that murine gamma interferon inhibits bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	176-185	interferon gamma	Mus musculus	150-166
2465144-15	1988	These results suggest an inhibitory action of gamma interferon on collagen accumulation and fibroblast proliferation associated with lymphocyte accumulation in the lungs of mice following bleomycin administration.	Bleomycin	188-197	interferon gamma	Mus musculus	46-62
3435704-9	1987	Some tumours which were resistant to cis-platinum showed sensitivity to adriamycin and bleomycin, particularly those from untreated patients.	Bleomycin	87-96	cytokine inducible SH2 containing protein	Homo sapiens	37-40
2461572-0	1988	Metabolic inactivation of bleomycin analogs by bleomycin hydrolase.	Bleomycin	26-35	bleomycin hydrolase	Homo sapiens	47-66
2445468-2	1987	When cells were grown in complete medium with 10% fetal bovine serum, GRP78 mRNA was increased 4- to 9-fold in 3-methylcholanthrene (MCA; Clones 15 and 16)-, bleomycin (Bleo 1)-, and ultraviolet light (UV-C3)-transformed cell lines compared to nontransformed 10T1/2 clone 8 cells (Cl 8) at similar cell number and growth phase.	Bleomycin	158-167	heat shock protein 5	Mus musculus	70-75
2454874-2	1988	Two days after bleomycin treatment total lung SOD, CAT, and GSHP activities were significantly (p less than .025) depressed between 15 and 25%.	Bleomycin	15-24	catalase	Rattus norvegicus	51-54
2465537-1	1988	The DNase I footprinting analysis shows binding sites of approximately two or three base pairs, in particular 5"-XGC sequences, for the green-colored Co(III) and fully oxidized Fe(III) complexes of bleomycin (BLM).	Bleomycin	198-207	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	150-157
2465537-1	1988	The DNase I footprinting analysis shows binding sites of approximately two or three base pairs, in particular 5"-XGC sequences, for the green-colored Co(III) and fully oxidized Fe(III) complexes of bleomycin (BLM).	Bleomycin	198-207	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	153-156
2445468-2	1987	When cells were grown in complete medium with 10% fetal bovine serum, GRP78 mRNA was increased 4- to 9-fold in 3-methylcholanthrene (MCA; Clones 15 and 16)-, bleomycin (Bleo 1)-, and ultraviolet light (UV-C3)-transformed cell lines compared to nontransformed 10T1/2 clone 8 cells (Cl 8) at similar cell number and growth phase.	Bleomycin	169-173	heat shock protein 5	Mus musculus	70-75
2444216-0	1987	Bleomycin-detectable iron in knee-joint synovial fluid from arthritic patients and its relationship to the extracellular antioxidant activities of caeruloplasmin, transferrin and lactoferrin.	Bleomycin	0-9	transferrin	Homo sapiens	163-174
2446466-4	1987	Using selective inhibitors of DNA polymerases, it was shown that the DNA polymerase involved in the bleomycin-induced DNA synthesis was DNA polymerase beta.	Bleomycin	100-109	polymerase (DNA directed), beta	Mus musculus	136-155
2446466-5	1987	In addition to DNA polymerase beta, an exonuclease which converts bleomycin-damaged DNA into suitable template-primers for repair DNA synthesis appeared to be present in the permeable cell extract.	Bleomycin	66-75	polymerase (DNA directed), beta	Mus musculus	15-34
2447954-1	1987	The anti-tumor antibiotics neocarzinostatin and bleomycin specifically oxidize deoxyribose in DNA at the C-5" and C-4" positions, respectively.	Bleomycin	48-57	complement C5	Homo sapiens	105-108
2447954-1	1987	The anti-tumor antibiotics neocarzinostatin and bleomycin specifically oxidize deoxyribose in DNA at the C-5" and C-4" positions, respectively.	Bleomycin	48-57	complement C4A (Rodgers blood group)	Homo sapiens	114-117
2441682-9	1987	These results indicate that nuclear NADPH-cytochrome P-450 reductase redox cycles the bleomycin-Fe(III/II) complex and that the reduced complex activates oxygen, whereby hydroxyl radicals are formed which damage the deoxyribose of nuclear DNA.	Bleomycin	86-95	cytochrome p450 oxidoreductase	Homo sapiens	36-68
2440356-7	1987	Cleavage of 125I-labeled human factor X by BAL from bleomycin-challenged marmosets yielded a 55,500 Mr product that comigrated with factor Xa, the appearance of which correlated strongly with amidolytic evidence of factor Xa activity.	Bleomycin	52-61	coagulation factor X	Homo sapiens	132-141
2440356-7	1987	Cleavage of 125I-labeled human factor X by BAL from bleomycin-challenged marmosets yielded a 55,500 Mr product that comigrated with factor Xa, the appearance of which correlated strongly with amidolytic evidence of factor Xa activity.	Bleomycin	52-61	coagulation factor X	Homo sapiens	215-224
2433976-3	1987	In bleomycin-induced disease, the degree of lung disease was different in some of the different strains of mice and, in some strains, was related to H-2 locus genes since all strains with H-2b haplotypes were high responders, whereas most of the strains with H-2a, H-2d, and H-2k haplotypes were low responders.	Bleomycin	3-12	histocompatibility-2, MHC	Mus musculus	149-152
2436565-1	1987	The schedule-dependent effect of bleomycin (BLM) on human squamous cell carcinoma (SCC) was investigated using a xenografted SCC line originating from the head and neck region.	Bleomycin	33-42	serpin family B member 3	Homo sapiens	83-86
2445487-0	1987	Enhancement of interleukin-2 release in rats by treatment with bleomycin and adriamycin in vivo.	Bleomycin	63-72	interleukin 2	Rattus norvegicus	15-28
2445487-1	1987	Spleen cells from rats previously injected with bleomycin (10 mg/kg) or Adriamycin (1 mg/kg) were able to release higher levels of interleukin-2 (IL-2) than cells from untreated animals.	Bleomycin	48-57	interleukin 2	Rattus norvegicus	131-144
2445487-1	1987	Spleen cells from rats previously injected with bleomycin (10 mg/kg) or Adriamycin (1 mg/kg) were able to release higher levels of interleukin-2 (IL-2) than cells from untreated animals.	Bleomycin	48-57	interleukin 2	Rattus norvegicus	146-150
2448175-0	1987	Calmodulin antagonist W 13 prevents DNA repair after bleomycin treatment of human urological tumor cells growing on extracellular matrix.	Bleomycin	53-62	calmodulin 1	Homo sapiens	0-10
2462531-1	1987	When NADPH-cytochrome P-450 reductase isolated from rat liver microsomes was aerobically incubated with bleomycin, FeCl3, NADPH and DNA parallel NADPH and oxygen were consumed and malondialdehyde was formed.	Bleomycin	104-113	cytochrome p450 oxidoreductase	Rattus norvegicus	5-37
2462531-4	1987	This indicates that a nuclear NADPH-enzyme, presumably NADPH-cytochrome P-450 reductase, is able to redox cycle a bleomycin-iron-complex which in the reduced form can activate oxygen to a DNA-damaging reactive species.	Bleomycin	114-123	cytochrome p450 oxidoreductase	Rattus norvegicus	55-87
2441572-0	1987	Potentiation of sensitivity to bleomycin and the drug-induced DNA damage in EMT6 cells by the calmodulin inhibitor trifluoperazine.	Bleomycin	31-40	calmodulin 2	Mus musculus	94-104
2441572-1	1987	It has been shown that inhibitors of calmodulin can increase the sensitivity of rodent cells to Bleomycin by interfering with DNA repair functions.	Bleomycin	96-105	calmodulin 2	Mus musculus	37-47
2448175-6	1987	This lethal effect could be potentiated by the addition of calmodulin antagonist W-13 that prevents the repair of DNA strand breaks and DNA cross-links caused by bleomycin.	Bleomycin	162-171	calmodulin 1	Homo sapiens	59-69
2448255-4	1987	Cytotoxic antitumor agents of 5-fluorouracil (5-FU), cyclophosphamide (CY) and bleomycin (BLM) suppressed TNF production in mice primed with CP and challenged with LPS.	Bleomycin	79-88	tumor necrosis factor	Mus musculus	106-109
2431800-0	1986	Induction of rat liver O6-alkylguanine-DNA alkyltransferase by bleomycin.	Bleomycin	63-72	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	23-59
2432621-0	1986	Bleomycin enhances the tyrosinase activity of human malignant melanoma cells in culture.	Bleomycin	0-9	tyrosinase	Homo sapiens	23-33
2432621-2	1986	Therefore we investigated the effect of bleomycin on the tyrosinase activity.	Bleomycin	40-49	tyrosinase	Homo sapiens	57-67
2432621-4	1986	Incubation of pigmented human melanoma cells in the presence of bleomycin containing culture medium (1-100 ng/ml) at 37 degrees C for different periods of time resulted in a marked increase of tyrosinase activity.	Bleomycin	64-73	tyrosinase	Homo sapiens	193-203
2432621-12	1986	These results suggest that bleomycin is able to enhance tyrosinase activity in intact cell systems.	Bleomycin	27-36	tyrosinase	Homo sapiens	56-66
2430600-0	1986	Ameliorating effect of murine interferon gamma on bleomycin-induced lung collagen fibrosis in mice.	Bleomycin	50-59	interferon gamma	Mus musculus	30-46
2428481-1	1986	The O6-methylguanine-DNA-methyltransferase (methyltransferase) activity was determined in a rat hepatoma cell line after treatment with ultraviolet or gamma-irradiation, heat treatment, or incubation with cis-diamminedichloroplatinum(II),2-methyl-9-hydroxyellipticinium, or bleomycin.	Bleomycin	274-283	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	4-42
2428947-1	1986	Long-term follow-up results of two studies using cyclophosphamide, doxorubicin, vincristine, and prednisone plus bleomycin (CHOP-Bleo) for the treatment of diffuse large-cell lymphoma are presented.	Bleomycin	113-122	DNA damage inducible transcript 3	Homo sapiens	124-128
2429940-0	1986	Potentiation of release of interleukin-2 by bleomycin.	Bleomycin	44-53	interleukin 2	Rattus norvegicus	27-40
2429940-1	1986	The antineoplastic drug bleomycin, which has not been shown to have immunosuppressive activity, was tested for its effect on concanavalin A-induced interleukin-2 production.	Bleomycin	24-33	interleukin 2	Rattus norvegicus	148-161
2429940-3	1986	However, using a suboptimal dose of concanavalin A, bleomycin increased interleukin-2 release significantly.	Bleomycin	52-61	interleukin 2	Rattus norvegicus	72-85
2429940-7	1986	It is suggested that bleomycin, and probably other cytotoxic drugs, may modulate the immune response through its effects on the release of immunostimulating cytokines such as interleukin-1 and -2.	Bleomycin	21-30	interleukin 2	Rattus norvegicus	175-195
2426952-11	1986	Associated with this indication of macrophage stimulation was an increase in spontaneous macrophage production of fibroblast growth factor (MDGF) activity as a result of bleomycin instillation.	Bleomycin	170-179	pro-platelet basic protein	Mus musculus	140-144
2429553-0	1986	Effects of a calmodulin inhibitor on bleomycin-induced lung inflammation in hamsters.	Bleomycin	37-46	calmodulin 1	Homo sapiens	13-23
2429553-2	1986	Previous studies have shown that bleomycin-induced pulmonary fibrosis is accompanied by elevated levels of calcium and calmodulin, which are important in the regulation of many biologic processes.	Bleomycin	33-42	calmodulin 1	Homo sapiens	119-129
2429553-3	1986	The authors have further extended these observations and assessed the effect of a calmodulin inhibitor, trifluoperazine, on bleomycin-induced lung damage with biochemical, morphometric, and bronchoalveolar lavage techniques.	Bleomycin	124-133	calmodulin 1	Homo sapiens	82-92
2426952-13	1986	In contrast, bleomycin treatment caused a reduction in alveolar macrophage interleukin-1 (IL-1) production, and NDGA treatment did not alter this reduction, which suggests that MDGF is separate from IL-1 in this case, and that MDGF played a more dominant role, at least in this model of pulmonary fibrosis.	Bleomycin	13-22	interleukin 1 complex	Mus musculus	90-94
2426952-15	1986	The results of this study have thus demonstrated the importance of alveolar macrophage stimulation and increased production of MDGF in the pathogenesis of bleomycin-induced pulmonary fibrosis.	Bleomycin	155-164	pro-platelet basic protein	Mus musculus	127-131
2428790-0	1986	Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumor cells.	Bleomycin	15-24	calmodulin 2	Mus musculus	45-55
2430315-0	1986	The combined effect of bleomycin and irradiation on mouse lip mucosa.	Bleomycin	23-32	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	58-61
2425674-3	1986	The metal-free deamide metabolite of BLM, which is nontoxic, also inhibited ACE activity from bovine endothelial cell homogenates and serum.	Bleomycin	37-40	angiotensin I converting enzyme	Bos taurus	76-79
2424783-0	1986	The fibronectin content of canine lungs is increased in bleomycin-induced fibrosis.	Bleomycin	56-65	fibronectin 1	Canis lupus familiaris	4-15
2424783-6	1986	Lungs from beagles in which fibrosis had been induced with bleomycin contained 0.99% Fn, more than a twofold increase over normal.	Bleomycin	59-68	fibronectin 1	Canis lupus familiaris	85-87
2425674-4	1986	Incubation of intact cultured pulmonary artery endothelial cells for 1 h with metal-free BLM produced a concentration-dependent inhibition of cellular ACE activity, which was persistent, lasting at least 24 h after drug removal.	Bleomycin	89-92	angiotensin I converting enzyme	Bos taurus	151-154
2423656-4	1986	It is now appreciated that calmodulin antagonists are cytotoxic, can restore the sensitivity of resistant cells to drugs such as doxorubicin and vincristine, and can augment the cytotoxicity of bleomycin.	Bleomycin	194-203	calmodulin 1	Homo sapiens	27-37
2429519-0	1986	Oxygen radical formation during redox cycling of bleomycin-Fe(III) catalyzed by NADPH-cytochrome P-450 reductase of liver microsomes and nuclei.	Bleomycin	49-58	cytochrome p450 oxidoreductase	Homo sapiens	80-112
2426736-3	1986	The effect of the combination of single dose irradiation and bleomycin on the mucosa of the mouse lip was investigated.	Bleomycin	61-70	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	98-101
2421873-0	1986	Increased lethality of calmodulin antagonists and bleomycin to human bone marrow and bleomycin-resistant malignant cells.	Bleomycin	85-94	calmodulin 1	Homo sapiens	23-33
2421873-2	1986	A 1-h exposure to nontoxic concentrations of the calmodulin antagonists melittin (0.5 microM), pimozide (5 microM), and chlorpromazine (20 microM) increased the lethality of bleomycin to human ovarian carcinoma cells (SK-OV).	Bleomycin	174-183	calmodulin 1	Homo sapiens	49-59
2421873-4	1986	Maximum enhancement of bleomycin lethality by calmodulin antagonists was seen when the antagonist was present simultaneously with bleomycin rather than before or after bleomycin.	Bleomycin	23-32	calmodulin 1	Homo sapiens	46-56
2421873-4	1986	Maximum enhancement of bleomycin lethality by calmodulin antagonists was seen when the antagonist was present simultaneously with bleomycin rather than before or after bleomycin.	Bleomycin	130-139	calmodulin 1	Homo sapiens	46-56
2421873-4	1986	Maximum enhancement of bleomycin lethality by calmodulin antagonists was seen when the antagonist was present simultaneously with bleomycin rather than before or after bleomycin.	Bleomycin	130-139	calmodulin 1	Homo sapiens	46-56
2421873-7	1986	These results demonstrate that calmodulin antagonists can significantly increase the lethality of bleomycin to some but not all human tumor cells and that nonmalignant hematological human cells may also be affected by this combination.	Bleomycin	98-107	calmodulin 1	Homo sapiens	31-41
2418860-2	1986	Evidence in the literature suggests that hyperthermia (HT) or inhibitors of calmodulin can increase the sensitivity of rodent cells to bleomycin (BLM) by interfering with DNA repair functions.	Bleomycin	135-144	calmodulin 2	Mus musculus	76-86
2439200-10	1986	Bleomycin hydrolase activity is low in lungs and skin, the two major sites of normal tissue toxicities, and levels of this enzyme have been elevated in some but not all tumour cell lines selected for resistance to bleomycin.	Bleomycin	214-223	bleomycin hydrolase	Homo sapiens	0-19
2418156-1	1985	After intravenous injection of therapeutic doses of bleomycin only small amounts could be measured in glioma tissue obtained at operation in patients with malignant gliomas and the drug was rapidly cleared from the blood (T1/2 = 2 hrs).	Bleomycin	52-61	interleukin 1 receptor like 1	Homo sapiens	222-230
2417511-5	1986	We report that alveolar lavage fluid obtained following acute lung injury induced by bleomycin in the rat contains large amounts of soluble growth factor activity not found in lung lavage fluid from normal animals.	Bleomycin	85-94	myotrophin	Rattus norvegicus	140-153
2415693-7	1985	Compared to our previous study using cisplatin-vincristine-bleomycin (COB) chemotherapy, our present regimen has a higher CR rate (P less than .008).	Bleomycin	59-68	metabolism of cobalamin associated B	Homo sapiens	70-73
2417738-8	1986	Inhibitor studies suggested that DNA polymerase alpha plays a preferential role in repair label in the intranucleosomal region of nuclear chromatin and DNA polymerase beta in the completion of repair patches in bleomycin-pretreated permeable cells.	Bleomycin	211-220	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	33-53
2417738-8	1986	Inhibitor studies suggested that DNA polymerase alpha plays a preferential role in repair label in the intranucleosomal region of nuclear chromatin and DNA polymerase beta in the completion of repair patches in bleomycin-pretreated permeable cells.	Bleomycin	211-220	DNA polymerase beta	Homo sapiens	152-171
2412562-0	1985	Oxy radical formation during redox cycling of the bleomycin-iron (III) complex by NADPH-cytochrome P-450 reductase.	Bleomycin	50-59	cytochrome p450 oxidoreductase	Rattus norvegicus	82-114
2413849-0	1985	Bleomycin selectively elevates mRNA levels for procollagen and fibronectin following acute lung injury.	Bleomycin	0-9	fibronectin 1	Rattus norvegicus	63-74
2413849-3	1985	Individual mRNAs for procollagens I and III and for fibronectin were selectively enriched 2- to 4-fold above total RNA during the first week after bleomycin instillation.	Bleomycin	147-156	fibronectin 1	Rattus norvegicus	52-63
2412562-1	1985	Bleomycin was aerobically incubated with FeCl3, NADPH, isolated rat-liver microsomal cytochrome P-450 reductase and methional.	Bleomycin	0-9	cytochrome p450 oxidoreductase	Rattus norvegicus	85-111
2412562-6	1985	These results indicate that oxy radicals are formed after reduction of the bleomycin-Fe-complex by NADPH-cytochrome P-450 reductase.	Bleomycin	75-84	cytochrome p450 oxidoreductase	Rattus norvegicus	99-131
2579442-8	1985	Among patients who have multiple resistance to drugs such as vinblastine, bleomycin, and cis-platinum, 50% have achieved remission when treated with the EP/OMB schedule (VP-16 and cis-platinum alternated with vincristine, methotrexate, and bleomycin) repeated at short intervals.	Bleomycin	74-83	host cell factor C1	Homo sapiens	170-175
2409975-0	1985	Catalase enhances damage to DNA by bleomycin-iron(II): the role of hydroxyl radicals.	Bleomycin	35-44	catalase	Homo sapiens	0-8
2579318-0	1985	Enhanced bleomycin-induced DNA damage and cytotoxicity with calmodulin antagonists.	Bleomycin	9-18	calmodulin 2	Mus musculus	60-70
2579318-1	1985	A wide variety of structurally different calmodulin antagonists enhanced the cytotoxicity of bleomycin A2 to leukemic L1210 cells.	Bleomycin	93-105	calmodulin 2	Mus musculus	41-51
2579318-3	1985	The most potent blockers of L1210 calmodulin activity, melittin and mastoparan, were the most potent potentiators of bleomycin A2 cytotoxicity.	Bleomycin	117-129	calmodulin 2	Mus musculus	34-44
2412886-0	1985	Poly(ADP-ribose) synthetase activity during bleomycin-induced lung fibrosis in hamsters.	Bleomycin	44-53	poly(ADP-ribose) polymerase 1	Homo sapiens	0-27
2409069-6	1985	Furthermore, activities of catalase and superoxide dismutase in lung homogenates were higher than control and were further augmented by exposure to 100% O2 for 64 h. These biochemical changes may account, at least in part, for the mitigation of the toxic effects of hyperoxia, as shown by the delayed appearance of arterial hypoxemia, and the 50% increase in survival time when bleomycin injected rabbits were exposed to 100% O2 35 days postinjection.	Bleomycin	378-387	catalase	Oryctolagus cuniculus	27-35
2579845-1	1985	In the present study, the effects of intratracheal administration of bleomycin have been examined on daily food intake and on plasma levels of glucose, cortisol, and insulin, and on lung levels of calmodulin, calcium, and collagen in hamsters.	Bleomycin	69-78	insulin	Homo sapiens	166-173
3880810-2	1985	CBP (cyclophosphamide, bleomycin, and cisplatin) and AFP (doxorubicin, 5-fluorouracil, and cisplatin) had shown activity in generation II of this study (EST 2575).	Bleomycin	23-32	CREB binding protein	Homo sapiens	0-3
2425386-0	1985	Reduction of vanadate by some psychotropic drugs (chlorpromazine, imipramine and dosulepin) and the effect of bleomycine on Na, K-ATPase.	Bleomycin	110-120	dynein axonemal heavy chain 8	Homo sapiens	130-136
2578174-0	1985	Secretion of macrophage-derived growth factor during acute lung injury induced by bleomycin.	Bleomycin	82-91	myotrophin	Rattus norvegicus	32-45
2578174-4	1985	Growth factor activity secreted in 24 h by untreated macrophages was compared to that from normal macrophages stimulated in vitro by bacterial lipopolysaccharide (LPS) and from macrophages retrieved from lungs injured by intratracheal administration of bleomycin.	Bleomycin	253-262	myotrophin	Rattus norvegicus	0-13
2425386-2	1985	Bleomycine forms an (inactive) complex with +4V which may explain the disinhibition of the brain microsomal Na+-K+ ATPase in the presence of vanadyl.	Bleomycin	0-10	dynein axonemal heavy chain 8	Homo sapiens	115-121
6209143-0	1984	Angiotensin-converting enzyme: an indicator of bleomycin-induced pulmonary toxicity in humans?	Bleomycin	47-56	angiotensin I converting enzyme	Homo sapiens	0-29
6084519-0	1984	Bleomycin may be activated for DNA cleavage by NADPH-cytochrome P-450 reductase.	Bleomycin	0-9	cytochrome p450 oxidoreductase	Homo sapiens	47-79
6084519-1	1984	In the presence of NADPH and O2, NADPH-cytochrome P-450 reductase was found to activate Fe(III)-bleomycin A2 for DNA strand scission.	Bleomycin	96-108	cytochrome p450 oxidoreductase	Homo sapiens	33-65
6084519-2	1984	Consistent with observations made previously when cccDNA was incubated in the presence of bleomycin and Fe(II) + O2 or Fe(III) + C6H5IO, degradation of DNA by NADPH-cytochrome P-450 reductase activated Fe(III)-bleomycin A2 produced both single- and double-strand nicks with concomitant formation of malondialdehyde (precursors).	Bleomycin	90-99	cytochrome p450 oxidoreductase	Homo sapiens	159-191
6084519-2	1984	Consistent with observations made previously when cccDNA was incubated in the presence of bleomycin and Fe(II) + O2 or Fe(III) + C6H5IO, degradation of DNA by NADPH-cytochrome P-450 reductase activated Fe(III)-bleomycin A2 produced both single- and double-strand nicks with concomitant formation of malondialdehyde (precursors).	Bleomycin	210-222	cytochrome p450 oxidoreductase	Homo sapiens	159-191
6209387-1	1984	The metabolism of bleomycin (BLM) A2 by BLM hydrolase in the 105,000 X g supernatant fraction of homogenates obtained from freshly isolated and cultured pulmonary cells was assayed by high-pressure liquid chromatography.	Bleomycin	18-27	lethal (2) 34Fc	Drosophila melanogaster	34-36
6203171-0	1984	Potentiation of bleomycin lethality by anticalmodulin drugs: a role for calmodulin in DNA repair.	Bleomycin	16-25	LOC100759184	Cricetulus griseus	43-53
6208427-2	1984	We have found a new 111In-bleomycin complex (BLMC), which has high affinity to tumor, does not bind to transferrin and is stable in vivo.	Bleomycin	26-35	transferrin	Homo sapiens	103-114
6209573-3	1984	The action of beta-aminoethylisothiouronium bromide hydrobromide (AET) and sodium fluoride (NaF) on the clastogenic activity of Trenimon, cyclophosphamide, and bleomycin was tested on cultures of human peripheral lymphocytes with and without the addition of rat liver S9 mix.	Bleomycin	160-169	C-X-C motif chemokine ligand 8	Homo sapiens	92-95
6199445-0	1984	Measurement of cross-linked elastin synthesis in bleomycin-induced pulmonary fibrosis using a highly sensitive assay for desmosine and isodesmosine.	Bleomycin	49-58	elastin	Homo sapiens	28-35
6199445-1	1984	Cross-linked elastin synthesis was measured in the intratracheal bleomycin model of interstitial pulmonary fibrosis by incorporation of 14C-lysine into the elastin-specific crosslinks, desmosine and isodesmosine.	Bleomycin	65-74	elastin	Homo sapiens	13-20
6199445-3	1984	The results indicate that crosslinked elastin synthesis is significantly elevated from controls (p less than 0.05) at 1 to 3 weeks after exposure to bleomycin and returns to normal by 5 weeks.	Bleomycin	149-158	elastin	Homo sapiens	38-45
6199872-3	1984	Superoxide dismutase (SOD) significantly inhibited bleomycin-mediated DNA deoxyribose cleavage, indicating the involvement of reactive oxygen.	Bleomycin	51-60	superoxide dismutase 1	Homo sapiens	0-20
6199872-3	1984	Superoxide dismutase (SOD) significantly inhibited bleomycin-mediated DNA deoxyribose cleavage, indicating the involvement of reactive oxygen.	Bleomycin	51-60	superoxide dismutase 1	Homo sapiens	22-25
6193871-1	1983	Bleomycin, vincristine, or mitomycin C, when added to HeLa cells simultaneously with human fibroblast interferon (IFN-beta), caused a decrease in cell density and inhibited DNA synthesis compared with HeLa cells treated with IFN-beta alone.	Bleomycin	0-9	interferon beta 1	Homo sapiens	114-122
6193871-1	1983	Bleomycin, vincristine, or mitomycin C, when added to HeLa cells simultaneously with human fibroblast interferon (IFN-beta), caused a decrease in cell density and inhibited DNA synthesis compared with HeLa cells treated with IFN-beta alone.	Bleomycin	0-9	interferon beta 1	Homo sapiens	225-233
6193871-3	1983	HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase.	Bleomycin	76-85	interferon beta 1	Homo sapiens	24-32
6193871-3	1983	HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase.	Bleomycin	76-85	interferon beta 1	Homo sapiens	47-55
6195486-1	1983	A clinical picture compatible with the syndrome of inappropriate ADH (antidiuretic hormone) secretion was observed in two patients receiving vinblastine-bleomycin chemotherapy.	Bleomycin	153-162	arginine vasopressin	Homo sapiens	70-90
6195772-1	1983	Intratracheal administration of one unit of bleomycin increased significantly the glucose-6-phosphate dehydrogenase activity to 147, 135, 163, 207, 278, and 148% of the control at 1, 2, 4, 7, 14, and 21 days post-treatment, respectively.	Bleomycin	44-53	glucose-6-phosphate dehydrogenase	Homo sapiens	82-115
6191410-0	1983	Prolonged reduction in serum angiotensin converting enzyme activity after treatment of rabbits with bleomycin.	Bleomycin	100-109	angiotensin-converting enzyme	Oryctolagus cuniculus	29-58
6191410-6	1983	217, 524-529, 1981) demonstrated that subacute bleomycin (BLM) administration (5 mg/kg) to rabbits three times weekly for 4 weeks produced a marked decrease in serum angiotensin converting enzyme (ACE) activity in addition to producing both morphological and biochemical evidence of pulmonary endothelial damage.	Bleomycin	47-56	angiotensin-converting enzyme	Oryctolagus cuniculus	166-195
6191410-6	1983	217, 524-529, 1981) demonstrated that subacute bleomycin (BLM) administration (5 mg/kg) to rabbits three times weekly for 4 weeks produced a marked decrease in serum angiotensin converting enzyme (ACE) activity in addition to producing both morphological and biochemical evidence of pulmonary endothelial damage.	Bleomycin	47-56	angiotensin-converting enzyme	Oryctolagus cuniculus	197-200
6191410-6	1983	217, 524-529, 1981) demonstrated that subacute bleomycin (BLM) administration (5 mg/kg) to rabbits three times weekly for 4 weeks produced a marked decrease in serum angiotensin converting enzyme (ACE) activity in addition to producing both morphological and biochemical evidence of pulmonary endothelial damage.	Bleomycin	58-61	angiotensin-converting enzyme	Oryctolagus cuniculus	166-195
6191410-6	1983	217, 524-529, 1981) demonstrated that subacute bleomycin (BLM) administration (5 mg/kg) to rabbits three times weekly for 4 weeks produced a marked decrease in serum angiotensin converting enzyme (ACE) activity in addition to producing both morphological and biochemical evidence of pulmonary endothelial damage.	Bleomycin	58-61	angiotensin-converting enzyme	Oryctolagus cuniculus	197-200
6192687-2	1983	Unscheduled, i.e., repair, DNA synthesis in rat liver nuclei, and in bleomycin-treated permeable SR-C3H/He and XC cells was mostly attributed to DNA polymerase beta.	Bleomycin	69-78	DNA polymerase beta	Rattus norvegicus	145-164
6831444-3	1983	The UV-2237-ADMR line also exhibited increased resistance to N-trifluoroacetyladriamycin-24-valerate, daunorubicin, actinomycin D, amsacrine, mitomycin C, vinblastine, and vincristine but not to bleomycin.	Bleomycin	195-204	G protein-coupled receptor 182	Mus musculus	12-16
6191677-6	1983	A major complication during CHOP-Bleo regimen was myelosuppression, and peripheral neuropathy and reversible interstitial pneumonitis (2 cases) were also observed.	Bleomycin	33-37	DNA damage inducible transcript 3	Homo sapiens	28-32
6188468-0	1983	Photolabelling of dopamine-beta-hydroxylase by bleomycin.	Bleomycin	47-56	dopamine beta-hydroxylase	Homo sapiens	18-43
6189659-5	1983	In patients treated with the vinblastine and bleomycin regimen, plasma retinol levels were higher at the beginning of the fourth course than at the start of the treatment, possibly due to improved synthesis of RBP.	Bleomycin	45-54	retinol binding protein 4	Homo sapiens	210-213
6199058-4	1983	Bleomycin is a strong, reversible inhibitor of the enzyme, dopamine beta-hydroxylase (EC 1.14.17.1) in the dark.	Bleomycin	0-9	dopamine beta-hydroxylase	Homo sapiens	59-84
6317371-4	1983	However, for a number of these drugs, namely adriamycin, daunomycin, bleomycin, and dacarbazine, which are only weakly mutagenic at the HGPRT locus, a relatively strong and clear mutagenic response was observed at the AK locus.	Bleomycin	69-78	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	136-141
6317371-4	1983	However, for a number of these drugs, namely adriamycin, daunomycin, bleomycin, and dacarbazine, which are only weakly mutagenic at the HGPRT locus, a relatively strong and clear mutagenic response was observed at the AK locus.	Bleomycin	69-78	adenosine kinase	Cricetulus griseus	218-220
6186274-2	1982	Co(II) interacts with bleomycin in aqueous solution, in the presence of air, to give a short-lived mononuclear superoxo Co(III) complex (I).	Bleomycin	22-31	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-6
6203548-4	1984	The most pronounced effect was observed when BLM was given 2 h before irradiation (DEF = 2.40), at which interval the D0 surprisingly increased by a factor of 1.4.	Bleomycin	45-48	proline-serine-threonine phosphatase-interacting protein 1	Mus musculus	83-90
6539305-4	1984	Three patterns of response were observed with the VP16 -213-resistant cells showing: marked cross-resistance to vincristine and teniposide , collateral sensitivity to 5- fluorouracil , hydroxyurea and cis-platinum, and comparable responses to the parent line for adriamycin, bleomycin, dibromodulcitol and methotrexate.	Bleomycin	275-284	host cell factor C1	Homo sapiens	50-54
6203752-4	1984	Only one elevated CEA level after chemotherapy was associated with bleomycin pneumonitis.	Bleomycin	67-76	CEA cell adhesion molecule 3	Homo sapiens	18-21
6715418-6	1984	They were also slightly more resistant to other unrelated drugs such as adriamycin, colchicine, bleomycin, and chloroquine, and in particular, they showed about threefold higher resistance to ricin, a toxin of Ricinus communis.	Bleomycin	96-105	ricin	Ricinus communis	192-197
6201676-9	1984	Endotracheal bleomycin administration alone caused significant reductions in catalase activity at 2 days and 2 weeks after treatment, whereas glutathione peroxidase activity increased above control untreated animals at 2 and 4 weeks, respectively.	Bleomycin	13-22	catalase	Homo sapiens	77-85
6201676-13	1984	Catalase also was higher in the LPS plus bleomycin group (by 22.2%, p less than 0.05) than the bleomycin group alone.	Bleomycin	41-50	catalase	Homo sapiens	0-8
6201676-13	1984	Catalase also was higher in the LPS plus bleomycin group (by 22.2%, p less than 0.05) than the bleomycin group alone.	Bleomycin	95-104	catalase	Homo sapiens	0-8
6200138-4	1984	Scavengers of hydrogen peroxide and hydroxyl radicals, including catalase and benzoate and inhibitors of microsomal cytochrome P-450-dependent monooxygenases such as 1-benzylimidazole, metyrapone and alpha-naphthoflavone, had no inhibitory effects on bleomycin-mediated DNA chain breakage.	Bleomycin	251-260	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	116-132
6202656-5	1984	It is suggested that the potentiating effect of bleomycin is not on suppressor cell function, as with cyclophosphamide, but might have an effect on local interleukin 2 production, particularly if given when T-cell proliferation is on the increase.	Bleomycin	48-57	interleukin-2	Cavia porcellus	154-167
6085803-6	1984	For Co-57- and Co-55 bleomycin the somatically effective doses are 0.26 +/- 0.03 rad/mCi (70 +/- 9 mu Gy/MBq) and 0.63 +/- 0.09 rad/mCi (171 +/- 23 mu Gy/MBq), respectively.	Bleomycin	21-30	multiciliate differentiation and DNA synthesis associated cell cycle protein	Mus musculus	85-98
6200777-1	1984	Bleomycin was found to be cytotoxic and mutagenic in the CHO/HGPRT forward mutation assay.	Bleomycin	0-9	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	61-66
6193871-5	1983	These results indicate that, under these experimental conditions, the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase and protein kinase can be induced by IFN-beta in cells treated with bleomycin, vincristine, or mitomycin C.	Bleomycin	234-243	interferon beta 1	Homo sapiens	203-211
6193871-8	1983	The possibility that IFN-beta potentiates the cytotoxic effects of bleomycin and mitomycin C on HeLa cells is also discussed.	Bleomycin	67-76	interferon beta 1	Homo sapiens	21-29
6192486-3	1983	Current studies of cisplatin and bleomycin, which have been used together in clinical practice, revealed a significant alteration in the profile of RBC morphology; specifically a reduction in the number of "bowl" shaped cells.	Bleomycin	33-42	RNA, 7SL, cytoplasmic 263, pseudogene	Homo sapiens	148-151
6411709-5	1983	At high doses of damage, the fraction of repair synthesis mediated by DNA polymerase alpha reaches a maximal level which is dependent on the damaging agent; the maximal level of polymerase alpha involvement is about 80% for UV radiation and N-acetoxy-2-acetylaminofluorene, about 70% for N-methyl-N-nitrosourea, and about 40% for bleomycin.	Bleomycin	330-339	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	70-90
6191604-0	1983	Changes in plasma concentrations of prostaglandins and plasma angiotensin-converting enzyme during bleomycin-induced lung fibrosis in hamsters.	Bleomycin	99-108	angiotensin I converting enzyme	Homo sapiens	62-91
6188571-3	1983	After intravenous bolus, bleomycin concentrations were adequately described by a two-compartment open model with a mean t1/2 alpha and t1/2 beta of 0.3 +/- 0.1 and 3.2 +/- 0.7 hr (mean +/- SEM).	Bleomycin	25-34	interleukin 1 receptor like 1	Homo sapiens	120-165
6189041-0	1983	Long-term results of patients with advanced diffuse, non-Hodgkin"s lymphoma treated with cyclophosphamide, doxorubicin, vincristine, prednisone and bleomycin (CHOP-Bleo).	Bleomycin	148-157	DNA damage inducible transcript 3	Homo sapiens	159-163
6185218-1	1982	Incubation of supercoiled plasmid DNA (both pBR 322 and pPLC-28) with increasing concentrations of bleomycin in the presence and absence of light (300-350 nm) showed extensive conversion of supercoiled to linear DNA which occurred at much lower levels of bleomycin (BLM) in the light than in the dark.	Bleomycin	99-108	translocator protein	Homo sapiens	44-47
6179928-0	1982	cdc9 ligase-defective mutants of Saccharomyces cerevisiae exhibit lowered resistance to lethal effects of bleomycin.	Bleomycin	106-115	DNA ligase (ATP) CDC9	Saccharomyces cerevisiae S288C	0-4
6179928-1	1982	Conditional ligase-deficient mutants of Saccharomyces cerevisiae were more sensitive than their parental (CDC9) strain to dose-dependent killing by bleomycin, even when mutant cells were pregrown and exposed to the antibiotic at permissive temperatures.	Bleomycin	148-157	DNA ligase (ATP) CDC9	Saccharomyces cerevisiae S288C	106-110
6179928-2	1982	Pretreatment incubation at the restrictive temperature (37 degrees C) under growing or nongrowing conditions enhanced bleomycin killing of both cdc9-1 and cdc9-9 mutants.	Bleomycin	118-127	GPI-anchor transamidase subunit GAB1	Saccharomyces cerevisiae S288C	144-161
7152202-4	1982	In combinations of Hu IFN-alpha with anticancer agents such as bleomycin, mitomycin C, and cytosine arabinoside in certain concentration ranges, antagonism was noticed when Hu IFN-alpha and anticancer agents were added simultaneously to the cell culture.	Bleomycin	63-72	interferon alpha 1	Homo sapiens	22-31
7152202-4	1982	In combinations of Hu IFN-alpha with anticancer agents such as bleomycin, mitomycin C, and cytosine arabinoside in certain concentration ranges, antagonism was noticed when Hu IFN-alpha and anticancer agents were added simultaneously to the cell culture.	Bleomycin	63-72	interferon alpha 1	Homo sapiens	176-185
6186997-0	1982	[Results of treatment of the lymphoblastic and immunoblastic malignant lymphomas using the CHOP-bleo protocol (cyclophosphamide, doxorubicin, vincristine, bleomycin and prednisolone)].	Bleomycin	96-100	DNA damage inducible transcript 3	Homo sapiens	91-95
6179448-1	1982	A new multiple-drug protocol consisting of cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine, known as COP-BLAM, was administered to 48 patients with stage III or IV diffuse histiocytic lymphoma.	Bleomycin	86-95	caspase recruitment domain family member 16	Homo sapiens	137-140
6185388-2	1982	Neo-enactin markedly potentiated the action of the antitumor agents bleomycin and vincristine in vitro.	Bleomycin	68-77	nidogen 1	Homo sapiens	4-11
6177398-1	1982	Computer analyses of DNA sequencing data obtained using various restriction fragments of pBR 322 DNA indicate that a trinucleotide sequence (-Pyr-G-C-) is the most preferred site for cleavage by the antitumor antibiotic bleomycin A2.	Bleomycin	220-229	translocator protein	Homo sapiens	89-92
6185218-2	1982	Preliminary results indicate that superoxide dismutase (SOD) may offer DNA more protection against bleomycin in the dark than in the light conditions.	Bleomycin	99-108	superoxide dismutase 1	Homo sapiens	34-54
6185218-2	1982	Preliminary results indicate that superoxide dismutase (SOD) may offer DNA more protection against bleomycin in the dark than in the light conditions.	Bleomycin	99-108	superoxide dismutase 1	Homo sapiens	56-59
6174223-1	1982	We have investigated the site-specific cleavage of DNA by the antitumor antibiotics talisomycin and bleomycin by using 5"- or 3"-terminal 32P-labeled restriction fragments of pBR 322 DNA.	Bleomycin	100-109	translocator protein	Homo sapiens	175-178
6174227-1	1982	A unique DNA-binding protein was detected that inhibited DNA degradation induced by bleomycin and was decreased in sera of cancer patients.	Bleomycin	84-93	zinc finger protein 763	Homo sapiens	9-28
6174228-2	1982	This report gives the results of assays of sera from patients for the bleomycin inhibitor protein (BIP) using the Pseudomonas bacteriophage covalently closed circular DNA fluorescence technique standardized for DNA breakage induced by bleomycin.	Bleomycin	70-79	heat shock protein family A (Hsp70) member 5	Homo sapiens	99-102
6176245-0	1982	Possible involvement of DNA polymerases alpha and beta in bleomycin-induced unscheduled DNA synthesis in permeable HeLa cells.	Bleomycin	58-67	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	24-45
6177438-8	1982	This case suggest that VP16-213 combined with bleomycin + cis-platinum has great activity against NSGCT of the testis and may have a different spectrum of activity from vinblastine, bleomycin, and cis-platinum, making it a valuable addition to the drugs available for the management of these tumours.	Bleomycin	182-191	host cell factor C1	Homo sapiens	23-27
6184252-2	1982	Effects of various OH scavengers, superoxide dismutase and catalase on the formation of malondialdehyde-like products from DNA by bleomycin-Fe2+ were studied.	Bleomycin	130-139	catalase	Homo sapiens	59-67
6171347-0	1981	Inhibition of bleomycin-induced DNA breakage by superoxide dismutase.	Bleomycin	14-23	superoxide dismutase 1	Homo sapiens	48-68
6171347-1	1981	Inhibition of bleomycin (BLM)-induced DNA breakage by superoxide dismutase (SOD) has been reported and presumed to be due to its removal of the superoxide free radicals generated by BLM in the presence of iron(II).	Bleomycin	14-23	superoxide dismutase 1	Homo sapiens	54-74
6171347-1	1981	Inhibition of bleomycin (BLM)-induced DNA breakage by superoxide dismutase (SOD) has been reported and presumed to be due to its removal of the superoxide free radicals generated by BLM in the presence of iron(II).	Bleomycin	14-23	superoxide dismutase 1	Homo sapiens	76-79
6171347-1	1981	Inhibition of bleomycin (BLM)-induced DNA breakage by superoxide dismutase (SOD) has been reported and presumed to be due to its removal of the superoxide free radicals generated by BLM in the presence of iron(II).	Bleomycin	25-28	superoxide dismutase 1	Homo sapiens	54-74
6171347-1	1981	Inhibition of bleomycin (BLM)-induced DNA breakage by superoxide dismutase (SOD) has been reported and presumed to be due to its removal of the superoxide free radicals generated by BLM in the presence of iron(II).	Bleomycin	25-28	superoxide dismutase 1	Homo sapiens	76-79
6174345-3	1981	Biochemical analyses showed bleomycin treatment caused marked increases in the total amounts of RNA, DNA, mixed protein, collagen and elastin when compared to controls (P less than 0.001 in all cases).	Bleomycin	28-37	elastin	Oryctolagus cuniculus	134-141
6170751-0	1981	Collagen lysyl oxidase activity in the lung increases during bleomycin-induced lung fibrosis.	Bleomycin	61-70	lysyl oxidase	Rattus norvegicus	9-22
6170751-7	1981	Lysyl oxidase specific activity in the lung was elevated significantly 3 days after bleomycin treatment, peaked 14 days after bleomycin treatment at 230% above the control value and was returned toward normal 28 days after treatment.	Bleomycin	84-93	lysyl oxidase	Rattus norvegicus	0-13
6170751-7	1981	Lysyl oxidase specific activity in the lung was elevated significantly 3 days after bleomycin treatment, peaked 14 days after bleomycin treatment at 230% above the control value and was returned toward normal 28 days after treatment.	Bleomycin	126-135	lysyl oxidase	Rattus norvegicus	0-13
6170751-8	1981	The increase of lysyl oxidase activity preceded the maximal increase of total lung hydroxyproline and desmosine which occurred 28 days after bleomycin instillation.	Bleomycin	141-150	lysyl oxidase	Rattus norvegicus	16-29
6171284-0	1981	Mononuclear and binuclear Co(III)-dioxygen adducts of bleomycin.	Bleomycin	54-63	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	26-33
6171276-0	1981	Inhibition of DNA polymerase alpha by bleomycin.	Bleomycin	38-47	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	14-34
6169729-7	1981	The addition of dexamethasone (0.1 microM) and bleomycin (1 microgram/ml) increased soluble elastin production by cultured cells 180% and 50%, respectively, whereas theophylline (5 micrograms/ml) depressed production 50% and antagonized stimulation by dexamethasone.	Bleomycin	47-56	elastin	Bos taurus	92-99
6169344-0	1981	Bleomycin-resistant cells contain increased bleomycin-hydrolase activities.	Bleomycin	0-9	bleomycin hydrolase	Homo sapiens	44-63
6167026-0	1981	Angiotensin converting enzyme activity in mice after subacute bleomycin administration.	Bleomycin	62-71	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	0-29
6164390-1	1981	We have studied the Cu(II), Co(II), and Fe(III) complexes of the antineoplastic drug bleomycin by using electron spin--echo envelope spectroscopy.	Bleomycin	85-94	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	28-33
6165918-0	1981	[A case of alpha-fetoprotein producing primary intracranial embryonal carcinoma treated with combination chemotherapy with cis-platinum, vinblastine and bleomycin (author"s transl)].	Bleomycin	153-162	alpha fetoprotein	Homo sapiens	11-28
6165918-21	1981	It was emphasized that the combination chemotherapy with cis-platinum, vinblastine and bleomycin is effective remission-induction treatment for AFP producing primary intracranial embryonal carcinoma.	Bleomycin	87-96	alpha fetoprotein	Homo sapiens	144-147
6157067-0	1980	Combination of cis-platinum, oncovin, and bleomycin (COB) prior to surgery and/or radiotherapy in advanced untreated epidermoid cancer of the head and neck.	Bleomycin	42-51	metabolism of cobalamin associated B	Homo sapiens	53-56
6165056-0	1981	Current status of PEP bleomycin studies in Japan.	Bleomycin	22-31	progestagen associated endometrial protein	Homo sapiens	18-21
6162468-0	1980	Characterisation of guanidino-containing antibiotics: field desorption mass spectrometry of bleomycin B2 and phleomycins D1 and E.	Bleomycin	92-101	immunoglobulin kappa variable 5-2	Homo sapiens	102-129
6159967-0	1980	Assessment of bleomycin lung toxicity using angiotensin-converting enzyme in pulmonary lavage.	Bleomycin	14-23	angiotensin I converting enzyme	Rattus norvegicus	44-73
6159967-1	1980	Activity of the dipeptidyl hydrolase angiotensin-converting enzyme has been observed to be altered by treatment with bleomycin.	Bleomycin	117-126	angiotensin I converting enzyme	Rattus norvegicus	37-66
6159967-3	1980	Serum activity of angiotensin-converting enzyme increased only 23% after a single intratracheal instillation of bleomycin.	Bleomycin	112-121	angiotensin I converting enzyme	Rattus norvegicus	18-47
6159967-5	1980	However, angiotensin-converting enzyme activity in alveolar lavage fluid from bleomycin-treated rats was elevated 30-fold above the barely detectable levels found in control animals.	Bleomycin	78-87	angiotensin I converting enzyme	Rattus norvegicus	9-38
6159967-7	1980	Maximum elevation of lavage angiotensin-converting enzyme activity occurred 3 days following bleomycin instillation.	Bleomycin	93-102	angiotensin I converting enzyme	Rattus norvegicus	28-57
6159967-10	1980	Elevated lavage angiotensin-converting enzyme levels were detected after doses of bleomycin too low to cause significant sequelae of pulmonary fibrosis.	Bleomycin	82-91	angiotensin I converting enzyme	Rattus norvegicus	16-45
6159967-11	1980	Lavage angiotensin-converting enzyme is a sensitive monitor of tissue response to bleomycin.	Bleomycin	82-91	angiotensin I converting enzyme	Rattus norvegicus	7-36
6157425-0	1980	Bleomycin-induced synthesis of type I procollagen by human lung and skin fibroblasts in culture.	Bleomycin	0-9	collagen type I alpha 2 chain	Homo sapiens	31-49
6157425-8	1980	The results indicate that the increased procollagen synthesis induced by bleomycin in fibroblast cultures is predominantly directed towards the synthesis of type I procollagen.	Bleomycin	73-82	collagen type I alpha 2 chain	Homo sapiens	157-175
6155927-7	1980	Intermittent bolus bleomycin at 8 u.kg/day had a terminal-phase plasma t1/2 of 15 min and a total 6-day plasma AUC of 90.8mu.h/ml.	Bleomycin	19-28	interleukin 1 receptor like 1	Homo sapiens	71-81
6157665-0	1980	Inhibition of dopamine-beta-hydroxylase, A copper enzyme, by bleomycin.	Bleomycin	61-70	dopamine beta-hydroxylase	Homo sapiens	14-39
6157665-1	1980	Bleomycin was found to be one of the most potent inhibitors of dopamine-beta-hydroxylase.	Bleomycin	0-9	dopamine beta-hydroxylase	Homo sapiens	63-88
63157-3	1976	Gamma rays and 2 low doses of bleomycin gave rise to typical reproductive death in generations 1 and 2 but 100 mug of the drug produced frequent interphase death.	Bleomycin	30-39	tryptophanyl-tRNA synthetase 1	Homo sapiens	0-16
6153927-2	1980	This fact implies a peculiar response to (BLM) treatment with Bleomycin, a drug which appears to be proliferation-dependent.	Bleomycin	62-71	Bloom syndrome, RecQ like helicase	Mus musculus	42-45
6153149-0	1980	Combination chemotherapy with cis-diamminedichloroplatinum, oncovin, and bleomycin (COB) in advanced head and neck cancer: phase II.	Bleomycin	73-82	metabolism of cobalamin associated B	Homo sapiens	84-87
89110-8	1979	Elastin accumulated in the lower lobes of the irradiated animals through compensatory growth and in the bleomycin-associated lungs through excessive production.	Bleomycin	104-113	elastin	Papio anubis	0-7
76454-0	1978	Increased elastin and collagen content in the lungs of hamsters receiving an intratracheal injection of bleomycin.	Bleomycin	104-113	elastin	Homo sapiens	10-17
94197-14	1979	Here particularly the COP-scheme proved to be favourable, if necessary in connection with bleomycin, adriamycin or methotrexat; also BCNU or dakarbacin are possible.	Bleomycin	90-99	caspase recruitment domain family member 16	Homo sapiens	22-25
93598-3	1979	The results of potentiometric titration also indicate that the stability of bleomycin-metal complexes is in the order Fe(II) less than Co(II) less than Ni(II) less than Cu(II) greater than Zn(II) and that these divalent metal complexes have a similar coordination environment.	Bleomycin	76-85	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	135-141
81104-0	1978	Selective response of DNA polymerase beta to bleomycin-induced breaks in DNA.	Bleomycin	45-54	DNA polymerase beta	Homo sapiens	22-41
80226-5	1978	Cu(II), Zn(II), and Co(II) inhibit degradation of DNA by bleomycin and Fe(II) in the absence of added reducing agents.	Bleomycin	57-66	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	20-26
77145-3	1978	Bleomycin PEP thus selected may become a useful agent.	Bleomycin	0-9	progestagen associated endometrial protein	Homo sapiens	10-13
77341-2	1977	In order to achieve improved effect of treatment, 21 cases (stage II-III/TNM) were given supplementary chemotherapy with bleomycin or vincristine-bleomycin.	Bleomycin	121-130	teneurin transmembrane protein 1	Homo sapiens	60-76
77341-2	1977	In order to achieve improved effect of treatment, 21 cases (stage II-III/TNM) were given supplementary chemotherapy with bleomycin or vincristine-bleomycin.	Bleomycin	146-155	teneurin transmembrane protein 1	Homo sapiens	60-76
62401-5	1976	However, when the labeled bleomycin is exposed to serum transferrin (and to other as yet unidentified ligands in the body) a difference in stability becomes obvious.	Bleomycin	26-35	transferrin	Homo sapiens	56-67
61044-7	1976	N-Acetyl-beta-glucosaminidase, one of the degradation enzymes for acidic glycosaminoglycans released into the cultured medium, was decreased significantly by bleomycin.	Bleomycin	158-167	O-GlcNAcase	Rattus norvegicus	0-29
57822-1	1976	DNA polymerases alpha and beta from Molt-4 cells are inhibited by bleomycin, whereas DNA polymerase gamma assayed with poly-(A)-(dT)12-18 as the template primer or terminal deoxynucleotidyl transferase assayed with activated DNA, poly(dA), (dG)12-18 or (dA)12-18 as the initiator are not inhibited by this antibiotic.	Bleomycin	66-75	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	0-21
57822-7	1976	The results obtained in this study indicate that bleomycin inhibits DNA polymerases alpha and beta by a thiol reagent-dependent interaction with the template.	Bleomycin	49-58	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	68-89
63962-5	1976	A bleomycin-inactivating enzyme which distributes widely in animal cells was shown to be a new aminopeptidase B which hydrolyzes beta-aminoalanine amide group.	Bleomycin	2-11	arginyl aminopeptidase (aminopeptidase B)	Mus musculus	95-111
33905374-8	2021	In this study, SRSF6 protein was found to be increased in cells of tuberculous pleural effusions (TBPE) from patients, and decellularized TBPE, bleomycin and TGFB1 were confirmed to increase SRSF6 levels in PMCs.	Bleomycin	144-153	serine and arginine rich splicing factor 6	Homo sapiens	191-196
4129378-0	1973	Relations between histology, TNM-Category and results of treatment with methotrexate-bleomycin-combination in squamous cell carcinomas of the oral cavity.	Bleomycin	85-94	teneurin transmembrane protein 1	Homo sapiens	29-32
33787325-10	2021	Moreover, bleomycin was found to activate VEGF/Src signaling which increased PMCs permeability.	Bleomycin	10-19	vascular endothelial growth factor A	Homo sapiens	42-46
33787325-10	2021	Moreover, bleomycin was found to activate VEGF/Src signaling which increased PMCs permeability.	Bleomycin	10-19	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	47-50
33787325-11	2021	In vivo, inhibition of VEGF/Src signaling prevented bleomycin-induced sub-pleural pulmonary fibrosis.	Bleomycin	52-61	vascular endothelial growth factor A	Homo sapiens	23-27
33787325-11	2021	In vivo, inhibition of VEGF/Src signaling prevented bleomycin-induced sub-pleural pulmonary fibrosis.	Bleomycin	52-61	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	28-31
33242499-0	2021	Function-blocking RHAMM peptides attenuate fibrosis and promote anti-fibrotic adipokines in a bleomycin-induced murine model of systemic sclerosis.	Bleomycin	94-103	hyaluronan mediated motility receptor (RHAMM)	Mus musculus	18-23
33242499-4	2021	The purpose of this study is to test the efficacy of two function-blocking RHAMM peptides, NPI-110 and NPI-106, in reducing skin fibrosis in a bleomycin-induced mouse model of systemic sclerosis.	Bleomycin	143-152	hyaluronan mediated motility receptor (RHAMM)	Mus musculus	75-80
5531009-0	1970	[Treatment of lung cancer (especially small-sized) with Bleomycin--significance of CPBP therapy].	Bleomycin	56-65	Kruppel like factor 6	Homo sapiens	83-87
34013490-10	2021	CONCLUSION: The results of the present study revealed that oral and topical DHA administration ameliorated tissue fibrosis and protected dermal blood vessels from bleomycin-induced EndoMT.	Bleomycin	163-172	endoglin	Mus musculus	181-187
34022711-0	2021	Exosomes derived from miR-16-5p-overexpressing keratinocytes attenuates bleomycin-induced skin fibrosis.	Bleomycin	72-81	microRNA 16-1	Mus musculus	22-28
34054916-12	2021	LTBP2 was upregulated in the lungs of the bleomycin-induced PF mouse model and TGF-beta1-stimulated mouse and human fibroblasts.	Bleomycin	42-51	latent transforming growth factor beta binding protein 2	Mus musculus	0-5
33978489-4	2021	In this study, we observed SRF expression localized to mesenchymal compartments, areas of dense fibrosis, and fibroblastic foci in human (IPF and normal) and bleomycin-treated mouse lungs.	Bleomycin	158-167	serum response factor	Homo sapiens	27-30
33978489-9	2021	Together, these data demonstrate that SRF plays a critical role in LMC myofibroblast expansion during bleomycin-induced pulmonary fibrosis.	Bleomycin	102-111	serum response factor	Mus musculus	38-41
33955200-2	2021	METHODS: Bleomycin-induced SSc (BLM-SSc) model mice were treated with anti-CD20 antibody, and skin and lung fibrosis was evaluated histopathologically.	Bleomycin	9-18	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	75-79
33974566-3	2021	Specifically, SARS-CoV-2 infection after application of low-doses of the acute-lung-injury stimulants bleomycin or ricin caused a severe disease in CD-1 mice, manifested by sustained body weight loss and mortality rates of >50%.	Bleomycin	102-111	CD1c molecule	Homo sapiens	148-152
33964960-3	2021	METHODS: Bleomycin (BLM)-induced skin fibrosis was generated with Fli1+/- and wild-type mice.	Bleomycin	9-18	Friend leukemia integration 1	Mus musculus	66-70
33964960-3	2021	METHODS: Bleomycin (BLM)-induced skin fibrosis was generated with Fli1+/- and wild-type mice.	Bleomycin	20-23	Friend leukemia integration 1	Mus musculus	66-70
33952237-11	2021	In addition, BLM-induced elevation of HO-1 (heme oxygenase-1) and 3-NT (3-nitrotyrosine) was alleviated by TUDCA.	Bleomycin	13-16	heme oxygenase 1	Mus musculus	38-42
33952237-11	2021	In addition, BLM-induced elevation of HO-1 (heme oxygenase-1) and 3-NT (3-nitrotyrosine) was alleviated by TUDCA.	Bleomycin	13-16	heme oxygenase 1	Mus musculus	44-60
33938323-3	2021	Significantly greater inflammation and fibrosis by bleomycin were developed in Muc5ac-/- lungs compared to Muc5ac+/+ lungs.	Bleomycin	51-60	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	79-83
33938323-3	2021	Significantly greater inflammation and fibrosis by bleomycin were developed in Muc5ac-/- lungs compared to Muc5ac+/+ lungs.	Bleomycin	51-60	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	79-85
33938323-10	2021	Lung E-cadherin level was relatively lower in Muc5ac-/- than in Muc5ac+/+ basally and after bleomycin, RSV, and ozone exposure.	Bleomycin	92-101	cadherin 1	Homo sapiens	5-15
33577398-8	2021	In vivo functional significance of PINK1 in the regulation of MAVS signaling was evaluated from both murine modeling of Influenza viral infection and bleomycin-induced experimental pulmonary fibrosis, respectively, wherein MAVS plays important roles.	Bleomycin	150-159	PTEN induced putative kinase 1	Mus musculus	35-40
33577398-8	2021	In vivo functional significance of PINK1 in the regulation of MAVS signaling was evaluated from both murine modeling of Influenza viral infection and bleomycin-induced experimental pulmonary fibrosis, respectively, wherein MAVS plays important roles.	Bleomycin	150-159	mitochondrial antiviral signaling protein	Mus musculus	62-66
33577398-11	2021	Additionally, in vivo studies revealed that MAVS-mediated pulmonary antiviral innate immune responses and fibrotic responses after bleomycin injury, respectively, were enhanced in PINK1 deficiency.	Bleomycin	131-140	mitochondrial antiviral signaling protein	Mus musculus	44-48
33577398-11	2021	Additionally, in vivo studies revealed that MAVS-mediated pulmonary antiviral innate immune responses and fibrotic responses after bleomycin injury, respectively, were enhanced in PINK1 deficiency.	Bleomycin	131-140	PTEN induced putative kinase 1	Mus musculus	180-185
33502034-0	2021	Impact of ENaC down-regulation in transgenic mice on the outcomes of acute lung injury induced by bleomycin.	Bleomycin	98-107	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	10-14
33502034-2	2021	Our goal was to dissect how the down-regulation of ENaC, the major driving force for alveolar fluid clearance, impacts acute lung injury outcomes induced by bleomycin, featuring alveolar damage, as observed during ARDS exudative phase.	Bleomycin	157-166	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	51-55
33515677-8	2021	DKK1 was capable of suppressing the profibrogenic differentiation of LR-MSCs and bleomycin-induced pulmonary fibrosis.	Bleomycin	81-90	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	0-4
33984694-3	2021	The aim of our study was to combine ECT with PARP inhibitor olaparib, which could inhibit the repair of bleomycin or cisplatin induced DNA damage and potentiate the effectiveness of ECT.	Bleomycin	104-113	collagen type XI alpha 2 chain	Homo sapiens	45-49
33984694-7	2021	Combined therapy of ECT with bleomycin and olaparib potentiated the effectiveness of ECT in BRCA1 mutated HCC1937, but not in non-mutated HCC1143 cells.	Bleomycin	29-38	BRCA1 DNA repair associated	Homo sapiens	92-97
33994367-3	2021	We herein aimed to determine if YAP1 gene knockdown, a member of the Hippo/YAP signal pathway, in the bleomycin (BLM)-induced mouse model of IPF, inhibits onset of senescence of AECs and alleviates IPF.	Bleomycin	102-111	yes-associated protein 1	Mus musculus	32-36
33994367-3	2021	We herein aimed to determine if YAP1 gene knockdown, a member of the Hippo/YAP signal pathway, in the bleomycin (BLM)-induced mouse model of IPF, inhibits onset of senescence of AECs and alleviates IPF.	Bleomycin	102-111	yes-associated protein 1	Mus musculus	32-35
33994367-3	2021	We herein aimed to determine if YAP1 gene knockdown, a member of the Hippo/YAP signal pathway, in the bleomycin (BLM)-induced mouse model of IPF, inhibits onset of senescence of AECs and alleviates IPF.	Bleomycin	113-116	yes-associated protein 1	Mus musculus	32-36
33994367-3	2021	We herein aimed to determine if YAP1 gene knockdown, a member of the Hippo/YAP signal pathway, in the bleomycin (BLM)-induced mouse model of IPF, inhibits onset of senescence of AECs and alleviates IPF.	Bleomycin	113-116	yes-associated protein 1	Mus musculus	32-35
33662577-6	2021	CCN2 deletion significantly reduced pulmonary interstitial scarring and fibrosis following bleomycin-instillation, as assessed by fibrotic scores (wildtype bleomycin 3.733 +- 0.2667 vs CCN2 knockout (KO) bleomycin 4.917 +- 0.3436, p < 0.05) and micro-CT.	Bleomycin	91-100	cellular communication network factor 2	Mus musculus	0-4
33662577-6	2021	CCN2 deletion significantly reduced pulmonary interstitial scarring and fibrosis following bleomycin-instillation, as assessed by fibrotic scores (wildtype bleomycin 3.733 +- 0.2667 vs CCN2 knockout (KO) bleomycin 4.917 +- 0.3436, p < 0.05) and micro-CT.	Bleomycin	156-165	cellular communication network factor 2	Mus musculus	0-4
33662577-6	2021	CCN2 deletion significantly reduced pulmonary interstitial scarring and fibrosis following bleomycin-instillation, as assessed by fibrotic scores (wildtype bleomycin 3.733 +- 0.2667 vs CCN2 knockout (KO) bleomycin 4.917 +- 0.3436, p < 0.05) and micro-CT.	Bleomycin	156-165	cellular communication network factor 2	Mus musculus	0-4
33760118-11	2021	The silencing of DLEU2 inhibited the TGF-beta1-induced proliferation, migration and epithelial-mesenchymal transition (EMT) of A549 cells and bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	142-151	deleted in lymphocytic leukemia, 2	Mus musculus	17-22
33735625-0	2021	Liproxstatin-1 alleviates bleomycin-induced alveolar epithelial cells injury and mice pulmonary fibrosis via attenuating inflammation, reshaping redox equilibrium, and suppressing ROS/p53/alpha-SMA pathway.	Bleomycin	26-35	transformation related protein 53, pseudogene	Mus musculus	184-187
33735625-0	2021	Liproxstatin-1 alleviates bleomycin-induced alveolar epithelial cells injury and mice pulmonary fibrosis via attenuating inflammation, reshaping redox equilibrium, and suppressing ROS/p53/alpha-SMA pathway.	Bleomycin	26-35	actin alpha 2, smooth muscle, aorta	Mus musculus	188-197
33929970-4	2021	Bleomycin-induced pulmonary fibrosis in mice exhibited that AOBEE improved forced vital capacity (FVC) and alveolar structure and inhibited alpha-SMA, vimentin, and collagen expression.	Bleomycin	0-9	actin alpha 2, smooth muscle, aorta	Mus musculus	140-149
33929970-4	2021	Bleomycin-induced pulmonary fibrosis in mice exhibited that AOBEE improved forced vital capacity (FVC) and alveolar structure and inhibited alpha-SMA, vimentin, and collagen expression.	Bleomycin	0-9	vimentin	Mus musculus	151-159
33903093-9	2021	Inhibition of XIAP also ameliorated fibrosis induced by bleomycin, topoI and overexpression of Wnt10b in well-tolerated doses.	Bleomycin	56-65	X-linked inhibitor of apoptosis	Mus musculus	14-18
33901873-4	2021	Remarkably, we found that dopamine (DA) receptor D1 (D1R) and DA receptor D2 (D2R) were both upregulated in myofibroblasts in lungs of IPF patients and a bleomycin (BLM)-induced mouse model.	Bleomycin	154-163	dopamine receptor D1	Homo sapiens	26-51
33901873-4	2021	Remarkably, we found that dopamine (DA) receptor D1 (D1R) and DA receptor D2 (D2R) were both upregulated in myofibroblasts in lungs of IPF patients and a bleomycin (BLM)-induced mouse model.	Bleomycin	154-163	dopamine receptor D2	Homo sapiens	78-81
33901873-4	2021	Remarkably, we found that dopamine (DA) receptor D1 (D1R) and DA receptor D2 (D2R) were both upregulated in myofibroblasts in lungs of IPF patients and a bleomycin (BLM)-induced mouse model.	Bleomycin	165-168	dopamine receptor D1	Homo sapiens	26-51
33901873-4	2021	Remarkably, we found that dopamine (DA) receptor D1 (D1R) and DA receptor D2 (D2R) were both upregulated in myofibroblasts in lungs of IPF patients and a bleomycin (BLM)-induced mouse model.	Bleomycin	165-168	dopamine receptor D2	Homo sapiens	78-81
33922418-4	2021	EchA treatment reduces the number of activated myofibroblasts expressing alpha-SMA, vimentin, and phosphorylated Smad3 in bleomycin-induced scleroderma.	Bleomycin	122-131	SMAD family member 3	Mus musculus	113-118
33888146-10	2021	Bleomycin, etoposide, and cisplatin (BEP therapy) which is commonly used for nongestational choriocarcinoma (malignant germ cell tumor) and surgical resection of the uterus, bilateral ovaries, and an affected part of the left lung led to the nadir level of hCG, but the tumor relapsed and levels of hCG again increased.	Bleomycin	0-9	cathepsin G	Homo sapiens	257-260
33888146-10	2021	Bleomycin, etoposide, and cisplatin (BEP therapy) which is commonly used for nongestational choriocarcinoma (malignant germ cell tumor) and surgical resection of the uterus, bilateral ovaries, and an affected part of the left lung led to the nadir level of hCG, but the tumor relapsed and levels of hCG again increased.	Bleomycin	0-9	cathepsin G	Homo sapiens	299-302
33881353-0	2021	Inhibition of Macrophage Migration Inhibitory Factor (MIF) as a Therapeutic Target in Bleomycin-InducedPulmonary Fibrosis Rats.	Bleomycin	86-95	macrophage migration inhibitory factor	Rattus norvegicus	14-52
33881353-0	2021	Inhibition of Macrophage Migration Inhibitory Factor (MIF) as a Therapeutic Target in Bleomycin-InducedPulmonary Fibrosis Rats.	Bleomycin	86-95	macrophage migration inhibitory factor	Rattus norvegicus	54-57
33881353-2	2021	Here we investigated antifibrotic effect of MIF knockdown in Bleomycin (BLM)-induced pulmonary fibrosis rats.	Bleomycin	61-70	macrophage migration inhibitory factor	Rattus norvegicus	44-47
33894177-3	2021	We report that treatment with a RUNX1 inhibitor (Ro24-7429), previously found to be safe, though ineffective, as a Tat inhibitor in patients with HIV, robustly ameliorates lung fibrosis and inflammation in the bleomycin-induced PF mouse model.	Bleomycin	210-219	RUNX family transcription factor 1	Homo sapiens	32-37
33887217-7	2021	In vivo studies further show that deletion of PAI-1 in adult mice reduces p53, p21, and Bax proteins as well as apoptosis sensitivity in ATII cells but the opposite effects in lung fibroblasts, associated with an attenuation of lung fibrosis after bleomycin challenge.	Bleomycin	248-257	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	46-51
33093124-4	2021	Here, using an established model of pulmonary fibrosis, we demonstrate that MAVS plays as a critical mediator of multiple DAMPs signalling pathways and the consequent lung fibrosis after bleomycin-induced injury in vivo After bleomycin injury, the expression of MAVS was mainly observed in macrophages.	Bleomycin	187-196	mitochondrial antiviral signaling protein	Homo sapiens	76-80
33093124-4	2021	Here, using an established model of pulmonary fibrosis, we demonstrate that MAVS plays as a critical mediator of multiple DAMPs signalling pathways and the consequent lung fibrosis after bleomycin-induced injury in vivo After bleomycin injury, the expression of MAVS was mainly observed in macrophages.	Bleomycin	187-196	mitochondrial antiviral signaling protein	Homo sapiens	262-266
33093124-4	2021	Here, using an established model of pulmonary fibrosis, we demonstrate that MAVS plays as a critical mediator of multiple DAMPs signalling pathways and the consequent lung fibrosis after bleomycin-induced injury in vivo After bleomycin injury, the expression of MAVS was mainly observed in macrophages.	Bleomycin	226-235	mitochondrial antiviral signaling protein	Homo sapiens	76-80
33093124-5	2021	In addition, multimeric MAVS aggregation, a key event of MAVS signalling activation, was significantly increased and persisted in bleomycin-injured lungs.	Bleomycin	130-139	mitochondrial antiviral signaling protein	Homo sapiens	24-28
33093124-5	2021	In addition, multimeric MAVS aggregation, a key event of MAVS signalling activation, was significantly increased and persisted in bleomycin-injured lungs.	Bleomycin	130-139	mitochondrial antiviral signaling protein	Homo sapiens	57-61
33647319-4	2021	Herein, we investigated the role of TNFalpha in macrophage responses to bleomycin.	Bleomycin	72-81	tumor necrosis factor	Mus musculus	36-44
33647319-12	2021	Conversely, it reduced the abundance of mature proinflammatory (Ly6C+) IM in the tissue at 7 d and immature pro-fibrotic IM at 21 d. Taken together, these data suggest that TNFalpha inhibition has beneficial effects in bleomycin induced injury, restoring epithelial function and reducing numbers of profibrotic IM and the extent of pulmonary fibrosis.	Bleomycin	219-228	tumor necrosis factor	Mus musculus	173-181
33493092-6	2021	In this study, we examine the effects of Notch3 deletion in pulmonary fibrosis and we demonstrate that Notch3-deficient lungs are protected from lung injury with significant reduced collagen deposition post-bleomycin administration.	Bleomycin	207-216	notch receptor 3	Homo sapiens	103-109
33493092-7	2021	The induction of profibrotic genes is reduced in bleomycin-treated Notch3 Knock-out lungs that consistently present fewer alphaSMA-positive myofibroblasts.	Bleomycin	49-58	notch receptor 3	Homo sapiens	67-73
33493092-7	2021	The induction of profibrotic genes is reduced in bleomycin-treated Notch3 Knock-out lungs that consistently present fewer alphaSMA-positive myofibroblasts.	Bleomycin	49-58	actin alpha 1, skeletal muscle	Homo sapiens	122-130
33144678-0	2021	IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages.	Bleomycin	39-48	interleukin 4	Mus musculus	90-94
33144678-3	2021	In this study, we determined that IL-24, an IL-20 subfamily cytokine member, was increased both in the serum of IPF patients and the bronchoalveolar lavage fluid (BALF) of mice following bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	187-196	interleukin 24	Homo sapiens	34-39
33502034-11	2021	A non-significant trend in enhanced weight loss and mortality rates was observed after the bleomycin challenge in alphaENaC(-/-)Tg+, compared to wild-type (WT) mice.	Bleomycin	91-100	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	114-123
33753282-4	2021	In this study, we evaluated the potential of the radical scavenging CNP conjugated to microRNA-146a (termed CNP-miR146a) in preventing acute lung injury (ALI) following exposure to bleomycin.	Bleomycin	181-190	microRNA 146a	Homo sapiens	86-99
33784491-8	2021	CD148 fibroblast-specific knockout mice displayed increased pulmonary fibrosis after bleomycin challenge compared to control mice.	Bleomycin	85-94	protein tyrosine phosphatase, receptor type, J	Mus musculus	0-5
33507753-11	2021	A further study in mice models of bleomycin-induced pulmonary fibrosis confirms that NADPH oxidase 4 (NOX4) acts as a "button" to regulate H2O2 levels.	Bleomycin	34-43	NADPH oxidase 4	Mus musculus	85-100
33507753-11	2021	A further study in mice models of bleomycin-induced pulmonary fibrosis confirms that NADPH oxidase 4 (NOX4) acts as a "button" to regulate H2O2 levels.	Bleomycin	34-43	NADPH oxidase 4	Mus musculus	102-106
33753282-4	2021	In this study, we evaluated the potential of the radical scavenging CNP conjugated to microRNA-146a (termed CNP-miR146a) in preventing acute lung injury (ALI) following exposure to bleomycin.	Bleomycin	181-190	microRNA 146a	Homo sapiens	112-119
33740813-3	2021	Our studies revealed that NEK1 KO cells resulted in increased apoptosis and hypersensitivity to the alkylator methyl methanesulfonate, the radiomimetic bleomycin, and UVC light, yet increased resistance to the crosslinker cisplatin.	Bleomycin	152-161	NIMA related kinase 1	Homo sapiens	26-30
33706759-8	2021	ACE2 and TMPRSS2 were also expressed in FSP-1+ lung fibroblasts in bleomycin-induced pulmonary fibrosis, and when combined with PM exposure, they were further upregulated.	Bleomycin	67-76	angiotensin converting enzyme 2	Homo sapiens	0-4
33723255-7	2021	Furthermore, administration of NP-011 reversed bleomycin-induced lung fibrosis in mice also via ERK signaling suppression and collagen reduction.	Bleomycin	47-56	mitogen-activated protein kinase 1	Mus musculus	96-99
32978308-5	2021	Intriguingly, genes associated with pulmonary fibrosis were highly upregulated in Regnase1-deficient ILC2s compared with wild-type, and supplementation of Regnase-1-deficient ILC2s augmented bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	191-200	zinc finger CCCH type containing 12A	Mus musculus	155-164
33706759-8	2021	ACE2 and TMPRSS2 were also expressed in FSP-1+ lung fibroblasts in bleomycin-induced pulmonary fibrosis, and when combined with PM exposure, they were further upregulated.	Bleomycin	67-76	S100 calcium binding protein A4	Homo sapiens	40-45
33706759-8	2021	ACE2 and TMPRSS2 were also expressed in FSP-1+ lung fibroblasts in bleomycin-induced pulmonary fibrosis, and when combined with PM exposure, they were further upregulated.	Bleomycin	67-76	transmembrane serine protease 2	Homo sapiens	9-16
32506869-0	2021	In vivo therapeutic success of MicroRNA-155 antagomir in a mouse model of pulmonary fibrosis induced by bleomycin.	Bleomycin	104-113	microRNA 155	Mus musculus	31-43
32694760-6	2021	Furthermore, in bleomycin-treated mice, the upregulated protein level of HGF in lungs by oral curcumin was highly correlated with its anti-PF effect, which was further confirmed by coadministration of c-Met inhibitor SU11274.	Bleomycin	16-25	hepatocyte growth factor	Mus musculus	73-76
32694760-6	2021	Furthermore, in bleomycin-treated mice, the upregulated protein level of HGF in lungs by oral curcumin was highly correlated with its anti-PF effect, which was further confirmed by coadministration of c-Met inhibitor SU11274.	Bleomycin	16-25	met proto-oncogene	Mus musculus	201-206
32887938-7	2021	Bleomycin-induced lung fibrosis was reduced in mice transiently transfected with siRNA-MUC4.	Bleomycin	0-9	mucin 4	Mus musculus	87-91
33639908-7	2021	RESULTS: Here, we found that bleomycin induces the activation of the HIF-1alpha/TGFbeta1 signalling pathway and further enhances the migration and proliferation of fibroblasts through the epithelial mesenchymal transition (EMT).	Bleomycin	29-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	69-79
33639908-7	2021	RESULTS: Here, we found that bleomycin induces the activation of the HIF-1alpha/TGFbeta1 signalling pathway and further enhances the migration and proliferation of fibroblasts through the epithelial mesenchymal transition (EMT).	Bleomycin	29-38	transforming growth factor beta 1	Homo sapiens	80-88
33622407-0	2021	A critical role of AREG for bleomycin-induced skin fibrosis.	Bleomycin	28-37	amphiregulin	Mus musculus	19-23
33622407-10	2021	During bleomycin-induced skin fibrosis, a commonly used mouse model for skin fibrosis, Areg is up-regulated throughout the fibrogenesis and is associated with elevated cell proliferation in the dermis.	Bleomycin	7-16	amphiregulin	Mus musculus	87-91
33622407-13	2021	Furthermore, we found that inhibiting MEK, a downstream signaling effector of Areg, by selumetinib also effectively blocked bleomycin-based skin fibrosis model.	Bleomycin	124-133	midkine	Mus musculus	38-41
33622407-13	2021	Furthermore, we found that inhibiting MEK, a downstream signaling effector of Areg, by selumetinib also effectively blocked bleomycin-based skin fibrosis model.	Bleomycin	124-133	amphiregulin	Mus musculus	78-82
33535851-0	2021	The involvement of leucine-rich alpha-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.	Bleomycin	101-110	leucine-rich alpha-2-glycoprotein 1	Mus musculus	19-52
33535851-8	2021	RESULTS: LRG KO mice display an inhibition of fibrosis in the skin in association with a decrease of dermal thickness, collagen deposition, and phospho-Smad3 expression after bleomycin.	Bleomycin	175-184	leucine-rich alpha-2-glycoprotein 1	Mus musculus	9-12
33535851-9	2021	Serum LRG concentration significantly increased in WT mice after bleomycin.	Bleomycin	65-74	leucine-rich alpha-2-glycoprotein 1	Mus musculus	6-9
33535851-10	2021	There was also a suppression of inflammation and fibrosis in the LRG KO mouse lung indicated by a reduction of lung weight, collagen content, and phospho-Smad2 expression after bleomycin.	Bleomycin	177-186	leucine-rich alpha-2-glycoprotein 1	Mus musculus	65-68
32636079-11	2021	VIP followed by TGP might be an alternative first- and second-line conventional regimen for patients with metastatic GCC in this granulocyte colony-stimulating factor era, especially for patients at a high risk of bleomycin-induced pulmonary toxicity.	Bleomycin	214-223	vasoactive intestinal peptide	Homo sapiens	0-3
33253593-9	2021	These changes were associated with an increased number of cells that stained positive for TUNEL and cleaved caspase 3 in the FKBP13-/- lungs, indicating a heightened cellular sensitivity to bleomycin.	Bleomycin	190-199	caspase 3	Mus musculus	108-117
33253593-9	2021	These changes were associated with an increased number of cells that stained positive for TUNEL and cleaved caspase 3 in the FKBP13-/- lungs, indicating a heightened cellular sensitivity to bleomycin.	Bleomycin	190-199	FK506 binding protein 2	Mus musculus	125-131
33253593-10	2021	Our findings suggest that FKBP13 is a potential biomarker for severity or progression of interstitial lung diseases, and that it has a biologically relevant role in protecting mice against bleomycin-induced injury, inflammation and fibrosis.	Bleomycin	189-198	FK506 binding protein 2	Mus musculus	26-32
33671452-0	2021	Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-beta1 Signaling Pathway.	Bleomycin	24-33	transforming growth factor beta 1	Homo sapiens	79-88
33671452-8	2021	In conclusion, regorafenib attenuates bleomycin-induced pulmonary fibrosis by suppressing the TGF-beta1 signaling pathway.	Bleomycin	38-47	transforming growth factor beta 1	Homo sapiens	94-103
33549106-9	2021	RESULTS: The expression of SNHG16 was significantly up-regulated in bleomycin-(BLM) induced lung fibrosis and transforming growth factor-beta (TGF-beta)-induced fibroblast.	Bleomycin	68-77	small nucleolar RNA host gene 16	Homo sapiens	27-33
33549109-4	2021	In this study, we found that CXCL16 and its receptor C-X-C motif chemokine receptor 6 (CXCR6) were upregulated in bleomycin induced EMT in human alveolar type II-like epithelial A549 cells.	Bleomycin	114-123	C-X-C motif chemokine ligand 16	Homo sapiens	29-35
33549109-4	2021	In this study, we found that CXCL16 and its receptor C-X-C motif chemokine receptor 6 (CXCR6) were upregulated in bleomycin induced EMT in human alveolar type II-like epithelial A549 cells.	Bleomycin	114-123	C-X-C motif chemokine receptor 6	Homo sapiens	53-85
33549109-4	2021	In this study, we found that CXCL16 and its receptor C-X-C motif chemokine receptor 6 (CXCR6) were upregulated in bleomycin induced EMT in human alveolar type II-like epithelial A549 cells.	Bleomycin	114-123	C-X-C motif chemokine receptor 6	Homo sapiens	87-92
33549109-5	2021	Synergistic effect of CXCL16 and bleomycin in promoting EMT occurrence, extracellular matrix (ECM) excretion, as well as the pro-inflammatory and pro-fibrotic cytokines productions in A549 cells were observed, and those biological functions were impaired by CXCL16 siRNA.	Bleomycin	33-42	C-X-C motif chemokine ligand 16	Homo sapiens	258-264
33216617-4	2021	Using RT-qPCR, MiR-107 level was compared between clinical or bleomycin-induced PF and normal pulmonary tissues.	Bleomycin	62-71	microRNA 107	Homo sapiens	15-22
32577797-6	2021	Our data suggest that IL-38 may inhibit bleomycin-induced pulmonary inflammation and fibrosis through its anti-inflammatory effect and regulation of IL-1beta/IL-1Ra balance, and IL-38 may be a new strategy for the treatment of pulmonary fibrosis.	Bleomycin	40-49	interleukin 1 receptor antagonist	Mus musculus	158-164
33188462-7	2021	In pre-injured lungs without ventilation, the expression of SP-C was reduced by bleomycin; while, there were fewer and larger LB compared to healthy lungs.	Bleomycin	80-89	surfactant protein C	Rattus norvegicus	60-64
32577797-6	2021	Our data suggest that IL-38 may inhibit bleomycin-induced pulmonary inflammation and fibrosis through its anti-inflammatory effect and regulation of IL-1beta/IL-1Ra balance, and IL-38 may be a new strategy for the treatment of pulmonary fibrosis.	Bleomycin	40-49	interleukin 1 alpha	Mus musculus	149-157
32914382-0	2021	MiR-200a inversely correlates with Hedgehog and TGF-beta canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model.	Bleomycin	152-161	microRNA 200a	Homo sapiens	0-8
33443087-4	2021	In this report, MAP3K8 mRNA levels were found decreased in the lungs of IPF patients and of mice upon bleomycin-induced pulmonary fibrosis.	Bleomycin	102-111	mitogen-activated protein kinase kinase kinase 8	Homo sapiens	16-22
32989231-8	2021	miR-184 overexpression attenuated bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	34-43	microRNA 184	Homo sapiens	0-7
32989231-10	2021	In conclusion, the miR-184/TP63 axis modulates the TGF-beta1-induced fibrotic alterations in epithelial cell lines and bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	119-128	microRNA 184	Mus musculus	19-26
32989231-10	2021	In conclusion, the miR-184/TP63 axis modulates the TGF-beta1-induced fibrotic alterations in epithelial cell lines and bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	119-128	transformation related protein 63	Mus musculus	27-31
33495418-0	2021	Resveratrol alleviates bleomycin-induced pulmonary fibrosis via suppressing HIF-1alpha and NF-kappaB expression.	Bleomycin	23-32	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	76-86
33603790-4	2021	We first showed that after treatment with bleomycin in vitro, rat patellar TSCs (PTSCs) underwent senescence, characterized by morphological alterations, induction of senescence-associated beta-galactosidase (SA-beta-gal) activity, and an increase in p53, p21, and p62 protein expression.	Bleomycin	42-51	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	251-254
33603790-4	2021	We first showed that after treatment with bleomycin in vitro, rat patellar TSCs (PTSCs) underwent senescence, characterized by morphological alterations, induction of senescence-associated beta-galactosidase (SA-beta-gal) activity, and an increase in p53, p21, and p62 protein expression.	Bleomycin	42-51	KRAS proto-oncogene, GTPase	Rattus norvegicus	256-259
33603790-4	2021	We first showed that after treatment with bleomycin in vitro, rat patellar TSCs (PTSCs) underwent senescence, characterized by morphological alterations, induction of senescence-associated beta-galactosidase (SA-beta-gal) activity, and an increase in p53, p21, and p62 protein expression.	Bleomycin	42-51	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	265-268
33531801-4	2021	Rcn3 in type II alveolar epithelial cell (AECIIs) has been reported to play a critical role in regulating perinatal lung development and bleomycin-induced lung injury-repair processes.	Bleomycin	137-146	reticulocalbin 3	Homo sapiens	0-4
33486938-8	2021	Results: The HDAC2 activity in lung tissue of mice in the bleomycin group was significantly higher than that in the no operation group (2.00+-0.40 vs 1.00+-0.23, P<0.05) and the saline group (2.00+-0.40 vs 1.48+-0.33, P<0.05).	Bleomycin	58-67	histone deacetylase 2	Mus musculus	13-18
33486938-9	2021	The HDAC2 activity in the bleomycin group was significantly higher than that in the no operation group (2.40+-0.28 vs 1.00+-0.23, P<0.01, 2.23+-0.41 vs 1.00+-0.23, P<0.01) and the saline group (2.40+-0.28 vs 1.39+-0.23, P<0.05, 2.23+-0.41 vs 1.35+-0.42, P<0.05).	Bleomycin	26-35	histone deacetylase 2	Mus musculus	4-9
33486938-10	2021	The change trend of HDAC2 activity between the bleomycin group and the saline group was different.	Bleomycin	47-56	histone deacetylase 2	Mus musculus	20-25
33486938-12	2021	14 days after tracheal administration, HDAC4 activity in the bleomycin group and the saline group were significantly higher than that in the no operation group (1.18+-0.36 vs 1.00+-0.12, P<0.01, 1.09+-0.33 vs 1.00+-0.12, P<0.01).	Bleomycin	61-70	histone deacetylase 4	Mus musculus	39-44
33495418-7	2021	Furthermore, resveratrol alleviates bleomycin-induced pulmonary fibrosis by suppressing HIF-1alpha and NF-kappaB expression, indicating its potential as a promising therapeutic drug candidate.	Bleomycin	36-45	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	88-98
33519439-2	2020	Recently, our proteomic results revealed that the expression levels of MYH9 protein are notably upregulated in lung tissues of bleomycin-treated rats.	Bleomycin	127-136	myosin heavy chain 9-like 1	Rattus norvegicus	71-75
33462186-0	2021	Correction to: ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin"s lymphoma and testicular cancer cells.	Bleomycin	61-70	ASH2 like, histone lysine methyltransferase complex subunit	Homo sapiens	15-20
33413668-0	2021	Bleomycin induces fibrotic transformation of bone marrow stromal cells to treat height loss of intervertebral disc through the TGFbetaR1/Smad2/3 pathway.	Bleomycin	0-9	SMAD family member 2	Rattus norvegicus	137-144
33413668-9	2021	The pro-fibrotic effect of bleomycin on AF cells and BMSCs was in part due to the activation of the TGFbeta-TGFbetaR1-SMAD2/3 signaling pathway.	Bleomycin	27-36	SMAD family member 2	Homo sapiens	118-125
33413668-11	2021	CONCLUSION: Locally, injection of bleomycin in rats" IVD induced rapid fibrosis and maintained its height through the TGFbeta-TGFbetaR1-SMAD2/3 signaling pathway.	Bleomycin	34-43	SMAD family member 2	Rattus norvegicus	136-143
33007201-4	2021	FSTL1 nAbs attenuated bleomycin-induced pulmonary and dermal fibrosis in vivo and transforming growth factor (TGF)-beta1-induced dermal fibrosis ex vivo in human skin.	Bleomycin	22-31	follistatin like 1	Homo sapiens	0-5
33402751-0	2021	Correction: IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages.	Bleomycin	51-60	interleukin 24	Mus musculus	12-17
33402751-0	2021	Correction: IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages.	Bleomycin	51-60	interleukin 4	Mus musculus	102-106
33393489-4	2021	In mice, fibrosis due to inhaled bleomycin engendered netrin-1-expressing macrophages and fibroblasts, remodeled adrenergic nerves, and augmented noradrenaline.	Bleomycin	33-42	netrin 1	Mus musculus	54-62
33026236-5	2021	In vivo, bleomycin induced LOX mRNA expression in lung tissues, and LOX activity increased in the circulation of mice with pulmonary fibrosis, suggesting that circulating LOX parallels levels in lung tissues.	Bleomycin	9-18	lysyl oxidase	Mus musculus	27-30
33026236-8	2021	In vivo, LOX synergistically exacerbated fibrosis in bleomycin-treated mice.	Bleomycin	53-62	lysyl oxidase	Mus musculus	9-12
33080042-0	2021	Dysregulation of BMP9/BMPR2/SMAD Signaling Pathway Contributes to the Bleomycin-induced Pulmonary Fibrosis and Pulmonary Hypertension in a Rat Model.	Bleomycin	70-79	growth differentiation factor 2	Homo sapiens	17-21
33074715-4	2021	Here, we demonstrated that there was a markedly increased lactate in the conditioned media of TGF-beta1 (transforming growth factor-beta1)-induced lung myofibroblasts and in the BAL fluids (BALFs) from mice with TGF-beta1- or bleomycin-induced lung fibrosis.	Bleomycin	226-235	transforming growth factor, beta 1	Mus musculus	94-103
33074715-4	2021	Here, we demonstrated that there was a markedly increased lactate in the conditioned media of TGF-beta1 (transforming growth factor-beta1)-induced lung myofibroblasts and in the BAL fluids (BALFs) from mice with TGF-beta1- or bleomycin-induced lung fibrosis.	Bleomycin	226-235	transforming growth factor, beta 1	Mus musculus	105-137
33285108-0	2021	Overcoming interferon (IFN)-gamma resistance ameliorates transforming growth factor (TGF)-beta-mediated lung fibroblast-to-myofibroblast transition and bleomycin-induced pulmonary fibrosis.	Bleomycin	152-161	interferon gamma	Homo sapiens	11-33
33285108-2	2021	In bleomycin (BLM)-induced lung fibrosis, the marked expression of phospho-Src homology-2 domain-containing phosphatase (SHP) 2, phospho-signal transducer and activator of transcription (STAT) 3, and suppressor of cytokine signaling (SOCS) 3 was highly associated with pulmonary parenchymal lesions and collagen deposition.	Bleomycin	3-12	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	67-127
33285108-2	2021	In bleomycin (BLM)-induced lung fibrosis, the marked expression of phospho-Src homology-2 domain-containing phosphatase (SHP) 2, phospho-signal transducer and activator of transcription (STAT) 3, and suppressor of cytokine signaling (SOCS) 3 was highly associated with pulmonary parenchymal lesions and collagen deposition.	Bleomycin	3-12	signal transducer and activator of transcription 3	Homo sapiens	137-194
33285108-2	2021	In bleomycin (BLM)-induced lung fibrosis, the marked expression of phospho-Src homology-2 domain-containing phosphatase (SHP) 2, phospho-signal transducer and activator of transcription (STAT) 3, and suppressor of cytokine signaling (SOCS) 3 was highly associated with pulmonary parenchymal lesions and collagen deposition.	Bleomycin	3-12	suppressor of cytokine signaling 3	Homo sapiens	200-241
33285108-2	2021	In bleomycin (BLM)-induced lung fibrosis, the marked expression of phospho-Src homology-2 domain-containing phosphatase (SHP) 2, phospho-signal transducer and activator of transcription (STAT) 3, and suppressor of cytokine signaling (SOCS) 3 was highly associated with pulmonary parenchymal lesions and collagen deposition.	Bleomycin	14-17	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	67-127
33285108-2	2021	In bleomycin (BLM)-induced lung fibrosis, the marked expression of phospho-Src homology-2 domain-containing phosphatase (SHP) 2, phospho-signal transducer and activator of transcription (STAT) 3, and suppressor of cytokine signaling (SOCS) 3 was highly associated with pulmonary parenchymal lesions and collagen deposition.	Bleomycin	14-17	signal transducer and activator of transcription 3	Homo sapiens	137-194
33285108-2	2021	In bleomycin (BLM)-induced lung fibrosis, the marked expression of phospho-Src homology-2 domain-containing phosphatase (SHP) 2, phospho-signal transducer and activator of transcription (STAT) 3, and suppressor of cytokine signaling (SOCS) 3 was highly associated with pulmonary parenchymal lesions and collagen deposition.	Bleomycin	14-17	suppressor of cytokine signaling 3	Homo sapiens	200-241
33068010-0	2021	Bleomycin: a novel osteogenesis inhibitor of dental follicle cells via TGF-beta1/SMAD7/RUNX2 pathway.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	71-80
33068010-0	2021	Bleomycin: a novel osteogenesis inhibitor of dental follicle cells via TGF-beta1/SMAD7/RUNX2 pathway.	Bleomycin	0-9	SMAD family member 7	Homo sapiens	81-86
32673071-4	2021	METHODS: CCR2+ cells were investigated in mice with bleomycin or radiation-induced fibrosis, and human subjects with IPF.	Bleomycin	52-61	chemokine (C-C motif) receptor 2	Mus musculus	9-13
33325762-0	2021	Effects of cannabinoid receptor 2 synthetic agonist, AM1241, on bleomycin induced pulmonary fibrosis.	Bleomycin	64-73	cannabinoid receptor 2	Rattus norvegicus	11-33
33080042-0	2021	Dysregulation of BMP9/BMPR2/SMAD Signaling Pathway Contributes to the Bleomycin-induced Pulmonary Fibrosis and Pulmonary Hypertension in a Rat Model.	Bleomycin	70-79	bone morphogenetic protein receptor type 2	Rattus norvegicus	22-27
33290968-0	2021	Pinocembrin relieves lipopolysaccharide and bleomycin induced lung inflammation via inhibiting TLR4-NF-kappaB-NLRP3 inflammasome signaling pathway.	Bleomycin	44-53	toll-like receptor 4	Mus musculus	95-99
32096250-0	2021	Antifibrogenic effects of C-C chemokine receptor type 2 antagonist in a bleomycin-induced scleroderma model.	Bleomycin	72-81	chemokine (C-C motif) receptor 2	Mus musculus	26-55
32096250-2	2021	We examined the efficacy of CCR2 antagonist (RS-504393) in a mouse model of scleroderma induced by bleomycin.	Bleomycin	99-108	chemokine (C-C motif) receptor 2	Mus musculus	28-32
32592422-12	2021	DKK-1 is also reduced in the bleomycin mouse modelandpro-fibrotic genes elevated.	Bleomycin	29-38	dickkopf WNT signaling pathway inhibitor 1	Mus musculus	0-5
33068010-0	2021	Bleomycin: a novel osteogenesis inhibitor of dental follicle cells via TGF-beta1/SMAD7/RUNX2 pathway.	Bleomycin	0-9	RUNX family transcription factor 2	Homo sapiens	87-92
33290968-0	2021	Pinocembrin relieves lipopolysaccharide and bleomycin induced lung inflammation via inhibiting TLR4-NF-kappaB-NLRP3 inflammasome signaling pathway.	Bleomycin	44-53	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	100-109
33290968-0	2021	Pinocembrin relieves lipopolysaccharide and bleomycin induced lung inflammation via inhibiting TLR4-NF-kappaB-NLRP3 inflammasome signaling pathway.	Bleomycin	44-53	NLR family, pyrin domain containing 3	Mus musculus	110-115
33169236-9	2021	The anti-S100A8/A9 neutralizing antibody inhibited the effects of S100A8/A9 on fibroblasts and suppressed the progression of fibrosis in bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Bleomycin	137-146	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	9-18
33169236-9	2021	The anti-S100A8/A9 neutralizing antibody inhibited the effects of S100A8/A9 on fibroblasts and suppressed the progression of fibrosis in bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Bleomycin	148-151	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	9-18
33139318-0	2021	Therapeutic Effect of Neuraminidase-1-Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis.	Bleomycin	78-87	neuraminidase 1	Mus musculus	22-37
33139318-3	2021	We now have tested the ability of a broad-spectrum neuraminidase inhibitor, 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA), to modulate the in vivo response to acute intratracheal bleomycin challenge as an experimental model of pulmonary fibrosis.	Bleomycin	184-193	neuraminidase 1	Homo sapiens	51-64
33139318-13	2021	SIGNIFICANCE STATEMENT: Neuraminidase-1-selective therapeutic targeting in the acute and chronic bleomycin models of pulmonary fibrosis reverses pulmonary collagen deposition, accumulation of lymphocytes in the lungs, and the disease-associated loss of body weight-all without observable toxic effects.	Bleomycin	97-106	neuraminidase 1	Mus musculus	24-39
33144389-4	2021	The sialidase NEU3 is upregulated in fibrosis, and mice lacking Neu3 show attenuated bleomycin-induced increases in active TGF-beta1 in the lungs, and attenuated pulmonary fibrosis.	Bleomycin	85-94	neuraminidase 3	Mus musculus	64-68
33144389-4	2021	The sialidase NEU3 is upregulated in fibrosis, and mice lacking Neu3 show attenuated bleomycin-induced increases in active TGF-beta1 in the lungs, and attenuated pulmonary fibrosis.	Bleomycin	85-94	transforming growth factor, beta 1	Mus musculus	123-132
33139318-6	2021	A predominant expression and pronounced elevation in the levels of NEU1 mRNA were observed in patients with idiopathic pulmonary fibrosis and bleomycin-challenged mice compared with their corresponding controls, whereas NEU2, NEU3, and NEU4 were expressed at far lower levels.	Bleomycin	142-151	neuraminidase 1	Homo sapiens	67-71
33139318-7	2021	The levels of mRNA for the NEU1 chaperone, protective protein/cathepsin A (PPCA), were also elevated by bleomycin.	Bleomycin	104-113	neuraminidase 1	Mus musculus	27-31
33139318-7	2021	The levels of mRNA for the NEU1 chaperone, protective protein/cathepsin A (PPCA), were also elevated by bleomycin.	Bleomycin	104-113	cathepsin A	Homo sapiens	43-73
33139318-7	2021	The levels of mRNA for the NEU1 chaperone, protective protein/cathepsin A (PPCA), were also elevated by bleomycin.	Bleomycin	104-113	cathepsin A	Mus musculus	75-79
33139318-8	2021	Western blotting analyses demonstrated bleomycin-induced elevations in protein expression of both NEU1 and PPCA in mouse lungs.	Bleomycin	39-48	neuraminidase 1	Mus musculus	98-102
33139318-8	2021	Western blotting analyses demonstrated bleomycin-induced elevations in protein expression of both NEU1 and PPCA in mouse lungs.	Bleomycin	39-48	cathepsin A	Mus musculus	107-111
33139318-9	2021	Two known selective NEU1 inhibitors, C9-pentyl-amide-DANA (C9-BA-DANA) and C5-hexanamido-C9-acetamido-DANA, dramatically reduced bleomycin-induced loss of body weight, accumulation of pulmonary lymphocytes, and deposition of collagen.	Bleomycin	129-138	neuraminidase 1	Mus musculus	20-24
33139318-11	2021	Moreover, in the acute bleomycin model, C9-BA-DANA attenuated NEU1-mediated desialylation and shedding of the mucin-1 ectodomain.	Bleomycin	23-32	neuraminidase 1	Mus musculus	62-66
33341025-0	2021	Betulinic acid attenuated bleomycin-induced pulmonary fibrosis by effectively intervening Wnt/beta-catenin signaling.	Bleomycin	26-35	wingless-type MMTV integration site family, member 3A	Mus musculus	90-93
33127511-3	2021	Herein, a downregulation of EI24 levels in the lungs from mouse pulmonary fibrosis (PF) model and lung epithelial cells was observed in response to bleomycin (BLM) or transforming growth factor-beta1 (TGF-beta1).	Bleomycin	148-157	etoposide induced 2.4 mRNA	Mus musculus	28-32
33341025-0	2021	Betulinic acid attenuated bleomycin-induced pulmonary fibrosis by effectively intervening Wnt/beta-catenin signaling.	Bleomycin	26-35	catenin (cadherin associated protein), beta 1	Mus musculus	94-106
33172983-4	2020	Recently, agonism of Dopamine Receptor D1 (DRD1), which is predominantly expressed on fibroblasts in the lung, has been shown to accelerate tissue repair and clearance of ECM following bleomycin injury in mice.	Bleomycin	185-194	dopamine receptor D1	Mus musculus	21-41
33277324-2	2021	Herein we demonstrated that lungs originated from different types of PF patients including coronavirus disease 2019, systemic sclerosis associated interstitial lung disease and idiopathic pulmonary fibrosis, and mice following bleomycin (BLM)-induced PF are characterized by the altered methyl-CpG-binding domain 2 (MBD2) expression in macrophages.	Bleomycin	227-236	methyl-CpG binding domain protein 2	Mus musculus	287-314
33277324-2	2021	Herein we demonstrated that lungs originated from different types of PF patients including coronavirus disease 2019, systemic sclerosis associated interstitial lung disease and idiopathic pulmonary fibrosis, and mice following bleomycin (BLM)-induced PF are characterized by the altered methyl-CpG-binding domain 2 (MBD2) expression in macrophages.	Bleomycin	227-236	methyl-CpG binding domain protein 2	Mus musculus	316-320
33172983-4	2020	Recently, agonism of Dopamine Receptor D1 (DRD1), which is predominantly expressed on fibroblasts in the lung, has been shown to accelerate tissue repair and clearance of ECM following bleomycin injury in mice.	Bleomycin	185-194	dopamine receptor D1	Mus musculus	43-47
33217428-6	2020	Interestingly, the mutation of the equivalent residue in human Ku80 increases sensitivity to bleomycin in several cancer cell lines, suggesting that this mechanism is conserved in humans.	Bleomycin	93-102	X-ray repair cross complementing 5	Homo sapiens	63-67
33376743-8	2020	Interestingly, we found that si-THBS1 inhibited the occurrence and development of bleomycin-induced hypertrophic scars in vivo and downregulated TGF-beta1 expression.	Bleomycin	82-91	thrombospondin 1	Mus musculus	32-37
33293795-10	2020	In vitro results suggested that SIRT1-mediated mTOR degradation ameliorated bleomycin (BLM)-induced fibrosis and inflammation.	Bleomycin	76-85	sirtuin 1	Homo sapiens	32-37
33293795-10	2020	In vitro results suggested that SIRT1-mediated mTOR degradation ameliorated bleomycin (BLM)-induced fibrosis and inflammation.	Bleomycin	76-85	mechanistic target of rapamycin kinase	Homo sapiens	47-51
33293795-10	2020	In vitro results suggested that SIRT1-mediated mTOR degradation ameliorated bleomycin (BLM)-induced fibrosis and inflammation.	Bleomycin	87-90	sirtuin 1	Homo sapiens	32-37
33293795-10	2020	In vitro results suggested that SIRT1-mediated mTOR degradation ameliorated bleomycin (BLM)-induced fibrosis and inflammation.	Bleomycin	87-90	mechanistic target of rapamycin kinase	Homo sapiens	47-51
33039355-4	2020	In loss of function studies, blocking antibodies revealed that lymphangiogenesis 14 days after bleomycin was dependent on Vegfr3 signaling, but not on Vegfr2.	Bleomycin	95-104	FMS-like tyrosine kinase 4	Mus musculus	122-128
33039355-8	2020	In gain of function studies, expansion of the lung lymphatic network by transgenic overexpression of Vegfc in CCSP/VEGF-C mice reduced macrophage accumulation and fibrosis and accelerated recovery after bleomycin.	Bleomycin	203-212	vascular endothelial growth factor C	Mus musculus	101-106
33055012-10	2020	We found that local injection of CXCL17 attenuated bleomycin-induced skin fibrosis in mice.	Bleomycin	51-60	chemokine (C-X-C motif) ligand 17	Mus musculus	33-39
32915635-0	2020	PAD4 Deficiency Improves Bleomycin-induced Neutrophil Extracellular Traps and Fibrosis in Mouse Lung.	Bleomycin	25-34	MMTV LTR integration site 4	Mus musculus	0-4
32805318-7	2020	Our findings reveal that DNA-PKcs hypo O-GlcNAcylation affects its kinase activity and that the bleomycin-induced Ser2056 phosphorylation, is modulated by DNA-PKcs O-GlcNAcylation.	Bleomycin	96-105	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	25-33
32805318-7	2020	Our findings reveal that DNA-PKcs hypo O-GlcNAcylation affects its kinase activity and that the bleomycin-induced Ser2056 phosphorylation, is modulated by DNA-PKcs O-GlcNAcylation.	Bleomycin	96-105	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	155-163
32658336-0	2020	Modulation of Bleomycin-induced oxidative stress and pulmonary fibrosis by N-acetylcysteine in Ratsvia AMPK/SIRT1/ NF-Kbeta.	Bleomycin	14-23	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	103-107
32658336-0	2020	Modulation of Bleomycin-induced oxidative stress and pulmonary fibrosis by N-acetylcysteine in Ratsvia AMPK/SIRT1/ NF-Kbeta.	Bleomycin	14-23	sirtuin 1	Rattus norvegicus	108-113
33262481-5	2020	In mice, therapeutic targeting of IL-11 with antibodies can arrest and reverse bleomycin-induced pulmonary fibrosis and inflammation.	Bleomycin	79-88	interleukin 11	Mus musculus	34-39
33055012-3	2020	OBJECTIVE: Our aim was to examine the anti-fibrotic potential of CXCL17, a newly discovered chemokine, in cultured skin fibroblasts and in a bleomycin-induced SSc mouse model.	Bleomycin	141-150	chemokine (C-X-C motif) ligand 17	Mus musculus	65-71
32725139-2	2020	Dysregulated NF-kappaB signalling alters normal skin physiology and deletion of cRel limits bleomycin-induced skin fibrosis.	Bleomycin	92-101	REL proto-oncogene, NF-kB subunit	Homo sapiens	80-84
33259471-0	2020	Rehmannia Radix Extract Relieves Bleomycin-Induced Pulmonary Fibrosis in Mice via Transforming Growth Factor beta1 (TGF-beta1).	Bleomycin	33-42	transforming growth factor, beta 1	Mus musculus	82-114
33259471-0	2020	Rehmannia Radix Extract Relieves Bleomycin-Induced Pulmonary Fibrosis in Mice via Transforming Growth Factor beta1 (TGF-beta1).	Bleomycin	33-42	transforming growth factor, beta 1	Mus musculus	116-125
32335129-4	2020	PHA-543613, a alpha7nAchR-specific agonist did not only prevent but also reversed established skin fibrosis of mice injected with bleomycin.	Bleomycin	130-139	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	14-25
32900484-0	2020	Serpina3n is closely associated with fibrotic procession and knockdown ameliorates bleomycin-induced pulmonary fibrosis.	Bleomycin	83-92	serine (or cysteine) peptidase inhibitor, clade A, member 3N	Mus musculus	0-9
33027868-0	2020	The Effects of Chronic Intermittent Hypoxia in Bleomycin-induced lung injury on Pulmonary Fibrosis via Regulating the NF-kappaB/Nrf2 Signaling Pathway.	Bleomycin	47-56	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	118-127
33027868-0	2020	The Effects of Chronic Intermittent Hypoxia in Bleomycin-induced lung injury on Pulmonary Fibrosis via Regulating the NF-kappaB/Nrf2 Signaling Pathway.	Bleomycin	47-56	nuclear factor, erythroid derived 2, like 2	Mus musculus	128-132
33257682-0	2020	ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin"s lymphoma and testicular cancer cells.	Bleomycin	46-55	ASH2 like, histone lysine methyltransferase complex subunit	Homo sapiens	0-5
33257682-3	2020	Using a whole-genome CRISPR/Cas9 gene knockout approach, we identified ASH2L, a core component of the H3K4 methyl transferase complex, as a protein required for bleomycin sensitivity in L1236 Hodgkin lymphoma.	Bleomycin	161-170	ASH2 like, histone lysine methyltransferase complex subunit	Homo sapiens	71-76
33257682-4	2020	Knocking down ASH2L in these cells and in the NT2D1 testicular cancer cell line rendered them resistant to bleomycin, etoposide, and cisplatin but did not affect their sensitivity toward ATM or ATR inhibitors.	Bleomycin	107-116	ASH2 like, histone lysine methyltransferase complex subunit	Homo sapiens	14-19
32900484-4	2020	METHODS: We induced pulmonary fibrosis in mice by silica and bleomycin respectively and determined Serpina3n in lung tissues, and then verified the expression of Serpina3n and its correlation with pulmonary fibrosis at seven time points in a bleomycin longstanding model.	Bleomycin	242-251	serine (or cysteine) peptidase inhibitor, clade A, member 3N	Mus musculus	162-171
32900484-5	2020	Moreover, adeno-associated virus type 9 (AAV9)-mediated Serpina3n knockdown was used to treat pulmonary fibrosis in the bleomycin model, whose possible mechanisms would be preliminarily explored by detecting chymotrypsin C as an example.	Bleomycin	120-129	serine (or cysteine) peptidase inhibitor, clade A, member 3N	Mus musculus	56-65
32900484-7	2020	Notably, the expression of Serpina3n peaked during the 3rd week and then decreased until nearly normal levels during the 10th week, which was closely related to fibrotic procession in bleomycin-treated mice.	Bleomycin	184-193	serine (or cysteine) peptidase inhibitor, clade A, member 3N	Mus musculus	27-36
32900484-8	2020	AAV-mediated Serpina3n knockdown in the lung tissues alleviated bleomycin-induced fibrotic symptoms at various levels and disinhibit chymotrypsin C.	Bleomycin	64-73	serine (or cysteine) peptidase inhibitor, clade A, member 3N	Mus musculus	13-22
33319168-3	2020	Three days post-bleomycin, the inflammatory profile was typified by acute innate inflammation, pronounced neutrophilia, especially of SiglecF+ neutrophils, and alveolar macrophage loss.	Bleomycin	16-25	sialic acid binding Ig-like lectin F	Mus musculus	134-141
33154445-1	2020	Exaggerated transforming growth factor-beta 1 (TGFbeta1) expression worsens fibroproliferation following bleomycin-induced lung injury in alcohol-fed mice.	Bleomycin	105-114	transforming growth factor, beta 1	Mus musculus	12-45
33154445-1	2020	Exaggerated transforming growth factor-beta 1 (TGFbeta1) expression worsens fibroproliferation following bleomycin-induced lung injury in alcohol-fed mice.	Bleomycin	105-114	transforming growth factor, beta 1	Mus musculus	47-55
33138822-6	2020	RESULTS: The expression of H19 mRNA was up-regulated in fibrotic lungs patients with IPF as well as in lungs tissues that obtained from bleomycin-treated mice.	Bleomycin	136-145	H19 imprinted maternally expressed transcript	Homo sapiens	27-30
33086033-2	2020	Here, we report that in response to radiation, oxidative stress, or bleomycin, the E3 ubiquitin ligase FBW7 mediates cell senescence and tissue fibrosis through telomere uncapping.	Bleomycin	68-77	F-box and WD-40 domain protein 7	Mus musculus	103-107
33138822-7	2020	H19-/- mice suppressed bleomycin-mediated pulmonary inflammation and inhibited the Il6/Stat3 signaling.	Bleomycin	23-32	H19, imprinted maternally expressed transcript	Mus musculus	0-3
32739525-7	2020	TGF-beta1 neutralized antibody attenuated bleomycin-induced pulmonary fibrosis.	Bleomycin	42-51	transforming growth factor, beta 1	Mus musculus	0-9
32739525-10	2020	Blocking CD147 signaling also prevented bleomycin-induced pulmonary fibrosis.	Bleomycin	40-49	basigin	Mus musculus	9-14
32971116-9	2020	We found bleomycin induced increases of Lgl1 protein and decreases of PAR-3A protein, and bleomycin-induced PAR-3A depression was mediated by increased-Lgl1.	Bleomycin	9-18	LLGL1 scribble cell polarity complex component	Mus musculus	40-44
32799115-8	2020	Furthermore, the antifibrosis effect of AhR signaling activation was also confirmed in bleomycin induced scleroderma mouse model.	Bleomycin	87-96	aryl-hydrocarbon receptor	Mus musculus	40-43
32795835-6	2020	Blockage of IGF-1R decreases lung tissue damage and increases survival in bleomycin-induced as well as H1N1 influenza-related lung injury in animal models.	Bleomycin	74-83	insulin like growth factor 1 receptor	Homo sapiens	12-18
33097029-2	2020	Our previous studies found that bleomycin and tunicamycin could induce ER stress and consequently trigger EMT accompanying with IL-32 overexpression.	Bleomycin	32-41	interleukin 32	Homo sapiens	128-133
32700121-2	2020	CD34 is a sialomucin, with pan-selectin affinity and recently shown to protect the endothelial barrier in a bleomycin-induced lung injury model.	Bleomycin	108-117	CD34 antigen	Mus musculus	0-4
32952652-0	2020	Polydatin prevents bleomycin-induced pulmonary fibrosis by inhibiting the TGF-beta/Smad/ERK signaling pathway.	Bleomycin	19-28	transforming growth factor alpha	Rattus norvegicus	74-82
32952652-0	2020	Polydatin prevents bleomycin-induced pulmonary fibrosis by inhibiting the TGF-beta/Smad/ERK signaling pathway.	Bleomycin	19-28	Eph receptor B1	Rattus norvegicus	88-91
32958689-3	2020	We demonstrate in mouse models of allergen- and bleomycin-driven airway inflammation that neutralization of the TNF family cytokine TL1A through Ab blocking or genetic deletion of its receptor DR3 restricted increases in peribronchial smooth muscle mass and accumulation of lung collagen, primary features of remodeling.	Bleomycin	48-57	tumor necrosis factor (ligand) superfamily, member 15	Mus musculus	132-136
32958689-3	2020	We demonstrate in mouse models of allergen- and bleomycin-driven airway inflammation that neutralization of the TNF family cytokine TL1A through Ab blocking or genetic deletion of its receptor DR3 restricted increases in peribronchial smooth muscle mass and accumulation of lung collagen, primary features of remodeling.	Bleomycin	48-57	tumor necrosis factor receptor superfamily, member 25	Mus musculus	193-196
32971116-9	2020	We found bleomycin induced increases of Lgl1 protein and decreases of PAR-3A protein, and bleomycin-induced PAR-3A depression was mediated by increased-Lgl1.	Bleomycin	90-99	LLGL1 scribble cell polarity complex component	Mus musculus	152-156
33097591-5	2020	In the murine bleomycin model of pulmonary fibrosis, Acod1-/- mice develop persistent fibrosis, unlike wild-type (WT) littermates.	Bleomycin	14-23	aconitate decarboxylase 1	Mus musculus	53-58
32971116-11	2020	Lgl1 siRNA prevented apical-basal polarity loss in bleomycin-treated AECIIs.	Bleomycin	51-60	LLGL1 scribble cell polarity complex component	Mus musculus	0-4
32971116-13	2020	Bleomycin induced pulmonary fibrosis, but this was attenuated in Lgl1-conditional knockout mice.	Bleomycin	0-9	LLGL1 scribble cell polarity complex component	Mus musculus	65-69
33069066-4	2020	Human B-cell lymphoma-2 (Bcl-2)-protein inhibitors, including the (R)-enantiomer of the natural product gossypol, were observed to efficiently inhibit AspH, as does the antitumor antibiotic bleomycin A2.	Bleomycin	190-202	BCL2 apoptosis regulator	Homo sapiens	6-23
33093510-5	2020	The aim of the present study was to study the possible beneficial effects of the administration of the GLP-1R agonist, liraglutide, in the pathogenesis of the fibrotic process in an animal model of pulmonary fibrosis induced by bleomycin.	Bleomycin	228-237	glucagon like peptide 1 receptor	Homo sapiens	103-109
33096674-5	2020	One antagonist of the GHRH-R used in recent studies reviewed here, MIA-602, lessens both inflammation and fibrosis in a mouse model of bleomycin lung injury.	Bleomycin	135-144	growth hormone releasing hormone receptor	Mus musculus	22-28
33092214-9	2020	The underlying mechanisms for the protective effect of MI-2 bleomycin induced pulmonary fibrosis may be attributed to its inhibition on NF-kappaB pathway.	Bleomycin	60-69	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	136-145
33092214-10	2020	This is the first report showing the therapeutic role of MALT1 inhibition in a bleomycin model of pulmonary fibrosis, thus supporting further preclinical and clinical studies.	Bleomycin	79-88	MALT1 paracaspase	Mus musculus	57-62
33149810-7	2020	Furthermore, increased mitochondrial dynamic regulation and mitophagy were detected in pulmonary tissues of the bleomycin-induced Mutyh -/- model mice, which could reduce the pulmonary epithelial cell apoptosis.	Bleomycin	112-121	mutY DNA glycosylase	Mus musculus	130-135
33069066-4	2020	Human B-cell lymphoma-2 (Bcl-2)-protein inhibitors, including the (R)-enantiomer of the natural product gossypol, were observed to efficiently inhibit AspH, as does the antitumor antibiotic bleomycin A2.	Bleomycin	190-202	BCL2 apoptosis regulator	Homo sapiens	24-30
33069066-6	2020	With regard to the clinical use of bleomycin A2 and of the Bcl-2 inhibitor venetoclax, the results suggest that possible side-effects mediated through the inhibition of AspH and other 2OG oxygenases should be considered.	Bleomycin	35-44	aspartate beta-hydroxylase	Homo sapiens	169-173
32551949-9	2020	Finally, we found that inducible expression of ATF4 in mouse alveolar epithelial cells aggravated pulmonary UPRmt, lung inflammation, body weight loss and death upon bleomycin induced lung injury.	Bleomycin	166-175	activating transcription factor 4	Mus musculus	47-51
32828905-1	2020	We reported that bleomycin (BLM)-induced pulmonary fibrosis was exacerbated in the prostaglandin transporter gene (Slco2a1)-deficient mice (Slco2a1(-/-)).	Bleomycin	17-26	solute carrier organic anion transporter family, member 2a1	Mus musculus	83-108
32828905-1	2020	We reported that bleomycin (BLM)-induced pulmonary fibrosis was exacerbated in the prostaglandin transporter gene (Slco2a1)-deficient mice (Slco2a1(-/-)).	Bleomycin	17-26	solute carrier organic anion transporter family, member 2a1	Mus musculus	115-122
32828905-1	2020	We reported that bleomycin (BLM)-induced pulmonary fibrosis was exacerbated in the prostaglandin transporter gene (Slco2a1)-deficient mice (Slco2a1(-/-)).	Bleomycin	17-26	solute carrier organic anion transporter family, member 2a1	Mus musculus	140-147
32828905-1	2020	We reported that bleomycin (BLM)-induced pulmonary fibrosis was exacerbated in the prostaglandin transporter gene (Slco2a1)-deficient mice (Slco2a1(-/-)).	Bleomycin	28-31	solute carrier organic anion transporter family, member 2a1	Mus musculus	83-108
32828905-1	2020	We reported that bleomycin (BLM)-induced pulmonary fibrosis was exacerbated in the prostaglandin transporter gene (Slco2a1)-deficient mice (Slco2a1(-/-)).	Bleomycin	28-31	solute carrier organic anion transporter family, member 2a1	Mus musculus	115-122
32828905-1	2020	We reported that bleomycin (BLM)-induced pulmonary fibrosis was exacerbated in the prostaglandin transporter gene (Slco2a1)-deficient mice (Slco2a1(-/-)).	Bleomycin	28-31	solute carrier organic anion transporter family, member 2a1	Mus musculus	140-147
32828905-7	2020	Therefore, Slco2a1-deficient male mice were found to be more susceptible to BLM-treatment.	Bleomycin	76-79	solute carrier organic anion transporter family, member 2a1	Mus musculus	11-18
33101446-0	2020	Feibi Recipe Reduced Pulmonary Fibrosis Induced by Bleomycin in Mice by Regulating BRP39/IL-17 and TGFbeta1/Smad3 Signal Pathways.	Bleomycin	51-60	chitinase-like 1	Mus musculus	83-88
33101446-0	2020	Feibi Recipe Reduced Pulmonary Fibrosis Induced by Bleomycin in Mice by Regulating BRP39/IL-17 and TGFbeta1/Smad3 Signal Pathways.	Bleomycin	51-60	interleukin 17A	Mus musculus	89-94
33101446-0	2020	Feibi Recipe Reduced Pulmonary Fibrosis Induced by Bleomycin in Mice by Regulating BRP39/IL-17 and TGFbeta1/Smad3 Signal Pathways.	Bleomycin	51-60	transforming growth factor, beta 1	Mus musculus	99-107
33101446-0	2020	Feibi Recipe Reduced Pulmonary Fibrosis Induced by Bleomycin in Mice by Regulating BRP39/IL-17 and TGFbeta1/Smad3 Signal Pathways.	Bleomycin	51-60	SMAD family member 3	Mus musculus	108-113
33020583-0	2020	Spred2-deficiency enhances the proliferation of lung epithelial cells and alleviates pulmonary fibrosis induced by bleomycin.	Bleomycin	115-124	sprouty-related EVH1 domain containing 2	Mus musculus	0-6
33020583-2	2020	Here, we examined the role of Sprouty-related EVH-1-domain-containing protein (Spred) 2, a negative regulator of the MAPK-ERK pathway, in the development of bleomycin (BLM)-induced pulmonary fibrosis (PF).	Bleomycin	157-166	sprouty-related EVH1 domain containing 2	Mus musculus	30-87
32841217-8	2020	Treatment of fLfs or mice having bleomycin- or TGF-beta1-induced lung fibrosis with CSP/CSP7, reduced the expression of glycolytic enzymes and HIF-1alpha.	Bleomycin	33-42	DnaJ heat shock protein family (Hsp40) member C5	Mus musculus	84-87
32841217-8	2020	Treatment of fLfs or mice having bleomycin- or TGF-beta1-induced lung fibrosis with CSP/CSP7, reduced the expression of glycolytic enzymes and HIF-1alpha.	Bleomycin	33-42	hypoxia inducible factor 1, alpha subunit	Mus musculus	143-153
32912432-6	2020	In addition, GA diminished the increase in the numbers of CD4+CD69+ and CD8+CD69+ T cells and dendritic cells induced by bleomycin, and reduced the residence of inflammatory cells in the lung tissues.	Bleomycin	121-130	CD4 antigen	Mus musculus	58-61
32912432-6	2020	In addition, GA diminished the increase in the numbers of CD4+CD69+ and CD8+CD69+ T cells and dendritic cells induced by bleomycin, and reduced the residence of inflammatory cells in the lung tissues.	Bleomycin	121-130	CD69 antigen	Mus musculus	76-80
33155239-0	2020	Evogliptin attenuates bleomycin-induced lung fibrosis via inhibiting TGF-beta/Smad signaling in fibroblast.	Bleomycin	22-31	transforming growth factor alpha	Mus musculus	69-77
32808374-5	2020	Bleomycin-induced pulmonary fibrosis was established in wild-type (WT) and Ogg1-/- mice.	Bleomycin	0-9	8-oxoguanine DNA-glycosylase 1	Mus musculus	75-79
32808374-11	2020	Moreover, we demonstrated that Ogg1 deficiency relieved pulmonary fibrosis in bleomycin-treated mice.	Bleomycin	78-87	8-oxoguanine DNA-glycosylase 1	Mus musculus	31-35
32808374-12	2020	Ogg1 knockout decreased the bleomycin-induced expression of Smad7 and phosphorylation of Smad2/3 in mice.	Bleomycin	28-37	8-oxoguanine DNA-glycosylase 1	Mus musculus	0-4
32808374-12	2020	Ogg1 knockout decreased the bleomycin-induced expression of Smad7 and phosphorylation of Smad2/3 in mice.	Bleomycin	28-37	SMAD family member 7	Mus musculus	60-65
32808374-12	2020	Ogg1 knockout decreased the bleomycin-induced expression of Smad7 and phosphorylation of Smad2/3 in mice.	Bleomycin	28-37	SMAD family member 2	Mus musculus	89-96
33130749-3	2020	Bleomycin, etoposide, and cisplatin(BEP)chemotherapy resulted decreased his serum AFP.	Bleomycin	0-9	alpha fetoprotein	Homo sapiens	82-85
32762376-0	2020	Atractylenolide III attenuates Bleomycin-induced experimental pulmonary fibrosis and oxidative stress in rat model via Nrf2/NQO1/HO-1 pathway activation.	Bleomycin	31-40	NFE2 like bZIP transcription factor 2	Rattus norvegicus	119-123
32762376-0	2020	Atractylenolide III attenuates Bleomycin-induced experimental pulmonary fibrosis and oxidative stress in rat model via Nrf2/NQO1/HO-1 pathway activation.	Bleomycin	31-40	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	124-128
32762376-0	2020	Atractylenolide III attenuates Bleomycin-induced experimental pulmonary fibrosis and oxidative stress in rat model via Nrf2/NQO1/HO-1 pathway activation.	Bleomycin	31-40	heme oxygenase 1	Rattus norvegicus	129-133
32731178-0	2020	Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix.	Bleomycin	49-58	dipeptidyl peptidase 4	Homo sapiens	16-20
32731178-0	2020	Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix.	Bleomycin	49-58	dipeptidyl peptidase 4	Homo sapiens	21-25
32731178-9	2020	RESULTS: Vildagliptin effectively attenuated inflammation and fibrosis in bleomycin-induced pulmonary tissue via inhibiting the activity of CD26/DPP4.	Bleomycin	74-83	dipeptidyl peptidase 4	Homo sapiens	140-144
32731178-9	2020	RESULTS: Vildagliptin effectively attenuated inflammation and fibrosis in bleomycin-induced pulmonary tissue via inhibiting the activity of CD26/DPP4.	Bleomycin	74-83	dipeptidyl peptidase 4	Homo sapiens	145-149
33071807-15	2020	After bleomycin treatment cellular markers of endoplasmic reticulum stress (p-Perk and p-EIF-2alpha) were positive within the septal wall and ventilation with PEEP = 1 cmH2O ventilation increased the surface area stained positively for p-EIF-2alpha.	Bleomycin	6-15	eukaryotic translation initiation factor 2A	Rattus norvegicus	89-99
33071807-15	2020	After bleomycin treatment cellular markers of endoplasmic reticulum stress (p-Perk and p-EIF-2alpha) were positive within the septal wall and ventilation with PEEP = 1 cmH2O ventilation increased the surface area stained positively for p-EIF-2alpha.	Bleomycin	6-15	eukaryotic translation initiation factor 2A	Rattus norvegicus	238-248
32947367-0	2020	Sex-determining region Y-box 2-positive alveolar cells are responsive to bleomycin-induced lung injury.	Bleomycin	73-82	SRY-box transcription factor 2	Homo sapiens	0-30
32938936-6	2020	In the murine bleomycin-induced lung fibrosis model, GSK3008348 engages alphavbeta6, induces prolonged inhibition of TGFbeta signaling and reduces lung collagen deposition and serum C3M, a marker of IPF disease progression.	Bleomycin	14-23	transforming growth factor alpha	Mus musculus	117-124
32482644-9	2020	Knockout of PGC-1alpha in fibroblasts prevented skin fibrosis induced by bleomycin and by overexpression of a constitutively active TGFbeta receptor type I.	Bleomycin	73-82	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	12-22
33042414-0	2020	Olmesartan alleviates bleomycin-mediated vascular smooth muscle cell senescence via the miR-665/SDC1 axis.	Bleomycin	22-31	microRNA 665	Homo sapiens	88-95
33042414-0	2020	Olmesartan alleviates bleomycin-mediated vascular smooth muscle cell senescence via the miR-665/SDC1 axis.	Bleomycin	22-31	syndecan 1	Homo sapiens	96-100
32937976-3	2020	This study aimed to examine the association of p38 activity in the lungs with bleomycin (BLM)-induced pulmonary fibrosis and its transcriptomic profiling.	Bleomycin	78-87	mitogen-activated protein kinase 14	Mus musculus	47-50
32937976-3	2020	This study aimed to examine the association of p38 activity in the lungs with bleomycin (BLM)-induced pulmonary fibrosis and its transcriptomic profiling.	Bleomycin	89-92	mitogen-activated protein kinase 14	Mus musculus	47-50
32585629-3	2020	This study showed that miR-301a was overexpressed in a bleomycin-induced murine model of pulmonary fibrosis and patients with idiopathic pulmonary fibrosis (IPF).	Bleomycin	55-64	microRNA 301	Mus musculus	23-31
32585629-5	2020	The genetic ablation of miR-301a in mice reduced bleomycin-induced lung fibrosis, and the downregulation of miR-301a restrained proliferation and activation of fibroblasts.	Bleomycin	49-58	microRNA 301	Mus musculus	24-32
32585629-7	2020	The blocking of miR-301a by the intravenous injection of antagomiR-301a inhibited the proliferation of fibroblasts and the structural destruction of lung tissues in the bleomycin-induced lung fibrosis mouse model.	Bleomycin	169-178	microRNA 301	Mus musculus	16-24
32720744-6	2020	FOXO3a ablation in MEFs harboring the mutational reporter gene lacZ resulted in an increase in genome rearrangements after bleomycin treatment; conversely, overexpression of human FOXO3a was found to suppress mutation accumulation in response to bleomycin.	Bleomycin	123-132	forkhead box O3	Homo sapiens	0-6
32720744-6	2020	FOXO3a ablation in MEFs harboring the mutational reporter gene lacZ resulted in an increase in genome rearrangements after bleomycin treatment; conversely, overexpression of human FOXO3a was found to suppress mutation accumulation in response to bleomycin.	Bleomycin	123-132	forkhead box O3	Homo sapiens	180-186
32720744-6	2020	FOXO3a ablation in MEFs harboring the mutational reporter gene lacZ resulted in an increase in genome rearrangements after bleomycin treatment; conversely, overexpression of human FOXO3a was found to suppress mutation accumulation in response to bleomycin.	Bleomycin	246-255	forkhead box O3	Homo sapiens	0-6
32720744-6	2020	FOXO3a ablation in MEFs harboring the mutational reporter gene lacZ resulted in an increase in genome rearrangements after bleomycin treatment; conversely, overexpression of human FOXO3a was found to suppress mutation accumulation in response to bleomycin.	Bleomycin	246-255	forkhead box O3	Homo sapiens	180-186
32482644-10	2020	Moreover, pharmacological inhibition of PGC-1alpha by SR18292 induced regression of pre-established, bleomycin-induced skin fibrosis.	Bleomycin	101-110	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	40-50
32619930-0	2020	Inhibition of PIM1 kinase attenuates bleomycin-induced pulmonary fibrosis in mice by modulating the ZEB1/E-cadherin pathway in alveolar epithelial cells.	Bleomycin	37-46	proviral integration site 1	Mus musculus	14-18
32656894-4	2020	In the bleomycin (BLM) model of lung fibrosis, CKO mice had reduced fibrosis, lesser fibroblast ERK activation, and diminished immune cell STAT3 phosphorylation.	Bleomycin	18-21	mitogen-activated protein kinase 1	Mus musculus	96-99
32656894-4	2020	In the bleomycin (BLM) model of lung fibrosis, CKO mice had reduced fibrosis, lesser fibroblast ERK activation, and diminished immune cell STAT3 phosphorylation.	Bleomycin	18-21	signal transducer and activator of transcription 3	Mus musculus	139-144
32377772-0	2020	Zingerone ameliorates oxidative stress and inflammation in bleomycin-induced pulmonary fibrosis: modulation of the expression of TGF-beta1 and iNOS.	Bleomycin	59-68	transforming growth factor, beta 1	Rattus norvegicus	129-138
32619930-0	2020	Inhibition of PIM1 kinase attenuates bleomycin-induced pulmonary fibrosis in mice by modulating the ZEB1/E-cadherin pathway in alveolar epithelial cells.	Bleomycin	37-46	zinc finger E-box binding homeobox 1	Mus musculus	100-104
32619930-0	2020	Inhibition of PIM1 kinase attenuates bleomycin-induced pulmonary fibrosis in mice by modulating the ZEB1/E-cadherin pathway in alveolar epithelial cells.	Bleomycin	37-46	cadherin 1	Mus musculus	105-115
32619930-3	2020	In the current study, we investigated whether PIM1 inhibition would improve bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	87-90	proviral integration site 1	Mus musculus	46-50
32434004-3	2020	USP13 was increased in primary adult lung fibroblasts isolated from bleomycin-challenged mice and transforming growth factor (TGF)-beta1-treated primary mouse lung fibroblasts.	Bleomycin	68-77	ubiquitin specific peptidase 13 (isopeptidase T-3)	Mus musculus	0-5
32434004-4	2020	In a bleomycin-induced murine model of lung fibrosis, USP13-deficient mice showed reduced ECM levels such as fibronectin (FN) and collagen compared with wild-type mice.	Bleomycin	5-14	ubiquitin specific peptidase 13 (isopeptidase T-3)	Mus musculus	54-59
33312213-8	2020	The data showed that wnt and beta-catenin gene expression were elevated in grape sap treated animals versus bleomycin group (P < 0.01 and 0.001, respectively).	Bleomycin	108-117	Wnt family member 2	Rattus norvegicus	21-24
33312213-8	2020	The data showed that wnt and beta-catenin gene expression were elevated in grape sap treated animals versus bleomycin group (P < 0.01 and 0.001, respectively).	Bleomycin	108-117	catenin beta 1	Rattus norvegicus	29-41
32491951-9	2020	Dermo1-Cre/Ptpraf/f mice were protected from bleomycin-induced pulmonary fibrosis, whereas Sftpc-CreERT2/Ptpraf/f mice developed pulmonary fibrosis equivalent to controls.	Bleomycin	45-54	twist basic helix-loop-helix transcription factor 2	Mus musculus	0-6
32848143-3	2020	Here we show that an ER protein disulfide isomerase, thioredoxin domain containing 5 (TXNDC5), is highly upregulated in the lung tissues from both patients with idiopathic pulmonary fibrosis and a mouse model of bleomycin (BLM)-induced PF.	Bleomycin	212-221	epiregulin	Homo sapiens	21-23
32848143-3	2020	Here we show that an ER protein disulfide isomerase, thioredoxin domain containing 5 (TXNDC5), is highly upregulated in the lung tissues from both patients with idiopathic pulmonary fibrosis and a mouse model of bleomycin (BLM)-induced PF.	Bleomycin	212-221	thioredoxin domain containing 5	Homo sapiens	53-84
32848143-3	2020	Here we show that an ER protein disulfide isomerase, thioredoxin domain containing 5 (TXNDC5), is highly upregulated in the lung tissues from both patients with idiopathic pulmonary fibrosis and a mouse model of bleomycin (BLM)-induced PF.	Bleomycin	212-221	thioredoxin domain containing 5	Homo sapiens	86-92
32848143-3	2020	Here we show that an ER protein disulfide isomerase, thioredoxin domain containing 5 (TXNDC5), is highly upregulated in the lung tissues from both patients with idiopathic pulmonary fibrosis and a mouse model of bleomycin (BLM)-induced PF.	Bleomycin	223-226	epiregulin	Homo sapiens	21-23
32848143-3	2020	Here we show that an ER protein disulfide isomerase, thioredoxin domain containing 5 (TXNDC5), is highly upregulated in the lung tissues from both patients with idiopathic pulmonary fibrosis and a mouse model of bleomycin (BLM)-induced PF.	Bleomycin	223-226	thioredoxin domain containing 5	Homo sapiens	53-84
32848143-3	2020	Here we show that an ER protein disulfide isomerase, thioredoxin domain containing 5 (TXNDC5), is highly upregulated in the lung tissues from both patients with idiopathic pulmonary fibrosis and a mouse model of bleomycin (BLM)-induced PF.	Bleomycin	223-226	thioredoxin domain containing 5	Homo sapiens	86-92
32831060-7	2020	Samples with high hub genes expression presented with better response to immune check point block (ICB) therapy and sensitivity to bleomycin and methotrexate.	Bleomycin	131-140	ELAV like RNA binding protein 2	Homo sapiens	18-21
32831060-10	2020	Patients with high hub gene expression had a better response to ICB treatment, bleomycin and methotrexate.	Bleomycin	79-88	ELAV like RNA binding protein 2	Homo sapiens	19-22
32882513-4	2020	These developmental defects worsen lipopolysaccharide-induced acute lung injury and bleomycin-induced lung fibrosis in adult Adamts18-deficient mice.	Bleomycin	84-93	a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 18	Mus musculus	125-133
32764262-2	2020	We reported increased sphingosine kinase 1 (SPHK1) in IPF lungs and that SPHK1 inhibition using genetic and pharmacologic approaches reduces murine bleomycin-induced pulmonary fibrosis.	Bleomycin	148-157	sphingosine kinase 1	Mus musculus	22-42
32764262-2	2020	We reported increased sphingosine kinase 1 (SPHK1) in IPF lungs and that SPHK1 inhibition using genetic and pharmacologic approaches reduces murine bleomycin-induced pulmonary fibrosis.	Bleomycin	148-157	sphingosine kinase 1	Mus musculus	73-78
32953731-0	2020	Ligustilide modulates oxidative stress, apoptosis, and immunity to avoid pathological damages in bleomycin induced pulmonary fibrosis rats via inactivating TLR4/MyD88/NF-KB P65.	Bleomycin	97-106	toll-like receptor 4	Rattus norvegicus	156-160
32953731-12	2020	Conclusions: LIG improved bleomycin-induced PF with improved ventilation, reduced fibroblast, reduced oxidative stress and apoptosis, and rebalanced Th1/Th2 immunity, through TLR4/MyD88/NF-kappaB P65 signaling.	Bleomycin	26-35	toll-like receptor 4	Rattus norvegicus	175-179
32953731-12	2020	Conclusions: LIG improved bleomycin-induced PF with improved ventilation, reduced fibroblast, reduced oxidative stress and apoptosis, and rebalanced Th1/Th2 immunity, through TLR4/MyD88/NF-kappaB P65 signaling.	Bleomycin	26-35	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	180-185
32311453-10	2020	Bleomycin increases lung ROS and downregulates caveolin-1 leading to fibroblast proliferation and fibrosis.	Bleomycin	0-9	caveolin 1	Rattus norvegicus	47-57
32311453-11	2020	Combined cigarette smoke and bleomycin exposure, results in differential caveolin-1 expression and heterogeneous parenchymal remodeling with alternating areas of emphysema and fibrosis.	Bleomycin	29-38	caveolin 1	Rattus norvegicus	73-83
32535102-0	2020	Myricetin ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-beta signaling via targeting HSP90beta.	Bleomycin	22-31	transforming growth factor alpha	Mus musculus	81-89
32596871-0	2020	Toll interacting protein protects bronchial epithelial cells from bleomycin-induced apoptosis.	Bleomycin	66-75	toll interacting protein	Homo sapiens	0-24
32596871-8	2020	Using overexpression and silencing approaches, we demonstrate that TOLLIP protects cells from bleomycin-induced apoptosis using primary bronchial epithelial cells and BEAS-2B cells.	Bleomycin	94-103	toll interacting protein	Homo sapiens	67-73
31786302-0	2020	A novel peptide binding to the C-terminal domain of connective tissue growth factor for the treatment of bleomycin-induced pulmonary fibrosis.	Bleomycin	105-114	cellular communication network factor 2	Homo sapiens	52-83
32535538-0	2020	Effect of curcumin on IL-17A mediated pulmonary AMPK kinase/cyclooxygenase-2 expressions via activation of NFkappaB in bleomycin-induced acute lung injury in vivo.	Bleomycin	119-128	interleukin 17A	Mus musculus	22-28
32535538-2	2020	Bleomycin (BLM) injury activates the pro-inflammatory cytokine Interleukin L-17A which regulates the expression of COX-2 and inhibits P-AMPKalpha in BLM/IL-17A exposed mice upon activation of NFkappaB and other inflammatory molecules the actual mechanism behind which remains unclear.	Bleomycin	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	115-120
32535538-2	2020	Bleomycin (BLM) injury activates the pro-inflammatory cytokine Interleukin L-17A which regulates the expression of COX-2 and inhibits P-AMPKalpha in BLM/IL-17A exposed mice upon activation of NFkappaB and other inflammatory molecules the actual mechanism behind which remains unclear.	Bleomycin	0-9	interleukin 17A	Mus musculus	153-159
32535538-2	2020	Bleomycin (BLM) injury activates the pro-inflammatory cytokine Interleukin L-17A which regulates the expression of COX-2 and inhibits P-AMPKalpha in BLM/IL-17A exposed mice upon activation of NFkappaB and other inflammatory molecules the actual mechanism behind which remains unclear.	Bleomycin	11-14	cytochrome c oxidase II, mitochondrial	Mus musculus	115-120
32535538-2	2020	Bleomycin (BLM) injury activates the pro-inflammatory cytokine Interleukin L-17A which regulates the expression of COX-2 and inhibits P-AMPKalpha in BLM/IL-17A exposed mice upon activation of NFkappaB and other inflammatory molecules the actual mechanism behind which remains unclear.	Bleomycin	11-14	interleukin 17A	Mus musculus	153-159
32428667-0	2020	Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis.	Bleomycin	21-30	NLR family, pyrin domain containing 3	Mus musculus	73-78
31997260-11	2020	Furthermore, a significant increase was seen in lung GSH content, catalase, and GPx activities in the Crocin/Bleomycin-treated group as compared with Bleomycin-treated group.	Bleomycin	109-118	catalase	Rattus norvegicus	66-74
33841872-0	2021	Complement C5 inhibition reverses bleomycin-induced thrombotic microangiopathy.	Bleomycin	34-43	complement C5	Homo sapiens	0-13
32751253-4	2020	The direct LAP1:TRF2 binding was validated in vitro by blot overlay and in vivo by co-immunoprecipitation after hydrogen peroxide and bleomycin treatments.	Bleomycin	134-143	torsin 1A interacting protein 1	Homo sapiens	11-15
32751253-4	2020	The direct LAP1:TRF2 binding was validated in vitro by blot overlay and in vivo by co-immunoprecipitation after hydrogen peroxide and bleomycin treatments.	Bleomycin	134-143	telomeric repeat binding factor 2	Homo sapiens	16-20
32751253-6	2020	The involvement of LAP1 and TRF2 in the DDR was confirmed by their increased nuclear protein levels after bleomycin treatment, evaluated by immunoblotting, as well as by their co-localization with DDR factors at the NE and within the nucleoplasm, assessed by immunocytochemistry.	Bleomycin	106-115	torsin 1A interacting protein 1	Homo sapiens	19-23
32751253-6	2020	The involvement of LAP1 and TRF2 in the DDR was confirmed by their increased nuclear protein levels after bleomycin treatment, evaluated by immunoblotting, as well as by their co-localization with DDR factors at the NE and within the nucleoplasm, assessed by immunocytochemistry.	Bleomycin	106-115	telomeric repeat binding factor 2	Homo sapiens	28-32
32766584-0	2020	A Novel CD206 Targeting Peptide Inhibits Bleomycin Induced Pulmonary Fibrosis in Mice.	Bleomycin	41-50	mannose receptor, C type 1	Mus musculus	8-13
32649526-0	2020	Corrigendum: Follistatin-Like 1 Promotes Bleomycin-Induced Pulmonary Fibrosis Through the Transforming Growth Factor Beta 1/Mitogen-Activated Protein Kinase Signaling Pathway.	Bleomycin	41-50	follistatin like 1	Homo sapiens	13-31
32649526-0	2020	Corrigendum: Follistatin-Like 1 Promotes Bleomycin-Induced Pulmonary Fibrosis Through the Transforming Growth Factor Beta 1/Mitogen-Activated Protein Kinase Signaling Pathway.	Bleomycin	41-50	transforming growth factor beta 1	Homo sapiens	90-123
31776321-5	2020	Furthermore, we determined the role of the selected miRNA in an in-vivo pulmonary fibrosis model.ResultsMiRNA array analysis revealed that miR-22 expression was increased by up to 2 fold on day 7 after bleomycin treatment compared with that in vehicle-treated mice.	Bleomycin	202-211	microRNA 22	Mus musculus	139-145
31776321-10	2020	In vivo, administration of a miR-22 mimic on day 10 after bleomycin challenge ameliorated pulmonary fibrosis lesions accompanied by decreased alpha-SMA expression in the model mice.ConclusionsExosomal miR-22 modulates fibroblast-to-myofibroblast differentiation.	Bleomycin	58-67	microRNA 22	Mus musculus	29-35
31776321-10	2020	In vivo, administration of a miR-22 mimic on day 10 after bleomycin challenge ameliorated pulmonary fibrosis lesions accompanied by decreased alpha-SMA expression in the model mice.ConclusionsExosomal miR-22 modulates fibroblast-to-myofibroblast differentiation.	Bleomycin	58-67	actin alpha 2, smooth muscle, aorta	Mus musculus	142-151
31776321-10	2020	In vivo, administration of a miR-22 mimic on day 10 after bleomycin challenge ameliorated pulmonary fibrosis lesions accompanied by decreased alpha-SMA expression in the model mice.ConclusionsExosomal miR-22 modulates fibroblast-to-myofibroblast differentiation.	Bleomycin	58-67	microRNA 22	Mus musculus	201-207
32630842-4	2020	Ku70 immunoprecipitations and immunoblots confirmed our theory that Ku70-deacetylation, Ku70/FLIP complex, myofibroblast resistance to apoptosis, cell survival, and lung fibrosis in bleomycin-treated mice, are reduced and regulated by CMH.	Bleomycin	182-191	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	68-72
32630813-1	2020	In contrast to normal regenerating tissue, resistance to Fas- and FasL-positive T cell-induced apoptosis were detected in myofibroblasts from fibrotic-lungs of humans and mice following bleomycin (BLM) exposure.	Bleomycin	186-195	Fas ligand	Homo sapiens	66-70
32630842-4	2020	Ku70 immunoprecipitations and immunoblots confirmed our theory that Ku70-deacetylation, Ku70/FLIP complex, myofibroblast resistance to apoptosis, cell survival, and lung fibrosis in bleomycin-treated mice, are reduced and regulated by CMH.	Bleomycin	182-191	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	0-4
32630825-0	2020	Nintedanib Reduces Neutrophil Chemotaxis via Activating GRK2 in Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	64-73	G protein-coupled receptor kinase 2	Mus musculus	56-60
32374674-5	2020	GAS5 expression was downregulated in cultured fibroblasts by TGF-beta and in resident fibroblasts from bleomycin-treated skin tissues.	Bleomycin	103-112	growth arrest specific 5	Mus musculus	0-4
32374674-9	2020	Importantly, local delivery of GAS5 via adenoviral vector suppressed bleomycin-induced skin fibrosis in mice.	Bleomycin	69-78	growth arrest specific 5	Mus musculus	31-35
32729248-8	2020	Further top ACE2 regulators in vivo or in primary cells include erlotinib and bleomycin in the lung and vancomycin, cisplatin, and probenecid in the kidney.	Bleomycin	78-87	angiotensin converting enzyme 2	Homo sapiens	12-16
32616042-0	2020	CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis.	Bleomycin	66-75	cyclin dependent kinase 4	Homo sapiens	0-6
32519817-5	2020	Lastly, administration of the GLS1 inhibitor CB-839 attenuated bleomycin-induced pulmonary fibrosis.	Bleomycin	63-72	glutaminase	Homo sapiens	30-34
32115350-0	2020	Corrigendum to "Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis" [Int.	Bleomycin	47-56	ATPase, class II, type 9A	Mus musculus	27-30
32115350-0	2020	Corrigendum to "Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis" [Int.	Bleomycin	47-56	thymoma viral proto-oncogene 1	Mus musculus	111-114
32115350-0	2020	Corrigendum to "Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis" [Int.	Bleomycin	47-56	mechanistic target of rapamycin kinase	Mus musculus	115-119
32115350-0	2020	Corrigendum to "Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis" [Int.	Bleomycin	47-56	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	120-126
32548952-0	2020	Asiaticoside might attenuate bleomycin-induced pulmonary fibrosis by activating cAMP and Rap1 signalling pathway assisted by A2AR.	Bleomycin	29-38	RAS-related protein 1a	Mus musculus	89-93
32103153-3	2020	Here we show that TSLP receptor (TSLPR)-deficient mice (Tslpr-/-) and mice treated with anti-TSLP antibodies exhibited increased airway inflammation and morbidity rates after bleomycin-induced tissue damage.	Bleomycin	175-184	cytokine receptor-like factor 2	Mus musculus	18-31
32103153-3	2020	Here we show that TSLP receptor (TSLPR)-deficient mice (Tslpr-/-) and mice treated with anti-TSLP antibodies exhibited increased airway inflammation and morbidity rates after bleomycin-induced tissue damage.	Bleomycin	175-184	cytokine receptor-like factor 2	Mus musculus	33-38
32103153-3	2020	Here we show that TSLP receptor (TSLPR)-deficient mice (Tslpr-/-) and mice treated with anti-TSLP antibodies exhibited increased airway inflammation and morbidity rates after bleomycin-induced tissue damage.	Bleomycin	175-184	cytokine receptor-like factor 2	Mus musculus	56-61
32103153-3	2020	Here we show that TSLP receptor (TSLPR)-deficient mice (Tslpr-/-) and mice treated with anti-TSLP antibodies exhibited increased airway inflammation and morbidity rates after bleomycin-induced tissue damage.	Bleomycin	175-184	thymic stromal lymphopoietin	Mus musculus	18-22
32103153-5	2020	Consistent with this finding, we showed that TSLP reduces caspase-1 and caspase-3 activity levels in primary human bronchial epithelial cells treated with bleomycin via Bcl-xL up-regulation.	Bleomycin	155-164	thymic stromal lymphopoietin	Homo sapiens	45-49
32103153-5	2020	Consistent with this finding, we showed that TSLP reduces caspase-1 and caspase-3 activity levels in primary human bronchial epithelial cells treated with bleomycin via Bcl-xL up-regulation.	Bleomycin	155-164	caspase 1	Homo sapiens	58-67
32103153-5	2020	Consistent with this finding, we showed that TSLP reduces caspase-1 and caspase-3 activity levels in primary human bronchial epithelial cells treated with bleomycin via Bcl-xL up-regulation.	Bleomycin	155-164	caspase 3	Homo sapiens	72-81
32103153-5	2020	Consistent with this finding, we showed that TSLP reduces caspase-1 and caspase-3 activity levels in primary human bronchial epithelial cells treated with bleomycin via Bcl-xL up-regulation.	Bleomycin	155-164	BCL2 like 1	Homo sapiens	169-175
32022972-2	2020	Here, we show that COM1 confers the tolerance against DNA damages for rice plants caused by the chemicals, bleomycin and mitomycin C, while COM1 mutation did not compromise HR efficiencies and HR factors (RAD51 and RAD51 paralogs) localization to irradiation-induced DSBs.	Bleomycin	107-116	nuclear protein transcription regulator 1	Mus musculus	19-23
32423816-0	2020	Asiaticoside attenuates bleomycin-induced pulmonary fibrosis in A2aR-/- mice by promoting the BMP7/Smad1/5 signaling pathway.	Bleomycin	24-33	adenosine A2a receptor	Mus musculus	64-68
32423816-0	2020	Asiaticoside attenuates bleomycin-induced pulmonary fibrosis in A2aR-/- mice by promoting the BMP7/Smad1/5 signaling pathway.	Bleomycin	24-33	bone morphogenetic protein 7	Mus musculus	94-98
32423816-0	2020	Asiaticoside attenuates bleomycin-induced pulmonary fibrosis in A2aR-/- mice by promoting the BMP7/Smad1/5 signaling pathway.	Bleomycin	24-33	SMAD family member 1	Mus musculus	99-106
32630842-4	2020	Ku70 immunoprecipitations and immunoblots confirmed our theory that Ku70-deacetylation, Ku70/FLIP complex, myofibroblast resistance to apoptosis, cell survival, and lung fibrosis in bleomycin-treated mice, are reduced and regulated by CMH.	Bleomycin	182-191	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	68-72
32305327-5	2020	GDF15 mRNA expression was elevated in the lungs of bleomycin-treated mice, revealed by comprehensive gene analysis.	Bleomycin	51-60	growth differentiation factor 15	Mus musculus	0-5
32305327-7	2020	Bleomycin administration in mice resulted in a marked increase in senescence-associated beta-galactosidase-positive and p16INK4a-positive lung structural cells including alveolar epithelial cells and macrophages.	Bleomycin	0-9	cyclin dependent kinase inhibitor 2A	Mus musculus	120-128
32305327-8	2020	Immunohistochemical staining using anti-GDF15 antibody and increased mRNA expression of GDF15 in bleomycin-induced senescent A549 cells indicated that GDF15 is produced from alveolar epithelial cells undergoing bleomycin-induced cellular senescence.	Bleomycin	97-106	growth differentiation factor 15	Mus musculus	88-93
32305327-8	2020	Immunohistochemical staining using anti-GDF15 antibody and increased mRNA expression of GDF15 in bleomycin-induced senescent A549 cells indicated that GDF15 is produced from alveolar epithelial cells undergoing bleomycin-induced cellular senescence.	Bleomycin	97-106	growth differentiation factor 15	Mus musculus	88-93
32550106-10	2020	Besides, phosphorylated SMAD2, phosphorylated SMAD3, phosphorylated Akt and phosphorylated ERK1/2 were all significantly increased after bleomycin treatment and decreased to normal levels after metformin intervention.	Bleomycin	137-146	AKT serine/threonine kinase 1	Homo sapiens	68-71
32550106-10	2020	Besides, phosphorylated SMAD2, phosphorylated SMAD3, phosphorylated Akt and phosphorylated ERK1/2 were all significantly increased after bleomycin treatment and decreased to normal levels after metformin intervention.	Bleomycin	137-146	mitogen-activated protein kinase 3	Homo sapiens	91-97
31872544-8	2020	Interruption of the LTB4 -BLT1 axis in mouse models of SSc significantly mitigated dermal and pulmonary fibrosis, with 54.00% and 52.65% fewer alpha-smooth muscle actin-positive myofibroblasts accumulating in the skin and lungs of mice, respectively, after bleomycin challenge.	Bleomycin	257-266	leukotriene B4 receptor 1	Mus musculus	26-30
32130565-6	2020	In a bleomycin-induced mouse pulmonary fibrosis model, msFGFR2c alleviate pulmonary fibrosis and suppress the decrease in pro-SPC levels.	Bleomycin	5-14	surfactant associated protein C	Mus musculus	122-129
32187849-5	2020	Using a combination of in vitro and in vivo studies, we found that MTA1 was significantly up-regulated in bleomycin-induced fibrosis rats and TGF-beta1-treated alveolar type II epithelial (RLE-6TN) cells.	Bleomycin	106-115	metastasis associated 1	Rattus norvegicus	67-71
32017927-8	2020	Our results showed that inhibition of ERK1/2 signaling and the ubiquitous calpains both attenuated bleomycin (BLM)-induced lung fibrosis in mice.	Bleomycin	99-108	mitogen-activated protein kinase 3	Mus musculus	38-44
32017927-8	2020	Our results showed that inhibition of ERK1/2 signaling and the ubiquitous calpains both attenuated bleomycin (BLM)-induced lung fibrosis in mice.	Bleomycin	110-113	mitogen-activated protein kinase 3	Mus musculus	38-44
32017927-12	2020	Our study indicated that inhibition of the ERK1/2-ubiquitous calpains pathway protected pulmonary fibrosis from BLM, possibly via inhibition of EMT.	Bleomycin	112-115	mitogen-activated protein kinase 3	Homo sapiens	43-49
32187849-9	2020	Moreover, inhibition of MTA1 effectively attenuated bleomycin-induced fibrosis in rats.	Bleomycin	52-61	metastasis associated 1	Rattus norvegicus	24-28
32278510-0	2020	Protective effect of bleomycin on 5-azacitidine induced cytotoxicity and apoptosis in mice hematopoietic stem cells via Bcl-2/Bax and HMGB1 signaling pathway.	Bleomycin	21-30	B cell leukemia/lymphoma 2	Mus musculus	120-125
32352211-0	2020	HIP/PAP protects against bleomycin-induced lung injury and inflammation and subsequent fibrosis in mice.	Bleomycin	25-34	regenerating islet-derived 3 beta	Mus musculus	0-7
32352211-4	2020	Adenovirus-mediated HIP/PAP expression markedly alleviated bleomycin (BLM)-induced lung injury, inflammation, and fibrosis in mice.	Bleomycin	59-68	regenerating family member 3 alpha	Homo sapiens	20-27
32352211-4	2020	Adenovirus-mediated HIP/PAP expression markedly alleviated bleomycin (BLM)-induced lung injury, inflammation, and fibrosis in mice.	Bleomycin	70-73	regenerating family member 3 alpha	Homo sapiens	20-27
32323806-0	2020	Baicalin alleviates bleomycin-induced pulmonary fibrosis and fibroblast proliferation in rats via the PI3K/AKT signaling pathway.	Bleomycin	20-29	AKT serine/threonine kinase 1	Rattus norvegicus	107-110
32278510-0	2020	Protective effect of bleomycin on 5-azacitidine induced cytotoxicity and apoptosis in mice hematopoietic stem cells via Bcl-2/Bax and HMGB1 signaling pathway.	Bleomycin	21-30	BCL2-associated X protein	Mus musculus	126-129
32278510-0	2020	Protective effect of bleomycin on 5-azacitidine induced cytotoxicity and apoptosis in mice hematopoietic stem cells via Bcl-2/Bax and HMGB1 signaling pathway.	Bleomycin	21-30	high mobility group box 1	Mus musculus	134-139
32253243-0	2020	IRAK-M Regulates Monocyte Trafficking to the Lungs in Response to Bleomycin Challenge.	Bleomycin	66-75	interleukin-1 receptor-associated kinase 3	Mus musculus	0-6
32421439-0	2020	MicroRNA regulation post-bleomycin due to the R213G extracellular superoxide dismutase variant is predicted to suppress inflammatory and immune pathways.	Bleomycin	25-34	superoxide dismutase 3, extracellular	Mus musculus	52-86
32421439-2	2020	A naturally occurring single nucleotide polymorphism in the key extracellular antioxidant enzyme, extracellular superoxide dismutase (EC-SOD), results in an arginine to glycine substitution (R213G) which promotes resolution of inflammation and protection against bleomycin-induced ALI.	Bleomycin	263-272	superoxide dismutase 3, extracellular	Mus musculus	98-132
32421439-2	2020	A naturally occurring single nucleotide polymorphism in the key extracellular antioxidant enzyme, extracellular superoxide dismutase (EC-SOD), results in an arginine to glycine substitution (R213G) which promotes resolution of inflammation and protection against bleomycin-induced ALI.	Bleomycin	263-272	superoxide dismutase 3, extracellular	Mus musculus	134-140
32421439-3	2020	Previously we found that mice harboring the R213G mutation in EC-SOD exhibit a transcriptomic profile consistent with a striking suppression of inflammatory and immune pathways 7 days post-bleomycin.	Bleomycin	189-198	superoxide dismutase 3, extracellular	Mus musculus	62-68
32471489-7	2020	The anti-fibrotic potential of TRIM72 was tested with bleomycin-treated transgenic mice.	Bleomycin	54-63	tripartite motif-containing 72	Mus musculus	31-37
32453709-3	2020	Here, we found that lncRNA ZFAS1 was upregulated in bleomycin (BLM)-induced PF rats lung tissues and transforming growth factor-beta1 (TGF-beta1)-treated HFL1 cells, and positively correlated with the expression of solute carrier family 38 member 1 (SLC38A1), which is an important regulator of lipid peroxidation.	Bleomycin	52-61	ZNFX1 antisense RNA 1	Homo sapiens	27-32
32453709-3	2020	Here, we found that lncRNA ZFAS1 was upregulated in bleomycin (BLM)-induced PF rats lung tissues and transforming growth factor-beta1 (TGF-beta1)-treated HFL1 cells, and positively correlated with the expression of solute carrier family 38 member 1 (SLC38A1), which is an important regulator of lipid peroxidation.	Bleomycin	52-61	solute carrier family 38, member 1	Rattus norvegicus	215-248
32453709-3	2020	Here, we found that lncRNA ZFAS1 was upregulated in bleomycin (BLM)-induced PF rats lung tissues and transforming growth factor-beta1 (TGF-beta1)-treated HFL1 cells, and positively correlated with the expression of solute carrier family 38 member 1 (SLC38A1), which is an important regulator of lipid peroxidation.	Bleomycin	52-61	solute carrier family 38, member 1	Rattus norvegicus	250-257
32528292-0	2020	Polyporus Polysaccharide Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Suppressing Myofibroblast Differentiation via TGF-beta/Smad2/3 Pathway.	Bleomycin	37-46	transforming growth factor alpha	Mus musculus	123-131
32528292-0	2020	Polyporus Polysaccharide Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Suppressing Myofibroblast Differentiation via TGF-beta/Smad2/3 Pathway.	Bleomycin	37-46	SMAD family member 2	Mus musculus	132-139
32456371-20	2020	(5) On ID 7, p62 mRNA expression in the skin tissue of mice in bleomycin group was significantly lower than that in simple PBS group (t=0.93, P<0.05).	Bleomycin	63-72	nucleoporin 62	Mus musculus	13-16
32456371-21	2020	On ID 14 and 21, the mRNA expressions of p62, LC3 II, and Beclin-1 in the skin tissue of mice in bleomycin group were significantly higher than those in blank control group (t=0.74, 0.70, 0.58, 0.49, 0.51, 0.74, P<0.05) and simple PBS group (t=0.94, 0.65, 0.65, 0.77, 0.49, 0.51, P<0.05).	Bleomycin	97-106	nucleoporin 62	Mus musculus	41-44
32456371-21	2020	On ID 14 and 21, the mRNA expressions of p62, LC3 II, and Beclin-1 in the skin tissue of mice in bleomycin group were significantly higher than those in blank control group (t=0.74, 0.70, 0.58, 0.49, 0.51, 0.74, P<0.05) and simple PBS group (t=0.94, 0.65, 0.65, 0.77, 0.49, 0.51, P<0.05).	Bleomycin	97-106	beclin 1, autophagy related	Mus musculus	58-66
32456371-22	2020	On ID 28, the mRNA expressions of p62 and Beclin-1 in the skin tissue of mice in bleomycin group were significantly lower than those in blank control group (t=0.50, 0.44, P<0.05) and simple PBS group (t=0.97, 0.55, P<0.05), and that of LC3 II was significantly higher than that in blank control group and simple PBS group, respectively (t=0.51, 0.98, P <0.01).	Bleomycin	81-90	nucleoporin 62	Mus musculus	34-37
32456371-22	2020	On ID 28, the mRNA expressions of p62 and Beclin-1 in the skin tissue of mice in bleomycin group were significantly lower than those in blank control group (t=0.50, 0.44, P<0.05) and simple PBS group (t=0.97, 0.55, P<0.05), and that of LC3 II was significantly higher than that in blank control group and simple PBS group, respectively (t=0.51, 0.98, P <0.01).	Bleomycin	81-90	beclin 1, autophagy related	Mus musculus	42-50
32456371-24	2020	On ID 14, the protein expressions of p62 and Beclin-1 in the skin tissue of mice in bleomycin group were significantly higher than those in blank control group (t=0.86, 0.89, P<0.05) and simple PBS group (t=0.42, 0.89, P<0.05).	Bleomycin	84-93	nucleoporin 62	Mus musculus	37-40
32456371-24	2020	On ID 14, the protein expressions of p62 and Beclin-1 in the skin tissue of mice in bleomycin group were significantly higher than those in blank control group (t=0.86, 0.89, P<0.05) and simple PBS group (t=0.42, 0.89, P<0.05).	Bleomycin	84-93	beclin 1, autophagy related	Mus musculus	45-53
32456371-25	2020	On ID 21, the protein expressions of p62, LC3 II, and Beclin-1 in the skin tissue of mice in bleomycin group were significantly higher than those in blank control group and simple PBS group (t=0.82, 0.45, 0.50, 0.79, 0.51, 0.50, P<0.01).	Bleomycin	93-102	nucleoporin 62	Mus musculus	37-40
32456371-25	2020	On ID 21, the protein expressions of p62, LC3 II, and Beclin-1 in the skin tissue of mice in bleomycin group were significantly higher than those in blank control group and simple PBS group (t=0.82, 0.45, 0.50, 0.79, 0.51, 0.50, P<0.01).	Bleomycin	93-102	beclin 1, autophagy related	Mus musculus	54-62
32456371-26	2020	On ID 28, the protein expressions of p62, LC3 II, and Beclin-1 in the skin tissue of mice in bleomycin group were significantly lower than those in blank control group and simple PBS group (t=0.77, 0.54, 0.52, 0.50, 0.51, 0.50, P<0.05).	Bleomycin	93-102	nucleoporin 62	Mus musculus	37-40
32456371-26	2020	On ID 28, the protein expressions of p62, LC3 II, and Beclin-1 in the skin tissue of mice in bleomycin group were significantly lower than those in blank control group and simple PBS group (t=0.77, 0.54, 0.52, 0.50, 0.51, 0.50, P<0.05).	Bleomycin	93-102	beclin 1, autophagy related	Mus musculus	54-62
32253243-5	2020	In this study, we sought to determine how IL-1R-associated kinase-M (IRAK-M), a negative regulator of TLR signaling, modulates monocyte trafficking into the lungs in response to bleomycin.	Bleomycin	178-187	interleukin-1 receptor-associated kinase 3	Mus musculus	69-75
32253243-6	2020	Our data indicate that after bleomycin challenge, mice lacking IRAK-M have decreased monocyte trafficking and reduced Mo-AMs in their lungs.	Bleomycin	29-38	interleukin-1 receptor-associated kinase 3	Mus musculus	63-69
32253243-7	2020	Although IRAK-M expression did not regulate differences in chemokines, cytokines, or adhesion molecules associated with monocyte recruitment, IRAK-M was necessary for CCR2 upregulation following bleomycin challenge.	Bleomycin	195-204	interleukin-1 receptor-associated kinase 3	Mus musculus	142-148
32253243-7	2020	Although IRAK-M expression did not regulate differences in chemokines, cytokines, or adhesion molecules associated with monocyte recruitment, IRAK-M was necessary for CCR2 upregulation following bleomycin challenge.	Bleomycin	195-204	chemokine (C-C motif) receptor 2	Mus musculus	167-171
31860803-0	2020	FGFR2 is Required for AEC2 Homeostasis and Survival Following Bleomycin-Induced Lung Injury.	Bleomycin	62-71	fibroblast growth factor receptor 2	Mus musculus	0-5
31860803-7	2020	After intratracheal bleomycin administration, SPC-TCKO mice had increased mortality, lung edema, and BAL total protein, and flow cytometry and immunofluorescence revealed a loss of AEC2s.	Bleomycin	20-29	sparse coat	Mus musculus	46-49
31860803-8	2020	To reduce mortality of SPC-TCKO mice to &lt;50%, a 25-fold dose reduction of bleomycin was required.	Bleomycin	77-86	sparse coat	Mus musculus	23-26
31860803-9	2020	Surviving bleomycin-injured SPC-TCKO mice had increased collagen deposition, fibrosis, alphaSMA expression, and decreased epithelial gene expression.	Bleomycin	10-19	sparse coat	Mus musculus	28-31
31860803-9	2020	Surviving bleomycin-injured SPC-TCKO mice had increased collagen deposition, fibrosis, alphaSMA expression, and decreased epithelial gene expression.	Bleomycin	10-19	actin alpha 2, smooth muscle, aorta	Mus musculus	87-95
31860803-10	2020	Inducible inactivation of individual Fgfrs 2 or 3 revealed that Fgfr2, but not Fgfr3, was responsible for the increased mortality and lung injury after bleomycin administration.	Bleomycin	152-161	fibroblast growth factor receptor 2	Mus musculus	64-69
31860803-11	2020	In conclusion, AEC2-specific FGFR2 is critical for survival in response to bleomycin induced lung injury.	Bleomycin	75-84	fibroblast growth factor receptor 2	Mus musculus	29-34
31922885-8	2020	In contrast, mice with lung epithelial cell-specific deletion of CCL12 were protected from bleomycin-induced fibrosis and had expression of CCL2 and CCL7 similar to that of control mice treated with bleomycin.	Bleomycin	91-100	chemokine (C-C motif) ligand 12	Mus musculus	65-70
31922885-8	2020	In contrast, mice with lung epithelial cell-specific deletion of CCL12 were protected from bleomycin-induced fibrosis and had expression of CCL2 and CCL7 similar to that of control mice treated with bleomycin.	Bleomycin	199-208	chemokine (C-C motif) ligand 12	Mus musculus	65-70
32162383-8	2020	Moreover, marked elevation of LOX, TGF-beta and alpha-SMA was observed in bleomycin-treated VM samples.	Bleomycin	74-83	lysyl oxidase	Homo sapiens	30-33
32162383-8	2020	Moreover, marked elevation of LOX, TGF-beta and alpha-SMA was observed in bleomycin-treated VM samples.	Bleomycin	74-83	transforming growth factor alpha	Homo sapiens	35-43
32162383-8	2020	Moreover, marked elevation of LOX, TGF-beta and alpha-SMA was observed in bleomycin-treated VM samples.	Bleomycin	74-83	actin alpha 1, skeletal muscle	Homo sapiens	48-57
32162383-9	2020	Furthermore, our in vitro data demonstrated that both recombinant TGF-beta and bleomycin induced obvious increase of LOX expression and activity and a concomitant increase in ECM components in HUVEC, which could be reversed by LOX inhibition.	Bleomycin	79-88	lysyl oxidase	Homo sapiens	117-120
32162383-9	2020	Furthermore, our in vitro data demonstrated that both recombinant TGF-beta and bleomycin induced obvious increase of LOX expression and activity and a concomitant increase in ECM components in HUVEC, which could be reversed by LOX inhibition.	Bleomycin	79-88	lysyl oxidase	Homo sapiens	227-230
32436415-0	2020	Downregulation of PTEN mediates bleomycin-induced premature senescence in lung cancer cells by suppressing autophagy.	Bleomycin	32-41	phosphatase and tensin homolog	Homo sapiens	18-22
32436415-2	2020	We aimed to investigate the role of phosphatase and tensin homolog deleted on chromosome ten (PTEN) in bleomycin-induced premature senescence in lung cancer cells.	Bleomycin	103-112	phosphatase and tensin homolog	Homo sapiens	94-98
32436415-7	2020	PTEN expression was decreased and key downstream molecules in the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway were gradually activated following bleomycin treatment.	Bleomycin	183-192	phosphatase and tensin homolog	Homo sapiens	0-4
32436415-7	2020	PTEN expression was decreased and key downstream molecules in the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway were gradually activated following bleomycin treatment.	Bleomycin	183-192	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	66-91
32436415-7	2020	PTEN expression was decreased and key downstream molecules in the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway were gradually activated following bleomycin treatment.	Bleomycin	183-192	AKT serine/threonine kinase 1	Homo sapiens	99-102
32436415-7	2020	PTEN expression was decreased and key downstream molecules in the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway were gradually activated following bleomycin treatment.	Bleomycin	183-192	mechanistic target of rapamycin kinase	Homo sapiens	103-132
32436415-7	2020	PTEN expression was decreased and key downstream molecules in the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway were gradually activated following bleomycin treatment.	Bleomycin	183-192	mechanistic target of rapamycin kinase	Homo sapiens	134-138
32436415-10	2020	CONCLUSIONS: Downregulation of PTEN mediates bleomycin-induced premature senescence in lung cancer cells by suppressing autophagy via the PI3K/Akt/mTOR pathway.	Bleomycin	45-54	phosphatase and tensin homolog	Homo sapiens	31-35
32436415-10	2020	CONCLUSIONS: Downregulation of PTEN mediates bleomycin-induced premature senescence in lung cancer cells by suppressing autophagy via the PI3K/Akt/mTOR pathway.	Bleomycin	45-54	AKT serine/threonine kinase 1	Homo sapiens	143-146
32436415-10	2020	CONCLUSIONS: Downregulation of PTEN mediates bleomycin-induced premature senescence in lung cancer cells by suppressing autophagy via the PI3K/Akt/mTOR pathway.	Bleomycin	45-54	mechanistic target of rapamycin kinase	Homo sapiens	147-151
32349726-5	2020	Therefore, the aim of the present study was to investigate if the dietary antioxidant quercetin can exert anti-fibrotic effects in a mouse model of bleomycin-induced pulmonary fibrogenesis through Nrf2-dependent restoration of redox imbalance.	Bleomycin	148-157	nuclear factor, erythroid derived 2, like 2	Mus musculus	197-201
32349726-9	2020	Upon bleomycin treatment, quercetin-fed mice displayed reduced expression of collagen (COL1A2) and fibronectin (FN1) and a tendency of reduced inflammatory lesions (2.8 +- 0.7 versus 1.9 +- 0.8).	Bleomycin	5-14	collagen, type I, alpha 2	Mus musculus	77-93
32281584-4	2020	In bleomycin-induced mouse scleroderma skin, the number of LC3-positive puncta was significantly higher than that in phosphate buffered salts-injected control skin after 4 weeks of treatment.	Bleomycin	3-12	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	59-62
32601321-4	2020	Next, we further studied the potential inhibitory effect of G-CSF administration in mice with lung fibrosis induced by bleomycin.	Bleomycin	119-128	colony stimulating factor 3 (granulocyte)	Mus musculus	60-65
32601321-7	2020	The results showed that both preventative and therapeutic G-CSF administration could significantly inhibit bleomycin-induced pulmonary fibrosis.	Bleomycin	107-116	colony stimulating factor 3 (granulocyte)	Mus musculus	58-63
32601321-10	2020	In conclusion, G-CSF exerted antifibrotic effects in bleomycin-induced lung fibrosis, in part by promoting BMSC homing to injured lung tissues via SDF-1/CXCR4 chemotaxis.	Bleomycin	53-62	colony stimulating factor 3 (granulocyte)	Mus musculus	15-20
31884830-4	2020	In this study, miR-182-5p was highly expressed in pulmonary tissues of BLM-induced fibrotic mice.	Bleomycin	71-74	microRNA 182	Mus musculus	15-22
32320335-2	2020	In this study, we investigated the influence of XPC, PMAIP1/Noxa and TLR4 genetic variants on the development of bleomycin-induced lung injury (BILI) in south Indian patients with Hodgkin lymphoma.	Bleomycin	113-122	toll like receptor 4	Homo sapiens	69-73
32006666-0	2020	Blocking TG2 attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting EMT.	Bleomycin	24-33	transglutaminase 2, C polypeptide	Mus musculus	9-12
32006666-7	2020	RESULTS: bleomycin succeeded to induce pulmonary fibrosis in mice, with increased TG2 expression, EMT and Akt activation.	Bleomycin	9-18	transglutaminase 2, C polypeptide	Mus musculus	82-85
32006666-7	2020	RESULTS: bleomycin succeeded to induce pulmonary fibrosis in mice, with increased TG2 expression, EMT and Akt activation.	Bleomycin	9-18	thymoma viral proto-oncogene 1	Mus musculus	106-109
32006666-10	2020	CONCLUSION: Blocking TG2 reduces bleomycin-induced pulmonary fibrosis in mice via inhibiting EMT.	Bleomycin	33-42	transglutaminase 2, C polypeptide	Mus musculus	21-24
32981275-10	2020	Conclusion: The results suggest that small dose Cap can reverse alveolar epithelial cells EMT and alleviate bleomycin-induced pulmonary fibrosis in mice by inhibiting ERK1/2/eIF3asignaling pathway, which is related to agitating TRPV1 receptor and releasing of CGRP.	Bleomycin	108-117	mitogen-activated protein kinase 3	Mus musculus	167-173
32981275-10	2020	Conclusion: The results suggest that small dose Cap can reverse alveolar epithelial cells EMT and alleviate bleomycin-induced pulmonary fibrosis in mice by inhibiting ERK1/2/eIF3asignaling pathway, which is related to agitating TRPV1 receptor and releasing of CGRP.	Bleomycin	108-117	eukaryotic translation initiation factor 3, subunit A	Mus musculus	174-178
32981275-10	2020	Conclusion: The results suggest that small dose Cap can reverse alveolar epithelial cells EMT and alleviate bleomycin-induced pulmonary fibrosis in mice by inhibiting ERK1/2/eIF3asignaling pathway, which is related to agitating TRPV1 receptor and releasing of CGRP.	Bleomycin	108-117	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	228-233
32981275-10	2020	Conclusion: The results suggest that small dose Cap can reverse alveolar epithelial cells EMT and alleviate bleomycin-induced pulmonary fibrosis in mice by inhibiting ERK1/2/eIF3asignaling pathway, which is related to agitating TRPV1 receptor and releasing of CGRP.	Bleomycin	108-117	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	260-264
32349726-9	2020	Upon bleomycin treatment, quercetin-fed mice displayed reduced expression of collagen (COL1A2) and fibronectin (FN1) and a tendency of reduced inflammatory lesions (2.8 +- 0.7 versus 1.9 +- 0.8).	Bleomycin	5-14	fibronectin 1	Mus musculus	99-110
32349726-9	2020	Upon bleomycin treatment, quercetin-fed mice displayed reduced expression of collagen (COL1A2) and fibronectin (FN1) and a tendency of reduced inflammatory lesions (2.8 +- 0.7 versus 1.9 +- 0.8).	Bleomycin	5-14	fibronectin 1	Mus musculus	112-115
32349726-12	2020	CONCLUSION: Quercetin exerts anti-fibrogenic and anti-inflammatory effects on bleomycin-induced pulmonary damage in mice possibly through modulation of the redox balance by inducing Nrf2.	Bleomycin	78-87	nuclear factor, erythroid derived 2, like 2	Mus musculus	182-186
32390869-0	2020	Protein Kinase C delta (PKCdelta) Attenuates Bleomycin Induced Pulmonary Fibrosis via Inhibiting NF-kappaB Signaling Pathway.	Bleomycin	45-54	protein kinase C, delta	Mus musculus	0-22
32390869-0	2020	Protein Kinase C delta (PKCdelta) Attenuates Bleomycin Induced Pulmonary Fibrosis via Inhibiting NF-kappaB Signaling Pathway.	Bleomycin	45-54	protein kinase C, delta	Mus musculus	24-32
32390869-0	2020	Protein Kinase C delta (PKCdelta) Attenuates Bleomycin Induced Pulmonary Fibrosis via Inhibiting NF-kappaB Signaling Pathway.	Bleomycin	45-54	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	97-106
32390869-3	2020	Here, we reported that PKCdelta deficiency (PKCdelta-/-) aggravated bleomycin (BLM)-induced pulmonary fibrosis and inflammation.	Bleomycin	68-77	protein kinase C, delta	Mus musculus	23-31
32253243-5	2020	In this study, we sought to determine how IL-1R-associated kinase-M (IRAK-M), a negative regulator of TLR signaling, modulates monocyte trafficking into the lungs in response to bleomycin.	Bleomycin	178-187	interleukin-1 receptor-associated kinase 3	Mus musculus	42-67
32244228-3	2020	Following experiments showed reduced Kl in isolated pulmonary fibroblasts from bleomycin-exposed mice, and demonstrated that recombinant KL effectively mitigated pulmonary fibrosis in an ex vivo model and alleviated TGF-beta-induced pulmonary fibroblasts activation, migration, and ECM production in vitro, which was partially ascribed to FOXF1 and CAV1, two highly co-expressed genes of KL in the IPF.	Bleomycin	79-88	klotho	Mus musculus	137-139
32337277-0	2020	CXXC5 Attenuates Pulmonary Fibrosis in a Bleomycin-Induced Mouse Model and MLFs by Suppression of the CD40/CD40L Pathway.	Bleomycin	41-50	CXXC finger 5	Mus musculus	0-5
32337277-6	2020	(2) In bleomycin-induced mice, the expression of CD40 and CD40L increased at both transcriptional and protein levels, and the same changes were observed in alpha-smooth muscle actin (alpha-SMA) and collagen type I (Colla I).	Bleomycin	7-16	CD40 antigen	Mus musculus	49-53
32337277-6	2020	(2) In bleomycin-induced mice, the expression of CD40 and CD40L increased at both transcriptional and protein levels, and the same changes were observed in alpha-smooth muscle actin (alpha-SMA) and collagen type I (Colla I).	Bleomycin	7-16	CD40 ligand	Mus musculus	58-63
32337277-6	2020	(2) In bleomycin-induced mice, the expression of CD40 and CD40L increased at both transcriptional and protein levels, and the same changes were observed in alpha-smooth muscle actin (alpha-SMA) and collagen type I (Colla I).	Bleomycin	7-16	actin alpha 2, smooth muscle, aorta	Mus musculus	183-192
31697569-4	2020	FENDRR expression in lung tissues from patients with IPF and mice with bleomycin-induced pulmonary fibrosis was determined by quantitative real-time polymerase chain reaction.	Bleomycin	71-80	FOXF1 adjacent non-coding developmental regulatory RNA	Homo sapiens	0-6
32272967-6	2020	The mouse model of bleomycin-induced fibrosis was used to evaluate the production of alpha2AP on the development of fibrosis.	Bleomycin	19-28	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	85-93
32032580-7	2020	In the present study, bleomycin (BLM)-induced skin fibrosis model was applied to keratinocyte-specific Nrf2 knockout (Nrf2(K)-KO) mice generated with Keratin 14-Cre/loxp system.	Bleomycin	22-31	nuclear factor, erythroid derived 2, like 2	Mus musculus	103-107
32032580-7	2020	In the present study, bleomycin (BLM)-induced skin fibrosis model was applied to keratinocyte-specific Nrf2 knockout (Nrf2(K)-KO) mice generated with Keratin 14-Cre/loxp system.	Bleomycin	33-36	nuclear factor, erythroid derived 2, like 2	Mus musculus	103-107
32032580-7	2020	In the present study, bleomycin (BLM)-induced skin fibrosis model was applied to keratinocyte-specific Nrf2 knockout (Nrf2(K)-KO) mice generated with Keratin 14-Cre/loxp system.	Bleomycin	33-36	keratin 14	Mus musculus	150-160
32032580-8	2020	BLM treatment significantly suppressed Nrf2 expression in the epidermis.	Bleomycin	0-3	nuclear factor, erythroid derived 2, like 2	Mus musculus	39-43
32044184-0	2020	HSP70 induction by bleomycin metal core analogs.	Bleomycin	19-28	heat shock protein family A (Hsp70) member 4	Homo sapiens	0-5
32044184-2	2020	We are interested in HSP70 induction capability of an antitumor antibiotic bleomycin which produces oxidative stress by iron chelate formation and oxygen activation in a cell.	Bleomycin	75-84	heat shock protein family A (Hsp70) member 4	Homo sapiens	21-26
32044184-3	2020	The HSP70 induction activity of bleomycin and its six metal core analogs was examined, and a compound HPH-1Trt of 10 muM was found to induce this protein in a pheochromocytoma cell line and some T cell and monocytic cell lines.	Bleomycin	32-41	heat shock protein family A (Hsp70) member 4	Homo sapiens	4-9
31646730-0	2020	COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence.	Bleomycin	42-51	cytochrome c oxidase II, mitochondrial	Mus musculus	0-5
31646730-0	2020	COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence.	Bleomycin	42-51	epoxide hydrolase 2, cytoplasmic	Mus musculus	6-9
31753588-0	2020	CXCL16/CXCR6 axis promotes bleomycin-induced fibrotic process in MRC-5 cells via the PI3K/AKT/FOXO3a pathway.	Bleomycin	27-36	C-X-C motif chemokine ligand 16	Homo sapiens	0-6
31753588-0	2020	CXCL16/CXCR6 axis promotes bleomycin-induced fibrotic process in MRC-5 cells via the PI3K/AKT/FOXO3a pathway.	Bleomycin	27-36	C-X-C motif chemokine receptor 6	Homo sapiens	7-12
31753588-0	2020	CXCL16/CXCR6 axis promotes bleomycin-induced fibrotic process in MRC-5 cells via the PI3K/AKT/FOXO3a pathway.	Bleomycin	27-36	AKT serine/threonine kinase 1	Homo sapiens	90-93
31753588-0	2020	CXCL16/CXCR6 axis promotes bleomycin-induced fibrotic process in MRC-5 cells via the PI3K/AKT/FOXO3a pathway.	Bleomycin	27-36	forkhead box O3	Homo sapiens	94-100
31753588-5	2020	The effect of anti-CXCL16 antibody on the bleomycin-induced fibrogenesis in cultured MRC-5 cells was also evaluated.	Bleomycin	42-51	C-X-C motif chemokine ligand 16	Homo sapiens	19-25
32272967-8	2020	Next, we showed that macrophage reduction by a macrophage-depleting agent, clodronate, attenuated the progression of fibrosis and the production of alpha2AP and HMGB1 in the bleomycin-induced mice.	Bleomycin	174-183	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	148-156
32272967-8	2020	Next, we showed that macrophage reduction by a macrophage-depleting agent, clodronate, attenuated the progression of fibrosis and the production of alpha2AP and HMGB1 in the bleomycin-induced mice.	Bleomycin	174-183	high mobility group box 1	Mus musculus	161-166
32272967-10	2020	Furthermore, the blockade of IL-4 signaling by IL-4Ralpha neutralizing antibodies attenuated the progression of fibrosis and the production of alpha2AP and HMGB1 in the bleomycin-induced mice.	Bleomycin	169-178	interleukin 4	Mus musculus	29-33
32272967-10	2020	Furthermore, the blockade of IL-4 signaling by IL-4Ralpha neutralizing antibodies attenuated the progression of fibrosis and the production of alpha2AP and HMGB1 in the bleomycin-induced mice.	Bleomycin	169-178	interleukin 4 receptor, alpha	Mus musculus	47-57
32272967-10	2020	Furthermore, the blockade of IL-4 signaling by IL-4Ralpha neutralizing antibodies attenuated the progression of fibrosis and the production of alpha2AP and HMGB1 in the bleomycin-induced mice.	Bleomycin	169-178	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	143-151
32272967-10	2020	Furthermore, the blockade of IL-4 signaling by IL-4Ralpha neutralizing antibodies attenuated the progression of fibrosis and the production of alpha2AP and HMGB1 in the bleomycin-induced mice.	Bleomycin	169-178	high mobility group box 1	Mus musculus	156-161
31697569-8	2020	MEASUREMENTS AND MAIN RESULTS: The expression of FENDRR was down-regulated in fibrotic human and mouse lungs as well as primary lung fibroblasts isolated from bleomycin-treated mice.	Bleomycin	159-168	FOXF1 adjacent non-coding developmental regulatory RNA	Homo sapiens	49-55
31697569-12	2020	Adenovirus-mediated FENDRR gene transfer in the mouse lung attenuated bleomycin-induced lung fibrosis and improved lung function.	Bleomycin	70-79	Foxf1 adjacent non-coding developmental regulatory RNA	Mus musculus	20-26
31364255-8	2020	MSC inhibited BiP expression in bleomycin-induced ER stress, attenuating ER stress via the protein kinase RNA-like ER kinase (PERK)-Nrf2 pathway.	Bleomycin	32-41	heat shock protein 5	Mus musculus	14-17
31364255-8	2020	MSC inhibited BiP expression in bleomycin-induced ER stress, attenuating ER stress via the protein kinase RNA-like ER kinase (PERK)-Nrf2 pathway.	Bleomycin	32-41	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	91-124
31364255-8	2020	MSC inhibited BiP expression in bleomycin-induced ER stress, attenuating ER stress via the protein kinase RNA-like ER kinase (PERK)-Nrf2 pathway.	Bleomycin	32-41	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	126-130
31364255-8	2020	MSC inhibited BiP expression in bleomycin-induced ER stress, attenuating ER stress via the protein kinase RNA-like ER kinase (PERK)-Nrf2 pathway.	Bleomycin	32-41	nuclear factor, erythroid derived 2, like 2	Mus musculus	132-136
31364255-10	2020	CONCLUSION: Our data suggest that MSC operate on ER stress via several pathways, but the PERK-Nrf2 pathway revealed to be the main functioning pathway in our bleomycin model.	Bleomycin	158-167	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	89-93
31364255-10	2020	CONCLUSION: Our data suggest that MSC operate on ER stress via several pathways, but the PERK-Nrf2 pathway revealed to be the main functioning pathway in our bleomycin model.	Bleomycin	158-167	nuclear factor, erythroid derived 2, like 2	Mus musculus	94-98
32210149-2	2020	In this study, we found increased levels of miR-34 at times of fibrosis resolution following injury, in myofibroblasts from Bleomycin-treated mouse lungs, which correlates with susceptibility to cell death induced by immune cells.	Bleomycin	124-133	microRNA 34a	Homo sapiens	44-50
32187520-6	2020	Rbm7 deletion suppressed bleomycin-induced fibrosis and at a cellular level, suppressed apoptosis of nonhematopoietic cells.	Bleomycin	25-34	RNA binding motif protein 7	Homo sapiens	0-4
32192225-1	2020	The sphingosine kinase 1 (SPHK1)/sphingosine-1-phosphate (S1P) signaling axis is emerging as a key player in the development of idiopathic pulmonary fibrosis (IPF) and bleomycin (BLM)-induced lung fibrosis in mice.	Bleomycin	168-177	sphingosine kinase 1	Mus musculus	4-24
32192225-1	2020	The sphingosine kinase 1 (SPHK1)/sphingosine-1-phosphate (S1P) signaling axis is emerging as a key player in the development of idiopathic pulmonary fibrosis (IPF) and bleomycin (BLM)-induced lung fibrosis in mice.	Bleomycin	168-177	sphingosine kinase 1	Mus musculus	26-31
32192225-1	2020	The sphingosine kinase 1 (SPHK1)/sphingosine-1-phosphate (S1P) signaling axis is emerging as a key player in the development of idiopathic pulmonary fibrosis (IPF) and bleomycin (BLM)-induced lung fibrosis in mice.	Bleomycin	168-177	sphingosine-1-phosphate receptor 1	Mus musculus	58-61
32059792-3	2020	Here, we report that the loss of autophagy-related 5 (Atg5) in AT2 cells worsened bleomycin-induced lung injury.	Bleomycin	82-91	autophagy related 5	Homo sapiens	33-52
31646730-5	2020	In this study, we observed a disorder in the cyclooxygenase-2/cytochrome P450 (COX-2/CYP) metabolism of ARA in the lungs of PF mice induced by bleomycin (BLM).	Bleomycin	143-152	prostaglandin-endoperoxide synthase 2	Mus musculus	45-61
31646730-5	2020	In this study, we observed a disorder in the cyclooxygenase-2/cytochrome P450 (COX-2/CYP) metabolism of ARA in the lungs of PF mice induced by bleomycin (BLM).	Bleomycin	143-152	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	62-77
31646730-5	2020	In this study, we observed a disorder in the cyclooxygenase-2/cytochrome P450 (COX-2/CYP) metabolism of ARA in the lungs of PF mice induced by bleomycin (BLM).	Bleomycin	143-152	cytochrome c oxidase II, mitochondrial	Mus musculus	79-84
31646730-5	2020	In this study, we observed a disorder in the cyclooxygenase-2/cytochrome P450 (COX-2/CYP) metabolism of ARA in the lungs of PF mice induced by bleomycin (BLM).	Bleomycin	143-152	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	85-88
31646730-5	2020	In this study, we observed a disorder in the cyclooxygenase-2/cytochrome P450 (COX-2/CYP) metabolism of ARA in the lungs of PF mice induced by bleomycin (BLM).	Bleomycin	154-157	prostaglandin-endoperoxide synthase 2	Mus musculus	45-61
31646730-5	2020	In this study, we observed a disorder in the cyclooxygenase-2/cytochrome P450 (COX-2/CYP) metabolism of ARA in the lungs of PF mice induced by bleomycin (BLM).	Bleomycin	154-157	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	62-77
31646730-5	2020	In this study, we observed a disorder in the cyclooxygenase-2/cytochrome P450 (COX-2/CYP) metabolism of ARA in the lungs of PF mice induced by bleomycin (BLM).	Bleomycin	154-157	cytochrome c oxidase II, mitochondrial	Mus musculus	79-84
31646730-5	2020	In this study, we observed a disorder in the cyclooxygenase-2/cytochrome P450 (COX-2/CYP) metabolism of ARA in the lungs of PF mice induced by bleomycin (BLM).	Bleomycin	154-157	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	85-88
31646730-9	2020	We found that PTUPB alleviated the pathological changes of lung tissue and collagen deposition, as well as reduced senescence marker molecules (p16Ink4a and p53-p21Waf1/Cip1 ) in the lungs of mice treated by BLM.	Bleomycin	208-211	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	169-173
32269725-0	2020	Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.	Bleomycin	22-31	insulin-like growth factor 1	Mus musculus	82-87
32027623-3	2020	In this study, we found that pulmonary ApoE was almost exclusively produced by Mo-AMs in mice with bleomycin induced lung fibrosis.	Bleomycin	99-108	apolipoprotein E	Mus musculus	39-43
32027623-6	2020	Furthermore, interference of ApoE/LRP1 interaction impaired the resolution of lung fibrosis in bleomycin treated wild-type mice.	Bleomycin	95-104	apolipoprotein E	Mus musculus	29-33
32027623-6	2020	Furthermore, interference of ApoE/LRP1 interaction impaired the resolution of lung fibrosis in bleomycin treated wild-type mice.	Bleomycin	95-104	low density lipoprotein receptor-related protein 1	Mus musculus	34-38
32242386-0	2020	Notch signaling pathway mediates the immunomodulatory mechanism of Yangfei Huoxue decoction alleviating bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	104-113	notch receptor 2	Rattus norvegicus	0-5
32269725-7	2020	Our study showed that intratracheal injection of bleomycin induced pulmonary fibrosis in mice, with observed elevation in collagen, fibronectin and alpha-SMA level, characterized by the enhanced IGF-1 and PI3K expression.	Bleomycin	49-58	fibronectin 1	Mus musculus	132-143
32269725-7	2020	Our study showed that intratracheal injection of bleomycin induced pulmonary fibrosis in mice, with observed elevation in collagen, fibronectin and alpha-SMA level, characterized by the enhanced IGF-1 and PI3K expression.	Bleomycin	49-58	actin alpha 2, smooth muscle, aorta	Mus musculus	148-157
32269725-7	2020	Our study showed that intratracheal injection of bleomycin induced pulmonary fibrosis in mice, with observed elevation in collagen, fibronectin and alpha-SMA level, characterized by the enhanced IGF-1 and PI3K expression.	Bleomycin	49-58	insulin-like growth factor 1	Mus musculus	195-200
32269725-9	2020	Our results show that metformin attenuates bleomycin-induced pulmonary fibrosis via IGF-1 pathway.	Bleomycin	43-52	insulin-like growth factor 1	Mus musculus	84-89
32160239-7	2020	Specifically, an anti-RSPO3 antibody, OMP-131R10, when dosed therapeutically, attenuated fibrosis in carbon tetrachloride (CCl4)-induced liver fibrosis, bleomycin-induced pulmonary and skin fibrosis models.	Bleomycin	153-162	R-spondin 3	Homo sapiens	22-27
32161282-0	2020	Endothelial-specific Loss of IFT88 Promotes Endothelial-to-Mesenchymal Transition and Exacerbates Bleomycin-induced Pulmonary Fibrosis.	Bleomycin	98-107	intraflagellar transport 88	Mus musculus	29-34
32161282-10	2020	Cardiac and pulmonary endothelial cells isolated from the Ift88endo mice demonstrated signs of EndMT and bleomycin treatment exacerbated pulmonary fibrosis in Ift88endo mice.	Bleomycin	105-114	intraflagellar transport 88	Mus musculus	58-63
32161282-10	2020	Cardiac and pulmonary endothelial cells isolated from the Ift88endo mice demonstrated signs of EndMT and bleomycin treatment exacerbated pulmonary fibrosis in Ift88endo mice.	Bleomycin	105-114	intraflagellar transport 88	Mus musculus	159-164
32059792-3	2020	Here, we report that the loss of autophagy-related 5 (Atg5) in AT2 cells worsened bleomycin-induced lung injury.	Bleomycin	82-91	autophagy related 5	Homo sapiens	54-58
32059792-3	2020	Here, we report that the loss of autophagy-related 5 (Atg5) in AT2 cells worsened bleomycin-induced lung injury.	Bleomycin	82-91	angiotensin II receptor type 2	Homo sapiens	63-66
32104240-6	2020	Lung and bronchoalveolar lavage fluid CXCR4 and CXCL12 expression was upregulated by in vivo bleomycin administration, which was partially inhibited by pre-treatment with AMD3100.	Bleomycin	93-102	C-X-C motif chemokine receptor 4	Homo sapiens	38-43
32440328-10	2020	Moreover, NAC attenuated bleomycin-induced increased expression of TGF-beta1 and total lung collagen levels.	Bleomycin	25-34	transforming growth factor, beta 1	Rattus norvegicus	67-76
32521909-0	2020	Bleomycin inhibits proliferation and promotes apoptosis of brain glioma cells via TGF-beta/Smad signaling pathway.	Bleomycin	0-9	transforming growth factor alpha	Homo sapiens	82-90
32521909-0	2020	Bleomycin inhibits proliferation and promotes apoptosis of brain glioma cells via TGF-beta/Smad signaling pathway.	Bleomycin	0-9	SMAD family member 4	Homo sapiens	91-95
32521909-1	2020	PURPOSE: To investigate the influence of bleomycin (BLM) on the proliferation and apoptosis of brain glioma cells through transforming growth factor-beta (TGF-beta)/Smads signaling pathway.	Bleomycin	41-50	tumor necrosis factor	Homo sapiens	122-153
32521909-1	2020	PURPOSE: To investigate the influence of bleomycin (BLM) on the proliferation and apoptosis of brain glioma cells through transforming growth factor-beta (TGF-beta)/Smads signaling pathway.	Bleomycin	41-50	transforming growth factor alpha	Homo sapiens	155-163
31541181-5	2020	Using a bleomycin mouse model, we found that highly expressed Wnt10a was secreted by LR-MSCs undergoing myofibroblastic differentiation.	Bleomycin	8-17	wingless-type MMTV integration site family, member 10A	Mus musculus	62-68
31822523-13	2020	Further, the AIM2 inflammasome, a multiprotein complex essential for sensing cytosolic bacterial DNA as a danger signal, is an important regulator of this GLUT1-mediated fibrosis and genetic deficiency of AIM2 reduced bleomycin-induced fibrosis after S. pneumoniae infection (WT/PBS, n=6; WT/Bleomycin+S.	Bleomycin	218-227	absent in melanoma 2	Mus musculus	13-17
31822523-13	2020	Further, the AIM2 inflammasome, a multiprotein complex essential for sensing cytosolic bacterial DNA as a danger signal, is an important regulator of this GLUT1-mediated fibrosis and genetic deficiency of AIM2 reduced bleomycin-induced fibrosis after S. pneumoniae infection (WT/PBS, n=6; WT/Bleomycin+S.	Bleomycin	218-227	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	155-160
31822523-13	2020	Further, the AIM2 inflammasome, a multiprotein complex essential for sensing cytosolic bacterial DNA as a danger signal, is an important regulator of this GLUT1-mediated fibrosis and genetic deficiency of AIM2 reduced bleomycin-induced fibrosis after S. pneumoniae infection (WT/PBS, n=6; WT/Bleomycin+S.	Bleomycin	218-227	absent in melanoma 2	Mus musculus	205-209
31822523-13	2020	Further, the AIM2 inflammasome, a multiprotein complex essential for sensing cytosolic bacterial DNA as a danger signal, is an important regulator of this GLUT1-mediated fibrosis and genetic deficiency of AIM2 reduced bleomycin-induced fibrosis after S. pneumoniae infection (WT/PBS, n=6; WT/Bleomycin+S.	Bleomycin	292-301	absent in melanoma 2	Mus musculus	13-17
31822523-13	2020	Further, the AIM2 inflammasome, a multiprotein complex essential for sensing cytosolic bacterial DNA as a danger signal, is an important regulator of this GLUT1-mediated fibrosis and genetic deficiency of AIM2 reduced bleomycin-induced fibrosis after S. pneumoniae infection (WT/PBS, n=6; WT/Bleomycin+S.	Bleomycin	292-301	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	155-160
31822523-13	2020	Further, the AIM2 inflammasome, a multiprotein complex essential for sensing cytosolic bacterial DNA as a danger signal, is an important regulator of this GLUT1-mediated fibrosis and genetic deficiency of AIM2 reduced bleomycin-induced fibrosis after S. pneumoniae infection (WT/PBS, n=6; WT/Bleomycin+S.	Bleomycin	292-301	absent in melanoma 2	Mus musculus	205-209
32075634-0	2020	Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-beta-induced fibroblast to myofibroblast differentiation.	Bleomycin	21-30	transforming growth factor alpha	Mus musculus	72-80
31757562-4	2020	When BLM exists, BLM with Fe2+ as irreversible cofactor can specifically recognize and cleave of the 5"-GC-3" active site of DNA2, resulting in reduced precipitation deposited on the electrode and recovery of PEC signal.	Bleomycin	5-8	DNA replication helicase/nuclease 2	Homo sapiens	125-129
31757562-4	2020	When BLM exists, BLM with Fe2+ as irreversible cofactor can specifically recognize and cleave of the 5"-GC-3" active site of DNA2, resulting in reduced precipitation deposited on the electrode and recovery of PEC signal.	Bleomycin	17-20	DNA replication helicase/nuclease 2	Homo sapiens	125-129
31816044-9	2020	Finally, results are presented indicating a critical role for APE1 nuclease activities in resistance to the genotoxins methyl methanesulphonate and bleomycin, supporting biologically important functions as an AP endonuclease and 3"-phosphodiesterase, respectively.	Bleomycin	148-157	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	62-66
32053892-2	2020	The Fas/FasL apoptotic pathway has been shown to be involved in human idiopathic pulmonary fibrosis (IPF) and bleomycin-induced lung fibrosis in rodents.	Bleomycin	110-119	Fas ligand	Homo sapiens	8-12
32053892-7	2020	MMP-7 knockout (KO) mice were shown to be protected from bleomycin (BLM)-induced lung fibrosis.	Bleomycin	57-66	matrix metallopeptidase 7	Mus musculus	0-5
32033616-0	2020	Aryl hydrocarbon receptor signals attenuate lung fibrosis in the bleomycin-induced mouse model for pulmonary fibrosis through increase of regulatory T cells.	Bleomycin	65-74	aryl-hydrocarbon receptor	Mus musculus	0-25
32033616-5	2020	METHODS: BLM was administered intratracheally to C57BL/6JJcl mice and either 5,11-dihydroindolo[3,2-b]carbazole-6-carboxaldehyde (FICZ), a natural AhR ligand, or vehicle was subsequently injected intraperitoneally on day 0, 1, and 2 from BLM administration.	Bleomycin	9-12	aryl-hydrocarbon receptor	Mus musculus	147-150
32033616-11	2020	CONCLUSIONS: Our findings suggest that stimulation of AhR signals attenuated lung fibrosis by increasing Tregs and suppressing inflammatory T cell subsets in a BLM-induced fibrosis model.	Bleomycin	160-163	aryl-hydrocarbon receptor	Mus musculus	54-57
32019905-13	2020	RESULTS The expression of RIPK1 and RIPK3 in lung tissues of BLM induced mice was increased.	Bleomycin	61-64	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	26-31
32019905-13	2020	RESULTS The expression of RIPK1 and RIPK3 in lung tissues of BLM induced mice was increased.	Bleomycin	61-64	receptor-interacting serine-threonine kinase 3	Mus musculus	36-41
32019905-14	2020	The degree of pulmonary fibrosis and expression of alpha-SMA, collagen IV, collagen I, FN, and TGF-ss in lung tissues of BLM induced mice was enhanced.	Bleomycin	121-124	actin alpha 2, smooth muscle, aorta	Mus musculus	51-60
31907997-7	2020	Furthermore, lung fibrosis and EndoMT responses were reduced in VEC-miR-155 mice but significantly enhanced in VEC-SHIP-1 mice after BLM challenge.	Bleomycin	133-136	inositol polyphosphate-5-phosphatase D	Mus musculus	111-121
31907997-8	2020	SHIP-1 knockdown in HUVEC cells resulted in enhanced EndoMT induced by BLM.	Bleomycin	71-74	inositol polyphosphate-5-phosphatase D	Mus musculus	0-6
31874367-0	2020	S-Allylmercaptocysteine attenuates Bleomycin-induced pulmonary fibrosis in mice via suppressing TGF-beta1/Smad and oxidative stress pathways.	Bleomycin	35-44	transforming growth factor, beta 1	Mus musculus	96-105
31874367-3	2020	In this study, we attempted to explore the function of SAMC in inhibiting bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	74-83	solute carrier family 25 member 26	Homo sapiens	55-59
31874367-3	2020	In this study, we attempted to explore the function of SAMC in inhibiting bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	85-88	solute carrier family 25 member 26	Homo sapiens	55-59
31874367-6	2020	The results indicate that SAMC could significantly ameliorate the pathological structure, and decrease inflammatory cell infiltration and pro-inflammatory cytokines in bronchoalveolar lavage fluid (BALF) in BLM-induced pulmonary fibrosis mice.	Bleomycin	207-210	solute carrier family 25 member 26	Homo sapiens	26-30
31874367-7	2020	SAMC showed an anti-fibrosis effect by increasing anti-oxidants like HO-1, GSH and SOD as well as decreasing hydroxyproline (HYP) in BLM-induced mice.	Bleomycin	133-136	solute carrier family 25 member 26	Homo sapiens	0-4
31318036-0	2020	Adipose-derived stem cells and adipose-derived stem cell- conditioned medium modulate in situ imbalance between collagen I- and collagen V-mediated IL-17 immune response recovering bleomycin pulmonary fibrosis.	Bleomycin	181-190	interleukin 17A	Rattus norvegicus	148-153
32440328-9	2020	Indeed, there was decrease in the MMP-9/TIMP ratio in bleomycin-instilled rats, which increased with NAC treatment.	Bleomycin	54-63	matrix metallopeptidase 9	Rattus norvegicus	34-39
32440328-9	2020	Indeed, there was decrease in the MMP-9/TIMP ratio in bleomycin-instilled rats, which increased with NAC treatment.	Bleomycin	54-63	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	40-44
31476316-4	2020	Estrogen inhibition, obtained through gene inactivation for the estrogen receptor-alpha (ERKOalpha) or treatment with tamoxifen, exacerbated skin fibrosis in the bleomycin model and in Tsk-1 mice.	Bleomycin	162-171	estrogen receptor 1 (alpha)	Mus musculus	64-87
32163236-9	2020	Here, platelets from mice with bleomycin-induced PH demonstrate increased 5-HT 2A R expression providing further evidence of both platelet activation and increased 5-HT signaling in this model.	Bleomycin	31-40	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	74-81
32102985-3	2020	FPR-1-deficient (fpr1-/-) mice were protected from bleomycin-induced pulmonary fibrosis but developed renal and hepatic fibrosis normally.	Bleomycin	51-60	formyl peptide receptor 1	Mus musculus	0-5
32102985-3	2020	FPR-1-deficient (fpr1-/-) mice were protected from bleomycin-induced pulmonary fibrosis but developed renal and hepatic fibrosis normally.	Bleomycin	51-60	formyl peptide receptor 1	Mus musculus	17-21
31935199-6	2020	Furthermore, expression of the CFIm subunits is associated with matrix stiffness in vivo in a bleomycin-induced mouse model of pulmonary fibrosis.	Bleomycin	94-103	cleavage and polyadenylation specific factor 6	Mus musculus	31-35
31879190-9	2020	Collectively, our results demonstrate that SERCA2a gene transfer attenuates bleomycin (BLM)-induced PF by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI Axis.	Bleomycin	76-85	signal transducer and activator of transcription 3	Homo sapiens	119-124
31879190-9	2020	Collectively, our results demonstrate that SERCA2a gene transfer attenuates bleomycin (BLM)-induced PF by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI Axis.	Bleomycin	76-85	forkhead box M1	Homo sapiens	125-130
31879190-9	2020	Collectively, our results demonstrate that SERCA2a gene transfer attenuates bleomycin (BLM)-induced PF by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI Axis.	Bleomycin	76-85	SKI like proto-oncogene	Homo sapiens	157-161
31879190-9	2020	Collectively, our results demonstrate that SERCA2a gene transfer attenuates bleomycin (BLM)-induced PF by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI Axis.	Bleomycin	76-85	SKI proto-oncogene	Homo sapiens	162-165
31879190-9	2020	Collectively, our results demonstrate that SERCA2a gene transfer attenuates bleomycin (BLM)-induced PF by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI Axis.	Bleomycin	87-90	signal transducer and activator of transcription 3	Homo sapiens	119-124
31879190-9	2020	Collectively, our results demonstrate that SERCA2a gene transfer attenuates bleomycin (BLM)-induced PF by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI Axis.	Bleomycin	87-90	forkhead box M1	Homo sapiens	125-130
31879190-9	2020	Collectively, our results demonstrate that SERCA2a gene transfer attenuates bleomycin (BLM)-induced PF by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI Axis.	Bleomycin	87-90	SKI like proto-oncogene	Homo sapiens	157-161
31879190-9	2020	Collectively, our results demonstrate that SERCA2a gene transfer attenuates bleomycin (BLM)-induced PF by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI Axis.	Bleomycin	87-90	SKI proto-oncogene	Homo sapiens	162-165
31757866-7	2020	Finally, mice with CFIm25 deletion in fibroblasts show exaggerated skin fibrosis upon bleomycin treatment, and CFIm25 restoration attenuates bleomycin-induced skin fibrosis.	Bleomycin	86-95	nudix hydrolase 21	Homo sapiens	19-25
31757866-7	2020	Finally, mice with CFIm25 deletion in fibroblasts show exaggerated skin fibrosis upon bleomycin treatment, and CFIm25 restoration attenuates bleomycin-induced skin fibrosis.	Bleomycin	141-150	nudix hydrolase 21	Homo sapiens	111-117
31631444-5	2020	Based on the experimental observation, it was demonstrated that with TGF-beta as a central mediator of fibrosis progression, a cross-talk between epithelial-mesenchymal transition (EMT) and senescence upon bleomycin treatment occurs.	Bleomycin	206-215	transforming growth factor beta 1	Homo sapiens	69-77
31631444-10	2020	Furthermore, the expressions of senescence markers, such as p21 and p53, were upregulated upon bleomycin treatment, thereby intensifying the fibrotic condition.	Bleomycin	95-104	H3 histone pseudogene 16	Homo sapiens	60-63
31631444-10	2020	Furthermore, the expressions of senescence markers, such as p21 and p53, were upregulated upon bleomycin treatment, thereby intensifying the fibrotic condition.	Bleomycin	95-104	tumor protein p53	Homo sapiens	68-71
32104240-6	2020	Lung and bronchoalveolar lavage fluid CXCR4 and CXCL12 expression was upregulated by in vivo bleomycin administration, which was partially inhibited by pre-treatment with AMD3100.	Bleomycin	93-102	C-X-C motif chemokine ligand 12	Homo sapiens	48-54
31959382-3	2020	OBJECTIVE: We investigated the impact of CD103 loss on bleomycin-induced skin fibrosis because CD103 is a critical molecule determining DC phenotypes.	Bleomycin	55-64	integrin alpha E, epithelial-associated	Mus musculus	41-46
31959382-4	2020	METHODS: Bleomycin-induced skin fibrosis was generated with Cd103-/- mice.	Bleomycin	9-18	integrin alpha E, epithelial-associated	Mus musculus	60-65
31959382-7	2020	RESULTS: CD103 loss decreased bleomycin-induced dermal thickness and collagen contents, along with TGF-beta1 and CTGF suppression.	Bleomycin	30-39	integrin alpha E, epithelial-associated	Mus musculus	9-14
32029695-5	2020	We found that Fam13a was down-regulated in mouse lungs of bleomycin-induced pulmonary fibrosis model.	Bleomycin	58-67	family with sequence similarity 13, member A	Mus musculus	14-20
31959382-8	2020	Treg proportion was increased, while Th1/Th2/Th17 cell proportions were decreased in the skin of bleomycin-treated Cd103-/- mice.	Bleomycin	97-106	negative elongation factor complex member C/D, Th1l	Mus musculus	37-40
31959382-8	2020	Treg proportion was increased, while Th1/Th2/Th17 cell proportions were decreased in the skin of bleomycin-treated Cd103-/- mice.	Bleomycin	97-106	integrin alpha E, epithelial-associated	Mus musculus	115-120
31959382-9	2020	Bleomycin injection enhanced CD11b-CD103- DC proportion in wild-type mice, which was further augmented in Cd103-/- mice.	Bleomycin	0-9	integrin alpha M	Mus musculus	29-34
31959382-9	2020	Bleomycin injection enhanced CD11b-CD103- DC proportion in wild-type mice, which was further augmented in Cd103-/- mice.	Bleomycin	0-9	integrin alpha E, epithelial-associated	Mus musculus	35-40
31959382-9	2020	Bleomycin injection enhanced CD11b-CD103- DC proportion in wild-type mice, which was further augmented in Cd103-/- mice.	Bleomycin	0-9	integrin alpha E, epithelial-associated	Mus musculus	106-111
31959382-10	2020	Importantly, RALDH1/ALDH1A1 enzyme oxidizing retinaldehyde to retinoic acid, an inducer of Tregs, was preferentially expressed by CD11b-CD103- DCs and its expression levels were elevated in bleomycin-injected skin lesions, to a greater extent in Cd103-/- mice than in wild-type mice.	Bleomycin	190-199	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	13-19
31959382-10	2020	Importantly, RALDH1/ALDH1A1 enzyme oxidizing retinaldehyde to retinoic acid, an inducer of Tregs, was preferentially expressed by CD11b-CD103- DCs and its expression levels were elevated in bleomycin-injected skin lesions, to a greater extent in Cd103-/- mice than in wild-type mice.	Bleomycin	190-199	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	20-27
31959382-10	2020	Importantly, RALDH1/ALDH1A1 enzyme oxidizing retinaldehyde to retinoic acid, an inducer of Tregs, was preferentially expressed by CD11b-CD103- DCs and its expression levels were elevated in bleomycin-injected skin lesions, to a greater extent in Cd103-/- mice than in wild-type mice.	Bleomycin	190-199	integrin alpha M	Mus musculus	130-135
31959382-10	2020	Importantly, RALDH1/ALDH1A1 enzyme oxidizing retinaldehyde to retinoic acid, an inducer of Tregs, was preferentially expressed by CD11b-CD103- DCs and its expression levels were elevated in bleomycin-injected skin lesions, to a greater extent in Cd103-/- mice than in wild-type mice.	Bleomycin	190-199	integrin alpha E, epithelial-associated	Mus musculus	136-141
31959382-10	2020	Importantly, RALDH1/ALDH1A1 enzyme oxidizing retinaldehyde to retinoic acid, an inducer of Tregs, was preferentially expressed by CD11b-CD103- DCs and its expression levels were elevated in bleomycin-injected skin lesions, to a greater extent in Cd103-/- mice than in wild-type mice.	Bleomycin	190-199	integrin alpha E, epithelial-associated	Mus musculus	246-251
31959382-12	2020	CONCLUSION: This study identified a critical role of dermal DCs as a regulator of Treg development through RALDH1 in bleomycin-treated mice and possibly in human SSc.	Bleomycin	117-126	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	107-113
31830521-6	2020	Here, we found that LSD1 expression was elevated in lung tissues of mice with bleomycin-induced pulmonary fibrosis and lung fibroblasts treated with transforming growth factor-beta1 (TGF-beta1).	Bleomycin	78-87	lysine (K)-specific demethylase 1A	Mus musculus	20-24
31868203-0	2020	Bleomycin induces epithelial-to-mesenchymal transition via bFGF/PI3K/ESRP1 signaling in pulmonary fibrosis.	Bleomycin	0-9	fibroblast growth factor 2	Homo sapiens	59-63
31868203-0	2020	Bleomycin induces epithelial-to-mesenchymal transition via bFGF/PI3K/ESRP1 signaling in pulmonary fibrosis.	Bleomycin	0-9	epithelial splicing regulatory protein 1	Homo sapiens	69-74
31868203-3	2020	Here, we identified that the pulmonary fibrosis inducer bleomycin simultaneously increased the expression of bFGF and TGF-beta1 and inhibited epithelial-specific regulatory protein (ESRP1) expression in vivo and in vitro.	Bleomycin	56-65	fibroblast growth factor 2	Homo sapiens	109-113
31868203-3	2020	Here, we identified that the pulmonary fibrosis inducer bleomycin simultaneously increased the expression of bFGF and TGF-beta1 and inhibited epithelial-specific regulatory protein (ESRP1) expression in vivo and in vitro.	Bleomycin	56-65	transforming growth factor beta 1	Homo sapiens	118-127
31868203-3	2020	Here, we identified that the pulmonary fibrosis inducer bleomycin simultaneously increased the expression of bFGF and TGF-beta1 and inhibited epithelial-specific regulatory protein (ESRP1) expression in vivo and in vitro.	Bleomycin	56-65	epithelial splicing regulatory protein 1	Homo sapiens	182-187
31868203-5	2020	Notably, we determined that bFGF activates PI3K/Akt signaling, and treatment with the PI3K/Akt inhibitor LY294002 inhibited bleomycin-induced cell morphology changes and EMT.	Bleomycin	124-133	fibroblast growth factor 2	Homo sapiens	28-32
31868203-5	2020	Notably, we determined that bFGF activates PI3K/Akt signaling, and treatment with the PI3K/Akt inhibitor LY294002 inhibited bleomycin-induced cell morphology changes and EMT.	Bleomycin	124-133	AKT serine/threonine kinase 1	Homo sapiens	91-94
31868203-6	2020	In addition, the effects of LY294002 on bleomycin-induced EMT were inhibited by ESRP1 silencing in A549 cells.	Bleomycin	40-49	epithelial splicing regulatory protein 1	Homo sapiens	80-85
31868203-7	2020	Taken together, these findings suggest that bleomycin induced EMT through downregulating ESRP1 by simultaneously increasing bFGF and TGF-beta1 in pulmonary fibrosis.	Bleomycin	44-53	epithelial splicing regulatory protein 1	Homo sapiens	89-94
31868203-7	2020	Taken together, these findings suggest that bleomycin induced EMT through downregulating ESRP1 by simultaneously increasing bFGF and TGF-beta1 in pulmonary fibrosis.	Bleomycin	44-53	fibroblast growth factor 2	Homo sapiens	124-128
31868203-7	2020	Taken together, these findings suggest that bleomycin induced EMT through downregulating ESRP1 by simultaneously increasing bFGF and TGF-beta1 in pulmonary fibrosis.	Bleomycin	44-53	transforming growth factor beta 1	Homo sapiens	133-142
31937306-0	2020	Amelioration of bleomycin-induced pulmonary fibrosis via TGF-beta-induced Smad and non-Smad signaling pathways in galectin-9-deficient mice and fibroblast cells.	Bleomycin	16-25	transforming growth factor alpha	Mus musculus	57-65
31937306-0	2020	Amelioration of bleomycin-induced pulmonary fibrosis via TGF-beta-induced Smad and non-Smad signaling pathways in galectin-9-deficient mice and fibroblast cells.	Bleomycin	16-25	lectin, galactose binding, soluble 9	Mus musculus	114-124
31937306-3	2020	The aim of this study was to determine the role of galectin-9 in the pathogenesis of bleomycin-induced systemic sclerosis (SSc).	Bleomycin	85-94	lectin, galactose binding, soluble 9	Mus musculus	51-61
31937306-5	2020	Lung fibrosis was induced using bleomycin in galectin-9 wild-type and knockout mice.	Bleomycin	32-41	lectin, galactose binding, soluble 9	Mus musculus	45-55
31937306-12	2020	CONCLUSIONS: Our findings suggest that lack of galectin-9 protects against bleomycin-induced SSc.	Bleomycin	75-84	lectin, galactose binding, soluble 9	Mus musculus	47-57
31901889-12	2020	CONCLUSION: Taken together, celastrol is identified a novel selective CB2 agonist using a new developed arrestin-based SLCA, and CB2 activation by celastrol reduces the inflammatory response, and prevents the development of dermal fibrosis in bleomycin-induced systemic sclerosis mouse model.	Bleomycin	243-252	cannabinoid receptor 2 (macrophage)	Mus musculus	129-132
31801904-7	2020	Bleomycin-induced lung fibrosis was reduced in mice treated with GO-201 and in MUC1-knockout mice.	Bleomycin	0-9	mucin 1, transmembrane	Mus musculus	79-83
31866272-4	2020	Among them, the most potent JAK3 inhibitor, namely 8e (IC50 = 1.38 nM), significantly reduced the degree of airsacculitis and fibrosis according to hematoxylin-eosin (HE) staining assay for the lung tissue in the bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Bleomycin	213-222	Janus kinase 3	Mus musculus	28-32
31866272-4	2020	Among them, the most potent JAK3 inhibitor, namely 8e (IC50 = 1.38 nM), significantly reduced the degree of airsacculitis and fibrosis according to hematoxylin-eosin (HE) staining assay for the lung tissue in the bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Bleomycin	224-227	Janus kinase 3	Mus musculus	28-32
32029695-6	2020	Of note, genetic deletion of Fam13a exacerbated the lung fibrosis induced by bleomycin in association with enhanced EMT in mice.	Bleomycin	77-86	family with sequence similarity 13, member A	Mus musculus	29-35
31747308-6	2020	In addition, bleomycin increased numbers of c-kit+ mast cells, eosinophils and ILC2 in lungs of mice, whereas they were not significantly increased in anti-SCF248 treated animals.	Bleomycin	13-22	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	44-49
31935227-3	2020	Herein we demonstrate prominent activation of JNK in bronchial epithelia using the mouse models of bleomycin- or AdTGFbeta1-induced fibrosis.	Bleomycin	99-108	mitogen-activated protein kinase 8	Mus musculus	46-49
31935227-7	2020	Our results demonstrate that ablation of Jnk1 from airway epithelia resulted in a strong protection from bleomycin- or adenovirus expressing active transforming growth factor beta-1 (AdTGFbeta1)-induced fibrosis.	Bleomycin	105-114	mitogen-activated protein kinase 8	Mus musculus	41-45
31536655-15	2020	M(IL-4/13)-S protected IK cells from bleomycin-induced fibrosis.	Bleomycin	37-46	interleukin 4	Homo sapiens	2-6
31617733-4	2020	Of the four mammalian sialidases, we previously detected only NEU3 in the bronchoalveolar lavage fluid from mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	118-127	neuraminidase 3	Homo sapiens	62-66
31747308-7	2020	Finally, mesenchymal cell specific deletion of SCF significantly attenuated bleomycin-mediated lung fibrosis and associated fibrotic gene expression.	Bleomycin	76-85	kit ligand	Mus musculus	47-50
31820686-8	2020	When miR-205 was overexpressed, the lung injury by BLM-induced fibrosis was obviously improved.	Bleomycin	51-54	microRNA 205	Rattus norvegicus	5-12
31350829-10	2020	DPP4-knockout mice were less sensitive to bleomycin-induced dermal and pulmonary fibrosis (p&lt;0.0001).	Bleomycin	42-51	dipeptidylpeptidase 4	Mus musculus	0-4
31350829-11	2020	Treatment with DPP4 inhibitors promoted regression of fibrosis induced by bleomycin- or chronic graft-versus-host disease and ameliorated fibrosis in TSK1 mice (p&lt;0.001).	Bleomycin	74-83	dipeptidylpeptidase 4	Mus musculus	15-19
31441735-3	2020	OBJECTIVE: The aim of the study was to evaluate effect of curcumin as an intervention on two prognostic markers EGFR and Ki67 in bleomycin induced basal alveolar epithelial cells and C57BL/6 mice.	Bleomycin	129-138	epidermal growth factor receptor	Mus musculus	112-116
31441735-3	2020	OBJECTIVE: The aim of the study was to evaluate effect of curcumin as an intervention on two prognostic markers EGFR and Ki67 in bleomycin induced basal alveolar epithelial cells and C57BL/6 mice.	Bleomycin	129-138	antigen identified by monoclonal antibody Ki 67	Mus musculus	121-125
31678213-0	2020	CD4+CD25+ Tregs as dependent factor in the course of bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	53-62	CD4 antigen	Mus musculus	0-3
31678213-3	2020	We here explored the relationship between peripheral blood CD4+CD25+ Tregs and the course of bleomycin-induced PF in mice.	Bleomycin	93-102	CD4 antigen	Mus musculus	59-62
31678213-7	2020	The trend of CD4+CD25+ Tregs changes was increased firstly, decreased, increased again from 7th to 28th days after bleomycin instillation, which had great relevance with alveolitis and fibrosis scores.	Bleomycin	115-124	CD4 antigen	Mus musculus	13-16
31678213-11	2020	These findings suggested that the dynamic changes of CD4+CD25+ Tregs as dependent factor might designate a different course of PF induced by bleomycin in mice, and might be a selected drug use indicator for therapy of PF.	Bleomycin	141-150	CD4 antigen	Mus musculus	53-56
31883832-7	2020	RESULTS: The severity of fibrosis in the skin and lung was significantly less in CD22-/-, CD72-/-, and CD22-/-/CD72-/- mice than in WT mice in the bleomycin-induced model.	Bleomycin	147-156	CD22 antigen	Mus musculus	103-107
31883832-8	2020	In the skin of bleomycin-treated mice, the numbers of CD3+ T cells, CD8+ T cells, and F4/80+ macrophages were significantly lower in CD22-/-, CD72-/-, and CD22-/-/CD72-/- mice than in WT mice.	Bleomycin	15-24	adhesion G protein-coupled receptor E1	Mus musculus	86-91
31883832-8	2020	In the skin of bleomycin-treated mice, the numbers of CD3+ T cells, CD8+ T cells, and F4/80+ macrophages were significantly lower in CD22-/-, CD72-/-, and CD22-/-/CD72-/- mice than in WT mice.	Bleomycin	15-24	CD22 antigen	Mus musculus	133-137
31883832-8	2020	In the skin of bleomycin-treated mice, the numbers of CD3+ T cells, CD8+ T cells, and F4/80+ macrophages were significantly lower in CD22-/-, CD72-/-, and CD22-/-/CD72-/- mice than in WT mice.	Bleomycin	15-24	CD72 antigen	Mus musculus	142-146
31883832-8	2020	In the skin of bleomycin-treated mice, the numbers of CD3+ T cells, CD8+ T cells, and F4/80+ macrophages were significantly lower in CD22-/-, CD72-/-, and CD22-/-/CD72-/- mice than in WT mice.	Bleomycin	15-24	CD22 antigen	Mus musculus	155-159
31883832-8	2020	In the skin of bleomycin-treated mice, the numbers of CD3+ T cells, CD8+ T cells, and F4/80+ macrophages were significantly lower in CD22-/-, CD72-/-, and CD22-/-/CD72-/- mice than in WT mice.	Bleomycin	15-24	CD72 antigen	Mus musculus	163-167
33259780-2	2020	We demonstrated in an alveolar epithelial cell line A549/ABCA3 that certain microRNAs were associated with bleomycin induced epithelial-mesenchymal transition (EMT) which is closely related to pulmonary fibrosis.	Bleomycin	107-116	ATP-binding cassette, sub-family A (ABC1), member 3	Mus musculus	57-62
31659758-0	2020	Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-beta1 signalling pathway.	Bleomycin	21-30	transforming growth factor, beta 1	Mus musculus	66-75
33259780-8	2020	RESULTS: We found that bleomycin significantly suppressed the intracellular expression and extracellular release of miR-484 in A549/ABCA3 cells.	Bleomycin	23-32	microRNA 484	Mus musculus	116-123
33259780-8	2020	RESULTS: We found that bleomycin significantly suppressed the intracellular expression and extracellular release of miR-484 in A549/ABCA3 cells.	Bleomycin	23-32	ATP-binding cassette, sub-family A (ABC1), member 3	Mus musculus	132-137
33259780-12	2020	In contrast, the significant decrease in miR-484 expression in the lung tissue or plasma of bleomycin-administered mice suggested that miR-484 expression was closely correlated with bleomycin-induced lung injury.	Bleomycin	92-101	microRNA 484	Mus musculus	41-48
33259780-12	2020	In contrast, the significant decrease in miR-484 expression in the lung tissue or plasma of bleomycin-administered mice suggested that miR-484 expression was closely correlated with bleomycin-induced lung injury.	Bleomycin	92-101	microRNA 484	Mus musculus	135-142
33259780-12	2020	In contrast, the significant decrease in miR-484 expression in the lung tissue or plasma of bleomycin-administered mice suggested that miR-484 expression was closely correlated with bleomycin-induced lung injury.	Bleomycin	182-191	microRNA 484	Mus musculus	41-48
33259780-12	2020	In contrast, the significant decrease in miR-484 expression in the lung tissue or plasma of bleomycin-administered mice suggested that miR-484 expression was closely correlated with bleomycin-induced lung injury.	Bleomycin	182-191	microRNA 484	Mus musculus	135-142
31665549-6	2020	DNA damage induced by bleomycin dissociates MDM2 from the p53/HERC2/NEURL4 complex and increases the phosphorylation and acetylation of oligomeric p53 bound to HERC2 and NEURL4.	Bleomycin	22-31	MDM2 proto-oncogene	Homo sapiens	44-48
31665549-6	2020	DNA damage induced by bleomycin dissociates MDM2 from the p53/HERC2/NEURL4 complex and increases the phosphorylation and acetylation of oligomeric p53 bound to HERC2 and NEURL4.	Bleomycin	22-31	tumor protein p53	Homo sapiens	58-61
31665549-6	2020	DNA damage induced by bleomycin dissociates MDM2 from the p53/HERC2/NEURL4 complex and increases the phosphorylation and acetylation of oligomeric p53 bound to HERC2 and NEURL4.	Bleomycin	22-31	HECT and RLD domain containing E3 ubiquitin protein ligase 2	Homo sapiens	62-67
31665549-6	2020	DNA damage induced by bleomycin dissociates MDM2 from the p53/HERC2/NEURL4 complex and increases the phosphorylation and acetylation of oligomeric p53 bound to HERC2 and NEURL4.	Bleomycin	22-31	neuralized E3 ubiquitin protein ligase 4	Homo sapiens	68-74
31665549-6	2020	DNA damage induced by bleomycin dissociates MDM2 from the p53/HERC2/NEURL4 complex and increases the phosphorylation and acetylation of oligomeric p53 bound to HERC2 and NEURL4.	Bleomycin	22-31	tumor protein p53	Homo sapiens	147-150
31665549-6	2020	DNA damage induced by bleomycin dissociates MDM2 from the p53/HERC2/NEURL4 complex and increases the phosphorylation and acetylation of oligomeric p53 bound to HERC2 and NEURL4.	Bleomycin	22-31	HECT and RLD domain containing E3 ubiquitin protein ligase 2	Homo sapiens	160-165
31665549-6	2020	DNA damage induced by bleomycin dissociates MDM2 from the p53/HERC2/NEURL4 complex and increases the phosphorylation and acetylation of oligomeric p53 bound to HERC2 and NEURL4.	Bleomycin	22-31	neuralized E3 ubiquitin protein ligase 4	Homo sapiens	170-176
31155950-6	2020	As well, our data demonstrated that acute BLM-induced fibrosis was accompanied by an oxidative stress in lung tissue as assessed by an increase of lipid peroxidation as well as antioxidant enzyme activities depletion such as superoxide dismutase (SOD) and catalase (CAT).	Bleomycin	42-45	catalase	Rattus norvegicus	256-264
31155950-6	2020	As well, our data demonstrated that acute BLM-induced fibrosis was accompanied by an oxidative stress in lung tissue as assessed by an increase of lipid peroxidation as well as antioxidant enzyme activities depletion such as superoxide dismutase (SOD) and catalase (CAT).	Bleomycin	42-45	catalase	Rattus norvegicus	266-269
31608667-5	2020	BLM induced collagen deposition, increased lipid peroxidation (MDA) and decreased superoxide dismutase (SOD) and catalase (CAT) activities.	Bleomycin	0-3	catalase	Rattus norvegicus	123-126
31848318-6	2019	In a mouse model of bleomycin-induced lung fibrosis, Lonidamine reduced the expression of genes encoding profibrotic markers (collagenIotaalpha1, EDA-fibronectin, alpha smooth muscle actin, and connective tissue growth factor) and stabilized or improved lung function as assessed by measurement of peripheral blood oxygenation.	Bleomycin	20-29	cellular communication network factor 2	Mus musculus	194-225
31940650-1	2020	BACKGROUND: To study the protective effects of ganoderic acid A (GAA) on bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	73-82	glucosidase, alpha, acid	Mus musculus	65-68
31940650-1	2020	BACKGROUND: To study the protective effects of ganoderic acid A (GAA) on bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	84-87	glucosidase, alpha, acid	Mus musculus	65-68
31882807-6	2019	The increases in vascular endothelial growth factor (VEGF) expression and endothelial cell proliferation in bleomycin-infused lung segments were significantly reduced in sheep treated with the senicapoc, when compared to vehicle-treated controls.	Bleomycin	108-117	vascular endothelial growth factor A	Ovis aries	17-51
31940650-11	2020	In addition, GAA significantly decreased the levels of TGF-beta, p-smad3, p-IkappaB, and p-NF-kappaB, compared with those in BLM group.	Bleomycin	125-128	glucosidase, alpha, acid	Mus musculus	13-16
31940650-12	2020	CONCLUSION: GAA has protective effect on BLM-induced lung injury, and TGF-beta/Smad-3/NF-kappaB signaling pathway may play an important role in the pathogenesis of BLM-induced lung injury.	Bleomycin	41-44	glucosidase, alpha, acid	Mus musculus	12-15
31940650-12	2020	CONCLUSION: GAA has protective effect on BLM-induced lung injury, and TGF-beta/Smad-3/NF-kappaB signaling pathway may play an important role in the pathogenesis of BLM-induced lung injury.	Bleomycin	164-167	glucosidase, alpha, acid	Mus musculus	12-15
31940650-12	2020	CONCLUSION: GAA has protective effect on BLM-induced lung injury, and TGF-beta/Smad-3/NF-kappaB signaling pathway may play an important role in the pathogenesis of BLM-induced lung injury.	Bleomycin	164-167	transforming growth factor, beta 1	Mus musculus	70-78
31940650-12	2020	CONCLUSION: GAA has protective effect on BLM-induced lung injury, and TGF-beta/Smad-3/NF-kappaB signaling pathway may play an important role in the pathogenesis of BLM-induced lung injury.	Bleomycin	164-167	SMAD family member 3	Mus musculus	79-85
31940650-12	2020	CONCLUSION: GAA has protective effect on BLM-induced lung injury, and TGF-beta/Smad-3/NF-kappaB signaling pathway may play an important role in the pathogenesis of BLM-induced lung injury.	Bleomycin	164-167	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	86-95
31873099-0	2019	Caveolin-1 gene therapy inhibits inflammasome activation to protect from bleomycin-induced pulmonary fibrosis.	Bleomycin	73-82	caveolin 1	Homo sapiens	0-10
31873099-3	2019	We show that Cav-1 expression was downregulated both in alveolar epithelial type I cells in bleomycin-injured mouse lungs and in lung sections from IPF patients.	Bleomycin	92-101	caveolin 1, caveolae protein	Mus musculus	13-18
31873099-5	2019	Gene transfer of a plasmid expressing Cav-1 using transthoracic electroporation reduced infiltration of neutrophils and monocytes/macrophages and protected from subsequent bleomycin-induced pulmonary fibrosis.	Bleomycin	172-181	caveolin 1	Homo sapiens	38-43
31873099-6	2019	Overexpression of Cav-1 suppressed bleomycin- or silica-induced activation of caspase-1 and maturation of pro-IL-1beta to secrete cleaved IL-1beta both in mouse lungs and in primary type I cells.	Bleomycin	35-44	caveolin 1, caveolae protein	Mus musculus	18-23
31873099-6	2019	Overexpression of Cav-1 suppressed bleomycin- or silica-induced activation of caspase-1 and maturation of pro-IL-1beta to secrete cleaved IL-1beta both in mouse lungs and in primary type I cells.	Bleomycin	35-44	caspase 1	Mus musculus	78-87
31873099-6	2019	Overexpression of Cav-1 suppressed bleomycin- or silica-induced activation of caspase-1 and maturation of pro-IL-1beta to secrete cleaved IL-1beta both in mouse lungs and in primary type I cells.	Bleomycin	35-44	interleukin 1 beta	Mus musculus	138-146
31873099-7	2019	These results demonstrate that gene transfer of Cav-1 downregulates inflammasome activity and protects from subsequent bleomycin-mediated pulmonary fibrosis.	Bleomycin	119-128	caveolin 1	Homo sapiens	48-53
31757863-0	2019	Cutting Edge: Involvement of the Immunoreceptor CD300c2 on Alveolar Macrophages in Bleomycin-Induced Lung Fibrosis.	Bleomycin	83-92	CD300C molecule 2	Mus musculus	48-55
31757863-3	2019	In this article, we show that mice deficient in the immunoreceptor CD300c2 (also called MAIR-II, LMIR2, and CLM-4) showed longer survival; less collagen deposition in the lung; lower levels of neutrophil chemoattractants, such as TNF-alpha, CXCL1, and CCL2; and fewer neutrophils in the bronchoalveolar fluid than wild-type mice after intratracheal administration of bleomycin (BLM).	Bleomycin	367-376	CD300C molecule 2	Mus musculus	67-74
31757863-3	2019	In this article, we show that mice deficient in the immunoreceptor CD300c2 (also called MAIR-II, LMIR2, and CLM-4) showed longer survival; less collagen deposition in the lung; lower levels of neutrophil chemoattractants, such as TNF-alpha, CXCL1, and CCL2; and fewer neutrophils in the bronchoalveolar fluid than wild-type mice after intratracheal administration of bleomycin (BLM).	Bleomycin	367-376	CD300C molecule 2	Mus musculus	88-95
31757863-3	2019	In this article, we show that mice deficient in the immunoreceptor CD300c2 (also called MAIR-II, LMIR2, and CLM-4) showed longer survival; less collagen deposition in the lung; lower levels of neutrophil chemoattractants, such as TNF-alpha, CXCL1, and CCL2; and fewer neutrophils in the bronchoalveolar fluid than wild-type mice after intratracheal administration of bleomycin (BLM).	Bleomycin	367-376	CD300C molecule 2	Mus musculus	97-102
31757863-3	2019	In this article, we show that mice deficient in the immunoreceptor CD300c2 (also called MAIR-II, LMIR2, and CLM-4) showed longer survival; less collagen deposition in the lung; lower levels of neutrophil chemoattractants, such as TNF-alpha, CXCL1, and CCL2; and fewer neutrophils in the bronchoalveolar fluid than wild-type mice after intratracheal administration of bleomycin (BLM).	Bleomycin	367-376	CD300C molecule 2	Mus musculus	108-113
31757863-3	2019	In this article, we show that mice deficient in the immunoreceptor CD300c2 (also called MAIR-II, LMIR2, and CLM-4) showed longer survival; less collagen deposition in the lung; lower levels of neutrophil chemoattractants, such as TNF-alpha, CXCL1, and CCL2; and fewer neutrophils in the bronchoalveolar fluid than wild-type mice after intratracheal administration of bleomycin (BLM).	Bleomycin	378-381	CD300C molecule 2	Mus musculus	67-74
31757863-3	2019	In this article, we show that mice deficient in the immunoreceptor CD300c2 (also called MAIR-II, LMIR2, and CLM-4) showed longer survival; less collagen deposition in the lung; lower levels of neutrophil chemoattractants, such as TNF-alpha, CXCL1, and CCL2; and fewer neutrophils in the bronchoalveolar fluid than wild-type mice after intratracheal administration of bleomycin (BLM).	Bleomycin	378-381	CD300C molecule 2	Mus musculus	88-95
31757863-3	2019	In this article, we show that mice deficient in the immunoreceptor CD300c2 (also called MAIR-II, LMIR2, and CLM-4) showed longer survival; less collagen deposition in the lung; lower levels of neutrophil chemoattractants, such as TNF-alpha, CXCL1, and CCL2; and fewer neutrophils in the bronchoalveolar fluid than wild-type mice after intratracheal administration of bleomycin (BLM).	Bleomycin	378-381	CD300C molecule 2	Mus musculus	97-102
31757863-3	2019	In this article, we show that mice deficient in the immunoreceptor CD300c2 (also called MAIR-II, LMIR2, and CLM-4) showed longer survival; less collagen deposition in the lung; lower levels of neutrophil chemoattractants, such as TNF-alpha, CXCL1, and CCL2; and fewer neutrophils in the bronchoalveolar fluid than wild-type mice after intratracheal administration of bleomycin (BLM).	Bleomycin	378-381	CD300C molecule 2	Mus musculus	108-113
31757863-4	2019	We also found that BLM administration induced the release of the danger-associated molecular pattern HMGB-1, which caused CD300c2-deficient alveolar macrophages, via TLR4, to produce lower levels of neutrophil chemoattractants than wild-type alveolar macrophages.	Bleomycin	19-22	high mobility group box 1	Mus musculus	101-107
31757863-4	2019	We also found that BLM administration induced the release of the danger-associated molecular pattern HMGB-1, which caused CD300c2-deficient alveolar macrophages, via TLR4, to produce lower levels of neutrophil chemoattractants than wild-type alveolar macrophages.	Bleomycin	19-22	CD300C molecule 2	Mus musculus	122-129
31757863-4	2019	We also found that BLM administration induced the release of the danger-associated molecular pattern HMGB-1, which caused CD300c2-deficient alveolar macrophages, via TLR4, to produce lower levels of neutrophil chemoattractants than wild-type alveolar macrophages.	Bleomycin	19-22	toll-like receptor 4	Mus musculus	166-170
31757863-5	2019	Our findings demonstrate that CD300c2 contributes to BLM-induced inflammatory responses mediated by alveolar macrophages.	Bleomycin	53-56	CD300C molecule 2	Mus musculus	30-37
31826982-4	2019	Full-length caveolin-1 scaffolding domain peptide (CSP; amino acids 82 to 101 of Cav1: DGIWKASFTTFTVTKYWFYR) inhibits AEC apoptosis and fLf activation and expansion and attenuates PF in bleomycin (BLM)-induced lung injury in mice.	Bleomycin	186-195	caveolin 1, caveolae protein	Mus musculus	12-22
31826982-4	2019	Full-length caveolin-1 scaffolding domain peptide (CSP; amino acids 82 to 101 of Cav1: DGIWKASFTTFTVTKYWFYR) inhibits AEC apoptosis and fLf activation and expansion and attenuates PF in bleomycin (BLM)-induced lung injury in mice.	Bleomycin	186-195	caveolin 1, caveolae protein	Mus musculus	81-85
31826982-4	2019	Full-length caveolin-1 scaffolding domain peptide (CSP; amino acids 82 to 101 of Cav1: DGIWKASFTTFTVTKYWFYR) inhibits AEC apoptosis and fLf activation and expansion and attenuates PF in bleomycin (BLM)-induced lung injury in mice.	Bleomycin	197-200	caveolin 1, caveolae protein	Mus musculus	12-22
31826982-4	2019	Full-length caveolin-1 scaffolding domain peptide (CSP; amino acids 82 to 101 of Cav1: DGIWKASFTTFTVTKYWFYR) inhibits AEC apoptosis and fLf activation and expansion and attenuates PF in bleomycin (BLM)-induced lung injury in mice.	Bleomycin	197-200	caveolin 1, caveolae protein	Mus musculus	81-85
31535412-16	2019	In addition, H2 inhalation also inhibited BLM-induced epithelial-mesenchymal transitions (EMT) by inhibiting TGF-beta1 to increase the expression level of epithelial cell marker E-cadherin while decrease the expression level of mesenchymal cell marker vimentin in a time-dependent manner.	Bleomycin	42-45	transforming growth factor, beta 1	Rattus norvegicus	109-118
31670506-5	2019	Furthermore, this probe was successfully used to reflect FAP up-regulation in the lung homogenates of the bleomycin-induced idiopathic pulmonary fibrosis (IPF) mice.	Bleomycin	106-115	fibroblast activation protein	Mus musculus	57-60
31145635-7	2019	Increased expression of ECT2 was verified by qPCR and Western blotting in bleomycin-induced lung fibrosis and human IPF tissue.	Bleomycin	74-83	epithelial cell transforming 2	Homo sapiens	24-28
31535412-0	2019	Hydrogen inhalation attenuated bleomycin-induced pulmonary fibrosis by inhibiting TGF-beta1 and relevant oxidative stress and EMT.	Bleomycin	31-40	transforming growth factor, beta 1	Rattus norvegicus	82-91
32237397-1	2019	The aim of this paper was to investigate the effect of Dilong( geosaurus) on the expressions of fibrotic factors TGF-beta1 and alpha-SMA in bleomycin-induced pulmonary fibrosis mice.	Bleomycin	140-149	transforming growth factor, beta 1	Mus musculus	113-122
32237397-1	2019	The aim of this paper was to investigate the effect of Dilong( geosaurus) on the expressions of fibrotic factors TGF-beta1 and alpha-SMA in bleomycin-induced pulmonary fibrosis mice.	Bleomycin	140-149	actin alpha 2, smooth muscle, aorta	Mus musculus	127-136
31589215-8	2019	Furthermore, we show that BMN consisting of HA and bleomycin can inhibit the proliferation of human hypertrophic scar fibroblasts (hHSFs) and the secretion of transforming growth factor-beta (TGF-beta1) in vitro.	Bleomycin	51-60	transforming growth factor beta 1	Homo sapiens	192-201
31777533-0	2019	Pirfenidone activates cannabinoid receptor 2 in a mouse model of bleomycin-induced pulmonary fibrosis.	Bleomycin	65-74	cannabinoid receptor 2 (macrophage)	Mus musculus	22-44
31777533-12	2019	The results demonstrated that CB2R protein and mRNA levels increased with increasing fibrosis in mice with BLM-induced IPF.	Bleomycin	107-110	cannabinoid receptor 2 (macrophage)	Mus musculus	30-34
31777533-15	2019	In conclusion, pirfenidone attenuated and activated CB2R in BLM-treated mice.	Bleomycin	60-63	cannabinoid receptor 2 (macrophage)	Mus musculus	52-56
31560857-0	2019	Redistribution of EC-SOD resolves bleomycin-induced inflammation via increased apoptosis of recruited alveolar macrophages.	Bleomycin	34-43	superoxide dismutase 3, extracellular	Mus musculus	18-24
31704290-0	2019	Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis.	Bleomycin	31-40	thymoma viral proto-oncogene 1	Mus musculus	95-98
31704290-0	2019	Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis.	Bleomycin	31-40	mechanistic target of rapamycin kinase	Mus musculus	99-103
31704290-0	2019	Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis.	Bleomycin	31-40	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	104-110
31704290-6	2019	Moreover, Tan IIA partially reversed bleomycin-induced EndoMT both in vivo and in vitro.	Bleomycin	37-46	ATPase, class II, type 9A	Mus musculus	14-17
31704290-7	2019	Additionally, Tan IIA mitigated the diminution of tube formation in endothelial cells induced by bleomycin.	Bleomycin	97-106	ATPase, class II, type 9A	Mus musculus	18-21
31704290-8	2019	Furthermore, mechanistically, the activation of the Akt/mTOR/p70S6K pathway was found to be involved in bleomycin-treated SSc mouse model, which was alleviated by Tan IIA.	Bleomycin	104-113	thymoma viral proto-oncogene 1	Mus musculus	52-55
31704290-8	2019	Furthermore, mechanistically, the activation of the Akt/mTOR/p70S6K pathway was found to be involved in bleomycin-treated SSc mouse model, which was alleviated by Tan IIA.	Bleomycin	104-113	mechanistic target of rapamycin kinase	Mus musculus	56-60
31704290-8	2019	Furthermore, mechanistically, the activation of the Akt/mTOR/p70S6K pathway was found to be involved in bleomycin-treated SSc mouse model, which was alleviated by Tan IIA.	Bleomycin	104-113	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	61-67
31705517-4	2019	METHODS:  Transgenic C57BL/6 mice with doxycycline inducible lung-specific urokinase plasminogen activator (uPA) expression or littermate controls were treated (day 0) with bleomycin or saline.	Bleomycin	173-182	plasminogen activator, urokinase	Mus musculus	108-111
31775746-0	2019	Vitamin D deficiency exacerbates bleomycin-induced pulmonary fibrosis partially through aggravating TGF-beta/Smad2/3-mediated epithelial-mesenchymal transition.	Bleomycin	33-42	SMAD family member 2	Mus musculus	109-116
31775746-9	2019	EMT was measured and transforming growth factor-beta (TGF-beta)/Smad3 signaling was evaluated in the lungs of BLM-treated mice.	Bleomycin	110-113	SMAD family member 3	Mus musculus	64-69
31775746-13	2019	By contrast, vimentin and alpha-SMA, two EMT markers, were upregulated in the lungs of BLM-treated mice.	Bleomycin	87-90	vimentin	Mus musculus	13-21
31775746-13	2019	By contrast, vimentin and alpha-SMA, two EMT markers, were upregulated in the lungs of BLM-treated mice.	Bleomycin	87-90	actin alpha 2, smooth muscle, aorta	Mus musculus	26-35
31775746-14	2019	Pulmonary TGF-beta/Smad3 signaling was activated in BLM-induced lung fibrosis.	Bleomycin	52-55	SMAD family member 3	Mus musculus	19-24
31775746-16	2019	Moreover, feeding VDD diet aggravated BLM-induced TGF-beta/Smad3 activation and subsequent EMT in the lungs.	Bleomycin	38-41	SMAD family member 3	Mus musculus	59-64
31775746-18	2019	Additional experiment showed that Cyp27b1 gene knockout, leading to active vitamin D3 deficiency, exacerbated BLM-induced pulmonary fibrosis.	Bleomycin	110-113	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	34-41
31775746-19	2019	Moreover, Cyp27b1 gene knockout aggravated pulmonary TGF-beta/Smad2/3 activation and subsequent EMT in BLM-induced lung fibrosis.	Bleomycin	103-106	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	10-17
31775746-20	2019	CONCLUSION: Vitamin D deficiency exacerbates BLM-induced pulmonary fibrosis partially through aggravating TGF-beta/Smad2/3-mediated EMT in the lungs.	Bleomycin	45-48	SMAD family member 2	Mus musculus	115-122
31824505-4	2019	Methods: The pulmonary expression of folate receptor-beta was analyzed in patients with different subtypes of ILD as well as in bleomycin (BLM)-treated mice and respective controls using immunohistochemistry.	Bleomycin	128-137	folate receptor beta	Homo sapiens	37-57
31824505-4	2019	Methods: The pulmonary expression of folate receptor-beta was analyzed in patients with different subtypes of ILD as well as in bleomycin (BLM)-treated mice and respective controls using immunohistochemistry.	Bleomycin	139-142	folate receptor beta	Homo sapiens	37-57
31824505-9	2019	In the mouse model of BLM-induced ILD, pulmonary accumulation of 18F-AzaFol reflected macrophage-related disease development with good correlation of folate receptor-beta positivity with radiotracer uptake.	Bleomycin	22-25	folate receptor 2 (fetal)	Mus musculus	150-170
31819797-7	2019	Lung injury was achieved due to bleomycin exposure at all time points as indicated by impaired lung mechanics, pathologic lung architecture (from day 14), and cellular and protein accumulation in the alveolar space accompanied by a minor decrease in lung tissue VE-cadherin at day 14.	Bleomycin	32-41	cadherin 5	Mus musculus	262-273
31600171-6	2019	We confirmed model predictions by demonstrating that expression of POU2AF1, previously unassociated with lung fibrosis but proposed by the model as regulator, is increased in B lymphocytes in IPF lungs and that POU2AF1-knockout mice were protected from bleomycin-induced lung fibrosis.	Bleomycin	253-262	POU domain, class 2, associating factor 1	Mus musculus	67-74
31600171-6	2019	We confirmed model predictions by demonstrating that expression of POU2AF1, previously unassociated with lung fibrosis but proposed by the model as regulator, is increased in B lymphocytes in IPF lungs and that POU2AF1-knockout mice were protected from bleomycin-induced lung fibrosis.	Bleomycin	253-262	POU domain, class 2, associating factor 1	Mus musculus	211-218
31535412-16	2019	In addition, H2 inhalation also inhibited BLM-induced epithelial-mesenchymal transitions (EMT) by inhibiting TGF-beta1 to increase the expression level of epithelial cell marker E-cadherin while decrease the expression level of mesenchymal cell marker vimentin in a time-dependent manner.	Bleomycin	42-45	cadherin 1	Rattus norvegicus	178-188
31535412-16	2019	In addition, H2 inhalation also inhibited BLM-induced epithelial-mesenchymal transitions (EMT) by inhibiting TGF-beta1 to increase the expression level of epithelial cell marker E-cadherin while decrease the expression level of mesenchymal cell marker vimentin in a time-dependent manner.	Bleomycin	42-45	vimentin	Rattus norvegicus	252-260
31717986-0	2019	Thymoquinone-PLGA-PVA Nanoparticles Ameliorate Bleomycin-Induced Pulmonary Fibrosis in Rats via Regulation of Inflammatory Cytokines and iNOS Signaling.	Bleomycin	47-56	nitric oxide synthase 2	Rattus norvegicus	137-141
31885648-0	2019	Kangfuxin Oral Liquid Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-beta1/Smad Pathway.	Bleomycin	33-42	transforming growth factor beta 1	Homo sapiens	78-87
31781172-4	2019	RTS1 was among the genes that when singly deleted cause sensitivity to bleomycin.	Bleomycin	71-80	protein phosphatase 2A regulatory subunit RTS1	Saccharomyces cerevisiae S288C	0-4
31781172-5	2019	We investigate whether Rts1 plays a role in the repair of bleomycin-induced DNA lesions.	Bleomycin	58-67	protein phosphatase 2A regulatory subunit RTS1	Saccharomyces cerevisiae S288C	23-27
31781172-6	2019	We show that deletion of the RTS1 gene in the rad51 null background, lacking Rad51 known to be involved in the repair of bleomycin-induced DNA lesions, resulted in double mutants that were sensitized to bleomycin and not to other DNA damaging agents that creates DNA adducts.	Bleomycin	121-130	protein phosphatase 2A regulatory subunit RTS1	Saccharomyces cerevisiae S288C	29-33
31781172-6	2019	We show that deletion of the RTS1 gene in the rad51 null background, lacking Rad51 known to be involved in the repair of bleomycin-induced DNA lesions, resulted in double mutants that were sensitized to bleomycin and not to other DNA damaging agents that creates DNA adducts.	Bleomycin	121-130	recombinase RAD51	Saccharomyces cerevisiae S288C	46-51
31781172-6	2019	We show that deletion of the RTS1 gene in the rad51 null background, lacking Rad51 known to be involved in the repair of bleomycin-induced DNA lesions, resulted in double mutants that were sensitized to bleomycin and not to other DNA damaging agents that creates DNA adducts.	Bleomycin	203-212	protein phosphatase 2A regulatory subunit RTS1	Saccharomyces cerevisiae S288C	29-33
31781172-6	2019	We show that deletion of the RTS1 gene in the rad51 null background, lacking Rad51 known to be involved in the repair of bleomycin-induced DNA lesions, resulted in double mutants that were sensitized to bleomycin and not to other DNA damaging agents that creates DNA adducts.	Bleomycin	203-212	recombinase RAD51	Saccharomyces cerevisiae S288C	46-51
31781172-7	2019	We further show that Rts1 has the ability to bind to DNA and in its absence cells displayed an increase in the frequency of both spontaneous and bleomycin-induced mutations compared to the parent.	Bleomycin	145-154	protein phosphatase 2A regulatory subunit RTS1	Saccharomyces cerevisiae S288C	21-25
31483681-4	2019	Using a bleomycin-induced model of pulmonary fibrosis, we found that MKP-5-deficient mice were protected from the development of lung fibrosis, expressed reduced levels of hydroxyproline and fibrogenic genes, and displayed marked polarization towards an M1-macrophage phenotype.	Bleomycin	8-17	dual specificity phosphatase 10	Mus musculus	69-74
31173491-5	2019	In the bleomycin model, daily subcutaneous bleomycin injection increased serum CX3 CL1 levels (P &lt; 0.05) and augmented lesional CX3 CL1 expression.	Bleomycin	7-16	C-X3-C motif chemokine ligand 1	Homo sapiens	79-86
31439591-10	2019	IRF7 KO mice demonstrated attenuated dermal fibrosis and inflammation compared with wild-type mice in response to bleomycin.	Bleomycin	114-123	interferon regulatory factor 7	Mus musculus	0-4
31173491-5	2019	In the bleomycin model, daily subcutaneous bleomycin injection increased serum CX3 CL1 levels (P &lt; 0.05) and augmented lesional CX3 CL1 expression.	Bleomycin	7-16	C-X3-C motif chemokine ligand 1	Homo sapiens	131-138
31173491-5	2019	In the bleomycin model, daily subcutaneous bleomycin injection increased serum CX3 CL1 levels (P &lt; 0.05) and augmented lesional CX3 CL1 expression.	Bleomycin	43-52	C-X3-C motif chemokine ligand 1	Homo sapiens	79-86
31173491-5	2019	In the bleomycin model, daily subcutaneous bleomycin injection increased serum CX3 CL1 levels (P &lt; 0.05) and augmented lesional CX3 CL1 expression.	Bleomycin	43-52	C-X3-C motif chemokine ligand 1	Homo sapiens	131-138
31173491-6	2019	Simultaneous administration of anti-CX3 CL1 mAb or CX3 CR1 deficiency significantly suppressed the dermal thickness, collagen content, and capillary loss caused by bleomycin (P &lt; 0.05).	Bleomycin	164-173	doublecortin like kinase 1	Homo sapiens	40-43
31173491-6	2019	Simultaneous administration of anti-CX3 CL1 mAb or CX3 CR1 deficiency significantly suppressed the dermal thickness, collagen content, and capillary loss caused by bleomycin (P &lt; 0.05).	Bleomycin	164-173	C-X3-C motif chemokine receptor 1	Homo sapiens	51-58
31173491-7	2019	Injection of bleomycin induced expression of pSmad3 and TGFbeta1 in the skin, which was inhibited by anti-CX3 CL1 mAb.	Bleomycin	13-22	transforming growth factor beta 1	Homo sapiens	56-64
31173491-7	2019	Injection of bleomycin induced expression of pSmad3 and TGFbeta1 in the skin, which was inhibited by anti-CX3 CL1 mAb.	Bleomycin	13-22	C-X3-C motif chemokine ligand 1	Homo sapiens	106-113
31398421-0	2019	Protective effect of peptide DR8 on bleomycin-induced pulmonary fibrosis by regulating the TGF-beta/MAPK signaling pathway and oxidative stress.	Bleomycin	36-45	transforming growth factor, beta 1	Mus musculus	91-99
31505074-3	2019	A previous study found elevated levels of GAB1 in bleomycin (BLM)-induced fibrotic lungs, but the effects of GAB1 in SSc remain unclear.	Bleomycin	50-59	GRB2 associated binding protein 1	Homo sapiens	42-46
31431059-7	2019	In vitro knockdown of LC3B sensitized mouse lung epithelial cells to bleomycin-induced apoptosis, but its overexpression was protective.	Bleomycin	69-78	microtubule-associated protein 1 light chain 3 beta	Mus musculus	22-26
31431059-8	2019	In vivo, LC3B-/- mice displayed increased susceptibility to bleomycin-induced lung injury and fibrosis.	Bleomycin	60-69	microtubule-associated protein 1 light chain 3 beta	Mus musculus	9-13
31672942-2	2019	Using single (self-resolving) or repetitive (nonresolving) intratracheal administration of bleomycin in type 1 collagen-GFP reporter mice, we report that Thy-1 surface expression, but not mRNA, is reversibly diminished in activated fibroblasts and myofibroblasts in self-resolving fibrosis.	Bleomycin	91-100	thymus cell antigen 1, theta	Mus musculus	154-159
31672942-3	2019	However, Thy-1 mRNA expression is silenced in lung with nonresolving fibrosis following repetitive bleomycin administration, associated with persistent activation of alphav integrin.	Bleomycin	99-108	thymus cell antigen 1, theta	Mus musculus	9-14
31672942-3	2019	However, Thy-1 mRNA expression is silenced in lung with nonresolving fibrosis following repetitive bleomycin administration, associated with persistent activation of alphav integrin.	Bleomycin	99-108	integrin alpha V	Mus musculus	166-181
31672942-4	2019	Thy1-null mice showed progressive alphav integrin activation and myofibroblast accumulation after a single dose of bleomycin.	Bleomycin	115-124	thymus cell antigen 1, theta	Mus musculus	0-4
31398421-0	2019	Protective effect of peptide DR8 on bleomycin-induced pulmonary fibrosis by regulating the TGF-beta/MAPK signaling pathway and oxidative stress.	Bleomycin	36-45	mitogen-activated protein kinase 1	Mus musculus	100-104
31519861-9	2019	IL-37 significantly decreased inflammation and collagen deposition in bleomycin-exposed mouse lungs, which was reversed by treatment with the autophagy inhibitor 3-methyladenine.	Bleomycin	70-79	interleukin 37	Homo sapiens	0-5
31323300-0	2019	beta-carboline alkaloids attenuate bleomycin induced pulmonary fibrosis in mice through inhibiting NF-kb/p65 phosphorylation and epithelial-mesenchymal transition.	Bleomycin	35-44	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	105-108
31724341-9	2019	Although the TNF-alpha level in BAL of bleomycin-treated mice was reduced by dexamethasone, the neutrophil infiltration remained unchanged.	Bleomycin	39-48	tumor necrosis factor	Mus musculus	13-22
31106564-11	2019	Finally, ST2 deficiency diminished the bleomycin-induced B7H3 and IL-13 upregulation, suggesting a role for type 2 innate lymphoid cells (ILC2).	Bleomycin	39-48	interleukin 1 receptor-like 1	Mus musculus	9-12
31106564-11	2019	Finally, ST2 deficiency diminished the bleomycin-induced B7H3 and IL-13 upregulation, suggesting a role for type 2 innate lymphoid cells (ILC2).	Bleomycin	39-48	interleukin 13	Mus musculus	66-71
31534007-6	2019	Bleomycin-induced lung fibrosis development in mouse models with genetic manipulation of GPx4 were examined.	Bleomycin	0-9	glutathione peroxidase 4	Mus musculus	89-93
31534007-10	2019	Heterozygous GPx4-deficient mice showed enhancement of bleomycin-induced lung fibrosis, which was attenuated in GPx4-transgenic mice in association with lipid peroxidation and SMAD signaling.	Bleomycin	55-64	glutathione peroxidase 4	Mus musculus	13-17
31534007-10	2019	Heterozygous GPx4-deficient mice showed enhancement of bleomycin-induced lung fibrosis, which was attenuated in GPx4-transgenic mice in association with lipid peroxidation and SMAD signaling.	Bleomycin	55-64	glutathione peroxidase 4	Mus musculus	112-116
31614900-7	2019	In carbon black/bleomycin-treated mice, knockdown of protease-activated receptor-1 (PAR-1) markedly downregulated alpha-smooth muscle actin (alpha-SMA) and fibronectin, and attenuated pleural fibrosis.	Bleomycin	16-25	coagulation factor II (thrombin) receptor	Mus musculus	53-82
31614900-7	2019	In carbon black/bleomycin-treated mice, knockdown of protease-activated receptor-1 (PAR-1) markedly downregulated alpha-smooth muscle actin (alpha-SMA) and fibronectin, and attenuated pleural fibrosis.	Bleomycin	16-25	coagulation factor II (thrombin) receptor	Mus musculus	84-89
31614900-7	2019	In carbon black/bleomycin-treated mice, knockdown of protease-activated receptor-1 (PAR-1) markedly downregulated alpha-smooth muscle actin (alpha-SMA) and fibronectin, and attenuated pleural fibrosis.	Bleomycin	16-25	actin alpha 2, smooth muscle, aorta	Mus musculus	141-150
31591327-1	2019	CD44, an adhesion-molecule promoting cell-migration, is shown here to increase in stress conditions following bleomycin-induced apoptosis in alveolar epithelial cells (AECs), a main target of lung injury.	Bleomycin	110-119	CD44 antigen	Mus musculus	0-4
30943369-7	2019	We present evidence that mice with ablation of fibroblast Gls1 are protected from bleomycin-induced lung fibrosis.	Bleomycin	82-91	glutaminase	Homo sapiens	58-62
31591327-0	2019	Increased Regeneration Following Stress-Induced Lung Injury in Bleomycin-Treated Chimeric Mice with CD44 Knockout Mesenchymal Cells.	Bleomycin	63-72	CD44 antigen	Mus musculus	100-104
31591327-7	2019	Bleomycin-treated chimeric CD44KO-mice had decreased EMT markers, ATM, and mesenchymal cells (alpha-SMA+) accumulation in lung, increased surfactant-b, diminished lung mesenchymal cell motility, and increased lung tissue regenerative capacity following bleomycin injury, as indicated by lung collagen content and semiquantitave morphological index scoring.	Bleomycin	0-9	ataxia telangiectasia mutated	Mus musculus	66-69
31584978-11	2019	Quite unexpectedly, mice with PPAR-gamma deficient macrophages were more resistant to bleomycin-induced weight loss whereas extracellular matrix deposition was unaffected compared to controls.	Bleomycin	86-95	peroxisome proliferator activated receptor gamma	Mus musculus	30-40
30943369-8	2019	We show that the Gls1 inhibitor, CB-839, is therapeutically efficacious in treating both bleomycin- and transforming growth factor-beta1-induced pulmonary fibrosis.	Bleomycin	89-98	glutaminase	Homo sapiens	17-21
31750010-7	2019	Lastly, upon bleomycin challenge, Myr-Akt mice showed enhanced collagen deposition, increased F4/80+ and CD45+ cells, reduced autophagy genes Beclin-1, Lc3a, and Lc3b expression, and a shorter life-span than WT littermates.	Bleomycin	13-22	thymoma viral proto-oncogene 1	Mus musculus	38-41
31750010-7	2019	Lastly, upon bleomycin challenge, Myr-Akt mice showed enhanced collagen deposition, increased F4/80+ and CD45+ cells, reduced autophagy genes Beclin-1, Lc3a, and Lc3b expression, and a shorter life-span than WT littermates.	Bleomycin	13-22	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	152-156
31750010-7	2019	Lastly, upon bleomycin challenge, Myr-Akt mice showed enhanced collagen deposition, increased F4/80+ and CD45+ cells, reduced autophagy genes Beclin-1, Lc3a, and Lc3b expression, and a shorter life-span than WT littermates.	Bleomycin	13-22	microtubule-associated protein 1 light chain 3 beta	Mus musculus	162-166
31527305-6	2019	Increased expression levels of aging-associated markers (P21WAF1 and SA-beta-gal) in AECs treated with bleomycin were found.	Bleomycin	103-112	serum amyloid A1 cluster	Homo sapiens	69-76
31432710-4	2019	Gdf15 expression is induced in response to telomere dysfunction and bleomycin challenge in mice.	Bleomycin	68-77	growth differentiation factor 15	Mus musculus	0-5
31432710-5	2019	Gdf15 mRNA is expressed by lung epithelial cells, and protein can be detected in peripheral blood and bronchoalveolar lavage following bleomycin challenge in mice.	Bleomycin	135-144	growth differentiation factor 15	Mus musculus	0-5
31589296-9	2019	Our in-depth analysis of SCCmec-resistant gene phylogenies reveals that genes such as blaZ, ble, kmA, and tetK that are responsible for beta-lactam, bleomycin, kanamycin, and tetracycline resistance in S. aureus were laterally transferred from non-Staphylococcus sources.	Bleomycin	149-158	bleomycin resistance protein Ble	Staphylococcus aureus	92-95
31392398-0	2019	Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin.	Bleomycin	101-110	growth hormone releasing hormone receptor	Mus musculus	0-41
31392398-2	2019	We hypothesized that a GHRH receptor (GHRH-R) antagonist, MIA-602, would inhibit bleomycin-induced lung inflammation and/or fibrosis in C57Bl/6J mice.	Bleomycin	81-90	growth hormone releasing hormone receptor	Mus musculus	23-36
31392398-2	2019	We hypothesized that a GHRH receptor (GHRH-R) antagonist, MIA-602, would inhibit bleomycin-induced lung inflammation and/or fibrosis in C57Bl/6J mice.	Bleomycin	81-90	growth hormone releasing hormone receptor	Mus musculus	38-44
31392398-8	2019	Multiple genes related to chemotaxis, IL-1, chemokines, regulation of inflammation, and extracellular signal-regulated kinases (ERK) were upregulated in lungs of mice treated with bleomycin and MIA-602.	Bleomycin	180-189	interleukin 1 complex	Mus musculus	38-42
31554736-5	2019	IL-11 receptor subunit alpha-1 (Il11ra1)-deleted mice, whose lung fibroblasts are unresponsive to profibrotic stimulation, are protected from fibrosis in the bleomycin mouse model of pulmonary fibrosis.	Bleomycin	158-167	interleukin 11 receptor, alpha chain 1	Mus musculus	0-30
31554736-5	2019	IL-11 receptor subunit alpha-1 (Il11ra1)-deleted mice, whose lung fibroblasts are unresponsive to profibrotic stimulation, are protected from fibrosis in the bleomycin mouse model of pulmonary fibrosis.	Bleomycin	158-167	interleukin 11 receptor, alpha chain 1	Mus musculus	32-39
31641391-5	2019	And in bleomycin-induced PF model, the expression of alpha-SMA and P27 was upregulated.	Bleomycin	7-16	interferon alpha inducible protein 27	Homo sapiens	67-70
31527305-8	2019	Bleomycin induced AEC senescence was reversed by Akt2 knockdown and the pharmacological inhibitors (LY294002 and MK2206) of the Akt pathway.	Bleomycin	0-9	AKT serine/threonine kinase 2	Homo sapiens	49-53
31527305-8	2019	Bleomycin induced AEC senescence was reversed by Akt2 knockdown and the pharmacological inhibitors (LY294002 and MK2206) of the Akt pathway.	Bleomycin	0-9	AKT serine/threonine kinase 1	Homo sapiens	49-52
31501415-3	2019	In this study, we demonstrated that the number of CD41+ megakaryocytes increased in bleomycin (BLM)-induced lung fibrosis tissues through the Chemokine (CXCmotif) ligand 12/Chemokine receptor 4 (CXCL12/CXCR4) axis.	Bleomycin	84-93	integrin subunit alpha 2b	Homo sapiens	50-54
31509566-9	2019	These results demonstrate that FBP may prevent bleomycin-induced PF development through reduced expression of collagen and other ECM components mediated by a reduced TIMP-1 and MMP2 expression.	Bleomycin	47-56	tissue inhibitor of metalloproteinase 1	Mus musculus	166-172
31509566-9	2019	These results demonstrate that FBP may prevent bleomycin-induced PF development through reduced expression of collagen and other ECM components mediated by a reduced TIMP-1 and MMP2 expression.	Bleomycin	47-56	matrix metallopeptidase 2	Mus musculus	177-181
31501415-3	2019	In this study, we demonstrated that the number of CD41+ megakaryocytes increased in bleomycin (BLM)-induced lung fibrosis tissues through the Chemokine (CXCmotif) ligand 12/Chemokine receptor 4 (CXCL12/CXCR4) axis.	Bleomycin	84-93	C-X-C motif chemokine ligand 12	Homo sapiens	195-201
31501415-3	2019	In this study, we demonstrated that the number of CD41+ megakaryocytes increased in bleomycin (BLM)-induced lung fibrosis tissues through the Chemokine (CXCmotif) ligand 12/Chemokine receptor 4 (CXCL12/CXCR4) axis.	Bleomycin	84-93	C-X-C motif chemokine receptor 4	Homo sapiens	202-207
31501415-3	2019	In this study, we demonstrated that the number of CD41+ megakaryocytes increased in bleomycin (BLM)-induced lung fibrosis tissues through the Chemokine (CXCmotif) ligand 12/Chemokine receptor 4 (CXCL12/CXCR4) axis.	Bleomycin	95-98	integrin subunit alpha 2b	Homo sapiens	50-54
31501415-3	2019	In this study, we demonstrated that the number of CD41+ megakaryocytes increased in bleomycin (BLM)-induced lung fibrosis tissues through the Chemokine (CXCmotif) ligand 12/Chemokine receptor 4 (CXCL12/CXCR4) axis.	Bleomycin	95-98	C-X-C motif chemokine ligand 12	Homo sapiens	195-201
31501415-3	2019	In this study, we demonstrated that the number of CD41+ megakaryocytes increased in bleomycin (BLM)-induced lung fibrosis tissues through the Chemokine (CXCmotif) ligand 12/Chemokine receptor 4 (CXCL12/CXCR4) axis.	Bleomycin	95-98	C-X-C motif chemokine receptor 4	Homo sapiens	202-207
31501417-6	2019	Tm4sf5-null mice exhibited attenuated bleomycin-induced pulmonary fibrosis with lower CD44v8-10 and ESRPs levels than wild-type mice.	Bleomycin	38-47	transmembrane 4 superfamily member 5	Mus musculus	0-6
31483105-4	2019	In this model, repetitive intradermal injections of the cytotoxic agent bleomycin trigger progressive skin thickening, associated with excessive accumulation of collagen, infiltration of immune cells, and formation of alpha-smooth muscle actin (alpha-SMA)-positive myofibroblasts.	Bleomycin	72-81	actin alpha 2, smooth muscle, aorta	Mus musculus	218-243
31552041-5	2019	We found that intradermal administration of WKYMVm, an Fpr2-specific agonist, alleviated bleomycin-induced scleroderma fibrosis in mice and decreased dermal thickness in scleroderma skin.	Bleomycin	89-98	formyl peptide receptor 2	Mus musculus	55-59
31126957-12	2019	In vivo, deletion of Runx3 in dendritic cell leads to spontaneous induction of skin fibrosis in untreated mice and increased severity of bleomycin-induced skin fibrosis.	Bleomycin	137-146	runt related transcription factor 3	Mus musculus	21-26
31177096-9	2019	Knockdown of HHAT in the skin of mice ameliorated bleomycin-induced and topoisomerase-induced skin fibrosis.	Bleomycin	50-59	hedgehog acyltransferase	Mus musculus	13-17
31387171-4	2019	We found that angiotensin-converting enzyme 2 (ACE2) /Ang-(1-7)/MasR were decreased in the lungs of mice with IPF induced by bleomycin, and were negatively correlated with Tgfb1 mRNA expression.	Bleomycin	125-134	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	14-45
31387171-4	2019	We found that angiotensin-converting enzyme 2 (ACE2) /Ang-(1-7)/MasR were decreased in the lungs of mice with IPF induced by bleomycin, and were negatively correlated with Tgfb1 mRNA expression.	Bleomycin	125-134	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	47-51
31387171-4	2019	We found that angiotensin-converting enzyme 2 (ACE2) /Ang-(1-7)/MasR were decreased in the lungs of mice with IPF induced by bleomycin, and were negatively correlated with Tgfb1 mRNA expression.	Bleomycin	125-134	angiopoietin like 3	Homo sapiens	54-62
31176171-0	2019	The role of vascular endothelial growth factor receptor 1 tyrosine kinase signaling in bleomycin-induced pulmonary fibrosis.	Bleomycin	87-96	vascular endothelial growth factor A	Mus musculus	12-46
31483105-4	2019	In this model, repetitive intradermal injections of the cytotoxic agent bleomycin trigger progressive skin thickening, associated with excessive accumulation of collagen, infiltration of immune cells, and formation of alpha-smooth muscle actin (alpha-SMA)-positive myofibroblasts.	Bleomycin	72-81	actin alpha 2, smooth muscle, aorta	Mus musculus	245-254
31556264-2	2019	microRNA-155 (miR-155), the expression of which has been related to bleomycin-induced idiopathic pulmonary fibrosis, has been involved in TGF-beta induced epithelial-mesenchymal transition.	Bleomycin	68-77	microRNA 155	Homo sapiens	0-12
31298961-0	2019	The novel inhibitor PRI-724 for Wnt/beta-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	75-84	catenin (cadherin associated protein), beta 1	Mus musculus	36-48
31298961-0	2019	The novel inhibitor PRI-724 for Wnt/beta-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	75-84	CREB binding protein	Mus musculus	49-52
31298961-9	2019	In the fibrotic lungs induced by bleomycin, beta-catenin was stained strongly in macrophages, but the staining of beta-catenin in alveolar epithelial cells and fibroblasts was weak.	Bleomycin	33-42	catenin (cadherin associated protein), beta 1	Mus musculus	44-56
31228816-11	2019	RESULTS: ATF3 was dramatically upregulated in lung tissues from both bleomycin-induced mice and patients with RA-ILD compared with controls.	Bleomycin	69-78	activating transcription factor 3	Mus musculus	9-13
31934168-1	2019	This study aims to investigate the effects of TRB3 on the EMT and MAPK signaling pathways in a bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Bleomycin	95-104	tribbles pseudokinase 3	Mus musculus	46-50
31934168-1	2019	This study aims to investigate the effects of TRB3 on the EMT and MAPK signaling pathways in a bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Bleomycin	106-109	tribbles pseudokinase 3	Mus musculus	46-50
31934168-8	2019	In conclusion, exogenous regulation of TRB3 may have effects on bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	64-73	tribbles pseudokinase 3	Mus musculus	39-43
31556264-2	2019	microRNA-155 (miR-155), the expression of which has been related to bleomycin-induced idiopathic pulmonary fibrosis, has been involved in TGF-beta induced epithelial-mesenchymal transition.	Bleomycin	68-77	microRNA 155	Homo sapiens	14-21
31556264-2	2019	microRNA-155 (miR-155), the expression of which has been related to bleomycin-induced idiopathic pulmonary fibrosis, has been involved in TGF-beta induced epithelial-mesenchymal transition.	Bleomycin	68-77	transforming growth factor beta 1	Homo sapiens	138-146
31611754-9	2019	Hesperidin significantly inhibited BLM-induced down-regulated lung Nrf2 and HO-1 as well as up-regulated TNF-alpha, IL-1beta, IL-6, collagen-1, TGF-beta, and Smad-3 mRNA expressions.	Bleomycin	35-38	NFE2 like bZIP transcription factor 2	Rattus norvegicus	67-71
30878675-6	2019	Conversely, application of recombinant BMP6 significantly ameliorated dermal fibrosis in this preclinical bleomycin-induced sclerosis model, and herewith provided proof of concept for the successful treatment of this fibrotic skin disease.	Bleomycin	106-115	bone morphogenetic protein 6	Mus musculus	39-43
31302203-0	2019	Pregnancy exposure to carbon black nanoparticles exacerbates bleomycin-induced lung fibrosis in offspring via disrupting LKB1-AMPK-ULK1 axis-mediated autophagy.	Bleomycin	61-70	serine/threonine kinase 11	Homo sapiens	121-125
31302203-0	2019	Pregnancy exposure to carbon black nanoparticles exacerbates bleomycin-induced lung fibrosis in offspring via disrupting LKB1-AMPK-ULK1 axis-mediated autophagy.	Bleomycin	61-70	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	126-130
31302203-0	2019	Pregnancy exposure to carbon black nanoparticles exacerbates bleomycin-induced lung fibrosis in offspring via disrupting LKB1-AMPK-ULK1 axis-mediated autophagy.	Bleomycin	61-70	unc-51 like autophagy activating kinase 1	Homo sapiens	131-135
31611754-0	2019	Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways.	Bleomycin	23-32	transforming growth factor, beta 1	Rattus norvegicus	91-100
31611754-0	2019	Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways.	Bleomycin	23-32	SMAD family member 3	Rattus norvegicus	101-106
31611754-0	2019	Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways.	Bleomycin	23-32	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	107-111
31611754-0	2019	Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways.	Bleomycin	23-32	NFKB inhibitor alpha	Rattus norvegicus	116-128
31432144-0	2019	HIF-1alpha promotes NLRP3 inflammasome activation in bleomycin-induced acute lung injury.	Bleomycin	53-62	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	0-10
31432144-0	2019	HIF-1alpha promotes NLRP3 inflammasome activation in bleomycin-induced acute lung injury.	Bleomycin	53-62	NLR family, pyrin domain containing 3	Rattus norvegicus	20-25
31611754-9	2019	Hesperidin significantly inhibited BLM-induced down-regulated lung Nrf2 and HO-1 as well as up-regulated TNF-alpha, IL-1beta, IL-6, collagen-1, TGF-beta, and Smad-3 mRNA expressions.	Bleomycin	35-38	tumor necrosis factor	Rattus norvegicus	105-114
31611754-9	2019	Hesperidin significantly inhibited BLM-induced down-regulated lung Nrf2 and HO-1 as well as up-regulated TNF-alpha, IL-1beta, IL-6, collagen-1, TGF-beta, and Smad-3 mRNA expressions.	Bleomycin	35-38	interleukin 1 beta	Rattus norvegicus	116-124
31611754-9	2019	Hesperidin significantly inhibited BLM-induced down-regulated lung Nrf2 and HO-1 as well as up-regulated TNF-alpha, IL-1beta, IL-6, collagen-1, TGF-beta, and Smad-3 mRNA expressions.	Bleomycin	35-38	interleukin 6	Rattus norvegicus	126-130
31611754-9	2019	Hesperidin significantly inhibited BLM-induced down-regulated lung Nrf2 and HO-1 as well as up-regulated TNF-alpha, IL-1beta, IL-6, collagen-1, TGF-beta, and Smad-3 mRNA expressions.	Bleomycin	35-38	transforming growth factor, beta 1	Rattus norvegicus	144-152
31611754-9	2019	Hesperidin significantly inhibited BLM-induced down-regulated lung Nrf2 and HO-1 as well as up-regulated TNF-alpha, IL-1beta, IL-6, collagen-1, TGF-beta, and Smad-3 mRNA expressions.	Bleomycin	35-38	SMAD family member 3	Rattus norvegicus	158-164
31611754-12	2019	Hesperidin alleviates BLM-induced IPF via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) to reduce collagen deposition during pulmonary fibrosis.	Bleomycin	22-25	transforming growth factor, beta 1	Rattus norvegicus	56-65
31611754-12	2019	Hesperidin alleviates BLM-induced IPF via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) to reduce collagen deposition during pulmonary fibrosis.	Bleomycin	22-25	SMAD family member 3	Rattus norvegicus	66-71
31611754-12	2019	Hesperidin alleviates BLM-induced IPF via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) to reduce collagen deposition during pulmonary fibrosis.	Bleomycin	22-25	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	72-76
31611754-12	2019	Hesperidin alleviates BLM-induced IPF via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) to reduce collagen deposition during pulmonary fibrosis.	Bleomycin	22-25	NFKB inhibitor alpha	Rattus norvegicus	81-93
31611754-12	2019	Hesperidin alleviates BLM-induced IPF via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) to reduce collagen deposition during pulmonary fibrosis.	Bleomycin	22-25	NFE2 like bZIP transcription factor 2	Rattus norvegicus	184-188
31611754-12	2019	Hesperidin alleviates BLM-induced IPF via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) to reduce collagen deposition during pulmonary fibrosis.	Bleomycin	22-25	tumor necrosis factor	Rattus norvegicus	229-238
31611754-12	2019	Hesperidin alleviates BLM-induced IPF via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) to reduce collagen deposition during pulmonary fibrosis.	Bleomycin	22-25	interleukin 1 beta	Rattus norvegicus	240-248
31611754-12	2019	Hesperidin alleviates BLM-induced IPF via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) to reduce collagen deposition during pulmonary fibrosis.	Bleomycin	22-25	interleukin 6	Rattus norvegicus	254-258
30457362-3	2019	In this review, we discuss the current clinical approaches for IPF and review members of LOX family-LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in IPF patients and in animal models of bleomycin-induced pulmonary fibrosis.	Bleomycin	175-184	lysyl oxidase	Homo sapiens	89-92
31432144-3	2019	The objective of the present study was to investigate whether HIF-1alpha could regulate activation of the NLRP3 inflammasome and its potential function and specific mechanism in bleomycin (BLM)-induced ALI.	Bleomycin	178-187	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	62-72
31432144-3	2019	The objective of the present study was to investigate whether HIF-1alpha could regulate activation of the NLRP3 inflammasome and its potential function and specific mechanism in bleomycin (BLM)-induced ALI.	Bleomycin	178-187	NLR family, pyrin domain containing 3	Rattus norvegicus	106-111
31434287-6	2019	We also found that DROSHA and AIM2 protein expression were increased in alveolar macrophages of lung tissues in a mouse model of bleomycin-induced pulmonary fibrosis.	Bleomycin	129-138	drosha, ribonuclease type III	Mus musculus	19-25
31434287-6	2019	We also found that DROSHA and AIM2 protein expression were increased in alveolar macrophages of lung tissues in a mouse model of bleomycin-induced pulmonary fibrosis.	Bleomycin	129-138	absent in melanoma 2	Mus musculus	30-34
31283910-8	2019	Consistent with the in vitro results, the inhibitor of miR-130a effectively ameliorated excessive collagen deposition in bleomycin-induced skin fibrosis mouse model.	Bleomycin	121-130	microRNA 130a	Mus musculus	55-63
31152749-9	2019	Concentrations of the pro-inflammatory cytokine IL-1beta were increased in bronchoalveolar lavage fluid after a single pulmonary dose of liposomes to rats with inflamed lungs, but no other significant changes in lung inflammatory markers were identified in healthy or bleomycin-challenged rats.	Bleomycin	268-277	interleukin 1 alpha	Rattus norvegicus	48-56
31393853-5	2019	Here, we demonstrate that syndecan-1 is overexpressed by the epithelium in the lungs of IPF patients and in murine models after bleomycin injury.	Bleomycin	128-137	syndecan 1	Homo sapiens	26-36
31388677-7	2019	Even when more abundantly present than after exposure to the radiomimetic bleomycin, Cr(VI)-stabilized p53 showed a much more limited activation of its target genes in two types of primary human cells.	Bleomycin	74-83	tumor protein p53	Homo sapiens	103-106
31090437-3	2019	Of the PLD isoenzymes, the protein expression of PLD2, but not PLD1, was upregulated in lung tissues from IPF patients and bleomycin challenged mice.	Bleomycin	123-132	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	7-10
31090437-3	2019	Of the PLD isoenzymes, the protein expression of PLD2, but not PLD1, was upregulated in lung tissues from IPF patients and bleomycin challenged mice.	Bleomycin	123-132	phospholipase D2	Homo sapiens	49-53
31090437-4	2019	Both PLD1 (Pld1-/-)- and PLD2 (Pld2-/-)-deficient mice were protected against bleomycin-induced lung inflammation and fibrosis, thereby establishing the role of PLD in fibrogenesis.	Bleomycin	78-87	phospholipase D1	Mus musculus	5-9
31090437-4	2019	Both PLD1 (Pld1-/-)- and PLD2 (Pld2-/-)-deficient mice were protected against bleomycin-induced lung inflammation and fibrosis, thereby establishing the role of PLD in fibrogenesis.	Bleomycin	78-87	phospholipase D2	Mus musculus	25-29
31090437-4	2019	Both PLD1 (Pld1-/-)- and PLD2 (Pld2-/-)-deficient mice were protected against bleomycin-induced lung inflammation and fibrosis, thereby establishing the role of PLD in fibrogenesis.	Bleomycin	78-87	phospholipase D2	Mus musculus	31-35
31090437-4	2019	Both PLD1 (Pld1-/-)- and PLD2 (Pld2-/-)-deficient mice were protected against bleomycin-induced lung inflammation and fibrosis, thereby establishing the role of PLD in fibrogenesis.	Bleomycin	78-87	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	5-8
31090437-5	2019	The role of PLD1 and PLD2 in bleomycin-induced lung epithelial injury was investigated by infecting bronchial airway epithelial cells (Beas2B) with catalytically inactive mutants of PLD (hPLD1-K898R or mPld2-K758R) or downregulation of expression of PLD1 or PLD2 with siRNA.	Bleomycin	29-38	phospholipase D1	Mus musculus	12-16
31090437-6	2019	Bleomycin stimulated mitochondrial (mt) superoxide production, mtDNA damage, and apoptosis in Beas2B cells, which was attenuated by the catalytically inactive mutants of PLD or PLD2 siRNA.	Bleomycin	0-9	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	170-173
31090437-6	2019	Bleomycin stimulated mitochondrial (mt) superoxide production, mtDNA damage, and apoptosis in Beas2B cells, which was attenuated by the catalytically inactive mutants of PLD or PLD2 siRNA.	Bleomycin	0-9	phospholipase D2	Homo sapiens	177-181
31090437-7	2019	These results show a role for PLD1 and PLD2 in bleomycin-induced generation of mt reactive oxygen species, mt DNA damage, and apoptosis of lung epithelial cells in mice.	Bleomycin	47-56	phospholipase D1	Mus musculus	30-34
31090437-7	2019	These results show a role for PLD1 and PLD2 in bleomycin-induced generation of mt reactive oxygen species, mt DNA damage, and apoptosis of lung epithelial cells in mice.	Bleomycin	47-56	phospholipase D2	Mus musculus	39-43
31108104-0	2019	Progranulin Promotes Bleomycin-Induced Skin Sclerosis by Enhancing Transforming Growth Factor-beta/Smad3 Signaling through Up-Regulation of Transforming Growth Factor-beta Type I Receptor.	Bleomycin	21-30	granulin	Mus musculus	0-11
31108104-0	2019	Progranulin Promotes Bleomycin-Induced Skin Sclerosis by Enhancing Transforming Growth Factor-beta/Smad3 Signaling through Up-Regulation of Transforming Growth Factor-beta Type I Receptor.	Bleomycin	21-30	SMAD family member 3	Mus musculus	99-104
31108104-3	2019	Because systemic sclerosis (SSc) is a prototypical fibrosis-related disorder, here, the aim was to clarify the role and mechanism of PGRN in bleomycin (BLM)-induced model of SSc for the first time.	Bleomycin	141-150	granulin	Mus musculus	133-137
31188013-0	2019	Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-beta and chronic bleomycin-induced fibrosis.	Bleomycin	110-119	fibroblast activation protein	Mus musculus	25-54
31188013-5	2019	Using histological analyses, quantification of soluble collagen content, and flow cytometry, we found that loss of FAP+ cells exacerbated fibrosis in the bleomycin model, a phenotype largely recapitulated by the genetic deletion of FAP, indicating that FAP plays a role in this model.	Bleomycin	154-163	fibroblast activation protein	Mus musculus	115-118
31204746-9	2019	Definitive evidence demonstrated that this ternary ERK2-siRNA delivery system significantly prevented the migration of VSMCs and decreased the dermal thickness in bleomycin-treated mice.	Bleomycin	163-172	mitogen-activated protein kinase 1	Mus musculus	51-55
30920024-12	2019	Besides, evidently enhanced CXCL14, yet reduced PPM1A, was found in bleomycin-induced rat pulmonary fibrosis, confirming the roles of CXCL14 and its potential association with PPM1A in IPF in vivo.	Bleomycin	68-77	C-X-C motif chemokine ligand 14	Rattus norvegicus	28-34
30920024-12	2019	Besides, evidently enhanced CXCL14, yet reduced PPM1A, was found in bleomycin-induced rat pulmonary fibrosis, confirming the roles of CXCL14 and its potential association with PPM1A in IPF in vivo.	Bleomycin	68-77	protein phosphatase, Mg2+/Mn2+ dependent, 1A	Rattus norvegicus	48-53
30920024-12	2019	Besides, evidently enhanced CXCL14, yet reduced PPM1A, was found in bleomycin-induced rat pulmonary fibrosis, confirming the roles of CXCL14 and its potential association with PPM1A in IPF in vivo.	Bleomycin	68-77	C-X-C motif chemokine ligand 14	Rattus norvegicus	134-140
30920024-12	2019	Besides, evidently enhanced CXCL14, yet reduced PPM1A, was found in bleomycin-induced rat pulmonary fibrosis, confirming the roles of CXCL14 and its potential association with PPM1A in IPF in vivo.	Bleomycin	68-77	protein phosphatase, Mg2+/Mn2+ dependent, 1A	Rattus norvegicus	176-181
30457362-3	2019	In this review, we discuss the current clinical approaches for IPF and review members of LOX family-LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in IPF patients and in animal models of bleomycin-induced pulmonary fibrosis.	Bleomycin	175-184	lysyl oxidase	Homo sapiens	100-103
30457362-3	2019	In this review, we discuss the current clinical approaches for IPF and review members of LOX family-LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in IPF patients and in animal models of bleomycin-induced pulmonary fibrosis.	Bleomycin	175-184	lysyl oxidase like 1	Homo sapiens	105-110
30457362-3	2019	In this review, we discuss the current clinical approaches for IPF and review members of LOX family-LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in IPF patients and in animal models of bleomycin-induced pulmonary fibrosis.	Bleomycin	175-184	lysyl oxidase like 2	Homo sapiens	112-117
30457362-3	2019	In this review, we discuss the current clinical approaches for IPF and review members of LOX family-LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in IPF patients and in animal models of bleomycin-induced pulmonary fibrosis.	Bleomycin	175-184	lysyl oxidase like 3	Homo sapiens	119-124
30457362-3	2019	In this review, we discuss the current clinical approaches for IPF and review members of LOX family-LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in IPF patients and in animal models of bleomycin-induced pulmonary fibrosis.	Bleomycin	175-184	lysyl oxidase like 4	Homo sapiens	129-134
30674010-2	2019	We have recently demonstrated a protective effect of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) in rat models of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and bleomycin-induced pulmonary fibrosis.	Bleomycin	202-211	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	57-77
31125560-3	2019	Our data indicated that P120 expression increased in lung fibrotic foci and primary lung fibroblasts isolated from bleomycin- (BLM) challenged mice, compared to controls.	Bleomycin	115-124	catenin (cadherin associated protein), delta 1	Mus musculus	24-28
30674010-2	2019	We have recently demonstrated a protective effect of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) in rat models of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and bleomycin-induced pulmonary fibrosis.	Bleomycin	202-211	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	79-82
31173221-0	2019	Kisspeptin-13 inhibits bleomycin-induced pulmonary fibrosis through GPR54 in mice.	Bleomycin	23-32	KiSS-1 metastasis-suppressor	Mus musculus	0-10
31173221-0	2019	Kisspeptin-13 inhibits bleomycin-induced pulmonary fibrosis through GPR54 in mice.	Bleomycin	23-32	KISS1 receptor	Mus musculus	68-73
31173221-5	2019	The purpose of the present study was to evaluate the role of KP-13 (a product of the KISS1 gene) in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis model.	Bleomycin	102-111	KiSS-1 metastasis-suppressor	Mus musculus	85-90
31085231-9	2019	Bleomycin decreased SIRT3 protein expression, whereas increased HIF-1alpha activation and TGF-beta1 release in the mouse macrophage cell line RAW264.7, which were attenuated by probucol treatment.	Bleomycin	0-9	sirtuin 3	Mus musculus	20-25
31085231-3	2019	We found that bleomycin-induced lung fibrosis was associated with increased transforming growth factor (TGF)-beta1, alpha-smooth muscle actin (alpha-SMA) and decreased E-cadherin expression in lung tissues, indicating EMT formation.	Bleomycin	14-23	transforming growth factor, beta 1	Mus musculus	76-114
31085231-3	2019	We found that bleomycin-induced lung fibrosis was associated with increased transforming growth factor (TGF)-beta1, alpha-smooth muscle actin (alpha-SMA) and decreased E-cadherin expression in lung tissues, indicating EMT formation.	Bleomycin	14-23	actin alpha 2, smooth muscle, aorta	Mus musculus	116-141
31085231-3	2019	We found that bleomycin-induced lung fibrosis was associated with increased transforming growth factor (TGF)-beta1, alpha-smooth muscle actin (alpha-SMA) and decreased E-cadherin expression in lung tissues, indicating EMT formation.	Bleomycin	14-23	actin alpha 2, smooth muscle, aorta	Mus musculus	143-152
31085231-3	2019	We found that bleomycin-induced lung fibrosis was associated with increased transforming growth factor (TGF)-beta1, alpha-smooth muscle actin (alpha-SMA) and decreased E-cadherin expression in lung tissues, indicating EMT formation.	Bleomycin	14-23	cadherin 1	Mus musculus	168-178
31085231-5	2019	Probucol treatment attenuated bleomycin-induced TGF-beta1 production, EMT and pulmonary fibrosis, meanwhile it suppressed bleomycin-induced oxidative stress.	Bleomycin	30-39	transforming growth factor, beta 1	Mus musculus	48-57
31085231-6	2019	Bleomycin treatment resulted in decreases in protein expressions of Sirtuin 3 (SIRT3) in the lung, which were restored by ROS scavenger NAC and probucol treatment, suggesting that probucol might restore SIRT3 expression by suppressing bleomycin-induced oxidative stress.	Bleomycin	0-9	sirtuin 3	Mus musculus	68-77
31085231-6	2019	Bleomycin treatment resulted in decreases in protein expressions of Sirtuin 3 (SIRT3) in the lung, which were restored by ROS scavenger NAC and probucol treatment, suggesting that probucol might restore SIRT3 expression by suppressing bleomycin-induced oxidative stress.	Bleomycin	0-9	sirtuin 3	Mus musculus	79-84
31085231-6	2019	Bleomycin treatment resulted in decreases in protein expressions of Sirtuin 3 (SIRT3) in the lung, which were restored by ROS scavenger NAC and probucol treatment, suggesting that probucol might restore SIRT3 expression by suppressing bleomycin-induced oxidative stress.	Bleomycin	0-9	NLR family, pyrin domain containing 1A	Mus musculus	136-139
31085231-6	2019	Bleomycin treatment resulted in decreases in protein expressions of Sirtuin 3 (SIRT3) in the lung, which were restored by ROS scavenger NAC and probucol treatment, suggesting that probucol might restore SIRT3 expression by suppressing bleomycin-induced oxidative stress.	Bleomycin	0-9	sirtuin 3	Mus musculus	203-208
31085231-6	2019	Bleomycin treatment resulted in decreases in protein expressions of Sirtuin 3 (SIRT3) in the lung, which were restored by ROS scavenger NAC and probucol treatment, suggesting that probucol might restore SIRT3 expression by suppressing bleomycin-induced oxidative stress.	Bleomycin	235-244	sirtuin 3	Mus musculus	68-77
31085231-6	2019	Bleomycin treatment resulted in decreases in protein expressions of Sirtuin 3 (SIRT3) in the lung, which were restored by ROS scavenger NAC and probucol treatment, suggesting that probucol might restore SIRT3 expression by suppressing bleomycin-induced oxidative stress.	Bleomycin	235-244	sirtuin 3	Mus musculus	79-84
31085231-7	2019	In the mouse alveolar type II epithelial cell line MLE-12, probucol treatment leads to an increase in SIRT3 expression in bleomycin-treated AT-II cells, which might contribute to the inhibitory effect of probucol on EMT through suppressing hypoxia inducible factor (HIF)-1alpha/TGF-beta1 pathway.	Bleomycin	122-131	sirtuin 3	Mus musculus	102-107
31085231-7	2019	In the mouse alveolar type II epithelial cell line MLE-12, probucol treatment leads to an increase in SIRT3 expression in bleomycin-treated AT-II cells, which might contribute to the inhibitory effect of probucol on EMT through suppressing hypoxia inducible factor (HIF)-1alpha/TGF-beta1 pathway.	Bleomycin	122-131	hypoxia inducible factor 1, alpha subunit	Mus musculus	240-277
31085231-7	2019	In the mouse alveolar type II epithelial cell line MLE-12, probucol treatment leads to an increase in SIRT3 expression in bleomycin-treated AT-II cells, which might contribute to the inhibitory effect of probucol on EMT through suppressing hypoxia inducible factor (HIF)-1alpha/TGF-beta1 pathway.	Bleomycin	122-131	transforming growth factor, beta 1	Mus musculus	278-287
31358769-5	2019	Loss of MFN1, MFN2 or inhibiting lipid synthesis via fatty acid synthase deficiency in AEC2 cells exacerbates bleomycin-induced lung fibrosis.	Bleomycin	110-119	mitofusin 1	Mus musculus	8-12
31358001-13	2019	Finally, in mouse model of bleomycin-induced pulmonary fibrosis, therapeutic application of tannic acid resulted in a significant reduction of lung fibrosis, decrease in collagen-1 content and of Smad2 phosphorylation in the lungs.	Bleomycin	27-36	SMAD family member 2	Mus musculus	196-201
31358782-5	2019	Removal of alpha-synuclein in human cells leads to increased DNA double-strand break (DSB) levels after bleomycin treatment and a reduced ability to repair these DSBs.	Bleomycin	104-113	synuclein alpha	Homo sapiens	11-26
33543008-0	2019	CCN1 expression by fibroblasts is required for bleomycin-induced skin fibrosis.	Bleomycin	47-56	cyclin A2	Mus musculus	0-4
31343988-6	2019	Fbln1c interacted with fibronectin, periostin and tenascin-c in collagen deposits following bleomycin challenge.	Bleomycin	92-101	fibronectin 1	Homo sapiens	23-34
31343988-6	2019	Fbln1c interacted with fibronectin, periostin and tenascin-c in collagen deposits following bleomycin challenge.	Bleomycin	92-101	tenascin C	Homo sapiens	50-60
31331325-0	2019	Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-beta1/Smad3 signaling pathway.	Bleomycin	42-51	PCNA clamp associated factor	Homo sapiens	99-106
31331325-0	2019	Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-beta1/Smad3 signaling pathway.	Bleomycin	42-51	transforming growth factor beta 1	Homo sapiens	111-120
31331325-0	2019	Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-beta1/Smad3 signaling pathway.	Bleomycin	42-51	SMAD family member 3	Homo sapiens	121-126
31316008-5	2019	Mice lacking functional CAPN9 owing to biallelic targeting of Capn9 were viable and fertile but showed overt protection from bleomycin-induced lung fibrosis, carbon tetrachloride-induced liver fibrosis, and angiotensin II-induced cardiac fibrosis and dysfunction.	Bleomycin	125-134	calpain 9	Mus musculus	24-29
31316008-5	2019	Mice lacking functional CAPN9 owing to biallelic targeting of Capn9 were viable and fertile but showed overt protection from bleomycin-induced lung fibrosis, carbon tetrachloride-induced liver fibrosis, and angiotensin II-induced cardiac fibrosis and dysfunction.	Bleomycin	125-134	calpain 9	Mus musculus	62-67
33543008-8	2019	CCN1-deficient mice were resistant to bleomycin-induced skin fibrosis, as visualized by reduced collagen accumulation and skin thickness suggesting that deposition/accumulation of collagen is impaired in the absence of CCN1.	Bleomycin	38-47	cyclin A2	Mus musculus	0-4
31100425-12	2019	Treatment with MSC-MVs significantly inhibited BLM-induced apoptosis and fibrosis in lung tissues and PI3K/AKT/mTOR activation, which was reversed by HGF mRNA deficient MVs.	Bleomycin	47-50	hepatocyte growth factor	Homo sapiens	150-153
31081931-16	2019	Chronic alcohol ingestion augmented lung-specific IL-17 expression following bleomycin-induced lung injury.	Bleomycin	77-86	interleukin 17A	Mus musculus	50-55
31042083-4	2019	In this study, KL levels were assessed in human plasma and primary lung fibroblasts from patients with idiopathic pulmonary fibrosis (IPF-FB) and in lung tissue from mice exposed to bleomycin, which showed significant downregulation when compared with controls.	Bleomycin	182-191	klotho	Homo sapiens	15-17
31042083-7	2019	Interestingly, fibroblast growth factor 23 (FGF23), a proinflammatory circulating protein for which KL is a coreceptor, was upregulated in IPF and bleomycin lungs.	Bleomycin	147-156	fibroblast growth factor 23	Homo sapiens	15-42
31042083-7	2019	Interestingly, fibroblast growth factor 23 (FGF23), a proinflammatory circulating protein for which KL is a coreceptor, was upregulated in IPF and bleomycin lungs.	Bleomycin	147-156	fibroblast growth factor 23	Homo sapiens	44-49
31182654-8	2019	After bleomycin injury in young mice, PGC1alpha expression drops transiently but then increases prior to fibrosis resolution.	Bleomycin	6-15	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	38-47
30838865-3	2019	In the current study, we assessed the role of myeloid PP2A in regulation of lung injury induced by lipopolysaccharide (LPS) or bleomycin delivered intratracheally.	Bleomycin	127-136	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	54-58
31115492-0	2019	NMDA receptor activation inhibits the protective effect of BM-MSCs on bleomycin-induced lung epithelial cell damage by inhibiting ERK signaling and the paracrine factor HGF.	Bleomycin	70-79	mitogen-activated protein kinase 1	Mus musculus	130-133
31115492-0	2019	NMDA receptor activation inhibits the protective effect of BM-MSCs on bleomycin-induced lung epithelial cell damage by inhibiting ERK signaling and the paracrine factor HGF.	Bleomycin	70-79	hepatocyte growth factor	Mus musculus	169-172
31127033-4	2019	We observed that in the lineage-tracing transgenic mice Cdh5-CreERT2::R26R-EYFP, endothelial-derived cells (EdCs) underwent fibrosis after treatment with bleomycin, and EdCs retrieved from the lung showed expression of endothelial-to-mesenchymal transition (EndoMT) markers.	Bleomycin	154-163	cadherin 5	Mus musculus	56-60
31056253-7	2019	We provide evidence that depletion of PDCD11 decreased the formation of gamma-H2AX foci and the phosphorylation of DNA damage response (DDR) signaling intermediates in response to camptothecin or bleomycin, resulting in increased cellular resistance to DNA damage.	Bleomycin	196-205	programmed cell death 11	Homo sapiens	38-44
31211697-7	2019	In a bleomycin induced lung injury model, conditional deletion of TAZ in AEC2s dramatically reduced AEC1 regeneration during recovery, leading to exacerbated alveolar lesions and fibrosis.	Bleomycin	5-14	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	66-69
30543447-9	2019	Hsp70-knockout mice subjected to an inhalational bleomycin model of pulmonary fibrosis demonstrated accelerated fibrosis versus wild-type control animals.	Bleomycin	49-58	heat shock protein 1B	Mus musculus	0-5
30965234-10	2019	These results suggest that the protective effects of TG on pulmonary fibrosis induced by bleomycin are related to regulation of the TGF-beta1/Smad signalling pathway and MMP system.	Bleomycin	89-98	transforming growth factor, beta 1	Mus musculus	132-141
30965234-10	2019	These results suggest that the protective effects of TG on pulmonary fibrosis induced by bleomycin are related to regulation of the TGF-beta1/Smad signalling pathway and MMP system.	Bleomycin	89-98	SMAD family member 7	Mus musculus	142-146
30370641-5	2019	Bleomycin (BLM)-induced PF in Nrf2-knockout (Nrf2-/- ) and wild-type (WT) mice and transforming growth factor beta1 (TGF-beta1)-induced EMT in rat type II alveolar epithelial cell line (RLE-6TN) and human alveolar epithelial cell line (A549) were established to observe the relationship among Nrf2, HMGB1, and EMT by western blot and immunohistochemistry.	Bleomycin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	30-34
30370641-5	2019	Bleomycin (BLM)-induced PF in Nrf2-knockout (Nrf2-/- ) and wild-type (WT) mice and transforming growth factor beta1 (TGF-beta1)-induced EMT in rat type II alveolar epithelial cell line (RLE-6TN) and human alveolar epithelial cell line (A549) were established to observe the relationship among Nrf2, HMGB1, and EMT by western blot and immunohistochemistry.	Bleomycin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	45-49
30370641-5	2019	Bleomycin (BLM)-induced PF in Nrf2-knockout (Nrf2-/- ) and wild-type (WT) mice and transforming growth factor beta1 (TGF-beta1)-induced EMT in rat type II alveolar epithelial cell line (RLE-6TN) and human alveolar epithelial cell line (A549) were established to observe the relationship among Nrf2, HMGB1, and EMT by western blot and immunohistochemistry.	Bleomycin	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	45-49
30370641-5	2019	Bleomycin (BLM)-induced PF in Nrf2-knockout (Nrf2-/- ) and wild-type (WT) mice and transforming growth factor beta1 (TGF-beta1)-induced EMT in rat type II alveolar epithelial cell line (RLE-6TN) and human alveolar epithelial cell line (A549) were established to observe the relationship among Nrf2, HMGB1, and EMT by western blot and immunohistochemistry.	Bleomycin	0-9	high mobility group box 1	Homo sapiens	299-304
30370641-5	2019	Bleomycin (BLM)-induced PF in Nrf2-knockout (Nrf2-/- ) and wild-type (WT) mice and transforming growth factor beta1 (TGF-beta1)-induced EMT in rat type II alveolar epithelial cell line (RLE-6TN) and human alveolar epithelial cell line (A549) were established to observe the relationship among Nrf2, HMGB1, and EMT by western blot and immunohistochemistry.	Bleomycin	11-14	nuclear factor, erythroid derived 2, like 2	Mus musculus	30-34
30370641-5	2019	Bleomycin (BLM)-induced PF in Nrf2-knockout (Nrf2-/- ) and wild-type (WT) mice and transforming growth factor beta1 (TGF-beta1)-induced EMT in rat type II alveolar epithelial cell line (RLE-6TN) and human alveolar epithelial cell line (A549) were established to observe the relationship among Nrf2, HMGB1, and EMT by western blot and immunohistochemistry.	Bleomycin	11-14	nuclear factor, erythroid derived 2, like 2	Mus musculus	45-49
30370641-5	2019	Bleomycin (BLM)-induced PF in Nrf2-knockout (Nrf2-/- ) and wild-type (WT) mice and transforming growth factor beta1 (TGF-beta1)-induced EMT in rat type II alveolar epithelial cell line (RLE-6TN) and human alveolar epithelial cell line (A549) were established to observe the relationship among Nrf2, HMGB1, and EMT by western blot and immunohistochemistry.	Bleomycin	11-14	NFE2 like bZIP transcription factor 2	Homo sapiens	45-49
30847938-0	2019	Mangiferin attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting TLR4/p65 and TGF-beta1/Smad2/3 pathway.	Bleomycin	22-31	toll-like receptor 4	Mus musculus	86-90
30847938-0	2019	Mangiferin attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting TLR4/p65 and TGF-beta1/Smad2/3 pathway.	Bleomycin	22-31	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	91-94
30847938-0	2019	Mangiferin attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting TLR4/p65 and TGF-beta1/Smad2/3 pathway.	Bleomycin	22-31	transforming growth factor, beta 1	Mus musculus	99-108
30847938-0	2019	Mangiferin attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting TLR4/p65 and TGF-beta1/Smad2/3 pathway.	Bleomycin	22-31	SMAD family member 2	Mus musculus	109-116
31135379-4	2019	Here we show that Bleomycin-induced lung fibrosis is attenuated upon myeloid-inactivation of Fra-2 and aggravated in Fra-2tg bone marrow chimeras.	Bleomycin	18-27	fos-like antigen 2	Mus musculus	93-98
31135379-8	2019	Therapeutic administration of a Fra-2/AP-1 inhibitor reduces ColVI expression and ameliorates fibrosis in Fra-2tg mice and in the Bleomycin model.	Bleomycin	130-139	fos-like antigen 2	Mus musculus	32-37
31135379-8	2019	Therapeutic administration of a Fra-2/AP-1 inhibitor reduces ColVI expression and ameliorates fibrosis in Fra-2tg mice and in the Bleomycin model.	Bleomycin	130-139	jun proto-oncogene	Mus musculus	38-42
30988156-2	2019	Recently, H19 was reported to be upregulated in fibrotic rat lung and play a stimulative role in bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	97-106	H19, imprinted maternally expressed transcript (non-protein coding)	Rattus norvegicus	10-13
30988156-2	2019	Recently, H19 was reported to be upregulated in fibrotic rat lung and play a stimulative role in bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	108-111	H19, imprinted maternally expressed transcript (non-protein coding)	Rattus norvegicus	10-13
30105924-3	2019	RESULTS: In this study, we found that tanshinone IIA (Tan-IIA), an active component in the root of Salvia miltiorrhiza Bunge, can suppress reactive oxygen species (ROS)-mediated activation of myofibroblast and reduce extracellular matrix deposition in bleomycin (BLM)-challenged mice through the regulation of nuclear factor-erythroid 2-related factor 2 (Nrf2).	Bleomycin	252-261	ATPase, class II, type 9A	Mus musculus	49-52
30105924-3	2019	RESULTS: In this study, we found that tanshinone IIA (Tan-IIA), an active component in the root of Salvia miltiorrhiza Bunge, can suppress reactive oxygen species (ROS)-mediated activation of myofibroblast and reduce extracellular matrix deposition in bleomycin (BLM)-challenged mice through the regulation of nuclear factor-erythroid 2-related factor 2 (Nrf2).	Bleomycin	252-261	ATPase, class II, type 9A	Mus musculus	58-61
30926564-0	2019	Vitamin C increases DNA breaks and suppresses DNA damage-independent activation of ATM by bleomycin.	Bleomycin	90-99	ATM serine/threonine kinase	Homo sapiens	83-86
30926564-6	2019	Higher cytotoxicity of bleomycin occurred in cells with normal and shRNA-depleted p53.	Bleomycin	23-32	tumor protein p53	Homo sapiens	82-85
30926564-9	2019	The presence of ascorbate in bleomycin-treated cells suppressed a DSB-independent activation of the ATM-CHK2 axis by blocking superoxide radical.	Bleomycin	29-38	ATM serine/threonine kinase	Homo sapiens	100-103
30926564-9	2019	The presence of ascorbate in bleomycin-treated cells suppressed a DSB-independent activation of the ATM-CHK2 axis by blocking superoxide radical.	Bleomycin	29-38	checkpoint kinase 2	Homo sapiens	104-108
31110176-7	2019	Remarkably, EP300 inhibition reduces fibrotic hallmarks of in vitro (patient-derived primary fibroblast), in vivo (bleomycin mouse model), and ex vivo (precision-cut lung slices, PCLS) IPF models.	Bleomycin	115-124	E1A binding protein p300	Homo sapiens	12-17
31164820-4	2019	PARP-1 deficient mice exhibited reduced lung fibrosis in response to bleomycin treatment compared to wild-type controls.	Bleomycin	69-78	poly (ADP-ribose) polymerase family, member 1	Mus musculus	0-6
31095524-6	2019	Inhibition of CBX5/G9a pathway in fibroblasts elevates PGC1alpha, attenuates TGFbeta- and matrix stiffness-promoted H3K9 methylation, and reduces collagen accumulation in the lungs following bleomycin injury.	Bleomycin	191-200	chromobox 5	Homo sapiens	14-18
30892080-6	2019	Furthermore, we found that pharmacological inhibition of the mTORC1 complex with rapamycin not only restored mitochondrial homeostasis but also reduced cellular senescence to bleomycin in lung epithelial cells.	Bleomycin	175-184	CREB regulated transcription coactivator 1	Mus musculus	61-67
31164820-6	2019	The aim of the study was to evaluate the cross-talk between PARP-1 and H4R in a model of bleomycin-induced lung fibrosis in PARP-1-/- and WT mice.	Bleomycin	89-98	poly (ADP-ribose) polymerase family, member 1	Mus musculus	60-66
31095524-6	2019	Inhibition of CBX5/G9a pathway in fibroblasts elevates PGC1alpha, attenuates TGFbeta- and matrix stiffness-promoted H3K9 methylation, and reduces collagen accumulation in the lungs following bleomycin injury.	Bleomycin	191-200	euchromatic histone lysine methyltransferase 2	Homo sapiens	19-22
31164820-6	2019	The aim of the study was to evaluate the cross-talk between PARP-1 and H4R in a model of bleomycin-induced lung fibrosis in PARP-1-/- and WT mice.	Bleomycin	89-98	histamine receptor H4	Mus musculus	71-74
31164820-6	2019	The aim of the study was to evaluate the cross-talk between PARP-1 and H4R in a model of bleomycin-induced lung fibrosis in PARP-1-/- and WT mice.	Bleomycin	89-98	poly (ADP-ribose) polymerase family, member 1	Mus musculus	124-130
33405750-8	2019	Further, Eng-PF tissues could be used to model different facets of IPF disease, including epithelial injury with the addition of bleomycin and cellular recruitment by perfusion of cells through the hydrogel microchannel.	Bleomycin	129-138	endoglin	Homo sapiens	9-12
30852423-0	2019	Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice.	Bleomycin	55-64	interleukin 10	Mus musculus	27-32
31075901-7	2019	Our data suggest that an increased constitutive JAM-A protein level in P2X7 receptor knockout mice may have a protective effect against bleomycin-induced lung injury.	Bleomycin	136-145	F11 receptor	Mus musculus	48-53
31075901-7	2019	Our data suggest that an increased constitutive JAM-A protein level in P2X7 receptor knockout mice may have a protective effect against bleomycin-induced lung injury.	Bleomycin	136-145	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	71-84
31075901-8	2019	Bleomycin-treated precision-cut lung slices from P2X7 receptor knockout mice responded with a lower increase in mRNA expression of JAM-A than bleomycin-treated precision-cut lung slices from wildtype mice.	Bleomycin	0-9	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	49-62
31075901-8	2019	Bleomycin-treated precision-cut lung slices from P2X7 receptor knockout mice responded with a lower increase in mRNA expression of JAM-A than bleomycin-treated precision-cut lung slices from wildtype mice.	Bleomycin	0-9	F11 receptor	Mus musculus	131-136
31075901-8	2019	Bleomycin-treated precision-cut lung slices from P2X7 receptor knockout mice responded with a lower increase in mRNA expression of JAM-A than bleomycin-treated precision-cut lung slices from wildtype mice.	Bleomycin	142-151	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	49-62
30785343-7	2019	Mmp13-null mice exhibited more extensive inflammation at 7 days after bleomycin treatment, and it was characterized by increased macrophage infiltration and significant alterations in proinflammatory cytokines.	Bleomycin	70-79	matrix metallopeptidase 13	Mus musculus	0-5
30852423-3	2019	We describe an innovative hydrogel-based approach to deliver recombinant IL-10 to the lung for the prevention and reversal of pulmonary fibrosis in a mouse model of bleomycin-induced lung injury.	Bleomycin	165-174	interleukin 10	Mus musculus	73-78
30293251-6	2019	On the 28th day after bleomycin treatment, severe inflammation and fibrosis were observed in lung tissues from wild type mice, while lung tissues from S1P2 deficient mice showed less inflammation and fibrosis.	Bleomycin	22-31	sphingosine-1-phosphate receptor 2	Mus musculus	151-155
30293251-0	2019	Deficiency of Sphingosine-1-Phosphate Receptor 2 (S1P2) Attenuates Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	67-76	sphingosine-1-phosphate receptor 2	Mus musculus	14-48
30293251-0	2019	Deficiency of Sphingosine-1-Phosphate Receptor 2 (S1P2) Attenuates Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	67-76	sphingosine-1-phosphate receptor 2	Mus musculus	50-54
30293251-8	2019	Taken together, pro-inflammatory and pro-fibrotic functions of S1P2 were elucidated using a bleomycin-induced fibrosis model.	Bleomycin	92-101	sphingosine-1-phosphate receptor 2	Mus musculus	63-67
30293251-5	2019	On the 7th day after bleomycin administration, S1P2 deficient mice exhibited significantly less pulmonary inflammation, including cell infiltration and pro-inflammatory cytokine induction, than the wild type mice.	Bleomycin	21-30	sphingosine-1-phosphate receptor 2	Mus musculus	47-51
30885568-0	2019	New SIRT2 inhibitors: Histidine-based bleomycin spin-off.	Bleomycin	38-47	sirtuin 2	Homo sapiens	4-9
31105865-0	2019	Low-molecular-weight fucoidan attenuates bleomycin-induced pulmonary fibrosis: possible role in inhibiting TGF-beta1-induced epithelial-mesenchymal transition through ERK pathway.	Bleomycin	41-50	transforming growth factor, beta 1	Mus musculus	107-116
30902828-5	2019	We found that bleomycin could induce the cell surface translocation of ANXA2 in lung epithelial cells through exosomal secretion, associated with enhanced interaction between ANXA2 and p11.	Bleomycin	14-23	annexin A2	Mus musculus	71-76
30902828-5	2019	We found that bleomycin could induce the cell surface translocation of ANXA2 in lung epithelial cells through exosomal secretion, associated with enhanced interaction between ANXA2 and p11.	Bleomycin	14-23	annexin A2	Mus musculus	175-180
30902828-5	2019	We found that bleomycin could induce the cell surface translocation of ANXA2 in lung epithelial cells through exosomal secretion, associated with enhanced interaction between ANXA2 and p11.	Bleomycin	14-23	S100 calcium binding protein A10 (calpactin)	Mus musculus	185-188
30902828-6	2019	Knockdown of ANXA2 or blocking membrane ANXA2 mitigated bleomycin-induced activation of nuclear factor (NF)-kappaB pathway and production of pro-inflammatory cytokine IL-6 in lung epithelial cells.	Bleomycin	56-65	annexin A2	Mus musculus	13-18
30902828-6	2019	Knockdown of ANXA2 or blocking membrane ANXA2 mitigated bleomycin-induced activation of nuclear factor (NF)-kappaB pathway and production of pro-inflammatory cytokine IL-6 in lung epithelial cells.	Bleomycin	56-65	annexin A2	Mus musculus	40-45
30902828-6	2019	Knockdown of ANXA2 or blocking membrane ANXA2 mitigated bleomycin-induced activation of nuclear factor (NF)-kappaB pathway and production of pro-inflammatory cytokine IL-6 in lung epithelial cells.	Bleomycin	56-65	interleukin 6	Mus musculus	167-171
30902828-7	2019	ANXA2-deficient (ANXA2-/-) mice treated with bleomycin exhibit reduced pulmonary fibrosis along with decreased cytokine production compared with bleomycin-challenged wild-type mice.	Bleomycin	45-54	annexin A2	Mus musculus	0-5
30902828-7	2019	ANXA2-deficient (ANXA2-/-) mice treated with bleomycin exhibit reduced pulmonary fibrosis along with decreased cytokine production compared with bleomycin-challenged wild-type mice.	Bleomycin	45-54	annexin A2	Mus musculus	17-22
30902828-7	2019	ANXA2-deficient (ANXA2-/-) mice treated with bleomycin exhibit reduced pulmonary fibrosis along with decreased cytokine production compared with bleomycin-challenged wild-type mice.	Bleomycin	145-154	annexin A2	Mus musculus	0-5
30902828-8	2019	Further, the surface ANXA2 inhibitor TM601 could ameliorate fibrotic and inflammatory response in bleomycin-treated mice.	Bleomycin	98-107	annexin A2	Mus musculus	21-26
30902828-9	2019	Taken together, our results indicated that, in addition to disturbing autophagic flux, ANXA2 can contribute to bleomycin-induced pulmonary fibrosis by mediating inflammatory response.	Bleomycin	111-120	annexin A2	Mus musculus	87-92
32039344-7	2019	A recently developed analog, CCG-257081, which co crystallizes with pirin, is also effective in the prevention of bleomycin-induced dermal fibrosis.	Bleomycin	114-123	pirin	Homo sapiens	68-73
30870716-3	2019	We have previously demonstrated the protective effects of IL-18 binding protein (IL-18BP) against bleomycin (BLM)-induced pulmonary fibrosis (PF) via inhibition of epithelial-to-mesenchymal transition.	Bleomycin	98-107	interleukin 18 binding protein	Mus musculus	58-79
30870716-3	2019	We have previously demonstrated the protective effects of IL-18 binding protein (IL-18BP) against bleomycin (BLM)-induced pulmonary fibrosis (PF) via inhibition of epithelial-to-mesenchymal transition.	Bleomycin	98-107	interleukin 18 binding protein	Mus musculus	81-88
30870716-3	2019	We have previously demonstrated the protective effects of IL-18 binding protein (IL-18BP) against bleomycin (BLM)-induced pulmonary fibrosis (PF) via inhibition of epithelial-to-mesenchymal transition.	Bleomycin	109-112	interleukin 18 binding protein	Mus musculus	58-79
30870716-3	2019	We have previously demonstrated the protective effects of IL-18 binding protein (IL-18BP) against bleomycin (BLM)-induced pulmonary fibrosis (PF) via inhibition of epithelial-to-mesenchymal transition.	Bleomycin	109-112	interleukin 18 binding protein	Mus musculus	81-88
30869194-2	2019	Using reanalysing Gene Expression Omnibus data, here, we show for the first time that TSPAN1 was markedly down-regulated in lung tissue of patient with idiopathic PF (IPF) and verified the reduced protein expression of TSPAN1 in lung tissue samples of patient with IPF and bleomycin-induced PF mice.	Bleomycin	273-282	tetraspanin 1	Homo sapiens	86-92
30869194-2	2019	Using reanalysing Gene Expression Omnibus data, here, we show for the first time that TSPAN1 was markedly down-regulated in lung tissue of patient with idiopathic PF (IPF) and verified the reduced protein expression of TSPAN1 in lung tissue samples of patient with IPF and bleomycin-induced PF mice.	Bleomycin	273-282	tetraspanin 1	Homo sapiens	219-225
30098420-4	2019	Compared to WT mice, 10 days after IT bleomycin, RHAMM KO mice had less weight loss, less increase in respiratory rate, and fewer CD45+ cells in the lung.	Bleomycin	38-47	hyaluronan mediated motility receptor (RHAMM)	Mus musculus	49-54
30902828-0	2019	Cell-surface translocation of annexin A2 contributes to bleomycin-induced pulmonary fibrosis by mediating inflammatory response in mice.	Bleomycin	56-65	annexin A2	Mus musculus	30-40
30902828-3	2019	Our previous study showed that bleomycin bound directly to annexin A2 (ANXA2, or p36), leading to development of pulmonary fibrosis by impeding transcription factor EB (TFEB)-induced autophagic flux.	Bleomycin	31-40	annexin A2	Mus musculus	59-69
30902828-3	2019	Our previous study showed that bleomycin bound directly to annexin A2 (ANXA2, or p36), leading to development of pulmonary fibrosis by impeding transcription factor EB (TFEB)-induced autophagic flux.	Bleomycin	31-40	annexin A2	Mus musculus	71-76
30902828-3	2019	Our previous study showed that bleomycin bound directly to annexin A2 (ANXA2, or p36), leading to development of pulmonary fibrosis by impeding transcription factor EB (TFEB)-induced autophagic flux.	Bleomycin	31-40	annexin A2	Mus musculus	81-84
30902828-3	2019	Our previous study showed that bleomycin bound directly to annexin A2 (ANXA2, or p36), leading to development of pulmonary fibrosis by impeding transcription factor EB (TFEB)-induced autophagic flux.	Bleomycin	31-40	transcription factor EB	Mus musculus	144-167
30902828-3	2019	Our previous study showed that bleomycin bound directly to annexin A2 (ANXA2, or p36), leading to development of pulmonary fibrosis by impeding transcription factor EB (TFEB)-induced autophagic flux.	Bleomycin	31-40	transcription factor EB	Mus musculus	169-173
30902828-4	2019	Here, we demonstrated that ANXA2 also played a critical role in bleomycin-induced inflammation, which represents another major cause of bleomycin-induced pulmonary fibrosis.	Bleomycin	64-73	annexin A2	Mus musculus	27-32
30902828-4	2019	Here, we demonstrated that ANXA2 also played a critical role in bleomycin-induced inflammation, which represents another major cause of bleomycin-induced pulmonary fibrosis.	Bleomycin	136-145	annexin A2	Mus musculus	27-32
31105865-0	2019	Low-molecular-weight fucoidan attenuates bleomycin-induced pulmonary fibrosis: possible role in inhibiting TGF-beta1-induced epithelial-mesenchymal transition through ERK pathway.	Bleomycin	41-50	mitogen-activated protein kinase 1	Mus musculus	167-170
31105865-12	2019	Collectively, our results preliminary suggested that LMWF could attenuate bleomycin-induced PF by inhibiting TGF-beta1-induced EMT through ERK signaling.	Bleomycin	74-83	transforming growth factor, beta 1	Mus musculus	109-118
31105865-12	2019	Collectively, our results preliminary suggested that LMWF could attenuate bleomycin-induced PF by inhibiting TGF-beta1-induced EMT through ERK signaling.	Bleomycin	74-83	mitogen-activated protein kinase 1	Mus musculus	139-142
30663834-16	2019	In addition, we report hyperactivity of bleomycin-exposed pulmonary arteries to a thromboxane A2 receptor (Tbxa2r) agonist.	Bleomycin	40-49	thromboxane A2 receptor	Homo sapiens	82-105
30666825-0	2019	Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9.	Bleomycin	23-32	matrix metallopeptidase 9	Mus musculus	123-149
30928090-0	2019	S-allyl-l-cysteine attenuates bleomycin-induced pulmonary fibrosis and inflammation via AKT/NF-kappaB signaling pathway in mice.	Bleomycin	30-39	thymoma viral proto-oncogene 1	Mus musculus	88-91
30928090-0	2019	S-allyl-l-cysteine attenuates bleomycin-induced pulmonary fibrosis and inflammation via AKT/NF-kappaB signaling pathway in mice.	Bleomycin	30-39	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	92-101
30824326-4	2019	We found that lung microbiota was dysregulated, and the dysregulated microbiota in turn induced production of interleukin-17B (IL-17B) during bleomycin-induced mouse lung fibrosis.	Bleomycin	142-151	interleukin 17B	Mus musculus	110-125
30824326-4	2019	We found that lung microbiota was dysregulated, and the dysregulated microbiota in turn induced production of interleukin-17B (IL-17B) during bleomycin-induced mouse lung fibrosis.	Bleomycin	142-151	interleukin 17B	Mus musculus	127-133
30572104-10	2019	Moreover, in vitro studies revealed that CSE had superimposed effect on bleomycin-induced activation of TGF-beta-Smad2/3 and -Akt signaling.	Bleomycin	72-81	transforming growth factor, beta 1	Mus musculus	104-112
30572104-12	2019	Taken together, these findings represent the first evidence that cigarette smoking aggravated bleomycin-induced pulmonary fibrosis via TGF-beta1 signaling.	Bleomycin	94-103	transforming growth factor, beta 1	Mus musculus	135-144
30326727-0	2019	Deficiency of CRTH2, a Prostaglandin D2 Receptor, Aggravates Bleomycin-induced Pulmonary Inflammation and Fibrosis.	Bleomycin	61-70	prostaglandin D2 receptor 2	Mus musculus	14-19
30326727-0	2019	Deficiency of CRTH2, a Prostaglandin D2 Receptor, Aggravates Bleomycin-induced Pulmonary Inflammation and Fibrosis.	Bleomycin	61-70	prostaglandin D receptor	Mus musculus	23-48
30326727-3	2019	Compared with wild-type mice, CRTH2-/- mice treated with bleomycin exhibited significantly higher mortality, enhanced accumulation of inflammatory cells 14-21 days after bleomycin injection, reduced pulmonary compliance, and increased levels of collagen and total protein in the lungs.	Bleomycin	57-66	prostaglandin D2 receptor 2	Mus musculus	30-35
30326727-3	2019	Compared with wild-type mice, CRTH2-/- mice treated with bleomycin exhibited significantly higher mortality, enhanced accumulation of inflammatory cells 14-21 days after bleomycin injection, reduced pulmonary compliance, and increased levels of collagen and total protein in the lungs.	Bleomycin	170-179	prostaglandin D2 receptor 2	Mus musculus	30-35
30326727-6	2019	We consider that the disease model is driven by gammadeltaT cells that express CRTH2; thus, the adoptive transfer of gammadeltaT cells could ameliorate bleomycin-induced alveolar inflammation and fibrosis.	Bleomycin	152-161	prostaglandin D2 receptor 2	Mus musculus	79-84
30850350-8	2019	FINDINGS: We found that bleomycin induced up-regulation of miR-4739 in pleural mesothelial cells (PMCs).	Bleomycin	24-33	microRNA 4739	Homo sapiens	59-67
31066254-10	2019	Additionally, in skin tissues of bleomycin-treated animals, both pro and active forms of MMP9 and MMP2 were increased (p&lt;0.05).	Bleomycin	33-42	matrix metallopeptidase 9	Mus musculus	89-93
31066254-10	2019	Additionally, in skin tissues of bleomycin-treated animals, both pro and active forms of MMP9 and MMP2 were increased (p&lt;0.05).	Bleomycin	33-42	matrix metallopeptidase 2	Mus musculus	98-102
30776489-5	2019	We have shown that PCLS during in vitro incubation retain characteristics of bleomycin model with increased expression of fibrosis related genes ACTA2 (alpha-smooth muscle actin), COL1A1 (collagen 1), FN1 (fibronectin 1), MMP12 (matrix metalloproteinase 12) and TIMP1 (tissue inhibitor of metalloproteinases).	Bleomycin	77-86	actin alpha 2, smooth muscle, aorta	Mus musculus	145-150
30776489-5	2019	We have shown that PCLS during in vitro incubation retain characteristics of bleomycin model with increased expression of fibrosis related genes ACTA2 (alpha-smooth muscle actin), COL1A1 (collagen 1), FN1 (fibronectin 1), MMP12 (matrix metalloproteinase 12) and TIMP1 (tissue inhibitor of metalloproteinases).	Bleomycin	77-86	collagen, type I, alpha 1	Mus musculus	180-186
30776489-5	2019	We have shown that PCLS during in vitro incubation retain characteristics of bleomycin model with increased expression of fibrosis related genes ACTA2 (alpha-smooth muscle actin), COL1A1 (collagen 1), FN1 (fibronectin 1), MMP12 (matrix metalloproteinase 12) and TIMP1 (tissue inhibitor of metalloproteinases).	Bleomycin	77-86	fibronectin 1	Mus musculus	201-204
31049028-0	2019	Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung Fibrosis and Skeletal Muscle Wasting in a Bleomycin-Induced Lung Injury Mouse Model.	Bleomycin	107-116	interleukin 6	Mus musculus	13-17
31049028-0	2019	Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung Fibrosis and Skeletal Muscle Wasting in a Bleomycin-Induced Lung Injury Mouse Model.	Bleomycin	107-116	interleukin 33	Mus musculus	22-27
31049028-5	2019	Here, we found that BLM-induced lung fibrosis with thickened interstitial lung tissue, including fibronectin and collagen, was correlated with the increased serum concentrations of IL-6 and IL-33 and accompanied by reduced lung function, including FRC (functional residual capacity), C chord (lung compliance), IC (inspiratory capacity), VC (vital capacity), TLC (total lung capacity), and FVC (forced vital capacity) (p &lt; 0.05).	Bleomycin	20-23	fibronectin 1	Mus musculus	97-108
31049028-5	2019	Here, we found that BLM-induced lung fibrosis with thickened interstitial lung tissue, including fibronectin and collagen, was correlated with the increased serum concentrations of IL-6 and IL-33 and accompanied by reduced lung function, including FRC (functional residual capacity), C chord (lung compliance), IC (inspiratory capacity), VC (vital capacity), TLC (total lung capacity), and FVC (forced vital capacity) (p &lt; 0.05).	Bleomycin	20-23	interleukin 6	Mus musculus	181-185
31049028-5	2019	Here, we found that BLM-induced lung fibrosis with thickened interstitial lung tissue, including fibronectin and collagen, was correlated with the increased serum concentrations of IL-6 and IL-33 and accompanied by reduced lung function, including FRC (functional residual capacity), C chord (lung compliance), IC (inspiratory capacity), VC (vital capacity), TLC (total lung capacity), and FVC (forced vital capacity) (p &lt; 0.05).	Bleomycin	20-23	interleukin 33	Mus musculus	190-195
30663834-16	2019	In addition, we report hyperactivity of bleomycin-exposed pulmonary arteries to a thromboxane A2 receptor (Tbxa2r) agonist.	Bleomycin	40-49	thromboxane A2 receptor	Homo sapiens	107-113
31482149-6	2019	In vivo, IGFBP-4 reduced bleomycin-induced collagen production and histologic evidence of fibrosis.	Bleomycin	25-34	insulin like growth factor binding protein 4	Homo sapiens	9-16
30144053-2	2019	In the current study, we identified the expression of microRNA-9 (miR-9) and anoctamin-1 (ANO1) in IPF mouse models induced by bleomycin, and their effects on inflammation and fibroblast proliferation through the transforming growth factor-beta (TGF-beta)-Smad3 pathway.	Bleomycin	127-136	anoctamin 1, calcium activated chloride channel	Mus musculus	77-88
30144053-2	2019	In the current study, we identified the expression of microRNA-9 (miR-9) and anoctamin-1 (ANO1) in IPF mouse models induced by bleomycin, and their effects on inflammation and fibroblast proliferation through the transforming growth factor-beta (TGF-beta)-Smad3 pathway.	Bleomycin	127-136	anoctamin 1, calcium activated chloride channel	Mus musculus	90-94
29923060-6	2019	RESULTS: After 2 weeks, bleomycin significantly increased the pressure at the airway opening (PAO), a functional parameter related to fibrosis-induced lung stiffness, and induced diffuse lung interstitium fibrosis, with upregulation of inflammation (IL1beta, MCP1) and tissue remodeling (COL1A1, COL3A1, ET1, MMP7, PDGFa, alphaSMA, SNAI1) markers.	Bleomycin	24-33	interleukin 1 beta	Rattus norvegicus	250-257
29923060-6	2019	RESULTS: After 2 weeks, bleomycin significantly increased the pressure at the airway opening (PAO), a functional parameter related to fibrosis-induced lung stiffness, and induced diffuse lung interstitium fibrosis, with upregulation of inflammation (IL1beta, MCP1) and tissue remodeling (COL1A1, COL3A1, ET1, MMP7, PDGFa, alphaSMA, SNAI1) markers.	Bleomycin	24-33	mast cell protease 1-like 1	Rattus norvegicus	259-263
29923060-6	2019	RESULTS: After 2 weeks, bleomycin significantly increased the pressure at the airway opening (PAO), a functional parameter related to fibrosis-induced lung stiffness, and induced diffuse lung interstitium fibrosis, with upregulation of inflammation (IL1beta, MCP1) and tissue remodeling (COL1A1, COL3A1, ET1, MMP7, PDGFa, alphaSMA, SNAI1) markers.	Bleomycin	24-33	collagen type I alpha 1 chain	Rattus norvegicus	288-294
29923060-6	2019	RESULTS: After 2 weeks, bleomycin significantly increased the pressure at the airway opening (PAO), a functional parameter related to fibrosis-induced lung stiffness, and induced diffuse lung interstitium fibrosis, with upregulation of inflammation (IL1beta, MCP1) and tissue remodeling (COL1A1, COL3A1, ET1, MMP7, PDGFa, alphaSMA, SNAI1) markers.	Bleomycin	24-33	collagen type III alpha 1 chain	Rattus norvegicus	296-302
29923060-6	2019	RESULTS: After 2 weeks, bleomycin significantly increased the pressure at the airway opening (PAO), a functional parameter related to fibrosis-induced lung stiffness, and induced diffuse lung interstitium fibrosis, with upregulation of inflammation (IL1beta, MCP1) and tissue remodeling (COL1A1, COL3A1, ET1, MMP7, PDGFa, alphaSMA, SNAI1) markers.	Bleomycin	24-33	endothelin 1	Rattus norvegicus	304-307
29923060-6	2019	RESULTS: After 2 weeks, bleomycin significantly increased the pressure at the airway opening (PAO), a functional parameter related to fibrosis-induced lung stiffness, and induced diffuse lung interstitium fibrosis, with upregulation of inflammation (IL1beta, MCP1) and tissue remodeling (COL1A1, COL3A1, ET1, MMP7, PDGFa, alphaSMA, SNAI1) markers.	Bleomycin	24-33	matrix metallopeptidase 7	Rattus norvegicus	309-313
29923060-6	2019	RESULTS: After 2 weeks, bleomycin significantly increased the pressure at the airway opening (PAO), a functional parameter related to fibrosis-induced lung stiffness, and induced diffuse lung interstitium fibrosis, with upregulation of inflammation (IL1beta, MCP1) and tissue remodeling (COL1A1, COL3A1, ET1, MMP7, PDGFa, alphaSMA, SNAI1) markers.	Bleomycin	24-33	platelet derived growth factor subunit A	Rattus norvegicus	315-320
29923060-6	2019	RESULTS: After 2 weeks, bleomycin significantly increased the pressure at the airway opening (PAO), a functional parameter related to fibrosis-induced lung stiffness, and induced diffuse lung interstitium fibrosis, with upregulation of inflammation (IL1beta, MCP1) and tissue remodeling (COL1A1, COL3A1, ET1, MMP7, PDGFa, alphaSMA, SNAI1) markers.	Bleomycin	24-33	snail family transcriptional repressor 1	Rattus norvegicus	332-337
30474696-0	2019	Amitriptyline attenuates bleomycin-induced pulmonary fibrosis: modulation of the expression of NF-kappabeta, iNOS, and Nrf2.	Bleomycin	25-34	nuclear factor kappa B subunit 1	Homo sapiens	95-107
30653976-0	2019	Macrophage-secreted TSLP and MMP9 promote bleomycin-induced pulmonary fibrosis.	Bleomycin	42-51	thymic stromal lymphopoietin	Rattus norvegicus	20-24
30653976-0	2019	Macrophage-secreted TSLP and MMP9 promote bleomycin-induced pulmonary fibrosis.	Bleomycin	42-51	matrix metallopeptidase 9	Rattus norvegicus	29-33
30732588-8	2019	Tnfsf10-/- and mice treated with the PP2A activator AAL(s) were largely protected against bleomycin-induced reductions in lung function and fibrotic changes.	Bleomycin	90-99	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	0-7
30830875-7	2019	Finally, we demonstrate that deletion of CFIm25 in fibroblasts or myofibroblast precursors using either the Col1a1 or the Foxd1 promoter enhances pulmonary fibrosis after bleomycin exposure in mice.	Bleomycin	171-180	nudix hydrolase 21	Homo sapiens	41-47
30732588-8	2019	Tnfsf10-/- and mice treated with the PP2A activator AAL(s) were largely protected against bleomycin-induced reductions in lung function and fibrotic changes.	Bleomycin	90-99	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	37-41
30717786-0	2019	Increased expression of lung TRPV1/TRPA1 in a cough model of bleomycin-induced pulmonary fibrosis in Guinea pigs.	Bleomycin	61-70	transient receptor potential cation channel subfamily V member 1	Cavia porcellus	29-34
30717786-0	2019	Increased expression of lung TRPV1/TRPA1 in a cough model of bleomycin-induced pulmonary fibrosis in Guinea pigs.	Bleomycin	61-70	transient receptor potential cation channel subfamily A member 1	Cavia porcellus	35-40
30717786-9	2019	Cough sensitivity to capsaicin in bleomycin-treated animals was significantly increased on days 13 and 27. qPCR showed that expression of TRPV1 and TRPA1 was positively correlated each other and significantly upregulated in lung tissues of model group compared with that of controls, which was further supported by immunohistochemistry.	Bleomycin	34-43	transient receptor potential cation channel subfamily V member 1	Cavia porcellus	138-143
30717786-9	2019	Cough sensitivity to capsaicin in bleomycin-treated animals was significantly increased on days 13 and 27. qPCR showed that expression of TRPV1 and TRPA1 was positively correlated each other and significantly upregulated in lung tissues of model group compared with that of controls, which was further supported by immunohistochemistry.	Bleomycin	34-43	transient receptor potential cation channel subfamily A member 1	Cavia porcellus	148-153
30717786-11	2019	CONCLUSION: Expression of TRPV1/TRPA1 was upregulated in the chronic cough related to bleomycin induced pulmonary fibrosis in guinea pigs, which provided new insights into the mechanism of IPF-associated cough hypersensitivity.	Bleomycin	86-95	transient receptor potential cation channel subfamily V member 1	Cavia porcellus	26-31
30717786-11	2019	CONCLUSION: Expression of TRPV1/TRPA1 was upregulated in the chronic cough related to bleomycin induced pulmonary fibrosis in guinea pigs, which provided new insights into the mechanism of IPF-associated cough hypersensitivity.	Bleomycin	86-95	transient receptor potential cation channel subfamily A member 1	Cavia porcellus	32-37
30136377-13	2019	CONCLUSION: Exercise training restores bleomycin-induced downregulation of pulmonary CBS/CSE expression, thus contributing to the increased H2 S generation and suppression of TGF-beta1/Smad and LRP-6/beta-catenin signalling pathways, EMT and lung fibrosis.	Bleomycin	39-48	cystathionase (cystathionine gamma-lyase)	Mus musculus	89-92
30918525-10	2019	Conclusion: CAE effectively delayed the progression of BLM-induced pulmonary fibrosis in pulmonary fibrosis mice and a possible mechanism is the inhibition of cell apoptosis of NF-kappaB/p38-mediated signaling pathway.	Bleomycin	55-58	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	177-186
30918525-10	2019	Conclusion: CAE effectively delayed the progression of BLM-induced pulmonary fibrosis in pulmonary fibrosis mice and a possible mechanism is the inhibition of cell apoptosis of NF-kappaB/p38-mediated signaling pathway.	Bleomycin	55-58	mitogen-activated protein kinase 14	Mus musculus	187-190
30136377-13	2019	CONCLUSION: Exercise training restores bleomycin-induced downregulation of pulmonary CBS/CSE expression, thus contributing to the increased H2 S generation and suppression of TGF-beta1/Smad and LRP-6/beta-catenin signalling pathways, EMT and lung fibrosis.	Bleomycin	39-48	transforming growth factor, beta 1	Mus musculus	175-184
30136377-13	2019	CONCLUSION: Exercise training restores bleomycin-induced downregulation of pulmonary CBS/CSE expression, thus contributing to the increased H2 S generation and suppression of TGF-beta1/Smad and LRP-6/beta-catenin signalling pathways, EMT and lung fibrosis.	Bleomycin	39-48	SMAD family member 4	Mus musculus	185-189
30136377-13	2019	CONCLUSION: Exercise training restores bleomycin-induced downregulation of pulmonary CBS/CSE expression, thus contributing to the increased H2 S generation and suppression of TGF-beta1/Smad and LRP-6/beta-catenin signalling pathways, EMT and lung fibrosis.	Bleomycin	39-48	low density lipoprotein receptor-related protein 6	Mus musculus	194-199
30136377-13	2019	CONCLUSION: Exercise training restores bleomycin-induced downregulation of pulmonary CBS/CSE expression, thus contributing to the increased H2 S generation and suppression of TGF-beta1/Smad and LRP-6/beta-catenin signalling pathways, EMT and lung fibrosis.	Bleomycin	39-48	catenin (cadherin associated protein), beta 1	Mus musculus	200-212
30548445-7	2019	In vitro experiments showed increased expression levels of senescent markers and augmented senescence-associated secretory phenotype (SASP) in AECs treated with bleomycin (Blm); however, PTEN was reduced significantly following IkappaB, IKK, and NF-kappaB activation after stimulation with Blm in AECs.	Bleomycin	161-170	phosphatase and tensin homolog	Homo sapiens	187-191
30230348-3	2019	We report that P311 is switched on in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and in the mouse model of bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	127-136	neuronal regeneration related protein	Mus musculus	15-19
30136377-9	2019	Bleomycin-induced lung fibrosis was associated with increased alpha smooth muscle actin (alpha-SMA) and decreased E-cadherin expression (P &lt; 0.01).	Bleomycin	0-9	actin alpha 2, smooth muscle, aorta	Mus musculus	62-87
30136377-9	2019	Bleomycin-induced lung fibrosis was associated with increased alpha smooth muscle actin (alpha-SMA) and decreased E-cadherin expression (P &lt; 0.01).	Bleomycin	0-9	actin alpha 2, smooth muscle, aorta	Mus musculus	89-98
30136377-9	2019	Bleomycin-induced lung fibrosis was associated with increased alpha smooth muscle actin (alpha-SMA) and decreased E-cadherin expression (P &lt; 0.01).	Bleomycin	0-9	cadherin 1	Mus musculus	114-124
30136377-11	2019	Moreover, exercise training restored bleomycin-induced downregulation of cystathionine-beta-synthase (CBS) and cystathionine-gamma-lyase (CSE) expression, as well as H2 S generation in lung tissue (P &lt; 0.01).	Bleomycin	37-46	cystathionine beta-synthase	Mus musculus	73-100
30136377-11	2019	Moreover, exercise training restored bleomycin-induced downregulation of cystathionine-beta-synthase (CBS) and cystathionine-gamma-lyase (CSE) expression, as well as H2 S generation in lung tissue (P &lt; 0.01).	Bleomycin	37-46	cystathionase (cystathionine gamma-lyase)	Mus musculus	111-136
30136377-11	2019	Moreover, exercise training restored bleomycin-induced downregulation of cystathionine-beta-synthase (CBS) and cystathionine-gamma-lyase (CSE) expression, as well as H2 S generation in lung tissue (P &lt; 0.01).	Bleomycin	37-46	cystathionase (cystathionine gamma-lyase)	Mus musculus	138-141
30136377-12	2019	NaHS treatment attenuated bleomycin-induced TGF-beta1 production, activation of LRP-6/beta-catenin signalling, EMT and lung fibrosis (P &lt; 0.01 except for beta-catenin: P &lt; 0.05).	Bleomycin	26-35	transforming growth factor, beta 1	Mus musculus	44-53
30136377-12	2019	NaHS treatment attenuated bleomycin-induced TGF-beta1 production, activation of LRP-6/beta-catenin signalling, EMT and lung fibrosis (P &lt; 0.01 except for beta-catenin: P &lt; 0.05).	Bleomycin	26-35	low density lipoprotein receptor-related protein 6	Mus musculus	80-85
30136377-12	2019	NaHS treatment attenuated bleomycin-induced TGF-beta1 production, activation of LRP-6/beta-catenin signalling, EMT and lung fibrosis (P &lt; 0.01 except for beta-catenin: P &lt; 0.05).	Bleomycin	26-35	catenin (cadherin associated protein), beta 1	Mus musculus	86-98
30230348-3	2019	We report that P311 is switched on in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and in the mouse model of bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	138-141	neuronal regeneration related protein	Mus musculus	15-19
30175895-9	2019	In a mouse model of bleomycin-induced fibrosis (n = 5-8) and in a TSK mouse model (a genetic model of SSc) (n = 5-10), deficient expression of MFG-E8 significantly enhanced both pulmonary and skin fibrosis, and administration of rMFG-E8 significantly inhibited bleomycin-induced dermal fibrosis.	Bleomycin	20-29	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	143-149
30175895-9	2019	In a mouse model of bleomycin-induced fibrosis (n = 5-8) and in a TSK mouse model (a genetic model of SSc) (n = 5-10), deficient expression of MFG-E8 significantly enhanced both pulmonary and skin fibrosis, and administration of rMFG-E8 significantly inhibited bleomycin-induced dermal fibrosis.	Bleomycin	261-270	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	143-149
30450767-5	2019	Intriguingly, TRPV4 deletion in mice suppressed expression of mesenchymal markers, NCAD and alpha-SMA, in a bleomycin-induced murine skin fibrosis model.	Bleomycin	108-117	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	14-19
30521874-10	2019	DNase I-positive CD4+ T cells overexpressing EndoG demonstrated decreased progression towards bleomycin-induced apoptosis.	Bleomycin	94-103	endonuclease G	Homo sapiens	45-50
30736900-13	2019	administration also decreased the expression of alpha-SMA in bleomycin-induced mice.	Bleomycin	61-70	actin alpha 2, smooth muscle, aorta	Mus musculus	48-57
31250599-8	2019	CONCLUSION: Yiqi Huayu Hutan decoction can significantly improve the pulmonary fibrosis which is induced by bleomycin, and the mechanism is related to the inhibition of the expression of TGF-beta/Snail pathway of transcription TGF-beta1.	Bleomycin	108-117	transforming growth factor, beta 1	Rattus norvegicus	187-195
30915776-0	2019	MiR-34b-5p knockdown attenuates bleomycin-induced pulmonary fibrosis by targeting tissue inhibitor of metalloproteinase 3 (TIMP3).	Bleomycin	32-41	tissue inhibitor of metalloproteinase 3	Mus musculus	82-121
30915776-0	2019	MiR-34b-5p knockdown attenuates bleomycin-induced pulmonary fibrosis by targeting tissue inhibitor of metalloproteinase 3 (TIMP3).	Bleomycin	32-41	tissue inhibitor of metalloproteinase 3	Mus musculus	123-128
30915776-8	2019	MiR-34b-5p knockdown in vivo attenuated the bleomycin-induced pulmonary fibrosis in wild-type mice, displayed by a reduced expression of Col1A1, fibronectin (Fn), and alpha-SMA.	Bleomycin	44-53	fibronectin 1	Mus musculus	145-156
30915776-8	2019	MiR-34b-5p knockdown in vivo attenuated the bleomycin-induced pulmonary fibrosis in wild-type mice, displayed by a reduced expression of Col1A1, fibronectin (Fn), and alpha-SMA.	Bleomycin	44-53	fibronectin 1	Mus musculus	158-160
30915776-8	2019	MiR-34b-5p knockdown in vivo attenuated the bleomycin-induced pulmonary fibrosis in wild-type mice, displayed by a reduced expression of Col1A1, fibronectin (Fn), and alpha-SMA.	Bleomycin	44-53	actin alpha 2, smooth muscle, aorta	Mus musculus	167-176
30915776-11	2019	CONCLUSIONS: MiR-34b-5p knockdown appears to enhance the resistance to bleomycin by regulating its target gene TIMP3 during the pathogenesis of lung fibrosis.	Bleomycin	71-80	tissue inhibitor of metalloproteinase 3	Mus musculus	111-116
30696809-11	2019	Finally, Ttc3 mRNA levels were significantly increased and Smurf2 protein levels were significantly decreased in the lungs of mice treated with bleomycin as compared with the lungs of control mice.	Bleomycin	144-153	tetratricopeptide repeat domain 3	Mus musculus	9-13
30696809-11	2019	Finally, Ttc3 mRNA levels were significantly increased and Smurf2 protein levels were significantly decreased in the lungs of mice treated with bleomycin as compared with the lungs of control mice.	Bleomycin	144-153	SMAD specific E3 ubiquitin protein ligase 2	Mus musculus	59-65
31250599-8	2019	CONCLUSION: Yiqi Huayu Hutan decoction can significantly improve the pulmonary fibrosis which is induced by bleomycin, and the mechanism is related to the inhibition of the expression of TGF-beta/Snail pathway of transcription TGF-beta1.	Bleomycin	108-117	transforming growth factor, beta 1	Rattus norvegicus	227-236
30527805-0	2019	Neutralization of IL-18 by IL-18 binding protein ameliorates bleomycin-induced pulmonary fibrosis via inhibition of epithelial-mesenchymal transition.	Bleomycin	61-70	interleukin 18	Mus musculus	18-23
30634956-5	2019	Notably, activation of GLP-1 receptor by GLP-1 analogue liraglutide directly attenuated RVSP and PVR in MCT-induced PH, as well as bleomycin- and chronic hypoxia-induced PH.	Bleomycin	131-140	glucagon like peptide 1 receptor	Homo sapiens	23-37
30634956-5	2019	Notably, activation of GLP-1 receptor by GLP-1 analogue liraglutide directly attenuated RVSP and PVR in MCT-induced PH, as well as bleomycin- and chronic hypoxia-induced PH.	Bleomycin	131-140	glucagon	Homo sapiens	23-28
30527805-0	2019	Neutralization of IL-18 by IL-18 binding protein ameliorates bleomycin-induced pulmonary fibrosis via inhibition of epithelial-mesenchymal transition.	Bleomycin	61-70	interleukin 18 binding protein	Mus musculus	27-48
30358439-10	2019	Furthermore, NCC170 treatment significantly decreased fibrosis measured by Ashcroft score as well as expression of type 1 collagen and fibronectin in bleomycin-treated mouse lungs.	Bleomycin	150-159	fibronectin 1	Mus musculus	135-146
30625178-5	2019	In vivo, we show that bleomycin exposure to murine lungs causes early ER stress to activate IRE1alpha and the terminal UPR prior to development of pulmonary fibrosis.	Bleomycin	22-31	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	92-101
30625178-6	2019	Small-molecule IRE1alpha kinase-inhibiting RNase attenuators (KIRAs) that we developed were used to evaluate the contribution of IRE1alpha activation to bleomycin-induced pulmonary fibrosis.	Bleomycin	153-162	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	15-24
30719057-0	2019	Yangyin Yiqi Mixture Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats through Inhibiting TGF-beta1/Smad Pathway and Epithelial to Mesenchymal Transition.	Bleomycin	33-42	transforming growth factor, beta 1	Rattus norvegicus	97-106
31037627-2	2019	The development of new drugs for IPF has increased the necessity of identifying biomarkers for predicting clinical behavior and the selection of the appropriate treatment strategy for individual patient.We and another group found that periostin, a matricellular protein expressed specifically in areas of ongoing fibrotic lesions, such as fibroblastic foci in lung tissues from human IPF or murine bleomycin-induced lung injury models.	Bleomycin	398-407	periostin	Homo sapiens	235-244
31037627-3	2019	Murine bleomycin-induced lung injury was improved by the constant suppression of periostin expression and treatment with neutralizing anti-periostin antibodies at the fibroproliferative phase.	Bleomycin	7-16	periostin, osteoblast specific factor	Mus musculus	81-90
31037627-3	2019	Murine bleomycin-induced lung injury was improved by the constant suppression of periostin expression and treatment with neutralizing anti-periostin antibodies at the fibroproliferative phase.	Bleomycin	7-16	periostin, osteoblast specific factor	Mus musculus	139-148
30130411-4	2019	Increased concentrations of activated MK2 were expressed in IPF lung and in the mouse bleomycin model of lung fibrosis.	Bleomycin	86-95	MAP kinase-activated protein kinase 2	Mus musculus	38-41
30130411-9	2019	More importantly, MK2 inhibition attenuated hyaluronan accumulation and reduced collagen content in bleomycin-injured mouse lungs in vivo.	Bleomycin	100-109	MAP kinase-activated protein kinase 2	Mus musculus	18-21
30130411-10	2019	Conditional deletion of MK2 in fibroblasts attenuated bleomycin-induced lung fibrosis.	Bleomycin	54-63	MAP kinase-activated protein kinase 2	Mus musculus	24-27
31210057-0	2019	Peptide PD29 treats bleomycin-induced pulmonary fibrosis by inhibiting the TGF-beta/smad signaling pathway.	Bleomycin	20-29	transforming growth factor, beta 1	Rattus norvegicus	75-83
30982371-2	2019	Pathway inhibition at the level of the downstream Gli transcription factors Gli1 and Gli2 (by GANT61) ameliorates lung fibrosis in the bleomycin model, whereas inhibition proximally at the level of HH ligand (by anti Hh antibody 5E1) or Smo (by GDC-0449) of the canonical pathway does not, implicating Gli1 and/or Gli2 as a key target.	Bleomycin	135-144	GLI-Kruppel family member GLI1	Mus musculus	76-80
29926545-11	2019	In a bleomycin-induced lung injury mouse model, RA decreased the expression of TGF-beta1 and Smad3 at 1 and 3 weeks.	Bleomycin	5-14	transforming growth factor, beta 1	Mus musculus	79-88
30982371-2	2019	Pathway inhibition at the level of the downstream Gli transcription factors Gli1 and Gli2 (by GANT61) ameliorates lung fibrosis in the bleomycin model, whereas inhibition proximally at the level of HH ligand (by anti Hh antibody 5E1) or Smo (by GDC-0449) of the canonical pathway does not, implicating Gli1 and/or Gli2 as a key target.	Bleomycin	135-144	GLI-Kruppel family member GLI2	Mus musculus	85-89
30106602-4	2019	We show that Raf1-tr has increased binding to DNA-dependent protein kinase (DNA-PK), which inhibits DNA-PK function and causes amplification of irradiation- and bleomycin-induced DNA damage.	Bleomycin	161-170	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	13-17
30106602-4	2019	We show that Raf1-tr has increased binding to DNA-dependent protein kinase (DNA-PK), which inhibits DNA-PK function and causes amplification of irradiation- and bleomycin-induced DNA damage.	Bleomycin	161-170	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	46-74
30106602-4	2019	We show that Raf1-tr has increased binding to DNA-dependent protein kinase (DNA-PK), which inhibits DNA-PK function and causes amplification of irradiation- and bleomycin-induced DNA damage.	Bleomycin	161-170	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	76-82
30106602-5	2019	We found that the human colorectal cancer cell line, HCT-116, displayed reduced expression of Raf1-tr, and reintroduction of Raf1-tr sensitized the cells to bleomycin-induced apoptosis.	Bleomycin	157-166	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	94-98
30106602-5	2019	We found that the human colorectal cancer cell line, HCT-116, displayed reduced expression of Raf1-tr, and reintroduction of Raf1-tr sensitized the cells to bleomycin-induced apoptosis.	Bleomycin	157-166	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	125-129
30106602-6	2019	Furthermore, we identified differential Raf1-tr expression in breast cancer cell lines and showed that breast cancer cells with increased Raf1-tr expression become sensitized to bleomycin-induced apoptosis.	Bleomycin	178-187	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	40-44
30106602-6	2019	Furthermore, we identified differential Raf1-tr expression in breast cancer cell lines and showed that breast cancer cells with increased Raf1-tr expression become sensitized to bleomycin-induced apoptosis.	Bleomycin	178-187	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	138-142
30391100-9	2019	Knockdown of the SCN5A and SCN10A variants in human macrophages reduced the severity of dsDNA breaks induced by treatment with bleomycin and type 1 interferon.	Bleomycin	127-136	sodium voltage-gated channel alpha subunit 5	Homo sapiens	17-22
30391100-9	2019	Knockdown of the SCN5A and SCN10A variants in human macrophages reduced the severity of dsDNA breaks induced by treatment with bleomycin and type 1 interferon.	Bleomycin	127-136	sodium voltage-gated channel alpha subunit 10	Homo sapiens	27-33
30655107-7	2019	METHODS: Locally injectable PGN-NP were prepared and subcutaneously administered to bleomycin (BLM)-induced scleroderma model mice.	Bleomycin	84-93	SPG7, paraplegin matrix AAA peptidase subunit	Mus musculus	28-31
31553994-6	2019	The administration of SA (IP) suppressed BLM-induced lung fibrosis characterized as the inhibition of collagen deposition, TGF-beta accumulation in bronchoalveolar lavage fluid, and the expression of FN and collagen 1a2 in lung tissue.	Bleomycin	41-44	transforming growth factor, beta 1	Mus musculus	123-131
31553994-6	2019	The administration of SA (IP) suppressed BLM-induced lung fibrosis characterized as the inhibition of collagen deposition, TGF-beta accumulation in bronchoalveolar lavage fluid, and the expression of FN and collagen 1a2 in lung tissue.	Bleomycin	41-44	fibronectin 1	Mus musculus	200-202
29926545-11	2019	In a bleomycin-induced lung injury mouse model, RA decreased the expression of TGF-beta1 and Smad3 at 1 and 3 weeks.	Bleomycin	5-14	SMAD family member 3	Mus musculus	93-98
30219680-11	2018	We demonstrated that SA ameliorates BLM-induced lung injuries through inhibition of apoptosis and induction of Nrf2/HO-1-mediated antioxidant enzymes via NF-kappaB inhibition.	Bleomycin	36-39	NFE2 like bZIP transcription factor 2	Rattus norvegicus	111-115
30596712-0	2018	Blockade of platelet-derived growth factor receptor-beta, not receptor-alpha ameliorates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	89-98	platelet derived growth factor receptor, beta polypeptide	Mus musculus	12-56
30567353-0	2018	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	77-86	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	0-38
30567353-0	2018	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	77-86	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	40-43
30567353-3	2018	OBJECTIVES: We tested the effects of two small molecules targeting MIF on bleomycin (BLM)-induced collagen deposition, PH, and vascular remodeling in mouse lungs.	Bleomycin	74-83	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	67-70
30530916-0	2018	Accelerated aging induced by deficiency of Zmpste24 protects old mice to develop bleomycin-induced pulmonary fibrosis.	Bleomycin	81-90	zinc metallopeptidase, STE24	Mus musculus	43-51
30530916-4	2018	We found that young WT and Zmpste24(-/-) mice developed a similar fibrotic response to bleomycin.	Bleomycin	87-96	zinc metallopeptidase, STE24	Mus musculus	27-35
30560874-5	2018	HIF-1alpha and the pro-apoptotic ER stress marker C/EBP homologous protein (CHOP) were co-expressed in hyperplastic AECs from bleomycin-treated mice and IPF lungs, not in controls.	Bleomycin	126-135	hypoxia inducible factor 1, alpha subunit	Mus musculus	0-10
30560874-5	2018	HIF-1alpha and the pro-apoptotic ER stress marker C/EBP homologous protein (CHOP) were co-expressed in hyperplastic AECs from bleomycin-treated mice and IPF lungs, not in controls.	Bleomycin	126-135	DNA-damage inducible transcript 3	Mus musculus	50-74
30560874-5	2018	HIF-1alpha and the pro-apoptotic ER stress marker C/EBP homologous protein (CHOP) were co-expressed in hyperplastic AECs from bleomycin-treated mice and IPF lungs, not in controls.	Bleomycin	126-135	DNA-damage inducible transcript 3	Mus musculus	76-80
30560893-3	2018	In mice, we demonstrate that Muc5b concentration in bronchoalveolar epithelia is related to impaired mucociliary clearance (MCC) and to the extent and persistence of bleomycin-induced lung fibrosis.	Bleomycin	166-175	mucin 5, subtype B, tracheobronchial	Mus musculus	29-34
30560893-5	2018	Our findings suggest that mucociliary dysfunction might play a causative role in bleomycin-induced pulmonary fibrosis in mice overexpressing Muc5b, and that MUC5B in distal airspaces is a potential therapeutic target in humans with IPF.	Bleomycin	81-90	mucin 5, subtype B, tracheobronchial	Mus musculus	141-146
30273543-4	2018	Here, our in vivo studies showed that SAB had a strong anti-inflammatory effect on bleomycin-instilled mice by inhibiting inflammatory cell infiltration and inflammatory cytokine production.	Bleomycin	83-92	SH3-domain binding protein 5 (BTK-associated)	Mus musculus	38-41
30273543-5	2018	Moreover, SAB protected endothelial cells against oxidative stress injury and inhibited endothelial cell apoptosis in bleomycin-treated mice.	Bleomycin	118-127	SH3-domain binding protein 5 (BTK-associated)	Mus musculus	10-13
30510259-3	2018	We found that the expression of Ninj1 in a patient cohort was upregulated in the lung specimens of idiopathic pulmonary fibrosis patients as well as mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	159-168	ninjurin 1	Homo sapiens	32-37
29940125-6	2018	The bleomycin or TGF-beta administration caused the increase of sphingosine-1-phosphate (S1P) level in pulmonary tissue and HELF cells, as well as its activation-required kinase, sphingosine kinase 1 (SphK1), and its degradation enzyme, sphinogosine-1-phosphate lyase (S1PL).	Bleomycin	4-13	sphingosine kinase 1	Homo sapiens	179-199
29940125-6	2018	The bleomycin or TGF-beta administration caused the increase of sphingosine-1-phosphate (S1P) level in pulmonary tissue and HELF cells, as well as its activation-required kinase, sphingosine kinase 1 (SphK1), and its degradation enzyme, sphinogosine-1-phosphate lyase (S1PL).	Bleomycin	4-13	sphingosine kinase 1	Homo sapiens	201-206
29940125-6	2018	The bleomycin or TGF-beta administration caused the increase of sphingosine-1-phosphate (S1P) level in pulmonary tissue and HELF cells, as well as its activation-required kinase, sphingosine kinase 1 (SphK1), and its degradation enzyme, sphinogosine-1-phosphate lyase (S1PL).	Bleomycin	4-13	sphingosine-1-phosphate lyase 1	Homo sapiens	237-267
29940125-6	2018	The bleomycin or TGF-beta administration caused the increase of sphingosine-1-phosphate (S1P) level in pulmonary tissue and HELF cells, as well as its activation-required kinase, sphingosine kinase 1 (SphK1), and its degradation enzyme, sphinogosine-1-phosphate lyase (S1PL).	Bleomycin	4-13	sphingosine-1-phosphate lyase 1	Homo sapiens	269-273
30219680-11	2018	We demonstrated that SA ameliorates BLM-induced lung injuries through inhibition of apoptosis and induction of Nrf2/HO-1-mediated antioxidant enzymes via NF-kappaB inhibition.	Bleomycin	36-39	heme oxygenase 1	Rattus norvegicus	116-120
30470612-11	2018	INTERPRETATION: The application of the combined siRNAs of SPARC, CCR2, and SMAD3 genes ameliorated inflammation and fibrosis in bleomycin-induced mice.	Bleomycin	128-137	secreted acidic cysteine rich glycoprotein	Mus musculus	58-63
30470612-11	2018	INTERPRETATION: The application of the combined siRNAs of SPARC, CCR2, and SMAD3 genes ameliorated inflammation and fibrosis in bleomycin-induced mice.	Bleomycin	128-137	chemokine (C-C motif) receptor 2	Mus musculus	65-69
30470612-11	2018	INTERPRETATION: The application of the combined siRNAs of SPARC, CCR2, and SMAD3 genes ameliorated inflammation and fibrosis in bleomycin-induced mice.	Bleomycin	128-137	SMAD family member 3	Mus musculus	75-80
29598007-0	2018	AAV6-Mediated IL-10 Expression in the Lung Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice.	Bleomycin	55-64	interleukin 10	Mus musculus	14-19
30320382-4	2018	The present study aimed to detect LOXL2 expression in mice with bleomycin (BLM)-induced pulmonary fibrosis, and explore the effects of silencing LOXL2 on the proliferation, activation and fibrosis process of mouse lung fibroblasts (MLFs).	Bleomycin	64-73	lysyl oxidase-like 2	Mus musculus	34-39
30320382-4	2018	The present study aimed to detect LOXL2 expression in mice with bleomycin (BLM)-induced pulmonary fibrosis, and explore the effects of silencing LOXL2 on the proliferation, activation and fibrosis process of mouse lung fibroblasts (MLFs).	Bleomycin	75-78	lysyl oxidase-like 2	Mus musculus	34-39
30524284-9	2018	In vivo lung tissue from bleomycin-treated mice showed EPRS-dependent STAT6 phosphorylation and ECM production.	Bleomycin	25-34	glutamyl-prolyl-tRNA synthetase	Mus musculus	55-59
30524284-9	2018	In vivo lung tissue from bleomycin-treated mice showed EPRS-dependent STAT6 phosphorylation and ECM production.	Bleomycin	25-34	signal transducer and activator of transcription 6	Mus musculus	70-75
30049844-0	2018	Bleomycin-enhanced alternative splicing of fibroblast growth factor receptor 2 induces epithelial to mesenchymal transition in lung fibrosis.	Bleomycin	0-9	fibroblast growth factor receptor 2	Mus musculus	43-78
30049844-2	2018	Herein, we aimed to explore the underlying mechanisms of lung fibrosis mediated by EMT, with a focus on the alternative splicing of fibroblast growth factor receptor 2 (FGFR2), using bleomycin (BLM)-induced lung fibrotic and transgenic mouse models.	Bleomycin	183-192	fibroblast growth factor receptor 2	Mus musculus	132-167
30049844-2	2018	Herein, we aimed to explore the underlying mechanisms of lung fibrosis mediated by EMT, with a focus on the alternative splicing of fibroblast growth factor receptor 2 (FGFR2), using bleomycin (BLM)-induced lung fibrotic and transgenic mouse models.	Bleomycin	183-192	fibroblast growth factor receptor 2	Mus musculus	169-174
30049844-2	2018	Herein, we aimed to explore the underlying mechanisms of lung fibrosis mediated by EMT, with a focus on the alternative splicing of fibroblast growth factor receptor 2 (FGFR2), using bleomycin (BLM)-induced lung fibrotic and transgenic mouse models.	Bleomycin	194-197	fibroblast growth factor receptor 2	Mus musculus	132-167
30049844-2	2018	Herein, we aimed to explore the underlying mechanisms of lung fibrosis mediated by EMT, with a focus on the alternative splicing of fibroblast growth factor receptor 2 (FGFR2), using bleomycin (BLM)-induced lung fibrotic and transgenic mouse models.	Bleomycin	194-197	fibroblast growth factor receptor 2	Mus musculus	169-174
30367690-0	2018	Withaferin A attenuates bleomycin-induced scleroderma by targeting FoxO3a and NF-kappabeta signaling: Connecting fibrosis and inflammation.	Bleomycin	24-33	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	78-90
30529286-5	2018	Overexpression of wild type RNF126, but not catalytically-inactive mutant RNF126 (CC229/232AA), diminished ubiquitination of H2A histone family member X (H2AX), and subsequent bleomycin-induced focus formation of total ubiquitin FK2, TP53-binding protein 1 (53BP1), and receptor-associated protein 80 (RAP80).	Bleomycin	176-185	ring finger protein 126	Homo sapiens	28-34
30291375-5	2018	The expression of TSPAN1 was examined in vivo using the bleomycin-induced lung fibrosis model and tissue sample of IPF patients.	Bleomycin	56-65	tetraspanin 1	Homo sapiens	18-24
30291375-7	2018	RESULTS: In our study, we found that TSPAN1 was markedly down-regulated in lung tissue of patients with idiopathic pulmonary fibrosis (IPF) and in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	147-156	tetraspanin 1	Homo sapiens	37-43
30470231-9	2018	Moreover, we demonstrated that suppression of the Wnt/beta-catenin signaling pathway could attenuate myofibroblast differentiation of LR-MSCs induced by M2 macrophages and bleomycin-induced pulmonary fibrosis.	Bleomycin	172-181	catenin (cadherin associated protein), beta 1	Mus musculus	54-66
29925920-7	2018	A similar pattern of TGF-beta/Smads signaling activation and the enhancing role of telomere shortening in pulmonary fibrosis are also confirmed in bleomycin-induced model.	Bleomycin	147-156	transforming growth factor, beta 1	Mus musculus	21-29
29598007-10	2018	Furthermore, IL-10 significantly improved survival in bleomycin-induced mice.	Bleomycin	54-63	interleukin 10	Mus musculus	13-18
30377686-2	2018	Previous studies showed that antiflammin-1 (the active fragment of uteroglobin) effectively inhibited bleomycin-induced pulmonary fibrosis.	Bleomycin	102-111	secretoglobin family 1A member 1	Homo sapiens	67-78
30347408-11	2018	In addition, oridonin could significantly inhibit BLM-induced upregulation of alpha-SMA and COL1A1 and the phosphorylation of Smad2/3 in lung tissues of mice.	Bleomycin	50-53	actin alpha 2, smooth muscle, aorta	Mus musculus	78-87
30347408-11	2018	In addition, oridonin could significantly inhibit BLM-induced upregulation of alpha-SMA and COL1A1 and the phosphorylation of Smad2/3 in lung tissues of mice.	Bleomycin	50-53	collagen, type I, alpha 1	Mus musculus	92-98
30347408-11	2018	In addition, oridonin could significantly inhibit BLM-induced upregulation of alpha-SMA and COL1A1 and the phosphorylation of Smad2/3 in lung tissues of mice.	Bleomycin	50-53	SMAD family member 2	Mus musculus	126-133
30030077-0	2018	Polysaccharides from Dendrobium officinale inhibit bleomycin-induced pulmonary fibrosis via the TGFbeta1-Smad2/3 axis.	Bleomycin	51-60	transforming growth factor, beta 1	Rattus norvegicus	96-104
30030077-0	2018	Polysaccharides from Dendrobium officinale inhibit bleomycin-induced pulmonary fibrosis via the TGFbeta1-Smad2/3 axis.	Bleomycin	51-60	SMAD family member 2	Rattus norvegicus	105-110
30030077-4	2018	Our data showed that PDO significantly ameliorated indices for both pulmonary inflammation and fibrosis in a bleomycin (BLM)-induced pulmonary fibrosis model in rats, which was associated with inactivation of transforming growth factor beta1 (TGFbeta1)-Smad2/3 signaling pathway.	Bleomycin	109-118	transforming growth factor, beta 1	Rattus norvegicus	243-251
30253845-8	2018	Lung transduction of adenovirus expressing p53 reduced bleomycin-induced PF in wild-type or caveolin-1-deficient mice.	Bleomycin	55-64	transformation related protein 53, pseudogene	Mus musculus	43-46
29727583-10	2018	Bleomycin-challenged PTP-BL-/- mice, while developing inflammatory lung injury, exhibited reduced pulmonary fibrosis compared with wild-type mice.	Bleomycin	0-9	protein tyrosine phosphatase, non-receptor type 13	Mus musculus	21-27
30253845-8	2018	Lung transduction of adenovirus expressing p53 reduced bleomycin-induced PF in wild-type or caveolin-1-deficient mice.	Bleomycin	55-64	caveolin 1, caveolae protein	Mus musculus	92-102
30024304-6	2018	Lung miR-26a was significantly decreased 7 days after bleomycin injury, and, on the basis of enrichment of predicted gene targets, it was identified as a putative regulator of cell adhesion, including the gene targets EphA2, KDR, and ROCK1, important in altered barrier function.	Bleomycin	54-63	microRNA 26a-1	Homo sapiens	5-12
30033591-0	2018	VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARgamma- and CB2 receptor-dependent pathways.	Bleomycin	59-68	cannabinoid receptor 2	Homo sapiens	131-134
30024304-7	2018	Lung EphA2 mRNA, and protein increased in the bleomycin-injured lung.	Bleomycin	46-55	EPH receptor A2	Homo sapiens	5-10
30033591-0	2018	VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARgamma- and CB2 receptor-dependent pathways.	Bleomycin	59-68	peroxisome proliferator activated receptor gamma	Homo sapiens	116-125
30033591-10	2018	It prevented skin fibrosis, myofibroblast differentiation and ERK1/2 phosphorylation in bleomycin-induced skin fibrosis.	Bleomycin	88-97	mitogen-activated protein kinase 3	Homo sapiens	62-68
30173367-2	2018	Genetic mapping studies completed in offspring derived from these inbred strains revealed the inheritance of C57BL/6J alleles at loci, including the major locus on chromosome 17, called Blmpf1 bleomycin-induced pulmonary fibrosis 1, to be linked to pulmonary fibrosis in treated mice.	Bleomycin	193-202	bleomycin-induced pulmonary fibrosis 1	Mus musculus	186-192
29956068-7	2018	Finally, IL-37 treatment inhibited the expression of monocyte chemoattractant protein-1, IL-6, and tumor necrosis factor-alpha, but increased the expression of interferon-gamma in lung tissues from bleomycin-challenged mice.	Bleomycin	198-207	interferon gamma	Mus musculus	160-176
29676521-5	2018	The effect of apelin injections on bleomycin-induced dermal fibrosis in mice was investigated.	Bleomycin	35-44	apelin	Mus musculus	14-20
29676521-11	2018	Administration of apelin significantly inhibited bleomycin-induced dermal fibrosis in mice.	Bleomycin	49-58	apelin	Homo sapiens	18-24
30173367-8	2018	We conclude that Blmpf1genes contributing to the susceptibility to bleomycin-induced pulmonary fibrosis could alter the adaptive immune response of C57BL/6J mice.	Bleomycin	67-76	bleomycin-induced pulmonary fibrosis 1	Mus musculus	17-23
30201409-0	2018	Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.	Bleomycin	55-64	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	31-34
30201409-5	2018	In this report, we examined head-to-head the efficacy of a potent inhibitor of ATX (PF-8380), that has not been tested in pulmonary fibrosis models, and an antagonist of LPAR1 (AM095) in bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	187-196	lysophosphatidic acid receptor 1	Homo sapiens	170-175
30257700-4	2018	METHODS AND RESULTS: Exposure of mice to bleomycin (BLM) resulted in significant accumulation of cells that express neutrophilic markers Gr-1HighCD11b+Ly-6GHighF4/80-CD115-CD49d-.	Bleomycin	41-50	colony stimulating factor 1 receptor	Mus musculus	166-171
30257700-4	2018	METHODS AND RESULTS: Exposure of mice to bleomycin (BLM) resulted in significant accumulation of cells that express neutrophilic markers Gr-1HighCD11b+Ly-6GHighF4/80-CD115-CD49d-.	Bleomycin	41-50	integrin alpha 4	Mus musculus	172-177
30257954-5	2018	PD-1+CD4+ T cells with reduced proliferative capacity and increased transforming growth factor-beta (TGF-beta)/interleukin-17A (IL-17A) expression were detected in IPF, sarcoidosis, and bleomycin CD4+ T cells.	Bleomycin	186-195	CD4 molecule	Sus scrofa	5-8
30257954-5	2018	PD-1+CD4+ T cells with reduced proliferative capacity and increased transforming growth factor-beta (TGF-beta)/interleukin-17A (IL-17A) expression were detected in IPF, sarcoidosis, and bleomycin CD4+ T cells.	Bleomycin	186-195	transforming growth factor alpha	Sus scrofa	101-109
30319721-9	2018	In the present study, Qingfei Xieding administration significantly attenuated bleomycin-induced pulmonary fibrosis in mice by reducing lung coefficient, wet/dry, NO, HYP, and MDA as well as the expression of iNOS, CTGF, alpha-SMA, FN, and DNA damage.	Bleomycin	78-87	actin alpha 2, smooth muscle, aorta	Mus musculus	220-229
29913150-0	2018	SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	48-57	SMAD family member 3	Mus musculus	30-35
29676583-0	2018	Reticulocalbin 3 Deficiency in Alveolar Epithelium Exacerbated Bleomycin-induced Pulmonary Fibrosis.	Bleomycin	63-72	reticulocalbin 3, EF-hand calcium binding domain	Mus musculus	0-16
29676583-3	2018	In this study, we found marked induction of Rcn3 expression in alveolar epithelium during bleomycin-induced pulmonary fibrosis, which is most obvious in alveolar epithelial type II cells (AECIIs).	Bleomycin	90-99	reticulocalbin 3, EF-hand calcium binding domain	Mus musculus	44-48
29676583-5	2018	Although Rcn3 deletion did not cause obvious abnormalities in the lung architecture and mechanics, the exposure of Rcn3-deleted mice to bleomycin led to exacerbated pulmonary fibrosis and reduced lung mechanics.	Bleomycin	136-145	reticulocalbin 3, EF-hand calcium binding domain	Mus musculus	115-119
29676583-6	2018	These Rcn3-deleted mice also displayed enhanced alveolar epithelial cell (AEC) apoptosis and ER stress after bleomycin treatment, which was confirmed by in vitro studies both in primary AECIIs and mouse lung epithelial cells.	Bleomycin	109-118	reticulocalbin 3, EF-hand calcium binding domain	Mus musculus	6-10
29676583-9	2018	Collectively, these findings indicate that bleomycin-induced upregulation of Rcn3 in AECIIs appears to contribute to AECII survival and wound healing.	Bleomycin	43-52	reticulocalbin 3, EF-hand calcium binding domain	Mus musculus	77-81
29730026-0	2018	Activities of recombinant human bleomycin hydrolase on bleomycins and engineered analogues revealing new opportunities to overcome bleomycin-induced pulmonary toxicity.	Bleomycin	55-65	bleomycin hydrolase	Homo sapiens	32-51
29730026-3	2018	The organ specificity of BLM-induced toxicity has been correlated with the expression of the hBLMH gene, encoding the human bleomycin hydrolase (hBLMH), which is poorly expressed in the lung.	Bleomycin	25-28	bleomycin hydrolase	Homo sapiens	93-98
29730026-3	2018	The organ specificity of BLM-induced toxicity has been correlated with the expression of the hBLMH gene, encoding the human bleomycin hydrolase (hBLMH), which is poorly expressed in the lung.	Bleomycin	25-28	bleomycin hydrolase	Homo sapiens	124-143
29730026-3	2018	The organ specificity of BLM-induced toxicity has been correlated with the expression of the hBLMH gene, encoding the human bleomycin hydrolase (hBLMH), which is poorly expressed in the lung.	Bleomycin	25-28	bleomycin hydrolase	Homo sapiens	145-150
29730026-4	2018	hBLMH hydrolyzes BLMs into the biologically inactive deamido BLMs, thereby protecting organs from BLM-induced toxicity.	Bleomycin	17-21	bleomycin hydrolase	Homo sapiens	0-5
30186404-11	2018	Furthermore, the bleomycin-induced increased protein expression of periostin and TGF-beta1 was also significantly suppressed by pirfenidone on days 14 (P&lt;0.01) and 28 (data not shown).	Bleomycin	17-26	periostin	Rattus norvegicus	67-76
30021376-0	2018	Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-beta1/SMADs pathway.	Bleomycin	29-38	SPARC related modular calcium binding 2	Mus musculus	15-20
30021376-0	2018	Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-beta1/SMADs pathway.	Bleomycin	29-38	transforming growth factor, beta 1	Mus musculus	89-98
30021376-0	2018	Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-beta1/SMADs pathway.	Bleomycin	40-43	SPARC related modular calcium binding 2	Mus musculus	15-20
30021376-0	2018	Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-beta1/SMADs pathway.	Bleomycin	40-43	transforming growth factor, beta 1	Mus musculus	89-98
30021376-3	2018	Here we aimed to calculate the effects and molecular mechanism of SMOC2 on the progression and severity of lung fibrosis in murine bleomycin (BLM)-induced mice.	Bleomycin	131-140	SPARC related modular calcium binding 2	Mus musculus	66-71
30021376-3	2018	Here we aimed to calculate the effects and molecular mechanism of SMOC2 on the progression and severity of lung fibrosis in murine bleomycin (BLM)-induced mice.	Bleomycin	142-145	SPARC related modular calcium binding 2	Mus musculus	66-71
30186404-11	2018	Furthermore, the bleomycin-induced increased protein expression of periostin and TGF-beta1 was also significantly suppressed by pirfenidone on days 14 (P&lt;0.01) and 28 (data not shown).	Bleomycin	17-26	transforming growth factor, beta 1	Rattus norvegicus	81-90
29943845-3	2018	Consistent with previous studies, miR-21 inhibition reduced ECM protein levels in bleomycin (BLM)-induced mouse model of PF.	Bleomycin	82-91	microRNA 21a	Mus musculus	34-40
29775223-0	2018	Curcumin down-regulates IL-17A mediated p53-fibrinolytic system in bleomycin induced acute lung injury in vivo.	Bleomycin	67-76	interleukin 17A	Mus musculus	24-30
29943845-3	2018	Consistent with previous studies, miR-21 inhibition reduced ECM protein levels in bleomycin (BLM)-induced mouse model of PF.	Bleomycin	93-96	microRNA 21a	Mus musculus	34-40
29873400-0	2018	Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation.	Bleomycin	37-46	fibroblast growth factor 2	Mus musculus	0-26
29873400-2	2018	Mice lacking FGF2 have increased mortality and impaired epithelial recovery after bleomycin exposure, supporting a protective or reparative function following lung injury.	Bleomycin	82-91	fibroblast growth factor 2	Mus musculus	13-17
29873400-7	2018	This beneficial effect was seen when FGF2 overexpression was induced at day 0 or day 7 after bleomycin.	Bleomycin	93-102	fibroblast growth factor 2	Mus musculus	37-41
29873400-12	2018	In summary, overexpression of FGF2 protects against bleomycin-induced pulmonary fibrosis in vivo and reverses TGFbeta1-induced collagen and alphaSMA expression and stress fiber formation in lung fibroblasts in vitro, without affecting either inflammation or epithelial gene expression.	Bleomycin	52-61	fibroblast growth factor 2	Homo sapiens	30-34
30127999-0	2018	Bleomycin inhibits proliferation and induces apoptosis in TPC-1 cells through reversing M2-macrophages polarization.	Bleomycin	0-9	two pore segment channel 1	Homo sapiens	58-63
30416782-2	2018	In idiopathic pulmonary fibrosis (IPF), decorin is expressed in fibrotic lesions; furthermore, intratracheal gene transfer of decorin has been demonstrated to inhibit bleomycin-induced pulmonary fibrosis.	Bleomycin	167-176	decorin	Homo sapiens	126-133
30127999-9	2018	In addition, to verify the effect of BLM-treated M2 macrophages on thyroid carcinoma cells, a co-culture system of macrophages and the human PTC cell line TPC-1, was established.	Bleomycin	37-40	two pore segment channel 1	Homo sapiens	155-160
30347923-9	2018	Compared with the control group, the pulmonary tissue of the bleomycin group showed significant fibrosis, including significant disturbed alveolar structure, marked thickening of the interalveolar septa and dense interstitial infiltration by inflammatory cells and fibroblasts, and concomitantly with the decrease in plasma CGRP and expression of CGRP.	Bleomycin	61-70	calcitonin-related polypeptide alpha	Rattus norvegicus	324-328
30004839-0	2018	R213G polymorphism in SOD3 protects against bleomycin-induced inflammation and attenuates induction of proinflammatory pathways.	Bleomycin	44-53	superoxide dismutase 3, extracellular	Mus musculus	22-26
30347923-9	2018	Compared with the control group, the pulmonary tissue of the bleomycin group showed significant fibrosis, including significant disturbed alveolar structure, marked thickening of the interalveolar septa and dense interstitial infiltration by inflammatory cells and fibroblasts, and concomitantly with the decrease in plasma CGRP and expression of CGRP.	Bleomycin	61-70	calcitonin-related polypeptide alpha	Rattus norvegicus	347-351
30347923-10	2018	Importantly the expression of E-cadherin and ZO-1 was decreased and expression of Notch1, eIF3a, collagen I, vimentin and alpha-SMA was increased in bleomycin group (P&lt;0.05 or P&lt;0.01).	Bleomycin	149-158	cadherin 1	Rattus norvegicus	30-40
30347923-10	2018	Importantly the expression of E-cadherin and ZO-1 was decreased and expression of Notch1, eIF3a, collagen I, vimentin and alpha-SMA was increased in bleomycin group (P&lt;0.05 or P&lt;0.01).	Bleomycin	149-158	tight junction protein 1	Rattus norvegicus	45-49
30347923-10	2018	Importantly the expression of E-cadherin and ZO-1 was decreased and expression of Notch1, eIF3a, collagen I, vimentin and alpha-SMA was increased in bleomycin group (P&lt;0.05 or P&lt;0.01).	Bleomycin	149-158	notch receptor 1	Rattus norvegicus	82-88
30347923-10	2018	Importantly the expression of E-cadherin and ZO-1 was decreased and expression of Notch1, eIF3a, collagen I, vimentin and alpha-SMA was increased in bleomycin group (P&lt;0.05 or P&lt;0.01).	Bleomycin	149-158	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	90-95
30347923-10	2018	Importantly the expression of E-cadherin and ZO-1 was decreased and expression of Notch1, eIF3a, collagen I, vimentin and alpha-SMA was increased in bleomycin group (P&lt;0.05 or P&lt;0.01).	Bleomycin	149-158	vimentin	Rattus norvegicus	109-117
30347923-10	2018	Importantly the expression of E-cadherin and ZO-1 was decreased and expression of Notch1, eIF3a, collagen I, vimentin and alpha-SMA was increased in bleomycin group (P&lt;0.05 or P&lt;0.01).	Bleomycin	149-158	actin gamma 2, smooth muscle	Rattus norvegicus	122-131
30154568-7	2018	Moreover, HOPX expression was increased in AECs from bleomycin-instilled mouse lungs in vivo.	Bleomycin	53-62	HOP homeobox	Mus musculus	10-14
30082522-0	2018	Follistatin-Like 1 Promotes Bleomycin-Induced Pulmonary Fibrosis through the Transforming Growth Factor Beta 1/Mitogen-Activated Protein Kinase Signaling Pathway.	Bleomycin	28-37	follistatin-like 1	Mus musculus	0-18
30082522-0	2018	Follistatin-Like 1 Promotes Bleomycin-Induced Pulmonary Fibrosis through the Transforming Growth Factor Beta 1/Mitogen-Activated Protein Kinase Signaling Pathway.	Bleomycin	28-37	transforming growth factor, beta 1	Mus musculus	77-110
30060832-8	2018	We also observed significant downregulation of IL-17 A in Treg-depleted mice after bleomycin delivery.	Bleomycin	83-92	interleukin 17A	Mus musculus	47-54
29420051-10	2018	Finally, decreased CDKN2B expression was noted in fibroblasts from a murine model of fibrosis, and Cdkn2b-/- mice developed greater histologic fibrosis after bleomycin injury.	Bleomycin	158-167	cyclin dependent kinase inhibitor 2B	Mus musculus	99-105
29967351-7	2018	In a bleomycin model of lung fibrosis in mice, metformin therapeutically accelerates the resolution of well-established fibrosis in an AMPK-dependent manner.	Bleomycin	5-14	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	135-139
30121056-0	2018	Octreotide ameliorates dermal fibrosis in bleomycin-induced scleroderma Background/aim: Insulin-like growth factor (IGF)-I is a differentiation and growth factor.	Bleomycin	42-51	insulin-like growth factor 1	Mus musculus	88-122
30127784-4	2018	A mouse model of bleomycin-induced pulmonary fibrosis demonstrated S100A4+ macrophages as main source for extracellular S100A4 in the inflammatory phase.	Bleomycin	17-26	S100 calcium binding protein A4	Mus musculus	67-73
30127784-4	2018	A mouse model of bleomycin-induced pulmonary fibrosis demonstrated S100A4+ macrophages as main source for extracellular S100A4 in the inflammatory phase.	Bleomycin	17-26	S100 calcium binding protein A4	Mus musculus	120-126
30127784-7	2018	Accordingly, absence or neutralization of S100A4 significantly attenuated bleomycin-induced lung fibrosis in vivo.	Bleomycin	74-83	S100 calcium binding protein A4	Homo sapiens	42-48
29722566-0	2018	Inhibition of Raf1 ameliorates bleomycin-induced pulmonary fibrosis through attenuation of TGF-beta1 signaling.	Bleomycin	31-40	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	14-18
29722566-0	2018	Inhibition of Raf1 ameliorates bleomycin-induced pulmonary fibrosis through attenuation of TGF-beta1 signaling.	Bleomycin	31-40	transforming growth factor beta 1	Homo sapiens	91-100
29722566-3	2018	Here, we demonstrate that the Raf1 inhibitor GW5074 ameliorates lung fibrosis in bleomycin-induced pulmonary fibrosis.	Bleomycin	81-90	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	30-34
29574322-4	2018	The aim of our study was to illustrate electrochemotherapy as an effective treatment for pancreatic cancer along with the expression change in stemness genes (Nanog, Sox2 and Oct3/4) in pancreatic cancer cells post electrochemotherapy with bleomycin, cisplatin and oxaliplatin.	Bleomycin	240-249	Nanog homeobox	Homo sapiens	159-164
29574322-4	2018	The aim of our study was to illustrate electrochemotherapy as an effective treatment for pancreatic cancer along with the expression change in stemness genes (Nanog, Sox2 and Oct3/4) in pancreatic cancer cells post electrochemotherapy with bleomycin, cisplatin and oxaliplatin.	Bleomycin	240-249	SRY-box transcription factor 2	Homo sapiens	166-170
29574322-4	2018	The aim of our study was to illustrate electrochemotherapy as an effective treatment for pancreatic cancer along with the expression change in stemness genes (Nanog, Sox2 and Oct3/4) in pancreatic cancer cells post electrochemotherapy with bleomycin, cisplatin and oxaliplatin.	Bleomycin	240-249	POU class 5 homeobox 1	Homo sapiens	175-181
29777878-4	2018	Treatment of mice with bleomycin-induced PF using the PEI-C/siPAI-1 polyplexes resulted in a significant down-regulation of the PAI-1 expression and decreased collagen deposition in the lung.	Bleomycin	23-32	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	62-67
29808357-0	2018	IL-17A suppresses and curcumin up-regulates Akt expression upon bleomycin exposure.	Bleomycin	64-73	interleukin 17A	Homo sapiens	0-6
29808357-0	2018	IL-17A suppresses and curcumin up-regulates Akt expression upon bleomycin exposure.	Bleomycin	64-73	AKT serine/threonine kinase 1	Homo sapiens	44-47
29808357-1	2018	Pro-inflammatory cytokine IL-17A modulates the expression of Akt in bleomycin (BLM) administered alveolar basal epithelial cells, the mechanism behind which remains unclear.	Bleomycin	68-77	interleukin 17A	Homo sapiens	26-32
29808357-1	2018	Pro-inflammatory cytokine IL-17A modulates the expression of Akt in bleomycin (BLM) administered alveolar basal epithelial cells, the mechanism behind which remains unclear.	Bleomycin	68-77	AKT serine/threonine kinase 1	Homo sapiens	61-64
29808357-1	2018	Pro-inflammatory cytokine IL-17A modulates the expression of Akt in bleomycin (BLM) administered alveolar basal epithelial cells, the mechanism behind which remains unclear.	Bleomycin	79-82	interleukin 17A	Homo sapiens	26-32
29808357-1	2018	Pro-inflammatory cytokine IL-17A modulates the expression of Akt in bleomycin (BLM) administered alveolar basal epithelial cells, the mechanism behind which remains unclear.	Bleomycin	79-82	AKT serine/threonine kinase 1	Homo sapiens	61-64
30060832-9	2018	In addition, the study also suggested that Treg depletion led to considerable upregulation of IFN-gamma after bleomycin administration.	Bleomycin	110-119	interferon gamma	Mus musculus	94-103
33168508-5	2018	RESULTS: Compared with the control mice, the mice with bleomycin-induced lung fibrosis exhibited significantly increased levels of MIF in the lung tissue and bronchoalveolar lavage fluid (BALF).	Bleomycin	55-64	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	131-134
30009261-9	2018	A bleomycin-induced scleroderma model was induced in mice with a B cell-specific deficiency in IL-6 or IL-10.	Bleomycin	2-11	interleukin 6	Mus musculus	95-99
29898959-4	2018	Targeted disruption of STAT3 signaling in myeloid cells significantly accelerated development of pathological skin fibrosis in a model of chronic bleomycin-induced tissue injury, whereas the impact on wound closure dynamics and quality of healing after acute excision skin injury was minor.	Bleomycin	146-155	signal transducer and activator of transcription 3	Mus musculus	23-28
29898959-5	2018	Chronic bleomycin-mediated tissue damage in control mice provoked an antifibrotic gene signature in macrophages that was characterized by upregulated expression of IL-10, SOCS3, and decorin.	Bleomycin	8-17	interleukin 10	Mus musculus	164-169
29898959-5	2018	Chronic bleomycin-mediated tissue damage in control mice provoked an antifibrotic gene signature in macrophages that was characterized by upregulated expression of IL-10, SOCS3, and decorin.	Bleomycin	8-17	suppressor of cytokine signaling 3	Mus musculus	171-176
30009261-9	2018	A bleomycin-induced scleroderma model was induced in mice with a B cell-specific deficiency in IL-6 or IL-10.	Bleomycin	2-11	interleukin 10	Mus musculus	103-108
29788478-10	2018	Thus, a minimal threshold of FANCJ catalytic activity is required to overcome replication stress induced by aphidicolin or telomestatin, or to repair bleomycin-induced DNA breakage.	Bleomycin	150-159	BRCA1 interacting helicase 1	Homo sapiens	29-34
29985428-8	2018	Furthermore, Topo IIbeta knockout cells exhibited increased sensitivity to bleomycin and decreased DSB repair mediated by homologous recombination (HR), implicating the role of Topo IIbeta in HR-mediated DSB repair.	Bleomycin	75-84	DNA topoisomerase II beta	Homo sapiens	13-24
29788478-9	2018	However, FANCJ-R707C expressed in fancj-/- cells conferred resistance to the DNA polymerase inhibitor aphidicolin, G-quadruplex ligand telomestatin, or DNA strand-breaker bleomycin, whereas FANCJ-H396D failed.	Bleomycin	171-180	BRCA1 interacting helicase 1	Homo sapiens	9-14
29475397-5	2018	Furthermore, as increased FASN expression was also observed to correlate with the degree of lung fibrosis in bleomycin-treated mice, inhibition of FASN was examined in a murine-treatment model of pulmonary fibrosis.	Bleomycin	109-118	fatty acid synthase	Mus musculus	26-30
29788478-9	2018	However, FANCJ-R707C expressed in fancj-/- cells conferred resistance to the DNA polymerase inhibitor aphidicolin, G-quadruplex ligand telomestatin, or DNA strand-breaker bleomycin, whereas FANCJ-H396D failed.	Bleomycin	171-180	BRCA1 interacting helicase 1	Homo sapiens	34-39
29997685-0	2018	Combination of Salvia miltiorrhiza and ligustrazine attenuates bleomycin-induced pulmonary fibrosis in rats via modulating TNF-alpha and TGF-beta.	Bleomycin	63-72	tumor necrosis factor	Rattus norvegicus	123-132
29565179-3	2018	The aim of this study was to evaluate the relationship between complement component 3 (C3) and MUC5B in patients with IPF and in bleomycin-induced lung injury in mice.	Bleomycin	129-138	complement C3	Homo sapiens	87-89
29565179-3	2018	The aim of this study was to evaluate the relationship between complement component 3 (C3) and MUC5B in patients with IPF and in bleomycin-induced lung injury in mice.	Bleomycin	129-138	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	95-100
29565179-7	2018	In mice, while bleomycin exposure increased Muc5b protein expression, C3-deficient mice were protected from bleomycin-induced lung injury.	Bleomycin	15-24	mucin 5, subtype B, tracheobronchial	Mus musculus	44-49
29864937-6	2018	Bleomycin-instilled mice were administered with pirfenidone (PFD) or FGF21 daily for 3 weeks from 7 days after instillation of BLM.	Bleomycin	0-9	fibroblast growth factor 21	Mus musculus	69-74
29864937-8	2018	At the same time, FGF21 also markedly reversed the activity of SOD and T-AOC, decreased the enhanced content of MDA and increased the expression of Nrf-2 in the lungs of BLM-treated mice.	Bleomycin	170-173	fibroblast growth factor 21	Mus musculus	18-23
29864937-8	2018	At the same time, FGF21 also markedly reversed the activity of SOD and T-AOC, decreased the enhanced content of MDA and increased the expression of Nrf-2 in the lungs of BLM-treated mice.	Bleomycin	170-173	nuclear factor, erythroid derived 2, like 2	Mus musculus	148-153
29988569-0	2018	The IL-33 Receptor ST2 Regulates Pulmonary Inflammation and Fibrosis to Bleomycin.	Bleomycin	72-81	interleukin 33	Mus musculus	4-9
29666896-9	2018	Furthermore, we found differentiated embryonic chondrocyte-expressed gene 1 (DEC1), an important transcription factor, was upregulated in both patients with idiopathic pulmonary fibrosis and in bleomycin-induced lung fibrosis.	Bleomycin	194-203	basic helix-loop-helix family, member e40	Mus musculus	77-81
29666896-10	2018	DEC1 was suppressed by calpeptin in bleomycin-induced mice model.	Bleomycin	36-45	basic helix-loop-helix family, member e40	Mus musculus	0-4
30116473-6	2018	In this work, we used cells deficient for PINK1, a mitochondrial kinase involved in mitochondrial quality control whose loss of function leads to the accumulation of dysfunctional mitochondria, challenged with inducers of DNA damage, namely, ionizing radiation and the radiomimetic bleomycin.	Bleomycin	282-291	PTEN induced kinase 1	Homo sapiens	42-47
29996289-13	2018	The level of TGF-beta(1) in plasma, BALF and lung tissue were also decreased in mice treated with metformin compared with bleomycin model mice [(2.32+-0.68) vs (4.59+-0.45) ng/ml, (0.81+-0.09) vs (1.40+-0.06) ng/ml, (17.12+-0.83) vs (21.25+-0.69) ng/mg, all P&lt;0.05].	Bleomycin	122-131	transforming growth factor, beta 1	Mus musculus	13-24
29947539-0	2018	Endothelial-derived endothelin-1 promotes pulmonary vascular remodeling in bleomycin-induced pulmonary fibrosis.	Bleomycin	75-84	endothelin 1	Mus musculus	20-32
29947539-8	2018	Compared to Wild type mice, bleomycin-induced VEETKO mice had lower ET-1 peptide levels (15.4 pg/mg vs. 31.2 pg/mg, p&lt;0.01).	Bleomycin	28-37	endothelin 1	Mus musculus	68-72
29947539-12	2018	In conclusion, endothelial-derived endothelin-1 promotes pulmonary vascular remodeling secondary to bleomycin-induced pulmonary fibrosis.	Bleomycin	100-109	endothelin 1	Mus musculus	35-47
29940932-7	2018	Levels of von Willebrand factor, plasminogen activator inhibitor-1 and matrix metalloproteinase-12 were elevated in lung endothelial cells isolated from bleomycin-treated mice at days 7 and 21.	Bleomycin	153-162	matrix metallopeptidase 12	Mus musculus	71-98
29940932-10	2018	When endothelial cells were treated with TGF-beta, alpha-smooth muscle actin (SMA) expression and collagen production were increased only in those cells from bleomycin-treated mouse lungs.	Bleomycin	158-167	transforming growth factor, beta 1	Mus musculus	41-49
29940932-10	2018	When endothelial cells were treated with TGF-beta, alpha-smooth muscle actin (SMA) expression and collagen production were increased only in those cells from bleomycin-treated mouse lungs.	Bleomycin	158-167	immunoglobulin mu binding protein 2	Mus musculus	51-76
29940932-10	2018	When endothelial cells were treated with TGF-beta, alpha-smooth muscle actin (SMA) expression and collagen production were increased only in those cells from bleomycin-treated mouse lungs.	Bleomycin	158-167	immunoglobulin mu binding protein 2	Mus musculus	78-81
29940932-11	2018	Thapsigargin-induced prostaglandin I2 and nitric oxide production, decreased in endothelial cells from bleomycin-treated mouse lungs, compared with controls, was further suppressed by TGF-beta.	Bleomycin	103-112	transforming growth factor, beta 1	Mus musculus	184-192
29988569-0	2018	The IL-33 Receptor ST2 Regulates Pulmonary Inflammation and Fibrosis to Bleomycin.	Bleomycin	72-81	interleukin 1 receptor-like 1	Mus musculus	19-22
29654756-0	2018	PPM1B depletion in U2OS cells supresses cell growth through RB1-E2F1 pathway and stimulates bleomycin-induced cell death.	Bleomycin	92-101	protein phosphatase, Mg2+/Mn2+ dependent 1B	Homo sapiens	0-5
29704504-0	2018	Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition.	Bleomycin	31-40	mechanistic target of rapamycin kinase	Mus musculus	14-18
29704504-2	2018	In bleomycin-induced pulmonary fibrosis mice, we observed that inhibition of mTOR (mammalia target of rapamycin) attenuated IPF.	Bleomycin	3-12	mechanistic target of rapamycin kinase	Mus musculus	77-81
29704504-3	2018	Rapamycin suppressed the down-regulation of E-cadherin and up-regulation of fibronectin in bleomycin-induced pulmonary fibrosis mice.	Bleomycin	91-100	fibronectin 1	Mus musculus	76-87
29704504-8	2018	Bleomycin induced pulmonary fibrosis and EMT in mice, while mTOR repression inhibited bleomycin-induced pulmonary fibrosis and attenuated EMT in vivo.	Bleomycin	86-95	mechanistic target of rapamycin kinase	Mus musculus	60-64
29871641-0	2018	Parthenolide attenuated bleomycin-induced pulmonary fibrosis via the NF-kappaB/Snail signaling pathway.	Bleomycin	24-33	snail family zinc finger 1	Mus musculus	79-84
29871641-9	2018	We further demonstrated that PTL attenuated BLM-induced PF primarily via inhibition of the NF-kappaB/Snail signaling pathway.	Bleomycin	44-47	snail family zinc finger 1	Mus musculus	101-106
29654756-5	2018	Notably, PPM1B depletion significantly sensitised U2OS cells to bleomycin-induced cell death at a minimal effective concentration.	Bleomycin	64-73	protein phosphatase, Mg2+/Mn2+ dependent 1B	Homo sapiens	9-14
29634284-9	2018	Finally, loss of Gas6 expression decreased lung fibrotic responses to bleomycin and treatment with R428 inhibited pulmonary fibrosis in humanized SCID/Bg mice.	Bleomycin	70-79	growth arrest specific 6	Mus musculus	17-21
29910813-6	2018	Finally, we inhibit S100a4 in vivo in the bleomycin-induced lung fibrosis model by treatment with niclosamide.	Bleomycin	42-51	S100 calcium binding protein A4	Mus musculus	20-26
29859040-9	2018	Upon subjection to treatment with bleomycin and methyl methanesulfonate (MMS), nsn1 plants exhibited hypersensitivity to the genotoxic agents.	Bleomycin	34-43	GTP-binding family protein	Arabidopsis thaliana	79-83
29554631-2	2018	Bleomycin induced gammaH2AX and p53 in a dose- and time-dependent manner and had little cytotoxic effect.	Bleomycin	0-9	cellular tumor antigen p53	Oncorhynchus mykiss	32-35
29469612-7	2018	ACKR2 was upregulated acutely in response to bleomycin and normalized over time.	Bleomycin	45-54	atypical chemokine receptor 2	Mus musculus	0-5
29469612-13	2018	Moreover, depletion of gammadeltaT cells worsened the clinical symptoms induced by bleomycin and reversed the phenotype of ACKR2-/- mice exposed to bleomycin.	Bleomycin	148-157	atypical chemokine receptor 2	Mus musculus	123-128
29469612-14	2018	ACKR2 controls the CC chemokine expression that drives the influx of CCR2+ and CCR5+ IFNgamma-producing gammadeltaT cells, tuning the Th17 response that mediated pulmonary fibrosis triggered by bleomycin instillation.	Bleomycin	194-203	atypical chemokine receptor 2	Mus musculus	0-5
29469612-14	2018	ACKR2 controls the CC chemokine expression that drives the influx of CCR2+ and CCR5+ IFNgamma-producing gammadeltaT cells, tuning the Th17 response that mediated pulmonary fibrosis triggered by bleomycin instillation.	Bleomycin	194-203	interferon gamma	Mus musculus	85-93
29447007-11	2018	Bleomycin significantly increased IL-4 serum level and decreased that of INF-gamma in the serum.	Bleomycin	0-9	interleukin 4	Rattus norvegicus	34-38
29411215-3	2018	In the present study, we found that the expression of H19 was significantly increased in transforming growth factor-beta (TGF-beta)-induced fibroblast proliferation and bleomycin-(BLM) induced lung fibrosis (p &lt; 0.05).	Bleomycin	169-178	H19 imprinted maternally expressed transcript	Homo sapiens	54-57
29813125-2	2018	Platelet-derived growth factor receptor beta (PDGFRbeta+) cells constitute a major population of contractile myofibroblasts in the lung following bleomycin-induced fibrosis.	Bleomycin	146-155	platelet derived growth factor receptor, beta polypeptide	Mus musculus	0-44
29733296-5	2018	Finally, genetic deletion of FOXM1 in fibroblasts or administration of the FOXM1 inhibitor Siomycin A in a therapeutic protocol attenuated bleomycin-induced pulmonary fibrosis.	Bleomycin	139-148	forkhead box M1	Homo sapiens	29-34
29733296-5	2018	Finally, genetic deletion of FOXM1 in fibroblasts or administration of the FOXM1 inhibitor Siomycin A in a therapeutic protocol attenuated bleomycin-induced pulmonary fibrosis.	Bleomycin	139-148	forkhead box M1	Homo sapiens	75-80
29686050-5	2018	Furthermore, we show that nuclear translocation of TFEB occurs in alveolar macrophages of myeloid-specific Lamtor1 conditional knockout mice and that these mice are hypersensitive to intratracheal administration of LPS and bleomycin.	Bleomycin	223-232	transcription factor EB	Mus musculus	51-55
29844390-11	2018	Moreover, siRNA-mediated inhibition of Fzd10 prevented TGF-beta1-induced myofibroblast differentiation of LR-MSCs in vitro and impaired bleomycin-induced pulmonary fibrosis.	Bleomycin	136-145	frizzled class receptor 10	Homo sapiens	39-44
29813125-2	2018	Platelet-derived growth factor receptor beta (PDGFRbeta+) cells constitute a major population of contractile myofibroblasts in the lung following bleomycin-induced fibrosis.	Bleomycin	146-155	platelet derived growth factor receptor, beta polypeptide	Mus musculus	46-56
29795645-11	2018	Our results demonstrate that inhibition of LDHA with the inhibitor gossypol is effective at both preventing and treating bleomycin-induced pulmonary fibrosis, and suggests that LDHA may be a potential therapeutic target for pulmonary fibrosis.	Bleomycin	121-130	lactate dehydrogenase A	Mus musculus	43-47
30002599-2	2018	We have previously shown in bleomycin-treated chimeric Thy1-deficient mice with wild-type lymphocytes that Thy1-deficient fibroblasts accumulate and promote fibrosis and an "inflammation-free" environment.	Bleomycin	28-37	thymus cell antigen 1, theta	Mus musculus	55-59
30002599-2	2018	We have previously shown in bleomycin-treated chimeric Thy1-deficient mice with wild-type lymphocytes that Thy1-deficient fibroblasts accumulate and promote fibrosis and an "inflammation-free" environment.	Bleomycin	28-37	thymus cell antigen 1, theta	Mus musculus	107-111
29345193-6	2018	Following treatment with bleomycin, pulmonary expression of the rate-limiting enzyme of 5-HT synthesis, tryptophan hydroxylase-1 (Tph1), was significantly increased.	Bleomycin	25-34	tryptophan hydroxylase 1	Mus musculus	104-128
29782549-3	2018	We show here that genetic deletion of S1pr2 strikingly attenuated lung fibrosis induced by repeated injections of bleomycin in mice.	Bleomycin	114-123	sphingosine-1-phosphate receptor 2	Mus musculus	38-43
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	interleukin 13	Mus musculus	85-90
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	interleukin 4	Mus musculus	95-99
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	arginase, liver	Mus musculus	129-139
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	resistin like alpha	Mus musculus	141-146
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	resistin like alpha	Mus musculus	147-153
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	chemokine (C-C motif) ligand 17	Mus musculus	155-160
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	chemokine (C-C motif) ligand 24	Mus musculus	165-170
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	sphingosine-1-phosphate receptor 2	Mus musculus	238-243
29782549-8	2018	BALF cells from bleomycin-administered wild-type mice showed a marked increase in phosphorylation of STAT6, a transcription factor which is activated downstream of IL-13, compared with saline-administered wild-type mice.	Bleomycin	16-25	signal transducer and activator of transcription 6	Mus musculus	101-106
29782549-8	2018	BALF cells from bleomycin-administered wild-type mice showed a marked increase in phosphorylation of STAT6, a transcription factor which is activated downstream of IL-13, compared with saline-administered wild-type mice.	Bleomycin	16-25	interleukin 13	Mus musculus	164-169
29782549-9	2018	Interestingly, in bleomycin-administered S1pr2-/- mice, STAT6 phosphorylation in BALF cells was substantially diminished compared with wild-type mice.	Bleomycin	18-27	sphingosine-1-phosphate receptor 2	Mus musculus	41-46
29782549-9	2018	Interestingly, in bleomycin-administered S1pr2-/- mice, STAT6 phosphorylation in BALF cells was substantially diminished compared with wild-type mice.	Bleomycin	18-27	signal transducer and activator of transcription 6	Mus musculus	56-61
29782549-10	2018	Finally, pharmacological S1PR2 blockade in S1pr2+/+ mice alleviated bleomycin-induced lung fibrosis.	Bleomycin	68-77	sphingosine-1-phosphate receptor 2	Mus musculus	25-30
29782549-10	2018	Finally, pharmacological S1PR2 blockade in S1pr2+/+ mice alleviated bleomycin-induced lung fibrosis.	Bleomycin	68-77	sphingosine-1-phosphate receptor 2	Mus musculus	43-48
29019702-0	2018	Inhibition of Phosphoglycerate Dehydrogenase Attenuates Bleomycin-induced Pulmonary Fibrosis.	Bleomycin	56-65	phosphoglycerate dehydrogenase	Homo sapiens	14-44
29019702-6	2018	Similarly, intratracheal administration of bleomycin resulted in increased expression of PHGDH in mouse lungs, localized to fibrotic regions.	Bleomycin	43-52	3-phosphoglycerate dehydrogenase	Mus musculus	89-94
29019702-9	2018	Mice treated with the PHGDH inhibitor beginning 7 days after intratracheal instillation of bleomycin had attenuation of lung fibrosis.	Bleomycin	91-100	3-phosphoglycerate dehydrogenase	Mus musculus	22-27
29678906-7	2018	Consistent with a pivotal role for this pathway in driving persistent fibrosis, a STAT3 inhibitor attenuated murine pulmonary fibrosis when administered in a therapeutic fashion after bleomycin injury.	Bleomycin	184-193	signal transducer and activator of transcription 3	Mus musculus	82-87
29345193-6	2018	Following treatment with bleomycin, pulmonary expression of the rate-limiting enzyme of 5-HT synthesis, tryptophan hydroxylase-1 (Tph1), was significantly increased.	Bleomycin	25-34	tryptophan hydroxylase 1	Mus musculus	130-134
29345193-9	2018	In addition, we found that treatment with ketanserin activated pulmonary MAPK and Akt signaling in mice exposed to bleomycin.	Bleomycin	115-124	thymoma viral proto-oncogene 1	Mus musculus	82-85
29735018-4	2018	Our current study revealed that a combination of bleomycin and AA significantly enhanced the expression of FAS gene, which is involved in programmed cell death (apoptosis) and caspases 3 and 8 compared to either bleomycin or AA alone implying that activation of extrinsic apoptotic pathway plays a major role in their (bleomycin + AA) tumoricidal action.	Bleomycin	49-58	caspase 3	Homo sapiens	176-192
29431122-8	2018	The effect of PARP-1 inactivation was investigated in bleomycin-induced and topoisomerase-induced fibrosis as well as in tight-skin-1 (Tsk-1) mice.	Bleomycin	54-63	poly (ADP-ribose) polymerase family, member 1	Mus musculus	14-20
29431122-14	2018	PARP-1 deficiency induced a more severe fibrotic response to bleomycin with increased dermal thickening, hydroxyproline content and myofibroblast counts.	Bleomycin	61-70	poly (ADP-ribose) polymerase family, member 1	Mus musculus	0-6
29498146-0	2018	Periostin antisense oligonucleotide suppresses bleomycin-induced formation of a lung premetastatic niche for melanoma.	Bleomycin	47-56	periostin, osteoblast specific factor	Mus musculus	0-9
29498146-5	2018	We found that periostin was widely expressed in fibrotic lesions of mice with bleomycin-induced lung fibrosis, and that up-regulation of periostin expression coincided with activation of myofibroblasts positive for alpha-smooth muscle actin.	Bleomycin	78-87	periostin, osteoblast specific factor	Mus musculus	14-23
29498146-7	2018	Inhibition of periostin expression by giving an intratracheal antisense oligonucleotide targeting periostin mRNA was found to suppress bleomycin-induced lung fibrosis and thereby to attenuate metastatic colonization of the lung by melanoma cells.	Bleomycin	135-144	periostin, osteoblast specific factor	Mus musculus	14-23
29498146-7	2018	Inhibition of periostin expression by giving an intratracheal antisense oligonucleotide targeting periostin mRNA was found to suppress bleomycin-induced lung fibrosis and thereby to attenuate metastatic colonization of the lung by melanoma cells.	Bleomycin	135-144	periostin, osteoblast specific factor	Mus musculus	98-107
29498146-8	2018	Our results indicate that periostin is a key player in the development of bleomycin-induced fibrosis and consequent enhancement of tumor cell colonization in the lung.	Bleomycin	74-83	periostin, osteoblast specific factor	Mus musculus	26-35
29283216-0	2018	A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	106-115	vascular endothelial growth factor A	Mus musculus	67-71
29740320-7	2018	DRDE-30 significantly blunted BLM-induced oxidative stress, inflammation and fibrosis in the lungs evidenced by reduced oxidative damage, endothelial barrier dysfunction, Myeloperoxidase (MPO) activity, pro-inflammatory cytokine release and protection of tissue architecture, that could be linked to enhanced anti-oxidant defense system and suppression of redox-sensitive pro-inflammatory signaling cascades.	Bleomycin	30-33	myeloperoxidase	Mus musculus	188-191
29283216-3	2018	EXPERIMENTAL DESIGN: The authors have used shotgun lipidomics in a bleomycin (BLM) mouse model of pulmonary fibrosis with vascular endothelial growth factor (VEGF)-inhibitor CBO-P11 as a therapeutic measure, to identify a comprehensive set of lipids that contribute to the pathogenesis of pulmonary fibrosis.	Bleomycin	67-76	vascular endothelial growth factor A	Mus musculus	158-162
29363258-7	2018	Furthermore, conditional deletion of ATF3 in type II lung epithelial cells protects mice from bleomycin-induced lung fibrosis.	Bleomycin	94-103	activating transcription factor 3	Mus musculus	37-41
29675024-4	2018	In this study, we first analyzed a bleomycin-induced mouse model, which showed that higher expression of IL-1beta, but not IL-18, was correlated to pulmonary cell infiltration and fibrosis.	Bleomycin	35-44	interleukin 1 beta	Mus musculus	105-113
29849496-0	2018	Serotonin Exhibits Accelerated Bleomycin-Induced Pulmonary Fibrosis through TPH1 Knockout Mouse Experiments.	Bleomycin	31-40	tryptophan hydroxylase 1	Mus musculus	76-80
29507108-0	2018	RGC32 Promotes Bleomycin-Induced Systemic Sclerosis in a Murine Disease Model by Modulating Classically Activated Macrophage Function.	Bleomycin	15-24	regulator of cell cycle	Mus musculus	0-5
29507108-3	2018	In this study, we show that response gene to complement 32 (RGC32) is abundantly expressed in mouse macrophages in the early stage of bleomycin-induced SSc.	Bleomycin	134-143	regulator of cell cycle	Mus musculus	28-58
29507108-3	2018	In this study, we show that response gene to complement 32 (RGC32) is abundantly expressed in mouse macrophages in the early stage of bleomycin-induced SSc.	Bleomycin	134-143	regulator of cell cycle	Mus musculus	60-65
29849916-2	2018	In this study, we tried to reveal the model of action between high-mobility group box 1 (HMGB1) and alpha-smooth muscle actin (alpha-SMA) and the protective role of gefitinib in pulmonary fibrosis induced by the administration of bleomycin aerosol in mice.	Bleomycin	230-239	high mobility group box 1	Mus musculus	89-94
29849916-12	2018	The present study suggested that gefitinib could alleviate lung fibrosis through the HMGB1/NOXs-ROS/EGFR-MAPKs-AP-1/NF-kappaB signal in bleomycin-induced pulmonary fibrosis.	Bleomycin	136-145	high mobility group box 1	Mus musculus	85-90
29849916-12	2018	The present study suggested that gefitinib could alleviate lung fibrosis through the HMGB1/NOXs-ROS/EGFR-MAPKs-AP-1/NF-kappaB signal in bleomycin-induced pulmonary fibrosis.	Bleomycin	136-145	epidermal growth factor receptor	Mus musculus	100-104
29849916-12	2018	The present study suggested that gefitinib could alleviate lung fibrosis through the HMGB1/NOXs-ROS/EGFR-MAPKs-AP-1/NF-kappaB signal in bleomycin-induced pulmonary fibrosis.	Bleomycin	136-145	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125
29731719-5	2018	Although previous studies suggest that administration of ACE2 prevents PH secondary to bleomycin-induced murine IPF, it is unknown whether ACE2 can reverse or treat existing disease.	Bleomycin	87-96	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	57-61
29731719-8	2018	ACE2 or vehicle was administered via osmotic pump for the final 2 weeks, beginning 3 weeks after bleomycin.	Bleomycin	97-106	angiotensin converting enzyme 2	Homo sapiens	0-4
29731719-13	2018	Conclusion: Collectively, our findings enumerate that ACE2 treatment improved pulmonary vascular muscularization following bleomycin exposure, concomitant with increased SOD2 expression.	Bleomycin	123-132	angiotensin converting enzyme 2	Homo sapiens	54-58
29707125-1	2018	Transcription factor hepatocyte nuclear factor 1-beta (HNF-1beta) enhances checkpoint kinase 1 (Chk1) activation and promotes G2/M cell cycle progression in ovarian clear cell carcinoma (CCC) following exposure to diverse genotoxic agents including bleomycin.	Bleomycin	249-258	HNF1 homeobox B	Felis catus	55-64
29707125-5	2018	Loss-of-function studies using RNAi-mediated gene silencing indicated that HNF-1beta facilitated the Claspin expression after treatment with a genotoxic agent bleomycin, resulting in accumulation of phosphorylated Chk1 (p-Chk1) and promotion of survival in CCC cell lines.	Bleomycin	159-168	HNF1 homeobox B	Felis catus	75-84
29707125-5	2018	Loss-of-function studies using RNAi-mediated gene silencing indicated that HNF-1beta facilitated the Claspin expression after treatment with a genotoxic agent bleomycin, resulting in accumulation of phosphorylated Chk1 (p-Chk1) and promotion of survival in CCC cell lines.	Bleomycin	159-168	claspin	Felis catus	101-108
29707125-5	2018	Loss-of-function studies using RNAi-mediated gene silencing indicated that HNF-1beta facilitated the Claspin expression after treatment with a genotoxic agent bleomycin, resulting in accumulation of phosphorylated Chk1 (p-Chk1) and promotion of survival in CCC cell lines.	Bleomycin	159-168	checkpoint kinase 1	Felis catus	214-218
29599817-0	2018	Wenyang Huazhuo Tongluo formula inhibits fibrosis via suppressing Wnt/beta-catenin signaling pathway in a Bleomycin-induced systemic sclerosis mouse model.	Bleomycin	106-115	wingless-type MMTV integration site family, member 1	Mus musculus	66-69
29115860-4	2018	Lysyl oxidase-like (LOXL) 1 belongs to the cross-linking enzyme family and has been shown to be up-regulated in active fibrotic regions of bleomycin-treated mice and patients with IPF.	Bleomycin	139-148	lysyl oxidase-like 1	Mus musculus	0-27
29393339-8	2018	Furthermore, the NALP3 inflammasome was found to be activated in bleomycin-induced pulmonary fibrosis in mice, and this activation was relieved by a nuclear factor (NF)-kappaB inhibitor.	Bleomycin	65-74	NLR family, pyrin domain containing 3	Mus musculus	17-22
29393339-8	2018	Furthermore, the NALP3 inflammasome was found to be activated in bleomycin-induced pulmonary fibrosis in mice, and this activation was relieved by a nuclear factor (NF)-kappaB inhibitor.	Bleomycin	65-74	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	149-175
29393339-10	2018	Additionally, the NALP3 inflammasome contributes to the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	71-80	NLR family, pyrin domain containing 3	Mus musculus	18-23
29211497-8	2018	In the present study, we used a genetic approach to determine the roles of ROCK1 and ROCK2 in a mouse model of bleomycin-induced pulmonary fibrosis.	Bleomycin	111-120	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	75-80
29211497-8	2018	In the present study, we used a genetic approach to determine the roles of ROCK1 and ROCK2 in a mouse model of bleomycin-induced pulmonary fibrosis.	Bleomycin	111-120	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	85-90
29211497-9	2018	Using ROCK1- or ROCK2-haploinsufficient mice, we found that reduced expression of either ROCK1 or ROCK2 was sufficient to protect them from bleomycin-induced pulmonary fibrosis.	Bleomycin	140-149	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	6-11
29211497-9	2018	Using ROCK1- or ROCK2-haploinsufficient mice, we found that reduced expression of either ROCK1 or ROCK2 was sufficient to protect them from bleomycin-induced pulmonary fibrosis.	Bleomycin	140-149	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	89-94
29211497-9	2018	Using ROCK1- or ROCK2-haploinsufficient mice, we found that reduced expression of either ROCK1 or ROCK2 was sufficient to protect them from bleomycin-induced pulmonary fibrosis.	Bleomycin	140-149	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	16-21
29211497-11	2018	Interestingly, ROCK1- and ROCK2-haploinsufficient mice exhibited similar protection from bleomycin-induced vascular leak, myofibroblast differentiation, and fibrosis; however, ROCK1-haploinsufficient mice demonstrated greater attenuation of epithelial cell apoptosis.	Bleomycin	89-98	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	15-20
29599817-12	2018	Conclusion: This present study demonstrates that WYHZTL formula has anti-fibrosis effect in Bleomycin-induced SSc mouse model in a dosage-dependent manner, and the molecular mechanism may be related to the inhibition of Wnt/beta-catenin signaling pathway.	Bleomycin	92-101	wingless-type MMTV integration site family, member 1	Mus musculus	220-223
29599817-12	2018	Conclusion: This present study demonstrates that WYHZTL formula has anti-fibrosis effect in Bleomycin-induced SSc mouse model in a dosage-dependent manner, and the molecular mechanism may be related to the inhibition of Wnt/beta-catenin signaling pathway.	Bleomycin	92-101	catenin (cadherin associated protein), beta 1	Mus musculus	224-236
29636695-0	2018	The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury.	Bleomycin	166-175	angiotensin II receptor, type 2	Rattus norvegicus	14-44
29636695-14	2018	Collectively, our findings indicate that stimulation of the AT2 receptor by C21 attenuates bleomycin-induced lung injury and associated cardiopulmonary pathology, which needs to be further explored as a promising approach for the clinical treatment of IPF and Group III PH.	Bleomycin	91-100	angiotensin II receptor, type 2	Rattus norvegicus	60-63
29599817-0	2018	Wenyang Huazhuo Tongluo formula inhibits fibrosis via suppressing Wnt/beta-catenin signaling pathway in a Bleomycin-induced systemic sclerosis mouse model.	Bleomycin	106-115	catenin (cadherin associated protein), beta 1	Mus musculus	70-82
29408570-0	2018	Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-gamma and subsequent expression of HGF in colons.	Bleomycin	42-51	peroxisome proliferator activated receptor gamma	Mus musculus	119-129
29623041-2	2018	Inadequate therapy motivated us to explore the effect of vimentin inhibitor Withaferin A, as an anti-fibrotic agent against TGF-beta1-induced in vitro fibrotic events and Bleomycin induced in vivo fibrosis with an emphasis on epithelial to mesenchymal transition (EMT), extracellular matrix deposition (ECM), inflammation, and angiogenesis.	Bleomycin	171-180	vimentin	Homo sapiens	57-65
29623041-9	2018	Phosphorylation of Smad 2/3 induced by TGF-beta1 and Bleomycin were significantly inhibited.	Bleomycin	53-62	SMAD family member 2	Homo sapiens	19-27
29361132-7	2018	Finally, we show an effective PARP3- or PARP2-catalyzed ADP-ribosylation of high-molecular-weight (~3-kb) DNA molecules, PARP-mediated DNA PARylation in cell-free extracts and a persisting signal of anti-PAR antibodies in a serially purified genomic DNA from bleomycin-treated poly(ADP-ribose) glycohydrolase-depleted HeLa cells.	Bleomycin	259-268	poly(ADP-ribose) polymerase family member 3	Homo sapiens	30-35
29361132-7	2018	Finally, we show an effective PARP3- or PARP2-catalyzed ADP-ribosylation of high-molecular-weight (~3-kb) DNA molecules, PARP-mediated DNA PARylation in cell-free extracts and a persisting signal of anti-PAR antibodies in a serially purified genomic DNA from bleomycin-treated poly(ADP-ribose) glycohydrolase-depleted HeLa cells.	Bleomycin	259-268	poly(ADP-ribose) polymerase 2	Homo sapiens	40-45
29361132-7	2018	Finally, we show an effective PARP3- or PARP2-catalyzed ADP-ribosylation of high-molecular-weight (~3-kb) DNA molecules, PARP-mediated DNA PARylation in cell-free extracts and a persisting signal of anti-PAR antibodies in a serially purified genomic DNA from bleomycin-treated poly(ADP-ribose) glycohydrolase-depleted HeLa cells.	Bleomycin	259-268	poly(ADP-ribose) polymerase 1	Homo sapiens	30-34
29427412-6	2018	In this article, we demonstrate that Gal-3 accumulates in exaggerated quantities in bronchoalveolar lavage fluids, and traffics abnormally and accumulates intracellularly in lung fibroblasts and macrophages from bleomycin-treated pale ear, HPS-1-deficient mice.	Bleomycin	212-221	lectin, galactose binding, soluble 3	Mus musculus	37-42
29544542-8	2018	Additionally, HPH-15 suppressed the phosphorylation of Smad3 in various cells, including macrophages in the bleomycin-injected skin.	Bleomycin	108-117	SMAD family member 3	Homo sapiens	55-60
29408570-0	2018	Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-gamma and subsequent expression of HGF in colons.	Bleomycin	42-51	hepatocyte growth factor	Mus musculus	159-162
29518161-8	2018	In the bleomycin-induced pulmonary fibrosis model, TLR2 expression was detected in 29.5% (18/61) and 26.9% (21/78) of pulmonary nodose/jugular neurons and DRG neurons, respectively.	Bleomycin	7-16	toll like receptor 2	Homo sapiens	51-55
29538340-12	2018	Bleomycin decreased VEGFR2 and GTPCH-1 only in WT mice.	Bleomycin	0-9	kinase insert domain protein receptor	Mus musculus	20-26
29529050-0	2018	Transmembrane protease, serine 4 (TMPRSS4) is upregulated in IPF lungs and increases the fibrotic response in bleomycin-induced lung injury.	Bleomycin	110-119	transmembrane protease, serine 4	Mus musculus	0-32
29529050-0	2018	Transmembrane protease, serine 4 (TMPRSS4) is upregulated in IPF lungs and increases the fibrotic response in bleomycin-induced lung injury.	Bleomycin	110-119	transmembrane protease, serine 4	Mus musculus	34-41
29529050-10	2018	The lung fibrotic response evaluated at 28 days after bleomycin injury was markedly attenuated in the haplodeficient and deficient TMPRSS4 mice.	Bleomycin	54-63	transmembrane protease, serine 4	Mus musculus	131-138
29515024-3	2018	The aim of this study was to determine the role of periplakin during lung injury and remodeling in a mouse model of lung fibrosis induced by bleomycin.	Bleomycin	141-150	periplakin	Mus musculus	51-61
29515024-4	2018	We found that periplakin expression was downregulated in the whole lung and in alveolar epithelial cells following bleomycin-induced injury.	Bleomycin	115-124	periplakin	Mus musculus	14-24
29515024-5	2018	Deletion of the Ppl gene in mice improved survival and reduced lung fibrosis development after bleomycin-induced injury.	Bleomycin	95-104	periplakin	Mus musculus	16-19
29518161-9	2018	TLR5 was also detected in 55.7% (34/61) and 42.3% (33/78) of pulmonary nodose/jugular neurons and DRG neurons, respectively, in the bleomycin-induced pulmonary fibrosis model.	Bleomycin	132-141	toll like receptor 5	Homo sapiens	0-4
29518161-11	2018	In conclusion, TLR2 and TLR5 expression is enhanced, especially in vagal neurons, in the bleomycin-induced fibrosis model group when compared to the saline treated control group.	Bleomycin	89-98	toll like receptor 2	Homo sapiens	15-19
29518161-11	2018	In conclusion, TLR2 and TLR5 expression is enhanced, especially in vagal neurons, in the bleomycin-induced fibrosis model group when compared to the saline treated control group.	Bleomycin	89-98	toll like receptor 5	Homo sapiens	24-28
29488175-8	2018	Eng+/- mice subjected to bleomycin challenge show a marked decrease in dermal thickness (P &lt; 0.005) and reduced collagen content and decreased collagen I, fibronectin, alpha-smooth muscle actin levels as compared to Eng+/+ mice, both under basal and bleomycin treated conditions.	Bleomycin	25-34	endoglin	Mus musculus	0-3
29212801-6	2018	Expression of HMGB1 and thrombin was elevated before that of TGF-beta1 and alpha-SMA and remained high during the fibrotic phase after bleomycin instillation.	Bleomycin	135-144	high mobility group box 1	Mus musculus	14-19
29212801-6	2018	Expression of HMGB1 and thrombin was elevated before that of TGF-beta1 and alpha-SMA and remained high during the fibrotic phase after bleomycin instillation.	Bleomycin	135-144	coagulation factor II	Mus musculus	24-32
29779106-0	2018	Modular Nanotransporter with P21 Fragment Inhibits DNA Repair after Bleomycin Treatment.	Bleomycin	68-77	H3 histone pseudogene 16	Homo sapiens	29-32
29779106-2	2018	This p21 fragment in MNT can significantly inhibit DNA repair in A431 human carcinoma cells after bleomycin treatment.	Bleomycin	98-107	H3 histone pseudogene 16	Homo sapiens	5-8
29122847-5	2018	Next, adenoviral overexpression of HAT before bleomycin challenge attenuated lung injury as well as extracellular matrix deposition in the bleomycin-induced pulmonary fibrosis model.	Bleomycin	46-55	transmembrane serine protease 11D	Homo sapiens	35-38
29122847-5	2018	Next, adenoviral overexpression of HAT before bleomycin challenge attenuated lung injury as well as extracellular matrix deposition in the bleomycin-induced pulmonary fibrosis model.	Bleomycin	139-148	transmembrane serine protease 11D	Homo sapiens	35-38
29488175-8	2018	Eng+/- mice subjected to bleomycin challenge show a marked decrease in dermal thickness (P &lt; 0.005) and reduced collagen content and decreased collagen I, fibronectin, alpha-smooth muscle actin levels as compared to Eng+/+ mice, both under basal and bleomycin treated conditions.	Bleomycin	25-34	fibronectin 1	Mus musculus	158-169
29488175-8	2018	Eng+/- mice subjected to bleomycin challenge show a marked decrease in dermal thickness (P &lt; 0.005) and reduced collagen content and decreased collagen I, fibronectin, alpha-smooth muscle actin levels as compared to Eng+/+ mice, both under basal and bleomycin treated conditions.	Bleomycin	25-34	endoglin	Mus musculus	219-222
29488175-8	2018	Eng+/- mice subjected to bleomycin challenge show a marked decrease in dermal thickness (P &lt; 0.005) and reduced collagen content and decreased collagen I, fibronectin, alpha-smooth muscle actin levels as compared to Eng+/+ mice, both under basal and bleomycin treated conditions.	Bleomycin	253-262	endoglin	Mus musculus	0-3
29488175-10	2018	Our findings suggest that endoglin haploinsufficiency in mice ameliorates bleomycin-induced skin fibrosis suggesting that endoglin represents a pro-fibrotic factor in the mouse skin.	Bleomycin	74-83	endoglin	Mus musculus	26-34
29415756-7	2018	RESULTS: Th2- and Th17-like cell proportions in skin-homing Tregs were increased in bleomycin-treated Fli1 +/- mice compared with bleomycin-treated wild-type mice, whereas Th1-, Th2-, and Th17-like cell proportions in splenic Tregs were comparable.	Bleomycin	84-93	Friend leukemia integration 1	Mus musculus	102-106
28731277-0	2018	TNF-alpha-induced NF-kappaB activation promotes myofibroblast differentiation of LR-MSCs and exacerbates bleomycin-induced pulmonary fibrosis.	Bleomycin	105-114	tumor necrosis factor	Homo sapiens	0-9
28731277-0	2018	TNF-alpha-induced NF-kappaB activation promotes myofibroblast differentiation of LR-MSCs and exacerbates bleomycin-induced pulmonary fibrosis.	Bleomycin	105-114	nuclear factor kappa B subunit 1	Homo sapiens	18-27
28731277-4	2018	In this study, we found that the pro-inflammatory cytokine TNF-alpha and the transcription factor nuclear factor kappa B (NF-kappaB) p65 subunit were both upregulated in bleomycin-induced fibrotic lung tissue.	Bleomycin	170-179	tumor necrosis factor	Homo sapiens	59-68
28731277-4	2018	In this study, we found that the pro-inflammatory cytokine TNF-alpha and the transcription factor nuclear factor kappa B (NF-kappaB) p65 subunit were both upregulated in bleomycin-induced fibrotic lung tissue.	Bleomycin	170-179	nuclear factor kappa B subunit 1	Homo sapiens	98-120
28731277-4	2018	In this study, we found that the pro-inflammatory cytokine TNF-alpha and the transcription factor nuclear factor kappa B (NF-kappaB) p65 subunit were both upregulated in bleomycin-induced fibrotic lung tissue.	Bleomycin	170-179	nuclear factor kappa B subunit 1	Homo sapiens	122-131
28731277-4	2018	In this study, we found that the pro-inflammatory cytokine TNF-alpha and the transcription factor nuclear factor kappa B (NF-kappaB) p65 subunit were both upregulated in bleomycin-induced fibrotic lung tissue.	Bleomycin	170-179	RELA proto-oncogene, NF-kB subunit	Homo sapiens	133-136
28731277-7	2018	Moreover, we demonstrated that suppression of the NF-kappaB signaling could attenuate myofibroblast differentiation of LR-MSCs and bleomycin-induced pulmonary fibrosis which were accompanied with decreased expression of beta-catenin.	Bleomycin	131-140	nuclear factor kappa B subunit 1	Homo sapiens	50-59
28731277-7	2018	Moreover, we demonstrated that suppression of the NF-kappaB signaling could attenuate myofibroblast differentiation of LR-MSCs and bleomycin-induced pulmonary fibrosis which were accompanied with decreased expression of beta-catenin.	Bleomycin	131-140	catenin beta 1	Homo sapiens	220-232
30873483-7	2018	Results: C/EBPdelta deficient mice developed pulmonary fibrosis to a similar degree as wildtype mice as evident from similar Ashcroft scores, hydroxyproline levels and expression levels of collagen, fibronectin and alpha-smooth muscle actin at both 14 and 21 days after bleomycin instillation.	Bleomycin	270-279	CCAAT/enhancer binding protein (C/EBP), delta	Mus musculus	9-19
29466367-6	2018	Assessment of histone H2AX phosphorylation revealed that recognition and repair of DNA double-strand breaks (DSBs) induced by bleomycin or gamma-ray irradiation were attenuated; moreover, Cleaved Caspase-3 levels were decreased with pre-conditioning under hypoxia: opposing phenomena were ascertained by knockdown of DEC2.	Bleomycin	126-135	basic helix-loop-helix family member e41	Homo sapiens	317-321
29415756-7	2018	RESULTS: Th2- and Th17-like cell proportions in skin-homing Tregs were increased in bleomycin-treated Fli1 +/- mice compared with bleomycin-treated wild-type mice, whereas Th1-, Th2-, and Th17-like cell proportions in splenic Tregs were comparable.	Bleomycin	84-93	negative elongation factor complex member C/D, Th1l	Mus musculus	18-21
29415756-11	2018	CONCLUSIONS: Fli1 haploinsufficiency increases the proportions of Th2- and Th17-like Tregs in bleomycin-induced profibrotic skin conditions, in which IL-33-producing dermal fibroblasts contribute to Th2-like Treg transdifferentiation, suggesting a critical role of Fli1 deficiency in the interaction of dermal fibroblasts with immune cells in pathological skin fibrosis.	Bleomycin	94-103	Friend leukemia integration 1	Mus musculus	13-17
29415756-11	2018	CONCLUSIONS: Fli1 haploinsufficiency increases the proportions of Th2- and Th17-like Tregs in bleomycin-induced profibrotic skin conditions, in which IL-33-producing dermal fibroblasts contribute to Th2-like Treg transdifferentiation, suggesting a critical role of Fli1 deficiency in the interaction of dermal fibroblasts with immune cells in pathological skin fibrosis.	Bleomycin	94-103	interleukin 33	Mus musculus	150-155
29409529-10	2018	In rats administered JSI-124, a dual inhibitor of p-JAK2/p-STAT3, at a dose of 1 mg/kg/day, bleomycin-induced lung fibrosis was reduced and collagen deposition in the lung was inhibited, as were JAK2 and STAT3 activation and several markers of fibrosis, autophagy, senescence, and anti-apoptosis.	Bleomycin	92-101	Janus kinase 2	Rattus norvegicus	52-56
29409529-10	2018	In rats administered JSI-124, a dual inhibitor of p-JAK2/p-STAT3, at a dose of 1 mg/kg/day, bleomycin-induced lung fibrosis was reduced and collagen deposition in the lung was inhibited, as were JAK2 and STAT3 activation and several markers of fibrosis, autophagy, senescence, and anti-apoptosis.	Bleomycin	92-101	signal transducer and activator of transcription 3	Rattus norvegicus	59-64
29415439-0	2018	Inhibiting Skp2 E3 Ligase Suppresses Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	37-46	S-phase kinase-associated protein 2	Mus musculus	11-15
29409529-10	2018	In rats administered JSI-124, a dual inhibitor of p-JAK2/p-STAT3, at a dose of 1 mg/kg/day, bleomycin-induced lung fibrosis was reduced and collagen deposition in the lung was inhibited, as were JAK2 and STAT3 activation and several markers of fibrosis, autophagy, senescence, and anti-apoptosis.	Bleomycin	92-101	Janus kinase 2	Rattus norvegicus	195-199
29415439-4	2018	We examined whether disrupting Skp2 suppressed pulmonary fibrosis in a bleomycin (BLM)-induced mouse model and found that pulmonary fibrosis was significantly suppressed in Skp2-deficient mice compared with controls.	Bleomycin	71-80	S-phase kinase-associated protein 2	Mus musculus	31-35
29409529-10	2018	In rats administered JSI-124, a dual inhibitor of p-JAK2/p-STAT3, at a dose of 1 mg/kg/day, bleomycin-induced lung fibrosis was reduced and collagen deposition in the lung was inhibited, as were JAK2 and STAT3 activation and several markers of fibrosis, autophagy, senescence, and anti-apoptosis.	Bleomycin	92-101	signal transducer and activator of transcription 3	Rattus norvegicus	204-209
29415439-4	2018	We examined whether disrupting Skp2 suppressed pulmonary fibrosis in a bleomycin (BLM)-induced mouse model and found that pulmonary fibrosis was significantly suppressed in Skp2-deficient mice compared with controls.	Bleomycin	71-80	S-phase kinase-associated protein 2	Mus musculus	173-177
28986417-4	2018	RUNX2 expression was up-regulated in lung homogenates from patients with IPF and in experimental bleomycin-induced lung fibrosis.	Bleomycin	97-106	RUNX family transcription factor 2	Homo sapiens	0-5
29415439-4	2018	We examined whether disrupting Skp2 suppressed pulmonary fibrosis in a bleomycin (BLM)-induced mouse model and found that pulmonary fibrosis was significantly suppressed in Skp2-deficient mice compared with controls.	Bleomycin	82-85	S-phase kinase-associated protein 2	Mus musculus	31-35
29415439-4	2018	We examined whether disrupting Skp2 suppressed pulmonary fibrosis in a bleomycin (BLM)-induced mouse model and found that pulmonary fibrosis was significantly suppressed in Skp2-deficient mice compared with controls.	Bleomycin	82-85	S-phase kinase-associated protein 2	Mus musculus	173-177
28915065-0	2018	Targeting Hypoxia-Inducible Factor-1alpha/Pyruvate Dehydrogenase Kinase 1 Axis by Dichloroacetate Suppresses Bleomycin-induced Pulmonary Fibrosis.	Bleomycin	109-118	hypoxia inducible factor 1, alpha subunit	Mus musculus	10-41
28915065-0	2018	Targeting Hypoxia-Inducible Factor-1alpha/Pyruvate Dehydrogenase Kinase 1 Axis by Dichloroacetate Suppresses Bleomycin-induced Pulmonary Fibrosis.	Bleomycin	109-118	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	42-73
28915065-4	2018	Bleomycin-induced pulmonary fibrotic progression was evaluated in two independent, fibroblast-specific, promoter-driven, hypoxia-inducible factor (Hif) 1A knockout mouse models and in glycolytic inhibitor, dichloroacetate-treated mice.	Bleomycin	0-9	hypoxia inducible factor 1, alpha subunit	Mus musculus	121-154
28915065-7	2018	Inhibition of the HIF-1alpha/PDK1 axis by genomic deletion of Hif1A or pharmacological inhibition of PDK1 significantly attenuated bleomycin-induced pulmonary fibrosis.	Bleomycin	131-140	hypoxia inducible factor 1, alpha subunit	Mus musculus	18-28
28915065-7	2018	Inhibition of the HIF-1alpha/PDK1 axis by genomic deletion of Hif1A or pharmacological inhibition of PDK1 significantly attenuated bleomycin-induced pulmonary fibrosis.	Bleomycin	131-140	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	29-33
28915065-7	2018	Inhibition of the HIF-1alpha/PDK1 axis by genomic deletion of Hif1A or pharmacological inhibition of PDK1 significantly attenuated bleomycin-induced pulmonary fibrosis.	Bleomycin	131-140	hypoxia inducible factor 1, alpha subunit	Mus musculus	62-67
28915065-7	2018	Inhibition of the HIF-1alpha/PDK1 axis by genomic deletion of Hif1A or pharmacological inhibition of PDK1 significantly attenuated bleomycin-induced pulmonary fibrosis.	Bleomycin	131-140	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	101-105
29217661-2	2018	Investigating ex vivo-cultured (myo)fibroblasts from human IPF lungs as well as fibroblasts isolated from bleomycin-challenged mice, Forkhead box O3 (FoxO3) transcription factor was found to be less expressed, hyperphosphorylated, and nuclear-excluded relative to non-diseased controls.	Bleomycin	106-115	forkhead box O3	Mus musculus	133-148
29217661-2	2018	Investigating ex vivo-cultured (myo)fibroblasts from human IPF lungs as well as fibroblasts isolated from bleomycin-challenged mice, Forkhead box O3 (FoxO3) transcription factor was found to be less expressed, hyperphosphorylated, and nuclear-excluded relative to non-diseased controls.	Bleomycin	106-115	forkhead box O3	Mus musculus	150-155
29217661-5	2018	Importantly, mice with global- (Foxo3-/-) or fibroblast-specific (Foxo3f.b-/-) FoxO3 knockout displayed enhanced susceptibility to bleomycin challenge, with augmented fibrosis, loss of lung function, and increased mortality.	Bleomycin	131-140	forkhead box O3	Mus musculus	32-37
29217661-5	2018	Importantly, mice with global- (Foxo3-/-) or fibroblast-specific (Foxo3f.b-/-) FoxO3 knockout displayed enhanced susceptibility to bleomycin challenge, with augmented fibrosis, loss of lung function, and increased mortality.	Bleomycin	131-140	forkhead box O3	Mus musculus	79-84
29217661-6	2018	Activation of FoxO3 with UCN-01, a staurosporine derivative currently investigated in clinical cancer trials, reverted the IPF myofibroblast phenotype in vitro and blocked the bleomycin-induced lung fibrosis in vivo These studies implicate FoxO3 as a critical integrator of pro-fibrotic signaling in lung fibrosis and pharmacological reconstitution of FoxO3 as a novel treatment strategy.	Bleomycin	176-185	forkhead box O3	Homo sapiens	14-19
29185215-0	2018	Nickle(II) ions exacerbate bleomycin-induced pulmonary inflammation and fibrosis by activating the ROS/Akt signaling pathway.	Bleomycin	27-36	thymoma viral proto-oncogene 1	Mus musculus	103-106
29297621-11	2018	Intranasal instillation of 10 mug hAEC Exo 1 day following bleomycin challenge reduced lung inflammation, while treatment at day 7 improved tissue-to-airspace ratio and reduced fibrosis.	Bleomycin	59-68	5'-3' exoribonuclease 1	Mus musculus	39-42
29456817-0	2018	S100A9 aggravates bleomycin-induced dermal fibrosis in mice via activation of ERK1/2 MAPK and NF-kappaB pathways.	Bleomycin	18-27	S100 calcium binding protein A9 (calgranulin B)	Mus musculus	0-6
29456817-0	2018	S100A9 aggravates bleomycin-induced dermal fibrosis in mice via activation of ERK1/2 MAPK and NF-kappaB pathways.	Bleomycin	18-27	mitogen-activated protein kinase 3	Mus musculus	78-84
29456817-0	2018	S100A9 aggravates bleomycin-induced dermal fibrosis in mice via activation of ERK1/2 MAPK and NF-kappaB pathways.	Bleomycin	18-27	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	94-103
28902433-0	2018	Curcumin alleviates IL-17A-mediated p53-PAI-1 expression in bleomycin-induced alveolar basal epithelial cells.	Bleomycin	60-69	interleukin 17A	Homo sapiens	20-26
28902433-0	2018	Curcumin alleviates IL-17A-mediated p53-PAI-1 expression in bleomycin-induced alveolar basal epithelial cells.	Bleomycin	60-69	tumor protein p53	Homo sapiens	36-39
28902433-0	2018	Curcumin alleviates IL-17A-mediated p53-PAI-1 expression in bleomycin-induced alveolar basal epithelial cells.	Bleomycin	60-69	serpin family E member 1	Homo sapiens	40-45
29386571-4	2018	Previously we have shown attenuated fibrosis in systemic bleomycin-treated mice following treatment with two 5-HT2B receptor antagonists (EXT5 and EXT9).	Bleomycin	57-66	5-hydroxytryptamine (serotonin) receptor 2B	Mus musculus	109-115
29386571-6	2018	Gene expressions in lung tissues from systemic bleomycin-treated mice were examined, revealing significant increased expression of Cdkn1alpha (a gene coding for p21), particularly in distal regions of the lung.	Bleomycin	47-56	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	131-141
29386571-6	2018	Gene expressions in lung tissues from systemic bleomycin-treated mice were examined, revealing significant increased expression of Cdkn1alpha (a gene coding for p21), particularly in distal regions of the lung.	Bleomycin	47-56	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	161-164
29348392-4	2018	The senescence-associated beta-galactosidase activity, the protein expression of P16 and P21, and inflammatory-related marker gene levels IL-1beta, IL-6, and TNF-alpha were increased in bleomycin-treated AFSCs in a dose-dependent manner.	Bleomycin	186-195	galactosidase beta 1	Homo sapiens	26-44
29670467-2	2018	In the present study, the expression of tumor necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) was key to the resolution of bleomycin-induced pulmonary fibrosis.	Bleomycin	141-150	tumor necrosis factor	Homo sapiens	40-103
29670467-2	2018	In the present study, the expression of tumor necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) was key to the resolution of bleomycin-induced pulmonary fibrosis.	Bleomycin	141-150	TNF superfamily member 10	Homo sapiens	105-110
29362432-5	2018	Here, we observed the effects of Nrf2 pathway and Numb on bleomycin(BLM)-induced PF in Nrf2-knockout (Nrf2-/-) and wild-type (WT) mice.	Bleomycin	58-67	nuclear factor, erythroid derived 2, like 2	Mus musculus	87-91
29362432-5	2018	Here, we observed the effects of Nrf2 pathway and Numb on bleomycin(BLM)-induced PF in Nrf2-knockout (Nrf2-/-) and wild-type (WT) mice.	Bleomycin	58-67	nuclear factor, erythroid derived 2, like 2	Mus musculus	87-91
29362432-5	2018	Here, we observed the effects of Nrf2 pathway and Numb on bleomycin(BLM)-induced PF in Nrf2-knockout (Nrf2-/-) and wild-type (WT) mice.	Bleomycin	68-71	nuclear factor, erythroid derived 2, like 2	Mus musculus	87-91
29362432-5	2018	Here, we observed the effects of Nrf2 pathway and Numb on bleomycin(BLM)-induced PF in Nrf2-knockout (Nrf2-/-) and wild-type (WT) mice.	Bleomycin	68-71	nuclear factor, erythroid derived 2, like 2	Mus musculus	87-91
29362432-7	2018	We found BLM-induced lung fibrosis were more severe in Nrf2-/- mice compared to WT mice with reduced expressions of HO-1 and NQO1.	Bleomycin	9-12	nuclear factor, erythroid derived 2, like 2	Mus musculus	55-59
29362432-7	2018	We found BLM-induced lung fibrosis were more severe in Nrf2-/- mice compared to WT mice with reduced expressions of HO-1 and NQO1.	Bleomycin	9-12	heme oxygenase 1	Mus musculus	116-120
29362432-7	2018	We found BLM-induced lung fibrosis were more severe in Nrf2-/- mice compared to WT mice with reduced expressions of HO-1 and NQO1.	Bleomycin	9-12	NAD(P)H dehydrogenase, quinone 1	Mus musculus	125-129
29348392-4	2018	The senescence-associated beta-galactosidase activity, the protein expression of P16 and P21, and inflammatory-related marker gene levels IL-1beta, IL-6, and TNF-alpha were increased in bleomycin-treated AFSCs in a dose-dependent manner.	Bleomycin	186-195	cyclin dependent kinase inhibitor 2A	Homo sapiens	81-84
29348392-4	2018	The senescence-associated beta-galactosidase activity, the protein expression of P16 and P21, and inflammatory-related marker gene levels IL-1beta, IL-6, and TNF-alpha were increased in bleomycin-treated AFSCs in a dose-dependent manner.	Bleomycin	186-195	H3 histone pseudogene 16	Homo sapiens	89-92
29348392-4	2018	The senescence-associated beta-galactosidase activity, the protein expression of P16 and P21, and inflammatory-related marker gene levels IL-1beta, IL-6, and TNF-alpha were increased in bleomycin-treated AFSCs in a dose-dependent manner.	Bleomycin	186-195	interleukin 1 beta	Homo sapiens	138-146
29348392-4	2018	The senescence-associated beta-galactosidase activity, the protein expression of P16 and P21, and inflammatory-related marker gene levels IL-1beta, IL-6, and TNF-alpha were increased in bleomycin-treated AFSCs in a dose-dependent manner.	Bleomycin	186-195	interleukin 6	Homo sapiens	148-152
29348392-4	2018	The senescence-associated beta-galactosidase activity, the protein expression of P16 and P21, and inflammatory-related marker gene levels IL-1beta, IL-6, and TNF-alpha were increased in bleomycin-treated AFSCs in a dose-dependent manner.	Bleomycin	186-195	tumor necrosis factor	Homo sapiens	158-167
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Bleomycin	132-141	matrix metallopeptidase 3	Homo sapiens	53-58
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Bleomycin	132-141	matrix metallopeptidase 13	Homo sapiens	60-66
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Bleomycin	132-141	interleukin 1 beta	Homo sapiens	68-76
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Bleomycin	132-141	interleukin 6	Homo sapiens	78-82
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Bleomycin	132-141	tumor necrosis factor	Homo sapiens	84-93
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Bleomycin	132-141	cyclin dependent kinase inhibitor 2A	Homo sapiens	117-120
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Bleomycin	132-141	H3 histone pseudogene 16	Homo sapiens	125-128
29161447-8	2018	In addition, depletion of Pol beta results in cellular sensitivity to bleomycin and DNA protein kinase catalytic subunit inhibitors due to defective repair of DSBs.	Bleomycin	70-79	DNA polymerase beta	Homo sapiens	26-34
29070530-10	2018	Pharmacological inhibition of JMJD3 ameliorated bleomycin-induced and topoI-induced fibrosis in well-tolerated doses.	Bleomycin	48-57	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	30-35
29225172-0	2018	Role of allograft inflammatory factor-1 in bleomycin-induced lung fibrosis.	Bleomycin	43-52	allograft inflammatory factor 1	Mus musculus	8-39
29225172-3	2018	Here, we used an animal model of bleomycin-induced lung fibrosis to analyze the expression of AIF-1 and examine its function in lung fibrosis.	Bleomycin	33-42	allograft inflammatory factor 1	Mus musculus	94-99
29225172-4	2018	The results showed that AIF-1 was expressed on lung tissues, specifically macrophages, from mice with bleomycin-induced lung fibrosis.	Bleomycin	102-111	allograft inflammatory factor 1	Mus musculus	24-29
29301327-5	2018	Moreover, non-replicative, TLS-capable DNA polymerases can negatively impact cancer treatment by synthesizing DNA past lesions generated from treatments such as cisplatin, oxaliplatin, etoposide, bleomycin, and radiotherapy.	Bleomycin	196-205	FUS RNA binding protein	Homo sapiens	27-30
28800254-5	2018	In in vivo studies of bleomycin-induced lung fibrosis in mice, SIRT1 activation with resveratrol reduced collagen production when it was administered either prophylactically during the inflammatory stage or after the development of fibrosis.	Bleomycin	22-31	sirtuin 1	Mus musculus	63-68
28850249-0	2018	Deletion of c-FLIP from CD11bhi Macrophages Prevents Development of Bleomycin-induced Lung Fibrosis.	Bleomycin	68-77	CASP8 and FADD like apoptosis regulator	Homo sapiens	12-18
28850249-6	2018	Using this system, we were able to show that eliminating CD11bhi MPhi present 7-14 days after bleomycin injury was sufficient to protect mice from fibrosis.	Bleomycin	94-103	CD1d1 antigen	Mus musculus	57-61
30450979-1	2018	Ephrin type-A receptor 2 (EphA2) is a transmembrane receptor which is upregulated in injured lungs, including those treated with bleomycin.	Bleomycin	129-138	Eph receptor A2	Mus musculus	0-24
30450979-1	2018	Ephrin type-A receptor 2 (EphA2) is a transmembrane receptor which is upregulated in injured lungs, including those treated with bleomycin.	Bleomycin	129-138	Eph receptor A2	Mus musculus	26-31
29079188-0	2018	KLF2 attenuates bleomycin-induced pulmonary fibrosis and inflammation with regulation of AP-1.	Bleomycin	16-25	Kruppel-like factor 2	Rattus norvegicus	0-4
29079188-0	2018	KLF2 attenuates bleomycin-induced pulmonary fibrosis and inflammation with regulation of AP-1.	Bleomycin	16-25	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	89-93
29793317-7	2018	RESULTS: Administration of bleomycin caused pulmonary fibrosis in rats as evidenced by characteristic structural changes in histopathology, increased inflammatory cells in bronchoalveolar lavage fluid, elevated lipid peroxidation marker, depleted endogenous antioxidants and increased inflammatory mediators (TNF-alpha, IL-6).	Bleomycin	27-36	tumor necrosis factor	Rattus norvegicus	309-318
29793317-7	2018	RESULTS: Administration of bleomycin caused pulmonary fibrosis in rats as evidenced by characteristic structural changes in histopathology, increased inflammatory cells in bronchoalveolar lavage fluid, elevated lipid peroxidation marker, depleted endogenous antioxidants and increased inflammatory mediators (TNF-alpha, IL-6).	Bleomycin	27-36	interleukin 6	Rattus norvegicus	320-324
29793317-8	2018	There were also increased levels of TGF-beta, Smad2/3, ERK1/2, p38, JNK, fibronectin, hydroxyproline and type I collagen in bleomycin-control group.	Bleomycin	124-133	mitogen-activated protein kinase 8	Rattus norvegicus	68-71
29793317-8	2018	There were also increased levels of TGF-beta, Smad2/3, ERK1/2, p38, JNK, fibronectin, hydroxyproline and type I collagen in bleomycin-control group.	Bleomycin	124-133	fibronectin 1	Rattus norvegicus	73-84
29793317-13	2018	CONCLUSION: These data suggest that metformin protects against bleomycin-induced pulmonary fibrosis through activation of AMPK and amelioration of TGF-beta signaling pathways.	Bleomycin	63-72	transforming growth factor, beta 1	Rattus norvegicus	147-155
29990989-10	2018	Furthermore, we observed that knockdown of MCM2 or MCM6 could statistically inhibit the foci formation of 53BP1 in HepG2 cell nuclei upon bleomycin-induced DNA damage (P &lt; 0.01).	Bleomycin	138-147	minichromosome maintenance complex component 2	Homo sapiens	43-47
29172997-0	2018	Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux.	Bleomycin	51-60	annexin A2	Mus musculus	18-23
29172997-0	2018	Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux.	Bleomycin	51-60	annexin A2	Mus musculus	25-35
29172997-0	2018	Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux.	Bleomycin	51-60	transcription factor EB	Mus musculus	109-113
29172997-4	2018	Here, using a chemical proteomics approach, we identify ANXA2 (annexin A2) as a direct binding target of bleomycin.	Bleomycin	105-114	annexin A2	Mus musculus	56-61
29172997-4	2018	Here, using a chemical proteomics approach, we identify ANXA2 (annexin A2) as a direct binding target of bleomycin.	Bleomycin	105-114	annexin A2	Mus musculus	63-73
29172997-5	2018	The interaction of bleomycin with ANXA2 was corroborated both in vitro and in vivo.	Bleomycin	19-28	annexin A2	Mus musculus	34-39
29172997-6	2018	Genetic depletion of anxa2 in mice mitigates bleomycin-induced pulmonary fibrosis.	Bleomycin	45-54	annexin A2	Mus musculus	21-26
29172997-7	2018	We further demonstrate that Glu139 (E139) of ANXA2 is required for bleomycin binding in lung epithelial cells.	Bleomycin	67-76	annexin A2	Mus musculus	45-50
29172997-8	2018	A CRISPR-Cas9-engineered ANXA2E139A mutation in lung epithelial cells ablates bleomycin binding and activates TFEB (transcription factor EB), a master regulator of macroautophagy/autophagy, resulting in substantial acceleration of autophagic flux.	Bleomycin	78-87	annexin A2	Mus musculus	25-30
29172997-9	2018	Pharmacological activation of TFEB elevates bleomycin-initiated autophagic flux, inhibits apoptosis and proliferation of epithelial cells, and ameliorates pulmonary fibrosis in bleomycin-treated mice.	Bleomycin	44-53	transcription factor EB	Mus musculus	30-34
29172997-9	2018	Pharmacological activation of TFEB elevates bleomycin-initiated autophagic flux, inhibits apoptosis and proliferation of epithelial cells, and ameliorates pulmonary fibrosis in bleomycin-treated mice.	Bleomycin	177-186	transcription factor EB	Mus musculus	30-34
29172997-11	2018	Collectively, our data demonstrate that ANXA2 is a specific bleomycin target, and bleomycin binding with ANXA2 impedes TFEB-induced autophagic flux, leading to induction of pulmonary fibrosis.	Bleomycin	60-69	annexin A2	Mus musculus	40-45
29172997-11	2018	Collectively, our data demonstrate that ANXA2 is a specific bleomycin target, and bleomycin binding with ANXA2 impedes TFEB-induced autophagic flux, leading to induction of pulmonary fibrosis.	Bleomycin	60-69	transcription factor EB	Mus musculus	119-123
29172997-11	2018	Collectively, our data demonstrate that ANXA2 is a specific bleomycin target, and bleomycin binding with ANXA2 impedes TFEB-induced autophagic flux, leading to induction of pulmonary fibrosis.	Bleomycin	82-91	annexin A2	Mus musculus	105-110
29172997-11	2018	Collectively, our data demonstrate that ANXA2 is a specific bleomycin target, and bleomycin binding with ANXA2 impedes TFEB-induced autophagic flux, leading to induction of pulmonary fibrosis.	Bleomycin	82-91	transcription factor EB	Mus musculus	119-123
29990989-10	2018	Furthermore, we observed that knockdown of MCM2 or MCM6 could statistically inhibit the foci formation of 53BP1 in HepG2 cell nuclei upon bleomycin-induced DNA damage (P &lt; 0.01).	Bleomycin	138-147	minichromosome maintenance complex component 6	Homo sapiens	51-55
29990989-10	2018	Furthermore, we observed that knockdown of MCM2 or MCM6 could statistically inhibit the foci formation of 53BP1 in HepG2 cell nuclei upon bleomycin-induced DNA damage (P &lt; 0.01).	Bleomycin	138-147	tumor protein p53 binding protein 1	Homo sapiens	106-111
29705800-7	2018	RESULTS: A549 cells switched from a cobblestone-like appearance to an elongated fibroblast like appearance after exposure to tunicamycin or bleomycin, accompanied by increased expression of N-cadherin, alpha-SMA and Collagen I.	Bleomycin	140-149	cadherin 2	Homo sapiens	190-200
29510393-0	2018	A STAT6 Inhibitor AS1517499 Reduces Preventive Effects of Apoptotic Cell Instillation on Bleomycin-Induced Lung Fibrosis by Suppressing PPARgamma.	Bleomycin	89-98	signal transducer and activator of transcription 6	Mus musculus	2-7
29510393-0	2018	A STAT6 Inhibitor AS1517499 Reduces Preventive Effects of Apoptotic Cell Instillation on Bleomycin-Induced Lung Fibrosis by Suppressing PPARgamma.	Bleomycin	89-98	peroxisome proliferator activated receptor gamma	Mus musculus	136-145
29510393-5	2018	RESULTS: Our data demonstrate that apoptotic cell instillation after bleomycin results in prolonged enhancement of STAT6 phosphorylation in alveolar macrophages and lung.	Bleomycin	69-78	signal transducer and activator of transcription 6	Mus musculus	115-120
29510393-6	2018	Co-administration of the STAT6 inhibitor, AS1517499, reversed the enhanced PPARgamma expression and activity induced by apoptotic cell instillation after bleomycin treatment.	Bleomycin	154-163	signal transducer and activator of transcription 6	Mus musculus	25-30
29510393-6	2018	Co-administration of the STAT6 inhibitor, AS1517499, reversed the enhanced PPARgamma expression and activity induced by apoptotic cell instillation after bleomycin treatment.	Bleomycin	154-163	peroxisome proliferator activated receptor gamma	Mus musculus	75-84
29510393-9	2018	CONCLUSION: These results indicate that prolonged STAT6 activation following one-time apoptotic cell instillation facilitates continuous PPARgamma activation, resulting in the resolution of bleomycin-induced lung inflammation and fibrosis.	Bleomycin	190-199	signal transducer and activator of transcription 6	Mus musculus	50-55
29510393-9	2018	CONCLUSION: These results indicate that prolonged STAT6 activation following one-time apoptotic cell instillation facilitates continuous PPARgamma activation, resulting in the resolution of bleomycin-induced lung inflammation and fibrosis.	Bleomycin	190-199	peroxisome proliferator activated receptor gamma	Mus musculus	137-146
29705800-8	2018	Meanwhile, GRP78 was upregulated in A549 cells exposed to tunicamycin or bleomycin.	Bleomycin	73-82	heat shock protein family A (Hsp70) member 5	Homo sapiens	11-16
29705800-10	2018	Moreover, tunicamycin and bleomycin promoted the expression of HDAC2 and HDAC6, and HDACs inhibitor SAHA abrogated the morphological and biochemical changes in A549 cells.	Bleomycin	26-35	histone deacetylase 2	Homo sapiens	63-68
29705800-10	2018	Moreover, tunicamycin and bleomycin promoted the expression of HDAC2 and HDAC6, and HDACs inhibitor SAHA abrogated the morphological and biochemical changes in A549 cells.	Bleomycin	26-35	histone deacetylase 6	Homo sapiens	73-78
32524006-5	2018	Ubiquitous overexpression of AGT enhanced the profibrotic effect of bleomycin given at suboptimal doses.	Bleomycin	68-77	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	29-32
28488693-4	2018	Using a model of bleomycin-induced lung injury and fibrosis, we now demonstrate that ICOS expression enhances survival from lung injury rather than regulating fibrogenesis.	Bleomycin	17-26	inducible T cell costimulator	Homo sapiens	85-89
29200204-3	2018	We also found that Dio2-knockout mice exhibited enhanced bleomycin-induced lung fibrosis.	Bleomycin	57-66	deiodinase, iodothyronine, type II	Mus musculus	19-23
28488693-5	2018	Of ICOS-expressing cells, type 2 innate lymphocytes (ILC2s) are the first to respond to bleomycin-induced injury, and this expansion is ICOS dependent.	Bleomycin	88-97	inducible T cell costimulator	Homo sapiens	3-7
28488693-5	2018	Of ICOS-expressing cells, type 2 innate lymphocytes (ILC2s) are the first to respond to bleomycin-induced injury, and this expansion is ICOS dependent.	Bleomycin	88-97	inducible T cell costimulator	Homo sapiens	136-140
28987380-9	2017	Our pro-fibrotic in vitro model, consisting of bleomycin-triggered BEAS-2B cells, shows that quercetin boosts the antioxidant response, by increasing Nrf2 activity, and decreases pro-inflammatory cytokine production in a concentration-dependent manner.	Bleomycin	47-56	NFE2 like bZIP transcription factor 2	Homo sapiens	150-154
29138212-0	2017	Bax-inhibiting peptide attenuates bleomycin-induced lung injury in mice.	Bleomycin	34-43	BCL2-associated X protein	Mus musculus	0-3
29138212-3	2017	Bax-inhibiting peptide V5 (BIP-V5) exhibits membrane permeability and inhibits the activation of Bax.The purpose of this study was to investigate whether the control of Bax activity by BIP-V5 reduces the degree of bleomycin-induced lung injury.	Bleomycin	214-223	BCL2-associated X protein	Mus musculus	0-3
29311918-0	2017	GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFbeta1/Smad-Mediated Epithelial-to-Mesenchymal Transition.	Bleomycin	21-30	transforming growth factor, beta 1	Mus musculus	81-89
28821630-0	2017	IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis.	Bleomycin	28-37	interleukin 17A	Mus musculus	0-6
28821630-6	2017	Wild-type mice subjected to IL-17A neutralization and IL-17A knockout (il17a-/- ) mice were protected against bleomycin (BLEO)-induced fibrosis and collagen deposition.	Bleomycin	110-119	interleukin 17A	Mus musculus	54-60
28821630-6	2017	Wild-type mice subjected to IL-17A neutralization and IL-17A knockout (il17a-/- ) mice were protected against bleomycin (BLEO)-induced fibrosis and collagen deposition.	Bleomycin	110-119	interleukin 17A	Mus musculus	71-76
28821630-6	2017	Wild-type mice subjected to IL-17A neutralization and IL-17A knockout (il17a-/- ) mice were protected against bleomycin (BLEO)-induced fibrosis and collagen deposition.	Bleomycin	121-125	interleukin 17A	Mus musculus	54-60
28821630-6	2017	Wild-type mice subjected to IL-17A neutralization and IL-17A knockout (il17a-/- ) mice were protected against bleomycin (BLEO)-induced fibrosis and collagen deposition.	Bleomycin	121-125	interleukin 17A	Mus musculus	71-76
28821630-8	2017	BLEO-induced local C" activation [C3a, C5a, and terminal C" complex (C5b-9)] was attenuated in il17a-/- mice, and IL-17A neutralization prevented the loss of epithelial C" inhibitors (C" receptor-1 related isoform Y and decay accelerating factor), and an increase in local TUNEL levels.	Bleomycin	0-4	interleukin 17A	Mus musculus	95-100
28821630-8	2017	BLEO-induced local C" activation [C3a, C5a, and terminal C" complex (C5b-9)] was attenuated in il17a-/- mice, and IL-17A neutralization prevented the loss of epithelial C" inhibitors (C" receptor-1 related isoform Y and decay accelerating factor), and an increase in local TUNEL levels.	Bleomycin	0-4	interleukin 17A	Mus musculus	114-120
28821630-12	2017	B., Vittal, R. IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis.	Bleomycin	43-52	interleukin 17A	Mus musculus	15-21
29131071-0	2018	Highly Selective Endothelin-1 Receptor A Inhibition Prevents Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice.	Bleomycin	61-70	endothelin receptor type A	Mus musculus	17-38
29131071-3	2018	OBJECTIVES: We addressed the role of highly selective ET-1 receptor A (ETA) inhibition in the pathogenesis of experimental pulmonary fibrosis by bleomycin (BLM).	Bleomycin	145-154	endothelin receptor type A	Mus musculus	54-69
29131071-3	2018	OBJECTIVES: We addressed the role of highly selective ET-1 receptor A (ETA) inhibition in the pathogenesis of experimental pulmonary fibrosis by bleomycin (BLM).	Bleomycin	145-154	endothelin receptor type A	Mus musculus	71-74
29131071-3	2018	OBJECTIVES: We addressed the role of highly selective ET-1 receptor A (ETA) inhibition in the pathogenesis of experimental pulmonary fibrosis by bleomycin (BLM).	Bleomycin	156-159	endothelin receptor type A	Mus musculus	54-69
29131071-3	2018	OBJECTIVES: We addressed the role of highly selective ET-1 receptor A (ETA) inhibition in the pathogenesis of experimental pulmonary fibrosis by bleomycin (BLM).	Bleomycin	156-159	endothelin receptor type A	Mus musculus	71-74
29131071-10	2018	CONCLUSIONS: We conclude that in our BLM-induced pulmonary fibrosis model, prophylactic highly selective ETA inhibition improves survival, preserves lung function, attenuates lung injury, and reduces collagen deposition.	Bleomycin	37-40	endothelin receptor type A	Mus musculus	105-108
29203799-0	2017	Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration.	Bleomycin	51-60	chemokine (C-X3-C motif) ligand 1	Mus musculus	29-35
29203799-0	2017	Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration.	Bleomycin	51-60	chemokine (C-X3-C motif) receptor 1	Mus musculus	36-42
28884252-7	2017	The synthesis of collagen and more positive alpha-SMA staining were also observed in bleomycin-induced dermal fibrosis model of BALB/c mice treated with subcutaneous miR-192 mimics injection, whereas the inhibition of miR-192 decreased the expression of Col1, Col3 and alpha-SMA.	Bleomycin	85-94	actin alpha 2, smooth muscle, aorta	Mus musculus	44-53
28884252-7	2017	The synthesis of collagen and more positive alpha-SMA staining were also observed in bleomycin-induced dermal fibrosis model of BALB/c mice treated with subcutaneous miR-192 mimics injection, whereas the inhibition of miR-192 decreased the expression of Col1, Col3 and alpha-SMA.	Bleomycin	85-94	microRNA 192	Mus musculus	166-173
28884252-7	2017	The synthesis of collagen and more positive alpha-SMA staining were also observed in bleomycin-induced dermal fibrosis model of BALB/c mice treated with subcutaneous miR-192 mimics injection, whereas the inhibition of miR-192 decreased the expression of Col1, Col3 and alpha-SMA.	Bleomycin	85-94	microRNA 192	Mus musculus	218-225
28884252-7	2017	The synthesis of collagen and more positive alpha-SMA staining were also observed in bleomycin-induced dermal fibrosis model of BALB/c mice treated with subcutaneous miR-192 mimics injection, whereas the inhibition of miR-192 decreased the expression of Col1, Col3 and alpha-SMA.	Bleomycin	85-94	actin alpha 2, smooth muscle, aorta	Mus musculus	269-278
29158503-5	2017	Decreased expression of KLF4 was first observed in human IPF lung tissues and models of bleomycin-induced pulmonary fibrosis.	Bleomycin	88-97	Kruppel like factor 4	Homo sapiens	24-28
29279415-6	2017	The amount of LRG in the lungs of wild-type (WT) mice was increased by bleomycin administration prior to fibrosis development.	Bleomycin	71-80	leucine-rich alpha-2-glycoprotein 1	Mus musculus	14-17
29158503-6	2017	Transgenic mice with overexpression of KLF4 were subjected to bleomycin-induced pulmonary fibrosis model and showed attenuated lung fibrosis and EMT compared to wild type group.	Bleomycin	62-71	Kruppel-like factor 4 (gut)	Mus musculus	39-43
29158503-10	2017	Our results demonstrates that KLF4 plays an important role in bleomycin-induced lung fibrosis through suppressing TGFbeta1-induced EMT.	Bleomycin	62-71	Kruppel like factor 4	Homo sapiens	30-34
29158503-10	2017	Our results demonstrates that KLF4 plays an important role in bleomycin-induced lung fibrosis through suppressing TGFbeta1-induced EMT.	Bleomycin	62-71	transforming growth factor beta 1	Homo sapiens	114-122
28775096-7	2017	Importantly, in vivo findings demonstrated that IL-13 augments matrix metalloproteinase (MMP)-2 and MMP9 activity that has also been shown to increase migration and invasiveness of fibroblasts in the lungs during bleomycin-induced pulmonary fibrosis.	Bleomycin	213-222	interleukin 13	Mus musculus	48-53
28657777-0	2017	Epithelial Deletion of Sulf2 Exacerbates Bleomycin-Induced Lung Injury, Inflammation, and Mortality.	Bleomycin	41-50	sulfatase 2	Mus musculus	23-28
29133960-5	2017	The fibrotic response in Clusterin deficient (CLU-/-) mice persisted after bleomycin and it was associated with increased DNA damage, reduced DNA repair responses, and elevated cellular senescence.	Bleomycin	75-84	clusterin	Mus musculus	25-34
28657777-5	2017	Consistent with our findings in human IPF lungs, bleomycin treatment in mice resulted in up-regulation of Sulf2 mRNA in whole-lung extracts and overexpression of Sulf2 protein in type II AECs on lung tissue sections.	Bleomycin	49-58	sulfatase 2	Mus musculus	162-167
28657777-6	2017	Sulf2 protein was detectable in bronchoalveolar lavage fluid at baseline, and its level was significantly increased after bleomycin exposure.	Bleomycin	122-131	sulfatase 2	Mus musculus	0-5
28775096-7	2017	Importantly, in vivo findings demonstrated that IL-13 augments matrix metalloproteinase (MMP)-2 and MMP9 activity that has also been shown to increase migration and invasiveness of fibroblasts in the lungs during bleomycin-induced pulmonary fibrosis.	Bleomycin	213-222	matrix metallopeptidase 2	Mus musculus	63-95
28657777-8	2017	After bleomycin exposure, Sulf2 CKO mice exhibited enhanced neutrophil infiltration in the lung, with elevated levels of total protein, lactate dehydrogenase, and cytokines (granulocyte colony-stimulating factor and interferon-gamma-inducible protein 10) in bronchoalveolar lavage fluid compared with wild-type littermates.	Bleomycin	6-15	sulfatase 2	Mus musculus	26-31
28657777-10	2017	Finally, Sulf2 CKO mice suffered increased mortality after bleomycin exposure.	Bleomycin	59-68	sulfatase 2	Mus musculus	9-14
28657777-4	2017	In this study, we hypothesized that Sulf2 plays a regulatory role in alveolar epithelial injury and repair, using the murine bleomycin model.	Bleomycin	125-134	sulfatase 2	Mus musculus	36-41
28657777-5	2017	Consistent with our findings in human IPF lungs, bleomycin treatment in mice resulted in up-regulation of Sulf2 mRNA in whole-lung extracts and overexpression of Sulf2 protein in type II AECs on lung tissue sections.	Bleomycin	49-58	sulfatase 2	Mus musculus	106-111
28775096-7	2017	Importantly, in vivo findings demonstrated that IL-13 augments matrix metalloproteinase (MMP)-2 and MMP9 activity that has also been shown to increase migration and invasiveness of fibroblasts in the lungs during bleomycin-induced pulmonary fibrosis.	Bleomycin	213-222	matrix metallopeptidase 9	Mus musculus	100-104
28822966-10	2017	Further experiments showed that the antifibrotic and anti-inflammatory effects of NRG-1 were reproducible in mouse models of bleomycin-induced dermal and pulmonary fibrosis.	Bleomycin	125-134	neuregulin 1	Mus musculus	82-87
28678521-6	2017	Moreover, in a bleomycin-based model of acute lung injury, megalin+/- animals (the megalin-/- variant is lethal due to postnatal respiratory failure) showed a marked increase in intra-alveolar protein and more severe lung injury compared with wild-type littermates.	Bleomycin	15-24	low density lipoprotein receptor-related protein 2	Mus musculus	59-66
28751023-6	2017	Our data indicated that LYCAT expression was up-regulated in primary lung fibroblasts isolated from IPF patients and bleomycin-challenged mice, compared to controls.	Bleomycin	117-126	lysocardiolipin acyltransferase 1	Homo sapiens	24-29
28810065-7	2017	In vivo olodaterol significantly attenuated the bleomycin-induced increase in lung weight, reduced bronchoalveolar lavage cell counts and inhibited release of pro-fibrotic mediators (TGF-ss, MMP-9 and tissue inhibitor of metalloproteinase-1).	Bleomycin	48-57	matrix metallopeptidase 9	Homo sapiens	191-196
28701304-6	2017	We demonstrate that hypoxia-inducible factor 1-alpha (HIF1A) inhibition in late stages of bleomycin-induced injury attenuates pulmonary fibrosis in association, with reductions in ADORA2B expression in AAMs.	Bleomycin	90-99	hypoxia inducible factor 1 subunit alpha	Homo sapiens	20-52
28701304-6	2017	We demonstrate that hypoxia-inducible factor 1-alpha (HIF1A) inhibition in late stages of bleomycin-induced injury attenuates pulmonary fibrosis in association, with reductions in ADORA2B expression in AAMs.	Bleomycin	90-99	hypoxia inducible factor 1 subunit alpha	Homo sapiens	54-59
29067109-4	2017	It was demonstrated that TIAM1 expression was significantly increased in fibrotic lung tissue and lung fibroblasts from bleomycin (BLM)-treated mice compared with control mice (P&lt;0.05).	Bleomycin	120-129	T cell lymphoma invasion and metastasis 1	Mus musculus	25-30
29067109-4	2017	It was demonstrated that TIAM1 expression was significantly increased in fibrotic lung tissue and lung fibroblasts from bleomycin (BLM)-treated mice compared with control mice (P&lt;0.05).	Bleomycin	131-134	T cell lymphoma invasion and metastasis 1	Mus musculus	25-30
28961490-10	2017	However, HDAC4 activity changed significantly with the progression of the disease in bleomycin group.	Bleomycin	85-94	histone deacetylase 4	Mus musculus	9-14
28598023-0	2017	Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway.	Bleomycin	41-50	Rous sarcoma oncogene	Mus musculus	138-141
28598023-5	2017	In this study, we suggested hypothesized that nintedanib can suppress MV-augmented bleomycin-induced EMT and pulmonary fibrosis by inhibiting the Src pathway.	Bleomycin	83-92	Rous sarcoma oncogene	Mus musculus	146-149
29079731-0	2017	Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis.	Bleomycin	84-93	AKT serine/threonine kinase 1	Homo sapiens	31-34
28757441-2	2017	Our previous study demonstrated that aminoguanidine (AG), a preferred iNOS inhibitor, prevents bleomycin-induced injury and fibrosis in the lung.	Bleomycin	95-104	nitric oxide synthase 2	Rattus norvegicus	70-74
29079731-7	2017	We demonstrated that bleomycin can activate ER stress associated proteins, including GRP78, CHOP, and ATF-4, both in vitro and in vivo.	Bleomycin	21-30	heat shock protein family A (Hsp70) member 5	Homo sapiens	85-90
29079731-7	2017	We demonstrated that bleomycin can activate ER stress associated proteins, including GRP78, CHOP, and ATF-4, both in vitro and in vivo.	Bleomycin	21-30	DNA damage inducible transcript 3	Homo sapiens	92-96
29079731-7	2017	We demonstrated that bleomycin can activate ER stress associated proteins, including GRP78, CHOP, and ATF-4, both in vitro and in vivo.	Bleomycin	21-30	activating transcription factor 4	Homo sapiens	102-107
29079731-8	2017	PI3K/AKT acts upstream of ER stress to affect lung fibroblast proliferation, resulting in bleomycin-induced pulmonary fibrosis.	Bleomycin	90-99	AKT serine/threonine kinase 1	Homo sapiens	5-8
29057934-4	2017	PTP4A1 and its close homolog PTP4A2 are critical promoters of TGFbeta signaling in primary dermal fibroblasts and of bleomycin-induced fibrosis in vivo.	Bleomycin	117-126	protein tyrosine phosphatase 4A1	Homo sapiens	0-6
30258924-4	2017	We investigates SMARCA4 function in lung fibrosis by establishing PF mice model with bleomycin firstly and found that the expression of SMARCA4 was mainly enhanced in alveolar type II (ATII) cells.	Bleomycin	85-94	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Mus musculus	16-23
30258924-4	2017	We investigates SMARCA4 function in lung fibrosis by establishing PF mice model with bleomycin firstly and found that the expression of SMARCA4 was mainly enhanced in alveolar type II (ATII) cells.	Bleomycin	85-94	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Mus musculus	136-143
29084974-5	2017	In vivo, AngII exacerbated bleomycin (BLM)-induced lung fibrosis in rats, and elevated mir-21 and the NLRP3 inflammasome.	Bleomycin	27-36	angiotensinogen	Rattus norvegicus	9-14
29084974-5	2017	In vivo, AngII exacerbated bleomycin (BLM)-induced lung fibrosis in rats, and elevated mir-21 and the NLRP3 inflammasome.	Bleomycin	38-41	angiotensinogen	Rattus norvegicus	9-14
29057934-4	2017	PTP4A1 and its close homolog PTP4A2 are critical promoters of TGFbeta signaling in primary dermal fibroblasts and of bleomycin-induced fibrosis in vivo.	Bleomycin	117-126	protein tyrosine phosphatase 4A2	Homo sapiens	29-35
29045477-12	2017	In bleomycin-treated mouse lungs, HDAC6 expression was increased, and Tubastatin repressed type-1 collagen expression.	Bleomycin	3-12	histone deacetylase 6	Mus musculus	34-39
29045477-13	2017	However, in HDAC6 KO mice, bleomycin-induced type-1 collagen expression was not repressed compared to WT mice.	Bleomycin	27-36	histone deacetylase 6	Mus musculus	12-17
28726637-4	2017	miR-101 expression was determined in lung tissues from patients with IPF and mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	87-96	microRNA 101a	Mus musculus	0-7
29038604-0	2017	Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis.	Bleomycin	107-116	interleukin 6	Mus musculus	26-30
29038604-5	2017	Airway physiology measurements at day 21 demonstrated that overexpression of OSM or IL-6 exacerbated bleomycin-induced lung elastance, consistent with histopathological assessment of extracellular matrix and myofibroblast accumulation.	Bleomycin	101-110	interleukin 6	Mus musculus	84-88
29038604-8	2017	In conclusion, the gp130 cytokines IL-6 and OSM contribute to the accumulation of profibrotic macrophages and enhancement of bleomycin-induced lung fibrosis.	Bleomycin	125-134	interleukin 6 signal transducer	Mus musculus	19-24
29038604-8	2017	In conclusion, the gp130 cytokines IL-6 and OSM contribute to the accumulation of profibrotic macrophages and enhancement of bleomycin-induced lung fibrosis.	Bleomycin	125-134	interleukin 6	Mus musculus	35-39
28726637-6	2017	The expression of miR-101 was down-regulated in fibrotic lungs from patients with IPF and bleomycin-treated mice.	Bleomycin	90-99	microRNA 101a	Mus musculus	18-25
28726637-9	2017	Adenovirus-mediated miR-101 gene transfer in the mouse lung attenuated bleomycin-induced lung fibrosis and improved lung function.	Bleomycin	71-80	microRNA 101a	Mus musculus	20-27
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	119-128	growth arrest and DNA damage inducible alpha	Homo sapiens	179-186
28722352-4	2017	Silencing PAI-1 or inhibition of PAI-1 activity in cultured rat ATII (L2) cells leads to decreases in p53 serine 18 phosphorylation (p53S18P ), p53 and p21 protein expressions; an increase in retinoblastoma protein phosphorylation (ppRb); and a reduction in the sensitivity to bleomycin- and doxorubicin-induced senescence.	Bleomycin	277-286	serpin family E member 1	Rattus norvegicus	10-15
28722352-4	2017	Silencing PAI-1 or inhibition of PAI-1 activity in cultured rat ATII (L2) cells leads to decreases in p53 serine 18 phosphorylation (p53S18P ), p53 and p21 protein expressions; an increase in retinoblastoma protein phosphorylation (ppRb); and a reduction in the sensitivity to bleomycin- and doxorubicin-induced senescence.	Bleomycin	277-286	serpin family E member 1	Rattus norvegicus	33-38
28722352-6	2017	In vivo studies, using ATII cell-specific PAI-1 conditional knockout mouse model generated recently in this laboratory, further support the role of PAI-1 in the activation of p53-p21-Rb cell cycle repression pathway, ATII cell senescence, and lung fibrosis induced by bleomycin.	Bleomycin	268-277	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	148-153
28722352-6	2017	In vivo studies, using ATII cell-specific PAI-1 conditional knockout mouse model generated recently in this laboratory, further support the role of PAI-1 in the activation of p53-p21-Rb cell cycle repression pathway, ATII cell senescence, and lung fibrosis induced by bleomycin.	Bleomycin	268-277	transformation related protein 53, pseudogene	Mus musculus	175-178
28945500-4	2017	We found that injury elicited by bleomycin feeding or bacterial infection increased the production of two BMP ligands (Dpp and Gbb) in enterocytes (ECs), leading to elevated BMP signaling in progenitor cells that drove an expansion of ISCs by promoting their symmetric self-renewing division.	Bleomycin	33-42	glass bottom boat	Drosophila melanogaster	106-109
28945500-4	2017	We found that injury elicited by bleomycin feeding or bacterial infection increased the production of two BMP ligands (Dpp and Gbb) in enterocytes (ECs), leading to elevated BMP signaling in progenitor cells that drove an expansion of ISCs by promoting their symmetric self-renewing division.	Bleomycin	33-42	decapentaplegic	Drosophila melanogaster	119-122
28945500-4	2017	We found that injury elicited by bleomycin feeding or bacterial infection increased the production of two BMP ligands (Dpp and Gbb) in enterocytes (ECs), leading to elevated BMP signaling in progenitor cells that drove an expansion of ISCs by promoting their symmetric self-renewing division.	Bleomycin	33-42	glass bottom boat	Drosophila melanogaster	127-130
28945500-4	2017	We found that injury elicited by bleomycin feeding or bacterial infection increased the production of two BMP ligands (Dpp and Gbb) in enterocytes (ECs), leading to elevated BMP signaling in progenitor cells that drove an expansion of ISCs by promoting their symmetric self-renewing division.	Bleomycin	33-42	glass bottom boat	Drosophila melanogaster	174-177
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	119-128	X-ray repair cross complementing 1	Homo sapiens	188-193
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	119-128	X-ray repair cross complementing 4	Homo sapiens	195-200
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	119-128	X-ray repair cross complementing 6	Homo sapiens	202-206
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	119-128	X-ray repair cross complementing 5	Homo sapiens	208-212
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	119-128	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	214-222
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	119-128	DNA ligase 4	Homo sapiens	227-231
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	130-134	growth arrest and DNA damage inducible alpha	Homo sapiens	179-186
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	130-134	X-ray repair cross complementing 1	Homo sapiens	188-193
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	130-134	X-ray repair cross complementing 4	Homo sapiens	195-200
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	130-134	X-ray repair cross complementing 6	Homo sapiens	202-206
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	130-134	X-ray repair cross complementing 5	Homo sapiens	208-212
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	130-134	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	214-222
28780472-3	2017	The purpose of this study was to evaluate the effect of 50-Hz electromagnetic field (EMF) in combination with CDDP and bleomycin (Bleo) on expression of some of DNA repair genes (GADD45A, XRCC1, XRCC4, Ku70, Ku80, DNA-PKcs and LIG4) in MCF-7 (breast cancer) and SH-SY5Y (neuroblastoma) cell lines.	Bleomycin	130-134	DNA ligase 4	Homo sapiens	227-231
29140132-10	2017	RAW 264.7 but not MLE-15 cells exposed to SWCNT and bleomycin had significantly less TGF-beta1 released in the presence of OPN-blocking antibody.	Bleomycin	52-61	transforming growth factor, beta 1	Mus musculus	85-94
28916223-7	2017	RESULTS: BET-bromodomain inhibition suppressed induction of DGKA in bleomycin-treated fibroblasts, reduced H3K27ac at the DGKA enhancer and repressed collagen marker gene expression.	Bleomycin	68-77	diacylglycerol kinase alpha	Homo sapiens	60-64
29340124-14	2017	We recommend G-CSF use in HL patients receiving bleomycin when needed to maintain dose intensity.	Bleomycin	48-57	colony stimulating factor 3	Homo sapiens	13-18
28662409-0	2017	Human placental mesenchymal stem cells of fetal origins-alleviated inflammation and fibrosis by attenuating MyD88 signaling in bleomycin-induced pulmonary fibrosis mice.	Bleomycin	127-136	myeloid differentiation primary response gene 88	Mus musculus	108-113
28662409-6	2017	The results showed an alleviated pulmonary inflammation and fibrosis in myeloid differentiation primary response gene 88 (MyD88)-deficient mice treated with bleomycin (BLM), accompanied with a reduced TGF-beta signaling and production of pro-fibrotic cytokines, including TNF-alpha, IL-1beta.	Bleomycin	157-166	myeloid differentiation primary response gene 88	Mus musculus	122-127
28662409-6	2017	The results showed an alleviated pulmonary inflammation and fibrosis in myeloid differentiation primary response gene 88 (MyD88)-deficient mice treated with bleomycin (BLM), accompanied with a reduced TGF-beta signaling and production of pro-fibrotic cytokines, including TNF-alpha, IL-1beta.	Bleomycin	157-166	transforming growth factor, beta 1	Mus musculus	201-209
28662409-6	2017	The results showed an alleviated pulmonary inflammation and fibrosis in myeloid differentiation primary response gene 88 (MyD88)-deficient mice treated with bleomycin (BLM), accompanied with a reduced TGF-beta signaling and production of pro-fibrotic cytokines, including TNF-alpha, IL-1beta.	Bleomycin	157-166	tumor necrosis factor	Mus musculus	272-281
28662409-6	2017	The results showed an alleviated pulmonary inflammation and fibrosis in myeloid differentiation primary response gene 88 (MyD88)-deficient mice treated with bleomycin (BLM), accompanied with a reduced TGF-beta signaling and production of pro-fibrotic cytokines, including TNF-alpha, IL-1beta.	Bleomycin	157-166	interleukin 1 beta	Mus musculus	283-291
28916223-6	2017	Hence, DGKA transcription was additionally induced by the radiomimetic drug bleomycin, and DGKA mRNA expression, histone H3K27 acetylation and downstream markers of profibrotic fibroblast activation after BET-bromodomain inhibition were determined.	Bleomycin	76-85	diacylglycerol kinase alpha	Homo sapiens	7-11
28743499-0	2017	All-trans retinoic acid attenuates bleomycin-induced pulmonary fibrosis via downregulating EphA2-EphrinA1 signaling.	Bleomycin	35-44	Eph receptor A2	Mus musculus	91-96
29033951-6	2017	In this study, we observed a novel effect of S1P5 on the inflammatory processes during low-dose bleomycin (BLM)-induced fibrogenesis in murine skin.	Bleomycin	96-105	sphingosine-1-phosphate receptor 5	Mus musculus	45-49
28743499-0	2017	All-trans retinoic acid attenuates bleomycin-induced pulmonary fibrosis via downregulating EphA2-EphrinA1 signaling.	Bleomycin	35-44	ephrin A1	Mus musculus	97-105
28743499-6	2017	Furthermore, bleomycin upregulated EphA2, EphrinA1, PI3K 110gamma, Akt, IL-6 and TNF-alpha.	Bleomycin	13-22	Eph receptor A2	Mus musculus	35-40
28743499-6	2017	Furthermore, bleomycin upregulated EphA2, EphrinA1, PI3K 110gamma, Akt, IL-6 and TNF-alpha.	Bleomycin	13-22	ephrin A1	Mus musculus	42-50
28743499-6	2017	Furthermore, bleomycin upregulated EphA2, EphrinA1, PI3K 110gamma, Akt, IL-6 and TNF-alpha.	Bleomycin	13-22	thymoma viral proto-oncogene 1	Mus musculus	67-70
28743499-6	2017	Furthermore, bleomycin upregulated EphA2, EphrinA1, PI3K 110gamma, Akt, IL-6 and TNF-alpha.	Bleomycin	13-22	interleukin 6	Mus musculus	72-76
28743499-6	2017	Furthermore, bleomycin upregulated EphA2, EphrinA1, PI3K 110gamma, Akt, IL-6 and TNF-alpha.	Bleomycin	13-22	tumor necrosis factor	Mus musculus	81-90
28743499-7	2017	However, administration of ATRA attenuated the upregulation of EphA2-EphrinA1 and PI3K-Akt after bleomycin instillation, and decreased pulmonary fibrosis.	Bleomycin	97-106	Eph receptor A2	Mus musculus	63-68
28938010-5	2017	Sonoporation and EGFR-MB had a strong cytotoxic effect on Ca9-22 cells with low-dose bleomycin.	Bleomycin	85-94	epidermal growth factor receptor	Homo sapiens	17-21
28743499-7	2017	However, administration of ATRA attenuated the upregulation of EphA2-EphrinA1 and PI3K-Akt after bleomycin instillation, and decreased pulmonary fibrosis.	Bleomycin	97-106	ephrin A1	Mus musculus	69-77
28938010-6	2017	Furthermore, bleomycin delivery using sonoporation with EGFR-MBs remarkably increased the number of apoptotic cells.	Bleomycin	13-22	epidermal growth factor receptor	Homo sapiens	56-60
28743499-7	2017	However, administration of ATRA attenuated the upregulation of EphA2-EphrinA1 and PI3K-Akt after bleomycin instillation, and decreased pulmonary fibrosis.	Bleomycin	97-106	thymoma viral proto-oncogene 1	Mus musculus	87-90
28938010-8	2017	Bleomycin delivery by sonoporation with EGFR-MBs exhibited remarkable antitumor activity.	Bleomycin	0-9	epidermal growth factor receptor	Homo sapiens	40-44
28743499-8	2017	In addition, ATRA suppressed IL-6 and TNF-alpha production induced by bleomycin-induced injury.	Bleomycin	70-79	interleukin 6	Mus musculus	29-33
28743499-8	2017	In addition, ATRA suppressed IL-6 and TNF-alpha production induced by bleomycin-induced injury.	Bleomycin	70-79	tumor necrosis factor	Mus musculus	38-47
28743499-9	2017	Collectively, these data suggest that ATRA attenuates bleomycin-induced pulmonary fibrosis by regulating EphA2-EphrinA1 and PI3K-Akt signaling.	Bleomycin	54-63	Eph receptor A2	Mus musculus	105-110
28743499-9	2017	Collectively, these data suggest that ATRA attenuates bleomycin-induced pulmonary fibrosis by regulating EphA2-EphrinA1 and PI3K-Akt signaling.	Bleomycin	54-63	ephrin A1	Mus musculus	111-119
28743499-9	2017	Collectively, these data suggest that ATRA attenuates bleomycin-induced pulmonary fibrosis by regulating EphA2-EphrinA1 and PI3K-Akt signaling.	Bleomycin	54-63	thymoma viral proto-oncogene 1	Mus musculus	129-132
28936122-9	2017	Bleomycin-triggered bronchiolar TGF-beta1 expression was reduced.	Bleomycin	0-9	transforming growth factor, beta 1	Mus musculus	32-41
28979687-0	2017	Activation of A2aR attenuates bleomycin-induced pulmonary fibrosis via the SDF-1/CXCR4 axis-related pathway.	Bleomycin	30-39	adenosine A2a receptor	Mus musculus	14-18
28979687-0	2017	Activation of A2aR attenuates bleomycin-induced pulmonary fibrosis via the SDF-1/CXCR4 axis-related pathway.	Bleomycin	30-39	chemokine (C-X-C motif) ligand 12	Mus musculus	75-80
28979687-0	2017	Activation of A2aR attenuates bleomycin-induced pulmonary fibrosis via the SDF-1/CXCR4 axis-related pathway.	Bleomycin	30-39	chemokine (C-X-C motif) receptor 4	Mus musculus	81-86
28979687-1	2017	Previous studies in our lab have demonstrated that Adenosine A2a receptor (A2aR) gene-knockout mice were vulnerable to pulmonary fibrosis induced by bleomycin (BLM).	Bleomycin	149-158	adenosine A2a receptor	Mus musculus	51-73
28979687-1	2017	Previous studies in our lab have demonstrated that Adenosine A2a receptor (A2aR) gene-knockout mice were vulnerable to pulmonary fibrosis induced by bleomycin (BLM).	Bleomycin	149-158	adenosine A2a receptor	Mus musculus	75-79
28979687-1	2017	Previous studies in our lab have demonstrated that Adenosine A2a receptor (A2aR) gene-knockout mice were vulnerable to pulmonary fibrosis induced by bleomycin (BLM).	Bleomycin	160-163	adenosine A2a receptor	Mus musculus	51-73
28979687-1	2017	Previous studies in our lab have demonstrated that Adenosine A2a receptor (A2aR) gene-knockout mice were vulnerable to pulmonary fibrosis induced by bleomycin (BLM).	Bleomycin	160-163	adenosine A2a receptor	Mus musculus	75-79
28943331-0	2017	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.	Bleomycin	51-60	colony stimulating factor 3	Homo sapiens	10-47
28263743-0	2017	Deficiency of Psgl-1 accelerates bleomycin (BLM)-induced lung fibrosis and inflammation in mice through activating PI3K/AKT.	Bleomycin	33-42	selectin, platelet (p-selectin) ligand	Mus musculus	14-20
28263743-0	2017	Deficiency of Psgl-1 accelerates bleomycin (BLM)-induced lung fibrosis and inflammation in mice through activating PI3K/AKT.	Bleomycin	33-42	thymoma viral proto-oncogene 1	Mus musculus	120-123
28263743-0	2017	Deficiency of Psgl-1 accelerates bleomycin (BLM)-induced lung fibrosis and inflammation in mice through activating PI3K/AKT.	Bleomycin	44-47	selectin, platelet (p-selectin) ligand	Mus musculus	14-20
28263743-0	2017	Deficiency of Psgl-1 accelerates bleomycin (BLM)-induced lung fibrosis and inflammation in mice through activating PI3K/AKT.	Bleomycin	44-47	thymoma viral proto-oncogene 1	Mus musculus	120-123
28263743-4	2017	In the present study, we attempted to clarify the AKT activation induced by Psgl-1 knockout in mice with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	105-114	thymoma viral proto-oncogene 1	Mus musculus	50-53
28263743-4	2017	In the present study, we attempted to clarify the AKT activation induced by Psgl-1 knockout in mice with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	105-114	selectin, platelet (p-selectin) ligand	Mus musculus	76-82
28263743-4	2017	In the present study, we attempted to clarify the AKT activation induced by Psgl-1 knockout in mice with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	116-119	thymoma viral proto-oncogene 1	Mus musculus	50-53
28263743-4	2017	In the present study, we attempted to clarify the AKT activation induced by Psgl-1 knockout in mice with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	116-119	selectin, platelet (p-selectin) ligand	Mus musculus	76-82
28878315-5	2017	Chol-HCQ also reduces the expression of connective tissue growth factor (CTGF) and phosphorylation of extracellular regulated protein kinase (p-ERK) in rats with bleomycin-induced pulmonary fibrosis.	Bleomycin	162-171	cellular communication network factor 2	Rattus norvegicus	40-71
28878315-6	2017	Chol-HCQ nanocarriers reduce early pulmonary inflammation and inhibit the CTGF/ERK signalling pathway in bleomycin-induced pulmonary fibrosis.	Bleomycin	105-114	cellular communication network factor 2	Rattus norvegicus	74-78
28943331-1	2017	OBJECTIVE: To examine the impact of granulocyte-colony stimulating factor (G-CSF) use on the incidence and severity of bleomycin-induced pneumonitis (BIP) in patients with germ cell tumor (GCT) receiving first-line chemotherapy.	Bleomycin	119-128	colony stimulating factor 3	Homo sapiens	36-73
28943331-1	2017	OBJECTIVE: To examine the impact of granulocyte-colony stimulating factor (G-CSF) use on the incidence and severity of bleomycin-induced pneumonitis (BIP) in patients with germ cell tumor (GCT) receiving first-line chemotherapy.	Bleomycin	119-128	colony stimulating factor 3	Homo sapiens	75-80
28658529-0	2017	AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.	Bleomycin	50-59	inositol polyphosphate-5-phosphatase D	Mus musculus	25-30
28667836-0	2017	Adenosine A2a Receptor Blockade Diminishes Wnt/beta-Catenin Signaling in a Murine Model of Bleomycin-Induced Dermal Fibrosis.	Bleomycin	91-100	adenosine A2a receptor	Mus musculus	0-22
28667836-0	2017	Adenosine A2a Receptor Blockade Diminishes Wnt/beta-Catenin Signaling in a Murine Model of Bleomycin-Induced Dermal Fibrosis.	Bleomycin	91-100	catenin (cadherin associated protein), beta 1	Mus musculus	47-59
28528914-9	2017	Furthermore, Lgals9 small interfering RNA suppressed dermal collagen deposition by increasing interferon-gamma production of skin-infiltrating CD4+ T cells in bleomycin-treated mice.	Bleomycin	159-168	lectin, galactose binding, soluble 9	Mus musculus	13-19
28557137-12	2017	Another important lung DC subset CD11c+CD11b+ expression is suppressed by the absence of TGF-beta after bleomycin administration.	Bleomycin	104-113	integrin subunit alpha X	Homo sapiens	33-38
28557137-12	2017	Another important lung DC subset CD11c+CD11b+ expression is suppressed by the absence of TGF-beta after bleomycin administration.	Bleomycin	104-113	integrin subunit alpha M	Homo sapiens	39-44
28528914-9	2017	Furthermore, Lgals9 small interfering RNA suppressed dermal collagen deposition by increasing interferon-gamma production of skin-infiltrating CD4+ T cells in bleomycin-treated mice.	Bleomycin	159-168	interferon gamma	Mus musculus	94-110
28687632-3	2017	In this report, we found that levels of both Gab1 and Gab2 were elevated in M2-polarized macrophages isolated from bleomycin-induced fibrotic lungs.	Bleomycin	115-124	growth factor receptor bound protein 2-associated protein 1	Mus musculus	45-49
28687632-5	2017	Furthermore, in vivo conditional removal of Gab1 (Gab1MyKO) and germ line knock-out of Gab2 (Gab2-/-) in macrophages prevented a bias toward the M2 phenotype and attenuated bleomycin-induced fibrotic lung remodeling.	Bleomycin	173-182	growth factor receptor bound protein 2-associated protein 2	Mus musculus	93-97
28687632-3	2017	In this report, we found that levels of both Gab1 and Gab2 were elevated in M2-polarized macrophages isolated from bleomycin-induced fibrotic lungs.	Bleomycin	115-124	growth factor receptor bound protein 2-associated protein 2	Mus musculus	54-58
28687632-5	2017	Furthermore, in vivo conditional removal of Gab1 (Gab1MyKO) and germ line knock-out of Gab2 (Gab2-/-) in macrophages prevented a bias toward the M2 phenotype and attenuated bleomycin-induced fibrotic lung remodeling.	Bleomycin	173-182	growth factor receptor bound protein 2-associated protein 2	Mus musculus	87-91
28814671-5	2017	Lung-specific overexpression of VEGF significantly protected mice following intratracheal bleomycin challenge, with a decrease in fibrosis and bleomycin-induced cell death observed in the VEGF transgenic mice.	Bleomycin	90-99	vascular endothelial growth factor A	Mus musculus	32-36
28814671-5	2017	Lung-specific overexpression of VEGF significantly protected mice following intratracheal bleomycin challenge, with a decrease in fibrosis and bleomycin-induced cell death observed in the VEGF transgenic mice.	Bleomycin	143-152	vascular endothelial growth factor A	Mus musculus	32-36
28814671-5	2017	Lung-specific overexpression of VEGF significantly protected mice following intratracheal bleomycin challenge, with a decrease in fibrosis and bleomycin-induced cell death observed in the VEGF transgenic mice.	Bleomycin	143-152	vascular endothelial growth factor A	Mus musculus	188-192
28694203-0	2017	Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways.	Bleomycin	51-60	epoxide hydrolase 2, cytoplasmic	Mus musculus	0-25
28817691-0	2017	Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype.	Bleomycin	59-68	Rac family small GTPase 2	Mus musculus	0-4
28817691-3	2017	In the present study, we have defined a molecular mechanism by which signals transmitted from the extracellular matrix via the alpha4beta1 integrin lead to the activation of Rac2 which regulates alternative macrophage differentiation, a signaling axis within the pulmonary macrophage compartment required for bleomycin induced pulmonary fibrosis.	Bleomycin	309-318	Rac family small GTPase 2	Mus musculus	174-178
28817691-4	2017	Mice deficient in Rac2 were protected against bleomycin-induced fibrosis and displayed diminished collagen deposition in association with lower expression of alternatively activated profibrotic macrophage markers.	Bleomycin	46-55	Rac family small GTPase 2	Mus musculus	18-22
28591554-0	2017	NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis.	Bleomycin	47-56	NLR family, pyrin domain containing 3	Rattus norvegicus	0-5
28591554-5	2017	In this study, we transfected NLRP3 siRNA into A549 and RLE-6TN cells and treated them with bleomycin (BLM) for 24h.	Bleomycin	92-101	NLR family, pyrin domain containing 3	Rattus norvegicus	30-35
28591554-5	2017	In this study, we transfected NLRP3 siRNA into A549 and RLE-6TN cells and treated them with bleomycin (BLM) for 24h.	Bleomycin	103-106	NLR family, pyrin domain containing 3	Rattus norvegicus	30-35
28694203-0	2017	Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways.	Bleomycin	51-60	mitogen-activated protein kinase 14	Mus musculus	114-117
28694203-0	2017	Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways.	Bleomycin	51-60	SMAD family member 3	Mus musculus	118-123
29113323-6	2017	The function of BMP3 was investigated in both fibroblast cells and a bleomycin-induced murine pulmonary fibrosis model.	Bleomycin	69-78	bone morphogenetic protein 3	Mus musculus	16-20
29113323-9	2017	Consistently, lower expression of BMP3 also was found in pulmonary fibrotic tissues of bleomycin-induced mice model.	Bleomycin	87-96	bone morphogenetic protein 3	Mus musculus	34-38
28532580-7	2017	Sirt1, activated by resveratrol (Res), ameliorated cutaneous inflammation and fibrosis in bleomycin (BLM)-induced scleroderma mice.	Bleomycin	90-99	sirtuin 1	Mus musculus	0-5
28478401-9	2017	Treatment with combined JAK1/JAK2 inhibitors or with JAK2 inhibitors in combination with HSP90 inhibitors was more effective than monotherapy with JAK2 inhibitors in bleomycin-induced pulmonary fibrosis and in adTBR-induced dermal fibrosis.	Bleomycin	166-175	Janus kinase 1	Homo sapiens	24-28
28478401-9	2017	Treatment with combined JAK1/JAK2 inhibitors or with JAK2 inhibitors in combination with HSP90 inhibitors was more effective than monotherapy with JAK2 inhibitors in bleomycin-induced pulmonary fibrosis and in adTBR-induced dermal fibrosis.	Bleomycin	166-175	Janus kinase 2	Homo sapiens	29-33
28478401-9	2017	Treatment with combined JAK1/JAK2 inhibitors or with JAK2 inhibitors in combination with HSP90 inhibitors was more effective than monotherapy with JAK2 inhibitors in bleomycin-induced pulmonary fibrosis and in adTBR-induced dermal fibrosis.	Bleomycin	166-175	Janus kinase 2	Homo sapiens	53-57
28478401-9	2017	Treatment with combined JAK1/JAK2 inhibitors or with JAK2 inhibitors in combination with HSP90 inhibitors was more effective than monotherapy with JAK2 inhibitors in bleomycin-induced pulmonary fibrosis and in adTBR-induced dermal fibrosis.	Bleomycin	166-175	heat shock protein 90 alpha family class A member 1	Homo sapiens	89-94
28478401-9	2017	Treatment with combined JAK1/JAK2 inhibitors or with JAK2 inhibitors in combination with HSP90 inhibitors was more effective than monotherapy with JAK2 inhibitors in bleomycin-induced pulmonary fibrosis and in adTBR-induced dermal fibrosis.	Bleomycin	166-175	Janus kinase 2	Homo sapiens	53-57
28586109-7	2017	Diminished TGF-beta-induced chemotaxis of Fyn-deficient cells was also observed in an in vivo model of MC migration (bleomycin-induced scleroderma).	Bleomycin	117-126	transforming growth factor, beta 1	Mus musculus	11-19
28586109-7	2017	Diminished TGF-beta-induced chemotaxis of Fyn-deficient cells was also observed in an in vivo model of MC migration (bleomycin-induced scleroderma).	Bleomycin	117-126	Fyn proto-oncogene	Mus musculus	42-45
28532580-7	2017	Sirt1, activated by resveratrol (Res), ameliorated cutaneous inflammation and fibrosis in bleomycin (BLM)-induced scleroderma mice.	Bleomycin	101-104	sirtuin 1	Mus musculus	0-5
28932540-0	2017	Dynamic expression of transformating growth factor-beta1 and caveolin-1 in the lung of Bleomycin-induced interstitial lung disease.	Bleomycin	87-96	caveolin 1	Rattus norvegicus	61-71
28811360-6	2017	In wild-type mice, intratracheal bleomycin administration increased midkine expression in lung tissue.	Bleomycin	33-42	midkine	Mus musculus	68-75
28571757-6	2017	As a result, we observed an increase of HMGB1 in bronchoalveolar lavage fluid (BALF) in bleomycin (BLM)-treated rats as compared to non-treated rats (control group).	Bleomycin	88-97	high mobility group box 1	Rattus norvegicus	40-45
28571757-6	2017	As a result, we observed an increase of HMGB1 in bronchoalveolar lavage fluid (BALF) in bleomycin (BLM)-treated rats as compared to non-treated rats (control group).	Bleomycin	99-102	high mobility group box 1	Rattus norvegicus	40-45
28005404-4	2017	MEASUREMENTS AND MAIN RESULTS: Here, we demonstrate that application of C1INH alleviates bleomycin-induced lung injury via direct interaction with extracellular histones.	Bleomycin	89-98	serpin family G member 1	Homo sapiens	72-77
28676645-10	2017	Moreover, KIF5A was notably upregulated along with Col-1 and alpha-smooth muscle actin in pleural thickening in the carbon-black bleomycin mouse model.	Bleomycin	129-138	kinesin family member 5A	Mus musculus	10-15
28678919-0	2017	microRNA-142-3p inhibits apoptosis and inflammation induced by bleomycin through down-regulation of Cox-2 in MLE-12 cells.	Bleomycin	63-72	cytochrome c oxidase II, mitochondrial	Mus musculus	100-105
28678919-6	2017	As a result, cell viability was significantly decreased, as well as apoptosis and the expression of IL-1 and TNF-alpha were remarkably increased after 50 and 100 mug/mL of bleomycin administration.	Bleomycin	172-181	interleukin 1 complex	Mus musculus	100-104
28678919-6	2017	As a result, cell viability was significantly decreased, as well as apoptosis and the expression of IL-1 and TNF-alpha were remarkably increased after 50 and 100 mug/mL of bleomycin administration.	Bleomycin	172-181	tumor necrosis factor	Mus musculus	109-118
28678919-8	2017	Up-regulation of Cox-2 and inactivation of PI3K/AKT/mTOR were found in bleomycin-pretreated cells, while these abnormal regulations were partially abolished by miR-142-3p overexpression and NS-398.	Bleomycin	71-80	cytochrome c oxidase II, mitochondrial	Mus musculus	17-22
28678919-8	2017	Up-regulation of Cox-2 and inactivation of PI3K/AKT/mTOR were found in bleomycin-pretreated cells, while these abnormal regulations were partially abolished by miR-142-3p overexpression and NS-398.	Bleomycin	71-80	thymoma viral proto-oncogene 1	Mus musculus	48-51
28678919-8	2017	Up-regulation of Cox-2 and inactivation of PI3K/AKT/mTOR were found in bleomycin-pretreated cells, while these abnormal regulations were partially abolished by miR-142-3p overexpression and NS-398.	Bleomycin	71-80	mechanistic target of rapamycin kinase	Mus musculus	52-56
28678919-9	2017	In conclusion, this study demonstrated that miR-142-3p overexpression protected bleomycin-induced injury in lung epithelial MLE-12 cells, possibly via regulating Cox-2 expression and PI3K/AKT/mTOR signaling pathway.	Bleomycin	80-89	cytochrome c oxidase II, mitochondrial	Mus musculus	162-167
28678919-9	2017	In conclusion, this study demonstrated that miR-142-3p overexpression protected bleomycin-induced injury in lung epithelial MLE-12 cells, possibly via regulating Cox-2 expression and PI3K/AKT/mTOR signaling pathway.	Bleomycin	80-89	thymoma viral proto-oncogene 1	Mus musculus	188-191
28678919-9	2017	In conclusion, this study demonstrated that miR-142-3p overexpression protected bleomycin-induced injury in lung epithelial MLE-12 cells, possibly via regulating Cox-2 expression and PI3K/AKT/mTOR signaling pathway.	Bleomycin	80-89	mechanistic target of rapamycin kinase	Mus musculus	192-196
28385811-5	2017	Modified B-MSCs were intravenously administered to mice at day 7 after bleomycin instillation, and the mice were euthanized at day 14 Bleomycin-injured animals that were treated with let-7d cells were found to recover quicker from the initial weight loss compared with the other treatment groups.	Bleomycin	134-143	microRNA let7d	Mus musculus	183-189
28655914-0	2017	IGF1R deficiency attenuates acute inflammatory response in a bleomycin-induced lung injury mouse model.	Bleomycin	61-70	insulin-like growth factor I receptor	Mus musculus	0-5
28672967-7	2017	The daily intraperitoneal injection of artesunate (1 mg/kg) in rats was determined to inhibit bleomycin-induced overexpression of alpha-SMA and type IV collagen proteins, and inhibit the Notch signaling pathway, in lung tissues.	Bleomycin	94-103	actin gamma 2, smooth muscle	Rattus norvegicus	130-139
28483669-6	2017	In the present study, we used an adenovirus packaging FUT8 shRNA to infect a bleomycin-induced pulmonary fibrosis mouse model and determined the effect of CF on pulmonary fibrosis by analyzing the mechanism of CF-mediated pericyte transformation.	Bleomycin	77-86	fucosyltransferase 8	Mus musculus	54-58
28752966-0	2017	[The Study of the Effect and Mechanism of Glucagon Like Peptide-1 in Bleomycin-induced Pulmonary Fibrosis in Mice].	Bleomycin	69-78	glucagon	Mus musculus	42-65
28752966-1	2017	OBJECTIVE: To investigate the potential value and mechanisms of glucagon like peptide-1 (GLP-1) on bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	99-108	glucagon	Mus musculus	64-87
28752966-1	2017	OBJECTIVE: To investigate the potential value and mechanisms of glucagon like peptide-1 (GLP-1) on bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	99-108	glucagon	Mus musculus	89-94
28476015-0	2017	Synergistic protection of Schizandrin B and Glycyrrhizic acid against bleomycin-induced pulmonary fibrosis by inhibiting TGF-beta1/Smad2 pathways and overexpression of NOX4.	Bleomycin	70-79	transforming growth factor, beta 1	Mus musculus	121-130
28543309-4	2017	KGF expressing adenovirus vector, which prevented bleomycin-induced pulmonary fibrosis in a previous study, was constructed.	Bleomycin	50-59	fibroblast growth factor 7	Mus musculus	0-3
28655914-4	2017	After bleomycin-induced lung injury, IGF1R-deficient mice demonstrated improved survival within a week.	Bleomycin	6-15	insulin-like growth factor I receptor	Mus musculus	37-42
28606286-13	2017	The level of TGF-beta(1) in BALF and lung tissue were also decreased in mice treated with C(60) (10 mg kg(-1) d(-1)) compared with bleomycin model mice, but the difference had no statistical significance[(9.38+-5.32) vs (23.60+-8.96) pg/ml, (2.89+-0.35) vs (6.44+-2.95) pg/mg, both P&gt;0.05].	Bleomycin	131-140	transforming growth factor, beta 1	Mus musculus	13-24
28595637-9	2017	While not expressed in normal ATIIC phenotypes, the exosome miR-371b-5p expression is significantly induced after hiPSC-ATIICs or hATIICs (human primary ATIICs) are subjected to bleomycin-induced injury.	Bleomycin	178-187	microRNA 371b	Homo sapiens	60-68
28209630-4	2017	RESULTS: Specific inhibition of PDE4 by rolipram and apremilast had potent antifibrotic effects in bleomycin-induced skin fibrosis models, in the topoisomerase I mouse model and in murine sclerodermatous chronic graft-versus-host disease.	Bleomycin	99-108	phosphodiesterase 4A	Homo sapiens	32-36
28577568-10	2017	BLM-treated PARK2 KO mice demonstrated augmentation of lung fibrosis and oxidative modifications compared to those of BLM-treated wild type mice, which were efficiently attenuated by PFD.	Bleomycin	0-3	parkin RBR E3 ubiquitin protein ligase	Mus musculus	12-17
28385812-7	2017	Similarly, SIRT7 was decreased in lung tissues of bleomycin-challenged mice.	Bleomycin	50-59	sirtuin 7	Mus musculus	11-16
27746237-5	2017	METHODS: Bleomycin-induced lung fibrosis in wild-type and miR-155-/- mice was analyzed by histology, collagen, and profibrotic gene expression.	Bleomycin	9-18	microRNA 155	Mus musculus	58-65
28258190-9	2017	Asbestos- or bleomycin-induced lung fibrosis, AEC mtDNA damage, and apoptosis in wild-type mice were amplified in Sirt3-/- animals.	Bleomycin	13-22	sirtuin 3	Mus musculus	114-119
28343070-0	2017	The activation of Akt/mTOR pathway by bleomycin in Epithelial-to-mesenchymal transition of human submandibular gland cells: A treatment mechanism of bleomycin for mucoceles of the salivary glands.	Bleomycin	38-47	AKT serine/threonine kinase 1	Homo sapiens	18-21
28343070-0	2017	The activation of Akt/mTOR pathway by bleomycin in Epithelial-to-mesenchymal transition of human submandibular gland cells: A treatment mechanism of bleomycin for mucoceles of the salivary glands.	Bleomycin	38-47	mechanistic target of rapamycin kinase	Homo sapiens	22-26
28343070-0	2017	The activation of Akt/mTOR pathway by bleomycin in Epithelial-to-mesenchymal transition of human submandibular gland cells: A treatment mechanism of bleomycin for mucoceles of the salivary glands.	Bleomycin	149-158	AKT serine/threonine kinase 1	Homo sapiens	18-21
28343070-0	2017	The activation of Akt/mTOR pathway by bleomycin in Epithelial-to-mesenchymal transition of human submandibular gland cells: A treatment mechanism of bleomycin for mucoceles of the salivary glands.	Bleomycin	149-158	mechanistic target of rapamycin kinase	Homo sapiens	22-26
28463231-6	2017	Thus, enhanced Wnt/beta-catenin signaling in ABCG2+ MPCs drives a phenotype of persistent microvascular dysfunction, abnormal angiogenesis, and subsequent exacerbation of bleomycin-induced fibrosis.	Bleomycin	171-180	catenin beta 1	Homo sapiens	19-31
28463231-6	2017	Thus, enhanced Wnt/beta-catenin signaling in ABCG2+ MPCs drives a phenotype of persistent microvascular dysfunction, abnormal angiogenesis, and subsequent exacerbation of bleomycin-induced fibrosis.	Bleomycin	171-180	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	45-50
28132855-0	2017	Bone Marrow-Derived Mesenchymal Stem Cells Expressing Thioredoxin 1 Attenuate Bleomycin-Induced Skin Fibrosis and Oxidative Stress in Scleroderma.	Bleomycin	78-87	thioredoxin 1	Mus musculus	54-67
28132855-3	2017	The present study investigated the therapeutic potential of bone marrow-derived mesenchymal stem cells (BMSCs) expressing thioredoxin 1 (Trx-1) in treating SSc-mediated skin disease after transplantation into a bleomycin-induced murine model.	Bleomycin	211-220	thioredoxin 1	Mus musculus	137-142
28455433-3	2017	We report that AKT2 deficiency (Akt2-/-) protected against bleomycin-induced pulmonary fibrosis and inflammation.	Bleomycin	59-68	AKT serine/threonine kinase 2	Homo sapiens	32-36
28132855-7	2017	Trx-1-overexpressing BMSCs also promoted the formation of tubular-like structures by endothelial progenitor cells, indicating that Trx-1 can promote angiogenesis in bleomycin-induced SSc.	Bleomycin	165-174	thioredoxin 1	Mus musculus	0-5
28132855-7	2017	Trx-1-overexpressing BMSCs also promoted the formation of tubular-like structures by endothelial progenitor cells, indicating that Trx-1 can promote angiogenesis in bleomycin-induced SSc.	Bleomycin	165-174	thioredoxin 1	Mus musculus	131-136
28487960-0	2017	Sulforaphane prevents bleomycin-induced pulmonary fibrosis in mice by inhibiting oxidative stress via nuclear factor erythroid 2-related factor-2 activation.	Bleomycin	22-31	nuclear factor, erythroid derived 2, like 2	Mus musculus	102-145
28132855-8	2017	These results demonstrate that the transplantation of Trx-1-overexpressing BMSCs restored normal skin tissue in a mouse model of bleomycin-induced SSc, highlighting the therapeutic potential of engineered BMSCs for treating SSc.	Bleomycin	129-138	thioredoxin 1	Mus musculus	54-59
29029436-0	2017	XIST/miR-139 axis regulates bleomycin (BLM)-induced extracellular matrix (ECM) and pulmonary fibrosis through beta-catenin.	Bleomycin	28-37	inactive X specific transcripts	Mus musculus	0-4
29029436-2	2017	In the present study, we investigated the hypothesis that XIST play a promotive role in bleomycin (BLM)-induced ECM and pulmonary fibrosis; XIST exerts its effect through miR-139 regulation.	Bleomycin	99-102	inactive X specific transcripts	Mus musculus	58-62
29029436-0	2017	XIST/miR-139 axis regulates bleomycin (BLM)-induced extracellular matrix (ECM) and pulmonary fibrosis through beta-catenin.	Bleomycin	28-37	microRNA 139	Mus musculus	5-12
29029436-0	2017	XIST/miR-139 axis regulates bleomycin (BLM)-induced extracellular matrix (ECM) and pulmonary fibrosis through beta-catenin.	Bleomycin	28-37	catenin (cadherin associated protein), beta 1	Mus musculus	110-122
29029436-0	2017	XIST/miR-139 axis regulates bleomycin (BLM)-induced extracellular matrix (ECM) and pulmonary fibrosis through beta-catenin.	Bleomycin	39-42	inactive X specific transcripts	Mus musculus	0-4
29029436-0	2017	XIST/miR-139 axis regulates bleomycin (BLM)-induced extracellular matrix (ECM) and pulmonary fibrosis through beta-catenin.	Bleomycin	39-42	microRNA 139	Mus musculus	5-12
29029436-0	2017	XIST/miR-139 axis regulates bleomycin (BLM)-induced extracellular matrix (ECM) and pulmonary fibrosis through beta-catenin.	Bleomycin	39-42	catenin (cadherin associated protein), beta 1	Mus musculus	110-122
29029436-2	2017	In the present study, we investigated the hypothesis that XIST play a promotive role in bleomycin (BLM)-induced ECM and pulmonary fibrosis; XIST exerts its effect through miR-139 regulation.	Bleomycin	88-97	inactive X specific transcripts	Mus musculus	58-62
28545512-6	2017	Expression of Ang/Tie2 was analysed in different animal models: VEGF transgenic (tg) mice, hypoxia model, bleomycin-induced skin fibrosis, and tight skin 1 (TSK1) mice.	Bleomycin	106-115	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	14-17
28415591-6	2017	Finally, experiments were performed in pursuit of the involved mechanisms.Compared to healthy individuals or vehicle treated animals, extracellular nucleotide levels in the BAL fluid were increased in patients with IPF and in mice after bleomycin administration, paralleled by a functional up-regulation of P2Y2R expression.	Bleomycin	237-246	purinergic receptor P2Y2	Homo sapiens	307-312
28415591-7	2017	Both bleomycin-induced inflammation and fibrosis were reduced in P2Y2R-deficient compared to wild type animals.	Bleomycin	5-14	purinergic receptor P2Y2	Homo sapiens	65-70
28545512-11	2017	The VEGF tg mouse model, the hypoxia, and the inflammation-dependent bleomycin model all showed a similar dysregulation of Ang/Tie2 as in SSc, which did not apply for the non-inflammatory TSK1 model.	Bleomycin	69-78	TEK receptor tyrosine kinase	Mus musculus	127-131
28545512-11	2017	The VEGF tg mouse model, the hypoxia, and the inflammation-dependent bleomycin model all showed a similar dysregulation of Ang/Tie2 as in SSc, which did not apply for the non-inflammatory TSK1 model.	Bleomycin	69-78	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	123-126
27982686-0	2017	The expression levels of Notch-related signaling molecules in pulmonary microvascular endothelial cells in bleomycin-induced rat pulmonary fibrosis.	Bleomycin	107-116	notch receptor 1	Rattus norvegicus	25-30
28365154-3	2017	Sirt1 expression in lung tissues of IPF patients and in a mouse model of bleomycin (BLM)-induced lung fibrosis were evaluated by immunofluorescence.	Bleomycin	73-82	sirtuin 1	Homo sapiens	0-5
28365154-3	2017	Sirt1 expression in lung tissues of IPF patients and in a mouse model of bleomycin (BLM)-induced lung fibrosis were evaluated by immunofluorescence.	Bleomycin	84-87	sirtuin 1	Homo sapiens	0-5
28533545-0	2017	Treatment effects of the traditional Chinese medicine Shenks in bleomycin-induced lung fibrosis through regulation of TGF-beta/Smad3 signaling and oxidative stress.	Bleomycin	64-73	transforming growth factor, beta 1	Mus musculus	118-126
28533545-0	2017	Treatment effects of the traditional Chinese medicine Shenks in bleomycin-induced lung fibrosis through regulation of TGF-beta/Smad3 signaling and oxidative stress.	Bleomycin	64-73	SMAD family member 3	Mus musculus	127-132
27982686-2	2017	Therefore, we aimed to investigate the expression level of Notch-related signaling molecules in PMVECs in bleomycin (BLM)-induced rat pulmonary fibrosis.	Bleomycin	106-115	notch receptor 1	Rattus norvegicus	59-64
27982686-2	2017	Therefore, we aimed to investigate the expression level of Notch-related signaling molecules in PMVECs in bleomycin (BLM)-induced rat pulmonary fibrosis.	Bleomycin	117-120	notch receptor 1	Rattus norvegicus	59-64
28213468-4	2017	Here, we determined whether Lefty A can attenuate bleomycin (BLM)-induced pulmonary fibrosis in vivo based on a novel therapeutic strategy where human embryonic kidney 293 (HEK293) cells are genetically engineered with the Lefty A-associated GFP gene.	Bleomycin	50-59	left-right determination factor 2	Homo sapiens	28-35
28213468-4	2017	Here, we determined whether Lefty A can attenuate bleomycin (BLM)-induced pulmonary fibrosis in vivo based on a novel therapeutic strategy where human embryonic kidney 293 (HEK293) cells are genetically engineered with the Lefty A-associated GFP gene.	Bleomycin	50-59	left right determination factor 1	Mus musculus	28-33
28213468-4	2017	Here, we determined whether Lefty A can attenuate bleomycin (BLM)-induced pulmonary fibrosis in vivo based on a novel therapeutic strategy where human embryonic kidney 293 (HEK293) cells are genetically engineered with the Lefty A-associated GFP gene.	Bleomycin	61-64	left-right determination factor 2	Homo sapiens	28-35
28273432-4	2017	We found induction of tumor suppressor protein, p53, and apoptosis with suppression of urokinase-type plasminogen activator (uPA) and the uPA receptor in AECs from the lungs of IPF patients, and in mice with bleomycin, cigarette smoke, silica, or sepsis-induced lung injury.	Bleomycin	208-217	plasminogen activator, urokinase	Homo sapiens	87-123
28273432-10	2017	AEC-specific suppression of miR-34a inhibited bleomycin-induced p53, PAI-1, and apoptosis and prevented PF, whereas overexpression of precursor-miR-34a increased p53, PAI-1, and apoptosis in AECs of mice unexposed to bleomycin.	Bleomycin	46-55	microRNA 34a	Mus musculus	28-35
28273432-4	2017	We found induction of tumor suppressor protein, p53, and apoptosis with suppression of urokinase-type plasminogen activator (uPA) and the uPA receptor in AECs from the lungs of IPF patients, and in mice with bleomycin, cigarette smoke, silica, or sepsis-induced lung injury.	Bleomycin	208-217	plasminogen activator, urokinase	Homo sapiens	125-128
28213468-4	2017	Here, we determined whether Lefty A can attenuate bleomycin (BLM)-induced pulmonary fibrosis in vivo based on a novel therapeutic strategy where human embryonic kidney 293 (HEK293) cells are genetically engineered with the Lefty A-associated GFP gene.	Bleomycin	61-64	left right determination factor 1	Mus musculus	28-33
28273432-4	2017	We found induction of tumor suppressor protein, p53, and apoptosis with suppression of urokinase-type plasminogen activator (uPA) and the uPA receptor in AECs from the lungs of IPF patients, and in mice with bleomycin, cigarette smoke, silica, or sepsis-induced lung injury.	Bleomycin	208-217	plasminogen activator, urokinase	Homo sapiens	138-141
28273432-10	2017	AEC-specific suppression of miR-34a inhibited bleomycin-induced p53, PAI-1, and apoptosis and prevented PF, whereas overexpression of precursor-miR-34a increased p53, PAI-1, and apoptosis in AECs of mice unexposed to bleomycin.	Bleomycin	46-55	transformation related protein 53, pseudogene	Mus musculus	64-67
28420366-0	2017	Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium.	Bleomycin	23-32	nuclear factor, erythroid derived 2, like 2	Mus musculus	82-86
28273432-10	2017	AEC-specific suppression of miR-34a inhibited bleomycin-induced p53, PAI-1, and apoptosis and prevented PF, whereas overexpression of precursor-miR-34a increased p53, PAI-1, and apoptosis in AECs of mice unexposed to bleomycin.	Bleomycin	46-55	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	69-74
28283477-9	2017	Mice with AEC-specific deletion of FAK did not exhibit spontaneous lung injury but did have significantly greater terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling-positive cells (18.6 vs. 7.1) per x200 field, greater bronchoalveolar lavage protein (3.2 vs. 1.8 mg/ml), and significantly greater death (77 vs. 19%) after bleomycin injury compared with littermate control mice.	Bleomycin	341-350	PTK2 protein tyrosine kinase 2	Mus musculus	35-38
28283478-9	2017	Annexin A2 gene deletion in mice reduced bleomycin-induced increases in bronchoalveolar lavage fluid (BALF) IL-6 levels and cell number (*P &lt; 0.05; n = 4-12).	Bleomycin	41-50	annexin A2	Mus musculus	0-10
28283478-9	2017	Annexin A2 gene deletion in mice reduced bleomycin-induced increases in bronchoalveolar lavage fluid (BALF) IL-6 levels and cell number (*P &lt; 0.05; n = 4-12).	Bleomycin	41-50	interleukin 6	Mus musculus	108-112
28284148-6	2017	UA combined with BLM was significantly more effective than BLM alone in inhibiting the tumor growth, arresting the cell cycle at G0/G1 phase, and promoting the cleaved caspase-3 and cleaved caspase-8 activities to induce cancer cellular apoptosis.	Bleomycin	17-20	caspase 8	Mus musculus	190-199
28284148-6	2017	UA combined with BLM was significantly more effective than BLM alone in inhibiting the tumor growth, arresting the cell cycle at G0/G1 phase, and promoting the cleaved caspase-3 and cleaved caspase-8 activities to induce cancer cellular apoptosis.	Bleomycin	59-62	caspase 8	Mus musculus	190-199
28422760-5	2017	We report that increased activity of the endocannabinoid/CB1R system parallels disease progression in the lungs of patients with idiopathic PF and in mice with bleomycin-induced PF and is associated with increased tissue levels of interferon regulatory factor-5.	Bleomycin	160-169	cannabinoid receptor 1	Homo sapiens	57-61
28263294-3	2017	A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation.	Bleomycin	32-41	latent transforming growth factor beta binding protein 4	Mus musculus	68-74
28263294-3	2017	A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation.	Bleomycin	32-41	thymus cell antigen 1, theta	Mus musculus	109-114
28263294-3	2017	A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation.	Bleomycin	32-41	transforming growth factor, beta 1	Mus musculus	177-185
28263294-3	2017	A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation.	Bleomycin	32-41	SMAD family member 3	Mus musculus	213-218
28263294-3	2017	A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation.	Bleomycin	43-46	latent transforming growth factor beta binding protein 4	Mus musculus	68-74
28263294-3	2017	A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation.	Bleomycin	43-46	thymus cell antigen 1, theta	Mus musculus	109-114
28263294-3	2017	A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation.	Bleomycin	43-46	transforming growth factor, beta 1	Mus musculus	177-185
28263294-3	2017	A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation.	Bleomycin	43-46	SMAD family member 3	Mus musculus	213-218
28027929-5	2017	Bleomycin treatment of Nrf2-null mice resulted in exaggerated fibrosis.	Bleomycin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	23-27
27869163-4	2017	Human and mouse cells deficient for Wwox also exhibit significantly enhanced survival of ionizing radiation and bleomycin treatment, agents that induce double-strand breaks (DSBs).	Bleomycin	112-121	WW domain-containing oxidoreductase	Mus musculus	36-40
28422173-8	2017	Furthermore, bleomycin-induced skin fibrosis was attenuated in Zeb2-cKO mice.	Bleomycin	13-22	zinc finger E-box binding homeobox 2	Mus musculus	63-67
28420366-0	2017	Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium.	Bleomycin	23-32	BTB and CNC homology 1, basic leucine zipper transcription factor 1	Mus musculus	87-92
28469786-6	2017	MLN4924 inhibited pro-inflammatory responses while maintaining or increasing the production of the anti-inflammatory mediators such as anti-inflammatory interleukins (ILs) following bleomycin administration, which is closely correlated to its blocking NF-kappaB-mediated signaling.	Bleomycin	182-191	nuclear factor kappa B subunit 1	Homo sapiens	252-261
27997810-11	2017	Furthermore, we demonstrated that phloretin, a potent inhibitor of GLUT1, significantly inhibited bleomycin-induced lung fibrosis in vivo.	Bleomycin	98-107	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	67-72
28420992-9	2017	In SSc patients, healthy AA, and mice treated systemically with bleomycin, adipocytes lose caveolin-1 and PPARgamma and the subcutaneous adipose layer is diminished.	Bleomycin	64-73	caveolin 1, caveolae protein	Mus musculus	91-101
28420992-9	2017	In SSc patients, healthy AA, and mice treated systemically with bleomycin, adipocytes lose caveolin-1 and PPARgamma and the subcutaneous adipose layer is diminished.	Bleomycin	64-73	peroxisome proliferator activated receptor gamma	Mus musculus	106-115
28351980-4	2017	Consistent with a defect in the AT2 stem cell population, Etv5 deficiency markedly reduced recovery following bleomycin-induced lung injury.	Bleomycin	110-119	ETS variant transcription factor 5	Homo sapiens	58-62
28115235-0	2017	Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.	Bleomycin	98-107	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	62-65
28060543-8	2017	These studies show that inhibiting the KCa3.1 ion channel is able to attenuate the early fibrogenic phase of bleomycin-dependent fibrosis and inhibits profibrotic behavior of primary sheep lung fibroblasts.	Bleomycin	109-118	potassium calcium-activated channel subfamily N member 4	Homo sapiens	39-45
28213501-4	2017	In this article, we show that DSBs induced by ionizing radiation, etoposide, or bleomycin suppress Rag1 and Rag2 mRNA levels in primary pre-B cells, pro-B cells, and pro-T cells, indicating that inhibition of Rag1 and Rag2 expression is a prevalent DSB response among immature lymphocytes.	Bleomycin	80-89	recombination activating 1	Homo sapiens	99-103
28213501-4	2017	In this article, we show that DSBs induced by ionizing radiation, etoposide, or bleomycin suppress Rag1 and Rag2 mRNA levels in primary pre-B cells, pro-B cells, and pro-T cells, indicating that inhibition of Rag1 and Rag2 expression is a prevalent DSB response among immature lymphocytes.	Bleomycin	80-89	recombination activating 2	Homo sapiens	108-112
28213501-4	2017	In this article, we show that DSBs induced by ionizing radiation, etoposide, or bleomycin suppress Rag1 and Rag2 mRNA levels in primary pre-B cells, pro-B cells, and pro-T cells, indicating that inhibition of Rag1 and Rag2 expression is a prevalent DSB response among immature lymphocytes.	Bleomycin	80-89	recombination activating 1	Homo sapiens	209-213
28213501-4	2017	In this article, we show that DSBs induced by ionizing radiation, etoposide, or bleomycin suppress Rag1 and Rag2 mRNA levels in primary pre-B cells, pro-B cells, and pro-T cells, indicating that inhibition of Rag1 and Rag2 expression is a prevalent DSB response among immature lymphocytes.	Bleomycin	80-89	recombination activating 2	Homo sapiens	218-222
28304344-0	2017	Nrf2 Regulates the Risk of a Diesel Exhaust Inhalation-Induced Immune Response during Bleomycin Lung Injury and Fibrosis in Mice.	Bleomycin	86-95	nuclear factor, erythroid derived 2, like 2	Mus musculus	0-4
28283678-0	2017	Deficiency of alpha7 nicotinic acetylcholine receptor attenuates bleomycin-induced lung fibrosis in mice.	Bleomycin	65-74	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	14-53
28283678-2	2017	However, whether alpha7 nAChR would play a role in regulating bleomycin (BLM)-induced lung fibrosis is less investigated.	Bleomycin	62-71	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	17-29
28325283-6	2017	We found that bleomycin treatment increased CHST15 expression in interstitial fibroblasts at day 14.	Bleomycin	14-23	carbohydrate sulfotransferase 15	Mus musculus	44-50
28386328-0	2017	Kallistatin protects against bleomycin-induced idiopathic pulmonary fibrosis by inhibiting angiogenesis and inflammation.	Bleomycin	29-38	serpin family A member 4	Rattus norvegicus	0-11
28386328-3	2017	This study aimed to demonstrate that kallistatin has beneficial effects on bleomycin (BLM)-induced pulmonary fibrosis in a rat model by inhibiting angiogenesis.	Bleomycin	75-84	serpin family A member 4	Rattus norvegicus	37-48
28386328-3	2017	This study aimed to demonstrate that kallistatin has beneficial effects on bleomycin (BLM)-induced pulmonary fibrosis in a rat model by inhibiting angiogenesis.	Bleomycin	86-89	serpin family A member 4	Rattus norvegicus	37-48
28386330-0	2017	Geniposide inhibited endothelial-mesenchymal transition via the mTOR signaling pathway in a bleomycin-induced scleroderma mouse model.	Bleomycin	92-101	mechanistic target of rapamycin kinase	Mus musculus	64-68
27777101-4	2017	Glycyrrhizin significantly ameliorated dermal fibrosis in bleomycin-treated mice, which was partly attributable to blockade of transforming growth factor-beta signaling in dermal fibroblasts through the down-regulation of thrombospondin 1, a latent transforming growth factor-beta receptor, and transcription factors Smad3 and Ets1.	Bleomycin	58-67	thrombospondin 1	Mus musculus	222-238
28316159-6	2017	Wild type and ACE2 over-expressing mice were instilled with bleomycin endotracheally (3.5 mg/kg) or the same volume saline.	Bleomycin	60-69	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	14-18
28316159-16	2017	In bleomycin induced lung fibrosis in mice, ACE2(+ /+) -BLM mice exhibited milder lung fibrosis and lower NOX4 protein level but higher LC3-IIprotein level compared with WT-BLM mice.	Bleomycin	3-12	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	44-48
28179498-9	2017	In conclusion, loss of Twist1 in collagen-producing cells led to increased bleomycin-induced pulmonary fibrosis, which is mediated by increased expression of CXCL12.	Bleomycin	75-84	twist family bHLH transcription factor 1	Homo sapiens	23-29
28179498-9	2017	In conclusion, loss of Twist1 in collagen-producing cells led to increased bleomycin-induced pulmonary fibrosis, which is mediated by increased expression of CXCL12.	Bleomycin	75-84	C-X-C motif chemokine ligand 12	Homo sapiens	158-164
27805412-3	2017	We used R213G mice expressing a naturally occurring single-nucleotide polymorphism, rs1799895, within the heparin-binding domain of SOD3, which results in an amino acid substitution at position 213 to test the hypothesis that the redistribution of SOD3 into the extracellular fluids would impart protection against bleomycin-induced lung fibrosis and secondary pulmonary hypertension (PH).	Bleomycin	315-324	superoxide dismutase 3, extracellular	Mus musculus	132-136
27805412-4	2017	In R213G mice, SOD3 content and activity was increased in extracellular fluids and decreased in lung at baseline, with greater increases in bronchoalveolar lavage fluid (BALF) SOD3 compared with wild-type mice 3 days after bleomycin.	Bleomycin	223-232	superoxide dismutase 3, extracellular	Mus musculus	15-19
27805412-9	2017	We conclude that the redistribution of SOD3 as a result of the R213G single-nucleotide polymorphism protects mice from bleomycin-induced fibrosis and secondary PH by improved resolution of alveolar inflammation.	Bleomycin	119-128	superoxide dismutase 3, extracellular	Mus musculus	39-43
28064010-4	2017	Results show an increment of pro-inflammatory cytokine interleukin (IL) -1beta secretion and caspase-1 activation during the senescence of endothelial cells induced by bleomycin.	Bleomycin	168-177	caspase 1	Homo sapiens	93-102
27649046-0	2017	MnTBAP Inhibits Bleomycin-Induced Pulmonary Fibrosis by Regulating VEGF and Wnt Signaling.	Bleomycin	16-25	vascular endothelial growth factor A	Homo sapiens	67-71
27649046-6	2017	Overall, the data show that the superoxide scavenger MnTBAP attenuates bleomycin-induced pulmonary fibrosis by targeting VEGF and Wnt signaling pathways.	Bleomycin	71-80	vascular endothelial growth factor A	Homo sapiens	121-125
27777101-4	2017	Glycyrrhizin significantly ameliorated dermal fibrosis in bleomycin-treated mice, which was partly attributable to blockade of transforming growth factor-beta signaling in dermal fibroblasts through the down-regulation of thrombospondin 1, a latent transforming growth factor-beta receptor, and transcription factors Smad3 and Ets1.	Bleomycin	58-67	SMAD family member 3	Mus musculus	317-322
27777101-4	2017	Glycyrrhizin significantly ameliorated dermal fibrosis in bleomycin-treated mice, which was partly attributable to blockade of transforming growth factor-beta signaling in dermal fibroblasts through the down-regulation of thrombospondin 1, a latent transforming growth factor-beta receptor, and transcription factors Smad3 and Ets1.	Bleomycin	58-67	E26 avian leukemia oncogene 1, 5' domain	Mus musculus	327-331
27777101-7	2017	These results indicate that glycyrrhizin ameliorates bleomycin-induced dermal fibrosis through the inhibition of fibroblast activation, T helper type 2-skewed immune polarization, M2 macrophage infiltration, and endothelial-to-mesenchymal transition and improves endothelial Fli1 deficiency-dependent vascular disintegrity, implying its potential as a disease-modifying drug for SSc.	Bleomycin	53-62	Friend leukemia integration 1	Mus musculus	275-279
28165468-7	2017	In vivo, Thy-1 deficient (Thy1-/-) mice displayed persistence of myofibroblasts in the resolution phase of bleomycin-induced fibrosis, associated with accumulation of collagen and failure of lung fibrosis resolution.	Bleomycin	107-116	thymus cell antigen 1, theta	Mus musculus	9-14
28165468-7	2017	In vivo, Thy-1 deficient (Thy1-/-) mice displayed persistence of myofibroblasts in the resolution phase of bleomycin-induced fibrosis, associated with accumulation of collagen and failure of lung fibrosis resolution.	Bleomycin	107-116	thymus cell antigen 1, theta	Mus musculus	26-30
28165468-9	2017	Collectively, these findings provide new evidence regarding the role and mechanisms of Thy-1 in initiating myofibroblast apoptosis that heralds the termination of the reparative response to bleomycin-induced lung injury.	Bleomycin	190-199	thymus cell antigen 1, theta	Mus musculus	87-92
28292882-0	2017	Cthrc1 lowers pulmonary collagen associated with bleomycin-induced fibrosis and protects lung function.	Bleomycin	49-58	collagen triple helix repeat containing 1	Mus musculus	0-6
27435108-3	2017	In bleomycin-induced fibrosis, periostin deficiency in structural or hematopoietic cells limits development of pulmonary fibrosis.	Bleomycin	3-12	periostin, osteoblast specific factor	Mus musculus	31-40
27435108-8	2017	Additionally, connective tissue growth factor (CTGF) mRNA expression was increased in fibrocytes treated with periostin whereas CTGF and lysl oxidase (LOX) mRNA expression was low in bleomycin-treated periostin-/- fibrocytes.	Bleomycin	183-192	cellular communication network factor 2	Mus musculus	14-45
27435108-8	2017	Additionally, connective tissue growth factor (CTGF) mRNA expression was increased in fibrocytes treated with periostin whereas CTGF and lysl oxidase (LOX) mRNA expression was low in bleomycin-treated periostin-/- fibrocytes.	Bleomycin	183-192	cellular communication network factor 2	Mus musculus	128-132
27435108-8	2017	Additionally, connective tissue growth factor (CTGF) mRNA expression was increased in fibrocytes treated with periostin whereas CTGF and lysl oxidase (LOX) mRNA expression was low in bleomycin-treated periostin-/- fibrocytes.	Bleomycin	183-192	lysyl oxidase	Mus musculus	137-149
27435108-8	2017	Additionally, connective tissue growth factor (CTGF) mRNA expression was increased in fibrocytes treated with periostin whereas CTGF and lysl oxidase (LOX) mRNA expression was low in bleomycin-treated periostin-/- fibrocytes.	Bleomycin	183-192	lysyl oxidase	Mus musculus	151-154
27435108-8	2017	Additionally, connective tissue growth factor (CTGF) mRNA expression was increased in fibrocytes treated with periostin whereas CTGF and lysl oxidase (LOX) mRNA expression was low in bleomycin-treated periostin-/- fibrocytes.	Bleomycin	183-192	periostin, osteoblast specific factor	Mus musculus	201-210
27435108-9	2017	These data suggest fibrocytes may augment bleomycin-induced fibrosis via secretion of periostin and other soluble factors that promote myofibroblast differentiation.	Bleomycin	42-51	periostin, osteoblast specific factor	Mus musculus	86-95
28248986-9	2017	The microarray data was confirmed with a PCR array analysis containing a set of genes involved in DNA damage signaling; with BBC3, CDKN1A, PCNA and PPM1D being significantly upregulated in both flight and ground cells after bleomycin treatment.	Bleomycin	224-233	BCL2 binding component 3	Homo sapiens	125-129
28292882-7	2017	Bleomycin injection increased TGF-beta in both Cthrc1-/- (66.37 +- 8.54 ng/mL) and WT (63.64 +- 8.09 ng/mL).	Bleomycin	0-9	transforming growth factor, beta 1	Mus musculus	30-38
28248986-9	2017	The microarray data was confirmed with a PCR array analysis containing a set of genes involved in DNA damage signaling; with BBC3, CDKN1A, PCNA and PPM1D being significantly upregulated in both flight and ground cells after bleomycin treatment.	Bleomycin	224-233	cyclin dependent kinase inhibitor 1A	Homo sapiens	131-137
28248986-9	2017	The microarray data was confirmed with a PCR array analysis containing a set of genes involved in DNA damage signaling; with BBC3, CDKN1A, PCNA and PPM1D being significantly upregulated in both flight and ground cells after bleomycin treatment.	Bleomycin	224-233	proliferating cell nuclear antigen	Homo sapiens	139-143
28248986-9	2017	The microarray data was confirmed with a PCR array analysis containing a set of genes involved in DNA damage signaling; with BBC3, CDKN1A, PCNA and PPM1D being significantly upregulated in both flight and ground cells after bleomycin treatment.	Bleomycin	224-233	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	148-153
28297588-0	2017	Oncostatin M-Preconditioned Mesenchymal Stem Cells Alleviate Bleomycin-Induced Pulmonary Fibrosis Through Paracrine Effects of the Hepatocyte Growth Factor.	Bleomycin	61-70	oncostatin M	Mus musculus	0-12
28245556-7	2017	Moreover, CISCFE combined with BLM promoted the ascites cell apoptosis, the activities of caspases 3 and 8, and up-regulated the protein expression of p53 and down-regulated the transforming growth factor-beta1 by activating the gene expression of miR-29b.	Bleomycin	31-34	caspase 3	Mus musculus	90-106
28245556-7	2017	Moreover, CISCFE combined with BLM promoted the ascites cell apoptosis, the activities of caspases 3 and 8, and up-regulated the protein expression of p53 and down-regulated the transforming growth factor-beta1 by activating the gene expression of miR-29b.	Bleomycin	31-34	transformation related protein 53, pseudogene	Mus musculus	151-154
28245556-7	2017	Moreover, CISCFE combined with BLM promoted the ascites cell apoptosis, the activities of caspases 3 and 8, and up-regulated the protein expression of p53 and down-regulated the transforming growth factor-beta1 by activating the gene expression of miR-29b.	Bleomycin	31-34	transforming growth factor, beta 1	Mus musculus	178-210
28131417-7	2017	Using cultured PMCs and a pulmonary fibrosis animal model, we found that miR-18a-5p was reduced in PMCs treated with bleomycin and that downregulation of miR-18a-5p contributed to EMT of PMCs.	Bleomycin	117-126	microRNA 18	Mus musculus	73-80
28131417-9	2017	Overexpression of miR-18a-5p prevented bleomycin-induced EMT of PMC and inhibited bleomycin-induced sub-pleural fibrosis in mice.	Bleomycin	39-48	microRNA 18	Mus musculus	18-25
28131417-9	2017	Overexpression of miR-18a-5p prevented bleomycin-induced EMT of PMC and inhibited bleomycin-induced sub-pleural fibrosis in mice.	Bleomycin	82-91	microRNA 18	Mus musculus	18-25
28234968-0	2017	Trichostatin A attenuates ventilation-augmented epithelial-mesenchymal transition in mice with bleomycin-induced acute lung injury by suppressing the Akt pathway.	Bleomycin	95-104	thymoma viral proto-oncogene 1	Mus musculus	150-153
28234968-3	2017	We hypothesized that trichostatin A (TSA), a HDAC inhibitor, can reduce MV-augmented bleomycin-induced EMT by inhibiting the HDAC4 and Akt pathways.	Bleomycin	85-94	histone deacetylase 4	Mus musculus	125-130
28234968-3	2017	We hypothesized that trichostatin A (TSA), a HDAC inhibitor, can reduce MV-augmented bleomycin-induced EMT by inhibiting the HDAC4 and Akt pathways.	Bleomycin	85-94	thymoma viral proto-oncogene 1	Mus musculus	135-138
28182573-6	2017	Furthermore, 17-DMAG improved lung function and decreased fibrosis and matrix metalloproteinase activity in the lungs of bleomycin-challenged mice.In conclusion, this is the first study to demonstrate that HSP90 inhibition blocks pulmonary fibroblast activation and ameliorates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	121-130	heat shock protein, 3	Mus musculus	206-211
28182573-6	2017	Furthermore, 17-DMAG improved lung function and decreased fibrosis and matrix metalloproteinase activity in the lungs of bleomycin-challenged mice.In conclusion, this is the first study to demonstrate that HSP90 inhibition blocks pulmonary fibroblast activation and ameliorates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	278-287	heat shock protein, 3	Mus musculus	206-211
28292882-7	2017	Bleomycin injection increased TGF-beta in both Cthrc1-/- (66.37 +- 8.54 ng/mL) and WT (63.64 +- 8.09 ng/mL).	Bleomycin	0-9	collagen triple helix repeat containing 1	Mus musculus	47-53
28292882-9	2017	Immunohistochemistry of Cthrc1-/- lung sections showed intracellular localization and activation of beta-catenin Y654 in areas of tissue remodeling that was not evident in WT Lung compliance was significantly reduced by bleomycin in Cthrc1-/- but there was no effect in WT animals.	Bleomycin	220-229	collagen triple helix repeat containing 1	Mus musculus	24-30
28292882-10	2017	These data suggest Cthrc1 reduces fibrotic tissue formation in bleomycin-induced lung fibrosis and the effect is potent enough to limit the decline in lung function.	Bleomycin	63-72	collagen triple helix repeat containing 1	Mus musculus	19-25
28159016-7	2017	Conversely, the alpha2AP neutralization improved vascular damage in a bleomycin-induced mouse model of SSc.	Bleomycin	70-79	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	16-24
27668462-1	2017	Previous studies established that attenuating Wnt/beta-catenin signaling limits lung fibrosis in the bleomycin mouse model of this disease, but the contribution of this pathway to distinct lung cell phenotypes relevant to tissue repair and fibrosis remains incompletely understood.	Bleomycin	101-110	catenin (cadherin associated protein), beta 1	Mus musculus	50-62
27668462-2	2017	Using microarray analysis, we found that bleomycin-injured lungs from mice that lack the Wnt coreceptor low density lipoprotein receptor-related protein 5 (Lrp5) and exhibit reduced fibrosis showed enrichment for pathways related to extracellular matrix processing, immunity, and lymphocyte proliferation, suggesting the contribution of an immune-matrix remodeling axis relevant to fibrosis.	Bleomycin	41-50	low density lipoprotein receptor-related protein 5	Mus musculus	156-160
27668462-4	2017	Analysis of lung immune cells by flow cytometry after bleomycin administration revealed that Lrp5-/- lungs contained significantly fewer Siglec Flow alveolar macrophages, a cell type previously implicated as positive effectors of fibrosis.	Bleomycin	54-63	low density lipoprotein receptor-related protein 5	Mus musculus	93-97
28357073-0	2017	Effect of bosentan is correlated with MMP-9/TIMP-1 ratio in bleomycin-induced pulmonary fibrosis.	Bleomycin	60-69	matrix metallopeptidase 9	Rattus norvegicus	38-43
27736153-11	2017	Mice carrying the Noonan syndrome-associated gain-of-function SHP2 mutation (SHP2D61G/+) were resistant to bleomycin-induced pulmonary fibrosis.	Bleomycin	107-116	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	62-66
27736153-12	2017	Restoration of SHP2 levels in vivo through lentiviral delivery blunted bleomycin-induced pulmonary fibrosis.	Bleomycin	71-80	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	15-19
28337296-6	2017	The results showed that neuronal apoptosis inhibitory protein (NAIP) was negatively regulated by p53 in MCF-7 cells, and NAIP expression was still high in bleomycin-treated MCF-7 cells.	Bleomycin	155-164	NLR family apoptosis inhibitory protein	Homo sapiens	24-61
28337296-6	2017	The results showed that neuronal apoptosis inhibitory protein (NAIP) was negatively regulated by p53 in MCF-7 cells, and NAIP expression was still high in bleomycin-treated MCF-7 cells.	Bleomycin	155-164	NLR family apoptosis inhibitory protein	Homo sapiens	121-125
28077599-0	2017	BLT1 Mediates Bleomycin-Induced Lung Fibrosis Independently of Neutrophils and CD4+ T Cells.	Bleomycin	14-23	leukotriene B4 receptor	Homo sapiens	0-4
28077599-3	2017	In this study, we demonstrated that BLT1-/- mice exhibited significantly attenuated bleomycin (BLM)-induced lung fibrosis.	Bleomycin	84-93	leukotriene B4 receptor 1	Mus musculus	36-40
28077599-3	2017	In this study, we demonstrated that BLT1-/- mice exhibited significantly attenuated bleomycin (BLM)-induced lung fibrosis.	Bleomycin	95-98	leukotriene B4 receptor 1	Mus musculus	36-40
27932059-5	2017	Fibrotic WT-mice showed a significant higher death rate while bleomycin-treated TRPC6-deficient mice were partly protected from fibrosis as a consequence of a lower production of collagen and an almost normal function of the respiratory system (reduced resistance and elastance compared to fibrotic WT-mice).	Bleomycin	62-71	transient receptor potential cation channel, subfamily C, member 6	Mus musculus	80-85
28357073-0	2017	Effect of bosentan is correlated with MMP-9/TIMP-1 ratio in bleomycin-induced pulmonary fibrosis.	Bleomycin	60-69	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	44-50
28357073-10	2017	In addition, the concentrations of MMP-9 and TIMP-1 appeared to be altered following bosentan treatment, improving the bleomycin-induced PF.	Bleomycin	119-128	matrix metallopeptidase 9	Rattus norvegicus	35-40
28357073-10	2017	In addition, the concentrations of MMP-9 and TIMP-1 appeared to be altered following bosentan treatment, improving the bleomycin-induced PF.	Bleomycin	119-128	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	45-51
28058814-5	2017	Dysregulation of TNKS1BP1 affected the sensitivity of A549 cells to several DNA damage agents including cisplatin, bleomycin, and ionizing radiation.	Bleomycin	115-124	tankyrase 1 binding protein 1	Homo sapiens	17-25
27815257-8	2017	Compared with wild-type controls, Sirt3-knockout mice showed exacerbated fibrosis after intratracheal instillation of bleomycin.	Bleomycin	118-127	sirtuin 3	Mus musculus	34-39
27704718-0	2017	HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-beta/SMAD signalling pathway.	Bleomycin	49-58	poly (ADP-ribose) polymerase family, member 1	Mus musculus	22-28
27704718-0	2017	HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-beta/SMAD signalling pathway.	Bleomycin	49-58	transforming growth factor, beta 1	Mus musculus	98-106
28049526-0	2017	Atrial natriuretic peptide protects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice : ANP for pulmonary fibrosis.	Bleomycin	44-53	natriuretic peptide type A	Mus musculus	0-26
28049526-0	2017	Atrial natriuretic peptide protects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice : ANP for pulmonary fibrosis.	Bleomycin	44-53	natriuretic peptide type A	Mus musculus	122-125
28049526-4	2017	We hypothesized that ANP would have anti-fibrotic and anti-inflammatory effects on bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	83-92	natriuretic peptide type A	Mus musculus	21-24
28049526-4	2017	We hypothesized that ANP would have anti-fibrotic and anti-inflammatory effects on bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	94-97	natriuretic peptide type A	Mus musculus	21-24
28049526-13	2017	CONCLUSIONS: ANP exerts protective effects on BLM-induced pulmonary fibrosis via vascular endothelial cells.	Bleomycin	46-49	natriuretic peptide type A	Mus musculus	13-16
28077319-3	2017	AIMS: The present study performed in rats instilled with bleomycin investigated a) the expressions of the insulin growth factor (IGF-1) and insulin growth factor binding protein 5 (IGFBP-5) and transforming growth factor (TGF-beta1) in the type II AECs, b) the role of type II AECs in EMT and extracellular matrix (ECM) formation and, c) the effect of pioglitazone on all the above parameters.	Bleomycin	57-66	insulin-like growth factor 1	Rattus norvegicus	129-134
28077319-3	2017	AIMS: The present study performed in rats instilled with bleomycin investigated a) the expressions of the insulin growth factor (IGF-1) and insulin growth factor binding protein 5 (IGFBP-5) and transforming growth factor (TGF-beta1) in the type II AECs, b) the role of type II AECs in EMT and extracellular matrix (ECM) formation and, c) the effect of pioglitazone on all the above parameters.	Bleomycin	57-66	insulin-like growth factor binding protein 5	Rattus norvegicus	140-179
28077319-3	2017	AIMS: The present study performed in rats instilled with bleomycin investigated a) the expressions of the insulin growth factor (IGF-1) and insulin growth factor binding protein 5 (IGFBP-5) and transforming growth factor (TGF-beta1) in the type II AECs, b) the role of type II AECs in EMT and extracellular matrix (ECM) formation and, c) the effect of pioglitazone on all the above parameters.	Bleomycin	57-66	insulin-like growth factor binding protein 5	Rattus norvegicus	181-188
28077319-3	2017	AIMS: The present study performed in rats instilled with bleomycin investigated a) the expressions of the insulin growth factor (IGF-1) and insulin growth factor binding protein 5 (IGFBP-5) and transforming growth factor (TGF-beta1) in the type II AECs, b) the role of type II AECs in EMT and extracellular matrix (ECM) formation and, c) the effect of pioglitazone on all the above parameters.	Bleomycin	57-66	transforming growth factor, beta 1	Rattus norvegicus	222-231
28077319-10	2017	CONCLUSIONS: IGFBP-5, IGF-1 and TGF-beta1 in the type II AECs play a key role in lung injury caused by bleomycin and pioglitazone attenuates the lung injury/fibrosis by restoring IGFBP-5 and IGF-1 and decreasing TGF-beta1 expressions in the type II AECs.	Bleomycin	103-112	insulin-like growth factor binding protein 5	Rattus norvegicus	13-20
28077319-10	2017	CONCLUSIONS: IGFBP-5, IGF-1 and TGF-beta1 in the type II AECs play a key role in lung injury caused by bleomycin and pioglitazone attenuates the lung injury/fibrosis by restoring IGFBP-5 and IGF-1 and decreasing TGF-beta1 expressions in the type II AECs.	Bleomycin	103-112	insulin-like growth factor 1	Rattus norvegicus	22-27
28077319-10	2017	CONCLUSIONS: IGFBP-5, IGF-1 and TGF-beta1 in the type II AECs play a key role in lung injury caused by bleomycin and pioglitazone attenuates the lung injury/fibrosis by restoring IGFBP-5 and IGF-1 and decreasing TGF-beta1 expressions in the type II AECs.	Bleomycin	103-112	transforming growth factor, beta 1	Rattus norvegicus	32-41
28379390-0	2017	Arid5a-deficient mice are highly resistant to bleomycin-induced lung injury.	Bleomycin	46-55	AT rich interactive domain 5A (MRF1-like)	Mus musculus	0-6
28379390-3	2017	We found that Arid5a-deficient mice were highly refractory to bleomycin (BLM)-induced lethality.	Bleomycin	62-71	AT rich interactive domain 5A (MRF1-like)	Mus musculus	14-20
28379390-3	2017	We found that Arid5a-deficient mice were highly refractory to bleomycin (BLM)-induced lethality.	Bleomycin	73-76	AT rich interactive domain 5A (MRF1-like)	Mus musculus	14-20
28379390-5	2017	Production of reactive oxygen species (ROS) in response to BLM-induced cellular damage was inhibited in Arid5a-deficient mice, potentially affecting the level of oxidized 1-palmitoyl-2-arachidonoyl-phosphaticylcholine (OxPAPC) production.	Bleomycin	59-62	AT rich interactive domain 5A (MRF1-like)	Mus musculus	104-110
29926601-0	2017	[Effects of calcitonin gene-related peptide on eIF3a and p27 expression in bleomycin-induced pulmonary fibrosis of rats].	Bleomycin	75-84	calcitonin-related polypeptide alpha	Rattus norvegicus	12-43
29926601-0	2017	[Effects of calcitonin gene-related peptide on eIF3a and p27 expression in bleomycin-induced pulmonary fibrosis of rats].	Bleomycin	75-84	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	57-60
29926601-1	2017	OBJECTIVE: To observe the effects of calcitonin gene-related peptide (CGRP) on eukaryotic translation initiation factor 3a (eIF3a) and p27 expression in bleomycin-induced pulmonary fibrosis of rats and its possible mechanism.	Bleomycin	153-162	calcitonin-related polypeptide alpha	Rattus norvegicus	37-68
29926601-1	2017	OBJECTIVE: To observe the effects of calcitonin gene-related peptide (CGRP) on eukaryotic translation initiation factor 3a (eIF3a) and p27 expression in bleomycin-induced pulmonary fibrosis of rats and its possible mechanism.	Bleomycin	153-162	calcitonin-related polypeptide alpha	Rattus norvegicus	70-74
29926601-1	2017	OBJECTIVE: To observe the effects of calcitonin gene-related peptide (CGRP) on eukaryotic translation initiation factor 3a (eIF3a) and p27 expression in bleomycin-induced pulmonary fibrosis of rats and its possible mechanism.	Bleomycin	153-162	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	124-129
29926601-1	2017	OBJECTIVE: To observe the effects of calcitonin gene-related peptide (CGRP) on eukaryotic translation initiation factor 3a (eIF3a) and p27 expression in bleomycin-induced pulmonary fibrosis of rats and its possible mechanism.	Bleomycin	153-162	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	135-138
29926601-9	2017	RESULTS: The expressions of eIF3a, alpha-SMA, and collagen I were increased and the expression of p27 was decreasing in pulmonary fibrosis rats induced by bleomycin.	Bleomycin	155-164	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	28-33
29926601-9	2017	RESULTS: The expressions of eIF3a, alpha-SMA, and collagen I were increased and the expression of p27 was decreasing in pulmonary fibrosis rats induced by bleomycin.	Bleomycin	155-164	actin gamma 2, smooth muscle	Rattus norvegicus	35-44
29926601-9	2017	RESULTS: The expressions of eIF3a, alpha-SMA, and collagen I were increased and the expression of p27 was decreasing in pulmonary fibrosis rats induced by bleomycin.	Bleomycin	155-164	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	98-101
29926601-12	2017	CONCLUSIONS: These results suggest that endogenous CGRP is related to the development of pulmonary fibrosis induced by bleomycin, and the inhibitory effect of CGRP on proliferation of lung fibroblasts involves the eIF3a/p27 signaling pathway.	Bleomycin	119-128	calcitonin-related polypeptide alpha	Rattus norvegicus	51-55
27815257-10	2017	In contrast, the transgenic mice with whole body Sirt3 overexpression were protected from bleomycin-induced mtDNA damage and development of lung fibrosis.	Bleomycin	90-99	sirtuin 3	Mus musculus	49-54
27909724-4	2017	In this study, we examined the expression of HSP27 in fibrotic lung tissue and fibroblasts from bleomycin (BLM)-challenged mice and human lung fibroblasts treated with transforming growth factor-beta (TGF-beta).	Bleomycin	96-105	heat shock protein 1	Mus musculus	45-50
27816453-0	2017	Glaucocalyxin A improves survival in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	37-46	galactosidase, alpha	Mus musculus	0-15
27816453-5	2017	Intraperitoneal administration of GLA (10 mg/kg) significantly reduced collagen deposition and hydroxyproline content in mouse lungs treated with bleomycin.	Bleomycin	146-155	galactosidase, alpha	Mus musculus	34-37
27816453-6	2017	Importantly, GLA significantly improved survival in bleomycin treated mice.	Bleomycin	52-61	galactosidase, alpha	Mus musculus	13-16
27816453-8	2017	Mechanistically, GLA alleviated the infiltration of macrophages and neutrophils in lungs, attenuated the increases of proinflammatory cytokines in lung tissue and bronchoalveolar lavage fluid, and inhibited the activation of NF-kappaB in fibrotic lungs induced by bleomycin.	Bleomycin	264-273	galactosidase, alpha	Mus musculus	17-20
29377033-1	2017	While our previous studies suggest that limiting bleomycin-induced complement activation suppresses TGF-beta signaling, the specific hierarchical interactions between TGF-beta and complement in lung fibrosis are unclear.	Bleomycin	49-58	transforming growth factor beta 1	Homo sapiens	100-108
27550926-2	2017	We evaluate the effects of pharmacological treatment with an angiotensin-converting enzyme 2 activator drug, associated with exercise, on the pulmonary lesions induced by bleomycin.	Bleomycin	171-180	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	61-92
29220597-5	2017	For the bleomycin-treated mice, staining of the post-BAL lung sections indicated that compared to the regular salt diet, high salt increased the number of Ly6c-positive macrophages and decreased the number of CD11c and CD206-positive macrophages and dendritic cells.	Bleomycin	8-17	lymphocyte antigen 6 complex, locus C1	Mus musculus	155-159
28816543-10	2017	This led to the identification of miR-541-5p as one of the miRNA candidates associated with bleomycin response.	Bleomycin	92-101	microRNA 541	Rattus norvegicus	34-41
28816543-13	2017	CONCLUSIONS: MiR-541-5p is a key effector in lung fibroblastsby by regulating PDE1A expression at protein translation level and its overexpression is protective against bleomycin-induced lung fibrosis.	Bleomycin	169-178	microRNA 541	Homo sapiens	13-20
27959382-0	2017	Bach1 siRNA attenuates bleomycin-induced pulmonary fibrosis by modulating oxidative stress in mice.	Bleomycin	23-32	BTB and CNC homology 1, basic leucine zipper transcription factor 1	Mus musculus	0-5
27942594-4	2016	Here, we identified miR-323a-3p to be downregulated in the epithelium of lungs with bronchiolitis obliterans syndrome (BOS) after lung transplantation, idiopathic pulmonary fibrosis (IPF), and murine bleomycin-induced fibrosis.	Bleomycin	200-209	microRNA 615	Mus musculus	20-23
27982105-5	2016	Here, bleomycin (BLM) was intratracheally injected into both Nrf2-knockout (Nrf2-/-) and wild-type mice to compare the development of PF.	Bleomycin	6-15	nuclear factor, erythroid derived 2, like 2	Mus musculus	61-65
27982105-7	2016	We found that BLM-induced EMT and lung fibrosis were more severe in Nrf2-/- mice compared to wild-type mice.	Bleomycin	14-17	nuclear factor, erythroid derived 2, like 2	Mus musculus	68-72
27992456-0	2016	Prostaglandin D2 Attenuates Bleomycin-Induced Lung Inflammation and Pulmonary Fibrosis.	Bleomycin	28-37	prostaglandin D2 synthase (brain)	Mus musculus	0-16
27992456-3	2016	Here, we investigated whether genetic disruption of hematopoietic PGD synthase (H-PGDS) affects the bleomycin-induced lung inflammation and pulmonary fibrosis in mouse.	Bleomycin	100-109	hematopoietic prostaglandin D synthase	Mus musculus	80-86
27992456-4	2016	Compared with H-PGDS naive (WT) mice, H-PGDS-deficient mice (H-PGDS-/-) represented increased collagen deposition in lungs 14 days after the bleomycin injection.	Bleomycin	141-150	hematopoietic prostaglandin D synthase	Mus musculus	38-44
27992456-8	2016	These observations suggest that H-PGDS-derived PGD2 plays a protective role in bleomycin-induced lung inflammation and pulmonary fibrosis.	Bleomycin	79-88	hematopoietic prostaglandin D synthase	Mus musculus	32-38
27942594-5	2016	Antagomirs for miR-323a-3p augment, and mimics suppress, murine lung fibrosis after bleomycin injury, indicating that this miR may govern profibrotic signals.	Bleomycin	84-93	microRNA 615	Mus musculus	15-18
27942594-5	2016	Antagomirs for miR-323a-3p augment, and mimics suppress, murine lung fibrosis after bleomycin injury, indicating that this miR may govern profibrotic signals.	Bleomycin	84-93	microRNA 615	Mus musculus	123-126
27486964-0	2016	Protein Kinase Czeta Inhibitor Promotes Resolution of Bleomycin-Induced Acute Lung Injury.	Bleomycin	54-63	protein kinase C, zeta	Mus musculus	0-20
27486964-5	2016	We found that mice injured with bleomycin and then treated with PKCzetai for one week showed decreased activation of PKCzeta, improved lung compliance, and decreased lung protein permeability compared to injured mice treated with DMSO.	Bleomycin	32-41	protein kinase C, zeta	Mus musculus	64-71
27390295-3	2016	METHODS: We evaluated the effect of a novel ATX inhibitor, PAT-048, on fibrosis and IL-6 expression in the mouse model of bleomycin-induced dermal fibrosis.	Bleomycin	122-131	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	44-47
27793798-10	2016	Similarly, in mice challenged with bleomycin, fibrotic lesions were found to be aggravated in Gab1Delta/Delta These observations suggest that the abolishment of Gab1 in AT-IIs impairs SP homeostasis, predisposing mice to lung injuries.	Bleomycin	35-44	growth factor receptor bound protein 2-associated protein 1	Mus musculus	94-98
27760762-0	2016	Endothelin-1-Rho kinase interactions impair lung structure and cause pulmonary hypertension after bleomycin exposure in neonatal rat pups.	Bleomycin	98-107	endothelin 1	Rattus norvegicus	0-12
27760762-7	2016	Bleomycin increased lung ET-1 protein expression by 65%, RV/LV+S by 60%, mean linear intercept (MLI) by 212%, and MWT by 140% and decreased radial alveolar count (RAC) and vessel density by 40 and 44%, respectively (P &lt; 0.01 for each comparison).	Bleomycin	0-9	endothelin 1	Rattus norvegicus	25-29
27390295-9	2016	IL-6 knockdown abrogated LPA-induced ATX expression in fibroblasts, and ATX inhibition attenuated IL-6 expression in fibroblasts and the skin of bleomycin-challenged mice.	Bleomycin	145-154	interleukin 6	Mus musculus	0-4
27390295-11	2016	CONCLUSION: ATX is required for the development and maintenance of dermal fibrosis in a mouse model of bleomycin-induced SSc and enables 2 major mediators of SSc fibrogenesis, LPA and IL-6, to amplify the production of each other.	Bleomycin	103-112	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	12-15
27390295-9	2016	IL-6 knockdown abrogated LPA-induced ATX expression in fibroblasts, and ATX inhibition attenuated IL-6 expression in fibroblasts and the skin of bleomycin-challenged mice.	Bleomycin	145-154	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	72-75
27390295-9	2016	IL-6 knockdown abrogated LPA-induced ATX expression in fibroblasts, and ATX inhibition attenuated IL-6 expression in fibroblasts and the skin of bleomycin-challenged mice.	Bleomycin	145-154	interleukin 6	Mus musculus	98-102
27105895-9	2016	In SSc animal models, bleomycin-treated skin exhibited the expression pattern of CRAMP, a murine homologue of LL-37, similar to that of LL-37 in SSc lesional skin.	Bleomycin	22-31	cathelicidin antimicrobial peptide	Mus musculus	81-86
27105895-9	2016	In SSc animal models, bleomycin-treated skin exhibited the expression pattern of CRAMP, a murine homologue of LL-37, similar to that of LL-37 in SSc lesional skin.	Bleomycin	22-31	cathelicidin antimicrobial peptide	Homo sapiens	110-115
27105895-9	2016	In SSc animal models, bleomycin-treated skin exhibited the expression pattern of CRAMP, a murine homologue of LL-37, similar to that of LL-37 in SSc lesional skin.	Bleomycin	22-31	cathelicidin antimicrobial peptide	Homo sapiens	136-141
27878273-0	2016	PI3K/Akt signaling is involved in the pathogenesis of bleomycin-induced pulmonary fibrosis via regulation of epithelial-mesenchymal transition.	Bleomycin	54-63	AKT serine/threonine kinase 1	Rattus norvegicus	5-8
27556497-0	2016	Calcitonin gene-related peptide down-regulates bleomycin-induced pulmonary fibrosis.	Bleomycin	47-56	calcitonin-related polypeptide alpha	Rattus norvegicus	0-31
27556497-1	2016	We have found that eIF3a plays an important role in bleomycin-induced pulmonary fibrosis, and up-regulation of eIF3a induced by TGF-beta1 is mediated via the ERK1/2 pathway.	Bleomycin	52-61	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	19-24
27556497-2	2016	Whether ERK1/2 - eIF3a signal pathway is involved in calcitonin gene-related peptide (CGRP)-mediated pathogenesis of bleomycin-induced pulmonary fibrosis remains unknown.	Bleomycin	117-126	mitogen activated protein kinase 3	Rattus norvegicus	8-14
27556497-2	2016	Whether ERK1/2 - eIF3a signal pathway is involved in calcitonin gene-related peptide (CGRP)-mediated pathogenesis of bleomycin-induced pulmonary fibrosis remains unknown.	Bleomycin	117-126	calcitonin-related polypeptide alpha	Rattus norvegicus	53-84
27556497-2	2016	Whether ERK1/2 - eIF3a signal pathway is involved in calcitonin gene-related peptide (CGRP)-mediated pathogenesis of bleomycin-induced pulmonary fibrosis remains unknown.	Bleomycin	117-126	calcitonin-related polypeptide alpha	Rattus norvegicus	86-90
27556497-5	2016	Sensory CGRP depletion by capsaicin exacerbated bleomycin-induced pulmonary fibrosis in rats, as shown by a significant disturbed alveolar structure, marked thickening of the interalveolar septa and dense interstitial infiltration by inflammatory cells and fibroblasts, accompanied with increased expression of TGF-beta1, eIF3a, phosphorylated ERK1/2, alpha-SMA, collagen I, and collagen III.	Bleomycin	48-57	calcitonin-related polypeptide alpha	Rattus norvegicus	8-12
27556497-5	2016	Sensory CGRP depletion by capsaicin exacerbated bleomycin-induced pulmonary fibrosis in rats, as shown by a significant disturbed alveolar structure, marked thickening of the interalveolar septa and dense interstitial infiltration by inflammatory cells and fibroblasts, accompanied with increased expression of TGF-beta1, eIF3a, phosphorylated ERK1/2, alpha-SMA, collagen I, and collagen III.	Bleomycin	48-57	transforming growth factor, beta 1	Rattus norvegicus	311-320
27556497-5	2016	Sensory CGRP depletion by capsaicin exacerbated bleomycin-induced pulmonary fibrosis in rats, as shown by a significant disturbed alveolar structure, marked thickening of the interalveolar septa and dense interstitial infiltration by inflammatory cells and fibroblasts, accompanied with increased expression of TGF-beta1, eIF3a, phosphorylated ERK1/2, alpha-SMA, collagen I, and collagen III.	Bleomycin	48-57	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	322-327
27556497-5	2016	Sensory CGRP depletion by capsaicin exacerbated bleomycin-induced pulmonary fibrosis in rats, as shown by a significant disturbed alveolar structure, marked thickening of the interalveolar septa and dense interstitial infiltration by inflammatory cells and fibroblasts, accompanied with increased expression of TGF-beta1, eIF3a, phosphorylated ERK1/2, alpha-SMA, collagen I, and collagen III.	Bleomycin	48-57	mitogen activated protein kinase 3	Rattus norvegicus	344-350
27556497-8	2016	These results suggest that endogenous CGRP is related to the development of pulmonary fibrosis induced by bleomycin, and the inhibitory effect of CGRP on proliferation of lung fibroblasts involves the ERK1/2 - eIF3a signaling pathway.	Bleomycin	106-115	calcitonin-related polypeptide alpha	Rattus norvegicus	38-42
27793508-7	2016	During the bleomycin treatment, changes in PARylation levels are only detectable in a few cells, and an increase in PARP-I and PARP-II mRNAs is only observed during the recovery period.	Bleomycin	11-20	Poly-(ADP-ribose) polymerase	Drosophila melanogaster	116-120
27793508-7	2016	During the bleomycin treatment, changes in PARylation levels are only detectable in a few cells, and an increase in PARP-I and PARP-II mRNAs is only observed during the recovery period.	Bleomycin	11-20	Poly-(ADP-ribose) polymerase	Drosophila melanogaster	127-131
27456753-0	2016	Activation of TGF-beta1 by AQP3-Mediated H2O2 Transport into Fibroblasts of a Bleomycin-Induced Mouse Model of Scleroderma.	Bleomycin	78-87	transforming growth factor, beta 1	Mus musculus	14-23
27456753-0	2016	Activation of TGF-beta1 by AQP3-Mediated H2O2 Transport into Fibroblasts of a Bleomycin-Induced Mouse Model of Scleroderma.	Bleomycin	78-87	aquaporin 3	Mus musculus	27-31
27456753-4	2016	We observed that H2O2 and AQP3 levels in mouse skin increased with the bleomycin injection period relative to phosphate-buffered saline-injected control mice.	Bleomycin	71-80	aquaporin 3	Mus musculus	26-30
27456753-5	2016	AQP3 mRNA and protein levels were higher in bleomycin mice fibroblasts than in phosphate-buffered saline mice fibroblasts, and AQP3 immunofluorescence signals in the cytoplasm and cell membrane of bleomycin mice fibroblasts were much stronger than those in phosphate-buffered saline mice fibroblasts.	Bleomycin	44-53	aquaporin 3	Mus musculus	0-4
26912566-8	2016	Upon bleomycin injections, skin interleukin (IL) 6 and IL-10 levels were significantly reduced upon abatacept treatment.	Bleomycin	5-14	interleukin 10	Mus musculus	55-60
27840320-4	2016	OBJECTIVE: To determine whether transgenic mice that express mitochondrial-targeted catalase (MCAT) have reduced lung fibrosis following exposure to asbestos or bleomycin and, if so, whether this occurs in association with reduced AEC mtDNA damage and apoptosis.	Bleomycin	161-170	malonyl CoA:ACP acyltransferase (mitochondrial)	Mus musculus	61-92
27840320-4	2016	OBJECTIVE: To determine whether transgenic mice that express mitochondrial-targeted catalase (MCAT) have reduced lung fibrosis following exposure to asbestos or bleomycin and, if so, whether this occurs in association with reduced AEC mtDNA damage and apoptosis.	Bleomycin	161-170	malonyl CoA:ACP acyltransferase (mitochondrial)	Mus musculus	94-98
27840320-15	2016	CONCLUSIONS: Our finding that MCAT mice have reduced pulmonary fibrosis, AEC mtDNA damage and apoptosis following exposure to asbestos or bleomycin suggests an important role for AEC mitochondrial H2O2-induced mtDNA damage in promoting lung fibrosis.	Bleomycin	138-147	malonyl CoA:ACP acyltransferase (mitochondrial)	Mus musculus	30-34
27456753-5	2016	AQP3 mRNA and protein levels were higher in bleomycin mice fibroblasts than in phosphate-buffered saline mice fibroblasts, and AQP3 immunofluorescence signals in the cytoplasm and cell membrane of bleomycin mice fibroblasts were much stronger than those in phosphate-buffered saline mice fibroblasts.	Bleomycin	197-206	aquaporin 3	Mus musculus	0-4
27456753-5	2016	AQP3 mRNA and protein levels were higher in bleomycin mice fibroblasts than in phosphate-buffered saline mice fibroblasts, and AQP3 immunofluorescence signals in the cytoplasm and cell membrane of bleomycin mice fibroblasts were much stronger than those in phosphate-buffered saline mice fibroblasts.	Bleomycin	197-206	aquaporin 3	Mus musculus	127-131
27456753-6	2016	Bleomycin-induced increases in H2O2, transforming growth factor-beta1, collagen type I, and collagen type III levels in bleomycin mice fibroblasts were blocked by silencing AQP3.	Bleomycin	0-9	transforming growth factor, beta 1	Mus musculus	31-109
27456753-6	2016	Bleomycin-induced increases in H2O2, transforming growth factor-beta1, collagen type I, and collagen type III levels in bleomycin mice fibroblasts were blocked by silencing AQP3.	Bleomycin	0-9	aquaporin 3	Mus musculus	173-177
27456753-6	2016	Bleomycin-induced increases in H2O2, transforming growth factor-beta1, collagen type I, and collagen type III levels in bleomycin mice fibroblasts were blocked by silencing AQP3.	Bleomycin	120-129	transforming growth factor, beta 1	Mus musculus	31-109
27456753-6	2016	Bleomycin-induced increases in H2O2, transforming growth factor-beta1, collagen type I, and collagen type III levels in bleomycin mice fibroblasts were blocked by silencing AQP3.	Bleomycin	120-129	aquaporin 3	Mus musculus	173-177
27456753-8	2016	These results demonstrate that AQP3-mediated transport of H2O2 into bleomycin mice fibroblasts activated transforming growth factor-beta1, and silencing AQP3 is a potential approach for treating scleroderma.	Bleomycin	68-77	aquaporin 3	Mus musculus	31-35
27456753-8	2016	These results demonstrate that AQP3-mediated transport of H2O2 into bleomycin mice fibroblasts activated transforming growth factor-beta1, and silencing AQP3 is a potential approach for treating scleroderma.	Bleomycin	68-77	transforming growth factor, beta 1	Mus musculus	105-137
27281171-3	2016	Here we show that a transcription factor, Twist1, controls angiogenesis through the angiopoietin-Tie2 pathway, and that deregulation of this mechanism mediates pathological angiogenesis and collagen deposition in a bleomycin-induced mouse pulmonary fibrosis model.	Bleomycin	215-224	twist basic helix-loop-helix transcription factor 1	Mus musculus	42-48
27895584-0	2016	Induced Pluripotent Stem Cells Inhibit Bleomycin-Induced Pulmonary Fibrosis in Mice through Suppressing TGF-beta1/Smad-Mediated Epithelial to Mesenchymal Transition.	Bleomycin	39-48	transforming growth factor, beta 1	Mus musculus	104-113
27895584-10	2016	In addition, iPS cell administration remarkably suppressed BLM-induced up-regulation of pulmonary inflammatory mediators, including tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and prostaglandin E2.	Bleomycin	59-62	tumor necrosis factor	Mus musculus	132-159
27895584-10	2016	In addition, iPS cell administration remarkably suppressed BLM-induced up-regulation of pulmonary inflammatory mediators, including tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and prostaglandin E2.	Bleomycin	59-62	interleukin 1 beta	Mus musculus	161-183
27895584-10	2016	In addition, iPS cell administration remarkably suppressed BLM-induced up-regulation of pulmonary inflammatory mediators, including tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and prostaglandin E2.	Bleomycin	59-62	prostaglandin-endoperoxide synthase 2	Mus musculus	238-254
27811936-3	2016	Recently, using a mouse model of bleomycin-induced lung fibrosis, we showed that TG2 is required to trigger inflammation via the induction of T helper type 17 (Th17) cell differentiation in response to tissue damage.	Bleomycin	33-42	transglutaminase 2, C polypeptide	Mus musculus	81-84
27686964-0	2016	The antifibrotic effects of alveolar macrophages 5-HT2C receptors blockade on bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	78-87	5-hydroxytryptamine receptor 2C	Rattus norvegicus	49-55
27916096-1	2016	Objective To observe the effect of miR-21 on bleomycin-induced pulmonary fibrosis in rats, and explore the related mechanism.	Bleomycin	45-54	microRNA 21	Rattus norvegicus	35-41
27916096-16	2016	Conclusion miR-21 promotes the progression of bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	46-55	microRNA 21	Rattus norvegicus	11-17
27894300-0	2016	Pleural inhibition of the caspase-1/IL-1beta pathway diminishes profibrotic lung toxicity of bleomycin.	Bleomycin	93-102	caspase 1	Homo sapiens	26-35
27894300-0	2016	Pleural inhibition of the caspase-1/IL-1beta pathway diminishes profibrotic lung toxicity of bleomycin.	Bleomycin	93-102	interleukin 1 beta	Homo sapiens	36-44
27894300-4	2016	In this work, we explored the role of IL-1beta/caspase-1 signaling in bleomycin lung toxicity and in pleural mesothelial cell transformation.	Bleomycin	70-79	interleukin 1 beta	Homo sapiens	38-46
27894300-4	2016	In this work, we explored the role of IL-1beta/caspase-1 signaling in bleomycin lung toxicity and in pleural mesothelial cell transformation.	Bleomycin	70-79	caspase 1	Homo sapiens	47-56
27894300-9	2016	TGF-beta1 was also overexpressed in pleural lavage fluid and was produced by pleural cells following intravenous bleomycin.	Bleomycin	113-122	transforming growth factor beta 1	Homo sapiens	0-9
27894300-11	2016	In vitro, caspase-1 inhibition interfered with Met5A cell transformation into the myofibroblast-like phenotype induced by bleomycin or TGF-beta1.	Bleomycin	122-131	caspase 1	Homo sapiens	10-19
27853171-9	2016	Further, elevated expression of USP11 and TbetaRII were detected in lung tissues from bleomycin-challenged mice and IPF patients.	Bleomycin	86-95	ubiquitin specific peptidase 11	Mus musculus	32-37
27853171-9	2016	Further, elevated expression of USP11 and TbetaRII were detected in lung tissues from bleomycin-challenged mice and IPF patients.	Bleomycin	86-95	transforming growth factor, beta receptor II	Mus musculus	42-50
27281171-3	2016	Here we show that a transcription factor, Twist1, controls angiogenesis through the angiopoietin-Tie2 pathway, and that deregulation of this mechanism mediates pathological angiogenesis and collagen deposition in a bleomycin-induced mouse pulmonary fibrosis model.	Bleomycin	215-224	TEK receptor tyrosine kinase	Mus musculus	97-101
27281171-7	2016	Bleomycin challenge up-regulates Twist1 Ser42 phosphorylation and Tie2 expression, increases blood vessel density, and induces collagen deposition in the mouse lung, whereas these effects are attenuated in Twist1fl/fl/Tie2-cre mice or in mice treated with Twist1S42A mutant construct.	Bleomycin	0-9	twist basic helix-loop-helix transcription factor 1	Mus musculus	33-39
27281171-7	2016	Bleomycin challenge up-regulates Twist1 Ser42 phosphorylation and Tie2 expression, increases blood vessel density, and induces collagen deposition in the mouse lung, whereas these effects are attenuated in Twist1fl/fl/Tie2-cre mice or in mice treated with Twist1S42A mutant construct.	Bleomycin	0-9	TEK receptor tyrosine kinase	Mus musculus	66-70
27281171-7	2016	Bleomycin challenge up-regulates Twist1 Ser42 phosphorylation and Tie2 expression, increases blood vessel density, and induces collagen deposition in the mouse lung, whereas these effects are attenuated in Twist1fl/fl/Tie2-cre mice or in mice treated with Twist1S42A mutant construct.	Bleomycin	0-9	twist basic helix-loop-helix transcription factor 1	Mus musculus	206-212
27281171-7	2016	Bleomycin challenge up-regulates Twist1 Ser42 phosphorylation and Tie2 expression, increases blood vessel density, and induces collagen deposition in the mouse lung, whereas these effects are attenuated in Twist1fl/fl/Tie2-cre mice or in mice treated with Twist1S42A mutant construct.	Bleomycin	0-9	TEK receptor tyrosine kinase	Mus musculus	218-222
27281171-8	2016	These results indicate that Twist1 Ser42 phosphorylation contributes to the pathogenesis of bleomycin-induced pulmonary fibrosis through angiopoietin-Tie2 signaling.	Bleomycin	92-101	twist basic helix-loop-helix transcription factor 1	Mus musculus	28-34
27281171-8	2016	These results indicate that Twist1 Ser42 phosphorylation contributes to the pathogenesis of bleomycin-induced pulmonary fibrosis through angiopoietin-Tie2 signaling.	Bleomycin	92-101	TEK receptor tyrosine kinase	Mus musculus	150-154
27306439-15	2016	This study demonstrated that FD, attenuates BLM-induced pulmonary inflammation and fibrosis in mice via inhibiting the activation of NALP3 inflammasome and the IL-1beta/IL-1R1/MyD88/ NF-kappaB pathway.	Bleomycin	44-47	NLR family, pyrin domain containing 3	Mus musculus	133-138
27307019-6	2016	In parallel, there was a significant upregulation of procollagen alpha1(I), alpha-SMA and TGF-beta transcripts in HOCl animals, whereas IL-1beta and MMP-13 mRNA levels were significantly increased in bleomycin-treated mice.	Bleomycin	200-209	interleukin 1 beta	Mus musculus	136-144
27307019-6	2016	In parallel, there was a significant upregulation of procollagen alpha1(I), alpha-SMA and TGF-beta transcripts in HOCl animals, whereas IL-1beta and MMP-13 mRNA levels were significantly increased in bleomycin-treated mice.	Bleomycin	200-209	matrix metallopeptidase 13	Mus musculus	149-155
27307019-8	2016	Subanalysis revealed that Scl mice exhibited a significant increase of inflammatory myeloid CD11b+  Ly6Clow-high  CD64low-high cells (HOCl&gt;bleomycin).	Bleomycin	142-151	integrin subunit alpha M	Homo sapiens	92-97
27480571-4	2016	In addition, enhanced GLUT1 expression is observed in fibrotic areas of lungs of both patients with idiopathic pulmonary fibrosis and mice that are subjected to a fibrosis-inducing bleomycin treatment.	Bleomycin	181-190	solute carrier family 2 member 1	Homo sapiens	22-27
27306439-15	2016	This study demonstrated that FD, attenuates BLM-induced pulmonary inflammation and fibrosis in mice via inhibiting the activation of NALP3 inflammasome and the IL-1beta/IL-1R1/MyD88/ NF-kappaB pathway.	Bleomycin	44-47	interleukin 1 beta	Mus musculus	160-168
27306439-15	2016	This study demonstrated that FD, attenuates BLM-induced pulmonary inflammation and fibrosis in mice via inhibiting the activation of NALP3 inflammasome and the IL-1beta/IL-1R1/MyD88/ NF-kappaB pathway.	Bleomycin	44-47	interleukin 1 receptor, type I	Mus musculus	169-175
27613097-0	2016	The effect of H19-miR-29b interaction on bleomycin-induced mouse model of idiopathic pulmonary fibrosis.	Bleomycin	41-50	H19, imprinted maternally expressed transcript	Mus musculus	14-17
27774992-6	2016	Additionally, we provided in vivo evidence suggesting that emodin apparently alleviated BLM-induced pulmonary fibrosis and improved pulmonary function by inhibiting TGF-beta1 signaling and subsequently repressing EMT, fibroblast activation and extracellular matrix (ECM) deposition.	Bleomycin	88-91	transforming growth factor, beta 1	Rattus norvegicus	165-174
27613097-4	2016	In the present study, we investigated the hypothesis that H19 play a promotive role in bleomycin-induced epithelial-mesenchymal transition of alveolar epithelial cell, and H19 exerts its effect through miR-29b regulation.	Bleomycin	87-96	H19, imprinted maternally expressed transcript	Mus musculus	58-61
27542805-6	2016	We then generated a bleomycin-induced interstitial pneumonia model using wild-type and Angptl2 KO mice.	Bleomycin	20-29	angiopoietin-like 2	Mus musculus	87-94
27777976-4	2016	Blocking MCP-1/CCR2 signaling in HPS mice with genetic deficiency of CCR2 or targeted deletion of MCP-1 in AECs normalized macrophage recruitment, decreased AEC apoptosis, and reduced lung fibrosis in these mice following treatment with low-dose bleomycin.	Bleomycin	246-255	mast cell protease 1	Mus musculus	9-14
27777976-4	2016	Blocking MCP-1/CCR2 signaling in HPS mice with genetic deficiency of CCR2 or targeted deletion of MCP-1 in AECs normalized macrophage recruitment, decreased AEC apoptosis, and reduced lung fibrosis in these mice following treatment with low-dose bleomycin.	Bleomycin	246-255	chemokine (C-C motif) receptor 2	Mus musculus	15-19
27777976-6	2016	Selective deletion of TGF-beta in myeloid cells or of TGF-beta signaling in AECs through deletion of TGFBR2 protected HPS mice from AEC apoptosis and bleomycin-induced fibrosis.	Bleomycin	150-159	transforming growth factor, beta 1	Mus musculus	54-62
27777976-6	2016	Selective deletion of TGF-beta in myeloid cells or of TGF-beta signaling in AECs through deletion of TGFBR2 protected HPS mice from AEC apoptosis and bleomycin-induced fibrosis.	Bleomycin	150-159	transforming growth factor, beta receptor II	Mus musculus	101-107
27542805-9	2016	We conclude that Angptl2 deficiency in lung epithelial cells and resident alveolar macrophages causes severe lung fibrosis seen following bleomycin treatment, suggesting that ANGPTL2 derived from these cell types plays a protective role against fibrosis in lung.	Bleomycin	138-147	angiopoietin-like 2	Mus musculus	17-24
27542805-7	2016	Bleomycin-treated wild-type mice showed specifically upregulated ANGPTL2 expression in areas of severe fibrosing interstitial pneumonia, while Angptl2 KO mice developed more severe lung fibrosis than did comparably treated wild-type mice.	Bleomycin	0-9	angiopoietin-like 2	Mus musculus	65-72
26873752-10	2016	Furthermore, candidate miRNA levels were decreased in the lung tissues of mice with bleomycin-induced pulmonary fibrosis, and intratracheal application of miR-19a, -19b, and 26b reduced the pulmonary fibrotic severity induced by bleomycin.	Bleomycin	84-93	microRNA 19a	Mus musculus	155-162
27908247-6	2016	MCM2 and MCM6 were knocked down by shRNAs, after which chromatin fraction and foci forming of MDC1 upon bleomycin-induced DNA damage were examined.	Bleomycin	104-113	mediator of DNA damage checkpoint 1	Homo sapiens	94-98
27908247-9	2016	Moreover, knockdown of MCM2 or MCM6 could significantly inhibit foci forming of MDC1 in TE-1 nuclei in response to bleomycin-induced DNA damage (p &lt; 0.001).	Bleomycin	115-124	minichromosome maintenance complex component 2	Homo sapiens	23-27
27908247-9	2016	Moreover, knockdown of MCM2 or MCM6 could significantly inhibit foci forming of MDC1 in TE-1 nuclei in response to bleomycin-induced DNA damage (p &lt; 0.001).	Bleomycin	115-124	minichromosome maintenance complex component 6	Homo sapiens	31-35
27908247-9	2016	Moreover, knockdown of MCM2 or MCM6 could significantly inhibit foci forming of MDC1 in TE-1 nuclei in response to bleomycin-induced DNA damage (p &lt; 0.001).	Bleomycin	115-124	mediator of DNA damage checkpoint 1	Homo sapiens	80-84
27513632-0	2016	miR-221 targets HMGA2 to inhibit bleomycin-induced pulmonary fibrosis by regulating TGF-beta1/Smad3-induced EMT.	Bleomycin	33-42	microRNA 221	Homo sapiens	0-7
27513632-0	2016	miR-221 targets HMGA2 to inhibit bleomycin-induced pulmonary fibrosis by regulating TGF-beta1/Smad3-induced EMT.	Bleomycin	33-42	high mobility group AT-hook 2	Homo sapiens	16-21
27513632-0	2016	miR-221 targets HMGA2 to inhibit bleomycin-induced pulmonary fibrosis by regulating TGF-beta1/Smad3-induced EMT.	Bleomycin	33-42	transforming growth factor beta 1	Homo sapiens	84-93
27513632-0	2016	miR-221 targets HMGA2 to inhibit bleomycin-induced pulmonary fibrosis by regulating TGF-beta1/Smad3-induced EMT.	Bleomycin	33-42	SMAD family member 3	Homo sapiens	94-99
26873752-10	2016	Furthermore, candidate miRNA levels were decreased in the lung tissues of mice with bleomycin-induced pulmonary fibrosis, and intratracheal application of miR-19a, -19b, and 26b reduced the pulmonary fibrotic severity induced by bleomycin.	Bleomycin	229-238	microRNA 19a	Mus musculus	155-162
27790277-0	2016	Increased Cellular NAD+ Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice.	Bleomycin	86-95	NAD(P)H dehydrogenase, quinone 1	Mus musculus	38-42
27388243-0	2016	Hepatocyte Growth Factor Is Required for Mesenchymal Stromal Cell Protection Against Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	85-94	hepatocyte growth factor	Mus musculus	0-24
27388243-5	2016	The role for hepatocyte growth factor (HGF) in MSC protection against bleomycin lung injury was examined using HGF knockdown MSC.	Bleomycin	70-79	hepatocyte growth factor	Mus musculus	39-42
27388243-5	2016	The role for hepatocyte growth factor (HGF) in MSC protection against bleomycin lung injury was examined using HGF knockdown MSC.	Bleomycin	70-79	musculin	Mus musculus	47-50
27388243-10	2016	In a murine model, early administration of MSC protected against bleomycin induced lung fibrosis and correlated with reduced levels of the proinflammatory cytokine interleukin-1beta, reduced levels of apoptosis, and significantly increased levels of HGF.	Bleomycin	65-74	musculin	Mus musculus	43-46
27388243-15	2016	Furthermore, this study translates these findings demonstrating an important role for HGF in the protective effects mediated by MSC in vivo in the bleomycin model.	Bleomycin	147-156	hepatocyte growth factor	Mus musculus	86-89
27388243-15	2016	Furthermore, this study translates these findings demonstrating an important role for HGF in the protective effects mediated by MSC in vivo in the bleomycin model.	Bleomycin	147-156	musculin	Mus musculus	128-131
27677175-0	2016	Aerobic Exercise Attenuated Bleomycin-Induced Lung Fibrosis in Th2-Dominant Mice.	Bleomycin	28-37	heart and neural crest derivatives expressed 2	Mus musculus	63-66
27667460-12	2016	The collagen content and the expression levels of MyD88 and TGF-beta in bleomycin treatment group were obviously higher than those in hfPMSCs transplantation group and negative control group.	Bleomycin	72-81	myeloid differentiation primary response gene 88	Mus musculus	50-55
27667460-12	2016	The collagen content and the expression levels of MyD88 and TGF-beta in bleomycin treatment group were obviously higher than those in hfPMSCs transplantation group and negative control group.	Bleomycin	72-81	transforming growth factor, beta 1	Mus musculus	60-68
28057998-1	2016	After cisplatin and bleomycin-containing chemotherapy (CTx) for testicular cancer, part of the patients may develop acute or long-term cardiovascular toxicity.	Bleomycin	20-29	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	55-58
28057998-2	2016	In the present case, we reported that a 58-year-old male patient presenting with testicular tumors who developed acute peripheral arterial disease during combination CTx with bleomycin, etoposide, and cisplatin.	Bleomycin	175-184	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	166-169
28057998-6	2016	The risk of causing factors of thromboembolism in patients with testicular cancer under cisplatin and bleomycin-containing CTx should be evaluated.	Bleomycin	102-111	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	123-126
27677175-7	2016	CONCLUSION: AE attenuated bleomycin-induced collagen deposition, inflammation and cytokines accumulation in the lungs of mice with a predominately Th2-background suggesting that therapeutic AE (15-44 days post injury) attenuates the pro-inflammatory, Th2 immune response and fibrosis in the bleomycin model.	Bleomycin	26-35	heart and neural crest derivatives expressed 2	Mus musculus	251-254
27649073-3	2016	We hypothesized that loss of Th17 cells via CD4-specific deletion of mTORC1 activity would abrogate the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	119-128	CD4 molecule	Homo sapiens	44-47
27658704-0	2016	Baicalin attenuates bleomycin-induced pulmonary fibrosis via adenosine A2a receptor related TGF-beta1-induced ERK1/2 signaling pathway.	Bleomycin	20-29	adenosine A2a receptor	Mus musculus	61-83
27658704-0	2016	Baicalin attenuates bleomycin-induced pulmonary fibrosis via adenosine A2a receptor related TGF-beta1-induced ERK1/2 signaling pathway.	Bleomycin	20-29	transforming growth factor, beta 1	Mus musculus	92-101
27658704-0	2016	Baicalin attenuates bleomycin-induced pulmonary fibrosis via adenosine A2a receptor related TGF-beta1-induced ERK1/2 signaling pathway.	Bleomycin	20-29	mitogen-activated protein kinase 3	Mus musculus	110-116
27658704-3	2016	This study was to explore the relationship of A2aR and TGF-beta1-induced ERK1/2 in bleomycin (BLM)-induced pulmonary fibrosis in mice, and to investigate whether A2aR mediate the anti-fibrosis effect of Baicalin on BLM-induced pulmonary fibrosis.	Bleomycin	83-92	adenosine A2a receptor	Mus musculus	46-50
27658704-3	2016	This study was to explore the relationship of A2aR and TGF-beta1-induced ERK1/2 in bleomycin (BLM)-induced pulmonary fibrosis in mice, and to investigate whether A2aR mediate the anti-fibrosis effect of Baicalin on BLM-induced pulmonary fibrosis.	Bleomycin	83-92	transforming growth factor, beta 1	Mus musculus	55-64
27658704-3	2016	This study was to explore the relationship of A2aR and TGF-beta1-induced ERK1/2 in bleomycin (BLM)-induced pulmonary fibrosis in mice, and to investigate whether A2aR mediate the anti-fibrosis effect of Baicalin on BLM-induced pulmonary fibrosis.	Bleomycin	83-92	mitogen-activated protein kinase 3	Mus musculus	73-79
27658704-3	2016	This study was to explore the relationship of A2aR and TGF-beta1-induced ERK1/2 in bleomycin (BLM)-induced pulmonary fibrosis in mice, and to investigate whether A2aR mediate the anti-fibrosis effect of Baicalin on BLM-induced pulmonary fibrosis.	Bleomycin	94-97	transforming growth factor, beta 1	Mus musculus	55-64
27658704-12	2016	We also showed that TGF-beta1 and p-ERK1/2 were upregulated in bleomycin-treated mice and expressed higher in A2aR-/- mice compared to A2aR+/+ mice.	Bleomycin	63-72	transforming growth factor, beta 1	Mus musculus	20-29
27658704-12	2016	We also showed that TGF-beta1 and p-ERK1/2 were upregulated in bleomycin-treated mice and expressed higher in A2aR-/- mice compared to A2aR+/+ mice.	Bleomycin	63-72	mitogen-activated protein kinase 3	Mus musculus	36-42
27658704-12	2016	We also showed that TGF-beta1 and p-ERK1/2 were upregulated in bleomycin-treated mice and expressed higher in A2aR-/- mice compared to A2aR+/+ mice.	Bleomycin	63-72	adenosine A2a receptor	Mus musculus	135-139
27658704-13	2016	Besides, bleomycin-treated A2aR+/+ mice had increased A2aR level in lungs.	Bleomycin	9-18	adenosine A2a receptor	Mus musculus	27-31
27658704-13	2016	Besides, bleomycin-treated A2aR+/+ mice had increased A2aR level in lungs.	Bleomycin	9-18	adenosine A2a receptor	Mus musculus	54-58
27658704-15	2016	Moreover, Increased TGF-beta1 and p-ERK1/2 expressions in bleomycin-treated A2aR-/- and A2aR+/+ mice were obviously diminished by baicalin.	Bleomycin	58-67	transforming growth factor, beta 1	Mus musculus	20-29
27658704-15	2016	Moreover, Increased TGF-beta1 and p-ERK1/2 expressions in bleomycin-treated A2aR-/- and A2aR+/+ mice were obviously diminished by baicalin.	Bleomycin	58-67	mitogen-activated protein kinase 3	Mus musculus	36-42
27658704-15	2016	Moreover, Increased TGF-beta1 and p-ERK1/2 expressions in bleomycin-treated A2aR-/- and A2aR+/+ mice were obviously diminished by baicalin.	Bleomycin	58-67	adenosine A2a receptor	Mus musculus	76-80
27658704-15	2016	Moreover, Increased TGF-beta1 and p-ERK1/2 expressions in bleomycin-treated A2aR-/- and A2aR+/+ mice were obviously diminished by baicalin.	Bleomycin	58-67	adenosine A2a receptor	Mus musculus	88-92
27658704-18	2016	CONCLUSIONS: Genetic inactivation of A2aR exacerbated the pathological processes of bleomycin-induced pulmonary fibrosis.	Bleomycin	84-93	adenosine A2a receptor	Mus musculus	37-41
27658704-19	2016	Together, baicalin could inhibit BLM-induced pulmonary fibrosis by upregulating A2aR, suggesting A2aR as a therapeutic target of baicalin for the treatment of pulmonary fibrosis.	Bleomycin	33-36	adenosine A2a receptor	Mus musculus	80-84
27658704-19	2016	Together, baicalin could inhibit BLM-induced pulmonary fibrosis by upregulating A2aR, suggesting A2aR as a therapeutic target of baicalin for the treatment of pulmonary fibrosis.	Bleomycin	33-36	adenosine A2a receptor	Mus musculus	97-101
27649073-3	2016	We hypothesized that loss of Th17 cells via CD4-specific deletion of mTORC1 activity would abrogate the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	119-128	CREB regulated transcription coactivator 1	Mus musculus	69-75
27500311-3	2016	One inhibitor displayed efficacy in a murine model of bleomycin-induced lung fibrosis similar to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests that blocking galectin-3 glycan recognition is an important antifibrotic drug target.	Bleomycin	54-63	lectin, galactose binding, soluble 3	Mus musculus	197-207
27356186-0	2016	Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition.	Bleomycin	54-63	lectin, galactose binding, soluble 3	Mus musculus	0-10
27658724-0	2016	Discordance in cathepsin B and cystatin C expressions in bronchoalveolar fluids between murine bleomycin-induced fibrosis and human idiopathic fibrosis.	Bleomycin	95-104	cystatin C	Mus musculus	31-41
27658724-1	2016	The activity of cysteine cathepsin B increased markedly in lung homogenates and in bronchoalveolar lavage fluids (BALF) of the mouse model of bleomycin-induced lung fibrosis after 14 days of challenge.	Bleomycin	142-151	cathepsin B	Mus musculus	25-36
26750756-0	2016	Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.	Bleomycin	86-95	interleukin 17A	Mus musculus	15-20
27604640-7	2016	UCHL5, Smad2, and Smad3 levels were increased in bleomycin-injured lungs.	Bleomycin	49-58	ubiquitin C-terminal hydrolase L5	Homo sapiens	0-5
27604640-7	2016	UCHL5, Smad2, and Smad3 levels were increased in bleomycin-injured lungs.	Bleomycin	49-58	SMAD family member 2	Homo sapiens	7-12
27604640-7	2016	UCHL5, Smad2, and Smad3 levels were increased in bleomycin-injured lungs.	Bleomycin	49-58	SMAD family member 3	Homo sapiens	18-23
27604640-8	2016	Administration of UCHL5 inhibitor, b-AP15, reduced the expression of FN, type I collagen, Smad2/Smad3, and the deposition of collagen in lung tissues in a bleomycin-induced model of pulmonary fibrosis.	Bleomycin	155-164	ubiquitin C-terminal hydrolase L5	Homo sapiens	18-23
27436123-10	2016	Nuclear overexpression of Trx1 restored Nrf2-ARE activity and attenuated alcohol-induced TGFbeta1 expression and alcohol-induced exaggerate response to bleomycin-induced acute lung injury.	Bleomycin	152-161	thioredoxin 1	Mus musculus	26-30
27083148-0	2016	The regulatory role of interferon-gamma producing gamma delta T cells via the suppression of T helper 17 cell activity in bleomycin-induced pulmonary fibrosis.	Bleomycin	122-131	interferon gamma	Mus musculus	23-39
27083148-4	2016	In wild-type (WT) mice exposed to bleomycin, pulmonary gammadeltaT cells were expanded and produced large amounts of interferon (IFN)-gamma and interleukin (IL)-17A.	Bleomycin	34-43	interferon gamma	Mus musculus	117-139
26987798-8	2016	Deletion of HAS2 in mouse mesenchymal cells increased the cellular senescence of fibroblasts in bleomycin-induced mouse lung fibrosis in vivo.	Bleomycin	96-105	hyaluronan synthase 2	Mus musculus	12-16
27083148-4	2016	In wild-type (WT) mice exposed to bleomycin, pulmonary gammadeltaT cells were expanded and produced large amounts of interferon (IFN)-gamma and interleukin (IL)-17A.	Bleomycin	34-43	interleukin 17A	Mus musculus	144-164
27083148-5	2016	Histological and biochemical analyses showed that bleomycin-induced IP was more severe in T cell receptor (TCR-delta-deficient (TCRdelta(-/-) ) mice than WT mice.	Bleomycin	50-59	T cell receptor delta chain	Mus musculus	107-141
27083148-6	2016	In TCRdelta(-/-) mice, pulmonary IL-17A(+) CD4(+) Tau cells expanded at days 7 and 14 after bleomycin exposure.	Bleomycin	92-101	interleukin 17A	Mus musculus	33-39
27083148-6	2016	In TCRdelta(-/-) mice, pulmonary IL-17A(+) CD4(+) Tau cells expanded at days 7 and 14 after bleomycin exposure.	Bleomycin	92-101	CD4 antigen	Mus musculus	43-46
27083148-12	2016	These results suggested that pulmonary gammadeltaT cells seem to play a regulatory role in the development of bleomycin-induced IP mouse model via the suppression of IL-17A production.	Bleomycin	110-119	interleukin 17A	Mus musculus	166-172
27928554-6	2016	RESULTS: Exposure to Bleo significantly induced AGT protein (p&lt;0.02), extracellular ANGII levels (p&lt; 0.005) and the active form of caspase-9 (p&lt;0.05) in neonatal lung tissue.	Bleomycin	21-25	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	48-51
27928554-6	2016	RESULTS: Exposure to Bleo significantly induced AGT protein (p&lt;0.02), extracellular ANGII levels (p&lt; 0.005) and the active form of caspase-9 (p&lt;0.05) in neonatal lung tissue.	Bleomycin	21-25	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	87-92
27928554-6	2016	RESULTS: Exposure to Bleo significantly induced AGT protein (p&lt;0.02), extracellular ANGII levels (p&lt; 0.005) and the active form of caspase-9 (p&lt;0.05) in neonatal lung tissue.	Bleomycin	21-25	caspase 9	Mus musculus	137-146
27928554-7	2016	Further, Bleo inducetion of both AGT protein and of caspase-9 were prevented by the ACE inhibitor lisinopril.	Bleomycin	9-13	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	33-36
27928554-7	2016	Further, Bleo inducetion of both AGT protein and of caspase-9 were prevented by the ACE inhibitor lisinopril.	Bleomycin	9-13	caspase 9	Mus musculus	52-61
27928554-7	2016	Further, Bleo inducetion of both AGT protein and of caspase-9 were prevented by the ACE inhibitor lisinopril.	Bleomycin	9-13	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	84-87
27621593-6	2016	IL-6 is also implicated in the pathogenesis of SSc in animal models as it is increased in mice with bleomycin-induced fibrosis, whereas neutralization of IL-6 in these mice prevents skin fibrosis.	Bleomycin	100-109	interleukin 6	Mus musculus	0-4
27475884-0	2016	Role of histamine H4 receptor ligands in bleomycin-induced pulmonary fibrosis.	Bleomycin	41-50	histamine receptor H4	Mus musculus	8-29
27582065-4	2016	We found that EZH2 was upregulated in the lungs of patients with IPF and in mice with bleomycin-induced lung fibrosis.	Bleomycin	86-95	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	14-18
27317904-0	2016	CD4(+)CD25(hi)Foxp3(+) Cells Exacerbate Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	40-49	CD4 molecule	Homo sapiens	0-3
27535718-6	2016	Genetic ablation of alpha6 in collagen-expressing mesenchymal cells or pharmacological blockade of matrix stiffness-regulated alpha6-expression protects mice against bleomycin injury-induced experimental lung fibrosis.	Bleomycin	166-175	gamma-aminobutyric acid (GABA) A receptor, subunit alpha 6	Mus musculus	20-26
27549302-9	2016	Pirfenidone treatment or direct overexpression of recombinant RGS2 in human lung fibroblasts inhibited the profibrotic effects of thrombin, whereas loss of RGS2 exacerbated bleomycin-induced pulmonary fibrosis and mortality in mice.	Bleomycin	173-182	regulator of G protein signaling 2	Homo sapiens	156-160
27317904-6	2016	IL-2 complex was used in vivo to expand CD4(+)CD25(hi)Foxp3(+) cells in the lung during intratracheal bleomycin challenge; however, this unexpectedly led to an increase in lung fibrosis.	Bleomycin	102-111	interleukin 2	Homo sapiens	0-4
27317904-6	2016	IL-2 complex was used in vivo to expand CD4(+)CD25(hi)Foxp3(+) cells in the lung during intratracheal bleomycin challenge; however, this unexpectedly led to an increase in lung fibrosis.	Bleomycin	102-111	CD4 molecule	Homo sapiens	40-43
27317904-9	2016	Mechanistically, we demonstrated that CD4(+)CD25(hi)Foxp3(+) cells undergo alterations during bleomycin challenge and the IL-2 complex had no effect on profibrotic (eg, transforming growth factor-beta) or type 17 immune response cytokines; however, there was a marked down-regulation of the type 1 and augmentation of the type 2 immune response cytokines from the lungs.	Bleomycin	94-103	CD4 molecule	Homo sapiens	38-41
27317685-7	2016	Bleomycin-induced increases in tissue neutrophils and macrophages and lung contents of LTB4 and tumor necrosis factor-alpha were all prevented by treatment with zileuton.	Bleomycin	0-9	tumor necrosis factor	Homo sapiens	87-123
26945694-8	2016	Enrichment of a TGFbeta-responsive signature was observed in both Tsk2/+ mice and mice with bleomycin-induced skin fibrosis.	Bleomycin	92-101	transforming growth factor, beta 1	Mus musculus	16-23
27317687-6	2016	In the bleomycin (BLM) model of lung fibrosis and PH, we also report decreased BMPR2 expression compared with control animals that correlated with vascular remodeling and PH.	Bleomycin	7-16	bone morphogenetic protein receptor type 2	Homo sapiens	79-84
27317687-6	2016	In the bleomycin (BLM) model of lung fibrosis and PH, we also report decreased BMPR2 expression compared with control animals that correlated with vascular remodeling and PH.	Bleomycin	18-21	bone morphogenetic protein receptor type 2	Homo sapiens	79-84
27112840-0	2016	Inhibition of Wnt/beta-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-beta1 and FGF-2.	Bleomycin	52-61	catenin (cadherin associated protein), beta 1	Mus musculus	18-30
26933834-10	2016	Bleomycin-exposed aged NLRP3(-/-) mice had reduced fibrosis compared with their wild-type age-matched counterparts.	Bleomycin	0-9	NLR family, pyrin domain containing 3	Mus musculus	23-28
26934670-7	2016	In vivo, we observed reduced myeloperoxidase release relative to neutrophil numbers in bleomycin-injured Mmp7(-/-) and Sdc1(-/-) mice.	Bleomycin	87-96	matrix metallopeptidase 7	Mus musculus	105-109
27112840-0	2016	Inhibition of Wnt/beta-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-beta1 and FGF-2.	Bleomycin	52-61	transforming growth factor, beta 1	Mus musculus	122-131
27112840-0	2016	Inhibition of Wnt/beta-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-beta1 and FGF-2.	Bleomycin	52-61	fibroblast growth factor 2	Mus musculus	136-141
27112840-3	2016	In the present study, we found that transforming growth factor-beta1 (TGF-beta1) and fibroblast growth factor 2 (FGF-2) were both upregulated in bleomycin-induced fibrotic lung tissue and primary murine alveolar epithelial Type II (ATII) cells treated with bleomycin.	Bleomycin	145-154	transforming growth factor, beta 1	Mus musculus	36-68
27112840-3	2016	In the present study, we found that transforming growth factor-beta1 (TGF-beta1) and fibroblast growth factor 2 (FGF-2) were both upregulated in bleomycin-induced fibrotic lung tissue and primary murine alveolar epithelial Type II (ATII) cells treated with bleomycin.	Bleomycin	145-154	transforming growth factor, beta 1	Mus musculus	70-79
27112840-3	2016	In the present study, we found that transforming growth factor-beta1 (TGF-beta1) and fibroblast growth factor 2 (FGF-2) were both upregulated in bleomycin-induced fibrotic lung tissue and primary murine alveolar epithelial Type II (ATII) cells treated with bleomycin.	Bleomycin	145-154	fibroblast growth factor 2	Mus musculus	85-111
27112840-3	2016	In the present study, we found that transforming growth factor-beta1 (TGF-beta1) and fibroblast growth factor 2 (FGF-2) were both upregulated in bleomycin-induced fibrotic lung tissue and primary murine alveolar epithelial Type II (ATII) cells treated with bleomycin.	Bleomycin	145-154	fibroblast growth factor 2	Mus musculus	113-118
27112840-3	2016	In the present study, we found that transforming growth factor-beta1 (TGF-beta1) and fibroblast growth factor 2 (FGF-2) were both upregulated in bleomycin-induced fibrotic lung tissue and primary murine alveolar epithelial Type II (ATII) cells treated with bleomycin.	Bleomycin	257-266	transforming growth factor, beta 1	Mus musculus	36-68
27541374-1	2016	PURPOSE: The purpose of this study is to investigate the serial changes in the SP-D concentrations of serum and bronchoalveolar lavage fluid (BALF) in a bleomycin-induced lung injury rat model and compare them with the levels of conventional biochemical markers.	Bleomycin	153-162	surfactant protein D	Rattus norvegicus	79-83
27112840-3	2016	In the present study, we found that transforming growth factor-beta1 (TGF-beta1) and fibroblast growth factor 2 (FGF-2) were both upregulated in bleomycin-induced fibrotic lung tissue and primary murine alveolar epithelial Type II (ATII) cells treated with bleomycin.	Bleomycin	257-266	transforming growth factor, beta 1	Mus musculus	70-79
27112840-3	2016	In the present study, we found that transforming growth factor-beta1 (TGF-beta1) and fibroblast growth factor 2 (FGF-2) were both upregulated in bleomycin-induced fibrotic lung tissue and primary murine alveolar epithelial Type II (ATII) cells treated with bleomycin.	Bleomycin	257-266	fibroblast growth factor 2	Mus musculus	85-111
27112840-3	2016	In the present study, we found that transforming growth factor-beta1 (TGF-beta1) and fibroblast growth factor 2 (FGF-2) were both upregulated in bleomycin-induced fibrotic lung tissue and primary murine alveolar epithelial Type II (ATII) cells treated with bleomycin.	Bleomycin	257-266	fibroblast growth factor 2	Mus musculus	113-118
27112840-6	2016	Moreover, in our study, we found that Wnt/beta-catenin signaling was activated both in vitro and in vivo as a result of bleomycin treatment.	Bleomycin	120-129	catenin (cadherin associated protein), beta 1	Mus musculus	42-54
27112840-7	2016	Interestingly, we also found that suppression of the Wnt/beta-catenin signaling could significantly attenuate bleomycin-induced PF accompanied with decreased expression of TGF-beta1 and FGF-2 in vitro and in vivo.	Bleomycin	110-119	catenin (cadherin associated protein), beta 1	Mus musculus	57-69
27112840-7	2016	Interestingly, we also found that suppression of the Wnt/beta-catenin signaling could significantly attenuate bleomycin-induced PF accompanied with decreased expression of TGF-beta1 and FGF-2 in vitro and in vivo.	Bleomycin	110-119	fibroblast growth factor 2	Mus musculus	186-191
27066886-6	2016	However, bleomycin-induced fibrosis in skin proceeded in a comparable manner in MMP-14(Sf+/+) and MMP-14(Sf-/-) mice, but resolution over time was impaired in MMP-14(Sf-/-) mice.	Bleomycin	9-18	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	80-86
27400124-4	2016	In a murine model, ablation of TBX4-expressing cells or disruption of TBX4 signaling attenuated lung fibrosis after bleomycin-induced injury.	Bleomycin	116-125	T-box 4	Mus musculus	31-35
27400124-4	2016	In a murine model, ablation of TBX4-expressing cells or disruption of TBX4 signaling attenuated lung fibrosis after bleomycin-induced injury.	Bleomycin	116-125	T-box 4	Mus musculus	70-74
27066886-6	2016	However, bleomycin-induced fibrosis in skin proceeded in a comparable manner in MMP-14(Sf+/+) and MMP-14(Sf-/-) mice, but resolution over time was impaired in MMP-14(Sf-/-) mice.	Bleomycin	9-18	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	98-104
27066886-6	2016	However, bleomycin-induced fibrosis in skin proceeded in a comparable manner in MMP-14(Sf+/+) and MMP-14(Sf-/-) mice, but resolution over time was impaired in MMP-14(Sf-/-) mice.	Bleomycin	9-18	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	98-104
27444321-0	2016	miR-877-3p targets Smad7 and is associated with myofibroblast differentiation and bleomycin-induced lung fibrosis.	Bleomycin	82-91	microRNA 877	Homo sapiens	0-7
27279470-8	2016	The protein levels of Vimentin and phospho-SMAD2 were upregulated, whereas the level of E-cadherin was downregulated in the MCMV+bleomycin group,.	Bleomycin	129-138	cadherin 1	Mus musculus	88-98
27358001-0	2016	IL-33/ST2 pathway in a bleomycin-induced pulmonary fibrosis model.	Bleomycin	23-32	interleukin 33	Homo sapiens	0-5
27358001-0	2016	IL-33/ST2 pathway in a bleomycin-induced pulmonary fibrosis model.	Bleomycin	23-32	ST2	Homo sapiens	6-9
27358001-12	2016	In conclusion, the IL-33/ST2 signaling pathway was found to be involved in the rodent model of pulmonary fibrosis induced by bleomycin.	Bleomycin	125-134	interleukin 33	Homo sapiens	19-24
27358001-12	2016	In conclusion, the IL-33/ST2 signaling pathway was found to be involved in the rodent model of pulmonary fibrosis induced by bleomycin.	Bleomycin	125-134	ST2	Homo sapiens	25-28
27135434-0	2016	GRP78 and CHOP modulate macrophage apoptosis and the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	68-77	heat shock protein 5	Mus musculus	0-5
27135434-0	2016	GRP78 and CHOP modulate macrophage apoptosis and the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	68-77	DNA-damage inducible transcript 3	Mus musculus	10-14
27135434-4	2016	We demonstrate here that Grp78(+/-) mice were strongly protected from bleomycin-induced fibrosis, as shown by immunohistochemical analysis, collagen content and lung function measurements.	Bleomycin	70-79	heat shock protein 5	Mus musculus	25-30
27135434-7	2016	In contrast, the administration of bleomycin to Chop(-/-) mice resulted in increased quasi-static elastance and extracellular matrix deposition associated with an increased number of parenchymal arginase-1-positive macrophages that were negative for cleaved caspase-3.	Bleomycin	35-44	DNA-damage inducible transcript 3	Mus musculus	48-52
27135434-7	2016	In contrast, the administration of bleomycin to Chop(-/-) mice resulted in increased quasi-static elastance and extracellular matrix deposition associated with an increased number of parenchymal arginase-1-positive macrophages that were negative for cleaved caspase-3.	Bleomycin	35-44	arginase, liver	Mus musculus	195-205
27135434-9	2016	GRP78- and CHOP-mediated macrophage apoptosis was found to protect against bleomycin-induced fibrosis.	Bleomycin	75-84	heat shock protein 5	Mus musculus	0-5
27135434-9	2016	GRP78- and CHOP-mediated macrophage apoptosis was found to protect against bleomycin-induced fibrosis.	Bleomycin	75-84	DNA-damage inducible transcript 3	Mus musculus	11-15
27135434-10	2016	Overall, we demonstrate here that the fibrotic response to bleomycin is dependent on GRP78-mediated events and provides evidence that macrophage polarization and apoptosis may play a role in this process.	Bleomycin	59-68	heat shock protein 5	Mus musculus	85-90
27444321-0	2016	miR-877-3p targets Smad7 and is associated with myofibroblast differentiation and bleomycin-induced lung fibrosis.	Bleomycin	82-91	SMAD family member 7	Homo sapiens	19-24
27444321-3	2016	We found that miR-877-3p sequestration inhibited the myofibroblast differentiation of LR-MSC and attenuates bleomycin-induced lung fibrosis by targeting Smad7.	Bleomycin	108-117	microRNA 877	Homo sapiens	14-21
27444321-3	2016	We found that miR-877-3p sequestration inhibited the myofibroblast differentiation of LR-MSC and attenuates bleomycin-induced lung fibrosis by targeting Smad7.	Bleomycin	108-117	SMAD family member 7	Homo sapiens	153-158
27679543-0	2016	Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors.	Bleomycin	25-34	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	51-55
27435875-4	2016	Superoxide dismutase 3 (Sod3), Gpx3, and Gpx activity were increased in mouse BALF during bleomycin-induced lung fibrosis.	Bleomycin	90-99	superoxide dismutase 3, extracellular	Mus musculus	0-22
27435875-4	2016	Superoxide dismutase 3 (Sod3), Gpx3, and Gpx activity were increased in mouse BALF during bleomycin-induced lung fibrosis.	Bleomycin	90-99	superoxide dismutase 3, extracellular	Mus musculus	24-28
27435875-4	2016	Superoxide dismutase 3 (Sod3), Gpx3, and Gpx activity were increased in mouse BALF during bleomycin-induced lung fibrosis.	Bleomycin	90-99	glutathione peroxidase 3	Mus musculus	31-35
27435875-4	2016	Superoxide dismutase 3 (Sod3), Gpx3, and Gpx activity were increased in mouse BALF during bleomycin-induced lung fibrosis.	Bleomycin	90-99	peroxiredoxin 6 pseudogene 2	Mus musculus	31-34
27247426-4	2016	We previously showed an association of the differences in collagen deposition in the lungs of bleomycin-treated mice with a reduced molar pro-MMP-9/TIMP-1 ratio.	Bleomycin	94-103	matrix metallopeptidase 9	Mus musculus	138-147
27247426-4	2016	We previously showed an association of the differences in collagen deposition in the lungs of bleomycin-treated mice with a reduced molar pro-MMP-9/TIMP-1 ratio.	Bleomycin	94-103	tissue inhibitor of metalloproteinase 1	Mus musculus	148-154
27279371-11	2016	Furthermore, bleomycin-induced lung fibrosis was enhanced in PARK2 knockout mice and subsequently inhibited by AG1296.	Bleomycin	13-22	parkin RBR E3 ubiquitin protein ligase	Mus musculus	61-66
27508041-7	2016	Lentivirus-mediated over-expression of miR-338* can alleviate lung fibrosis induced by bleomycin in mice.	Bleomycin	87-96	microRNA 338	Mus musculus	39-46
27508042-8	2016	MiR-338* was down-regulated in the lung tissue from mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	62-71	microRNA 338	Mus musculus	0-7
27508042-12	2016	Furthermore, in vivo, lentivirus-mediated over-expression of miR-338* can alleviate lung fibrosis induced by bleomycin in mice.	Bleomycin	109-118	microRNA 338	Mus musculus	61-68
27679543-0	2016	Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors.	Bleomycin	25-34	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	98-102
27679543-7	2016	Furthermore, the synergistic interaction between vemurafenib and ECT with bleomycin was demonstrated in the BRAF V600E mutated melanoma cells.	Bleomycin	74-83	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	108-112
27025963-9	2016	In vivo, compared with controls, N-WASP down-regulation increases survival and prevents lung edema in mice induced by bleomycin exposure-a lung injury model in which TGF-beta1 plays a critical role.	Bleomycin	118-127	WASP like actin nucleation promoting factor	Mus musculus	33-39
27471572-0	2016	Bleomycin (BLM) Induces Epithelial-to-Mesenchymal Transition in Cultured A549 Cells via the TGF-beta/Smad Signaling Pathway.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	92-100
27471572-0	2016	Bleomycin (BLM) Induces Epithelial-to-Mesenchymal Transition in Cultured A549 Cells via the TGF-beta/Smad Signaling Pathway.	Bleomycin	11-14	transforming growth factor beta 1	Homo sapiens	92-100
27377409-14	2016	miR-155ko mice developed milder lung fibrosis, survived longer, and weaker lung induction of several genes after bleomycin exposure compared to wild-type mice.	Bleomycin	113-122	microRNA 155	Mus musculus	0-7
26997256-5	2016	In the bleomycin model of skin fibrosis, FMOD(-/-) mice developed skin fibrosis to a similar degree compared to FMOD(+/+) mice.	Bleomycin	7-16	fibromodulin	Mus musculus	41-45
27025963-9	2016	In vivo, compared with controls, N-WASP down-regulation increases survival and prevents lung edema in mice induced by bleomycin exposure-a lung injury model in which TGF-beta1 plays a critical role.	Bleomycin	118-127	transforming growth factor, beta 1	Mus musculus	166-175
27206766-4	2016	The results showed that lung AREG expression was significantly induced in bleomycin-induced pulmonary fibrosis.	Bleomycin	74-83	amphiregulin	Homo sapiens	29-33
27206766-8	2016	Conversely, adoptive transfer of bone marrow-derived CD11c(+) cells from bleomycin-treated donor mice exacerbated pulmonary fibrosis, but not if the donor cells were made AREG deficient prior to transfer.	Bleomycin	73-82	integrin subunit alpha X	Homo sapiens	53-58
27206766-12	2016	These findings suggested that induced AREG specifically in recruited bone marrow-derived CD11c(+) cells promoted bleomycin-induced pulmonary fibrosis by activation of fibroblast telomerase reverse transcriptase-dependent proliferation, motility, and indirectly, myofibroblast differentiation.	Bleomycin	113-122	amphiregulin	Homo sapiens	38-42
27206766-12	2016	These findings suggested that induced AREG specifically in recruited bone marrow-derived CD11c(+) cells promoted bleomycin-induced pulmonary fibrosis by activation of fibroblast telomerase reverse transcriptase-dependent proliferation, motility, and indirectly, myofibroblast differentiation.	Bleomycin	113-122	integrin subunit alpha X	Homo sapiens	89-94
27270966-0	2016	Periostin Deficiency Causes Severe and Lethal Lung Injury in Mice With Bleomycin Administration.	Bleomycin	71-80	periostin, osteoblast specific factor	Mus musculus	0-9
26895395-11	2016	CONCLUSIONS: AT accelerates the resolution of lung inflammation and fibrosis in a model of bleomycin-induced lung fibrosis partly via attenuation of 5-HT/Akt signaling.	Bleomycin	91-100	thymoma viral proto-oncogene 1	Mus musculus	154-157
27270966-4	2016	Here, we show that the ECM architecture organized by periostin, a matricellular protein, plays a pivotal role in the survival of bleomycin-exposed mice.	Bleomycin	129-138	periostin, osteoblast specific factor	Mus musculus	53-62
27270966-6	2016	Although periostin-null mice displayed no significant difference in lung histology and air-blood permeability, they exhibited early lethality in a model of bleomycin-induced lung injury, compared with their wild-type counterparts.	Bleomycin	156-165	periostin, osteoblast specific factor	Mus musculus	9-18
27270966-7	2016	This early lethality may have been due to increased pulmonary leakage of blood fluid into the air space in the bleomycin-exposed periostin-null mice.	Bleomycin	111-120	periostin, osteoblast specific factor	Mus musculus	129-138
27358914-9	2016	Bleomycin- and AdTGFbeta-induced increases in collagen content, alpha-SMA, FAS S-glutathionylation, and total protein S-glutathionylation were strongly attenuated in Gstp-/- mice.	Bleomycin	0-9	actin alpha 2, smooth muscle, aorta	Mus musculus	64-73
27007017-3	2016	The results showed that, despite the phenotypic differences and different lengths of the putative truncated AtMRE11 proteins, all three atmre11 and the atatm-2 mutant lines exhibited common hypersensitivity to bleomycin treatment, where they only slightly reduced mitotic activity, indicating a G2/M checkpoint abrogation.	Bleomycin	210-219	DNA repair and meiosis protein (Mre11)	Arabidopsis thaliana	108-115
27007017-3	2016	The results showed that, despite the phenotypic differences and different lengths of the putative truncated AtMRE11 proteins, all three atmre11 and the atatm-2 mutant lines exhibited common hypersensitivity to bleomycin treatment, where they only slightly reduced mitotic activity, indicating a G2/M checkpoint abrogation.	Bleomycin	210-219	DNA repair and meiosis protein (Mre11)	Arabidopsis thaliana	136-143
27188426-6	2016	This investigation also determined longer bleomycin cleavage sequences, with preferred cleavage at 5"-GT*A and 5"- TGT* trinucleotide sequences, and 5"-TGT*A tetranucleotides.	Bleomycin	42-51	queuine tRNA-ribosyltransferase catalytic subunit 1	Homo sapiens	115-118
27327270-1	2016	BACKGROUND: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients.	Bleomycin	67-76	bleomycin hydrolase	Homo sapiens	12-31
27327270-1	2016	BACKGROUND: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients.	Bleomycin	67-76	bleomycin hydrolase	Homo sapiens	33-37
27327270-1	2016	BACKGROUND: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients.	Bleomycin	169-178	bleomycin hydrolase	Homo sapiens	12-31
27327270-1	2016	BACKGROUND: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients.	Bleomycin	169-178	bleomycin hydrolase	Homo sapiens	33-37
27327270-6	2016	CONCLUSION: Besides limitations of the current study, bleomycin pharmacokinetics should be further evaluated in patients with BLMH variations, hence identify those cases even in the frontline setting, where bleomycin should be omitted and replaced with targeted therapy.	Bleomycin	54-63	bleomycin hydrolase	Homo sapiens	126-130
27278104-5	2016	Experiments performed using a bleomycin-instilled mouse model of pulmonary fibrosis showed that Salvianolic acid B (SAB), the major ingredient of SM, had strong anti-inflammatory and anti-fibrotic effects through its inhibition of inflammatory cell infiltration, alveolar structure disruption, and collagen deposition.	Bleomycin	30-39	SH3-domain binding protein 5 (BTK-associated)	Mus musculus	116-119
27029074-0	2016	Preventive and therapeutic effects of thymosin beta4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis.	Bleomycin	88-97	thymosin, beta 4, X chromosome	Mus musculus	38-52
27029074-7	2016	Moreover, IHC and quantitative RT-PCR results demonstrated a significant decrease in BLEO-induced IL-17 and TGF-beta expression in lung tissue.	Bleomycin	85-89	interleukin 17A	Mus musculus	98-103
27029074-7	2016	Moreover, IHC and quantitative RT-PCR results demonstrated a significant decrease in BLEO-induced IL-17 and TGF-beta expression in lung tissue.	Bleomycin	85-89	transforming growth factor, beta 1	Mus musculus	108-116
27358914-9	2016	Bleomycin- and AdTGFbeta-induced increases in collagen content, alpha-SMA, FAS S-glutathionylation, and total protein S-glutathionylation were strongly attenuated in Gstp-/- mice.	Bleomycin	0-9	glutathione S-transferase pi 1	Homo sapiens	166-170
27358914-10	2016	Oropharyngeal administration of the GSTP inhibitor, TLK117, at a time when fibrosis was already apparent, attenuated bleomycin- and AdTGFbeta-induced remodeling, alpha-SMA, caspase activation, FAS S-glutathionylation, and total protein S-glutathionylation.	Bleomycin	117-126	glutathione S-transferase pi 1	Homo sapiens	36-40
27006447-4	2016	We found that bleomycin injury increases the bronchoalveolar lavage (BAL) fluid levels of ATX protein 17-fold.	Bleomycin	14-23	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	90-93
26884454-9	2016	In vivo RNAi-mediated silencing of CCN1 attenuates fibrogenic responses to bleomycin-induced lung injury.	Bleomycin	75-84	cyclin A2	Homo sapiens	35-39
26814616-6	2016	RESULTS: Up-regulation of Fra-2 was detected in bleomycin-challenged mice and in skin biopsy samples from SSc patients.	Bleomycin	48-57	fos-like antigen 2	Mus musculus	26-31
27006447-7	2016	Further, administration of the potent ATX inhibitor PAT-048 to bleomycin-challenged mice markedly decreased ATX activity systemically and in the lung, without effect on pulmonary LPA or fibrosis.	Bleomycin	63-72	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	38-41
27006447-7	2016	Further, administration of the potent ATX inhibitor PAT-048 to bleomycin-challenged mice markedly decreased ATX activity systemically and in the lung, without effect on pulmonary LPA or fibrosis.	Bleomycin	63-72	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	108-111
26974397-0	2016	Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis.	Bleomycin	60-69	secretory leukocyte peptidase inhibitor	Mus musculus	0-38
27162139-6	2016	FIEL1 overexpression significantly increases fibrosis in a bleomycin murine model, whereas FIEL1 knockdown attenuates fibrotic conditions.	Bleomycin	59-68	apoptosis resistant E3 ubiquitin protein ligase 1	Homo sapiens	0-5
27144281-0	2016	MAP3K19 Is a Novel Regulator of TGF-beta Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis.	Bleomycin	64-73	mitogen-activated protein kinase kinase kinase 19	Homo sapiens	0-7
27209208-0	2016	Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice.	Bleomycin	60-69	endothelin receptor type B	Mus musculus	12-29
27209208-5	2016	This study was conducted to evaluate the profibrotic function of ETB receptor signaling in a murine model of bleomycin (BLM)-induced scleroderma.	Bleomycin	109-118	endothelin receptor type B	Mus musculus	65-68
27209208-5	2016	This study was conducted to evaluate the profibrotic function of ETB receptor signaling in a murine model of bleomycin (BLM)-induced scleroderma.	Bleomycin	120-123	endothelin receptor type B	Mus musculus	65-68
27173636-3	2016	In a bleomycin-induced PF model, mice deficient in p-rex1 had well-preserved alveolar structure and survived significantly better than their wild type (WT) littermates.	Bleomycin	5-14	phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1	Mus musculus	51-57
27274768-12	2016	The expression of miR-9-5p was also detected in the skin and plasma in the mouse model of bleomycin-induced dermal fibrosis.	Bleomycin	90-99	microRNA 95	Homo sapiens	18-26
27150447-10	2016	Three courses of induction systemic chemotherapy (cisplatin, etoposide, and bleomycin) normalized his serum alpha-fetoprotein and DUPAN-2 levels.	Bleomycin	76-85	alpha fetoprotein	Homo sapiens	108-125
27144281-0	2016	MAP3K19 Is a Novel Regulator of TGF-beta Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis.	Bleomycin	64-73	transforming growth factor beta 1	Homo sapiens	32-40
27144281-3	2016	We investigated the role of a novel kinase, MAP3K19, upregulated in IPF tissue, in TGF-beta-induced signal transduction and in bleomycin-induced pulmonary fibrosis.	Bleomycin	127-136	mitogen-activated protein kinase kinase kinase 19	Homo sapiens	44-51
27144281-10	2016	Finally, in an animal model of IPF, inhibition of MAP3K19 strongly attenuated bleomycin-induced pulmonary fibrosis when administered either prophylactically ortherapeutically.	Bleomycin	78-87	mitogen-activated protein kinase kinase kinase 19	Homo sapiens	50-57
26488390-2	2016	We sought to determine whether loss of pVHL in fibroblasts prevents injury and fibrosis in mice that are treated with bleomycin.	Bleomycin	118-127	von Hippel-Lindau tumor suppressor	Mus musculus	39-43
26488390-7	2016	Suppression of pVHL also decreased bleomycin-induced Wnt signaling and prostaglandin E2 signaling but did not affect bleomycin-induced initial acute lung injury and lung inflammation.	Bleomycin	35-44	von Hippel-Lindau tumor suppressor	Mus musculus	15-19
26488390-8	2016	These results indicate that pVHL has a pivotal role in bleomycin-induced pulmonary fibrosis, possibly via an HIF-independent pathway.	Bleomycin	55-64	von Hippel-Lindau tumor suppressor	Mus musculus	28-32
26849959-9	2016	Moreover, bleomycin-induced lung fibrosis was attenuated in FZD8-deficient mice in vivo Although inhibition of canonical WNT signaling did not affect TGF-beta1-induced gene expression in vitro, noncanonical WNT-5B mimicked TGF-beta1-induced fibroblast activation.	Bleomycin	10-19	wingless-type MMTV integration site family, member 5B	Mus musculus	207-213
27033261-0	2016	Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients.	Bleomycin	64-73	homeostatic iron regulator	Homo sapiens	17-20
27033261-5	2016	We investigated the association between two common allelic variants of the HFE gene, H63D and C282Y, with development of pulmonary and renal toxicity during and after treatment with bleomycin- and cisplatin-containing chemotherapy.	Bleomycin	182-191	homeostatic iron regulator	Homo sapiens	75-78
27033261-12	2016	When validated and confirmed, HFE H63D genotyping may be used to identify patients with increased risk for pulmonary bleomycin toxicity.	Bleomycin	117-126	homeostatic iron regulator	Homo sapiens	30-33
26749424-0	2016	Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	118-127	netrin 1	Homo sapiens	0-8
26749424-12	2016	Netrin-1(+/-) mice were protected against bleomycin-induced lung fibrosis and fibrocyte accumulation.	Bleomycin	42-51	netrin 1	Mus musculus	0-8
26749424-14	2016	Netrin-1 regulates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	19-28	netrin 1	Mus musculus	0-8
27249616-0	2016	Sirt 1 activator attenuates the bleomycin-induced lung fibrosis in mice via inhibiting epithelial-to-mesenchymal transition (EMT).	Bleomycin	32-41	sirtuin 1	Mus musculus	0-6
27249616-5	2016	Moreover, resveratrol also inhibited the BLM-induced EMT-associated molecular events, such as reduced E-cadherin and elevated Collagen I and alpha-SMA.	Bleomycin	41-44	cadherin 1	Mus musculus	102-112
26849959-9	2016	Moreover, bleomycin-induced lung fibrosis was attenuated in FZD8-deficient mice in vivo Although inhibition of canonical WNT signaling did not affect TGF-beta1-induced gene expression in vitro, noncanonical WNT-5B mimicked TGF-beta1-induced fibroblast activation.	Bleomycin	10-19	transforming growth factor, beta 1	Mus musculus	223-232
26883801-4	2016	Patients with IPF and mice with bleomycin (BLM)-induced pulmonary fibrosis were affected by the altered Chop expression and ER stress.	Bleomycin	32-41	DNA-damage inducible transcript 3	Mus musculus	104-108
26883801-4	2016	Patients with IPF and mice with bleomycin (BLM)-induced pulmonary fibrosis were affected by the altered Chop expression and ER stress.	Bleomycin	43-46	DNA-damage inducible transcript 3	Mus musculus	104-108
29931963-1	2016	OBJECTIVE: To observe the expression of 5-Hydroxytryptamine 2B receptor (5-HTR2B) E-cadherin (E-cad) alpha-smooth muscle actin(alpha-SMA) in the bleomycin -induced pulmonary fibrosis tissue of rats.	Bleomycin	145-154	cadherin 1	Rattus norvegicus	82-92
27043297-6	2016	Using the structural information, we developed the modified anti-ATX DNA aptamer RB014, which exhibited in vivo efficacy in a bleomycin-induced pulmonary fibrosis mouse model.	Bleomycin	126-135	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	65-68
26599507-6	2016	MEASUREMENTS AND MAIN RESULTS: Matriptase expression and activity were up-regulated in IPF and bleomycin-induced pulmonary fibrosis.	Bleomycin	95-104	suppression of tumorigenicity 14 (colon carcinoma)	Mus musculus	31-41
26599507-9	2016	In the experimental bleomycin model, matriptase depletion, by the pharmacological inhibitor CM or by genetic down-regulation, diminished lung injury, collagen production, and transforming growth factor-beta expression and signaling.	Bleomycin	20-29	suppression of tumorigenicity 14 (colon carcinoma)	Mus musculus	37-47
26663085-9	2016	Conversely, restoration of FAP expression in the lungs of FAP-deficient mice decreases lung hydroxyproline content after intratracheal bleomycin to levels comparable with that of wild-type controls.	Bleomycin	135-144	fibroblast activation protein	Mus musculus	27-30
27071460-2	2016	METHODS: We evaluated the expression of WNT10A and TGF-beta in bleomycin (BLM)-treated mice and the interactions between TGF-beta or BLM and WNT10A in vitro.	Bleomycin	63-72	wingless-type MMTV integration site family, member 10A	Mus musculus	40-46
27071460-2	2016	METHODS: We evaluated the expression of WNT10A and TGF-beta in bleomycin (BLM)-treated mice and the interactions between TGF-beta or BLM and WNT10A in vitro.	Bleomycin	63-72	transforming growth factor, beta 1	Mus musculus	51-59
29931963-1	2016	OBJECTIVE: To observe the expression of 5-Hydroxytryptamine 2B receptor (5-HTR2B) E-cadherin (E-cad) alpha-smooth muscle actin(alpha-SMA) in the bleomycin -induced pulmonary fibrosis tissue of rats.	Bleomycin	145-154	cadherin 1	Rattus norvegicus	82-87
29931963-9	2016	Compared with bleomycin group, the corresponding mRNA and protein expression of 5-HTR2B and a-SMA in bleomycin+prednisone group had decreased (P&lt;0.05); however, the corresponding mRNA and protein expression of E-cad had increased(P&lt;0.05).	Bleomycin	101-110	cadherin 1	Rattus norvegicus	213-218
26378893-3	2016	We first show that transforming growth factor-beta1 and bleomycin increase X-linked IAP (XIAP) and cellular IAP (cIAP)-1 and -2 in murine lungs and mesenchymal cells.	Bleomycin	56-65	X-linked inhibitor of apoptosis	Mus musculus	89-93
26378893-3	2016	We first show that transforming growth factor-beta1 and bleomycin increase X-linked IAP (XIAP) and cellular IAP (cIAP)-1 and -2 in murine lungs and mesenchymal cells.	Bleomycin	56-65	baculoviral IAP repeat-containing 3	Mus musculus	99-127
26378893-4	2016	Functional blockade of XIAP and the cIAPs with AT-406, an orally bioavailable second mitochondria-derived activator of caspases (Smac) mimetic, abrogated bleomycin-induced lung fibrosis when given both prophylactically and therapeutically.	Bleomycin	154-163	X-linked inhibitor of apoptosis	Mus musculus	23-27
26378893-4	2016	Functional blockade of XIAP and the cIAPs with AT-406, an orally bioavailable second mitochondria-derived activator of caspases (Smac) mimetic, abrogated bleomycin-induced lung fibrosis when given both prophylactically and therapeutically.	Bleomycin	154-163	diablo, IAP-binding mitochondrial protein	Mus musculus	129-133
26661692-7	2016	Supporting these results, Ctsl mRNA levels were decreased in the skin of bleomycin-treated mice, an SSc animal model recapitulating its fibrotic aspect, and CTSL expression was enhanced in dermal small vessels of endothelial cell-specific Fli1 knockout mice, reminiscent of SSc vasculopathy.	Bleomycin	73-82	cathepsin L	Mus musculus	26-30
26521845-7	2016	A similar increase in Flii was observed in hypertrophic scars formed in mice post-treatment with bleomycin.	Bleomycin	97-106	flightless I actin binding protein	Mus musculus	22-26
26521845-8	2016	However, Flii-deficient (Flii(+/-) ) mice had reduced scarring in response to bleomycin evidenced by decreased dermal thickness, smaller cross-sectional scar areas, fewer myofibroblasts and a decreased collagen I/III ratio.	Bleomycin	78-87	flightless I actin binding protein	Mus musculus	9-13
26521845-9	2016	In contrast, bleomycin-treated Flii-overexpressing mice (Flii(Tg/Tg) ) showed increased scar dermal thickness, larger cross-sectional scar areas, more myofibroblasts and an increased collagen I/III ratio.	Bleomycin	13-22	flightless I actin binding protein	Mus musculus	31-35
26521845-9	2016	In contrast, bleomycin-treated Flii-overexpressing mice (Flii(Tg/Tg) ) showed increased scar dermal thickness, larger cross-sectional scar areas, more myofibroblasts and an increased collagen I/III ratio.	Bleomycin	13-22	flightless I actin binding protein	Mus musculus	57-61
27036297-2	2016	We have previously demonstrated that naringenin significantly reduced TGF-beta1 levels in bleomycin-induced lung fibrosis and effectively prevented pulmonary metastases of tumors.	Bleomycin	90-99	transforming growth factor, beta 1	Mus musculus	70-79
26750154-0	2016	Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-gamma in colon.	Bleomycin	26-35	hepatocyte growth factor	Mus musculus	107-131
26661692-7	2016	Supporting these results, Ctsl mRNA levels were decreased in the skin of bleomycin-treated mice, an SSc animal model recapitulating its fibrotic aspect, and CTSL expression was enhanced in dermal small vessels of endothelial cell-specific Fli1 knockout mice, reminiscent of SSc vasculopathy.	Bleomycin	73-82	Friend leukemia integration 1	Mus musculus	239-243
25545680-0	2016	Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis.	Bleomycin	120-129	interleukin 21 receptor	Mus musculus	50-56
26743600-5	2016	Conversely, the alpha2AP neutralization prevented not only profibrotic changes, but also the production of autoantibodies in bleomycin-induced mouse models of SSc.	Bleomycin	125-134	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	16-24
27055835-12	2016	MFAP4 levels were increased in BAL of bleomycin treated mice with pulmonary fibrosis.	Bleomycin	38-47	microfibrillar-associated protein 4	Mus musculus	0-5
26998906-1	2016	Modulation of chemokine CXCL12 and its receptor CXCR4 has been implicated in attenuation of bleomycin (BLM)-induced pulmonary fibrosis and carbon tetrachloride (CCl4)-induced hepatic injury.	Bleomycin	92-101	chemokine (C-X-C motif) ligand 12	Mus musculus	24-30
26998906-1	2016	Modulation of chemokine CXCL12 and its receptor CXCR4 has been implicated in attenuation of bleomycin (BLM)-induced pulmonary fibrosis and carbon tetrachloride (CCl4)-induced hepatic injury.	Bleomycin	92-101	chemokine (C-X-C motif) receptor 4	Mus musculus	48-53
26998906-1	2016	Modulation of chemokine CXCL12 and its receptor CXCR4 has been implicated in attenuation of bleomycin (BLM)-induced pulmonary fibrosis and carbon tetrachloride (CCl4)-induced hepatic injury.	Bleomycin	103-106	chemokine (C-X-C motif) ligand 12	Mus musculus	24-30
26998906-1	2016	Modulation of chemokine CXCL12 and its receptor CXCR4 has been implicated in attenuation of bleomycin (BLM)-induced pulmonary fibrosis and carbon tetrachloride (CCl4)-induced hepatic injury.	Bleomycin	103-106	chemokine (C-X-C motif) receptor 4	Mus musculus	48-53
26998906-0	2016	Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice.	Bleomycin	39-48	chemokine (C-X-C motif) ligand 12	Mus musculus	12-18
26998906-0	2016	Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice.	Bleomycin	50-53	chemokine (C-X-C motif) ligand 12	Mus musculus	12-18
26998906-0	2016	Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice.	Bleomycin	50-53	chemokine (C-X-C motif) receptor 4	Mus musculus	19-24
25589515-10	2016	Knockout of ATF3 protected mice from bleomycin-induced fibrosis and fibrosis induced by overexpression of a constitutively active TGFbeta receptor I.	Bleomycin	37-46	activating transcription factor 3	Mus musculus	12-16
26817844-7	2016	Intratracheal or intravenous delivery two or three times of amphiregulin or connective tissue growth factor SAMiRNAs significantly reduced the bleomycin- or TGF-beta-stimulated collagen accumulation in the lung and substantially restored the lung function of TGF-beta transgenic mice.	Bleomycin	143-152	amphiregulin	Mus musculus	60-72
26817844-7	2016	Intratracheal or intravenous delivery two or three times of amphiregulin or connective tissue growth factor SAMiRNAs significantly reduced the bleomycin- or TGF-beta-stimulated collagen accumulation in the lung and substantially restored the lung function of TGF-beta transgenic mice.	Bleomycin	143-152	cellular communication network factor 2	Mus musculus	76-107
26765958-4	2016	Using the bleomycin mouse model for fibrosis, we examined an array of BMP accessory proteins for changes in mRNA expression.	Bleomycin	10-19	bone morphogenetic protein 1	Homo sapiens	70-73
26765958-6	2016	Protein expression studies demonstrated increased levels of noggin, BAMBI, and FSTL1 in the lungs of bleomycin-treated mice and in the lungs of idiopathic pulmonary fibrosis patients.	Bleomycin	101-110	noggin	Mus musculus	60-66
26765958-6	2016	Protein expression studies demonstrated increased levels of noggin, BAMBI, and FSTL1 in the lungs of bleomycin-treated mice and in the lungs of idiopathic pulmonary fibrosis patients.	Bleomycin	101-110	BMP and activin membrane-bound inhibitor	Mus musculus	68-73
26765958-6	2016	Protein expression studies demonstrated increased levels of noggin, BAMBI, and FSTL1 in the lungs of bleomycin-treated mice and in the lungs of idiopathic pulmonary fibrosis patients.	Bleomycin	101-110	follistatin-like 1	Mus musculus	79-84
26971883-3	2016	Since the PI3K/PTEN pathway in myeloid cells influences their effector functions, we wanted to elucidate how sustained PI3K activity induced by cell-type specific genetic deficiency of its antagonist PTEN modulates IPF, in a murine model of bleomycin-induced pulmonary fibrosis (BIPF).	Bleomycin	241-250	phosphatase and tensin homolog	Mus musculus	200-204
26971883-5	2016	Analysis of alveolar lavage and lung cell composition revealed that PTEN(MyKO) mice exhibit reduced numbers of macrophages and T-cells in response to bleomycin, indicating an impaired recruitment function.	Bleomycin	150-159	phosphatase and tensin homolog	Mus musculus	68-72
25589515-10	2016	Knockout of ATF3 protected mice from bleomycin-induced fibrosis and fibrosis induced by overexpression of a constitutively active TGFbeta receptor I.	Bleomycin	37-46	transforming growth factor, beta 1	Mus musculus	130-137
25603829-8	2016	Moreover, siRNA-mediated knockdown of TRB3 exerted potent antifibrotic effects and ameliorated bleomycin as well as constitutively active TGF-beta receptor I-induced fibrosis with reduced dermal thickening, decreased hydroxyproline content and impaired myofibroblast differentiation.	Bleomycin	95-104	tribbles pseudokinase 3	Homo sapiens	38-42
26859835-0	2016	Heat Shock Protein 27 Plays a Pivotal Role in Myofibroblast Differentiation and in the Development of Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	102-111	heat shock protein family B (small) member 1	Homo sapiens	0-21
26660455-6	2016	Also, the number of CD31-positive blood vessels was markedly reduced in the bleomycin-treated skin.	Bleomycin	76-85	platelet/endothelial cell adhesion molecule 1	Mus musculus	20-24
26867682-5	2016	Accordingly, abrogation of Chk1 activity with UCN-01 and its expression with shChk1 increased sensitivity to bleomycin and radiation.	Bleomycin	109-118	checkpoint kinase 1	Homo sapiens	27-31
26577463-0	2016	Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-kappaB and TGF-beta1/Smad-2/-3 pathways.	Bleomycin	29-38	NFE2 like bZIP transcription factor 2	Rattus norvegicus	81-85
26577463-0	2016	Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-kappaB and TGF-beta1/Smad-2/-3 pathways.	Bleomycin	29-38	SMAD family member 2	Rattus norvegicus	151-160
26817817-0	2016	Astragalus injection attenuates bleomycin-induced pulmonary fibrosis via down-regulating Jagged1/Notch1 in lungs.	Bleomycin	32-41	jagged canonical Notch ligand 1	Rattus norvegicus	89-96
26817817-0	2016	Astragalus injection attenuates bleomycin-induced pulmonary fibrosis via down-regulating Jagged1/Notch1 in lungs.	Bleomycin	32-41	notch receptor 1	Rattus norvegicus	97-103
26817817-8	2016	KEY FINDINGS: BLM-induced severe alveolitis and pulmonary fibrosis; together with significant elevation of alpha-SMA, TGF-beta1, Jagged1 and Notch1.	Bleomycin	14-17	transforming growth factor, beta 1	Rattus norvegicus	118-127
26817817-8	2016	KEY FINDINGS: BLM-induced severe alveolitis and pulmonary fibrosis; together with significant elevation of alpha-SMA, TGF-beta1, Jagged1 and Notch1.	Bleomycin	14-17	jagged canonical Notch ligand 1	Rattus norvegicus	129-136
26817817-8	2016	KEY FINDINGS: BLM-induced severe alveolitis and pulmonary fibrosis; together with significant elevation of alpha-SMA, TGF-beta1, Jagged1 and Notch1.	Bleomycin	14-17	notch receptor 1	Rattus norvegicus	141-147
26919045-11	2016	Forced expression of OCT4 significantly increased the secondary sphere formation and cell migration, and reduced susceptibility of HBV-HCC cells to cisplatin, bleomycin, and doxorubicin.	Bleomycin	159-168	POU class 5 homeobox 1	Homo sapiens	21-25
26895702-3	2016	Given the pathophysiological importance of fibroblast activation in pulmonary fibrosis, we hypothesized that the anti-fibrotic and anti-inflammatory effects of exogenous CNP against bleomycin (BLM)-induced pulmonary fibrosis were exerted in part by the effect of CNP on pulmonary fibroblasts.	Bleomycin	182-191	natriuretic peptide type C	Mus musculus	170-173
26895702-3	2016	Given the pathophysiological importance of fibroblast activation in pulmonary fibrosis, we hypothesized that the anti-fibrotic and anti-inflammatory effects of exogenous CNP against bleomycin (BLM)-induced pulmonary fibrosis were exerted in part by the effect of CNP on pulmonary fibroblasts.	Bleomycin	193-196	natriuretic peptide type C	Mus musculus	170-173
26895702-8	2016	RESULTS: CNP reduced mRNA levels of the profibrotic cytokines interleukin (IL)-1beta and IL-6, as well as collagen deposition and the fibrotic area in lungs of mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	170-179	natriuretic peptide type C	Mus musculus	9-12
26895702-12	2016	CONCLUSIONS: These data suggest that CNP ameliorates bleomycin-induced pulmonary fibrosis by suppressing TGF-beta signaling and myofibroblastic differentiation in lung fibroblasts.	Bleomycin	53-62	natriuretic peptide type C	Mus musculus	37-40
26821114-0	2016	Fluorofenidone attenuates bleomycin-induced pulmonary fibrosis by inhibiting eukaryotic translation initiation factor 3a (eIF3a) in rats.	Bleomycin	26-35	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	122-127
26821114-12	2016	The results indicate that fluorofenidone significantly improves the pathological changes in lung tissues and reduces the deposition of collagen by inhibiting eIF3a in rats with bleomycin-induced PF.	Bleomycin	177-186	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	158-163
26859835-4	2016	In lung tissues of bleomycin-treated mice, HSP27 was strongly upregulated and substantially co-localized with alpha-SMA, OPN and type I collagen but not with proSP-C (a marker of type II alveolar epithelial cells), E-cadherin (a marker of epithelial cells) or F4/80 (a marker of macrophages).	Bleomycin	19-28	heat shock protein 1	Mus musculus	43-48
26859835-4	2016	In lung tissues of bleomycin-treated mice, HSP27 was strongly upregulated and substantially co-localized with alpha-SMA, OPN and type I collagen but not with proSP-C (a marker of type II alveolar epithelial cells), E-cadherin (a marker of epithelial cells) or F4/80 (a marker of macrophages).	Bleomycin	19-28	actin alpha 2, smooth muscle, aorta	Mus musculus	110-119
26859835-4	2016	In lung tissues of bleomycin-treated mice, HSP27 was strongly upregulated and substantially co-localized with alpha-SMA, OPN and type I collagen but not with proSP-C (a marker of type II alveolar epithelial cells), E-cadherin (a marker of epithelial cells) or F4/80 (a marker of macrophages).	Bleomycin	19-28	secreted phosphoprotein 1	Mus musculus	121-124
26859835-4	2016	In lung tissues of bleomycin-treated mice, HSP27 was strongly upregulated and substantially co-localized with alpha-SMA, OPN and type I collagen but not with proSP-C (a marker of type II alveolar epithelial cells), E-cadherin (a marker of epithelial cells) or F4/80 (a marker of macrophages).	Bleomycin	19-28	cadherin 1	Mus musculus	215-225
26859835-4	2016	In lung tissues of bleomycin-treated mice, HSP27 was strongly upregulated and substantially co-localized with alpha-SMA, OPN and type I collagen but not with proSP-C (a marker of type II alveolar epithelial cells), E-cadherin (a marker of epithelial cells) or F4/80 (a marker of macrophages).	Bleomycin	19-28	adhesion G protein-coupled receptor E1	Mus musculus	260-265
26859835-6	2016	Furthermore, airway delivery of HSP27 siRNA effectively suppressed bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	67-76	heat shock protein 1	Mus musculus	32-37
26414805-9	2016	Similar to the GVHD model, PAI-1 neutralization reduced dermal inflammation and fibrosis in the bleomycin model.	Bleomycin	96-105	serpin family E member 1	Homo sapiens	27-32
26310139-0	2016	Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	108-117	epoxide hydrolase 2, cytoplasmic	Mus musculus	0-25
26656160-7	2016	Incubation with bleomycin increased the p38 MAPK and JNK levels and downregulated EGFR pathway.	Bleomycin	16-25	mitogen-activated protein kinase 14	Homo sapiens	40-43
26656160-7	2016	Incubation with bleomycin increased the p38 MAPK and JNK levels and downregulated EGFR pathway.	Bleomycin	16-25	mitogen-activated protein kinase 8	Homo sapiens	53-56
26656160-7	2016	Incubation with bleomycin increased the p38 MAPK and JNK levels and downregulated EGFR pathway.	Bleomycin	16-25	epidermal growth factor receptor	Homo sapiens	82-86
26656160-8	2016	Coincubation of bleomycin with NAC reversed effects caused by bleomycin.	Bleomycin	16-25	X-linked Kx blood group	Homo sapiens	31-34
26656160-8	2016	Coincubation of bleomycin with NAC reversed effects caused by bleomycin.	Bleomycin	62-71	X-linked Kx blood group	Homo sapiens	31-34
26310139-3	2016	We test the effects of a selected sEH inhibitor, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), on bleomycin-induced pulmonary fibrosis (PF) in mice.	Bleomycin	120-129	epoxide hydrolase 2, cytoplasmic	Mus musculus	34-37
26310139-8	2016	TPPU decreased the transforming growth factor-beta1 (TGF-beta1), interleukin-1beta (IL-1beta) and IL-6 levels in the serum of bleomycin-stimulated mice.	Bleomycin	126-135	interleukin 6	Mus musculus	98-102
26310139-10	2016	Our results indicate that the inhibition of sEH attenuates bleomycin-induced inflammation and collagen deposition and therefore prevents bleomycin-induced PF in a mouse model.	Bleomycin	59-68	epoxide hydrolase 2, cytoplasmic	Mus musculus	44-47
26310139-10	2016	Our results indicate that the inhibition of sEH attenuates bleomycin-induced inflammation and collagen deposition and therefore prevents bleomycin-induced PF in a mouse model.	Bleomycin	137-146	epoxide hydrolase 2, cytoplasmic	Mus musculus	44-47
26526764-0	2016	Role of NOS2 in pulmonary injury and repair in response to bleomycin.	Bleomycin	59-68	nitric oxide synthase 2, inducible	Mus musculus	8-12
26526764-2	2016	In this study, we investigate the role of NOS2 in pulmonary inflammation/fibrosis in response to intratracheal bleomycin instillation (ITB) and to determine if these effects are related to macrophage phenotype.	Bleomycin	111-120	nitric oxide synthase 2, inducible	Mus musculus	42-46
26367492-7	2016	Our results confirmed that systemic administration of bleomycin exerts oxidative stress indicated by an increase in Sod1 at 0.33, 1, and 4w (P&lt;0.05).	Bleomycin	54-63	superoxide dismutase 1	Homo sapiens	116-120
26967475-6	2016	Moreover, a series of BLM-induced pathologic events, including endothelial-to-mesenchymal transition; ICAM-1 expression in endothelial cells; the infiltration of macrophages, mast cells, and lymphocytes; and M2 macrophage differentiation, were attenuated by Am80.	Bleomycin	22-25	intercellular adhesion molecule 1	Mus musculus	102-108
26911661-0	2016	Allograft inflammatory factor-1 in the pathogenesis of bleomycin-induced acute lung injury.	Bleomycin	55-64	allograft inflammatory factor 1	Mus musculus	0-31
26911661-4	2016	The current study used bleomycin-induced acute lung injury to analyze the expression of AIF-1 and to examine its function in acute lung injury.	Bleomycin	23-32	allograft inflammatory factor 1	Mus musculus	88-93
26911661-5	2016	Results showed that AIF-1 was significantly expressed in lung macrophages and increased in bronchoalveolar lavage fluid from mice with bleomycin-induced acute lung injury in comparison to control mice.	Bleomycin	135-144	allograft inflammatory factor 1	Mus musculus	20-25
26367492-10	2016	The present study suggests that bleomycin-induced reactive oxygen species (ROS) causes DNA stress affecting the endothelial niche, initiating repair processes including Wnt signaling.	Bleomycin	32-41	Wnt family member 3A	Homo sapiens	169-172
26768967-7	2016	Most of all, the inhaled Tac Alb-NPs displayed remarkable anti-fibrotic efficacy in mice with bleomycin-induced pulmonary fibrosis, which was much better than the efficacy resulting from intraperitoneal administration of Tac (60 mug/mouse) based on histopathological results (hematoxylin and eosin and Masson"s trichrome staining).	Bleomycin	94-103	albumin	Mus musculus	29-32
26779814-4	2016	Whereas the chemokine receptor CXCR7, expressed on PCECs, acts to prevent epithelial damage and ameliorate fibrosis after a single round of treatment with bleomycin or hydrochloric acid, repeated injury leads to suppression of CXCR7 expression and recruitment of vascular endothelial growth factor receptor 1 (VEGFR1)-expressing perivascular macrophages.	Bleomycin	155-164	atypical chemokine receptor 3	Mus musculus	31-36
26828700-5	2016	MiR-155(-/-) mice were resistant to bleomycin induced skin fibrosis.	Bleomycin	36-45	microRNA 155	Mus musculus	0-7
26828700-9	2016	Mice with miR-155 knockout or topical antagomir-155 treatment showed inhibited Wnt/beta-catenin and Akt signaling in skin upon bleomycin challenge.	Bleomycin	127-136	microRNA 155	Mus musculus	10-17
26828700-9	2016	Mice with miR-155 knockout or topical antagomir-155 treatment showed inhibited Wnt/beta-catenin and Akt signaling in skin upon bleomycin challenge.	Bleomycin	127-136	catenin (cadherin associated protein), beta 1	Mus musculus	83-95
26828700-9	2016	Mice with miR-155 knockout or topical antagomir-155 treatment showed inhibited Wnt/beta-catenin and Akt signaling in skin upon bleomycin challenge.	Bleomycin	127-136	thymoma viral proto-oncogene 1	Mus musculus	100-103
26763945-9	2016	Importantly, FAK inhibitor protects bleomycin-induced lung fibrosis in mice.	Bleomycin	36-45	PTK2 protein tyrosine kinase 2	Mus musculus	13-16
26763945-10	2016	FAK inhibitor blocks FAK activation and significantly reduces signaling cascade of fibroblast migration in bleomycin-challenged mice.	Bleomycin	107-116	PTK2 protein tyrosine kinase 2	Mus musculus	0-3
26763945-10	2016	FAK inhibitor blocks FAK activation and significantly reduces signaling cascade of fibroblast migration in bleomycin-challenged mice.	Bleomycin	107-116	PTK2 protein tyrosine kinase 2	Mus musculus	21-24
26763945-11	2016	Furthermore, FAK inhibitor decreases lung fibrotic score, collagen accumulation, fibronectin production, and myofibroblast differentiation in in bleomycin-challenged mice.	Bleomycin	145-154	PTK2 protein tyrosine kinase 2	Mus musculus	13-16
26763945-11	2016	Furthermore, FAK inhibitor decreases lung fibrotic score, collagen accumulation, fibronectin production, and myofibroblast differentiation in in bleomycin-challenged mice.	Bleomycin	145-154	fibronectin 1	Mus musculus	81-92
26545899-0	2016	CaMKII inhibition in type II pneumocytes protects from bleomycin-induced pulmonary fibrosis by preventing Ca2+-dependent apoptosis.	Bleomycin	55-64	calcium/calmodulin-dependent protein kinase II, beta	Mus musculus	0-6
26520185-11	2016	In addition, BLM-induced phosphorylation of pulmonary p38 MAPK and protein kinase B (Akt) was inhibited by calcitriol.	Bleomycin	13-16	mitogen-activated protein kinase 14	Mus musculus	54-62
26520185-11	2016	In addition, BLM-induced phosphorylation of pulmonary p38 MAPK and protein kinase B (Akt) was inhibited by calcitriol.	Bleomycin	13-16	thymoma viral proto-oncogene 1	Mus musculus	85-88
26738569-3	2016	The expression of TGF-beta1 and TREM-1 was increased on day 7, 14, and 21 after single intratracheal injection of bleomycin (BLM).	Bleomycin	114-123	transforming growth factor, beta 1	Mus musculus	18-27
26738569-3	2016	The expression of TGF-beta1 and TREM-1 was increased on day 7, 14, and 21 after single intratracheal injection of bleomycin (BLM).	Bleomycin	114-123	triggering receptor expressed on myeloid cells 1	Mus musculus	32-38
26520185-10	2016	Moreover, BLM-induced nuclear translocation of nuclear factor kappa B (NF-kappaB) p65 was blocked by calcitriol.	Bleomycin	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	47-69
26520185-10	2016	Moreover, BLM-induced nuclear translocation of nuclear factor kappa B (NF-kappaB) p65 was blocked by calcitriol.	Bleomycin	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	71-80
26520185-10	2016	Moreover, BLM-induced nuclear translocation of nuclear factor kappa B (NF-kappaB) p65 was blocked by calcitriol.	Bleomycin	10-13	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	82-85
26545899-5	2016	Thus we hypothesized that CaMKII inhibition alleviates fibrosis in response to bleomycin by attenuating apoptosis and ER stress of type II pneumocytes.	Bleomycin	79-88	calcium/calmodulin-dependent protein kinase II, beta	Mus musculus	26-32
26545899-6	2016	We first established that CaMKII was strongly expressed in the distal respiratory epithelium, in particular in surfactant protein-C-positive type II pneumocytes, and activated after bleomycin instillation.	Bleomycin	182-191	calcium/calmodulin-dependent protein kinase II, beta	Mus musculus	26-32
26545899-11	2016	These data demonstrate that CaMKII inhibition prevents type II pneumocyte apoptosis and development of pulmonary fibrosis in response to bleomycin.	Bleomycin	137-146	calcium/calmodulin-dependent protein kinase II, beta	Mus musculus	28-34
26523765-5	2016	Some esp1-ts mutants were hypersensitive to the microtubule poison benomyl and/or the DNA-damaging agent bleomycin.	Bleomycin	105-114	separase	Saccharomyces cerevisiae S288C	5-9
25180292-10	2016	Consistently, mice with fibroblast-specific knockdown of Sirt1 were less susceptible to bleomycin- or TBRIact-induced fibrosis.	Bleomycin	88-97	sirtuin 1	Mus musculus	57-62
26889245-9	2016	The treatment suppressed the increases in hydroxyproline content, MPO activity, TNF-alpha and TGF-beta levels and attenuated the reduction of SOD activity that were induced by bleomycin.	Bleomycin	176-185	tumor necrosis factor	Rattus norvegicus	80-89
26960158-8	2016	We compared oxidative stress parameters and found lower malondialdehyde and myeloperoxidase levels, and higher total sulfhydryl levels and catalase activities for the bleomycin + propolis group than for the bleomycin and bleomycin + prednisolone groups.	Bleomycin	167-176	myeloperoxidase	Rattus norvegicus	76-91
26372067-0	2016	Role of thioredoxin nitration in bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	33-42	thioredoxin 1	Rattus norvegicus	8-19
26889245-9	2016	The treatment suppressed the increases in hydroxyproline content, MPO activity, TNF-alpha and TGF-beta levels and attenuated the reduction of SOD activity that were induced by bleomycin.	Bleomycin	176-185	transforming growth factor, beta 1	Rattus norvegicus	94-102
26889245-6	2016	In addition, bleomycin administration increased the hydroxyproline content, myeloperoxidase (MPO) activity, tumor necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta levels and decreased the superoxide dismutase (SOD) activity in the rat lung tissues.	Bleomycin	13-22	myeloperoxidase	Rattus norvegicus	76-91
27797602-7	2016	RESULTS: Bleomycin increased intercellular adhesion molecule 1 (ICAM-1; CD54), vascular cell adhesion molecule (VCAM-1; CD106), and E-selectin (CD62E) expression, and increased monocyte chemoattractant protein (MCP-1) and interleukin (IL-8) release by endothelial cells.	Bleomycin	9-18	intercellular adhesion molecule 1	Homo sapiens	29-62
26889245-6	2016	In addition, bleomycin administration increased the hydroxyproline content, myeloperoxidase (MPO) activity, tumor necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta levels and decreased the superoxide dismutase (SOD) activity in the rat lung tissues.	Bleomycin	13-22	myeloperoxidase	Rattus norvegicus	93-96
26889245-6	2016	In addition, bleomycin administration increased the hydroxyproline content, myeloperoxidase (MPO) activity, tumor necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta levels and decreased the superoxide dismutase (SOD) activity in the rat lung tissues.	Bleomycin	13-22	tumor necrosis factor	Rattus norvegicus	108-141
27797599-5	2016	RESULTS: PDTC attenuated bleomycin-induced pulmonary fibrosis as evidenced by histological observations, decreased iNOS expression and prevention of bleomycin-induced altered total and differential leukocytes count.	Bleomycin	25-34	nitric oxide synthase 2	Rattus norvegicus	115-119
27797602-7	2016	RESULTS: Bleomycin increased intercellular adhesion molecule 1 (ICAM-1; CD54), vascular cell adhesion molecule (VCAM-1; CD106), and E-selectin (CD62E) expression, and increased monocyte chemoattractant protein (MCP-1) and interleukin (IL-8) release by endothelial cells.	Bleomycin	9-18	intercellular adhesion molecule 1	Homo sapiens	64-70
27797602-7	2016	RESULTS: Bleomycin increased intercellular adhesion molecule 1 (ICAM-1; CD54), vascular cell adhesion molecule (VCAM-1; CD106), and E-selectin (CD62E) expression, and increased monocyte chemoattractant protein (MCP-1) and interleukin (IL-8) release by endothelial cells.	Bleomycin	9-18	intercellular adhesion molecule 1	Homo sapiens	72-76
26324850-6	2016	Phosphorylated STAT-3 was elevated in lung biopsies from patients with idiopathic pulmonary fibrosis and bleomycin (BLM)-induced fibrotic murine lungs.	Bleomycin	105-114	signal transducer and activator of transcription 3	Homo sapiens	15-21
26396235-1	2016	Cyclooxygenase (COX)-2 has been shown to be involved in regulating basal airway function, bacterial LPS-induced airway hyperresponsiveness (AHR) and lung inflammation, and bleomycin-induced lung fibrosis; however, the cellular source of COX-2 that underlies these effects is unknown.	Bleomycin	172-181	cytochrome c oxidase II, mitochondrial	Mus musculus	0-22
26396235-1	2016	Cyclooxygenase (COX)-2 has been shown to be involved in regulating basal airway function, bacterial LPS-induced airway hyperresponsiveness (AHR) and lung inflammation, and bleomycin-induced lung fibrosis; however, the cellular source of COX-2 that underlies these effects is unknown.	Bleomycin	172-181	cytochrome c oxidase II, mitochondrial	Mus musculus	237-242
27797602-7	2016	RESULTS: Bleomycin increased intercellular adhesion molecule 1 (ICAM-1; CD54), vascular cell adhesion molecule (VCAM-1; CD106), and E-selectin (CD62E) expression, and increased monocyte chemoattractant protein (MCP-1) and interleukin (IL-8) release by endothelial cells.	Bleomycin	9-18	vascular cell adhesion molecule 1	Homo sapiens	112-118
27797602-7	2016	RESULTS: Bleomycin increased intercellular adhesion molecule 1 (ICAM-1; CD54), vascular cell adhesion molecule (VCAM-1; CD106), and E-selectin (CD62E) expression, and increased monocyte chemoattractant protein (MCP-1) and interleukin (IL-8) release by endothelial cells.	Bleomycin	9-18	vascular cell adhesion molecule 1	Homo sapiens	120-125
27797602-7	2016	RESULTS: Bleomycin increased intercellular adhesion molecule 1 (ICAM-1; CD54), vascular cell adhesion molecule (VCAM-1; CD106), and E-selectin (CD62E) expression, and increased monocyte chemoattractant protein (MCP-1) and interleukin (IL-8) release by endothelial cells.	Bleomycin	9-18	selectin E	Homo sapiens	132-142
27797602-7	2016	RESULTS: Bleomycin increased intercellular adhesion molecule 1 (ICAM-1; CD54), vascular cell adhesion molecule (VCAM-1; CD106), and E-selectin (CD62E) expression, and increased monocyte chemoattractant protein (MCP-1) and interleukin (IL-8) release by endothelial cells.	Bleomycin	9-18	selectin E	Homo sapiens	144-149
27797602-7	2016	RESULTS: Bleomycin increased intercellular adhesion molecule 1 (ICAM-1; CD54), vascular cell adhesion molecule (VCAM-1; CD106), and E-selectin (CD62E) expression, and increased monocyte chemoattractant protein (MCP-1) and interleukin (IL-8) release by endothelial cells.	Bleomycin	9-18	C-C motif chemokine ligand 2	Homo sapiens	211-216
27797602-10	2016	Under flow conditions, endothelial cells exposed to bleomycin supported increased neutrophil adhesion which was independent of ICAM-1 or E-selectin.	Bleomycin	52-61	intercellular adhesion molecule 1	Homo sapiens	127-133
27797602-10	2016	Under flow conditions, endothelial cells exposed to bleomycin supported increased neutrophil adhesion which was independent of ICAM-1 or E-selectin.	Bleomycin	52-61	selectin E	Homo sapiens	137-147
26638033-2	2016	Bleomycin was found to cleave preferentially at 5"-TGT*A-3" DNA sequences (where * is the cleavage site).	Bleomycin	0-9	queuine tRNA-ribosyltransferase catalytic subunit 1	Homo sapiens	51-54
26600069-0	2016	TRPM2 channels in alveolar epithelial cells mediate bleomycin-induced lung inflammation.	Bleomycin	52-61	transient receptor potential cation channel, subfamily M, member 2	Mus musculus	0-5
26604088-0	2016	Lentivirus expressing soluble ST2 alleviates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	45-54	interleukin 1 receptor-like 1	Mus musculus	30-33
26604088-1	2016	It has been shown that the expression of ST2, a receptor of interleukin (IL)-33, is elevated in the lungs of idiopathic pulmonary fibrosis patients and bleomycin-induced mouse models, however its contribution to the development of pulmonary fibrosis has yet to be tested.	Bleomycin	152-161	interleukin 1 receptor-like 1	Mus musculus	41-44
26604088-2	2016	In the present study, we treated mice by intranasal instillation of lentivirus expressing soluble ST2 and evaluated lung inflammation and fibrosis in the bleomycin-induced pulmonary fibrosis mouse model.	Bleomycin	154-163	interleukin 1 receptor-like 1	Mus musculus	98-101
26604088-6	2016	The results indicate that ST2 might prevent bleomycin-induced pulmonary fibrosis possibly through downregulating proinflammatory and profibrotic mediators.	Bleomycin	44-53	interleukin 1 receptor-like 1	Mus musculus	26-29
26638033-9	2016	However, the overall bleomycin DNA sequence specificity was very similar in the two environments, namely 5"-TGT*A-3".	Bleomycin	21-30	queuine tRNA-ribosyltransferase catalytic subunit 1	Homo sapiens	108-111
26153764-0	2016	A protective role for IL-13 receptor alpha 1 in bleomycin-induced pulmonary injury and repair.	Bleomycin	48-57	interleukin 13	Mus musculus	22-27
26153764-4	2016	We report dysregulated levels of IL-13 receptors in the lungs of bleomycin-treated mice and to some extent in idiopathic pulmonary fibrosis patients.	Bleomycin	65-74	interleukin 13	Mus musculus	33-38
26153764-6	2016	IL-13Ralpha1 regulated a striking array of genes in the lung following bleomycin administration and Il13ra1 deficiency resulted in exacerbated bleomycin-induced disease.	Bleomycin	71-80	interleukin 13 receptor, alpha 1	Mus musculus	0-12
26153764-6	2016	IL-13Ralpha1 regulated a striking array of genes in the lung following bleomycin administration and Il13ra1 deficiency resulted in exacerbated bleomycin-induced disease.	Bleomycin	143-152	interleukin 13 receptor, alpha 1	Mus musculus	100-107
26153764-7	2016	Increased pathology in bleomycin-treated Il13ra1(-/-) mice was due to IL-13Ralpha1 expression in structural and hematopoietic cells but not due to increased responsiveness to IL-17, IL-4, IL-13, increased IL-13Ralpha2 or type 1 IL-4R signaling.	Bleomycin	23-32	interleukin 13 receptor, alpha 1	Mus musculus	41-48
26153764-7	2016	Increased pathology in bleomycin-treated Il13ra1(-/-) mice was due to IL-13Ralpha1 expression in structural and hematopoietic cells but not due to increased responsiveness to IL-17, IL-4, IL-13, increased IL-13Ralpha2 or type 1 IL-4R signaling.	Bleomycin	23-32	interleukin 13 receptor, alpha 1	Mus musculus	70-82
26153764-7	2016	Increased pathology in bleomycin-treated Il13ra1(-/-) mice was due to IL-13Ralpha1 expression in structural and hematopoietic cells but not due to increased responsiveness to IL-17, IL-4, IL-13, increased IL-13Ralpha2 or type 1 IL-4R signaling.	Bleomycin	23-32	interleukin 13	Mus musculus	70-75
26153764-7	2016	Increased pathology in bleomycin-treated Il13ra1(-/-) mice was due to IL-13Ralpha1 expression in structural and hematopoietic cells but not due to increased responsiveness to IL-17, IL-4, IL-13, increased IL-13Ralpha2 or type 1 IL-4R signaling.	Bleomycin	23-32	interleukin 13 receptor, alpha 2	Mus musculus	205-233
26977316-8	2016	TNF-alpha, IL-1beta, and MDA levels and hydroxyproline content significantly increased (p &lt; 0.01) and GPx and SOD activities significantly decreased in bleomycin group (p &lt; 0.01).	Bleomycin	155-164	tumor necrosis factor	Rattus norvegicus	0-9
26425798-0	2016	A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis.	Bleomycin	108-117	vascular endothelial growth factor A	Homo sapiens	69-73
26425798-4	2016	Ingenuity Pathway Analysis of proteins modulated in response to bleomycin treatment identified PI3K/Akt and Wnt signaling as the most significant profibrotic pathways.	Bleomycin	64-73	AKT serine/threonine kinase 1	Homo sapiens	100-103
26425798-6	2016	Mechanistic/mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK) were identified to be key mediators of pro- and antifibrotic response, where bleomycin (BLM) treatment resulted in increased expression and VEGF inhibitor treatment attenuated expression of mTOR and ERK.	Bleomycin	174-183	mechanistic target of rapamycin kinase	Homo sapiens	43-47
26425798-6	2016	Mechanistic/mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK) were identified to be key mediators of pro- and antifibrotic response, where bleomycin (BLM) treatment resulted in increased expression and VEGF inhibitor treatment attenuated expression of mTOR and ERK.	Bleomycin	174-183	mitogen-activated protein kinase 1	Homo sapiens	53-90
26425798-6	2016	Mechanistic/mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK) were identified to be key mediators of pro- and antifibrotic response, where bleomycin (BLM) treatment resulted in increased expression and VEGF inhibitor treatment attenuated expression of mTOR and ERK.	Bleomycin	174-183	mitogen-activated protein kinase 1	Homo sapiens	92-95
26425798-6	2016	Mechanistic/mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK) were identified to be key mediators of pro- and antifibrotic response, where bleomycin (BLM) treatment resulted in increased expression and VEGF inhibitor treatment attenuated expression of mTOR and ERK.	Bleomycin	174-183	vascular endothelial growth factor A	Homo sapiens	237-241
26425798-6	2016	Mechanistic/mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK) were identified to be key mediators of pro- and antifibrotic response, where bleomycin (BLM) treatment resulted in increased expression and VEGF inhibitor treatment attenuated expression of mTOR and ERK.	Bleomycin	174-183	mechanistic target of rapamycin kinase	Homo sapiens	287-291
26425798-6	2016	Mechanistic/mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK) were identified to be key mediators of pro- and antifibrotic response, where bleomycin (BLM) treatment resulted in increased expression and VEGF inhibitor treatment attenuated expression of mTOR and ERK.	Bleomycin	174-183	mitogen-activated protein kinase 1	Homo sapiens	296-299
26925792-7	2016	The expression of heat shock proteins - HSP27 was examined by immunocytochemical ABC method.The cytotoxicity with different concentrations of bleomycin alone was not significantly decrease in both cell lines.	Bleomycin	142-151	heat shock protein family B (small) member 1	Homo sapiens	40-45
28442670-4	2016	Although the AFP returned to normal level after four courses of BEP (bleomycin, etoposide and cisplatin), the retroperitoneal lymph nodes continued to grow.	Bleomycin	69-78	alpha fetoprotein	Homo sapiens	13-16
26977316-8	2016	TNF-alpha, IL-1beta, and MDA levels and hydroxyproline content significantly increased (p &lt; 0.01) and GPx and SOD activities significantly decreased in bleomycin group (p &lt; 0.01).	Bleomycin	155-164	interleukin 1 beta	Rattus norvegicus	11-19
24021429-3	2016	Since the protein is involved in cancer pathology, we first investigated the effects of bleomycin, etoposide, and cisplatin (BEP) on MTA1 signaling in the testis.	Bleomycin	88-97	metastasis associated 1	Rattus norvegicus	133-137
26498248-7	2015	In separate studies, lung fibrotic changes 2 wk after treatment with bleomycin (0.25 U/kg IT) was significantly increased in GADD45a(-/-) mice compared with wild-type mice assessed by lung collagen content and histology.	Bleomycin	69-78	growth arrest and DNA-damage-inducible 45 alpha	Mus musculus	125-132
26782380-0	2015	Toll-like receptor 4 promotes fibrosis in bleomycin-induced lung injury in mice.	Bleomycin	42-51	toll-like receptor 4	Mus musculus	0-20
26782380-1	2015	The specific role of Toll-like receptor 4 (TLR4) in bleomycin-induced lung fibrosis of mice, a model of human idiopathic pulmonary fibrosis, has not been characterized.	Bleomycin	52-61	toll-like receptor 4	Mus musculus	21-41
26782380-1	2015	The specific role of Toll-like receptor 4 (TLR4) in bleomycin-induced lung fibrosis of mice, a model of human idiopathic pulmonary fibrosis, has not been characterized.	Bleomycin	52-61	toll-like receptor 4	Mus musculus	43-47
26782380-7	2015	Hydroxyproline content was significantly lower in TLR4(-/-) than in WT mice on day 21 after bleomycin injection (0.281 +- 0.022 vs 0.371 +- 0.047, P &lt; 0.05).	Bleomycin	92-101	toll-like receptor 4	Mus musculus	50-54
26782380-8	2015	Compared to WT mice, bleomycin-treated TLR4(-/-) mice expressed significantly lower type I collagen mRNA levels (mesenchymal marker; 11.069 +- 2.627 vs 4.589 +- 1.440, P &lt; 0.05).	Bleomycin	21-30	toll-like receptor 4	Mus musculus	39-43
26782380-10	2015	Bleomycin-treated TLR4(-/-) mice had a significantly lower mortality rate on day 21 than WT mice (33 vs 75%, P &lt; 0.05).	Bleomycin	0-9	toll-like receptor 4	Mus musculus	18-22
26782380-12	2015	Thus, bleomycin-induced pulmonary fibrosis is TLR4-dependent and TLR4 promoted fibrosis in bleomycin-challenged mice.	Bleomycin	6-15	toll-like receptor 4	Mus musculus	46-50
26782380-12	2015	Thus, bleomycin-induced pulmonary fibrosis is TLR4-dependent and TLR4 promoted fibrosis in bleomycin-challenged mice.	Bleomycin	6-15	toll-like receptor 4	Mus musculus	65-69
26782380-12	2015	Thus, bleomycin-induced pulmonary fibrosis is TLR4-dependent and TLR4 promoted fibrosis in bleomycin-challenged mice.	Bleomycin	91-100	toll-like receptor 4	Mus musculus	65-69
26498248-0	2015	Role of GADD45a in murine models of radiation- and bleomycin-induced lung injury.	Bleomycin	51-60	growth arrest and DNA-damage-inducible 45 alpha	Mus musculus	8-15
26598674-3	2015	In this study we examined IRF5-deficient (Irf5(-/-)) mice in the bleomycin-treated SSc murine model.	Bleomycin	65-74	interferon regulatory factor 5	Mus musculus	26-30
26658951-4	2015	Here, we show that Rad9A is hyperphosphorylated and accumulates in cells exposed to bleomycin.	Bleomycin	84-93	RAD9 checkpoint clamp component A	Homo sapiens	19-24
26658951-5	2015	Following the removal of bleomycin, Rad9A is polyubiquitinated, and Rad9A protein levels drop, indicating an active degradation process for Rad9A.	Bleomycin	25-34	RAD9 checkpoint clamp component A	Homo sapiens	36-41
26658951-5	2015	Following the removal of bleomycin, Rad9A is polyubiquitinated, and Rad9A protein levels drop, indicating an active degradation process for Rad9A.	Bleomycin	25-34	RAD9 checkpoint clamp component A	Homo sapiens	68-73
26658951-5	2015	Following the removal of bleomycin, Rad9A is polyubiquitinated, and Rad9A protein levels drop, indicating an active degradation process for Rad9A.	Bleomycin	25-34	RAD9 checkpoint clamp component A	Homo sapiens	68-73
26598674-4	2015	We show that dermal and pulmonary fibrosis induced by bleomycin is attenuated in Irf5(-/-) mice.	Bleomycin	54-63	interferon regulatory factor 5	Mus musculus	81-85
26245842-7	2015	Transcription factor Fli-1, a deficiency of which is involved in the activation of SSc dermal fibroblasts, served as a potent repressor of the progranulin gene, and Fli-1(+/-) mice and bleomycin-treated wild-type mice exhibited up-regulated expression of progranulin in dermal fibroblasts.	Bleomycin	185-194	Friend leukemia integration 1	Mus musculus	21-26
26640170-0	2015	Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury.	Bleomycin	70-79	stanniocalcin 1	Mus musculus	0-15
26640170-1	2015	Thrombin-induced and proteinase-activated receptor 1 (PAR1)-mediated signaling increases ROS production, activates ERK, and promotes inflammation and fibroblast proliferation in bleomycin-induced lung injury.	Bleomycin	178-187	coagulation factor II	Mus musculus	0-8
26640170-1	2015	Thrombin-induced and proteinase-activated receptor 1 (PAR1)-mediated signaling increases ROS production, activates ERK, and promotes inflammation and fibroblast proliferation in bleomycin-induced lung injury.	Bleomycin	178-187	coagulation factor II (thrombin) receptor	Mus musculus	21-52
26640170-1	2015	Thrombin-induced and proteinase-activated receptor 1 (PAR1)-mediated signaling increases ROS production, activates ERK, and promotes inflammation and fibroblast proliferation in bleomycin-induced lung injury.	Bleomycin	178-187	coagulation factor II (thrombin) receptor	Mus musculus	54-58
26640170-1	2015	Thrombin-induced and proteinase-activated receptor 1 (PAR1)-mediated signaling increases ROS production, activates ERK, and promotes inflammation and fibroblast proliferation in bleomycin-induced lung injury.	Bleomycin	178-187	mitogen-activated protein kinase 1	Mus musculus	115-118
26640170-2	2015	Stanniocalcin-1 (STC1) activates anti-oxidant pathways, inhibits inflammation and provides cytoprotection; hence, we hypothesized that STC1 will inhibit thrombin/PAR1 signaling and protect from bleomycin-induced pneumonitis.	Bleomycin	194-203	stanniocalcin 1	Mus musculus	0-15
26640170-2	2015	Stanniocalcin-1 (STC1) activates anti-oxidant pathways, inhibits inflammation and provides cytoprotection; hence, we hypothesized that STC1 will inhibit thrombin/PAR1 signaling and protect from bleomycin-induced pneumonitis.	Bleomycin	194-203	stanniocalcin 1	Mus musculus	17-21
26640170-2	2015	Stanniocalcin-1 (STC1) activates anti-oxidant pathways, inhibits inflammation and provides cytoprotection; hence, we hypothesized that STC1 will inhibit thrombin/PAR1 signaling and protect from bleomycin-induced pneumonitis.	Bleomycin	194-203	stanniocalcin 1	Mus musculus	135-139
26640170-4	2015	Lungs of bleomycin-treated WT mice display: severe pneumonitis; increased generation of superoxide; vascular leak; increased thrombin protein abundance and activity; activation of ERK; greater cytokine/chemokine release and infiltration with T-cells and macrophages.	Bleomycin	9-18	coagulation factor II	Mus musculus	125-133
26640170-4	2015	Lungs of bleomycin-treated WT mice display: severe pneumonitis; increased generation of superoxide; vascular leak; increased thrombin protein abundance and activity; activation of ERK; greater cytokine/chemokine release and infiltration with T-cells and macrophages.	Bleomycin	9-18	mitogen-activated protein kinase 1	Mus musculus	180-183
26640170-7	2015	In conclusion, STC1 blunts bleomycin-induced rise in thrombin protein and activity, diminishes thrombin-induced signaling through PAR1 to ERK, and inhibits bleomycin-induced pneumonitis.	Bleomycin	27-36	stanniocalcin 1	Mus musculus	15-19
26640170-7	2015	In conclusion, STC1 blunts bleomycin-induced rise in thrombin protein and activity, diminishes thrombin-induced signaling through PAR1 to ERK, and inhibits bleomycin-induced pneumonitis.	Bleomycin	27-36	coagulation factor II	Mus musculus	53-61
26640170-7	2015	In conclusion, STC1 blunts bleomycin-induced rise in thrombin protein and activity, diminishes thrombin-induced signaling through PAR1 to ERK, and inhibits bleomycin-induced pneumonitis.	Bleomycin	156-165	stanniocalcin 1	Mus musculus	15-19
26275723-11	2015	Moreover, bronchoalveolar lavage fluid concentrations of brain-derived neurotrophic factor, suggested to induce nerve remodelling in chronic cough, were also enhanced (day 1: saline, 14.21 pg/ml; bleomycin, 30.09 pg/ml).	Bleomycin	196-205	Bdnf	Cavia porcellus	57-90
26154059-0	2015	Kinetics of lung tissue factor expression and procoagulant activity in bleomycin induced acute lung injury.	Bleomycin	71-80	coagulation factor III	Mus musculus	17-30
26154059-2	2015	METHODS: To test the hypothesis that TF is upregulated early in the course of acute bleomycin lung injury and precedes increased permeability and inflammation we studied the early course of bleomycin-induced ALI in mice.	Bleomycin	84-93	coagulation factor III	Mus musculus	37-39
26391253-4	2015	Significant upregulation of PRMT1 expression was also observed in the lungs of bleomycin-treated mice.	Bleomycin	79-88	protein arginine N-methyltransferase 1	Mus musculus	28-33
26411348-0	2015	Total glycosides of Yupingfeng protects against bleomycin-induced pulmonary fibrosis in rats associated with reduced high mobility group box 1 activation and epithelial-mesenchymal transition.	Bleomycin	48-57	high mobility group box 1	Rattus norvegicus	117-142
26154059-13	2015	CONCLUSION: These data demonstrate that cytokine upregulation is the earliest response to bleomycin administration, followed by increased lung permeability, upregulation of TF, and recruitment of inflammatory cells.	Bleomycin	90-99	coagulation factor III	Mus musculus	173-175
26411348-4	2015	AIM: The present study was aimed to investigate the potential effects of total glycoside of Yupingfeng (YPF-G), the natural compound extracted from Yupingfeng san, on HMGB1 activation and EMT in bleomycin-induced PF, which was a serious disease of respiratory system.	Bleomycin	195-204	high mobility group box 1	Rattus norvegicus	167-172
26411348-11	2015	CONCLUSION: Our results demonstrated that YPF-G could ameliorate bleomycin-induced PF by reducing HMGB1 activation and reversing EMT.	Bleomycin	65-74	high mobility group box 1	Rattus norvegicus	98-103
25418835-4	2015	In the present study, we showed that forced expression of WT1[17AA(-)KTS(+)] isoform significantly inhibited apoptosis by DNA-damaging agents such as Doxorubicin, Mitomycin, Camptothesisn, and Bleomycin in immortalized fibroblast MRC5SV and cervical cancer HeLa cells.	Bleomycin	193-202	WT1 transcription factor	Homo sapiens	58-61
26519529-3	2015	These pulmonary CD8(+) T cells differentiate into IL-13-producing Tc2 cells and play a major role in a bleomycin-induced model of fibrosis.	Bleomycin	103-112	interleukin 13	Mus musculus	50-55
26519529-4	2015	Differentiation of these Tc2 cells in the lung requires IL-21, and bleomycin treated IL-21- and IL-21R-deficient mice develop inflammation but not fibrosis.	Bleomycin	67-76	interleukin 21	Mus musculus	85-90
26322414-0	2015	Lack of EC-SOD worsens alveolar and vascular development in a neonatal mouse model of bleomycin-induced bronchopulmonary dysplasia and pulmonary hypertension.	Bleomycin	86-95	superoxide dismutase 3, extracellular	Mus musculus	8-14
26322414-5	2015	We hypothesized that loss of EC-SOD would worsen PAH associated with BPD in a neonatal mouse model of bleomycin-induced BPD by disrupting the VEGF/NO signaling pathway.	Bleomycin	102-111	vascular endothelial growth factor A	Mus musculus	142-146
26322414-9	2015	Lack of EC-SOD and bleomycin treatment decreased lung total and phosphorylated VEGFR2 and eNOS protein expression.	Bleomycin	19-28	kinase insert domain protein receptor	Mus musculus	79-85
26322414-9	2015	Lack of EC-SOD and bleomycin treatment decreased lung total and phosphorylated VEGFR2 and eNOS protein expression.	Bleomycin	19-28	nitric oxide synthase 3, endothelial cell	Mus musculus	90-94
26322414-10	2015	CONCLUSION: EC-SOD is critical in preserving normal lung development and loss of EC-SOD results in disrupted alveolar development, PAH and vascular remodeling at baseline, which is further worsened with bleomycin and associated with decreased activation of VEGFR2.	Bleomycin	203-212	superoxide dismutase 3, extracellular	Mus musculus	12-18
26697175-2	2015	We exposed transgenic mice expressing mutant BMPR2 and control mice to repetitive intraperitoneal injections of bleomycin for 4 weeks.	Bleomycin	112-121	bone morphogenetic protein receptor, type II (serine/threonine kinase)	Mus musculus	45-50
26702074-6	2015	Ten days after bleomycin instillation, both the number of CEACAM6(+) cells and immunostaining intensity were elevated in injured lung areas, and there was increased co-localization with type I and II cell markers.	Bleomycin	15-24	CEA cell adhesion molecule 6	Homo sapiens	58-65
26545872-4	2015	The present in vivo study with RAGE null mice, we further confirmed the evidence that lack of RAGE evolves worse bleomycin-induced pulmonary fibrosis compared with control mice.	Bleomycin	113-122	advanced glycosylation end product-specific receptor	Mus musculus	94-98
26697175-5	2015	We found increased hypoxia-inducible factor (HIF)1-alpha stabilization in lungs of mutant-BMPR2-expressing mice compared to controls following bleomycin treatment.	Bleomycin	143-152	hypoxia inducible factor 1, alpha subunit	Mus musculus	19-56
26697175-5	2015	We found increased hypoxia-inducible factor (HIF)1-alpha stabilization in lungs of mutant-BMPR2-expressing mice compared to controls following bleomycin treatment.	Bleomycin	143-152	bone morphogenetic protein receptor, type II (serine/threonine kinase)	Mus musculus	90-95
26494779-9	2015	MSC therapy led to an improvement in bleomycin-induced lung collagen deposition in animal lungs and in the pulmonary fibrosis Ashcroft score in most studies.	Bleomycin	37-46	musculin	Homo sapiens	0-3
26494779-11	2015	Furthermore, MSC therapy was found to improve 14-day survival in animals with bleomycin-induced pulmonary fibrosis.	Bleomycin	78-87	musculin	Homo sapiens	13-16
26555817-2	2015	Its catalytic component, telomerase reverse transcriptase (TERT) is induced in lung fibroblasts from patients with fibrotic interstitial lung disease and in rodents with bleomycin-induced pulmonary fibrosis.	Bleomycin	170-179	telomerase reverse transcriptase	Homo sapiens	25-57
26286721-4	2015	RESULTS: S1PL expression was upregulated in fibrotic lung tissues and primary lung fibroblasts isolated from patients with IPF and bleomycin-challenged mice.	Bleomycin	131-140	sphingosine-1-phosphate lyase 1	Homo sapiens	9-13
26286721-7	2015	Knockdown of S1PL (Sgpl1(+/-)) in mice augmented bleomycin-induced pulmonary fibrosis, and patients with IPF reduced Sgpl1 mRNA expression in PBMCs exhibited higher severity of fibrosis and lower survival rate.	Bleomycin	49-58	sphingosine phosphate lyase 1	Mus musculus	13-17
26286721-7	2015	Knockdown of S1PL (Sgpl1(+/-)) in mice augmented bleomycin-induced pulmonary fibrosis, and patients with IPF reduced Sgpl1 mRNA expression in PBMCs exhibited higher severity of fibrosis and lower survival rate.	Bleomycin	49-58	sphingosine phosphate lyase 1	Mus musculus	19-24
26559674-2	2015	The latter activity was demonstrated using exogenously-administered recombinant SCGB3A2 in the bleomycin (BLM)-induced pulmonary fibrosis model.	Bleomycin	95-104	secretoglobin, family 3A, member 2	Mus musculus	80-87
26559674-2	2015	The latter activity was demonstrated using exogenously-administered recombinant SCGB3A2 in the bleomycin (BLM)-induced pulmonary fibrosis model.	Bleomycin	106-109	secretoglobin, family 3A, member 2	Mus musculus	80-87
26555817-2	2015	Its catalytic component, telomerase reverse transcriptase (TERT) is induced in lung fibroblasts from patients with fibrotic interstitial lung disease and in rodents with bleomycin-induced pulmonary fibrosis.	Bleomycin	170-179	telomerase reverse transcriptase	Homo sapiens	59-63
26358219-0	2015	Mesenchymal deficiency of Notch1 attenuates bleomycin-induced pulmonary fibrosis.	Bleomycin	44-53	notch 1	Mus musculus	26-32
26474459-4	2015	The number of macrophages were significantly reduced in lungs of PAR-1 antagonist (P1pal-12) treated animals upon bleomycin instillation.	Bleomycin	114-123	coagulation factor II thrombin receptor	Homo sapiens	65-70
26207697-10	2015	Activation of the 26S proteasome and increased expression of Rpn6 were detected during bleomycin-induced lung remodeling and fibrosis.	Bleomycin	87-96	proteasome 26S subunit, non-ATPase 11	Homo sapiens	61-65
26196843-9	2015	In vivo, MaR1 treatment significantly prolongs survival rate and attenuates destruction of lung architecture, as well as collagen deposition after bleomycin inhalation.	Bleomycin	147-156	matrix associated region 1	Mus musculus	9-13
25919965-0	2015	Nitric oxide mediates bleomycin-induced angiogenesis and pulmonary fibrosis via regulation of VEGF.	Bleomycin	22-31	vascular endothelial growth factor A	Homo sapiens	94-98
25919965-3	2015	We demonstrate that bleomycin treatment induces angiogenesis, and inhibition of the central angiogenic mediator VEGF using anti-VEGF antibody CBO-P11 significantly attenuates bleomycin-induced pulmonary fibrosis in vivo.	Bleomycin	175-184	vascular endothelial growth factor A	Homo sapiens	112-116
25919965-3	2015	We demonstrate that bleomycin treatment induces angiogenesis, and inhibition of the central angiogenic mediator VEGF using anti-VEGF antibody CBO-P11 significantly attenuates bleomycin-induced pulmonary fibrosis in vivo.	Bleomycin	175-184	vascular endothelial growth factor A	Homo sapiens	128-132
25919965-4	2015	Bleomycin-induced nitric oxide (NO) was observed to be the key upstream regulator of VEGF via the PI3k/Akt pathway.	Bleomycin	0-9	vascular endothelial growth factor A	Homo sapiens	85-89
25919965-4	2015	Bleomycin-induced nitric oxide (NO) was observed to be the key upstream regulator of VEGF via the PI3k/Akt pathway.	Bleomycin	0-9	AKT serine/threonine kinase 1	Homo sapiens	103-106
25919965-5	2015	VEGF regulated other important angiogenic proteins including PAI-1 and IL-8 in response to bleomycin exposure.	Bleomycin	91-100	vascular endothelial growth factor A	Homo sapiens	0-4
25919965-5	2015	VEGF regulated other important angiogenic proteins including PAI-1 and IL-8 in response to bleomycin exposure.	Bleomycin	91-100	serpin family E member 1	Homo sapiens	61-66
25919965-5	2015	VEGF regulated other important angiogenic proteins including PAI-1 and IL-8 in response to bleomycin exposure.	Bleomycin	91-100	C-X-C motif chemokine ligand 8	Homo sapiens	71-75
25919965-6	2015	Inhibition of NO and VEGF activity significantly mitigated bleomycin-induced angiogenic and fibrogenic responses.	Bleomycin	59-68	vascular endothelial growth factor A	Homo sapiens	21-25
25919965-7	2015	NO and VEGF are key mediators of bleomycin-induced pulmonary fibrosis, and could serve as important targets against this debilitating disease.	Bleomycin	33-42	vascular endothelial growth factor A	Homo sapiens	7-11
26196843-11	2015	These data indicate that MaR1 inhibits TGF-beta1-induced EMT and attenuates bleomycin-induced pulmonary fibrosis.	Bleomycin	76-85	matrix associated region 1	Mus musculus	25-29
26516022-6	2015	Mutation of PARG1 results in increased DNA damage level and enhanced cell death in plants after bleomycin treatment.	Bleomycin	96-105	Poly (ADP-ribose) glycohydrolase (PARG)	Arabidopsis thaliana	12-17
26516022-7	2015	PARG1 expression is induced primarily in root and shoot meristems by bleomycin and induction of PARG1 is dependent on ATM and ATR kinases.	Bleomycin	69-78	Poly (ADP-ribose) glycohydrolase (PARG)	Arabidopsis thaliana	0-5
26315535-8	2015	In the mouse model of bleomycin-induced LF, miR-9-5p dramatically reduces fibrogenesis and inhibition of miR-9-5p and prevents its anti-fibrotic effect both in vitro and in vivo.	Bleomycin	22-31	microRNA 95	Homo sapiens	44-52
26059457-8	2015	In accord with these findings, PINK1 expression appeared to be reduced in fibrotic lung tissue from bleomycin and a TGFbeta1-adenoviral model of lung fibrosis.	Bleomycin	100-109	PTEN induced putative kinase 1	Mus musculus	31-36
26261086-7	2015	In vivo FIZZ1 expression was significantly elevated in the murine bleomycin-induced dermal fibrosis model, which was associated with significant reduction in adipocyte marker gene expression and subcutaneous lipoatrophy.	Bleomycin	66-75	resistin like alpha	Mus musculus	8-13
26261086-8	2015	Finally, FIZZ1 knockout mice exhibited significantly reduced bleomycin-induced dermal fibrosis with greater preservation of the subcutaneous fat than wild-type mice.	Bleomycin	61-70	resistin like alpha	Mus musculus	9-14
26436920-6	2015	In vivo, inhibiting miR-142-5p and increasing miR-130a-3p expression with locked nucleic acid-modified oligonucleotides inhibits CCL4-induced liver fibrosis and bleomycin-induced lung fibrosis in mice.	Bleomycin	161-170	microRNA 130a	Homo sapiens	46-54
26315535-8	2015	In the mouse model of bleomycin-induced LF, miR-9-5p dramatically reduces fibrogenesis and inhibition of miR-9-5p and prevents its anti-fibrotic effect both in vitro and in vivo.	Bleomycin	22-31	microRNA 95	Homo sapiens	105-113
26055516-5	2015	Furthermore, Fli1 haploinsufficiency recapitulates tissue fibrosis, vascular activation and inflammation characteristic of SSc to a greater extent in bleomycin-treated mice.	Bleomycin	150-159	Friend leukemia integration 1	Mus musculus	13-17
26209236-0	2015	Pharmacological In Vivo Inhibition of S-Nitrosoglutathione Reductase Attenuates Bleomycin-Induced Inflammation and Fibrosis.	Bleomycin	80-89	alcohol dehydrogenase 5 (class III), chi polypeptide	Homo sapiens	38-68
26209236-8	2015	These changes were accompanied by an attenuation of BLM-induced elevations in pulmonary levels of profibrotic cytokines interleukin-6, monocyte chemoattractant protein-1, and transforming growth factor-beta (TGF-beta).	Bleomycin	52-55	interleukin 6	Homo sapiens	120-133
26209236-8	2015	These changes were accompanied by an attenuation of BLM-induced elevations in pulmonary levels of profibrotic cytokines interleukin-6, monocyte chemoattractant protein-1, and transforming growth factor-beta (TGF-beta).	Bleomycin	52-55	C-C motif chemokine ligand 2	Homo sapiens	135-169
26071646-8	2015	Bleomycin induced increases in TGF-beta1 via calpain activation in HLFs.	Bleomycin	0-9	transforming growth factor, beta 1	Mus musculus	31-40
26133229-0	2015	Involvement of Kruppel-like factor 9 in bleomycin-induced pulmonary toxicity.	Bleomycin	40-49	Kruppel like factor 9	Homo sapiens	15-36
24709861-9	2015	S100A4(-/-) mice were protected from bleomycin-induced skin fibrosis with reduced dermal thickening, decreased hydroxyproline content and lower myofibroblast counts.	Bleomycin	37-46	S100 calcium binding protein A4	Mus musculus	0-6
25680454-7	2015	RESULTS: Genetic deletion of LIGHT abolished lung TSLP expression driven by bleomycin, accompanied by near-complete absence of accumulation of lung collagen and alpha-smooth muscle actin.	Bleomycin	76-85	thymic stromal lymphopoietin	Homo sapiens	50-54
25781362-4	2015	Lipocalin-2 expression was evaluated in the skin of patients with SSc and bleomycin (BLM)-treated mice and in Fli1-deficient endothelial cells by reverse transcriptase-real time polymerase chain reaction, immunoblotting and/or immunohistochemistry.	Bleomycin	74-83	lipocalin 2	Homo sapiens	0-11
25781362-4	2015	Lipocalin-2 expression was evaluated in the skin of patients with SSc and bleomycin (BLM)-treated mice and in Fli1-deficient endothelial cells by reverse transcriptase-real time polymerase chain reaction, immunoblotting and/or immunohistochemistry.	Bleomycin	85-88	lipocalin 2	Homo sapiens	0-11
26138704-6	2015	Blockade of TGFbeta-ALK5 signalling attenuated lung collagen accumulation in bleomycin-alone injured mice, but this anti-fibrotic effect was reduced in the presence of concomitant viral infection.	Bleomycin	77-86	transforming growth factor, beta receptor I	Mus musculus	12-24
25959255-0	2015	Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.	Bleomycin	126-135	lysophosphatidic acid receptor 1	Mus musculus	55-59
25959255-0	2015	Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.	Bleomycin	126-135	lysophosphatidic acid receptor 3	Mus musculus	64-68
25680454-8	2015	Furthermore, recombinant LIGHT administered in vivo induced lung expression of TSLP in the absence of other inflammatory stimuli, and strikingly reproduced the primary features of bleomycin-driven disease in a TSLP-dependent manner.	Bleomycin	180-189	thymic stromal lymphopoietin	Homo sapiens	210-214
25877860-3	2015	We earlier reported berberine"s amelioration against TGF-beta1-mediated pro-fibrotic effects in bleomycin-induced pulmonary fibrosis.	Bleomycin	96-105	transforming growth factor, beta 1	Rattus norvegicus	53-62
25877860-7	2015	Berberine inhibited the bleomycin-induced raise in p-Smad 2/3 and enhanced Smad 7 expression.	Bleomycin	24-33	SMAD family member 2	Rattus norvegicus	53-61
25877860-4	2015	The present study aimed to determine the regulatory role of berberine on abrogated Smad 2/3 and FAK-dependent PI3K/Akt-mTOR signaling cascades in bleomycin-induced pulmonary fibrosis.	Bleomycin	146-155	protein tyrosine kinase 2	Rattus norvegicus	96-99
25877860-7	2015	Berberine inhibited the bleomycin-induced raise in p-Smad 2/3 and enhanced Smad 7 expression.	Bleomycin	24-33	SMAD family member 7	Rattus norvegicus	75-81
25877860-8	2015	Berberine blocked the activation of FAK and PI3K/Akt against bleomycin-induced dysregulation, with subsequent raise in PTEN expression.	Bleomycin	61-70	protein tyrosine kinase 2	Rattus norvegicus	36-39
25877860-4	2015	The present study aimed to determine the regulatory role of berberine on abrogated Smad 2/3 and FAK-dependent PI3K/Akt-mTOR signaling cascades in bleomycin-induced pulmonary fibrosis.	Bleomycin	146-155	AKT serine/threonine kinase 1	Rattus norvegicus	115-118
25877860-8	2015	Berberine blocked the activation of FAK and PI3K/Akt against bleomycin-induced dysregulation, with subsequent raise in PTEN expression.	Bleomycin	61-70	AKT serine/threonine kinase 1	Rattus norvegicus	49-52
25877860-4	2015	The present study aimed to determine the regulatory role of berberine on abrogated Smad 2/3 and FAK-dependent PI3K/Akt-mTOR signaling cascades in bleomycin-induced pulmonary fibrosis.	Bleomycin	146-155	mechanistic target of rapamycin kinase	Rattus norvegicus	119-123
26289430-11	2015	EIA revealed that BLM-induced IL-6 in BALF was biphasic, with the first increase from 0.5 to 3 dpi followed by the second increase from 8 to 10 dpi.	Bleomycin	18-21	interleukin 6	Mus musculus	30-34
25877860-10	2015	Cumulatively, through targeted inhibition of dysregulated Smad and FAK-dependent PI3K/Akt-mTOR signaling axis, berberine attenuated the fibrotic insults of bleomycin.	Bleomycin	156-165	protein tyrosine kinase 2	Rattus norvegicus	67-70
25877860-10	2015	Cumulatively, through targeted inhibition of dysregulated Smad and FAK-dependent PI3K/Akt-mTOR signaling axis, berberine attenuated the fibrotic insults of bleomycin.	Bleomycin	156-165	AKT serine/threonine kinase 1	Rattus norvegicus	86-89
25877860-10	2015	Cumulatively, through targeted inhibition of dysregulated Smad and FAK-dependent PI3K/Akt-mTOR signaling axis, berberine attenuated the fibrotic insults of bleomycin.	Bleomycin	156-165	mechanistic target of rapamycin kinase	Rattus norvegicus	90-94
25877860-11	2015	KEY MESSAGE: Berberine inhibits Smad 2/3 activation and enhances Smad 7 in bleomycin-induced rat lungs.	Bleomycin	75-84	SMAD family member 7	Rattus norvegicus	65-71
25877860-12	2015	Bleomycin-induced activation of FAK is inhibited by berberine.	Bleomycin	0-9	protein tyrosine kinase 2	Rattus norvegicus	32-35
25877860-13	2015	Berberine inhibits bleomycin-induced activation of PI3K/Akt cascade.	Bleomycin	19-28	AKT serine/threonine kinase 1	Rattus norvegicus	56-59
25586556-2	2015	In this study, we characterized PPARgamma induction by apoptotic cell instillation over the course of bleomycin-induced lung injury in C57BL/6 mice.	Bleomycin	102-111	peroxisome proliferator activated receptor gamma	Mus musculus	32-41
25586556-4	2015	Our data demonstrate that apoptotic cell instillation after bleomycin results in immediate and prolonged enhancement of PPARgamma mRNA and protein in alveolar macrophages and lung.	Bleomycin	60-69	peroxisome proliferator activated receptor gamma	Mus musculus	120-129
26330752-0	2015	Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat.	Bleomycin	16-25	aldo-keto reductase family 1 member B1	Rattus norvegicus	67-83
26330752-8	2015	In vivo, epalrestat treatment significantly ameliorated the bleomycin-mediated histological fibrosis alterations and blocked collagen deposition concomitantly with reversing bleomycin-induced expression up-regulation of TGF-beta1, AR, alpha-SMA and collagen I (both mRNA and protein).	Bleomycin	174-183	transforming growth factor, beta 1	Rattus norvegicus	220-229
26330752-8	2015	In vivo, epalrestat treatment significantly ameliorated the bleomycin-mediated histological fibrosis alterations and blocked collagen deposition concomitantly with reversing bleomycin-induced expression up-regulation of TGF-beta1, AR, alpha-SMA and collagen I (both mRNA and protein).	Bleomycin	174-183	aldo-keto reductase family 1 member B1	Rattus norvegicus	231-233
26005208-0	2015	The exacerbating roles of CCAAT/enhancer-binding protein homologous protein (CHOP) in the development of bleomycin-induced pulmonary fibrosis and the preventive effects of tauroursodeoxycholic acid (TUDCA) against pulmonary fibrosis in mice.	Bleomycin	105-114	DNA-damage inducible transcript 3	Mus musculus	26-75
26005208-0	2015	The exacerbating roles of CCAAT/enhancer-binding protein homologous protein (CHOP) in the development of bleomycin-induced pulmonary fibrosis and the preventive effects of tauroursodeoxycholic acid (TUDCA) against pulmonary fibrosis in mice.	Bleomycin	105-114	DNA-damage inducible transcript 3	Mus musculus	77-81
26005208-1	2015	The purpose of this study was to evaluate the role of CCAAT/enhancer-binding protein homologous protein (CHOP), an important transcription factor that regulates the inflammatory reaction during the endoplasmic reticulum (ER) stress response, in the development of pulmonary fibrosis induced by bleomycin (BLM) in mice.	Bleomycin	294-303	DNA-damage inducible transcript 3	Mus musculus	54-103
26005208-1	2015	The purpose of this study was to evaluate the role of CCAAT/enhancer-binding protein homologous protein (CHOP), an important transcription factor that regulates the inflammatory reaction during the endoplasmic reticulum (ER) stress response, in the development of pulmonary fibrosis induced by bleomycin (BLM) in mice.	Bleomycin	294-303	DNA-damage inducible transcript 3	Mus musculus	105-109
26005208-1	2015	The purpose of this study was to evaluate the role of CCAAT/enhancer-binding protein homologous protein (CHOP), an important transcription factor that regulates the inflammatory reaction during the endoplasmic reticulum (ER) stress response, in the development of pulmonary fibrosis induced by bleomycin (BLM) in mice.	Bleomycin	305-308	DNA-damage inducible transcript 3	Mus musculus	54-103
26005208-1	2015	The purpose of this study was to evaluate the role of CCAAT/enhancer-binding protein homologous protein (CHOP), an important transcription factor that regulates the inflammatory reaction during the endoplasmic reticulum (ER) stress response, in the development of pulmonary fibrosis induced by bleomycin (BLM) in mice.	Bleomycin	305-308	DNA-damage inducible transcript 3	Mus musculus	105-109
26010495-6	2015	Bleomycin-induction resulted in significant elevation of matrix metalloproteinase (MMP)-2 and -9 expression, increased RNA and protein expression of transforming growth factor (TGF)-beta1, Smads and alpha-smooth muscle actin (alpha-SMA).	Bleomycin	0-9	matrix metallopeptidase 2	Homo sapiens	57-96
26039104-4	2015	METHODS: We assessed FKBP10 expression in bleomycin-induced lung fibrosis (using quantitative reverse transcriptase-polymerase chain reaction, Western blot, and immunofluorescence), analyzed microarray data from 99 patients with IPF and 43 control subjects from a U.S. cohort, and performed Western blot analysis from 6 patients with IPF and 5 control subjects from a German cohort.	Bleomycin	42-51	FKBP prolyl isomerase 10	Homo sapiens	21-27
26039104-8	2015	MEASUREMENTS AND MAIN RESULTS: FKBP10 expression was up-regulated in bleomycin-induced lung fibrosis and IPF.	Bleomycin	69-78	FKBP prolyl isomerase 10	Homo sapiens	31-37
26263489-4	2015	The blaNDM-1 gene surrounded by an entire ISAba125 element and a bleomycin resistance gene bleMBL in these isolates were carried by diverse conjugatable plasmids (IncA/C, IncN, IncHI2 and untypeable) ranging from ~55 to ~360 kb.	Bleomycin	65-74	metallo-beta-lactamase NDM-1	Enterobacter cloacae	4-12
26178702-0	2015	Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF-gamma and TGF-beta.	Bleomycin	14-23	matrix metallopeptidase 9	Mus musculus	129-133
26178702-0	2015	Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF-gamma and TGF-beta.	Bleomycin	14-23	tissue inhibitor of metalloproteinase 1	Mus musculus	135-141
26178702-0	2015	Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF-gamma and TGF-beta.	Bleomycin	14-23	transforming growth factor, beta 1	Mus musculus	157-165
26010495-6	2015	Bleomycin-induction resulted in significant elevation of matrix metalloproteinase (MMP)-2 and -9 expression, increased RNA and protein expression of transforming growth factor (TGF)-beta1, Smads and alpha-smooth muscle actin (alpha-SMA).	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	149-187
25876794-0	2015	Oligosaccharide modification by N-acetylglucosaminyltransferase-V in macrophages are involved in pathogenesis of bleomycin-induced scleroderma.	Bleomycin	113-122	mannoside acetylglucosaminyltransferase 5	Mus musculus	32-65
26035385-9	2015	Moreover, we analyzed primary ATII cells from mice with bleomycin-induced lung injury, a model exhibiting activated Wnt/beta-catenin signaling in vivo.	Bleomycin	56-65	catenin (cadherin associated protein), beta 1	Mus musculus	120-132
25876794-6	2015	Expression of GnT-V was also elevated in bleomycin (BLM)-injected sclerotic skin, and MGAT5(-/-) mice were resistant to BLM-induced skin sclerosis with reduced collagen type 1 alpha1 content, suggesting the biological significance of GnT-V in skin sclerosis.	Bleomycin	41-50	mannoside acetylglucosaminyltransferase 5	Mus musculus	14-19
25876794-6	2015	Expression of GnT-V was also elevated in bleomycin (BLM)-injected sclerotic skin, and MGAT5(-/-) mice were resistant to BLM-induced skin sclerosis with reduced collagen type 1 alpha1 content, suggesting the biological significance of GnT-V in skin sclerosis.	Bleomycin	52-55	mannoside acetylglucosaminyltransferase 5	Mus musculus	14-19
26002989-7	2015	Bleomycin induced a significant elevation of PRA with a significant increase in hydroxyproline and TGF-beta1 in group III.	Bleomycin	0-9	transforming growth factor, beta 1	Mus musculus	99-108
25916750-6	2015	In patients with cHL receiving doxorubicin, bleomycin, vinblastine and dacarbazine, those expressing IGF-1R showed a trend towards better OS and event-free survival than IGF-1R-negative patients (P = 0.129 and P = 0.115 respectively), but statistical significance was not reached.	Bleomycin	44-53	insulin like growth factor 1 receptor	Homo sapiens	101-107
26339340-0	2015	Bone marrow mesenchymal stem cells protect against bleomycin-induced pulmonary fibrosis in rat by activating Nrf2 signaling.	Bleomycin	51-60	NFE2 like bZIP transcription factor 2	Rattus norvegicus	109-113
26178733-6	2015	Scgb3a2-transgenic and wild-type mice were subjected to bleomycin-induced pulmonary fibrosis model, and their lungs and bronchoalveolar lavage fluids were collected at various time points during 9 weeks post-bleomycin treatment for further analysis.	Bleomycin	56-65	secretoglobin, family 3A, member 2	Mus musculus	0-7
26178733-6	2015	Scgb3a2-transgenic and wild-type mice were subjected to bleomycin-induced pulmonary fibrosis model, and their lungs and bronchoalveolar lavage fluids were collected at various time points during 9 weeks post-bleomycin treatment for further analysis.	Bleomycin	208-217	secretoglobin, family 3A, member 2	Mus musculus	0-7
25409201-6	2015	Further, we show that reducing pulmonary lipid clearance by targeted deletion of the lipid efflux transporter ATP-binding cassette subfamily G member 1 increases foam cell formation and worsens lung fibrosis after bleomycin.	Bleomycin	214-223	ATP binding cassette subfamily G member 1	Mus musculus	110-151
26148346-0	2015	Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.	Bleomycin	91-100	spleen tyrosine kinase	Mus musculus	24-27
26148346-6	2015	We investigated the ability of a small drug, the Syk inhibitor, fostamatinib, to protect mice from bleomycin-induced SSc.	Bleomycin	99-108	spleen tyrosine kinase	Mus musculus	49-52
26148346-12	2015	CONCLUSIONS: The Syk inhibitor fostamatinib prevented bleomycin-induced fibrosis and inflammation in the skin and in the lung.	Bleomycin	54-63	spleen tyrosine kinase	Mus musculus	17-20
25957199-2	2015	Our previous study has found that eIF3a is involved in bleomycin-induced pulmonary fibrosis.	Bleomycin	55-64	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	34-39
25957199-7	2015	In vivo, L-mimosine treatment significantly ameliorated the bleomycin-mediated histological fibrosis alterations and blocked collagen deposition concomitantly with reversing bleomycin-induced expression up-regulation of eIF3a, alpha-SMA, collagen I and collagen III (both mRNA and protein) and expression down- regulation of p27.	Bleomycin	174-183	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	220-225
25957199-7	2015	In vivo, L-mimosine treatment significantly ameliorated the bleomycin-mediated histological fibrosis alterations and blocked collagen deposition concomitantly with reversing bleomycin-induced expression up-regulation of eIF3a, alpha-SMA, collagen I and collagen III (both mRNA and protein) and expression down- regulation of p27.	Bleomycin	174-183	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	325-328
25957199-10	2015	These results suggest that L-mimosine inhibited the progression of bleomycin-induced pulmonary fibrosis in rats via the eIF3a/p27 pathway.	Bleomycin	67-76	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	120-125
26005773-12	2015	Finally, MIF mRNA levels significantly increased at 6h (p&lt;0.001) and decreased at 48 h (p&lt;0.001) in control fibroblasts treated with bleomycin compared to control untreated.	Bleomycin	139-148	macrophage migration inhibitory factor	Homo sapiens	9-12
26005773-13	2015	Simultaneously, MIF supernatant protein levels increased after 48 h (p&lt;0.01) in bleomycin-treated fibroblasts respect to untreated ones.	Bleomycin	83-92	macrophage migration inhibitory factor	Homo sapiens	16-19
25929614-1	2015	Review of the management of 6 young girls with vaginal yolk sac tumor over 25 years showed that the alpha-fetoprotein levels normalized in 5/6 within 4 cycles of primary cisplatin, bleomycin, etoposide (PEB)/carboplatin, etoposide, bleomycin (JEB)/cisplatin, vinblastine, bleomycin (PVB) chemotherapy.	Bleomycin	232-241	alpha fetoprotein	Homo sapiens	100-117
25779936-4	2015	Herein we used a novel Tbx4 lung enhancer-driven Tet-On transgenic system to inhibit TGFbeta signalling in mouse lung-resident mesenchymal cells at different stages of bleomycin-induced fibrosis, by conditionally knocking out TGFbeta receptor II or expressing a dominant-negative TGFbeta receptor II.	Bleomycin	168-177	T-box 4	Mus musculus	23-27
25779936-4	2015	Herein we used a novel Tbx4 lung enhancer-driven Tet-On transgenic system to inhibit TGFbeta signalling in mouse lung-resident mesenchymal cells at different stages of bleomycin-induced fibrosis, by conditionally knocking out TGFbeta receptor II or expressing a dominant-negative TGFbeta receptor II.	Bleomycin	168-177	transforming growth factor, beta 1	Mus musculus	85-92
25779936-5	2015	Abrogation of mesenchymal TGFbeta signalling markedly attenuated bleomycin-induced fibrotic pathology, which was independent of altered early inflammation.	Bleomycin	65-74	transforming growth factor, beta 1	Mus musculus	26-33
25779936-6	2015	Furthermore, a novel TGFbeta downstream target gene P4HA3 (an alpha-subunit of collagen prolyl hydroxylase) was identified, and its expression was significantly increased in fibroblastic foci of both bleomycin-induced fibrotic mouse lungs and idiopathic pulmonary fibrosis patients" lungs.	Bleomycin	200-209	transforming growth factor, beta 1	Mus musculus	21-28
25929614-1	2015	Review of the management of 6 young girls with vaginal yolk sac tumor over 25 years showed that the alpha-fetoprotein levels normalized in 5/6 within 4 cycles of primary cisplatin, bleomycin, etoposide (PEB)/carboplatin, etoposide, bleomycin (JEB)/cisplatin, vinblastine, bleomycin (PVB) chemotherapy.	Bleomycin	181-190	alpha fetoprotein	Homo sapiens	100-117
25929614-1	2015	Review of the management of 6 young girls with vaginal yolk sac tumor over 25 years showed that the alpha-fetoprotein levels normalized in 5/6 within 4 cycles of primary cisplatin, bleomycin, etoposide (PEB)/carboplatin, etoposide, bleomycin (JEB)/cisplatin, vinblastine, bleomycin (PVB) chemotherapy.	Bleomycin	232-241	alpha fetoprotein	Homo sapiens	100-117
25539827-7	2015	The decreased expression of chemerin was significantly reversed by TGF-beta1 antisense oligonucleotide in cultured SSc dermal fibroblasts and chemerin expression was markedly decreased in dermal fibroblasts of bleomycin-treated mice.	Bleomycin	210-219	retinoic acid receptor responder (tazarotene induced) 2	Mus musculus	28-36
25547017-9	2015	Similar to human SSc, the same expression patterns of miR-130b, PPARgamma, and fibrosis-related genes were observed in the bleomycin-induced skin fibrosis model; TGF-beta induced the expression of miR-130b and fibrosis-related genes expression, but downregulated the expression of PPARgamma.	Bleomycin	123-132	microRNA 130b	Homo sapiens	54-62
25547017-9	2015	Similar to human SSc, the same expression patterns of miR-130b, PPARgamma, and fibrosis-related genes were observed in the bleomycin-induced skin fibrosis model; TGF-beta induced the expression of miR-130b and fibrosis-related genes expression, but downregulated the expression of PPARgamma.	Bleomycin	123-132	peroxisome proliferator activated receptor gamma	Homo sapiens	64-73
25547017-9	2015	Similar to human SSc, the same expression patterns of miR-130b, PPARgamma, and fibrosis-related genes were observed in the bleomycin-induced skin fibrosis model; TGF-beta induced the expression of miR-130b and fibrosis-related genes expression, but downregulated the expression of PPARgamma.	Bleomycin	123-132	transforming growth factor beta 1	Homo sapiens	162-170
25547017-9	2015	Similar to human SSc, the same expression patterns of miR-130b, PPARgamma, and fibrosis-related genes were observed in the bleomycin-induced skin fibrosis model; TGF-beta induced the expression of miR-130b and fibrosis-related genes expression, but downregulated the expression of PPARgamma.	Bleomycin	123-132	microRNA 130b	Homo sapiens	197-205
25547017-9	2015	Similar to human SSc, the same expression patterns of miR-130b, PPARgamma, and fibrosis-related genes were observed in the bleomycin-induced skin fibrosis model; TGF-beta induced the expression of miR-130b and fibrosis-related genes expression, but downregulated the expression of PPARgamma.	Bleomycin	123-132	peroxisome proliferator activated receptor gamma	Homo sapiens	281-290
25684348-3	2015	It was revealed that IQGAP1 expression levels were significantly decreased in lung fibroblasts isolated from bleomycin-challenged mice than in those of control mice.	Bleomycin	109-118	IQ motif containing GTPase activating protein 1	Mus musculus	21-27
25779936-6	2015	Furthermore, a novel TGFbeta downstream target gene P4HA3 (an alpha-subunit of collagen prolyl hydroxylase) was identified, and its expression was significantly increased in fibroblastic foci of both bleomycin-induced fibrotic mouse lungs and idiopathic pulmonary fibrosis patients" lungs.	Bleomycin	200-209	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide III	Mus musculus	52-57
25779936-8	2015	Moreover, inhibition of collagen prolyl hydroxylase by pyridine-2,5-dicarboxylate attenuated TGFbeta-stimulated collagen production in both cultured fibroblasts and bleomycin-induced mouse lung fibrosis.	Bleomycin	165-174	transforming growth factor, beta 1	Mus musculus	93-100
25539827-7	2015	The decreased expression of chemerin was significantly reversed by TGF-beta1 antisense oligonucleotide in cultured SSc dermal fibroblasts and chemerin expression was markedly decreased in dermal fibroblasts of bleomycin-treated mice.	Bleomycin	210-219	retinoic acid receptor responder (tazarotene induced) 2	Mus musculus	142-150
26140046-0	2015	Osteopontin Potentiates Pulmonary Inflammation and Fibrosis by Modulating IL-17/IFN-gamma-secreting T-cell Ratios in Bleomycin-treated Mice.	Bleomycin	117-126	secreted phosphoprotein 1	Mus musculus	0-11
26181367-4	2015	We observed that Sin3B expression is significantly up-regulated both at transcript and at protein level upon DNA damage induced by bleomycin drug, a radiomimetic agent.	Bleomycin	131-140	SIN3 transcription regulator family member B	Homo sapiens	17-22
25652403-8	2015	To meet the challenge of correct classification, flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in DSB repair genes disrupted the binding of BRCA1 to BARD1, PALB2, BRCA2 and FANCD2, phosphorylation of p53 or BRCA1 nuclear localization in response to DNA damage caused by diepoxybutane, mitomycin C and bleomycin.	Bleomycin	356-365	BRCA1 DNA repair associated	Homo sapiens	195-200
26147947-0	2015	Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	83-92	coagulation factor II (thrombin) receptor-like 1	Mus musculus	29-58
26147947-4	2015	Bleomycin was instilled intranasally into wild-type or PAR-2-deficient mice in the presence/absence of a specific PAR-2 antagonist (P2pal-18S).	Bleomycin	0-9	coagulation factor II (thrombin) receptor-like 1	Mus musculus	55-60
26121674-6	2015	Here, we demonstrate that BRCA1, a DNA damage repair sensor and transcription regulator, is in complex with IFI16 in the host cell nucleus, and their association increases in the presence of nuclear viral genomes during de novo KSHV, EBV and HSV-1 infection, and in latent KSHV or EBV infection, but not by DNA damage responses (DDR) induced by bleomycin and vaccinia virus cytoplasmic dsDNA.	Bleomycin	345-354	BRCA1 DNA repair associated	Homo sapiens	26-31
26121674-6	2015	Here, we demonstrate that BRCA1, a DNA damage repair sensor and transcription regulator, is in complex with IFI16 in the host cell nucleus, and their association increases in the presence of nuclear viral genomes during de novo KSHV, EBV and HSV-1 infection, and in latent KSHV or EBV infection, but not by DNA damage responses (DDR) induced by bleomycin and vaccinia virus cytoplasmic dsDNA.	Bleomycin	345-354	interferon gamma inducible protein 16	Homo sapiens	108-113
24618263-5	2015	RESULTS: LXR activation by the agonist T0901317 had antifibrotic effects in bleomycin-induced skin fibrosis, in the sclGvHD model and in Tsk-1 mice.	Bleomycin	76-85	nuclear receptor subfamily 1, group H, member 2	Mus musculus	9-12
24618263-7	2015	LXRalpha-, LXRbeta- and LXRalpha/beta-double-knockout mice showed a similar response to bleomycin as wildtype animals.	Bleomycin	88-97	nuclear receptor subfamily 1, group H, member 2	Mus musculus	11-32
24618263-8	2015	Low levels of the LXR target gene ABCA-1 in the skin of bleomycin-challenged and control mice suggested a low baseline activation of the antifibrotic LXR signalling, which, however, could be specifically activated by T0901317.	Bleomycin	56-65	nuclear receptor subfamily 1, group H, member 2	Mus musculus	18-21
24618263-8	2015	Low levels of the LXR target gene ABCA-1 in the skin of bleomycin-challenged and control mice suggested a low baseline activation of the antifibrotic LXR signalling, which, however, could be specifically activated by T0901317.	Bleomycin	56-65	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	34-40
24618263-8	2015	Low levels of the LXR target gene ABCA-1 in the skin of bleomycin-challenged and control mice suggested a low baseline activation of the antifibrotic LXR signalling, which, however, could be specifically activated by T0901317.	Bleomycin	56-65	nuclear receptor subfamily 1, group H, member 2	Mus musculus	150-153
25843005-3	2015	Pulmonary surfactant protein D (SP-D), an important biomarker of IPF, reportedly attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	92-101	surfactant associated protein D	Mus musculus	32-36
25672255-7	2015	In addition, BLM-induced increased expression of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, cyclooxygenase-2, prostaglandin E2, malondialdehyde, inducible nitric oxide synthase and nitric oxide in rats, which was also suppressed by Tan IIA injection.	Bleomycin	13-16	tumor necrosis factor	Rattus norvegicus	49-76
25672255-7	2015	In addition, BLM-induced increased expression of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, cyclooxygenase-2, prostaglandin E2, malondialdehyde, inducible nitric oxide synthase and nitric oxide in rats, which was also suppressed by Tan IIA injection.	Bleomycin	13-16	interleukin 1 beta	Rattus norvegicus	78-100
25672255-7	2015	In addition, BLM-induced increased expression of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, cyclooxygenase-2, prostaglandin E2, malondialdehyde, inducible nitric oxide synthase and nitric oxide in rats, which was also suppressed by Tan IIA injection.	Bleomycin	13-16	interleukin 6	Rattus norvegicus	102-106
25672255-7	2015	In addition, BLM-induced increased expression of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, cyclooxygenase-2, prostaglandin E2, malondialdehyde, inducible nitric oxide synthase and nitric oxide in rats, which was also suppressed by Tan IIA injection.	Bleomycin	13-16	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	108-124
25689283-3	2015	Previous studies have shown that bleomycin-induced lung fibrosis is diminished in both PAR-1 and PAR-2 deficient mice.	Bleomycin	33-42	coagulation factor II (thrombin) receptor	Mus musculus	87-92
25689283-3	2015	Previous studies have shown that bleomycin-induced lung fibrosis is diminished in both PAR-1 and PAR-2 deficient mice.	Bleomycin	33-42	pulmonary adenoma resistance 2	Mus musculus	97-102
25689283-10	2015	Strikingly, PAR-2 deficiency as well as pharmacological PAR-1 inhibition reduced bleomycin-induced pulmonary fibrosis to a similar extent.	Bleomycin	81-90	pulmonary adenoma resistance 2	Mus musculus	12-17
25689283-10	2015	Strikingly, PAR-2 deficiency as well as pharmacological PAR-1 inhibition reduced bleomycin-induced pulmonary fibrosis to a similar extent.	Bleomycin	81-90	coagulation factor II (thrombin) receptor	Mus musculus	56-61
25471004-4	2015	In this report, we aimed to present the treatment of KMS developing secondarily to giant cavernous hemangioma of the liver with transarterial chemoembolization using bleomycin.	Bleomycin	166-175	MKKS centrosomal shuttling protein	Homo sapiens	53-56
25844688-7	2015	On day 7, the combination therapy attenuated bleomycin-induced increase of total and differential inflammatory cell counts, total proteins, lung wet/dry weight ratio, myeloperoxidase activity, lung inflammatory cell infiltration more than individual agents alone.	Bleomycin	45-54	myeloperoxidase	Mus musculus	167-182
25950582-4	2015	We have found that, in contrast with animals, in Arabidopsis thaliana PARP2 (At4g02390), rather than PARP1 (At2g31320), makes the greatest contribution to PARP activity and organismal viability in response to genotoxic stresses caused by bleomycin, mitomycin C or gamma-radiation.	Bleomycin	238-247	poly(ADP-ribose) polymerase	Arabidopsis thaliana	70-75
25950582-4	2015	We have found that, in contrast with animals, in Arabidopsis thaliana PARP2 (At4g02390), rather than PARP1 (At2g31320), makes the greatest contribution to PARP activity and organismal viability in response to genotoxic stresses caused by bleomycin, mitomycin C or gamma-radiation.	Bleomycin	238-247	poly(ADP-ribose) polymerase 1	Homo sapiens	70-74
25943524-6	2015	Similarly, sea3  mutants exhibited a delay in colony formation in a BIR assay strain after double-strand break (DSB) induction as well as on the DNA-damaging agent bleomycin.	Bleomycin	164-173	Mtc5p	Saccharomyces cerevisiae S288C	11-15
25951185-9	2015	Bleomycin, and bleomycin-induced Fas-mediated apoptosis following treatment with anti-Fas activating mAb or control IgG, were assessed by Annexin V staining, FACS analysis, and confocal microscopy; caspase cleavage by Western blot; FLIP or Fas molecule detection by Western blot and flow cytometry.	Bleomycin	15-24	annexin A5	Homo sapiens	138-147
24431397-8	2015	Inhibition of CK2 prevented bleomycin-induced and TBR-induced skin fibrosis with decreased dermal thickening, lower myofibroblast counts and reduced accumulation of collagen.	Bleomycin	28-37	casein kinase 2, alpha prime polypeptide	Mus musculus	14-17
25844688-8	2015	Bosentan but not imatinib ameliorated superoxide dismutase and catalase activities, which were lowered following bleomycin instillation.	Bleomycin	113-122	catalase	Mus musculus	63-71
25844688-9	2015	On day 21, combination therapy ameliorated bleomycin-induced increase of fibrosis score, collagen deposition, protein and gene expression of SMA, mRNA levels of collagens-I and -III, matrix metalloproteinase-9 and -2 activities more than monotherapy.	Bleomycin	43-52	immunoglobulin mu binding protein 2	Mus musculus	141-144
25844688-9	2015	On day 21, combination therapy ameliorated bleomycin-induced increase of fibrosis score, collagen deposition, protein and gene expression of SMA, mRNA levels of collagens-I and -III, matrix metalloproteinase-9 and -2 activities more than monotherapy.	Bleomycin	43-52	matrix metallopeptidase 9	Mus musculus	146-216
25878193-5	2015	Accordingly, fibroblasts from ATM patients, which are defective in p53 activation, expressed reduced constitutive levels of AhR and treatment of cells with bleomycin did not appreciably increase the AhR levels.	Bleomycin	156-165	ATM serine/threonine kinase	Homo sapiens	30-33
25813392-0	2015	Different profiles of notch signaling in cigarette smoke-induced pulmonary emphysema and bleomycin-induced pulmonary fibrosis.	Bleomycin	89-98	notch 3	Mus musculus	22-27
25923111-0	2015	Prostaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced Fibrosis.	Bleomycin	63-72	solute carrier organic anion transporter family, member 2a1	Mus musculus	0-25
25923111-0	2015	Prostaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced Fibrosis.	Bleomycin	63-72	solute carrier organic anion transporter family, member 2a1	Mus musculus	27-30
25923111-0	2015	Prostaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced Fibrosis.	Bleomycin	63-72	solute carrier organic anion transporter family, member 2a1	Mus musculus	31-38
25923111-2	2015	The present study aimed to evaluate the pathophysiological relevance of SLCO2A1 to bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	83-92	solute carrier organic anion transporter family, member 2a1	Mus musculus	72-79
25923111-2	2015	The present study aimed to evaluate the pathophysiological relevance of SLCO2A1 to bleomycin (BLM)-induced pulmonary fibrosis in mice.	Bleomycin	94-97	solute carrier organic anion transporter family, member 2a1	Mus musculus	72-79
25848047-5	2015	Moreover, in vivo the bleomycin-induced down-regulation of peroxisomes was abrogated in transforming growth factor beta (TGF-beta) receptor II knockout mice indicating a role for TGF-beta signaling in the regulation of peroxisomes.	Bleomycin	22-31	transforming growth factor, beta receptor II	Mus musculus	121-142
25713320-4	2015	First, we demonstrated that CYR61 expression increases after bleomycin-induced lung injury.	Bleomycin	61-70	cellular communication network factor 1	Mus musculus	28-33
25848047-5	2015	Moreover, in vivo the bleomycin-induced down-regulation of peroxisomes was abrogated in transforming growth factor beta (TGF-beta) receptor II knockout mice indicating a role for TGF-beta signaling in the regulation of peroxisomes.	Bleomycin	22-31	transforming growth factor beta 1	Homo sapiens	121-129
26413189-3	2015	We previously reported that a matricellular protein, periostin (POSTN), contributes to pathogenesis of scleroderma as POSTN knockout mice were resistant to bleomycin (BLM)-induced scleroderma.	Bleomycin	156-165	periostin, osteoblast specific factor	Mus musculus	53-62
26413189-3	2015	We previously reported that a matricellular protein, periostin (POSTN), contributes to pathogenesis of scleroderma as POSTN knockout mice were resistant to bleomycin (BLM)-induced scleroderma.	Bleomycin	156-165	periostin, osteoblast specific factor	Mus musculus	64-69
25906080-0	2015	Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis.	Bleomycin	55-64	autophagy related 4B, cysteine peptidase	Mus musculus	23-28
25659898-8	2015	Adenoviral overexpression of IL-13Ralpha2 in the lung reduced bleomycin-induced fibrosis.	Bleomycin	62-71	interleukin 13 receptor subunit alpha 2	Homo sapiens	29-41
25906080-4	2015	In this study, we show for the first time, how autophagy disruption contributes to bleomycin-induced lung fibrosis in vivo using an Atg4b-deficient mouse as a model.	Bleomycin	83-92	autophagy related 4B, cysteine peptidase	Mus musculus	132-137
25906080-5	2015	Atg4b-deficient mice displayed a significantly higher inflammatory response at 7 d after bleomycin treatment associated with increased neutrophilic infiltration and significant alterations in proinflammatory cytokines.	Bleomycin	89-98	autophagy related 4B, cysteine peptidase	Mus musculus	0-5
25906080-7	2015	At 28 d post-bleomycin instillation Atg4b-deficient mice exhibited more extensive and severe fibrosis with increased collagen accumulation and deregulated extracellular matrix-related gene expression.	Bleomycin	13-22	autophagy related 4B, cysteine peptidase	Mus musculus	36-41
25906080-8	2015	Together, our findings indicate that the ATG4B protease and autophagy play a crucial role protecting epithelial cells against bleomycin-induced stress and apoptosis, and in the regulation of the inflammatory and fibrotic responses.	Bleomycin	126-135	autophagy related 4B, cysteine peptidase	Mus musculus	41-46
25140582-5	2015	Analysis of Hedgehog reemergence in vivo revealed that of all three Hedgehog isoforms, only SHH was significantly induced in bleomycin-injured lung along with Gli1.	Bleomycin	125-134	sonic hedgehog signaling molecule	Homo sapiens	92-95
25659898-9	2015	Our work shows that overexpression of IL-13Ralpha2 inhibits the IL-13 induction of fibrotic markers in vitro and inhibits bleomycin-induced pulmonary fibrosis.	Bleomycin	122-131	interleukin 13 receptor subunit alpha 2	Homo sapiens	38-50
25659898-9	2015	Our work shows that overexpression of IL-13Ralpha2 inhibits the IL-13 induction of fibrotic markers in vitro and inhibits bleomycin-induced pulmonary fibrosis.	Bleomycin	122-131	interleukin 13	Homo sapiens	38-43
25492803-0	2015	IL-21 induction of CD4+ T cell differentiation into Th17 cells contributes to bleomycin-induced fibrosis in mice.	Bleomycin	78-87	interleukin 21	Mus musculus	0-5
25504959-8	2015	Cell fate mapping studies in mice with the adiponectin promoter-driven Cre recombinase transgenic construct indicated that adiponectin-positive progenitors that are normally confined to the intradermal adipose tissue compartment were distributed throughout the lesional dermis over time, lost their adipocytic markers, and expressed myofibroblast markers in bleomycin-treated mice.	Bleomycin	358-367	adiponectin, C1Q and collagen domain containing	Mus musculus	123-134
25885656-0	2015	Megakaryoblastic leukemia-1 is required for the development of bleomycin-induced pulmonary fibrosis.	Bleomycin	63-72	myocardin related transcription factor A	Mus musculus	0-27
25435005-0	2015	Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury.	Bleomycin	118-127	angiotensin converting enzyme 2	Homo sapiens	78-109
25435005-1	2015	The aim of the present study was to evaluate the therapeutic effects of human umbilical cord mesenchymal stem cells (uMSCs) in the presence of angiotensin-converting enzyme 2 gene (ACE2; ACE2-uMSCs) on bleomycin (BLM)-induced lung injury and pulmonary fibrosis in mice.	Bleomycin	202-211	angiotensin converting enzyme 2	Homo sapiens	143-174
25435005-1	2015	The aim of the present study was to evaluate the therapeutic effects of human umbilical cord mesenchymal stem cells (uMSCs) in the presence of angiotensin-converting enzyme 2 gene (ACE2; ACE2-uMSCs) on bleomycin (BLM)-induced lung injury and pulmonary fibrosis in mice.	Bleomycin	202-211	angiotensin converting enzyme 2	Homo sapiens	181-185
25435005-1	2015	The aim of the present study was to evaluate the therapeutic effects of human umbilical cord mesenchymal stem cells (uMSCs) in the presence of angiotensin-converting enzyme 2 gene (ACE2; ACE2-uMSCs) on bleomycin (BLM)-induced lung injury and pulmonary fibrosis in mice.	Bleomycin	202-211	angiotensin converting enzyme 2	Homo sapiens	187-191
25435005-1	2015	The aim of the present study was to evaluate the therapeutic effects of human umbilical cord mesenchymal stem cells (uMSCs) in the presence of angiotensin-converting enzyme 2 gene (ACE2; ACE2-uMSCs) on bleomycin (BLM)-induced lung injury and pulmonary fibrosis in mice.	Bleomycin	213-216	angiotensin converting enzyme 2	Homo sapiens	143-174
25435005-1	2015	The aim of the present study was to evaluate the therapeutic effects of human umbilical cord mesenchymal stem cells (uMSCs) in the presence of angiotensin-converting enzyme 2 gene (ACE2; ACE2-uMSCs) on bleomycin (BLM)-induced lung injury and pulmonary fibrosis in mice.	Bleomycin	213-216	angiotensin converting enzyme 2	Homo sapiens	181-185
25435005-1	2015	The aim of the present study was to evaluate the therapeutic effects of human umbilical cord mesenchymal stem cells (uMSCs) in the presence of angiotensin-converting enzyme 2 gene (ACE2; ACE2-uMSCs) on bleomycin (BLM)-induced lung injury and pulmonary fibrosis in mice.	Bleomycin	213-216	angiotensin converting enzyme 2	Homo sapiens	187-191
25435005-4	2015	ACE2-uMSC injection following bleomycin pretreatment significantly alleviated lung injury in mice.	Bleomycin	30-39	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	0-4
25435005-6	2015	In conclusion, the results of the present study demonstrated that ACE2 and uMSCs had a synergistic therapeutic effect on bleomycin-induced acute lung injury.	Bleomycin	121-130	angiotensin converting enzyme 2	Homo sapiens	66-70
25435076-6	2015	The present study examined the roles of alveolar epithelial cell injury and profibrogenic cytokine release in EMT and their association with the Wnt/beta-catenin signaling pathway in a mouse model of bleomycin-induced pulmonary fibrosis.	Bleomycin	200-209	wingless-type MMTV integration site family, member 1	Mus musculus	145-148
25492803-4	2015	Here, using a bleomycin (BLM)-induced mouse model of skin fibrosis, we detected the frequency of CD4+/IL-17+ (Th17) cells, CD4+/IL-21+ T cells and IL-21+ Th17 cells in peripheral blood, skin and lungs, as well as the serum content of IL-17A and IL-21.	Bleomycin	25-28	interleukin 21	Mus musculus	147-152
25492803-4	2015	Here, using a bleomycin (BLM)-induced mouse model of skin fibrosis, we detected the frequency of CD4+/IL-17+ (Th17) cells, CD4+/IL-21+ T cells and IL-21+ Th17 cells in peripheral blood, skin and lungs, as well as the serum content of IL-17A and IL-21.	Bleomycin	25-28	interleukin 21	Mus musculus	147-152
25885656-4	2015	METHODS: Bleomycin or normal saline were intratracheally delivered to 9 to 12 week old female MKL1 (+,+) and MKL1 (-,-) mice.	Bleomycin	9-18	myocardin related transcription factor A	Mus musculus	94-98
25885656-4	2015	METHODS: Bleomycin or normal saline were intratracheally delivered to 9 to 12 week old female MKL1 (+,+) and MKL1 (-,-) mice.	Bleomycin	9-18	myocardin related transcription factor A	Mus musculus	109-113
25885656-9	2015	RESULTS: MKL1 (-,-) mice demonstrated increased survival, attenuated weight loss, and decreased collagen accumulation compared to wild-type animals 28-days after intratracheal instillation of bleomycin.	Bleomycin	192-201	myocardin related transcription factor A	Mus musculus	9-13
25885656-13	2015	CONCLUSIONS: Altogether, these data demonstrate that MKL1 plays a significant role in mediating the fibrotic response to bleomycin injury.	Bleomycin	121-130	myocardin related transcription factor A	Mus musculus	53-57
25762200-3	2015	We demonstrate that central pathophysiologic events in ALI (inflammation, IL-1beta levels, endothelial and alveolar epithelial barrier permeability, remodelling and fibrosis) are attenuated in the lungs of Vim(-/-) mice challenged with LPS, bleomycin and asbestos.	Bleomycin	241-250	vimentin	Mus musculus	206-209
25575513-3	2015	We have recently found that matrix metalloproteinase 19 (MMP-19)-deficient (Mmp19-/-) mice develop an exaggerated bleomycin-induced lung fibrosis, but the mechanisms are unclear.	Bleomycin	114-123	matrix metallopeptidase 19	Mus musculus	28-55
25575513-3	2015	We have recently found that matrix metalloproteinase 19 (MMP-19)-deficient (Mmp19-/-) mice develop an exaggerated bleomycin-induced lung fibrosis, but the mechanisms are unclear.	Bleomycin	114-123	matrix metallopeptidase 19	Mus musculus	57-63
25575513-3	2015	We have recently found that matrix metalloproteinase 19 (MMP-19)-deficient (Mmp19-/-) mice develop an exaggerated bleomycin-induced lung fibrosis, but the mechanisms are unclear.	Bleomycin	114-123	matrix metallopeptidase 19	Mus musculus	76-81
25849157-8	2015	RESULTS: Nog +/LacZ mice are a known model of increased BMP signaling and were partially protected from bleomycin-induced lung fibrosis with reduced Ashcroft score, reduced collagen content and preservation of pulmonary compliance.	Bleomycin	104-113	noggin	Mus musculus	9-12
25849157-9	2015	In bleomycin-induced lung fibrosis, TGFbeta and BMP signaling followed an inverse course, with dynamic activation of TGFbeta signaling and repression of BMP signaling activity.	Bleomycin	3-12	transforming growth factor, beta 1	Mus musculus	36-43
25849157-9	2015	In bleomycin-induced lung fibrosis, TGFbeta and BMP signaling followed an inverse course, with dynamic activation of TGFbeta signaling and repression of BMP signaling activity.	Bleomycin	3-12	transforming growth factor, beta 1	Mus musculus	117-124
25849157-11	2015	Derepression of BMP signaling in Nog +/LacZ mice protects against bleomycin-induced pulmonary fibrosis.	Bleomycin	66-75	noggin	Mus musculus	33-36
25785991-9	2015	Finally, Pink1-/- mice were more susceptible than control mice to bleomycin induced lung fibrosis.	Bleomycin	66-75	PTEN induced putative kinase 1	Mus musculus	9-14
26064283-4	2015	The present study aimed to investigate the effect of APS on TGF-beta signaling and its potential mechanism using a murine model of bleomycin-induced scleroderma.	Bleomycin	131-140	transforming growth factor, beta 1	Mus musculus	60-68
25762200-4	2015	Bone marrow chimeric mice lacking vimentin have reduced IL-1beta levels and attenuated lung injury and fibrosis following bleomycin exposure.	Bleomycin	122-131	vimentin	Mus musculus	34-42
25373521-4	2015	In this study, we show that MSCs can correct the inadequate-communication between epithelial and mesenchymal cells through STC1 (Stanniocalcin-1) secretion in a bleomycin-induced IPF model.	Bleomycin	161-170	stanniocalcin 1	Homo sapiens	123-127
25603270-5	2015	We show that GAPDH-deficient cells are more sensitive to bleomycin or methyl methanesulfonate.	Bleomycin	57-66	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	13-18
25373521-4	2015	In this study, we show that MSCs can correct the inadequate-communication between epithelial and mesenchymal cells through STC1 (Stanniocalcin-1) secretion in a bleomycin-induced IPF model.	Bleomycin	161-170	stanniocalcin 1	Homo sapiens	129-144
25888222-0	2015	IL-27 alleviates the bleomycin-induced pulmonary fibrosis by regulating the Th17 cell differentiation.	Bleomycin	21-30	interleukin 27	Mus musculus	0-5
25888222-3	2015	METHODS: In this study, we observed the expression of IL-27/IL-27R in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	87-96	interleukin 27	Mus musculus	54-59
25888222-3	2015	METHODS: In this study, we observed the expression of IL-27/IL-27R in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	87-96	interleukin 27 receptor, alpha	Mus musculus	60-66
25888222-3	2015	METHODS: In this study, we observed the expression of IL-27/IL-27R in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	98-101	interleukin 27	Mus musculus	54-59
25888222-3	2015	METHODS: In this study, we observed the expression of IL-27/IL-27R in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	98-101	interleukin 27 receptor, alpha	Mus musculus	60-66
25595781-0	2015	IRAK-M promotes alternative macrophage activation and fibroproliferation in bleomycin-induced lung injury.	Bleomycin	76-85	interleukin-1 receptor-associated kinase 3	Mus musculus	0-6
25595781-6	2015	Mice deficient in IRAK-M (IRAK-M(-/-)) were protected against bleomycin-induced fibrosis and displayed diminished collagen deposition in association with reduced production of IL-13 compared with wild-type (WT) control mice.	Bleomycin	62-71	interleukin-1 receptor-associated kinase 3	Mus musculus	18-24
25592322-10	2015	These findings suggest that eIF3a plays an important role in bleomycin-induced pulmonary fibrosis by regulating pulmonary fibroblasts  function, and up-regulation of eIF3a induced by TGF-beta1 is mediated via the ERK1/2 pathway.	Bleomycin	61-70	eukaryotic translation initiation factor 3, subunit J	Rattus norvegicus	28-33
25595781-6	2015	Mice deficient in IRAK-M (IRAK-M(-/-)) were protected against bleomycin-induced fibrosis and displayed diminished collagen deposition in association with reduced production of IL-13 compared with wild-type (WT) control mice.	Bleomycin	62-71	interleukin-1 receptor-associated kinase 3	Mus musculus	26-32
25592322-10	2015	These findings suggest that eIF3a plays an important role in bleomycin-induced pulmonary fibrosis by regulating pulmonary fibroblasts  function, and up-regulation of eIF3a induced by TGF-beta1 is mediated via the ERK1/2 pathway.	Bleomycin	61-70	mitogen activated protein kinase 3	Rattus norvegicus	213-219
25595781-9	2015	Using an in vitro coculture system, macrophages isolated from in vivo bleomycin-challenged WT, but not IRAK-M(-/-), mice promoted increased collagen and alpha-smooth muscle actin expression from lung fibroblasts in an IL-13-dependent fashion.	Bleomycin	70-79	interleukin 13	Mus musculus	218-223
25726143-2	2015	We have detected early (0, 1, 2, 5, 10 and 30 min) events in SSB rejoining in human leukocytes, with the alkaline comet assay, at a low concentration of bleomycin (BLM; 0.5 mug/ml).	Bleomycin	153-162	small RNA binding exonuclease protection factor La	Homo sapiens	61-64
25582705-4	2015	In this study, the effects of PA on the transforming growth factor-beta1 (TGF-beta1)-mediated epithelial-mesenchymal transition (EMT) in A549 cells, on the apoptosis of human type I alveolar epithelial cells (AT I), on the proliferation of human lung fibroblasts (HLF-1) in vitro, and on bleomycin (BLM)-induced pulmonary fibrosis in vivo were investigated.	Bleomycin	288-297	transforming growth factor beta 1	Homo sapiens	40-72
25582705-4	2015	In this study, the effects of PA on the transforming growth factor-beta1 (TGF-beta1)-mediated epithelial-mesenchymal transition (EMT) in A549 cells, on the apoptosis of human type I alveolar epithelial cells (AT I), on the proliferation of human lung fibroblasts (HLF-1) in vitro, and on bleomycin (BLM)-induced pulmonary fibrosis in vivo were investigated.	Bleomycin	288-297	transforming growth factor beta 1	Homo sapiens	74-83
25582705-4	2015	In this study, the effects of PA on the transforming growth factor-beta1 (TGF-beta1)-mediated epithelial-mesenchymal transition (EMT) in A549 cells, on the apoptosis of human type I alveolar epithelial cells (AT I), on the proliferation of human lung fibroblasts (HLF-1) in vitro, and on bleomycin (BLM)-induced pulmonary fibrosis in vivo were investigated.	Bleomycin	299-302	transforming growth factor beta 1	Homo sapiens	40-72
25582705-4	2015	In this study, the effects of PA on the transforming growth factor-beta1 (TGF-beta1)-mediated epithelial-mesenchymal transition (EMT) in A549 cells, on the apoptosis of human type I alveolar epithelial cells (AT I), on the proliferation of human lung fibroblasts (HLF-1) in vitro, and on bleomycin (BLM)-induced pulmonary fibrosis in vivo were investigated.	Bleomycin	299-302	transforming growth factor beta 1	Homo sapiens	74-83
25584011-0	2015	Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	39-48	follistatin-like 1	Mus musculus	9-27
25584011-4	2015	Haplodeletion of Fstl1 in mice or blockage of FSTL1 with a neutralizing antibody in mice reduced bleomycin-induced fibrosis in vivo.	Bleomycin	97-106	follistatin-like 1	Mus musculus	17-22
25584011-4	2015	Haplodeletion of Fstl1 in mice or blockage of FSTL1 with a neutralizing antibody in mice reduced bleomycin-induced fibrosis in vivo.	Bleomycin	97-106	follistatin-like 1	Mus musculus	46-51
25029475-6	2015	Significantly, pirfenidone attenuated the expression change of one (CTHRC1) translational gene marker in the bleomycin-induced lung fibrosis model, in transforming growth factor-beta1-treated primary human lung fibroblasts and transforming growth factor-beta1-treated human epithelial A549 cells.	Bleomycin	109-118	collagen triple helix repeat containing 1	Homo sapiens	68-74
25029475-6	2015	Significantly, pirfenidone attenuated the expression change of one (CTHRC1) translational gene marker in the bleomycin-induced lung fibrosis model, in transforming growth factor-beta1-treated primary human lung fibroblasts and transforming growth factor-beta1-treated human epithelial A549 cells.	Bleomycin	109-118	transforming growth factor beta 1	Homo sapiens	227-259
25385187-6	2015	RESULTS: Bleomycin induced more severe dermal fibrosis in Fli-1(+/-) mice than in wild-type mice.	Bleomycin	9-18	Friend leukemia integration 1	Mus musculus	58-63
25385187-8	2015	Dermal fibrosis in Fli-1(+/-) mice was also attributable to endothelial-to-mesenchymal transition, which is directly induced by Fli-1 deficiency and amplified by bleomycin.	Bleomycin	162-171	Friend leukemia integration 1	Mus musculus	19-24
25089563-10	2015	In vivo, constant infusion with Ang(1-7) or intratracheal instillation with lenti-ACE2 shifted the RAS balance toward the ACE2/Ang(1-7)/Mas axis, alleviated bleomycin-induced lung fibrosis, and inhibited the RhoA/Rock pathway by reducing NOX4-derived ROS.	Bleomycin	157-166	angiotensin converting enzyme 2	Homo sapiens	82-86
25590623-0	2015	Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.	Bleomycin	72-81	growth differentiation factor 15	Homo sapiens	0-32
25590623-0	2015	Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.	Bleomycin	72-81	growth differentiation factor 15	Homo sapiens	34-40
25673924-10	2015	In bleomycin-induced SSc mouse models, endogenous ligands for toll-like receptor 4 induced by bleomycin stimulated B cells to produce various fibrogenic cytokines and autoantibodies.	Bleomycin	3-12	toll-like receptor 4	Mus musculus	62-82
25673924-10	2015	In bleomycin-induced SSc mouse models, endogenous ligands for toll-like receptor 4 induced by bleomycin stimulated B cells to produce various fibrogenic cytokines and autoantibodies.	Bleomycin	94-103	toll-like receptor 4	Mus musculus	62-82
25760538-6	2015	Treatment of RLE/Abca3 cells with bleomycin (BLM) and methotrexate (MTX) induced similar morphological and mRNA expression changes.	Bleomycin	34-43	ATP binding cassette subfamily A member 3	Homo sapiens	17-22
25760538-6	2015	Treatment of RLE/Abca3 cells with bleomycin (BLM) and methotrexate (MTX) induced similar morphological and mRNA expression changes.	Bleomycin	45-48	ATP binding cassette subfamily A member 3	Homo sapiens	17-22
25527499-5	2015	In vivo, EC-specific ATG7 knock-out mice exhibit a basal reduction in endothelial-specific markers and demonstrate an increased susceptibility to bleomycin-induced pulmonary fibrosis and collagen accumulation.	Bleomycin	146-155	autophagy related 7	Mus musculus	21-25
25636879-10	2015	In conclusion, YTE could ameliorate BLM-induced lung fibrosis by alleviating HMGB1 activity and TGF-beta1 activation, suggesting therapeutic potential for PF.	Bleomycin	36-39	high mobility group box 1	Rattus norvegicus	77-82
25636879-10	2015	In conclusion, YTE could ameliorate BLM-induced lung fibrosis by alleviating HMGB1 activity and TGF-beta1 activation, suggesting therapeutic potential for PF.	Bleomycin	36-39	transforming growth factor, beta 1	Rattus norvegicus	96-105
25446881-9	2015	Over-expression of S1PL attenuated bleomycin-induced TGF-beta secretion and S1P mediated differentiation of human lung fibroblasts through regulation of autophagy.	Bleomycin	35-44	sphingosine-1-phosphate lyase 1	Homo sapiens	19-23
25446881-6	2015	Further, the expressions of SphK1 and S1PL were increased in lung tissues from patients with IPF and bleomycin-challenged mice.	Bleomycin	101-110	sphingosine kinase 1	Homo sapiens	28-33
25455454-8	2015	Moreover, BLM-induced pulmonary nuclear factor kappa B (NF-kappaB) p65 activation was blocked by PBA.	Bleomycin	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	32-54
25455454-8	2015	Moreover, BLM-induced pulmonary nuclear factor kappa B (NF-kappaB) p65 activation was blocked by PBA.	Bleomycin	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	56-65
25455454-8	2015	Moreover, BLM-induced pulmonary nuclear factor kappa B (NF-kappaB) p65 activation was blocked by PBA.	Bleomycin	10-13	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	67-70
25446881-9	2015	Over-expression of S1PL attenuated bleomycin-induced TGF-beta secretion and S1P mediated differentiation of human lung fibroblasts through regulation of autophagy.	Bleomycin	35-44	transforming growth factor beta 1	Homo sapiens	53-61
25446881-6	2015	Further, the expressions of SphK1 and S1PL were increased in lung tissues from patients with IPF and bleomycin-challenged mice.	Bleomycin	101-110	sphingosine-1-phosphate lyase 1	Homo sapiens	38-42
25446881-9	2015	Over-expression of S1PL attenuated bleomycin-induced TGF-beta secretion and S1P mediated differentiation of human lung fibroblasts through regulation of autophagy.	Bleomycin	35-44	sphingosine-1-phosphate receptor 1	Mus musculus	19-22
25446881-7	2015	Genetic knockdown of SphK1, but not SphK2, ameliorated bleomycin-induced pulmonary fibrosis in mice while deletion of S1PL (SGPL1(+/-)) in mice potentiated fibrosis post-bleomycin challenge.	Bleomycin	55-64	sphingosine kinase 1	Mus musculus	21-26
25446881-10	2015	Administration of SphK1 inhibitor 8 days post-bleomycin challenge reduced bleomycin-induced mortality and pulmonary fibrosis.	Bleomycin	46-55	sphingosine kinase 1	Homo sapiens	18-23
25446881-10	2015	Administration of SphK1 inhibitor 8 days post-bleomycin challenge reduced bleomycin-induced mortality and pulmonary fibrosis.	Bleomycin	74-83	sphingosine kinase 1	Homo sapiens	18-23
24988442-0	2015	Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin.	Bleomycin	111-120	fibroblast growth factor 2	Mus musculus	0-26
25447049-8	2015	Further, inhibition of Src kinase activity using caveolin-1 scaffolding domain peptide suppressed bleomycin-, transforming growth factor beta-, or passive cigarette smoke-induced EMT and restored uPA expression while suppressing PAI-1.	Bleomycin	98-107	caveolin 1, caveolae protein	Mus musculus	49-59
24988442-6	2015	Fgf2 is expressed in mouse and human lung epithelial and inflammatory cells, and, in response to bleomycin, Fgf2(-/-) mice have significantly increased mortality and weight loss.	Bleomycin	97-106	fibroblast growth factor 2	Mus musculus	0-4
24988442-6	2015	Fgf2 is expressed in mouse and human lung epithelial and inflammatory cells, and, in response to bleomycin, Fgf2(-/-) mice have significantly increased mortality and weight loss.	Bleomycin	97-106	fibroblast growth factor 2	Homo sapiens	108-112
24988442-9	2015	We conclude that FGF2 is not required for bleomycin-induced pulmonary fibrosis, but rather is essential for epithelial repair and maintaining epithelial integrity after bleomycin-induced lung injury in mice.	Bleomycin	169-178	fibroblast growth factor 2	Mus musculus	17-21
25173558-15	2015	It can be concluded that TRAIL death receptor expressions in particular are increased in testicular cancer cells via bleomycin treatment, and TRAIL-induced apoptosis is initiated.	Bleomycin	117-126	TNF superfamily member 10	Homo sapiens	25-30
25173558-0	2015	Bleomycin induced sensitivity to TRAIL/Apo-2L-mediated apoptosis in human seminomatous testicular cancer cells is correlated with upregulation of death receptors.	Bleomycin	0-9	TNF superfamily member 10	Homo sapiens	33-38
26098610-2	2015	In recent papers, we have shown that Tbeta4 exerts a widely protective role in mice treated with bleomycin, and in particular, we have demonstrated its inhibitory effects on both inflammation and early fibrosis.	Bleomycin	97-106	thymosin, beta 4, X chromosome	Mus musculus	37-43
25173558-0	2015	Bleomycin induced sensitivity to TRAIL/Apo-2L-mediated apoptosis in human seminomatous testicular cancer cells is correlated with upregulation of death receptors.	Bleomycin	0-9	TNF superfamily member 10	Homo sapiens	39-45
25173558-11	2015	Incubation of bleomycin alone caused a significant increase in caspase 3 activity in NCCIT.	Bleomycin	14-23	caspase 3	Homo sapiens	63-72
25173558-12	2015	Combined incubation with bleomycin and TRAIL lead to elevated caspase 3 activity in Ntera-2.	Bleomycin	25-34	caspase 3	Homo sapiens	62-71
25302613-4	2015	METHODS: We generated a murine model of bleomycin-induced SSc using TLR-4(-/-) mice and TLR-4(-/-) ;TSK/+ mice.	Bleomycin	40-49	toll-like receptor 4	Mus musculus	68-73
25302613-6	2015	RESULTS: Dermal and lung fibrosis was attenuated in bleomycin-treated TLR-4(-/-) mice compared with their wild-type counterparts.	Bleomycin	52-61	toll-like receptor 4	Mus musculus	70-75
25302613-7	2015	Inflammatory cell infiltration, expression of various inflammatory cytokines, and pathologic angiogenesis induced by bleomycin treatment were suppressed with TLR-4 deletion.	Bleomycin	117-126	toll-like receptor 4	Mus musculus	158-163
25302613-8	2015	Furthermore, the increased expression of interleukin-6 (IL-6) in fibroblasts, endothelial cells, and immune cells in response to bleomycin in vivo and to lipopolysaccharide in vitro was notably abrogated in the absence of TLR-4.	Bleomycin	129-138	interleukin 6	Mus musculus	41-54
25302613-8	2015	Furthermore, the increased expression of interleukin-6 (IL-6) in fibroblasts, endothelial cells, and immune cells in response to bleomycin in vivo and to lipopolysaccharide in vitro was notably abrogated in the absence of TLR-4.	Bleomycin	129-138	interleukin 6	Mus musculus	56-60
25302613-8	2015	Furthermore, the increased expression of interleukin-6 (IL-6) in fibroblasts, endothelial cells, and immune cells in response to bleomycin in vivo and to lipopolysaccharide in vitro was notably abrogated in the absence of TLR-4.	Bleomycin	129-138	toll-like receptor 4	Mus musculus	222-227
25302613-9	2015	Moreover, TLR-4 deletion was associated with alleviated B cell activation and skew toward a Th2/Th17 response against bleomycin treatment.	Bleomycin	118-127	toll-like receptor 4	Mus musculus	10-15
26202360-10	2015	The increases in lung CXCR2 by bleomycin were significantly reduced by CM at protein level, but not at mRNA level.	Bleomycin	31-40	chemokine (C-X-C motif) receptor 2	Mus musculus	22-27
25451236-5	2015	Upon bleomycin challenge, old mice experienced augmented PAI-1 induction and lung fibrosis as compared to young mice.	Bleomycin	5-14	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	57-62
25451236-6	2015	Most interestingly, we show that fewer (myo)fibroblasts underwent apoptosis and more (myo)fibroblasts with increased level of PAI-1 accumulated in the lung of old than in young mice after bleomycin challenge.	Bleomycin	188-197	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	126-131
25998889-0	2015	Angiotensin-Converting Enzyme 2 Attenuates Bleomycin-Induced Lung Fibrosis in Mice.	Bleomycin	43-52	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	0-31
25998889-10	2015	RESULTS: Exogenous ACE2 attenuated bleomycin-induced lung fibrosis by reversing the reduction of local ACE2 and by suppressing the elevation of AGT.	Bleomycin	35-44	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	19-23
25998889-10	2015	RESULTS: Exogenous ACE2 attenuated bleomycin-induced lung fibrosis by reversing the reduction of local ACE2 and by suppressing the elevation of AGT.	Bleomycin	35-44	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	103-107
25998889-13	2015	CONCLUSION: ACE2 attenuated bleomycin-induced lung fibrosis as an anti-inflammatory anti-apoptotic and anti-fibrotic agent, and it might be a promising therapeutic target for IPF.	Bleomycin	28-37	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	12-16
26151196-12	2015	The administration of TSA partially attenuated BLM-induced pulmonary fibrosis and increased the Sftpc mRNA expression in isolated ATII from bleomycin-treated lungs in vivo.	Bleomycin	140-149	surfactant associated protein C	Mus musculus	96-101
26098610-6	2015	The in vivo effects of Tbeta4 were assessed in CD1 mice treated with bleomycin.	Bleomycin	69-78	CD1 antigen complex	Mus musculus	47-50
25537989-8	2015	Autoradiographic analysis of lung sections and CD45 immunostaining confirm the higher and early recruitment of leukocytes in bleomycin-treated mice, compared with control mice.	Bleomycin	125-134	protein tyrosine phosphatase, receptor type, C	Mus musculus	47-51
25441030-4	2015	We show that murine BAFF levels were strongly increased in the bronchoalveolar space and lungs after bleomycin exposure.	Bleomycin	101-110	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	20-24
25441030-7	2015	We further demonstrate that bleomycin-induced BAFF expression and lung fibrosis were IL-1beta and IL-17A dependent.	Bleomycin	28-37	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	46-50
25441030-7	2015	We further demonstrate that bleomycin-induced BAFF expression and lung fibrosis were IL-1beta and IL-17A dependent.	Bleomycin	28-37	interleukin 1 beta	Mus musculus	85-93
25441030-7	2015	We further demonstrate that bleomycin-induced BAFF expression and lung fibrosis were IL-1beta and IL-17A dependent.	Bleomycin	28-37	interleukin 17A	Mus musculus	98-104
25441030-0	2015	B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis.	Bleomycin	39-48	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	0-24
25214363-5	2015	Bleomycin activation induced fibronectin-rich and collagen-poor ECM remodeling by PC, facilitating increased neutrophil transendothelial migration when compared with non-activated pericyte ECM (49.9 +- 3.4% versus 29.7 +- 1.4%).	Bleomycin	0-9	fibronectin 1	Homo sapiens	29-40
26300593-0	2015	Bleomycin-Treated Chimeric Thy1-Deficient Mice with Thy1-Deficient Myofibroblasts and Thy-Positive Lymphocytes Resolve Inflammation without Affecting the Fibrotic Response.	Bleomycin	0-9	thymus cell antigen 1, theta	Mus musculus	27-31
26300593-0	2015	Bleomycin-Treated Chimeric Thy1-Deficient Mice with Thy1-Deficient Myofibroblasts and Thy-Positive Lymphocytes Resolve Inflammation without Affecting the Fibrotic Response.	Bleomycin	0-9	thymus cell antigen 1, theta	Mus musculus	52-56
26300593-3	2015	Accumulation of Thy1-negative (Thy1(-)) myofibroblasts was shown in the lungs of humans with idiopathic pulmonary fibrosis (IPF) and of bleomycin-treated mice.	Bleomycin	136-145	Thy-1 cell surface antigen	Homo sapiens	16-20
26300593-3	2015	Accumulation of Thy1-negative (Thy1(-)) myofibroblasts was shown in the lungs of humans with idiopathic pulmonary fibrosis (IPF) and of bleomycin-treated mice.	Bleomycin	136-145	Thy-1 cell surface antigen	Homo sapiens	31-35
26300593-5	2015	Thy1 increased in mouse lung lymphocytes following bleomycin injury but decreased in myofibroblasts when fibrosis was at the highest point (14 days), as assessed by immunohistochemistry.	Bleomycin	51-60	thymus cell antigen 1, theta	Mus musculus	0-4
25214363-5	2015	Bleomycin activation induced fibronectin-rich and collagen-poor ECM remodeling by PC, facilitating increased neutrophil transendothelial migration when compared with non-activated pericyte ECM (49.9 +- 3.4% versus 29.7 +- 1.4%).	Bleomycin	0-9	multimerin 1	Homo sapiens	64-67
25771975-10	2015	Consistent transcriptional down-regulation of the stress response factors tested (i.e. BiP, mtHsp60, Hsp70) occurred in the direct effect indicating that bleomycin might induce an arrest of transcription correlated with decreased survival.	Bleomycin	154-163	heat shock protein 5	Mus musculus	87-90
25771975-10	2015	Consistent transcriptional down-regulation of the stress response factors tested (i.e. BiP, mtHsp60, Hsp70) occurred in the direct effect indicating that bleomycin might induce an arrest of transcription correlated with decreased survival.	Bleomycin	154-163	heat shock protein 1B	Mus musculus	101-106
25551570-8	2014	Instillation of both bleomycin and Ad vectors increased expression levels of TNFalpha and IL-1beta but not IL-10.	Bleomycin	21-30	tumor necrosis factor	Mus musculus	77-85
25551570-8	2014	Instillation of both bleomycin and Ad vectors increased expression levels of TNFalpha and IL-1beta but not IL-10.	Bleomycin	21-30	interleukin 1 beta	Mus musculus	90-98
25551570-9	2014	Instillation of bleomycin but not Ad increased the expression of IL-1alpha, IL-13 and IL-16.	Bleomycin	16-25	interleukin 1 alpha	Mus musculus	65-74
25551570-9	2014	Instillation of bleomycin but not Ad increased the expression of IL-1alpha, IL-13 and IL-16.	Bleomycin	16-25	interleukin 13	Mus musculus	76-81
25551570-9	2014	Instillation of bleomycin but not Ad increased the expression of IL-1alpha, IL-13 and IL-16.	Bleomycin	16-25	interleukin 16	Mus musculus	86-91
25551570-10	2014	Treatment with bleomycin or Ad vectors increased expression levels of integrin alpha1, alpha5, and alphav, MMP9, whereas treatment with bleomycin but not Ad vectors induced MMP2 expression levels.	Bleomycin	15-24	integrin alpha 1	Mus musculus	70-85
25551570-10	2014	Treatment with bleomycin or Ad vectors increased expression levels of integrin alpha1, alpha5, and alphav, MMP9, whereas treatment with bleomycin but not Ad vectors induced MMP2 expression levels.	Bleomycin	15-24	matrix metallopeptidase 9	Mus musculus	107-111
25551570-10	2014	Treatment with bleomycin or Ad vectors increased expression levels of integrin alpha1, alpha5, and alphav, MMP9, whereas treatment with bleomycin but not Ad vectors induced MMP2 expression levels.	Bleomycin	136-145	matrix metallopeptidase 2	Mus musculus	173-177
25551570-11	2014	Both bleomycin and Ad vectors induced mRNA levels of Wnt2, 2b, 5b, and Lrp6.	Bleomycin	5-14	low density lipoprotein receptor-related protein 6	Mus musculus	71-75
25349139-0	2014	The copper chelator tetrathiomolybdate regressed bleomycin-induced pulmonary fibrosis in mice, by reducing lysyl oxidase expressions.	Bleomycin	49-58	lysyl oxidase	Mus musculus	107-120
25536345-1	2014	In the present study, we noted that bleomycin induced growth inhibitory action was augmented by all the polyunsaturated fatty acids (PUFAs) tested on human neuroblastoma IMR-32 (0.5 x 10(4) cells/100 microl of IMR) cells (EPA &gt; DHA &gt; ALA = GLA = AA &gt; DGLA = LA: ~ 60, 40, 30, 10-20% respectively) at the maximum doses used.	Bleomycin	36-45	galactosidase alpha	Homo sapiens	246-249
25536345-4	2014	Pre-treatment with AA, GLA, DGLA and EPA and simultaneous treatment with all PUFAs used in the study augmented growth inhibitory action of bleomycin.	Bleomycin	139-148	galactosidase alpha	Homo sapiens	23-26
25358054-5	2014	METHODS: DCK expression was examined in the lungs of patients with IPF and mice exposed to bleomycin.	Bleomycin	91-100	deoxycytidine kinase	Homo sapiens	9-12
25358054-7	2014	MEASUREMENTS AND MAIN RESULTS: DCK was elevated in hyperplastic alveolar epithelial cells of patients with IPF and in mice exposed to bleomycin.	Bleomycin	134-143	deoxycytidine kinase	Homo sapiens	31-34
25358054-9	2014	Hypoxia-induced DCK expression was abolished by silencing hypoxia-inducible factor 1alpha and treatment of bleomycin-exposed mice with a DCK inhibitor attenuated pulmonary fibrosis in association with decreased epithelial cell proliferation.	Bleomycin	107-116	deoxycytidine kinase	Mus musculus	16-19
25664028-10	2014	CONCLUSION: our study suggests the potential in prevention of bleomycin-induced pulmonary fibrosis with NF-kappaB p65 antisense oligonucleotide.	Bleomycin	62-71	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	104-113
25664028-10	2014	CONCLUSION: our study suggests the potential in prevention of bleomycin-induced pulmonary fibrosis with NF-kappaB p65 antisense oligonucleotide.	Bleomycin	62-71	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	114-117
25489114-5	2014	In mice, injections of Slit2 inhibit bleomycin-induced lung fibrosis.	Bleomycin	37-46	slit guidance ligand 2	Mus musculus	23-28
25358054-9	2014	Hypoxia-induced DCK expression was abolished by silencing hypoxia-inducible factor 1alpha and treatment of bleomycin-exposed mice with a DCK inhibitor attenuated pulmonary fibrosis in association with decreased epithelial cell proliferation.	Bleomycin	107-116	deoxycytidine kinase	Mus musculus	137-140
24885373-2	2014	In contrast, we report that imatinib mesylate prevented bleomycin (BLM)-induced pulmonary fibrosis in mice by inhibiting platelet-derived growth factor receptor (PDGFR), even when it was administered only in the early phase.	Bleomycin	56-65	platelet derived growth factor receptor, beta polypeptide	Mus musculus	121-160
24885373-2	2014	In contrast, we report that imatinib mesylate prevented bleomycin (BLM)-induced pulmonary fibrosis in mice by inhibiting platelet-derived growth factor receptor (PDGFR), even when it was administered only in the early phase.	Bleomycin	56-65	platelet derived growth factor receptor, beta polypeptide	Mus musculus	162-167
24885373-2	2014	In contrast, we report that imatinib mesylate prevented bleomycin (BLM)-induced pulmonary fibrosis in mice by inhibiting platelet-derived growth factor receptor (PDGFR), even when it was administered only in the early phase.	Bleomycin	67-70	platelet derived growth factor receptor, beta polypeptide	Mus musculus	121-160
24885373-2	2014	In contrast, we report that imatinib mesylate prevented bleomycin (BLM)-induced pulmonary fibrosis in mice by inhibiting platelet-derived growth factor receptor (PDGFR), even when it was administered only in the early phase.	Bleomycin	67-70	platelet derived growth factor receptor, beta polypeptide	Mus musculus	162-167
24885478-5	2014	Compared with littermate wild-type (WT) mice, TGF-beta1(wt) Tg mice had over twofold-higher levels of latent TGF-beta1 in both plasma and lung tissue, and were protected from bleomycin-induced pulmonary inflammation, such as up-regulation of IL-1beta, TNF-alpha, and macrophage chemotactic protein-1, and infiltration of CD3(+) T cells and F4/80(+) macrophages.	Bleomycin	175-184	transforming growth factor, beta 1	Mus musculus	46-55
24885478-5	2014	Compared with littermate wild-type (WT) mice, TGF-beta1(wt) Tg mice had over twofold-higher levels of latent TGF-beta1 in both plasma and lung tissue, and were protected from bleomycin-induced pulmonary inflammation, such as up-regulation of IL-1beta, TNF-alpha, and macrophage chemotactic protein-1, and infiltration of CD3(+) T cells and F4/80(+) macrophages.	Bleomycin	175-184	interleukin 1 beta	Mus musculus	242-250
24885478-5	2014	Compared with littermate wild-type (WT) mice, TGF-beta1(wt) Tg mice had over twofold-higher levels of latent TGF-beta1 in both plasma and lung tissue, and were protected from bleomycin-induced pulmonary inflammation, such as up-regulation of IL-1beta, TNF-alpha, and macrophage chemotactic protein-1, and infiltration of CD3(+) T cells and F4/80(+) macrophages.	Bleomycin	175-184	tumor necrosis factor	Mus musculus	252-261
24885478-8	2014	In summary, mice overexpressing latent TGF-beta1 are protected from bleomycin-induced lung injury.	Bleomycin	68-77	transforming growth factor, beta 1	Mus musculus	39-48
24885478-9	2014	Triggering the Smad7 negative feedback mechanism to inhibit both NF-kappaB and TGF-beta/Smad signaling pathways, and enhancing the regulatory T cell response to counter-regulate T helper 17-mediated lung injury, are potential mechanisms by which latent TGF-beta1 protects against bleomycin-induced lung injury.	Bleomycin	280-289	SMAD family member 7	Mus musculus	15-20
24885478-9	2014	Triggering the Smad7 negative feedback mechanism to inhibit both NF-kappaB and TGF-beta/Smad signaling pathways, and enhancing the regulatory T cell response to counter-regulate T helper 17-mediated lung injury, are potential mechanisms by which latent TGF-beta1 protects against bleomycin-induced lung injury.	Bleomycin	280-289	SMAD family member 7	Mus musculus	15-19
24885478-9	2014	Triggering the Smad7 negative feedback mechanism to inhibit both NF-kappaB and TGF-beta/Smad signaling pathways, and enhancing the regulatory T cell response to counter-regulate T helper 17-mediated lung injury, are potential mechanisms by which latent TGF-beta1 protects against bleomycin-induced lung injury.	Bleomycin	280-289	transforming growth factor, beta 1	Mus musculus	253-262
25183266-10	2014	Electrochemotherapy with bleomycin is an effective option for skin tumours of the head and neck and is a feasible alternative in highly selected (small, primary, and not previously treated by chemotherapy) SCC of the oral cavity and oropharynx.	Bleomycin	25-34	serpin family B member 3	Homo sapiens	206-209
25472740-2	2014	Recently, SP-D has been shown to contribute to the pathogenesis of airway allergic inflammation and bleomycin-induced pulmonary fibrosis.	Bleomycin	100-109	surfactant associated protein D	Mus musculus	10-14
24985397-3	2014	OBJECTIVES: We aimed to determine the effects and mechanism of IL-33 on the development and severity of pulmonary fibrosis in murine bleomycin-induced fibrosis.	Bleomycin	133-142	interleukin 33	Mus musculus	63-68
24985397-7	2014	RESULTS: IL-33 is constitutively expressed in lung epithelial cells but is induced in macrophages by bleomycin.	Bleomycin	101-110	interleukin 33	Mus musculus	9-14
24985397-8	2014	Bleomycin enhanced the production of the mature but reduced full-length form of IL-33 in lung tissue.	Bleomycin	0-9	interleukin 33	Mus musculus	80-85
25348956-0	2014	Lysyl oxidase promotes bleomycin-induced lung fibrosis through modulating inflammation.	Bleomycin	23-32	lysyl oxidase	Mus musculus	0-13
25348956-2	2014	LOX expression is significantly upregulated in bleomycin (BLM)-induced lung fibrosis, and knockdown of LOX expression or inhibition of LOX activity alleviates the lung fibrosis.	Bleomycin	47-56	lysyl oxidase	Mus musculus	0-3
25348956-2	2014	LOX expression is significantly upregulated in bleomycin (BLM)-induced lung fibrosis, and knockdown of LOX expression or inhibition of LOX activity alleviates the lung fibrosis.	Bleomycin	58-61	lysyl oxidase	Mus musculus	0-3
25209833-0	2014	Total polysaccharide of Yupingfeng protects against bleomycin-induced pulmonary fibrosis via inhibiting transforming growth factor-beta1-mediated type I collagen abnormal deposition in rats.	Bleomycin	52-61	transforming growth factor, beta 1	Rattus norvegicus	104-136
25175023-3	2014	We investigated the expression of beta-catenin in lung fibroblasts from bleomycin (BLM)-challenged mice and human lung fibroblasts treated with transforming growth factor beta (TGF-beta) or lysophosphatidic acid (LPA) by western blot analysis.	Bleomycin	72-81	catenin (cadherin associated protein), beta 1	Mus musculus	34-46
25385603-3	2014	Importantly, RT-PCR assays of hMSCs for the inflammation-modulating protein TSG-6 expressed by the TNFalpha-stimulated gene 6 (TSG-6 or TNFAIP6) predicted their efficacy in sterile inflammation models for corneal injury, sterile peritonitis, and bleomycin-induced lung injury.	Bleomycin	246-255	TNF alpha induced protein 6	Homo sapiens	76-81
25385603-3	2014	Importantly, RT-PCR assays of hMSCs for the inflammation-modulating protein TSG-6 expressed by the TNFalpha-stimulated gene 6 (TSG-6 or TNFAIP6) predicted their efficacy in sterile inflammation models for corneal injury, sterile peritonitis, and bleomycin-induced lung injury.	Bleomycin	246-255	TNF alpha induced protein 6	Homo sapiens	127-132
25385603-3	2014	Importantly, RT-PCR assays of hMSCs for the inflammation-modulating protein TSG-6 expressed by the TNFalpha-stimulated gene 6 (TSG-6 or TNFAIP6) predicted their efficacy in sterile inflammation models for corneal injury, sterile peritonitis, and bleomycin-induced lung injury.	Bleomycin	246-255	TNF alpha induced protein 6	Homo sapiens	136-143
25155144-10	2014	Treatment with CAR agonist increased the activation of canonical TGFbeta signaling in murine models of SSc and exacerbated bleomycin-induced and TbetaRI-CA-induced fibrosis with increased dermal thickening, myofibroblast counts, and collagen accumulation.	Bleomycin	123-132	nuclear receptor subfamily 1, group I, member 3	Mus musculus	15-18
25175023-4	2014	The result showed that the expression of beta-catenin was significantly increased in lung fibrotic foci and lung fibroblasts from bleomycin-challenged mice.	Bleomycin	130-139	catenin (cadherin associated protein), beta 1	Mus musculus	41-53
25280005-12	2014	Interestingly, in a model of lung fibrosis induced by either bleomycin or silica, PDGF-D was down-regulated, which correlates with the production of TGFbeta and other fibrotic growth factors.	Bleomycin	61-70	platelet derived growth factor D	Homo sapiens	82-88
25070488-7	2014	Furthermore, we find that SIRT5 knockdown makes lung cancer cells more sensitive to drug (cis-diamminedichloroplatinum [CDDP], 5-fluorouracil [5-FU] or bleomycin) treatment in vitro and in vivo.	Bleomycin	152-161	sirtuin 5	Homo sapiens	26-31
25363222-19	2014	Bleomycin induced fibrosis has the relationship with p-SMAD2 in gene and protein levels, but TSA inhibit bleomycin-induced lung fibrosis effect with no relation with SMAD2 phosphorylation pathways.	Bleomycin	0-9	SMAD family member 2	Rattus norvegicus	55-60
25122876-6	2014	Genetic labeling of lung MSC in mice enabled determination of terminal lineage and localization of ABCG2 cells following intratracheal administration of bleomycin to elicit fibrotic lung injury.	Bleomycin	153-162	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	99-104
25317206-5	2014	RESULTS: During the course of bleomycin-induced lung fibrosis, Sfrp1 and Frzb expression are upregulated.	Bleomycin	30-39	secreted frizzled-related protein 1	Mus musculus	63-68
25317206-5	2014	RESULTS: During the course of bleomycin-induced lung fibrosis, Sfrp1 and Frzb expression are upregulated.	Bleomycin	30-39	frizzled-related protein	Mus musculus	73-77
25317206-9	2014	In vivo, Sfrp1 (-/-) and Frzb (-/-) mice showed identical responses to bleomycin in the lung compared to wild-type controls.	Bleomycin	71-80	secreted frizzled-related protein 1	Mus musculus	9-14
25280005-12	2014	Interestingly, in a model of lung fibrosis induced by either bleomycin or silica, PDGF-D was down-regulated, which correlates with the production of TGFbeta and other fibrotic growth factors.	Bleomycin	61-70	transforming growth factor beta 1	Homo sapiens	149-156
25317206-9	2014	In vivo, Sfrp1 (-/-) and Frzb (-/-) mice showed identical responses to bleomycin in the lung compared to wild-type controls.	Bleomycin	71-80	frizzled-related protein	Mus musculus	25-29
23918036-6	2014	In the proinflammatory bleomycin model, the profibrotic effect became more pronounced with induction of skin fibrosis in VEGF+/- tg mice and even more enhanced fibrosis in VEGF+/+ tg mice.	Bleomycin	23-32	vascular endothelial growth factor A	Mus musculus	121-125
23918036-6	2014	In the proinflammatory bleomycin model, the profibrotic effect became more pronounced with induction of skin fibrosis in VEGF+/- tg mice and even more enhanced fibrosis in VEGF+/+ tg mice.	Bleomycin	23-32	vascular endothelial growth factor A	Mus musculus	172-176
25166885-0	2014	Mesenchymal stem cell-based angiotensin-converting enzyme 2 in treatment of acute lung injury rat induced by bleomycin.	Bleomycin	109-118	angiotensin I converting enzyme 2	Rattus norvegicus	28-59
25166885-4	2014	Then we evaluated the therapeutic effect of HUMSCs harboring ACE2 on ALI, which induced by bleomycin (BLM) in rat model.	Bleomycin	91-100	angiotensin I converting enzyme 2	Rattus norvegicus	61-65
25270999-0	2014	Rikkunshito ameliorates cachexia associated with bleomycin-induced lung fibrosis in mice by stimulating ghrelin secretion.	Bleomycin	49-58	ghrelin	Mus musculus	104-111
25111852-0	2014	Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-kappaB in mice.	Bleomycin	35-44	glucagon	Mus musculus	0-23
25111852-0	2014	Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-kappaB in mice.	Bleomycin	35-44	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	103-112
25111852-16	2014	Our data found that BLM-induced lung inflammation and pulmonary fibrosis were significantly alleviated by GLP-1 treatment in mice, possibly through inactivation of NF-kappaB.	Bleomycin	20-23	glucagon	Mus musculus	106-111
25111852-16	2014	Our data found that BLM-induced lung inflammation and pulmonary fibrosis were significantly alleviated by GLP-1 treatment in mice, possibly through inactivation of NF-kappaB.	Bleomycin	20-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	164-173
24842054-8	2014	The loss of PAR-1 in vivo significantly attenuated bleomycin-induced skin fibrosis.	Bleomycin	51-60	coagulation factor II (thrombin) receptor	Mus musculus	12-17
25026360-8	2014	Glutathione-S-transferase (GST) which was inhibited by bleomycin (32.4 nmol/min/mg protein) induced by higher dose of silymarin (41 nmol/min/mg protein).	Bleomycin	55-64	hematopoietic prostaglandin D synthase	Mus musculus	0-25
25026360-8	2014	Glutathione-S-transferase (GST) which was inhibited by bleomycin (32.4 nmol/min/mg protein) induced by higher dose of silymarin (41 nmol/min/mg protein).	Bleomycin	55-64	hematopoietic prostaglandin D synthase	Mus musculus	27-30
25026360-10	2014	Catalase (CAT) was increased due to high dose of silymarin (65.7 micromol/min/ml protein) compare with bleomycin treated-mice.	Bleomycin	103-112	catalase	Mus musculus	0-8
25026360-11	2014	Myeloperoxidase (MPO) which was induced due to bleomycin (p &lt; 0.05) reduced again by high dose of silymarin (0.51 U/min/mg protein).	Bleomycin	47-56	myeloperoxidase	Mus musculus	0-15
25026360-11	2014	Myeloperoxidase (MPO) which was induced due to bleomycin (p &lt; 0.05) reduced again by high dose of silymarin (0.51 U/min/mg protein).	Bleomycin	47-56	myeloperoxidase	Mus musculus	17-20
25026360-12	2014	Bleomycin led to an increase in TNF-alpha and interleukin-6 (IL-6) (7.9 and 11.8 pg/ml).	Bleomycin	0-9	tumor necrosis factor	Mus musculus	32-41
25026360-12	2014	Bleomycin led to an increase in TNF-alpha and interleukin-6 (IL-6) (7.9 and 11.8 pg/ml).	Bleomycin	0-9	interleukin 6	Mus musculus	46-59
25026360-12	2014	Bleomycin led to an increase in TNF-alpha and interleukin-6 (IL-6) (7.9 and 11.8 pg/ml).	Bleomycin	0-9	interleukin 6	Mus musculus	61-65
24842054-9	2014	The bleomycin-induced increase in dermal thickness and ECM production was reduced significantly in PAR-1-deficient mice compared with wild-type mice.	Bleomycin	4-13	coagulation factor II (thrombin) receptor	Mus musculus	99-104
24798520-8	2014	lincRNA-p21 and ncRNA-CCND1 were the main molecules; exosome levels of them best reflect the change of their cellular levels upon exposure of the cells to bleomycin-induced DNA damage.	Bleomycin	155-164	tumor protein p53 pathway corepressor 1	Homo sapiens	0-11
25230586-4	2014	Repeated subcutaneous bleomycin-injections were given to wild type and fibromodulin-deficient mice, inducing pulmonary fibrosis.	Bleomycin	22-31	fibromodulin	Mus musculus	71-83
25230586-6	2014	Fibromodulin-deficient animals were not protected from fibrosis, but the composition of the matrix was affected, with decreased Collagen I in fibromodulin-deficient animals, both in controls (0.07 +- 0.04% vs. 0.18 +- 0.07% tissue area) and after bleomycin (0.37 +- 0.16% vs. 0.61 +- 0.21% tissue area).	Bleomycin	247-256	fibromodulin	Mus musculus	0-12
25230586-9	2014	In addition, the bleomycin-induced immune response was affected in fibromodulin-deficient animals.	Bleomycin	17-26	fibromodulin	Mus musculus	67-79
25356121-0	2014	Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-beta, Smad3 and JAK-STAT pathway.	Bleomycin	25-34	transforming growth factor, beta 1	Mus musculus	73-81
25356121-0	2014	Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-beta, Smad3 and JAK-STAT pathway.	Bleomycin	25-34	SMAD family member 3	Mus musculus	83-88
25198418-0	2014	Knock out of S1P3 receptor signaling attenuates inflammation and fibrosis in bleomycin-induced lung injury mice model.	Bleomycin	77-86	sphingosine-1-phosphate receptor 3	Mus musculus	13-17
25198418-4	2014	On the seventh day after bleomycin administration, S1P3 KO mice exhibited significantly less body weight loss and pulmonary inflammation than wild-type (WT) mice.	Bleomycin	25-34	sphingosine-1-phosphate receptor 3	Mus musculus	51-55
24798520-8	2014	lincRNA-p21 and ncRNA-CCND1 were the main molecules; exosome levels of them best reflect the change of their cellular levels upon exposure of the cells to bleomycin-induced DNA damage.	Bleomycin	155-164	RNANC	Homo sapiens	2-7
24798520-8	2014	lincRNA-p21 and ncRNA-CCND1 were the main molecules; exosome levels of them best reflect the change of their cellular levels upon exposure of the cells to bleomycin-induced DNA damage.	Bleomycin	155-164	cyclin D1	Homo sapiens	22-27
25063875-11	2014	Adam9 increases mortality, promotes lung injury, reduces lung compliance, and increases degradation of lung elastin during LPS- and/or bleomycin-mediated ALI.	Bleomycin	135-144	a disintegrin and metallopeptidase domain 9 (meltrin gamma)	Mus musculus	0-5
24955896-0	2014	Mechanical ventilation augments bleomycin-induced epithelial-mesenchymal transition through the Src pathway.	Bleomycin	32-41	Rous sarcoma oncogene	Mus musculus	96-99
24955896-9	2014	Our data suggest that high-VT mechanical ventilation-augmented EMT after bleomycin-induced ALI partially depends on the Src pathway.	Bleomycin	73-82	Rous sarcoma oncogene	Mus musculus	120-123
24898581-0	2014	Inhibition of Wnt/beta-catenin signaling promotes epithelial differentiation of mesenchymal stem cells and repairs bleomycin-induced lung injury.	Bleomycin	115-124	catenin (cadherin associated protein), beta 1	Mus musculus	18-30
24498991-0	2014	Depletion of folate receptor beta-expressing macrophages alleviates bleomycin-induced experimental skin fibrosis.	Bleomycin	68-77	folate receptor 2 (fetal)	Mus musculus	13-33
24498991-2	2014	Here, we investigated the infiltration of FRbeta-expressing macrophages in a murine model of bleomycin (BLM)-induced skin fibrosis and assessed the antifibrotic effects of depletion of FRbeta-expressing macrophages in this model using a recombinant immunotoxin to FRbeta.	Bleomycin	93-102	folate receptor 2 (fetal)	Mus musculus	42-48
24498991-2	2014	Here, we investigated the infiltration of FRbeta-expressing macrophages in a murine model of bleomycin (BLM)-induced skin fibrosis and assessed the antifibrotic effects of depletion of FRbeta-expressing macrophages in this model using a recombinant immunotoxin to FRbeta.	Bleomycin	104-107	folate receptor 2 (fetal)	Mus musculus	42-48
24898582-1	2014	Focus on "Inhibition of Wnt/beta-catenin signaling promotes epithelial differentiation of mesenchymal stem cells and repairs bleomycin-induced lung injury".	Bleomycin	125-134	catenin beta 1	Homo sapiens	28-40
24928277-8	2014	In addition, up-regulation of Gal-1 expression was demonstrated in a bleomycin (BLM)-induced mouse model of lung fibrosis in vivo.	Bleomycin	69-78	lectin, galactose binding, soluble 1	Mus musculus	30-35
24769130-0	2014	Daidzein exhibits anti-fibrotic effect by reducing the expressions of Proteinase activated receptor 2 and TGFbeta1/smad mediated inflammation and apoptosis in Bleomycin-induced experimental pulmonary fibrosis.	Bleomycin	159-168	F2R like trypsin receptor 1	Rattus norvegicus	70-101
24769130-0	2014	Daidzein exhibits anti-fibrotic effect by reducing the expressions of Proteinase activated receptor 2 and TGFbeta1/smad mediated inflammation and apoptosis in Bleomycin-induced experimental pulmonary fibrosis.	Bleomycin	159-168	transforming growth factor, beta 1	Rattus norvegicus	106-114
24655310-10	2014	Upregulation of the TGF-beta/CCN2 pathway was also detected in bleomycin-treated VM specimens.	Bleomycin	63-72	transforming growth factor beta 1	Homo sapiens	20-28
24655310-10	2014	Upregulation of the TGF-beta/CCN2 pathway was also detected in bleomycin-treated VM specimens.	Bleomycin	63-72	cellular communication network factor 2	Homo sapiens	29-33
24933624-6	2014	On day 7, the decreased superoxide dismutase and myeloperoxidase activities observed in the bleomycin group were significantly restored with PFPE treatment.	Bleomycin	92-101	myeloperoxidase	Mus musculus	49-64
24928277-8	2014	In addition, up-regulation of Gal-1 expression was demonstrated in a bleomycin (BLM)-induced mouse model of lung fibrosis in vivo.	Bleomycin	80-83	lectin, galactose binding, soluble 1	Mus musculus	30-35
24921217-3	2014	METHODS: We examined mice with impaired Wnt signaling caused by loss of the Wnt coreceptor Lrp5 in models of lung fibrosis induced by bleomycin or an adenovirus encoding an active form of transforming growth factor (TGF)-beta.	Bleomycin	134-143	low density lipoprotein receptor-related protein 5	Mus musculus	91-95
25059342-0	2014	Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.	Bleomycin	74-83	interleukin 6	Mus musculus	10-14
25059342-11	2014	Thereafter, mice were immunized against a small peptide derived from murine IL-6 and this strategy led in the bleomycin model to a 20% (P = 0.02) and 25% (P = 0.005) decrease of dermal thickness and hydroxyproline content, respectively.	Bleomycin	110-119	interleukin 6	Mus musculus	76-80
25059342-13	2014	Upon bleomycin injections, serum and skin IL-6 levels were increased after treatment with MR16-1 and were significantly reduced after anti-IL-6 active immunization.	Bleomycin	5-14	interleukin 6	Mus musculus	42-46
25059342-13	2014	Upon bleomycin injections, serum and skin IL-6 levels were increased after treatment with MR16-1 and were significantly reduced after anti-IL-6 active immunization.	Bleomycin	5-14	interleukin 6	Mus musculus	139-143
25059342-15	2014	Targeting IL-6 by both passive and active immunization strategies prevented the development of bleomycin-induced dermal fibrosis in mice.	Bleomycin	95-104	interleukin 6	Mus musculus	10-14
24921217-7	2014	Lrp5 null mice were protected against bleomycin-induced pulmonary fibrosis, an effect that was phenocopied by direct inhibition of beta-catenin signaling by the small molecular inhibitor of beta-catenin responsive transcription.	Bleomycin	38-47	low density lipoprotein receptor-related protein 5	Mus musculus	0-4
24921217-7	2014	Lrp5 null mice were protected against bleomycin-induced pulmonary fibrosis, an effect that was phenocopied by direct inhibition of beta-catenin signaling by the small molecular inhibitor of beta-catenin responsive transcription.	Bleomycin	38-47	catenin (cadherin associated protein), beta 1	Mus musculus	131-143
24921217-7	2014	Lrp5 null mice were protected against bleomycin-induced pulmonary fibrosis, an effect that was phenocopied by direct inhibition of beta-catenin signaling by the small molecular inhibitor of beta-catenin responsive transcription.	Bleomycin	38-47	catenin (cadherin associated protein), beta 1	Mus musculus	190-202
24450438-5	2014	We showed that the Hedgehog pathway was activated in bleomycin-induced lung fibrosis on Day 14 after injury, with an increased lung expression of the ligand, Sonic Hedgehog, and with increased messenger RNA expression and nuclear localization of GLI1 and GLI2.	Bleomycin	53-62	GLI-Kruppel family member GLI1	Mus musculus	246-250
24998426-9	2014	RESULTS: Bleomycin-induced mice, SSc dermal fibroblasts and TGF-beta1-induced NIH/3T3 fibroblasts showed higher levels of ECM gene transcriptions and collagen production.	Bleomycin	9-18	transforming growth factor, beta 1	Mus musculus	60-69
24450438-5	2014	We showed that the Hedgehog pathway was activated in bleomycin-induced lung fibrosis on Day 14 after injury, with an increased lung expression of the ligand, Sonic Hedgehog, and with increased messenger RNA expression and nuclear localization of GLI1 and GLI2.	Bleomycin	53-62	GLI-Kruppel family member GLI2	Mus musculus	255-259
24925646-1	2014	The CysLT2 receptor is involved in myocardial ischemia/reperfusion injury, differentiation of colorectal cancers, bleomycin-induced pulmonary inflammation and fibrosis.	Bleomycin	114-123	cysteinyl leukotriene receptor 2	Homo sapiens	4-10
24641440-6	2014	KEY RESULTS: Exacerbated cardiac, vascular and fibrotic pathology was observed in NPR-A KO animals, compared with WT mice, exposed to bleomycin.	Bleomycin	134-143	neuronal pentraxin receptor	Mus musculus	82-85
24599794-4	2014	Moreover, TPO1 overexpression, and not the related transporter gene QDR3, conferred upon the tpo1Delta imp2Delta double mutant parental resistance to bleomycin.	Bleomycin	150-159	Tpo1p	Saccharomyces cerevisiae S288C	10-14
24599794-0	2014	Upregulation of the Saccharomyces cerevisiae efflux pump Tpo1 rescues an Imp2 transcription factor-deficient mutant from bleomycin toxicity.	Bleomycin	121-130	Tpo1p	Saccharomyces cerevisiae S288C	57-61
24599794-4	2014	Moreover, TPO1 overexpression, and not the related transporter gene QDR3, conferred upon the tpo1Delta imp2Delta double mutant parental resistance to bleomycin.	Bleomycin	150-159	Tpo1p	Saccharomyces cerevisiae S288C	93-97
24470401-9	2014	Moreover, IL-20 supplementation by injection into the skin reversed skin fibrosis induced by bleomycin in mice (~0.5-fold).	Bleomycin	93-102	interleukin 20	Mus musculus	10-15
24599794-5	2014	We conclude that YAP1 overexpression rescues the imp2Delta mutant from bleomycin toxicity by triggering Tpo1 expression to expel the drug.	Bleomycin	71-80	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	17-21
24599794-6	2014	Our data provide the first evidence that bleomycin could be a substrate for the Tpo1 efflux pump.	Bleomycin	41-50	Tpo1p	Saccharomyces cerevisiae S288C	80-84
24769542-11	2014	Mepenzolate also decreased NADPH oxidase activity and active TGF-beta1 level or increased glutathione S-transferase (GST) activity in the presence of bleomycin treatment.	Bleomycin	150-159	hematopoietic prostaglandin D synthase	Mus musculus	117-120
24963635-2	2014	In human idiopathic pulmonary fibrosis and murine bleomycin-induced lung fibrosis, OPN is upregulated in type II alveolar epithelial cells (AEC II).	Bleomycin	50-59	secreted phosphoprotein 1	Mus musculus	83-86
24963635-7	2014	The DNA damaging reagents bleomycin and doxorubicin were found to induce OPN expression in A549, MLE12 and HPAEpiC.	Bleomycin	26-35	secreted phosphoprotein 1	Homo sapiens	73-76
24920662-7	2014	We also demonstrated that in bleomycin-treated mice, CHI3L1 expression was acutely and transiently decreased during the injury phase and returned toward and eventually exceeded baseline levels during the fibrotic phase.	Bleomycin	29-38	chitinase-like 1	Mus musculus	53-59
24779708-5	2014	We studied the LYCAT action on cardiolipin remodeling, mitochondrial reactive oxygen species generation, and apoptosis of alveolar epithelial cells under bleomycin challenge.	Bleomycin	154-163	lysocardiolipin acyltransferase 1	Mus musculus	15-20
24779708-6	2014	MEASUREMENTS AND MAIN RESULTS: LYCAT expression was significantly altered in PBMCs and lung tissues from patients with idiopathic pulmonary fibrosis (IPF), which was confirmed in two preclinical murine models of IPF, bleomycin- and radiation-induced pulmonary fibrosis.	Bleomycin	217-226	lysocardiolipin acyltransferase 1	Homo sapiens	31-36
24779708-8	2014	In both bleomycin- and radiation-induced pulmonary fibrosis murine models, hLYCAT overexpression reduced several indices of lung fibrosis, whereas down-regulation of native LYCAT expression by siRNA accentuated fibrogenesis.	Bleomycin	8-17	lysocardiolipin acyltransferase 1	Homo sapiens	75-81
24779708-9	2014	In vitro studies demonstrated that LYCAT modulated bleomycin-induced cardiolipin remodeling, mitochondrial membrane potential, reactive oxygen species generation, and apoptosis of alveolar epithelial cells, potential mechanisms of LYCAT-mediated lung protection.	Bleomycin	51-60	lysocardiolipin acyltransferase 1	Mus musculus	35-40
24779708-9	2014	In vitro studies demonstrated that LYCAT modulated bleomycin-induced cardiolipin remodeling, mitochondrial membrane potential, reactive oxygen species generation, and apoptosis of alveolar epithelial cells, potential mechanisms of LYCAT-mediated lung protection.	Bleomycin	51-60	lysocardiolipin acyltransferase 1	Mus musculus	231-236
24599794-0	2014	Upregulation of the Saccharomyces cerevisiae efflux pump Tpo1 rescues an Imp2 transcription factor-deficient mutant from bleomycin toxicity.	Bleomycin	121-130	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	73-77
24599794-1	2014	Yeast mutants lacking the transcriptional co-activator Imp2 are hypersensitive to the anticancer drug bleomycin, although the gene targets involved in this process remain elusive.	Bleomycin	102-111	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	55-59
24599794-2	2014	A search for multicopy suppressors that rescue the imp2Delta mutant from bleomycin toxicity revealed the transcriptional activator Yap1, which can turn on many target genes such as transporters involved in regulating drug resistance.	Bleomycin	73-82	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	131-135
24970330-0	2014	Rac2 is involved in bleomycin-induced lung inflammation leading to pulmonary fibrosis.	Bleomycin	20-29	Rac family small GTPase 2	Mus musculus	0-4
24970330-4	2014	For the studies described here we hypothesized that Rac2 deficiency protects mice from bleomycin-induced pulmonary fibrosis.	Bleomycin	87-96	Rac family small GTPase 2	Mus musculus	52-56
24970330-11	2014	We also showed that rac2-/- mice had significantly lower mortality (30%) than WT mice (70%) at day 21 of bleomycin treatment.	Bleomycin	105-114	Rac family small GTPase 2	Mus musculus	20-24
24970330-14	2014	CONCLUSION: Rac2 plays an important role in bleomycin-induced lung injury.	Bleomycin	44-53	Rac family small GTPase 2	Mus musculus	12-16
24941004-3	2014	In addition, P2X7 receptor-deficient mice show reduced inflammation and lung fibrosis after exposure with bleomycin.	Bleomycin	106-115	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	13-26
24941004-7	2014	Additional in vitro experiments with bleomycin treated precision cut lung slices showed a greater sensitivity of the P2X7 receptor knockout mice in terms of aquaporin-5 reduction as wild type animals.	Bleomycin	37-46	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	117-130
24941004-7	2014	Additional in vitro experiments with bleomycin treated precision cut lung slices showed a greater sensitivity of the P2X7 receptor knockout mice in terms of aquaporin-5 reduction as wild type animals.	Bleomycin	37-46	aquaporin 5	Mus musculus	157-168
24941004-8	2014	Finally, P2X7 receptor function was examined by using the alveolar epithelial cell lines E10 and MLE-12 for stimulation experiments with bleomycin.	Bleomycin	137-146	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	9-22
24726524-8	2014	Immunofluorescent staining indicated vimentin-positive epithelial cells frequently occurring in the thickened epidermis of BLM-treated mice.	Bleomycin	123-126	vimentin	Mus musculus	37-45
24759560-8	2014	Periostin null mice have shown reduced skin fibrosis in a bleomycin-induced SSc mouse model, indicating a key role of periostin in fibrosis.	Bleomycin	58-67	periostin, osteoblast specific factor	Mus musculus	0-9
24613476-0	2014	Thymosin beta4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice.	Bleomycin	101-110	thymosin, beta 4, X chromosome	Mus musculus	0-14
24698097-0	2014	Bleomycin-induced fibrosis in MC1 signalling-deficient C57BL/6J-Mc1r(e/e) mice further supports a modulating role for melanocortins in collagen synthesis of the skin.	Bleomycin	0-9	melanocortin 1 receptor	Mus musculus	30-33
24698097-0	2014	Bleomycin-induced fibrosis in MC1 signalling-deficient C57BL/6J-Mc1r(e/e) mice further supports a modulating role for melanocortins in collagen synthesis of the skin.	Bleomycin	0-9	melanocortin 1 receptor	Mus musculus	64-68
24698097-3	2014	alpha-MSH suppressed transforming growth factor-beta1 - and bleomycin (BLM)-induced collagen synthesis in vitro and in vivo.	Bleomycin	60-69	pro-opiomelanocortin-alpha	Mus musculus	0-9
24613476-5	2014	As expected, bleomycin-induced inflammation and lung damage were substantially reduced by Tbeta4 treatment in CD-1 mice, as shown by the significant reduction of (i) leukocytes in BALF, (ii) histological evidence of the lung damage, and (iii) total collagen content in the lung.	Bleomycin	13-22	thymosin, beta 4, X chromosome	Mus musculus	90-96
24613476-5	2014	As expected, bleomycin-induced inflammation and lung damage were substantially reduced by Tbeta4 treatment in CD-1 mice, as shown by the significant reduction of (i) leukocytes in BALF, (ii) histological evidence of the lung damage, and (iii) total collagen content in the lung.	Bleomycin	13-22	CD1 antigen complex	Mus musculus	110-114
24613476-6	2014	Importantly, the bleomycin-induced increase in the number of IL17-producing cells in the blood was significantly blocked by Tbeta4.	Bleomycin	17-26	interleukin 17A	Mus musculus	61-65
24613476-6	2014	Importantly, the bleomycin-induced increase in the number of IL17-producing cells in the blood was significantly blocked by Tbeta4.	Bleomycin	17-26	thymosin, beta 4, X chromosome	Mus musculus	124-130
24613476-7	2014	Accordingly, IHC and RT-PCR results demonstrated that Tbeta4 substantially inhibited bleomycin-induced IL-17 over-expression in the lung tissue.	Bleomycin	85-94	thymosin, beta 4, X chromosome	Mus musculus	54-60
24613476-7	2014	Accordingly, IHC and RT-PCR results demonstrated that Tbeta4 substantially inhibited bleomycin-induced IL-17 over-expression in the lung tissue.	Bleomycin	85-94	interleukin 17A	Mus musculus	103-108
24853267-6	2014	The mRNA levels of transforming growth factor (TGF)-beta were decreased in the bleomycin-treated skin of ET-1 knockout mice.	Bleomycin	79-88	transforming growth factor, beta 1	Mus musculus	47-56
24804869-9	2014	HNF-1beta (+) cells were treated with a CHK1 inhibitor after bleomycin treatment.	Bleomycin	61-70	HNF1 homeobox B	Homo sapiens	0-9
24804869-9	2014	HNF-1beta (+) cells were treated with a CHK1 inhibitor after bleomycin treatment.	Bleomycin	61-70	checkpoint kinase 1	Homo sapiens	40-44
24584660-1	2014	To investigate the influence of NF-kappaB antisense oligonucleotide on transdifferentiation of fibroblast in the pathological process of bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	137-146	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	32-41
24584660-11	2014	NF-kappaB antisense oligonucleotide can inhibit the transdifferentiation of fibroblast towards myofibroblast in the pathological process of bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	140-149	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	0-9
24393343-6	2014	Under bleomycin treatment, the expression levels of DNA repair genes were similar in clf-29 and wild type, thus CLF may also regulate HR via other mechanisms.	Bleomycin	6-15	SET domain-containing protein	Arabidopsis thaliana	85-88
24393343-6	2014	Under bleomycin treatment, the expression levels of DNA repair genes were similar in clf-29 and wild type, thus CLF may also regulate HR via other mechanisms.	Bleomycin	6-15	SET domain-containing protein	Arabidopsis thaliana	112-115
24886817-6	2014	Bleomycin exposure induced expression of MDA, IKKalpha, phosphorylated IKKalpha (p-IKKalpha), NF-kappaB P65, TNF-alpha and IL-1beta, and reduced I-kappaB expression in mice lung tissue or in BALF.	Bleomycin	0-9	conserved helix-loop-helix ubiquitous kinase	Mus musculus	46-54
24886817-6	2014	Bleomycin exposure induced expression of MDA, IKKalpha, phosphorylated IKKalpha (p-IKKalpha), NF-kappaB P65, TNF-alpha and IL-1beta, and reduced I-kappaB expression in mice lung tissue or in BALF.	Bleomycin	0-9	conserved helix-loop-helix ubiquitous kinase	Mus musculus	71-79
24886817-6	2014	Bleomycin exposure induced expression of MDA, IKKalpha, phosphorylated IKKalpha (p-IKKalpha), NF-kappaB P65, TNF-alpha and IL-1beta, and reduced I-kappaB expression in mice lung tissue or in BALF.	Bleomycin	0-9	conserved helix-loop-helix ubiquitous kinase	Mus musculus	71-79
24886817-6	2014	Bleomycin exposure induced expression of MDA, IKKalpha, phosphorylated IKKalpha (p-IKKalpha), NF-kappaB P65, TNF-alpha and IL-1beta, and reduced I-kappaB expression in mice lung tissue or in BALF.	Bleomycin	0-9	tumor necrosis factor	Mus musculus	109-118
24886817-6	2014	Bleomycin exposure induced expression of MDA, IKKalpha, phosphorylated IKKalpha (p-IKKalpha), NF-kappaB P65, TNF-alpha and IL-1beta, and reduced I-kappaB expression in mice lung tissue or in BALF.	Bleomycin	0-9	interleukin 1 beta	Mus musculus	123-131
24650563-5	2014	Mice genetically deficient in PTP-alpha (Ptpra(-/-)) were protected from pulmonary fibrosis induced by intratracheal bleomycin, with minimal alterations in the early inflammatory response or production of TGF-beta.	Bleomycin	117-126	protein phosphatase 2 protein activator	Mus musculus	30-39
24828408-1	2014	OBJECTIVES: Matrix metalloproteinase-8 (MMP-8) promotes lung fibrotic responses to bleomycin in mice.	Bleomycin	83-92	matrix metallopeptidase 8	Mus musculus	12-38
24828408-1	2014	OBJECTIVES: Matrix metalloproteinase-8 (MMP-8) promotes lung fibrotic responses to bleomycin in mice.	Bleomycin	83-92	matrix metallopeptidase 8	Mus musculus	40-45
24634909-4	2014	In addition, the sensor exhibited selectivity, as much smaller responses were obtained for high concentrations (~700 muM) of other commonly prescribed antibiotics such as amoxicillin, bleomycin and gentamicin.	Bleomycin	184-193	latexin	Homo sapiens	117-120
24279830-4	2014	The increase in TGF-beta1 expression during the progression of bleomycin-induced lung fibrosis in mice was associated with loss of mmu-miR-326.	Bleomycin	63-72	transforming growth factor, beta 1	Mus musculus	16-25
24279830-4	2014	The increase in TGF-beta1 expression during the progression of bleomycin-induced lung fibrosis in mice was associated with loss of mmu-miR-326.	Bleomycin	63-72	microRNA 326	Mus musculus	131-142
24811221-0	2014	Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.	Bleomycin	137-146	poly(U) binding splicing factor 60	Homo sapiens	24-49
24811221-0	2014	Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.	Bleomycin	137-146	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	62-67
24811221-0	2014	Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.	Bleomycin	137-146	cyclin dependent kinase inhibitor 1B	Homo sapiens	69-76
24811221-0	2014	Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.	Bleomycin	137-146	X-ray repair cross complementing 5	Homo sapiens	89-93
24811221-0	2014	Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.	Bleomycin	137-146	X-ray repair cross complementing 5	Homo sapiens	94-99
24556663-10	2014	Bleomycin caused increased macrophages and lymphocytes in the bronchoalveolar lavage (BAL) and elevated interleukin-1beta (IL-1beta), tissue inhibitor of metalloproteinase-1 (TIMP-1), and collagen in lung tissue.	Bleomycin	0-9	interleukin 1 beta	Homo sapiens	104-121
25283008-2	2014	The patient underwent 4 cycles of neoadjuvant chemotherapy (cisplatin, bleomycin, and etoposide), which normalized the AFP level and reduced the tumor size, allowing complete resection without a support of extracorporeal circulation.	Bleomycin	71-80	alpha fetoprotein	Homo sapiens	119-122
24556663-10	2014	Bleomycin caused increased macrophages and lymphocytes in the bronchoalveolar lavage (BAL) and elevated interleukin-1beta (IL-1beta), tissue inhibitor of metalloproteinase-1 (TIMP-1), and collagen in lung tissue.	Bleomycin	0-9	interleukin 1 beta	Homo sapiens	123-131
24556663-10	2014	Bleomycin caused increased macrophages and lymphocytes in the bronchoalveolar lavage (BAL) and elevated interleukin-1beta (IL-1beta), tissue inhibitor of metalloproteinase-1 (TIMP-1), and collagen in lung tissue.	Bleomycin	0-9	TIMP metallopeptidase inhibitor 1	Homo sapiens	134-173
24556663-10	2014	Bleomycin caused increased macrophages and lymphocytes in the bronchoalveolar lavage (BAL) and elevated interleukin-1beta (IL-1beta), tissue inhibitor of metalloproteinase-1 (TIMP-1), and collagen in lung tissue.	Bleomycin	0-9	TIMP metallopeptidase inhibitor 1	Homo sapiens	175-181
24571982-6	2014	Interestingly, the gamma-H2AX signal was localized to telomeres after treatment with bleomycin, cisplatin, and 4OOH-CPA, but not etoposide.	Bleomycin	85-94	H2A.X variant histone	Mus musculus	19-29
24998650-1	2014	OBJECTIVE: To evaluate the effect of water channel aquaporin 4 (AQP4) on bleomycin-induced lung fibrosis in mice.	Bleomycin	73-82	aquaporin 4	Mus musculus	64-68
24998650-8	2014	There was a tendency that serum TGF-beta1 and TNF-alpha levels increased in bleomycin-treated mice, but no significant difference was found between wild type and AQP4-/- mice.	Bleomycin	76-85	transforming growth factor, beta 1	Mus musculus	32-41
24998650-8	2014	There was a tendency that serum TGF-beta1 and TNF-alpha levels increased in bleomycin-treated mice, but no significant difference was found between wild type and AQP4-/- mice.	Bleomycin	76-85	tumor necrosis factor	Mus musculus	46-55
24762191-13	2014	Daily intraperitoneal injection of ATO (1 mg/kg) in C57BL/6 mice inhibits bleomycin induced lung alpha-1 type I collagen mRNA and protein expression.	Bleomycin	74-83	collagen, type I, alpha 1	Mus musculus	97-120
25083316-8	2014	However, the association of electric pulses along with the chemotherapeutic agent bleomycin was mandatory for HMGB1 release coincident with regimen-induced cell death.	Bleomycin	82-91	high mobility group box 1	Mus musculus	110-115
24172847-6	2014	Finally, Il1r1-/- and Il1a-/- mice exhibit reduced bronchoalveolar lavage (BAL) neutrophilia and collagen deposition in response to bleomycin treatment.	Bleomycin	132-141	interleukin 1 receptor, type I	Mus musculus	9-14
24172847-6	2014	Finally, Il1r1-/- and Il1a-/- mice exhibit reduced bronchoalveolar lavage (BAL) neutrophilia and collagen deposition in response to bleomycin treatment.	Bleomycin	132-141	interleukin 1 alpha	Mus musculus	22-26
24756129-0	2014	Microsomal prostaglandin E synthase-1 deficiency exacerbates pulmonary fibrosis induced by bleomycin in mice.	Bleomycin	91-100	prostaglandin E synthase	Mus musculus	0-37
24756129-3	2014	The current study aimed to investigate the role of mPGES-1 in pulmonary fibrosis induced by bleomycin in mice.	Bleomycin	92-101	prostaglandin E synthase	Mus musculus	51-58
24756129-4	2014	We found that mPGES-1 deficient (mPGES-1-/-) mice exhibited more severe fibrotic lesions with a decrease in PGE2 content in lungs after bleomycin treatment when compared with wild type (mPGES-1+/+) mice.	Bleomycin	136-145	prostaglandin E synthase	Mus musculus	14-21
24756129-4	2014	We found that mPGES-1 deficient (mPGES-1-/-) mice exhibited more severe fibrotic lesions with a decrease in PGE2 content in lungs after bleomycin treatment when compared with wild type (mPGES-1+/+) mice.	Bleomycin	136-145	prostaglandin E synthase	Mus musculus	33-40
24756129-4	2014	We found that mPGES-1 deficient (mPGES-1-/-) mice exhibited more severe fibrotic lesions with a decrease in PGE2 content in lungs after bleomycin treatment when compared with wild type (mPGES-1+/+) mice.	Bleomycin	136-145	prostaglandin E synthase	Mus musculus	33-40
24756129-5	2014	The mPGES-1 expression levels and PGE2 content were also decreased in bleomycin-treated mPGES-1+/+ mice compared to saline-treated mPGES-1+/+ mice.	Bleomycin	70-79	prostaglandin E synthase	Mus musculus	4-11
24756129-5	2014	The mPGES-1 expression levels and PGE2 content were also decreased in bleomycin-treated mPGES-1+/+ mice compared to saline-treated mPGES-1+/+ mice.	Bleomycin	70-79	prostaglandin E synthase	Mus musculus	88-95
24756129-5	2014	The mPGES-1 expression levels and PGE2 content were also decreased in bleomycin-treated mPGES-1+/+ mice compared to saline-treated mPGES-1+/+ mice.	Bleomycin	70-79	prostaglandin E synthase	Mus musculus	88-95
24756129-6	2014	Moreover, in both mPGES-1-/- and mPGES-1+/+ mice, bleomycin treatment reduced the expression levels of E prostanoid receptor 2 (EP2) and EP4 receptor in lungs, whereas had little effect on EP1 and EP3.	Bleomycin	50-59	prostaglandin E synthase	Mus musculus	18-25
24756129-6	2014	Moreover, in both mPGES-1-/- and mPGES-1+/+ mice, bleomycin treatment reduced the expression levels of E prostanoid receptor 2 (EP2) and EP4 receptor in lungs, whereas had little effect on EP1 and EP3.	Bleomycin	50-59	prostaglandin E synthase	Mus musculus	33-40
24756129-6	2014	Moreover, in both mPGES-1-/- and mPGES-1+/+ mice, bleomycin treatment reduced the expression levels of E prostanoid receptor 2 (EP2) and EP4 receptor in lungs, whereas had little effect on EP1 and EP3.	Bleomycin	50-59	prostaglandin E receptor 2 (subtype EP2)	Mus musculus	103-126
24756129-6	2014	Moreover, in both mPGES-1-/- and mPGES-1+/+ mice, bleomycin treatment reduced the expression levels of E prostanoid receptor 2 (EP2) and EP4 receptor in lungs, whereas had little effect on EP1 and EP3.	Bleomycin	50-59	prostaglandin E receptor 2 (subtype EP2)	Mus musculus	128-131
24756129-6	2014	Moreover, in both mPGES-1-/- and mPGES-1+/+ mice, bleomycin treatment reduced the expression levels of E prostanoid receptor 2 (EP2) and EP4 receptor in lungs, whereas had little effect on EP1 and EP3.	Bleomycin	50-59	prostaglandin E receptor 4 (subtype EP4)	Mus musculus	137-140
24756129-6	2014	Moreover, in both mPGES-1-/- and mPGES-1+/+ mice, bleomycin treatment reduced the expression levels of E prostanoid receptor 2 (EP2) and EP4 receptor in lungs, whereas had little effect on EP1 and EP3.	Bleomycin	50-59	prostaglandin E receptor 3 (subtype EP3)	Mus musculus	197-200
24508728-8	2014	CTGF reporter mice demonstrated increased CTGF promoter activity by lung epithelial cells acutely after bleomycin in vivo.	Bleomycin	104-113	cellular communication network factor 2	Mus musculus	0-4
24508728-8	2014	CTGF reporter mice demonstrated increased CTGF promoter activity by lung epithelial cells acutely after bleomycin in vivo.	Bleomycin	104-113	cellular communication network factor 2	Mus musculus	42-46
24508728-9	2014	Furthermore, mice with lung epithelial cell-specific deletion of CTGF had an attenuated fibrotic response to bleomycin.	Bleomycin	109-118	cellular communication network factor 2	Mus musculus	65-69
24782646-0	2014	Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2/ angiotensin-(1-7) axis in rats.	Bleomycin	26-35	angiotensin I converting enzyme 2	Rattus norvegicus	78-109
24708674-10	2014	In bleomycin-treated mice, bosentan prevented dermal fibrosis and increased Fli1 expression in lesional dermal fibroblasts.	Bleomycin	3-12	Friend leukemia integration 1	Mus musculus	76-80
24624895-2	2014	We evaluated whether ASC treatment could attenuate lung fibrosis induced by repetitive intratracheal bleomycin administration.	Bleomycin	101-110	steroid sulfatase	Mus musculus	21-24
24325577-7	2014	In contrast, fibrosis and alternative macrophage programming were prolonged in bleomycin-instilled TNF-alpha(-/-) mice.	Bleomycin	79-88	tumor necrosis factor	Mus musculus	99-108
24757152-9	2014	Cad-11-knockout mice injected with bleomycin had markedly attenuated dermal fibrosis, as quantified by measurements of skin thickness, collagen levels, myofibroblast accumulation, and profibrotic gene expression, in lesional skin as compared to the skin of wild-type mice.	Bleomycin	35-44	cadherin 11	Mus musculus	0-6
24757152-10	2014	In addition, anti-Cad-11 mAb decreased fibrosis at various time points in the bleomycin-induced dermal fibrosis model.	Bleomycin	78-87	cadherin 11	Homo sapiens	18-24
24695531-6	2014	Compared to wildtype C57BL/6 mice, we find that in Apcs-/- "SAP knock-out" mice, bleomycin induces a more persistent inflammatory response and increased fibrosis.	Bleomycin	81-90	amyloid P component, serum	Mus musculus	51-55
24695531-6	2014	Compared to wildtype C57BL/6 mice, we find that in Apcs-/- "SAP knock-out" mice, bleomycin induces a more persistent inflammatory response and increased fibrosis.	Bleomycin	81-90	amyloid P component, serum	Mus musculus	60-63
24168260-4	2014	We hypothesized that up-regulation of the ACE2/Ang-(1-7)/Mas axis protects against bleomycin (BLM)-induced pulmonary fibrosis by inhibiting the mitogen-activated protein kinase (MAPK)/NF-kappaB pathway.	Bleomycin	83-92	angiotensin converting enzyme 2	Homo sapiens	42-46
24168260-4	2014	We hypothesized that up-regulation of the ACE2/Ang-(1-7)/Mas axis protects against bleomycin (BLM)-induced pulmonary fibrosis by inhibiting the mitogen-activated protein kinase (MAPK)/NF-kappaB pathway.	Bleomycin	94-97	angiotensin converting enzyme 2	Homo sapiens	42-46
24624895-9	2014	Addition of ASC led to suppression of bleomycin-induced epithelial cell apoptosis and expression of TGF-beta.	Bleomycin	38-47	steroid sulfatase	Mus musculus	12-15
24624895-9	2014	Addition of ASC led to suppression of bleomycin-induced epithelial cell apoptosis and expression of TGF-beta.	Bleomycin	38-47	transforming growth factor, beta 1	Mus musculus	100-108
24624896-7	2014	Furthermore, beta-catenin nuclear translocation and activation was impaired in matrilysin-null mice when compared to wild-type mice after bleomycin-induced lung injury.	Bleomycin	138-147	catenin (cadherin associated protein), beta 1	Mus musculus	13-25
24624894-1	2014	Recent studies have demonstrated that peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) has a protective effect during lung injury induced by bleomycin and polymicrobial sepsis, but its function in pulmonary oxygen toxicity is unknown.	Bleomycin	164-173	peroxisome proliferator-activated receptor delta	Rattus norvegicus	38-91
24624894-1	2014	Recent studies have demonstrated that peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) has a protective effect during lung injury induced by bleomycin and polymicrobial sepsis, but its function in pulmonary oxygen toxicity is unknown.	Bleomycin	164-173	peroxisome proliferator-activated receptor delta	Rattus norvegicus	93-102
24624896-7	2014	Furthermore, beta-catenin nuclear translocation and activation was impaired in matrilysin-null mice when compared to wild-type mice after bleomycin-induced lung injury.	Bleomycin	138-147	matrix metallopeptidase 7	Mus musculus	79-89
24530178-9	2014	let-7a can be overexpressed in the mouse skin by intermittent intraperitoneal miRNA injection, and skin fibrosis induced by bleomycin in mice can be improved by the supplementation of let-7a.	Bleomycin	124-133	microRNA let7a-1	Mus musculus	184-190
24637114-4	2014	Using an in vivo bleomycin-induced lung fibrosis model, we reveal a clock "gated" pulmonary response to oxidative injury, with a more severe fibrotic effect when bleomycin was applied at a circadian nadir in NRF2 levels.	Bleomycin	17-26	nuclear factor, erythroid derived 2, like 2	Mus musculus	208-212
24721403-0	2014	[IL-17A promotes pulmonary inflammation in rats with pulmonary fibrosis induced by bleomycin].	Bleomycin	83-92	interleukin 17A	Rattus norvegicus	1-7
24637114-4	2014	Using an in vivo bleomycin-induced lung fibrosis model, we reveal a clock "gated" pulmonary response to oxidative injury, with a more severe fibrotic effect when bleomycin was applied at a circadian nadir in NRF2 levels.	Bleomycin	162-171	nuclear factor, erythroid derived 2, like 2	Mus musculus	208-212
24134540-2	2014	However, after influenza virus infection or bleomycin treatment, patches of p63(+) cells were observed in the damaged lung parenchyma.	Bleomycin	44-53	tumor protein p63	Homo sapiens	76-79
24632813-11	2014	Change in CD4 count was similar for patients receiving vincristine monotherapy and bleomycin/vincristine (p = 0.6).	Bleomycin	83-92	CD4 molecule	Homo sapiens	10-13
24525119-4	2014	Del-1 expression in the lung was decreased in the WT mice treated with bleomycin compared to control mice.	Bleomycin	71-80	EGF-like repeats and discoidin I-like domains 3	Mus musculus	0-5
24525119-5	2014	In addition, bleomycin-induced pulmonary fibrosis increased collagen deposition and TGF-beta production in the lung of Del-1(-/-) mice.	Bleomycin	13-22	transforming growth factor, beta 1	Mus musculus	84-92
24525119-5	2014	In addition, bleomycin-induced pulmonary fibrosis increased collagen deposition and TGF-beta production in the lung of Del-1(-/-) mice.	Bleomycin	13-22	EGF-like repeats and discoidin I-like domains 3	Mus musculus	119-124
24525119-6	2014	Finally, Del-1(-/-) mice treated with bleomycin displayed higher weight loss and greater mortality than did WT mice identically treated.	Bleomycin	38-47	EGF-like repeats and discoidin I-like domains 3	Mus musculus	9-14
24625972-3	2014	The presence of BI-1 inhibited the transforming growth factor-beta1-induced epithelial-mesenchymal transition of epithelial pulmonary cells and bleomycin-induced pulmonary fibrosis in a mouse model by enhancing collagen degradation, most likely by enhanced activation of the lysosomal V-ATPase through glycosylation.	Bleomycin	144-153	transmembrane BAX inhibitor motif containing 6	Mus musculus	16-20
24625972-5	2014	BI-1-induced degradation of collagen through lysosomal V-ATPase glycosylation and the involvement of calnexin were confirmed in a bleomycin-induced fibrosis mouse model.	Bleomycin	130-139	transmembrane BAX inhibitor motif containing 6	Mus musculus	0-4
24625972-5	2014	BI-1-induced degradation of collagen through lysosomal V-ATPase glycosylation and the involvement of calnexin were confirmed in a bleomycin-induced fibrosis mouse model.	Bleomycin	130-139	calnexin	Mus musculus	101-109
24525119-0	2014	Deficiency of developmental endothelial locus-1 (Del-1) aggravates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	67-76	EGF-like repeats and discoidin I-like domains 3	Mus musculus	14-47
24525119-0	2014	Deficiency of developmental endothelial locus-1 (Del-1) aggravates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	67-76	EGF-like repeats and discoidin I-like domains 3	Mus musculus	49-54
24033834-0	2014	Ghrelin prevents the development of dermal fibrosis in bleomycin-induced scleroderma.	Bleomycin	55-64	ghrelin	Mus musculus	0-7
24257024-7	2014	Inactivation of EVI exerted potent antifibrotic effects and reduced dermal thickening, myofibroblast differentiation and accumulation of collagen in the mouse models of bleomycin-induced and AdTBR-induced fibrosis.	Bleomycin	169-178	wntless WNT ligand secretion mediator	Mus musculus	16-19
24574231-2	2014	We undertook the present study to assess the contribution of Sox2-expressing skin progenitor cells to bleomycin-induced scleroderma.	Bleomycin	102-111	SRY (sex determining region Y)-box 2	Mus musculus	61-65
24574231-4	2014	Lineage tracing analysis was performed to assess whether cells expressing Sox2 are recruited to fibrotic lesions in response to bleomycin-induced scleroderma.	Bleomycin	128-137	SRY (sex determining region Y)-box 2	Mus musculus	74-78
24574231-5	2014	RESULTS: In response to bleomycin, Sox2-positive/alpha-smooth muscle actin-positive cells were recruited to fibrotic tissue.	Bleomycin	24-33	SRY (sex determining region Y)-box 2	Mus musculus	35-39
24574231-6	2014	CCN2-conditional knockout mice in which CCN2 was deleted from Sox2-expressing cells exhibited resistance to bleomycin-induced skin fibrosis.	Bleomycin	108-117	cellular communication network factor 2	Mus musculus	0-4
24574231-6	2014	CCN2-conditional knockout mice in which CCN2 was deleted from Sox2-expressing cells exhibited resistance to bleomycin-induced skin fibrosis.	Bleomycin	108-117	cellular communication network factor 2	Mus musculus	40-44
24574231-6	2014	CCN2-conditional knockout mice in which CCN2 was deleted from Sox2-expressing cells exhibited resistance to bleomycin-induced skin fibrosis.	Bleomycin	108-117	SRY (sex determining region Y)-box 2	Mus musculus	62-66
24574231-7	2014	Collectively, these results indicate that CCN2 is required for the recruitment of progenitor cells and that CCN2-expressing progenitor cells are essential for bleomycin-induced skin fibrosis.	Bleomycin	159-168	cellular communication network factor 2	Mus musculus	108-112
24574231-10	2014	CONCLUSION: Sox2-positive skin progenitor cells are required in order for bleomycin-induced skin fibrosis to occur, and CCN2 is required for the recruitment of these cells to the fibrotic lesion.	Bleomycin	74-83	SRY (sex determining region Y)-box 2	Mus musculus	12-16
24033834-4	2014	AIM: To evaluate the potential preventive effects of ghrelin on a mouse model of bleomycin (BLM)-induced scleroderma.	Bleomycin	81-90	ghrelin	Mus musculus	53-60
24307592-7	2014	We also show that alphaB-crystallin-deficient mice are protected from bleomycin-induced fibrosis.	Bleomycin	70-79	crystallin, alpha B	Mus musculus	18-35
24335440-13	2014	Intraperitoneal administration of FTY720 (S)-phosphonate every other day for 1 week in normal or bleomycin-injured mice maintains significantly higher lung sphingosine 1-phosphate receptor 1 expression compared with FTY720.	Bleomycin	97-106	sphingosine-1-phosphate receptor 1	Mus musculus	156-190
24520265-16	2014	Thus, thalidomide eased the degree of BLM-induced pulmonary fibrosis in rats by downregulating p-JNK and alpha-SMA expression.	Bleomycin	38-41	actin gamma 2, smooth muscle	Rattus norvegicus	105-114
24024554-0	2014	Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin-induced pleural injury.	Bleomycin	162-171	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	0-33
24453258-3	2014	We assessed the role of MCs and MC protease 4 (MCPT4), the mouse counterpart of human MC chymase, in a mouse model of bleomycin (BLM)-induced lung injury.	Bleomycin	118-127	mast cell protease 4	Mus musculus	47-52
24453258-3	2014	We assessed the role of MCs and MC protease 4 (MCPT4), the mouse counterpart of human MC chymase, in a mouse model of bleomycin (BLM)-induced lung injury.	Bleomycin	129-132	mast cell protease 4	Mus musculus	47-52
24507087-16	2014	Increased chemokine (CC motif) ligand-2 (CCL2) and CCL12 production in bleomycin-treated mouse lungs was significantly attenuated by pirfenidone (P = 0.0003 and P &lt; 0.0001, respectively).	Bleomycin	71-80	chemokine (C-C motif) receptor 2	Mus musculus	10-20
24507087-16	2014	Increased chemokine (CC motif) ligand-2 (CCL2) and CCL12 production in bleomycin-treated mouse lungs was significantly attenuated by pirfenidone (P = 0.0003 and P &lt; 0.0001, respectively).	Bleomycin	71-80	chemokine (C-C motif) ligand 2	Mus musculus	41-45
24507087-16	2014	Increased chemokine (CC motif) ligand-2 (CCL2) and CCL12 production in bleomycin-treated mouse lungs was significantly attenuated by pirfenidone (P = 0.0003 and P &lt; 0.0001, respectively).	Bleomycin	71-80	chemokine (C-C motif) ligand 12	Mus musculus	51-56
24507087-19	2014	CONCLUSIONS: Pirfenidone attenuated the fibrocyte pool size in bleomycin-treated mouse lungs via attenuation of CCL2 and CCL12 production in vivo, and fibrocyte migration was inhibited by pirfenidone in vitro.	Bleomycin	63-72	chemokine (C-C motif) ligand 2	Mus musculus	112-116
24507087-19	2014	CONCLUSIONS: Pirfenidone attenuated the fibrocyte pool size in bleomycin-treated mouse lungs via attenuation of CCL2 and CCL12 production in vivo, and fibrocyte migration was inhibited by pirfenidone in vitro.	Bleomycin	63-72	chemokine (C-C motif) ligand 12	Mus musculus	121-126
24516640-1	2014	FIZZ (found in inflammatory zone) 1, a member of a cysteine-rich secreted protein family, is highly induced in lung allergic inflammation and bleomycin induced lung fibrosis, and primarily expressed by airway and type II alveolar epithelial cells.	Bleomycin	142-151	resistin like alpha	Mus musculus	6-35
24516640-3	2014	The objective of this study was to investigate the in vivo effects of FIZZ1 on the development of lung fibrosis by evaluating bleomycin-induced pulmonary fibrosis in FIZZ1 deficient mice.	Bleomycin	126-135	resistin like alpha	Mus musculus	166-171
24516640-10	2014	These findings suggested that FIZZ1 exhibited profibrogenic properties essential for bleomycin induced pulmonary fibrosis, as reflected by its ability to induce myofibroblast differentiation and recruit bone marrow-derived cells.	Bleomycin	85-94	resistin like alpha	Mus musculus	30-35
24276150-11	2014	Our results also demonstrated that adenovirus-mediated CCN5 overexpression in a mouse model of bleomycin-induced IPF significantly decreased the hydroxyproline content in the lungs, as well as TGF-beta1 expression in bronchoalveolar lavage fluid.	Bleomycin	95-104	cellular communication network factor 5	Mus musculus	55-59
24504814-10	2014	This was mimicked in the bleomycin model of SSc, in which animals exposed to bleomycin had elevated expression levels of GDF-15 in lung tissue.	Bleomycin	25-34	growth differentiation factor 15	Homo sapiens	121-127
24504814-10	2014	This was mimicked in the bleomycin model of SSc, in which animals exposed to bleomycin had elevated expression levels of GDF-15 in lung tissue.	Bleomycin	77-86	growth differentiation factor 15	Homo sapiens	121-127
24504814-11	2014	Lung fibroblasts isolated from GDF-15-deficient mice showed reduced induction of interleukin-6 and CCL2 upon bleomycin stimulation.	Bleomycin	109-118	interleukin 6	Mus musculus	81-94
24504814-11	2014	Lung fibroblasts isolated from GDF-15-deficient mice showed reduced induction of interleukin-6 and CCL2 upon bleomycin stimulation.	Bleomycin	109-118	chemokine (C-C motif) ligand 2	Mus musculus	99-103
24276150-11	2014	Our results also demonstrated that adenovirus-mediated CCN5 overexpression in a mouse model of bleomycin-induced IPF significantly decreased the hydroxyproline content in the lungs, as well as TGF-beta1 expression in bronchoalveolar lavage fluid.	Bleomycin	95-104	transforming growth factor, beta 1	Mus musculus	193-202
24029744-4	2014	Bleomycin-induced lung fibrosis has been shown to be diminished in PAR-1-deficient mice.	Bleomycin	0-9	coagulation factor II (thrombin) receptor	Mus musculus	67-72
24291458-3	2014	Here we describe the expression of elastin, type V collagen and tenascin C during the development of bleomycin-induced lung fibrosis.	Bleomycin	101-110	elastin	Homo sapiens	35-42
24291458-3	2014	Here we describe the expression of elastin, type V collagen and tenascin C during the development of bleomycin-induced lung fibrosis.	Bleomycin	101-110	tenascin C	Homo sapiens	64-74
24291458-11	2014	New collagen formation during bleomycin-induced fibrosis was highly correlated to gene expression of elastin, type V collagen and tenascin C.	Bleomycin	30-39	elastin	Homo sapiens	101-108
24291458-11	2014	New collagen formation during bleomycin-induced fibrosis was highly correlated to gene expression of elastin, type V collagen and tenascin C.	Bleomycin	30-39	tenascin C	Homo sapiens	130-140
24344132-4	2014	Aortic carboxypeptidase-like protein (ACLP) is an extracellular matrix protein secreted by fibroblasts and myofibroblasts and is expressed in fibrotic human lung tissue and in mice with bleomycin-induced fibrosis.	Bleomycin	186-195	AE binding protein 1	Homo sapiens	0-36
24344132-4	2014	Aortic carboxypeptidase-like protein (ACLP) is an extracellular matrix protein secreted by fibroblasts and myofibroblasts and is expressed in fibrotic human lung tissue and in mice with bleomycin-induced fibrosis.	Bleomycin	186-195	AE binding protein 1	Homo sapiens	38-42
24344132-5	2014	Importantly, ACLP knockout mice are significantly protected from bleomycin-induced fibrosis.	Bleomycin	65-74	AE binding protein 1	Mus musculus	13-17
24269241-10	2014	The findings reveal the therapeutic potential of H2S for BLM-induced pulmonary fibrosis in male rats, which were at least partly due to inhibition NF-kappaB p65 expression and regulation of Th1/Th2 balance.	Bleomycin	57-60	synaptotagmin 1	Rattus norvegicus	157-160
24475259-8	2014	Coculture of these Egr3-induced gammadelta T cells with wildtype CD4+ T cells increases Th17 differentiation, and Egr3 TG mice are more susceptible to bleomycin-induced lung inflammation.	Bleomycin	151-160	early growth response 3	Mus musculus	19-23
24475259-8	2014	Coculture of these Egr3-induced gammadelta T cells with wildtype CD4+ T cells increases Th17 differentiation, and Egr3 TG mice are more susceptible to bleomycin-induced lung inflammation.	Bleomycin	151-160	early growth response 3	Mus musculus	114-118
24213919-6	2014	In the mouse as an experimental animal, human SCGB3A2 exhibited growth factor activity by promoting embryonic lung development in both ex vivo and in vivo systems and antifibrotic activity in the bleomycin-induced lung fibrosis model.	Bleomycin	196-205	secretoglobin family 3A member 2	Homo sapiens	46-53
24324142-7	2014	Pharmacological inhibition of TGF-beta signaling in vivo in mice, and genetic ablation of the nox4 gene in mice, protected against perturbed lung fluid balance in a bleomycin model of lung injury, highlighting a role for both proximal and distal components of this unique ENaC regulatory pathway in lung fluid balance.	Bleomycin	165-174	NADPH oxidase 4	Mus musculus	94-98
24596659-7	2014	In parallel, lung fibroblasts in older mice had lower expression of Thy-1 at baseline that increased transiently 7 days after bleomycin treatment but then rapidly waned such that 14 days after bleomycin treatment Thy-1 expression was again markedly lower.	Bleomycin	126-135	thymus cell antigen 1, theta	Mus musculus	68-73
24596659-7	2014	In parallel, lung fibroblasts in older mice had lower expression of Thy-1 at baseline that increased transiently 7 days after bleomycin treatment but then rapidly waned such that 14 days after bleomycin treatment Thy-1 expression was again markedly lower.	Bleomycin	193-202	thymus cell antigen 1, theta	Mus musculus	68-73
24596659-7	2014	In parallel, lung fibroblasts in older mice had lower expression of Thy-1 at baseline that increased transiently 7 days after bleomycin treatment but then rapidly waned such that 14 days after bleomycin treatment Thy-1 expression was again markedly lower.	Bleomycin	193-202	thymus cell antigen 1, theta	Mus musculus	213-218
23977848-4	2014	We demonstrate that the Nox4 isoform is up-regulated in the lungs of patients with IPF and in a rodent model of bleomycin-induced pulmonary fibrosis and vascular remodeling.	Bleomycin	112-121	NADPH oxidase 4	Homo sapiens	24-28
24003988-0	2014	Lung inflammation and thymic atrophy after bleomycin are controlled by the prostaglandin D2 receptor DP1.	Bleomycin	43-52	receptor accessory protein 5	Mus musculus	101-104
24003988-3	2014	DP1 deficiency aggravated the toxicity of bleo as indicated by enhanced body weight loss, mortality, and lung inflammation including bronchoalveolar permeability and neutrophilia.	Bleomycin	42-46	receptor accessory protein 5	Mus musculus	0-3
24003988-6	2014	Serum corticosterone was more elevated in DP1(-/-) mice after bleo than in wild-type (wt) mice.	Bleomycin	62-66	receptor accessory protein 5	Mus musculus	42-45
28942960-8	2014	Periostin null mice have shown reduced skin fibrosis in a bleomycin-induced SSc mouse model, indicating a key role of periostin in fibrosis.	Bleomycin	58-67	periostin, osteoblast specific factor	Mus musculus	0-9
23944988-9	2014	Bleomycin-induced canonical EMT markers, Snail1, Twist1, collagen I, as well as fibronectin protein and mRNA, were attenuated by methacycline (Day 17).	Bleomycin	0-9	snail family transcriptional repressor 1	Homo sapiens	41-47
23944988-9	2014	Bleomycin-induced canonical EMT markers, Snail1, Twist1, collagen I, as well as fibronectin protein and mRNA, were attenuated by methacycline (Day 17).	Bleomycin	0-9	twist family bHLH transcription factor 1	Homo sapiens	49-55
23944988-9	2014	Bleomycin-induced canonical EMT markers, Snail1, Twist1, collagen I, as well as fibronectin protein and mRNA, were attenuated by methacycline (Day 17).	Bleomycin	0-9	fibronectin 1	Homo sapiens	80-91
23947621-9	2014	Lung content of angiostatic thrombospondin-1 (TSP1) was increased significantly in the lungs of bleomycin-exposed animals, and was completely attenuated by treatment with Y-27632.	Bleomycin	96-105	thrombospondin 1	Rattus norvegicus	28-44
23947621-9	2014	Lung content of angiostatic thrombospondin-1 (TSP1) was increased significantly in the lungs of bleomycin-exposed animals, and was completely attenuated by treatment with Y-27632.	Bleomycin	96-105	thrombospondin 1	Rattus norvegicus	46-50
24242012-0	2014	Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs.	Bleomycin	70-79	tumor necrosis factor alpha induced protein 6	Mus musculus	24-29
24242012-3	2014	In this study, we elected to test the hypothesis that targeting the early phase of bleomycin-induced lung injury with systemic TSG-6 administration may produce therapeutic effects such as preventing the deterioration of lung function and increasing survival by modulation of the inflammatory cascade.	Bleomycin	83-92	tumor necrosis factor alpha induced protein 6	Mus musculus	127-132
24242012-10	2014	These findings demonstrated that the beneficial effects of TSG-6 in a model of bleomycin-induced lung injury are largely explained by the protein modulating the early inflammatory phase.	Bleomycin	79-88	tumor necrosis factor alpha induced protein 6	Mus musculus	59-64
24377569-0	2014	miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin.	Bleomycin	119-128	microRNA 126	Homo sapiens	0-7
24083993-0	2014	Proliferative phenotype of pulmonary microvascular endothelial cells plays a critical role in the overexpression of CTGF in the bleomycin-injured rat.	Bleomycin	128-137	cellular communication network factor 2	Rattus norvegicus	116-120
25101299-5	2014	Two additional strategies were explored to further enhance the cytotoxicity of bleomycin; a novel peptide drug ATX-101 which is known to impair DNA damage responses, and the protease inhibitor E-64 which may reduce bleomycin degradation by inhibition of bleomycin hydrolase.	Bleomycin	79-88	bleomycin hydrolase	Homo sapiens	254-273
24709185-14	2014	It was also demonstrated that rapamycin treatment reduced the expression of MMP-9 and TIMP-1 in lung tissue that was increased by bleomycin.	Bleomycin	130-139	matrix metallopeptidase 9	Rattus norvegicus	76-81
24709185-14	2014	It was also demonstrated that rapamycin treatment reduced the expression of MMP-9 and TIMP-1 in lung tissue that was increased by bleomycin.	Bleomycin	130-139	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	86-92
25942339-8	2014	The rate of cell migration differed with different treatments and so did the CD44 expression with expression being higher in 0.6mM concentration of bleomycin when compared to 0.4mM.	Bleomycin	148-157	CD44 molecule (Indian blood group)	Homo sapiens	77-81
23964118-12	2014	Loss of MMP28 results in reduced M2 polarization and protection from bleomycin-induced fibrosis.	Bleomycin	69-78	matrix metallopeptidase 28 (epilysin)	Mus musculus	8-13
23837438-0	2013	Interleukin-33 potentiates bleomycin-induced lung injury.	Bleomycin	27-36	interleukin 33	Mus musculus	0-14
23597142-0	2014	Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.	Bleomycin	164-173	colony stimulating factor 3	Homo sapiens	0-37
24959005-8	2014	The in vivo relevance of the interaction between the COX-2/PGE2 and HGF pathways through a positive feedback loop was shown in cultured alveolar macrophages following in vivo exposure of bleomycin-stimulated lungs to apoptotic cells.	Bleomycin	187-196	prostaglandin-endoperoxide synthase 2	Mus musculus	53-58
24959005-8	2014	The in vivo relevance of the interaction between the COX-2/PGE2 and HGF pathways through a positive feedback loop was shown in cultured alveolar macrophages following in vivo exposure of bleomycin-stimulated lungs to apoptotic cells.	Bleomycin	187-196	hepatocyte growth factor	Mus musculus	68-71
24102485-7	2014	On bleomycin treatment, many genes were altered in the wild-type but not in the triple mutant, suggesting that the RAD51 paralogs have roles in the regulation of gene transcription, providing an explanation for the hypersensitive phenotype of the triple mutant to bleomycin.	Bleomycin	3-12	RAS associated with diabetes protein 51	Arabidopsis thaliana	115-120
24102485-7	2014	On bleomycin treatment, many genes were altered in the wild-type but not in the triple mutant, suggesting that the RAD51 paralogs have roles in the regulation of gene transcription, providing an explanation for the hypersensitive phenotype of the triple mutant to bleomycin.	Bleomycin	264-273	RAS associated with diabetes protein 51	Arabidopsis thaliana	115-120
24374669-8	2014	CONCLUSIONS: The bleomycin infusion model stimulates dermal fibroproliferation, creating reproducible murine scars that are comparable to human hypertrophic scars in terms of histological features, collagen content and organization, cellularity, the presence of myofibroblasts, and expression of transforming growth factor beta1.	Bleomycin	17-26	transforming growth factor beta 1	Homo sapiens	296-328
25033545-6	2014	It was also demonstrated that FLNA dysfunctions can lead to sensitization of cells to ionizing irradiation or common chemotherapeutics: bleomycin and cisplatin.	Bleomycin	136-145	filamin A	Homo sapiens	30-34
24351828-0	2013	Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway.	Bleomycin	24-33	nitric oxide synthase 2	Rattus norvegicus	77-81
24351828-0	2013	Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway.	Bleomycin	24-33	cellular communication network factor 2	Rattus norvegicus	101-105
24300094-13	2013	Furthermore, andrographloide suppressed TGF-beta1 and alpha-SMA mRNA and protein expression in bleomycin-induced pulmonary fibrosis.	Bleomycin	95-104	transforming growth factor, beta 1	Mus musculus	40-49
24266925-7	2013	Deletion of CD39 and/or CD73 decreased the collagen content, and prevented skin thickening and tensile strength increase after bleomycin challenge.	Bleomycin	127-136	ectonucleoside triphosphate diphosphohydrolase 1	Mus musculus	12-16
24266925-7	2013	Deletion of CD39 and/or CD73 decreased the collagen content, and prevented skin thickening and tensile strength increase after bleomycin challenge.	Bleomycin	127-136	5' nucleotidase, ecto	Mus musculus	24-28
24137007-4	2014	In this report, we show that time-dependent kinetics of the NHEJ factors Ku80 and DNA-dependent protein kinase catalytic subunits (DNA-PKcs) in response to IR and bleomycin can be quantified by Number and Brightness analysis and Raster-scan Image Correlation Spectroscopy.	Bleomycin	163-172	X-ray repair cross complementing 5	Homo sapiens	73-77
24137007-4	2014	In this report, we show that time-dependent kinetics of the NHEJ factors Ku80 and DNA-dependent protein kinase catalytic subunits (DNA-PKcs) in response to IR and bleomycin can be quantified by Number and Brightness analysis and Raster-scan Image Correlation Spectroscopy.	Bleomycin	163-172	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	82-129
24137007-4	2014	In this report, we show that time-dependent kinetics of the NHEJ factors Ku80 and DNA-dependent protein kinase catalytic subunits (DNA-PKcs) in response to IR and bleomycin can be quantified by Number and Brightness analysis and Raster-scan Image Correlation Spectroscopy.	Bleomycin	163-172	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	131-139
24137007-5	2014	Fluorescent-tagged Ku80 and DNA-PKcs quickly mobilized in response to IR and bleomycin treatments consistent with prior reports using laser-generated DSBs.	Bleomycin	77-86	X-ray repair cross complementing 5	Homo sapiens	19-23
24137007-5	2014	Fluorescent-tagged Ku80 and DNA-PKcs quickly mobilized in response to IR and bleomycin treatments consistent with prior reports using laser-generated DSBs.	Bleomycin	77-86	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	28-36
24854244-4	2014	RESULTS: We found that the expression of HO-1 was significantly decreased in lung fibroblasts isolated from bleomycin-challenged mice in comparison with control mice.	Bleomycin	108-117	heme oxygenase 1	Mus musculus	41-45
24351828-7	2013	Atorvastatin also markedly decreased the expression of inducible nitric oxide synthase (iNOS) in lung tissues and, thus, prevented nitric oxide (NO) release in response to bleomycin challenge.	Bleomycin	172-181	nitric oxide synthase 2	Rattus norvegicus	55-86
24351828-7	2013	Atorvastatin also markedly decreased the expression of inducible nitric oxide synthase (iNOS) in lung tissues and, thus, prevented nitric oxide (NO) release in response to bleomycin challenge.	Bleomycin	172-181	nitric oxide synthase 2	Rattus norvegicus	88-92
24351828-9	2013	Taken together, atorvastatin significantly ameliorated bleomycin-induced pulmonary fibrosis in rats, via the inhibition of iNOS expression and the CTGF (CCN2)/ERK signaling pathway.	Bleomycin	55-64	nitric oxide synthase 2	Rattus norvegicus	123-127
24300094-13	2013	Furthermore, andrographloide suppressed TGF-beta1 and alpha-SMA mRNA and protein expression in bleomycin-induced pulmonary fibrosis.	Bleomycin	95-104	actin alpha 2, smooth muscle, aorta	Mus musculus	54-63
24300094-15	2013	Our findings indicate that andrographolide compromised bleomycin-induced pulmonary inflammation and fibrosis possibly through inactivation of NF-kappaB.	Bleomycin	55-64	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	142-151
24095924-12	2013	Furthermore, ERK5 inhibitor, BIX02189, inhibited lung fibrosis and improved survival rate in the bleomycin-induced lung fibrosis model.	Bleomycin	97-106	mitogen-activated protein kinase 7	Homo sapiens	13-17
23808384-0	2013	Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice.	Bleomycin	71-80	lysophosphatidic acid receptor 2	Mus musculus	0-32
23808384-6	2013	In the present study, we found that LPA2 knockout (Lpar2(-/-)) mice were protected against bleomycin-induced lung injury, fibrosis, and mortality, compared with wild-type control mice.	Bleomycin	91-100	lysophosphatidic acid receptor 2	Mus musculus	36-40
23808384-6	2013	In the present study, we found that LPA2 knockout (Lpar2(-/-)) mice were protected against bleomycin-induced lung injury, fibrosis, and mortality, compared with wild-type control mice.	Bleomycin	91-100	lysophosphatidic acid receptor 2	Mus musculus	51-56
23808384-7	2013	Furthermore, LPA2 deficiency attenuated the bleomycin-induced expression of fibronectin (FN), alpha-smooth muscle actin (alpha-SMA), and collagen in lung tissue, as well as levels of IL-6, transforming growth factor-beta (TGF-beta), and total protein in bronchoalveolar lavage fluid.	Bleomycin	44-53	fibronectin 1	Mus musculus	76-87
23808384-7	2013	Furthermore, LPA2 deficiency attenuated the bleomycin-induced expression of fibronectin (FN), alpha-smooth muscle actin (alpha-SMA), and collagen in lung tissue, as well as levels of IL-6, transforming growth factor-beta (TGF-beta), and total protein in bronchoalveolar lavage fluid.	Bleomycin	44-53	fibronectin 1	Mus musculus	89-91
23808384-7	2013	Furthermore, LPA2 deficiency attenuated the bleomycin-induced expression of fibronectin (FN), alpha-smooth muscle actin (alpha-SMA), and collagen in lung tissue, as well as levels of IL-6, transforming growth factor-beta (TGF-beta), and total protein in bronchoalveolar lavage fluid.	Bleomycin	44-53	actin alpha 2, smooth muscle, aorta	Mus musculus	94-119
23808384-7	2013	Furthermore, LPA2 deficiency attenuated the bleomycin-induced expression of fibronectin (FN), alpha-smooth muscle actin (alpha-SMA), and collagen in lung tissue, as well as levels of IL-6, transforming growth factor-beta (TGF-beta), and total protein in bronchoalveolar lavage fluid.	Bleomycin	44-53	actin alpha 2, smooth muscle, aorta	Mus musculus	121-130
23837438-2	2013	Substantial elevations in IL-33 expression were found in the lungs of patients with idiopathic pulmonary fibrosis and scleroderma lung disease, as well as in the bleomycin injury mouse model.	Bleomycin	162-171	interleukin 33	Homo sapiens	26-31
23808384-7	2013	Furthermore, LPA2 deficiency attenuated the bleomycin-induced expression of fibronectin (FN), alpha-smooth muscle actin (alpha-SMA), and collagen in lung tissue, as well as levels of IL-6, transforming growth factor-beta (TGF-beta), and total protein in bronchoalveolar lavage fluid.	Bleomycin	44-53	interleukin 6	Mus musculus	183-187
23808384-7	2013	Furthermore, LPA2 deficiency attenuated the bleomycin-induced expression of fibronectin (FN), alpha-smooth muscle actin (alpha-SMA), and collagen in lung tissue, as well as levels of IL-6, transforming growth factor-beta (TGF-beta), and total protein in bronchoalveolar lavage fluid.	Bleomycin	44-53	transforming growth factor, beta 1	Mus musculus	222-230
23837438-6	2013	Combined flIL-33 expression and bleomycin injury exerted a synergistic effect on pulmonary lymphocyte and collagen accumulation, which could be explained by synergistic regulation of the cytokines transforming growth factor-beta, IL-6, monocyte chemotactic protein-1, macrophage inflammatory protein\x{2013}1alpha, and tumor necrosis factor-alpha.	Bleomycin	32-41	interleukin 6	Mus musculus	230-234
23808384-11	2013	Together, our data indicate that the knockdown of LPA2 attenuated bleomycin-induced lung injury and pulmonary fibrosis, and this may be related to an inhibition of the LPA-induced expression of TGF-beta and the activation and differentiation of fibroblasts.	Bleomycin	66-75	lysophosphatidic acid receptor 2	Mus musculus	50-54
24013728-5	2013	RESULTS: In bleomycin and TSK1 mice, expression of activated p-PDGFRbeta (platelet derived growth factor receptor beta) and p-c-abl was ubiquitous with strong upregulation compared with controls.	Bleomycin	12-21	platelet derived growth factor receptor, beta polypeptide	Mus musculus	63-72
23413283-4	2013	METHODS: TSLP expression was analysed by immunohistochemistry in human SSc skin, primary lung fibrosis and mouse bleomycin-induced skin fibrosis, and by quantitative RT-PCR in mouse skin and cultured fibroblasts.	Bleomycin	113-122	thymic stromal lymphopoietin	Homo sapiens	9-13
23413283-7	2013	RESULTS: TSLP was overexpressed by epithelial cells, mast cells and fibroblasts in human SSc skin and lung fibrosis, and in the bleomycin model of scleroderma.	Bleomycin	128-137	thymic stromal lymphopoietin	Homo sapiens	9-13
23413283-9	2013	In TSLPR-deficient mice, bleomycin-induced fibrosis was significantly reduced in parallel with significantly reduced local expression of IL-13.	Bleomycin	25-34	cytokine receptor-like factor 2	Mus musculus	3-8
23413283-9	2013	In TSLPR-deficient mice, bleomycin-induced fibrosis was significantly reduced in parallel with significantly reduced local expression of IL-13.	Bleomycin	25-34	interleukin 13	Mus musculus	137-142
24013728-5	2013	RESULTS: In bleomycin and TSK1 mice, expression of activated p-PDGFRbeta (platelet derived growth factor receptor beta) and p-c-abl was ubiquitous with strong upregulation compared with controls.	Bleomycin	12-21	platelet derived growth factor receptor, beta polypeptide	Mus musculus	74-118
24013728-5	2013	RESULTS: In bleomycin and TSK1 mice, expression of activated p-PDGFRbeta (platelet derived growth factor receptor beta) and p-c-abl was ubiquitous with strong upregulation compared with controls.	Bleomycin	12-21	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	126-131
24238231-11	2013	In contrast, when lungs were treated with bleomycin, the proliferation of CCSP(pos)/SP-C(pos) cells was observed, but the type II alveolar epithelial cells never recovered to baseline.	Bleomycin	42-51	secretoglobin, family 1A, member 1 (uteroglobin)	Mus musculus	74-78
23975892-0	2013	CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model.	Bleomycin	85-94	chemokine (C-X-C motif) ligand 5	Mus musculus	0-5
23975892-4	2013	First, we reported an increase of CXCL6 levels in BALF from patients with IPF, as well as in the lung of mice, 24 h after bleomycin administration.	Bleomycin	122-131	C-X-C motif chemokine ligand 6	Homo sapiens	34-39
23975892-7	2013	In the later phase (14 days after bleomycin exposure), lymphocyte recruitment and fibrosis markers, such as collagen and TIMP-1, were diminished, as well as collagen deposition and fibrotic lesion the lung.	Bleomycin	34-43	tissue inhibitor of metalloproteinase 1	Mus musculus	121-127
23975892-8	2013	Therefore, the data suggest that CXCL6 contributes to experimental pulmonary fibrosis, and CXCL6 inhibition might be used to reduce lung toxicity associated with bleomycin treatment.	Bleomycin	162-171	chemokine (C-X-C motif) ligand 5	Mus musculus	91-96
23523661-0	2013	Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21.	Bleomycin	21-30	microRNA 21	Rattus norvegicus	88-94
23523661-8	2013	Baicalein remarkably decreased miR-21 levels and inhibited the increased expression of TGF-beta1 and p-Smad-2/3 in bleomycin-treated rats.	Bleomycin	115-124	transforming growth factor, beta 1	Rattus norvegicus	87-96
24260540-3	2013	The present work was designed to investigate the therapeutic potential of MR antagonism in bleomycin-induced acute lung injury and fibrosis.	Bleomycin	91-100	nuclear receptor subfamily 3, group C, member 2	Mus musculus	74-76
23928001-0	2013	Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.	Bleomycin	42-51	SMAD family member 2	Mus musculus	124-131
23928001-10	2013	Bleomycin induced severe PF and PH in mice, associated with an increased RhoA/ROCK activity in the lung.	Bleomycin	0-9	ras homolog family member A	Mus musculus	73-77
23928001-12	2013	Fasudil inhibited the increased activity of RhoA/ROCK pathway, and partly altered bleomycin-associated activation of TGF-beta1/Smad pathway, via inhibition of Smad2/3 phosphorylation.	Bleomycin	82-91	transforming growth factor, beta 1	Mus musculus	117-126
23928001-12	2013	Fasudil inhibited the increased activity of RhoA/ROCK pathway, and partly altered bleomycin-associated activation of TGF-beta1/Smad pathway, via inhibition of Smad2/3 phosphorylation.	Bleomycin	82-91	SMAD family member 2	Mus musculus	159-166
24260540-6	2013	Moreover, serial flow cytometry analysis in blood, BALF and enzymatically digested lung tissue, revealed that spironolactone could partially inhibit bleomycin-induced circulating Ly6C(hi) monocyte expansion, and reduce alternative activation (F4/80+CD11c+CD206+) of mononuclear phagocyte in alveoli, whereas the phenotype of interstitial macrophage (F4/80+CD11c-) remained unaffected by spironolactone during investigation.	Bleomycin	149-158	lymphocyte antigen 6 complex, locus C1	Mus musculus	179-183
24260540-6	2013	Moreover, serial flow cytometry analysis in blood, BALF and enzymatically digested lung tissue, revealed that spironolactone could partially inhibit bleomycin-induced circulating Ly6C(hi) monocyte expansion, and reduce alternative activation (F4/80+CD11c+CD206+) of mononuclear phagocyte in alveoli, whereas the phenotype of interstitial macrophage (F4/80+CD11c-) remained unaffected by spironolactone during investigation.	Bleomycin	149-158	adhesion G protein-coupled receptor E1	Mus musculus	243-248
24260540-6	2013	Moreover, serial flow cytometry analysis in blood, BALF and enzymatically digested lung tissue, revealed that spironolactone could partially inhibit bleomycin-induced circulating Ly6C(hi) monocyte expansion, and reduce alternative activation (F4/80+CD11c+CD206+) of mononuclear phagocyte in alveoli, whereas the phenotype of interstitial macrophage (F4/80+CD11c-) remained unaffected by spironolactone during investigation.	Bleomycin	149-158	integrin alpha X	Mus musculus	249-254
24260540-6	2013	Moreover, serial flow cytometry analysis in blood, BALF and enzymatically digested lung tissue, revealed that spironolactone could partially inhibit bleomycin-induced circulating Ly6C(hi) monocyte expansion, and reduce alternative activation (F4/80+CD11c+CD206+) of mononuclear phagocyte in alveoli, whereas the phenotype of interstitial macrophage (F4/80+CD11c-) remained unaffected by spironolactone during investigation.	Bleomycin	149-158	adhesion G protein-coupled receptor E1	Mus musculus	350-355
24260575-8	2013	Consequently, FHL2 knockout mice developed a severe and long-lasting lung pathology following bleomycin administration due to enhanced expression of tenascin C and impaired activation of inflammation-resolving macrophages.	Bleomycin	94-103	four and a half LIM domains 2	Mus musculus	14-18
24260540-6	2013	Moreover, serial flow cytometry analysis in blood, BALF and enzymatically digested lung tissue, revealed that spironolactone could partially inhibit bleomycin-induced circulating Ly6C(hi) monocyte expansion, and reduce alternative activation (F4/80+CD11c+CD206+) of mononuclear phagocyte in alveoli, whereas the phenotype of interstitial macrophage (F4/80+CD11c-) remained unaffected by spironolactone during investigation.	Bleomycin	149-158	integrin alpha X	Mus musculus	356-361
24260575-8	2013	Consequently, FHL2 knockout mice developed a severe and long-lasting lung pathology following bleomycin administration due to enhanced expression of tenascin C and impaired activation of inflammation-resolving macrophages.	Bleomycin	94-103	tenascin C	Mus musculus	149-159
24260540-7	2013	CONCLUSIONS/SIGNIFICANCE: The present work provides the experimental evidence that spironolactone could attenuate bleomycin-induced acute pulmonary injury and fibrosis, partially via inhibition of MR-mediated circulating monocyte and alveolar macrophage phenotype switching.	Bleomycin	114-123	nuclear receptor subfamily 3, group C, member 2	Mus musculus	197-199
23992520-0	2013	Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations.	Bleomycin	0-9	mechanistic target of rapamycin kinase	Homo sapiens	75-79
23742180-2	2013	Recently, we reported that the resolution of inflammation is impaired in Timp3(-/-) mice after bleomycin-induced lung injury.	Bleomycin	95-104	tissue inhibitor of metalloproteinase 3	Mus musculus	73-78
23838005-2	2013	Cells transformed by JAK2 V617F mutant exhibited resistance to anti-cancer drugs such as cisplatin (CDDP), mitomycin C (MMC) and bleomycin (BLM).	Bleomycin	129-138	Janus kinase 2	Homo sapiens	21-25
23838005-2	2013	Cells transformed by JAK2 V617F mutant exhibited resistance to anti-cancer drugs such as cisplatin (CDDP), mitomycin C (MMC) and bleomycin (BLM).	Bleomycin	140-143	Janus kinase 2	Homo sapiens	21-25
23958969-3	2013	Bleomycin administration reduced the body weight, altered antioxidant status (such as superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione) while it increased the lung weight, hydroxyproline content, collagen deposition and lipid peroxidation.	Bleomycin	0-9	catalase	Rattus norvegicus	108-116
23958969-3	2013	Bleomycin administration reduced the body weight, altered antioxidant status (such as superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione) while it increased the lung weight, hydroxyproline content, collagen deposition and lipid peroxidation.	Bleomycin	0-9	glutathione-disulfide reductase	Rattus norvegicus	142-163
23688655-3	2013	We characterized the SASP in a murine model of bleomycin-induced lung injury.	Bleomycin	47-56	aspartic peptidase, retroviral-like 1	Mus musculus	21-25
23688655-6	2013	gammaH2AX immunostaining of the bleomycin-treated lungs revealed double-strand breaks (DSBs), largely within E-cadherin-positive, beta4-integirn-positive alveolar epithelial cells.	Bleomycin	32-41	H2A.X variant histone	Mus musculus	0-9
23688655-6	2013	gammaH2AX immunostaining of the bleomycin-treated lungs revealed double-strand breaks (DSBs), largely within E-cadherin-positive, beta4-integirn-positive alveolar epithelial cells.	Bleomycin	32-41	cadherin 1	Mus musculus	109-119
23688655-10	2013	Persistent DNA damage and the SASP are induced in the process of bleomycin-induced lung injury and repair, suggesting that these events play an important role in the regulation of inflammation and tissue remodeling in bleomycin-induced pneumopathy.	Bleomycin	65-74	aspartic peptidase, retroviral-like 1	Mus musculus	30-34
23688655-10	2013	Persistent DNA damage and the SASP are induced in the process of bleomycin-induced lung injury and repair, suggesting that these events play an important role in the regulation of inflammation and tissue remodeling in bleomycin-induced pneumopathy.	Bleomycin	218-227	aspartic peptidase, retroviral-like 1	Mus musculus	30-34
23913859-7	2013	Moreover, using a murine treatment model of bleomycin-induced pulmonary fibrosis we found that inhibition of TGFbeta/PDGF and ErbB pathways with imatinib plus lapatinib, respectively, not only prevented myofibroblast gene expression to a greater extent than either drug alone, but also essentially stabilized gas exchange (oxygen saturation) as an overall measure of lung function.	Bleomycin	44-53	transforming growth factor, beta 1	Mus musculus	109-116
24118261-0	2013	Bleomycin inhibits adipogenesis and accelerates fibrosis in the subcutaneous adipose layer through TGF-beta1.	Bleomycin	0-9	transforming growth factor beta 1	Homo sapiens	99-108
24118261-4	2013	We found that bleomycin suppresses adipogenesis in adipose-derived stem cells (ASCs) and stimulates ASCs to express transforming growth factor beta1 (TGF-beta1), which suppresses adipogenesis and promotes fibrosis.	Bleomycin	14-23	transforming growth factor beta 1	Homo sapiens	116-148
24118261-4	2013	We found that bleomycin suppresses adipogenesis in adipose-derived stem cells (ASCs) and stimulates ASCs to express transforming growth factor beta1 (TGF-beta1), which suppresses adipogenesis and promotes fibrosis.	Bleomycin	14-23	transforming growth factor beta 1	Homo sapiens	150-159
24118261-6	2013	We concluded that in the skin affected by bleomycin-induced fibrosis, increased TGF-beta1 expression suppresses adipogenesis and promotes adipocyte fibrosis.	Bleomycin	42-51	transforming growth factor beta 1	Homo sapiens	80-89
23913859-7	2013	Moreover, using a murine treatment model of bleomycin-induced pulmonary fibrosis we found that inhibition of TGFbeta/PDGF and ErbB pathways with imatinib plus lapatinib, respectively, not only prevented myofibroblast gene expression to a greater extent than either drug alone, but also essentially stabilized gas exchange (oxygen saturation) as an overall measure of lung function.	Bleomycin	44-53	epidermal growth factor receptor	Mus musculus	126-130
24273579-0	2013	Expression of pulmonary aquaporin 1 is dramatically upregulated in mice with pulmonary fibrosis induced by bleomycin.	Bleomycin	107-116	aquaporin 1	Mus musculus	24-35
24339053-3	2013	In the present study, we attempted the local administration of tumor necrosis factor alpha antisense oligonucleotide and evaluated the treatment effects on pulmonary fibrosis in a bleomycin-induced pulmonary fibrosis mouse model.	Bleomycin	180-189	tumor necrosis factor	Mus musculus	63-90
24042439-0	2013	All-transretinoic acid ameliorates bleomycin-induced lung fibrosis by downregulating the TGF-beta1/Smad3 signaling pathway in rats.	Bleomycin	35-44	transforming growth factor, beta 1	Rattus norvegicus	89-98
24042439-0	2013	All-transretinoic acid ameliorates bleomycin-induced lung fibrosis by downregulating the TGF-beta1/Smad3 signaling pathway in rats.	Bleomycin	35-44	SMAD family member 3	Rattus norvegicus	99-104
23893664-6	2013	The expression of miR-30b in skin was evaluated in a bleomycin-induced dermal fibrosis model in mice and in SSc patients.	Bleomycin	53-62	microRNA 30b	Mus musculus	18-25
23893664-10	2013	Moreover, the expression of miR-30b was down-regulated in bleomycin-treated sclerotic skin and in affected skin in SSc patients.	Bleomycin	58-67	microRNA 30b	Homo sapiens	28-35
23922381-1	2013	Apoptotic cell instillation after bleomycin induces persistent HGF production and protects from pulmonary fibrosis, but the underlying mechanism remains unclear.	Bleomycin	34-43	hepatocyte growth factor	Mus musculus	63-66
23922381-2	2013	We investigated immediate and prolonged effects of in vivo instillation of apoptotic cells into bleomycin-stimulated mouse lungs (2 days old) on COX-2 expression in lung tissue and alveolar macrophages and PGE2 production in BALF.	Bleomycin	96-105	cytochrome c oxidase II, mitochondrial	Mus musculus	145-150
24273579-8	2013	RESULTS: Real-time PCR showed that AQP1 mRNA in bleomycin 1 w, 2 w, and 3 w groups increased by 377%, 880% and 823% respectively compared to that in the control group (p &lt; 0.01).	Bleomycin	48-57	aquaporin 1	Mus musculus	35-39
24507390-14	2013	The expression of MMP-2 in the bleomycin plus stem cell group was lower than the bleomycin group [(1.59 +- 0.59) vs (2.37 +- 0.68), P &lt; 0.05], but there was no difference between the control group and the stem cell group [(0.80 +- 0.69) vs (0.84 +- 0.77), P &gt; 0.05].	Bleomycin	31-40	matrix metallopeptidase 2	Mus musculus	18-23
24273579-9	2013	Western blotting showed that the expression of AQP1 protein in bleomycin 1 w, 2 w, and 3 w groups increased by 53%, 144%, and 141%, respectively (p &lt; 0.05).	Bleomycin	63-72	aquaporin 1	Mus musculus	47-51
24507390-14	2013	The expression of MMP-2 in the bleomycin plus stem cell group was lower than the bleomycin group [(1.59 +- 0.59) vs (2.37 +- 0.68), P &lt; 0.05], but there was no difference between the control group and the stem cell group [(0.80 +- 0.69) vs (0.84 +- 0.77), P &gt; 0.05].	Bleomycin	81-90	matrix metallopeptidase 2	Mus musculus	18-23
24507390-15	2013	The expression of TIMP-1 in the bleomycin plus stem cell group was higher than the bleomycin group [(1.95 +- 0.58) vs (0.79 +- 0.71), P &lt; 0.05], but there was no difference between the control group and the stem cell group [(1.10 +- 0.72) vs (1.32 +- 0.58), P &gt; 0.05].	Bleomycin	32-41	tissue inhibitor of metalloproteinase 1	Mus musculus	18-24
24273579-10	2013	AQP5 mRNA in bleomycin 1 w and 2 w group decreased by 78% and 66%, respectively (p &lt; 0.05).	Bleomycin	13-22	aquaporin 5	Mus musculus	0-4
24507390-15	2013	The expression of TIMP-1 in the bleomycin plus stem cell group was higher than the bleomycin group [(1.95 +- 0.58) vs (0.79 +- 0.71), P &lt; 0.05], but there was no difference between the control group and the stem cell group [(1.10 +- 0.72) vs (1.32 +- 0.58), P &gt; 0.05].	Bleomycin	83-92	tissue inhibitor of metalloproteinase 1	Mus musculus	18-24
24148527-3	2013	In patients with mild or moderate BIP, radiological signs disappear almost completely within nine months after discontinuation of bleomycin treatment.	Bleomycin	130-139	heat shock protein family A (Hsp70) member 5	Homo sapiens	34-37
24507391-13	2013	CONCLUSION: 1, 25 (OH) 2D3 was shown to reduce pulmonary fibrosis induced by bleomycin in mice, and its mechanisms might be associated with Wnt signaling suppression.	Bleomycin	77-86	wingless-type MMTV integration site family, member 3A	Mus musculus	140-143
23924232-9	2013	Foxd1 progenitor-derived pericytes expand after bleomycin lung injury, and activate expression of collagen-I(alpha)1 and the myofibroblast marker alphaSMA in fibrotic foci.	Bleomycin	48-57	forkhead box D1	Mus musculus	0-5
24113008-4	2013	The aim of this study is to investigates the expression of peptide transporter 2 (PEPT2) mRNA in the lungs of rats with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	120-129	solute carrier family 15 member 2	Rattus norvegicus	59-80
24113008-4	2013	The aim of this study is to investigates the expression of peptide transporter 2 (PEPT2) mRNA in the lungs of rats with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	120-129	solute carrier family 15 member 2	Rattus norvegicus	82-87
24113008-4	2013	The aim of this study is to investigates the expression of peptide transporter 2 (PEPT2) mRNA in the lungs of rats with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	131-134	solute carrier family 15 member 2	Rattus norvegicus	59-80
24113008-4	2013	The aim of this study is to investigates the expression of peptide transporter 2 (PEPT2) mRNA in the lungs of rats with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	131-134	solute carrier family 15 member 2	Rattus norvegicus	82-87
24103846-4	2013	METHODS: We first examined mice that express alphaSMA promoter upstream of GFP reporter treated with A12, a blocking antibody to IGF-1 receptor, after bleomycin induced lung injury.	Bleomycin	151-160	actin alpha 2, smooth muscle, aorta	Mus musculus	45-53
24103846-6	2013	RESULTS: After bleomycin injury, we found decreased number of alphaSMA-GFP + cells in A12 treated mice, validated by alphaSMA immunofluorescent staining.	Bleomycin	15-24	actin alpha 2, smooth muscle, aorta	Mus musculus	62-70
24103846-6	2013	RESULTS: After bleomycin injury, we found decreased number of alphaSMA-GFP + cells in A12 treated mice, validated by alphaSMA immunofluorescent staining.	Bleomycin	15-24	actin alpha 2, smooth muscle, aorta	Mus musculus	117-125
23642017-0	2013	Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	59-68	PTK2 protein tyrosine kinase 2	Mus musculus	24-45
24012780-0	2013	Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models.	Bleomycin	76-85	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	0-26
23924348-7	2013	Wild-type mice were treated with recombinant human syndecan-2 during the fibrotic phase of bleomycin-induced lung injury.	Bleomycin	91-100	syndecan 2	Homo sapiens	51-61
23979427-6	2013	Nuclei and cytoplasm of epithelial cells in day 3 and day 7 models of bleomycin-injured lung showed survivin-positive results, which is consistent with upregulated survivin mRNA expression.	Bleomycin	70-79	baculoviral IAP repeat-containing 5	Mus musculus	100-108
23619613-5	2013	Processing of polysialylated NCAM was reproduced in a mouse model by bleomycin administration leading to an activation of the inflammasome and secretion of interleukin (IL)-1beta.	Bleomycin	69-78	neural cell adhesion molecule 1	Mus musculus	29-33
23619613-5	2013	Processing of polysialylated NCAM was reproduced in a mouse model by bleomycin administration leading to an activation of the inflammasome and secretion of interleukin (IL)-1beta.	Bleomycin	69-78	interleukin 1 beta	Mus musculus	156-178
24175745-4	2013	Mice with LPAR1 knockout or tissue-specific ATX deletion have demonstrated reduced lung fibrosis following bleomycin challenge.	Bleomycin	107-116	lysophosphatidic acid receptor 1	Mus musculus	10-15
24175745-4	2013	Mice with LPAR1 knockout or tissue-specific ATX deletion have demonstrated reduced lung fibrosis following bleomycin challenge.	Bleomycin	107-116	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	44-47
24212843-13	2013	Skin and lung fibrosis was induced, and the levels of ET-1 in the plasma, skin and lungs were elevated in bleomycin-injected mice.	Bleomycin	106-115	DNA segment, Chr 9, MRC UK Mouse Genome Centre 40 expressed	Mus musculus	54-58
24212843-16	2013	Crocetin alleviates skin and lung fibrosis in a bleomycin-induced SSc mouse model, in part due to a reduction in ET-1.	Bleomycin	48-57	DNA segment, Chr 9, MRC UK Mouse Genome Centre 40 expressed	Mus musculus	113-117
23979427-6	2013	Nuclei and cytoplasm of epithelial cells in day 3 and day 7 models of bleomycin-injured lung showed survivin-positive results, which is consistent with upregulated survivin mRNA expression.	Bleomycin	70-79	baculoviral IAP repeat-containing 5	Mus musculus	164-172
23979427-10	2013	Bleomycin stimulation in both epithelial cell lines upregulated expression of survivin and apoptosis-related molecules.	Bleomycin	0-9	baculoviral IAP repeat-containing 5	Mus musculus	78-86
23979427-11	2013	Suppression of survivin expression with small interfering RNA rendered human lung epithelial cells susceptible to bleomycin-induced damage, with markedly upregulated activation of caspase-3, caspase-7, poly (ADP-ribose) polymerase, and lactate dehydrogenase activity and an increased number of dead cells compared with mock small interfering RNA-treated cells.	Bleomycin	114-123	baculoviral IAP repeat-containing 5	Mus musculus	15-23
23979427-12	2013	Overexpression of survivin via transfection resulted in these epithelial cells being resistant to bleomycin-induced cell damage, with reduced activation of apoptosis-related molecules and lactate dehydrogenase activity and fewer dead cells compared with results for mock-transfected cells.	Bleomycin	98-107	baculoviral IAP repeat-containing 5	Mus musculus	18-26
23896988-5	2013	We show that tissue damage caused by dextran sulfate sodium feeding stimulates dMyc expression via the Hpo pathway, whereas bleomycin feeding activates dMyc through the JAK-STAT and EGFR pathways.	Bleomycin	124-133	Myc	Drosophila melanogaster	152-156
24023853-7	2013	These experiments show that the expression of hMSH5 variants elicits different survival responses to anticancer drugs cisplatin, bleomycin, doxorubicin and camptothecin.	Bleomycin	129-138	mutS homolog 5	Homo sapiens	46-51
24082893-0	2013	Regulatory effect of caffeic acid phenethyl ester on type I collagen and interferon-gamma in bleomycin-induced pulmonary fibrosis in rat.	Bleomycin	93-102	interferon gamma	Rattus norvegicus	73-89
24082893-7	2013	Accordingly, the aim of the present study was to investigate the regulatory effects of CAPE on the levels of type I collagen (COL-1) and Interferon-gamma (IFN-gamma) in bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	169-178	interferon gamma	Rattus norvegicus	137-153
24082893-7	2013	Accordingly, the aim of the present study was to investigate the regulatory effects of CAPE on the levels of type I collagen (COL-1) and Interferon-gamma (IFN-gamma) in bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	169-178	interferon gamma	Rattus norvegicus	155-164
24063588-14	2013	MicroRNA-21 was significantly upregulated in isolated lung epithelial cells during bleomycin-induced lung fibrosis and human idiopathic pulmonary fibrosis.	Bleomycin	83-92	microRNA 21	Homo sapiens	0-11
23902766-6	2013	Also, MMP-1 promoted MLE12 cell migration through collagen I, accelerated wound closing, and protected cells from staurosporine- and bleomycin-induced apoptosis compared with mock cells (p &lt; 0.01).	Bleomycin	133-142	matrix metallopeptidase 13	Mus musculus	6-11
23642129-6	2013	Bleomycin-exposed GzmB(-/-) mice exhibited greater morbidity and mortality, which was associated with increased numbers of lung lymphocytes.	Bleomycin	0-9	granzyme B	Mus musculus	18-22
23642129-7	2013	Bleomycin induced an equal increase in CD4(+)/CD25(+)/FoxP3(+) Treg populations in WT and GzmB(-/-) mice.	Bleomycin	0-9	CD4 antigen	Mus musculus	39-42
23642129-7	2013	Bleomycin induced an equal increase in CD4(+)/CD25(+)/FoxP3(+) Treg populations in WT and GzmB(-/-) mice.	Bleomycin	0-9	forkhead box P3	Mus musculus	54-59
23642129-7	2013	Bleomycin induced an equal increase in CD4(+)/CD25(+)/FoxP3(+) Treg populations in WT and GzmB(-/-) mice.	Bleomycin	0-9	granzyme B	Mus musculus	90-94
23642129-9	2013	The expression of GzmB in NK cells of bleomycin-exposed WT mice was associated with greater lymphocyte apoptosis, reduced total lymphocyte numbers, and reduced pathology relative to GzmB(-/-) mice.	Bleomycin	38-47	granzyme B	Mus musculus	18-22
23642129-10	2013	Our data demonstrate that GzmB deficiency results in the exacerbation of lymphocytic inflammation during bleomycin-induced acute lung injury, which is associated with pathology, morbidity, and mortality.	Bleomycin	105-114	granzyme B	Mus musculus	26-30
23896988-5	2013	We show that tissue damage caused by dextran sulfate sodium feeding stimulates dMyc expression via the Hpo pathway, whereas bleomycin feeding activates dMyc through the JAK-STAT and EGFR pathways.	Bleomycin	124-133	hopscotch	Drosophila melanogaster	169-172
23987664-4	2013	We identified 11 microRNAs, including miR-21 and miR-34a, to be significantly differentially expressed (P &lt; 0.01) in lungs of bleomycin treated mice and confirmed these data with real time PCR measurements.	Bleomycin	129-138	microRNA 21a	Mus musculus	38-44
24327935-2	2013	We have recently described the molecular mechanisms whereby bleomycin can 1) promote endoplasmic reticulum stress, causing the immunogenic death of cancer cells and hence strengthening antitumor CD8+ T cell responses; and 2) induce the secretion of transforming growth factor beta (TGFbeta), which stimulates regulatory T cells.	Bleomycin	60-69	transforming growth factor beta 1	Homo sapiens	249-280
24327935-2	2013	We have recently described the molecular mechanisms whereby bleomycin can 1) promote endoplasmic reticulum stress, causing the immunogenic death of cancer cells and hence strengthening antitumor CD8+ T cell responses; and 2) induce the secretion of transforming growth factor beta (TGFbeta), which stimulates regulatory T cells.	Bleomycin	60-69	transforming growth factor beta 1	Homo sapiens	282-289
23656969-0	2013	Diallylsulfide attenuates excessive collagen production and apoptosis in a rat model of bleomycin induced pulmonary fibrosis through the involvement of protease activated receptor-2.	Bleomycin	88-97	F2R like trypsin receptor 1	Rattus norvegicus	152-181
23656969-6	2013	Bleomycin induced ROS levels may prompt to induce the expression of PAR-2 as well as extracellular matrix proteins (ECM), such as MMP 2 and 9, collagen specific proteins HSP-47, alpha-SMA, and cytokines IL-6, and IL-8RA.	Bleomycin	0-9	F2R like trypsin receptor 1	Rattus norvegicus	68-73
23656969-6	2013	Bleomycin induced ROS levels may prompt to induce the expression of PAR-2 as well as extracellular matrix proteins (ECM), such as MMP 2 and 9, collagen specific proteins HSP-47, alpha-SMA, and cytokines IL-6, and IL-8RA.	Bleomycin	0-9	interleukin 6	Rattus norvegicus	203-207
23656969-6	2013	Bleomycin induced ROS levels may prompt to induce the expression of PAR-2 as well as extracellular matrix proteins (ECM), such as MMP 2 and 9, collagen specific proteins HSP-47, alpha-SMA, and cytokines IL-6, and IL-8RA.	Bleomycin	0-9	C-X-C motif chemokine receptor 1	Rattus norvegicus	213-219
24011153-0	2013	[Effect of compound panax notoginsenoside granules on TGF-beta1/Smads signaling pathway in rats with bleomycin-induced pulmonary fibrosis].	Bleomycin	101-110	transforming growth factor, beta 1	Rattus norvegicus	54-63
23987664-4	2013	We identified 11 microRNAs, including miR-21 and miR-34a, to be significantly differentially expressed (P &lt; 0.01) in lungs of bleomycin treated mice and confirmed these data with real time PCR measurements.	Bleomycin	129-138	microRNA 34a	Mus musculus	49-56
23987664-8	2013	The relevance of the IGF-1 pathway in this model was then demonstrated by showing lung tissue of bleomycin treated C57BL/6J mice had increased expression of Igf1 and that increased numbers of Igf-1 positive cells, predominantly in macrophages, were detected in the lungs.	Bleomycin	97-106	insulin-like growth factor 1	Mus musculus	21-26
23987664-8	2013	The relevance of the IGF-1 pathway in this model was then demonstrated by showing lung tissue of bleomycin treated C57BL/6J mice had increased expression of Igf1 and that increased numbers of Igf-1 positive cells, predominantly in macrophages, were detected in the lungs.	Bleomycin	97-106	insulin-like growth factor 1	Mus musculus	157-161
23987664-8	2013	The relevance of the IGF-1 pathway in this model was then demonstrated by showing lung tissue of bleomycin treated C57BL/6J mice had increased expression of Igf1 and that increased numbers of Igf-1 positive cells, predominantly in macrophages, were detected in the lungs.	Bleomycin	97-106	insulin-like growth factor 1	Mus musculus	192-197
23927729-5	2013	Fibroblasts of bleomycin-injured lungs and saline-treated lungs were shown to be enriched in linneg Sca-1high, and myofibroblasts of bleomycin-injured lungs were shown to be enriched in linneg Sca-1low CD49ehigh.	Bleomycin	15-24	ataxin 1	Homo sapiens	100-105
23797032-6	2013	We also report that ChlR1-depleted cells display defects in the repair of double-strand breaks induced by the I-PpoI endonuclease and bleomycin.	Bleomycin	134-143	DEAD/H-box helicase 11	Homo sapiens	20-25
23967208-3	2013	After naphthalene, ozone or bleomycin-induced airway epithelial injury, surviving epithelial cells secrete Wnt7b which then activates the PSMC niche to induce Fgf10 expression.	Bleomycin	28-37	wingless-type MMTV integration site family, member 7B	Mus musculus	107-112
23967208-3	2013	After naphthalene, ozone or bleomycin-induced airway epithelial injury, surviving epithelial cells secrete Wnt7b which then activates the PSMC niche to induce Fgf10 expression.	Bleomycin	28-37	fibroblast growth factor 10	Mus musculus	159-164
23967234-0	2013	Amniotic fluid stem cells inhibit the progression of bleomycin-induced pulmonary fibrosis via CCL2 modulation in bronchoalveolar lavage.	Bleomycin	53-62	C-C motif chemokine ligand 2	Homo sapiens	94-98
23967234-8	2013	CCL2 expression increased in bleomycin-injured bronchoalveolar lavage (BAL), but significantly decreased following AFSC treatment at either day 0 or at day 14.	Bleomycin	29-38	C-C motif chemokine ligand 2	Homo sapiens	0-4
23759512-6	2013	Oral administration of 200 mg/kg per day Brd4 inhibitor JQ1 in a therapeutic dosing regimen substantially attenuated lung fibrosis induced by bleomycin in C57BL/6 mice.	Bleomycin	142-151	bromodomain containing 4	Mus musculus	41-45
23940685-2	2013	We and others have previously shown that Scgb1a1-expressing cells, most likely Clara cells, can give rise to newly generated alveolar type 2 cells (AT2s) in response to severe lung damage induced by either influenza virus infection or bleomycin treatment.	Bleomycin	235-244	secretoglobin family 1A member 1	Homo sapiens	41-48
23759512-7	2013	In conclusion, this study shows that the Brd4 inhibitor JQ1, administered in a therapeutic dosage, is capable of inhibiting the profibrotic effects of IPF LFs and attenuates bleomycin-induced lung fibrosis in mice.	Bleomycin	174-183	bromodomain containing 4	Mus musculus	41-45
23400328-1	2013	T helper 17 (Th17) cells that produce interleukin (IL)-17A and IL-17F have been found to participate in the development of bronchial asthma and bleomycin-induced pulmonary fibrosis.	Bleomycin	144-153	interleukin 17F	Homo sapiens	63-69
23526226-1	2013	In addition to its expression in stem cells and many cancers, telomerase activity is transiently induced in murine bleomycin (BLM)-induced pulmonary fibrosis with increased levels of telomerase transcriptase (TERT) expression, which is essential for fibrosis.	Bleomycin	115-124	telomerase reverse transcriptase	Mus musculus	183-207
23526226-1	2013	In addition to its expression in stem cells and many cancers, telomerase activity is transiently induced in murine bleomycin (BLM)-induced pulmonary fibrosis with increased levels of telomerase transcriptase (TERT) expression, which is essential for fibrosis.	Bleomycin	126-129	telomerase reverse transcriptase	Mus musculus	183-207
23526226-1	2013	In addition to its expression in stem cells and many cancers, telomerase activity is transiently induced in murine bleomycin (BLM)-induced pulmonary fibrosis with increased levels of telomerase transcriptase (TERT) expression, which is essential for fibrosis.	Bleomycin	126-129	telomerase reverse transcriptase	Mus musculus	209-213
23672275-0	2013	Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6.	Bleomycin	0-9	mucin 1, cell surface associated	Homo sapiens	74-78
23672275-3	2013	OBJECTIVES: This study aims to investigate the therapeutic effects and mechanisms of anti-KL-6 antibody on bleomycin-induced pulmonary fibrosis.	Bleomycin	107-116	mucin 1, cell surface associated	Homo sapiens	90-94
23672275-9	2013	RESULTS: Anti-KL-6 antibody significantly reduced the number of alveolar inflammatory leukocytes (total and differential counts) in BALF of mice with bleomycin-induced pulmonary fibrosis as well as the content of hydroxyproline in the lung tissues.	Bleomycin	150-159	mucin 1, cell surface associated	Homo sapiens	14-18
23739922-4	2013	Elevated expression of PAR-3, but not PAR-4, was detected in the lungs of idiopathic pulmonary fibrosis (IPF) patients and in bleomycin-induced lung fibrosis in mice.	Bleomycin	126-135	coagulation factor II thrombin receptor like 2	Homo sapiens	23-28
23708668-1	2013	Bleomycin hydrolase (BLH) affects bleomycin chemotherapy through inactivation of bleomycin with deamination.	Bleomycin	34-43	bleomycin hydrolase	Homo sapiens	0-19
23708668-1	2013	Bleomycin hydrolase (BLH) affects bleomycin chemotherapy through inactivation of bleomycin with deamination.	Bleomycin	34-43	bleomycin hydrolase	Homo sapiens	21-24
23708668-1	2013	Bleomycin hydrolase (BLH) affects bleomycin chemotherapy through inactivation of bleomycin with deamination.	Bleomycin	81-90	bleomycin hydrolase	Homo sapiens	0-19
23708668-1	2013	Bleomycin hydrolase (BLH) affects bleomycin chemotherapy through inactivation of bleomycin with deamination.	Bleomycin	81-90	bleomycin hydrolase	Homo sapiens	21-24
23708668-4	2013	In the present study, we showed that the levels of BLH were significantly reduced during apoptosis induced by the antitumor agents bleomycin, etoposide and hydroxycamptothecin, and inhibited by the caspase inhibitors Q-VD-oph and Z-DEVD-FMK.	Bleomycin	131-140	bleomycin hydrolase	Homo sapiens	51-54
23657402-6	2013	Similar to human SSc, the expression of miR-21 increased in the bleomycin induced skin fibrosis.	Bleomycin	64-73	microRNA 21	Homo sapiens	40-46
23856246-5	2013	Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation.	Bleomycin	192-201	tumor protein p53	Homo sapiens	97-101
24067367-0	2013	Genetic ablation of caveolin-2 sensitizes mice to bleomycin-induced injury.	Bleomycin	50-59	caveolin 2	Mus musculus	20-30
24067367-7	2013	Treatment of wild-type mice with the pulmonary fibrosis-inducer bleomycin reduced the expression of Cav-2 and its phosphorylation at tyrosine 19.	Bleomycin	64-73	caveolin 2	Mus musculus	100-105
24067367-8	2013	Importantly, Cav-2(-/-) mice, but not Cav-1(-/-) mice, were more sensitive to bleomycin-induced lung injury in comparison to wild-type mice.	Bleomycin	78-87	caveolin 2	Mus musculus	13-18
24067367-10	2013	The lung injury observed in bleomycin-treated Cav-2(-/-) mice was not associated with alterations in the TGF-beta signaling pathway and/or in the ability to produce collagen.	Bleomycin	28-37	caveolin 2	Mus musculus	46-51
24067367-11	2013	However, apoptosis and proliferation were more prominent in lungs of bleomycin-treated Cav-2(-/-) mice.	Bleomycin	69-78	caveolin 2	Mus musculus	87-92
24067367-12	2013	Since Cav-1(-/-) mice also lack Cav-2 expression and show a different outcome after bleomycin treatment, we conclude that Cav-1 and Cav-2 have distinct roles in bleomycin induced-lung fibrosis, and that the balance of both proteins determines the development of the fibrotic process.	Bleomycin	161-170	caveolin 1, caveolae protein	Mus musculus	122-127
23856246-5	2013	Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation.	Bleomycin	192-201	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	103-107
24067367-12	2013	Since Cav-1(-/-) mice also lack Cav-2 expression and show a different outcome after bleomycin treatment, we conclude that Cav-1 and Cav-2 have distinct roles in bleomycin induced-lung fibrosis, and that the balance of both proteins determines the development of the fibrotic process.	Bleomycin	161-170	caveolin 2	Mus musculus	132-137
23856246-5	2013	Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation.	Bleomycin	192-201	ATPase family AAA domain containing 5	Homo sapiens	120-125
23470623-0	2013	Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis.	Bleomycin	103-112	MAP kinase-activated protein kinase 2	Mus musculus	31-90
23526221-8	2013	We observed significant up-regulation of IL-1beta and IL-6 in bronchoalveolar lavage fluid (BALF) in bleomycin-induced lung fibrosis in vivo.	Bleomycin	101-110	interleukin 1 beta	Homo sapiens	41-49
23526221-8	2013	We observed significant up-regulation of IL-1beta and IL-6 in bronchoalveolar lavage fluid (BALF) in bleomycin-induced lung fibrosis in vivo.	Bleomycin	101-110	interleukin 6	Homo sapiens	54-58
23526221-9	2013	Importantly, primary fibrotic ATII cells isolated from lungs subjected to bleomycin secreted enhanced IL-1beta and IL-6 in vitro.	Bleomycin	74-83	interleukin 1 beta	Homo sapiens	102-110
23470623-4	2013	In the murine bleomycin model of pulmonary fibrosis, we observed robust, activated MK2 expression on Day 7 (prefibrotic stage) and Day 14 (postfibrotic stage).	Bleomycin	14-23	MAP kinase-activated protein kinase 2	Mus musculus	83-86
23526221-9	2013	Importantly, primary fibrotic ATII cells isolated from lungs subjected to bleomycin secreted enhanced IL-1beta and IL-6 in vitro.	Bleomycin	74-83	interleukin 6	Homo sapiens	115-119
23386420-7	2013	The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level.	Bleomycin	44-53	caspase 3	Homo sapiens	131-148
23665346-2	2013	We used a mouse model of bleomycin (BLM)-induced lung injury to understand the involvement of p53-mediated changes in urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) levels in the regulation of alveolar epithelial injury.	Bleomycin	25-34	transformation related protein 53, pseudogene	Mus musculus	94-97
23665346-2	2013	We used a mouse model of bleomycin (BLM)-induced lung injury to understand the involvement of p53-mediated changes in urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) levels in the regulation of alveolar epithelial injury.	Bleomycin	25-34	plasminogen activator, urokinase	Mus musculus	118-154
23665346-2	2013	We used a mouse model of bleomycin (BLM)-induced lung injury to understand the involvement of p53-mediated changes in urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) levels in the regulation of alveolar epithelial injury.	Bleomycin	25-34	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	165-198
23665346-2	2013	We used a mouse model of bleomycin (BLM)-induced lung injury to understand the involvement of p53-mediated changes in urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) levels in the regulation of alveolar epithelial injury.	Bleomycin	36-39	transformation related protein 53, pseudogene	Mus musculus	94-97
23583295-9	2013	The significantly increased binding of p65 and c-Jun to the CCL2 promoter was also observed in the lung tissue of bleomycin-induced pulmonary fibrosis murine model.	Bleomycin	114-123	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	39-42
23583295-9	2013	The significantly increased binding of p65 and c-Jun to the CCL2 promoter was also observed in the lung tissue of bleomycin-induced pulmonary fibrosis murine model.	Bleomycin	114-123	jun proto-oncogene	Mus musculus	47-52
23583295-9	2013	The significantly increased binding of p65 and c-Jun to the CCL2 promoter was also observed in the lung tissue of bleomycin-induced pulmonary fibrosis murine model.	Bleomycin	114-123	chemokine (C-C motif) ligand 2	Mus musculus	60-64
23386420-6	2013	Incubation with bleomycin (LD50 ) and H2O2 for 24 h increased Caspase-3, -8, -9 activities, Cyt-c and Bax levels and decreased Bcl-2 levels.	Bleomycin	16-25	caspase 3	Homo sapiens	62-79
23386420-6	2013	Incubation with bleomycin (LD50 ) and H2O2 for 24 h increased Caspase-3, -8, -9 activities, Cyt-c and Bax levels and decreased Bcl-2 levels.	Bleomycin	16-25	BCL2 associated X, apoptosis regulator	Homo sapiens	102-105
23386420-6	2013	Incubation with bleomycin (LD50 ) and H2O2 for 24 h increased Caspase-3, -8, -9 activities, Cyt-c and Bax levels and decreased Bcl-2 levels.	Bleomycin	16-25	BCL2 apoptosis regulator	Homo sapiens	127-132
23386420-7	2013	The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level.	Bleomycin	44-53	BCL2 associated X, apoptosis regulator	Homo sapiens	161-164
23386420-7	2013	The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level.	Bleomycin	44-53	BCL2 apoptosis regulator	Homo sapiens	223-228
23386420-7	2013	The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level.	Bleomycin	93-102	caspase 3	Homo sapiens	131-148
23386420-7	2013	The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level.	Bleomycin	93-102	BCL2 associated X, apoptosis regulator	Homo sapiens	161-164
23386420-7	2013	The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level.	Bleomycin	93-102	BCL2 apoptosis regulator	Homo sapiens	223-228
23386420-7	2013	The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level.	Bleomycin	93-102	caspase 3	Homo sapiens	131-148
23386420-7	2013	The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level.	Bleomycin	93-102	BCL2 associated X, apoptosis regulator	Homo sapiens	161-164
23386420-7	2013	The concurrent incubation of NT2 cells with bleomycin/H2O2 and NAC (5 mM) for 24 h abolished bleomycin/H2O2-dependent increases in Caspase-3, -8, -9 activities, Bax and Cyt-c levels and bleomycin/H2O2-dependent decrease in Bcl-2 level.	Bleomycin	93-102	BCL2 apoptosis regulator	Homo sapiens	223-228
23840329-11	2013	In vivo experiments showed that HGF-expressing BMSC attenuated bleomycin induced pulmonary fibrosis in the rat, indicating a beneficial role of bone marrow derived, HGF secreting stem cells in lung fibrosis.	Bleomycin	63-72	hepatocyte growth factor	Rattus norvegicus	32-35
23696313-0	2013	Kinetics of nuclear phosphorylation (gamma-H2AX) in human lymphocytes treated in vitro with UVB, bleomycin and mitomycin C.	Bleomycin	97-106	H2A.X variant histone	Homo sapiens	43-47
23570914-0	2013	Suppression of nuclear factor erythroid 2-related factor 2 via extracellular signal-regulated kinase contributes to bleomycin-induced oxidative stress and fibrogenesis.	Bleomycin	116-125	nuclear factor, erythroid derived 2, like 2	Mus musculus	15-58
23570914-3	2013	Treatment of C57 BL/6 mice with bleomycin increased fibroblast viability and collagen production and significantly downregulated Nrf2.	Bleomycin	32-41	nuclear factor, erythroid derived 2, like 2	Mus musculus	129-133
23570914-5	2013	In a cell-based model, bleomycin suppressed Nrf2 activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.	Bleomycin	23-32	nuclear factor, erythroid derived 2, like 2	Mus musculus	44-48
23570914-6	2013	To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.	Bleomycin	35-44	nuclear factor, erythroid derived 2, like 2	Mus musculus	94-98
23570914-6	2013	To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.	Bleomycin	35-44	nuclear factor, erythroid derived 2, like 2	Mus musculus	182-186
23570914-6	2013	To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.	Bleomycin	135-144	nuclear factor, erythroid derived 2, like 2	Mus musculus	94-98
23570914-6	2013	To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.	Bleomycin	135-144	nuclear factor, erythroid derived 2, like 2	Mus musculus	182-186
23570914-6	2013	To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.	Bleomycin	135-144	nuclear factor, erythroid derived 2, like 2	Mus musculus	94-98
23570914-6	2013	To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.	Bleomycin	135-144	nuclear factor, erythroid derived 2, like 2	Mus musculus	182-186
23677473-8	2013	In a murine model of acute respiratory distress syndrome, aspirated bleomycin induces a significant increase in the number of neutrophils in the lungs after 3 d. Oropharyngeal aspiration of DPPIV inhibits the bleomycin-induced accumulation of mouse neutrophils.	Bleomycin	68-77	dipeptidylpeptidase 4	Mus musculus	190-195
23677473-8	2013	In a murine model of acute respiratory distress syndrome, aspirated bleomycin induces a significant increase in the number of neutrophils in the lungs after 3 d. Oropharyngeal aspiration of DPPIV inhibits the bleomycin-induced accumulation of mouse neutrophils.	Bleomycin	209-218	dipeptidylpeptidase 4	Mus musculus	190-195
23840329-13	2013	Since HGF-transfected BMSC reduce bleomycin induced lung fibrosis in the bleomycin lung injury and fibrosis model, we assume that HGF-expressing, bone-marrow derived stem cells in UIP have antifibrotic properties.	Bleomycin	34-43	hepatocyte growth factor	Rattus norvegicus	6-9
23840329-13	2013	Since HGF-transfected BMSC reduce bleomycin induced lung fibrosis in the bleomycin lung injury and fibrosis model, we assume that HGF-expressing, bone-marrow derived stem cells in UIP have antifibrotic properties.	Bleomycin	73-82	hepatocyte growth factor	Rattus norvegicus	6-9
23562440-7	2013	In a model of bleomycin-induced skin fibrosis, Nfkb1(-/-) and c-Rel(-/-) mice displayed opposite phenotypes, with c-Rel(-/-) mice being protected and Nfkb1(-/-) developing more fibrosis than wild-type mice.	Bleomycin	14-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	47-52
23590642-0	2013	14-3-3epsilon boosts bleomycin-induced DNA damage response by inhibiting the drug-resistant activity of MVP.	Bleomycin	21-30	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	Homo sapiens	0-13
23527830-8	2013	RESULTS: Compared with controls, Bleomycin increased RVSP, RV/(LV+S), BNP levels, HPC and CTGF transcription and decreased LC significantly.	Bleomycin	33-42	natriuretic peptide B	Rattus norvegicus	70-73
23527830-8	2013	RESULTS: Compared with controls, Bleomycin increased RVSP, RV/(LV+S), BNP levels, HPC and CTGF transcription and decreased LC significantly.	Bleomycin	33-42	cellular communication network factor 2	Rattus norvegicus	90-94
23758685-0	2013	Expression profiling of genes regulated by Fra-1/AP-1 transcription factor during bleomycin-induced pulmonary fibrosis.	Bleomycin	82-91	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	43-48
23758685-0	2013	Expression profiling of genes regulated by Fra-1/AP-1 transcription factor during bleomycin-induced pulmonary fibrosis.	Bleomycin	82-91	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	49-53
23758685-2	2013	We recently demonstrated that loss of Fra-1 leads to exacerbated bleomycin-induced pulmonary fibrosis, accompanied by enhanced expression of various inflammatory and fibrotic genes.	Bleomycin	65-74	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	38-43
23758685-3	2013	To better understand the molecular mechanisms by which Fra-1 confers protection during bleomycin-induced lung injury, genome-wide mRNA expression profiling was performed.	Bleomycin	87-96	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	55-60
23371063-7	2013	After bleomycin injury in the adult lung, there are abundant Gli1(nlacZ)-positive mesenchymal cells in fibrotic lesions and increased numbers of Gli1(nlacZ)-positive cells in preserved alveolar septa.	Bleomycin	6-15	GLI-Kruppel family member GLI1	Mus musculus	61-65
23562440-7	2013	In a model of bleomycin-induced skin fibrosis, Nfkb1(-/-) and c-Rel(-/-) mice displayed opposite phenotypes, with c-Rel(-/-) mice being protected and Nfkb1(-/-) developing more fibrosis than wild-type mice.	Bleomycin	14-23	reticuloendotheliosis oncogene	Mus musculus	62-67
23585227-0	2013	Regulation of myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by adrenomedullin.	Bleomycin	48-57	adrenomedullin	Homo sapiens	88-102
23518201-3	2013	Selenium"s ability to alter the phosphorylation of the H2AX, a histone protein that functions in the reduction of DNA damage by recruiting repair proteins to the damage site, following exposure to ionizing radiation and bleomycin was investigated.	Bleomycin	220-229	H2A.X variant histone	Homo sapiens	55-59
23585227-8	2013	CRLR expression was also dramatically increased in lungs from bleomycin-treated mice.	Bleomycin	62-71	calcitonin receptor-like	Mus musculus	0-4
23585227-10	2013	Finally, sensitization of ADM signaling by transgenic overexpression of RAMP2 in myofibroblasts resulted in enhanced survival and reduced pulmonary fibrosis in the bleomycin model of the disease.	Bleomycin	164-173	receptor activity modifying protein 2	Homo sapiens	72-77
23161903-7	2013	Dnam1-/- mice were protected from bleomycin-induced dermal fibrosis with reduction of dermal thickening (75+-5%, p=0.03), hydroxyproline content (46+-8%, p=0.04) and myofibroblast counts (39+-5%, p=0.01).	Bleomycin	34-43	CD226 antigen	Mus musculus	0-5
23161903-10	2013	Consistent with the gene inactivation strategy, treatment of mice with DNAM-1 neutralising mAb prevented dermal fibrosis induced by bleomycin with reduction of dermal thickness (64+-6%, p=0.002), hydroxyproline content (61+-8%, p=0.004) and myofibroblast counts (83+-12%, p=0.002).	Bleomycin	132-141	CD226 antigen	Mus musculus	71-77
23518201-4	2013	METHODS: Human cell lines that were either exposed to selenium or were transfected with a GPx-1 expression construct were exposed to ionizing radiation or bleomycin.	Bleomycin	155-164	glutathione peroxidase 1	Homo sapiens	90-95
23457217-14	2013	Finally, we found that miR-145(-/-) mice are protected from bleomycin-induced pulmonary fibrosis.	Bleomycin	60-69	microRNA 145a	Mus musculus	23-30
23457217-16	2013	miR-145 deficiency is protective against bleomycin-induced lung fibrosis, suggesting that miR-145 may be a potential target in the development of novel therapies to treat pathological fibrotic disorders.	Bleomycin	41-50	microRNA 145a	Mus musculus	0-7
23457217-16	2013	miR-145 deficiency is protective against bleomycin-induced lung fibrosis, suggesting that miR-145 may be a potential target in the development of novel therapies to treat pathological fibrotic disorders.	Bleomycin	41-50	microRNA 145a	Mus musculus	90-97
23401096-0	2013	Essential role of stem cell factor-c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis.	Bleomycin	63-72	KIT ligand	Homo sapiens	18-34
23401096-0	2013	Essential role of stem cell factor-c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis.	Bleomycin	63-72	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	35-40
23001851-8	2013	Concurrent use of curcumin with bleomycin decreased caspase activities and Bax and Cyt-c levels compared to their separate effects in NCCIT cells.	Bleomycin	32-41	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78
23401096-5	2013	Fibrosis was induced by intratracheal instillation of bleomycin (BLM), which caused increased SCF levels in plasma, bronchoalveolar lavage fluid (BALF) and lung tissue, as well as increased expression by lung fibroblasts.	Bleomycin	54-63	KIT ligand	Homo sapiens	94-97
23790735-10	2013	CONCLUSIONS: The results of this study indicated that irbesartan attenuated the development of bleomycin-induced pulmonary fibrosis in mice by decreasing TGF-beta1 and MCP-1 via blocking of ATI, by binding to CCR2b, and by PPARgamma-mediated inhibition of inflammation.	Bleomycin	95-104	transforming growth factor, beta 1	Mus musculus	154-163
23435873-6	2013	In a subacute bleomycin inflammation model, SP-D levels were 4,625 and 367 ng/ml in BAL and serum, respectively, 8 days after exposure.	Bleomycin	14-23	surfactant associated protein D	Mus musculus	44-48
23746238-1	2013	OBJECTIVE: To investigate the effect of the anti-laminin receptor 1 (anti-LAMR1) monoclonal antibody (mAb) on rat pulmonary fibrosis induced by bleomycin.	Bleomycin	144-153	ribosomal protein SA	Rattus norvegicus	74-79
23746238-11	2013	CONCLUSION: LAMR1 mAb can evidently alleviate pulmonary fibrosis induced by bleomycin in rats.	Bleomycin	76-85	ribosomal protein SA	Rattus norvegicus	12-17
23523906-12	2013	Berberine inhibited the bleomycin mediated activation of inflammatory mediator nuclear factor kappa B (NF-kappaB) and suppressed its downstream target inducible nitric oxide synthase (iNOS).	Bleomycin	24-33	nitric oxide synthase 2	Rattus norvegicus	184-188
24028731-15	2013	CONCLUSION: Ang1-7 has anti-fibrous effect upon bleomycin-induced pulmonary fibrosis in rats and such an effect of Ang1-7 may be associated with AngII-induced expression of TGF-beta1.	Bleomycin	48-57	angiogenin	Rattus norvegicus	12-16
24028731-15	2013	CONCLUSION: Ang1-7 has anti-fibrous effect upon bleomycin-induced pulmonary fibrosis in rats and such an effect of Ang1-7 may be associated with AngII-induced expression of TGF-beta1.	Bleomycin	48-57	angiotensinogen	Rattus norvegicus	145-150
24028731-15	2013	CONCLUSION: Ang1-7 has anti-fibrous effect upon bleomycin-induced pulmonary fibrosis in rats and such an effect of Ang1-7 may be associated with AngII-induced expression of TGF-beta1.	Bleomycin	48-57	transforming growth factor, beta 1	Rattus norvegicus	173-182
23523906-14	2013	Taken together, this study reveals the beneficial effects of berberine against bleomycin mediated fibrotic challenge through activating Nrf2 and suppressing NF-kappaB dependent inflammatory and TGF-beta1 mediated fibrotic events.	Bleomycin	79-88	NFE2 like bZIP transcription factor 2	Rattus norvegicus	136-140
23705004-4	2013	RESULTS: The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P = 0.016), while patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P = 0.048).	Bleomycin	191-200	keratin 81	Homo sapiens	13-18
23612611-6	2013	When Hsp90 activity is blocked, ILK is ubiquitinated by CHIP and degraded by the proteasome, resulting in impaired fibroblast migration and a dramatic reduction in the fibrotic response to bleomycin in mice.	Bleomycin	189-198	heat shock protein, 3	Mus musculus	5-10
23612611-6	2013	When Hsp90 activity is blocked, ILK is ubiquitinated by CHIP and degraded by the proteasome, resulting in impaired fibroblast migration and a dramatic reduction in the fibrotic response to bleomycin in mice.	Bleomycin	189-198	integrin linked kinase	Mus musculus	32-35
23442250-4	2013	In this study, we examined the therapeutic effect of HSA-Trx on an IPF animal model of bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	87-96	thioredoxin 1	Mus musculus	57-60
23436317-0	2013	CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.	Bleomycin	67-76	CD109 antigen	Mus musculus	0-5
23436317-4	2013	The aim of the present study was to examine the ability of CD109 to prevent skin fibrosis in a mouse model of bleomycin-induced SSc.	Bleomycin	110-119	CD109 antigen	Mus musculus	59-64
23436317-5	2013	METHODS: Transgenic mice overexpressing CD109 in the epidermis and their wild-type (WT) littermates were injected with bleomycin in phosphate buffered saline (PBS) or with PBS alone every other day for 21 days or 28 days.	Bleomycin	119-128	CD109 antigen	Mus musculus	40-45
23436317-8	2013	RESULTS: Transgenic mice overexpressing CD109 in the epidermis showed resistance to bleomycin-induced skin fibrosis, as evidenced by a significant decrease in dermal thickness, collagen crosslinking, collagen and fibronectin content, and phospho-Smad2/3 levels, as compared to their WT littermates.	Bleomycin	84-93	CD109 antigen	Mus musculus	40-45
23432979-3	2013	This study examined the effect of LTC4 in LTC4 synthase-overexpressed transgenic mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	91-100	leukotriene C4 synthase	Mus musculus	42-55
23306833-5	2013	Pulmonary fibrosis was induced by instilling bleomycin intratracheally into ECE-1 heterozygous knockout mice (ECE-1(+/-)) and their wild-type control mice (ECE-1(+/+)).	Bleomycin	45-54	endothelin converting enzyme 1	Mus musculus	76-81
23487425-8	2013	Genetically deleting either Ip-10 or Mip-1alpha in Mmp-8(-/-) mice abrogates their lung inflammatory response to bleomycin, but reconstitutes their lung fibrotic response to bleomycin.	Bleomycin	113-122	chemokine (C-C motif) ligand 3	Mus musculus	37-47
23487425-8	2013	Genetically deleting either Ip-10 or Mip-1alpha in Mmp-8(-/-) mice abrogates their lung inflammatory response to bleomycin, but reconstitutes their lung fibrotic response to bleomycin.	Bleomycin	174-183	chemokine (C-X-C motif) ligand 10	Mus musculus	28-33
23487425-8	2013	Genetically deleting either Ip-10 or Mip-1alpha in Mmp-8(-/-) mice abrogates their lung inflammatory response to bleomycin, but reconstitutes their lung fibrotic response to bleomycin.	Bleomycin	174-183	chemokine (C-C motif) ligand 3	Mus musculus	37-47
23487425-9	2013	Studies of bleomycin-treated Mmp-8 bone marrow chimeric mice show that both leukocytes and lung parenchymal cells are sources of profibrotic MMP-8 during bleomycin-mediated lung fibrosis.	Bleomycin	11-20	matrix metallopeptidase 8	Mus musculus	29-34
23487425-9	2013	Studies of bleomycin-treated Mmp-8 bone marrow chimeric mice show that both leukocytes and lung parenchymal cells are sources of profibrotic MMP-8 during bleomycin-mediated lung fibrosis.	Bleomycin	11-20	matrix metallopeptidase 8	Mus musculus	141-146
23487425-9	2013	Studies of bleomycin-treated Mmp-8 bone marrow chimeric mice show that both leukocytes and lung parenchymal cells are sources of profibrotic MMP-8 during bleomycin-mediated lung fibrosis.	Bleomycin	154-163	matrix metallopeptidase 8	Mus musculus	141-146
23487425-10	2013	Thus, during bleomycin-mediated lung injury, MMP-8 dampens the lung acute inflammatory response, but promotes lung fibrosis by reducing lung levels of IP-10 and MIP-1alpha.	Bleomycin	13-22	matrix metallopeptidase 8	Mus musculus	45-50
23487425-10	2013	Thus, during bleomycin-mediated lung injury, MMP-8 dampens the lung acute inflammatory response, but promotes lung fibrosis by reducing lung levels of IP-10 and MIP-1alpha.	Bleomycin	13-22	chemokine (C-X-C motif) ligand 10	Mus musculus	151-156
23487425-10	2013	Thus, during bleomycin-mediated lung injury, MMP-8 dampens the lung acute inflammatory response, but promotes lung fibrosis by reducing lung levels of IP-10 and MIP-1alpha.	Bleomycin	13-22	chemokine (C-C motif) ligand 3	Mus musculus	161-171
23396195-9	2013	Analyses of the transplantation of sorted CD31-positive hiPSC-ECs into the bleomycin-induced SSc mouse model demonstrated that these cells participate in recovery of the damaged vessels.	Bleomycin	75-84	platelet/endothelial cell adhesion molecule 1	Mus musculus	42-46
23487425-0	2013	Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury.	Bleomycin	61-70	matrix metallopeptidase 8	Mus musculus	27-53
23487425-3	2013	Mmp-8 steady state mRNA and protein levels increase in whole lung and bronchoalveolar lavage samples when WT mice are treated with bleomycin.	Bleomycin	131-140	matrix metallopeptidase 8	Mus musculus	0-5
23487425-6	2013	Compared with bleomycin-treated WT mice, bleomycin-treated Mmp-8(-/-) mice have greater lung inflammation, but reduced lung fibrosis.	Bleomycin	41-50	matrix metallopeptidase 8	Mus musculus	59-64
23487425-7	2013	Whereas bleomycin-treated Mmp-8(-/-) and WT mice have similar lung levels of several pro- and antifibrotic mediators (TGF-beta, IL-13, JE, and IFN-gamma), Mmp-8(-/-) mice have higher lung levels of IFN-gamma-inducible protein-10 (IP-10) and MIP-1alpha.	Bleomycin	8-17	matrix metallopeptidase 8	Mus musculus	26-31
23487425-7	2013	Whereas bleomycin-treated Mmp-8(-/-) and WT mice have similar lung levels of several pro- and antifibrotic mediators (TGF-beta, IL-13, JE, and IFN-gamma), Mmp-8(-/-) mice have higher lung levels of IFN-gamma-inducible protein-10 (IP-10) and MIP-1alpha.	Bleomycin	8-17	interleukin 13	Mus musculus	128-133
23487425-7	2013	Whereas bleomycin-treated Mmp-8(-/-) and WT mice have similar lung levels of several pro- and antifibrotic mediators (TGF-beta, IL-13, JE, and IFN-gamma), Mmp-8(-/-) mice have higher lung levels of IFN-gamma-inducible protein-10 (IP-10) and MIP-1alpha.	Bleomycin	8-17	interferon gamma	Mus musculus	143-152
23487425-7	2013	Whereas bleomycin-treated Mmp-8(-/-) and WT mice have similar lung levels of several pro- and antifibrotic mediators (TGF-beta, IL-13, JE, and IFN-gamma), Mmp-8(-/-) mice have higher lung levels of IFN-gamma-inducible protein-10 (IP-10) and MIP-1alpha.	Bleomycin	8-17	chemokine (C-X-C motif) ligand 10	Mus musculus	198-228
23487425-7	2013	Whereas bleomycin-treated Mmp-8(-/-) and WT mice have similar lung levels of several pro- and antifibrotic mediators (TGF-beta, IL-13, JE, and IFN-gamma), Mmp-8(-/-) mice have higher lung levels of IFN-gamma-inducible protein-10 (IP-10) and MIP-1alpha.	Bleomycin	8-17	chemokine (C-X-C motif) ligand 10	Mus musculus	230-235
23487425-7	2013	Whereas bleomycin-treated Mmp-8(-/-) and WT mice have similar lung levels of several pro- and antifibrotic mediators (TGF-beta, IL-13, JE, and IFN-gamma), Mmp-8(-/-) mice have higher lung levels of IFN-gamma-inducible protein-10 (IP-10) and MIP-1alpha.	Bleomycin	8-17	chemokine (C-C motif) ligand 3	Mus musculus	241-251
23487425-8	2013	Genetically deleting either Ip-10 or Mip-1alpha in Mmp-8(-/-) mice abrogates their lung inflammatory response to bleomycin, but reconstitutes their lung fibrotic response to bleomycin.	Bleomycin	113-122	chemokine (C-X-C motif) ligand 10	Mus musculus	28-33
23306833-12	2013	Bleomycin instillation on Day 14 induced the accumulation of M2 macrophages expressing CGRP receptors in ECE-1(+/-) mice.	Bleomycin	0-9	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	87-91
23306833-12	2013	Bleomycin instillation on Day 14 induced the accumulation of M2 macrophages expressing CGRP receptors in ECE-1(+/-) mice.	Bleomycin	0-9	endothelin converting enzyme 1	Mus musculus	105-110
23291432-6	2013	RESULTS: Activation of PXR effectively inhibited the development of bleomycin-induced dermal fibrosis and induced the regression of established dermal fibrosis as assessed by skin thickening, hydroxyproline content and myofibroblasts.	Bleomycin	68-77	nuclear receptor subfamily 1, group I, member 2	Mus musculus	23-26
23291432-9	2013	Consistent with these findings, IL-13 levels were reduced in bleomycin-challenged murine skin upon PXR activation.	Bleomycin	61-70	interleukin 13	Mus musculus	32-37
23291432-9	2013	Consistent with these findings, IL-13 levels were reduced in bleomycin-challenged murine skin upon PXR activation.	Bleomycin	61-70	nuclear receptor subfamily 1, group I, member 2	Mus musculus	99-102
23517551-4	2013	We also showed that expression of SPARC in the lung was upregulated in the murine bleomycin-induced pulmonary fibrosis model, which was inhibited by TGF-beta receptor I inhibitor.	Bleomycin	82-91	secreted acidic cysteine rich glycoprotein	Mus musculus	34-39
23517551-4	2013	We also showed that expression of SPARC in the lung was upregulated in the murine bleomycin-induced pulmonary fibrosis model, which was inhibited by TGF-beta receptor I inhibitor.	Bleomycin	82-91	transforming growth factor, beta 1	Mus musculus	149-157
23258232-6	2013	The expression of PIR-B was assessed (by quantitative PCR and flow cytometry) after bleomycin treatment.	Bleomycin	84-93	paired Ig-like receptor B	Mus musculus	18-23
23258232-9	2013	PIR-B was up-regulated in lung myeloid cells after bleomycin administration.	Bleomycin	51-60	paired Ig-like receptor B	Mus musculus	0-5
23258232-10	2013	Bleomycin-treated Pirb(-/-) mice displayed increased lung histopathology and an increased expression of collagen and of the IL-4-associated profibrogenic markers Relm-alpha, MMP-12, TIMP-1, and osteopontin, which were localized to alveolar macrophages.	Bleomycin	0-9	paired Ig-like receptor B	Mus musculus	18-22
23258232-10	2013	Bleomycin-treated Pirb(-/-) mice displayed increased lung histopathology and an increased expression of collagen and of the IL-4-associated profibrogenic markers Relm-alpha, MMP-12, TIMP-1, and osteopontin, which were localized to alveolar macrophages.	Bleomycin	0-9	interleukin 4	Mus musculus	124-128
23258232-10	2013	Bleomycin-treated Pirb(-/-) mice displayed increased lung histopathology and an increased expression of collagen and of the IL-4-associated profibrogenic markers Relm-alpha, MMP-12, TIMP-1, and osteopontin, which were localized to alveolar macrophages.	Bleomycin	0-9	resistin like alpha	Mus musculus	162-172
23258232-10	2013	Bleomycin-treated Pirb(-/-) mice displayed increased lung histopathology and an increased expression of collagen and of the IL-4-associated profibrogenic markers Relm-alpha, MMP-12, TIMP-1, and osteopontin, which were localized to alveolar macrophages.	Bleomycin	0-9	matrix metallopeptidase 12	Mus musculus	174-180
23258232-10	2013	Bleomycin-treated Pirb(-/-) mice displayed increased lung histopathology and an increased expression of collagen and of the IL-4-associated profibrogenic markers Relm-alpha, MMP-12, TIMP-1, and osteopontin, which were localized to alveolar macrophages.	Bleomycin	0-9	tissue inhibitor of metalloproteinase 1	Mus musculus	182-188
23258232-10	2013	Bleomycin-treated Pirb(-/-) mice displayed increased lung histopathology and an increased expression of collagen and of the IL-4-associated profibrogenic markers Relm-alpha, MMP-12, TIMP-1, and osteopontin, which were localized to alveolar macrophages.	Bleomycin	0-9	secreted phosphoprotein 1	Mus musculus	194-205
23315259-0	2013	Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis.	Bleomycin	42-51	sphingosine kinase 1	Mus musculus	10-30
23315259-5	2013	Also, the expression of SphK1 was increased in lung tissues from patients with IPF and bleomycin-challenged mice.	Bleomycin	87-96	sphingosine kinase 1	Homo sapiens	24-29
23315259-6	2013	Knockdown of SphK1, but not SphK2, increased survival and resistance to pulmonary fibrosis in bleomycin-challenged mice.	Bleomycin	94-103	sphingosine kinase 1	Mus musculus	13-18
23315259-8	2013	Knockdown of SphK1 or treatment with SphK inhibitor attenuated S1P generation and TGF-beta secretion in a bleomycin-induced lung fibrosis mouse model that was accompanied by reduced phosphorylation of Smad2 and MAPKs in lung tissue.	Bleomycin	106-115	sphingosine kinase 1	Mus musculus	13-18
23315259-8	2013	Knockdown of SphK1 or treatment with SphK inhibitor attenuated S1P generation and TGF-beta secretion in a bleomycin-induced lung fibrosis mouse model that was accompanied by reduced phosphorylation of Smad2 and MAPKs in lung tissue.	Bleomycin	106-115	transforming growth factor, beta 1	Mus musculus	82-90
23315259-8	2013	Knockdown of SphK1 or treatment with SphK inhibitor attenuated S1P generation and TGF-beta secretion in a bleomycin-induced lung fibrosis mouse model that was accompanied by reduced phosphorylation of Smad2 and MAPKs in lung tissue.	Bleomycin	106-115	SMAD family member 2	Mus musculus	201-206
23315259-9	2013	In vitro, bleomycin-induced expression of SphK1 in lung fibroblast was found to be TGF-beta dependent.	Bleomycin	10-19	sphingosine kinase 1	Mus musculus	42-47
23315259-9	2013	In vitro, bleomycin-induced expression of SphK1 in lung fibroblast was found to be TGF-beta dependent.	Bleomycin	10-19	transforming growth factor, beta 1	Mus musculus	83-91
23320620-7	2013	RESULTS: Compared with BLEO-treated mice, BLEO-treated mice who received Tbeta4 did not lose as much weight and had a higher survival rate.	Bleomycin	42-46	thymosin, beta 4, X chromosome	Mus musculus	73-79
23306543-0	2013	beta-catenin in the alveolar epithelium protects from lung fibrosis after intratracheal bleomycin.	Bleomycin	88-97	catenin (cadherin associated protein), beta 1	Mus musculus	0-12
23306543-2	2013	OBJECTIVES: We aimed to determine the role of beta-catenin in alveolar epithelium during bleomycin-induced lung fibrosis.	Bleomycin	89-98	catenin (cadherin associated protein), beta 1	Mus musculus	46-58
23306543-6	2013	MEASUREMENTS AND MAIN RESULTS: Increased beta-catenin expression was noted in lung parenchyma after bleomycin.	Bleomycin	100-109	catenin (cadherin associated protein), beta 1	Mus musculus	41-53
23306543-7	2013	Mice with selective deletion of beta-catenin in AECs had greater AEC death at 1 week after bleomycin, followed by increased numbers of fibroblasts and enhanced lung fibrosis as determined by semiquantitative histological scoring and total collagen content.	Bleomycin	91-100	catenin (cadherin associated protein), beta 1	Mus musculus	32-44
23306543-9	2013	In vitro, beta-catenin-deficient AECs showed increased bleomycin-induced cytotoxicity as well as reduced proliferation and impaired wound closure.	Bleomycin	55-64	catenin (cadherin associated protein), beta 1	Mus musculus	10-22
23306543-10	2013	Consistent with these findings, mice with AEC beta-catenin deficiency showed delayed recovery after bleomycin.	Bleomycin	100-109	catenin (cadherin associated protein), beta 1	Mus musculus	46-58
23306543-11	2013	CONCLUSIONS: beta-Catenin in the alveolar epithelium protects against bleomycin-induced fibrosis.	Bleomycin	70-79	catenin (cadherin associated protein), beta 1	Mus musculus	13-25
23239499-9	2013	Genome-wide and linkage region-specific association studies revealed 11 pulmonary expressed genes (including the autophagy gene Cep55, and Masp2, which is a complement component) to contain polymorphisms significantly associated with bleomycin-induced fibrotic lung disease.	Bleomycin	234-243	centrosomal protein 55	Mus musculus	128-133
23239499-9	2013	Genome-wide and linkage region-specific association studies revealed 11 pulmonary expressed genes (including the autophagy gene Cep55, and Masp2, which is a complement component) to contain polymorphisms significantly associated with bleomycin-induced fibrotic lung disease.	Bleomycin	234-243	mannan-binding lectin serine peptidase 2	Mus musculus	139-144
23320620-0	2013	Thymosin beta4 protects C57BL/6 mice from bleomycin-induced damage in the lung.	Bleomycin	42-51	thymosin, beta 4, X chromosome	Mus musculus	0-14
23320620-8	2013	Moreover, BLEO-induced inflammation and lung damage were substantially reduced by Tbeta4 treatment, as demonstrated by the significant reduction in oedema, total collagen content, lung infiltration by leucocytes, MPO activity in lung homogenates, and histological evidence of the ongoing lung fibrosis.	Bleomycin	10-14	thymosin, beta 4, X chromosome	Mus musculus	82-88
23320620-8	2013	Moreover, BLEO-induced inflammation and lung damage were substantially reduced by Tbeta4 treatment, as demonstrated by the significant reduction in oedema, total collagen content, lung infiltration by leucocytes, MPO activity in lung homogenates, and histological evidence of the ongoing lung fibrosis.	Bleomycin	10-14	myeloperoxidase	Mus musculus	213-216
23320620-10	2013	CONCLUSIONS: This is the first report that shows a Tbeta4 protective role in lung toxicity associated with BLEO in a mouse model.	Bleomycin	107-111	thymosin, beta 4, X chromosome	Mus musculus	51-57
23306545-11	2013	Similarly, miR-17~92 expression was reduced in the lungs of bleomycin-treated mice.	Bleomycin	60-69	Mir17 host gene (non-protein coding)	Mus musculus	11-20
23658942-1	2010	APE1 is a key component of the base excision repair (BER) pathway that is responsible for repair of DNA damage caused by many anti-cancer agents such as bleomycin and temozolomide.	Bleomycin	153-162	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	0-4
23306545-12	2013	Treatment with 5"-aza-2"-deoxycytidine in a murine bleomycin-induced pulmonary fibrosis model reduced fibrotic gene and DNMT-1 expression, enhanced miR-17~92 cluster expression, and attenuated pulmonary fibrosis.	Bleomycin	51-60	DNA methyltransferase (cytosine-5) 1	Mus musculus	120-126
23306545-12	2013	Treatment with 5"-aza-2"-deoxycytidine in a murine bleomycin-induced pulmonary fibrosis model reduced fibrotic gene and DNMT-1 expression, enhanced miR-17~92 cluster expression, and attenuated pulmonary fibrosis.	Bleomycin	51-60	Mir17 host gene (non-protein coding)	Mus musculus	148-157
23207668-2	2013	OBJECTIVES: We aimed to compare the efficacy of hMSC in preventing bleomycin-induced lung injury in immunocompromised SCID and immunocompetent C57Bl/6 mice.	Bleomycin	67-76	musculin	Homo sapiens	48-52
23124680-10	2013	The alpha2AP deficiency attenuated bleomycin-induced fibrosis and PGF(2alpha) synthesis, while the administration of PGF(2alpha) to alpha2AP-deficient mice facilitated alpha2AP deficiency-attenuated fibrosis.	Bleomycin	35-44	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	4-12
23161884-2	2013	We showed previously that null mutation of Smad3, a critical node in the TGF-beta pathway, protects mice against fibrosis induced by bleomycin.	Bleomycin	133-142	SMAD family member 3	Mus musculus	43-48
23141927-5	2013	These profibrotic responses were abrogated by both genetic and pharmacological disruption of TLR4 signaling in vitro, and skin fibrosis induced by bleomycin in vivo was attenuated in mice harboring a mutated TLR4.	Bleomycin	147-156	toll-like receptor 4	Mus musculus	208-212
23784839-8	2013	Finally, exposure of spermatocytes to double strand break DNA-damaging agents such as cisplatin, bleomycin or etoposide also induced ATR relocalization and intense H2AX phosphorylation and led to anomalies in synaptonemal assembly.	Bleomycin	97-106	ataxia telangiectasia and Rad3 related	Mus musculus	133-136
23784839-8	2013	Finally, exposure of spermatocytes to double strand break DNA-damaging agents such as cisplatin, bleomycin or etoposide also induced ATR relocalization and intense H2AX phosphorylation and led to anomalies in synaptonemal assembly.	Bleomycin	97-106	H2A.X variant histone	Mus musculus	164-168
23614921-0	2013	Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	44-53	chemokine (C-X-C motif) receptor 4	Mus musculus	24-29
23614921-3	2013	To explore the antifibrotic effects of blockade of CXCR4, we used a specific antagonist for CXCR4, AMD3100, in bleomycin-induced pulmonary fibrosis model in mice.	Bleomycin	111-120	chemokine (C-X-C motif) receptor 4	Mus musculus	92-97
23124168-0	2013	Effect of antisense TIMP-1 cDNA on the expression of TIMP-1 and MMP-2 in lung tissue with pulmonary fibrosis induced by bleomycin.	Bleomycin	120-129	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	20-26
23124168-0	2013	Effect of antisense TIMP-1 cDNA on the expression of TIMP-1 and MMP-2 in lung tissue with pulmonary fibrosis induced by bleomycin.	Bleomycin	120-129	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	53-59
23124168-0	2013	Effect of antisense TIMP-1 cDNA on the expression of TIMP-1 and MMP-2 in lung tissue with pulmonary fibrosis induced by bleomycin.	Bleomycin	120-129	matrix metallopeptidase 2	Rattus norvegicus	64-69
23124168-1	2013	The aim of this study was to observe the effect of antisense tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) cDNA on the concentration of hydroxyproline (HYP) and the expression of TIMP-1 and matrix metalloproteinase-2 (MMP-2) in the lung tissue of rats with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	267-276	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	61-107
23124168-1	2013	The aim of this study was to observe the effect of antisense tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) cDNA on the concentration of hydroxyproline (HYP) and the expression of TIMP-1 and matrix metalloproteinase-2 (MMP-2) in the lung tissue of rats with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	267-276	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	109-115
23124168-1	2013	The aim of this study was to observe the effect of antisense tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) cDNA on the concentration of hydroxyproline (HYP) and the expression of TIMP-1 and matrix metalloproteinase-2 (MMP-2) in the lung tissue of rats with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	278-281	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	61-107
23124168-1	2013	The aim of this study was to observe the effect of antisense tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) cDNA on the concentration of hydroxyproline (HYP) and the expression of TIMP-1 and matrix metalloproteinase-2 (MMP-2) in the lung tissue of rats with bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	278-281	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	109-115
24390105-7	2013	A peptide derived from the C-terminus of endostatin suppressed ECM production in fibroblasts in the presence of transforming growth factor-beta (TGF-beta), prevented TGF-beta-induced dermal fibrosis ex vivo in human skin, and ameliorated skin and pulmonary fibrosis induced by bleomycin in vivo.	Bleomycin	277-286	collagen type XVIII alpha 1 chain	Homo sapiens	41-51
23516459-6	2013	The efficacy of SPA-DXM-NLP against lung injury was assessed in a rat model of bleomycin-induced acute lung injury.	Bleomycin	79-88	surfactant protein A1	Rattus norvegicus	16-19
23689683-7	2013	RESULTS: IL-17R was increased significantly at 14 days in the bleomycin-induced pulmonary fibroblast model, exogenous IL-17 significantly promoted the proliferation of the pulmonary fibroblasts in primary culture and obviously increased the expression of alpha-smooth muscle actin and type I and type III collagen in the fibroblasts.	Bleomycin	62-71	interleukin 17 receptor A	Mus musculus	9-15
23689683-7	2013	RESULTS: IL-17R was increased significantly at 14 days in the bleomycin-induced pulmonary fibroblast model, exogenous IL-17 significantly promoted the proliferation of the pulmonary fibroblasts in primary culture and obviously increased the expression of alpha-smooth muscle actin and type I and type III collagen in the fibroblasts.	Bleomycin	62-71	interleukin 17A	Mus musculus	9-14
23239155-10	2013	The lungs of bleomycin-treated SOPten(Delta/Delta) mice showed increased pAkt, pS6K, Snail, and matrix metalloproteinase expressions and decreased claudin-4, E-cadherin, and laminin-beta1 expressions.	Bleomycin	13-22	snail family zinc finger 1	Mus musculus	85-90
23239155-10	2013	The lungs of bleomycin-treated SOPten(Delta/Delta) mice showed increased pAkt, pS6K, Snail, and matrix metalloproteinase expressions and decreased claudin-4, E-cadherin, and laminin-beta1 expressions.	Bleomycin	13-22	claudin 4	Mus musculus	147-156
23239155-10	2013	The lungs of bleomycin-treated SOPten(Delta/Delta) mice showed increased pAkt, pS6K, Snail, and matrix metalloproteinase expressions and decreased claudin-4, E-cadherin, and laminin-beta1 expressions.	Bleomycin	13-22	cadherin 1	Mus musculus	158-168
23258231-5	2013	Increased sensitivity to bleomycin-induced lung fibrosis was observed in adult mice exposed to neonatal hyperoxia, and was associated with increased numbers of leukocytes and an accumulation of active transforming growth factor (TGF)-beta1 in the lung.	Bleomycin	25-34	transforming growth factor, beta 1	Mus musculus	201-239
23195894-9	2013	We show that interaction between Gph and GAPDH increases in cells challenged with bleomycin, suggesting involvement of GAPDH in cellular processes linked to DNA repair mechanisms.	Bleomycin	82-91	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	41-46
23195894-9	2013	We show that interaction between Gph and GAPDH increases in cells challenged with bleomycin, suggesting involvement of GAPDH in cellular processes linked to DNA repair mechanisms.	Bleomycin	82-91	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	119-124
23260200-9	2013	Furthermore, PARP-1-deficient mice exhibited reduced pulmonary fibrosis in response to bleomycin-induced lung injury, relative to wild-type controls.	Bleomycin	87-96	poly (ADP-ribose) polymerase family, member 1	Mus musculus	13-19
23102621-0	2013	Noncovalenly PEGylated CTGF siRNA/PDMAEMA complex for pulmonary treatment of bleomycin-induced lung fibrosis.	Bleomycin	77-86	cellular communication network factor 2	Rattus norvegicus	23-27
23134111-3	2013	We studied whether targeted gene transfer of HGF specifically to AECII improves lung fibrosis in bleomycin-induced lung fibrosis.	Bleomycin	97-106	hepatocyte growth factor	Rattus norvegicus	45-48
23134111-9	2013	We conclude that targeted HGF gene transfer specifically to AECII decreases bleomycin-induced lung fibrosis and may therefore represent a novel cell-specific gene transfer technology to treat pulmonary fibrosis.	Bleomycin	76-85	hepatocyte growth factor	Rattus norvegicus	26-29
23097221-5	2013	Recent reports identified a critical enzyme, dimethylarginine dimethylaminohydrolase (DDAH), which is exceedingly active in patients suffering from IPF and in mice treated with bleomycin.	Bleomycin	177-186	dimethylarginine dimethylaminohydrolase 1	Homo sapiens	45-84
23097221-5	2013	Recent reports identified a critical enzyme, dimethylarginine dimethylaminohydrolase (DDAH), which is exceedingly active in patients suffering from IPF and in mice treated with bleomycin.	Bleomycin	177-186	dimethylarginine dimethylaminohydrolase 1	Homo sapiens	86-90
23476100-0	2013	Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis.	Bleomycin	24-33	interleukin 22	Homo sapiens	0-14
23476100-4	2013	Here we investigated the effect of IL-22 on alveolar epithelial cells in the bleomycin- (BLM-) induced pulmonary fibrosis.	Bleomycin	77-86	interleukin 22	Homo sapiens	35-40
23115324-0	2013	BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis.	Bleomycin	143-152	delta/notch like EGF repeat containing	Homo sapiens	0-3
23115324-7	2013	This study is the first demonstration of a role for Brd2 and Brd4 proteins in mediating the responses of LFs after growth factor stimulation and in driving the induction of lung fibrosis in mice in response to bleomycin challenge.	Bleomycin	210-219	bromodomain containing 2	Mus musculus	52-56
23115324-7	2013	This study is the first demonstration of a role for Brd2 and Brd4 proteins in mediating the responses of LFs after growth factor stimulation and in driving the induction of lung fibrosis in mice in response to bleomycin challenge.	Bleomycin	210-219	bromodomain containing 4	Mus musculus	61-65
24113622-3	2013	Here we show that Elovl6 expression is significantly downregulated after an intratracheal instillation of bleomycin (BLM) and in human lung with idiopathic pulmonary fibrosis.	Bleomycin	106-115	ELOVL fatty acid elongase 6	Homo sapiens	18-24
23341783-0	2013	Positional cloning reveals strain-dependent expression of Trim16 to alter susceptibility to bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	92-101	tripartite motif-containing 16	Mus musculus	58-64
23341783-2	2013	The chemotherapeutic agent bleomycin induces pulmonary fibrosis in susceptible C57BL/6J mice but not in mice of the C3H/HeJ strain, and this differential strain response has been used in prior studies to map bleomycin-induced pulmonary fibrosis susceptibility loci named Blmpf1 and Blmpf2.	Bleomycin	27-36	bleomycin-induced pulmonary fibrosis 1	Mus musculus	271-277
23341783-2	2013	The chemotherapeutic agent bleomycin induces pulmonary fibrosis in susceptible C57BL/6J mice but not in mice of the C3H/HeJ strain, and this differential strain response has been used in prior studies to map bleomycin-induced pulmonary fibrosis susceptibility loci named Blmpf1 and Blmpf2.	Bleomycin	27-36	bleomycin-induced pulmonary fibrosis 2	Mus musculus	282-288
23341783-3	2013	In this study we isolated the quantitative trait gene underlying Blmpf2 initially by histologically phenotyping the bleomycin-induced lung disease of sublines of congenic mice to reduce the linkage region to 13 genes.	Bleomycin	116-125	bleomycin-induced pulmonary fibrosis 2	Mus musculus	65-71
23341783-5	2013	Over-expression of Trim16 by plasmid injection increased pulmonary fibrosis, and bronchoalveolar lavage levels of both interleukin 12/23-p40 and neutrophils, in bleomycin treated B6.C3H-Blmpf2 subcongenic mice compared to subcongenic mice treated with bleomycin only, which follows the C57BL/6J versus C3H/HeJ strain difference in these traits.	Bleomycin	161-170	tripartite motif-containing 16	Mus musculus	19-25
23341783-5	2013	Over-expression of Trim16 by plasmid injection increased pulmonary fibrosis, and bronchoalveolar lavage levels of both interleukin 12/23-p40 and neutrophils, in bleomycin treated B6.C3H-Blmpf2 subcongenic mice compared to subcongenic mice treated with bleomycin only, which follows the C57BL/6J versus C3H/HeJ strain difference in these traits.	Bleomycin	252-261	tripartite motif-containing 16	Mus musculus	19-25
23341783-6	2013	In summary we demonstrate that genetic variation in Trim16 leads to its strain-dependent expression, which alters susceptibility to bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	132-141	tripartite motif-containing 16	Mus musculus	52-58
23472066-0	2013	14-3-3epsilon mediates the cell fate decision-making pathways in response of hepatocellular carcinoma to Bleomycin-induced DNA damage.	Bleomycin	105-114	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	Homo sapiens	0-13
23021499-1	2013	AIM: Our previous investigation demonstrated that plasminogen activator inhibitor-1 (PAI-1) siRNA ameliorated bleomycin (BLM)-induced rat lung fibrosis.	Bleomycin	110-119	serpin family E member 1	Rattus norvegicus	50-83
23021499-1	2013	AIM: Our previous investigation demonstrated that plasminogen activator inhibitor-1 (PAI-1) siRNA ameliorated bleomycin (BLM)-induced rat lung fibrosis.	Bleomycin	110-119	serpin family E member 1	Rattus norvegicus	85-90
23021499-1	2013	AIM: Our previous investigation demonstrated that plasminogen activator inhibitor-1 (PAI-1) siRNA ameliorated bleomycin (BLM)-induced rat lung fibrosis.	Bleomycin	121-124	serpin family E member 1	Rattus norvegicus	50-83
23021499-1	2013	AIM: Our previous investigation demonstrated that plasminogen activator inhibitor-1 (PAI-1) siRNA ameliorated bleomycin (BLM)-induced rat lung fibrosis.	Bleomycin	121-124	serpin family E member 1	Rattus norvegicus	85-90
23207668-4	2013	One million hMSC were administered intravenously 24 h following the induction of bleomycin lung injury.	Bleomycin	81-90	musculin	Homo sapiens	12-16
20301284-8	1993	Agents/circumstances to avoid: Because TDP1 codes for a DNA repair enzyme, genotoxic anti-cancer drugs such as camptothecins (e.g., irinotecan and topotecan) and bleomycin are likely to be extremely harmful and possibly fatal; exposure to radiation is likely to be extremely harmful and possibly fatal.	Bleomycin	162-171	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	39-43
22982510-4	2012	Bleomycin significantly increased lung weight and the levels of Lactate dehydrogenase, total leucocytic count, total protein and mucin in bronchoalveolar lavage and these effects were significantly ameliorated by TQ treatment.	Bleomycin	0-9	solute carrier family 13 member 2	Rattus norvegicus	129-134
22833167-4	2012	The mechanism by which IL-17A contributes to bleomycin-induced fibrosis was investigated in vivo and in vitro.	Bleomycin	45-54	interleukin 17A	Mus musculus	23-29
23043074-10	2012	Periostin expression was upregulated quickly after treatment with bleomycin and remained elevated.	Bleomycin	66-75	periostin	Homo sapiens	0-9
23043074-11	2012	Periostin(-/-) mice were protected from bleomycin-induced fibrosis.	Bleomycin	40-49	periostin, osteoblast specific factor	Mus musculus	0-9
22915616-8	2012	Consistently, pharmacological inhibition of FAAH significantly exacerbated bleomycin-induced fibrosis.	Bleomycin	75-84	fatty acid amide hydrolase	Mus musculus	44-48
22940535-9	2012	Co-incubation with NAC significantly decreased lipid hydroperoxide, 8-isoprostane, protein carbonyl content and TBARS levels increased by bleomycin and H(2)O(2).	Bleomycin	138-147	X-linked Kx blood group	Homo sapiens	19-22
22940535-11	2012	It can be concluded that NAC diminishes oxidative stress in human testicular cancer cells induced by bleomycin and H(2)O(2).	Bleomycin	101-110	X-linked Kx blood group	Homo sapiens	25-28
22441751-0	2012	A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	41-50	elastase, neutrophil expressed	Mus musculus	2-21
22441751-7	2012	In the bleomycin-induced early-stage pulmonary fibrosis model, the neutrophil elastase level was increased in the lungs.	Bleomycin	7-16	elastase, neutrophil expressed	Mus musculus	67-86
22441751-10	2012	These results suggest that sivelestat alleviated bleomycin-induced pulmonary fibrosis via inhibition of both TGF-beta activation and inflammatory cell recruitment in the lung.	Bleomycin	49-58	transforming growth factor, beta 1	Mus musculus	109-117
23076812-0	2012	Action of bleomycin is affected by bleomycin hydrolase but not by caveolin-1.	Bleomycin	10-19	bleomycin hydrolase	Homo sapiens	35-54
23076812-3	2012	To clarify whether BLH confers             the resistance to bleomycin in tumor cells, it is necessary to further investigate             the roles of BLH and its combination with other factors such as caveolin-1 in             the action of bleomycin.	Bleomycin	61-70	bleomycin hydrolase	Homo sapiens	19-22
23076812-3	2012	To clarify whether BLH confers             the resistance to bleomycin in tumor cells, it is necessary to further investigate             the roles of BLH and its combination with other factors such as caveolin-1 in             the action of bleomycin.	Bleomycin	242-251	bleomycin hydrolase	Homo sapiens	19-22
23076812-3	2012	To clarify whether BLH confers             the resistance to bleomycin in tumor cells, it is necessary to further investigate             the roles of BLH and its combination with other factors such as caveolin-1 in             the action of bleomycin.	Bleomycin	242-251	caveolin 1	Homo sapiens	202-212
23076812-5	2012	The relationship             between action of bleomycin and cellular amount of BLH was detected by the MTT             method and western blotting in the human leukemia cell line HL-60, HeLa cervical             cancer cells and HaCaT immortalized keratinocyte cells.	Bleomycin	47-56	bleomycin hydrolase	Homo sapiens	80-83
23076812-6	2012	The sensitivity to bleomycin             was increased in HeLa cells after knockdown of BLH mRNA by RNA interference.	Bleomycin	19-28	bleomycin hydrolase	Homo sapiens	88-91
23076812-7	2012	There             is no relationship between caveolin-1 levels and action of bleomycin, although             the distribution of the cell cycle was altered in the caveolin-1-knockdown HeLa             cells after treatment with bleomycin.	Bleomycin	228-237	caveolin 1	Homo sapiens	163-173
23076812-8	2012	In addition, regulation of BLH and caveolin-1             expression in HeLa and HaCaT cells was observed in a concentration-dependent manner             after exposure to bleomycin.	Bleomycin	172-181	bleomycin hydrolase	Homo sapiens	27-30
23076812-8	2012	In addition, regulation of BLH and caveolin-1             expression in HeLa and HaCaT cells was observed in a concentration-dependent manner             after exposure to bleomycin.	Bleomycin	172-181	caveolin 1	Homo sapiens	35-45
23076812-10	2012	Although caveolin-1 can respond             to bleomycin treatment, it is unrelated to bleomycin sensitivity.	Bleomycin	47-56	caveolin 1	Homo sapiens	9-19
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	45-54	caspase 3	Homo sapiens	176-185
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	45-54	caspase 8	Homo sapiens	187-196
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	45-54	caspase 9	Homo sapiens	202-211
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	45-54	cytochrome c, somatic	Homo sapiens	227-232
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	45-54	BCL2 associated X, apoptosis regulator	Homo sapiens	237-240
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	45-54	BCL2 apoptosis regulator	Homo sapiens	274-279
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	136-145	caspase 3	Homo sapiens	176-185
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	136-145	caspase 8	Homo sapiens	187-196
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	136-145	caspase 9	Homo sapiens	202-211
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	136-145	cytochrome c, somatic	Homo sapiens	227-232
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	136-145	BCL2 associated X, apoptosis regulator	Homo sapiens	237-240
22562160-8	2012	We found half of the lethal dose (LD(50)) of bleomycin on NCCIT cell viability as 120 mug/ml after incubation for 72 h. Incubation with bleomycin (LD(50)) induced increases in caspase-3, caspase-8, and caspase-9 activities and Cyt-c and Bax protein levels and a decrease in Bcl-2 level.	Bleomycin	136-145	BCL2 apoptosis regulator	Homo sapiens	274-279
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	34-43	caspase 3	Homo sapiens	99-108
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	34-43	caspase 9	Homo sapiens	113-122
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	34-43	BCL2 associated X, apoptosis regulator	Homo sapiens	135-138
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	34-43	cytochrome c, somatic	Homo sapiens	144-149
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	34-43	BCL2 apoptosis regulator	Homo sapiens	191-196
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	caspase 3	Homo sapiens	99-108
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	caspase 9	Homo sapiens	113-122
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	BCL2 associated X, apoptosis regulator	Homo sapiens	135-138
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	cytochrome c, somatic	Homo sapiens	144-149
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	BCL2 apoptosis regulator	Homo sapiens	191-196
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	caspase 3	Homo sapiens	99-108
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	caspase 9	Homo sapiens	113-122
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	BCL2 associated X, apoptosis regulator	Homo sapiens	135-138
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	cytochrome c, somatic	Homo sapiens	144-149
22562160-9	2012	Co-incubation of NCCIT cells with bleomycin and 10 mM NAC abolished bleomycin-induced increases in caspase-3 and caspase-9 activities, Bax, and Cyt-c levels and bleomycin-induced decrease in Bcl-2 level.	Bleomycin	68-77	BCL2 apoptosis regulator	Homo sapiens	191-196
22833167-6	2012	RESULTS: The loss of IL-17A significantly attenuated bleomycin-induced skin fibrosis, whereas a deficiency of IFNgamma or IL-4 did not.	Bleomycin	53-62	interleukin 17A	Mus musculus	21-27
22833167-7	2012	Leukocyte infiltration and the expression of TGFbeta and CTGF messenger RNA in bleomycin-injected skin were significantly reduced in IL-17A-deficient mice compared with wild-type (WT) mice.	Bleomycin	79-88	transforming growth factor, beta 1	Mus musculus	45-52
22833167-7	2012	Leukocyte infiltration and the expression of TGFbeta and CTGF messenger RNA in bleomycin-injected skin were significantly reduced in IL-17A-deficient mice compared with wild-type (WT) mice.	Bleomycin	79-88	cellular communication network factor 2	Mus musculus	57-61
22833167-7	2012	Leukocyte infiltration and the expression of TGFbeta and CTGF messenger RNA in bleomycin-injected skin were significantly reduced in IL-17A-deficient mice compared with wild-type (WT) mice.	Bleomycin	79-88	interleukin 17A	Mus musculus	133-139
22833167-8	2012	Daily bleomycin injections induced the expression of IL-17A in the skin and potent IL-17A producers in splenic CD4+ T cells from WT mice.	Bleomycin	6-15	interleukin 17A	Mus musculus	53-59
22833167-8	2012	Daily bleomycin injections induced the expression of IL-17A in the skin and potent IL-17A producers in splenic CD4+ T cells from WT mice.	Bleomycin	6-15	interleukin 17A	Mus musculus	83-89
22819196-9	2012	Similarly, bleomycin (25-200mug/mL) plus (111)In-DTPA-anti-gammaH2AX-Tat resulted in a lower SF compared to bleomycin alone.	Bleomycin	108-117	H2A.X variant histone	Mus musculus	59-68
23042199-0	2012	Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway.	Bleomycin	26-35	caveolin 1, caveolae protein	Mus musculus	102-112
22859522-8	2012	Mmp19(-/-) mice showed a significantly increased lung fibrotic response to bleomycin compared with WT mice.	Bleomycin	75-84	matrix metallopeptidase 19	Mus musculus	0-5
23091481-0	2012	Induction of p53-inducible microRNA miR-34 by gamma radiation and bleomycin are different.	Bleomycin	66-75	tumor protein p53	Homo sapiens	13-16
23091481-0	2012	Induction of p53-inducible microRNA miR-34 by gamma radiation and bleomycin are different.	Bleomycin	66-75	microRNA 34a	Homo sapiens	36-42
23091481-6	2012	Here we studied the expression of miR-34 in HeLa and MCF-7 cells exposed to genotoxic stress-induced by bleomycin (BLM) or gamma-radiation.	Bleomycin	104-113	microRNA 34a	Homo sapiens	34-40
22859522-12	2012	In WT mice, PTGS2 was significantly increased in bronchoalveolar lavage and lung tissues after bleomycin-induced fibrosis, but not in Mmp19(-/-) mice.	Bleomycin	95-104	prostaglandin-endoperoxide synthase 2	Mus musculus	12-17
23045972-6	2012	We have observed significant protective effects of Tbeta4 on bleomycin-induced lung damage, the main outcomes being the halting of the inflammatory process and a substantial reduction of histological evidence of lung injury.	Bleomycin	61-70	thymosin beta 4 X-linked	Homo sapiens	51-57
22074790-4	2012	We show that one single nanopulse with a duration of 10 ns and a field strength of 40 kV/cm is sufficient to allow the uptake of at least 500 molecules of bleomycin in 20% of the cells when the external bleomycin concentration is 3 muM.	Bleomycin	155-164	latexin	Homo sapiens	232-235
22684844-3	2012	We examined bleomycin-induced inflammation and fibrosis in mice carrying a mutation in the shared IL-6 family receptor gp130.	Bleomycin	12-21	interleukin 6	Mus musculus	98-102
22459774-3	2012	We recently reported that inhalation of lecithinized SOD (PC-SOD) ameliorated bleomycin-induced pulmonary fibrosis.	Bleomycin	78-87	superoxide dismutase 1	Homo sapiens	53-56
22459774-3	2012	We recently reported that inhalation of lecithinized SOD (PC-SOD) ameliorated bleomycin-induced pulmonary fibrosis.	Bleomycin	78-87	superoxide dismutase 1	Homo sapiens	58-64
22459774-4	2012	We here studied effects of PC-SOD on bleomycin-induced pulmonary fibrosis and lung dysfunction and compared the results to those obtained with pirfenidone, a newly developed drug for IPF.	Bleomycin	37-46	superoxide dismutase 1	Homo sapiens	27-33
22459774-7	2012	RESULTS: Both inhalation of PC-SOD and oral administration of pirfenidone ameliorated bleomycin-induced pulmonary fibrosis and changes in lung mechanics.	Bleomycin	86-95	superoxide dismutase 1	Homo sapiens	28-34
22459774-10	2012	PC-SOD suppressed the bleomycin-induced pulmonary inflammatory response and production of superoxide anions in the lung more effectively than pirfenidone.	Bleomycin	22-31	superoxide dismutase 1	Homo sapiens	0-6
22892132-0	2012	Expression of 150-kDa oxygen-regulated protein (ORP150) stimulates bleomycin-induced pulmonary fibrosis and dysfunction in mice.	Bleomycin	67-76	hypoxia up-regulated 1	Mus musculus	14-46
22892132-0	2012	Expression of 150-kDa oxygen-regulated protein (ORP150) stimulates bleomycin-induced pulmonary fibrosis and dysfunction in mice.	Bleomycin	67-76	hypoxia up-regulated 1	Mus musculus	48-54
22892132-6	2012	Treatment of mice with bleomycin induced the expression of ORP150 in the lung.	Bleomycin	23-32	hypoxia up-regulated 1	Mus musculus	59-65
22892132-7	2012	Bleomycin-induced inflammatory responses were slightly exacerbated in ORP150(+/-) mice compared to wild-type mice.	Bleomycin	0-9	hypoxia up-regulated 1	Mus musculus	70-76
22892132-8	2012	On the other hand, bleomycin-induced pulmonary fibrosis, alteration of lung mechanics and respiratory dysfunction was clearly ameliorated in the ORP150(+/-) mice.	Bleomycin	19-28	hypoxia up-regulated 1	Mus musculus	145-151
22892132-9	2012	Bleomycin-induced increases in pulmonary levels of both active TGF-beta1 and myofibroblasts were suppressed in ORP150(+/-) mice.	Bleomycin	0-9	transforming growth factor, beta 1	Mus musculus	63-72
22892132-9	2012	Bleomycin-induced increases in pulmonary levels of both active TGF-beta1 and myofibroblasts were suppressed in ORP150(+/-) mice.	Bleomycin	0-9	hypoxia up-regulated 1	Mus musculus	111-117
22892132-10	2012	These results suggest that although ORP150 is protective against bleomycin-induced lung injury, this protein could stimulate bleomycin-induced pulmonary fibrosis by increasing pulmonary levels of TGF-beta1 and myofibroblasts.	Bleomycin	65-74	hypoxia up-regulated 1	Mus musculus	36-42
22892132-10	2012	These results suggest that although ORP150 is protective against bleomycin-induced lung injury, this protein could stimulate bleomycin-induced pulmonary fibrosis by increasing pulmonary levels of TGF-beta1 and myofibroblasts.	Bleomycin	125-134	transforming growth factor, beta 1	Mus musculus	196-205
22493012-2	2012	We previously demonstrated that treatment of mice with IGF-1 receptor-blocking antibody (A12) improved early survival in bleomycin-induced lung injury.	Bleomycin	121-130	insulin-like growth factor 1	Mus musculus	55-60
22582174-9	2012	We show that myofibroblasts from lungs of humans with idiopathic pulmonary fibrosis and from bleomycin-treated versus normal saline-treated mice up-regulate c-FLIP levels.	Bleomycin	93-102	CASP8 and FADD-like apoptosis regulator	Mus musculus	157-163
22459774-13	2012	CONCLUSIONS: These results suggest that the superior activity of PC-SOD to pirfenidone against bleomycin-induced pulmonary fibrosis and lung dysfunction is due to its unique antioxidant activity.	Bleomycin	95-104	superoxide dismutase 1	Homo sapiens	65-71
23064322-7	2012	VirE2-expressing Arabidopsis plants were more susceptible to the DNA damaging chemical bleomycin and showed increased stable transformation.	Bleomycin	87-96	type IV secretion system single-stranded DNA binding protein VirE2	Agrobacterium tumefaciens	0-5
22963202-3	2012	In one patient, a combination of bleomycin, etoposide, and cisplatin was effective after initial surgery for malignant GCT.	Bleomycin	33-42	glutaminyl-peptide cyclotransferase	Homo sapiens	119-122
22684844-3	2012	We examined bleomycin-induced inflammation and fibrosis in mice carrying a mutation in the shared IL-6 family receptor gp130.	Bleomycin	12-21	interleukin 6 signal transducer	Mus musculus	119-124
22684844-6	2012	These findings are of therapeutic relevance, since we confirmed abundant STAT3 activation in fibrotic lungs from IPF patients and showed that genetic reduction of Stat3 protected mice from bleomycin-induced lung fibrosis.	Bleomycin	189-198	signal transducer and activator of transcription 3	Homo sapiens	163-168
22826322-5	2012	Murine modeling shows that in comparison with wild-type mice, bleomycin-induced pulmonary fibrosis was significantly reduced in Chit1-/- mice and significantly enhanced in lungs from Chit1 overexpressing transgenic animals.	Bleomycin	62-71	chitinase 1 (chitotriosidase)	Mus musculus	128-133
22744972-2	2012	Human HGF, which was expressed specifically by alveolar epithelial type II cells after gene transfer, attenuated the bleomycin-induced pulmonary fibrosis in an animal model.	Bleomycin	117-126	hepatocyte growth factor	Homo sapiens	6-9
22826322-5	2012	Murine modeling shows that in comparison with wild-type mice, bleomycin-induced pulmonary fibrosis was significantly reduced in Chit1-/- mice and significantly enhanced in lungs from Chit1 overexpressing transgenic animals.	Bleomycin	62-71	chitinase 1 (chitotriosidase)	Mus musculus	183-188
22538524-6	2012	At the same time, ddm1 plants were similar to wild-type plants in sensitivity to temperature and bleomycin stresses.	Bleomycin	97-106	chromatin remodeling 1	Arabidopsis thaliana	18-22
22496351-9	2012	Immunohistochemical analysis showed induction of TRAIL in bleomycin-treated wild-type mice.	Bleomycin	58-67	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	49-54
22354771-10	2012	Moreover, Ptch(+/-) mice with increased hedgehog signaling were more sensitive to bleomycin-induced dermal fibrosis.	Bleomycin	82-91	patched 1	Mus musculus	10-14
22751926-8	2012	Bleomycin-induced pulmonary fibrosis was accompanied by increased interactions between Fas-ERp57-GSTP1 and S-glutathionylation of Fas.	Bleomycin	0-9	protein disulfide isomerase family A member 3	Homo sapiens	91-96
22751926-8	2012	Bleomycin-induced pulmonary fibrosis was accompanied by increased interactions between Fas-ERp57-GSTP1 and S-glutathionylation of Fas.	Bleomycin	0-9	glutathione S-transferase pi 1	Homo sapiens	97-102
22659583-5	2012	Oral administration of either rosiglitazone (5 mg/kg/d) or fenofibrate (100 mg/kg/d) for 14 days, attenuated the severity of bleomycin-induced lung injury and fibrosis through decreasing lung water contents, lung fibrotic grading, lung hydroxyproline contents and lung transforming growth factor-beta1 levels; with no significant difference between them.	Bleomycin	125-134	transforming growth factor, beta 1	Rattus norvegicus	269-301
22687607-0	2012	Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice.	Bleomycin	86-95	MER proto-oncogene tyrosine kinase	Mus musculus	23-26
22687607-4	2012	During bleomycin-induced acute lung injury in mice, membrane-bound Mer expression decreased, but production of soluble Mer and activity as well as expression of disintegrin and metalloproteinase 17 (ADAM17) were enhanced .	Bleomycin	7-16	MER proto-oncogene tyrosine kinase	Mus musculus	67-70
22687607-4	2012	During bleomycin-induced acute lung injury in mice, membrane-bound Mer expression decreased, but production of soluble Mer and activity as well as expression of disintegrin and metalloproteinase 17 (ADAM17) were enhanced .	Bleomycin	7-16	MER proto-oncogene tyrosine kinase	Mus musculus	119-122
22687607-4	2012	During bleomycin-induced acute lung injury in mice, membrane-bound Mer expression decreased, but production of soluble Mer and activity as well as expression of disintegrin and metalloproteinase 17 (ADAM17) were enhanced .	Bleomycin	7-16	a disintegrin and metallopeptidase domain 17	Mus musculus	199-205
22687607-8	2012	Additional bleomycin-induced inflammatory responses reduced by TAPI-0 treatment included inflammatory cell recruitment into the lungs, levels of total protein and lactate dehydrogenase activity in bronchoalveolar lavage fluid, as well as caspase-3 and caspase-9 activity and alveolar epithelial cell apoptosis in lung tissue.	Bleomycin	11-20	caspase 3	Mus musculus	238-247
22687607-8	2012	Additional bleomycin-induced inflammatory responses reduced by TAPI-0 treatment included inflammatory cell recruitment into the lungs, levels of total protein and lactate dehydrogenase activity in bronchoalveolar lavage fluid, as well as caspase-3 and caspase-9 activity and alveolar epithelial cell apoptosis in lung tissue.	Bleomycin	11-20	caspase 9	Mus musculus	252-261
22687607-9	2012	Importantly, the effects of TAPI-0 on bleomycin-induced inflammation and apoptosis were reversed by coadministration of specific Mer-neutralizing antibodies.	Bleomycin	38-47	MER proto-oncogene tyrosine kinase	Mus musculus	129-132
22687607-10	2012	These findings suggest that restored membrane-bound Mer expression by TAPI-0 treatment may help resolve lung inflammation and apoptosis after bleomycin treatment.	Bleomycin	142-151	MER proto-oncogene tyrosine kinase	Mus musculus	52-55
22691970-5	2012	METHODS: Effect of a mouse anti-VEGF antibody was monitored on acute toxicity studying radiation-induced intestinal ulceration (12 Gy TBI); on subacute toxicity using a model of oral mucositis (16.5 Gy); on late radiation injuries by monitoring lung fibrosis (bleomycin and 19 Gy).	Bleomycin	260-269	vascular endothelial growth factor A	Mus musculus	32-36
22441736-0	2012	Apoptotic cell instillation after bleomycin attenuates lung injury through hepatocyte growth factor induction.	Bleomycin	34-43	hepatocyte growth factor	Homo sapiens	75-99
22441736-4	2012	We investigated the direct effect of in vivo exposure to apoptotic cells in bleomycin-stimulated lungs (2 days old) on HGF induction.	Bleomycin	76-85	hepatocyte growth factor	Homo sapiens	119-122
22441736-5	2012	Furthermore, sequential changes of bleomycin-induced HGF production following apoptotic cell instillation related to the changes in inflammatory and fibrotic responses were assessed.	Bleomycin	35-44	hepatocyte growth factor	Homo sapiens	53-56
22441736-6	2012	At 2 h after apoptotic cell instillation into bleomycin-stimulated lungs, the levels of HGF mRNA and protein production, and apoptotic cell clearance by alveolar macrophages were enhanced.	Bleomycin	46-55	hepatocyte growth factor	Homo sapiens	88-91
22441736-7	2012	Furthermore, HGF induction persistently increased following apoptotic cell instillation up to 21 days after bleomycin treatment.	Bleomycin	108-117	hepatocyte growth factor	Homo sapiens	13-16
22441736-11	2012	These findings indicate that in vivo exposure to apoptotic cells enhances transcriptional HGF production in bleomycin-stimulated lungs, resulting in attenuation of lung injury and fibrosis.	Bleomycin	108-117	hepatocyte growth factor	Homo sapiens	90-93
22592804-9	2012	This loss of epithelial integrity in CD151 KO lungs was further exacerbated by intratracheal bleomycin exposure, resulting in severe fibrosis with increased mortality.	Bleomycin	93-102	CD151 antigen	Mus musculus	37-42
22691970-6	2012	RESULTS: Combination of irradiation with anti-VEGF antibody enhanced intestinal damages with severe epithelial ulcerations, had no adverse impact on oral mucositis and dramatically worsened the fibrotic picture induced by bleomycin and irradiation to the lung.	Bleomycin	222-231	vascular endothelial growth factor A	Mus musculus	46-50
22595795-9	2012	However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNbeta gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine).	Bleomycin	153-162	interferon beta 1	Homo sapiens	99-107
22613712-3	2012	After acute, bleomycin injury, Pin1(-/-) mice showed reduced, pulmonary expression of collagens, tissue inhibitors of metalloproteinases, and fibrogenic cytokines but increased matrix metalloproteinases, compared with WT mice, despite similar levels of inflammation.	Bleomycin	13-22	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	31-35
22659625-0	2012	siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats.	Bleomycin	60-69	serpin family E member 1	Rattus norvegicus	14-47
22561461-3	2012	Here, the involvement of hypoxia and SP-D modulation was evaluated in a model of bleomycin-induced lung injury.	Bleomycin	81-90	surfactant protein D	Homo sapiens	37-41
22561461-5	2012	Tissue hypoxia and altered SP-D levels were present in bleomycin-induced fibrotic lesions.	Bleomycin	55-64	surfactant protein D	Homo sapiens	27-31
22582114-0	2012	Therapeutic hypercapnia prevents bleomycin-induced pulmonary hypertension in neonatal rats by limiting macrophage-derived tumor necrosis factor-alpha.	Bleomycin	33-42	tumor necrosis factor	Rattus norvegicus	122-149
22582114-7	2012	Inhibition of TNF-alpha signaling with the soluble TNF-2 receptor etanercept (0.4 mg/kg ip from days 1-14 on alternate days) prevented bleomycin-induced PHT without decreasing tissue macrophages and, similar to CO(2), had no effect on arrested alveolar development.	Bleomycin	135-144	tumor necrosis factor	Rattus norvegicus	14-23
22582114-8	2012	Our findings are consistent with a preventive effect of therapeutic hypercapnia with 7% CO(2) on bleomycin-induced PHT via attenuation of macrophage-derived TNF-alpha.	Bleomycin	97-106	tumor necrosis factor	Rattus norvegicus	157-166
22621404-0	2012	Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO.	Bleomycin	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-15
22621404-2	2012	We report on the development of a liposome delivery system that targets Her-2 overexpressing breast cancer cells and breaches the endosomal barrier, delivering bleomycin to the cytoplasm.	Bleomycin	160-169	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-77
22621404-6	2012	When calcein is replaced by bleomycin, the liposomes effectively reduce viability of five different Her-2 overexpressing cell lines (BT-474, SKBR-3, MCF-7/Her18, HCC-1954 and MDA-453) while harming to a much lesser extent Her-2 negative breast cell lines (MCF-7, MCF-12a and MCF-10a).	Bleomycin	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-105
22362388-6	2012	The apparent protective effect against bleomycin-induced fibrosis in cav-1(-/-) mice was attributed to reduce cellular senescence and apoptosis in cav-1(-/-) epithelial cells during the early phase of lung injury.	Bleomycin	39-48	caveolin 1, caveolae protein	Mus musculus	69-74
22362388-6	2012	The apparent protective effect against bleomycin-induced fibrosis in cav-1(-/-) mice was attributed to reduce cellular senescence and apoptosis in cav-1(-/-) epithelial cells during the early phase of lung injury.	Bleomycin	39-48	caveolin 1, caveolae protein	Mus musculus	147-152
22362388-7	2012	Reduced matrix metalloproteinase (MMP)-2 and MMP-9 expressions indicated a low profile of senescence-associated secretory phenotype (SASP) in the bleomycin-injured cav-1(-/-) mice.	Bleomycin	146-155	matrix metallopeptidase 2	Mus musculus	8-40
22362388-7	2012	Reduced matrix metalloproteinase (MMP)-2 and MMP-9 expressions indicated a low profile of senescence-associated secretory phenotype (SASP) in the bleomycin-injured cav-1(-/-) mice.	Bleomycin	146-155	matrix metallopeptidase 9	Mus musculus	45-50
22362388-7	2012	Reduced matrix metalloproteinase (MMP)-2 and MMP-9 expressions indicated a low profile of senescence-associated secretory phenotype (SASP) in the bleomycin-injured cav-1(-/-) mice.	Bleomycin	146-155	caveolin 1, caveolae protein	Mus musculus	164-169
22362388-8	2012	However, IL-6 and macrophage inflammatory protein 2 were increased in WT and cav-1(-/-) mice after bleomycin challenge, suggesting that bleomycin-induced inflammatory response substantiated the SASP pool.	Bleomycin	99-108	caveolin 1, caveolae protein	Mus musculus	77-82
22362388-8	2012	However, IL-6 and macrophage inflammatory protein 2 were increased in WT and cav-1(-/-) mice after bleomycin challenge, suggesting that bleomycin-induced inflammatory response substantiated the SASP pool.	Bleomycin	136-145	caveolin 1, caveolae protein	Mus musculus	77-82
22362388-9	2012	Thus, loss of cav-1 attenuates early injury response to bleomycin by limiting stress-induced cellular senescence/apoptosis in epithelial cells.	Bleomycin	56-65	caveolin 1, caveolae protein	Mus musculus	14-19
22726462-10	2012	Overexpression of Fizz1 prior to challenge or following challenge with bleomycin or silica did not significantly alter airway inflammation or fibrosis compared to control mice.	Bleomycin	71-80	resistin like alpha	Mus musculus	18-23
22294631-8	2012	Furthermore, BAY 41-2272 stopped the development of bleomycin-induced dermal fibrosis and skin fibrosis in Tsk-1 mice, preventing dermal and hypodermal thickening, reducing the numbers of myofibroblasts and reducing the hydroxyproline content.	Bleomycin	52-61	testis-specific serine kinase 1	Mus musculus	107-112
22694981-3	2012	The increased numbers of HSP47-positive type II pneumocytes as well as fibroblasts were also diminished by pirfenidone in an animal model of pulmonary fibrosis induced by bleomycin.	Bleomycin	171-180	serpin family H member 1	Homo sapiens	25-30
23259863-7	2012	Recently we have further shown that FGF10 signaling, a process that is necessary for distal lung morphogenesis, can also antagonize bleomycin-induced lung fibrosis in adult mice by a mechanism involving inhibition of active TGF beta ligand bioavailability.	Bleomycin	132-141	fibroblast growth factor 10	Mus musculus	36-41
23259863-7	2012	Recently we have further shown that FGF10 signaling, a process that is necessary for distal lung morphogenesis, can also antagonize bleomycin-induced lung fibrosis in adult mice by a mechanism involving inhibition of active TGF beta ligand bioavailability.	Bleomycin	132-141	transforming growth factor beta 1	Homo sapiens	224-232
22503555-4	2012	When treated with an endotracheal bleomycin injection, C/EBPbeta CKO mice showed significant attenuation of pulmonary fibrosis relative to control C/EBPbeta-intact mice.	Bleomycin	34-43	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	55-64
22503555-4	2012	When treated with an endotracheal bleomycin injection, C/EBPbeta CKO mice showed significant attenuation of pulmonary fibrosis relative to control C/EBPbeta-intact mice.	Bleomycin	34-43	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	147-156
22469952-7	2012	Curcumin (20 microM), bleomycin (400 microg/ml) and H2O2 (400 microM) incubation for 24 h decreased the viability of NTera-2 cells, and increased caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreased Bcl-2 levels.	Bleomycin	22-31	caspase 3	Homo sapiens	146-166
22402440-5	2012	Immunohistology demonstrated OPN on fibroblast-like and inflammatory cells in SSc skin and lesional skin from mice in the bleomycin (bleo)-induced dermal fibrosis model.	Bleomycin	122-131	secreted phosphoprotein 1	Mus musculus	29-32
22402440-5	2012	Immunohistology demonstrated OPN on fibroblast-like and inflammatory cells in SSc skin and lesional skin from mice in the bleomycin (bleo)-induced dermal fibrosis model.	Bleomycin	122-126	secreted phosphoprotein 1	Mus musculus	29-32
22402440-6	2012	OPN-deficient (OPN(-/-)) mice developed less dermal fibrosis compared with wild-type (WT) mice in the bleo-induced dermal fibrosis model.	Bleomycin	102-106	secreted phosphoprotein 1	Mus musculus	0-3
22571259-11	2012	CONCLUSIONS: DBTG had an inhibitory effect on bleomycin-induced pulmonary fibrosis and its effect may be associated with the ability of DBTG to inhibit the synthesis of extracellular matrix and balance the MMP/TIMP-1 system.	Bleomycin	46-55	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	210-216
22469952-7	2012	Curcumin (20 microM), bleomycin (400 microg/ml) and H2O2 (400 microM) incubation for 24 h decreased the viability of NTera-2 cells, and increased caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreased Bcl-2 levels.	Bleomycin	22-31	BCL2 associated X, apoptosis regulator	Homo sapiens	179-182
22469952-7	2012	Curcumin (20 microM), bleomycin (400 microg/ml) and H2O2 (400 microM) incubation for 24 h decreased the viability of NTera-2 cells, and increased caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreased Bcl-2 levels.	Bleomycin	22-31	cytochrome c, somatic	Homo sapiens	199-211
22469952-7	2012	Curcumin (20 microM), bleomycin (400 microg/ml) and H2O2 (400 microM) incubation for 24 h decreased the viability of NTera-2 cells, and increased caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreased Bcl-2 levels.	Bleomycin	22-31	BCL2 apoptosis regulator	Homo sapiens	233-238
22469952-8	2012	The concurrent use of curcumin with bleomycin induced caspase-3, -8 and -9 activities to a greater extent in NTera-2 cells than the use of each drug alone.	Bleomycin	36-45	caspase 3	Homo sapiens	54-74
22246130-0	2012	Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury.	Bleomycin	42-51	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	0-31
22246130-5	2012	We hypothesized that ACE2 prevents Bleomycin (BLM)-induced lung injury.	Bleomycin	35-44	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	21-25
22246130-5	2012	We hypothesized that ACE2 prevents Bleomycin (BLM)-induced lung injury.	Bleomycin	46-49	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	21-25
22429962-0	2012	Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury.	Bleomycin	182-191	cytokine receptor-like factor 1	Mus musculus	0-22
22395530-5	2012	This was evidenced by the findings that mice or pulmonary fibroblasts null for Smad3 were protected against bleomycin or TGF-beta1-induced loss of miR-29 along with fibrosis in vivo and in vitro.	Bleomycin	108-117	SMAD family member 3	Mus musculus	79-84
28058186-6	2012	The resulting stably transfectants (termed SHB for pcBIH, SPB for pcBIP, and SNB for pcBSN) exhibited bleomycin/hygromycin, bleomycin/puromycin, or bleomycin/neomycin, as expected.	Bleomycin	102-111	src homology 2 domain-containing transforming protein B	Mus musculus	43-46
28058186-6	2012	The resulting stably transfectants (termed SHB for pcBIH, SPB for pcBIP, and SNB for pcBSN) exhibited bleomycin/hygromycin, bleomycin/puromycin, or bleomycin/neomycin, as expected.	Bleomycin	124-133	src homology 2 domain-containing transforming protein B	Mus musculus	43-46
28058186-6	2012	The resulting stably transfectants (termed SHB for pcBIH, SPB for pcBIP, and SNB for pcBSN) exhibited bleomycin/hygromycin, bleomycin/puromycin, or bleomycin/neomycin, as expected.	Bleomycin	124-133	src homology 2 domain-containing transforming protein B	Mus musculus	43-46
22409285-6	2012	Our results revealed that bleomycin induced cytotoxicity (lactate dehydrogenase leak), morphological alterations (rounding of cells and filipodia formation), and cytoskeletal rearrangement (actin stress fiber formation and alterations of tight junction proteins, ZO-1 and occludin) in a dose-dependent fashion.	Bleomycin	26-35	tight junction protein 1	Bos taurus	263-280
22643035-16	2012	BrdU+CD45+ cells increased by 0.7-fold and SPC+CC10+ bronchoalveolar stem cells (BASC), decreased by ~40-fold post-bleomycin.	Bleomycin	115-124	sparse coat	Mus musculus	43-46
22246863-6	2012	To explore this possibility, we administered BLM to periostin-deficient mice, and they subsequently showed a reduction of pulmonary fibrosis.	Bleomycin	45-48	periostin, osteoblast specific factor	Mus musculus	52-61
22287613-4	2012	Our results show that lung-specific overexpression of CCL2 protected mice from bleomycin-induced lung injury, characterized by significantly reduced mortality, reduced neutrophil accumulation, and decreased accumulation of the inflammatory mediators IL-6, CXCL2 (macrophage inflammatory protein-2), and CXCL1 (keratinocyte-derived chemokine).	Bleomycin	79-88	chemokine (C-C motif) ligand 2	Mus musculus	54-58
22429962-8	2012	Administration of CLF-1/CLC to both uninjured and bleomycin-injured mice led to the pulmonary accumulation of CD4(+) T cells.	Bleomycin	50-59	cytokine receptor-like factor 1	Mus musculus	18-23
22429962-8	2012	Administration of CLF-1/CLC to both uninjured and bleomycin-injured mice led to the pulmonary accumulation of CD4(+) T cells.	Bleomycin	50-59	CD4 antigen	Mus musculus	110-113
22402139-5	2012	Hedgehog signalling was inhibited by the selective inhibitor LDE223 and by small interfering RNA against Smo in the models of bleomycin-induced dermal fibrosis and in tight-skin-1 mice.	Bleomycin	126-135	smoothened, frizzled class receptor	Mus musculus	105-108
22328737-10	2012	By contrast, fibroblast-specific deletion of beta-catenin significantly reduced bleomycin-induced dermal fibrosis.	Bleomycin	80-89	catenin (cadherin associated protein), beta 1	Mus musculus	45-57
22258492-8	2012	Inhibition of JNK prevented dermal thickening, myofibroblast differentiation and the accumulation of collagen in a dose-dependent manner in mice challenged with bleomycin and in TSK1 mice.	Bleomycin	161-170	mitogen-activated protein kinase 8	Mus musculus	14-17
22402139-7	2012	Inhibition of Smo either by LDE223 or by small interfering RNA prevented dermal thickening, myofibroblast differentiation and accumulation of collagen upon challenge with bleomycin.	Bleomycin	171-180	smoothened, frizzled class receptor	Mus musculus	14-17
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Bleomycin	158-167	colony stimulating factor 3	Homo sapiens	14-51
22348305-3	2012	We found that the Bach1-p53 interaction was inhibited by oncogenic Ras, bleomycin, and hydrogen peroxide.	Bleomycin	72-81	BTB and CNC homology 1, basic leucine zipper transcription factor 1	Mus musculus	18-23
22348305-3	2012	We found that the Bach1-p53 interaction was inhibited by oncogenic Ras, bleomycin, and hydrogen peroxide.	Bleomycin	72-81	transformation related protein 53, pseudogene	Mus musculus	24-27
22492165-8	2012	Pharmacologic or siRNA-mediated targeting of FAK resulted in marked abrogation of bleomycin-induced lung fibrosis in mice.	Bleomycin	82-91	PTK2 protein tyrosine kinase 2	Mus musculus	45-48
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Bleomycin	158-167	colony stimulating factor 3	Homo sapiens	53-58
22296221-3	2012	Moreover, G-CSF is expensive (pegfilgrastim: EUR 1540/cycle; 300 mug filgrastim for 7 days: EUR 700/cycle) and is associated with side effects including bone pain and increased risk of bleomycin lung toxicity.	Bleomycin	185-194	colony stimulating factor 3	Homo sapiens	10-15
22344408-6	2012	NCX 466 and naproxen dose-dependently prevented bleomycin-induced airway stiffness and collagen accumulation.	Bleomycin	48-57	T cell leukemia, homeobox 2	Mus musculus	0-3
22344408-0	2012	Prevention of bleomycin-induced lung fibrosis in mice by a novel approach of parallel inhibition of cyclooxygenase and nitric-oxide donation using NCX 466, a prototype cyclooxygenase inhibitor and nitric-oxide donor.	Bleomycin	14-23	T cell leukemia, homeobox 2	Mus musculus	147-150
22502865-3	2012	Previously, we showed that loss of PPARgamma expression in fibroblasts resulted in enhanced bleomycin-induced skin fibrosis.	Bleomycin	92-101	peroxisome proliferator activated receptor gamma	Homo sapiens	35-44
22558986-10	2012	CONCLUSION: After inhaled BUD,  the expressions of TGF-beta1,  PDGF-A,  Smad4 and PAI-1 in lung tissue could be decreased,  and the extent of alveolitis and pulmonary fibrosis could be improved in bleomycin-induced pulmonary fibrosis rats.	Bleomycin	197-206	transforming growth factor, beta 1	Rattus norvegicus	51-60
22375014-1	2012	Tyrosyl-DNA phosphodiesterase 1 (Tdp1) repairs topoisomerase I cleavage complexes (Top1cc) by hydrolyzing their 3"-phosphotyrosyl DNA bonds and repairs bleomycin-induced DNA damage by hydrolyzing 3"-phosphoglycolates.	Bleomycin	152-161	tyrosyl-DNA phosphodiesterase 1	Gallus gallus	0-31
22375014-1	2012	Tyrosyl-DNA phosphodiesterase 1 (Tdp1) repairs topoisomerase I cleavage complexes (Top1cc) by hydrolyzing their 3"-phosphotyrosyl DNA bonds and repairs bleomycin-induced DNA damage by hydrolyzing 3"-phosphoglycolates.	Bleomycin	152-161	tyrosyl-DNA phosphodiesterase 1	Gallus gallus	33-37
22375014-4	2012	We found that Tdp1-/- cells were not only hypersensitive to camptothecin and bleomycin but also to etoposide, methyl methanesulfonate (MMS), H(2)O(2), and ionizing radiation.	Bleomycin	77-86	tyrosyl-DNA phosphodiesterase 1	Gallus gallus	14-18
22095546-7	2012	MEASUREMENTS AND MAIN RESULTS: Transforming growth factor (TGF)-beta and bleomycin-induced lung fibrosis was dramatically reduced in mice deficient in galectin-3, manifest by reduced TGF-beta1-induced EMT and myofibroblast activation and collagen production.	Bleomycin	73-82	lectin, galactose binding, soluble 3	Mus musculus	151-161
22322299-2	2012	Transgenic mice overexpressing TNF-alpha in type II alveolar epithelial cells under the control of the surfactant protein (SP)-C promoter develop pulmonary inflammation and emphysema but are resistant to induction of fibrosis by administration of bleomycin or transforming growth factor-beta.	Bleomycin	247-256	tumor necrosis factor	Mus musculus	31-40
22021336-3	2012	We now show that LPA signaling through its receptor LPA(1) promotes epithelial cell apoptosis induced by bleomycin injury.	Bleomycin	105-114	lysophosphatidic acid receptor 1	Mus musculus	52-57
22095546-7	2012	MEASUREMENTS AND MAIN RESULTS: Transforming growth factor (TGF)-beta and bleomycin-induced lung fibrosis was dramatically reduced in mice deficient in galectin-3, manifest by reduced TGF-beta1-induced EMT and myofibroblast activation and collagen production.	Bleomycin	73-82	transforming growth factor, beta 1	Mus musculus	183-192
22095546-9	2012	A novel inhibitor of galectin-3, TD139, blocked TGF-beta-induced beta-catenin activation in vitro and in vivo and attenuated the late-stage progression of lung fibrosis after bleomycin.	Bleomycin	175-184	galectin 3	Homo sapiens	21-31
22033267-7	2012	Intrapulmonary delivery of aerosolized siRNAs of TGF-beta1 with sequences common to humans and rodents significantly inhibited bleomycin-induced pulmonary fibrosis in the acute and chronic phases of the disease and in a dose-dependent manner.	Bleomycin	127-136	transforming growth factor beta 1	Homo sapiens	49-58
22095546-9	2012	A novel inhibitor of galectin-3, TD139, blocked TGF-beta-induced beta-catenin activation in vitro and in vivo and attenuated the late-stage progression of lung fibrosis after bleomycin.	Bleomycin	175-184	transforming growth factor beta 1	Homo sapiens	48-56
22246178-11	2012	CONCLUSIONS: Statin use is associated with ILA among smokers in the COPDGene study and enhances bleomycin-induced lung inflammation and fibrosis in the mouse through a mechanism involving enhanced NLRP3-inflammasome activation.	Bleomycin	96-105	NLR family, pyrin domain containing 3	Mus musculus	197-202
22198976-3	2012	OBJECTIVES: The goal of this study was to test the hypothesis that SP-D plays an important role in lung fibrosis using a mouse model of fibrosis induced by bleomycin (BLM).	Bleomycin	156-165	surfactant associated protein D	Mus musculus	67-71
22192844-0	2012	Activation of P2X7R and downstream effects in bleomycin treated lung epithelial cells.	Bleomycin	46-55	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	14-19
22198238-11	2012	Our findings also revealed that bleomycin inhibited Akt activation and suppressed bcl-2.	Bleomycin	32-41	thymoma viral proto-oncogene 1	Mus musculus	52-55
22198238-11	2012	Our findings also revealed that bleomycin inhibited Akt activation and suppressed bcl-2.	Bleomycin	32-41	B cell leukemia/lymphoma 2	Mus musculus	82-87
22198238-13	2012	CONCLUSION: Our observations reveal possible mechanisms for the inhibitory effects of bleomycin on hemangiomagenesis, and raise the possibility that bcl-2 might be an important therapeutic target in the treatment of hemangiomas.	Bleomycin	86-95	B cell leukemia/lymphoma 2	Mus musculus	149-154
22188586-0	2012	Local injection of latency-associated peptide, a linker propeptide specific for active form of transforming growth factor-beta1, inhibits dermal sclerosis in bleomycin-induced murine scleroderma.	Bleomycin	158-167	centromere protein J	Mus musculus	19-45
22188586-0	2012	Local injection of latency-associated peptide, a linker propeptide specific for active form of transforming growth factor-beta1, inhibits dermal sclerosis in bleomycin-induced murine scleroderma.	Bleomycin	158-167	transforming growth factor, beta 1	Mus musculus	95-127
22188586-2	2012	In this study, we demonstrate the antifibrotic effects of local administration of latency-associated peptide (LAP), a linker propeptide that specifically converts the active form of TGF-beta1 to the inactive from, in the bleomycin (BLM)-induced scleroderma mouse model.	Bleomycin	221-230	centromere protein J	Mus musculus	82-108
22188586-2	2012	In this study, we demonstrate the antifibrotic effects of local administration of latency-associated peptide (LAP), a linker propeptide that specifically converts the active form of TGF-beta1 to the inactive from, in the bleomycin (BLM)-induced scleroderma mouse model.	Bleomycin	221-230	centromere protein J	Mus musculus	110-113
22188586-2	2012	In this study, we demonstrate the antifibrotic effects of local administration of latency-associated peptide (LAP), a linker propeptide that specifically converts the active form of TGF-beta1 to the inactive from, in the bleomycin (BLM)-induced scleroderma mouse model.	Bleomycin	221-230	transforming growth factor, beta 1	Mus musculus	182-191
22177985-1	2012	The truncated [1+9-76] CCL2 analogue, also known as 7ND, has been described in numerous reports as an anti-inflammatory and anti-fibrotic agent in a wide spectrum of animal models, e.g. models of cardiovascular disease, graft versus host disease and bleomycin-induced pulmonary fibrosis.	Bleomycin	250-259	C-C motif chemokine ligand 2	Homo sapiens	23-27
22250783-12	2012	The expression of IL-17A, IL-10, IL-6, and TGF-beta mRNAs were higher in the bleomycin group than in the normal group.	Bleomycin	77-86	interleukin 17A	Mus musculus	18-24
22250783-12	2012	The expression of IL-17A, IL-10, IL-6, and TGF-beta mRNAs were higher in the bleomycin group than in the normal group.	Bleomycin	77-86	interleukin 10	Mus musculus	26-31
22250783-12	2012	The expression of IL-17A, IL-10, IL-6, and TGF-beta mRNAs were higher in the bleomycin group than in the normal group.	Bleomycin	77-86	interleukin 6	Mus musculus	33-37
22250783-12	2012	The expression of IL-17A, IL-10, IL-6, and TGF-beta mRNAs were higher in the bleomycin group than in the normal group.	Bleomycin	77-86	transforming growth factor, beta 1	Mus musculus	43-51
22250783-15	2012	ATRA may ease the bleomycin-induced pulmonary fibrosis by inhibiting the expression of IL-6 and TGF-beta, shifting the Treg/Th17 ratio and reducing the secretion of IL-17A.	Bleomycin	18-27	interleukin 6	Mus musculus	87-91
22250783-15	2012	ATRA may ease the bleomycin-induced pulmonary fibrosis by inhibiting the expression of IL-6 and TGF-beta, shifting the Treg/Th17 ratio and reducing the secretion of IL-17A.	Bleomycin	18-27	transforming growth factor, beta 1	Mus musculus	96-104
22250783-15	2012	ATRA may ease the bleomycin-induced pulmonary fibrosis by inhibiting the expression of IL-6 and TGF-beta, shifting the Treg/Th17 ratio and reducing the secretion of IL-17A.	Bleomycin	18-27	interleukin 17A	Mus musculus	165-171
21984393-3	2012	On days 17-21 following intratracheal bleomycin administration, ~4% of GFP-positive epithelial-derived cells expressed vimentin or alpha-smooth muscle actin (alpha-SMA).	Bleomycin	38-47	vimentin	Mus musculus	119-127
21984393-3	2012	On days 17-21 following intratracheal bleomycin administration, ~4% of GFP-positive epithelial-derived cells expressed vimentin or alpha-smooth muscle actin (alpha-SMA).	Bleomycin	38-47	actin alpha 2, smooth muscle, aorta	Mus musculus	131-156
21984393-3	2012	On days 17-21 following intratracheal bleomycin administration, ~4% of GFP-positive epithelial-derived cells expressed vimentin or alpha-smooth muscle actin (alpha-SMA).	Bleomycin	38-47	actin alpha 2, smooth muscle, aorta	Mus musculus	158-167
21940816-7	2012	uPARAP(-/-) mice are protected from changes in lung permeability after acute lung injury and have increased collagen content after bleomycin injury.	Bleomycin	131-140	mannose receptor, C type 2	Mus musculus	0-6
22466555-4	2012	Treatment with HSYA also alleviated bleomycin-induced increase of mRNA level of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta and transforming growth factor (TGF)-beta1 in lung homogenates.	Bleomycin	36-45	interleukin 1 beta	Mus musculus	115-137
22003091-5	2012	In experimental bleomycin-induced lung injury, the levels of mRNA encoding tight junction proteins were reduced, particularly those of claudin-18.	Bleomycin	16-25	claudin 18	Homo sapiens	135-145
22003091-8	2012	In addition, we analyzed the influence of transforming growth factor-beta (TGF-beta), a critical mediator of pulmonary fibrosis that is upregulated after bleomycin-induced lung injury, on tight junctions in vitro.	Bleomycin	154-163	transforming growth factor beta 1	Homo sapiens	75-83
22003091-10	2012	These results suggest that bleomycin-induced lung injury causes pathogenic alterations in tight junctions and that such alterations seem to be induced by TGF-beta.	Bleomycin	27-36	transforming growth factor beta 1	Homo sapiens	154-162
21799118-0	2012	Eph-A2 promotes permeability and inflammatory responses to bleomycin-induced lung injury.	Bleomycin	59-68	Eph receptor A2	Mus musculus	0-6
21799118-6	2012	In early bleomycin injury in WT mice, the expression of both EphA2 and ephrin-A1 increased.	Bleomycin	9-18	Eph receptor A2	Mus musculus	61-66
21799118-6	2012	In early bleomycin injury in WT mice, the expression of both EphA2 and ephrin-A1 increased.	Bleomycin	9-18	ephrin A1	Mus musculus	71-80
21799118-8	2012	Bleomycin caused less accumulation of lung leukocytes in EphA2 KO animals than in WT animals, suggesting that EphA2 regulates inflammation.	Bleomycin	0-9	Eph receptor A2	Mus musculus	57-62
21799118-8	2012	Bleomycin caused less accumulation of lung leukocytes in EphA2 KO animals than in WT animals, suggesting that EphA2 regulates inflammation.	Bleomycin	0-9	Eph receptor A2	Mus musculus	110-115
21799118-10	2012	After bleomycin injury, EphA2 KO animals produced less CXCL1 and CCL2 than WT animals.	Bleomycin	6-15	Eph receptor A2	Mus musculus	24-29
22051193-5	2012	We found that reduction of filamin-A sensitizes cancer cells to chemotherapy reagents bleomycin and cisplatin, delays the repair of not only DSBs but also single strand breaks (SSBs) and interstrand crosslinks (ICLs), and increases chromosome breaks after the drug treatment.	Bleomycin	86-95	filamin A	Homo sapiens	27-36
22051193-7	2012	We further inhibited the expression of filamin-A in melanoma cells, and found that this confers an increased sensitivity to bleomycin and cisplatin treatment in a mouse xenograft tumor model.	Bleomycin	124-133	filamin, alpha	Mus musculus	39-48
21990376-6	2012	Immunohistochemical studies demonstrated CDH11 expression on fibroblasts, epithelial cells, and alveolar macrophages of patients with pulmonary fibrosis and mice given bleomycin.	Bleomycin	168-177	cadherin 11	Homo sapiens	41-46
21990376-7	2012	Interestingly, CDH11-deficient mice had decreased fibrotic endpoints in the bleomycin model of pulmonary fibrosis compared to wild-type mice.	Bleomycin	76-85	cadherin 11	Mus musculus	15-20
21990376-8	2012	Furthermore, anti-CDH11-neutralizing monoclonal antibodies successfully treated established pulmonary fibrosis induced by bleomycin.	Bleomycin	122-131	cadherin 11	Mus musculus	18-23
22184372-7	2012	Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone).	Bleomycin	160-169	POF1B actin binding protein	Homo sapiens	19-22
22184372-7	2012	Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone).	Bleomycin	213-222	POF1B actin binding protein	Homo sapiens	19-22
22062220-3	2012	We found that genetic or pharmacologic inhibition of TLR4 exacerbates bleomycin-induced pulmonary inflammation, fibrosis, dysfunction, and animal death through promoting formation of an immunosuppressive tissue microenvironment and attenuating autophagy-associated degradation of collagen and cell death in the fibrotic lung tissues.	Bleomycin	70-79	toll-like receptor 4	Mus musculus	53-57
22062222-6	2012	C57BL/6 mice with BLM induced scleroderma had elevated serum IL-6 levels and more severe dermal sclerosis than Il-6KO mice.	Bleomycin	18-21	interleukin 6	Mus musculus	61-65
22223332-5	2012	To elucidate the mechanism of action, the effect of pycnidione on the signal transduction of the G2 checkpoint was analyzed, showing that the increased phospho-cyclin dependent kinase-1 (CDK1) level caused by bleomycin was abrogated in the presence of pycnidione, indicating that cells did not arrest at the G2 phase.	Bleomycin	209-218	cyclin dependent kinase 1	Homo sapiens	152-185
22223332-5	2012	To elucidate the mechanism of action, the effect of pycnidione on the signal transduction of the G2 checkpoint was analyzed, showing that the increased phospho-cyclin dependent kinase-1 (CDK1) level caused by bleomycin was abrogated in the presence of pycnidione, indicating that cells did not arrest at the G2 phase.	Bleomycin	209-218	cyclin dependent kinase 1	Homo sapiens	187-191
22223332-7	2012	Thus, we concluded that pycnidione abrogated bleomycin-induced G2 arrest by decreasing Chk1 and Chk2.	Bleomycin	45-54	checkpoint kinase 1	Homo sapiens	87-91
22223332-7	2012	Thus, we concluded that pycnidione abrogated bleomycin-induced G2 arrest by decreasing Chk1 and Chk2.	Bleomycin	45-54	checkpoint kinase 2	Homo sapiens	96-100
22687409-0	2012	Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	81-90	fibroblast growth factor receptor 2	Mus musculus	29-64
22687409-4	2012	In Western blotting of the right lung tissues and immunohistochemical assay, we found the level of p-FGFRs, p-mitogen activated protein kinase (MAPK) and p-Smad3 in the mice of bleomycin (BLM) group treated with msFGFR2 was down dramatically compared with the mice of BLM group, which suggested the activations of FGF and TGF-beta signals were blocked meanwhile.	Bleomycin	177-186	SMAD family member 3	Mus musculus	156-161
22687409-4	2012	In Western blotting of the right lung tissues and immunohistochemical assay, we found the level of p-FGFRs, p-mitogen activated protein kinase (MAPK) and p-Smad3 in the mice of bleomycin (BLM) group treated with msFGFR2 was down dramatically compared with the mice of BLM group, which suggested the activations of FGF and TGF-beta signals were blocked meanwhile.	Bleomycin	177-186	transforming growth factor, beta 1	Mus musculus	322-330
22466555-4	2012	Treatment with HSYA also alleviated bleomycin-induced increase of mRNA level of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta and transforming growth factor (TGF)-beta1 in lung homogenates.	Bleomycin	36-45	transforming growth factor, beta 1	Mus musculus	142-180
22507554-6	2012	Compared to Sftpc(+/+) mice receiving bleomycin alone, Sftpc(+/+) mice administered hAECs 24 h after bleomycin exposure had decreased expression of proinflammatory genes, decreased macrophage and neutrophil infiltration, fibrosis, collagen content, and alpha-smooth muscle actin as well as a significant improvement in lung function.	Bleomycin	101-110	surfactant associated protein C	Mus musculus	55-60
22507554-9	2012	The ability of hAECs to mitigate bleomycin-induced lung injury is abolished in Sftpc(-/-) mice, suggesting that hAECs require normal host macrophage function to exert their reparative effects.	Bleomycin	33-42	surfactant associated protein C	Mus musculus	79-84
22442961-0	2012	[Effects of granulocyte colony-stimulating factor on experimental bleomycin-induced pulmonary fibrosis].	Bleomycin	66-75	colony stimulating factor 3	Homo sapiens	12-49
22442961-2	2012	It is established that G-CSF significantly increases infiltration of alveolar and alveolar duct interstitium by inflammation cells (lymphocytes, neutrophils, plasmocytes) and increases collagen deposition in lung under conditions of bleomycin introduction.	Bleomycin	233-242	colony stimulating factor 3	Homo sapiens	23-28
22419889-2	2012	It has been shown that filamin-A facilitates DNA repair and filamin-A proficient cells are more resistant to ionizing radiation, bleomycin, and cisplatin.	Bleomycin	129-138	filamin A	Homo sapiens	60-69
22911870-12	2012	CONCLUSION: Periostin plays an essential role in the pathogenesis of Bleomycin-induced scleroderma in mice.	Bleomycin	69-78	periostin, osteoblast specific factor	Mus musculus	12-21
22942703-0	2012	Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	44-53	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	11-21
22398790-4	2012	In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed.	Bleomycin	10-19	SMAD family member 3	Mus musculus	87-94
22398790-4	2012	In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed.	Bleomycin	10-19	SMAD family member 2	Mus musculus	98-105
22398790-4	2012	In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed.	Bleomycin	10-19	actin alpha 2, smooth muscle, aorta	Mus musculus	192-217
22398790-4	2012	In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed.	Bleomycin	10-19	actin alpha 2, smooth muscle, aorta	Mus musculus	219-223
22398790-4	2012	In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed.	Bleomycin	10-19	SMAD family member 3	Mus musculus	98-105
22398790-4	2012	In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed.	Bleomycin	163-172	SMAD family member 3	Mus musculus	87-94
22398790-4	2012	In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed.	Bleomycin	163-172	SMAD family member 2	Mus musculus	98-105
22398790-4	2012	In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed.	Bleomycin	163-172	SMAD family member 3	Mus musculus	98-105
22570622-10	2012	In agreement with a primary role of anaphase bridge intermediates in the polyploidization process, treatment of HMEC-hTERT cells with bleomycin, which produces chromatin bridges through illegimitate repair, resulted in tetraploid binucleated cells.	Bleomycin	134-143	telomerase reverse transcriptase	Homo sapiens	117-122
22911824-4	2012	Fra-1 knockdown in human lung epithelial cells caused the upregulation of mesenchymal marker N-cadherin, concomitant with a downregulation of the epithelial phenotype marker E-cadherin, under basal conditions and in response to bleomycin and TGF-beta1.	Bleomycin	228-237	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	0-5
22366009-1	2012	OBJECTIVE: To investigate the effects of interleukin-17 (IL-17) on the proliferation, transformation and collagen synthesis of the lung fibroblasts in mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	161-170	interleukin 17A	Mus musculus	41-55
22366009-1	2012	OBJECTIVE: To investigate the effects of interleukin-17 (IL-17) on the proliferation, transformation and collagen synthesis of the lung fibroblasts in mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	161-170	interleukin 17A	Mus musculus	57-62
22366009-2	2012	METHODS: In a mouse model of pulmonary fibrosis established by intratracheal administration of 5 mg/kg bleomycin, the dynamic expressions of IL-17/IL-17 receptor (IL-17R) mRNAs were detected by RT-PCR.	Bleomycin	103-112	interleukin 17 receptor A	Mus musculus	141-161
22366009-2	2012	METHODS: In a mouse model of pulmonary fibrosis established by intratracheal administration of 5 mg/kg bleomycin, the dynamic expressions of IL-17/IL-17 receptor (IL-17R) mRNAs were detected by RT-PCR.	Bleomycin	103-112	interleukin 17 receptor A	Mus musculus	163-169
22366009-5	2012	RESULTS: IL-17/IL-17R mRNA levels were increased obviously in the pulmonary fibroblasts of rats with pulmonary fibrosis, and the highest expressions occurred at 14 days following bleomycin administration.	Bleomycin	179-188	interleukin 17A	Rattus norvegicus	9-14
22366009-5	2012	RESULTS: IL-17/IL-17R mRNA levels were increased obviously in the pulmonary fibroblasts of rats with pulmonary fibrosis, and the highest expressions occurred at 14 days following bleomycin administration.	Bleomycin	179-188	interleukin 17 receptor A	Rattus norvegicus	15-21
22366009-7	2012	CONCLUSION: IL-17 can promote the proliferation, transformation, and collagen synthesis of the pulmonary fibroblasts from rats with bleomycin-induced pulmonary fibrosis.	Bleomycin	132-141	interleukin 17A	Rattus norvegicus	12-17
23119022-0	2012	Regeneration of alveolar type I and II cells from Scgb1a1-expressing cells following severe pulmonary damage induced by bleomycin and influenza.	Bleomycin	120-129	secretoglobin, family 1A, member 1 (uteroglobin)	Mus musculus	50-57
22916109-8	2012	However, upon tissue-injury, either with naphthalene or bleomycin, the canonical BMP-pathways is re-activated, in bronchial or alveolar epithelial cells respectively, in a manner reminiscent to early lung development and in tissue areas where reparatory progenitor cells reside.	Bleomycin	56-65	bone morphogenetic protein 1	Homo sapiens	81-84
22509410-5	2012	We have previously found that inhibition of MetAP2 with fumagillin in bleomycin-injured mice decreased pulmonary fibrosis by selectively decreasing the proliferation of lung myofibroblasts.	Bleomycin	70-79	methionine aminopeptidase 2	Mus musculus	44-50
22123957-12	2011	Similarly, epithelial cells labeled with our Scgb1a1-CreER allele do not give rise to fibroblasts but generate both AEC2 and AEC1 cells in response to bleomycin-induced lung injury.	Bleomycin	151-160	secretoglobin, family 1A, member 1 (uteroglobin)	Mus musculus	45-52
22470441-6	2012	The differentiated cells were used in xenograft transplantation studies in bleomycin-treated Rag2gammaC(-/-) mice.	Bleomycin	75-84	recombination activating gene 2	Mus musculus	93-97
23006535-0	2012	N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats.	Bleomycin	70-79	lysyl oxidase	Rattus norvegicus	35-48
21983071-4	2011	In this study, we demonstrate enhanced myofibroblast contraction in bleomycin-induced lung fibrosis in mice and in fibroblastic foci of human subjects with IPF, using phosphorylation of the regulatory myosin light chain (MLC(20)) as a biomarker of in vivo cellular contractility.	Bleomycin	68-77	myosin light chain 12B	Homo sapiens	221-228
21996315-0	2011	Ghrelin ameliorates bleomycin-induced acute lung injury by protecting alveolar epithelial cells and suppressing lung inflammation.	Bleomycin	20-29	ghrelin	Mus musculus	0-7
21996315-5	2011	Ghrelin or saline was given to mice daily starting 1 day after bleomycin administration.	Bleomycin	63-72	ghrelin	Mus musculus	0-7
22001347-0	2011	SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage.	Bleomycin	56-65	secreted protein acidic and cysteine rich	Homo sapiens	0-5
22037577-9	2011	These results suggest that vFLIP-mediated transcriptional regulation such as Wip1/PPM1D repression is involved in chemosensitization to bleomycin.	Bleomycin	136-145	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	77-81
22001347-2	2011	In the context of bleomycin-induced pulmonary fibrosis, we demonstrated that the matricellular protein termed secreted protein acidic and rich in cysteine (SPARC) distinctly regulates inflammation and collagen deposition, depending on its cellular origin.	Bleomycin	18-27	secreted protein acidic and cysteine rich	Homo sapiens	110-154
22001347-2	2011	In the context of bleomycin-induced pulmonary fibrosis, we demonstrated that the matricellular protein termed secreted protein acidic and rich in cysteine (SPARC) distinctly regulates inflammation and collagen deposition, depending on its cellular origin.	Bleomycin	18-27	secreted protein acidic and cysteine rich	Homo sapiens	156-161
21748431-4	2011	2011 May 11) shows that mice containing a version of ets2 that is incapable of being phosphorylated are resistant to bleomycin-induced lung fibrosis.	Bleomycin	117-126	E26 avian leukemia oncogene 2, 3' domain	Mus musculus	53-57
21873331-8	2011	Inhibition of GSK-3 aggravated experimental fibrosis in bleomycin-challenged mice and in tsk-1 mice.	Bleomycin	56-65	glycogen synthase kinase 3 beta	Mus musculus	14-19
22037577-0	2011	Novel regulatory role for Kaposi"s sarcoma-associated herpesvirus-encoded vFLIP in chemosensitization to bleomycin.	Bleomycin	105-114	K13	Human gammaherpesvirus 8	74-79
22037577-4	2011	However, here we showed that vFLIP expression uniquely sensitized HEK293 cells to bleomycin and its derivatives.	Bleomycin	82-91	K13	Human gammaherpesvirus 8	29-34
22037577-9	2011	These results suggest that vFLIP-mediated transcriptional regulation such as Wip1/PPM1D repression is involved in chemosensitization to bleomycin.	Bleomycin	136-145	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	82-87
22037577-5	2011	Chemosensitization to bleomycin by vFLIP accompanied accumulation of gamma-H2AX and G2/M-arrest of cells, while bleomycin-induced DNA damage checkpoints, such as phosphorylation of Chk2 and foci formation of Rad51, were similarly detected in both parental and vFLIP-expressing cells, suggesting that primary DNA damage was not affected by vFLIP.	Bleomycin	22-31	K13	Human gammaherpesvirus 8	35-40
22037577-5	2011	Chemosensitization to bleomycin by vFLIP accompanied accumulation of gamma-H2AX and G2/M-arrest of cells, while bleomycin-induced DNA damage checkpoints, such as phosphorylation of Chk2 and foci formation of Rad51, were similarly detected in both parental and vFLIP-expressing cells, suggesting that primary DNA damage was not affected by vFLIP.	Bleomycin	22-31	checkpoint kinase 2	Homo sapiens	181-185
21562315-6	2011	Ets-2 (A72/A72) mice were protected from bleomycin-induced pulmonary fibrosis, compared with ets-2 (WT/WT) mice.	Bleomycin	41-50	E26 avian leukemia oncogene 2, 3' domain	Mus musculus	0-5
22037577-5	2011	Chemosensitization to bleomycin by vFLIP accompanied accumulation of gamma-H2AX and G2/M-arrest of cells, while bleomycin-induced DNA damage checkpoints, such as phosphorylation of Chk2 and foci formation of Rad51, were similarly detected in both parental and vFLIP-expressing cells, suggesting that primary DNA damage was not affected by vFLIP.	Bleomycin	22-31	RAD51 recombinase	Homo sapiens	208-213
22037577-5	2011	Chemosensitization to bleomycin by vFLIP accompanied accumulation of gamma-H2AX and G2/M-arrest of cells, while bleomycin-induced DNA damage checkpoints, such as phosphorylation of Chk2 and foci formation of Rad51, were similarly detected in both parental and vFLIP-expressing cells, suggesting that primary DNA damage was not affected by vFLIP.	Bleomycin	22-31	K13	Human gammaherpesvirus 8	260-265
22037577-5	2011	Chemosensitization to bleomycin by vFLIP accompanied accumulation of gamma-H2AX and G2/M-arrest of cells, while bleomycin-induced DNA damage checkpoints, such as phosphorylation of Chk2 and foci formation of Rad51, were similarly detected in both parental and vFLIP-expressing cells, suggesting that primary DNA damage was not affected by vFLIP.	Bleomycin	22-31	K13	Human gammaherpesvirus 8	260-265
22037577-5	2011	Chemosensitization to bleomycin by vFLIP accompanied accumulation of gamma-H2AX and G2/M-arrest of cells, while bleomycin-induced DNA damage checkpoints, such as phosphorylation of Chk2 and foci formation of Rad51, were similarly detected in both parental and vFLIP-expressing cells, suggesting that primary DNA damage was not affected by vFLIP.	Bleomycin	112-121	checkpoint kinase 2	Homo sapiens	181-185
22037577-5	2011	Chemosensitization to bleomycin by vFLIP accompanied accumulation of gamma-H2AX and G2/M-arrest of cells, while bleomycin-induced DNA damage checkpoints, such as phosphorylation of Chk2 and foci formation of Rad51, were similarly detected in both parental and vFLIP-expressing cells, suggesting that primary DNA damage was not affected by vFLIP.	Bleomycin	112-121	RAD51 recombinase	Homo sapiens	208-213
22037577-5	2011	Chemosensitization to bleomycin by vFLIP accompanied accumulation of gamma-H2AX and G2/M-arrest of cells, while bleomycin-induced DNA damage checkpoints, such as phosphorylation of Chk2 and foci formation of Rad51, were similarly detected in both parental and vFLIP-expressing cells, suggesting that primary DNA damage was not affected by vFLIP.	Bleomycin	112-121	K13	Human gammaherpesvirus 8	260-265
22037577-5	2011	Chemosensitization to bleomycin by vFLIP accompanied accumulation of gamma-H2AX and G2/M-arrest of cells, while bleomycin-induced DNA damage checkpoints, such as phosphorylation of Chk2 and foci formation of Rad51, were similarly detected in both parental and vFLIP-expressing cells, suggesting that primary DNA damage was not affected by vFLIP.	Bleomycin	112-121	K13	Human gammaherpesvirus 8	260-265
22037577-7	2011	Additionally, cAMP-response element (CRE)- and p53-dependent transcriptional reporter activity was negatively regulated by vFLIP in the presence of bleomycin.	Bleomycin	148-157	tumor protein p53	Homo sapiens	47-50
22037577-7	2011	Additionally, cAMP-response element (CRE)- and p53-dependent transcriptional reporter activity was negatively regulated by vFLIP in the presence of bleomycin.	Bleomycin	148-157	K13	Human gammaherpesvirus 8	123-128
22037577-8	2011	Interestingly, a negative regulatory phosphatase essential for G2 checkpoint recovery and for dephosphorylation of gamma-H2AX, Wip1/PPM1D, whose gene promoter is regulated by p53, CRE and NF-kappaB, was selectively downregulated in vFLIP-expressing cells after bleomycin treatment.	Bleomycin	261-270	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	127-131
22037577-8	2011	Interestingly, a negative regulatory phosphatase essential for G2 checkpoint recovery and for dephosphorylation of gamma-H2AX, Wip1/PPM1D, whose gene promoter is regulated by p53, CRE and NF-kappaB, was selectively downregulated in vFLIP-expressing cells after bleomycin treatment.	Bleomycin	261-270	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	132-137
22037577-8	2011	Interestingly, a negative regulatory phosphatase essential for G2 checkpoint recovery and for dephosphorylation of gamma-H2AX, Wip1/PPM1D, whose gene promoter is regulated by p53, CRE and NF-kappaB, was selectively downregulated in vFLIP-expressing cells after bleomycin treatment.	Bleomycin	261-270	tumor protein p53	Homo sapiens	175-178
22037577-8	2011	Interestingly, a negative regulatory phosphatase essential for G2 checkpoint recovery and for dephosphorylation of gamma-H2AX, Wip1/PPM1D, whose gene promoter is regulated by p53, CRE and NF-kappaB, was selectively downregulated in vFLIP-expressing cells after bleomycin treatment.	Bleomycin	261-270	nuclear factor kappa B subunit 1	Homo sapiens	188-197
22037577-8	2011	Interestingly, a negative regulatory phosphatase essential for G2 checkpoint recovery and for dephosphorylation of gamma-H2AX, Wip1/PPM1D, whose gene promoter is regulated by p53, CRE and NF-kappaB, was selectively downregulated in vFLIP-expressing cells after bleomycin treatment.	Bleomycin	261-270	K13	Human gammaherpesvirus 8	232-237
22037577-9	2011	These results suggest that vFLIP-mediated transcriptional regulation such as Wip1/PPM1D repression is involved in chemosensitization to bleomycin.	Bleomycin	136-145	K13	Human gammaherpesvirus 8	27-32
21562315-8	2011	Immunohistochemical staining of lung sections from bleomycin-treated ets-2 (WT/WT) mice and from patients with idiopathic pulmonary fibrosis demonstrated increased staining of phosphorylated ets-2 that colocalized with Type I collagen expression and to fibroblastic foci.	Bleomycin	51-60	E26 avian leukemia oncogene 2, 3' domain	Mus musculus	69-74
21562315-8	2011	Immunohistochemical staining of lung sections from bleomycin-treated ets-2 (WT/WT) mice and from patients with idiopathic pulmonary fibrosis demonstrated increased staining of phosphorylated ets-2 that colocalized with Type I collagen expression and to fibroblastic foci.	Bleomycin	51-60	E26 avian leukemia oncogene 2, 3' domain	Mus musculus	191-196
21792841-11	2011	Furthermore, NLRP3(-/-)  mice and ASC(-/-)  mice were resistant to bleomycin-induced skin fibrosis, which suggests a key role for the inflammasome in in vivo fibrosis.	Bleomycin	67-76	NLR family, pyrin domain containing 3	Mus musculus	13-18
21930967-0	2011	TLR2-mediated production of IL-27 and chemokines by respiratory epithelial cells promotes bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	90-99	toll-like receptor 2	Mus musculus	0-4
21302298-0	2011	TGFbeta- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR).	Bleomycin	13-22	AKT serine/threonine kinase 1	Homo sapiens	82-85
21302298-0	2011	TGFbeta- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR).	Bleomycin	13-22	mechanistic target of rapamycin kinase	Homo sapiens	90-119
21302298-0	2011	TGFbeta- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR).	Bleomycin	13-22	mechanistic target of rapamycin kinase	Homo sapiens	121-125
21302298-3	2011	In the current study, we investigated the importance of Akt1 in TGFbeta- and bleomycin-induced synthesis and secretion of ECM proteins by fibroblasts.	Bleomycin	77-86	AKT serine/threonine kinase 1	Homo sapiens	56-60
21302298-5	2011	Treatment with TGFbeta and bleomycin also resulted in increased phosphorylation of Akt, mammalian target of rapamycin (mTOR) and their downstream signaling partners, p70S6 Kinase, Ribosomal S6 protein and 4E-BP1, resulting in the activation of this pathway.	Bleomycin	27-36	AKT serine/threonine kinase 1	Homo sapiens	83-86
21302298-5	2011	Treatment with TGFbeta and bleomycin also resulted in increased phosphorylation of Akt, mammalian target of rapamycin (mTOR) and their downstream signaling partners, p70S6 Kinase, Ribosomal S6 protein and 4E-BP1, resulting in the activation of this pathway.	Bleomycin	27-36	mechanistic target of rapamycin kinase	Homo sapiens	88-117
21302298-5	2011	Treatment with TGFbeta and bleomycin also resulted in increased phosphorylation of Akt, mammalian target of rapamycin (mTOR) and their downstream signaling partners, p70S6 Kinase, Ribosomal S6 protein and 4E-BP1, resulting in the activation of this pathway.	Bleomycin	27-36	mechanistic target of rapamycin kinase	Homo sapiens	119-123
21811007-9	2011	Using transient transfection, we demonstrated that KuEnls is able to bind laser damage in the nucleus of Ku80-deficient cells within 10 sec and remains bound for up to 2 h. The Mt-Ku fusion protein was over-expressed in U2OS cells and this increased the sensitivity of the cells to bleomycin sulfate.	Bleomycin	282-299	X-ray repair cross complementing 5	Homo sapiens	105-109
21302298-6	2011	The effects of TGFbeta and bleomycin on ECM synthesis were blunted by pre-treatment with an mTOR inhibitor rapamycin.	Bleomycin	27-36	mechanistic target of rapamycin kinase	Homo sapiens	92-96
21302298-7	2011	Whereas mTOR is responsible for the transcriptional regulation of a number of ECM proteins, adhesion molecules and matrix metalloproteases (MMPs), synthesis of major ECM proteins such as fibronectin and collagens (types I, II and V) by fibroblasts in response to TGFbeta and bleomycin is regulated by mTOR at the translational level.	Bleomycin	275-284	mechanistic target of rapamycin kinase	Homo sapiens	8-12
22011168-0	2011	Endogenous annexin A1 counter-regulates bleomycin-induced lung fibrosis.	Bleomycin	40-49	annexin A1	Mus musculus	11-21
21930967-0	2011	TLR2-mediated production of IL-27 and chemokines by respiratory epithelial cells promotes bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	90-99	interleukin 27	Mus musculus	28-33
21239607-2	2011	In the present study, the protective effects of Prx I on the development of bleomycin-induced acute pulmonary inflammation and pulmonary fibrosis were investigated using Prx I-deficient mice.	Bleomycin	76-85	peroxiredoxin 1	Mus musculus	48-53
21615674-9	2011	Genotoxic stress induced by bleomycin and oxidative stress enhanced susceptibility of young mice to pneumonia and was positively correlated with enhanced p16, inflammation, and LR levels.	Bleomycin	28-37	cyclin dependent kinase inhibitor 2A	Mus musculus	154-157
21330466-2	2011	In this study, the increased expression of NT4/5 and of its cognate receptor, the neurotrophic tyrosine kinase receptor Type 2 (TrkB), was observed in human lungs explanted from patients with idiopathic pulmonary fibrosis (IPF), and in lungs from mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	257-266	neurotrophin 4	Homo sapiens	43-48
21330466-2	2011	In this study, the increased expression of NT4/5 and of its cognate receptor, the neurotrophic tyrosine kinase receptor Type 2 (TrkB), was observed in human lungs explanted from patients with idiopathic pulmonary fibrosis (IPF), and in lungs from mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	257-266	neurotrophic receptor tyrosine kinase 2	Homo sapiens	82-126
21330466-2	2011	In this study, the increased expression of NT4/5 and of its cognate receptor, the neurotrophic tyrosine kinase receptor Type 2 (TrkB), was observed in human lungs explanted from patients with idiopathic pulmonary fibrosis (IPF), and in lungs from mice with bleomycin-induced pulmonary fibrosis.	Bleomycin	257-266	neurotrophic receptor tyrosine kinase 2	Homo sapiens	128-132
21330466-4	2011	Increased concentrations of NT4/5 and TrkB were evident in ATII isolated from the lungs of bleomycin-treated mice.	Bleomycin	91-100	neurotrophin 5	Mus musculus	28-33
21330466-4	2011	Increased concentrations of NT4/5 and TrkB were evident in ATII isolated from the lungs of bleomycin-treated mice.	Bleomycin	91-100	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	38-42
21871427-6	2011	Conversely, MMP-3-null mice were protected against bleomycin-induced pulmonary fibrosis.	Bleomycin	51-60	matrix metallopeptidase 3	Mus musculus	12-17
21871427-8	2011	These processes were inhibited in bleomycin-treated MMP-3-null mice, as assessed by cytosolic translocation of beta-catenin and cyclin D1 expression.	Bleomycin	34-43	matrix metallopeptidase 3	Mus musculus	52-57
21871427-8	2011	These processes were inhibited in bleomycin-treated MMP-3-null mice, as assessed by cytosolic translocation of beta-catenin and cyclin D1 expression.	Bleomycin	34-43	catenin (cadherin associated protein), beta 1	Mus musculus	111-123
21871427-8	2011	These processes were inhibited in bleomycin-treated MMP-3-null mice, as assessed by cytosolic translocation of beta-catenin and cyclin D1 expression.	Bleomycin	34-43	cyclin D1	Mus musculus	128-137
21961991-3	2011	This study aims to test the inhibition of 5-lipooxygenase (5-LOX) by boswellic acid (BA) extract in an experimental model of pulmonary fibrosis using bleomycin (BL).	Bleomycin	150-159	lysyl oxidase	Rattus norvegicus	61-64
21943210-11	2011	Administration of prominin-1(+) cells 2 hours after bleomycin instillation protects from pulmonary fibrosis, and some of progenitors differentiate into alveolar type II epithelial cells.	Bleomycin	52-61	prominin 1	Mus musculus	18-28
21943210-13	2011	Bleomycin challenge enhances accumulation of bone marrow-derived prominin-1(+) cells within inflamed lung.	Bleomycin	0-9	prominin 1	Mus musculus	65-75
21741938-0	2011	Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage.	Bleomycin	102-111	C-C motif chemokine ligand 2	Homo sapiens	79-83
21764988-0	2011	PGI synthase overexpression protects against bleomycin-induced mortality and is associated with increased Nqo 1 expression.	Bleomycin	45-54	prostaglandin I2 (prostacyclin) synthase	Mus musculus	0-12
21764988-2	2011	Previous studies have suggested that signaling through the prostaglandin (PG) I(2) receptor may protect against bleomycin-induced ALI in mice.	Bleomycin	112-121	prostaglandin I receptor (IP)	Mus musculus	59-91
21764988-3	2011	We found that mice that overexpress PGI synthase (PGIS) in the airway epithelium were significantly protected against bleomycin-induced mortality and had reduced parenchymal consolidation, apoptosis of lung tissue, and generation of F(2)-isoprostanes compared with littermate wild-type controls.	Bleomycin	118-127	prostaglandin I2 (prostacyclin) synthase	Mus musculus	36-48
21764988-3	2011	We found that mice that overexpress PGI synthase (PGIS) in the airway epithelium were significantly protected against bleomycin-induced mortality and had reduced parenchymal consolidation, apoptosis of lung tissue, and generation of F(2)-isoprostanes compared with littermate wild-type controls.	Bleomycin	118-127	prostaglandin I2 (prostacyclin) synthase	Mus musculus	50-54
21764988-5	2011	PGI(2) induction of Nqo 1 provides a possible novel mechanism by which this prostanoid protects against bleomycin-induced mortality and identifies a potential therapeutic target for human ALI.	Bleomycin	104-113	NAD(P)H quinone dehydrogenase 1	Homo sapiens	20-25
21831962-0	2011	CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.	Bleomycin	82-91	calmodulin 1	Homo sapiens	7-17
21831962-10	2011	We conclude that CaM inhibition contributes to CBP501"s activity in sensitizing cancer cells to cisplatin or bleomycin.	Bleomycin	109-118	calmodulin 1	Homo sapiens	17-20
21841134-5	2011	Neutralization of IL-17A in vivo promoted the resolution of bleomycin-induced acute inflammation, attenuated pulmonary fibrosis, and increased survival.	Bleomycin	60-69	interleukin 17A	Homo sapiens	18-24
21131445-0	2011	Keratinocyte growth factor gene transduction ameliorates pulmonary fibrosis induced by bleomycin in mice.	Bleomycin	87-96	fibroblast growth factor 7	Mus musculus	0-26
21131445-2	2011	We demonstrate here that bleomycin-induced pulmonary fibrosis in mice is ameliorated by intratracheal administration of keratinocyte growth factor (KGF)-expressing adenovirus vector.	Bleomycin	25-34	fibroblast growth factor 7	Mus musculus	120-146
21131445-2	2011	We demonstrate here that bleomycin-induced pulmonary fibrosis in mice is ameliorated by intratracheal administration of keratinocyte growth factor (KGF)-expressing adenovirus vector.	Bleomycin	25-34	fibroblast growth factor 7	Mus musculus	148-151
21131445-6	2011	Intratracheal instillation of Ad-KGF at 1 week after the first administration of bleomycin increased KGF mRNA expression in the lungs compared with the fibrosis-induced mice that received saline alone.	Bleomycin	81-90	fibroblast growth factor 7	Mus musculus	33-36
21131445-6	2011	Intratracheal instillation of Ad-KGF at 1 week after the first administration of bleomycin increased KGF mRNA expression in the lungs compared with the fibrosis-induced mice that received saline alone.	Bleomycin	81-90	fibroblast growth factor 7	Mus musculus	101-104
21239607-5	2011	Furthermore, the level of 8-isoprostane, an oxidative stress marker, and the concentration and alveolar macrophage expression of macrophage migration inhibitory factor were elevated in the lungs of Prx I-deficient mice after bleomycin administration.	Bleomycin	225-234	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	129-167
21665960-8	2011	Addition of purified ANGII or bleomycin-induced caspase activation, nuclear fragmentation, and JNK phosphorylation in cultured AECs.	Bleomycin	30-39	mitogen-activated protein kinase 8	Homo sapiens	95-98
21239607-6	2011	The exacerbation of bleomycin-induced pulmonary inflammation and fibrosis in Prx I-deficient mice was inhibited by treatment with N-acetyl-L-cysteine, a radical scavenger, or with (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester, a tautomerase inhibitor of macrophage migration inhibitory factor.	Bleomycin	20-29	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	283-321
21169555-7	2011	Furthermore, increased Grp78 immunoreactivity was observed in AT2 cells of mice after bleomycin injury, supporting a role for ER stress in epithelial abnormalities in fibrosis in vivo.	Bleomycin	86-95	heat shock protein 5	Mus musculus	23-28
21239607-7	2011	These findings suggest that mice lacking Prx I are highly susceptible to bleomycin-induced pulmonary inflammation and fibrosis because of increases in pulmonary oxidant levels and macrophage migration inhibitory factor activity in response to bleomycin.	Bleomycin	73-82	peroxiredoxin 1	Mus musculus	41-46
21239607-7	2011	These findings suggest that mice lacking Prx I are highly susceptible to bleomycin-induced pulmonary inflammation and fibrosis because of increases in pulmonary oxidant levels and macrophage migration inhibitory factor activity in response to bleomycin.	Bleomycin	73-82	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	180-218
21239607-7	2011	These findings suggest that mice lacking Prx I are highly susceptible to bleomycin-induced pulmonary inflammation and fibrosis because of increases in pulmonary oxidant levels and macrophage migration inhibitory factor activity in response to bleomycin.	Bleomycin	243-252	peroxiredoxin 1	Mus musculus	41-46
21239607-7	2011	These findings suggest that mice lacking Prx I are highly susceptible to bleomycin-induced pulmonary inflammation and fibrosis because of increases in pulmonary oxidant levels and macrophage migration inhibitory factor activity in response to bleomycin.	Bleomycin	243-252	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	180-218
21843105-5	2011	Tdp1 inhibitors should synergize not only with Top1-targeting drugs (camptothecins, indenoisoquinolines), but also with bleomycin, topoisomerase II (Top2) inhibitors (etoposide, doxorubicin) and DNA alkylating agents.	Bleomycin	120-129	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-4
21596473-8	2011	When the ATII-like cells were exposed to either bleomycin or a TGF(b1)-EGF cocktail, they underwent phenotypic changes including acquisition of a mesenchymal/fibroblastic morphology, upregulation of mesenchymal markers (Col1, Vim, a-Sma, and S100A4), and downregulation of surfactant proteins and E-cadherin.	Bleomycin	48-57	vimentin	Mus musculus	226-229
21596473-8	2011	When the ATII-like cells were exposed to either bleomycin or a TGF(b1)-EGF cocktail, they underwent phenotypic changes including acquisition of a mesenchymal/fibroblastic morphology, upregulation of mesenchymal markers (Col1, Vim, a-Sma, and S100A4), and downregulation of surfactant proteins and E-cadherin.	Bleomycin	48-57	immunoglobulin mu binding protein 2	Mus musculus	233-236
21596473-8	2011	When the ATII-like cells were exposed to either bleomycin or a TGF(b1)-EGF cocktail, they underwent phenotypic changes including acquisition of a mesenchymal/fibroblastic morphology, upregulation of mesenchymal markers (Col1, Vim, a-Sma, and S100A4), and downregulation of surfactant proteins and E-cadherin.	Bleomycin	48-57	S100 calcium binding protein A4	Mus musculus	242-248
21596473-8	2011	When the ATII-like cells were exposed to either bleomycin or a TGF(b1)-EGF cocktail, they underwent phenotypic changes including acquisition of a mesenchymal/fibroblastic morphology, upregulation of mesenchymal markers (Col1, Vim, a-Sma, and S100A4), and downregulation of surfactant proteins and E-cadherin.	Bleomycin	48-57	cadherin 1	Mus musculus	297-307
21734232-4	2011	We found that the vitronectin-binding capacity of PAI-1 was the primary determinant required for its ability to exacerbate lung scarring induced by intratracheal bleomycin administration.	Bleomycin	162-171	vitronectin	Mus musculus	18-29
21642472-5	2011	Bleomycin treatment also induced pVHL in lung fibroblasts, but not in alveolar type II cells.	Bleomycin	0-9	von Hippel-Lindau tumor suppressor	Homo sapiens	33-37
21734232-4	2011	We found that the vitronectin-binding capacity of PAI-1 was the primary determinant required for its ability to exacerbate lung scarring induced by intratracheal bleomycin administration.	Bleomycin	162-171	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	50-55
21734232-5	2011	The critical role of the vitronectin-binding function of PAI-1 in fibrosis was confirmed in the bleomycin model using mice genetically modified to express the mutant PAI-1 proteins.	Bleomycin	96-105	vitronectin	Mus musculus	25-36
21734232-5	2011	The critical role of the vitronectin-binding function of PAI-1 in fibrosis was confirmed in the bleomycin model using mice genetically modified to express the mutant PAI-1 proteins.	Bleomycin	96-105	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	57-62
21513813-5	2011	NOX4 is increased in pulmonary fibroblasts from IPF patients and deletion of Nox4 in mice prevents bleomycin-induced pulmonary fibrosis.	Bleomycin	99-108	NADPH oxidase 4	Homo sapiens	0-4
21513813-5	2011	NOX4 is increased in pulmonary fibroblasts from IPF patients and deletion of Nox4 in mice prevents bleomycin-induced pulmonary fibrosis.	Bleomycin	99-108	NADPH oxidase 4	Homo sapiens	77-81
21921419-6	2011	CCN6 was highly expressed in the lung tissues of mice treated with bleomycin.	Bleomycin	67-76	cellular communication network factor 6	Mus musculus	0-4
21520061-7	2011	The synthesis and secretion of TGF-beta1 and CTGF protein were up-regulated in PMVECs isolated from bleomycin (BLM)-treated rats, most prominently at 7 days post-instillation.	Bleomycin	100-109	transforming growth factor, beta 1	Rattus norvegicus	31-40
21520061-7	2011	The synthesis and secretion of TGF-beta1 and CTGF protein were up-regulated in PMVECs isolated from bleomycin (BLM)-treated rats, most prominently at 7 days post-instillation.	Bleomycin	100-109	cellular communication network factor 2	Rattus norvegicus	45-49
21746810-0	2011	Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice.	Bleomycin	131-140	transglutaminase 2, C polypeptide	Mus musculus	11-29
21746810-3	2011	Here, we show that in a lung injury model, bleomycin induced the secretion of IL-6 by epithelial cells in a transglutaminase 2 (TG2)-dependent manner.	Bleomycin	43-52	interleukin 6	Mus musculus	78-82
21746810-3	2011	Here, we show that in a lung injury model, bleomycin induced the secretion of IL-6 by epithelial cells in a transglutaminase 2 (TG2)-dependent manner.	Bleomycin	43-52	transglutaminase 2, C polypeptide	Mus musculus	108-126
21746810-3	2011	Here, we show that in a lung injury model, bleomycin induced the secretion of IL-6 by epithelial cells in a transglutaminase 2 (TG2)-dependent manner.	Bleomycin	43-52	transglutaminase 2, C polypeptide	Mus musculus	128-131
22152313-1	2011	To investigate the effect of hepatitis B virus X protein(HBx) on CtBP-interacting protein(CtIP) which is an important repair factor of DNA double strand break damage in HepG2 cells induced by bleomycin.	Bleomycin	192-201	X protein	Hepatitis B virus	57-60
21575650-10	2011	Bleomycin induced a significant increase in hydroxyproline level and activated NF-kappaB, p65 expression in the lung.	Bleomycin	0-9	synaptotagmin 1	Rattus norvegicus	90-93
22097728-1	2011	OBJECTIVE: To investigate whether connective tissue growth factor (CGGF) is expressed in mast cells (MCs) in lung in the development of bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	136-145	cellular communication network factor 2	Rattus norvegicus	34-65
22097728-1	2011	OBJECTIVE: To investigate whether connective tissue growth factor (CGGF) is expressed in mast cells (MCs) in lung in the development of bleomycin (BLM)-induced pulmonary fibrosis.	Bleomycin	147-150	cellular communication network factor 2	Rattus norvegicus	34-65
22152313-1	2011	To investigate the effect of hepatitis B virus X protein(HBx) on CtBP-interacting protein(CtIP) which is an important repair factor of DNA double strand break damage in HepG2 cells induced by bleomycin.	Bleomycin	192-201	RB binding protein 8, endonuclease	Homo sapiens	90-94
22152313-5	2011	After being induced by bleomycin, the percentage of apoptotic cell was 16.90%+/-0.89% in HBx stably expressing HepG2 cell line and 15.30%+/-0.86% in control cell line, respectively (q = 2.074, P is more than to 0.05).	Bleomycin	23-32	X protein	Hepatitis B virus	89-92
21515915-11	2011	Moreover, JunD(-/-) mice were protected from bleomycin-induced fibrosis with reduced dermal thickening, decreased myofibroblast counts and lower collagen content of lesional skin.	Bleomycin	45-54	jun D proto-oncogene	Mus musculus	10-14
21781306-4	2011	RESULTS: We investigated the role of acetyl modification in regulating apoptotic activity of Abl and the results showed that DNA strand break-inducing agents, ionizing radiation and bleomycin induced Abl acetylation.	Bleomycin	182-191	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	93-96
21781306-4	2011	RESULTS: We investigated the role of acetyl modification in regulating apoptotic activity of Abl and the results showed that DNA strand break-inducing agents, ionizing radiation and bleomycin induced Abl acetylation.	Bleomycin	182-191	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	200-203
20833968-4	2011	CCL3/MIP-1alpha concentrations in lung homogenates increased significantly with time after bleomycin challenge, and this was accompanied by increased number of leukocytes and elevated levels of CCL2/monocyte chemoattractant protein (MCP)-1, CCL5/regulated upon activation, normal T cell expressed and secreted, TNF-alpha and transforming growth factor-beta(1), and pulmonary fibrosis.	Bleomycin	91-100	chemokine (C-C motif) ligand 3	Mus musculus	0-4
20833968-4	2011	CCL3/MIP-1alpha concentrations in lung homogenates increased significantly with time after bleomycin challenge, and this was accompanied by increased number of leukocytes and elevated levels of CCL2/monocyte chemoattractant protein (MCP)-1, CCL5/regulated upon activation, normal T cell expressed and secreted, TNF-alpha and transforming growth factor-beta(1), and pulmonary fibrosis.	Bleomycin	91-100	chemokine (C-C motif) ligand 3	Mus musculus	5-15
20833968-7	2011	In conclusion, targeting CCL3/MIP-1alpha by treatment with evasin-1 is beneficial in the context of bleomycin-induced lung injury, even when treatment is started after the fibrogenic insult.	Bleomycin	100-109	chemokine (C-C motif) ligand 3	Mus musculus	25-29
20833968-7	2011	In conclusion, targeting CCL3/MIP-1alpha by treatment with evasin-1 is beneficial in the context of bleomycin-induced lung injury, even when treatment is started after the fibrogenic insult.	Bleomycin	100-109	chemokine (C-C motif) ligand 3	Mus musculus	30-40
21749980-10	2011	Immunohistochemistry of a bleomycin-induced model of pulmonary fibrosis and lung specimens from patients with idiopathic interstitial pneumonias showed that Notch was strongly expressed in myofibroblasts, identified as SMA-positive cells.	Bleomycin	26-35	notch receptor 1	Rattus norvegicus	157-162
21708929-4	2011	We found that targeted overexpression of HAS2 (HA synthase 2) by myofibroblasts produced an aggressive phenotype leading to severe lung fibrosis and death after bleomycin-induced injury.	Bleomycin	161-170	hyaluronan synthase 2	Mus musculus	41-45
21708929-4	2011	We found that targeted overexpression of HAS2 (HA synthase 2) by myofibroblasts produced an aggressive phenotype leading to severe lung fibrosis and death after bleomycin-induced injury.	Bleomycin	161-170	hyaluronan synthase 2	Mus musculus	47-60
21790287-7	2011	Using the bleomycin-induced dermal fibrosis model, it has now been demonstrated that STAT4-deficient mice have reduced dermal fibrosis in part via STAT4-dependent alterations in T-cell proliferation and cytokine production.	Bleomycin	10-19	signal transducer and activator of transcription 4	Mus musculus	85-90
21586614-9	2011	After local X-ray irradiation or bleomycin treatment, the anti-gammaH2AX-Tat probes produced fluorescent and single photon emission computed tomography signals in the tumors that were proportionate to the delivered radiation dose and the amount of gammaH2AX present.	Bleomycin	33-42	H2A.X variant histone	Mus musculus	63-72
21790287-7	2011	Using the bleomycin-induced dermal fibrosis model, it has now been demonstrated that STAT4-deficient mice have reduced dermal fibrosis in part via STAT4-dependent alterations in T-cell proliferation and cytokine production.	Bleomycin	10-19	signal transducer and activator of transcription 4	Mus musculus	147-152
21602491-4	2011	Given the greater homology to rodent FIZZ2, analyzing the role of FIZZ2 in a rodent model of bleomycin-induced pulmonary fibrosis would be of greater potential relevance to human fibrotic lung disease.	Bleomycin	93-102	resistin like beta	Homo sapiens	66-71
21602491-5	2011	The results showed that FIZZ2 was highly induced in lungs of rodents with bleomycin-induced pulmonary fibrosis and of human patients with idiopathic pulmonary fibrosis.	Bleomycin	74-83	resistin like beta	Homo sapiens	24-29
21478551-0	2011	Secretoglobin 3A2 suppresses bleomycin-induced pulmonary fibrosis by transforming growth factor beta signaling down-regulation.	Bleomycin	29-38	complement factor B	Mus musculus	89-100
22214165-0	2011	[Expression of epidermal growth factor receptor and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin in rats].	Bleomycin	106-115	epidermal growth factor receptor	Rattus norvegicus	15-47
22214165-0	2011	[Expression of epidermal growth factor receptor and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin in rats].	Bleomycin	106-115	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	65-72
22214165-1	2011	OBJECTIVE: To study the expression of the epidermal growth factor receptor (EGFR) and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin (BLM) in rats.	Bleomycin	140-149	epidermal growth factor receptor	Rattus norvegicus	42-74
22214165-1	2011	OBJECTIVE: To study the expression of the epidermal growth factor receptor (EGFR) and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin (BLM) in rats.	Bleomycin	140-149	epidermal growth factor receptor	Rattus norvegicus	76-80
22214165-1	2011	OBJECTIVE: To study the expression of the epidermal growth factor receptor (EGFR) and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin (BLM) in rats.	Bleomycin	140-149	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	99-106
22214165-1	2011	OBJECTIVE: To study the expression of the epidermal growth factor receptor (EGFR) and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin (BLM) in rats.	Bleomycin	151-154	epidermal growth factor receptor	Rattus norvegicus	42-74
22214165-1	2011	OBJECTIVE: To study the expression of the epidermal growth factor receptor (EGFR) and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin (BLM) in rats.	Bleomycin	151-154	epidermal growth factor receptor	Rattus norvegicus	76-80
22214165-1	2011	OBJECTIVE: To study the expression of the epidermal growth factor receptor (EGFR) and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin (BLM) in rats.	Bleomycin	151-154	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	99-106
22214165-12	2011	EGFR expression was increased gradually on the 14th and 28th day (0.17 +/- 0.02 and 0.28 +/- 0.04) in Iressa group ,that was significantly lower than the BLM group (0.27 +/- 0.04 and 0.34 +/- 0.02) (P &lt; 0.01).	Bleomycin	154-157	epidermal growth factor receptor	Rattus norvegicus	0-4
21677199-5	2011	In cultured alveolar epithelial type II cells from bleomycin-induced fibrotic mouse lungs, inhibition of DDAH suppressed proliferation and induced apoptosis in an ADMA-dependent manner.	Bleomycin	51-60	dimethylarginine dimethylaminohydrolase 2	Mus musculus	105-109
21677199-7	2011	In mice with bleomycin-induced pulmonary fibrosis, the DDAH inhibitor L-291 reduced collagen deposition and normalized lung function.	Bleomycin	13-22	dimethylarginine dimethylaminohydrolase 2	Mus musculus	55-59
21677199-8	2011	In bleomycin-induced fibrosis, inducible nitric oxide synthase inhibition decreased fibrosis, but an even stronger reduction was observed after inhibition of DDAH.	Bleomycin	3-12	dimethylarginine dimethylaminohydrolase 2	Mus musculus	158-162
21533992-0	2011	MEK inhibition suppresses the development of lung fibrosis in the bleomycin model.	Bleomycin	66-75	midkine	Mus musculus	0-3
21533992-8	2011	In particular, to assess whether PD98059 treatment influences MAPKs pathway, we have also investigated the expression of activated ERK and JNK after bleomycin-induced pulmonary fibrosis, showing that the inhibition of the cascade reduces the inflammatory processes that lead to the appearance of the fibrosis.	Bleomycin	149-158	mitogen-activated protein kinase 1	Mus musculus	131-134
21670280-5	2011	After intratracheal bleomycin, L188Q SFTPC-expressing mice developed exaggerated lung fibrosis and reduced static lung compliance compared with controls.	Bleomycin	20-29	surfactant associated protein C	Mus musculus	37-42
21670280-6	2011	Bleomycin-treated L188Q SFTPC mice also demonstrated increased apoptosis of alveolar epithelial cells and greater numbers of fibroblasts in the lungs.	Bleomycin	0-9	surfactant associated protein C	Mus musculus	24-29
21478551-7	2011	Histological examination in conjunction with inflammatory cell counts in bronchoalveolar lavage fluids demonstrated that SCGB3A2 suppressed bleomycin-induced pulmonary fibrosis.	Bleomycin	140-149	secretoglobin, family 3A, member 2	Mus musculus	121-128
21478551-8	2011	Microarray analysis was carried out using RNAs from lungs of bleomycin-treated mice with or without SCGB3A2 and normal mice treated with SCGB3A2.	Bleomycin	61-70	secretoglobin, family 3A, member 2	Mus musculus	100-107
21441353-0	2011	TGFbeta signaling in lung epithelium regulates bleomycin-induced alveolar injury and fibroblast recruitment.	Bleomycin	47-56	transforming growth factor, beta 1	Mus musculus	0-7
20705943-0	2011	The effect of class II transactivator mutations on bleomycin-induced lung inflammation and fibrosis.	Bleomycin	51-60	class II transactivator	Mus musculus	14-37
20705943-1	2011	IFN-gamma expression increases during the inflammatory response after bleomycin injury in mice.	Bleomycin	70-79	interferon gamma	Mus musculus	0-9
20705943-3	2011	Because IFN-gamma stimulates class II transactivator (CIITA) expression, which activates major histocompatibility class (MHC) II and represses collagen expression, it was hypothesized that CIITA mediates IFN-gamma action after bleomycin injury.	Bleomycin	227-236	interferon gamma	Mus musculus	8-17
20705943-3	2011	Because IFN-gamma stimulates class II transactivator (CIITA) expression, which activates major histocompatibility class (MHC) II and represses collagen expression, it was hypothesized that CIITA mediates IFN-gamma action after bleomycin injury.	Bleomycin	227-236	class II transactivator	Mus musculus	29-52
20705943-3	2011	Because IFN-gamma stimulates class II transactivator (CIITA) expression, which activates major histocompatibility class (MHC) II and represses collagen expression, it was hypothesized that CIITA mediates IFN-gamma action after bleomycin injury.	Bleomycin	227-236	class II transactivator	Mus musculus	54-59
20705943-3	2011	Because IFN-gamma stimulates class II transactivator (CIITA) expression, which activates major histocompatibility class (MHC) II and represses collagen expression, it was hypothesized that CIITA mediates IFN-gamma action after bleomycin injury.	Bleomycin	227-236	class II transactivator	Mus musculus	189-194
20705943-3	2011	Because IFN-gamma stimulates class II transactivator (CIITA) expression, which activates major histocompatibility class (MHC) II and represses collagen expression, it was hypothesized that CIITA mediates IFN-gamma action after bleomycin injury.	Bleomycin	227-236	interferon gamma	Mus musculus	204-213
20705943-7	2011	When mice were exposed to intratracheal bleomycin, both strains of CIITA mutant mice retained body weight and altered inflammation at 14 days after bleomycin injury compared with bleomycin-treated wild-type mice.	Bleomycin	40-49	class II transactivator	Mus musculus	67-72
20705943-7	2011	When mice were exposed to intratracheal bleomycin, both strains of CIITA mutant mice retained body weight and altered inflammation at 14 days after bleomycin injury compared with bleomycin-treated wild-type mice.	Bleomycin	148-157	class II transactivator	Mus musculus	67-72
20705943-7	2011	When mice were exposed to intratracheal bleomycin, both strains of CIITA mutant mice retained body weight and altered inflammation at 14 days after bleomycin injury compared with bleomycin-treated wild-type mice.	Bleomycin	148-157	class II transactivator	Mus musculus	67-72
21317313-12	2011	CONCLUSIONS: Leptin signaling is required for bleomycin-induced lung fibrosis.	Bleomycin	46-55	leptin	Homo sapiens	13-19
21441353-8	2011	Attenuation of TGFbeta signaling in lung epithelium provides protection from bleomycin-induced fibrosis, indicating a critical role for the epithelium in transducing the profibrotic effects of this cytokine.	Bleomycin	77-86	transforming growth factor, beta 1	Mus musculus	15-22
21441353-2	2011	We aimed to elucidate how transforming growth factor-beta (TGFbeta) signaling in lung epithelium impacts lung fibrosis in the intratracheal bleomycin model.	Bleomycin	140-149	transforming growth factor, beta 1	Mus musculus	59-66
21312186-5	2011	In the mouse model of bleomycin-induced dermal fibrosis and in tight skin 1 mice, Notch signaling was inhibited by the gamma-secretase inhibitor DAPT and by overexpression of a Notch-1 antisense construct.	Bleomycin	22-31	notch 1	Mus musculus	82-87
21239537-3	2011	Immunohistochemistry of lung tissue from a mouse bleomycin (BLM)-induced pulmonary fibrosis model revealed that expression of HIF-1alpha and PAI-1 was predominantly induced in alveolar macrophages.	Bleomycin	49-58	hypoxia inducible factor 1, alpha subunit	Mus musculus	126-136
21239537-3	2011	Immunohistochemistry of lung tissue from a mouse bleomycin (BLM)-induced pulmonary fibrosis model revealed that expression of HIF-1alpha and PAI-1 was predominantly induced in alveolar macrophages.	Bleomycin	49-58	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	141-146
21239537-3	2011	Immunohistochemistry of lung tissue from a mouse bleomycin (BLM)-induced pulmonary fibrosis model revealed that expression of HIF-1alpha and PAI-1 was predominantly induced in alveolar macrophages.	Bleomycin	60-63	hypoxia inducible factor 1, alpha subunit	Mus musculus	126-136
21239537-3	2011	Immunohistochemistry of lung tissue from a mouse bleomycin (BLM)-induced pulmonary fibrosis model revealed that expression of HIF-1alpha and PAI-1 was predominantly induced in alveolar macrophages.	Bleomycin	60-63	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	141-146
21370225-5	2011	RESULTS: The expression of Wnt-10b was increased in lesional skin biopsy specimens from patients with SSc and in those obtained from mice with bleomycin-induced fibrosis.	Bleomycin	143-152	Wnt family member 10B	Homo sapiens	27-34
21514423-6	2011	Levels of Egr-2 were elevated in lesional tissue from mice with bleomycin-induced scleroderma.	Bleomycin	64-73	early growth response 2	Mus musculus	10-15
21305523-9	2011	RESULTS: The LPA1 -KO mice were markedly resistant to bleomycin-induced increases in dermal thickness and collagen content, whereas the LPA2-KO mice were as susceptible as the WT mice.	Bleomycin	54-63	lysophosphatidic acid receptor 1	Mus musculus	13-17
21305523-10	2011	Bleomycin-induced increases in dermal alpha-SMA+ and phospho-Smad2+ cells were abrogated in LPA1-KO mice.	Bleomycin	0-9	actin alpha 2, smooth muscle, aorta	Mus musculus	38-47
21305523-10	2011	Bleomycin-induced increases in dermal alpha-SMA+ and phospho-Smad2+ cells were abrogated in LPA1-KO mice.	Bleomycin	0-9	lysophosphatidic acid receptor 1	Mus musculus	92-96
21312186-5	2011	In the mouse model of bleomycin-induced dermal fibrosis and in tight skin 1 mice, Notch signaling was inhibited by the gamma-secretase inhibitor DAPT and by overexpression of a Notch-1 antisense construct.	Bleomycin	22-31	notch 1	Mus musculus	177-184
21305523-11	2011	Pharmacologic antagonism of LPA1 with AM095 significantly attenuated bleomycin-induced dermal fibrosis when administered according to either a preventive regimen or two therapeutic regimens.	Bleomycin	69-78	lysophosphatidic acid receptor 1	Mus musculus	28-32
21312186-7	2011	Overexpression of a Notch antisense construct prevented bleomycin-induced fibrosis and hypodermal thickening in tight skin 1 mice.	Bleomycin	56-65	notch 1	Mus musculus	20-25
21312187-11	2011	CONCLUSION: Inhibition of thrombin using the oral direct thrombin inhibitor dabigatran etexilate has marked antiinflammatory and antifibrotic effects in a bleomycin model of pulmonary fibrosis.	Bleomycin	155-164	coagulation factor II	Mus musculus	26-34
21447148-1	2011	BACKGROUND: The current study utilized a Bleomycin-induced model of skin fibrosis to investigate the neo-epitope CO3-610 (KNGETGPQGP), a fragment of collagen III released during matrix metalloproteinase-9 (MMP9) degradation of the protein, we have previously described as a novel biomarker for liver fibrosis.	Bleomycin	41-50	matrix metallopeptidase 9	Mus musculus	206-210
20539010-0	2011	Lung extracellular superoxide dismutase overexpression lessens bleomycin-induced pulmonary hypertension and vascular remodeling.	Bleomycin	63-72	superoxide dismutase 3, extracellular	Mus musculus	5-39
20539010-3	2011	We used a model of pulmonary hypertension secondary to bleomycin-induced pulmonary fibrosis to test the hypothesis that an imbalance in extracellular superoxide and its antioxidant defense, extracellular superoxide dismutase, will promote pulmonary vascular remodeling and pulmonary hypertension.	Bleomycin	55-64	superoxide dismutase 3, extracellular	Mus musculus	190-224
20539010-4	2011	We exposed transgenic mice overexpressing lung extracellular superoxide dismutase and wild-type littermates to a single dose of intratracheal bleomycin, and evaluated the mice weekly for up to 35 days.	Bleomycin	142-151	superoxide dismutase 3, extracellular	Mus musculus	47-81
20539010-6	2011	The overexpression of extracellular superoxide dismutase protected against late remodeling within the medial, adventitial, and intimal layers of the vessel wall after the administration of bleomycin, and attenuated pulmonary hypertension at the same late time point.	Bleomycin	189-198	superoxide dismutase 3, extracellular	Mus musculus	22-56
20539010-8	2011	The overexpression of extracellular superoxide dismutase attenuated late pulmonary hypertension and significantly improved survival after exposure to bleomycin.	Bleomycin	150-159	superoxide dismutase 3, extracellular	Mus musculus	22-56
21265950-0	2011	A novel single-chain-Fv antibody against connective tissue growth factor attenuates bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	84-93	cellular communication network factor 2	Mus musculus	41-72
21265950-3	2011	In the present study, the protective effect of anti-CTGF scFv against bleomycin (BL)-induced pulmonary fibrosis was investigated in mice.	Bleomycin	70-79	cellular communication network factor 2	Mus musculus	52-56
21265950-3	2011	In the present study, the protective effect of anti-CTGF scFv against bleomycin (BL)-induced pulmonary fibrosis was investigated in mice.	Bleomycin	81-83	cellular communication network factor 2	Mus musculus	52-56
20945375-8	2011	In a murine model of bleomycin (BLM)-induced pulmonary fibrosis, ginsan significantly suppressed accumulation of collagen, alpha-SMA, and TGF-beta.	Bleomycin	32-35	actin alpha 2, smooth muscle, aorta	Mus musculus	123-132
21160137-2	2011	The DNA repair protein Ku70 is a key contributor to chemoresistance to anticancer agents, e.g., etoposide and bleomycin, or radioresistance.	Bleomycin	110-119	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	23-27
20581099-8	2011	In response to bleomycin treatment, measures of fibrosis and inflammation, along with CTGF and collagen I mRNA concentrations, were increased in TSP-1-deficient mice compared with WT mice.	Bleomycin	15-24	cellular communication network factor 2	Mus musculus	86-90
20581099-9	2011	Notably, Smad 2/3 signaling was of equal strength in WT and TSP-1 knockout mice treated with bleomycin, suggesting that TSP-1 is not required for the activation of TGF-beta.	Bleomycin	93-102	SMAD family member 2	Mus musculus	9-17
21148207-1	2011	The yeast QDR3 gene encodes a plasma membrane drug : H(+) antiporter of the DHA1 family that was described as conferring resistance against the drugs quinidine, cisplatin and bleomycin and the herbicide barban, similar to its close homologue QDR2.	Bleomycin	175-184	Qdr3p	Saccharomyces cerevisiae S288C	10-14
21148207-1	2011	The yeast QDR3 gene encodes a plasma membrane drug : H(+) antiporter of the DHA1 family that was described as conferring resistance against the drugs quinidine, cisplatin and bleomycin and the herbicide barban, similar to its close homologue QDR2.	Bleomycin	175-184	cation transporter	Saccharomyces cerevisiae S288C	242-246
21251944-0	2011	Links between DNA polymerase beta expression and sensitivity to bleomycin.	Bleomycin	64-73	polymerase (DNA directed), beta	Mus musculus	14-33
21411739-4	2011	In the bleomycin-induced mouse lung fibrosis model, loss of either beta-arrestin1 or beta-arrestin2 resulted in protection from mortality, inhibition of matrix deposition, and protected lung function.	Bleomycin	7-16	arrestin, beta 1	Mus musculus	67-81
21411739-4	2011	In the bleomycin-induced mouse lung fibrosis model, loss of either beta-arrestin1 or beta-arrestin2 resulted in protection from mortality, inhibition of matrix deposition, and protected lung function.	Bleomycin	7-16	arrestin, beta 2	Mus musculus	85-99
21185199-6	2011	In vivo, treatment of mice with P17 2days after bleomycin administration decreased lung fibrosis, areas of myofibroblast-like cells and lymphocyte infiltrate.	Bleomycin	48-57	family with sequence similarity 72, member A	Mus musculus	32-35
21360510-7	2011	RESULTS: Stat4(-/-) mice were protected against bleomycin-induced dermal fibrosis, with a reduction in dermal thickening (mean +- SEM 65 +- 3% decrease; P = 0.03), hydroxyproline content (68 +- 5% decrease; P = 0.02), and myofibroblast counts (71 +- 6% decrease; P = 0.005).	Bleomycin	48-57	signal transducer and activator of transcription 4	Mus musculus	9-14
21356368-0	2011	gammadelta T cells attenuate bleomycin-induced fibrosis through the production of CXCL10.	Bleomycin	29-38	chemokine (C-X-C motif) ligand 10	Mus musculus	82-88
21185940-6	2011	It lowered levels of cyclin kinase inhibitor p21, affected G1 to S phase cell cycle transition; partially blocked the elevation in p53 transcriptional activity, p21 and Bcl-2-associated X protein (Bax) levels caused by bleomycin, but had no influence on enhancement of Bax in response to staurosporine.	Bleomycin	219-228	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	45-48
21487520-6	2011	found that RAGE null mice were protected from bleomycin-induced fibrosis and suggested the effect was due to a lack of HMGB1 induced RAGE signaling.	Bleomycin	46-55	advanced glycosylation end product-specific receptor	Mus musculus	11-15
21487520-11	2011	A lack of RAGE was found to be protective against bleomycin injury in both in vivo and in vitro studies.	Bleomycin	50-59	advanced glycosylation end product-specific receptor	Mus musculus	10-14
21185940-6	2011	It lowered levels of cyclin kinase inhibitor p21, affected G1 to S phase cell cycle transition; partially blocked the elevation in p53 transcriptional activity, p21 and Bcl-2-associated X protein (Bax) levels caused by bleomycin, but had no influence on enhancement of Bax in response to staurosporine.	Bleomycin	219-228	transformation related protein 53, pseudogene	Mus musculus	131-134
21185940-6	2011	It lowered levels of cyclin kinase inhibitor p21, affected G1 to S phase cell cycle transition; partially blocked the elevation in p53 transcriptional activity, p21 and Bcl-2-associated X protein (Bax) levels caused by bleomycin, but had no influence on enhancement of Bax in response to staurosporine.	Bleomycin	219-228	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	161-164
21185940-6	2011	It lowered levels of cyclin kinase inhibitor p21, affected G1 to S phase cell cycle transition; partially blocked the elevation in p53 transcriptional activity, p21 and Bcl-2-associated X protein (Bax) levels caused by bleomycin, but had no influence on enhancement of Bax in response to staurosporine.	Bleomycin	219-228	BCL2-associated X protein	Mus musculus	169-195
21185940-6	2011	It lowered levels of cyclin kinase inhibitor p21, affected G1 to S phase cell cycle transition; partially blocked the elevation in p53 transcriptional activity, p21 and Bcl-2-associated X protein (Bax) levels caused by bleomycin, but had no influence on enhancement of Bax in response to staurosporine.	Bleomycin	219-228	BCL2-associated X protein	Mus musculus	197-200
20926985-0	2011	STY39, a novel alpha-melanocyte-stimulating hormone analogue, attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice.	Bleomycin	73-82	pro-opiomelanocortin-alpha	Mus musculus	15-51
20926985-3	2011	In the current study, we investigated the effect of a novel alpha-melanocyte-stimulating hormone analog, STY39, on bleomycin (BLM)-induced pulmonary inflammation and fibrosis in mice.	Bleomycin	115-124	pro-opiomelanocortin-alpha	Mus musculus	60-96
20926985-3	2011	In the current study, we investigated the effect of a novel alpha-melanocyte-stimulating hormone analog, STY39, on bleomycin (BLM)-induced pulmonary inflammation and fibrosis in mice.	Bleomycin	126-129	pro-opiomelanocortin-alpha	Mus musculus	60-96
21106707-0	2011	A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity.	Bleomycin	73-82	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	27-33
21081487-0	2011	Distinct roles of Ape1 protein in the repair of DNA damage induced by ionizing radiation or bleomycin.	Bleomycin	92-101	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	18-22
21106707-0	2011	A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity.	Bleomycin	73-82	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	34-38
21111848-3	2011	Early intervention with hemin, an HO-1 inducer, abrogated bleomycin-induced pulmonary fibrosis (fibrotic/reparative score decrease from 21.0+-2.4 to 13.8+-1.7, P&lt;0.01), and early intervention with CrMP, an HO-1 inhibitor, worsened bleomycin-induced pulmonary fibrosis (fibrotic/reparative score increase from 21.0+-2.4 to 32.5+-2.9, P&lt;0.01).	Bleomycin	58-67	heme oxygenase 1	Mus musculus	34-38
21111848-3	2011	Early intervention with hemin, an HO-1 inducer, abrogated bleomycin-induced pulmonary fibrosis (fibrotic/reparative score decrease from 21.0+-2.4 to 13.8+-1.7, P&lt;0.01), and early intervention with CrMP, an HO-1 inhibitor, worsened bleomycin-induced pulmonary fibrosis (fibrotic/reparative score increase from 21.0+-2.4 to 32.5+-2.9, P&lt;0.01).	Bleomycin	58-67	heme oxygenase 1	Mus musculus	209-213
21048214-3	2011	The role of PI3Kgamma in mediating bleomycin-induced pulmonary inflammation and fibrosis in mice and potential mechanisms involved was investigated here.	Bleomycin	35-44	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	12-21
20962852-8	2011	In contrast, a limited but significant number of CD45-positive collagen-producing cells migrated from BM following bleomycin injection.	Bleomycin	115-124	protein tyrosine phosphatase, receptor type, C	Mus musculus	49-53
21048214-7	2011	PI3Kgamma KO mice had greater survival and weight recovery and less fibrosis than WT mice after bleomycin instillation.	Bleomycin	96-105	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	0-9
21048214-13	2011	PI3Kgamma deficiency confers protection against bleomycin-induced pulmonary injury, angiogenesis, and fibrosis through the modulation of leukocyte, fibroblast, and endothelial cell functions.	Bleomycin	48-57	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	0-9
21266028-0	2011	mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis.	Bleomycin	35-44	prostaglandin E synthase	Mus musculus	0-7
21223583-7	2011	Immunohistochemical analyses were performed to determine whether TLR3 was expressed in skin biopsies in the bleomycin-induced skin fibrosis model and in patients with SSc.	Bleomycin	108-117	toll like receptor 3	Homo sapiens	65-69
21223583-12	2011	TLR3 expression was observed in dermal fibroblasts and inflammatory cells from skin biopsies from patients with SSc as well as in the bleomycin-induced skin fibrosis model.	Bleomycin	134-143	toll like receptor 3	Homo sapiens	0-4
20936632-0	2011	CCN2 is required for bleomycin-induced skin fibrosis in mice.	Bleomycin	21-30	cellular communication network factor 2	Mus musculus	0-4
20936632-3	2011	The aim of this study was to assess whether adult mice bearing a smooth muscle cell/fibroblast-specific deletion of CCN2 are resistant to bleomycin-induced skin scleroderma.	Bleomycin	138-147	cellular communication network factor 2	Mus musculus	116-120
21266028-5	2011	mPGES-1 expressions in scleroderma fibroblasts and in fibroblasts derived from bleomycin-exposed mice were assessed by Western blot analysis.	Bleomycin	79-88	prostaglandin E synthase	Mus musculus	0-7
20936632-8	2011	RESULTS: The loss of CCN2 resulted in resistance to bleomycin-induced skin fibrosis.	Bleomycin	52-61	cellular communication network factor 2	Mus musculus	21-25
21266028-8	2011	RESULTS: Compared to normal skin fibroblasts, mPGES-1 protein expression was elevated in systemic sclerosis (SSc) fibroblasts and in bleomycin-exposed mice.	Bleomycin	133-142	prostaglandin E synthase	Mus musculus	46-53
20936632-11	2011	Collectively, these results indicate that CCN2 is essential for bleomycin-induced skin fibrosis, likely due to a defect in myofibroblast recruitment.	Bleomycin	64-73	cellular communication network factor 2	Mus musculus	42-46
21266028-9	2011	Compared to WT mice, mPGES-1-null mice were resistant to bleomycin-induced inflammation, cutaneous thickening, collagen production and myofibroblast formation.	Bleomycin	57-66	prostaglandin E synthase	Mus musculus	21-28
21266028-10	2011	CONCLUSIONS: mPGES-1 expression is required for bleomycin-induced skin fibrogenesis.	Bleomycin	48-57	prostaglandin E synthase	Mus musculus	13-20
21158940-7	2011	PAR(2) -induced intracellular calcium mobilization was only measurable in HDF after bleomycin pretreatment.	Bleomycin	84-93	F2R like trypsin receptor 1	Homo sapiens	0-6
21158940-9	2011	Intriguingly, bleomycin activated PAR(2) in HDF indicating that fibrosis-promoting factors have a direct effect on PAR(2) expression and functionality.	Bleomycin	14-23	F2R like trypsin receptor 1	Homo sapiens	34-39
21158940-9	2011	Intriguingly, bleomycin activated PAR(2) in HDF indicating that fibrosis-promoting factors have a direct effect on PAR(2) expression and functionality.	Bleomycin	14-23	F2R like trypsin receptor 1	Homo sapiens	115-120
20937408-3	2011	In order to gain a better understanding of the molecular basis of this phenomenon, caveolin-1-enriched microdomains of untreated and bleomycin-treated growth-arrested A549 cells were analysed for differential protein expression using 2-D DIGE followed by LC-MS/MS.	Bleomycin	133-142	caveolin 1	Homo sapiens	83-93
20937408-5	2011	We show that MGr1-Ag becomes partly localised in lipid rafts following bleomycin treatment, and that MGr1-Ag and caveolin-1 occur in a common protein complex in vivo using co-immunoprecipitation studies.	Bleomycin	71-80	MGR1	Homo sapiens	13-17
20937408-6	2011	GST pull-down assays demonstrated an increased interaction between MGr1-Ag and caveolin-1 following bleomycin treatment in vitro.	Bleomycin	100-109	MGR1	Homo sapiens	67-71
21044893-1	2011	Serum amyloid P (SAP), a member of the pentraxin family of proteins inhibits bleomycin-induced lung fibrosis through an inhibition of pulmonary fibrocyte and pro-fibrotic alternative (M2) macrophage accumulation.	Bleomycin	77-86	amyloid P component, serum	Homo sapiens	17-20
20937408-0	2011	Bleomycin treatment of A549 human lung cancer cells results in association of MGr1-Ag and caveolin-1 in lipid rafts.	Bleomycin	0-9	MGR1	Homo sapiens	78-82
20937408-0	2011	Bleomycin treatment of A549 human lung cancer cells results in association of MGr1-Ag and caveolin-1 in lipid rafts.	Bleomycin	0-9	caveolin 1	Homo sapiens	90-100
20937408-6	2011	GST pull-down assays demonstrated an increased interaction between MGr1-Ag and caveolin-1 following bleomycin treatment in vitro.	Bleomycin	100-109	caveolin 1	Homo sapiens	79-89
20937408-7	2011	Our results reveal MGr1-Ag as a novel lipid raft protein; its increased association with caveolin-1 in bleomycin-induced cell cycle arrest and subsequent cellular senescence might contribute to the success of chemotherapy.	Bleomycin	103-112	MGR1	Homo sapiens	19-23
20937408-7	2011	Our results reveal MGr1-Ag as a novel lipid raft protein; its increased association with caveolin-1 in bleomycin-induced cell cycle arrest and subsequent cellular senescence might contribute to the success of chemotherapy.	Bleomycin	103-112	caveolin 1	Homo sapiens	89-99
21190578-3	2010	METHODS: The present study evaluates the expression of catalase mRNA and protein in human interstitial pneumonias and in mouse bleomycin-induced lung injury.	Bleomycin	127-136	catalase	Homo sapiens	55-63
22096546-3	2011	We recently reported that expression of heat shock protein 70 (HSP70) protects against bleomycin-induced pulmonary fibrosis, an animal model of pulmonary fibrosis.	Bleomycin	87-96	heat shock protein 1B	Mus musculus	40-61
22096546-3	2011	We recently reported that expression of heat shock protein 70 (HSP70) protects against bleomycin-induced pulmonary fibrosis, an animal model of pulmonary fibrosis.	Bleomycin	87-96	heat shock protein 1B	Mus musculus	63-68
22096546-10	2011	Furthermore, oral co-administration of geranylgeranylacetone (GGA), an inducer of HSP70, suppressed gefitinib-induced exacerbation of bleomycin-induced pulmonary fibrosis.	Bleomycin	134-143	heat shock protein 1B	Mus musculus	82-87
22096546-11	2011	Taken together, these findings suggest that gefitinib-induced exacerbation of bleomycin-induced pulmonary fibrosis is mediated by suppression of pulmonary expression of HSP70 and that an inducer of HSP70 expression, such as GGA, may be therapeutically beneficial for the treatment of gefitinib-induced pulmonary fibrosis.	Bleomycin	78-87	heat shock protein 1B	Mus musculus	169-174
21778693-0	2011	Mobilization of bone marrow cells by CSF3 protects mice from bleomycin-induced lung injury.	Bleomycin	61-70	colony stimulating factor 3 (granulocyte)	Mus musculus	37-41
21778693-3	2011	OBJECTIVES: The aim of this study was to determine the effect of the mobilization of autologous bone marrow-derived cells by granulocyte colony-stimulating factor (CSF3) on bleomycin-induced lung injury in mice.	Bleomycin	173-182	colony stimulating factor 3 (granulocyte)	Mus musculus	125-162
21778693-3	2011	OBJECTIVES: The aim of this study was to determine the effect of the mobilization of autologous bone marrow-derived cells by granulocyte colony-stimulating factor (CSF3) on bleomycin-induced lung injury in mice.	Bleomycin	173-182	colony stimulating factor 3 (granulocyte)	Mus musculus	164-168
21778693-5	2011	Bleomycin lung injury was induced in these bone marrow-reconstituted mice and unreconstituted C57Bl/6J mice, and some mice were treated with recombinant CSF3.	Bleomycin	0-9	colony stimulating factor 3 (granulocyte)	Mus musculus	153-157
21778693-6	2011	Lung histology, survival, cytokine expression and matrix metalloproteinase (MMP) expression were evaluated to determine the effect of CSF3 after bleomycin-induced lung injury.	Bleomycin	145-154	colony stimulating factor 3 (granulocyte)	Mus musculus	134-138
21778693-8	2011	Importantly, CSF3 attenuated bleomycin-induced lung injury and improved survival.	Bleomycin	29-38	colony stimulating factor 3 (granulocyte)	Mus musculus	13-17
21778693-9	2011	Furthermore, CSF3 administration regulated transforming growth factor-beta, interferon-gamma, MMP9 and tissue inhibitors of MMP1 expression during bleomycin injury.	Bleomycin	147-156	colony stimulating factor 3 (granulocyte)	Mus musculus	13-17
21778693-9	2011	Furthermore, CSF3 administration regulated transforming growth factor-beta, interferon-gamma, MMP9 and tissue inhibitors of MMP1 expression during bleomycin injury.	Bleomycin	147-156	matrix metallopeptidase 13	Mus musculus	124-128
21778693-10	2011	CONCLUSIONS: These data demonstrated that the mobilization of bone marrow-derived cells by CSF3 has a protective effect against bleomycin-induced lung injury and fibrosis.	Bleomycin	128-137	colony stimulating factor 3 (granulocyte)	Mus musculus	91-95
21135509-0	2011	Epithelium-specific deletion of TGF-beta receptor type II protects mice from bleomycin-induced pulmonary fibrosis.	Bleomycin	77-86	transforming growth factor, beta receptor II	Mus musculus	32-57
21998664-1	2011	BACKGROUND: Although C/EBPbeta(ko) mice are refractory to Bleomycin-induced lung fibrosis the molecular mechanisms remain unknown.	Bleomycin	58-67	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	21-30
21998664-2	2011	Here we show that blocking the ribosomal S-6 kinase (RSK) phosphorylation of the CCAAT/Enhancer Binding Protein (C/EBP)-beta on Thr217 (a RSK phosphoacceptor) with either a single point mutation (Ala217), dominant negative transgene or a blocking peptide containing the mutated phosphoacceptor ameliorates the progression of lung injury and fibrosis induced by Bleomycin in mice.	Bleomycin	361-370	ribosomal protein S6 kinase polypeptide 1	Mus musculus	31-51
21998664-2	2011	Here we show that blocking the ribosomal S-6 kinase (RSK) phosphorylation of the CCAAT/Enhancer Binding Protein (C/EBP)-beta on Thr217 (a RSK phosphoacceptor) with either a single point mutation (Ala217), dominant negative transgene or a blocking peptide containing the mutated phosphoacceptor ameliorates the progression of lung injury and fibrosis induced by Bleomycin in mice.	Bleomycin	361-370	ribosomal protein S6 kinase polypeptide 1	Mus musculus	53-56
21998664-2	2011	Here we show that blocking the ribosomal S-6 kinase (RSK) phosphorylation of the CCAAT/Enhancer Binding Protein (C/EBP)-beta on Thr217 (a RSK phosphoacceptor) with either a single point mutation (Ala217), dominant negative transgene or a blocking peptide containing the mutated phosphoacceptor ameliorates the progression of lung injury and fibrosis induced by Bleomycin in mice.	Bleomycin	361-370	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	113-124
21998664-2	2011	Here we show that blocking the ribosomal S-6 kinase (RSK) phosphorylation of the CCAAT/Enhancer Binding Protein (C/EBP)-beta on Thr217 (a RSK phosphoacceptor) with either a single point mutation (Ala217), dominant negative transgene or a blocking peptide containing the mutated phosphoacceptor ameliorates the progression of lung injury and fibrosis induced by Bleomycin in mice.	Bleomycin	361-370	ribosomal protein S6 kinase polypeptide 1	Mus musculus	138-141
21998664-3	2011	METHODOLOGY/PRINCIPAL FINDINGS: Mice expressing the non-phosphorylatable C/EBPbeta-Ala217 transgene had a marked reduction in lung injury on day-13 after Bleomycin exposure, compared to C/EBPbeta(wt) mice, judging by the decrease of CD68(+) activated monocytes/macrophages, bone marrow-derived CD45(+) cells and lung cytokines as well as by the normal surfactant protein-C expression by lung pneumocytes.	Bleomycin	154-163	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	73-82
21998664-4	2011	On day-21 after Bleomycin treatment, C/EBPbeta(wt) mice but not mice expressing the dominant negative C/EBPbeta-Ala217 transgene developed severe lung fibrosis as determined by quantitative collagen assays.	Bleomycin	16-25	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	37-46
21998664-6	2011	Treatment of C/EBPbeta(wt) mice with a cell permeant, C/EBPbeta peptide that inhibits phosphorylation of C/EBPbeta on Thr217 (40 microg instilled intracheally on day-2 and day-6 after the single Bleomycin dose) also blocked the progression of lung injury and fibrosis induced by Bleomycin.	Bleomycin	195-204	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	54-63
21998664-6	2011	Treatment of C/EBPbeta(wt) mice with a cell permeant, C/EBPbeta peptide that inhibits phosphorylation of C/EBPbeta on Thr217 (40 microg instilled intracheally on day-2 and day-6 after the single Bleomycin dose) also blocked the progression of lung injury and fibrosis induced by Bleomycin.	Bleomycin	195-204	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	54-63
21998664-6	2011	Treatment of C/EBPbeta(wt) mice with a cell permeant, C/EBPbeta peptide that inhibits phosphorylation of C/EBPbeta on Thr217 (40 microg instilled intracheally on day-2 and day-6 after the single Bleomycin dose) also blocked the progression of lung injury and fibrosis induced by Bleomycin.	Bleomycin	279-288	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	54-63
21998664-6	2011	Treatment of C/EBPbeta(wt) mice with a cell permeant, C/EBPbeta peptide that inhibits phosphorylation of C/EBPbeta on Thr217 (40 microg instilled intracheally on day-2 and day-6 after the single Bleomycin dose) also blocked the progression of lung injury and fibrosis induced by Bleomycin.	Bleomycin	279-288	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	54-63
21858022-4	2011	RESULTS: We show that bleomycin or IL-1beta-induced lung injury leads to increased expression of early IL-23p19, and IL-17A or IL-17F expression.	Bleomycin	22-31	interleukin 23, alpha subunit p19	Mus musculus	103-111
21858022-4	2011	RESULTS: We show that bleomycin or IL-1beta-induced lung injury leads to increased expression of early IL-23p19, and IL-17A or IL-17F expression.	Bleomycin	22-31	interleukin 17A	Mus musculus	117-123
21858022-4	2011	RESULTS: We show that bleomycin or IL-1beta-induced lung injury leads to increased expression of early IL-23p19, and IL-17A or IL-17F expression.	Bleomycin	22-31	interleukin 17F	Mus musculus	127-133
21660239-6	2011	Rapamycin-treatment increased weight loss and decreased survival of bleomycin-treated Sftpc(+/+) and Sftpc(-/-) mice.	Bleomycin	68-77	surfactant associated protein C	Mus musculus	101-111
21660239-8	2011	Further, rapamycin treatment augmented airway resistance and reduced lung compliance of bleomycin-treated Sftpc(-/-) mice.	Bleomycin	88-97	surfactant associated protein C	Mus musculus	106-116
21212602-0	2011	Blockade of the Wnt/beta-catenin pathway attenuates bleomycin-induced pulmonary fibrosis.	Bleomycin	52-61	catenin (cadherin associated protein), beta 1	Mus musculus	20-32
21212602-7	2011	The level of beta-catenin expression was increased in the epithelial cells of bleomycin-administered mice.	Bleomycin	78-87	catenin (cadherin associated protein), beta 1	Mus musculus	13-25
21212602-8	2011	Intratracheal treatment with beta-catenin siRNA significantly reduced beta-catenin expression, pulmonary fibrosis and collagen synthesis in bleomycin-administered mice compared with controls, with no significant effect on the inflammatory response.	Bleomycin	140-149	catenin (cadherin associated protein), beta 1	Mus musculus	29-41
21212602-8	2011	Intratracheal treatment with beta-catenin siRNA significantly reduced beta-catenin expression, pulmonary fibrosis and collagen synthesis in bleomycin-administered mice compared with controls, with no significant effect on the inflammatory response.	Bleomycin	140-149	catenin (cadherin associated protein), beta 1	Mus musculus	70-82
21212602-10	2011	Blockade of the Wnt/beta-catenin pathway by beta-catenin siRNA decreased bleomycin-induced pulmonary fibrosis in the murine model.	Bleomycin	73-82	catenin (cadherin associated protein), beta 1	Mus musculus	20-32
21212602-10	2011	Blockade of the Wnt/beta-catenin pathway by beta-catenin siRNA decreased bleomycin-induced pulmonary fibrosis in the murine model.	Bleomycin	73-82	catenin (cadherin associated protein), beta 1	Mus musculus	44-56
21319376-9	2011	CONCLUSION: Atorvastatin inhibits the synthesis and release of MMP-9 and TIMP-1 in the lung tissue of rats with bleomycin-induced pulmonary fibrosis, and has no significant effect on circulating MMP-9 and TIMP-1, which may be associated with the attenuation of experimental pulmonary fibrosis in rats.	Bleomycin	112-121	matrix metallopeptidase 9	Rattus norvegicus	63-68
21190578-4	2010	We examined the degree of bleomycin-induced inflammation and fibrosis in the mice with lowered catalase activity.	Bleomycin	26-35	catalase	Mus musculus	95-103
21190578-7	2010	In C57BL/6J mice, catalase activity was suppressed along with downregulation of catalase mRNA in whole lung homogenates after bleomycin administration.	Bleomycin	126-135	catalase	Mus musculus	18-26
21190578-7	2010	In C57BL/6J mice, catalase activity was suppressed along with downregulation of catalase mRNA in whole lung homogenates after bleomycin administration.	Bleomycin	126-135	catalase	Mus musculus	80-88
21190578-9	2010	CONCLUSIONS: Taken together, these findings demonstrate diminished catalase expression and activity in human pulmonary fibrosis and suggest the protective role of catalase against bleomycin-induced inflammation and subsequent fibrosis.	Bleomycin	180-189	catalase	Homo sapiens	163-171
21150327-2	2010	We showed that Cdk4(-/-) mice had impaired recruitment of lymphocytes following bleomycin model of acute lung injury.	Bleomycin	80-89	cyclin-dependent kinase 4	Mus musculus	15-19